[
    {
        "Question": "Concizumab is used for which diseases?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nConcizumab is used for which diseases?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Concizumab is developed for hemophilia A and B.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nConcizumab is used to treat hemophilia A and B with and without inhibitors.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer accurately recalls and mentions both hemophilia A and B, which are the diseases concizumab is developed for, as per the reference answers. Additionally, it correctly includes the detail about 'with and without inhibitors,' which adds valuable context.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise, focusing only on the relevant diseases (hemophilia A and B) and the specific conditions (with and without inhibitors). No extraneous or irrelevant information is included.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition of information. The answer concisely states the diseases concizumab is used for and the conditions, without repeating any points.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is clear, fluent, and easily understandable. The sentence structure is straightforward, making it highly readable."
    },
    {
        "Question": "What type of extracolonic tumors does the PMS2 germline mutation cause?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat type of extracolonic tumors does the PMS2 germline mutation cause?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Heterozygous PMS2 mutation carriers were at small increased risk for colorectal and endometrial cancer but not for any other Lynch syndrome-associated cancer.', 'The PMS2 germline mutation is associated with an increased risk of developing colorectal cancers (CRCs) that differ from sporadic CRCs in genetic and histologic features. In addition, tumors from patients with PMS2-associated Lynch syndrome have been found to be distinct from colorectal tumors associated with defects in other mismatch repair genes. , However, the PMS2 germline mutation does not cause extracolonic tumors, such as brain tumors, haematological malignancies, and signs of neurofibromatosis type 1, which are more commonly associated with biallelic MMR gene mutations. , In summary, the PMS2 germline mutation is primarily linked to the development of colorectal cancers with unique genetic and histological features, whereas extracolonic tumors are more frequently observed in individuals with biallelic MMR gene mutations.', 'PMS2 is a mismatch repair gene that plays a critical role in maintaining genomic integrity. A germline mutation in PMS2 is associated with Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer syndrome). This mutation increases the risk of colorectal cancer and other extracolonic malignancies such as endometrial, ovarian, gastric, small bowel, pancreatic, ureter, and renal pelvis cancer', 'The PMS2 germline mutation leads to café-au-lait macules, colonic polyps, and a unique range of tumors.', 'PMS2 is one of the four DNA mismatch repair proteins, which plays a significant role in maintaining genomic stability. PMS2 germline mutation results in Lynch syndrome, which predisposes to various extracolonic tumors, including endometrial, ovarian, gastric, and urothelial cancers.', 'PMS2 is a gene associated with Lynch syndrome, which is a hereditary predisposition to colorectal and extracolonic cancers. The extracolonic tumors associated with PMS2 germline mutation include gynecologic (endometrial and ovarian), urologic (urinary tract and renal pelvis), small bowel, pancreas, stomach, biliary tract, and skin (sebaceous neoplasms).', 'PMS2 germline mutation causes extracolonic tumors in regions such as the endometrium, ovary, urinary tract, lymphoma, stomach, pancreas small bowel and brain.', 'The PMS2 gene is one of the mismatch repair genes that play a crucial role in maintaining genomic stability. Germline mutations in the PMS2 gene can lead to Lynch syndrome, which is an autosomal dominant disorder characterized by an increased risk of developing colorectal and other types of cancer. However, compared to other MMR genes such as MLH1 and MSH2, PMS2 germline mutations are less common and associated with a lower risk of cancer development. , Extracolonic tumors associated with PMS2 germline mutations include endometrial, gastric, small bowel, biliary tract, pancreatic, brain (usually glioblastoma), sebaceous skin tumors, and transitional cell carcinomas of the ureter and renal pelvis. However, it is important to note that the risk of developing extracolonic tumors in individuals with PMS2 mutations is lower than in those with MLH1 or MSH2 mutations. , It is also worth mentioning that PMS2 germline mutations have be', 'The PMS2 germline mutation causes a severe colorectal cancer and multiple adenoma phenotype without extraintestinal cancer. The patient presented with multiple gastrointestinal tumors, which could not be distinguished clinically from cases with attenuated familial adenomatous polyposis or MUTYH-associated polyposis. In addition, the cumulative incidence of extracolonic tumors was higher in females than males (p = 0.001), including uterus and breast cancers. However, path_MLH1 variants are significantly more associated with the development of colorectal cancer than extracolonic tumors, while path_MSH2 variants show a greater frequency of extracolonic cancers, including ovarian cancer.', 'PMS2 germline mutations are associated with an increased risk of extracolonic tumors, including tumors in regions such as the endometrium, ovary, urinary tract, lymphoma, stomach, pancreas, small bowel, and brain in individuals with Lynch Syndrome.', 'Germline mutations of the PMS2 gene are associated with an increased risk of colorectal cancer in individuals with hereditary nonpolyposis colorectal cancer (HNPCC) syndrome. However, PMS2 germline mutations are rarely associated with extracolonic tumors in familial aggregation of colorectal cancers.', 'The PMS2 germline mutation is associated with an increased risk of developing various extracolonic malignancies, including but not limited to endometrial cancer, ovarian cancer, stomach cancer, small intestine cancer, hepatobiliary tract cancers (liver and bile duct), urinary tract tumors (kidney and ureter), brain tumors such as gliomas, skin cancers like melanoma, and pancreas cancer. The exact spectrum of extracolonic tumors can vary among different studies and populations, but these are the most commonly reported types associated with PMS2 mutations.', \"Lynch syndrome, which can be caused by PMS2 germline mutations, predisposes to various extracolonic cancers including endometrial cancer, ovarian cancer, stomach cancer, renal pelvis and ureteral cancer, small bowel cancer, hepatobiliary tract cancer, pancreatic cancer, glioblastoma multiforme (in Turcot's variant), sebaceous skin tumors (in Muir-Torre variant), and more recently identified, breast and prostate cancers.\", 'The PMS2 germline mutation is associated with an increased risk of colorectal and endometrial cancer, but not with other Lynch syndrome-associated cancers. Heterozygous PMS2 mutation carriers have a small increased risk for colorectal and endometrial cancer. However, the mutation does not seem to increase the risk of other extracolonic tumors. Therefore, the answer is that PMS2 germline mutation causes colorectal and endometrial cancer, but not other Lynch syndrome-associated cancers.', 'The PMS2 germline mutation is associated with a slightly increased risk for colorectal and endometrial cancer. However, it does not appear to increase the risk for any other types of cancer associated with Lynch syndrome. Lynch syndrome is a genetic disorder that increases the risk of many types of cancer, particularly cancers of the colon (colorectal cancer) and endometrium.', 'The PMS2 germline mutation is associated with a slightly increased risk for colorectal and endometrial cancer. However, it does not appear to increase the risk for any other types of cancer associated with Lynch syndrome.', 'The PMS2 germline mutation does not cause any extracolonic tumors.', 'The PMS2 germline mutation is associated with an increased risk of developing extracolonic tumors, specifically endometrial cancer.', 'The PMS2 germline mutation can cause several extracolonic tumors. These include cancers of the ovary, stomach, liver and biliary system, bladder, kidney, brain, breast, and prostate, as well as small bowel cancer. It is essential to monitor individuals with PMS2 mutations closely for these potential malignancies.', 'Based on the provided abstract, a study was conducted to determine the age-specific cumulative risk (penetrance) of various cancers for carriers of heterozygous pathogenic PMS2 variants. The research involved a large dataset from a global collaboration and used modified segregation analysis while considering both genotyped and nongenotyped relatives. , The results showed that PMS2 mutation carriers had an increased risk for colorectal cancer and endometrial cancer compared to the general population. However, there was no clear evidence of an elevated risk for ovarian, gastric, hepatobiliary, bladder, renal, brain, breast, prostate, or small bowel cancer. , In conclusion, the PMS2 germline mutation primarily causes an increased risk for colorectal and endometrial cancers. The study did not find a significant association between PMS2 germline mutations and other Lynch syndrome-associated extracolonic tumors.', 'The PMS2 germline mutation is predominantly associated with colorectal and endometrial cancer within the Lynch tumor spectrum. However, there is no clear evidence of an increased risk of other extracolonic tumors such as ovarian, gastric, hepatobiliary, bladder, renal, brain, breast, prostate, or small bowel cancer.', 'The PMS2 germline mutation causes extracolonic tumors, including endometrial cancer and colorectal and endometrial cancer.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the PMS2 germline mutation is associated with an increased risk of the following extracolonic tumors:\n\n* Endometrial cancer (mentioned in several relations, including relations 9, 18, 39, 71, and 103)\n* Ovarian cancer (mentioned in relations 10, 26, 48, and 114)\n* Stomach cancer (mentioned in relations 7, 41, and 59)\n* Small bowel cancer (mentioned in relations 20 and 102)\n* Brain tumors (mentioned in relation 105)\n* Sebaceous gland malignancies (mentioned in the description of LYNCH SYNDROME in the Entities table)\n\nIt is worth noting that these are the extracolonic tumors mentioned in the relations data, and the actual list of tumors associated with PMS2 germline mutation may be broader.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer includes most of the key extracolonic tumors associated with PMS2 germline mutation, such as endometrial, ovarian, stomach, small bowel, brain tumors, and sebaceous gland malignancies. However, it misses some less common but still relevant tumors like pancreatic, ureter, and renal pelvis cancers mentioned in other reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include irrelevant information. It focuses solely on the extracolonic tumors linked to PMS2 germline mutation, supporting each claim with references from the provided data.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat information unnecessarily. Each type of tumor is mentioned once, and the references to the relations are varied and specific.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is very readable and fluent. The use of bullet points and clear references enhances its clarity. The note at the end about the potential broader list of tumors adds a thoughtful touch without disrupting the flow."
    },
    {
        "Question": "Do stroke patients have a lower risk of Obstructive Sleep Apnea?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nDo stroke patients have a lower risk of Obstructive Sleep Apnea?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Obstructive sleep apnea (OSA) is a common sleep disorder characterized by repetitive cessation or reduction in airflow during sleep and stroke patients have a higher risk of OSA.', 'No, stroke patients do not have a lower risk of obstructive sleep apnea (OSA). In fact, studies suggest that the prevalence of OSA is higher among stroke patients compared to the general population. One study found that 79% of acute ischemic stroke patients had OSA, and another study found that 58% of stroke patients had OSA. Additionally, a study found that the severity of OSA was associated with poorer functional outcomes in stroke patients. This suggests that stroke patients are at higher risk for OSA and that proper screening and treatment of OSA may be important for their recovery and overall health. ', 'Actually, stroke patients tend to have a higher risk of developing Obstructive Sleep Apnea.', 'No, the majority of stroke patients have clinically significant obstructive sleep apnea (OSA). Observational studies have shown an increased risk of ischemic stroke in patients with untreated OSA, but results are not statistically significant. RCTs and meta-analyses have shown no significant ischemic stroke risk reduction in CPAP treated patients with OSA.', 'There are no studies suggesting that stroke patients have a lower risk of Obstructive Sleep Apnea', 'No, the fact that stroke patients have a higher risk of sleep-disordered breathing (SDB) and atrial fibrillation (AF) suggests that they have an increased, not decreased, risk of Obstructive Sleep Apnea.', 'No, stroke patients have a higher risk of Obstructive Sleep Apnea.', 'No, the majority of stroke patients have clinically significant obstructive sleep apnea (OSA), which indicates that stroke patients actually have a higher risk of OSA rather than a lower risk.', 'No, sleep-disordered breathing (SDB) is highly prevalent after stroke and is considered to be a risk factor for poor post-stroke outcomes.', 'Yes, obstructive sleep apnea is associated with stroke risk.', 'No, stroke patients do not have a lower risk of Obstructive Sleep Apnea.', 'No, stroke patients actually have a higher risk of sleep-disordered breathing, including obstructive sleep apnea, which is considered a risk factor for poor post-stroke outcomes.', '”We conclude that there is a significant association between stroke and OSA, and that the occurrence of stroke in patients with OSA is approximately 3 times higher than in the general population.\"}', 'No, stroke patients do not have a lower risk of Obstructive Sleep Apnea (OSA). In fact, sleep-disordered breathing (SDB) is highly prevalent after stroke and is considered to be a risk factor for poor post-stroke outcomes.', 'No, in fact, stroke patients have a higher risk of Obstructive Sleep Apnea. Sleep-disordered breathing, which includes Obstructive Sleep Apnea, is highly prevalent after a stroke and is considered a risk factor for poor post-stroke outcomes.', 'No, stroke patients do not have a lower risk of Obstructive Sleep Apnea. In fact, they may have a higher risk due to the increased prevalence of sleep-disordered breathing after an ischemic stroke.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, it appears that stroke patients may not have a lower risk of Obstructive Sleep Apnea (OSA). In fact, the data suggests that stroke patients may have a higher risk of OSA.\n\nAccording to study 21, \"Obstructive sleep apnea linked to wake-up strokes\", patients with mild to moderate ischemic stroke who experienced a wake-up stroke (WUS) had a significantly higher apnea-hypopnea index (AHI) and obstructive apnea index (OAI) compared to those who did not experience a WUS. This suggests that OSA may be a risk factor for WUS in stroke patients.\n\nAdditionally, study 19, \"Dissociation of obstructive sleep apnea from hypersomnolence and obesity in patients with stroke\", found that patients with stroke who had OSA had significantly lower Epworth Sleepiness Scale (ESS) scores and body mass index (BMI) compared to a community sample with the same severity of OSA. This suggests that OSA may be more difficult to diagnose in stroke patients due to the dissociation between OSA and hypersomnolence and obesity.\n\nHowever, it's worth noting that study 14, \"Sex Differences in Obstructive Sleep Apnea after Stroke\", found that female sex was an independent predictor of greater functional impairment, increased stroke severity, and greater post-stroke depressive symptoms in patients with post-stroke OSA, despite having lower OSA severity.\n\nOverall, the data suggests that stroke patients may have a higher risk of OSA, but the relationship between OSA and stroke is complex and may be influenced by various factors, including sex and severity of OSA.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer effectively recalls the main point from the reference answers, which is that stroke patients have a higher risk of OSA. It also includes additional study-specific details (e.g., AHI, OAI, ESS scores, BMI, and sex differences) that support this conclusion. However, it slightly misses mentioning some of the broader prevalence statistics from the reference answers (e.g., '79% of acute ischemic stroke patients had OSA').",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise, sticking closely to relevant information about OSA risk in stroke patients and avoiding unrelated details. However, the mention of sex differences in OSA complications, while relevant, slightly strays from the core focus on risk prevalence.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information unnecessarily. Each point adds new insights or supporting evidence without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to follow. It logically progresses from the general risk conclusion to supporting study details without losing clarity."
    },
    {
        "Question": "Should all babies diagnosed with spina bifida be operated within the first week of life?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nShould all babies diagnosed with spina bifida be operated within the first week of life?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['No, not all babies diagnosed with spina bifida should be operated on within the first week of life. The recommendation for treatment depends on the type and severity of spina bifida. Myelomeningocele, the most severe form, may benefit from prenatal surgery, which involves operating on the fetus while it is still in the uterus, before the 26th week of gestation. This approach can decrease the need for ventriculoperitoneal shunt placement and improve motor function compared to standard postnatal surgery. , On the other hand, spina bifida occulta, a milder form, usually does not require any surgical intervention, as many people with this condition do not experience symptoms. For some forms of spina bifida, such as meningocele, surgery may be recommended after birth to prevent infection and aid in protecting the spinal cord. , In summary, the decision for spina bifida treatment, including the timing and type of surgery, should be made on a case-by-case basis, taking into account various factors such as gestational age, lesion level, associated defects, and family considerations. Therefore, it is essential to consult with medical professionals specializing in fetal and pediatric care for personalized recommendations and guidance.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data tables, there is no direct evidence to support the conclusion that all babies diagnosed with spina bifida should be operated within the first week of life. However, the data suggests that early surgical repair, ideally within the first 2-3 days of life, is generally recommended to improve outcomes and reduce the risk of complications.\n\nTable 12, \"A case study of ReachAnother Foundation as a change champion for developing spina bifida neurosurgical care and advocating for primary prevention in Ethiopia,\" mentions that babies born with spina bifida require early closure surgery, ideally within the first 2-3 days after birth. This is consistent with the general consensus in the medical community that early surgical repair is beneficial for babies with spina bifida.\n\nTable 11, \"Factors associated with the timeliness of postnatal surgical repair of spina bifida,\" suggests that infants with hydrocephalus are more likely to have timely repair, which is consistent with the idea that early surgical intervention can improve outcomes for babies with spina bifida.\n\nHowever, Table 15, \"Revisiting MOMS criteria for prenatal repair of spina bifida: upper gestational-age limit should be raised and assessment of prenatal motor function rather than anatomical level improves prediction of postnatal function,\" suggests that late fetal surgical repair, up to 30 weeks of gestation, does not negatively impact motor-function outcome. This raises the possibility that some babies may benefit from a more nuanced approach to surgical timing, taking into account individual factors such as the severity of the defect and the baby's overall health.\n\nIn summary, while there is no clear evidence to support the conclusion that all babies with spina bifida should be operated within the first week of life, the data suggests that early surgical repair, ideally within the first 2-3 days of life, is generally recommended to improve outcomes and reduce the risk of complications. However, individualized decision-making and consideration of factors such as hydrocephalus and prenatal motor function may be necessary to determine the optimal timing of surgical repair for each baby.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer effectively summarizes the data from the provided tables, addressing the benefits of early surgical repair and the possibility of a individualized approach. However, it does not explicitly mention all types of spina bifida (e.g., spina bifida occulta and meningocele) and their differing surgical needs, which are covered in the reference answers. Hence, the recall is good but not exhaustive.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise in discussing early surgical repair and the considerations for timing based on the provided tables. It does not include irrelevant information, but it could be more precise in differentiating between types of spina bifida and their specific surgical indications, as seen in the reference answers.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not overly repeat information, and each point adds new insights, though it reiterates the point about early surgical repair benefits without significant redundancy.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-structured and fluent, with clear transitions between points. However, the reliance on referencing tables (e.g., 'Table 12, Table 11') slightly disrupts the flow compared to the narrative style of the reference answers."
    },
    {
        "Question": "What is Oculopharyngeal Muscular Dystrophy (OPMD)?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is Oculopharyngeal Muscular Dystrophy (OPMD)?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Oculopharyngeal muscular dystrophy (OPMD) is a rare late-onset intractable neuromuscular disease, characterized by slowly progressive ocular, facial, pharyngeal and distal limb muscle weakness.', 'Oculopharyngeal muscular dystrophy (OPMD) is a rare genetic disorder that affects the muscles in the eyes, throat, and limbs. It is caused by an abnormality in the PABPN1 gene, which codes for a protein involved in the development of muscle cells. The mutation leads to the accumulation of proteins in the nuclei of muscle cells, forming inclusions that disrupt normal cellular function. Symptoms typically begin in adulthood and progress slowly over time, affecting muscles responsible for eyelid movement, swallowing, and limb movement. Treatment options are limited, but research into the genetic mechanisms of OPMD is ongoing to develop potential therapeutic strategies.', 'Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset genetic disorder characterized by progressive eyelid drooping, difficulty swallowing, and proximal limb weakness. It typically manifests after the age of 50 and is caused by a mutation in the PABPN1 gene.', 'Oculopharyngeal Muscular Dystrophy (OPMD) is a late-onset progressive neuromuscular disorder, characterized by ptosis (droopy eyelids), dysphagia (difficulty swallowing), and limb-girdle weakness. It is inherited in an autosomal dominant manner due to mutations in the PABPN1 gene.', 'Oculopharyngeal Muscular Dystrophy (OPMD) is a late-onset, autosomal dominant muscular dystrophy characterized by ptosis, dysphagia, and proximal limb weakness. It is caused by an abnormal expansion of a GCG repeat in the PABPN1 gene.\\n\\nThe PABPN1 gene codes for a nuclear protein that is involved in RNA processing. OPMD is primarily a muscle disease, but it also presents in a minority of patients with sensorineural hearing loss. The age of onset, severity of symptoms, and the rate of progression are highly variable.', 'Oculopharyngeal Muscular Dystrophy (OPMD) is a rare, late-onset genetic disorder characterized by progressive bilateral ptosis (drooping of the upper eyelids), dysphagia (difficulty swallowing), and limitation of extraocular movements, which can lead to diplopia (double vision). The disease may also progress to proximal limb muscle weakness. OPMD is caused by an expansion of a GCN trinucleotide repeat in the poly(adenylate)-binding protein nuclear1 (PABPN1) gene, leading to the accumulation of mutated PABPN1 protein and formation of intranuclear inclusions in affected tissues. It is inherited in an autosomal dominant or recessive manner, with variable penetrance and expressivity. While OPMD is considered a rare disorder, it may be underdiagnosed due to its nonspecific symptoms and the lack of awareness among healthcare professionals. Genetic testing can confirm the diagnosis and aid in appropriate clinical management.', 'Oculopharyngeal muscular dystrophy (OPMD) is a late-onset myopathic genetic disorder characterized by chronic progressive dysphagia and ptosis with or without proximal limb weakness. It is caused by an abnormal alanine-encoding (GCN) trinucleotide repeat expansion in the first exon of the poly(A)-binding protein nuclear 1 (PABPN1) gene. OPMD can be inherited in an autosomal dominant or, rarely, autosomal recessive manner.', 'Oculopharyngeal muscular dystrophy (OPMD) is a late-onset autosomal dominant inherited disorder characterized by progressive ptosis, dysphagia and proximal limb weakness. It is caused by an abnormal expansion of a trinucleotide repeat in the gene PABPN1, leading to aggregation of expanded protein into inclusions in muscle fibers.', 'Oculopharyngeal muscular dystrophy (OPMD) is a late-onset myopathic genetic disorder characterized by chronic progressive dysphagia and ptosis with or without proximal limb weakness. It is caused by the abnormal expansion of the alanine-encoding (GCN)n trinucleotide repeat in the exon 1 of the PABPN1 gene. OPMD can be inherited in an autosomal dominant or recessive manner, with the dominant form being more common. The disease is characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness.', 'Oculopharyngeal muscular dystrophy (OPMD) is a late-onset intractable myopathy, characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness.', 'oculopharyngeal muscular dystrophy (OPMD) is a late-onset intractable myopathy, characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness.', 'Oculopharyngeal Muscular Dystrophy (OPMD) is a late-onset intractable myopathy, characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness.', 'Oculopharyngeal muscular dystrophy (OPMD) is a late-onset, intractable myopathy characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness.', 'Oculopharyngeal Muscular Dystrophy (OPMD) is a late-onset disease characterized by slowly progressive weakness in the eyelids (ptosis), difficulty swallowing (dysphagia), and weakness in the proximal limbs.', 'OPMD is a late-onset intractable myopathy, characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness. It is an autosomal dominant disease caused by the expansion of a GCG trinucleotide repeat in exon 1 of the PABPN1 gene.', 'Oculopharyngeal Muscular Dystrophy (OPMD) is a late-onset intractable myopathy characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness.', 'Oculopharyngeal Muscular Dystrophy (OPMD) is a genetic disorder characterized by a late-onset, slowly progressive muscle disease, or myopathy. It primarily affects the muscles of the upper eyelids (leading to ptosis or drooping of the eyelids) and the throat, causing difficulty in swallowing (dysphagia). Additionally, it can cause weakness in the proximal limbs, which are closer to the center of the body. The onset of this disease typically occurs in adulthood, often in individuals aged 40 to 60 years. OPMD is caused by mutations in the PABPN1 gene and is inherited in an autosomal dominant manner.', 'Oculopharyngeal Muscular Dystrophy (OPMD) is a genetic disorder characterized by muscle weakness that begins in adulthood, typically affecting the eyelids (leading to ptosis), throat muscles (causing dysphagia), and proximal limb muscles.', \"Oculopharyngeal Muscular Dystrophy (OPMD) is a type of late-onset myopathy, which is a disease that affects the muscles. It's characterized by slowly progressive symptoms such as ptosis, which is drooping or falling of the upper or lower eyelid, dysphagia, which is difficulty swallowing, and weakness in the proximal limbs, which are the limbs closest to the body's midline. This condition typically becomes apparent in adulthood\", 'Oculopharyngeal muscular dystrophy (OPMD) is a late-onset, incurable myopathy that affects the muscles of the eyelids, throat, and upper limbs. It causes progressive ptosis, difficulty swallowing, and weakness in the arms and legs. OPMD is an inherited disorder caused by mutations in the SGCB gene, which encodes a protein involved in maintaining muscle structure and function. The condition typically presents in individuals aged 50 to 69 years old and progresses slowly over time, leading to significant functional impairment and disability.', \"Oculopharyngeal Muscular Dystrophy (OPMD) is a rare, late-onset neuromuscular disease characterized by progressive muscle weakness in the ocular, facial, pharyngeal, and distal limb muscles. It is caused by mutations in four genes, including CGG repeats in the 5'-untranslated region of LRP12, GIPC1, NOTCH2NLC, and RILPL1. The disease is characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness, and patients may also experience suffocation, regurgitation of food, and aspiration pneumonia. Autologous myoblast transplantation has been suggested as a potential therapeutic approach to reduce swallowing problems in OPMD patients. Recent studies have shed light on the genetic and molecular mechanisms underlying OPMD, but more research is needed to fully understand its pathogenesis and develop effective treatments.\", 'Oculopharyngeal Muscular Dystrophy (OPMD) is a rare, late-onset, and progressive muscle disorder characterized by ptosis, dysphagia, and proximal limb weakness.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nOculopharyngeal Muscular Dystrophy (OPMD) is a late-onset, progressive muscle disorder characterized by impaired swallowing, chewing, and speaking. It is an autosomal dominant genetic disorder caused by an abnormal expansion of a (GCG) trinucleotide repeat in the polyadenylate-binding protein nuclear 1 (PABPN1) gene. This expansion leads to a polyalanine tract in the PABPN1 protein, which forms intranuclear inclusions and disrupts muscle function.\n\nOPMD typically presents with symptoms such as:\n\n* Droopy eyelids (ptosis)\n* Difficulty swallowing (dysphagia)\n* Progressive weakness of the muscles of the face, neck, and limbs\n* Intranuclear inclusions in muscle fibers\n\nThe disease is usually diagnosed in individuals over the age of 40, and its progression is slow, but it can lead to significant disability and complications, such as aspiration pneumonia and malnutrition. There is no cure for OPMD, but treatment options are available to manage its symptoms and slow its progression.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers most of the key aspects of OPMD, including the genetic cause (PABPN1 gene and GCG trinucleotide repeat expansion), symptoms (ptosis, dysphagia, muscle weakness), and complications (aspiration pneumonia, malnutrition). However, it misses some details like the adult-onset nature (typically after age 40 is mentioned, but not emphasized as strongly as in references) and the variability in inheritance (autosomal recessive is not mentioned).",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise and avoids irrelevant information. All details provided are relevant to OPMD, including the genetic mechanism, clinical features, and complications. No extraneous details are included.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat information. Each point is mentioned once and logically structured, with no redundant statements.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-written, clear, and fluent. The use of bullet points for symptoms enhances readability, and the overall structure is easy to follow without unnecessary complexity."
    },
    {
        "Question": "What is the mechanisms of action of Dersimelagon?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the mechanisms of action of Dersimelagon?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Dersimelagon is a novel orally administered selective agonist for melanocortin receptor 1 that is being investigated for the treatment of erythropoietic protoporphyria, X-linked protoporphyria, and diffuse cutaneous systemic sclerosis.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, Dersimelagon's mechanism of action involves the activation of the melanocortin 1 receptor (MC1R) to increase levels of skin eumelanin. This is supported by several sources:\n\n* Source 1: \"Melanogenic effect of dersimelagon (MT-7117), a novel oral melanocortin 1 receptor agonist\" states that Dersimelagon is a selective agonist for the melanocortin 1 receptor, which stimulates the production of eumelanin.\n* Source 2: \"Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis\" states that Dersimelagon activates the melanocortin 1 receptor, exerting anti-inflammatory and anti-fibrotic effects.\n* Source 3: \"Elucidation of Melanogenesis Cascade for Identifying Pathophysiology and Therapeutic Approach of Pigmentary Disorders and Melanoma\" provides a detailed explanation of the melanogenesis cascade, which involves the activation of the melanocortin 1 receptor to stimulate the production of eumelanin.\n\nAdditionally, the relations table shows that Dersimelagon interacts with the melanocortin 1 receptor (Relation 9), which further supports its mechanism of action.\n\nOverall, the available data suggests that Dersimelagon's mechanism of action is the activation of the melanocortin 1 receptor to increase levels of skin eumelanin.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers the mechanism of action of Dersimelagon, including its role as a selective agonist for the melanocortin 1 receptor (MC1R), the stimulation of eumelanin production, and the anti-inflammatory and anti-fibrotic effects. The answer also references multiple sources for validation.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and focused on the mechanisms of action of Dersimelagon. It does not include irrelevant information and directly addresses the activation of MC1R, eumelanin production, and related therapeutic effects.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer effectively avoids repetition. Each piece of information is presented once, and the explanation flows logically without redundant statements.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is clear, well-structured, and easily readable. The use of bullet points and logical progression enhances fluency and comprehension."
    },
    {
        "Question": "What proportion of risk is attributable to obesity in colorectal cancer women development?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat proportion of risk is attributable to obesity in colorectal cancer women development?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The men in the obese/obese group had a higher risk of colon cancer than women (hazard ratio\\u2009=\\u20091.13 [1.10-1.17] in men, and hazard ratio\\u2009=\\u20091.04 [1.01-1.18] in women, P\\u2009=\\u20090.001).', 'The population attributable fractions (PAFs) for excess weight were 24.3% for colon and 18.9% for rectum among women. This means that approximately 24.3% of colon cancer cases and 18.9% of rectum cancer cases in women are attributable to obesity.', 'The study found that approximately 15.8% of the total costs in obesity-related cancers among women can be reduced, with a significant portion of this reduction coming from post-menopausal breast, liver, and colorectal cancers. However, the study does not provide a specific proportion of risk attributable to obesity in colorectal cancer women development.', \"The exact proportion of colorectal cancer risk that is attributable to obesity can vary depending on the study and the population being considered. However, research has consistently shown that there is a positive association between excess body weight and an increased risk of developing colorectal cancer, particularly in women. Studies have estimated that approximately 3-5% of all colorectal cancers may be attributable to obesity among women. It's important to note that these estimates are based on observational studies and can fluctuate due to factors such as study design, sample size, and the specific measures used to define obesity.\", 'The population attributable fraction (PAF) for obesity in colorectal cancer in women is 9%.', 'According to the provided information, the proportion of colorectal cancer risk attributable to obesity in women varies by population:\\n\\n- In Italian women, a decrease in waist-to-hip ratio below 0.82 might reduce colorectal cancer by 19%.\\n\\n- In Pacific women, the population attributable fraction (PAF) for obesity was 19%. \\n\\n- In Maori women, the PAF for obesity was 14%.\\n\\n- In European/other women, the PAF for obesity was 8%.\\n\\nOverall, obesity increases the risk of colorectal cancer in women by around 19%, but this varies from 8-19% depending on the specific population. The relative risk is estimated to be about 1.5 times higher in obese women compared to normal-weight women.', '1.04 [1.01-1.18]', 'According to the provided snippets, the risk of colon cancer in women is associated with increasing waist circumference and waist-hip ratio, with a higher risk observed in men compared to women. Specifically, the hazard ratio for colon cancer in women was found to be 1.04 (95% CI: 1.01-1.18) per 10-cm increase in waist circumference, and 1.20 (95% CI: 1.08-1.33) per 0.1-unit increase in waist-hip ratio. However, the proportion of risk attributable to obesity in colorectal cancer women development is not explicitly stated in the provided snippets. , Therefore, we cannot provide a specific proportion of risk attributable to obesity in colorectal cancer women development based on the given information. However, it is clear that obesity is a significant risk factor for colon cancer in both men and women, and that the association between obesity and colon cancer risk varies by sex and cancer site.', 'The hazard ratio for colon cancer risk in obese women is 1.04 [1.01-1.18], indicating a slight increase in risk associated with obesity.', 'The proportion of risk attributable to obesity in the development of colorectal cancer among women is 1.04 (95% CI: 1.01-1.18).', '”BMI and/or the number of CTCs were significantly associated with the risk of CRC (P values of less than 0.001 for all). The proportion of risk attributable to BIM was 31% (95% confidence interval: 27% to 35%). The proportion of risk attributable to the number of CTCs was 49% (95% confidence interval: 43% to 55%).”}</s>', 'The proportion of risk attributable to obesity in colorectal cancer women development is 1.20 for each 0.1-unit increase in waist-hip ratio.', '16% of risk of colorectal cancer in women development is attributable to obesity.', \"The exact proportion of risk attributable to obesity in colorectal cancer development in women is not specified in the provided documents. However, they do provide relative risk (RR) values for increases in waist circumference and waist-hip ratio, which are measures often associated with obesity. For every 10-cm increase in waist circumference, the RR is 1.16, and for every 0.1-unit increase in waist-hip ratio, the RR is 1.20. Additionally, the hazard ratio for colon cancer in obese women is 1.04, suggesting that obesity increases the risk of colon cancer in women by 4%. It's important to note that these are not direct measures of the proportion of risk attributable to obesity, but rather indications of the relative risk compared to non-obese individuals.\", 'Obesity increases the risk of developing colorectal cancer in women by a factor ranging from 1.04 to 1.18.', 'According to the study, the proportion of risk attributable to obesity in colorectal cancer women development is 1.04 (hazard ratio) [1.01-1.18] in women, which means that obesity increases the risk of colorectal cancer in women by 4% (1.04-1.00) compared to non-obese women. This suggests that obesity plays a role in the development of colorectal cancer in women, but the effect size is relatively small compared to other risk factors.', \"The specific proportion of risk attributable to obesity in colorectal cancer development in women is not explicitly stated in the provided snippets. However, it is indicated that an increase in waist circumference and waist-hip ratio is associated with an increased risk of colon cancer in women. For every 10-cm increase in waist circumference, the relative risk (RR) increases by 1.16. Similarly, for every 0.1-unit increase in waist-hip ratio, the RR increases by 1.20. Furthermore, women in the obese group had a hazard ratio of 1.04 for colon cancer, indicating a slightly increased risk compared to non-obese women. It's important to note that the association between obesity and colon and rectal cancer risk varies by sex and cancer site\", 'The risk of colon cancer increased with increasing waist circumference (per 10-cm increase) in both men (RR: 1.33; 95% CI: 1.19, 1.49) and women (RR: 1.16; 95% CI: 1.09, 1.23) and with increasing waist-hip ratio (per 0.1-unit increase) in both men (RR: 1.43; 95% CI: 1.19, 1.71) and women (RR: 1.20; 95% CI: 1.08, 1.33). The men in the obese/obese group had a higher risk of colon cancer than women (hazard ratio\\\\u2009=\\\\u20091.13 [1.10-1.17] in men, and hazard ratio\\\\u2009=\\\\u20091.04 [1.01-1.18] in women, P\\\\u2009=\\\\u20090.001).', 'Obesity contributes to an increased risk of colorectal cancer development in women, with a hazard ratio of 1.04 to 1.18. This indicates that a proportion of the risk of colon cancer in women can be attributed to obesity.', 'The proportion of risk attributable to obesity in colorectal cancer development in women varies depending on the cancer site. For colon cancer, a 5-unit increase in body mass index (BMI) is associated with a 12% increased risk in women. However, for rectal cancer, there is a weak or no association between BMI and risk in women. Therefore, the proportion of risk attributable to obesity in colorectal cancer development in women is higher for colon cancer compared to rectal cancer.', 'The proportion of risk attributable to obesity in colorectal cancer development in women is approximately 1.13-1.17 times that of men.', 'The exact percentage may vary, but providing an approximate range or qualitative description would be helpful.   The study found that approximately 10-25% of colorectal cancer cases in women are attributable to obesity.', 'In women, colon cancer risk increased by 16% per 10-cm increase in waist circumference (RR: 1.16; 95% CI: 1.09, 1.23) and by 20% per 0.1-unit increase in waist-hip ratio (RR: 1.20; 95% CI: 1.08, 1.33). Obese women had a 4% higher risk of colon cancer compared to non-obese women (hazard ratio = 1.04; 95% CI: 1.01-1.18).', 'In women, 1.04 times higher risk of colorectal cancer development is attributable to obesity.', 'In women, obesity is associated with a 16% increased risk of developing colorectal cancer. This means that approximately 16% of the risk of colorectal cancer in women can be attributed to obesity.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the answer is not directly available. However, we can make an educated estimate based on the associations found in the relations table.\n\nFrom the relations table, we can see that obesity is associated with an increased risk of colorectal cancer in women. Specifically, relation 1 states that \"Obesity is a risk factor for colorectal cancer in postmenopausal women\" and relation 26 states that \"Obesity is a risk factor for colorectal cancer in postmenopausal women, with a 5-unit increase in BMI related to an increased risk of colon cancer in both men and women.\"\n\nHowever, we need to find the proportion of risk attributable to obesity. To do this, we can look at the hazard ratios (HRs) for the association between obesity and colorectal cancer in women.\n\nRelation 37 states that \"Body mass index is a risk factor for colorectal cancer in postmenopausal women\" with an HR of 1.25 per 10 cm increment in waist circumference. This suggests that for every 10 cm increase in waist circumference, the risk of colorectal cancer increases by 25% in postmenopausal women.\n\nRelation 10 states that \"Greater body size (overall and abdominal adiposity) was positively associated with colorectal cancer development in men. For women, abdominal adiposity, rather than overall body size, was associated with a greater colorectal cancer risk.\"\n\nHowever, we cannot directly calculate the proportion of risk attributable to obesity from these relations. But we can use the HRs to estimate the proportion of risk attributable to obesity.\n\nLet's assume that the HR for the association between obesity and colorectal cancer in women is approximately 1.25 (based on relation 37). This means that for every 10 cm increase in waist circumference, the risk of colorectal cancer increases by 25%.\n\nTo estimate the proportion of risk attributable to obesity, we can use the formula:\n\nProportion of risk attributable to obesity = (HR - 1) / HR\n\nPlugging in the value of HR = 1.25, we get:\n\nProportion of risk attributable to obesity = (1.25 - 1) / 1.25 = 0.2 or 20%\n\nThis means that approximately 20% of the risk of colorectal cancer in women is attributable to obesity.\n\nHowever, please note that this is a rough estimate and should be interpreted with caution. The actual proportion of risk attributable to obesity may be higher or lower, and more research is needed to confirm this estimate.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer recalls multiple references from the provided data, such as hazard ratios (HRs) and relations between obesity and colorectal cancer. However, it misses some specific proportions like the 9% PAF or the 16% increased risk mentioned in some reference answers.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer provides a rough estimate (20%) of the risk attributable to obesity but does not stay strictly within the exact figures available in the reference answers. It extrapolates from the data which, while logical, detracts from precision.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not repeat the same information. It constructs a narrative using different data points to arrive at the estimate.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is very readable and fluent. It clearly explains the steps taken to arrive at the estimate and acknowledges the limitations of the approach."
    },
    {
        "Question": "Has MDMA(ecstasy) been successfully used to treat PTSD disorder?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nHas MDMA(ecstasy) been successfully used to treat PTSD disorder?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes MDMA, a compound belonging to the family of entactogens, has been demonstrated to be useful to treat post-traumatic stress disorders.', 'Yes, MDMA-assisted psychotherapy has shown promise in treating PTSD', 'Yes, MDMA-assisted therapy has shown high efficacy in treating PTSD.', 'MDMA (ecstasy) has been used in conjunction with psychotherapy to treat PTSD disorder and preliminary studies suggest that MDMA-assisted psychotherapy can be a safe and effective treatment approach for PTSD.', 'Yes, MDMA-assisted psychotherapy has shown promise in addressing PTSD disorder among female subgroups.', 'Yes, MDMA-assisted therapy (MDMA-AT) has been successfully used to treat PTSD disorder.', 'Yes, 3,4-methylenedioxymethamphetamine (MDMA) has been used effectively to treat post-traumatic stress disorder (PTSD), with Phase III clinical trial evidence.', 'Yes, MDMA has been successfully used to treat PTSD disorder.', 'Yes, MDMA-assisted psychotherapy is effective for posttraumatic stress disorder.', 'No, MDMA (ecstasy) has not been successfully used to treat PTSD disorder.', 'Yes, clinical trials have shown promising safety and efficacy for the use of MDMA (ecstasy) in conjunction with psychotherapy for the treatment of posttraumatic stress disorder (PTSD). However, the mechanisms underlying this treatment form remain largely unestablished.', 'Yes, MDMA has been successfully used as an adjunct to psychotherapy for treating PTSD, showing promising results in clinical trials over the last two decades.', '”Three patients with severe, treatment-resistant post-traumatic stress disorder (PTSD) were successfully treated with a single high-dose (300-mg) of 3,4-methylenedioxymethamphetamine (MDMA), also known as ecstasy, in a controlled clinical trial\"}', 'Yes, MDMA-assisted psychotherapy has shown promising safety and efficacy in the treatment of PTSD.', 'Yes, MDMA has been successfully used to treat PTSD disorder in conjunction with psychotherapy. Clinical trials have shown promising safety and efficacy, but the mechanisms underlying this treatment form remain largely unestablished.', 'Yes, MDMA has been successfully used in treating PTSD.', 'Yes, 3,4-methylenedioxymethamphetamine (MDMA) as an adjunct to psychotherapy for the treatment of PTSD has been studied increasingly for the last two decades and has shown promising results through quantitative data.', 'Yes, MDMA has been used successfully in conjunction with psychotherapy to treat PTSD. Clinical trials have shown promising results, although the exact mechanisms underlying this treatment are still being studied.', 'Yes, MDMA (ecstasy) has been successfully used to treat PTSD disorder. Clinical trials have shown promising safety and efficacy, but the mechanisms underlying this treatment form remain largely unestablished.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, MDMA (Ecstasy) has been shown to be effective in treating PTSD in several studies. \n\nIn a randomized, double-blind, placebo-controlled phase 3 study, MDMA-assisted therapy was found to be highly efficacious in individuals with severe PTSD, with 67% of participants no longer meeting the criteria for PTSD after three sessions. The effects were also durable, with 67% no longer diagnosable after one year and 74% at nearly four years.\n\nAdditionally, a systematic review and meta-analysis of 16 articles found that MDMA demonstrated a net positive effect on symptoms of PTSD, with a cumulative sample size of 168 patients. The review also found that the pharmacological profile of MDMA may provide direction for future drug developments to treat patients with treatment-resistant psychiatric disorders.\n\nHowever, it's essential to note that while these studies suggest that MDMA-assisted therapy may be effective in treating PTSD, more research is needed to fully understand its efficacy and potential risks.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers all necessary information, including specific clinical trial results (e.g., 67% efficacy, durability of effects), a systematic review and meta-analysis (16 articles, 168 patients), and a balanced note on the need for further research. This aligns well with the reference answers, which also highlight efficacy, clinical trials, and the need for more research.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is highly precise, focusing solely on MDMA's efficacy in treating PTSD without introducing irrelevant information. It provides clear, data-supported statements (e.g., phase 3 study results, meta-analysis findings) and avoids tangential details, matching the precision seen in the reference answers.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer avoids redundancy. Each point (clinical trial results, meta-analysis, need for further research) is distinct and contributes new information. There is no unnecessary repetition, mirroring the conciseness of the reference answers.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is exceptionally clear and fluent, with well-structured sentences and logical flow. It uses accessible language while maintaining scientific rigor (e.g., 'randomized, double-blind, placebo-controlled,' 'systematic review and meta-analysis'). This matches the high readability standards of the reference answers."
    },
    {
        "Question": "What is a spillover event?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is a spillover event?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['A spillover event is the transmission of a pathogen from one host species to another. It involves the physical transfer of viral or other infectious particles across species boundaries, and is often the trigger for infectious disease outbreaks and emergence events. Spillover events can be influenced by factors like host ecology, environment, habitat fragmentation, biodiversity loss, livestock density, and human-animal interactions.', 'A spillover event is a situation in which a pathogen or disease agent is transmitted from one species to another, often through an intermediate host or vector. This can occur in various contexts, including between wildlife and domestic animals, or between humans and animals. The main cause of spillover events is habitat loss and fragmentation, which can lead to increased contact between different species and create opportunities for transmission.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nA spillover event is the transfer of a pathogen (such as a virus, bacteria, or parasite) from one host species to another, often resulting in the emergence of a new infectious disease in the new host species. This can occur when a pathogen jumps from an animal host to a human host, or from a wildlife host to a domestic animal host.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer captures the essential definition of a spillover event, including the transfer of a pathogen from one host species to another and the potential for disease emergence. However, it omits details about influencing factors such as host ecology, environment, habitat fragmentation, and human-animal interactions mentioned in the reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and focuses solely on the key aspects of a spillover event without including irrelevant information. It succinctly describes the transfer of pathogens between species and the resulting disease emergence.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each point is made clearly and concisely without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-written, fluent, and easy to understand. It uses clear and simple language to convey the concept of a spillover event effectively."
    },
    {
        "Question": "How can Emery-Dreifuss Muscular Dystrophy (EDMD) be inherited?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nHow can Emery-Dreifuss Muscular Dystrophy (EDMD) be inherited?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['EDMD can be inherited in an X-linked recessive, autosomal dominant or autosomal recessive fashion.', 'Emery-Dreifuss Muscular Dystrophy (EDMD) can be inherited in an X-linked recessive, autosomal dominant, or autosomal recessive fashion.', 'Emery-Dreifuss Muscular Dystrophy (EDMD) can be inherited in an X-linked, autosomal dominant, or autosomal recessive fashion.', 'Yes, EDMD can be inherited in an X-linked, autosomal dominant, or autosomal recessive fashion.', 'Emery-Dreifuss Muscular Dystrophy can be inherited through X-linked, autosomal dominant, or autosomal recessive patterns.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nEmery-Dreifuss Muscular Dystrophy (EDMD) can be inherited in two main ways:\n\n1.  **Autosomal Dominant Inheritance**: This is the most common form of EDMD, accounting for about 50-60% of cases. In autosomal dominant EDMD, a single copy of the mutated gene is enough to cause the disease. This means that if one parent has the mutated gene, there is a 50% chance that each child will inherit the mutated gene and develop the disease.\n2.  **X-linked Recessive Inheritance**: This form of EDMD is caused by mutations in the EMD gene, which is located on the X chromosome. In X-linked recessive EDMD, the mutated gene is located on the X chromosome, and the disease is more common in males than females. Females can be carriers of the mutated gene but usually do not develop the disease themselves, as they have two X chromosomes and only one needs to be mutated to cause the disease. Males, who have only one X chromosome, are more likely to develop the disease if they inherit the mutated gene.\n\nIt's worth noting that there are also other forms of EDMD, including autosomal recessive and autosomal dominant forms caused by mutations in other genes, such as the LMNA gene. However, autosomal dominant and X-linked recessive inheritance are the most common forms of the disease.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers all the inheritance patterns for EDMD, including autosomal dominant, X-linked recessive, and mentions the existence of autosomal recessive forms. It also provides additional details about the genes involved (EMD and LMNA) and the implications for males and females, which are not present in the reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and sticks to the topic of inheritance patterns in EDMD. It does not include irrelevant information, focusing only on the genetic aspects and implications for inheritance.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information. Each inheritance pattern is explained clearly and distinctly, and additional details are provided without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, easy to read, and fluent. It uses bullet points to organize information and provides clear explanations for each inheritance pattern, enhancing readability."
    },
    {
        "Question": "Can valproate be used during pregnancy?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nCan valproate be used during pregnancy?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['No. Valproate is associated with high risk of malformations and should no be used during pregnancy.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, valproate is a medication used to treat epilepsy and other neurological disorders, but it is contraindicated during pregnancy due to its teratogenic effects. \n\nValproate has been associated with an increased risk of neural tube defects, congenital malformations, and developmental disorders in the fetus. The risk of birth defects is dose-dependent, with higher risks at dosages above 1000 mg/day. Polytherapy involving treatment with more than one AED also seems to be associated with an increased risk of birth defects compared to monotherapy.\n\nTherefore, the use of valproate during pregnancy should be avoided if possible, and alternative treatments should be considered.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer provides comprehensive details about the risks associated with valproate during pregnancy, including neural tube defects, congenital malformations, developmental disorders, and dose-dependent risks. It also mentions the importance of considering alternative treatments. However, it does not strictly adhere to the reference answer's brevity.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer focuses on relevant risks and considerations regarding valproate use during pregnancy without introducing irrelevant details. The mention of epilepsy and neurological disorders, while contextually useful, was not in the reference answer.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information. Each point is distinct and contributes additional relevant details (e.g., dose-dependence, polytherapy risks) without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand. It presents complex medical information clearly and logically."
    },
    {
        "Question": "Which dietary compounds are associated with colorectal cancer incidence?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhich dietary compounds are associated with colorectal cancer incidence?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Red and red processed meat, lower intakes of dietary fiber and alcohol are associated with colorectal cancer incidence', 'Several dietary compounds have been associated with colorectal cancer incidence, including fiber, folate, methionine, vitamins B6, B12, C, E, selenium, and lycopene. A case-control study conducted in Melbourne, Australia found that high intakes of folate, methionine, vitamins B6 and B12, and selenium were associated with a lower risk of colorectal cancer. Additionally, dietary vitamins E and C, and lycopene showed protective effects against colorectal cancer. Other compounds such as phenolic compounds, carotenoids, iridoids, nitrogen compounds, organosulfur compounds, phytosterols, essential oil compounds, and polyunsaturated fatty acids have also been found to have chemopreventive properties against colorectal cancer in vitro, laboratory animals, and clinical trials. These compounds may act through various molecular and biochemical mechanisms, including inhibition of cell growth, apoptosis, interaction with gut microbiota, and regulation of cellular signal transduction pathways.', 'There is a considerable consensus in the scientific community that colorectal cancer (CRC) is associated with the consumption of high levels of fat, processed and red meats and low intake of fruit, vegetables and fiber. Specific dietary components that have been identified to play a role in CRC carcinogenesis include heme iron, phosphatidylcholine, bile acids, heterocyclic amines (HCAs), polycyclic aromatic hydrocarbons (PAHs) and advanced glycation end products (AGEs).', 'Dietary fiber, dairy products, calcium and folate are negatively associated with colorectal cancer risk, while processed red meat, alcohol, obesity and lack of physical activity increase the risk. Diets high in fruits, vegetables and fish are inversely associated with colorectal cancer.', 'Dietary compounds associated with colorectal cancer incidence include red meat, saturated fats, bile acids, and fatty acids, which are linked to increased risk. Conversely, calcium, probiotics, and prebiotics are associated with a decrease in fecal water toxicity and potentially lower colorectal cancer risk. Additionally, a proinflammatory diet, high-DII diets, and specific dietary components like alcohol and certain types of fats have been linked to an increased risk of colorectal cancer, particularly for colon cancer. The insulin-like growth factor (IGF) system components and plasma IGF-I levels have also been correlated with colon cancer incidence rates.', 'Several dietary compounds have been associated with colorectal cancer incidence, including vegetables, fiber, meat, folate, calcium, phytochemicals, and alcohol. Vegetables, particularly cruciferous vegetables, have been found to be associated with a lower risk of colorectal cancer. Fiber alone does not account for this association. Meat consumption, especially when cooked and producing mutagenic compounds like heterocyclic amines, is associated with an increased risk. Other dietary factors such as folate, calcium, and phytochemicals may also play a role. Alcohol consumption has been inconsistently associated with increased risk. It is important to note that personalized nutrition and protective diets are areas of ongoing research in colorectal cancer prevention.', 'Dietary factors that have been associated with an increased risk of colorectal cancer include high intake of red and processed meats, as well as foods rich in saturated fats. Conversely, diets high in fiber, particularly from whole grains, fruits, and vegetables, are believed to reduce the risk of CRC due to their potential to modulate gut microbiota composition and improve bowel function. Additionally, some studies have suggested that certain dietary components such as folate, calcium, vitamin D, and antioxidants may also play a role in colorectal cancer prevention. However, it is important to note that the relationship between specific dietary compounds and CRC incidence can be complex and may vary depending on other factors like overall diet quality, lifestyle habits, genetic predisposition, and individual metabolic differences.', 'Dietary compounds that have been associated with colorectal cancer incidence include red meat, processed meat, unprocessed red meat, total white meat, poultry and fish, and meat-related compounds such as heme iron, nitrate, nitrite, heterocyclic amines (HCAs), and benzo(a)pyrene (B(a)P). A meta-analysis of 18 studies found that specific flavonoid subclasses, such as procyanidins and isoflavones, showed protective effects against colorectal cancer risk. However, there was no enough evidence indicating that increased consumption of total flavonoids were significantly associated with reduced risk of colorectal cancer. The highest quintile of heme iron was associated with increased cancer risk only in the distal colon and rectum, while the highest quintile of HCAs and nitrate/nitrite were associated with increased risk of total colorectal cancer. Right and left subsites of the colon may have distinct susceptibilities to meat and possibly other dietary risk factors, suggesting that the causes of colorectal cancer may vary across anatomical subsites.', 'High meat and fat diets, low starch, low fiber, low vegetable diets, high-meat diets that increase the level of nitrosatable material in the colon, processed or red meat, low dietary fiber, alcohol, low intake of fruits, vegetables and cereals, high intake of animal fat, low intake of polyphenols, low intake of spices, low intake of vitamin B12, cholesterol, total fat, saturated fat, animal protein, energy, iron, refined carbohydrates, low intake of n-3 fatty acids, insoluble fiber, folate, flavonoids, vitamin E, isoflavones, beta-carotene, selenium, copper, vitamin B6, low intake of deep-yellow vegetables, dark-green vegetables, onions and garlic.', 'Dietary compounds associated with colorectal cancer incidence include: * Total lipid, saturated fatty acids, and monounsaturated fatty acids (increased incidence) * Dietary fiber and vitamin C (reduced incidence) * Traditional rice cake consumption (inversely associated with colorectal cancer incidence)', 'Several dietary compounds are associated with colorectal cancer incidence:\\n\\nPositively associated (increased risk):\\n- High intake of fat and oil (both plant and animal types)\\n- High intake of animal protein \\n- Diets high in animal fat\\n- Consumption of processed or red meat, especially when cooked at high temperatures\\n- Diets low in fiber and high in refined carbohydrates like sugar\\n\\nInversely associated (decreased risk):\\n- High intake of plant protein\\n- High intake of carbohydrates and cereals\\n- High intake of total fiber, cereal fiber, calcium, and phosphorus \\n- Diet high in vegetables like Brussels sprouts, cabbage and broccoli\\n- Micronutrients involved in DNA methylation, synthesis and repair (folate, methionine, vitamins B6 and B12) \\n- Micronutrients with antioxidant properties (selenium, vitamins E and C, lycopene)\\n\\nIn summary, a diet high in fiber, calcium, certain vitamins and minerals, and vegetables, but low in animal fat and red/processed meat, is associated with reduced colorectal cancer risk. Specific dietary components can influence colorectal cancer risk, likely through effects on inflammation and DNA damage/repair.', \"Based on the provided snippets, there are several dietary compounds that have been associated with colorectal cancer incidence. These include: * High intake of red meat, which has been positively associated with risk of colorectal, colon, rectal, and lung cancers. * High intake of processed meat, which has been positively associated with risk of breast, colorectal, colon, rectal, and lung cancers. * Low intake of dietary fiber, which has been inversely associated with risk of colorectal cancer. * High intake of dietary calcium, which has been inversely associated with risk of colorectal cancer. * High intake of yogurt, which has been inversely associated with risk of colorectal cancer. , It is important to note that these associations are based on observational studies and further research is needed to confirm the findings and understand the underlying mechanisms. Additionally, it's worth mentioning that other factors such as lifestyle, genetics, and environmental factors may also play a role in colorectal cancer development.\", 'High intake of red meat and processed meat is associated with an increased risk of colorectal cancer. This includes both colon and rectal cancers. On the other hand, higher intakes of dietary fiber, dietary calcium, and yogurt, as well as lower intakes of alcohol, are associated with a lower risk of colorectal cancer. Therefore, a diet rich in fiber, calcium, and yogurt, and low in red and processed meat and alcohol, may help reduce the risk of developing colorectal cancer.', 'High intake of red meat and processed meat is associated with an increased risk of colorectal, colon, and rectal cancers. This includes meats like beef, pork, and lamb, as well as processed meats such as sausages, hot dogs, and deli meats. On the other hand, higher intakes of dietary fiber, dietary calcium, and yogurt, as well as lower intakes of alcohol, are associated with a lower risk of colorectal cancer. Therefore, a diet rich in fiber, calcium, and yogurt, and low in red and processed meats and alcohol, may help reduce the risk of developing colorectal cancer.', 'Dietary fiber, dietary calcium, and yogurt are associated with lower colorectal cancer incidence, while high red meat and processed meat intake is associated with higher colorectal cancer incidence.', 'Dietary compounds associated with colorectal cancer incidence include dietary fiber, dietary calcium, and yogurt, which are associated with a lower risk of colorectal cancer. On the other hand, alcohol, red meat, and processed meat are associated with a higher risk of colorectal cancer.', 'The incidence of colorectal cancer is associated with higher intakes of red and processed meats, and lower intakes of dietary fiber, dietary calcium, yogurt, as well as alcohol consumption.', 'Some dietary compounds associated with colorectal cancer incidence are red meat, processed meat, and alcohol. A diet low in fiber and calcium may also increase the risk. However, consuming yogurt has been found to have a protective effect.', 'The umbrella review of meta-analyses indicates that certain dietary factors are associated with colorectal cancer (CRC) incidence. Specifically, there is convincing evidence of an association between higher intakes of dietary fiber, dietary calcium, and yogurt, as well as lower intakes of alcohol and red meat, with a lower risk of CRC. On the other hand, high consumption of red meat and processed meat is associated with an increased risk of CRC, colon cancer, rectal cancer, and lung cancer. Moreover, total red and processed meat consumption is positively associated with greater risks of colorectal, colon, rectal, lung, and renal cell cancers. Therefore, these dietary compounds have been consistently linked to CRC incidence and should be considered in strategies for cancer prevention.', 'The incidence of colorectal cancer (CRC) is associated with both dietary compounds and habits. According to the umbrella review, there is strong evidence that a higher intake of dietary fiber, dietary calcium, and yogurt is associated with a lower risk of CRC. On the other hand, higher consumption of alcohol and red meat is linked to an increased risk of CRC. Specifically, high red meat intake is positively associated with the risk of CRC, among other types of cancer. Similarly, high processed meat intake is also positively associated with the risk of CRC. Therefore, a diet rich in fiber, calcium, and yogurt, and low in alcohol, red meat, and processed meat, could potentially reduce the risk of developing CRC', 'Higher intakes of dietary fiber, dietary calcium, and yogurt are associated with a lower risk of colorectal cancer. Conversely, high intake of alcohol and red meat, including processed meat, is associated with an increased risk of colorectal cancer.', 'There is convincing evidence that higher intakes of dietary fiber, dietary calcium, and yogurt are associated with a lower risk of colorectal cancer. On the other hand, higher intakes of red meat and alcohol are associated with an increased risk of colorectal cancer.', 'The dietary compounds associated with colorectal cancer incidence are red meat and processed meat. High red meat intake was positively associated with risk of breast cancer, endometrial cancer, colorectal cancer, colon cancer, rectal cancer, lung cancer, and hepatocellular carcinoma, and high processed meat intake was positively associated with risk of breast, colorectal, colon, rectal, and lung cancers.', 'The umbrella review of meta-analyses of prospective observational studies found convincing evidence of an association between lower colorectal cancer (CRC) risk and higher intakes of dietary fiber, dietary calcium, and yogurt. Additionally, there was evidence of an inverse association between moderate alcohol consumption and CRC risk. The review also found that high red meat intake was positively associated with risk of CRC, colon cancer, rectal cancer, lung cancer, and hepatocellular carcinoma, while high processed meat intake was positively associated with risk of breast, colorectal, colon, rectal, and lung cancers. Furthermore, higher risk of colorectal, colon, rectal, lung, and renal cell cancers were observed with high total red and processed meat consumption.', 'Red meat, processed meat, yogurt, dietary fiber, dietary calcium, and alcohol are associated with colorectal cancer incidence.', 'Based on the evidence, the following dietary factors are associated with colorectal cancer (CRC) risk:\\n\\nHigher CRC risk is associated with higher intakes of alcohol and red/processed meat.\\n\\nLower CRC risk is associated with higher intakes of dietary fiber, dietary calcium, and yogurt.\\n\\nIn summary, diets high in fiber, calcium and yogurt, and low in alcohol and red/processed meats are linked to reduced colorectal cancer incidence.', 'Higher intakes of dietary fiber, dietary calcium, and yogurt are associated with a lower risk of colorectal cancer. Conversely, higher intakes of alcohol and red meat are associated with an increased risk of colorectal cancer.', 'Lower intake of dietary fiber, dietary calcium, and yogurt are associated with higher risk of colorectal cancer. On the other hand, higher intake of alcohol and red meat, particularly processed meat, is associated with an increased risk of colorectal cancer.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, the following dietary compounds are associated with colorectal cancer incidence:\n\n**Increased risk:**\n\n1. Red meat (associated with increased risk of colorectal cancer, studies 2, 3, 6, 9, 11, 13, 15, 16)\n2. Processed meat (associated with increased risk of colorectal cancer, studies 4, 5, 6, 9, 11, 13)\n3. High-fat diets (associated with increased risk of colorectal cancer, studies 5, 6, 15)\n4. High-sugar diets (associated with increased risk of colorectal cancer, study 10)\n5. High-calorie diets (associated with increased risk of colorectal cancer, study 15)\n\n**Decreased risk:**\n\n1. Fruits and vegetables (associated with lower risk of colorectal cancer, studies 7, 8, 9, 11, 14)\n2. Dietary fiber (associated with lower risk of colorectal cancer, studies 5, 9, 10, 15)\n3. Omega-3 fatty acids (associated with lower risk of colorectal cancer, study 6)\n4. Calcium (associated with lower risk of colorectal cancer, studies 9, 10, 15)\n5. Vitamin D (associated with lower risk of colorectal cancer, studies 9, 10, 15)\n6. Selenium (associated with lower risk of colorectal cancer, study 10)\n7. Vitamins A, C, and E (associated with lower risk of colorectal cancer, study 10)\n8. Fatty acids (medium-chain and odd-chain saturated fatty acids and highly unsaturated fatty acids) (associated with lower risk of colorectal cancer, study 10)\n\nPlease note that these associations are based on the provided data and may not be exhaustive or definitive.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer captures a broad range of dietary compounds associated with colorectal cancer incidence, both positively and negatively. It references multiple studies (though the exact numbering is unclear), indicating a good recall of major dietary associations mentioned in the reference answers. However, it misses some compounds like folate, methionine, and certain phytochemicals that were highlighted in the references.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer is precise in listing dietary compounds but includes some vague categories like 'high-fat diets' and 'high-sugar diets,' which are less specific than the compounds mentioned in the references (e.g., 'saturated fatty acids' or 'refined carbohydrates'). Some entries like 'fatty acids' are overly broad and not explicitly reflected in the references.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of the same information. Each compound or dietary factor is mentioned once under the relevant category (increased or decreased risk).",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clearly divided into 'Increased risk' and 'Decreased risk' sections, and each item is listed concisely. The note at the end clarifies the scope of the answer, enhancing readability."
    },
    {
        "Question": "What is the relationship between  Electroporation (EP) and DNA vaccines?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the relationship between  Electroporation (EP) and DNA vaccines?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Electroporation (EP) is an effective way to increase the DNA vaccines immunogenicity.', 'Electroporation (EP) is a physical method used to facilitate the entry of DNA vaccines (plasmid DNA molecules) into cells, significantly improving their efficacy by inducing humoral and cellular immune responses by over 400- and 35-fold respectively.', 'Electroporation (EP) is a method of delivering DNA vaccines that significantly increases transfection efficacy and the subsequent vaccine-specific immune responses.', 'Electroporation (EP) is a method that has been shown to significantly augment the transfection efficacy and the subsequent vaccine-specific immune responses of DNA vaccines.', 'Electroporation allows efficient delivery of DNA into cells and tissues, improving the expression of therapeutic or immunogenic proteins that are encoded by plasmid DNA, which is used in DNA vaccines.', 'Electroporation (EP) is an effective way to increase the immunogenicity of DNA vaccines.', 'Yes, electroporation is an effective way to increase the immunogenicity of DNA.', 'Electroporation (EP) is a method that increases the immunogenicity of DNA vaccines, particularly plasmid DNA vaccines.', 'Electroporation (EP) is a method used to increase the immunogenicity of DNA vaccines.', 'Electroporation (EP) is an effective way to increase the immunogenicity of plasmid DNA vaccine.', 'Electroporation (EP) is associated with increasing the immunogenicity of DNA vaccines.', 'Electroporation (EP) is a technique used to increase the immunogenicity of DNA vaccines. It involves the use of an electric field to create temporary pores in the cell membrane, allowing the DNA to enter the cell and be expressed as antigens, which can stimulate an immune response.', 'Electroporation (EP) effectively enhances the immunogenicity of DNA vaccines.', 'Electroporation (EP) increases the immunogenicity of DNA vaccines.', 'Electroporation (EP) is an effective way to increase the immunogenicity of DNA vaccines. EP is used to deliver plasmid DNA vaccines, enhancing the immune response induced by the vaccine.', 'Electroporation (EP) is used to enhance the effectiveness of DNA vaccines by increasing their immunogenicity. This means it helps to boost the immune response triggered by the DNA vaccines.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nElectroporation (EP) is a method used to deliver DNA vaccines into cells, and it has been shown to enhance the immunogenicity of DNA vaccines by increasing the uptake of DNA by cells and stimulating immune responses. EP involves the application of electrical pulses to the skin or muscle tissue, creating temporary pores in the cell membrane, allowing the DNA to enter the cell.\n\nThe relationship between EP and DNA vaccines is as follows:\n\n*   EP increases the efficiency of DNA vaccine delivery: EP can increase the uptake of DNA by cells, leading to higher levels of antigen expression and immune responses.\n*   EP enhances immune responses: EP has been shown to stimulate both humoral and cellular immune responses, making it an effective method for delivering DNA vaccines.\n*   EP can be used to deliver DNA vaccines to specific tissues: EP can be targeted to specific tissues, such as the skin or muscle, allowing for more precise delivery of the vaccine.\n*   EP has been shown to be safe and tolerable: EP has been used in clinical trials and has been shown to be safe and tolerable in humans.\n\nOverall, EP is a promising method for delivering DNA vaccines, and its use has the potential to enhance the effectiveness of DNA vaccines and improve immune responses.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer covers all key points mentioned in the reference answers, including the mechanism of EP (creating pores, increasing DNA uptake), the enhancement of immune responses (humoral and cellular), the potential for targeted delivery, and the safety of EP in clinical use. It also introduces additional relevant details not explicitly stated in the reference answers (e.g., targeted tissue delivery).",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is concise and avoids irrelevant information. It clearly focuses on the relationship between EP and DNA vaccines, providing specific details (e.g., antigen expression, immune response stimulation) without straying into unrelated topics.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "Each point is distinct and non-repetitive. The answer logically progresses from EP's mechanism to its benefits in vaccine delivery, immune response enhancement, tissue targeting, and safety, without restating the same idea redundantly.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to follow. The bullet points enhance clarity, and the language is straightforward while maintaining scientific accuracy. No grammatical or stylistic issues hinder comprehension."
    },
    {
        "Question": "Is measles immunisation the best public health approach to reduce incidence of measles worldwide?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs measles immunisation the best public health approach to reduce incidence of measles worldwide?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Measles immunisation is considered to be the best public health approach to reduce the incidence of measles worldwide.', 'Yes, measles immunisation is the best public health approach to reduce incidence of measles worldwide.', 'Yes. Measles immunisation is the best public health approach to reduce incidence of measles worldwide.', 'Measles immunization is considered the best public health approach to reduce the incidence of measles worldwide. Routine vaccination supplemented by planned campaigns has been the core strategy for measles control and elimination efforts. Vaccination helps to build immunity against the measles virus, preventing infection and reducing the risk of transmission. It is a cost-effective intervention that has been proven to be highly effective in reducing measles cases and outbreaks. However, it is important to note that the success of measles immunization programs also depends on factors such as vaccine coverage, access to healthcare, and public awareness. Therefore, a comprehensive approach that includes vaccination, surveillance, and public health education is crucial in achieving global measles control and elimination.', 'The administration of two doses of measles vaccines is the most effective strategy to prevent and eliminate measles.', 'Yes, measles immunization is the best public health approach to reduce incidence of measles worldwide.', 'Yes, measles immunisation is the best public health approach to reduce the incidence of measles worldwide.', 'Yes, measles immunisation is the best public health approach to reduce the incidence of measles worldwide. By renewing efforts to vaccinate all children with 2 MCV doses and strengthening surveillance, measles outbreaks can be prevented and progress towards measles elimination can be accelerated.', 'Yes, the administration of two doses of measles vaccines is the most effective strategy to prevent and eliminate measles.', 'Yes, measles immunisation is the best public health approach to reduce the incidence of measles worldwide. It is highly effective and has been proven to prevent outbreaks and accelerate progress toward measles elimination.', 'Yes, measles immunisation is the best public health approach to reduce the incidence of measles worldwide. By renewing efforts to vaccinate all children with 2 MCV doses and strengthening surveillance, outbreaks can be prevented and progress toward measles elimination can be accelerated.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, measles immunisation is widely considered the most effective public health approach to reduce the incidence of measles worldwide. According to the data, measles immunisation has been shown to be highly effective in preventing measles, with a vaccine efficacy of 93% or higher in some studies (e.g., #3, #4, #15). The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) recommend two doses of measles-containing vaccine (MCV) for all children to achieve high population immunity and prevent measles outbreaks (e.g., #2, #17).\n\nThe data also highlights the importance of maintaining high levels of population immunity to prevent measles outbreaks (e.g., #3, #4, #20). In areas with low vaccination coverage, measles outbreaks can occur, leading to significant morbidity and mortality (e.g., #11, #21).\n\nWhile there are some challenges to achieving high vaccination coverage, such as logistical and financial constraints, the data suggests that measles immunisation is a cost-effective and sustainable approach to reducing measles incidence worldwide (e.g., #21, #22).\n\nIn fact, the data shows that measles immunisation has been instrumental in reducing measles mortality and incidence in many parts of the world (e.g., #3, #4, #15). For example, in the United States, measles was declared eliminated in 2000 due to high vaccination coverage, and in Finland, a nationwide vaccination program led to a drastic fall in the incidence of measles, mumps, and rubella (e.g., #24).\n\nOverall, the data supports the conclusion that measles immunisation is the best public health approach to reduce the incidence of measles worldwide.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers all necessary points regarding measles immunization as the best public health approach. It includes details on vaccine efficacy, recommendations from WHO and CDC, the importance of high vaccination coverage, challenges, and examples of success (e.g., U.S. and Finland).",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and to the point, focusing solely on measles immunization without introducing irrelevant information. Each statement directly supports the conclusion that immunization is the best approach.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no unnecessary repetition in the answer. Each piece of information is presented clearly and logically, without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to follow. The logical flow from efficacy to recommendations, challenges, and outcomes enhances readability."
    },
    {
        "Question": "What type of DMD can golodirsen be used for?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat type of DMD can golodirsen be used for?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.', 'Golodirsen is used for treating Duchenne muscular dystrophy that can benefit from exon 53 skipping.', 'Golodirsen is approved by the FDA for the treatment of Duchenne Muscular Dystrophy (DMD) patients who are amenable to exon 53 skipping.', 'Golodirsen is approved for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.', 'Golodirsen (VYONDYS 53TM) can be used for specific types of Duchenne Muscular Dystrophy (DMD) that are amenable to exon 53 skipping.', 'Golodirsen can be used for Duchenne muscular dystrophy (DMD) patients who are amenable to exon 53 skipping.', 'Golodirsen can be used for Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.', 'Golodirsen can be used to treat Duchenne muscular dystrophy (DMD) patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.', 'Golodirsen can be used for Duchenne muscular dystrophy (DMD) with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.', 'Golodirsen (Vyondys 53™) is approved for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.', 'Golodirsen is approved for the treatment of DMD in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.', 'Golodirsen (Vyondys 53™) can be used for treating Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.', 'Golodirsen is used for treating DMD in patients who have a specific mutation that can be treated by skipping exon 53.', 'Golodirsen can be used for the treatment of DMD in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.', 'Golodirsen (Vyondys 53™) can be used for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.', 'Golodirsen can be used for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.', 'Golodirsen is a drug that can be used for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.', 'Golodirsen (Vyondys 53™) is an antisense oligonucleotide designed to induce exon 53 skipping in patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation of the DMD gene that is amenable to this specific form of therapy.', 'Golodirsen can be used for DMD with a confirmed mutation amenable to exon 53 skipping.', 'Golodirsen can be used for the treatment of Duchenne Muscular Dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the data provided, golodirsen can be used to treat Duchenne muscular dystrophy (DMD) patients who are amenable to exon 53 skipping. This means that golodirsen is specifically designed to target and skip exon 53 of the DMD gene, which is a common mutation in DMD patients.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately recalls all necessary information from the reference answers, stating that golodirsen is used for DMD patients who are amenable to exon 53 skipping, which aligns perfectly with the reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information. It focuses solely on the indication of golodirsen for DMD patients with exon 53 skipping, which is the key point from the reference answers.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. It clearly states the indication for golodirsen and adds a brief explanation about its mechanism without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is easily readable and fluent, with clear and concise language that effectively communicates the intended information."
    },
    {
        "Question": "What are active ingredients of Trikafta?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are active ingredients of Trikafta?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Trikafta includes elexacaftor/tezacaftor/ivacaftor.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, the active ingredients of Trikafta are:\n\n1. Elexacaftor (VX-445)\n2. Tezacaftor (VX-661)\n3. Ivacaftor (VX-770)\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately lists all three active ingredients of Trikafta (elexacaftor, tezacaftor, and ivacaftor) and includes their respective VX codes, which adds additional useful information not specified in the reference answer.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The response is concise and directly addresses the question without including any irrelevant details. Each listed ingredient is pertinent to the question asked.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each active ingredient is listed clearly and only once, along with its VX code.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured and clearly formatted, making it easy to read. The use of a numbered list for the ingredients enhances readability and comprehension."
    },
    {
        "Question": "What proportion of alteration in NTRK genes are attributable to colorectal cancer?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat proportion of alteration in NTRK genes are attributable to colorectal cancer?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['In common cancers, rates were consistently below 0.5%. Rare morphological subtypes, colorectal microsatellite instability, and driver mutation exclusion cancers had higher rates.', 'According to the literature review, NTRK gene fusions are found in approximately 0.2% to 0.3% of colorectal cancers. This means that out of every 100 colorectal cancers, 2 to 3 cases will have an NTRK gene fusion. Therefore, the proportion of alterations in NTRK genes attributable to colorectal cancer is relatively low, but still significant enough to consider testing for these fusions in certain subgroups of patients.', 'The proportion of alteration in NTRK genes attributable to colorectal cancer (CRC) is around 10% in the pan-cancer population, and 0.2% of CRCs (9/4569) were positive for Pan-Trk IHC. Additionally, the prevalence of NTRK fusion in CRC was 0.18%, with 46 unique NTRK-fusion partner pairs, of which 33 were not previously reported. TRK positivity was observed in 19% of MLH1-methylated MSI-high CRCs, 17% of sessile serrated lesions with dysplasia (SSLDs), and 4% of sessile serrated lesions (SSLs). However, NTRK gene alterations are not enriched in gastric cancer (GC) with dMMR but are specifically enriched in cases of GAHED.', '0.25% of patients analyzed had NTRK gene fusions and the most common were breast cancer, colorectal cancer (CRC), and sarcoma.', 'The exact proportion of NTRK gene alterations attributable to colorectal cancer (CRC) is not provided in the text. However, the text does mention that NTRK gene fusions are found in approximately 0.16-0.3% of CRCs and that they are more frequent in MMR-deficient/BRAFV600E wild-type tumors (5.3%). Additionally, the study found that 7% of MSI-high CRC cohort had NTRK gene fusions. It is important to note that these frequencies are based on specific patient populations and may not be generalizable to all patients with CRC.', 'The proportion of alterations in NTRK genes attributable to colorectal cancer is relatively low, with NTRK gene fusions occurring in approximately 1% of colorectal cancer cases.', \"According to the provided text, approximately 7% of colorectal cancers (CRCs) have NTRK gene fusions. This means that about 7% of alterations in NTRK genes are attributable to CRC. However, it's important to note that not all NTRK alterations are necessarily driver mutations or functional, and some may be passengers or non-pathogenic variants. Therefore, the actual proportion of NTRK alterations that contribute to the development and progression of CRC is likely lower than 7%.\", 'The prevalence of NTRK gene fusions in colorectal cancer is generally low, ranging from approximately 0.23% to 0.7% in most studies. However, one study found a higher prevalence of around 7% specifically in the microsatellite instability-high (MSI-high) colorectal cancer subgroup.', \"Based on the information provided in the snippet, it is not possible to directly determine the proportion of alterations in NTRK genes that are attributable to colorectal cancer. The snippet discusses the rates of cancers in general and mentions rare morphological subtypes, microsatellite instability, and driver mutation exclusion cancers having higher rates, but it does not provide specific details about NTRK gene alterations or their association with colorectal cancer. , However, it is known that NTRK gene fusions can occur across various tumor types, including colorectal cancer, but they are considered rare events. According to a study published in Cancer Discovery, the frequency of NTRK gene fusions in colorectal cancer is estimated to be around 0.18-0.23% (Cancer Discov. 2017 Aug;7(8):824-836). , Therefore, while it's challenging to provide an exact proportion based on the given snippet, it can be inferred that alterations in NTRK genes attributable to colorectal cancer are relatively rare events.\", 'Alterations in NTRK genes attributable to colorectal cancer account for 0.5% of cases, with higher rates observed in rare morphological subtypes and those with microsatellite instability.', 'The proportion of alteration in NTRK genes attributable to colorectal cancer is below 0.5%.', 'Alterations in NTRK genes attributable to colorectal cancer account for approximately 0.5% and are associated with colorectal microsatellite instability.', 'The text does not provide specific information on the proportion of alteration in NTRK genes attributable to colorectal cancer. It mentions that common cancers have rates consistently below 0.5%, and that rare morphological subtypes, colorectal microsatellite instability, and driver mutation exclusion cancers have higher rates. However, it does not specify the rate for colorectal cancer or NTRK gene alterations.', 'Rates of NTRK gene alteration were consistently below 0.5% in common cancers, but in rare morphological subtypes and colorectal microsatellite instability, and driver mutation exclusion cancers, higher rates of NTRK gene alteration were reported.', 'The proportion of alteration in NTRK genes attributable to colorectal cancer is 0.0001%.', 'Approximately less than 0.5% of alterations in NTRK genes are associated with colorectal cancer. NTRK gene fusions have been identified as oncogenic drivers across various tumor types; however, they are relatively rare in colorectal cancer, making up a very small proportion of genetic changes observed in this cancer type.', 'According to the systematic review, the proportion of NTRK gene fusions attributable to colorectal cancer is not specifically stated. However, it is mentioned that rare morphological subtypes, such as colorectal microsatellite instability, and driver mutation exclusion cancers have higher rates of NTRK fusions. The review also notes that the prevalence of NTRK fusions in common cancers, including colorectal cancer, is consistently below 0.5%. Therefore, it can be inferred that the proportion of NTRK alterations attributable to colorectal cancer is likely low, but further large-scale, standardized genomic data are needed to characterize NTRK fusion epidemiology in this specific cancer type.', 'In common cancers, rates of NTRK gene alterations were consistently below 0.5%. Rare morphological subtypes, colorectal microsatellite instability, and driver mutation exclusion cancers had higher rates.', 'In colorectal cancer, the proportion of alterations in NTRK genes is consistently below 0.5%. However, rare morphological subtypes, colorectal microsatellite instability, and driver mutation exclusion cancers show higher rates of alterations in NTRK genes.', 'The proportion of alteration in NTRK genes attributable to colorectal cancer is not well established in the literature. However, it is known that NTRK gene alterations are relatively rare in colorectal cancer, occurring in approximately 1-3% of cases. Therefore, the proportion of alteration in NTRK genes attributable to colorectal cancer is likely to be small.', 'The rate of alterations in NTRK genes among common cancers is generally below 0.5%, with rare morphological subtypes, colorerectal microsatellite instability (MSI) tumors, and driver mutation exclusion cancers having higher rates. Colorectal cancer specifically has been found to have a higher prevalence of NTRK gene alterations compared to other common cancers, although the exact rate can vary depending on factors such as MSI status and the presence or absence of certain driver mutations.', 'The rates of NTRK gene alterations were consistently below 0.5% in common cancers. However, colorectal cancers with microsatellite instability had higher rates of NTRK alterations compared to common cancers overall.', 'The proportion of alterations in NTRK genes attributable to colorectal cancer is below 0.5%.', 'The proportion of alterations in NTRK genes attributable to colorectal cancer is consistently below 0.5%. However, it is important to note that rare morphological subtypes, colorectal microsatellite instability, and driver mutation exclusion cancers may have higher rates of NTRK gene alterations.', '0.5% or less.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to table 21 in the Relations section, NTRK fusions are found in 0.23% of 7008 tumors screened, with a range of 0.03-0.70% across various cancer types. However, no specific data is available on the proportion of NTRK alterations attributable to colorectal cancer alone.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "3",
        "Information Recall Explanation": "The answer mentions the percentage of NTRK fusions found in a broad screening (0.23% of 7008 tumors) and provides a range across various cancer types. However, it fails to provide specific data on the proportion attributable to colorectal cancer, which is the main focus of the question. This lack of direct relevance lowers the score.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer is precise in its reporting of the data it does provide (0.23% in 7008 tumors and a 0.03-0.70% range). It succinctly states that no specific data on colorectal cancer is available, avoiding any irrelevant details. This precision helps maintain a good score.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition in the answer. It concisely presents the available data without redundancy, earning it a high score in this criterion.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is clear and well-structured, making it easy to read and understand. The use of specific figures and a straightforward explanation of their limitations enhances readability, justifying the top score."
    },
    {
        "Question": "Please list the Janus Kinase inhibitors used to treat Inflammatory Bowel Disease(IBD)",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nPlease list the Janus Kinase inhibitors used to treat Inflammatory Bowel Disease(IBD)\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Several small-molecule JAK inhibitors (JAKis) including abrocitinib, baricitinib, filgotinib,  peficitinib, tofacitinib, risankizumab upadacitinib, deucavacitinib are now approved for the treatment of various immune-mediated inflammatory diseases.', 'The Janus Kinase inhibitors that are currently being used or investigated for the treatment of Inflammatory Bowel Disease (IBD) include: , 1. Tofacitinib, 2. Filgotinib, 3. Upadacitinib, 4. TD-1473, 5. Peficitinib, 6. Pf-06651600/Pf-06700841 , These JAK inhibitors target the JAK-STAT pathway, which is strongly involved in the pathophysiology of IBD. They are being evaluated for their efficacy and safety in treating patients with active ulcerative colitis.', 'Tofacitinib is a Janus Kinase inhibitor used for treating Inflammatory Bowel Disease.', \"The Janus Kinase (JAK) inhibitors used to treat Inflammatory Bowel Disease (IBD) include:\\n\\n1. Tofacitinib\\n2. Filgotinib\\n3. Upadacitinib\\n\\nThese JAK inhibitors have been approved by the US Food and Drug Administration (FDA) for moderate-to-severe active ulcerative colitis (UC) and are considered advanced therapies for IBD. Tofacitinib is a pan-JAK inhibitor, primarily of JAK1 and JAK3, while filgotinib and upadacitinib are selective JAK-1 inhibitors. These JAK inhibitors have shown increased remission rates in patients with Crohn's disease, although there are currently no approved JAK inhibitors for this indication.\", 'The Janus Kinase (JAK) inhibitors currently used or being investigated for the treatment of Inflammatory Bowel Disease (IBD) include: , 1. Tofacitinib (approved for moderate-to-severe active ulcerative colitis), 2. Upadacitinib (selective JAK-1 inhibitor, in late-stage clinical trials for IBD), 3. Filgotinib (selective JAK-1 inhibitor, in late-stage clinical trials for IBD), 4. TD-1473 (JAK3/Tyk2 inhibitor, under investigation in phase II trials for IBD), 5. Peficitinib (JAK inhibitor, under investigation in phase II trials for IBD), 6. Pf-06651600/Pf-06700841 (JAK inhibitors, under investigation in phase II trials for IBD)', 'The following Janus Kinase (JAK) inhibitors are used to treat inflammatory bowel disease (IBD):, 1. Filgotinib, 2. Upadacitinib, 3. Tofacitinib, 4. Peficitinib, 5. Pf-06651600/Pf-06700841, 6. TD-1473', 'The Janus Kinase inhibitors used to treat Inflammatory Bowel Disease(IBD) are tofacitinib, upadacitinib, and filgotinib.', 'The Janus Kinase (JAK) inhibitors used to treat Inflammatory Bowel Disease (IBD) include tofacitinib and upadacitinib.', 'The following are Janus Kinase inhibitors used to treat Inflammatory Bowel Disease (IBD): , 1. Tofacitinib, 2. Filgotinib, 3. Upadacitinib, 4. GSK2586184 (Janus kinase 1 selective inhibitor)', 'The Janus Kinase (JAK) inhibitors used to treat Inflammatory Bowel Disease (IBD) include Tofacitinib and Upadacitinib.', 'Upadacitinib, filgotinib, tofacitinib, and upadacitinib can be used to treat Inflammatory Bowel Disease (IBD).', 'The Janus Kinase inhibitors used to treat Inflammatory Bowel Disease (IBD) include Tofacitinib, Upadacitinib, Filgotinib, and Deucravacitinib.', 'The Janus Kinase inhibitors used to treat Inflammatory Bowel Disease (IBD) include upadacitinib, filgotinib, tofacitinib, and deucravacitinib.', 'Upadacitinib, filgotinib, tofacitinib, and deucravacitinib are Janus Kinase inhibitors used to treat Inflammatory Bowel Disease (IBD).', 'The Janus Kinase inhibitors used to treat Inflammatory Bowel Disease(IBD) are Tofacitinib, Upadacitinib, Filgotinib and Deucravacitinib.', 'Upadacitinib, filgotinib, tofacitinib and deucravacitinib are Janus Kinase inhibitors used to treat Inflammatory Bowel Disease(IBD).', 'The Janus Kinase (JAK) inhibitors used to treat Inflammatory Bowel Disease (IBD) include tofacitinib, upadacitinib, filgotinib, and deucravacitinib.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data tables, the following Janus Kinase (JAK) inhibitors are used to treat Inflammatory Bowel Disease (IBD):\n\n1. Tofacitinib\n2. Upadacitinib\n3. Filgotinib\n4. PF-06651600/PF-06700841 (a small molecule inhibitor of Janus kinases)\n5. PF-06826647 (a TYK2 inhibitor)\n6. Janus Kinase Inhibitors (a class of medications that block the activity of Janus kinases)\n\nNote that this list may not be exhaustive, as the data tables only provide a snapshot of the available information.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer correctly lists several JAK inhibitors used for IBD, including Tofacitinib, Upadacitinib, Filgotinib, and PF-06651600/PF-06700841. However, it includes irrelevant entries like 'Janus Kinase Inhibitors' (a class, not a specific drug) and 'PF-06826647' (a TYK2 inhibitor, not a confirmed JAK inhibitor for IBD). Some approved/investigated JAK inhibitors like Peficitinib and Deucravacitinib are missing.",
        "Information Precision Score": 2,
        "Information Precision Explanation": "The answer includes imprecise or irrelevant information such as 'Janus Kinase Inhibitors' (a redundant class label) and 'PF-06826647' (a TYK2 inhibitor without clear relevance to IBD). It also mislabels PF-06651600/PF-06700841 as a single entry when they are distinct compounds. The disclaimer about the non-exhaustive list is unnecessary.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "There is no repetition of the same drug names, but redundancy is introduced by listing 'Janus Kinase Inhibitors' as an entry despite it being a class description.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-structured and easy to read, with clear numbering and concise drug names. However, the inclusion of non-relevant entries slightly detracts from clarity."
    },
    {
        "Question": "Are only babies and young children at risk of severe malaria in endemic areas?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nAre only babies and young children at risk of severe malaria in endemic areas?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['No, everybody is at risk, though the people at highest risk are young children and pregnant women.', 'While young children are particularly vulnerable to developing severe malaria in endemic areas, they are not the only ones at risk. In fact, anyone who is not immune to the disease can develop severe malaria if they become infected with the Plasmodium parasite. However, young children and pregnant women tend to be more susceptible to severe forms of the disease due to their weaker immune systems and other factors. For example, in areas where malaria is endemic, babies and young children are not yet immune to the disease, making them more vulnerable to severe symptoms. Similarly, pregnant women may experience altered B cell responses associated with changes in BAFF levels, which can increase their risk of developing severe malaria. Therefore, while anyone can develop severe malaria in endemic areas, young children and pregnant women are at particularly high risk.', 'While babies and young children are indeed at a higher risk of severe malaria in endemic areas, they are not the only ones susceptible to the disease. Pregnant women, for instance, can also experience significant health issues due to malaria, such as low birth weight, stillbirth, and severe anaemia. Additionally, adults can contract severe forms of malaria, including cerebral malaria. Therefore, it is not accurate to say that only babies and young children are at risk of severe malaria in endemic areas.', 'No, severe malaria can affect people of all ages in endemic areas, including pregnant women and their unborn babies.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the answer is no, not only babies and young children are at risk of severe malaria in endemic areas.\n\nAccording to the data, severe malaria can affect individuals of various age groups, including adults (e.g., severe malaria in adults in India, severe malaria in pregnant women, etc.). However, it is indeed true that young children, particularly those under the age of 5, are disproportionately affected by malaria due to their lack of immunity.\n\nFor example, the data mentions that \"Young African children\" are a demographic group who are \"disproportionately affected by malaria due to their lack of immunity\" (Rank 2), and \"Children under the age of 5 are disproportionately affected by malaria\" (Rank 51).\n\nAdditionally, the data also mentions that \"Adults can be treated for malaria with artesunate, artemether, or quinine\" (Rank 141), indicating that adults can also be affected by malaria.\n\nTherefore, while young children are indeed at higher risk, severe malaria can affect individuals of various age groups in endemic areas.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer captures all necessary information, including the fact that severe malaria is not limited to babies and young children but also affects adults and pregnant women. It provides specific examples (e.g., severe malaria in adults in India) and references demographic groups disproportionately affected by malaria (young African children).",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include irrelevant information. It focuses strictly on the key points regarding the risk of severe malaria across different age groups, particularly emphasizing young children, adults, and pregnant women.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not excessively repeat the same information. However, it does reiterate the point about young children being disproportionately affected, which could have been slightly more concise.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand. It logically presents the information, using clear examples and references to reinforce the points made."
    },
    {
        "Question": "What types of glucosteroids are used for the management of Duchenne muscular dystrophy?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat types of glucosteroids are used for the management of Duchenne muscular dystrophy?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The glucosteroids used for the management of Duchenne muscular dystrophy are prednisone, prednisolone and deflazacort.', 'Deflazacort and prednisone are the types of glucocorticoids used for managing Duchenne muscular dystrophy.', 'Glucocorticoids such as prednisone, prednisolone, deflazacort are used for the management of Duchenne muscular dystrophy.', 'Glucocorticoids such as prednisone and deflazacort are used for the management of Duchenne muscular dystrophy.', 'Glucocorticoids, such as prednisone and deflazacort, are commonly used for the management of Duchenne muscular dystrophy.', 'Prednisolone and deflazacort are steroids that help to reduce muscle inflammation and are used as treatments for Duchenne muscular dystrophy.', 'Deflazacort, prednisone, and prednisolone are glucosteroids used for the management of Duchenne muscular dystrophy.', 'Prednisone and deflazacort are the glucosteroids used for the management of Duchenne muscular dystrophy (DMD).', 'The types of glucosteroids used for the management of Duchenne muscular dystrophy are deflazacort, prednisone, and prednisolone.', 'Prednisone and deflazacort are two different types of corticosteroids. Prednisone is a glucocorticoid and deflazacort is a synthetic corticosteroid used for the management of Duchenne muscular dystrophy.', 'Prednisone and deflazacort are steroids that help to reduce muscle inflammation and are used as treatments for DMD.', 'Prednisone and deflazacort are glucosteroids used for the management of Duchenne muscular dystrophy.', 'Prednisone, Deflazacort, and Prednisolone are types of glucocorticoids used in the management of Duchenne muscular dystrophy. These glucocorticoids can be used in different regimes, including daily and intermittent.', 'Prednisone and Deflazacort are the glucocorticoids used for treating Duchenne muscular dystrophy.', 'The types of glucocorticoids used for the management of Duchenne muscular dystrophy (DMD) are deflazacort and prednisone/prednisolone.', 'Prednisone and Deflazacort are the types of glucocorticoids used for the management of Duchenne muscular dystrophy.', 'Prednisone and deflazacort are two types of glucosteroids used for the management of Duchenne muscular dystrophy.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the data, the following types of glucocorticoids are used for the management of Duchenne muscular dystrophy:\n\n1. Prednisone: A glucocorticoid medication commonly used to treat Duchenne muscular dystrophy, which has been shown to provide interim functional improvement for boys with the disease.\n2. Deflazacort: A corticosteroid medication used to treat Duchenne muscular dystrophy, which has a similar effect on muscle strength as prednisone and can improve muscle strength, motor function, and pulmonary function, while reducing the need for scoliosis surgery and cardiomyopathy.\n3. Prednisolone: A corticosteroid medication used to treat Duchenne muscular dystrophy, which can improve muscle strength, motor function, and pulmonary function, while reducing the need for scoliosis surgery and cardiomyopathy.\n4. Glucocorticoids: A class of steroid hormones that have anti-inflammatory and immunosuppressive properties, which may be used as a treatment for Duchenne muscular dystrophy.\n5. Glucocorticoid steroids: A type of steroid hormone that is used to treat various diseases, including Duchenne muscular dystrophy, by reducing inflammation and suppressing the immune system.\n\nNote that these glucocorticoids are used to manage the symptoms of Duchenne muscular dystrophy, but they do not cure the disease.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer comprehensively lists all the necessary glucocorticoids (prednisone, deflazacort, prednisolone) used for the management of Duchenne muscular dystrophy, along with additional relevant information about their effects. This exceeds the basic recall seen in some reference answers.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer includes precise details about each glucocorticoid, such as their effects on muscle strength, motor function, and other clinical outcomes. However, points 4 and 5 are somewhat redundant and less directly relevant as they broadly describe glucocorticoids instead of focusing on specific medications for DMD.",
        "Information Repetition Score": "3",
        "Information Repetition Explanation": "The answer repeats the effects of deflazacort and prednisolone in a very similar manner, and the general description of glucocorticoids (points 4 and 5) overlaps without adding new relevant information.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured, clearly organized, and fluent. Each point is easy to understand, making this answer highly readable."
    },
    {
        "Question": "Cilta-cel was developed for treatment of which disease?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nCilta-cel was developed for treatment of which disease?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Cilta-cel, a BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nCilta-cel, also known as ciltacabtagene autoleucel, was developed for the treatment of relapsed or refractory multiple myeloma.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately reports that cilta-cel was developed for the treatment of multiple myeloma, specifically mentioning 'relapsed or refractory multiple myeloma,' which aligns with the reference answer. The additional detail (relapsed/refractory) is clinically relevant and does not detract from recall.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer provides precise and relevant information without including any extraneous details. The mention of the alternate name 'ciltacabtagene autoleucel' and the specific indication (relapsed/refractory multiple myeloma) is appropriate and targeted.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. The details are concise and presented only once.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is clearly written, fluent, and easy to understand. The use of both the abbreviated name ('Cilta-cel') and the full name ('ciltacabtagene autoleucel') enhances clarity without compromising readability."
    },
    {
        "Question": "Which oncogene somatic mutations are associated to in situ carcinoma evolution from colonic polyp adenomas?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhich oncogene somatic mutations are associated to in situ carcinoma evolution from colonic polyp adenomas?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['APC, BRAF, EGFR, NRAS, KRAS, PIK3CA, POLE, POLD1, SMAD4, PTEN, and TP53 are oncogene somatic mutations associated to in situ carcinoma evolution from colonic polyp adenomas.', 'Several studies have investigated the association between oncogene somatic mutations and the evolution of in situ carcinoma from colonic polyp adenomas. One study published in the journal Cancer Research found that acquired TP53 or PIK3CA somatic mutations are potential predictors for malignancy development in colorectal adenomas. The study analyzed the genome of 124 polyps and tumors from 40 patients and found that TP53 and PIK3CA mutations were more frequent in tumor tissues than in polyps. Another study published in the journal Gut found that KRAS gene mutations are more common in colorectal villous adenomas and in situ carcinomas than in carcinomas. The study analyzed 134 adenomas, 84 in situ carcinomas, and 171 carcinomas and found that KRAS mutations were present in 61.9% of adenomas, 67.8% of in situ carcinomas, and just 31.6% of carcinomas. These studies suggest that TP53, PIK3CA, and KRAS somatic mutations are associated with the evolution of in situ carcinoma from colonic polyp adenomas.', 'The most common somatic mutations associated to in situ carcinoma evolution from colonic polyp adenomas are the APC, TP53 and KRAS mutations.', 'Somatic mutations in the KRAS, STK11, and BRAF oncogenes are associated with the evolution of colonic polyp adenomas into in situ carcinomas.', 'There are several oncogene somatic mutations that have been associated with the evolution of in situ carcinoma from colonic polyp adenomas. These include mutations in the APC, KRAS, and TP53 genes. The APC gene is a tumor suppressor gene that is often mutated in early stage colon adenomas, while KRAS and TP53 mutations are more commonly found in later stage adenomas and carcinomas. Other genes that have been implicated in this process include BRAF, PIK3CA, and SMAD4. It is important to note that the development and progression of colon cancer is a complex process that involves the accumulation of multiple genetic alterations, and the specific mutations present in any given tumor may vary.', 'Somatic mutations in APC and KRAS are associated to the evolution of in situ carcinoma from colonic polyp adenomas. APC mutations occur at the earliest stages of the adenoma-carcinoma sequence, whereas KRAS mutations appear in the later phases. In addition to these two genes, some publications suggest the relevance of TP53 and PIK3CA in the context of colonic adenocarcinomas.', 'The oncogene somatic mutations associated with the evolution of in situ carcinoma from colonic polyp adenomas include APC, KRAS, and TP53. These genes are involved in the WNT signaling pathway, MAPK signaling pathway, and cell cycle regulation, respectively. The frequency of these mutations increases as the severity of the lesion progresses from low-grade adenoma to high-grade adenoma to in situ carcinoma. However, the presence of any singular mutation is not associated with the occurrence of subsequent adenoma or colorectal cancer (CRC).', 'KRAS gene mutations are more common in colorectal villous adenomas and in situ carcinomas than in carcinomas. TP53 or PIK3CA somatic mutations can be found in tumor tissues but not in polyps, and they are potential predictors for malignancy development. BRAF and KRAS mutations occur early in the putative serrated polyp neoplasia pathway and are associated with acquired mutator and suppressor gene inactivation by CpG island methylation of promoter regions. , In summary, KRAS, TP53, PIK3CA, BRAF, and KRAS mutations are associated with the evolution of in situ carcinoma from colonic polyp adenomas.', 'The oncogene somatic mutations associated to in situ carcinoma evolution from colonic polyp adenomas are KRAS and BRAF.', 'The evolution from colonic polyp adenomas to in situ carcinoma is associated with somatic mutations in oncogenes such as APC, KRAS, and TP53. These mutations play a crucial role in the progression of adenomas to carcinoma by promoting uncontrolled cell growth and inhibiting normal cellular processes. Identifying these mutations can help in understanding the molecular mechanisms underlying this progression and may have implications for early detection and targeted therapies in colorectal cancer.', 'The somatic mutations in the APC (adenomatous polyposis coli) gene are commonly associated with the evolution of in situ carcinoma from colonic polyp adenomas. Mutations in the APC gene lead to dysregulation of the Wnt signaling pathway, resulting in uncontrolled cell proliferation and the development of colorectal cancer.', 'The oncogenes KRAS and BRAF are frequently mutated in colorectal cancer, particularly in serrated lesions that can progress to carcinoma. Somatic mutations in these genes have been associated with the evolution of adenomas into in situ carcinomas. For example, activating mutations in KRAS (e.g., G12D) are common early events in colorectal tumorigenesis and may drive the growth of adenomatous polyps. Subsequent acquisition of additional genetic alterations, including those affecting TP53 or APC genes, can lead to further progression towards invasive carcinoma. BRAF mutations (e.g., V600E) are often found in serrated lesions and have been linked to the development of CpG island methylator phenotype (CIMP)-positive tumors, which are characterized by widespread promoter hypermethylation and a high rate of microsatellite instability (MS', 'Somatic mutations in oncogenes KRAS and BRAF have been linked to the development of in situ carcinoma from colonic polyp adenomas. Studies have shown that KRAS mutations are present in a significant proportion of adenomas, particularly those with dysplasia, and are associated with progression to in situ carcinoma. BRAF mutations have also been detected in a subset of serrated polyps, which can progress to in situ carcinoma. The presence of these oncogene mutations suggests that they play a role in the evolution of adenomas to in situ carcinoma, although the exact mechanisms are not fully understood. Further research is needed to determine the frequency and significance of these mutations in different types of colonic polyps and to explore their potential as markers for early detection and prognosis.', 'The study analyzed the mutational spectrum of well-known genes involved in colorectal cancer (CRC), including APC, BRAF, EGFR, NRAS, KRAS, PIK3CA, POLE, POLD1, SMAD4, PTEN, and TP53, in a large series of 96 adenomas and in situ carcinomas using high-throughput genotyping. The results showed that the frequency of pathogenic variants in these genes was high, with APC, KRAS, and TP53 mutations being the most common. Notably, the frequency of KRAS mutation was associated with the presence of villous histology and methylation of the APC promoter. However, no association was found between the presence of any singular mutation and the occurrence of subsequent adenoma or CRC. The study supports the multistep model of gradual accumulation of mutations, especially in driver genes such as APC, TP53, and KRAS, during the evolution of in situ carcinoma from colonic polyp adenomas.', 'Somatic mutations in the Ki-ras oncogene are associated with the progression of colonic adenomas to in situ carcinomas. Ki-ras mutations occur in approximately 50% of colorectal carcinomas and a similar percentage of intermediate to late-stage adenomas. The frequency of Ki-ras mutations increases with adenoma size, villous histology, and high-grade dysplasia, which are features associated with adenoma progression. In contrast, p53 mutations are more often detected in large, late-stage adenomas containing carcinoma, suggesting they occur later in the adenoma-carcinoma sequence.', 'The most commonly associated oncogene somatic mutations in the evolution of in situ carcinoma from colonic polyp adenomas are mutations in the APC (adenomatous polyposis coli) gene and the KRAS gene. Mutations in the APC gene are early events in the adenoma-carcinoma sequence, leading to dysregulated Wnt signaling and increased cell proliferation. KRAS mutations, on the other hand, occur later in the progression to carcinoma and are associated with increased cell survival and resistance to apoptosis.', 'Loss of heterozygosity (LOH) at chromosome 3p is significantly associated with colorectal cancers arising de novo.', 'The oncogene somatic mutations associated with in situ carcinoma evolution from colonic polyp adenomas are APC, KRAS, and TP53. These genes were found to have higher mutation frequencies in in situ carcinoma samples compared to adenoma samples. Specifically, the APC gene had a mutation frequency of 42.9-56.0% in adenoma samples and 54.5% in in situ carcinoma samples. Similarly, the KRAS gene had a mutation frequency of 32.7-32.0% in adenoma samples and 45.5% in in situ carcinoma samples. The TP53 gene had a mutation frequency of 8.2-20.0% in adenoma samples and 18.2% in in situ carcinoma samples. These findings suggest that these genes play a role in the progression of colonic polyp adenomas to in situ carcinoma.', 'KRAS, PIK3CA, TP53, POLD1, POLE, NRAS, EGFR, and SMAD4 mutations are associated with in situ carcinoma evolution from colonic polyp adenomas.', 'The APC, KRAS, and TP53 genes are somatic mutations associated with the evolution of in situ carcinoma from colonic polyp adenomas.', 'The oncogene somatic mutations associated with in situ carcinoma evolution from colonic polyp adenomas are APC, KRAS, and TP53.', 'The oncogene somatic mutations associated with in situ carcinoma evolution from colonic polyp adenomas are KRAS, TP53, and APC.', 'APC, KRAS, TP53, PIK3CA, NRAS, EGFR, POLD1, and POLE oncogene somatic mutations are associated with in situ carcinoma evolution from colonic polyp adenomas.', 'The oncogene somatic mutations associated with the evolution of in situ carcinoma from colonic polyp adenomas include mutations in the APC, KRAS, and TP53 genes. These mutations were found to have slightly lower frequencies in adenoma samples compared to in situ carcinoma samples, suggesting their potential role in the progression of the disease. Other genes such as BRAF, EGFR, NRAS, PIK3CA, POLE, POLD1, SMAD4, and PTEN may also be involved, but the specific snippets provided do not detail their association with in situ carcinoma evolution from colonic polyp adenomas.', 'The oncogene somatic mutations associated with the evolution of in situ carcinoma from colonic polyp adenomas include mutations in the APC, KRAS, and TP53 genes. These mutations are slightly more frequent in in situ carcinoma samples compared to adenoma samples. Other genes that may be involved include BRAF, EGFR, NRAS, PIK3CA, POLE, POLD1, SMAD4, and PTEN. However, the specific mutation frequencies can vary. For instance, the APC gene mutation frequency ranges from 42.9% to 56.0%, the KRAS gene mutation frequency ranges from 32.7% to 45.5%, and the TP53 gene mutation frequency ranges from 8.2% to 20.0%.', 'KRAS, APC and TP53 are the oncogenes most frequently mutated in colonic adenoma-to-carcinoma sequence. This process can be driven by the genetic alterations of these genes. KRAS mutations seem to be the most common event in these progression followed by APC and TP53 mutations.', 'The APC, KRAS and TP53 mutation frequencies were slightly lower in adenoma samples than in in situ carcinoma samples.', 'The oncogene somatic mutations associated with in situ carcinoma evolution from colonic polyp adenomas are APC, BRAF, EGFR, NRAS, KRAS, PIK3CA, POLE, POLD1, SMAD4, PTEN, and TP53.', 'The oncogene somatic mutations associated with the evolution of in situ carcinoma from colonic polyp adenomas include mutations in the APC, KRAS, TP53, BRAF, and PIK3CA genes. These mutations are known to play a role in the progression from adenoma to carcinoma, with their frequencies found to be slightly lower in adenoma samples than in in situ carcinoma samples.', 'Oncogene somatic mutations associated with in situ carcinoma evolution from colonic polyp adenomas include KRAS, BRAF, and TP53. These mutations are commonly found in adenomatous polyps and are thought to drive the progression of these lesions to invasive cancer. Other genes, such as APC, SMAD4, and MSH2, may also be mutated in this process.', 'The abstract describes a study investigating the mutation profile of driver genes in colorectal adenomas and in situ carcinomas. The research found that the APC, KRAS, and TP53 genes had lower mutation frequencies in adenoma samples compared to in situ carcinoma samples. Specifically, the frequency distribution for these genes among low-grade adenomas, high-grade adenomas, and in situ carcinomas were: APC (42.9%, 56.0%, 54.5%), KRAS (32.7%, 32.0%, 45.5%), and TP53 (8.2%, 20.0%, 18.2%). However, the study did not find any association between the presence of singular mutations and the occurrence of subsequent adenoma or colorectal cancer (CRC). The data supports a multistep model of gradual accumulation of mutations in driver genes, such as APC, TP53, and KRAS, during the evolution from colonic polyp adenomas to in situ carcinomas. Therefore, somatic mutations in APC, KRAS, and TP53 are associated with the evolution of in situ carcinoma from colonic polyp adenomas.', 'The evolution of in situ carcinoma from colonic polyp adenomas is associated with several oncogene somatic mutations. These include mutations in the APC, KRAS, and TP53 genes. Other genes that may be involved are BRAF, EGFR, NRAS, PIK3CA, POLE, POLD1, SMAD4, and PTEN. The mutation frequencies of APC, KRAS, and TP53 were found to be slightly lower in adenoma samples than in in situ carcinoma samples, indicating their potential role in the progression of the disease', 'The oncogene somatic mutations associated with the evolution from colonic polyp adenomas to in situ carcinoma include mutations in the APC, KRAS, and TP53 genes. The frequencies of these mutations were slightly lower in adenoma samples compared to in situ carcinoma samples. Additionally, mutations in genes such as BRAF, EGFR, NRAS, PIK3CA, POLE, POLD1, SMAD4, and PTEN were also observed in the study.', 'The somatic mutations in the APC, KRAS, and TP53 oncogenes are associated with the evolution of in situ carcinoma from colonic polyp adenomas. The mutation frequencies of these genes were slightly lower in adenoma samples compared to in situ carcinoma samples. Specifically, the frequency distribution of mutations based on grade was as follows: APC gene - low-grade adenoma: 42.9%, high-grade adenoma: 56.0%, in situ carcinoma: 54.5%; KRAS gene - low-grade adenoma: 32.7%, high-grade adenoma: 32.0%, in situ carcinoma: 45.5%; TP53 gene - low-grade adenoma: 8.2%, high-grade adenoma: 20.0%, in situ carcinoma: 18.2%. Therefore, these oncogene mutations play a role in the multistep model of gradual accumulation of mutations leading to the development of in situ carcinoma from colonic polyp adenomas.', 'The somatic mutations associated with in situ carcinoma evolution from colonic polyp adenomas are APC, KRAS, and TP53.', 'The APC, KRAS, and TP53 gene mutation frequencies were found to be slightly lower in adenoma samples compared to in situ carcinoma samples. These findings suggest that alterations in these genes might play a role in the progression from adenomatous polyps to colorectal cancer.', 'The study found that the frequency of pathogenic variants in well-known genes involved in colorectal cancer (CRC) was high in a large series of adenomas and in situ carcinomas. The APC, KRAS, and TP53 mutation frequencies were slightly lower in adenoma samples than in in situ carcinoma samples. The occurrence of KRAS mutation was associated with villous histology, and methylation of the APC promoter was associated with POLE genetic variations. However, no association was found between any singular mutation and the occurrence of subsequent adenoma or CRC. The data supports the multistep model of gradual accumulation of mutations, especially in driver genes such as APC, TP53, and KRAS, during the transition from colonic polyp adenomas to in situ carcinoma.', 'APC, KRAS and TP53 somatic mutations are associated with the evolution of colonic polyp adenomas to in situ carcinomas. The mutation frequencies of these genes were slightly lower in adenoma samples compared to in situ carcinoma samples, suggesting their role in the progression from adenoma to carcinoma.', 'The oncogene somatic mutations associated with the evolution of in situ carcinoma from colonic polyp adenomas are APC, KRAS, and TP53.', 'The oncogene somatic mutations associated with in situ carcinoma evolution from colonic polyp adenomas include APC, KRAS, and TP53 mutations, with frequencies slightly lower in adenoma samples compared to in situ carcinoma samples.', 'The APC, KRAS, and TP53 mutations are associated with in situ carcinoma evolution from colonic polyp adenomas.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the data, the following oncogene somatic mutations are associated with the evolution of in situ carcinoma from colonic polyp adenomas:\n\n1. KRAS mutations: The KRAS gene is often mutated in colonic polyps and is associated with the progression of adenomas to carcinomas.\n2. BRAF V600E mutations: The BRAF V600E mutation is a common mutation in colorectal cancer and is associated with the development of colorectal cancer, including the evolution of adenomas to carcinomas.\n3. PIK3CA mutations: The PIK3CA gene is involved in the PI3K/AKT signaling pathway and is associated with the development of colorectal cancer, including the evolution of adenomas to carcinomas.\n\nThese mutations are commonly found in colonic polyps and are associated with the progression of adenomas to carcinomas. However, it's worth noting that the presence of these mutations does not necessarily predict the development of carcinoma, and other factors such as environmental and lifestyle factors, as well as other genetic mutations, also play a role in the evolution of adenomas to carcinomas.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer correctly identifies KRAS, BRAF V600E, and PIK3CA as somatic mutations associated with the evolution of in situ carcinoma from colonic polyp adenomas. However, it misses several other key mutations mentioned in the reference answers, such as APC, TP53, EGFR, NRAS, POLE, POLD1, SMAD4, PTEN, and others. Thus, while it captures some important information, it is incomplete.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise in identifying specific mutations (KRAS, BRAF V600E, PIK3CA) and their roles in the adenoma-carcinoma sequence. However, it includes a brief note at the end about environmental and lifestyle factors, which, while relevant to the broader context of colorectal cancer, slightly detracts from the precision of the answer focused on somatic mutations.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information. Each mutation is described once with its associated role in the progression of colonic polyps to carcinomas.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clearly written, and easy to follow. The use of bullet points enhances readability, and the language is fluent and appropriate for the topic."
    },
    {
        "Question": "What is prurigo nodularis?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is prurigo nodularis?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Prurigo nodularis (PN) is a chronic neuroimmune skin disease characterized by bilaterally distributed pruritic hyperkeratotic nodules on extremities and trunk.  The lesions are very pruritic and the condition may occur in any age group.', \"Prurigo nodularis is a chronic skin condition characterized by the development of multiple intensely itchy nodules. It's associated with severe itching and can occur due to various underlying conditions, including dermatological, systemic, neurological, or psychiatric issues.\", 'Prurigo nodularis is a chronic inflammatory skin condition characterized by the presence of pruritic nodules.', 'Prurigo nodularis (PN) is a chronic skin disease that manifests with severe itchy, firm, hyperkeratotic nodules distributed on the trunk and the extremities symmetrically.', 'Prurigo nodularis (PN) is a debilitating inflammatory skin disease characterized by red to violaceous pruritic lesions.', 'Prurigo nodularis (PN) is a chronic neuroimmune skin disease characterized by bilaterally distributed pruritic hyperkeratotic nodules on extremities and trunk.', 'Prurigo nodularis is a chronic neuroimmune skin disease characterized by bilaterally distributed pruritic hyperkeratotic nodules on extremities and trunk.', 'chronic neuroimmune skin disease characterized by bilaterally distributed pruritic hyperkeratotic nodules on extremities and trunk', 'Prurigo nodularis (PN) is a chronic neuroimmune skin disease characterized by bilaterally distributed pruritic hyperkeratotic nodules on extremities and trunk. It is an understudied inflammatory skin disease that is characterized by intense itching, hyperkeratosis, and the formation of nodules. The exact cause of PN is unknown, but it is believed to be associated with a dysregulated immune response and possible genetic predisposition. The disease can have a significant impact on quality of life due to its chronic nature, physical discomfort, and emotional distress. Treatment options for PN are limited and often focus on managing symptoms rather than addressing the underlying cause.', 'Prurigo nodularis is an understudied inflammatory skin disease characterized by pruritic, hyperkeratotic nodules.', 'Prurigo nodularis (PN) is a chronic, inflammatory skin disease characterized by pruritic, hyperkeratotic nodules that are bilaterally distributed on the extremities and trunk.', 'Prurigo nodularis (PN) is a chronic neuroimmune skin disease. It is characterized by pruritic, hyperkeratotic nodules that are distributed bilaterally on the extremities and trunk. It is an inflammatory skin condition that is extremely itchy.', 'Prurigo nodularis is an extremely pruritic, chronic inflammatory skin disease characterized by bilaterally distributed pruritic hyperkeratotic nodules on extremities and trunk.', 'Prurigo nodularis is a chronic neuroimmune skin disease characterized by pruritic hyperkeratotic nodules on extremities and trunk.', 'Prurigo nodularis (PN) is a chronic neuroimmune skin disease characterized by bilaterally distributed pruritic hyperkeratotic nodules on extremities and trunk. It is an understudied inflammatory skin disease characterized by pruritic, hyperkeratotic nodules.', 'Prurigo nodularis (PN) is a chronic inflammatory skin condition characterized by the presence of itchy, firm nodules that are often hyperkeratotic and distributed bilaterally on the extremities and trunk.', 'Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by extremely pruritic (itchy), hyperkeratotic (thickened skin) nodules that are typically distributed bilaterally on the extremities and trunk.', 'Prurigo nodularis (PN) is a chronic skin disease characterized by itchy, raised bumps on the arms, legs, and trunk.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nPrurigo nodularis is a chronic inflammatory skin disease characterized by the presence of intensely pruritic, hyperkeratotic nodules on the skin. It is a rare condition that can be debilitating for patients, causing significant distress and impairment in daily life. The exact cause of prurigo nodularis is not fully understood, but it is believed to involve neuroimmune dysregulation and chronic scratching.\n\nSymptoms of prurigo nodularis include:\n\n* Intensely itchy, hyperkeratotic nodules on the skin\n* Pruritus (itching) that can be severe and debilitating\n* Skin lesions that can be localized or generalized\n* Nodules that can be symmetrically distributed on the trunk and extremities\n\nPrurigo nodularis can be associated with various dermatological, systemic, neurological, and psychiatric conditions, and it is more common in individuals with a history of atopic dermatitis or other skin conditions.\n\nThere is currently no approved therapy for prurigo nodularis, but treatment options include topical corticosteroids, capsaicin, calcineurin inhibitors, ultraviolet (UV) therapy, and systemic administration of antihistamines, anticonvulsants, mu-opioid receptor antagonists, and immunosuppressants. Multimodal therapy is often used to achieve optimal results.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers all necessary details about prurigo nodularis, including its definition, symptoms, associated conditions, and treatment options. It aligns well with the reference answers, providing a thorough overview of the condition.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and sticks to the relevant details about prurigo nodularis. There is no irrelevant information, and every point made is pertinent to understanding the condition.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer avoids repetition and presents information in a clear, concise manner. Each point is distinct and adds new information, ensuring there is no redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to read. It uses clear language and bullet points to enhance readability, making it accessible to a wide audience."
    },
    {
        "Question": "What is the main cause of spillover events?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the main cause of spillover events?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The main cause of spillover events is the disruption of habitats of the reservoir species.', 'The main causes of spillover events include human land modification, domestication, horizontal gene transfer, microbial succession, climate change, biodiversity loss, and globalization.', 'The main cause of spillover events and emerging infectious diseases is cross-species transmission of pathogens, particularly from animals to humans (zoonoses). Key drivers that facilitate this process include:\\n\\n1. Increased contact and sharing of space between wildlife, humans, and domesticated animals, often due to human intrusion into natural habitats.\\n\\n2. Agricultural intensification, animal trade, and certain herd management practices.\\n\\n3. High mutation and recombination rates in some viruses (e.g., coronaviruses) that enable host jumping and adaptation to new species.\\n\\n4. Specific human behaviors, such as hunting, butchering, and consuming wild animal meat, especially in hotspots like bushmeat markets.\\n\\n5. Domestication of wild animals as pets or for other purposes, bringing them into close proximity with humans.\\n\\nIn summary, the growing human-animal interface, coupled with the ability of some pathogens to adapt to new hosts, is the key driver of zoonotic spillover events.', 'The main cause of spillover events is the interaction between wildlife, domestic animals, and humans, often influenced by factors such as habitat loss, agricultural practices, and land use for food production. Spillover events occur when pathogens are transmitted from one species to another, leading to potential outbreaks of zoonotic diseases. Factors like habitat destruction and encroachment into wildlife areas can increase the risk of spillover events, highlighting the importance of understanding and managing these interactions to prevent disease transmission.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided tables and sources, the main cause of spillover events is not explicitly stated in a single source. However, several sources suggest that environmental disturbances, such as habitat fragmentation, biodiversity loss, and human activities that alter the environment, increase the risk of spillover events. \n\nSource 12, \"Synthesizing the connections between environmental disturbances and zoonotic spillover,\" states that anthropogenic disturbances in the environment, such as deforestation, habitat fragmentation, and wildlife exploitation, lead to changes in ecological niches, increased contact between humans and other animals, and changes in the incidence and load of pathogens in animal populations, all of which can increase the risk of spillover events.\n\nSource 5, \"Whence the next pandemic? The intersecting global geography of the animal-human interface, poor health systems and air transit centrality reveals conduits for high-impact spillover,\" suggests that the intersection of animal-human interfaces, poor health systems, and global connectivity via air travel increases the risk of high-impact spillover events.\n\nSource 6, \"Domestication and microbiome succession may drive pathogen spillover,\" proposes that domestication, horizontal gene transfer, and microbiome succession are essential in the process of pathogen spillover.\n\nTherefore, while there is no single main cause of spillover events, environmental disturbances and human activities that alter the environment appear to be significant contributors to the risk of spillover events.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer provides a comprehensive view of the causes of spillover events, citing multiple sources that cover environmental disturbances, human activities, and biological factors. While it does not explicitly state a single main cause, it aggregates several key points from the reference answers, such as habitat fragmentation, biodiversity loss, and human-animal interface.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise, focusing only on the causes of spillover events without introducing irrelevant information. It accurately summarizes the key points from the sources provided and avoids tangential details.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. Each point is distinct and contributes to a broader understanding of the causes of spillover events.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-structured and fluent, making it easy to follow. The use of source references adds credibility but slightly disrupts the flow. Overall, it is readable but could be slightly improved for smoother transitions."
    },
    {
        "Question": "What are the most commonly used pain scales for the measurement of pain in ICU?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are the most commonly used pain scales for the measurement of pain in ICU?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The most common pain scales used to measure pain in ICU are the following: critical-care pain observation tool (CPOT) and behavioral pain scale (BPS).', 'The Behavioral Pain Scale and the Critical-Care Pain Observation Tool are the most commonly used scales for measuring pain in ICU patients.', 'The two pain measurement tools that are most commonly used in intensive care units for the assessment of pain are the Numeric Rating Scale (NRS) and the Critical-Care Pain Observation Tool (CPOT). Other tools are Visual Analogue Scale (VAS), Verbal Rating Scale (VRS) and the Faces Pain Scale (FPS).', 'For self-reported pain in ICU patients, the NRS is the most common pain scale, with most studies reporting it as the first choice, and the VAS is the second most common scale.\\nFor critically ill, non-communicative, or sedated ICU patients, behavioural pain scales are preferred.', 'The most commonly used pain scales for the measurement of pain in ICU are the Numeric Rating Scale (NRS), the Visual Analog Scale (VAS), the Behavioral Pain Scale (BPS), and the Critical Care Pain Observation Tool (CPOT).', 'The most commonly used pain scales for measuring pain in ICU patients include the Behavioral Pain Scale (BPS), Critical Care Pain Observation Tool (CPOT), Non-verbal Pain Scale (NVPS), and the Confusion Assessment Method for the ICU (CAM-ICU). The BPS and CPOT are considered to be the most valid and reliable for this purpose, according to available evidence.', 'The most commonly used pain scales for the measurement of pain in ICU are the Numerical Rating Scale (NRS), the Visual Analog Scale (VAS), the Behavioral Pain Scale (BPS) and the Critical Care Pain Observation Tool (CPOT).', 'The most commonly used pain scales for the measurement of pain in the ICU are the Critical Care Pain Observation Tool (CPOT), the Behavioral Pain Scale (BPS), the Visual Analog Scale (VAS), and the Face, Legs, Activity, Cry, Consolability (FLACC) Behavioral Scale.', 'The most commonly used pain scales for the measurement of pain in ICU include the Visual Analog Scale (horizontal and vertical line orientation), the Verbal Descriptor Scale, the 0-10 oral Numeric Rating Scale, the 0-10 visually enlarged laminated Numeric Rating Scale, the Critical-Care Pain Observation Tool, the Behavioral Pain Scale, and the Nonverbal Adult Pain Assessment Scale.', 'The most commonly used pain scales for the measurement of pain in the ICU include the Critical Care Pain Observation Tool (CPOT), Behavioral Pain Scale (BPS), Visual Analog Scale (VAS), Verbal Descriptor Scale (VDS), Numeric Rating Scale (NRS), Face, Legs, Activity, Cry, Consolability (FLACC) Behavioral Scale, Glasgow composite pain scale, and Neonatal Pain, Agitation, and Sedation Scale (N-PASS) and Neonatal Infant Pain Scale (NIPS) for infants.', 'The most commonly used pain scales for the measurement of pain in ICU are the Critical-care pain observation tool (CPOT) and the behavioral pain scale (BPS).', 'The Behavioral Pain Scale (BPS) and the Critical-Care Pain Observation Tool (CPOT) are the most valid and reliable pain assessment instruments developed to objectively assess pain in sedated intensive care patients.', 'Critical Care Pain Observation Tool (CPOT) and the Behavioral Pain Scale (BPS)', 'CPOT, BPS, and the Behavioral Pain Scale are commonly used for the measurement of pain in ICU.', 'The two most commonly used pain scales for the measurement of pain in ICU are the Behavioral Pain Scale (BPS) and the Critical Care Pain Observation Tool (CPOT).', 'The most commonly used pain scales for measuring pain in the ICU are the Behavioral Pain Scale (BPS) and the Critical Care Pain Observation Tool (CPOT).', 'The most commonly used pain scales for the measurement of pain in ICU are the Behavioral Pain Scale (BPS) and the Critical Care Pain Observation Tool (CPOT).', 'The most commonly used pain scales for the measurement of pain in ICU include the Critical Care Pain Observation Tool (CPOT), Behavioral Pain Scale (BPS), BPS, CPOT, Zurich Observation Pain Assessment (ZOPA), Behavioral Pain Scale, and Numeric Rating Scale (NRS).', 'The most commonly used pain scales for the measurement of pain in ICU are the critical-care pain observation tool (CPOT) and the behavioral pain scale (BPS).', 'The Behavioral Pain Scale and the Critical Care Pain Observation Tool are the most commonly used scales for assessing pain in ICU patients, with Zurich Observation Pain Assessment also being used.', 'The most commonly used pain scales for the measurement of pain in ICU are the Critical Care Pain Observation Tool (CPOT) and the Behavioral Pain Scale (BPS).', 'The most commonly used pain scales for the measurement of pain in the ICU are the Critical Care Pain Observation Tool (CPOT) and the Behavioral Pain Scale (BPS). These scales have been validated and are recommended for use in patients who are unable to self-report their pain, such as those who are sedated, intubated, or mechanically ventilated.', 'The most commonly used pain scales for the measurement of pain in ICU are the Critical-Care Pain Observation Tool (CPOT) and the Behavioral Pain Scale (BPS).', 'The two most commonly used pain scales for measuring pain in critically ill patients in the ICU who are unable to self-report pain are the Behavioral Pain Scale (BPS) and the Critical Care Pain Observation Tool (CPOT). Both scales have been validated for assessing pain intensity in mechanically ventilated and unconscious ICU patients.', 'The most commonly used pain scales for the measurement of pain in ICU are the Critical-care pain observation tool (CPOT), Behavioral pain scale (BPS), and Zurich Observation Pain Assessment (ZOPA).', 'The most commonly used pain scales for the measurement of pain in the ICU are the Behavioral Pain Scale (BPS) and the Critical Care Pain Observation Tool (CPOT). These scales have been validated and shown to have good validity and reliability in assessing pain in nonverbal and mechanically ventilated ICU patients.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the most commonly used pain scales for the measurement of pain in ICU are:\n\n1. **Critical Care Pain Observation Tool (CPOT)**: Used in 12 studies, with a total of 101 patients evaluated, and found to have good criterion and discriminant validity.\n2. **Behavioral Pain Scale (BPS)**: Used in 10 studies, with a total of 90 patients evaluated, and found to have good criterion and discriminant validity.\n3. **Zurich Observation Pain Assessment (ZOPA)**: Used in 1 study, with 24 patients evaluated, and found to be concordant with the BPS and CPOT in detecting pain in nonverbal ICU patients.\n4. **Visual Analog Scale (VAS)**: Used in 1 study, with 41 conscious patients evaluated, and found to be correlated with both CPOT and BPS scores.\n\nThese pain scales are widely used in the ICU setting due to their ability to assess pain in patients who are unable to self-report, such as those who are sedated, intubated, or mechanically ventilated.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer recalls most of the key pain scales mentioned in the reference answers, including CPOT, BPS, ZOPA, and VAS. However, it does omit some scales like NRS, FLACC, and others that were mentioned in the references. The inclusion of details like the number of studies and patients evaluated adds depth.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise, focusing only on the pain scales relevant to the ICU setting and their utility. It avoids irrelevant details, sticking closely to the topic without unnecessary digression.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of the same information. Each pain scale is introduced clearly with its own details and relevance, ensuring the information is concise and non-repetitive.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clear, and fluent. The use of bullet points and specific details enhances readability, making it easy to follow and understand."
    },
    {
        "Question": "What medication were tested in the PEMMELA trial?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat medication were tested in the PEMMELA trial?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['PEMMELA was a single-arm phase 2 study that tested pembrolizumab plus lenvatinib as second-line and third-line for patients with pleural mesothelioma.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, I could not find any information on a trial called \"PEMMELA\".\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "1",
        "Information Recall Explanation": "The answer fails to recall any information about the 'PEMMELA' trial, despite the reference answer clearly stating the medications tested (pembrolizumab plus lenvatinib).",
        "Information Precision Score": "1",
        "Information Precision Explanation": "The answer is precise in stating that no information was found, but this precision is misplaced as it does not address the actual query or reference answer correctly.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition of information in the answer.",
        "Readability Score": "4",
        "Readability Explanation": "The answer is clear and fluent, but its failure to address the actual question lowers its effectiveness."
    },
    {
        "Question": "What is the pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Perturbations of the colonic microbiota can contribute to the initiation and progression of colorectal cancer, leading to an increase in pathogenic bacteria as Bilophila wadsworthia, as well as Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum. This can contribute to disease through increasing carcinogenic metabolite/toxin production, inducing inflammation, and activating oncogenic signaling. On the other hand, pathogenic bacteria have heightened iron acquisition mechanisms.', 'The pathophysiological mechanism by which the microbiota produces malignant lesions in colonic mucosa involves several steps: , 1. Dysbiosis: An imbalance of the gut microbiota, characterized by an overgrowth of harmful bacteria and a decrease in beneficial bacteria., 2. Inflammation: The dysbiotic microbiota triggers chronic inflammation in the colonic mucosa, leading to the activation of pro-inflammatory cytokines and the production of reactive oxygen species (ROS)., 3. DNA damage: The chronic inflammation caused by the dysbiotic microbiota leads to DNA damage, mutations, and epigenetic changes in the colonic epithelial cells., 4. Malignant transformation: The accumulation of DNA damage and epigenetic changes can eventually lead to the transformation of colonic epithelial cells into cancer cells, resulting in the formation of malignant lesions., 5. Immune evasion: Cancer cells can evade the host immune system by suppressing immune responses or producing immune suppressive factors, allowing them to progress and metastasize. , In summary, the pathophysiological mechanism by which the microbiota produces malignant lesions in colonic mucosa involves dysbiosis, inflammation, DNA damage, malignant transformation, and immune evasion.', '1) Interactions between the gut microbiota and epithelial cells:\\ni) Microbiota-associated enzymes can cleave the glycan portions of mucin, thereby generating free oligosaccharides that can serve as a source of carbon and energy for commensal bacteria. Mucin glycosylation in the colon is altered by bacterial colonization, resulting in differences in mucin glycosylation in the healthy and diseased gut.\\nii) Microbiota-associated enzymes can modify epigenetic regulators in colonic epithelial cells by altering cellular metabolism.\\niii) Bacterial metabolites (such as phenol, p-cresol, indole, and their derivatives) can enter systemic circulation and lead to cancer development.\\n2) Interactions between the gut microbiota and the host immune system:', 'The pathophysiological mechanism involves a diet-associated shift in gut microbiota, known as the microbial sulfur diet, which causes injuries and inflammation to the colonic mucosa. This inflammatory environment fosters conditions conducive to the development of colorectal cancer (CRC).', 'The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa is through bacterial accumulation in the lamina propria, leading to reductions in Tuft cells, goblet cells, and the mucus barrier of the colonic epithelium. This is due to bacterial induction of prostaglandin production by myeloid cells.', '1) The microbiota is the microorganisms that inhabit our body, and is responsible for producing an environment rich in bacterial products such as amino acids, short-chain fatty acids, indoles, vitamins, gases, and lipopolysaccharides.\\n2) Indoles produced by microbiota can cause an increase in the level of intestinal inflammation, and lipopolysaccharides can lead to changes in the intestinal epithelial layer, allowing the passage of bacterial products, stimulating oncogenic pathways.\\n3) Bacterial products produced by the microbiota are implicated in the development and progression of CRC by inducing DNA damage, activation of proto-oncogenes, inhibition of tumour suppressor genes, induction of angiogenesis, and stimulation of local inflammation.\\n4) The interaction between the microbiota', 'In order to induce malignant lesions in the colon, gut microbes need to promote chromosomal instability by favoring conditions for accumulation of replication errors, and producing mutagenic and inflammatory metabolites. In addition, these microbes produce anaerobic hydrogen sulfide, which inhibits DNA repair pathways in epithelial cells, leading to aneuploidy and chromosomal instability. In addition, microbes may interact with dietary substances to produce mutagenic compounds, such as heterocyclic aromatic amines, and genotoxins, which produce DNA strand breaks, alkylating agents and hydrogen peroxide that can cause oxidative damage to DNA.', 'The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa is bacterial accumulation in the lamina propria and bacterial induction of prostaglandin production by myeloid cells.', \"The microbiota's pathophysiological mechanism for producing malignant lesions in colonic mucosa involves several key processes, including the generation of reactive metabolites and carcinogens, alterations in host carbohydrate expression, and induction of chronic mucosal inflammation. A diet-associated shift in gut microbiota, known as the microbial sulfur diet, can provoke injuries and inflammation to the colonic mucosa, partly explaining the rising incidence of early-onset colorectal cancer (EOCRC). This shift is influenced by an animal-based diet, which causes a disruption in the homeostasis of hydrogen sulfide concentration due to bacterial sulfur metabolism. Gut microbial and fungal profiles in patients with colorectal adenomas with low-grade dysplasia (ALGD) show alterations compared to normal controls, contributing to the development of intestinal cancer by regulating specific metabolic pathways. Mucosal samples are more relevant for evaluating microbiota's pathophysiological involvement in CRC carcinogenesis, while non-invasive stool sampling could be beneficial for early CRC detection strategies. The gut microbiome, encompassing bacteria, viruses, fungi, and other microbes, plays a critical role in colon cancer development through various mechanisms and metabolites. Understanding the mechanisms of microbiome-colon cancer interactions can provide insights into effective prevention and treatment approaches for colon cancer.\", \"The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves several interconnected processes. Firstly, the gut microbiome influences the host's nutrition and immune system, and an imbalance in the microbiota, also known as dysbiosis, can lead to the development of harmful bacteria that can damage the colonic mucosa. Secondly, certain members of the colonic microbiota have been shown to produce reactive metabolites and carcinogens, such as trimethylamine-N-oxide (TMAO), which can alter host cellular metabolism and promote the growth of cancer cells. Thirdly, the colonic microbiota can also induce chronic mucosal inflammation, which creates an environment conducive to the progression of malignant lesions. Lastly, alterations in host carbohydrate expression can also contribute to the development of colorectal cancer. Overall, the pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves a complex interplay between the host and the gut microbiome, highlighting the importance of maintaining a healthy balance of gut bacteria to prevent the development of colorectal cancer.\", 'The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves bacterial accumulation in the lamina propria, leading to bacterial induction of prostaglandin production by myeloid cells. This process results in reductions in Tuft cells, goblet cells, and the mucus barrier of the colonic epithelium in the normal colonic mucosa.', 'The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa is not fully understood. However, dysbiosis in the gut microbiota, characterized by an imbalance in the composition and function of the microbial community, has been implicated in the pathogenesis of colorectal cancer. Specific bacterial species, such as Fusobacterium nucleatum, have been associated with the development and progression of colorectal cancer through various mechanisms, including inflammation, immune modulation, and alteration of the tumor microenvironment.', 'The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves various factors and processes, including alterations in the gut microbiota composition, inflammation, genotype-related causes, and host responses. The gut microbiota can potentially induce colorectal carcinoma through mechanisms such as producing pro-inflammatory cytokines or metabolites that promote tumor growth and survival, altering the colonic interleukin levels, and modulating the mucosal host defense system. Additionally, gut microbiota can influence the development of intestinal lesions by regulating butyrate production, which is essential for maintaining intestinal homeostasis. Furthermore, certain bacteria or their metabolites may contribute to immunosuppression and damage to the intestinal mucosa, leading to an increased risk of colore', 'The pathophysiological mechanism by which the microbiota produces malignant lesions in colonic mucosa is complex and involves multiple steps. The gut microbiome influences the development of colorectal cancer (CRC) through several mechanisms, including the production of carcinogens, inflammation, immune response, and competition for nutrients. The gut microbiota can produce carcinogens, such as nitrosamines, through nitrogen reduction and ammonia production, which can lead to DNA damage and mutations in colonic epithelial cells. Additionally, the gut microbiome influences the immune response by modulating T cell function, cytokine production, and anti-tumor immunity. Dysbiosis, an imbalance of the gut microbiota, can also lead to increased inflammation in the colonic mucosa, promoting a pro-tumorigenic environment. Furthermore, bacterial overgrowth, especially of sulfur-reducing bacteria, can produce hydrogen sulfide, which has been linked to CRC development. Hydrogen sulfide can cause DNA damage and inhibit the function of tumor suppressor proteins, leading to uncontrolled cell growth and proliferation. Competition for nutrients between commensal bacteria and the host can also contribute to malignant transformation. Overall, the gut microbiome plays a critical role in CRC development through multiple pathways, emphasizing the importance of understanding the relationship between the gut microbiome and colonic mucosa health.', 'The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves several steps. High-fat, high-protein, low-fiber diets can cause an unfavorable microbial environment in the human colon, predisposing some individuals towards large bowel diseases. The irregular emptying of rapidly fermentable ileal digesta into the colon causes a surge in microbial activity. The sudden availability of rapidly fermentable substrate generates a large microbial population that soon depletes its substrate. For microorganisms to perpetuate, they must induce enzymes to ferment dying or dead microbes (cannibalism) in addition to colonic epithelial mucosa and mucins. As the carbohydrate-to-nitrogen ratio of the colonic contents decreases, the fermentation becomes more proteolytic and subacute levels of fermentation products such as ammonia may be generated. Carcinogens are concentrated within a small colonic mass and the probability of precancerous lesions and polyps developing in the colonic mucosa is directly related to the severity, frequency, and duration of these microbial \"feast or famine\" situations in the colon.\\n\\nCertain bacteria, such as Escherichia coli, have acquired the ability to induce chronic inflammation and/or produce toxins, such as cyclomodulin, which could participate in the carcinogenesis process. An increased level of mucosa-associated and internalized E. coli was observed in the tumors', 'A diet-associated shift in gut microbiota, called the microbial sulfur diet, provokes injuries and inflammation to the colonic mucosa through bacterial sulfur metabolism, contributing to the development of colorectal cancer (CRC).', 'The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa is not fully understood. However, dysbiosis in the gut microbiota, characterized by an imbalance in the composition and function of the microbial community, has been implicated in the development of colorectal cancer. Specific changes in the gut microbiome can lead to chronic inflammation, alteration of the intestinal barrier function, production of genotoxic metabolites, and modulation of the immune response, all of which contribute to the initiation and progression of malignant lesions in the colonic mucosa.', 'The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves a complex interplay between the gut microbiome and the host immune system. Perturbations in the balance of protective and pathogenic bacteria can lead to an overgrowth of harmful microorganisms, which can produce carcinogenic metabolites/toxins, induce inflammation, and activate oncogenic signaling pathways. This can ultimately result in the development of malignant lesions in the colonic mucosa. The outcompetition of protective bacteria by pathogenic bacteria, such as sulfidogenic bacteria and Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum, can also contribute to the development of colon cancer.', 'Perturbations of the colonic microbiota can contribute to the initiation and progression of colorectal cancer by increasing pathogenic bacteria at the expense of protective bacteria, leading to heightened production of carcinogenic metabolites/toxins, induction of inflammation, and activation of oncogenic signaling pathways.', 'Perturbations of the colonic microbiota can contribute to the initiation and progression of colorectal cancer through several mechanisms. These include an increase in pathogenic bacteria at the expense of protective bacteria, leading to an increase in carcinogenic metabolite/toxin production, inducing inflammation, and activating oncogenic signaling. Pathogenic bacteria have heightened iron acquisition mechanisms and tend to outcompete protective bacteria for free iron. Alterations in communication between the mucosal immune system and gut microbial communities have been implicated as the core defect that leads to chronic intestinal inflammation and cancer development. Multiple proposed pathogenic microorganisms, such as sulfidogenic bacteria including Bilophila wadsworthia, as well as Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum, have been associated with colorectal cancer.', 'The pathophysiological mechanism involves perturbations of the colonic microbiota, leading to an increase in pathogenic bacteria. These bacteria produce carcinogenic metabolites/toxins, induce inflammation, and activate oncogenic signaling. Additionally, they outcompete protective bacteria for free iron, and alterations in communication between the mucosal immune system and gut microbial communities can lead to chronic intestinal inflammation and cancer development.', 'The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves perturbations of the colonic microbiota leading to an increase in pathogenic bacteria at the expense of protective bacteria, which can contribute to disease through increasing carcinogenic metabolite/toxin production, inducing inflammation, and activating oncogenic signaling. Additionally, alterations in communication between the mucosal immune system and gut microbial communities have been implicated as the core defect that leads to chronic intestinal inflammation and cancer development.', '”The primary treatment for major depressive disorder (MDD) in the PEMMELA (Paroxetine/Fluoxetine) trial was duloxetine and fluoxetine. Participants were randomly assigned to receive either paroxetine or fluoxetine. The medications were given in a dosing range of 40-80mg/day for paroxetine/fluoxetine (dosed 3 times a week for 8 weeks, then 1 time a week for 4 weeks, and then dosed 1 time a day for the maintenance period) or placebo, for up to 13 weeks.”}</s>', 'Perturbations of the colonic microbiota can contribute to the initiation and progression of colorectal cancer by increasing pathogenic bacteria at the expense of protective bacteria, leading to enhanced production of carcinogenic metabolites/toxins, induction of inflammation, and activation of oncogenic signaling pathways.', 'The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves several steps. First, perturbations in the colonic microbiota can lead to an increase in pathogenic bacteria and a decrease in protective bacteria. These pathogenic bacteria often have heightened iron acquisition mechanisms, allowing them to outcompete the protective bacteria. This imbalance can contribute to disease by increasing the production of carcinogenic metabolites and toxins. Additionally, these changes can induce inflammation and activate oncogenic signaling. Furthermore, alterations in communication between the mucosal immune system and gut microbial communities can lead to chronic intestinal inflammation and cancer development. Some of the proposed pathogenic microorganisms include sulfidogenic bacteria such as Bilophila wadsworthia, Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum.', 'The pathophysiological mechanism involves perturbations in the colonic microbiota, leading to an increase in pathogenic bacteria and a decrease in protective bacteria. This imbalance can contribute to colorectal cancer initiation and progression. Pathogenic bacteria, which have heightened iron acquisition mechanisms, can outcompete protective bacteria for free iron. This can lead to increased production of carcinogenic metabolites and toxins, induction of inflammation, and activation of oncogenic signaling. Additionally, alterations in communication between the mucosal immune system and gut microbial communities can lead to chronic intestinal inflammation and cancer development. Certain pathogenic microorganisms, such as Bilophila wadsworthia, Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum, have been implicated in this process.', 'The microbiota is involved in colorectal cancer. The proliferation of pathogenic bacteria leads to a decrease of beneficial bacteria, thereby increasing the production of carcinogenic metabolites and toxins, activating inflammation and oncogenic signaling.', 'The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves perturbations in the colonic microbiota that lead to an increase in pathogenic bacteria at the expense of protective bacteria. This can contribute to disease through increasing carcinogenic metabolite/toxin production, inducing inflammation, and activating oncogenic signaling. Most pathogenic bacteria have heightened iron acquisition mechanisms and therefore tend to outcompete protective bacteria for free iron. Alterations in communication between the mucosal immune system and gut microbial communities have been implicated as the core defect that leads to chronic intestinal inflammation and cancer development. Multiple proposed pathogenic microorganisms, including sulfidogenic bacteria such as Bilophila wadsworthia, as well as Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum, have been implicated in this process.', 'The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves several steps. Perturbations in the colonic microbiota lead to an increase in pathogenic bacteria and a decrease in protective bacteria. These pathogenic bacteria, including Bilophila wadsworthia, Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum, contribute to disease progression by increasing the production of carcinogenic metabolites and toxins, inducing inflammation, and activating oncogenic signaling pathways. Additionally, a disruption in the normal communication between the mucosal immune system and gut microbial communities can lead to a dysregulated immune response, resulting in chronic intestinal inflammation. Over time, this chronic inflammation can cause damage to the colonic mucosa, leading to the development of malignant lesions. Furthermore, some pathogenic bacteria have enhanced iron acquisition mechanisms, which allow them to outcompete protective bacteria, potentially causing damage to the colonic mucosa. Further research is needed to establish a direct link between these mechanisms and the development of malignant lesions in the colonic mucosa.', 'The microbiota contributes to the formation of malignant lesions in the colonic mucosa by increasing the presence of pathogenic bacteria, which outcompete protective bacteria for resources like iron. This imbalance leads to higher production of carcinogenic metabolites and toxins, induces inflammation, and activates oncogenic signaling pathways. Specific bacteria implicated in this process include sulfidogenic bacteria such as Bilophila wadsworthia, Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum.', 'The microbiota can produce malignant lesions in colonic mucosa by generating carcinogenic metabolites and toxins, such as hydrogen sulfide from sulfidogenic bacteria like Bilophila wadsworthia. Additionally, certain bacteria like Streptococcus bovis and Helicobacter pylori are linked to inflammation and oncogenic signaling pathways, respectively. Dysbiosis, or an imbalance in the gut microbiota, is also associated with colorectal cancer, highlighting the importance of maintaining a healthy balance of gut bacteria to prevent cancer development.', \"The gut microbiota can contribute to the development of colorectal cancer (CRC) through various pathophysiological mechanisms. One key mechanism is the production of carcinogenic metabolites and toxins by certain bacteria, such as sulfidogenic bacteria like Bilophila wadsworthia, Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum. These bacteria can alter the gut environment and create an inflammatory microenvironment that promotes the growth of malignant cells in the colonic mucosa. Additionally, the gut microbiota can also influence the host's immune system, leading to immune dysregulation and increased susceptibility to cancer development. For example, alterations in communication between the mucosal immune system and gut microbial communities have been implicated as a core defect that leads to chronic intestinal inflammation and cancer development. Overall, the pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves a complex interplay between bacterial metabolites, immune dysregulation, and inflammation.\", 'The microbiota in the colon can contribute to the development of malignant lesions in the colonic mucosa through several mechanisms. Certain pathogenic bacteria can outcompete protective bacteria, leading to an increase in harmful bacteria. These bacteria can produce carcinogenic metabolites or toxins, which can damage the cells in the colonic mucosa and lead to the development of cancer. Additionally, these bacteria can induce inflammation, which can also contribute to cancer development. Furthermore, alterations in the communication between the mucosal immune system and gut microbial communities can lead to chronic intestinal inflammation and cancer development. Some of the bacteria implicated in this process include Bilophila wadsworthia, Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum', 'Perturbations of the colonic microbiota can contribute to the initiation and progression of colorectal cancer, leading to an increase in pathogenic bacteria at the expense of protective bacteria. This can contribute to disease through increasing carcinogenic metabolite/toxin production, inducing inflammation, and activating oncogenic signaling. Most pathogenic bacteria have heightened iron acquisition mechanisms and therefore tend to outcompete protective bacteria for free iron. Multiple proposed pathogenic microorganisms including sulfidogenic bacteria such as Bilophila wadsworthia, as well as Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum.', 'The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves perturbations in the colonic microbiota, leading to an increase in pathogenic bacteria that produce carcinogenic metabolites, induce inflammation, and activate oncogenic signaling. Pathogenic bacteria often have heightened iron acquisition mechanisms, outcompeting protective bacteria for free iron. Additionally, alterations in communication between the mucosal immune system and gut microbial communities can lead to chronic intestinal inflammation and cancer development. Specific pathogenic microorganisms implicated in this process include Bilophila wadsworthia, Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum.', 'Perturbations of the colonic microbiota can contribute to the initiation and progression of colorectal cancer. This can occur through increasing carcinogenic metabolite/toxin production, inducing inflammation, and activating oncogenic signaling. Alterations in communication between the mucosal immune system and gut microbial communities play a key role in the development of chronic intestinal inflammation and cancer. The imbalance in the microbiota can lead to an increase in pathogenic bacteria at the expense of protective bacteria, further contributing to disease progression.', 'The pathophysiological mechanism by which the microbiota contribute to the development of malignant lesions in colonic mucosa involves several steps. First, perturbations in the composition and diversity of the gut microbial community can lead to an imbalance between protective and pathogenic bacteria. This imbalance allows for increased growth of pathogenic bids that have heightened iron acquisition mechanisms, enabling them to outcompete protective bacteria for free iron. Second, this shift in the microbiota can lead to an increase in carcinogenic metabolite and toxin production by the pathogenic bacteria, which can damage colonic mucosal cells and promote their transformation into cancerous cells. Third, the presence of these pathogenic bacteria can induce chronic inflammation in the colonic mucosa, further promoting tumorigenesis', 'The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves perturbations of the colonic microbiota, leading to an increase in pathogenic bacteria at the expense of protective bacteria. This can contribute to disease through increasing carcinogenic metabolite/toxin production, inducing inflammation, and activating oncogenic signaling. Alterations in communication between the mucosal immune system and gut microbial communities have been implicated as the core defect that leads to chronic intestinal inflammation and cancer development.', 'Perturbations of the colonic microbiota can contribute to colorectal cancer through several pathogenic mechanisms:\\n\\n1. Increasing production of carcinogenic metabolites and toxins by pathogenic bacteria\\n2. Inducing inflammation in the colonic mucosa\\n3. Activating oncogenic signaling pathways\\n\\nPathogenic bacteria tend to outcompete protective bacteria for free iron using heightened iron acquisition mechanisms. This leads to an increase in pathogenic bacteria at the expense of protective bacteria.\\n\\nSpecific pathogenic bacteria implicated include sulfidogenic bacteria like Bilophila wadsworthia, Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum. \\n\\nAlterations in communication between the mucosal immune system and gut microbial communities are thought to be the core defect leading to chronic intestinal inflammation and cancer development.', 'The pathophysiological mechanism involves an imbalance in the colonic microbiota, leading to an increase in pathogenic bacteria. These bacteria produce carcinogenic metabolites and toxins, induce inflammation, and activate oncogenic signaling, which can initiate and progress the development of malignant lesions in the colonic mucosa', 'Perturbations of the colonic microbiota can lead to an increase in pathogenic bacteria and a decrease in protective bacteria. This imbalance can result in the production of carcinogenic metabolites/toxins, induction of inflammation, and activation of oncogenic signaling. Pathogenic bacteria often have heightened iron acquisition mechanisms, allowing them to outcompete protective bacteria for free iron.', 'The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves perturbations in the colonic microbiota that lead to an increase in pathogenic bacteria at the expense of protective bacteria. This can contribute to disease through increasing carcinogenic metabolite/toxin production, inducing inflammation, and activating oncogenic signaling.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, the pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa is not explicitly stated in the tables. However, based on the information provided in the sources, it appears that certain bacteria, such as Fusobacterium nucleatum, Enterotoxigenic Bacteroides fragilis (ETBF), and colibactin-producing Escherichia coli, may play a role in the development of colorectal cancer through various mechanisms, including:\n\n1. Production of pro-inflammatory cytokines and metabolites: These bacteria can produce metabolites such as secondary bile salts, hydrogen sulfide, and trimethylamine-N-oxide (TMAO), which can promote inflammation and DNA damage, leading to the development of cancer.\n2. Alteration of the colonic epithelial cell barrier: These bacteria can disrupt the tight junctions between epithelial cells, leading to increased permeability and allowing toxins and carcinogens to penetrate the epithelium and cause damage.\n3. Activation of oncogenic pathways: Certain bacteria, such as ETBF, can activate oncogenic pathways, such as the RHEB/mTOR pathway, which can promote cell proliferation and survival.\n4. Production of genotoxins: Colibactin-producing E. coli can produce colibactin, a genotoxin that induces double-strand DNA breaks, leading to genetic instability and cancer.\n\nIt is essential to note that these mechanisms are not mutually exclusive, and the exact pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa is likely to be complex and multifactorial.\n\nReferences:\n\n* Source 3: \"Gut Microbiota, Inflammation, and Colorectal Cancer\"\n* Source 6: \"Gut microbiota-derived metabolites in CRC progression and causation\"\n* Source 10: \"Long noncoding RNA BFAL1 mediates enterotoxigenic Bacteroides fragilis-related carcinogenesis in colorectal cancer via the RHEB/mTOR pathway\"\n* Source 12: \"Exploring the Role of Gut Microbiome in Colon Cancer\"\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers several key mechanisms by which microbiota contribute to malignant lesions, including inflammation, DNA damage, and oncogenic pathway activation. It mentions specific bacteria and their roles, which are relevant to the reference answers. However, it does not fully incorporate all aspects mentioned in the reference answers, such as dysbiosis or immune evasion.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and focuses on the mechanisms without adding irrelevant information. Each point is directly related to the pathophysiological impact of microbiota on colonic mucosa.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information. Each mechanism described is distinct and adds new insights into the process.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-structured and fluent, making it easy to understand. The use of bullet points enhances clarity. However, a more integrated narrative could slightly improve readability."
    },
    {
        "Question": "is carotenodermia caused by an excess of lycopene in the diet?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nis carotenodermia caused by an excess of lycopene in the diet?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Carotenodermia is a yellow to orange skin discoloration due to epidermal deposition of carotene.', 'No, carotenodermia is caused by an excess of beta-carotene, not lycopene.', 'No, carotenodermia is caused by an excess of beta-carotene in the diet.', 'No, carotenodermia is a yellow to orange skin discoloration due to epidermal deposition of carotene.', 'Carotenodermia is a yellow-orange coloration of the skin caused by high levels of serum carotenoids, mostly due to the excessive intake of carotenoid-rich foods.', 'No, carotenodermia is not caused by an excess of lycopene in the diet.', 'Carotenodermia is a yellow to orange skin discoloration caused by epidermal deposition of carotene, not lycopene. Consuming an excess of carotene-rich vegetables, rather than lycopene-rich ones, can lead to carotenodermia.', 'No, carotenodermia is not caused by an excess of lycopene in the diet. It is typically due to the deposition of carotene in the skin.', 'No, carotenodermia is caused by an excess of carotene in the diet.', 'No, carotenodermia is not caused by an excess of lycopene in the diet. It is caused by an excess of carotene, not lycopene.', 'Yes, carotenodermia can be caused by an excess intake of lycopene.', 'No. Carotenodermia is a yellow to orange skin discoloration due to epidermal deposition of carotene.', 'No, carotenodermia is caused by an excess of carotenoids in the diet.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, carotenodermia is caused by an abnormal accumulation of carotenoids in the body, which can be due to various factors such as excessive intake of carotenoid-rich foods or supplements, abnormality in the conversion of beta-carotene to vitamin A, or hyperlipidemia. However, there is no direct evidence in the data that links an excess of lycopene specifically to carotenodermia. In fact, one of the sources mentions that beta-carotene, not lycopene, was used in a study to induce carotenemia in humans, suggesting that beta-carotene may be more closely associated with carotenemia than lycopene.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer provides a comprehensive explanation of carotenodermia, mentioning the accumulation of carotenoids and potential causes like excessive intake of carotenoid-rich foods, issues with beta-carotene conversion, or hyperlipidemia. However, it missed explicitly stating that carotenodermia is specifically caused by beta-carotene, as emphasized in some reference answers.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer focuses on the main points without including irrelevant information. It correctly differentiates lycopene from beta-carotene, aligning with most reference answers. However, it could be more precise by directly stating that beta-carotene, not carotenoids in general, is the primary cause.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each point is distinct and contributes uniquely to the explanation.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand. It presents the information logically and clearly."
    },
    {
        "Question": "Which are the two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis)?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhich are the two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis)?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Rmtricitabine and tenofovir are the main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis).', 'The standard PrEP regimen primarily consists of Tenofovir disoproxil fumarate and Emtricitabine.', 'Tenofovir (TFV) and Tenofovir disoproxil fumarate (TDF) are the two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis).', '2 antiretroviral agents, tenofovir disoproxil fumarate and emtricitabine.', 'Tenofovir (TFV) and emtricitabine (FTC) are the two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis).', 'The two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis) are emtricitabine/tenofovir disoproxil fumarate (Truvada).', 'The two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis) are Tenofovir (TFV) and Tenofovir disoproxil fumarate (TDF).', 'The two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis) are tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC).', 'The two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis) are tenofovir and emtricitabine.', 'The two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis) are Tenofovir and Emtricitabine.', 'Tenofovir and emtricitabine are the two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis).', 'The two main active ingredients of the standard PrEP are tenofovir and emtricitabine.', 'The two main active ingredients of the standard Pre-Exposure Prophylaxis (PrEP) against HIV infection are emtricitabine and tenofovir. These two drugs work together to prevent the HIV virus from establishing a permanent infection in the body.', 'The standard PrEP regimen consists of a fixed-dose combination of two active ingredients: tenofovir disoproxil fumarate and emtricitabine.', 'The standard Pre-Exposure Prophylaxis (PrEP) regimen primarily consists of two active ingredients: tenofovir and emtricitabine. These two antiretroviral drugs are combined to form the standard PrEP medication, which is used to prevent HIV infection in individuals who are at high risk.', 'The two main active ingredients in the standard PrEP regimen are tenofovir and emtricitabine.', 'The two main active ingredients of the standard Pre-Exposure Prophylaxis (PrEP) are tenofovir and emtricitabine.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, the two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis) are:\n\n1. Tenofovir Disoproxil Fumarate (TDF)\n2. Emtricitabine (FTC)\n\nThese two medications are commonly used in combination as a single tablet, often referred to as Truvada.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer correctly identifies the two main active ingredients of standard PrEP (Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC)) and mentions their common combination as Truvada, which aligns perfectly with the reference answers.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise and only includes relevant information about the two main active ingredients without adding any extraneous details. It accurately specifies the full names (including abbreviations) of the active ingredients.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat any information unnecessarily. It clearly states the two active ingredients and their combination in a single tablet, providing all necessary information in a concise manner.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured, easy to read, and fluent. It presents the information in a clear and logical format, making it accessible to the reader."
    },
    {
        "Question": "What is the cause of Leigh syndrome?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the cause of Leigh syndrome?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Leigh syndrome may result from several defects of mitochondrial enzyme complexes, including pyruvate dehydrogenase complex, and respiratory chain complexes I, II, III, IV, V.', 'Leigh syndrome is caused by various genetic defects, including m.9185T>C MTATP6 variant, Surf1 gene mutations, G8363A mitochondrial DNA mutation, deficiencies in the FAO enzyme short-chain enoyl-CoA hydratase 1 (ECHS1) and defects of 16 mitochondrial DNA (mtDNA) genes and approaching 100 nuclear genes.', 'Leigh syndrome is a genetically heterogeneous neurodegenerative disorder caused by mutations in nuclear genes or mitochondrial DNA that impair mitochondrial energy metabolism. Over 75 different causative gene mutations have been identified, with approximately 75% being nuclear DNA mutations and 25% mitochondrial DNA mutations. These mutations affect various components of the mitochondrial respiratory chain complexes, pyruvate metabolism, vitamin and cofactor transport and metabolism, mtDNA maintenance, mitochondrial gene expression, protein quality control, lipid remodeling, dynamics, and toxicity.', 'Leigh syndrome is caused by various genetic mutations that affect mitochondrial function, leading to impaired energy production and neurodegeneration. These mutations can involve genes related to mitochondrial DNA or nuclear DNA, resulting in deficiencies in oxidative phosphorylation and the accumulation of toxic metabolites. The exact cause of Leigh syndrome can vary among individuals, with over 110 different genes implicated in its development.', 'Leigh syndrome may result from different enzyme defects, most notably pyruvate dehydrogenase complex deficiency, cytochrome c oxidase deficiency, complex I deficiency, and complex V deficiency associated with the recently described NARP point mutation.', 'Leigh syndrome can be caused by several defects of mitochondrial enzyme complexes, including pyruvate dehydrogenase complex, respiratory chain complexes I, II, III, IV, and V. Additionally, it can also be caused by cytochrome c oxidase deficiency, complex I deficiency, and complex V deficiency associated with the NARP point mutation.', 'Leigh syndrome can be caused by defects in mitochondrial enzyme complexes, such as pyruvate dehydrogenase complex deficiency and respiratory chain complexes I, II, III, IV, V.', 'Leigh syndrome may result from several defects of mitochondrial enzyme complexes, including pyruvate dehydrogenase complex.', 'Leigh syndrome is caused by defects in mitochondrial enzyme complexes, including pyruvate dehydrogenase complex deficiency, cytochrome c oxidase deficiency, complex I deficiency, complex V deficiency, and the NARP point mutation.', 'Leigh syndrome is a rare inherited neurometabolic disorder. It is caused by several defects of mitochondrial enzyme complexes, including pyruvate dehydrogenase complex, and respiratory chain complexes I, II, III, IV, V.', 'Leigh syndrome is caused by defects in mitochondrial enzyme complexes, including pyruvate dehydrogenase complex, respiratory chain complexes I, II, III, IV, V, and the recently described NARP point mutation.', 'Leigh syndrome is a severe neurological disorder caused by defects in several mitochondrial enzyme complexes. These include the pyruvate dehydrogenase complex and respiratory chain complexes I, II, III, IV, and V. Additionally, complex V deficiency associated with the NARP point mutation and cytochrome c oxidase deficiency can also lead to Leigh syndrome.', 'Leigh syndrome can be caused by defects in mitochondrial enzyme complexes, including deficiencies in pyruvate dehydrogenase complex, cytochrome c oxidase, complex I, and complex V, as well as mutations like the NARP point mutation.', 'Leigh syndrome may result from different enzyme defects, most notably pyruvate dehydrogenase complex deficiency, cytochrome c oxidase deficiency, complex I deficiency, and complex V deficiency.', 'Leigh syndrome can result from defects in mitochondrial enzyme complexes, including pyruvate dehydrogenase complex, and respiratory chain complexes I, II, III, IV, and V. Deficiencies in enzymes such as pyruvate dehydrogenase complex, cytochrome c oxidase, complex I, and complex V can contribute to the development of Leigh syndrome.', 'The cause of Leigh syndrome is a result of different enzyme defects, most notably pyruvate dehydrogenase complex deficiency, cytochrome c oxidase deficiency, complex I deficiency, and complex V deficiency associated with the recently described NARP point mutation.', 'Leigh syndrome may result from different enzyme defects, most notably pyruvate dehydrogenase complex deficiency, cytochrome c oxidase deficiency, and complex I deficiency.', 'Leigh syndrome may result from several defects of mitochondrial enzyme complexes, including pyruvate dehydrogenase complex deficiency, cytochrome c oxidase deficiency, complex I deficiency, complex II deficiency, complex III deficiency, complex IV deficiency, and complex V deficiency associated with the NARP point mutation.', 'Leigh syndrome is caused by defects in mitochondrial enzyme complexes. These can include the pyruvate dehydrogenase complex, and respiratory chain complexes I, II, III, IV, and V.', 'Leigh syndrome can result from various defects in mitochondrial enzyme complexes, including pyruvate dehydrogenase complex deficiency, respiratory chain complexes I, II, III, IV, and V deficiencies. Specifically, it can be caused by defects in pyruvate dehydrogenase complex, cytochrome c oxidase deficiency, complex I deficiency, and complex V deficiency associated with the NARP point mutation.', 'Leigh syndrome is caused by several defects of mitochondrial enzyme complexes, including pyruvate dehydrogenase complex, and respiratory chain complexes I, II, III, IV, V.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, Leigh syndrome is a complex and heterogeneous disorder with multiple causes. The data suggests that Leigh syndrome can be caused by mutations in both mitochondrial DNA (mtDNA) and nuclear DNA (nDNA).\n\nSpecifically, the data indicates that Leigh syndrome is often associated with mutations in the following genes:\n\n* Mitochondrial DNA (mtDNA) genes, including:\n\t+ MT-ND5 m.13513G>A mutation\n\t+ m.3685T > C variant (MT-ND1 p.Tyr127His)\n\t+ m.8993 T>G variant\n\t+ Other mtDNA mutations, such as T8993C mitochondrial DNA mutation and G14459A mutation\n* Nuclear DNA (nDNA) genes, including:\n\t+ SURF1 gene mutations\n\t+ NDUFS1 gene mutations\n\t+ Other nuclear genes associated with mitochondrial respiratory chain function, such as pyruvate dehydrogenase complex and electron transport chain complexes I, II, III, IV, V\n\nIn addition, the data suggests that Leigh syndrome can also be caused by defects in mitochondrial function, including:\n\n* Mitochondrial respiratory chain enzyme defects\n* Mitochondrial DNA maintenance defects\n* Mitochondrial gene expression and protein quality control defects\n* Lipid remodeling and dynamics defects\n* Toxicity and stress response defects\n\nOverall, the data suggests that Leigh syndrome is a complex disorder with multiple potential causes, and a comprehensive diagnostic approach is necessary to identify the underlying genetic or biochemical defect.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "4",
        "Information Recall Explanation": "The answer covers a broad range of genetic and functional defects associated with Leigh syndrome, including mutations in both mitochondrial and nuclear DNA, and various mitochondrial functional defects. However, it does not mention some specific examples like the NARP point mutation, which is frequently referenced in the provided answers.",
        "Information Precision Score": "3",
        "Information Precision Explanation": "The answer includes relevant information about the causes of Leigh syndrome but also introduces some less commonly mentioned mutations (e.g., MT-ND5 m.13513G>A, m.3685T > C variant) which are not present in the reference answers, potentially adding irrelevant details.",
        "Information Repetition Score": "4",
        "Information Repetition Explanation": "The answer does not repeat information redundantly, but it occasionally restates the idea of multiple causes without much variation, which slightly affects its score.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured, logically organized, and easy to follow. It uses clear bullet points and summary statements to enhance readability."
    },
    {
        "Question": "What is Primary Diffuse Meningeal Melanomatosis?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is Primary Diffuse Meningeal Melanomatosis?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Primary Diffuse Meningeal Melanomatosis is a rare variant of meningeal melanoma that causes diffusely invasive lesions of the pia mater with a tumor of melanocytic origin.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nPrimary diffuse meningeal melanomatosis (PDMM) is a rare and aggressive form of central nervous system melanoma that affects the meninges, the protective membranes surrounding the brain and spinal cord. It is a diffuse, malignant tumor that involves the leptomeninges, which are the thin, innermost layers of the meninges that cover the brain and spinal cord.\n\nPDMM is a type of primary melanocytic tumor of the central nervous system, which means it arises from melanocytes, the cells that produce melanin, within the meninges. It is characterized by the presence of melanin-producing cells in the meninges, which can lead to a range of symptoms, including seizures, hydrocephalus, cranial nerve damage, and cognitive impairment.\n\nPDMM is often difficult to diagnose, as its symptoms can mimic those of other conditions, such as lymphoma, leukemia, neurosarcoidosis, or metastatic carcinoma. Diagnosis typically requires a combination of clinical evaluation, imaging studies (such as MRI and CT scans), cerebrospinal fluid analysis, and histopathological examination of tissue samples.\n\nThe prognosis for PDMM is generally poor, with a median survival time of around 5-6 months. Treatment options are limited, and may include surgery, radiation therapy, and chemotherapy, although the effectiveness of these treatments is often variable.\n\nPDMM is a rare condition, with an estimated incidence of 1 in 20 million people. It is often associated with other melanocytic tumors, such as melanocytomas, and can be a component of neurocutaneous melanosis, a rare genetic disorder characterized by the presence of melanocytic nevi and tumors in the skin and central nervous system.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer covers all the necessary information about Primary Diffuse Meningeal Melanomatosis (PDMM), including its description, origin, symptoms, diagnostic challenges, prognosis, treatment options, and rarity. It goes beyond the reference answer by providing additional details such as associated conditions and incidence rate.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer is precise and mostly avoids irrelevant information. However, it includes some details that, while valuable, are not strictly necessary for a basic understanding of PDMM, such as the association with neurocutaneous melanosis. This slightly detracts from precision.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. Each point is introduced and discussed once, making the response concise and free of redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured, fluent, and easily readable. It uses clear and professional language appropriate for a biomedical context, and the information is presented in a logical sequence."
    },
    {
        "Question": "Do black race patients have worse survival in colorectal cancer?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nDo black race patients have worse survival in colorectal cancer?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes, black patients with Stage IV colorectal cancer have worse survival if they are older age and did not receive chemotherapy. Black patients in the study population were more likely to be female, have medical comorbidities, and come from areas with lower average income and baseline education. Among patients younger than 45 years, black patients had significantly increased hazard of death compared to white patients. , It is worth noting that outcomes in colorectal cancer treatment are historically worse in Black people and residents of rural areas. The intersection of race and rurality worsens outcomes, with the poorest outcomes observed in black individuals in rural areas. Genomics also play a role, as black patients have a higher incidence of colorectal cancer and worse survival rates when compared to white people.', 'yes, African-Americans have the lowest survival compared to other race categories (3 years survival rate in African-Americans = 61%, 3 years survival rate in Caucasians = 73%)', 'Yes, studies have shown that Black patients with colorectal cancer have worse overall survival (OS) compared to White patients. This disparity persists even when controlling for demographic and pathologic factors, suggesting that the underlying factors are complex and not well understood. However, a study examining stage IV colorectal cancer patients found no significant differences in proportional hazard of death between black and white patients aged 45 years or older. Among those younger than 45 years, younger black patients had significantly increased hazard of death. Another study found that Black patients with metastatic colorectal cancer have worse survival than white patients, even when controlling for insurance status and receipt of chemotherapy. However, a retrospective analysis of the randomized CALGB/SWOG 80405 trial found no difference in OS, progression-free survival (PFS), or response to therapy between Black and White patients treated on the clinical trial. These findings suggest that access to care and differences in treatment may be responsible for racial disparities in colorectal cancer.', 'Yes, studies have shown that black race patients have worse survival in colorectal cancer. Multiple analyses have demonstrated that black patients with nonmetastatic colon cancer have poorer overall survival and cancer-specific survival compared to white patients, even after accounting for socioeconomic and clinical factors. This disparity in survival persists across different stages of the disease. Additionally, black patients with stage IV colorectal cancer have been found to have worse overall survival compared to white patients. Factors such as lower rates of receiving chemotherapy and a higher incidence of colon cancer in black patients may contribute to these disparities.', 'Yes, according to the study, unmatched black patients with colorectal cancer (CRC) have worse absolute 5-year survival rates compared to unmatched white patients (57.3% vs 66.5%, respectively). The unadjusted survival analysis also found a 15% higher chance of dying for black patients compared to white patients. However, after adjusting for patient, tumor, and demographic variables, the increased risk of death for black patients was marginally reduced. Interestingly, the study found that insurance coverage differences accounted for approximately half of the disparity in survival rate between black and white patients with CRC aged 18-64 years old. After adjusting for differences in treatment, the increased risk of death for black patients disappeared. Therefore, while the study suggests that black race is a significant factor associated with worse survival in CRC, other factors such as insurance coverage and access to appropriate treatment may also contribute to this disparity.', 'Yes, black patients with colorectal cancer (CRC) have worse survival compared to white patients. The absolute 5-year survival difference between black and white unmatched patients with CRC is 9.2%. However, after adjustment for differences in treatment, the increased risk of death for black patients disappeared. Insurance coverage differences accounted for approximately one half of the disparity in survival rate of black vs white patients with CRC, 18-64 years old.', 'Yes, black race patients initially showed a 15% higher chance of dying compared to white patients in unadjusted survival analysis.', \"Yes, according to the data from the National Cancer Database, black patients do have a worse survival rate in colorectal cancer compared to white patients. The unadjusted survival analysis found a 15% higher chance of dying for black patients compared to white patients. Even after adjusting for patient, tumor, and demographic variables, the risk of death was still marginally higher for black patients. The absolute 5-year survival difference between black and white patients was 9.2% (57.3% for black patients vs 66.5% for white patients). However, it's important to note that after adjusting for differences in treatment, the increased risk of death for black patients disappeared. Additionally, insurance coverage differences accounted for approximately half of the disparity in survival rates.\", 'Yes, studies have shown that black patients with colorectal cancer (CRC) initially have a worse survival rate compared to white patients. The absolute 5-year survival difference was found to be 9.2% lower for black patients. However, this disparity was found to be significantly influenced by factors such as insurance coverage and differences in treatment. When these factors were adjusted for, the increased risk of death for black patients disappeared. This suggests that the survival disparity is not due to race itself, but rather to socioeconomic and healthcare access factors.', 'Yes, black race patients have worse survival in colorectal cancer compared to white race patients. The absolute 5-year survival difference between black and white unmatched patients with CRC was 9.2% (57.3% for black patients vs 66.5% for white patients; P < 0.0001). However, after adjusting for differences in treatment, the increased risk of death for black patients disappeared.', 'Yes, black patients have worse survival rates in colorectal cancer compared to white patients. According to the study, black patients had a lower 5-year survival rate compared to white patients (57.3% vs 66.5%). The study found that differences in insurance coverage and tumor characteristics accounted for approximately half of the disparity in survival rates between black and white patients. Additionally, black patients had lower rates of consultation with surgery, medical oncology, and radiation oncology, and received less treatment with surgery, chemotherapy, and radiotherapy. Adjusting for patient, tumor, and demographic variables marginally reduced the risk of death for black patients, but after adjustment for differences in treatment, the increased risk of death for black patients disappeared. These findings suggest that racial disparities in access to healthcare and treatment contribute to inferior survival outcomes for black patients with colorectal cancer.', \"Yes, black patients with colorectal cancer (CRC) generally have a worse survival rate compared to white patients. The absolute 5-year survival difference between black and white patients was 9.2% (57.3% for black patients vs 66.5% for white patients). Furthermore, unadjusted survival analysis found a 15% higher chance of dying for black patients compared with white patients. However, it's important to note that after adjusting for differences in treatment, the increased risk of death for black patients disappeared. This suggests that the disparity in survival rates may be largely due to differences in treatment and insurance coverage\", 'Yes, black race patients have worse survival in colorectal cancer.The absolute 5-year survival difference between black and white unmatched patients with CRC was 9.2% (57.3% for black patients vs 66.5% for white patients; P <.0001).In an analysis of data from the National Cancer Database, we found that insurance coverage differences accounted for approximately one half of the disparity in survival rate of black vs white patients with CRC, 18-64 years old;Unadjusted survival analysis found a 15% higher chance of dying for black patients compared with white patients (hazard ratio [HR] = 1.15; 95% confidence interval (CI) = 1.08 to 1.22; P <.001). Adjustment for patient, tumor, and demographic variables marginally reduced the risk of death (HR = 1.08; 95% CI = 1.01 to 1.15; P =.03). After adjustment for differences in treatment, the increased risk of death for black patients disappeared', 'Yes, black patients with colorectal cancer have worse survival compared to white patients. The absolute 5-year survival difference between black and white patients was 9.2% (57.3% for black patients vs 66.5% for white patients). Unadjusted analysis found a 15% higher chance of dying for black patients compared to white patients. After adjusting for patient, tumor, and demographic variables, the increased risk of death for black patients was reduced but still present. Insurance coverage differences accounted for about half of the survival disparity between black and white colorectal cancer patients aged 18-64 years old.', 'Yes, black patients with colorectal cancer have a worse survival rate compared to white patients. The 5-year survival difference is 9.2%, with 57.3% for black patients and 66.5% for white patients.', 'Yes, studies have shown that black race patients with colorectal cancer have worse survival compared to white patients. In a study analyzing data from the National Cancer Database, it was found that black patients had a 9.2% lower 5-year survival rate compared to white patients. However, when adjusting for patient, tumor, and demographic variables, the risk of death was marginally reduced. Furthermore, after accounting for differences in treatment, the increased risk of death for black patients disappeared. Insurance coverage differences were found to account for approximately half of the survival rate disparity between black and white patients with colorectal cancer.', 'Yes, black race patients have worse survival in colorectal cancer, with an absolute 5-year survival difference of 9.2% compared to white patients.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, there is evidence suggesting that black patients may have worse survival rates in colorectal cancer. \n\nRelation id 21 indicates that \"Black patients have lower five-year survival rates compared to White patients.\" Relation id 27 also states that \"Five-year survival rates for Black patients are lower compared to White patients.\" Additionally, Relation id 33 states that \"Black patients are younger than white patients with colorectal cancer\" and Relation id 34 states that \"Blacks have a lower colorectal cancer survival rate than Whites.\"\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer acknowledges the lower survival rates among Black patients compared to White patients, which is a key point from the reference answers. However, it misses important details such as the specific survival rate percentages (e.g., 57.3% vs. 66.5%), the role of insurance coverage, and treatment differences that account for disparities, which are frequently mentioned in the references.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer focuses on the survival disparity without introducing irrelevant information. It stays on topic by addressing the racial differences in survival rates for colorectal cancer, which aligns well with the references provided.",
        "Information Repetition Score": 3,
        "Information Repetition Explanation": "The answer repeats the concept of lower survival rates in Black patients multiple times (e.g., 'lower five-year survival rates' and 'lower colorectal cancer survival rate'), which slightly detracts from its conciseness. However, the repetition is not excessive and serves to reinforce the main point.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured and easy to understand. The sentences are clear and logically connected, making the information accessible without unnecessary complexity."
    },
    {
        "Question": "Can Antioxidant curcumin kill tumor cells?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nCan Antioxidant curcumin kill tumor cells?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes,  Antioxidant curcumin can kill tumor cells', 'Antioxidant curcumin has been shown to induce apoptosis in tumor cells.', 'Yes, curcumin has been shown to have the ability to kill tumor cells.', 'Antioxidant curcumin has been shown to have antitumor effects, which can result in the death of tumor cells.', 'Yes, antioxidant curcumin can kill tumor cells by inducing oxidative stress.', 'Yes, curcumin is a potent antioxidant and kills cancerous cells.', 'Yes, curcumin has been shown to exhibit anti-tumor effects in various types of cancer, including colorectal cancer, by inducing cell death in tumor cells.', 'Yes, antioxidant curcumin can kill tumor cells by inducing apoptosis and inhibiting malignant progression.', 'Yes, curcumin can kill tumor cells through its antioxidant properties and various mechanisms of action.', 'Yes, antioxidant curcumin can kill tumor cells by regulating miR-206 expression', 'Yes, Curcumin can kill tumor cells.', 'Yes, curcumin can kill tumor cells by inducing apoptosis and inhibiting malignant progression.', 'Yes, curcumin can kill tumor cells by regulating miR-206 expression, which inhibits colon cancer malignant progression and promotes T cell killing.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data tables, yes, antioxidant curcumin can kill tumor cells. Curcumin has been shown to induce apoptosis (cell death) in various types of cancer cells, including colorectal, ovarian, breast, and pancreatic cancer cells. It does this through various mechanisms, including the generation of reactive oxygen species (ROS), disruption of microtubule assembly, and inhibition of cell cycle progression.\n\nFor example, in study #22, curcumin was shown to induce apoptosis in human ovarian cancer cells (Ho-8910) by down-regulating anti-apoptotic proteins (Bcl-2 and Bcl-X(L)) and up-regulating pro-apoptotic proteins (p53 and Bax).\n\nAdditionally, study #20 found that curcumin inhibited microtubule assembly in cancer cells, leading to cell death.\n\nHowever, it's worth noting that the effectiveness of curcumin in killing tumor cells can vary depending on the type of cancer, the concentration of curcumin used, and the duration of treatment.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers the information provided in the reference answers, including the ability of curcumin to kill tumor cells through various mechanisms such as inducing apoptosis, generating ROS, disrupting microtubule assembly, and inhibiting cell cycle progression. It also provides specific examples from studies, which enhances the recall of detailed information.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise, focusing only on relevant information about how curcumin kills tumor cells. It does not include any irrelevant details, and all mentioned mechanisms and examples are directly related to the question.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. Each piece of information is presented clearly and concisely, contributing new insights or examples without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is very readable and fluent. The structure is logical, with a clear introduction, detailed body, and a concluding note on the variables affecting effectiveness. The use of specific examples and clear language enhances readability."
    },
    {
        "Question": "Should we treat all patients with glaucoma?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nShould we treat all patients with glaucoma?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes, treating all glaucoma patients is essential to prevent the progression of visual field defects.', \"Yes, it is generally recommended to treat all patients diagnosed with glaucoma. Glaucoma is a group of eye conditions that can lead to irreversible vision loss and even blindness if left untreated. The main goal of treatment is to lower intraocular pressure (IOP) to prevent further damage to the optic nerve. Treatment options include medications, laser treatments, and surgeries. Each patient's situation is unique, so a personalized treatment plan should be developed in consultation with an eye care professional. Early detection and consistent management are key to preserving vision and preventing progression of glaucoma.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, glaucoma is a group of chronic, progressive disorders of the optic nerve that can lead to blindness if left untreated. The data suggests that intraocular pressure is the only known modifiable risk factor for glaucoma, and that lowering intraocular pressure can prevent the progression of visual field defects.\n\nThe data also highlights the importance of early detection and treatment of glaucoma, as well as the need for regular monitoring and follow-up to assess the effectiveness of treatment.\n\nHowever, the data does not provide a clear answer to the question of whether all patients with glaucoma should be treated. The decision to treat glaucoma should be made on a case-by-case basis, taking into account the individual patient's needs and circumstances.\n\nIn general, the data suggests that treatment of glaucoma should be aimed at preserving visual function and quality of life, and that a holistic approach should be taken to manage the disease, considering the \"biopsychosociospiritual\" profile of each patient.\n\nIn particular, the data suggests that patients with advanced glaucoma may benefit from aggressive IOP lowering to the low teens or single digits to protect remaining vision, and that vision rehabilitation and psychosocial support should also be considered to optimize remaining vision and improve quality of life.\n\nIn summary, while the data does not provide a clear answer to the question of whether all patients with glaucoma should be treated, it suggests that treatment should be individualized and aimed at preserving visual function and quality of life, and that a holistic approach should be taken to manage the disease.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers most of the key points from the reference answers, including the importance of intraocular pressure, early detection, treatment options, and individualized care. However, it does not explicitly mention specific treatment methods like medications, laser treatments, or surgeries.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is highly precise, focusing on the relevant details about glaucoma treatment without including any extraneous information. It clearly addresses the key points needed to answer the question.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "There is minimal repetition in the answer. The points are made clearly and concisely, though the concept of individualized treatment is reiterated slightly in different contexts.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured and easy to follow. The language is clear, and the points are logically organized, making it highly readable and fluent."
    },
    {
        "Question": "What is the mechanism of action of Pegozafermin?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the mechanism of action of Pegozafermin?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Pegozafermin is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue in development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, Pegozafermin is a glycopegylated fibroblast growth factor 21 (FGF21) analogue. The table does not explicitly state the mechanism of action of Pegozafermin, but it can be inferred from the description of FGF21 and its effects. FGF21 is a hormone that plays a key role in regulating glucose and lipid metabolism, and it has been shown to have beneficial effects on insulin sensitivity, glucose homeostasis, and lipid metabolism.\n\nTherefore, it is likely that Pegozafermin, as a FGF21 analogue, works by mimicking the action of FGF21 to regulate glucose and lipid metabolism, potentially leading to improvements in insulin sensitivity, glucose homeostasis, and lipid profiles.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer mentions that Pegozafermin is a glycopegylated FGF21 analogue and infers its mechanism of action based on FGF21’s role in glucose and lipid metabolism. However, it does not explicitly confirm the mechanism or reference the long-acting property or specific indications (NASH and severe hypertriglyceridemia) mentioned in the reference answer, leaving some gaps.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer stays focused on Pegozafermin's inferred mechanism without introducing irrelevant details. While speculative, the information aligns logically with FGF21's known functions and avoids straying from the topic.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat information. It introduces the drug’s classification, explains FGF21’s role, and infers the mechanism concisely without redundancy.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is clear and logically structured, though the speculative phrasing ('it is likely that') slightly reduces fluency. Overall, it is coherent and easy to follow."
    },
    {
        "Question": "What is the indication for Alirocumab?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the indication for Alirocumab?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Alirocumab, sold under the brand name Praluent, is a medication used as a second-line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment', 'Alirocumab is indicated for the prevention of cardiovascular risk, and for patients with heterozygous familial hypercholesterolemia, atherosclerotic cardiovascular disease, or hypercholesterolemia who require additional LDL-C lowering.', 'Alirocumab is indicated for the treatment of hypercholesterolaemic patients unable to meet LDL-C targets, as an adjunct to diet in addition/alternative to LLT.', 'Alirocumab is a fully human immunoglobulin G1 monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9) approved for the treatment of hypercholesterolemia in high-risk patients.', 'The indication for Alirocumab is for patients who have high cardiovascular risk from established atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia and who are unable to achieve LDL-C targets with maximally tolerated dose of statins with or without other lipid-lowering drugs.', 'Alirocumab is indicated for the treatment of hypercholesterolemia in high-risk patients, heterozygous familial hypercholesterolemia, and clinical atherosclerotic cardiovascular disease where low-density lipoprotein cholesterol (LDLC) lowering is insufficient.', 'Alirocumab is indicated for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional lowering of LDL-cholesterol.', 'Alirocumab is used for treatment of low-density lipoprotein cholesterol.', 'Alirocumab is indicated for cholesterol and triglyceride metabolism, acting on them.', 'Alirocumab is a PCSK9 inhibitor that is used to decrease LDL-cholesterol levels in patients who have not been able to achieve target levels with other treatments. It is approved for clinical use by European regulatory authorities.', 'The indication for Alirocumab is lowering LDL cholesterol levels.', 'Alirocumab is indicated for the treatment of hypertriglyceridemia.', 'Alirocumab is indicated for LDL-cholesterol reduction.', 'Alirocumab is indicated for the treatment of hypercholesterolemia.', 'Alirocumab is primarily used to lower LDL-cholesterol levels.', 'Alirocumab is an anti-PCSK9 monoclonal antibody that is used for the treatment of high cholesterol.', 'The indication for Alirocumab is to reduce LDL-cholesterol and triglyceride metabolism.', 'Alirocumab is a PCSK9 inhibitor indicated for lowering LDL cholesterol. It is used in patients who cannot achieve target LDL cholesterol levels with other lipid-lowering therapies.', 'Alirocumab is indicated for the reduction of low-density lipoprotein cholesterol (LDL-cholesterol), particularly in patients who have not been able to achieve target LDL-cholesterol levels with traditional treatments.', 'The indication for Alirocumab is to reduce LDL cholesterol levels in patients who have not achieved their target LDL cholesterol levels with maximally tolerated statin therapy or in patients who are intolerant to statins.', 'Alirocumab is indicated for the treatment of hypertriglyceridemia in adults with established cardiovascular disease or diabetes mellitus type 2 and mixed dyslipidemia.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAlirocumab is indicated for the treatment of adults with:\n\n1. Heterozygous familial hypercholesterolemia (HeFH) to reduce the risk of cardiovascular events.\n2. Atherosclerotic cardiovascular disease (ASCVD) to reduce the risk of major adverse cardiovascular events.\n3. Statin-intolerant patients to reduce LDL-C levels.\n\nIt is also indicated for the treatment of patients with mixed dyslipidemia who are unable to reach their LDL-C targets with maximally tolerated statin therapy.\n\nSource: Data from tables 4, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer covers all major indications for Alirocumab as referenced in the provided sources, including heterozygous familial hypercholesterolemia (HeFH), atherosclerotic cardiovascular disease (ASCVD), statin-intolerant patients, and mixed dyslipidemia. It also mentions the reduction of cardiovascular events and LDL-C levels, which is comprehensive.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise but includes a minor redundancy by mentioning 'to reduce LDL-C levels' in multiple contexts (for statin-intolerant patients and mixed dyslipidemia). However, no irrelevant information is reported.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "There is slight repetition regarding LDL-C reduction, but overall, the information is presented concisely without unnecessary duplication.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is very well-structured, clear, and easy to follow. The bullet points enhance readability, and the language is fluent and professional."
    },
    {
        "Question": "Is there an approved vaccine against Helicobacter pylori?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs there an approved vaccine against Helicobacter pylori?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['No. There is currently no approved vaccine against Helicobacter pylori.', 'No, there is currently no approved vaccine for Helicobacter pylori.', 'No, there is currently no approved vaccine against Helicobacter pylori.', 'No, there is no approved vaccine against Helicobacter pylori', 'No, there is no approved vaccine against Helicobacter pylori.', 'No, there is not an approved vaccine against Helicobacter pylori.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThere is no approved vaccine against Helicobacter pylori.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer correctly recalls the essential information from the reference answers, stating that there is no approved vaccine against Helicobacter pylori.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information, directly addressing the question about the availability of a vaccine.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information; it provides a clear and concise statement without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is easily readable and fluent, with a simple and straightforward sentence structure that clearly conveys the information."
    },
    {
        "Question": "What disease can be treated with Tebentafusp?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat disease can be treated with Tebentafusp?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Tebentafusp is approved for uveal melanoma.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data tables, Tebentafusp is approved for the treatment of metastatic uveal melanoma (UM) in HLA-A*02:01-positive adult patients.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer accurately reports that Tebentafusp is approved for uveal melanoma, which matches the reference answer. Additionally, it provides extra relevant details like the specific indication (metastatic uveal melanoma) and the patient population (HLA-A*02:01-positive adults).",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information. It clearly states the disease (metastatic uveal melanoma) and the specific patient population, which adds relevant context without straying from the core topic.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition of information in the answer. The details provided are concise and each piece of information is unique and necessary.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured and easy to read. It flows logically from the treatment (Tebentafusp) to the disease (metastatic uveal melanoma) and the specific patient criteria, making it highly readable and fluent."
    },
    {
        "Question": "When was Havana Syndrome first recognized?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhen was Havana Syndrome first recognized?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Since 2016, an array of claims and public discourse have circulated in the medical community over the origin and nature of a mysterious condition dubbed \"Havana Syndrome,\" so named as it was first identified in Cuba.', 'Havana Syndrome is the name given to the group of neurological symptoms that first occurred among the staff at the U.S. embassy in Havana, Cuba in 2016.', 'Havana Syndrome was first recognized in the year 2016.', 'Havana syndrome is a term used to describe a cluster of neurological symptoms that have been reported by United States and Canadian diplomats, intelligence officers, and other government employees, mainly in Havana, Cuba, between 2016 and 2018.', 'Havana syndrome is a term that was first coined by US diplomats and intelligence personnel in 2016 in Havana, Cuba, to describe a series of strange symptoms, including dizziness, hearing loss, headaches, and cognitive impairment.', 'Havana Syndrome was first recognized in 2016.', 'Havana Syndrome was first recognized in late 2016 when U.S. diplomatic personnel in Havana, Cuba, reported experiencing unusual symptoms including hearing loss, cognitive issues, and other neurological problems.', 'Havana Syndrome was first recognized in Havana, Cuba in late 2016 when several U.S. diplomats and embassy staff reported experiencing unexplained neurological symptoms.', 'Havana Syndrome was first recognized in late 2016 when several U.S. diplomats stationed in Havana, Cuba, reported experiencing a range of unexplained neurological symptoms.', 'In 2016 diplomatic personnel serving in Havana, Cuba began reporting audible sensory phenomena paired with onset of complex and persistent neurological symptoms consistent with brain injury.', 'The phenomenon now known as Havana Syndrome was first recognized in 2016 when U.S. diplomats serving in Havana, Cuba reported hearing strange noises accompanied by a constellation of unexplained health effects.', 'The Havana Syndrome was first recognized in 2016 when U.S. diplomats serving in Havana, Cuba reported hearing strange noises accompanied by a constellation of unexplained health effects.', 'Havana Syndrome was first recognized in 2016 when U.S. diplomats serving in Havana, Cuba reported hearing strange noises and experiencing unexplained health effects.', 'In 2016, Havana Syndrome was first recognized when U.S. diplomats serving in Havana, Cuba reported hearing strange noises accompanied by a constellation of unexplained health effects.', 'Havana Syndrome is a term used to describe a series of unexplained neurological symptoms experienced by diplomatic personnel serving in Havana, Cuba, beginning in 2016.', ' Havana Syndrome was first recognized in 2016 when U.S. diplomats serving in Havana, Cuba reported hearing strange noises accompanied by a constellation of unexplained health effects.', 'Havana Syndrome was first recognized in 2016 when diplomatic personnel serving in Havana, Cuba reported audible sensory phenomena paired with complex and persistent neurological symptoms consistent with brain injury.', 'Havana Syndrome was first recognized in 2016 when diplomatic personnel serving in Havana, Cuba, reported audible sensory phenomena paired with complex and persistent neurological symptoms consistent with brain injury.', 'Havana Syndrome was first recognized in 2016 when U.S. diplomats serving in Havana, Cuba reported hearing strange noises accompanied by a constellation of unexplained health effects.', 'Havana Syndrome was first recognized in 2016 when U.S. diplomats serving in Havana, Cuba began reporting audible sensory phenomena paired with onset of complex and persistent neurological symptoms consistent with brain injury.', 'Havana Syndrome was first recognized in 2016 when diplomatic personnel in Havana, Cuba reported experiencing unusual sensory phenomena and neurological symptoms.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nHavana Syndrome was first recognized in 2016, when American and Canadian diplomats and other government personnel serving in Havana, Cuba, began reporting unusual symptoms, including hearing loss, dizziness, and cognitive difficulties, after being exposed to an unknown energy source.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately recalls the key information from the reference answers, including the year (2016), the location (Havana, Cuba), the affected individuals (American and Canadian diplomats and government personnel), and the symptoms (hearing loss, dizziness, cognitive difficulties). It also mentions the exposure to an unknown energy source, which aligns with details in some reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is highly precise, focusing only on the essential details without including any irrelevant information. It clearly states the recognition year, affected individuals, and symptoms without straying from the core facts.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information. Each piece of information is stated clearly and concisely without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easily understandable. It presents the information in a logical and coherent manner, making it highly readable."
    },
    {
        "Question": "Is Marburg virus a member of the family of the Ebola virus (Filoviridae)?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs Marburg virus a member of the family of the Ebola virus (Filoviridae)?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes, Marburg virus is a member of the family of the Ebola virus (Filoviridae).', 'Yes, the Marburg virus is part of the Filoviridae family, just like the Ebola virus.', 'Yes, Marburg virus is a member of the Filoviridae family, which also includes Ebola virus.', 'Yes, Marburg virus belongs to the filovirus family along with Ebola virus.', 'Yes, Marburg virus is a member of the family of Filoviridae, the same family as the Ebola virus.', 'Yes, Marburg virus and Ebola virus belong to the family Filoviridae.', 'Yes, Marburg virus and Ebola virus are both members of the family Filoviridae, which is a family of viruses known for causing severe hemorrhagic fever outbreaks in humans and nonhuman primates.', 'Yes, Marburg virus is a member of the family Filoviridae, which also includes the Ebola virus. The family Filoviridae is comprised of two genera: Marburgvirus and Ebolavirus. Marburg virus belongs to the Marburgvirus genus, while the Ebola virus belongs to the Ebolavirus genus.', 'Yes, Marburg virus is a member of the family Filoviridae, which also includes the Ebola virus.', 'Yes, Marburg virus is a member of the family Filoviridae, which also includes ebolaviruses.', 'Yes, Marburg virus is a member of the same family as the Ebola virus, both belonging to the Filoviridae family.', 'Yes, the Marburg virus is part of the Filoviridae family, just like Ebola.', 'Yes, the Marburg virus is a member of the Filoviridae family, which also includes the Ebola virus.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, Marburg virus is a member of the family Filoviridae, which includes both Marburg and Ebola viruses.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer correctly recalls all necessary information by stating that the Marburg virus is a member of the family Filoviridae and includes the Ebola virus, which aligns perfectly with the reference answers.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information; it directly addresses the question about the relationship between Marburg and Ebola viruses within the Filoviridae family.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times; it succinctly states the relationship between the viruses without redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is easily readable, fluent, and well-structured, making it clear and understandable for anyone reading it."
    },
    {
        "Question": "Explain the action of Domperidone.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nExplain the action of Domperidone.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Domperidone is a peripherally acting dopamine2-receptor antagonist', 'Domperidone is a dopamine D2 receptor antagonist that increases prolactin release through a blockade of dopamine D2 receptors in the pituitary gland. Increased prolactin levels will enhance breast milk production.', 'Domperidone is a dopamine receptor antagonist that accelerates gastric emptying but has less effect on bowel motility.', 'Domperidone is a dopamine-2 (D2) receptor antagonist that stimulates the release of stored prolactin in the anterior pituitary.', 'Domperidone stimulates gastric muscle contraction by antagonizing the inhibitory effects of dopamine on postsynaptic cholinergic neurons in the myenteric plexus.', 'Domperidone is a dopamine D2 receptor inhibitor that stimulates pituitary gonadotropins.', 'Domperidone is a dopamine D2 receptor inhibitor that stimulates pituitary gonadotropins and a dopamine-2 (D2) receptor antagonist that stimulates the release of stored prolactin in the anterior pituitary.', 'Domperidone is a dopamine-2 (D2) receptor antagonist. It works by inhibiting the D2 receptors, which leads to the stimulation of the release of stored prolactin in the anterior pituitary and also stimulates pituitary gonadotropins.', '”Patients received oral aciclovir for 84 days starting 96 hours after randomization and continued on oral aciclovir for 60 days after discharge”}</s>', 'Domperidone is a dopamine-2 (D2) receptor antagonist that stimulates the release of stored prolactin in the anterior pituitary. It is prescribed off-label in Canada and Australia to promote lactation in prolactin-deficient women.', 'Domperidone is a dopamine-2 (D2) receptor antagonist that inhibits dopamine receptors in the anterior pituitary. This inhibition stimulates the release of prolactin and gonadotropins stored in the anterior pituitary gland.', 'Domperidone works by blocking dopamine receptors in the brain. This inhibition results in an increase in the release of prolactin from the anterior pituitary gland, which can stimulate lactation']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nDomperidone is a dopamine antagonist that acts as a peripheral dopamine-2 (D2) receptor antagonist. It works by blocking the action of dopamine in the periphery, specifically in the gastrointestinal tract and other peripheral tissues, rather than in the central nervous system.\n\nWhen domperidone is administered, it binds to D2 receptors in the gastrointestinal tract, which are responsible for regulating gut motility and gastric emptying. By blocking these receptors, domperidone increases the tone of the lower esophageal sphincter, enhances gastric contractions, and accelerates gastric emptying.\n\nDomperidone also has antiemetic properties, which means it helps to prevent nausea and vomiting. This is thought to be due to its ability to block dopamine receptors in the chemoreceptor trigger zone (CTZ) of the brain, which is involved in the regulation of nausea and vomiting.\n\nAdditionally, domperidone has been shown to increase the release of prolactin, a hormone involved in milk production, which is why it is sometimes used off-label to stimulate lactation.\n\nOverall, the action of domperidone is to:\n\n* Increase gastric motility and emptying\n* Prevent nausea and vomiting\n* Stimulate milk production (off-label use)\n\nIt is worth noting that domperidone does not readily cross the blood-brain barrier, which reduces the risk of central nervous system side effects.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers all the essential aspects of Domperidone's action, including its role as a dopamine antagonist, its effects on gastrointestinal motility, its antiemetic properties, and its off-label use to stimulate lactation. These points align well with the reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include irrelevant information. It focuses specifically on the mechanisms and effects of Domperidone, without straying into unrelated details.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. Each point is distinct and contributes to a full understanding of Domperidone's action without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is written in a clear and fluent manner. The use of bullet points for summarizing the overall action enhances readability and makes the information easy to follow."
    },
    {
        "Question": "Which age group should never be tested for HIV infection?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhich age group should never be tested for HIV infection?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['There is no age group that should never be tested for HIV infection. In fact, the World Health Organization recommends that all people aged 15-64 years old get tested for HIV at least once in their lifetime, and those at high risk of infection get tested annually. Children born to mothers living with HIV also need to be tested regularly as they are at a higher risk of acquiring the virus through mother-to-child transmission. Early diagnosis and treatment of HIV can significantly improve health outcomes and reduce the risk of transmission. Therefore, it is important for all individuals, regardless of age, to know their HIV status and take appropriate measures to protect themselves and their partners.', 'There is no age group that should never be tested for HIV infection. The CDC recommends that all adults, adolescents, and pregnant women in health-care settings be offered HIV testing, and that those at high risk for HIV infection be tested at least annually. Additionally, the WHO recommends that all people aged 15-64 years should be offered an HIV test at least once in their lifetime. It is important to note that anyone can be at risk for HIV infection regardless of age, gender, or sexual orientation.', 'There is no age group that should never be tested for HIV infection. HIV testing is recommended for all individuals, regardless of age, as early detection and treatment can improve outcomes and prevent transmission.', 'There is no age group that should never be tested for HIV infection. Testing for HIV is important for everyone, regardless of age, to ensure early detection and appropriate care.', 'There is no age group that should never be tested for HIV infection.', 'There is no specific age group that should never be tested for HIV infection. Early testing and diagnosis is crucial for effective treatment and prevention of HIV transmission.', \"There is no age group that should never be tested for HIV infection. HIV can affect individuals of all ages, from newborns to older adults. In fact, late diagnosis of HIV is a significant issue, particularly among older individuals, heterosexuals, and non-Europeans. Therefore, it's crucial to get tested regardless of age to ensure early detection and treatment. This can help reduce the burden of late presentation and advanced disease\", 'No age group should be excluded from HIV testing. Early diagnosis and treatment are crucial in managing HIV infection and preventing its spread. Testing for HIV should be encouraged for all individuals, regardless of age, to ensure timely intervention and appropriate care.', 'There is no specific age group that should never be tested for HIV infection. HIV testing is recommended for everyone, regardless of age, as early diagnosis and treatment can help prevent the progression of the disease and reduce the risk of transmission to others.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, I do not see any information that suggests a specific age group should never be tested for HIV infection. In fact, the data suggests that HIV testing is recommended for various age groups, including adolescents and young adults (e.g., relations 7, 9, 10, 13, 14, 109).\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer correctly states that there is no age group that should never be tested for HIV infection, which aligns with the reference answers. However, it lacks the detailed recommendations from authoritative sources (e.g., WHO, CDC) and examples of high-risk groups (e.g., children born to mothers living with HIV) mentioned in the references.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer stays on topic and does not include irrelevant information. It focuses on the fact that HIV testing is recommended for various age groups, although it could be more precise by directly citing authoritative guidelines.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information. It succinctly delivers its point without redundancy.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is clear and easy to understand. However, the mention of 'relations 7, 9, 10, 13, 14, 109' without context may slightly detract from readability for those unfamiliar with these references."
    },
    {
        "Question": "Can fingolimod be used during pregnancy?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nCan fingolimod be used during pregnancy?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['No. Fingolimod has teratogenic potential and therefore should not be used during pregnancy.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data tables, fingolimod is contraindicated during pregnancy due to suspected risk of congenital malformations. However, in certain situations, fingolimod can be continued into pregnancy, such as for patients with high disease activity at high risk of relapse and disability progression, as mentioned in relation 9 \"WOMEN WITH MULTIPLE SCLEROSIS\" and \"FINGOLIMOD TREATMENT\".\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer mentions that fingolimod is contraindicated during pregnancy due to suspected risk of congenital malformations, which aligns with the reference answer. However, it also introduces additional context (high disease activity scenarios) not mentioned in the reference answer, which somewhat dilutes the core message.",
        "Information Precision Score": 2,
        "Information Precision Explanation": "The answer includes irrelevant details about exceptions (high disease activity scenarios) that are not part of the reference answer's straightforward 'No' recommendation. This additional information detracts from precision.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "There is no direct repetition of the same information, but the answer could be more concise.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is readable and fluent, though the additional context about exceptions slightly complicates the clarity compared to the simpler reference answer."
    },
    {
        "Question": "What does capnography measure?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat does capnography measure?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Capnography provides real-time measurement of carbon dioxide (CO2) in respiratory gases.', 'Capnography is a tool for continuous monitoring of carbon dioxide (CO2) concentration in exhaled gases during anesthesia and respiratory support.', 'Capnography measures the amount of carbon dioxide in exhaled air, indicating how well CO2 is being eliminated from the body.', 'Capnography is the measurement of carbon dioxide (CO2) concentration in a gas mixture.', \"Capnography measures the concentration of carbon dioxide (CO2) in exhaled breath. It provides real-time monitoring of the patient's ventilation and helps assess the adequacy of respiratory function.\", 'Capnography measures carbon dioxide in expired air.', 'Capnography measures the amount of carbon dioxide (CO2) in exhaled breath.', 'Capnography measures the concentration of carbon dioxide in exhaled air.', 'Capnography measures the amount of carbon dioxide in expired air.', 'Capnography measures carbon dioxide, volumetric capnography (VCAP) and arterial CO2 partial pressure, and arterial CO2 partial pressure.', 'Capnography is a non-invasive monitoring technique that measures the concentration or partial pressure of carbon dioxide (CO2) in exhaled breath, also known as end-tidal CO2 (EtCO2), over time to assess the adequacy of ventilation and the presence of abnormal ventilation or apnea.', \"Capnography measures end-tidal carbon dioxide concentrations. This means it monitors the amount of carbon dioxide that is exhaled at the end of each breath. It's a useful tool because it can detect abnormal ventilation or apnoea early.\", 'Capnography measures the concentration of carbon dioxide (CO2) in exhaled breath as a function of time, known as the capnogram.', 'Capnography measures end-tidal carbon dioxide concentrations, which can detect abnormal ventilation or apnoea early during cardiopulmonary resuscitation.', 'Capnography is a monitoring tool used in medicine that measures the concentration of carbon dioxide in the respiratory gases. It is often used during cardiopulmonary resuscitation to measure arterial CO2 partial pressure (PCO2). Additionally, it is used for monitoring end-tidal carbon dioxide concentrations.', 'Capnography measures the concentration of carbon dioxide at the end of exhalation, and it can detect abnormal breathing patterns or the absence of breath.', 'Capnography measures the concentration of carbon dioxide in the respiratory gases, which is a vital parameter during anesthesia and intensive care. It is used to monitor the inhaled and exhaled concentration or partial pressure of carbon dioxide. This can help detect abnormal ventilation or apnoea early', 'Capnography measures carbon dioxide concentration in exhaled air.', 'Capnography measures end-tidal carbon dioxide (CO2) concentrations during respiration. It can detect abnormal ventilation or apnea by monitoring CO2 levels in exhaled breath.', 'Capnography measures the concentration of carbon dioxide in the respiratory gases, specifically the end-tidal carbon dioxide concentrations. It is used to monitor the inhaled and exhaled concentration or partial pressure of carbon dioxide.', 'Capnography measures the end-tidal carbon dioxide (CO2) concentration in exhaled breath. It provides a non-invasive and continuous assessment of ventilation and can detect abnormal ventilation or apnea early during cardiopulmonary resuscitation.', 'Capnography measures the concentration of carbon dioxide in exhaled breath, which can be used to monitor the effectiveness of cardiopulmonary resuscitation.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nCapnography measures the concentration or partial pressure of carbon dioxide (CO2) in the respiratory gas, typically in the exhaled breath. It provides a continuous and non-invasive measurement of the level of CO2 in the air exhaled by a patient, which can be used to assess various aspects of respiratory function, including ventilation, perfusion, and metabolism.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer successfully captures the core idea of measuring CO2 concentration or partial pressure in respiratory gas, particularly exhaled breath. It also includes the non-invasive and continuous nature of the measurement, as well as its utility in assessing respiratory function. However, it could further elaborate on specific clinical applications (e.g., anesthesia, CPR) or mention 'end-tidal CO2,' which is a common term used in capnography.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and focuses on the key aspects of capnography: the measurement of CO2 in exhaled breath and its clinical relevance (ventilation, perfusion, metabolism). No irrelevant or extraneous information is provided.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer is concise and does not repeat any information. It efficiently communicates its points without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is clear, fluent, and easy to understand. The phrasing is professional yet accessible, making it readable for a wide audience."
    },
    {
        "Question": "Should men be immunized against Human Papilloma Virus?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nShould men be immunized against Human Papilloma Virus?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes, HPV is one of the most common causes of STD, and can cause genital warts and cancer (cervical, anal, vulvar, vaginal, penile, and oropharyngeal) in men and women.', 'Yes, men should be immunized against the Human Papilloma Virus (HPV). The HPV vaccine is highly effective in preventing HPV-related cancers and other diseases. HPV is known to contribute to several types of cancers in men, including those of the mouth, throat, anus, and penis, as well as causing genital warts. Additionally, HPV can cause cancers of the anus, oral cavity, and oropharynx in both men and women. Therefore, immunization against HPV can help reduce the risk of these cancers and diseases, making it beneficial for both genders.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, yes, men should be immunized against Human Papillomavirus (HPV). The data indicates that HPV is a common sexually transmitted infection that can cause various diseases, including genital warts, anal cancer, penile cancer, and oropharyngeal cancer, in both men and women.\n\nSeveral studies and health organizations, such as the Advisory Committee on Immunization Practices (ACIP) and the American College of Obstetricians and Gynecologists (ACOG), recommend that males aged 11-12 years should receive the HPV vaccine, and catch-up vaccination is recommended for males aged 13-21 years who were not vaccinated previously.\n\nThe data also shows that the HPV vaccine is effective in preventing HPV-related diseases in men, including genital warts, anal cancer, and penile cancer. Additionally, vaccinating men against HPV can also help reduce the transmission of HPV to their female partners, which can help prevent cervical cancer and other HPV-related diseases in women.\n\nOverall, the data suggests that HPV immunization is an important public health measure for preventing HPV-related diseases in both men and women, and that men should be immunized against HPV to protect their health and the health of their partners.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer comprehensively recalls all necessary information about why men should be immunized against HPV, including the diseases it can cause in men (genital warts, anal cancer, penile cancer, oropharyngeal cancer) and the benefits of vaccination (preventing transmission to female partners and reducing cervical cancer). It also mentions recommendations from authoritative bodies like ACIP and ACOG.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information. It focuses solely on the topic of HPV immunization in men, detailing the diseases prevented by the vaccine and the public health rationale behind vaccination.",
        "Information Repetition Score": "4",
        "Information Repetition Explanation": "The answer avoids significant repetition, but there is a slight overlap in mentioning the diseases caused by HPV (e.g., oropharyngeal cancer is mentioned again in the context of reducing transmission to female partners). However, this does not detract substantially from the clarity.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is highly readable and fluent. The structure is logical, transitions are smooth, and the language is clear and accessible to a broad audience."
    },
    {
        "Question": "Is sectoral Heterochromia associated with Crohn's disease?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs sectoral Heterochromia associated with Crohn's disease?\n\nHere are some reference answers:\n\n**Reference Answers:**\n[\"No. There are no published reports to suggest an association of sectoral Heterochromia with Crohn's disease.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThere is no information in the provided data tables that suggests a direct association between sectoral heterochromia and Crohn's disease.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "3",
        "Information Recall Explanation": "The answer correctly states that there is no direct association between sectoral heterochromia and Crohn's disease, but it does not explicitly reference the lack of published reports, which is a key detail in the reference answer. Thus, some necessary information is omitted.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer is precise and does not include irrelevant information. It directly addresses the question without adding extraneous details.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat any information. It makes its point clearly and concisely without redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is easily readable and fluent. It uses clear language and a straightforward structure."
    },
    {
        "Question": "List the most effective treatment methods for Madelung disease.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nList the most effective treatment methods for Madelung disease.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Lipectomy and liposuction are considered to be the most effective treatment methods for Madelung disease;', 'The most effective treatments for Madelung disease are lipectomy and liposuction.', 'Lipectomy and liposuction are considered to be the most effective treatment methods for Madelung disease.', 'The most effective treatment methods for Madelung disease are lipectomy and liposuction.', 'The most effective treatment methods for Madelung disease include lipectomy, liposuction, combined lipectomy and liposuction, and abstinence from alcohol.', 'Surgical resection of adipose tissue or liposuction is the most effective treatment methods for Madelung disease.', 'The most effective treatment methods for Madelung disease include surgical resection of adipose tissue and liposuction, which are commonly used to address the symptoms of the disorder.', 'The most effective treatment methods for Madelung disease are liposuction, surgical resection, and open surgical approach.', 'The most effective treatment methods for Madelung disease include liposuction, open surgical approach, surgical resection, lipectomy, surgical resection of adipose tissue, and considering the choice between liposuction versus surgery.', 'The most effective treatment methods for Madelung disease are surgical resection of adipose tissue or liposuction.', 'The most effective treatments for Madelung disease include surgical removal of the adipose tissue and liposuction.', 'The most effective treatment methods for Madelung disease can be liposuction, open surgical approach, and surgical resection.', 'The most effective treatment methods for Madelung disease are surgical resection of adipose tissue and liposuction. These treatments aim to remove the excessive fat deposits associated with the disease.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the most effective treatment methods for Madelung disease are:\n\n1. Surgical resection: This is the main method of improving the appearance, ensuring eradication of the tumor, and reducing the possibility of recurrence. (Source: Madelung Disease Epidemiology and Clinical Characteristics: a Systemic Review, Madelung's Disease - Case Series and Treatment by Tumescent Liposuction or Lipectomy)\n2. Lipectomy: This involves the surgical removal of fatty tissue and can be performed using a tumescent technique to reduce bleeding and improve the operative field. (Source: Lipectomy for madelung disease using tumescent technique: a cross-sectional study, Surgical therapy of Madelung's disease in the head and neck area)\n3. Liposuction: This is a minimally invasive procedure that can be used to remove excess fat and improve the appearance of the affected area. (Source: Madelung Disease Epidemiology and Clinical Characteristics: a Systemic Review, Surgical therapy of Madelung's disease in the head and neck area)\n4. Tumescent liposuction: This is a modified liposuction technique that uses a tumescent solution to reduce bleeding and improve the operative field. (Source: Lipectomy for madelung disease using tumescent technique: a cross-sectional study)\n5. Combined lipectomy and liposuction: This involves a combination of surgical removal of fatty tissue and liposuction, which can be performed in multiple stages. (Source: Combined surgical lipectomy and liposuction in the treatment of benign symmetrical lipomatosis of the head and neck)\n\nIt's worth noting that the most effective treatment method may vary depending on the individual case and the location and severity of the disease. A multidisciplinary approach, including medical and surgical treatments, may be necessary to achieve optimal results.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer effectively lists all the most effective treatment methods for Madelung disease as provided in the references, including surgical resection, lipectomy, liposuction, tumescent liposuction, and combined lipectomy and liposuction. The detailed explanations for each method enhance the completeness of the information.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer precisely focuses on the treatment methods for Madelung disease without including any irrelevant information. Each treatment method is described concisely and accurately, aligned with the references provided.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each treatment method is introduced and explained clearly without redundancy, maintaining a structured and efficient presentation of the information.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is highly readable and fluent. The use of bullet points and clear, concise sentences makes it easy to follow. The addition of sources for each method also adds to the credibility and clarity of the information provided."
    },
    {
        "Question": "What are common side effects of the progesterone-only pill (POP)?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are common side effects of the progesterone-only pill (POP)?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The progestogen-only pill may change your periods (lighter, more frequent or stop altogether). \\nBleeding (spotting) between periods.\\nAcne. \\nMood swings.\\nWeight gain. \\nChanges to libido.\\n\\nSpeak to a pharmacist or doctor if you have side effects that are a problem for you.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data tables, common side effects of the progesterone-only pill (POP) include:\n\n* Breakthrough bleeding and irregular spotting (mentioned in relation to the progesterone-only pill in several sources, including a study on the new progestin-only pill, Drospirenone 4 mg-only pill (DOP) in 24+4 regimen, and a review on progestogen-only pills and bleeding disturbances)\n* Abnormal bleeding patterns (mentioned in a study on the impact of drospirenone-only pill on coagulation markers and bleeding patterns)\n* Unscheduled bleeding/spotting (mentioned in a study on the impact of drospirenone-only pill on coagulation markers and bleeding patterns)\n* Amenorrhea (mentioned in a study on the impact of drospirenone-only pill on coagulation markers and bleeding patterns)\n\nIt's worth noting that these side effects are not exhaustive, and other side effects may occur. Additionally, the severity and frequency of these side effects can vary depending on the individual and the specific POP being used.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers several common side effects of the progesterone-only pill (POP), including breakthrough bleeding, irregular spotting, abnormal bleeding patterns, unscheduled bleeding/spotting, and amenorrhea. However, it misses other notable side effects such as acne, mood swings, weight gain, and changes to libido mentioned in the reference answers.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer is precise in listing specific bleeding-related side effects, but it lacks precision by not including other common side effects. The focus on bleeding patterns makes the answer somewhat narrow.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. Each listed side effect is distinct, though they are all related to bleeding patterns.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is clearly written and well-structured, making it easy to understand. The use of bullet points enhances readability. However, the mention of data tables and specific studies, while informative, could slightly detract from fluency for a general audience."
    },
    {
        "Question": "What is the mechanism of action of Peresolimab?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the mechanism of action of Peresolimab?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Peresolimab is a humanized IgG1 monoclonal antibody designed to stimulate the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, Peresolimab (entity ID 2) is a humanized IgG1 monoclonal antibody that stimulates the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway. This is stated in the description of entity ID 2, \"A humanized IgG1 monoclonal antibody designed to stimulate the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway.\"\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer fully captures the reference answer by stating that Peresolimab is a humanized IgG1 monoclonal antibody designed to stimulate the endogenous PD-1 inhibitory pathway. All necessary information is reported.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information. It strictly mentions the mechanism of action of Peresolimab as described in the reference.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition of information. The answer clearly and succinctly states the mechanism of action without redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is easily readable and fluent, clearly conveying the mechanism of action of Peresolimab in a concise and understandable manner."
    },
    {
        "Question": "Explain the difference between eosinophilic esophagitis and reflux-induced esophagitis.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nExplain the difference between eosinophilic esophagitis and reflux-induced esophagitis.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['EoE can be distinguished from GERD using a scoring system of clinical and endoscopic features. Many aspects of EoE were statistically distinct from GERD when controlling for age. Male sex, dysphagia, history of food impaction, absence of pain/heartburn, linear furrowing, and white papules were the distinguishing variables', 'Eosinophilic esophagitis is a chronic immune-mediated disease characterized by eosinophilic infiltration due to antigen exposure, while reflux-induced esophagitis is typically caused by the backflow of stomach acid into the esophagus.', 'Eosinophilic esophagitis is a chronic, immune-mediated disease characterized by eosinophilic infiltration, leading to esophageal dysfunction and inflammation, while reflux-induced esophagitis is a condition caused by the backflow of stomach acid into the esophagus, causing inflammation and damage to the esophageal lining.', 'Eosinophilic esophagitis is a chronic immune-mediated disease characterized by eosinophilic infiltration due to antigen exposure, while reflux-induced esophagitis is caused by the backflow of stomach acid into the esophagus, leading to inflammation.', 'Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disease characterized by eosinophilic infiltration, leading to esophageal dysfunction, inflammation, and fibrosis in the absence of gastroesophageal reflux. Reflux-induced esophagitis is caused by gastric acid reflux, leading to chronic esophagitis, and its course of treatment is different from EoE.', 'Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disease characterized by eosinophilic infiltration, leading to esophageal dysfunction, inflammation, and fibrosis. Gastroesophageal reflux disease (GERD) is a condition in which acid from the stomach enters the esophagus.', 'Eosinophilic esophagitis (EoE) and reflux-induced esophagitis are two different conditions that affect the esophagus. \\n\\nEosinophilic esophagitis is a chronic, immune-mediated disease characterized by eosinophilic infiltration, leading to esophageal dysfunction, inflammation, and asal cell hyperplasia. It is an emerging form of food allergy and is associated with antigen-driven type 2 inflammation. The cause of EoE is thought to be due to an inflammatory response triggered by exposure to dietary or environmental antigen.\\n\\nOn the other hand, reflux-induced esophagitis, also known as gastroesophageal reflux disease (GERD), is a condition in which acid from the stomach enters the esophagus. It is a chronic condition that can cause symptoms such as heartburn, chest pain, and difficulty swallowing. Reflux-induced esophagitis is caused by a', 'Eosinophilic esophagitis (EoE) is a chronic and progressive immune-mediated disease of the esophagus associated with antigen-driven type 2 inflammation and symptoms of esophageal dysfunction. In contrast, gastroesophageal reflux disease (GERD) is a condition in which acid from the stomach enters the esophagus.', 'Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disease characterized by eosinophilic infiltration, leading to esophageal dysfunction, inflammation, and tissue damage. Reflux-induced esophagitis, on the other hand, is caused by the backflow of stomach contents into the esophagus, leading to inflammation and damage to the esophageal lining. EoE is not caused by reflux, but rather by an immune response to an unknown trigger.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nEosinophilic esophagitis (EoE) and reflux-induced esophagitis are two distinct conditions that affect the esophagus, but they have different underlying pathophysiology and clinical presentations.\n\nEosinophilic esophagitis is a chronic immune-mediated disease characterized by an infiltration of eosinophils, a type of white blood cell, into the esophageal mucosa. This leads to inflammation, damage to the esophageal lining, and symptoms such as dysphagia (difficulty swallowing), food impaction, and chest pain. EoE is often associated with allergies, particularly food allergies, and can be triggered by exposure to allergens such as peanuts, milk, or soy.\n\nReflux-induced esophagitis, on the other hand, is a condition caused by the backflow of stomach acid into the esophagus, leading to inflammation and damage to the esophageal lining. This is often a result of gastroesophageal reflux disease (GERD), where the lower esophageal sphincter (LES) is weakened, allowing stomach acid to flow back up into the esophagus. Symptoms of reflux-induced esophagitis include heartburn, regurgitation, and difficulty swallowing.\n\nKey differences between the two conditions include:\n\n1. **Eosinophilic infiltrate**: EoE is characterized by a significant eosinophilic infiltrate, whereas reflux-induced esophagitis typically has a minimal or absent eosinophilic infiltrate.\n2. **Symptoms**: EoE often presents with dysphagia, food impaction, and chest pain, whereas reflux-induced esophagitis is more commonly associated with heartburn, regurgitation, and difficulty swallowing.\n3. **Response to treatment**: EoE typically requires treatment with topical corticosteroids or elemental diet, whereas reflux-induced esophagitis can often be managed with proton pump inhibitors (PPIs) or other acid-reducing medications.\n4. **Histopathology**: EoE is characterized by a distinct histopathological pattern, including increased eosinophils, basal cell hyperplasia, and eosinophilic microabscesses, whereas reflux-induced esophagitis typically shows a more nonspecific inflammatory infiltrate.\n5. **Association with allergies**: EoE is often associated with allergies, particularly food allergies, whereas reflux-induced esophagitis is not typically linked to allergies.\n\nIn summary, while both conditions can cause inflammation and damage to the esophagus, eosinophilic esophagitis is a distinct entity characterized by a significant eosinophilic infiltrate, specific symptoms, and a different response to treatment.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer comprehensively covers the key differences between eosinophilic esophagitis (EoE) and reflux-induced esophagitis, including pathophysiology, clinical presentations, symptoms, treatment responses, and histopathology. However, it could slightly improve by explicitly mentioning the absence of GERD in EoE and the antigen-driven nature of EoE, as seen in the references.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer provides relevant and precise information without including unnecessary details. Each point made directly addresses the differences between the two conditions, aligning well with the reference answers.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of the same information. The answer clearly and succinctly differentiates between the two conditions without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand. The use of bullet points for key differences enhances clarity and readability."
    },
    {
        "Question": "What are the most common symptoms of fibroids?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are the most common symptoms of fibroids?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['heavy/painful periods\\nabdominal pain\\nlower back pain\\na frequent need to urinate\\nconstipation\\npain or discomfort during sex', 'The most common symptoms associated with uterine fibroids are heavy menstrual bleeding, painful menstrual cramping, prolonged periods, anemia, frequent urination, back pain, pelvic pressure, and, in rare cases, infertility or miscarriage.', 'The most common symptoms of fibroids are heavy or prolonged menstrual bleeding, abnormal uterine bleeding, resultant anemia, pelvic pain, infertility, and/or recurrent pregnancy loss. Other symptoms include pressure sensations, dysmenorrhea, chronic pelvic pain, increased urinary frequency, bowel disturbance, bladder dysfunction, and pain during intercourse. Some women with fibroids may not experience any symptoms.', 'The most common symptoms of uterine fibroids include heavy menstrual bleeding, abnormal uterine bleeding, anemia, pelvic pain, infertility, miscarriages, an enlarged abdomen, pressure symptoms involving the bladder and bowels (such as frequent urination or constipation), pain during intercourse, dysfunctions of bladder/bowel leading to urinary incontinence/retention, and chronic vaginal discharge.', 'The most common symptoms of uterine fibroids include:\\n\\n1. Heavy or prolonged menstrual bleeding (menorrhagia) which can lead to anemia\\n2. Pelvic pain and pressure \\n3. Painful periods (dysmenorrhea)\\n4. Increased abdominal girth or enlarged abdomen\\n5. Frequent urination, urinary incontinence or retention due to pressure on the bladder\\n6. Constipation or bowel disturbance due to pressure on the bowels\\n7. Pain during intercourse\\n8. Infertility or recurrent pregnancy loss\\n\\nSome women with fibroids may be asymptomatic while others experience a combination of these symptoms. Abnormal bleeding, pelvic pain/pressure and an enlarged abdomen are the most frequently reported symptoms.', 'Fibroids, also known as uterine fibroids, can sometimes be asymptomatic, meaning they present no noticeable symptoms. However, when symptoms do occur, they can include heavy menstrual bleeding, which can lead to anemia and tiredness, and pelvic pressure and pain. Other common symptoms include chronic vaginal discharge, pain during periods, and pain during intercourse. Some people with fibroids may also experience a protrusion of the abdomen and dysfunctions of the bladder or bowel, leading to urinary incontinence or retention, and constipation. Additionally, fibroids can be associated with reproductive issues such as impaired fertility, complications with conceiving, and adverse obstetric outcomes.', 'The most common symptoms of fibroids include being asymptomatic, heavy menstrual bleeding, pelvic pressure, and pain. Other symptoms can include abnormal menstrual bleeding, anaemia, tiredness, chronic vaginal discharge, pain during periods, protrusion of the abdomen, pain during intercourse, dysfunctions of bladder/bowel, urinary incontinence/retention, constipation, impaired fertility, conceiving complications, and adverse obstetric outcomes.', 'The most common symptoms of fibroids include heavy menstrual bleeding, pelvic pressure, pain during periods, anaemia, tiredness, chronic vaginal discharge, protrusion of the abdomen, pain during intercourse, bladder and bowel dysfunctions, urinary incontinence or retention, constipation, impaired fertility, conceiving complications, and adverse obstetric outcomes.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the data provided, the most common symptoms of fibroids are:\n\n1. Menorrhagia (heavy menstrual bleeding)\n2. Pelvic pain\n3. Abnormal uterine bleeding\n4. Pelvic pressure\n5. Infertility\n6. Dysmenorrhea (painful menstruation)\n7. Constipation\n8. Urinary frequency or retention\n9. Bloating\n10. Back pain\n\nThese symptoms are mentioned in various relations and entities related to fibroids, indicating their association with the condition.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer recalls all the necessary information from the reference answers, including heavy menstrual bleeding (menorrhagia), pelvic pain, abnormal uterine bleeding, pelvic pressure, infertility, dysmenorrhea, constipation, urinary frequency/retention, bloating, and back pain. It covers all major symptoms mentioned in the references.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include irrelevant information. All the listed symptoms are directly related to fibroids, as confirmed by the reference answers.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of the same information in the answer. Each symptom is listed clearly and concisely without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is very readable and well-structured, with each symptom listed in a clear, numbered format. The language is fluent and easy to understand."
    },
    {
        "Question": "What is the target of Selpercatinib?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the target of Selpercatinib?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Selpercatinib is an orally-administered, selective inhibitor of rearranged during transfection (RET) kinase approved for the treatment of advanced RET fusion-positive non-small cell lung cancer (NSCLC).']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nSelpercatinib is a highly selective RET kinase inhibitor, which means it targets the RET (Rearranged during Transfection) protein tyrosine kinase. Specifically, it targets the RET receptor tyrosine kinase pathway, which is involved in the development of certain types of cancer, such as medullary thyroid cancer, non-small cell lung cancer, and other solid tumors with RET gene fusions or mutations.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer includes all the necessary information about Selpercatinib being a selective RET kinase inhibitor and targeting the RET receptor tyrosine kinase pathway. It also mentions its relevance to specific cancers (medullary thyroid cancer, non-small cell lung cancer, and other solid tumors with RET gene fusions or mutations), which is more detailed than the reference answer.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information. It focuses solely on the target of Selpercatinib and its implications in specific cancers, aligning well with the reference answer.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information. It clearly describes the target (RET kinase) and its role in various cancers without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easily understandable. It uses appropriate terminology while maintaining clarity, making it accessible to readers."
    },
    {
        "Question": "What is IL-35?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is IL-35?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['IL-35 is a member of the IL-12 family and is an immunosuppressive and anti-inflammatory cytokine secreted mainly by regulatory cells. Structurally, IL-35 is a heterodimeric cytokine. Interleukin 35 (IL-35) is involved in the pathogenesis of endometriosis by suppressing immunoreaction and promoting endometrial cell proliferation', 'IL-35 is a heterodimeric cytokine belonging to the IL-12 family, composed of the IL-12p35 and Ebi3 subunits, known for its immunosuppressive activities.', 'IL-35 is a novel cytokine that suppresses the immune response through the expansion of regulatory T cells and suppression of Th17 cell development. It includes two subunits, p35 and Epstein-Barr virus-induced gene 3, and activates subsequent signaling pathways by binding to receptors to mediate signal transduction, thereby modulating the immunoregulatory functions of T cells, B cells, macrophages, and other immune cell types. IL-35 has been found to be overexpressed in a variety of cancers and may exert its function both on antitumor immune responses as well as directly on tumor cells. Plasma IL35 levels have been found to be lower in ITP patients and negatively correlated with the levels of T helper-1 cells in ITP patients, suggesting that IL-35 appears to contribute to the loss of immunological self-tolerance in ITP patients by modulating T cells and immunoregulatory cytokines.', 'IL-35 is a new IL-12 family member, comprised of Ebi3 and p35.\\nIL-35 has a different mode of action than the other IL-12 cytokines: IL-12 and IL-23 enhance IFN-gamma production, and IL-27 induces Tbet and STAT-1 signaling.\\nIL-35, on the other hand, does not signal via a receptor chain but acts by directly stimulating suppressive T regulatory cells.', 'IL-35 is a novel cytokine suppressing the immune response through the expansion of regulatory T cells and suppression of Th17 cell development.', 'IL-35 is a cytokine that belongs to the IL-12 family. It is an immunosuppressive and anti-inflammatory cytokine secreted mainly by regulatory cells. IL-35 has therapeutic and diagnostic potential in cancer and autoimmune diseases.', 'Interleukin 35 (IL-35) is involved in the pathogenesis of endometriosis by suppressing immunoreaction and promoting endometrial cell proliferation.', 'Interleukin-35 (IL-35), secreted by regulatory T cells (Treg) and B cells, is immunosuppressive under both physiological and pathological conditions.', 'IL-35 is an anti-inflammatory cytokine that mediates immunosuppression of T cells in various physiological and pathological conditions.', 'IL-35 is a cytokine, a type of protein, that is secreted by regulatory T cells and B cells. It plays an immunosuppressive role under both physiological and pathological conditions, meaning it can suppress or reduce the immune response.', 'IL-35 is a type of interleukin that mediates immunosuppression of T cells in autoimmune diseases, secreted by regulatory T cells and B cells.', 'IL-35 is an anti-inflammatory cytokine secreted by regulatory T cells (Treg) and B cells, exerting immunosuppressive effects in various physiological and pathological conditions.', 'Interleukin-35 (IL-35) is a heterodimeric cytokine consisting of two subunits, IL-12A and EBV-induced gene 3 (EBI3), that is produced mainly by regulatory T cells (Treg cells) and inhibits the activation of T helper (Th1 and Th17) and dendritic cells to exert anti-inflammatory effects.', 'IL-35 is a cytokine that is involved in the pathogenesis of endometriosis by suppressing immunoreaction and promoting endometrial cell proliferation.', 'Interleukin 35 (IL-35) is a cytokine that is secreted by regulatory T cells (Treg) and B cells, and is immunosuppressive under both physiological and pathological conditions.', 'IL-35 is an immunosuppressive cytokine that is secreted by regulatory T cells (Treg) and B cells. It plays a role in maintaining Treg phenotypes, suppressing CD8+ T-cell activation, and mediating immunosuppression in autoimmune diseases and sepsis.', 'IL-35 is a cytokine that is produced by T cells and regulates the immune response. It is a member of the interleukin 1 family and is involved in the regulation of immune responses, particularly in the context of autoimmune diseases.', 'IL-35 is an anti-inflammatory cytokine that is secreted by regulatory T cells and B cells, known for its immunosuppressive effects under both physiological and pathological conditions.', 'IL-35 (Interleukin-35) is an anti-inflammatory cytokine secreted by regulatory T cells (Treg) and B cells. It has immunosuppressive effects on T cells under both physiological and pathological conditions, and is involved in mediating immunosuppression in autoimmune diseases.', 'IL-35 is an immunosuppressive cytokine, which is secreted by regulatory T cells and B cells. It plays a role in suppressing the immune response under both normal and pathological conditions', 'IL-35 is a cytokine that is involved in immunosuppression. It is secreted by regulatory T cells (Treg) and B cells. IL-35 mediates immunosuppression of T cells in autoimmune diseases.', 'IL-35 is a cytokine that downregulates the immune response of effector CD4+ T cells in sepsis by restricting high mobility group box-1 protein-dependent autophagy.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nIL-35 is a cytokine that is part of the IL-12 cytokine family. It is a heterodimer composed of two subunits, p35 and EBI3, and plays a crucial role in regulating the immune response. IL-35 has immunosuppressive effects, which means it helps to suppress or reduce the activity of the immune system. It does this by inducing the expansion of regulatory T cells and regulatory B cells, which are types of immune cells that help to prevent the immune system from overreacting and causing damage to the body.\n\nIL-35 has been shown to be involved in various immune-related processes, including the regulation of inflammation, the suppression of autoimmune diseases, and the promotion of tolerance. It has been studied in the context of various diseases, including sepsis, autoimmune rheumatic diseases, and cancer.\n\nIL-35 has been found to have anti-inflammatory properties, and it has been shown to reduce the production of pro-inflammatory cytokines, such as TNF-alpha and IL-6, which are involved in the development of inflammation. It has also been shown to promote the production of anti-inflammatory cytokines, such as IL-10, which helps to reduce inflammation.\n\nOverall, IL-35 is an important cytokine that plays a crucial role in regulating the immune response and maintaining immune homeostasis. Its immunosuppressive effects make it a potential target for the treatment of autoimmune diseases and other conditions characterized by excessive immune activation.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer captures key aspects of IL-35 from the reference answers, such as its classification within the IL-12 family, its heterodimeric structure (p35 and EBI3), and its immunosuppressive role. However, it misses some details like its secretion by regulatory T cells (Treg) and B cells, and its role in specific conditions like endometriosis or ITP.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise, focusing on IL-35 without straying into irrelevant information. It accurately describes its structure, function, and implications in immune regulation without unnecessary details.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "There is a slight repetition regarding IL-35's immunosuppressive effects and its role in immune regulation, but the repetition is minimal and serves to reinforce key points rather than being redundant.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clear, and fluent, making it easy to understand. The sentences flow logically, and technical terms are explained in a straightforward manner."
    },
    {
        "Question": "What are the transmission mechanisms of the human Ebola infection?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are the transmission mechanisms of the human Ebola infection?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Ebolaviruses spread through contact via broken skin or mucous membranes in the eyes, nose, or mouth with:\\nBlood or body fluids of a person who is sick with or has died from Ebola disease.\\nObjects contaminated with body fluids from a person who is sick with or has died from Ebola disease.\\nInfected fruit bats and primates.\\nSemen from men survivors of Ebola disease (via oral, vaginal, or anal sex).', 'Human-to-human transmission of Ebola takes place through direct contact with broken skin, secretions, organs or other bodily fluids of infected people or surfaces and materials contaminated with these fluids. Exposure to objects contaminated with the virus, reuse of unsterilized needles or other sharp objects previously used for injecting infected patients can also transmit the virus. Burial ceremonies that involve direct contact with the body of the deceased person can also play a role in the transmission of Ebola. Sexual transmission, particularly among males, several weeks after recovery from the disease has been reported.', 'The transmission mechanisms of human Ebola infection are primarily through direct contact with infectious bodily fluids, such as blood, sweat, and saliva. This can occur through activities like touching, shaking hands, or being exposed to the vomit or diarrhea of an infected person. In addition, transmission can also happen through contact with contaminated objects and surfaces, including clothing and medical equipment. Airborne transmission has been suspected but not proven in some studies, and the role of aerosol transmission in Ebola virus spread is still being researched. The virus can also be transmitted through sexual contact, as well as from mother to child during pregnancy or breastfeeding. Healthcare workers are at higher risk of infection due to their exposure to patients with Ebola, highlighting the importance of proper personal protective equipment (PPE) and strict adherence to infection control protocols.', 'The transmission of human Ebola infection occurs through direct contact with infected bodily fluids, such as blood, semen, saliva, urine, and breast milk. It can also be transmitted through indirect contact with contaminated surfaces or objects. Sexual transmission has been documented, as the virus can persist in the testes. Additionally, Ebola virus can be transmitted from animals to humans through contact with infected animals or consumption of their meat. The virus is not transmitted through the air or by casual contact.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, the transmission mechanisms of the human Ebola infection are:\n\n1. Direct contact with infected bodily fluids, such as blood, semen, saliva, urine, and breast milk (Relation ID 2).\n2. Contact with contaminated objects, such as needles (Relation ID 9).\n3. Human-to-human transmission through direct contact with infected individuals (Relation ID 31).\n4. Indirect contact with infected individuals through contaminated surfaces or objects (Relation ID 10).\n5. Spillover events, where the virus is transmitted from animals to humans, often through close contact and pathogen spillover (Relation ID 13).\n\nThese transmission mechanisms are supported by the text sources provided, including:\n\n* Relation ID 2: \"Ebola virus can be transmitted through contact with infected urine.\"\n* Relation ID 9: \"Ebola virus disease can be transmitted through contaminated objects like needles.\"\n* Relation ID 31: \"Ebola virus disease is caused by the Ebola virus.\"\n* Relation ID 10: \"Transmission of EBOV has been described to occur via contact with infected bodily fluids, supported by data indicating that infectious EBOV could be cultured from blood, semen, saliva, urine, and breast milk.\"\n* Relation ID 13: \"Pathogen spillover often occurs at points of animal-human interface.\"\n\nIt is worth noting that the text sources also mention that Ebola virus can be transmitted through other means, such as through the bite of an infected animal (Relation ID 56), but these are not as well-supported by the data as the above-mentioned mechanisms.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers most of the key transmission mechanisms of Ebola, including direct contact with bodily fluids, contaminated objects, human-to-human transmission, and spillover events. However, it misses some nuances like the role of burial ceremonies, sexual transmission from survivors, and the specific mention of infected fruit bats and primates from the reference answers.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer is generally precise but includes some redundancy (e.g., 'direct contact with infected individuals' and 'direct contact with infected bodily fluids' could be merged for clarity). It also includes less-supported details like Relation ID 56, which is flagged as not well-supported, slightly detracting from precision.",
        "Information Repetition Score": 3,
        "Information Repetition Explanation": "The answer repeats the idea of 'direct contact' in multiple points (1, 3, and indirectly in 4), which could be streamlined. The enumeration of Relation IDs is somewhat repetitive and could be integrated more smoothly into the text.",
        "Readability Score": 3,
        "Readability Explanation": "The answer is structured clearly with numbered points, but the inclusion of Relation IDs disrupts flow and makes it less readable for a general audience. The phrasing is clinical but could be more fluent without sacrificing accuracy."
    },
    {
        "Question": "What is the mechanisms of action of Sotorasib?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the mechanisms of action of Sotorasib?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Sotorasib was the first-in-class KRAS inhibitor to reach the US and European market, and its pharmacological inhibition is restricted to the KRAS p.G12C mutation.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nSotorasib is a direct and irreversible covalent inhibitor of the KRAS(G12C) mutant protein. It targets the KRAS G12C mutation, which is a specific mutation in the KRAS gene that is found in some cases of lung cancer and is targeted by the drug Sotorasib. \n\nSotorasib works by binding to the KRAS G12C mutant protein and covalently modifying it, thereby inhibiting its ability to bind to and activate downstream signaling pathways that promote cell growth and survival. This leads to a decrease in tumor growth and an increase in tumor cell death.\n\nThe specific mechanism of action of Sotorasib is as follows:\n\n1. Sotorasib binds to the KRAS G12C mutant protein, forming a covalent bond.\n2. This binding causes a conformational change in the KRAS protein, which prevents it from binding to and activating downstream signaling pathways.\n3. The inhibition of downstream signaling pathways leads to a decrease in cell growth and an increase in cell death, resulting in tumor shrinkage and improved overall survival.\n\nOverall, Sotorasib is a targeted therapy that specifically targets the KRAS G12C mutation, which is a common driver of lung cancer. By inhibiting the KRAS G12C mutant protein, Sotorasib provides a new treatment option for patients with KRAS G12C-mutated lung cancer.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer provides a comprehensive explanation of the mechanism of action of Sotorasib, including its covalent binding to the KRAS G12C mutant protein, the conformational change it induces, and the subsequent inhibition of downstream signaling pathways. This covers all key aspects mentioned in the reference answer and expands with additional relevant details.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is highly precise, focusing solely on the mechanism of action of Sotorasib without including any irrelevant information. It accurately describes the drug's interaction with the KRAS G12C mutation and its effects on downstream pathways.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does a good job of avoiding excessive repetition. While it restates that Sotorasib targets the KRAS G12C mutation in different parts of the answer, it primarily elaborates on different aspects of the mechanism each time, maintaining clarity and flow.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured and easy to read. It uses clear and fluent language, breaks down the mechanism into a numbered list for clarity, and provides a coherent summary. The explanation is both detailed and accessible to the reader."
    },
    {
        "Question": "What is the vector for coxiella burnetii transmission?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the vector for coxiella burnetii transmission?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Ticks are the common vector for Coxiella burnetii', 'Ticks, including species like Hyalomma lusitanicum, I. ricinus, and Ornithodoros moubata, act as vectors for the transmission of Coxiella burnetii.', 'Ticks are the vector for coxiella burnetii transmission.', 'The vector for Coxiella burnetii transmission is primarily through inhalation of infectious aerosols, although ticks have also been suggested as potential vectors.', 'Coxiella burnetii is transmitted by ticks.', 'Yes, Coxiella burnetii is transmitted by ticks.', 'The vector for Coxiella burnetii transmission is ticks, specifically through tick feces and saliva.', 'Ticks are the vectors for transmitting Coxiella burnetii.', 'The vector for Coxiella burnetii transmission is ticks.', 'Coxiella burnetii is transmitted by ticks, including through their feces and saliva.', 'The vector for Coxiella burnetii transmission is the tick.', 'The vector for Coxiella burnetii transmission is primarily ticks.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nCoxiella burnetii, the causative agent of Q fever, can be transmitted through various vectors, including:\n\n* Ticks: Several tick species, such as Amblyomma, Dermacentor, and Hyalomma, have been found to carry C. burnetii and can transmit it to humans and animals.\n* Aerosols: C. burnetii can also be transmitted through inhalation of aerosols contaminated with the bacterium.\n* Co-feeding: Co-feeding, where an infected tick feeds on the same host as an uninfected tick, can also facilitate the transmission of C. burnetii.\n\nHowever, ticks are considered the primary vectors of C. burnetii transmission in many parts of the world.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers the vectors for Coxiella burnetii transmission, including ticks, aerosols, and co-feeding. It also specifies tick species such as Amblyomma, Dermacentor, and Hyalomma, which aligns well with the reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise, providing relevant details about the vectors without including any extraneous or irrelevant information. It clearly differentiates between primary and other transmission routes.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information. Each vector and mode of transmission is mentioned once, and the explanation is concise without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to read. The bullet points enhance clarity, and the concluding sentence summarizes the main point effectively."
    },
    {
        "Question": "Methotrexate is an antifolate medication.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nMethotrexate is an antifolate medication.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes', 'Yes, methotrexate is an antifolate medication', 'Yes, methotrexate is indeed an antifolate medication.', 'Yes, Methotrexate is an antifolate medication', 'Yes, Methotrexate is an antifolate medication.', 'Yes, that is correct. Methotrexate is an antifolate medication.', 'Yes, methotrexate is an antifolate medication.', 'Methotrexate (MTX) is an antifolate medication.', 'Yes, Methotrexate is indeed an antifolate medication.', 'Yes, Methotrexate (MTX) is an antifolate medication.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nMethotrexate is indeed an antifolate medication, which means it works by inhibiting the action of folate, a vital nutrient essential for various bodily functions, including DNA synthesis and repair.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer correctly identifies methotrexate as an antifolate medication and provides additional information about its mechanism of action (inhibiting folate). While the reference answers do not typically include the mechanism, this detail is not incorrect and enhances the answer.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is concise and directly addresses the question without including irrelevant information. The additional detail about folate's role is relevant and adds value.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information. It states the fact and elaborates briefly without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is clear, fluent, and easy to understand. The use of 'indeed' and the brief explanation improve readability."
    },
    {
        "Question": "Is GC1118 effective for glioblastoma?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs GC1118 effective for glioblastoma?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['No. GC1118 did not prolong progression free survival of patients with glioblastoma.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, GC1118 is mentioned as a treatment option for glioblastoma patients with EGFR amplification. According to relation 47, \"Glioblastoma patients with RET amplification may benefit from treatment with selpercatinib, which can penetrate the blood-brain barrier and target the RET protein.\" However, GC1118 is not explicitly mentioned as a treatment for glioblastoma in the provided data, but it is a drug used to treat recurrent glioblastoma patients with EGFR amplification (relation 81).\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 2,
        "Information Recall Explanation": "The answer partially recalls the necessary information by mentioning GC1118 and glioblastoma, but it largely misses the key point from the reference answers—that GC1118 did not prolong progression-free survival in glioblastoma patients. Instead, it introduces irrelevant details about RET amplification and selpercatinib.",
        "Information Precision Score": 1,
        "Information Precision Explanation": "The answer includes irrelevant information about RET amplification and selpercatinib, which is not related to the question about GC1118's effectiveness for glioblastoma. The core question is not directly addressed, leading to poor precision.",
        "Information Repetition Score": 3,
        "Information Repetition Explanation": "There is minimal repetition within the answer, but the inclusion of unrelated details (RET amplification, selpercatinib) detracts from the clarity of the response.",
        "Readability Score": 3,
        "Readability Explanation": "The answer is readable and fluent but suffers from logical disorganization due to the introduction of off-topic information. This affects overall coherence."
    },
    {
        "Question": "Is COACH syndrome a rare autosomal recessive genetic disease characterized by liver fibrosis and related to portal hypertension.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs COACH syndrome a rare autosomal recessive genetic disease characterized by liver fibrosis and related to portal hypertension.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, which leads to severe complications related to portal hypertension.', 'Yes, COACH syndrome is indeed a rare genetic condition involving liver fibrosis and portal hypertension.', 'Yes, COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, which can lead to severe complications related to portal hypertension.', 'Yes, COACH syndrome is a rare autosomal recessive genetic disease characterized by congenital hepatic fibrosis and portal hypertension.', 'Yes, COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, which leads to severe complications related to portal hypertension.', 'Yes, COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, leading to severe complications associated with portal hypertension.', 'Yes, COACH syndrome is a rare autosomal recessive genetic disease that is characterized by liver fibrosis leading to severe complications related to portal hypertension.', 'No, COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, which can lead to severe complications related to portal hypertension.', 'Yes, COACH syndrome is indeed a rare autosomal recessive genetic disease characterized by liver fibrosis, which can lead to severe complications related to portal hypertension.', 'Yes, COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis and related to portal hypertension.', '”the gene for COACH syndrome is located on chromosome 10\"}', 'Yes, COACH syndrome is a rare autosomal recessive genetic disease characterized by cerebellar vermis hypoplasia, oligophrenia, ataxia, coloboma, and hepatic fibrosis, and related to portal hypertension.', 'Yes, COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, which can lead to severe complications associated with portal hypertension.', 'Yes, COACH syndrome is a rare autosomal recessive genetic disease. It is characterized by liver fibrosis, which can lead to severe complications related to portal hypertension.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis and related to portal hypertension.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer accurately recalls all the necessary information about COACH syndrome being a rare autosomal recessive genetic disease characterized by liver fibrosis and its relation to portal hypertension, which aligns with the reference answers.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information. It succinctly states the key characteristics of COACH syndrome without adding extraneous details.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each piece of information is stated clearly and only once.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is easily readable and fluent. The sentence is well-structured and clearly conveys the information about COACH syndrome."
    },
    {
        "Question": "Which symptoms could indicate depression in young children?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhich symptoms could indicate depression in young children?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['sadness\\nirritability\\nabulia\\nfatigue\\ninability to concentrate\\neat too little or too much\\nsleep too little or too much\\nhave big changes in weight\\nfeelings of guilt, worthlessness, emptiness\\nhave thoughts about suicide \\nself-harming', \"Symptoms that could indicate depression in young children include: * Persistent feelings of sadness, hopelessness, and helplessness * Loss of interest in activities they used to enjoy * Changes in appetite or sleep patterns * Fatigue or loss of energy * Difficulty concentrating or making decisions * Thoughts of death or suicide * Behavioral problems, such as acting out or being more irritable than usual * Physical complaints, such as headaches or stomachaches, that do not have a clear medical cause. , It's important to note that young children may not be able to articulate their feelings of sadness or hopelessness, so it's important to pay attention to changes in their behavior and mood. If you suspect that your child may be experiencing depression, it's important to seek professional help from a mental health provider.\", 'Symptoms that could indicate depression in young children include persistent sadness or irritability, loss of interest in activities, changes in appetite or weight, sleep disturbances, fatigue or low energy, difficulty concentrating or making decisions, feelings of worthlessness or guilt, recurrent thoughts of death or suicide, physical complaints without a clear medical cause, and social withdrawal or isolation.', 'Symptoms of depression in young children can include persistent sadness, irritability, changes in appetite, difficulty sleeping, and a lack of interest in activities they once enjoyed.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data tables, the following symptoms could indicate depression in young children:\n\n1. **Irritability**: This is a common depressive behavior in children with depressive disorders (Relation id: 42).\n2. **Changes in appetite or sleep patterns**: These are emotional and behavioral changes that can occur in children, characterized by persistent feelings of sadness, hopelessness, and loss of interest in activities (Relation id: 6).\n3. **Loss of interest in activities**: This is a symptom of depression in children, characterized by a lack of interest in activities that they once enjoyed (Relation id: 5).\n4. **Sadness**: Feelings of sadness, hopelessness, and loss of interest in activities are associated with Sydenham's chorea (Relation id: 6).\n5. **Changes in facial expression**: Facial expression is a visible sign of pain in patients who are unable to self-report, and can also be a sign of depression in young children (Relation id: 81).\n6. **Sleep disturbances**: Sleep disturbances are a symptom of childhood depression (Relation id: 31).\n7. **Irritability and self-deprecation**: These are symptoms of depression in toddlers, as reported by parents (Relation id: 15).\n\nPlease note that these symptoms should not be used as a definitive diagnosis of depression in young children. A comprehensive evaluation by a qualified healthcare professional is necessary to diagnose depression in children.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers a broad range of symptoms that could indicate depression in young children, including irritability, changes in appetite or sleep patterns, loss of interest in activities, sadness, changes in facial expression, sleep disturbances, and irritability with self-deprecation. However, it misses some symptoms mentioned in the reference answers, such as fatigue, inability to concentrate, feelings of guilt or worthlessness, and thoughts of suicide.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer provides precise information about each symptom, including specific relation IDs that likely correspond to the provided data tables. There is no irrelevant information reported.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. Each symptom is listed and described distinctly.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-organized and fluent, making it easy to read. However, the inclusion of relation IDs (e.g., Relation id: 42) may slightly detract from readability for those unfamiliar with these references."
    },
    {
        "Question": "What are active ingredients of Paxlovid?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are active ingredients of Paxlovid?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Paxlovid is composed of nirmatrelvir and ritonavir.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe active ingredients of Paxlovid are nirmatrelvir and ritonavir.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer correctly includes both nirmatrelvir and ritonavir, which are the active ingredients of Paxlovid as per the reference answers. No necessary information is missing.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is concise and only includes the relevant active ingredients of Paxlovid, without any extraneous information.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each active ingredient is only mentioned once in a clear and straightforward manner.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is easily readable and fluent, with a clear and simple sentence structure that effectively communicates the information."
    },
    {
        "Question": "What is an Albatross plot used for?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is an Albatross plot used for?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The albatross plot is a novel graphical tool for presenting results of diversely reported studies in a systematic review', 'An Albatross plot is used to visually present the results of studies that are reported in diverse ways within a systematic review, showing the estimated direction of effects and helping interpret P values based on study sample sizes.', 'An Albatross plot is used for meta-analyses to combine the results of multiple studies of a common question. It allows an approximate examination of underlying effect sizes and the potential to identify sources of heterogeneity across studies.', 'The albatross plot is a novel graphical tool for presenting results of diversely reported studies in a systematic review.', 'An Albatross plot is used for presenting results of diversely reported studies in a systematic review.', 'The Albatross plot is used for presenting results of diversely reported studies in a systematic review.', 'Albatross plot is a graphical tool used in systematic reviews to present the results of studies that report the effect size or estimate for an outcome in diverse ways. It allows visual comparison of studies by displaying the effect size and confidence interval in a single plot.', 'An Albatross plot is a graphical tool used in systematic reviews to present the results of diversely reported studies. It helps to visualize and compare the findings of different studies, making it easier to identify patterns and trends in the data.', 'An Albatross plot is a graphical tool utilized in systematic reviews. Its primary function is to present the results of studies that have been reported in diverse ways, providing a visual representation that aids in the interpretation and comparison of these results.', 'The Albatross plot is used for presenting the results of studies that are reported in diverse ways within a systematic review.', 'An Albatross plot is a novel graphical tool for presenting results of diversely reported studies in a systematic review.', 'An Albatross plot is a graphical representation of the distribution of the number of patients with a given outcome in a clinical trial. It is used to visualize the distribution of outcomes in a trial and to identify potential issues with the trial design or conduct.', 'An albatross plot is a novel graphical tool for presenting results of diversely reported studies in a systematic review.', 'An Albatross plot is used for presenting the results of studies that are reported in diverse ways in a systematic review. It provides a graphical tool for visualizing and interpreting these results.', 'An Albatross plot is a novel graphical tool used for presenting the results of diversely reported studies in a systematic review. It helps to visually display the effect sizes and confidence intervals of individual studies, allowing for a comprehensive overview of the data and facilitating the interpretation of the overall findings.', 'An Albatross plot is used to present the results of diversely reported studies in a systematic review in a graphical format.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the Relations table, an Albatross plot is a graphical tool used to visualize and analyze data in systematic reviews and meta-analyses. It is specifically used to present results of diversely reported studies in a systematic review. The Albatross plot requires only a one-sided P-value and a total sample size from each study (or equivalently a two-sided P-value, direction of effect, and total sample size) to create a plot that allows an approximate examination of underlying effect sizes and the potential to identify sources of heterogeneity across studies.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately captures all essential aspects of an Albatross plot, including its use in systematic reviews to present diversely reported studies, the requirement of P-values and sample sizes, and its ability to examine effect sizes and heterogeneity sources. This aligns well with the reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is concise and directly relevant, providing no extraneous details. It clearly explains the purpose of an Albatross plot and the minimal data requirements (P-values and sample size) for its creation.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition in the answer. Each piece of information is presented once in a clear and logical manner.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand. The explanation flows naturally, making it accessible even to those unfamiliar with Albatross plots."
    },
    {
        "Question": "What should you do if you find an individual that you suspect has overdosed?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat should you do if you find an individual that you suspect has overdosed?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Call emergency services.\\nTry to wake the person up.\\nAdminister naloxone if you have it.\\nCardiopulmonary resuscitation.\\nStay until emergency services arrive.', 'If you find an individual who you suspect has overdosed, it is important to seek medical help immediately. Call emergency services or go to the emergency room if the person is unresponsive, difficulty breathing, or showing other signs of distress. If the person is conscious and able to speak, try to keep them awake and alert until medical help arrives. Do not leave the person alone, as their condition can worsen quickly. If you are trained in using naloxone, administer it according to the instructions provided. Remember that naloxone only works for opioid overdoses, so if the person is experiencing an alcohol or other drug overdose, do not use naloxone. Stay with the person and provide reassurance until medical help arrives. If possible, try to gather information about the substance they took, as this can be helpful for medical responders. Remember, seeking medical help immediately is crucial in preventing serious harm or death from an overdose.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, if you find an individual that you suspect has overdosed, you should follow these steps:\n\n1. **Call 911 or your local emergency number immediately**: This is the most critical step in getting the individual the help they need. Emergency responders, including paramedics and police, are trained to handle overdose situations and can provide life-saving interventions.\n2. **Administer naloxone (if available)**: If you have access to naloxone, which is an opioid antagonist that can reverse opioid overdose, you can administer it according to the instructions provided with the medication. Naloxone is available in many communities, and some states have laws that allow individuals to carry and administer it.\n3. **Provide CPR (if necessary)**: If the individual is not breathing or has no pulse, you should start CPR (cardiopulmonary resuscitation) according to the American Heart Association's guidelines. This can help keep the individual's heart and lungs functioning until emergency responders arrive.\n4. **Stay with the individual and provide reassurance**: If you are with the individual, stay with them and try to keep them calm and comfortable. Provide reassurance and try to keep them awake and talking.\n5. **Do not leave the individual alone**: If you are with the individual, do not leave them alone until emergency responders arrive. Opioid overdose can cause respiratory depression, which can lead to brain damage or death if the individual is left unattended.\n6. **Do not try to drive the individual to the hospital**: If you are with the individual, do not try to drive them to the hospital. Emergency responders will arrive quickly and can transport the individual to the hospital.\n7. **Follow up with medical treatment**: After the individual is stabilized, they will need to receive medical treatment to address the underlying cause of the overdose. This may include medication to manage withdrawal symptoms, counseling, and other forms of support.\n\nIt's essential to note that opioid overdose is a medical emergency, and prompt action is critical to prevent serious harm or death. If you are unsure about how to respond to an overdose, call 911 or your local emergency number for guidance.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers most of the critical steps outlined in the reference answers, such as calling emergency services, administering naloxone, providing CPR, and staying with the individual. It even adds useful additional information like not driving the individual to the hospital and following up with medical treatment. However, it slightly misses the nuance of naloxone being ineffective for non-opioid overdoses, which is present in the reference answers.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise and to the point, listing actionable steps without unnecessary fluff. However, it does include a minor redundant point ('Do not leave the individual alone' is implied by 'Stay with the individual and provide reassurance') and slightly strays from precision by mentioning follow-up medical treatment, which, while useful, isn't a direct action to take during the immediate emergency.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "There is minimal repetition, but some overlapping points like staying with the individual and not leaving them alone are mentioned separately. Overall, the answer avoids significant redundancy and keeps information concise.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is very clear, well-structured, and easy to follow. Each step is logically listed and explained, making it highly readable. The language is straightforward, and the use of numbered points enhances readability significantly."
    },
    {
        "Question": "What is the mechanism of action of sparsentan?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the mechanism of action of sparsentan?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Sparsentan is a single-molecule dual endothelin type-A and angiotensin II type 1 receptor antagonist for the treatment of immunoglobulin A (IgA) nephropathy and focal segmental glomerulosclerosis (FSGS).']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nSparsentan is a dual endothelin type A (ETA) and angiotensin II type 1 (AT1) receptor antagonist. \n\nAccording to the data, sparsentan acts by inhibiting the ETA and AT1 receptors, which are involved in the pathogenesis of focal segmental glomerulosclerosis (FSGS) and IgA nephropathy. \n\nSpecifically, sparsentan has been shown to inhibit the peak and late components of voltage-gated Na+ current (I(Na)) in pituitary GH3 somatolactotrophs, with an IC50 value of 15.04 μM for peak I(Na) and 1.21 μM for late I(Na).\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer correctly identifies sparsentan as a dual endothelin type A (ETA) and angiotensin II type 1 (AT1) receptor antagonist and mentions its role in the pathogenesis of IgA nephropathy and FSGS, which aligns with the reference. However, it introduces additional information about Na+ current inhibition in pituitary GH3 somatolactotrophs, which is not mentioned in the reference and might not be directly relevant to the primary mechanism of action.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer includes relevant information about the dual receptor antagonism of sparsentan. However, it contains extraneous details about Na+ current inhibition, which detracts from the precision, as this information was not part of the reference answer and may not be directly pertinent to the primary mechanism of action.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each point is made clearly without redundancy.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is fluent and well-structured, though the inclusion of highly specific scientific details (Na+ current inhibition) may slightly hinder readability for some audiences. The overall clarity is good."
    },
    {
        "Question": "Please summarize MuSK Antibody positive Myasthenia Gravis.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nPlease summarize MuSK Antibody positive Myasthenia Gravis.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Myasthenia gravis (MG) is a chronic autoimmune disorder in which antibodies destroy the communication between nerves and muscle, resulting in weakness of the skeletal muscles Approximately 5% of patients with MG, show positive results on muscle-specific kinase (MuSK) antibody testing and usually have severe symptoms, refractory disease, residual muscle atrophy, and poor prognosis.', 'Muscle-specific tyrosine kinase (MuSK) antibodies are present in some patients with myasthenia gravis (MG) who test negative for acetylcholine receptor (AChR) antibodies. MuSK antibodies do not appear to cause substantial AChR loss, complement deposition, or morphological damage. Patients with MuSK antibody-positive MG may have a recognizable electrodiagnostic (EDX) profile distinct from AChR antibody-positive MG. They include myotonic discharges, greater occurrence of myopathic appearing motor unit potentials in clinically mild disease, and symptoms leading to earlier testing. MuSK and seronegative MG patients are managed successfully with immunomodulatory therapies, but a higher proportion of MuSK MG patients have a refractory course.', 'MuSK Antibody positive Myasthenia Gravis is a rare, chronic neuromuscular disease that is distinct from thymomatous Myasthenia Gravis. It represents about 10-20% of all Myasthenia Gravis cases. It is more common in women, and is characterized by the presence of MuSK antibodies, which target a receptor tyrosine kinase in the postsynaptic muscle membrane. It is typically more severe than other forms of Myasthenia Gravis, and often responds well to treatments that target the immune system, such as rituximab and plasmapheresis.', 'Muscle-specific tyrosine kinase antibody positive myasthenia gravis (MuSK-MG) is characterized by autoantibodies targeting the MuSK protein at the neuromuscular junction, leading to weakness primarily in bulbar and proximal muscles. This condition represents a distinct subset of autoimmune MG, accounting for 5%-15% of cases. MuSK plays a crucial role in the agrin-signaling pathway and anchors the collagenic tail subunit (ColQ) of acetylcholinesterase (AChE), essential for muscle function. The diagnosis often involves single-fiber electromyography (SFEMG), especially in affected muscles. Treatment options include immunosuppressive therapies like tacrolimus, although their efficacy specifically in MuSK-MG requires further investigation. The role of thymectomy in treating MuSK-MG remains uncertain.', 'MuSK Antibody positive Myasthenia Gravis (MuSK MG) is a form of myasthenia gravis (MG) characterized by a relatively severe and progressive course, refractoriness to standard MG medications, and an increased risk of myasthenic crisis. It is often associated with bulbar and respiratory manifestations, a poor response to anticholinergics, and a generally good response to plasma exchange and rituximab. MuSK antibodies define a form of MG that can be difficult to diagnose, can be life-threatening, and may require additional treatments. MuSK MG patients have reduced B10 cells, a rare regulatory B-cell subset that potently blocks Th1 and Th17 responses, suggesting a potential mechanism for the breakdown in immune tolerance. Increased BAFF levels have been described in MuSK MG, as well as in acetylcholine receptor antibody-positive MG. MuSK antibodies are found in a variable proportion of AChR antibody negative MG patients, who are often young adult females with bulbar, neck, or respiratory muscle weakness. A girl with MuSK-antibody positive MG was reported to have developed a myopathy with severe generalized muscular weakness, muscle atrophy, and myopathic changes on electromyography, which is the first published example of a generalized myopathic syndrome in MG.', '1. Antibodies to MuSK in most cases are associated with myasthenia gravis that is mainly characterized by:\\n* Pure ocular disease in 75% of the cases\\n* Rapid progression of symptoms\\n* Increased risk for respiratory failure\\n* Low levels of anti-AChR antibodies\\n* Good response to cholinesterase inhibitors and steroids\\n2. A smaller percentage of patients also presents with a more aggressive phenotype.\\n3. MuSK antibody negative patients may also show MuSK-mediated autoimmunity.\\n4. MuSK antibody positive patients have significantly lower survival rates compared to the anti-AChR population.\\n5. Musk antibodies have no pathogenic role.\\n6. MuSK antibodies cause an impairment of the postsynaptic membrane in autoimmune myasthenia gravis.', 'Myasthenia Gravis (MG) is a chronic autoimmune disease that causes muscle weakness. It is a type of antibody-mediated disorder, in which the main immunoglobulin G (IgG) antibodies are directed against the muscle acetylcholine receptor (AChR). Myasthenia gravis can be divided into two subtypes according to the type of antibodies that are detected: muscle-specific kinase antibody (MuSK-MG) and acetylcholine receptor antibody-positive myasthenia gravis (AChR-MG). The clinical manifestations of MuSK-MG are different from those of AChR-MG. MuSK-MG is usually more severe and often affects the neck, throat, face, and respiratory muscles. The diagnosis of MuSK-MG is based on the detection of MuSK antibodies in the serum.', 'MuSK Antibody positive Myasthenia Gravis (MuSK-MG) is a subtype of autoimmune myasthenia gravis, accounting for 5 to 15% of all MG cases. It is characterized by the presence of autoantibodies against muscle-specific kinase (MuSK), a tyrosine kinase receptor involved in acetylcholine receptor clustering at the neuromuscular junction. MuSK-MG patients typically present with severe symptoms, including bulbar and respiratory involvement, and are less responsive to cholinesterase inhibitors than other MG subtypes. Immunosuppressive therapy is often required for effective disease management.', 'MuSK antibody positive Myasthenia Gravis (MG) is a subtype of MG characterized by the presence of antibodies against the muscle-specific kinase (MuSK). It is more common in females and typically presents with severe muscle weakness, especially involving the bulbar and respiratory muscles. Patients with MuSK antibody positive MG may have a more severe disease course and may not respond well to traditional MG treatments like acetylcholinesterase inhibitors.', 'MuSK antibody-positive myasthenia gravis (MuSK-MG) is a subtype of myasthenia gravis characterized by:\\n\\n1. Presence of autoantibodies against muscle-specific kinase (MuSK)\\n2. Prominent bulbar, neck, shoulder girdle, and respiratory muscle weakness\\n3. Early onset and generally worse disease severity compared to AChR antibody-positive MG\\n4. Tendency to develop muscle atrophy\\n5. Refractoriness to standard MG medications and increased risk of myasthenic crisis\\n6. Best response to corticosteroids and plasma exchange, poorest response to IVIG\\n7. About half of patients meet criteria for refractory MG\\n8. Long-term outcomes are favorable in about 60% of cases, but overall outcomes are not favorable, indicating need for more aggressive treatment\\n\\nIn summary, MuSK-MG is a distinct subtype of myasthenia gravis with specific clinical features, treatment responses, and prognosis that differ from the more common AChR antibody-positive form of the disease.', 'Muscle-specific kinase (MuSK) Antibody positive Myasthenia Gravis is predominantly seen in women of childbearing age and is characterized by focal muscle weakness, particularly in the neck, facial, and bulbar muscles, with pathogenic antibodies mainly belonging to the IgG4 subclass.', 'MuSK Antibody positive Myasthenia Gravis (MuSK MG) is a predominantly female-affecting, antibody-mediated disease characterized by focal muscle weakness and fatigability. The pathogenic antibodies in MuSK MG are mostly of the IgG4 subclass, which gives them specific properties and pathogenic profiles. MuSK MG is distinct from acetylcholine receptor antibody (Ab)-positive MG and requires specific diagnostic and therapeutic approaches.', 'MuSK Antibody positive Myasthenia Gravis (MG) is a type of MG characterized by focal muscle weakness and fatigability, particularly in the neck, facial, and bulbar muscles. It is an antibody-mediated disease, with the pathogenic antibodies mostly belonging to the immunoglobulin subclass IgG4. This condition is predominantly seen in women of childbearing age.', 'MuSK Antibody positive Myasthenia Gravis is a form of the autoimmune disease Myasthenia Gravis characterized by the presence of antibodies against muscle-specific tyrosine kinase (MuSK), predominantly affecting women of childbearing age, and clinically presenting with focal muscle weakness and fatigability.', 'Muscle-specific tyrosine kinase (MuSK) antibody positive Myasthenia Gravis (MG) is predominantly observed in women of childbearing age and is characterized by focal muscle weakness in the neck, facial, and bulbar muscles, often associated with the presence of IgG4 antibodies.', 'MuSK Antibody positive Myasthenia Gravis is a prototypical antibody-mediated disease characterized by predominantly focal muscle weakness (neck, facial, and bulbar muscles) and fatigability. The pathogenic antibodies mostly belong to the immunoglobulin subclass (Ig)G4, a feature which attributes them their specific properties and pathogenic profile.', 'MuSK Antibody positive Myasthenia Gravis (MuSK MG) is a rare autoimmune disorder characterized by the presence of antibodies against the muscle-specific tyrosine kinase (MuSK) protein. This condition is predominantly seen in women of childbearing age and is associated with focal muscle weakness, fatigability, and the presence of IgG4 antibodies.', 'Myasthenia gravis (MG) with muscle-specific tyrosine kinase (MuSK) antibodies (MMG) is predominantly seen in women of childbearing age. MMG is predominantly focal muscle weakness (neck, facial, and bulbar muscles) and fatigability. The pathogenic antibodies mostly belong to the immunoglobulin subclass (Ig)G4, a feature which attributes them their specific properties and pathogenic profile.', 'MuSK Antibody positive Myasthenia Gravis is a subtype of the autoimmune disease Myasthenia Gravis, characterized by the presence of antibodies against muscle-specific tyrosine kinase (MuSK), primarily affecting women of childbearing age and presenting with focal muscle weakness and fatigability.', 'Muscle-specific kinase (MuSK) antibody positive myasthenia gravis (MG) is a subtype of MG characterized by:\\n\\n1. Presence of autoantibodies against MuSK, predominantly of the IgG4 subclass.\\n2. More common in women of childbearing age.\\n3. Predominantly focal muscle weakness and fatigability, especially in neck, facial, and bulbar muscles.\\n4. Distinct pathogenic profile attributed to the specific properties of IgG4 autoantibodies.\\n5. Usually seronegative for anti-acetylcholine receptor (AChR) antibodies.\\n\\nThe distinct clinical features, autoantibody profile, and pathogenic mechanisms set MuSK MG apart from other subtypes of myasthenia gravis.', 'MuSK Antibody positive Myasthenia Gravis is a subtype of the autoimmune disease Myasthenia Gravis, characterized by muscle weakness and fatigue. It is caused by antibodies that target the muscle-specific kinase (MuSK), a protein involved in signal transmission to muscles. This condition is often seen in women of childbearing age and primarily affects neck, facial, and bulbar muscles']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nMuSK (Muscle-Specific Kinase) Antibody Positive Myasthenia Gravis (MG) is a type of autoimmune disease characterized by muscle weakness and fatigue, particularly affecting the muscles involved in eye and eyelid movements, swallowing, and speech. It is caused by autoantibodies against the MuSK protein, which plays a crucial role in the transmission of nerve signals to muscles.\n\nKey features of MuSK Antibody Positive MG:\n\n* Predominant bulbar and respiratory muscle weakness\n* Poor response to cholinesterase inhibitors\n* Higher risk of acute clinical decompensation requiring plasma exchange\n* Thymus involvement is not prominent\n* Distinct HLA alleles and core immunopathological patterns of pathology in neuromuscular junction, structure, and function\n* Classical treatment options are often less effective, with a need for prolonged and high doses of steroids to control symptoms\n* Exceptional clinical response to plasmapheresis and rituximab has been observed\n* Novel therapeutic monoclonal antibodies against B cells at different stages of their maturation (like plasmablasts), or against molecules involved in B cell activation, represent promising therapeutic targets\n* Chimeric autoantibody receptor T (CAAR-T) cells that are engineered to target antigen-specific B cells in MuSK-MG represent a milestone in the development of targeted immunotherapies.\n\nElectrodiagnostic (EDX) features of MuSK Antibody Positive MG include:\n\n* Myotonic discharges\n* Greater occurrence of myopathic appearing motor unit potentials (MUPs) in clinically mild disease\n* Symptoms leading to earlier testing\n\nMuscle atrophy is a rare phenomenon that is usually restricted to the facial muscles, but in some cases, it can be generalized, leading to a myopathic syndrome.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer comprehensively covers key aspects of MuSK Antibody Positive Myasthenia Gravis (MG), including clinical features, treatment responses, diagnostic features, and novel therapeutic approaches. It aligns well with the reference answers, mentioning specific points such as bulbar and respiratory muscle weakness, poor response to cholinesterase inhibitors, and the effectiveness of plasmapheresis and rituximab.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise and focuses exclusively on MuSK Antibody Positive MG without including irrelevant information. Each point is relevant to the disease subtype, such as the distinct HLA alleles, electrodiagnostic features, and targeted immunotherapies.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each point is distinct and contributes new information about MuSK Antibody Positive MG, such as the clinical features, treatment options, and diagnostic criteria.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured, fluent, and easy to read. It uses clear and concise language, and the information is presented in a logical manner, making it accessible to the reader."
    },
    {
        "Question": "Is it advisable to bring the fever down when it is supposedly meant to assist in the fight of disease?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs it advisable to bring the fever down when it is supposedly meant to assist in the fight of disease?\n\nHere are some reference answers:\n\n**Reference Answers:**\n[\"While fever is a common symptom in children and can cause distress, it's important to note that antipyretics, or fever-reducing medications, are typically used to alleviate discomfort rather than solely to reduce body temperature. Fever is part of the body's natural defense mechanism against illness, so the primary goal of treatment is to relieve distress, not necessarily to lower the fever. Therefore, it's not always advisable to bring the fever down just for the sake of reducing body temperature. It's more about managing the child's comfort level.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, it appears that fever can have both beneficial and detrimental effects depending on the context.\n\nSome studies suggest that fever can have beneficial effects in fighting infection, such as augmenting immune cell performance, inducing stress on pathogens and infected cells, and providing a nonspecific immune defense (e.g., study 4: \"Let fever do its job: The meaning of fever in the pandemic era\"). \n\nHowever, other studies indicate that antipyretic therapy (reducing fever) may be beneficial in certain situations, such as when the fever is caused by a bacterial infection (e.g., study 1: \"The role of CRP, PCT, IL-6 and presepsin in early diagnosis of bacterial infectious complications in paediatric haemato-oncological patients\") or when the patient has a pre-existing condition that may be exacerbated by fever (e.g., study 13: \"Antipyresis and fever\").\n\nIn general, it seems that the decision to bring down a fever should be based on individual circumstances and the underlying cause of the fever. If the fever is caused by a viral infection, it may be beneficial to allow it to run its course, as it may help the body fight off the infection. However, if the fever is caused by a bacterial infection or if the patient has a pre-existing condition that may be exacerbated by fever, antipyretic therapy may be beneficial.\n\nIt's also worth noting that some studies suggest that the timing and duration of fever may be more important than the absolute temperature level (e.g., study 9: \"Fever and hypothermia: two adaptive thermoregulatory responses to systemic inflammation\"). \n\nIn summary, while fever can have beneficial effects in fighting infection, the decision to bring it down should be based on individual circumstances and the underlying cause of the fever. It's always best to consult with a healthcare professional for personalized advice.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers multiple aspects of fever management, including its potential benefits and when antipyretic therapy might be advisable. It references studies and provides a balanced view, which aligns well with the complexity of the topic. However, it does not explicitly mention the primary goal of treatment as relieving discomfort, which is a key point in the reference answer.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise in detailing the conditions under which fever might be beneficial or detrimental. It avoids irrelevant information and stays focused on the topic. The inclusion of specific studies adds precision, though the absence of the discomfort-relief aspect slightly detracts from full precision.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no unnecessary repetition in the answer. Each point is made clearly and concisely, and the argument flows logically without redundancy.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-structured and easy to follow. The language is clear, and the use of studies is integrated smoothly into the narrative. A slight deduction is made for the complexity of some terms, which might be slightly technical for a general audience."
    },
    {
        "Question": "Can syphilis cause proctitis?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nCan syphilis cause proctitis?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes. Syphilis can cause proctitis.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, syphilis can cause proctitis. Syphilitic proctitis is a rare condition where the bacterium Treponema pallidum, which causes syphilis, infects the rectal mucosa, leading to inflammation and various symptoms such as pain on defecation, rectal bleeding, or ulceration.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer provides all the necessary information, confirming that syphilis can cause proctitis and further detailing the condition (syphilitic proctitis), the causative bacterium (Treponema pallidum), and associated symptoms.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information. It directly addresses the question with relevant details about syphilitic proctitis.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information. It succinctly presents the facts without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, easily readable, and fluent. The use of clinical terminology is appropriate and the information flows logically."
    },
    {
        "Question": "What disorder is considered off label use for domperidone?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat disorder is considered off label use for domperidone?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['A major side effect of domperidone is prolactinemia, allowing it to be used off-label for the purpose of inducing lactation.', 'Domperidone is a selective dopamine D2 receptor antagonist that was first developed as an antiemetic agent. The use of Domperidone in gastroparesis is off-label due to its peripheral effects. The main objective of this study is to assess quercetin antiemetic properties and domperidone as a positive control.', 'Domperidone is used off label for treating symptoms related to gastro-esophageal reflux disease, dyspepsia, and gastroparesis.', 'Domperidone is a medication most commonly used by pediatric gastroenterologists for treatment of symptoms associated with gastro-esophageal reflux disease, dyspepsia, and gastroparesis outside its authorized indication, i.e. off label use', 'Domperidone is used off label for the treatment of gastroparesis.', 'Domperidone is considered off label use for gastroparesis.', 'Domperidone is considered an off-label treatment for functional dyspepsia.', 'Inducing lactation, acute gastroenteritis treatment in pediatric patients, acute dystonia', 'Domperidone is commonly used off-label to stimulate milk production in mothers who have low milk supply. It is prescribed off-label in Canada and Australia to promote lactation in prolactin-deficient women.', 'Domperidone is considered off-label for the treatment of functional dyspepsia.', 'Domperidone is an antiemetic that is commonly used as an off-label prescription to induce lactation.', 'Domperidone is used off-label for the purpose of inducing lactation.', 'Domperidone is considered off-label for the disorder of lactation, specifically to induce lactation by acting as a dopamine-2 antagonist.', 'Domperidone is an antiemetic that is commonly used off-label to induce lactation in prolactin-deficient women.', 'Domperidone is commonly used off-label to induce lactation in women.', 'Domperidone is considered off label use for lactation.', 'Domperidone is considered off-label for promoting lactation in prolactin-deficient women.', 'Domperidone is a medication commonly used off-label for its potential to stimulate prolactin secretion and thus milk production.', 'Domperidone is used off-label to promote lactation in prolactin-deficient women.', ' Domperidone is considered off-label use for prolactin-deficient women to increase breast milk production.', 'Domperidone is used off-label to induce lactation in prolactin-deficient women.', 'Domperidone is a dopamine-2 antagonist used off-label to increase breast milk production.', 'Domperidone is commonly used off-label to induce lactation in prolactin-deficient women.', 'Domperidone is commonly used off-label as a galactagogue to increase breast milk production.', 'Domperidone is considered off label use for lactation, prolactin-deficient women, and Lactation induction.', 'Domperidone is commonly used as an off-label prescription to induce lactation and increase breast milk production in women with prolactin deficiency.', 'Domperidone is often used off-label for the treatment of lactation deficiency. It helps to increase the production of breast milk.', 'Domperidone is considered an off-label treatment for promoting lactation in prolactin-deficient women.', 'Domperidone is considered off-label use for inducing lactation in breastfeeding mothers.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data tables, domperidone is considered off-label use for the following disorders:\n\n1. Gastroparesis (treatment of symptoms associated with gastroparesis)\n2. Gastro-esophageal reflux disease (treatment of symptoms associated with gastro-esophageal reflux disease)\n3. Dyspepsia (treatment of symptoms associated with dyspepsia)\n4. Lactation stimulation (to induce lactation)\n\nThese uses are not approved by the FDA and are considered off-label uses of domperidone.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer comprehensively lists all the major off-label uses of domperidone mentioned in the reference answers, including gastroparesis, gastro-esophageal reflux disease, dyspepsia, and lactation stimulation.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information. It clearly states the specific disorders for which domperidone is used off-label.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each disorder is listed once and clearly described.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured, clear, and easy to read. The use of bullet points enhances readability, making the information easy to digest."
    },
    {
        "Question": "Which neurotransmitters are thought to play a role in obsessive compulsive disorder?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhich neurotransmitters are thought to play a role in obsessive compulsive disorder?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The neurotransmitters thought to play a role in obsessive-compulsive disorder (OCD) include:\\n\\n1. Serotonin\\n2. Dopamine \\n3. Glutamate\\n4. Gamma-aminobutyric acid (GABA)\\n\\nDysregulation of these neurotransmitter systems, especially serotonin, dopamine, and glutamate, within cortico-striatal-thalamo-cortical circuits is implicated in the pathophysiology of OCD. An imbalance between excitatory glutamate and inhibitory GABA neurotransmission may be particularly important.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the data provided, the following neurotransmitters are thought to play a role in obsessive-compulsive disorder (OCD):\n\n1. Serotonin (5-HT): Multiple studies suggest that serotonin is involved in the pathophysiology of OCD, and selective serotonin reuptake inhibitors (SSRIs) are effective in treating OCD.\n2. Dopamine (DA): Dopamine has been implicated in the pathophysiology of OCD, and dopamine antagonists have been shown to be effective in treating OCD.\n3. Glutamate: Glutamate has been linked to the pathophysiology of OCD, particularly in the cortico-striatal-thalamo-cortical circuitry.\n\nThese neurotransmitters are mentioned in the relations table as being associated with OCD, and their roles are further discussed in the sources table, particularly in sources 13, 14, 15, 16, and 20.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer lists all the key neurotransmitters (Serotonin, Dopamine, Glutamate) mentioned in the reference answer and provides additional details about their roles in OCD and treatment implications, enhancing the recall of necessary information.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise, focusing on the relevant neurotransmitters and their roles in OCD. However, it excludes Gamma-aminobutyric acid (GABA) from the reference answer but includes treatment-related details, which, while relevant, slightly deviate from the exact precision of the reference.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat information. Each neurotransmitter is discussed once with unique details about their implications in OCD and treatment.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, with clear enumeration of neurotransmitters and their roles. The language is fluent and easy to follow, making the answer highly readable."
    },
    {
        "Question": "Can denosumab cause jaw necrosis?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nCan denosumab cause jaw necrosis?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes. Denosumab can cause jaw necrosis']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, denosumab has been associated with jaw necrosis, also known as osteonecrosis of the jaw (ONJ). According to the data, denosumab is linked to jaw necrosis as a side effect, with 39 mentions of this association in the provided data tables. Additionally, there are several case reports and studies that describe denosumab-related osteonecrosis of the jaw (DRONJ), which shares similar clinical and radiological features with bisphosphonate-related osteonecrosis of the jaw (BRONJ). The exact pathogenesis of DRONJ is unknown, but it is thought to be related to the suppression of bone turnover in the jaw, which can lead to necrosis of the jaw bone. The risk of DRONJ appears to be increased in patients who have undergone tooth extraction, have a history of dental disease, or have received denosumab for an extended period.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer provides a comprehensive explanation of the association between denosumab and jaw necrosis, including additional details such as the alternative name (ONJ), data mentions, case reports, clinical features, possible pathogenesis, and risk factors. This exceeds the information provided in the reference answer.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer is highly precise, focusing on the question about denosumab and jaw necrosis without straying into irrelevant topics. The only minor deviation is the comparison to BRONJ, which is relevant but slightly expands the scope.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat the same information redundantly. Each statement adds new information or elaborates on the topic without reiterating previously mentioned points.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand. It uses clear language and logical flow, making it highly readable for both experts and non-experts."
    },
    {
        "Question": "What is DEXTR",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is DEXTR\n\nHere are some reference answers:\n\n**Reference Answers:**\n['DEXTR is a semi-automated data extraction tool for public health literature-based reviews: Dextr provides similar performance to manual extraction in terms of recall and precision and greatly reduces data extraction time.', 'DEXTR is a software tool for data extraction from scientific literature.', 'DEXTR is a semi-automated data extraction tool for public health literature-based reviews.', 'DEXTR is a software tool developed with Agile software methodology using a two-team approach. It provides similar performance to manual extraction in terms of recall and precision while significantly reducing data extraction time.', 'Dextr is a semi-automated data extraction tool for public health literature-based reviews.', 'Dextr is a semi-automated data extraction tool designed to address data-extraction challenges in public health literature-based reviews, particularly in the field of environmental health sciences.', 'DEXTR is a semi-automated data extraction tool designed for public health literature-based reviews. It addresses data-extraction challenges in environmental health sciences literature and provides a platform for further automation developments.', 'DEXTR is a semi-automated data extraction tool for public health literature-based reviews. It extracts information regarding population groups, intervention, comparison, outcome, and study design (PICOS) as well as study quality information from published articles.', 'Dextr is a semi-automated data extraction tool designed to address data-extraction challenges in environmental health sciences literature. It has a simple user interface, incorporates user verification and entity connecting, and provides a platform for further automation developments.', 'DEXTR is a tool for extracting data from environmental health sciences literature.', 'Dextr is a semi-automated data extraction tool designed for public health literature-based reviews. It aims to assist researchers in extracting relevant information from scientific literature to support their research.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nDEXTR is a semi-automated data extraction tool for public health literature-based reviews. It is a web-based tool that uses machine learning methods to extract data from environmental health and toxicology studies.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer captures key aspects of DEXTR such as being a semi-automated tool for public health literature-based reviews and its application in environmental health and toxicology studies. However, it misses some details like performance comparisons with manual extraction (recall and precision), the Agile methodology, and specific features like user verification.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise with no irrelevant information. It focuses accurately on DEXTR's purpose and methodology but omits minor yet relevant details found in some reference answers (e.g., PICOS extraction).",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information. It succinctly states the tool's purpose and method without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is clear, concise, and fluent. The sentence structure is straightforward, making it easy to understand."
    },
    {
        "Question": "What is the most common surgical treatment for hydrocephalus?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the most common surgical treatment for hydrocephalus?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The most common surgical treatment for hydrocephalus is the placement of a ventriculoperitoneal shunt.', 'Ventriculoperitoneal (VP) shunting is the most common neurosurgical treatment for hydrocephalus.', 'Ventriculoperitoneal (VP) shunt surgery is the most widely used neurosurgical procedure for the management of hydrocephalus.', \"The most common surgical treatment for hydrocephalus is Ventriculoperitoneal (VP) shunting, which involves the placement of a shunt system to divert excess cerebrospinal fluid from the brain's ventricles to the abdominal cavity, where it can be absorbed by the body.\", 'The most common surgical treatment for hydrocephalus is ventriculoperitoneal (VP) shunt placement. This procedure involves the insertion of a catheter into the ventricles of the brain to divert excess cerebrospinal fluid (CSF) into the peritoneal cavity, where it can be absorbed by the body.', 'The most common surgical treatment for hydrocephalus is ventriculoperitoneal shunt (VPS) insertion.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data provided, the most common surgical treatment for hydrocephalus is the Ventriculoperitoneal (VP) shunt, specifically the Ventriculoperitoneal Shunt Placement procedure.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately recalls the most common surgical treatment for hydrocephalus as the Ventriculoperitoneal (VP) shunt, which aligns perfectly with all the reference answers provided.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information. It specifically mentions the Ventriculoperitoneal Shunt Placement procedure, which is the core detail needed.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. The treatment is clearly stated once without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is easily readable and fluent. It presents the information in a clear and concise manner without any grammatical or structural issues."
    },
    {
        "Question": "Is Upadacitinib effective for Crohn’s Disease?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs Upadacitinib effective for Crohn’s Disease?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes. Upadacitinib is effective for Crohn’s Disease.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, Upadacitinib is effective for Crohn's Disease. It is mentioned in the Relations table (id: 3) that \"Upadacitinib is used to treat inflammatory bowel disease by inhibiting Janus kinases\". In the Relations table (id: 23), it is also mentioned that \"Upadacitinib is a Janus kinase 1 (JAK1) inhibitor\". Furthermore, in the Relations table (id: 13), it is stated that \"Crohn's disease is associated with dysregulation of Janus kinases, which are targeted by JAK inhibitors for treatment\". Additionally, in the Relations table (id: 9), it is mentioned that \"Janus Kinase inhibitors have potential for the treatment of moderate-severe Crohn's disease\". In the Relations table (id: 9), it is also mentioned that \"Janus Kinase Inhibitors are effective treatments for Crohn's disease\". In the Relations table (id: 15), it is stated that \"Inhibition of Janus kinases [JAKs] in Crohn's disease [CD] patients has shown conflicting results in clinical trials. Tofacitinib, a pan-JAK inhibitor, showed efficacy in ulcerative colitis [UC] and has been approved for the treatment of patients with moderate to severe UC. In contrast, studies in CD patients were disappointing and the primary end point of clinical remission could not be met in the respective phase II induction and maintenance trials. Subsequently, the clinical development of tofacitinib was discontinued in CD. In contrast, efficacy of filgotinib, a selective JAK1 inhibitor, in CD patients was demonstrated in the randomized, double-blinded, placebo-controlled phase II FITZROY study. Upadacitinib also showed promising results in a phase II trial in moderate to severe CD. Subsequently, phase III programmes in CD have been initiated for both substances, which are still ongoing. Several newer molecules of this class of orally administrated immunosuppressants are being tested in clinical programmes. The concern of side effects of systemic JAK inhibition is addressed by either exclusively intestinal action or higher selectivity [Tyk2 inhibitors]. In general, JAK inhibitors constitute a new promising class of drugs for the treatment of CD.\"\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer provides a comprehensive recall of information regarding Upadacitinib's effectiveness for Crohn’s Disease, including details from multiple Relations tables and specific references to clinical trials and studies.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise in detailing the effectiveness of Upadacitinib for Crohn’s Disease, but includes some extraneous details about other JAK inhibitors (e.g., Tofacitinib and Filgotinib) which, while relevant, slightly dilute the focus on Upadacitinib.",
        "Information Repetition Score": 3,
        "Information Repetition Explanation": "The answer repeats some information about JAK inhibitors and their role in treating Crohn’s Disease across different Relations tables, which could be consolidated for brevity.",
        "Readability Score": 3,
        "Readability Explanation": "The answer is informative but somewhat dense due to the inclusion of multiple references and technical details, which may slightly hinder readability for a general audience."
    },
    {
        "Question": "Is melatonin beneficial in the treatment of in cerebral ischemia-reperfusion injury:",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs melatonin beneficial in the treatment of in cerebral ischemia-reperfusion injury:\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes, melatonin is beneficial in treating cerebral ischemia-reperfusion injury:', 'Yes, melatonin is beneficial in treating cerebral ischemia-reperfusion injury.', 'Studies have suggested that melatonin is a potential therapeutic agent in cerebral ischemia reperfusion injury', 'Yes, melatonin is beneficial in the treatment of in cerebral ischemia-reperfusion injury.', 'Yes, melatonin has protective effects against cerebral ischemia/reperfusion injury.', 'Yes, melatonin is effective for treatment of cerebral ischemia-reperfusion injury.', 'Yes, melatonin has been shown to be beneficial in the treatment of cerebral ischemia/reperfusion injury by inducing autophagy, which helps in reducing the damage caused by the condition.', 'Yes, melatonin is beneficial in the treatment of cerebral ischemia-reperfusion injury.', '”The present study demonstrates that melatonin has a protective effect on brain tissue during ischemia-reperfusion injury\"}', 'Yes, melatonin regulates microglial polarization and protects against ischemic stroke-induced brain injury in mice, suggesting that it may be beneficial in the treatment of cerebral ischemia-reperfusion injury.', 'Yes, Melatonin improves cognitive function by suppressing endoplasmic reticulum stress and promoting synaptic plasticity during chronic cerebral hypoperfusion in rats.', 'Yes, melatonin is beneficial in the treatment of cerebral ischemia-reperfusion injury. It has been shown to have neuroprotective effects, reducing brain damage and improving cognitive function.', 'Yes, melatonin has been shown to be beneficial in the treatment of cerebral ischemia-reperfusion injury in mice.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, melatonin has been shown to be beneficial in the treatment of cerebral ischemia-reperfusion injury. The available data from various studies suggest that melatonin has neuroprotective effects against ischemia/reperfusion injury in the brain, including reducing infarct volume, neurophysiological deficits, lipid peroxidation, protein carbonyls, DNA damage, neuron and glial loss, and death of the animals. Melatonin's protective actions are believed to stem from its direct free radical scavenging and indirect antioxidant activities, possibly from its ability to limit free radical generation at the mitochondrial level and because of yet-undefined functions.\n\nSeveral studies have demonstrated that melatonin reduces the degree of tissue damage and limits the biobehavioral deficits associated with experimental models of ischemia/reperfusion injury in the brain. Melatonin has been shown to mitigate the effects of cerebral ischemia-reperfusion injury in various animal models, including rats, gerbils, and cats.\n\nMoreover, the circadian nuclear receptor RORalpha has been identified as a mediator of melatonin's neuroprotective effects against cerebral ischemia-reperfusion injury. RORalpha deficiency exacerbates apoptosis pathways mediated by endoplasmic-reticulum stress and mitochondria, and aggravates oxidative/nitrative stress after ischemia/reperfusion. Melatonin treatment significantly decreases infarct volume and cerebral apoptosis, and mitigates endoplasmic reticulum stress and mitochondrial dysfunction in RORalpha-deficient mice.\n\nOverall, the available evidence suggests that melatonin has the potential to be a novel therapeutic agent against cerebral ischemia-reperfusion injury, and its use in clinical trials for the purpose of improving stroke outcome should be seriously considered.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers all the necessary information regarding melatonin's benefits in treating cerebral ischemia-reperfusion injury. It includes details about neuroprotective effects, mechanisms of action (free radical scavenging, antioxidant activities), impact on various physiological markers (infarct volume, neurophysiological deficits, etc.), and evidence from different animal models. It also mentions the role of RORalpha and potential clinical implications.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is highly precise, focusing solely on melatonin's role in cerebral ischemia-reperfusion injury without including any irrelevant information. All details provided are directly relevant to the question and supported by the reference answers.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. Each point is distinct and contributes new insights, such as mechanisms of action, physiological effects, and the role of RORalpha, ensuring the information is varied and non-repetitive.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to read. It logically progresses from general neuroprotective effects to specific mechanisms and potential clinical applications, making the information accessible and engaging."
    },
    {
        "Question": "Are Hemoglobin-Based Oxygen Carriers approved for human use?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nAre Hemoglobin-Based Oxygen Carriers approved for human use?\n\nHere are some reference answers:\n\n**Reference Answers:**\n[\"Hemoglobin-Based Oxygen Carriers (HBOCs) are not widely approved for human use. As of now, no HBOC has been approved by the FDA and EMA, except for compassionate use. However, some products like Hemopure are in clinical use in South Africa and Russia. HemO2life has also been approved for organ preservation in organ transplantation in the European Union. Other products like OxyVita and Sanguinate are still undergoing active clinical studies. It's important to note that while these products are in use or under study, there is currently no widely accepted product used as an alternative to human blood in clinical settings with severe anemic conditions.\", 'No, currently there are no Hemoglobin-Based Oxygen Carriers (HBOCs) that have been approved for human use by the FDA and EMA, except for compassionate use. However, Hemopure is in clinical use in South Africa and Russia, and HemO2life has recently been approved for organ preservation in organ transplantation in the European Union.', 'No, Hemoglobin-Based Oxygen Carriers are not widely approved for human use. However, some products like Hemopure are in clinical use in South Africa and Russia, and HemO2life has been approved for organ preservation in organ transplantation in the European Union. But none have been approved by the FDA and EMA, except for compassionate use.', 'No, Hemoglobin-Based Oxygen Carriers (HBOCs) have not been approved for human use by the FDA and EMA, except for compassionate use. However, HBOCs have been approved for veterinary use in the European Union and the United States, and they are also being used for organ preservation in organ transplantation in the European Union. Some HBOCs are still undergoing active clinical studies.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, there is one Hemoglobin-Based Oxygen Carrier (HBOC) that is approved for human use, which is HBOC-201 (also known as Hemopure), a bovine-derived, modified haemoglobin that has been ultrapurified to remove any plasma proteins, RBC stroma, and potential pathogenic material. It is approved for use in South Africa.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "3",
        "Information Recall Explanation": "The answer correctly identifies Hemopure (HBOC-201) as approved for human use in South Africa, which is accurate. However, it misses other relevant details such as the approval of HemO2life for organ preservation in the EU, and the fact that no HBOC is approved by the FDA or EMA for general human use (except for compassionate use). The answer is partially complete.",
        "Information Precision Score": "3",
        "Information Precision Explanation": "The answer provides specific details about HBOC-201, including its purification process and approval in South Africa, which are precise but somewhat redundant. However, it does not include irrelevant information, which is good.",
        "Information Repetition Score": "2",
        "Information Repetition Explanation": "The answer contains minor repetition regarding the description of Hemopure (e.g., 'bovine-derived, modified haemoglobin that has been ultrapurified'). This could have been more concise.",
        "Readability Score": "4",
        "Readability Explanation": "The answer is well-structured, fluent, and easy to read. The description of HBOC-201 is clear, and the sentence flows logically."
    },
    {
        "Question": "Gantenerumab was developed for treatment of which disease?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nGantenerumab was developed for treatment of which disease?\n\nHere are some reference answers:\n\n**Reference Answers:**\n[\"Gantenerumab was developed for Alzheimer's disease.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nGantenerumab was developed for the treatment of Alzheimer's disease.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer correctly and fully reports that Gantenerumab was developed for the treatment of Alzheimer's disease, which matches the reference answer.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and only includes relevant information about the indicated disease (Alzheimer's disease), without adding unrelated details.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information; it clearly states the intended use of Gantenerumab once.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is easily readable and fluent, with clear and simple grammar."
    },
    {
        "Question": "Please list the congenital fibrinogen disorders.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nPlease list the congenital fibrinogen disorders.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Congenital fibrinogen disorders are rare pathologies of the haemostasis, comprising afibrinogenaemia, hypofibrinogenaemia, dysfibrinogenaemia and hypodysfibrinogenaemia.', 'The congenital fibrinogen disorders include afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia, and hypodysfibrinogenemia.', 'Congenital fibrinogen disorders include:\\n\\n* Afibrinogenemia (lack of fibrinogen)\\n* Hypofibrinogenemia (low levels of fibrinogen)\\n* Dysfibrinogenemia (abnormal function of fibrinogen)\\n* Hypodysfibrinogenemia (reduced levels and function of fibrinogen)\\n\\nThese disorders can be caused by mutations in one of the 3 genes encoding individual fibrinogen polypeptide chains, located on chromosome 4q28.', 'Congenital fibrinogen disorders are rare diseases affecting either the quantity (afibrinogenaemia and hypofibrinogenaemia) or the quality (dysfibrinogenaemia) or both (hypodysfibrinogenaemia) of fibrinogen.', 'Congenital fibrinogen disorders include afibrinogenaemia, hypofibrinogenaemia, dysfibrinogenaemia, and hypodysfibrinogenaemia. These disorders can affect the quantity, quality, or both of fibrinogen, leading to abnormal blood coagulation and potential bleeding or thrombotic complications.', 'The congenital fibrinogen disorders include afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia.', 'Congenital fibrinogen disorders include afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia, and hypodysfibrinogenemia.', 'Congenital fibrinogen disorders can be classified into two main types:\\n\\n1. Quantitative disorders (Type I deficiencies):\\n   - Afibrinogenemia (complete absence of fibrinogen)\\n   - Hypofibrinogenemia (decreased levels of fibrinogen)\\n\\n2. Qualitative disorders (Type II deficiencies):\\n   - Dysfibrinogenemia (normal or reduced antigen levels with disproportionately low functional activity)\\n   - Hypodysfibrinogenemia (reduced antigen levels with disproportionately low functional activity)\\n\\nThese disorders are caused by mutations in the genes coding for fibrinogen and can lead to a wide spectrum of biological and clinical features.', 'Congenital fibrinogen disorders include afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia.', 'Congenital fibrinogen disorders are a group of rare bleeding disorders (RBD). Afibrinogenemia as a subclass of these disorders would occurs as a result of mutations in fibrinogen gene.', 'congenital fibrinogen qualitative disorders, including dysfibrinogenemia and hypodysfibrinogenemia', 'Congenital fibrinogen disorders include: , 1. Afibrinogenemia: a rare bleeding disorder resulting from mutations in the fibrinogen gene, leading to a complete absence of fibrinogen in the blood., 2. Dysfibrinogenemia: a functional disorder characterized by abnormal fibrinogen that can cause both bleeding and thrombosis., 3. Hypodysfibrinogenemia: a milder form of dysfibrinogenemia, with reduced fibrinogen levels and variable clinical manifestations., 4. Familial hypofibrinogenemia: a rare inherited quantitative fibrinogen disorder characterized by decreased fibrinogen levels, often associated with bleeding symptoms., 5. Congenital dysfibrinogenemias: a group of rare bleeding disorders resulting from mutations in the amino-terminal end of fibrinogen α-chain, critical for fibrin polymerization.', 'Congenital fibrinogen disorders can be afibrinogenemia, dysfibrinogenemia, hypodysfibrinogenemia, hemorrhagic disorders, familial hypofibrinogenemia, and dysfibrinogenaemia.', 'Congenital fibrinogen disorders include:\\n\\n1. Afibrinogenemia: a complete absence of fibrinogen in the blood due to mutations in the fibrinogen gene.\\n2. Hypofibrinogenemia: a decrease in fibrinogen levels in the blood due to mutations in the fibrinogen gene.\\n3. Dysfibrinogenemia: a functional disorder of fibrinogen due to mutations in the fibrinogen gene, which can present with both bleeding and thrombotic symptoms.\\n4. Hypodysfibrinogenemia: a combination of low fibrinogen levels and dysfunctional fibrinogen due to mutations in the fibrinogen gene.\\n\\nThese disorders are rare and can have a wide range of clinical manifestations, from bleeding to thrombosis.', 'The congenital fibrinogen disorders include afibrinogenemia, dysfibrinogenemia, hypofibrinogenemia, and hypodysfibrinogenemia.', 'The congenital fibrinogen disorders include afibrinogenemia, dysfibrinogenemia, hypodysfibrinogenemia, and hypofibrinogenemia.', 'Congenital fibrinogen disorders include afibrinogenemia, dysfibrinogenemia, hypodysfibrinogenemia, hypofibrinogenemia, congenital fibrinogen disorders, hemorrhagic disorders, familial hypofibrinogenemia, and dysfibrinogenaemia.', 'Congenital fibrinogen disorders are rare pathologies of the hemostasis, comprising quantitative (afibrinogenemia, hypofibrinogenemia) and qualitative (dysfibrinogenemia and hypodysfibrinogenemia) disorders.', 'Congenital fibrinogen disorders include quantitative disorders such as afibrinogenemia, hypofibrinogenemia, and qualitative disorders such as dysfibrinogenemia and hypodysfibrinogenemia.', 'The congenital fibrinogen disorders are afibrinogenemia, dysfibrinogenemia, hypodysfibrinogenemia, and hypofibrinogenemia.', 'The congenital fibrinogen disorders include:\\n\\n1. Quantitative disorders:\\n   - Afibrinogenemia (complete absence of fibrinogen) \\n   - Hypofibrinogenemia (decreased fibrinogen levels)\\n\\n2. Qualitative disorders:  \\n   - Dysfibrinogenemia (abnormal fibrinogen function)\\n   - Hypodysfibrinogenemia (decreased fibrinogen levels and abnormal function)', 'The congenital fibrinogen disorders include Afibrinogenemia, Dysfibrinogenemia, and Hypodysfibrinogenemia.', 'Congenital fibrinogen disorders (CFD) are a group of rare bleeding disorders (RBD) that include afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia. Afibrinogenemia is a subclass of CFD that occurs due to mutations in the fibrinogen gene.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the congenital fibrinogen disorders are:\n\n1. Afibrinogenemia\n2. Hypofibrinogenemia\n3. Congenital dysfibrinogenemia\n4. Hypodysfibrinogenemia\n5. Congenital afibrinogenemia\n6. Congenital hypofibrinogenemia\n7. Congenital dysfibrinogenemia\n8. Hypodysfibrinogenemia\n9. Congenital afibrinogenemia\n10. Congenital fibrinogen disorder\n11. Congenital fibrinogen deficiency\n12. Type I fibrinogen defects\n13. Dysfibrinogenemia\n14. Hypodysfibrinogenemia\n15. Congenital fibrinogen disorders\n16. Congenital fibrinogen deficiencies\n17. Congenital fibrinogen deficiency\n18. Type II fibrinogen defects\n19. Hypodysfibrinogenemia\n20. Congenital fibrinogen disorder\n\nHowever, after removing duplicates and irrelevant entries, the list of congenital fibrinogen disorders can be simplified to:\n\n1. Afibrinogenemia\n2. Hypofibrinogenemia\n3. Congenital dysfibrinogenemia\n4. Hypodysfibrinogenemia\n5. Congenital fibrinogen disorder\n6. Congenital fibrinogen deficiency\n7. Type I fibrinogen defects\n8. Dysfibrinogenemia\n9. Type II fibrinogen defects\n10. Congenital fibrinogen disorders\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer captures the essential congenital fibrinogen disorders (afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia, and hypodysfibrinogenemia) as per the reference answers. However, the list includes redundant terms (e.g., 'Congenital dysfibrinogenemia', 'Congenital afibrinogenemia') and vague terms (e.g., 'Type I/II fibrinogen defects', 'Congenital fibrinogen disorder/deficiency') that are not standard classifications in the references, reducing the score.",
        "Information Precision Score": 2,
        "Information Precision Explanation": "The answer lacks precision due to the inclusion of non-standard or overly broad terms (e.g., 'Congenital fibrinogen disorder', 'Type I/II fibrinogen defects'). These terms are not consistently used in the reference answers, which focus on specific, well-defined disorders (quantitative/qualitative). Some entries are also unclear or irrelevant (e.g., 'Congenital fibrinogen deficiency' is not a distinct disorder in the references).",
        "Information Repetition Score": 2,
        "Information Repetition Explanation": "The answer suffers from significant repetition, especially in the initial list (e.g., 'Hypodysfibrinogenemia' appears 3 times, 'Congenital afibrinogenemia' appears twice). While the simplified list reduces duplicates, it still retains redundant terms ('Congenital dysfibrinogenemia' vs. 'Dysfibrinogenemia') and unclear variations ('Congenital fibrinogen disorder' vs. 'Congenital fibrinogen disorders').",
        "Readability Score": 3,
        "Readability Explanation": "The answer is structured logically with a clear attempt to simplify and remove duplicates, improving readability. However, the wording is inconsistent (e.g., mixing 'dysfibrinogenemia' with 'congenital dysfibrinogenemia'), and the use of non-standard terms ('Type I/II defects') may confuse readers familiar with the reference terminology. The phrasing could be more concise."
    },
    {
        "Question": "What are the current indications for thalidomide?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are the current indications for thalidomide?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Current indications are as follows: erythema nodosum leprosum, multiple myeloma,  Graft versus host disease, mycobacterial infection,  severe recurrent aphthous stomatitis,  primary brain malignancies, HIV- associated wasting syndrome, Crohn disease, Kaposi sarcoma, myelodysplastic syndrome, hematopoietic stem cell transplantation, hereditary hemorrhagic telangiectasia', \"The current indications for thalidomide include lepromatous nodular erythema, severe aphthosis, Jessner-Kanoff's cutaneous lymphocyte infiltration, discoid lupus erythematosis, chronic graft-versus-host reactions, prurigo nodularis, and actinic prurigo. It is also used off-label for conditions such as aphthous stomatitis, Behçet disease, pyoderma gangrenosum, chronic discoid lupus erythematosus, systemic lupus erythematosus, lichen planus, and sarcoidosis. Additionally, it is FDA approved for the acute treatment and suppression of the cutaneous manifestations of erythema nodosum leprosum (ENL).\", \"Thalidomide is currently indicated for the treatment of erythema nodosum leprosum, graft versus host disease, severe oral and genital ulcers associated with HIV and Behçet's disease, rheumatoid arthritis, discoid lupus erythematosus, sarcoidosis, relapsed/refractory multiple myeloma, Waldenstrom's macroglobulinemia, myelodysplastic syndromes, acute myeloid leukemia, myelofibrosis with myeloid metaplasia, renal cell carcinoma, malignant gliomas, prostate cancer, Kaposi's sarcoma, colorectal carcinoma, oral aphthous ulcers, Crohn's disease, and HIV/AIDS-associated wasting.\", \"Thalidomide is currently approved by the FDA for the acute treatment and suppression of the cutaneous manifestations of erythema nodosum leprosum (ENL), a systemic disorder that typically occurs after several years of antileprosy treatments, usually for lepromatous leprosy. In addition to its approved use, thalidomide is also used off-label for various dermatologic diseases such as aphthous stomatitis, Behçet disease, pyoderma gangrenosum, chronic discoid lupus erythematosus, systemic lupus erythematosus, lichen planus, prurigo nodularis and sarcoidosis. Furthermore, thalidomide has been approved for treating multiple myeloma since May 2006. Although thalidomide was initially introduced as a sedative/hypnotic medication, its use in dermatology and oncology has gained interest due to its anti-inflammatory, immunomodulatory, and anti-angiogenic effects. However, it is important to note that thalidomide's main side-effects of teratogenesis and peripheral neuropathy limit its use, and careful consideration should be given when prescribing this medication for therapeutic indications.\", \"The current indications for thalidomide include lepromatous nodular erythema, severe aphthosis, Jessner-Kanoff's cutaneous lymphocyte infiltration, discoid lupus erythematosus, chronic graft-versus-host reactions, and relapsed and/or refractory multiple myeloma (after the failure of standard therapies). Thalidomide is also used off-label for conditions such as aphthous stomatitis, Behçet disease, pyoderma gangrenosus, chronic discoid lupus erythematosus, systemic lupus erythematosus, lichen planus, prurigo nodularis, and sarcoidosis.\", 'Thalidomide is currently indicated for the management of adult rheumatologic skin conditions, particularly lupus erythematosus, as well as aphthous ulceration and cachexia in HIV disease, inflammatory bowel diseases, and several malignant diseases. It is also used in the treatment of aphthous stomatitis and chronic graft-versus-host disease in children, as well as actinic prurigo and epidermolysis bullosa pruriginosa.', 'Thalidomide is a medication with several indications. It is primarily used for treating multiple myeloma, a type of cancer, and erythema nodosum leprosum, a complication of leprosy. Other indications include aphthous ulceration and cachexia in HIV disease, inflammatory bowel diseases, and several malignant diseases. Thalidomide is also used in the management of adult rheumatologic skin conditions, especially lupus erythematosus. Additionally, it is indicated for aphthous stomatitis and chronic graft-versus-host disease in children. Off-label uses include conditions such as actinic prurigo and epidermolysis bullosa pruriginosa.', 'Thalidomide has several current indications, including: * Erythema nodosum leprosum * Aphthous ulceration and cachexia in HIV disease * Inflammatory bowel diseases * Malignant diseases * Second-line treatment for aphthous stomatitis * Chronic graft-versus-host disease in children * Actinic prurigo * Epidermolysis bullosa pruriginosa', 'Thalidomide is currently indicated for a variety of conditions including erythema nodosum leprosum, aphthous ulceration and cachexia in HIV disease, inflammatory bowel diseases, and several malignant diseases. It is also used in the management of adult rheumatologic skin conditions, especially lupus erythematosus, and in children for aphthous stomatitis and chronic graft-versus-host disease. Other indications include actinic prurigo and epidermolysis bullosa pruriginosa.', 'Thalidomide is currently indicated for the management of various rheumatologic skin conditions, including lupus erythematosus, aphthous stomatitis, and chronic graft-versus-host disease in children. It is also used in the treatment of actinic prurigo and epidermolysis bullosa pruriginosa. Additionally, thalidomide is effective in managing erythema nodosum leprosum, aphthous ulceration, and cachexia in HIV disease, inflammatory bowel diseases, and certain malignant diseases.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThalidomide is currently approved for the treatment of the following conditions:\n\n* Erythema nodosum leprosum (ENL), a complication of leprosy\n* Multiple myeloma, a type of blood cancer\n\nIt is also being investigated for the treatment of other conditions, including:\n\n* Relapsed or refractory multiple myeloma\n* Crohn's disease\n* Rheumatoid arthritis\n* Ankylosing spondylitis\n* Systemic sclerosis\n* HIV-associated wasting syndrome\n* Kaposi's sarcoma\n* Lupus erythematosus\n* Graft-versus-host disease\n* Leprosy\n* Certain types of cancer, including renal cell carcinoma, liver cancer, and thyroid cancer.\n\nIt's worth noting that thalidomide is not without risks, and its use is strictly controlled due to its potential for teratogenic effects.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "3",
        "Information Recall Explanation": "The answer captures some of the key indications for thalidomide (e.g., erythema nodosum leprosum, multiple myeloma, and other investigational uses like Crohn's disease, graft-versus-host disease, etc.), but misses several other approved and off-label uses mentioned in the reference answers, such as severe recurrent aphthous stomatitis, myelodysplastic syndrome, and Behçet disease.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer provides relevant and accurate indications without including excessive irrelevant details. However, it does lump 'certain types of cancer' loosely, which could be more precise by listing specific malignancies (e.g., renal cell carcinoma, liver cancer, thyroid cancer) separately.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer avoids repeating the same information or listing redundant conditions. Each indication is mentioned only once, ensuring concise and efficient communication.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured, with clear bullet points separating approved and investigational uses. The language is straightforward, and the inclusion of brief descriptions (e.g., 'a complication of leprosy') enhances understanding without overcomplicating the text."
    },
    {
        "Question": "What is the administration route of zavegepant?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the administration route of zavegepant?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Zavegepant is administered intranasally and used for migraine attacks.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the Relations table, zavegepant is administered via intranasal delivery.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "4",
        "Information Recall Explanation": "The answer correctly states the administration route of zavegepant (intranasal). However, it misses mentioning its use for migraine attacks, which is part of the full reference answer.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise and directly addresses the question without including any irrelevant information.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition of information in the answer; it succinctly provides the necessary detail once.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is clear, concise, and easily understandable. The phrasing is fluent and straightforward."
    },
    {
        "Question": "Brunner's gland hamartoma (BGH) is often asymptomatic and so how is it usually diagnosed?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nBrunner's gland hamartoma (BGH) is often asymptomatic and so how is it usually diagnosed?\n\nHere are some reference answers:\n\n**Reference Answers:**\n[\"Brunner's gland hamartoma (BGH) is a rare, benign tumor of the duodenum. It is mostly asymptomatic and usually found incidentally on routine esophagogastroduodenoscopy (EGD).\", \"Brunner's gland hamartoma is a rare benign duodenal tumor. It occurs in Brunner's glands, which are found in the duodenum and produce secretions that protect the duodenum from pancreatic enzymes, gastric acid, and other agents.\", \"Brunner's gland hamartomas (BGH) are rare, benign tumors of the duodenum and are often asymptomatic. They are usually diagnosed incidentally during esophagogastroduodenoscopy or upper gastrointestinal series.\", \"Brunner's gland hamartomas are rare tumors of duodenum, they are often discovered incidentally during esophagogastroduodenoscopy or upper gastrointestinal series.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBrunner's gland hamartoma (BGH) is often discovered incidentally during upper gastrointestinal endoscopy or imaging studies, such as upper gastrointestinal series or computed tomography (CT) scans. These procedures may be performed for unrelated reasons, and the BGH is found as an incidental finding.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately recalls the necessary information about how Brunner's gland hamartoma (BGH) is usually diagnosed, including the incidental nature of the discovery and the diagnostic methods such as upper gastrointestinal endoscopy and imaging studies (e.g., upper gastrointestinal series or CT scans). This aligns well with the reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer provides precise information without including irrelevant details. It focuses specifically on the diagnostic procedures and the incidental discovery of BGH, which is directly relevant to the question.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each piece of information is presented clearly and concisely without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is easily readable and fluent. The sentences are well-structured, and the information flows logically, making it easy to understand."
    },
    {
        "Question": "Is peritoneal dialysis the best option for infants with kidney failure?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs peritoneal dialysis the best option for infants with kidney failure?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes, peritoneal dialysis is often the preferred method for infants with kidney failure.', 'Peritoneal dialysis (PD), also known as automated peritoneal dialysis (APD), is indeed the most widely used method for chronic dialysis in children, especially in younger ones like infants. This method is often preferred because it can be done at home and is less disruptive to a child\\'s daily routine. However, the \"best\" option can vary depending on the specific circumstances of the child, including their overall health, the severity of their kidney failure, and other individual factors. Therefore, while PD is a common and often effective choice, it\\'s important to discuss all possible treatment options with a healthcare provider', \"Peritoneal dialysis (PD) is often considered the preferred option for infants with kidney failure. PD is a form of dialysis that uses the peritoneal membrane in the abdomen to remove waste products and excess fluid from the body. It is particularly suitable for infants because it can be performed at home, allowing for greater flexibility and minimizing the need for frequent hospital visits. PD also provides continuous dialysis, which can be beneficial for infants with unstable kidney function. However, the decision regarding the best dialysis option for infants should be made on an individual basis, taking into account factors such as the infant's overall health, the availability of resources, and the preferences of the parents or caregivers. It is important for the treating physician to carefully evaluate and discuss the various treatment options with the parents or caregivers to determine the most appropriate approach for each infant with kidney failure.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, peritoneal dialysis is indeed considered the preferred mode of renal replacement therapy for infants with kidney failure. This is evident from several sources:\n\n* The study \"Successful combined liver and kidney transplant for COACH syndrome and 5-yr follow-up\" (Source 13) mentions that peritoneal dialysis is the treatment of choice for infants with chronic kidney failure.\n* The article \"Care of the pediatric patient on chronic peritoneal dialysis\" (Source 16) states that peritoneal dialysis is the most commonly prescribed dialysis modality for infants and young children with kidney failure worldwide.\n* The study \"Practice patterns and outcomes of maintenance dialysis in children < 2 years of age: a report of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS)\" (Source 15) found that 89.8% of infants and toddlers younger than 2 years of age who initiated kidney replacement therapy started with peritoneal dialysis.\n\nHowever, it's essential to note that peritoneal dialysis may not be suitable for all infants, particularly those with certain conditions such as congenital diaphragmatic hernia (Source 12). In such cases, other forms of dialysis, like hemodialysis, may be considered.\n\nIn summary, peritoneal dialysis is generally considered the best option for infants with kidney failure, but individual circumstances may require alternative approaches.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer effectively recalls and synthesizes information from multiple sources to support the claim that peritoneal dialysis is the preferred option for infants with kidney failure. It also acknowledges exceptions (e.g., congenital diaphragmatic hernia), demonstrating a comprehensive recall of relevant details.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise, focusing solely on the relevance of peritoneal dialysis for infants with kidney failure. It avoids irrelevant details and provides specific examples (e.g., contraindications) without straying from the topic.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no unnecessary repetition. The answer presents the information concisely, using varied sources and explanations without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, logically organized, and clearly written. The use of bullet points and a summary enhances readability, making it easy to follow and understand."
    },
    {
        "Question": "Is Lecanemab approved for Alzheimer’s Disease?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs Lecanemab approved for Alzheimer’s Disease?\n\nHere are some reference answers:\n\n**Reference Answers:**\n[\"Yes. Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's disease (AD) to be initiated in early AD (mild cognitive impairment due to AD or mild AD dementia) with confirmed brain amyloid pathology.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, Lecanemab has been approved for the treatment of Alzheimer's disease.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "4",
        "Information Recall Explanation": "The answer correctly mentions that Lecanemab is approved for the treatment of Alzheimer's disease. However, it omits additional key details from the reference answer, such as the specific conditions of approval (early AD with confirmed amyloid pathology), the FDA trade name (Leqembi), and the approval in the United States.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer is precise and does not include irrelevant information, sticking strictly to the fact of approval. However, the lack of specific details (e.g., target patient population) slightly detracts from precision.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer is concise and does not repeat any information.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is straightforward, easily readable, and fluently expressed."
    },
    {
        "Question": "Can Ultrasonography be used to detect tumors in dogs and cats?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nCan Ultrasonography be used to detect tumors in dogs and cats?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Ultrasonography can be used as screening tests for dogs and cats, potentially representing an alternative to the invasive sampling methods required for cytological and histopathological analysis.', 'Yes, Ultrasonography can be used to detect tumors in dogs and cats but space for equipment is often limited in veterinary practices.', 'Yes, ultrasonography can be effectively used to detect tumors in dogs and cats.', 'Yes, ultrasonography can be used to detect tumors in dogs and cats.', 'Yes, Ultrasonography can be used to detect tumors in dogs and cats.', 'Yes, ultrasound can be used to detect tumors in dogs and cats.', 'uresonography is considered a useful tool for determining the extent of disease in small-animal patients with mast cell tumor if used in conjunction with histopathology or cytology.', 'No, Ultrasonography cannot be used to detect tumors in dogs and cats.', 'Yes, ultrasonography can be used to detect tumors in dogs and cats. It is considered a useful tool for determining the extent of disease in small-animal patients with mast cell tumor if used in conjunction with histopathology or cytology. Intraoperative ultrasonography can also help to delineate the extent of intradural tumors in dogs.', 'Yes, Ultrasonography can be used to detect tumors in dogs and cats, as it is a diagnostic tool commonly used to identify neoplastic and non-neoplastic focal renal lesions in these animals.', '”The use of diagnostic ultrasound has been reported in dogs and cats for the purpose of detecting tumors. This method has the advantage of being non-invasive, and the ultrasound images can be transmitted and recorded for future reference.\"}', 'Yes, ultrasonography can be used to detect both neoplastic and non-neoplastic focal renal lesions in dogs and cats.', 'Yes, ultrasonography (US) can be used to detect tumors in dogs and cats. It is a useful tool for determining the extent of disease in small-animal patients with mast cell tumor if used in conjunction with histopathology or cytology. In the case of intradural masses, intraoperative ultrasonography can help to delineate the extent of the tumor.', 'Yes, ultrasonography can detect tumors in dogs and cats.', 'Yes, Ultrasonography (US) is used to diagnose neoplastic and non-neoplastic focal renal lesions in dogs and cats.', 'Yes, ultrasonography can be used to detect tumors in dogs and cats. It is considered a useful tool for determining the extent of disease in small-animal patients with mast cell tumors and other neoplastic lesions, especially when used in conjunction with histopathology or cytology for confirmation.', 'Yes, ultrasonography is commonly used to detect tumors in dogs and cats. It is a useful tool for determining the extent of disease in small-animal patients with tumors, especially when used in conjunction with histopathology or cytology.', 'Yes, ultrasonography (US) can be used to detect tumors in dogs and cats.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, ultrasonography can be used to detect tumors in dogs and cats. \n\nUltrasonography has been used to diagnose various types of tumors in dogs and cats, including liver, spleen, lymph node, and intestinal tumors. The technique has been found to be useful in identifying masses, lesions, and other abnormalities in these organs. \n\nIn a study on ultrasonography of the liver and spleen in dogs and cats with lymphoma, it was found that ultrasonography had a sensitivity of 73.1% and a specificity of 93.9% for detecting lymphomatous infiltration of the spleen, and a sensitivity of 16.7% and a specificity of 91.0% for detecting lymphomatous infiltration of the liver. \n\nAnother study on ultrasonographic findings in abdominal mast cell disease found that ultrasonography was useful in identifying masses, lesions, and other abnormalities in the liver, spleen, and lymph nodes of dogs and cats with mast cell disease. \n\nIn addition, ultrasonography has been used to diagnose uterine tumors in dogs, with a study finding that ultrasonography was a useful method for demonstrating uterine body and/or cervical tumors, but was not possible to ascertain sonographically that a mass originated in a uterine horn unless there was associated evidence of uterine horn to which the mass could be traced. \n\nOverall, ultrasonography is a valuable tool for detecting tumors in dogs and cats, and can be used in conjunction with other diagnostic techniques such as biopsy and histopathology to confirm the diagnosis.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "4",
        "Information Recall Explanation": "The answer effectively recalls key information from the reference answers, confirming that ultrasonography can detect tumors in dogs and cats, and elaborates on specific studies and tumor types (e.g., liver, spleen, lymph node, intestinal, and uterine tumors). However, it misses mentioning the potential limitations mentioned in some reference answers (e.g., space constraints in veterinary practices).",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer is precise, focusing on the use of ultrasonography in detecting tumors in dogs and cats without adding irrelevant information. It provides specific examples (e.g., lymphoma, mast cell disease) and study findings, which are directly related to the topic.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer avoids unnecessary repetition, presenting a clear and concise flow of information. Each point builds on the previous one without redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured and fluent, making it easy to read and understand. The use of specific examples and study results adds depth without compromising clarity."
    },
    {
        "Question": "What is the first line treatment for severe Plasmodium falciparum malaria?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the first line treatment for severe Plasmodium falciparum malaria?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['First line treatment in severe Plasmodium falciparum malaria is artesunate.', '- For severe Plasmodium falciparum malaria, intravenous artesunate is the recommended first-line treatment. Intravenous artesunate is administered for 24 hours after clinical improvement is observed, followed by a full course of artemisinin-based combination therapy (ACT).', 'The first-line treatment for severe Plasmodium falciparum malaria is injectable artesunate.', 'The first-line treatment for severe Plasmodium falciparum malaria is intravenous artesunate. WHO recommends artesunate for the first 24 hours, followed by a combination of artemisinin derivatives and oral lumefantrine, for a total of 3 days.', 'Injectable artesunate is the first line treatment for severe Plasmodium falciparum malaria.', 'First-line treatment of severe P. falciparum malaria is based on IV artesunate.', 'Intravenous artesunate', 'Intravenous artesunate is the first-line treatment for severe Plasmodium falciparum malaria. If artesunate is not available, intravenous quinine should be started immediately as an alternative treatment.', 'Intravenous artesunate is the first-line treatment for severe falciparum malaria.', 'Yes, artesunate is the first-line treatment for severe malaria.', 'parenteral artesunate (ARS)', 'Parenteral artesunate is the first-line treatment for severe Plasmodium falciparum malaria.', 'Parenteral artesunate (ARS) is the first-line treatment for severe Plasmodium falciparum malaria.', 'Parenteral artesunate (ARS) is the first-line treatment for severe falciparum malaria.', 'The first-line treatment for severe Plasmodium falciparum malaria is parenteral artesunate (ARS). This is the global standard of care for severe malaria.', 'The first-line treatment for severe Plasmodium falciparum malaria is parenteral artesunate (ARS). This is also known as intravenous artesunate and is recognized as the global standard of care for severe malaria.', 'The first-line treatment for severe Plasmodium falciparum malaria is parenteral or intravenous artesunate.', 'Parenteral artesunate is the first-line treatment for severe falciparum malaria.', 'The first-line treatment for severe Plasmodium falciparum malaria is parenteral artesunate (ARS).', 'The first-line treatment for severe Plasmodium falciparum malaria is parenteral artesunate (ARS), which can be administered intravenously or intramuscularly.', 'Intravenous artesunate is the first-line treatment for severe Plasmodium falciparum malaria.', 'Intravenous artesunate is the first-line treatment and global standard of care for severe falciparum malaria.', 'The first-line treatment for severe Plasmodium falciparum malaria is intravenous artesunate.', 'Intravenous artesunate is the first line treatment for severe Plasmodium falciparum malaria.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe first-line treatment for severe Plasmodium falciparum malaria is intravenous artesunate. This is according to the World Health Organization (WHO) guidelines.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer accurately recalls the first-line treatment for severe Plasmodium falciparum malaria as intravenous artesunate and references WHO guidelines, which is consistent with all provided reference answers.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise, mentioning only the necessary treatment (intravenous artesunate) and the source (WHO guidelines), without including irrelevant details.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat any information; it states the treatment and its source succinctly without redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is clear, fluent, and easily understandable, with proper sentence structure and no grammatical errors."
    },
    {
        "Question": "Can Rozanolixizumab be used for treatment of multiple sclerosis?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nCan Rozanolixizumab be used for treatment of multiple sclerosis?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['No. Rozanolixizumab is approved for myasthenia gravis.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, Rozanolixizumab is a medication being investigated as a treatment for myasthenia gravis, which targets the CD19 receptor and reduces the production of antibodies. However, I could not find any information in the provided data that suggests Rozanolixizumab is being used or investigated as a treatment for multiple sclerosis.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "4",
        "Information Recall Explanation": "The answer correctly states that Rozanolixizumab is being investigated for myasthenia gravis and not for multiple sclerosis. However, it adds unnecessary detail about the mechanism of action (targeting CD19 receptor and reducing antibody production), which is not part of the reference answers.",
        "Information Precision Score": "3",
        "Information Precision Explanation": "The answer includes relevant information and correctly addresses the question, but it also includes extraneous details about the mechanism of action of Rozanolixizumab, which were not requested and are not part of the reference answers.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat any information. It clearly differentiates between the use of Rozanolixizumab for myasthenia gravis and the lack of information for multiple sclerosis.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand. The logical flow from the known use of the drug to the lack of evidence for multiple sclerosis is clear and coherent."
    },
    {
        "Question": "Are FOLFIRINOX plus Bevacizumab the preferred therapy for left-sided RAS wild type advanced colorectal cancer with aggressive clinical presentation?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nAre FOLFIRINOX plus Bevacizumab the preferred therapy for left-sided RAS wild type advanced colorectal cancer with aggressive clinical presentation?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['FOLFIRINOX plus bevacizumab is an option but without superior results in comparison to FOLFOX plus panitumumab for left-sided RAS wild type advanced colorectal cancer patients', 'FOLFIRINOX plus Bevacizumab is a preferred therapy for left-sided RAS wild-type advanced colorectal cancer with an aggressive clinical presentation. According to a study published in the Journal of Clinical Oncology, FOLFIRINOX plus Bevacizumab resulted in a median overall survival of 38.3 months for patients with left-sided RAS wild-type metastatic colorectal cancer, compared to 28.0 months for those treated with FOLFIRI plus bevacizumab. Additionally, the cost-effectiveness analysis showed that treatment with FOLFIRINOX plus Bevacizumab in Chinese patients with left-sided RAS wild-type mCRC may improve health outcomes and use financial resources more efficiently than FOLFIRI plus bevacizumab. However, it is important to note that the choice', 'Yes, the regimen including FOLFIRINOX plus Bevacizumab can be considered as a treatment option for patients with left-sided RAS wild type advanced colorectal cancer with aggressive clinical presentation.', 'No, FOLFIRINOX plus Bevacizumab is not the preferred therapy for left-sided RAS wild type advanced colorectal cancer with aggressive clinical presentation.', 'No. For left-sided RAS wild type advanced colorectal cancer with aggressive clinical presentation FOLFOXIRI plus Bevacizumab is preferred.', 'FOLFIRINOX plus Bevacizumab is not explicitly stated as the preferred therapy for left-sided RAS wild type advanced colorectal cancer with aggressive clinical presentation.\\n\\nCurrent guidelines recommend FOLFIRINOX (combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) as a first-line treatment option for patients with metastatic colorectal cancer (mCRC) without contraindications. Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is also recommended in combination with chemotherapy for first-line treatment of mCRC.\\n\\nHowever, the specific combination of FOLFIRINOX plus Bevacizumab for left-sided RAS wild type advanced colorectal cancer with aggressive clinical presentation is not explicitly mentioned in the guidelines. The decision should be individualized based on patient characteristics, comorbidities, and preferences.\\n\\nIt is important to consult the most recent guidelines and seek the advice of a medical oncologist for the most appropriate treatment plan.', 'Yes, FOLFIRINOX plus Bevacizumab are the preferred therapy for left-sided RAS wild type advanced colorectal cancer with aggressive clinical presentation.', 'FOLFIRINOX plus Bevacizumab may be a preferred therapy for left-sided RAS wild type advanced colorectal cancer with aggressive clinical presentation', \"The choice of treatment regimen for metastatic colorectal cancer (mCRC) depends on various factors, including tumor location, RAS mutation status, and the patient's clinical presentation. For left-sided mCRC with wild-type RAS, FOLFIRINOX plus bevacizumab is a promising option for patients with aggressive clinical presentations. The TRIBE study showed that FOLFOXIRI plus bevacizumab improved progression-free survival (PFS) and overall survival (OS) compared to FOLFIRI plus bevacizumab in mCRC patients, regardless of RAS mutation status. However, the toxicity profile of FOLFOXIRI is more significant than that of FOLFIRI, which may impact the patient's quality of life. Therefore, it is essential to consider the patient's preferences and potential impact on quality of life when choosing a treatment regimen. For left-sided mCRC with wild-type RAS, FOLFOXIRI plus bevacizumab may be a preferred option due to its superior efficacy, but it is essential to weigh the benefits against the potential drawbacks and consider alternative options, such as FOLFIRI plus bevacizumab or FOLFOX plus panitumumab. Ultimately, the choice of treatment regimen should be individualized based on the patient's clinical presentation, tumor characteristics, and preferences.\", 'Yes, FOLFIRINOX plus Bevacizumab is the preferred therapy for left-sided RAS wild type advanced colorectal cancer with aggressive clinical presentation.', 'FOLFIRINOX plus bevacizumab is a promising treatment option for left-sided RAS wild-type advanced colorectal cancer (mCRC) with an aggressive clinical presentation. A recent subgroup analysis of the TRIBE trial suggested that FOLFOXIRI plus bevacizumab may be a preferred option for the first-line treatment of only right-sided mCRC, regardless of RAS or BRAF status. However, our subanalysis of a phase II trial of the FOLFOXIRI triplet regimen plus bevacizumab in patients with mCRC who had RAS mutant tumors showed that tumor shrinkage was better and the duration of treatment was longer in patients with left-sided tumors than in those with right-sided tumors, leading to a higher rate of conversion to surgery in mCRC patients with left-sided tumors. The', \"According to a study called FIRE-3, FOLFIRINOX plus Bevacizumab may be a preferred therapy for left-sided RAS wild type advanced colorectal cancer with aggressive clinical presentation. However, the decision to use this treatment should be made on a case-by-case basis in consultation with a healthcare provider, as individual responses to treatment can vary, and other factors such as the patient's overall health and preferences should also be considered.\", 'Based on recent studies, FOLFIRINOX plus bevacizumab may be considered a preferred therapy for left-sided RAS wild-type advanced colorectal cancer with aggressive clinical presentation. These studies have shown that FOLFIRINOX plus bevacizumab can lead to better tumor shrinkage, longer treatment duration, and a higher rate of conversion to surgery in patients with left-sided tumors. However, treatment decisions should be individualized and take into account factors such as patient characteristics, tumor characteristics, and potential side effects of the treatment.', \"No. Although doublet chemotherapy plus anti-EGFRs remains the preferred treatment in patients with left-sided RAS/BRAF wild-type mCRC, FOLFOXIRI-bevacizumab is a valuable option able to provide similar, if not better, outcomes at the price of a moderate increase in toxicity and may be adopted based on patients' preference and potential impact on quality of life.\", 'No, doublet chemotherapy plus anti-EGFRs remains the preferred treatment in patients with left-sided RAS wild-type advanced colorectal cancer with aggressive clinical presentation.', 'FOLFIRINOX plus Bevacizumab might be the preferred therapy for left-sided RAS wild type advanced colorectal cancer with aggressive clinical presentation but more research is needed to determine this.', 'Yes, FOLCI3-203 (folv3) and Bevacis3ab are often used in combination with other therapies to manage advanced colorec0al cancer, including left-sided RAS wild type advanced colorec0al cancer with aggressive clinical presentation. Folic3-203 is a synthetic folic acid derivative with unique properties that make it useful as a therapeutic agent for various types of cancer. It is particularly effective at inhibitors of DNA separation and chromosome segregation, which can be important for treating left-sided RAS wild type advanced colorec0al cancer. ', \"The study suggests that FOLFOXIRI-bevacizumab is a valuable option for patients with left-sided RAS/BRAF wild-type mCRC, providing similar, if not better, outcomes compared to doublet chemotherapy plus anti-EGFRs. However, it is associated with a moderate increase in toxicity. Therefore, it may be adopted based on patients' preference and potential impact on quality of life. It is not specified if it is the preferred therapy for left-sided RAS wild type advanced colorectal cancer with aggressive clinical presentation.\", 'Based on the analysis from the trials mentioned (Valentino, TRIBE, TRIBE2, STEAM, and CHARTA), FOLFOXIRI-bevacizumab is indeed a valuable option for left-sided RAS wild-type advanced colorectal cancer, especially in aggressive cases. It provides comparable, if not superior, survival outcomes to FOLFOX-panitumumab, with a moderate increase in toxicity. This makes it a strong alternative, particularly when considering patient preference and quality of life impacts', 'no, FOLFIRINOX plus Bevacizumab is not the preferred therapy for left-sided RAS wild-type advanced colorectal cancer with aggressive clinical presentation. The preferred treatment remains doublet chemotherapy plus anti-EGFRs. However, FOLFOXIRI-bevacizumab is a valuable option that can provide similar or potentially better outcomes, albeit with a moderate increase in toxicity. This treatment may be chosen based on patient preference and potential impacts on quality of life.', \"As of my training data, the preferred therapy for left-sided RAS wild type advanced colorectal cancer with aggressive clinical presentation is FOLFOXIRI (oxaliplatin, irinotecan, and folinic acid) plus bevacizumab (a monoclonal antibody that targets vascular endothelial growth factor). This treatment regimen has shown superior progression-free survival and overall survival compared to FOLFOX (oxaliplatin and folinic acid) or XELOX (capecitabine and oxaliplatin) alone in clinical trials. However, the decision to use FOLFIRINOX plus Bevacizumab should be made on a case-by-case basis by a healthcare provider, taking into account the patient's individual characteristics and preferences, as well as potential side effects and toxicities associated with this treatment.\", '* The study suggests that FOLFIRINOX plus Bevacizumab may be the preferred therapy for left-sided RAS wild type advanced colorectal cancer with aggressive clinical presentation.\\n* However, this should be validated by further clinical trials.', \"The text does not explicitly state that FOLFIRINOX plus Bevacizumab is the preferred therapy for left-sided RAS wild type advanced colorectal cancer with an aggressive clinical presentation. However, it does suggest that FOLFOXIRI-bevacizumab could be a valuable option for patients with left-sided RAS/BRAF wild-type mCRC, providing similar or better outcomes compared to doublet chemotherapy plus anti-EGFRs, but at the cost of increased toxicity. The decision to adopt this treatment approach should consider patients' preferences and potential impact on quality of life. Further research may be needed to establish FOLFIRINOX plus Bevacizumab as the preferred therapy for specific subsets of colorectal cancer patients, such as those with aggressive clinical presentation.\", 'Based on the available evidence from randomized trials and propensity score-based analyses, FOLFOXIRI plus Bevacizumab is a viable treatment option for left-sided RAS wild type advanced colorectal cancer with aggressive clinical presentation. While doublet chemotherapy combined with anti-EGFRs remains the preferred first-line therapy due to its favorable safety profile and comparable efficacy, FOLFOXIRI plus Bevacizumab may offer improved survival outcomes at the cost of increased toxicity. The choice between these treatment options should be individualized, taking into account patient preferences, potential impact on quality of life, and a thorough risk-benefit assessment.', \"Based on the current evidence, FOLFIRINOX plus Bevacizumab is not the preferred therapy for left-sided RAS wild type advanced colorectal cancer with aggressive clinical presentation. The preferred treatment in this scenario is doublet chemotherapy plus anti-EGFR agents. However, FOLFIRINOX plus Bevacizumab can be considered as a valuable option, although it may be associated with a moderate increase in toxicity. The choice of therapy should be based on patients' preference and potential impact on quality of life.\", 'No, FOLFIRINOX plus Bevacizumab is not the preferred therapy for left-sided RAS wild type advanced colorectal cancer with aggressive clinical presentation. The context provided only compares FOLFOXIRI-bevacizumab with FOLFOX-panitumumab in five randomized trials, and a propensity score-based analysis was performed.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data tables, there is evidence suggesting that FOLFIRINOX plus Bevacizumab may be a viable treatment option for left-sided RAS wild-type advanced colorectal cancer with aggressive clinical presentation.\n\nThe TRIBE study (TRIBE-2) mentioned in the data tables (source 14) compared upfront FOLFOXIRI plus Bevacizumab with sequential administration of chemotherapy doublets, in combination with Bevacizumab, for patients with metastatic colorectal cancer. The study found that upfront FOLFOXIRI plus Bevacizumab followed by reintroduction of the same regimen after disease progression was associated with improved progression-free survival 2 compared to sequential administration of chemotherapy doublets.\n\nAdditionally, a case report (source 10) described a patient with BRAF V600E-mutated colorectal cancer who underwent conversion surgery after treatment with FOLFIRINOX plus Bevacizumab. This suggests that FOLFIRINOX plus Bevacizumab may be effective in treating aggressive clinical presentations of advanced colorectal cancer.\n\nHowever, it is essential to note that the data tables do not provide a definitive answer to whether FOLFIRINOX plus Bevacizumab is the preferred therapy for left-sided RAS wild-type advanced colorectal cancer with aggressive clinical presentation. Further research and clinical trials would be necessary to confirm the efficacy and safety of this treatment regimen in this specific patient population.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer recalls key information from the TRIBE study and a case report, suggesting the viability of FOLFIRINOX plus Bevacizumab for left-sided RAS wild-type advanced colorectal cancer. However, it does not explicitly mention comparison data with other therapies like FOLFOX plus panitumumab, which is mentioned in the reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and focuses only on the relevant information from the TRIBE study and case report without introducing irrelevant details. It specifically addresses the question about FOLFIRINOX plus Bevacizumab.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information. It presents a clear progression from the study findings to the case report and concludes with the need for further research, all without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easily understandable. It logically organizes the information and presents it in a clear and concise manner."
    },
    {
        "Question": "Amyloid-β is associated with what diseases?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nAmyloid-β is associated with what diseases?\n\nHere are some reference answers:\n\n**Reference Answers:**\n[\"Amyloid-β is associated with Alzheimer's disease as well as many other neurodegenerative diseases like Lewy body disease, multiple system atrophy, frontotemporal lobar degeneration, Parkinson's disease, and amyotrophic lateral sclerosis, as well as retinal neurodegenerative diseases like Glaucoma and age-related macular degeneration and progressive supranuclear palsy These proteins have also been linked to cardiovascular disease, cancer, traumatic brain injury, and diabetes\", \"Amyloid-β (Aβ) is a peptide with 38-42 amino acids associated with the pathogenesis of Alzheimer's disease (AD). The most common form, Aβ42, is the most neurotoxic.\", \"Amyloid-β is associated with Alzheimer's Disease and cerebral amyloid angiopathy.\", \"Amyloid-β is associated with Alzheimer's disease, amyloid-β-induced neurotoxicity and neurodegeneration, and other diseases.\", \"Amyloid-β is associated with Alzheimer's disease and cerebral amyloid angiopathy.\", \"Amyloid-β is associated with Alzheimer's disease, cerebral amyloid angiopathy, and AD.\", \"Amyloid-Î² (AÎ²) is associated with Alzheimer's disease (AD) and is known to promote chronic inflammatory responses in the brain. Additionally, AÎ² accumulation is also found in age-related macular degeneration (AMD) and glaucoma.\", \"Amyloid-Î² is associated with Alzheimer's disease and age-related macular degeneration.\", \"Amyloid-β is primarily associated with Alzheimer's disease and cerebral amyloid angiopathy.\", \"Amyloid-β is associated with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and others.\", \"Amyloid-β is associated with diseases such as Alzheimer's disease, Parkinson's disease, and type II diabetes, among others.\", \"Amyloid-β is associated with Alzheimer's disease, Parkinson's disease, and other amyloid diseases.\", \"Amyloid-β is associated with Alzheimer's disease, multiple sclerosis, and other neurodegenerative diseases.\", \"\\nAmyloid-β is associated with Alzheimer's disease, Down syndrome, Parkinson's disease, and certain types of cancer. (Note: The role of amyloid-β in Parkinson's disease and cancer is less clear.)\", \"Amyloid is associated with various diseases such as Alzheimer's disease, Parkinson's disease, type II diabetes, prion diseases, neurodevelopmental and neurodegenerative disorders, metabolic disorders, and certain types of cancer.\", \"Amyloid-β is associated with Alzheimer's disease, Parkinson's disease, and amyotrophic lateral scler\", 'Amyloid-β is associated with amyotrophic lateral sclerosis, cardiovascular disease, multiple system atrophy, progressive supranuclear palsy, cancer, traumatic brain injury.', \"Amyloid-β is associated with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, cardiovascular disease, cancer, traumatic brain injury, age-related macular degeneration, and glaucoma.\", \"Amyloid-β has been associated with neurodegenerative diseases like Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, as well as retinal neurodegenerative diseases like Glaucoma and age-related macular degeneration. Additionally, it has been linked to cardiovascular disease, cancer, traumatic brain injury, and diabetes\", \"Amyloid-β is associated with amyotrophic lateral sclerosis, cardiovascular disease, Alzheimer's disease, Parkinson's disease, cancer, traumatic brain injury, Glaucoma, and age-related macular degeneration.\", \"Amyloid-β (Aβ) has been associated with several neurological diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, as well as retinal neurodegenerative diseases like Glaucoma and age-related macular degeneration. Additionally, Aβ has also been linked to cardiovascular disease, cancer, traumatic brain injury, and diabetes.\", \"Amyloid-β is associated with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Glaucoma, age-related macular degeneration, cardiovascular disease, cancer, traumatic brain injury, and diabetes.\", \"Amyloid-β is associated with several neurodegenerative diseases including Alzheimer's disease (AD), Lewy body disease (LBD), multiple system atrophy (MSA), frontotemporal lobar degeneration-TDP-43 (FTLD-TDP) and progressive supranuclear palsy.\", \"Amyloid-β is associated with a range of diseases including Alzheimer's, Parkinson's, amyotrophic lateral sclerosis, Glaucoma, age-related macular degeneration, cardiovascular disease, cancer, traumatic brain injury, and diabetes.\", \"Amyloid-beta is associated with several diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Glaucoma, age-related macular degeneration, cardiovascular disease, cancer, traumatic brain injury, and diabetes.\", \"Amyloid-β is associated with neurodegenerative diseases such as Alzheimer's disease, Lewy body disease, multiple system atrophy, frontotemporal lobar degeneration-TDP-43, and progressive supranuclear palsy.\", \"Amyloid-β has been implicated in several neurodegenerative diseases beyond Alzheimer's disease, including Lewy body disease (LBD), multiple system atrophy (MSA), frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP), and progressive supranuclear palsy. Additionally, research has shown that amyloid-β may play a role in other neurological conditions such as Parkinson's disease and amyotrophic lateral sclerosis, as well as in non-neurological disorders like cardiovascular disease, cancer, traumatic brain injury, and diabetes.\", \"Amyloid-β (Aβ) is associated with several diseases beyond Alzheimer's disease, including Lewy body disease (LBD), multiple system atrophy (MSA), frontotemporal lobar degeneration-TDP-43 (FTLD-TDP), and progressive supranuclear palsy (PSP). Aβ deposition has also been linked to other neurological diseases, such as Parkinson's disease, amyotrophic lateral sclerosis, and retinal neurodegenerative diseases like Glaucoma and age-related macular degeneration. Additionally, Aβ has been implicated in cardiovascular disease, cancer, traumatic brain injury, and diabetes.\", \"Amyloid-β is associated with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, cardiovascular disease, cancer, traumatic brain injury, Glaucoma, and age-related macular degeneration.\", \"Amyloid-beta (Aβ) is associated with various neurodegenerative diseases, including Alzheimer's disease (AD), Lewy body disease (LBD), frontotemporal lobar degeneration-TDP-43 (FTLD-TDP), Parkinson's disease, amyotrophic lateral sclerosis, glaucoma, and age-related macular degeneration. Aβ has also been linked to cardiovascular disease, cancer, traumatic brain injury, and diabetes.\", \"Amyloid-beta is associated with a range of diseases, primarily neurodegenerative and retinal disorders. It is most notably linked to Alzheimer's disease but also connected to other conditions such as Parkinson's disease, amyotrophic lateral sclerosis, Glaucoma, and age-related macular degeneration.\", \"Amyloid-β is associated with neurodegenerative diseases such as Alzheimer's disease, Lewy body disease, multiple system atrophy, frontotemporal lobar degeneration-TDP-43, and progressive supranuclear palsy. It has also been implicated in other conditions including Parkinson's disease, amyotrophic lateral sclerosis, glaucoma, age-related macular degeneration, cardiovascular disease, cancer, traumatic brain injury, and diabetes.\", \"Amyloid-β is associated with neurodegenerative diseases beyond Alzheimer's disease, including Lewy body disease, multiple system atrophy, frontotemporal lobar degeneration-TDP-43, and progressive supranuclear palsy.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data tables, Amyloid-β is associated with the following diseases:\n\n* Alzheimer's disease (e.g., entities 2, 3, 5, 6, 7, 11, 13, 15, 17, 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104)\n* Cerebral amyloid angiopathy (e.g., entities 13, 33, 36, 37)\n* Amyloidosis (e.g., entities 3, 16, 17, 18, 24)\n* Cancer (e.g., entities 60, 61)\n* Atherosclerosis (e.g., entities 41)\n* Cardiovascular disease (e.g., entities 21, 101)\n* Dementia (e.g., entities 62, 63)\n* Degenerative diseases (e.g., entities 40, 80)\n* Neurodegenerative disorders (e.g., entities 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104)\n* Vascular dementia (e.g., entities 101)\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "3",
        "Information Recall Explanation": "The answer lists several diseases associated with Amyloid-β, including Alzheimer's disease, cerebral amyloid angiopathy, amyloidosis, cancer, and others. However, it misses some key diseases mentioned in the reference answers, such as Parkinson's disease, amyotrophic lateral sclerosis, glaucoma, and age-related macular degeneration. The inclusion of entity numbers is unnecessary and does not aid recall.",
        "Information Precision Score": "2",
        "Information Precision Explanation": "The answer includes some irrelevant details, such as the entity numbers (e.g., entities 2, 3, etc.), which do not contribute to understanding the diseases associated with Amyloid-β. Additionally, the categorization of some diseases is overly broad (e.g., 'degenerative diseases' and 'neurodegenerative disorders'), which lacks the precision seen in the reference answers.",
        "Information Repetition Score": "3",
        "Information Repetition Explanation": "There is some repetition in the listing of diseases, particularly in the broad categories like 'neurodegenerative disorders,' which overlap with more specific diseases already mentioned (e.g., Alzheimer's disease). The entity numbers are repeated excessively without adding value.",
        "Readability Score": "2",
        "Readability Explanation": "The answer is difficult to read due to the excessive and distracting use of entity numbers. The structure is unclear, and the broad categorizations make it less fluent compared to the concise and clear reference answers."
    },
    {
        "Question": "Which tick genus is the vector for Lyme disease?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhich tick genus is the vector for Lyme disease?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Ixodes is the tick genus that is known to be a vector for Lyme disease. Specifically, Ixodes scapularis, also known as the blacklegged tick or deer tick, is the primary vector of Lyme disease in the United States and Canada. Other species within the Ixodes genus, such as Ixodes holocyclus in Australia, have also been implicated in the transmission of Lyme disease.', 'Ixodes is the tick genus that is the vector for Lyme disease.', 'The tick genus Ixodes is the primary vector for Lyme disease. These ticks are found in various regions of North America and Europe, where they transmit the bacterium Borrelia burgdorferi to humans and other animals.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nIxodes is the tick genus that is the vector for Lyme disease, caused by the bacterium Borrelia burgdorferi.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer correctly identifies 'Ixodes' as the tick genus vector for Lyme disease and mentions the bacterium 'Borrelia burgdorferi.' However, it lacks some details found in the reference answers, such as specific species like 'Ixodes scapularis' or regional information.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise, providing only relevant information about the tick genus and the bacterium causing Lyme disease, without any irrelevant details.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each piece of information is mentioned only once.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is concise, clear, and easily understandable, making it highly readable."
    },
    {
        "Question": "Can lactate levels predict mortality in paediatric sepsis?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nCan lactate levels predict mortality in paediatric sepsis?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes, lactate can predict mortality in paediatric sepsis.', 'Yes, blood lactate levels can predict mortality in paediatric sepsis.', 'Yes, lactate levels can predict mortality in paediatric sepsis.', 'Yes, lactate levels can be used to predict mortality in pediatric sepsis.', 'Yes, lactate levels are associated with increased risk of mortality in paediatric sepsis.', 'Yes, in children with sepsis/severe sepsis/septic shock, serum lactate levels are associated with mortality.', 'Yes, lactate levels have been shown to predict mortality in paediatric sepsis.', 'Yes, in children with sepsis/severe sepsis/septic shock, serum lactate levels have shown significant and consistent associations with mortality, indicating that lactate levels can be a predictor of mortality in paediatric sepsis.', 'Yes. Serum lactate levels are significantly and consistently associated with mortality in pediatric sepsis.', 'Yes, serum lactate levels can predict mortality in paediatric sepsis.', 'Yes, serum lactate levels have been shown to be significantly associated with mortality in children with sepsis, severe sepsis, or septic shock.', 'Yes, in children with sepsis/severe sepsis/septic shock, serum lactate levels demonstrated significant and consistent associations with mortality.', 'Yes, high lactate levels have demonstrated significant associations with mortality in paediatric sepsis.', ' Yes, serum lactate levels have been shown to be a significant and consistent predictor of mortality in paediatric sepsis.', 'Yes, lactate levels are a significant predictor of mortality in pediatric sepsis.', 'yes, serum lactate levels are significantly associated with mortality in pediatric sepsis.', 'Yes. Serum lactate is significantly and consistently associated with mortality in pediatric sepsis.', 'Yes, serum lactate levels demonstrated significant and consistent associations with mortality in children with sepsis/severe sepsis/septic shock.', 'Yes, serum lactate levels have shown significant and consistent associations with mortality in children with sepsis.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data tables and sources, there is evidence to suggest that lactate levels can predict mortality in pediatric sepsis.\n\nSource 1 (ID: 2) states that \"lactate levels greater than 36 mg/dL were significantly associated with 30-day mortality in children with suspected sepsis\" (Association Between Early Lactate Levels and 30-Day Mortality in Clinically Suspected Sepsis in Children).\n\nSource 3 (ID: 3) found that \"lactate clearance was independently associated with survival after 8 hours\" in children with severe febrile illnesses in East Africa, including those with sepsis.\n\nSource 9 (ID: 9) also found that \"plasma lactate at 0 h and 6 h was significantly higher, and lactate clearance was significantly lower in non-survivors\" in pediatric sepsis patients.\n\nAdditionally, Source 10 (ID: 10) found that \"plasma lactate levels at 6 h had the highest accuracy (AUC = 0.83) for identifying mortality\" in pediatric sepsis patients.\n\nThese studies suggest that lactate levels, particularly high lactate levels or decreased lactate clearance, may be associated with increased mortality risk in pediatric sepsis. However, it's essential to note that lactate levels should be interpreted in the context of other clinical and laboratory findings, as sepsis is a complex condition with multiple contributing factors.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively addresses the question by providing detailed evidence from multiple sources (1, 3, 9, 10) that support the association between lactate levels and mortality in pediatric sepsis. It includes specifics about lactate levels, lactate clearance, and their predictive accuracy, which are all relevant to the question.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is highly precise, focusing solely on the relationship between lactate levels and mortality in pediatric sepsis. It avoids including irrelevant information and sticks to the evidence provided by the cited sources.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of the same information. The answer presents distinct pieces of evidence from different sources, each contributing unique details to support the conclusion.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clear, and fluent. It logically presents the evidence and concludes with a nuanced perspective on interpreting lactate levels in the context of sepsis, enhancing readability."
    },
    {
        "Question": "What is the use of fezolinetant?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the use of fezolinetant?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Fezolinetant is an oral, small molecule, neurokinin 3 receptor (NK3R) antagonist, approved for moderate to severe vasomotor symptoms (VMS) or hot flashes due to menopause.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nFezolinetant is a medication used to treat moderate to severe vasomotor symptoms (VMS) associated with menopause. It is a neurokinin 3 receptor antagonist, which means it works by blocking the action of neurokinin B, a substance that stimulates the thermoregulatory center in the brain, leading to hot flashes and other VMS. Fezolinetant is administered orally and has been shown to be effective in reducing the frequency and severity of VMS in clinical trials. It is a non-hormonal treatment option for women who may not be suitable for or prefer not to use hormone therapy.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer correctly identifies fezolinetant as a medication for moderate to severe vasomotor symptoms (VMS) due to menopause, its mechanism of action as a neurokinin 3 receptor antagonist, and its oral administration. It also mentions its non-hormonal nature and effectiveness in clinical trials, which are additional useful details. The only missing detail is the explicit mention of it being 'small molecule,' though this is somewhat implied.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information. All details provided are directly relevant to the use of fezolinetant in treating VMS associated with menopause.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information. It presents a cohesive explanation covering the use, mechanism of action, administration, and additional context about the medication without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to read. The information flows logically, and the language is clear and accessible to a general audience."
    },
    {
        "Question": "Which gene mutations confer acquired resistance to anti-EGFR therapy in advance colorectal cancer?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhich gene mutations confer acquired resistance to anti-EGFR therapy in advance colorectal cancer?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['In cetuximab-sensitive patients,  ARID1A, KRAS, BRAF, AKT1, PIK3CA and FGFR1 or ERBB2 mutations are associated to acquired resistance', 'Several gene mutations have been identified as conferring acquired resistance to anti-EGFR therapy in advanced colorectal cancer. These include mutations in PIK3CA, KRAS, NRAS, BRAF, and MAP2K1. Of note, PIK3CA mutations were found to promote cell viability in the presence of cetuximab, and KRAS and NRAS mutations are currently recognized as the best predictive factors for primary resistance. Additionally, ERBB2, EGFR, FGFR1, and PDGFRA mutations have been identified as potential mechanisms of primary resistance to anti-EGFR therapy. Therapeutic resistance to EGFR blockade can also be overcome through combinatorial therapies targeting actionable genes.', 'Answer 1: \\nKRAS and NRAS mutations have been associated with acquired resistance to anti-EGFR therapy in advanced colorectal cancer.\\nAnswer 2: \\nActivating BRAF mutations also cause resistance to anti-EGFR therapy\\nAnswer 3: \\nAdditional mutations that can lead to resistance to anti-EGFR therapy are TP53, PI3KCA, and PTEN', 'KRAS mutations can confer acquired resistance to anti-EGFR therapy in advanced colorectal cancer.', 'In advanced colorectal cancer, mutations in the KRAS gene are known to confer acquired resistance to anti-EGFR therapy. Additionally, mutations in other genes such as APC, TP53, SMAD4, and EGFR have also been associated with resistance to EGFR-targeted therapies in colorectal cancer. These mutations can lead to poorer clinical outcomes and reduced effectiveness of EGFR pathway inhibition.', 'The gene mutations that confer acquired resistance to anti-EGFR therapy in advanced colorectal cancer are:1. T790M mutation in exon 19 of the EGFR gene2. L858R mutation in exon 21 of the EGFR gene3. EGF A+61G polymorphism', 'KRAS, NRAS, BRAF, and PIK3CA gene mutations confer acquired resistance to anti-EGFR therapy in advance colorectal cancer.', '7 mutations have been consistently associated with acquired resistance to anti-EGFR therapy in colorectal cancer. These are RAS, BRAF, EGFR, PIK3CA, PTEN, NRAS, and KRAS. EGFR mutations can have a direct role or they can be secondary to the primary KRAS/NRAS/BRAF mutation. In case of colorectal cancer, the most commonly found mutations are KRAS, NRAS and BRAF.', 'Mutations in the KRAS gene are known to confer acquired resistance to anti-EGFR therapy in advanced colorectal cancer. These mutations are present in approximately 55% of patients with metastatic colorectal cancer and are associated with poorer clinical outcomes due to resistance to EGFR blockade.', 'Activating RAS gene mutations occur in approximately 55% of patients with metastatic colorectal cancer (mCRC) and are associated with poorer clinical outcomes due to epidermal growth factor receptor (EGFR) blockade resistance. It is well established in CRC that mutations in KRAS are predictive of resistance to EGFR pathway inhibition, and may predict for a poorer outcome with therapy.', '\\nKRAS, NRAS, BRAF (V600E), PIK3CA, and MET amplifications', '38-47% of patients with colorectal cancer have KRAS mutations, 3-8% have NRAS mutations and 5-10% have BRAF mutations.', 'KRAS mutations are the most common genetic alterations associated with acquired resistance to anti-EGFR therapy in advanced colorectal cancer. Other genetic alterations associated with acquired resistance to anti-EGFR therapy in advanced colorectal cancer include PIK3CA, PTEN, EGFR, and ERBB2.', 'Several studies have identified gene mutations that may contribute to acquired resistance to anti-EGFR therapy in metastatic colorectal cancer. In a study of 32 patients with acquired cetuximab resistance, seven (22%) carried five novel PIK3CA mutations (p.K944N, p.F930S, p.V955G, p.V955I, and p.K966E), while eight (25%) carried previously reported KRAS mutations. Functional studies showed that novel PIK3CA mutations promote cell viability in the presence of cetuximab. Only one novel PIK3CA mutation (p.K944N) was verified in one of the 27 patients with acquired resistance in a validation cohort, and simultaneous KRAS and PIK3CA hotspot mutations were detected in two patients. Among the above 59 acquired resistance patients', 'KRAS mutations are frequently associated with acquired resistance to anti-EGFR therapy in advanced colorectal cancer.', 'The gene mutations that confer acquired resistance to anti-EGFR therapy in advanced colorectal cancer are KRAS and NRAS mutations. These mutations define a population refractory to anti-EGFR monoclonal antibodies. Novel alterations in the ectodomain of EGFR have been identified in patients with acquired resistance to EGFR blockade, and amplifications and sequence alterations in KRAS and NRAS have been detected in specimens from patients with secondary resistance.', 'Somatic mutations of KRAS, EGFR, BRAF, T53, and HRAS occur in colorectal cancer (CRC) and confer acquired resistance to anti-EGFR therapy, resulting in poor prognosis.', 'The development of resistance to EGFR-targeted therapies is associated with various genetic alterations, including KRAS mutations and amplifications of genes such as MET and ERBB2. In particular, acquired gains of KRAS have been observed in 40% (4/10) of patients analyzed by whole genome sequencing and ultra-sensitive deep sequencing of resistance-associated genes. These findings suggest that the identification of a wide set of gene mutations, including those not typically associated with primary resistance to EGFR inhibitors, may be important for predicting acquired resistance and guiding individualized therapy in advanced colorectal cancer.', 'KRAS mutations are predictive of resistance to EGFR pathway inhibition, and may predict for a poorer outcome with therapy.', \"Several gene mutations have been identified as conferring acquired resistance to anti-EGFR therapy in advanced colorectal cancer. These include: * KRAS mutations, which are the most common mechanism of resistance * BRAF mutations * PIK3CA mutations * MET amplifications * ERBB2 amplifications * FGFR1 mutations * PDGFRA mutations * MAP2K1 mutations * Amplifications and sequence changes in the tyrosine kinase receptor adaptor gene IRS2 (in tumors with increased sensitivity to anti-EGFR therapy) , It's worth noting that the genetic landscape of resistance to EGFR blockade in colorectal cancer is complex, and multiple mechanisms of resistance can coexist within the same tumor.\", 'KRAS, NRAS, BRAF, and PIK3CA mutations can be associated with acquired resistance to anti-EGFR therapy in advanced colorectal cancer.', '\\nKRAS, NRAS (less common), BRAF V600E (less common), and PIK3CA mutations can confer acquired resistance to anti-EGFR therapy in advanced colorectal cancer. MET amplifications are also associated with acquired resistance in some patients.', 'Activating KRAS gene mutations, which occur in approximately 55% of patients with metastatic colorectal cancer (mCRC), are associated with resistance to EGFR pathway inhibition and poorer clinical outcomes with anti-EGFR therapy. It is well established in colorectal cancer that KRAS mutations are predictive of resistance to EGFR blockade.', 'Mutations in the KRAS gene are known to confer acquired resistance to anti-EGFR therapy in advanced colorectal cancer.', 'KRAS K117N and A146T mutations, BRAF V600E, AKT1 E17K, PIK3CA E542K, and FGFR1 or ERBB2 amplificatio', 'Two gene mutations, KRAS K117N and A146T, have been identified as conferring acquired resistance to anti-EGFR therapy in advanced colorectal cancer. These mutations are in addition to the BRAF V600E, AKT1 E17K, PIK3CA E542K, and FGFR1 or ERBB2 amplifications that are also associated with resistance to anti-EGFR therapy. Additionally, mutations in the ARID1A gene have been suggested to provide both an acquired and intrinsic mechanism of resistance to anti-EGFR therapies.', 'ARID1A mutations', 'Somatic mutations of the EGFR gene or the KRAS oncogene in patients with acquired colorectal cancer result in acquired resistance to anti-EGFR therapy.', 'In advanced colorectal cancer, gene mutations such as KRAS K117N, A146T, BRAF V600E, AKT1 E17K, PIK3CA E542K, and FGFR1 or ERBB2 amplifications have been associated with acquired resistance to anti-EGFR therapies. Additionally, ARID1A mutations have been identified as potential mechanisms of both acquired and intrinsic resistance to anti-EGFR therapies.', 'The gene mutations that confer acquired resistance to anti-EGFR therapy in advanced colorectal cancer are ARID1A mutations.', 'In advanced colorectal cancer, ARID1A mutations may provide both an acquired and intrinsic mechanism of resistance to anti-EGFR therapies. This suggests that changes in the ARID1A gene could be a factor in how well a patient responds to these treatments over time.', 'The gene mutations that confer acquired resistance to anti-EGFR therapy in advanced colorectal cancer are KRAS K117N, AKT1 E17K, BRAF V600E, PIK3CA E542K, and ARID1A.', 'ARID1A mutations are reported to be associated with acquired resistance to anti-EGFR therapy in advanced colorectal cancer. Other gene mutations that are commonly associated with acquired resistance to anti-EGFR therapy in advanced colorectal cancer include KRAS, NRAS and BRAF mutations.', 'ARID1A and A146T mutations confer acquired resistance to anti-EGFR therapy in advanced colorectal cancer.', 'ARID1A mutations may provide an acquired mechanism of resistance to anti-EGFR therapies in advanced colorectal cancer.', 'In advanced colorectal cancer, ARID1A mutations may provide an acquired mechanism of resistance to anti-EGFR therapies', 'In cetuximab-sensitive patients, we found KRAS K117N and A146T mutations in addition to BRAF V600E, AKT1 E17K, PIK3CA E542K, and FGFR1 or ERBB2 amplifications. ARID1A mutations may provide both an acquired and intrinsic mechanism of resistance to anti-EGFR therapies.', 'The main genes whose mutations confer acquired resistance to anti-EGFR therapy in advanced colorectal cancer are KRAS, BRAF, AKT1, PIK3CA, FGFR1 and ERBB2.', 'KRAS mutations are frequent drivers of acquired resistance to cetuximab in metastatic colorectal cancer. KRAS mutations in addition to BRAF, AKT1 E17K, PIK3CA E542K, and FGFR1 or ERBB2 amplifications drive primary and secondary resistance to anti-EGFR therapy in metastatic colorectal cancer.', 'In advanced colorectal cancer, acquired resistance to anti-EGFR therapy can be conferred by mutations in ARID1A, KRAS (K117N and A146T), BRAF V600E, AKT1 E17K, and PIK3CA E542K.', 'The genes that have been found to confer acquired resistance to anti-EGFR therapy in colorectal cancer include KRAS K117N and A146T mutations. These mutations, along with BRAF V600E, AKT1 E17K, PIK3CA E542K, and FGFR1 or ERBB2 amplifications, were identified in cetuximab-sensitive patients who developed resistance to the therapy. Additionally, ARID1A mutations may provide both an acquired and intrinsic mechanism of resistance to anti-EGFR therapies. These findings suggest that the presence of these gene mutations could be used as biomarkers to predict the likelihood of response to anti-EGFR therapy and to identify patients who may benefit from alternative treatment strategies. Further research is needed to fully understand the role of these gene mutations in the development of resistance to anti-EGFR therapy and to develop effective strategies to overcome', 'In the context of acquired resistance to anti-EGFR therapy in advanced colorectal cancer, ARID1A mutations have been identified as a potential mechanism.', 'The genomic analysis revealed that KRAS K117N and A146T mutations, as well as BRAF V600E, AKT1 E17K, PIK3CA E542K, and FGFR1 or ERBB2 amplifications, confer acquired resistance to anti-EGFR therapy in advanced colorectal cancer.', 'The clinical benefit of EGFR inhibitors differs in right and left colorectal cancer.ARID1A mutations may provide both an acquired and intrinsic mechanism of resistance to anti-EGFR therapies.The analysis of the immune microenvironment showed that immune infiltration was more common in RCC than LCC. The results of differential gene analysis showed that there were 360 differentially expressed genes, with 142 upregulated genes in LCC and 218 upregulated genes in RCC. The mutation frequency of RCC was generally higher than that of LCC. BRAF and KRAS gene mutations were the dominant genes mutations in RCC, and they had a strong mutual exclusion with APC, while APC gene mutation was the dominant gene mutation in LCC. This suggests that the molecular mechanisms of RCC and LCC differed.Patients with locally advanced colorectal cancer (LACRC) have a high risk of recurrence and metastasis, although neoadjuvant therapy may provide some benefit.', 'The study identified several gene mutations that confer acquired resistance to anti-EGFR therapy in advanced colorectal cancer. These include NRG1 and GNAS amplifications, KRAS K117N and A146T mutations, BRAF V600E, AKT1 E17K, PIK3CA E542K, and FGFR1 or ERBB2 amplifications. Additionally, ARID1A mutations were found to be associated with worse outcomes in patients treated with cetuximab-containing therapies, suggesting that these mutations may provide both an acquired and intrinsic mechanism of resistance to anti-EGFR therapies.', 'In advanced colorectal cancer, several gene mutations have been associated with acquired resistance to anti-EGFR therapies. These include KRAS K117N and A146T mutations, BRAF V600E, AKT1 E17K, PIK3CA E542K, FGFR1 or ERBB2 amplifications, and ARID1A mutations. The presence of these genetic alterations can provide both an acquired and intrinsic mechanism of resistance to anti-EGFR treatments, limiting their effectiveness in some patients with advanced colorectal cancer.', 'ARID1A mutations may provide both an acquired and intrinsic mechanism of resistance to anti-EGFR therapies.', 'KRAS K117N, AKT1 E17K, BRAF V600E, PIK3CA E542K, ARID1A, A146T, FGFR1 amplification, and ERBB2 amplification confer acquired resistance to anti-EGFR therapy in advanced colorectal cancer.', 'KRAS K117N and A146T mutations, BRAF V600E mutation, AKT1 E17K mutation, PIK3CA E542K mutation, and FGFR1 or ERBB2 amplifications can confer acquired resistance to anti-EGFR therapy like cetuximab in advanced colorectal cancer patients. Additionally, ARID1A mutations may provide both an acquired and intrinsic mechanism of resistance to anti-EGFR therapies.', 'ARID1A mutations may provide both an acquired and intrinsic mechanism of resistance to anti-EGFR therapies in advanced colorectal cancer.', 'In advanced colorectal cancer, gene mutations that confer acquired resistance to anti-EGFR therapy include KRAS K117N, KRAS A146T, BRAF V600E, AKT1 E17K, PIK3CA E542K, and FGFR1 or ERBB2 amplifications. Additionally, ARID1A mutations may provide both an acquired and intrinsic mechanism of resistance to anti-EGFR therapies.', 'KRAS K117N, A146T, BRAF V600E, AKT1 E17K, PIK3CA E542K, and FGFR1 or ERBB2 amplifications.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, the following gene mutations are associated with acquired resistance to anti-EGFR therapy in advanced colorectal cancer:\n\n1. KRAS mutations: The emergence of KRAS mutations is a common mechanism of acquired resistance to anti-EGFR therapy in colorectal cancer. These mutations can occur in the KRAS gene and can lead to the development of secondary resistance to anti-EGFR treatment.\n2. PIK3CA mutations: Mutations in the PIK3CA gene, which encodes the p110α subunit of PI3K, can also contribute to acquired resistance to anti-EGFR therapy. These mutations can activate the PI3K/AKT pathway, which can bypass the EGFR signaling pathway and lead to resistance to anti-EGFR treatment.\n3. BRAF V600E mutations: While BRAF mutations are not as common as KRAS mutations, they can also contribute to acquired resistance to anti-EGFR therapy.\n4. MET mutations: Amplification or mutation of the MET gene, which encodes the hepatocyte growth factor receptor, can also contribute to acquired resistance to anti-EGFR therapy.\n5. FGFR1 mutations: Mutations in the FGFR1 gene, which encodes the fibroblast growth factor receptor 1, have also been associated with acquired resistance to anti-EGFR therapy.\n\nThese gene mutations can lead to the development of secondary resistance to anti-EGFR therapy, making it essential to identify these mutations in patients with advanced colorectal cancer to determine the most effective treatment strategy.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers key mutations (KRAS, PIK3CA, BRAF V600E, MET, and FGFR1) associated with acquired resistance to anti-EGFR therapy, as noted in the reference answers. However, it misses some less common but still relevant mutations like NRAS, ERBB2, ARID1A, and specific KRAS variants (K117N, A146T), which are mentioned in the references.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and focuses only on gene mutations directly linked to acquired resistance in advanced colorectal cancer, without including irrelevant information.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of the same information. Each mutation is described clearly and concisely without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to read. Each mutation is introduced with a clear explanation of its role in resistance, making it accessible to a biomedical audience."
    },
    {
        "Question": "List the methods for pectus excavatum repair?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nList the methods for pectus excavatum repair?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Patients with Pectus Excavatum can be treated both surgically and non surgically with the vacuum bell procedure. The minimally invasive surgical procedure is called the Nuss operation.', 'Surgical methods for pectus excavatum repair can include sternocostal elevation, routine sternal elevation, detachment of the xiphoid process, direct sub-xiphoid retrosternal dissection, thoracoscopy, sternotomy, MIRPE, and even resuming contact sports post-operatively.', 'List the methods for pectus excavatum repair: sternocostal elevation, open Holcomb and Welch method, direct sub-xiphoid retrosternal dissection, thoracoscopy, Minimally invasive repair of pectus excavatum (MIRPE), MIRPE, sternal elevation, routine sternal elevation.', \"There are several methods for pectus excavatum repair, including:\\n\\n1. Minimally invasive surgery (Nuss procedure)\\n2. Open repair\\n3. Bar insertion and removal\\n4. Morphology-tailored bar shaping technique\\n5. Approaching the retrosternal space through an additional subxiphoid short incision\\n6. Lifting the sternum during bar placement\\n7. Placing the bar extrapleuraly\\n8. Bilateral thoracoscopic cryoanalgesia during minimally invasive pectus excavatum repair\\n\\nEach method has its own advantages, disadvantages, techniques employed, and associated complications. It is important to consider the individual patient's needs and the surgeon's expertise when choosing a method for pectus excavatum repair.\", 'The methods for pectus excavatum repair are the Nuss procedure, bar insertion and removal, and bilateral thoracoscopic cryoanalgesia during minimally invasive pectus excavatum repair.', '1. The Ravitch procedure, the classical procedure for pectus excavatum repair, was developed in 1949. It involves the resection of the affected costal cartilages and their substitution with a metal bar.\\n2. The Nuss procedure, a less invasive and simpler procedure for pectus excavatum repair was developed in 1987. It involves the placement of a metal bar under the sternum and ribs, pushing them into a correct position.\\n3. Minimally invasive techniques, including thoracoscopic assisted Ravitch procedure and minimally invasive Nuss procedure, have also been developed.', 'The methods for repairing pectus excavatum include Minimally Invasive Repair of Pectus Excavatum (MIRPE), the open Holcomb and Welch method, sternocostal elevation, and conservative sub-perichondral resection with xiphoid process detachment.', 'The methods for pectus excavatum repair are the following:, 1) open Holcomb technique, 2) Welch method, 3) minimally invasive repair of pectus excavatum (MIRPE), 4) Nuss procedure, 5) Ravitch procedure', 'The methods for pectus excavatum repair are:\\n\\n1. Minimally invasive surgery (Nuss procedure)\\n2. Open repair\\n3. Bar insertion and removal\\n4. Morphology-tailored bar shaping technique\\n5. Bilateral thoracoscopic cryoanalgesia during minimally invasive pectus excavatum repair', 'The main methods for pectus excavatum repair are:\\n\\n1. Minimally invasive repair (Nuss procedure): This has become the standard operation. It involves placing a metal bar behind the sternum to push it outwards. Technical variations include morphology-tailored asymmetric bar shaping, approaching the retrosternal space through an additional subxiphoid incision, lifting the sternum during bar placement, or placing the bar extrapleurally.\\n\\n2. Open repair: This is a traditional surgical approach involving resection of deformed cartilages and fixation of the sternum in a corrected position. \\n\\nBoth the Nuss procedure and open repair can provide safe and effective correction of pectus excavatum when performed with technical expertise.', 'The methods for pectus excavatum repair include:\\n\\n1. Minimally Invasive Repair: This technique involves the use of a curved steel bar that is individually shaped for each patient and placed through an endoscopically created retrosternal tunnel between two bilateral midaxillary line incisions.\\n\\n2. Nuss Technique: This is a modification of the minimally invasive repair method, where a curved steel bar is used to reshape the chest wall and correct the deformity.\\n\\n3. Highly Modified Ravitch Repair: This is an open surgical technique that involves the removal of abnormal cartilage and ribs, followed by reshaping of the chest wall using sutures and/or prosthetic materials.\\n\\n4. Prolene Polypropylene Mesh Repair: This technique involves the use of a mesh made of polypropylene to provide support and stability to the chest wall.\\n\\n5. Compression Techniques: In some cases, compression techniques using a brace may be used to correct the deformity, particularly in cases of pectus carinatum.\\n\\nIt is important to note that the choice of repair method depends on the severity of the pectus excavatum, patient factors, and surgeon preference.', 'The methods for pectus excavatum repair are:\\n- Vacuum bell therapy\\n- Nuss operation\\n- Surgical corre', 'Methods for pectus excavatum repair include surgical correction using a minimally invasive approach with a metal bar (Nuss operation), vacuum bell therapy as a non-surgical alternative, and other surgical and non-surgical treatments.', 'The methods for pectus excavatum repair include vacuum bell therapy, Nuss operation, minimally invasive approach, and surgical correction.', 'The methods for pectus excavatum repair include vacuum bell therapy, minimally invasive approach, Nuss operation, surgical correction, non-surgical treatment, metal bar correction, metal bar insertion, and preoperative evaluation.', 'Pectus excavatum repair methods include surgical approaches such as the Nuss procedure, in which a metal bar is used to correct the chest wall abnormality, and non-surgical treatment options such as vacuum bell therapy.', 'The methods for pectus excavatum repair include surgical correction, primarily using the Nuss procedure, and non-surgical treatment with devices like the vacuum bell. The Nuss procedure involves placing a metal bar to correct the chest wall, while the vacuum bell uses suction to help reshape the chest gradually', 'The methods for pectus excavatum repair include surgical correction with a minimally invasive approach using a metal bar, as well as non-surgical treatment with vacuum bell therapy.', 'Pectus excavatum and carinatum deformities are the most common congenital chest wall anomaly. They can be repaired with a minimally invasive approach using the Nuss technique. Simultaneous repair of PE and open heart surgery is safe and effective.', 'Pectus excavatum can be repaired using the Nuss operation, vacuum bell therapy, or a minimally invasive surgical approach involving a metal bar.', 'The methods for repairing pectus excavatum include the Nuss operation, which is a minimally invasive surgical approach using a metal bar to correct the chest wall, and vacuum bell therapy, a non-surgical option that uses a vacuum device to help reshape the chest.', 'Pectus excavatum deformities are usually repaired with a minimally invasive approach in which a metal bar is used to correct the chest wall abnormality.', 'The methods for pectus excavatum repair are vacuum bell therapy, Nuss operation, minimally invasive approach, surgical correction, and non-surgical treatment.', 'The main methods for pectus excavatum repair are:\\n\\n1. Surgical correction, most commonly using the minimally invasive Nuss procedure where a metal bar is used to correct the chest wall abnormality.\\n\\n2. Non-surgical treatment using the vacuum bell, which applies suction to gradually lift the sunken chest over time. This can be an alternative for patients who prefer to avoid surgery.', 'Pectus excavatum can be repaired using surgical and non-surgical methods. The surgical approach often involves the Nuss procedure, which uses a metal bar to correct the chest wall. Non-surgical methods include the use of a vacuum bell therapy, which can serve as an alternative for those preferring non-invasive options.', 'The methods for pectus excavatum repair include surgical correction using the Nuss procedure, Ravitch procedure, or the modified Ravitch procedure, as well as non-surgical correction using vacuum bell therapy.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data tables, the following methods for pectus excavatum repair are mentioned:\n\n1. Nuss procedure\n2. Minimally Invasive Repair of Pectus Excavatum (MIRPE)\n3. Ravitch procedure\n4. Minimally Invasive Pectus Excavatum Repair\n5. Minimally Invasive Endoscopic Repair\n6. Ravitch's technique\n7. Pectus bar placement\n8. Minimally Invasive Pectus Excavatum Repair (MIRPE) with thoracoscopic vision\n9. Vacuum bell therapy\n10. Combined Ravitch and Nuss procedure (CRN)\n11. Double Compression and Complete Fixation Bar (DCCF) system\n12. Minimally invasive repair with cryoablation (for pain management)\n13. Sternal elevation techniques (SETs), including the use of retractors, cranes, and customized hooks\n14. Open surgical repair (Highly Modified Ravitch Repair, HMRR)\n15. Minimally Invasive Repair of Pectus Excavatum (MIRPE) with bar removal\n\nNote that some of these methods may overlap or be variations of each other, but they are all mentioned in the provided data tables as being used for pectus excavatum repair.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively lists a wide range of methods for pectus excavatum repair, including both surgical and non-surgical options. It includes variations of the Nuss procedure, Ravitch procedure, MIRPE, vacuum bell therapy, and other specialized techniques, which are all referenced in the provided data tables.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise and focuses on listing methods for pectus excavatum repair without including irrelevant details. However, it notes that some methods may overlap or be variations of each other, which slightly affects precision.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer avoids significant repetition, but there are minor overlaps (e.g., 'Minimally Invasive Repair of Pectus Excavatum' and 'MIRPE' are mentioned separately). The note about potential overlaps acknowledges this.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clearly listed, and easy to read. The use of bullet points enhances readability, and the note at the end provides additional clarity."
    },
    {
        "Question": "Impact of pollution on asthma.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nImpact of pollution on asthma.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Air pollution and climate change have a significant impact on human health and well-being and contribute to the onset and aggravation of allergic rhinitis and asthma among other chronic respiratory diseases. High exposure to indoor allergens (house dust mites, pets, molds, etc), tobacco smoke, and other pollutants, which have an impact on respiratory health. Outdoor air pollution derived from traffic and other human activities not only has a direct negative effect on human health but also enhances the allergenicity of some plants. The effects of indoor air pollution, outdoor air pollution, and subsequent climate change on asthma and allergic rhinitis in children and adults. Air pollution has a negative impact on asthma outcomes in both adult and pediatric populations. The effect of various outdoor and indoor pollutants on asthma. Traffic-related air pollution, nitrogen dioxide and second-hand smoking (SHS) exposures represent significant risk factors for asthma development in children. Exposure to outdoor pollutants can induce asthma symptoms, exacerbations and decreases in lung function. Indoor pollutants such as heating sources and molds can also negatively impact the course of asthma.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe data suggests that pollution, specifically air pollution, has a significant impact on asthma. According to the relations table, air pollution is associated with an increased risk of asthma development in children (relation ID 27) and exacerbation of asthma symptoms (relation ID 22). The relations also indicate that air pollution contributes to the onset and aggravation of asthma (relation ID 22).\n\nFurthermore, the data suggests that specific types of pollution, such as particulate matter air pollution (relation ID 35) and traffic-related air pollution (relation ID 27), are also associated with an increased risk of asthma.\n\nAdditionally, the data suggests that other environmental factors, such as climate change (relation ID 24), can also contribute to the development and exacerbation of asthma.\n\nOverall, the data suggests that pollution is a significant risk factor for asthma and that reducing exposure to pollution can help to mitigate the risk of developing asthma and exacerbating symptoms.\n\nHere is a summary of the key points:\n\n* Air pollution is associated with an increased risk of asthma development in children\n* Air pollution contributes to the onset and aggravation of asthma\n* Particulate matter air pollution and traffic-related air pollution are specific types of pollution that are associated with an increased risk of asthma\n* Climate change can contribute to the development and exacerbation of asthma\n* Reducing exposure to pollution can help to mitigate the risk of developing asthma and exacerbating symptoms.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer captures most of the key points from the reference answers, such as the impact of air pollution (both outdoor and specific types like traffic-related), the role of climate change, and the exacerbation of asthma symptoms. However, it misses some details like indoor pollutants (e.g., molds, heating sources) and the distinction between adult and pediatric impacts.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and stays focused on the impact of pollution on asthma without introducing irrelevant information. Each point is directly relevant to the question.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not excessively repeat information, but there is slight redundancy in mentioning 'air pollution' multiple times when summarizing key points. However, this does not significantly detract from the overall clarity.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to follow. The use of bullet points for key summaries enhances readability. The language is clear and concise."
    },
    {
        "Question": "Do elevated levels of procalcitonin help in diagnosing paediatric sepsis?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nDo elevated levels of procalcitonin help in diagnosing paediatric sepsis?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes, PCT can be used to diagnose paediatric sepsis.', 'Yes, elevated levels of procalcitonin help in diagnosing paediatric sepsis.', 'Yes, elevated levels of procalcitonin help in diagnosing paediatric sepsis, particularly in differentiating between sepsis and septic shock and assessing disease severity.', 'Yes, elevated procalcitonin levels help in diagnosing paediatric sepsis', 'Yes, elevated procalcitonin levels are useful for diagnosing sepsis in kids.', 'Yes, elevated levels of procalcitonin are associated with the diagnosis of sepsis in children.', 'Yes, elevated levels of procalcitonin (PCT) help in diagnosing paediatric sepsis.', 'Yes, elevated procalcitonin levels are helpful in diagnosing paediatric sepsis.', 'Yes, elevated levels of procalcitonin (PCT) are used in clinical practice to assess sepsis and estimate disease severity, indicating its utility in diagnosing pediatric sepsis.', 'Yes, elevated levels of procalcitonin can help in diagnosing paediatric sepsis.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, elevated levels of procalcitonin have been shown to be a useful biomarker for diagnosing pediatric sepsis. Studies have demonstrated that procalcitonin levels are significantly elevated in children with sepsis, and can help to distinguish between bacterial and non-bacterial infections. According to the data, procalcitonin has been found to be a sensitive and specific biomarker for detecting sepsis in children, with a high area under the receiver operating curve (AUC) of 0.91 for predicting septic shock and mortality.\n\nProcalcitonin has been shown to be particularly useful in differentiating between viral and bacterial infections in children, as it is elevated in the presence of bacterial infections. Studies have also found that procalcitonin levels correlate with the severity of disease, and can be used as a prognostic marker for predicting the risk of complications and mortality in children with sepsis.\n\nHowever, it is essential to note that procalcitonin is not a definitive diagnostic tool, and should be used in conjunction with clinical evaluation and other diagnostic tests to confirm the diagnosis of sepsis. Additionally, procalcitonin levels can be influenced by various factors, such as age, sex, and underlying medical conditions, and should be interpreted in the context of the individual patient's clinical presentation.\n\nIn the provided data, there are several references that support the use of procalcitonin as a biomarker for diagnosing pediatric sepsis, including:\n\n* A study by the Pediatric Sepsis Definition Taskforce, which found that procalcitonin levels were significantly higher in children with sepsis and severe sepsis compared to those without sepsis.\n* A study by the Journal of Pediatrics, which found that procalcitonin levels were a useful predictor of septic shock and mortality in children.\n* A review by the European Journal of Pediatrics, which found that procalcitonin was a sensitive and specific biomarker for detecting sepsis in children.\n\nOverall, the available evidence suggests that elevated levels of procalcitonin can be a useful tool in diagnosing pediatric sepsis, and can help to guide clinical decision-making in the management of this condition.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively recalls all necessary information. It not only confirms that elevated procalcitonin levels help in diagnosing pediatric sepsis but also provides additional details about its utility in differentiating bacterial from non-bacterial infections, its prognostic value, and its correlation with disease severity. The answer also includes specific references to studies that support these claims.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and includes only relevant information. It details the diagnostic and prognostic utility of procalcitonin without straying into irrelevant topics. The cautionary note about interpreting procalcitonin in clinical context is also relevant.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. However, it does reinforce the utility of procalcitonin in different contexts (diagnostic, prognostic, differentiating infections), which could be seen as slightly repetitive but serves to emphasize key points.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is very readable and fluent. It is well-structured, logically organized, and uses clear language. The inclusion of specific studies adds credibility without disrupting the flow."
    },
    {
        "Question": "What is the mechanism of action of Zilebesiran?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the mechanism of action of Zilebesiran?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Zilebesiran, an investigational RNA interference therapeutic agent with a prolonged duration of action, inhibits hepatic angiotensinogen synthesis.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nZilebesiran is an RNA interference (RNAi) therapeutic agent that targets hepatic angiotensinogen, a protein involved in the renin-angiotensin system (RAS) that plays a key role in blood pressure regulation. By inhibiting hepatic angiotensinogen synthesis, zilebesiran reduces the production of angiotensin II, a potent vasoconstrictor that increases blood pressure.\n\nSpecifically, zilebesiran works by binding to the liver cells and inducing the degradation of the hepatic angiotensinogen mRNA, which is the genetic material that codes for the protein. This leads to a reduction in the levels of angiotensinogen in the blood, which in turn decreases the production of angiotensin II.\n\nBy inhibiting the RAS, zilebesiran lowers blood pressure by reducing the vasoconstrictive effects of angiotensin II on blood vessels, allowing for improved blood flow and reduced peripheral resistance. This mechanism of action makes zilebesiran a potential treatment for hypertension and other cardiovascular diseases associated with RAS dysregulation.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer includes all the necessary information from the reference answer, such as Zilebesiran being an RNA interference (RNAi) therapeutic agent that inhibits hepatic angiotensinogen synthesis. Additionally, it provides extra useful details about the role of the renin-angiotensin system (RAS) and the vasoconstrictive effects of angiotensin II, which are contextually relevant.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include irrelevant information. It focuses on the mechanism of action of Zilebesiran, detailing its effects on hepatic angiotensinogen, angiotensin II, and blood pressure regulation without straying from the topic.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of the same information. The answer logically builds upon the initial description of Zilebesiran’s mechanism, explaining each step clearly without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easily readable. The explanation flows logically from one point to the next, making it accessible for readers who may not be experts in the field."
    },
    {
        "Question": "Why does inflammatory bowel disease predispose to colorectal cancer?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhy does inflammatory bowel disease predispose to colorectal cancer?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Chronic inflammation and alterations in microbiome predispose inflammatory bowel disease to colorectal cancer.  Chronic inflammation is the driver of neoplastic progression, resulting in dysplastic precursor lesions that may arise in multiple areas of the colon through a process of field cancerization. Investigations have demonstrated a potential role for the microbiome in concert with the host immune system in the development of colitis-associated colorectal cancer (CAC).', 'Inflammatory bowel disease (IBD) predisposes to colorectal cancer because chronic inflammation in the gut can lead to DNA damage, mutations, and disruptions in normal cellular processes. This can result in the development of dysplastic cells, which can eventually become cancerous. Additionally, IBD can cause an increase in the number of stem cells in the colon, which can also contribute to the development of cancer. , Long answer:, Inflammatory bowel disease (IBD) is a chronic condition characterized by persistent inflammation in the gut. This inflammation can lead to damage to the DNA and disruptions in normal cellular processes, which can increase the risk of colorectal cancer. The exact mechanisms by which IBD predisposes to colorectal cancer are not fully understood, but several factors are thought to contribute: , 1. Chronic inflammation: Chronic inflammation in the gut', 'Inflammatory bowel disease is associated with dysplasia and mutations, for example in APC and TP53, that may predispose to colorectal cancer.', 'Inflammatory bowel disease (IBD) predisposes to colorectal cancer due to factors such as chronic inflammation, longer disease duration, greater extent of colitis, presence of primary sclerosing cholangitis, family history of colorectal cancer, and specific molecular alterations that promote carcinogenesis. Patients with IBD, especially those with colon involvement, have an increased risk of developing colorectal cancer, with pancolitis carrying a higher risk due to severe inflammation. The dysplasia-carcinoma cascade is a key pathway leading to colorectal cancer in IBD patients, with genetic predisposition and chronic inflammation playing significant roles in the promotion of cancer in the colon.', 'Inflammatory bowel disease (IBD) predisposes to colorectal cancer (CRC) due to the chronic inflammation and tissue damage caused by the disease. The chronic inflammation leads to the activation of various pro-inflammatory signaling pathways, including the NF-κB pathway, which promotes the proliferation and survival of cancer cells. Additionally, the chronic inflammation can lead to the inactivation of tumor suppressor genes, such as CYLD, which can further contribute to the development of colorectal cancer. Furthermore, the chronic inflammation can also lead to the development of dysplasia and the progression of precancerous lesions to invasive cancer. Therefore, the inactivation of CYLD in intestinal epithelial cells exacerbates colitis-associated colorectal carcinogenesis, highlighting the importance of targeting the inflammatory response in the prevention and treatment of colorectal cancer.', 'The predisposition to colorectal cancer in inflammatory bowel disease is the consequence of the uncontrolled chronic inflammatory response that leads to epithelial DNA damage, disruption of DNA repair mechanisms, cellular proliferation and angiogenesis.', 'Inflammatory bowel disease predisposes to colorectal cancer due to the cumulative impact of chronic inflammation, which leads to the development of inflammatory bowel disease-associated colorectal cancer (IBD-CRC) through mechanisms such as DNMT-mediated gene silencing and disruption of intestinal homeostasis.', 'Inflammatory bowel disease (IBD) predisposes to colorectal cancer (CRC) due to several factors, including genetic predisposition, long-standing inflammation, and molecular alterations. The risk increases with longer duration of colitis, greater anatomic extent of colitis, presence of primary sclerosing cholangitis, family history of CRC, and degree of inflammation of the bowel. Additionally, IBD-associated CRC (IBD-CRC) accounts for 1-2% of all CRC cases, but is considered a serious complication in IBD patients, accounting for approximately 15% of all deaths in IBD patients. Patients with IBD who have non-cholestatic liver disease might have a higher risk for colon cancer, even at a younger age.', \"Patients with inflammatory bowel disease (IBD) are subject to increased risks for the development of colorectal cancer (CRC), risks that are attributed to the duration and anatomic extent of disease in patients with ulcerative colitis and Crohn's disease. The magnitude of CRC risk increases with early age at IBD diagnosis, longer duration of symptoms, and extent of the disease, with pancolitis having a more severe inflammation burden and risk of the dysplasia-carcinoma cascade. Patients with long-standing inflammatory bowel disease (IBD) have an increased risk of developing colorectal cancer (CRC). Some investigators suggest that patients with extensive colitis have a genetic predisposition to CRC and that long-standing inflammation is not of primary importance in the promotion of cancer.\", \"\\nAnswer: Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, predisposes to colorectal cancer (CRC) due to several factors. Chronic inflammation in IBD leads to oxidative stress, DNA damage, and genetic instability, promoting the development of CRC. Additionally, inflammation can lead to the development of dysplasia, a precancerous lesion, and alter\", '3 mechanisms are suggested by which IBD predispose to the development of CAC. First, prolonged inflammation causes DNA damage, which then leads to genetic mutations that drive carcinogenesis. Second, an inflammatory microenvironment contributes to a tumor promoting environment. Third, IBD may cause chronic epithelial damage, which triggers compensatory regeneration of the colonic epithelium, leading to genomic instability.\\n\\nThese are just some examples of how the system can be used. The system is by no means perfect and some users may encounter difficulties or encounter errors in the system. This is also possible when users make use of very obscure or very colloquial phrasing that is not well-suited for machine processing. Nonetheless, the example queries provided above illustrate that the system can be used for a broad range of information needs and is able to generate useful information in most cases.', \"Inflammatory bowel diseases (IBD) like ulcerative colitis and Crohn's disease predispose individuals to colorectal cancer due to chronic inflammation. This prolonged inflammation leads to genetic alterations and disrupts intestinal homeostasis, contributing to the development of colorectal cancer. Factors such as longer duration of colitis, extensive anatomic involvement, presence of other inflammatory conditions like primary sclerosing cholangitis, and certain anti-inflammatory medications can influence this risk.\", 'Inflammatory bowel disease (IBD) predisposes to colorectal cancer (CRC) through chronic inflammation, which promotes growth of tumor cells, perturbs their differentiation, and supports the survival of cancer cells. Proinflammatory cytokines and transcription factors that are required for signaling by these cytokines, including TNFα, IL-6, IL-1β, NF-κB, and STATs, have emerged as potential targets for anticancer therapy in IBD-associated CRC.', \"Inflammatory bowel disease (IBD) predisposes to colorectal cancer due to several factors. These include the longer duration of the disease, extensive colitis, primary sclerosing cholangitis, family history of colorectal cancer, and the presence of chronic inflammation in the colon and rectum. The relative risk of colorectal cancer is increased in patients with ulcerative colitis, although there are geographical differences. In Crohn's disease, the relative risk of colorectal cancer is 2.5, and there is also an increased risk of small bowel cancer. Continuing colonic inflammation has been shown to be important in the development of colorectal cancer. Therefore, anti-inflammatory agents such as 5-aminosalicylates and immunomodulators have been considered as potential chemopreventive agents.\", \"Inflammatory bowel disease (IBD) predisposes to colorectal cancer (CRC) due to the chronic inflammation and tissue damage caused by the disease. Long-standing ulcerative colitis and Crohn's disease increase the risk of developing CRC, and patients with small intestinal Crohn's disease are at particularly high risk. Genetic factors that predispose to or are implicated in the chronic inflammatory process in IBD may also contribute to the increased risk of CRC. The risk of CRC in IBD appears to increase with longer duration and greater anatomic extent of the disease.\", 'The inflammatory bowel diseases (IBD) predispose to colorectal cancer (CRC) through multiple mechanisms. First, mutations in genes encoding inflammatory cytokines and the immune system are present in individuals who develop IBD. These include the genes encoding tumor necrosis factor (TNF) alpha, interleukin (IL) 1 beta, IL-8', \"Inflammatory bowel diseases (IBD), particularly ulcerative colitis and Crohn's disease, are associated with an increased risk of developing colorectal cancer due to chronic inflammation that can lead to DNA damage, altered cell growth regulation, and changes in the intestinal microbiome. The constant activation of inflammatory pathways in IBD patients may promote tumorigenesis through several mechanisms, including nuclear factor kappa B (NF-κB) signaling, oxidative stress leading to 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) formation, and epigenetic modifications such as DNA methylation. The specific molecular changes associated with IBD that increase the risk of colorectal cancer are not fully understood but may involve alterations in tumor suppressor genes, oncogenes, and other key regulatory pathways.\", 'Inflammatory bowel disease (IBD) predisposes to colorectal cancer due to chronic inflammation, which can lead to DNA damage and mutations in the colonic epithelium. The persistent inflammation in IBD creates an environment that promotes the development of dysplastic cells, which can progress to cancer over time. Additionally, IBD can cause changes in the gut microbiota, leading to the production of pro-inflammatory cytokines and chemokines that further exacerbate inflammation and promote carcinogenesis. The risk of colorectal cancer in IBD is also associated with the duration and extent of the disease, as well as the presence of other risk factors such as primary sclerosing cholangitis and family history of colorectal cancer.', '\\nInflammatory bowel disease (IBD) predisposes to colorectal cancer (CRC) due to several factors, including chronic inflammation that leads to oxidative stress, DNA damage, and genetic instability; the development of dysplasia, a precancerous lesion; altered intestinal microbiota with an increased prevalence of bacterial strains that promote inflammation and carcinogenesis; and genetic factors that increase the risk of CRC in IBD patients, even after controlling for inflammation and other factors.', 'Inflammatory bowel disease (IBD) predisposes to colorectal cancer (CRC) due to several factors:\\n\\n1. Long-standing inflammation of the bowel, with risk increasing with longer duration and greater extent of colitis. Chronic inflammation is thought to promote the dysplasia-carcinoma cascade.\\n\\n2. Earlier age at IBD diagnosis is associated with higher CRC risk. \\n\\n3. The presence of primary sclerosing cholangitis further increases risk.\\n\\n4. Family history of CRC also elevates risk in IBD patients.\\n\\n5. Molecular alterations found in sporadic CRC, like chromosomal instability, microsatellite instability, and hypermethylation, also contribute to colitis-associated carcinogenesis.\\n\\nIn summary, the chronic inflammatory state in IBD, especially with early onset and extensive colitis, along with genetic and molecular factors, predisposes to the development of CRC. The risk is significant, with IBD patients having a 6-fold higher likelihood of CRC compared to the general population.', \"Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, predisposes to colorectal cancer due to the chronic inflammation and damage to the intestinal epithelium. The continuous inflammation in IBD leads to genetic and epigenetic alterations, dysregulation of cellular pathways (such as RTK/RAS, PI3K, WNT, and TGFβ), and increased risk of chromosomal/microsatellite instabilities and aneuploidy, which can promote the development of colorectal cancer. Anti-inflammatory agents, such as 5-aminosalicylates and immunomodulators, are considered potential chemopreventive agents in IBD to reduce inflammation and the risk of colorectal cancer.\", 'The inflammatory bowel disease predisposes to colorectal cancer by inducing the activation of the Wnt/β-catenin signaling pathway, which leads to the suppression of tumor growth and promotion of tumor invasion.', 'Chronic inflammation in inflammatory bowel disease predisposes to colorectal cancer by creating a pro-tumorigenic microenvironment that promotes neoplastic progression.', 'Inflammatory bowel disease predisposes to colorectal cancer due to chronic inflammation, which drives neoplastic progression leading to dysplastic precursor lesions. This chronic inflammation creates a microenvironment that promotes the development of colitis-associated colorectal cancer (CAC). Preclinical investigations suggest that the microbiome, in conjunction with the host immune system, plays a potential role in the pathogenesis of CAC in individuals with inflammatory bowel disease. The concept of field cancerization explains how dysplastic precursor lesions can arise in multiple areas of the colon, further increasing the risk of colorectal cancer in individuals with chronic inflammation associated with inflammatory bowel disease.', 'Inflammatory bowel disease (IBD) predisposes to colorectal cancer (CRC) through chronic inflammation, which leads to dysplastic precursor lesions that may arise in multiple areas of the colon through a process of field cancerization.', 'Inflammatory bowel disease (IBD) predisposes to colorectal cancer primarily due to chronic inflammation. This ongoing inflammation can lead to neoplastic progression, where dysplastic precursor lesions develop in various areas of the colon, a phenomenon known as field cancerization. Additionally, preclinical studies suggest that the interaction between the microbiome and the host immune system plays a significant role in the development of colitis-associated colorectal cancer (CAC). This complex interplay exacerbates the inflammatory processes, further increasing the risk of cancer development in individuals with IBD.', 'Inflammatory bowel disease predisposes to colorectal cancer because chronic inflammation is the driver of neoplastic progression, resulting in dysplastic precursor lesions that may arise in multiple areas of the colon through a process of field cancerization.', 'Chronic inflammation in inflammatory bowel disease predisposes to colorectal cancer by driving neoplastic progression and promoting the development of dysplastic precursor lesions through a process of field cancerization.', 'Chronic inflammation is a known driver of neoplastic progression, and inflammatory bowel disease (IBD) is associated with an increased risk of colorectal cancer (CRC). This is thought to be due to the development of dysplastic precursor lesions in the colon, a process known as field cancerization. Preclinical investigations have suggested that the microbiome, in conjunction with the host immune system, may play a role in the development of colitis-associated colorectal cancer (CAC). However, the exact mechanisms by which IBD predisposes to CRC are not fully understood and are an active area of research.', 'Inflammatory bowel disease (IBD) predisposes to colorectal cancer due to chronic inflammation in the colon. This ongoing inflammation can lead to changes in the cells lining the colon, promoting abnormal growths and eventually cancerous lesions through a process known as field cancerization. Additionally, the interaction between the microbiome and the immune system in IBD patients can further contribute to the development of colorectal cancer', 'Chronic inflammation is the driver of neoplastic progression, resulting in dysplastic precursor lesions that may arise in multiple areas of the colon through a process of field cancerization. Inflammatory bowel disease predisposes to colorectal cancer through a process of field cancerization.', \"Inflammatory bowel disease (IBD) predisposes to colorectal cancer primarily due to chronic inflammation. This persistent inflammation can lead to neoplastic progression, where dysplastic precursor lesions develop in various areas of the colon. This process, known as field cancerization, is influenced by both the microbiome and the host immune system, which play roles in the development of colitis-associated colorectal cancer (CAC). Essentially, the ongoing inflammation in IBD creates an environment that promotes cancerous changes in the colon's cells.\", \"Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, is associated with an increased risk of colorectal cancer. The exact mechanisms underlying this association are not fully understood, but several factors are believed to contribute:\\n\\n1. Chronic inflammation: The chronic inflammation that characterizes IBD leads to the production of reactive oxygen and nitrogen species, as well as cytokines and growth factors, which can damage the DNA of colonic cells and promote the development of pre-cancerous lesions.\\n\\n2. Dysregulation of cell signaling pathways: Inflammation can also lead to dysregulation of cell signaling pathways, such as the Wnt and TGF-beta pathways, which are involved in cell proliferation, differentiation, and apoptosis. Dysregulation of these pathways can contribute to the development of colorectal cancer.\\n\\n3. Genetic factors: People with IBD have an increased risk of developing colorectal cancer, even after controlling for the effects of chronic inflammation. This suggests that genetic factors may also play a role in the association\", 'Inflammatory bowel disease (IBD) predisposes to colorectal cancer (CRC) because it causes chronic inflammation, which is the driver of neoplastic progression. This chronic inflammation leads to dysplastic precursor lesions that may arise in multiple areas of the colon through a process of field cancerization. Additionally, preclinical investigations have demonstrated a potential role for the microbiome in concert with the host immune system in the development of CAC, which is a type of colorectal cancer associated with IBD.', 'Patients with inflammatory bowel disease (IBD) have an increased risk of developing colorectal cancer. IBD-associated CRC has a similar biology to sporadic colon cancer. IBD-associated CRC has a similar molecular abnormality profile to sporadic colon cancer. The pathogenesis of IBD-associated CRC and sporadic colon cancer is still poorly understood.', 'Inflammatory bowel disease predisposes to colorectal cancer due to chronic inflammation acting as a key driver in the neoplastic progression. This ongoing inflammation leads to dysplastic precursor lesions, potentially arising in various areas of the colon through field cancerization, where the environment created by the combination of microbiome interactions and immune system responses promotes the development of colitis-associated colorectal cancer.', \"Inflammatory Bowel Disease (IBD) predisposes to colorectal cancer due to chronic inflammation, a key driver of neoplastic progression. This inflammation can lead to the formation of dysplastic precursor lesions in various colonic areas through a process known as field cancerization. The microbiome, in conjunction with the host immune system, has been implicated in the development of colitis-associated colorectal cancer (CAC), a common form of cancer in IBD patients. An altered gut microbiota can exacerbate inflammation and contribute to the dysplastic changes observed in CAC. Furthermore, the immune system's response to chronic inflammation can result in DNA damage and genomic instability, promoting tumor development. Therefore, the interplay between IBD-induced inflammation, the microbiome, and the host immune system increases the risk of colorectal cancer in patients with I\", 'Inflammatory bowel disease predisposes to colorectal cancer primarily because the chronic inflammation it causes can drive the progression of neoplastic changes. This inflammation leads to dysplastic precursor lesions, which can develop in multiple areas of the colon through a process known as field cancerization. Additionally, interactions between the microbiome and the host immune system in the context of colitis can further contribute to the development of colitis-associated colorectal cancer.', 'Patients with inflammatory bowel disease (IBD) are at increased risk of developing colorectal cancer (CRC) due to chronic inflammation. Chronic inflammation in IBD leads to neoplastic progression and the development of dysplastic precursor lesions in the colon. Colitis-associated CRC shares molecular similarities with sporadic CRC, and the microbiome and host immune system may play a role in its development.', 'Chronic inflammation is a key driver of neoplastic progression, leading to the development of colitis-associated colorectal cancer (CAC). Inflammatory bowel disease (IBD) predisposes individuals to CAC due to the persistent inflammation that is characteristic of IBD. This inflammation can result in dysplastic precursor lesions in multiple areas of the colon through a process known as field cancerization. Preclinical investigations have revealed that the microbiome, in conjunction with the host immune system, may play a significant role in the development of CAC in individuals with IBD. The complex interplay between the immune system, the microbiome, and chronic inflammation contributes to the increased risk of colorectal cancer in individuals with IBD.', 'Inflammatory bowel disease (IBD) predisposes to colorectal cancer because chronic inflammation drives neoplastic progression. The persistent inflammation in IBD leads to the development of dysplastic precursor lesions, which can arise in multiple areas of the colon through a process of field cancerization. Additionally, the microbiome and host immune system play a role in the development of colitis-associated colorectal cancer (CAC). Unique molecular differences occur in CAC, but their role in pathogenesis and behavior is not well understood. Nonconventional types of dysplasia have been recognized, but their natural history is not well defined. Dysplasia is a major risk factor for developing CAC, and advances have been made in endoscopic detection and removal of precancerous lesions, reducing the need for surgical resection.', 'Inflammatory bowel disease predisposes to colorectal cancer because chronic inflammation drives neoplastic progression, leading to dysplastic precursor lesions that can develop in multiple areas of the colon through a process known as field cancerization.', 'Chronic inflammation is the driver of neoplastic progression, resulting in dysplastic precursor lesions that may arise in multiple areas of the colon. Preclinical investigations have demonstrated a potential role for the microbiome in concert with the host immune system in the development of colitis-associated colorectal cancer (CAC)', 'Chronic inflammation in inflammatory bowel disease is the driver of neoplastic progression, resulting in dysplastic precursor lesions that may arise in multiple areas of the colon through a process of field cancerization. Preclinical investigations have also demonstrated a potential role for the microbiome in concert with the host immune system in the development of colitis-associated colorectal cancer (CAC).', 'Inflammatory bowel disease (IBD) predisposes to colorectal cancer due to chronic inflammation in the colon. This ongoing inflammation can lead to changes in the cells lining the colon, causing them to become abnormal or dysplastic, which increases the risk of developing cancer. This process is often referred to as colitis-associated colorectal cancer (CAC)', 'Inflammatory bowel disease (IBD) predisposes to colorectal cancer due to chronic inflammation. The persistent inflammation in the colon can lead to the development of dysplastic precursor lesions, which can progress to colorectal cancer. Additionally, the interaction between the microbiome and the host immune system may also play a role in the development of colitis-associated colorectal cancer.', 'Inflammatory bowel disease (IBD) predisposes to colorectal cancer because it causes chronic inflammation in the colon, which is the driver of neoplastic progression. This chronic inflammation leads to dysplastic precursor lesions that may arise in multiple areas of the colon through a process of field cancerization.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nInflammatory bowel disease (IBD), specifically conditions such as ulcerative colitis (UC) and Crohn's disease (CD), increases the risk of developing colorectal cancer (CRC) due to chronic inflammation of the colon. \n\nChronic inflammation leads to cellular damage, DNA mutations, and an increased risk of cancer. The exact mechanisms are not fully understood, but several factors contribute to the development of CRC in IBD patients:\n\n1. **Chronic inflammation**: Long-term inflammation causes damage to the lining of the colon, leading to the formation of precancerous lesions and an increased risk of cancer.\n2. **Genetic instability**: Chronic inflammation can lead to genetic mutations, including chromosomal instability, microsatellite instability, and hypermethylation, which are also found in sporadic CRC.\n3. **Increased cell proliferation**: Chronic inflammation promotes cell proliferation, which can lead to the accumulation of mutations and the development of cancer.\n4. **Impaired DNA repair**: Chronic inflammation can impair the body's ability to repair DNA damage, making it more likely for mutations to occur.\n5. **Imbalanced gut microbiome**: The gut microbiome plays a crucial role in the development of IBD and CRC. An imbalance in the gut microbiome, also known as dysbiosis, can contribute to the development of CRC.\n6. **Epigenetic changes**: Chronic inflammation can lead to epigenetic changes, such as changes in gene expression, which can contribute to the development of CRC.\n\nThese factors contribute to the increased risk of CRC in IBD patients, and the risk is higher in patients with a longer duration of disease, more extensive disease, and a history of primary sclerosing cholangitis (PSC) or family history of CRC.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer effectively covers all the necessary information regarding why inflammatory bowel disease (IBD) predisposes to colorectal cancer (CRC). It mentions chronic inflammation, genetic instability, increased cell proliferation, impaired DNA repair, imbalanced gut microbiome, epigenetic changes, and risk factors like disease duration, extent, primary sclerosing cholangitis, and family history of CRC. This comprehensive coverage aligns well with the reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and stays on topic without including irrelevant information. Each point made is directly related to the mechanisms and risk factors of CRC in IBD patients. The details provided are relevant and contribute to a clear understanding of the subject.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no unnecessary repetition of information. Each point is distinct and adds new, relevant details about the topic. The answer is well-structured, ensuring that the same information is not repeated in different sections.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is very readable and fluent. The use of numbered points helps organize the information clearly, making it easy to follow. The language is concise, and the explanation is straightforward, enhancing overall readability."
    },
    {
        "Question": "In what part of the body would a periprosthetic infection occur?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIn what part of the body would a periprosthetic infection occur?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['A periprosthetic infection would occur in close to a joint or  structure in close relation to an implant.', 'A periprosthetic infection can occur in any part of the body where artificial joint replacement has been performed, such as hip, knee, shoulder, elbow or ankle. It is a foreign-body-associated infection that affects the surrounding tissue of artificial implant.', 'A periprosthetic infection would occur in the joint, heart valves, or due to schroeteri.', 'Periprosthetic infections occur in the area surrounding the prosthetic joint.', 'A periprosthetic infection occurs in the tissue surrounding a prosthetic joint (i.e. knee or hip replacement).', 'A periprosthetic infection (PJI) is an infection that occurs around a prosthetic joint, such as a knee or hip replacement.', 'A periprosthetic infection would occur in the joint where the prosthesis is placed.', '\\nA periprosthetic infection would occur around an artificial joint replacement, such as in the hip, knee, shoulder, elbow, or ankle joint.', 'A periprosthetic infection is an infection occurring around a joint prosthesis. These types of infections often occur after total knee and hip arthroplasties.', 'A periprosthetic infection usually occurs in areas where prosthetics are implanted, such as joints, including the hip and knee.', 'Periprosthetic infection is a foreign-body-associated infection that is characterised by delayed osteomyelitis of bone tissue surrounding artificial joint replacement.', 'A periprosthetic infection can occur in various parts of the body depending on the type of prosthesis. In the context of total hip arthroplasty, periprosthetic infection can occur around the hip joint. In the context of shoulder arthroplasty, periprosthetic infection can occur around the shoulder joint.', 'Periprosthetic infection occurs in the joint space after joint replacement surgery.', 'A periprosthetic joint infection (PJI) occurs in the tissues surrounding a prosthetic joint, such as after total hip or knee replacement surgery. The infection can involve the joint space, bone, and soft tissues around the prosthetic implant.', 'A periprosthetic infection can occur in the area surrounding a prosthetic joint, such as the hip, knee, or shoulder.', 'Periprosthetic infections occur around artificial joints, most commonly in the hip and knee.', 'A periprosthetic joint infection (PJI) occurs in the area surrounding a joint replacement implant, such as a hip or knee replacement. It is an infection that affects the tissues around the prosthetic joint and can lead to serious complications if not treated promptly and effectively.', 'A periprosthetic infection would occur in the periprosthetic joint.', 'A periprosthetic infection would occur around the area of an artificial joint, such as those implanted during hip or knee replacement surgeries. This includes infections that can develop around hip replacements (THA) and knee replacements (TKA/UKA)', 'A periprosthetic infection would occur in a joint that has been replaced by a prosthesis.', 'A periprosthetic infection would occur around the area of an artificial joint, such as in the hip or knee, following procedures like total hip arthroplasty (THA) or total and unicompartmental knee arthroplasty (TKA/UKA).', 'Periprosthetic joint infections (PJI) are infections occurring around a total joint replacement. They could happen around the hip joint (THA) or knee joint (TKA/UKA).', 'A periprosthetic infection occurs in the joints, specifically in the hip or knee, after a total hip or knee arthroplasty surgery.', 'A periprosthetic infection occurs in the area around a prosthetic hip or knee joint.', 'Periprosthetic joint infection (PJI) is a complication of total hip arthroplasty (THA) or total knee arthroplasty (TKA) that occurs due to infection of the joint space.', 'A periprosthetic infection occurs around the area of an implanted prosthetic, such as in the hip or knee joints following total hip arthroplasty (THA) or total knee arthroplasty (TKA).', 'A periprosthetic infection can occur in the area surrounding a prosthetic joint, such as the hip or knee.', 'Periprosthetic infections occur in the part of the body where a prosthetic device has been implanted, such as the joint or bone.', 'A periprosthetic joint infection (PJI) would occur in the joint space of a prosthetic joint.', 'A periprosthetic joint infection (PJI) would occur around a prosthetic joint, such as after a total hip arthroplasty (THA) or total knee arthroplasty (TKA).', 'A periprosthetic infection occurs around the area of an implanted prosthesis, typically in joints such as the hip or knee.', 'A periprosthetic infection can occur in the area surrounding an implanted joint prosthesis, such as a total hip or knee replacement.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nA periprosthetic infection would occur in the body part where a prosthetic device is implanted, which can include the joints, such as the knee or hip, or other areas where prosthetic devices are used, such as the spine or bone fractures.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "4",
        "Information Recall Explanation": "The answer correctly identifies that periprosthetic infections occur where prosthetic devices are implanted, including joints like the knee or hip, and also mentions other areas such as the spine or bone fractures. While this is accurate, it slightly deviates from the emphasis on joint replacements in the reference answers.",
        "Information Precision Score": "3",
        "Information Precision Explanation": "The answer is somewhat precise but includes mention of the spine and bone fractures, which are less commonly referenced in the provided answers and might be considered slightly irrelevant in this specific context focused on joint replacements.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat any information unnecessarily. It clearly states the areas where periprosthetic infections can occur without redundancy.",
        "Readability Score": "4",
        "Readability Explanation": "The answer is clear and fluently written. It is easily understandable, though the inclusion of less common examples (spine, bone fractures) slightly detracts from the focus seen in the reference answers."
    },
    {
        "Question": "What is the estimated impact of social determinants of health on health outcomes?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the estimated impact of social determinants of health on health outcomes?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The impact of social determinants of health on health outcomes has been extensively studied and it is estimated that these factors play a significant role in shaping health outcomes. For example, studies have shown that people who experience poverty, unemployment, low education levels, poor housing conditions, and limited access to healthy food and safe living environments are more likely to develop chronic diseases, such as diabetes, cardiovascular disease, and mental health disorders. Additionally, social determinants can affect health outcomes indirectly by influencing health behaviors such as smoking, physical inactivity, and unhealthy eating habits. It is estimated that these factors can account for up to 40% of modifiable health risks. Addressing social determinants of health has the potential to improve health equity and reduce health disparities.', 'The social determinants of health have a significant impact on health outcomes, particularly for marginalized populations. Factors such as poverty, lack of education, and living in rural areas can increase the likelihood of adverse health outcomes, including teenage pregnancy and childbearing. According to the World Health Organization, social determinants account for an estimated 30-50% of health inequities. Addressing these factors through targeted interventions and policies can help reduce health disparities and improve overall health outcomes.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, social determinants of health (SDOH) have a significant impact on health outcomes. Studies have shown that a greater number of SDOH factors are associated with an increased risk of cancer mortality (Source 16). Specifically, having 1 SDOH factor is associated with a 39% increased risk of cancer mortality, having 2 SDOH factors is associated with a 61% increased risk, and having 3 or more SDOH factors is associated with a 109% increased risk (Source 16).\n\nAnother study found that specific social determinants of health factors, such as depression, are significantly and independently associated with mortality in adults with chronic kidney disease and diabetes (Source 17). The study also found that cumulative and dichotomous social determinants of health scores were significantly associated with mortality after adjusting for demographics, lifestyle variables, glycemic control, and comorbidities.\n\nFurthermore, research has shown that social determinants of health have a significant impact on health outcomes in type 2 diabetes, with studies finding that social determinants have an impact on glycemic control, LDL, and blood pressure (Source 15).\n\nOverall, the data suggests that social determinants of health have a significant impact on health outcomes, and that addressing these determinants is crucial for improving health outcomes and reducing health disparities.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer provides specific examples and statistics related to the impact of social determinants of health (SDOH) on health outcomes, such as cancer mortality, chronic kidney disease, and diabetes. However, it does not cover the broader range of SDOH factors mentioned in the reference answers, like poverty, education, and housing conditions. It also misses the estimated percentage of modifiable health risks (30–50%) cited in the reference answers.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer stays focused on the impact of SDOH on health outcomes and provides precise data related to specific health conditions. There is no irrelevant information. However, narrowing the scope to only certain conditions makes it less comprehensive compared to the broader impact described in the reference answers.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information. It presents distinct data points for different health conditions to illustrate the impact of SDOH.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured and clearly written. It logically presents its points with appropriate transitions, making it easy to follow."
    },
    {
        "Question": "Should corticosteroids be considered as adjunctive therapy in paediatric sepsis management?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nShould corticosteroids be considered as adjunctive therapy in paediatric sepsis management?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['No, there is uncertainty regarding the use of corticosteroids as adjunctive therapy.', 'No. Corticosteroids should not be considered as adjunctive therapy in paediatric sepsis management.', 'No, the safety and efficacy of stress-dose steroids as general adjunctive therapy for pediatric septic shock have not been established.', 'No. There is no definitive improvement in outcomes attributable to adjunctive corticosteroid therapy in the largest pediatric sepsis trial conducted to date.', 'No, corticosteroids should not be considered as adjunctive therapy in paediatric sepsis management.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, corticosteroids have been studied as adjunctive therapy in pediatric sepsis management, but the evidence is not conclusive. The Cochrane review on corticosteroids for treating sepsis in children and adults (study 16) found that corticosteroids probably reduce 28-day and hospital mortality among patients with sepsis, but also increase the risk of muscle weakness and hypernatraemia. However, the review also noted that the effects of corticosteroids in pediatric sepsis are uncertain due to the limited number of studies and the heterogeneity of the included trials.\n\nAnother study (study 15) on medication and fluid management of pediatric sepsis and septic shock noted that corticosteroids have been suggested as an adjunctive therapy for sepsis, but the evidence is not yet supported by research reports. The study highlighted the need for further research on the use of corticosteroids in pediatric sepsis management.\n\nA review of the literature on pediatric sepsis (study 17) suggested that corticosteroids may have a role in the management of pediatric sepsis, but more research is needed to determine their effectiveness and safety.\n\nA review of the history of adjunctive glucocorticoid treatment for pediatric sepsis (study 20) noted that while corticosteroids may have been used as adjunctive therapy for pediatric sepsis, the safety and efficacy of this approach have not been established. The review emphasized the need for pediatric-specific evidence-based medicine for adjunctive corticosteroid therapy for severe sepsis in children.\n\nIn summary, while corticosteroids have been studied as adjunctive therapy in pediatric sepsis management, the evidence is not conclusive, and more research is needed to determine their effectiveness and safety.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer captures most of the key points from the reference answers, such as the uncertainty and lack of conclusive evidence regarding the use of corticosteroids in pediatric sepsis. However, it does not explicitly state that corticosteroids should not be considered as adjunctive therapy, which is a clear conclusion in the reference answers.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise and does not include irrelevant information. It focuses on the need for further research and the current lack of conclusive evidence, which aligns well with the reference answers.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. Each paragraph introduces a new aspect or study related to the topic, maintaining a good flow without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to read. The use of clear and concise language, along with logical paragraph transitions, enhances its readability."
    },
    {
        "Question": "JYNNEOS vaccine is protective against which diseases?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nJYNNEOS vaccine is protective against which diseases?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Jynneos is smallpox and monkeypox vaccine.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe JYNNEOS vaccine is licensed to prevent smallpox and mpox (monkeypox) infections.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer correctly mentions that the JYNNEOS vaccine is protective against smallpox and mpox (monkeypox), which aligns perfectly with the reference answers. All necessary information is reported.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is concise and directly addresses the question without including any irrelevant information. It precisely states the two diseases the JYNNEOS vaccine is licensed to prevent.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each piece of information is mentioned only once, making the answer clear and efficient.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is easily readable and fluent, with a clear and straightforward sentence structure that effectively communicates the necessary information."
    },
    {
        "Question": "What is the optimal antiemetic treatment for FOLFIRINOX chemotherapy?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the optimal antiemetic treatment for FOLFIRINOX chemotherapy?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['A three-drug combination of 5-hydroxytryptamine-3 receptor antagonists (5HT3RA), dexamethasone (DEX), and neurokinin 1 receptor antagonists (NK1RA) for the prevention of chemotherapy-induced nausea and vomit during FOLFORINOX therapy', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy has not been definitively established. The FOLFIRINOX regimen is known to cause significant nausea and vomiting, and there is a need for effective antiemetic prophylaxis to prevent these adverse events. A study published in the Journal of Clinical Oncology found that a three-drug combination of 5-hydroxytryptamine-3 receptor antagonists (5HT3RA), dexamethasone (DEX), and neurokinin 1 receptor antagonists (NK1RA) was effective in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving FOLFIRINOX. However, the study also noted that the optimal antiemetic treatment for FOLFIRINOX may vary depending on patient factors and individual preferences. Other studies have suggested that', 'In this study, the researchers found that a three-drug regimen with aprepitant can significantly reduce the incidence of nausea and vomiting in patients with metastatic pancreatic cancer who received FOLFIRINOX chemotherapy.', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy is a combination of netupitant/palonosetron (NEPA; Akynzeo(®)) with >85% antiemetic efficacy.', '5-hydroxytryptamine 3 receptor (5-HT3R) antagonists and dexamethasone can be used to manage chemotherapy-induced nausea and vomiting in FOLFIRINOX. Other options include neurokinin-1 (NK1) receptor antagonists and other adjunctive medications such as aprepitant, palonosetron and olanzapine.', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy includes 5HT3RA, DEX, and NK1RA.', '\\nAnswer: Aprepitant, dexamethasone, and a 5-HT3 receptor antagonist (granisetron or palonosetron) before and after chemotherapy.', '5-hydroxytryptamine 3 (5-HT3) receptor antagonists are the optimal antiemetic treatments for FOLFIRINOX chemotherapy', 'The optimal antiemetic treatment for managing side effects from FOLFIRINOX chemotherapy includes a combination of 5-hydroxytryptamine-3 receptor antagonists (5HT3RA), dexamethasone (DEX), and neurokinin 1 receptor antagonists (NK1RA).', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy is 5-hydroxytryptamine-3 receptor antagonists (5HT3RA), dexamethasone (DEX), and neurokinin 1 receptor antagonists (NK1RA).', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy includes a three-drug regimen with aprepitant, dexamethasone, and 5-HT3 receptor antagonists. This regimen has been shown to improve the complete response rate during cycle 1 and reduce nausea and vomiting in patients treated with FOLFIRINOX for metastatic pancreatic cancer. However, enhanced antiemetic measures may be necessary as nausea and vomiting can persist beyond 5 days. In patients with diabetes mellitus complications, sparing of steroids and glycemic control should also be considered.', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy is a single oral dose of NEPA (Akynzeo®) plus 12 mg of dexamethasone. NEPA is a fixed-dose combination of netupitant, a neurokinin-1 receptor antagonist (NK1RA), and palonosetron, a 5-hydroxytryptamine type 3 receptor antagonist (5HT3RA), which has been shown to be effective in preventing chemotherapy-induced nausea and vomiting (CINV). This treatment has demonstrated therapeutic benefits in managing and prophylaxis of CINV events, both in naive patients and patients previously treated with serotonin receptor antagonists (5HT3-RA) and neurokinin-1 receptor antagonists (NK1-RA). Additionally, NEPA has been shown to be safe, both before and during the COVID-19 pandemic.', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy is prochlorperazine (PC), ondansetron (OD), and dexamethasone (Dex) or a combination of these agents.', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy has not been definitively established, as various regimens have been used in different clinical trials and real-world settings. However, a few studies suggest that a three-drug combination of 5-hydroxytryptamine-3 receptor antagonists (5HT3RA), dexamethasone (DEX), and neurokinin 1 receptor antagonists (NK1RA) may be effective in preventing chemotherapy-induced nausea and vomiting (CINV) associated with FOLFIRINOX. In a retrospective cohort study of patients with advanced pancreatic cancer, the complete response rate for CINV was 64.7% with this three-drug regimen, although the incidence of nausea and vomiting remained relatively high. Another study found that the addition of aprepitant to', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy is NEPA (netupitant/palonosetron). NEPA has been shown to effectively prevent nausea and vomiting induced by chemotherapy (CINV) in patients receiving FOLFIRINOX and Folfoxiri regimens. This combination of netupitant and palonosetron provides superior control of acute and delayed CINV compared to other antiemetic agents. NEPA can be safely used during the COVID-19 pandemic and has been proven to be effective in real-life studies.', 'CINV induced by mFFX was poorly controlled even with prophylactic antiemetic therapy using 5HT3RA, DEX, and NK1RA, and was found to persist beyond 5\\xa0days', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy, which consists of irinotecan, folinic acid, and fluorouracil (5-FU), is a multimodal approach that includes the following:\\n\\n1. Pregabalin (Lyrica) 150-300 mg orally twice daily starting 1-2 days before chemotherapy and continuing for 3 days.\\n\\n2. Dexamethasone (Decadron) 8 mg orally or intravenously (IV) twice daily starting 1-2 days before chemotherapy and continuing for 3 days.\\n\\n3. Palonosetron (Aloxi) 0.25 mg IV or subcutaneously (SC) before chemotherapy.\\n\\n4. O', '5HT3RA, DEX, and NK1RA', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy is prochlorperazine (PC), a commonly used antiemetic agent. Prochlorperazine (PC), a commonly used antiemetic agent, is the first-line antiemetic agent for patients receiving chemotherapy. Food and liquid restrictions are also', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy includes prophylactic antiemetic therapy using 5HT3RA, DEX.', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy is a combination of 5HT3RA and DEX.', \"The optimal antiemetic treatment for FOLFIRINOX (mFFX) chemotherapy typically includes a combination of a 5HT3 receptor antagonist (5HT3RA), dexamethasone (DEX), and a neurokinin-1 receptor antagonist (NK1RA). However, it's important to note that even with this prophylactic antiemetic therapy, control of chemotherapy-induced nausea and vomiting (CINV) can be challenging, and symptoms may persist beyond 5 days. This indicates a need for potentially adjusting the treatment approach or exploring additional supportive measures to better manage CINV in patients undergoing this regimen.\", 'The recommended antiemetic treatment for FOLFIRINOX chemotherapy is either 5HT3RA or a combination of 5HT3RA and DEX.', '5-HT3RA is a standard antiemetic therapy for FOLFIRINOX chemotherapy. However, patients receiving mFFX are at risk of developing chemotherapy-induced nausea and vomiting (CINV) that is refractory to conventional antiemetic therapy and can persist beyond 5 days. NK1-RA in addition to 5HT3RA and DEX should be used prophylactically to control CINV in mFFX.', ' The optimal antimycin D treatment for FOLFox chemotherapy is not well understood, and there is no one-solution approach that can eliminate the risk of antimycin D-resistance. Instead, there are several strategies that can be employed to mitigate the risk of antimycin D-resistance and improve the efficacy of FOLFox chemotherapy. These strategies include:', \"The optimal antiemetic treatment for FOLFIRINOX chemotherapy typically includes a combination of a 5HT3 receptor antagonist (5HT3RA), dexamethasone (DEX), and a neurokinin-1 receptor antagonist (NK1RA). This regimen aims to manage the nausea and vomiting associated with this highly emetogenic chemotherapy. However, it's important to note that even with these medications, control of chemotherapy-induced nausea and vomiting (CINV) can be challenging, and symptoms may persist beyond 5 days. Always consult with a healthcare provider for the most appropriate and individualized treatment plan\", 'CINV induced by mFFX was poorly controlled even with prophylactic antiemetic therapy using 5HT3RA, DEX, and NK1RA, and was found to persist beyond 5 days.', \"The optimal antiemetic treatment for FOLFIRINOX (mFFX) chemotherapy typically includes a combination of a 5HT3 receptor antagonist (5HT3RA), dexamethasone (DEX), and a neurokinin-1 receptor antagonist (NK1RA). However, it's important to note that even with this prophylactic antiemetic therapy, control of chemotherapy-induced nausea and vomiting (CINV) can be challenging, and symptoms may persist beyond 5 days. This indicates a need for potentially adjusting the treatment strategy or exploring additional supportive measures to better manage CINV in patients undergoing this regimen.\", \"5HT3RA (5-hydroxytryptamine receptor antagonist), DEX (dexamethasone) and NK1RA (neurokinin-1 receptor antagonist) are commonly used for prophylactic antiemetic therapy in patients undergoing FOLFIRINOX chemotherapy. However, if patient experiences poorly controlled CINV, additional or alternative antiemetic medications should be considered. Olanzapine, aprepitant and other antiemetics could be added to the regimen based on individual patient's needs.\", 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy is a combination of 5HT3RA, DEX, and NK1RA, with prophylactic therapy starting before the chemotherapy and continuing for at least 5 days after the treatment.', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy includes a combination of 5HT3 receptor antagonists, dexamethasone, and NK1 receptor antagonists.', \"The optimal antiemetic treatment for FOLFIRINOX chemotherapy is still a topic of debate. The snippet suggests that prophylactic antiemetic therapy using 5HT3RA, DEX, and NK1RA may not be effective in controlling CINV induced by mFFX. Recent studies suggest that olanzapine may be effective in preventing CINV in patients receiving FOLFIRINOX chemotherapy. However, further research is needed to confirm its efficacy and safety profile. It's essential to consider individual patient factors, such as age, gender, and previous antiemetic response, when choosing an antiemetic regimen.\", 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy is not specified in the provided context, but it mentions that CINV induced by mFFX was poorly controlled even with prophylactic antiemetic therapy using 5HT3RA, DEX, and NK1RA.', 'Based on the given context, the optimal antiemetic treatment for FOLFIRINOX chemotherapy, a standard chemotherapy regimen for advanced pancreatic cancer, should include a combination of 5-hydroxytryptamine-3 receptor antagonists (5HT3RA), dexamethasone (DEX), and neurokinin 1 receptor antagonists (NK1RA) for the prevention of chemotherapy-induced nausea and vomiting (CINV). However, it is important to note that CINV induced by FOLFIRINOX was poorly controlled even with this prophylactic antiemetic therapy, suggesting the need for enhanced antiemetic measures. Additionally, in patients with diabetes mellitus complications, sparing of steroids and glycemic control should be considered due to the risk of hyperglycemia.', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy has not been fully established, but current guidelines recommend a combination of agents to prevent CINV. The most effective prophylactic regimen typically includes a serotonin receptor antagonist (5HT3RA) such as ondansetron or granisetron, dexamethasone (DEX), and sometimes a neurokinin-1 receptor antagonist (NK1RA) like aprepitant. However, even with this combination therapy, some patients experience persistent nausea and vomiting, highlighting the need for more effective treatments to manage CINV induced by FOLFIRINOX chemotherapy.', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy has not been fully established, and the current standard of care consisting of a three-drug combination of 5-hydroxytryptamine-3 receptor antagonists (5HT3RA), dexamethasone (DEX), and neurokinin 1 receptor antagonists (NK1RA) may not be sufficient to control chemotherapy-induced nausea and vomiting (CINV). Enhanced antiemetic measures, such as additional medications or alternative regimens, may be necessary to improve CINV management for patients undergoing FOLFIRINOX therapy. However, the choice of antiemetic treatment should also consider potential side effects, such as hyperglycemia, and individual patient factors, including diabetes mellitus complications. Further research is needed to determine the most effective and safe antiemetic strategy for FOL', 'The recommended antiemetic treatment for FOLFIRINOX chemotherapy is a combination of 5HT3RA and DEX.', 'Based on the provided information, chemotherapy-induced nausea and vomiting (CINV) induced by modified FOLFIRINOX (mFFX) chemotherapy was poorly controlled even with prophylactic antiemetic therapy using a combination of a 5-HT3 receptor antagonist (5HT3RA), dexamethasone (DEX), and an NK-1 receptor antagonist (NK1RA). The CINV persisted beyond 5 days.\\n\\nThe text does not provide information on the optimal antiemetic treatment for FOLFIRINOX. It only indicates that the mentioned antiemetic combination was not fully effective in controlling CINV in this setting. More research would be needed to determine the best approach for managing CINV with this chemotherapy regimen.', 'The optimal antiemetic treatment for FOLFIRINOX chemotherapy includes prophylactic antiemetic therapy using 5HT3 receptor antagonists (5HT3RA), dexamethasone (DEX), and neurokinin-1 receptor antagonists (NK1RA).', \"The optimal antiemetic treatment for FOLFIRINOX chemotherapy includes a combination of multiple drugs. It is recommended to use a 5HT3 receptor antagonist (5HT3RA), dexamethasone (DEX), and a neurokinin-1 receptor antagonist (NK1RA) as prophylactic antiemetic therapy. However, in cases where CINV induced by FOLFIRINOX is poorly controlled even with this standard regimen, additional interventions may be required, such as the use of olanzapine or aprepitant. It is important to individualize the treatment based on the patient's specific needs and response to therapy.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data tables, the optimal antiemetic treatment for FOLFIRINOX chemotherapy is not explicitly stated. However, we can infer some information from the data.\n\nThe FOLFIRINOX regimen is a combination of fluorouracil, leucovorin, oxaliplatin, and irinotecan, and it is known to cause significant nausea and vomiting.\n\nIn the data tables, we can see that Domperidone is mentioned as a medication used to control cytotoxic-induced and postprandial nausea and vomiting in children, but it is not specifically mentioned in the context of FOLFIRINOX.\n\nHowever, the data table 1, entity 7, \"ANTIEMETIC THERAPY\" mentions that \"A treatment used to prevent or alleviate nausea and vomiting caused by chemotherapy.\" This suggests that antiemetic therapy is a general treatment for nausea and vomiting caused by chemotherapy, including FOLFIRINOX.\n\nAdditionally, the data table 8, entity 8, \"CANCER CHEMOTHERAPY\" mentions that \"A type of treatment that uses chemicals to kill cancer cells, where the gut microbiota has a clinically significant role.\" This suggests that the gut microbiota plays a role in the efficacy and toxicity of chemotherapy, including FOLFIRINOX.\n\nIn terms of specific antiemetic medications, the data tables do not provide a clear recommendation for FOLFIRINOX. However, based on general knowledge, the following antiemetic medications are commonly used to prevent nausea and vomiting caused by chemotherapy:\n\n* 5-HT3 receptor antagonists (e.g., ondansetron, granisetron)\n* Corticosteroids (e.g., dexamethasone)\n* NK1 receptor antagonists (e.g., aprepitant)\n* Dopamine receptor antagonists (e.g., metoclopramide)\n\nIt is essential to consult with a healthcare professional for personalized advice on antiemetic treatment for FOLFIRINOX chemotherapy.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer mentions that the optimal antiemetic treatment for FOLFIRINOX chemotherapy is not explicitly stated in the provided data, which is accurate. It also infers general information about antiemetic therapy and lists common antiemetic medications used in chemotherapy. However, it misses specific details from the reference answers, such as the three-drug combination of 5HT3RA, DEX, and NK1RA, which is highlighted in several references.",
        "Information Precision Score": 2,
        "Information Precision Explanation": "The answer includes some irrelevant information, such as the role of gut microbiota in chemotherapy, which is not directly related to the question about antiemetic treatment. While it lists common antiemetic medications, it does not precisely align with the specific recommendations found in the reference answers.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer avoids repeating the same information multiple times. It presents different pieces of information logically and sequentially without redundancy.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-structured and easy to follow. It uses clear language and transitions smoothly between points, making it accessible to the reader. The only minor drawback is the inclusion of somewhat tangential information about gut microbiota, which slightly detracts from readability."
    },
    {
        "Question": "Please list the symptoms of Havana syndrome",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nPlease list the symptoms of Havana syndrome\n\nHere are some reference answers:\n\n**Reference Answers:**\n['In 2016 diplomatic personnel serving in Havana, Cuba, began reporting audible sensory phenomena paired with onset of complex and persistent neurological symptoms consistent with brain injury. Vestibular, cognitive, hearing, sleep, and visual symptoms,', 'The Havana syndrome is a series of symptoms that include dizziness, fatigue, headache, cognitive deficits, tinnitus, and other symptoms consistent with a vestibular disorder.', 'The symptoms of Havana syndrome can be depression, anxiety, dyspnea, chest pain, post-traumatic stress disorder, cough, fatigue, and visual symptoms.', 'The symptoms of Havana syndrome include audible sensory phenomena, along with the onset of complex and persistent neurological symptoms consistent with brain injury.', 'Havana syndrome is a condition characterized by a range of symptoms including headache, dizziness, nausea, vomiting, and abdominal pain.', 'The symptoms of Havana syndrome include tinnitus, vertigo, cognitive difficulties, visual problems, depression, and anxiety.', 'Havana Syndrome is an umbrella term which includes various symptoms such as:\\n1. Sudden onset of vertigo/dizziness\\n2. Loss of hearing/auditory or olfactory sensations\\n3. Tinnitus\\n4. Nausea\\n5. Headache\\n6. Cognitive impairment\\n7. Visual disturbances\\n8. Insomnia\\n9. Fatigue', 'The symptoms of Havana syndrome include tinnitus, vertigo, cognitive difficulties, visual problems, visual symptoms, dyspnea, chest pain, and depression.', 'The symptoms of Havana syndrome, as reported in the document, include audible sensory phenomena paired with onset of complex and persistent neurological symptoms consistent with brain injury. The specific neurological symptoms are not detailed in the abstract.', 'The symptoms of Havana syndrome are audible sensory phenomena paired with onset of complex and persistent neurological symptoms consistent with brain injury.', 'Havana syndrome symptoms include cognitive impairment, experiences of auditory and sensory phenomena, general neurological symptoms, tinnitus, visual problems, and vertigo.', 'Havana syndrome (HS) is a rare neurological disorder characterized by a triad of symptoms including tinnitus, visual problems, vertigo, and cognitive difficulties.', 'Havana syndrome is a collection of symptoms reported by diplomatic personnel and their families residing in Havana, Cuba. The most common symptoms include intense ear pain in one or both ears, tinnitus, unsteadiness, and features of cognitive impairment. Other symptoms that have been reported include dizziness, headache, light sensitivity, hearing reduction, and cognitive complaints such as memory loss and difficulty concentrating. The exact cause of Havana syndrome is still unknown, but it has been suggested that it may be related to exposure to a localized noise or pressure sensation.', 'The symptoms of Havana syndrome include tinnitus, visual problems, vertigo, cognitive difficulties, auditory-vestibular symptoms, and nonspecific neurobehavioral symptoms.', 'The symptoms of Havana syndrome include tinnitus, visual problems, vertigo, and cognitive difficulties.', 'The symptoms of Havana syndrome include: * Dizziness * Ear pain * Tinnitus (ringing in the ears) * Cognitive impairment * Unsteadiness * Headache * Nausea and vomiting * Abdominal pain * Skin bleeding * Vaginal bleeding * Shock syndrome * Thrombocytopenia (low platelet count) * Hemoconcentration (increased concentration of red blood cells) * Increase in liver enzymes * Leukopenia (low white blood cell count) * Gallbladder wall thickening * Pleural effusion (fluid accumulation around the lungs) * Splenomegaly (enlarged spleen)', 'The symptoms of Havana syndrome are tinnitus, vertigo, cognitive difficulties, visual problems, neurological symptoms, cognitive impairment, visual symptoms, and dyspnea.', 'The symptoms of Havana syndrome are tinnitus, persistent neurological symptoms consistent with brain injury, visual problems, vertigo, neurologic symptoms, unusual neurologic symptoms, cognitive difficulties, and audible sensory phenomena paired with onset of complex.', 'The symptoms of Havana syndrome include tinnitus, visual problems, vertigo, and cognitive difficulties, which have been reported by individuals who experienced strange sounds, leading to an abrupt onset of these unusual clinical manifestations.', 'The symptoms of Havana syndrome include tinnitus, visual problems, vertigo, cognitive difficulties, and other neurological symptoms consistent with brain injury. These symptoms were reported by U.S. diplomats after encountering strange sounds while serving in Havana, Cuba.', 'The symptoms of Havana syndrome are:\\n-headaches\\n-nausea\\n-difficulty focusing\\n-vertigo\\n-tinnitus\\n-cognitive impairment\\n-dysphagia\\n-difficulty walking\\n-weakness\\n-pain', 'The symptoms of Havana syndrome include tinnitus, visual problems, vertigo, cognitive difficulties, audible sensory phenomena, unusual neurologic symptoms, MRI changes, and complex and persistent neurological symptoms consistent with brain injury.', 'Havana syndrome is characterized by an abrupt onset of unusual clinical symptoms including tinnitus, visual problems, vertigo, and cognitive difficulties.', 'The symptoms of Havana syndrome include tinnitus (ringing in the ears), visual problems, vertigo (a sensation of spinning), and cognitive difficulties such as memory loss and trouble concentrating', 'The symptoms of Havana syndrome are tinnitus, visual problems, vertigo, and cognitive difficulties.', 'The symptoms of Havana syndrome include:\\n- tinnitus,\\n- visual problems,\\n- vertigo,\\n- cognitive difficulties,\\n- headaches,\\n- sleep disturbances,\\n- dizziness,\\n- nausea,\\n- memory loss,\\n- disorientation,\\n- inability to focus,\\n- fatigue', 'Havana syndrome is characterized by a range of symptoms including tinnitus, visual problems, vertigo, and cognitive difficulties, which were reported by diplomats after encountering strange sounds.', 'The symptoms of Havana syndrome reported by US diplomats stationed in Cuba include tinnitus (ringing in the ears), vertigo or dizziness, cognitive difficulties such as memory loss and concentration problems, visual disturbances like light sensitivity or blurred vision, headaches, fatigue, sleep disorders, and mood changes.', 'The symptoms of Havana syndrome include: * Tinnitus (ringing in the ears) * Visual problems * Vertigo (dizziness) * Cognitive difficulties * Hearing loss * Sleep disturbances * Anxiety * Depression * Fatigue * Migraines * Sound sensitivity , These symptoms are thought to be caused by a combination of neurological and psychiatric factors, although the exact cause is still unknown.', 'The symptoms of Havana syndrome are tinnitus, visual problems, vertigo, cognitive difficulties, and audible sensory phenomena.', 'The symptoms of Havana syndrome include tinnitus, visual problems, vertigo, cognitive difficulties, and complex and persistent neurological symptoms consistent with brain injury. Unusual audible sensory phenomena have been reported paired with the onset of these symptoms.', 'Havana syndrome symptoms include tinnitus, visual problems, vertigo, cognitive difficulties, and persistent neurological symptoms consistent with brain injury.', 'The symptoms of Havana syndrome include tinnitus (ringing in the ears), visual problems, vertigo (dizziness), and cognitive difficulties. These symptoms are reported by diplomatic personnel who have been posted in Havana, Cuba between late 2016 and 2018 and have encountered strange sounds.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the data provided, the symptoms of Havana syndrome are:\n\n* Tinnitus\n* Visual problems\n* Vertigo\n* Cognitive difficulties\n* Dizziness\n* Headaches\n* Fatigue\n* Nausea\n* Vomiting\n* Hearing reduction\n* Light sensitivity\n* Vestibular injuries\n* Cognitive dysfunction\n* Pyramidal symptoms (in some cases)\n\nNote that some of these symptoms may be similar to those of other conditions, and the exact cause and nature of Havana syndrome are still unknown.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer captures almost all the symptoms mentioned in the reference answers, including tinnitus, visual problems, vertigo, cognitive difficulties, dizziness, headaches, fatigue, nausea, vomiting, hearing reduction, light sensitivity, vestibular injuries, cognitive dysfunction, and pyramidal symptoms. This comprehensive list indicates excellent information recall.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is highly precise, listing relevant symptoms without straying into irrelevant information. However, the inclusion of 'pyramidal symptoms (in some cases)' is less commonly mentioned in the reference answers, which slightly affects precision.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each symptom is listed once and clearly.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is very readable and fluent, with a clear bullet-point format that enhances comprehension. The note at the end adds context without disrupting readability."
    },
    {
        "Question": "What are common complications of prematurity for babies?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are common complications of prematurity for babies?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Common complications of prematurity for babies include respiratory distress syndrome (RDS), hyperbilirubinemia, gastroesophageal reflux (GERD), intraventricular hemorrhage (periventricular leukomalacia), retinopathy of prematurity (ROP), and necrotizing enterocolitis (NEC). Additionally, preterm infants are at higher risk for developmental delays, sensory processing difficulties, and other long-term health issues.', 'Common complications of prematurity for babies include bronchopulmonary dysplasia, intraventricular hemorrhage, necrotizing enterocolitis, retinopathy of prematurity, periventricular leukomalacia, intestinal failure, neurodevelopmental delay, and failure to thrive.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, common complications of prematurity for babies include:\n\n1. Respiratory Distress Syndrome (RDS): This is a condition that affects premature infants and can cause breathing difficulties.\n2. Infections: Premature infants are more susceptible to infections, including cytomegalovirus (CMV) and respiratory syncytial virus (RSV).\n3. Cytomegalovirus (CMV) infection: Premature infants are at higher risk of developing symptomatic CMV infection, which can cause a range of health problems.\n4. Mucormycosis: Premature infants are at increased risk of mucormycosis, a rare but serious fungal infection.\n5. Transient Hyperphenylalaninemia: Premature infants are at higher risk of transient hyperphenylalaninemia, a condition that can cause symptoms such as seizures and developmental delays.\n6. Premature Rupture of Membranes (PROM): Premature rupture of membranes is a risk factor for neonatal sepsis.\n7. Necrotizing Enterocolitis (NEC): This is a condition that affects the intestines of premature infants and can cause inflammation and damage.\n8. Intrauterine Growth Restriction (IUGR): Premature infants may experience intrauterine growth restriction, which can lead to low birth weight and other complications.\n9. Hypoglycemia: Premature infants may experience low blood sugar levels, which can cause symptoms such as seizures and lethargy.\n10. Hypertension: Premature infants may experience high blood pressure, which can increase the risk of complications such as kidney damage and heart problems.\n\nThese are just some of the common complications of prematurity for babies. It's essential for parents and caregivers to be aware of these risks and work closely with healthcare providers to monitor and manage any potential complications.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer lists several complications of prematurity, some of which are common (e.g., RDS, NEC) and some that are less commonly recognized (e.g., CMV, mucormycosis). However, it misses some key complications mentioned in the reference answers, such as hyperbilirubinemia, gastroesophageal reflux (GERD), and retinopathy of prematurity (ROP).",
        "Information Precision Score": 2,
        "Information Precision Explanation": "The answer includes numerous complications, many of which are not standard or commonly cited (e.g., CMV infection, mucormycosis, transient hyperphenylalaninemia, premature rupture of membranes). This dilutes the focus on the more typical prematurity complications.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not repeat the same information redundantly, though it includes many uncommon conditions that could make it seem cluttered. The structure is clear, with each complication listed separately.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-organized and easy to read, with clear enumeration and descriptions. The fluency is good, though the inclusion of somewhat obscure conditions might make comprehension slightly harder for non-experts."
    },
    {
        "Question": "What disease was studied in the ANGEL-ASPECT trial?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat disease was studied in the ANGEL-ASPECT trial?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['ANGEL-ASPECT studied large infarcts. It is a multicentre, prospective, randomised, open-label, blinded End-point trial to evaluate whether best medical management (BMM) combined with endovascular therapy improves neurological functional outcomes as compared with BMM alone in acute LVO patients with Alberta Stroke Program Early CT Score (ASPECTS) of 3-5 on non-contrast CT or infarct core volume range of 70-100\\u2009mL (defined as rCBF <30% on CT perfusion or ADC <620 on MRI) up to 24 hours from symptom onset or last seen well.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe disease studied in the ANGEL-ASPECT trial was acute anterior circulation large vessel occlusion (LVO).\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer correctly identifies the disease studied in the ANGEL-ASPECT trial as acute anterior circulation large vessel occlusion (LVO), which aligns with the reference answer. However, it does not mention additional details such as the specific score range (ASPECTS 3-5) or the infarct core volume range, which are part of the full context.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and directly addresses the question without including irrelevant information. It succinctly states the disease studied in the trial.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition in the answer. The information is presented clearly and concisely in a single statement.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is easily readable and fluent. It uses clear and straightforward language to convey the necessary information."
    },
    {
        "Question": "Why is the clinical benefit of EGFR inhibitors different in right and left colorectal cancer?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhy is the clinical benefit of EGFR inhibitors different in right and left colorectal cancer?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Tumors in the proximal colon (right side) and distal colon (left side) exhibit different molecular characteristics and histology. In the right-sided tumors, mutations in the DNA mismatch repair pathway are commonly observed; and these tumors generally have a flat histology. In the left-sided tumors, chromosomal instability pathway-related mutations, such as KRAS, APC, PIK3CA, p53 mutations are observed and these tumors demonstrate polypoid-like morphology. The analysis of the immune microenvironment showed that immune infiltration was more common in RCC than LCC.  This suggests that the molecular mechanisms of RCC and LCC differed.', 'The clinical benefit of EGFR inhibitors, such as cetuximab and panitumumab, differs between right and left colorectal cancer because of the distinct molecular characteristics of each subtype. Studies have shown that patients with KRAS wild-type (WT) left-sided tumors have a significantly improved overall survival, progression-free survival, and objective response rate when treated with EGFR inhibitors plus chemotherapy compared to right-sided primary tumors. In contrast, patients with RAS mutated or MSI-H tumors do not seem to benefit from the addition of EGFR inhibitors to their treatment regimen. The different response to anti-EGFR agents between left and right colon cancer may be due to the distinct expression of molecular pathways, such as BRAF mutation and MSI status, which are more prevalent in right colorectal cancers. Therefore, considering the side of origin', '1) The genetic makeup of right and left colorectal cancer is different. Right colon cancers are more commonly microsatellite instable and have more frequent BRAF mutations, whereas left colon cancers are more frequently KRAS mutated. EGFR inhibitors are less effective in KRAS mutated cancers. 2) EGFR inhibitors and anti-angiogenic therapy are known to have synergistic effects, which might be beneficial in left colon cancer because it is rich in microvessels.', 'The clinical benefit of EGFR inhibitors differs between right and left colorectal cancer due to molecular and genetic differences. Patients with left-sided colorectal cancer tend to benefit more from anti-EGFR therapy compared to those with right-sided colorectal cancer. This disparity may be attributed to variations in tumor biology, molecular characteristics, and response to treatment based on tumor location. Further research is needed to fully understand the underlying mechanisms driving this differential response to EGFR inhibitors in colorectal cancer based on tumor location.', 'The clinical benefit of EGFR inhibitors is different in right and left colorectal cancer due to differences in the expression of EGFR in these tumors. Right-sided colorectal cancer has a higher expression of EGFR than left-sided colorectal cancer, which may explain why EGFR inhibitors are more effective in right-sided tumors. This difference in EGFR expression may be due to differences in the genetic background of these tumors, with right-sided tumors having a higher frequency of mutations in genes involved in EGFR signaling.', 'This is probably because right and left colorectal cancers are different in genotype, expression of EGFR ligands, EGFR mutation and mutation of intracellular signaling proteins.', 'The clinical benefit of EGFR inhibitors appears to be different in right and left colorectal cancer (CRC), with patients with left-sided CRC seeming to benefit more. This difference may be due to the absence of randomized trials stratified based on tumor location, making it difficult to draw definitive conclusions. However, it is possible that underlying biological differences between right and left CRC, such as distinct molecular and genetic features, may contribute to this observed difference in response to EGFR inhibitors. Further research is needed to better understand the factors driving this observed difference in clinical benefit.', '\\nAnswer: The clinical benefit of EGFR inhibitors is different in right and left colorectal cancer due to differences in their molecular characteristics. Right-sided colorectal cancers (RSCC) are more commonly associated with wild-type KRAS and BRAF mutations, while left-sided colorectal cancers (LSCC) are more commonly associated with mutations in KRAS and BRAF. EGFR inhib', 'The clinical benefit of EGFR inhibitors varies between right and left colorectal cancer due to distinct epidemiological, clinicopathological characteristics, gene expression profiles, and genetic alterations. Left-sided tumors often have a better prognosis and respond more favorably to EGFR inhibitors like cetuximab or panitumumab, especially in KRAS/NRAS/BRAF wild-type cases. In contrast, right-sided tumors show limited benefit from these treatments, possibly due to different molecular profiles that include a higher prevalence of BRAF mutations and MSI status.', 'Right- and left-sided colorectal cancers differ in clinical and molecular characteristics. Some retrospective analyses suggested that patients with right-sided tumors derive less benefit from anti-epidermal growth factor receptor (EGFR) antibodies; however, molecular selection in those studies was not extensive. Cetuximab and panitumumab confer little', 'The clinical benefit of EGFR inhibitors is different in right and left colorectal cancer because the primary tumor location can be both prognostic and predictive in response to EGFR inhibitors. Cetuximab and panitumumab confer little benefit to patients with metastatic colorectal cancer in the primary tumor originated on the right side. On the other hand, EGFR inhibitors provide significant benefit compared with bevacizumab-containing therapy or chemotherapy alone for patients with left primary tumor.', 'The clinical benefit of EGFR inhibitors is different in right and left colorectal cancer due to the activation of different molecular pathways. Right colorectal cancers rely on the activation of pathways such as BRAF mutation and MSI status, which are not effectively targeted by EGFR inhibitors. On the other hand, left colorectal cancers are more responsive to EGFR inhibitors, leading to superior treatment outcomes.', 'The clinical benefit of EGFR inhibitors differs between right and left colorectal cancer due to differences in molecular pathways. Right colorectal cancers are more likely to have BRAF mutations and MSI status, which are associated with poor response to EGFR inhibitors. In contrast, left colorectal cancers are more likely to have RAS/BRAF wild-type status, which is associated with improved response to EGFR inhibitors. Therefore, the choice of EGFR inhibitors in metastatic colorectal cancer depends on the location of the primary tumor.', 'The clinical benefit of epidermal growth factor receptor (EGFR) inhibitors differs between right-sided and left-sided colorectal cancers due to distinct molecular profiles and tumor biology. Right-sided tumors are often associated with BRAF mutations, microsatellite instability (MSI), and the CpG island methylator phenotype (CIMP), which can lead to resistance to EGFR inhibitors. In contrast, left-sided tumors are more likely to have KRAS or NRAS mutations that do not confer resistance to these agents, making them more responsive to EGFR blockade. Additionally, the different anatomical locations of right and left colon may influence tumorigenesis and response to therapy due to variations in local microenvironments, blood supply, and lymphatic drainage.', '\\n There are molecular and tumor location-related differences between right and left colorectal cancer that may affect the response to EGFR inhibitors. Right-sided colorectal cancer (RCC) is more commonly associated with molecular features such as BRAF mutations, microsatellite instability, and CpG island methylation, which may make it less dependent on EGFR-mediated signaling pathways. Additionally, the location of the primary tumor may impact drug delivery and accessibility to the target. These factors may contribute to the observed differences in clinical benefit of EGFR inhibitors in RCC and left-sided colorectal cancer (LCC).', 'The provided information does not explain why the clinical benefit of EGFR inhibitors differs between right-sided and left-sided colorectal cancer. It only states that patients with left-sided colorectal cancer seem to benefit more from anti-EGFR therapy compared to patients with right-sided colorectal cancer, based on non-randomized data that should be interpreted cautiously. The underlying biological reasons for this difference are not provided.', 'The clinical benefit of EGFR inhibitors is different in right and left colorectal cancer due to the differences in tumor biology and response to treatment. Left-sided colorectal cancer (LCRC) patients benefit more from EGFR inhibitors and have a better prognosis, while right-sided colorectal cancer (RCRC) patients do not respond well to EGFR inhibitors. This difference is attributed to the higher antigenic load in RCRC tumors, making them more responsive to immunotherapies.', 'Tumors in the proximal colon (right side) and distal colon (left side) exhibit different molecular characteristics and histology. In the right-sided tumors, mutations in the DNA mismatch repair pathway are commonly observed; and these tumors generally have a flat histology. In the left-sided tumors, chromosomal instability pathway-related mutations, such as KRAS, APC, PIK3CA, p53 mutations are observed and these tumors demonstrate polypoid-like morphology.', 'The clinical benefit of EGFR inhibitors, such as cetuximab and panitumumab, is different in right and left colorectal cancer due to differences in molecular characteristics and histology.\\n\\nRight-sided colorectal cancer (RCC) is more commonly associated with mutations in the DNA mismatch repair pathway, leading to microsatellite instability (MSI). These tumors often have a flat or depressed appearance, known as sessile serrated adenomas or polyps (SSA/Ps). In contrast, left-sided colorectal cancer (LCC) is more commonly associated with chromosomal instability (CIN) and mutations in genes such as KRAS, APC, PIK3CA, and p53. These tumors often have a', 'The clinical benefit of EGFR inhibitors differs in right and left colorectal cancer due to the distinct molecular characteristics and histology of tumors in these locations. Right-sided tumors commonly exhibit mutations in the DNA mismatch repair pathway and have a flat histology, while left-sided tumors often show mutations in genes like KRAS, APC, PIK3CA, and p53, with a polypoid-like morphology. Additionally, immune infiltration is more common in right-sided colorectal cancer (RCC) compared to left-sided colorectal cancer (LCC). The mutation frequency and gene mutations also vary between RCC and LCC, with BRAF and KRAS mutations being dominant in RCC and APC mutations dominant in LCC, indicating different molecular mechanisms between the two sides of the colon.', 'The clinical benefit of EGFR inhibitors is different in right and left colorectal cancer because of the differences in the expression of EGFR in these tumors. EGFR is overexpressed in approximately 70% of right-sided colorectal cancers, but only in approximately 40% of left-sided cancers. This difference in EGFR expression may explain why EGFR inhibitors are more effective in right-sided colorectal cancer than in left-sided cancer.', 'The clinical benefit of EGFR inhibitors differs between right and left colorectal cancer primarily due to the distinct molecular characteristics and genetic mutations prevalent in tumors from these two locations. Right-sided colorectal cancers (RCC) often have mutations in the BRAF and KRAS genes, which are known to confer resistance to EGFR inhibitors. In contrast, left-sided colorectal cancers (LCC) typically exhibit mutations in the APC gene and have a different mutation profile that may respond more favorably to EGFR inhibitors. This variation in genetic mutations and molecular pathways between RCC and LCC leads to differences in how these cancers respond to treatment with EGFR inhibitors.', 'The clinical benefit of EGFR inhibitors is different in right and left colorectal cancer because right-sided tumors commonly have DNA mismatch repair pathway mutations, while left-sided tumors often exhibit chromosomal instability pathway-related mutations, leading to distinct molecular characteristics and histology that influence the response to EGFR inhibitors.', '1) Mutations in the DNA mismatch repair pathway are more commonly observed in right-sided colon cancers. 2) EGFR inhibitors are effective in tumors that have RAS and RAF wild-type. KRAS mutations are frequently observed in left-sided colon cancers. EGFR inhibitors have shown to be ineffective in tumors with RAS and RAF mutations. 3) Right-sided tumors generally have a flat histology, whereas left-sided tumors have polypoid-like morphology. These morphologic differences might also explain the differential benefit of EGFR inhibitors in right and left colorectal cancer.', 'The clinical benefit of EGFR inhibitors may differ in right and left colorectal cancer due to differences in molecular characteristics and histology. Right-sided tumors commonly have mutations in the DNA mismatch repair pathway and a flat histology, while left-sided tumors demonstrate chromosomal instability pathway-related mutations such as KRAS, APC, PIK3CA, p53 mutations and polypoid-like morphology. Additionally, the mutation frequency of right-sided colon cancer (RCC) is generally higher than that of left-sided colon cancer (LCC), with BRAF and KRAS gene mutations being the dominant genes mutations in RCC, and APC gene mutation being the dominant gene mutation in LCC. These molecular differences may contribute to the different clinical benefit of EGFR inhibitors in right and left colorectal cancer.', 'The clinical benefit of EGFR inhibitors differs between right and left colorectal cancer primarily due to the distinct molecular characteristics of tumors in these locations. Left-sided colorectal cancers (LCC) often have mutations in genes like KRAS, APC, and p53, which are part of the chromosomal instability pathway. These mutations are more responsive to EGFR inhibitors. In contrast, right-sided colorectal cancers (RCC) frequently exhibit mutations in the DNA mismatch repair pathway and have a higher mutation frequency, including prevalent BRAF and KRAS mutations, which can lead to resistance against EGFR inhibitors. Thus, the molecular profiles of RCC and LCC contribute to their different responses to these treatments', 'The clinical benefit of EGFR inhibitors differs in right and left colorectal cancer primarily due to the distinct molecular characteristics and genetic mutations prevalent in tumors from these two locations. Right-sided colorectal cancers (RCC) often have mutations in the BRAF and KRAS genes, which are known to confer resistance to EGFR inhibitors. In contrast, left-sided colorectal cancers (LCC) typically exhibit mutations in the APC gene, which do not directly impact the efficacy of EGFR inhibitors. This difference in genetic profiles between RCC and LCC leads to varying responses to EGFR-targeted therapies, making them more effective in LCC where KRAS and BRAF mutations are less common.', 'The clinical benefit of EGFR inhibitors, such as cetuximab and panitumumab, is different in right and left colorectal cancer due to differences in molecular characteristics and histology.\\n\\nRight-sided colorectal cancer (RCC) is more commonly associated with mutations in the DNA mismatch repair (MMR) pathway, leading to microsatellite instability (MSI). These tumors often have a flat or depressed histology and are less likely to express EGFR. As a result, EGFR inhibitors may not be effective in RCC due to a lack of target expression.\\n\\nLeft-sided colorectal cancer (LCC), on the other hand, is more commonly associated with chromosomal instability (CIN) and mutations in genes such as KRAS, APC, PIK3CA, and p53. These tumors often have a polypoid-like morphology and are more likely to express EGFR. In LCC, EGFR inhibitors can be effective in blocking the EGFR signaling pathway, which is often overactive in these tumors.\\n\\nIn summary', '1. Right-sided colorectal cancer is generally more resistant to EGFR inhibitor therapies, and this may be due to the fact that EGFR inhibitors are less active against mutations in DNA mismatch repair pathway, which are common in right-sided tumors.\\n2. Left-sided colorectal cancer generally demonstrates a more favorable response to EGFR inhibitor therapies. This may be because these tumors are associated with mutations in chromosomal instability pathway, such as KRAS, APC, PIK3CA, p53 mutations, which are susceptible to EGFR inhibitor therapies.', 'The clinical benefit of EGFR inhibitors may be different in right and left colorectal cancer due to differences in the molecular mechanisms of the tumors. In right-sided tumors, mutations in the DNA mismatch repair pathway are commonly observed, and these tumors generally have a flat histology. In contrast, left-sided tumors exhibit chromosomal instability pathway-related mutations, such as KRAS, APC, PIK3CA, and p53 mutations, and these tumors demonstrate polypoid-like morphology. Additionally, the immune microenvironment of RCC is more infiltrated than LCC, and the mutation frequency of RCC is generally higher than that of LCC. BRAF and KRAS gene mutations are the dominant gene mutations in RCC, while APC gene mutation is the dominant gene mutation in LCC. These differences in molecular mechanisms may affect the efficacy of EGFR inhibitors in treating right and left colorectal cancer.', 'Right-sided colorectal cancers have a higher frequency of BRAF and KRAS mutations, whereas left-sided tumors have a lower frequency of chromosomal instability pathway-related mutations. The clinical benefit of EGFR inhibitors in right- and left-sided colorectal cancer differs according to the tumor location.', 'The clinical benefit of EGFR inhibitors differs in right and left colorectal cancer due to distinct molecular characteristics and histological differences between tumors on the two sides. Right-sided colon cancers (RCC) often have mutations in the DNA mismatch repair pathway, leading to a flat histology, and exhibit higher mutation frequencies, including prevalent BRAF and KRAS mutations which are associated with resistance to EGFR inhibitors. Left-sided colon cancers (LCC), however, frequently harbor chromosomal instability pathway-related mutations such as APC, KRAS, PIK3CA, p53 mutations with a polypoid-like morphology. These genetic differences contribute to the varied response to EGFR inhibitors, with LCC generally showing a better response compared to RCC.', 'The clinical benefit of EGFR inhibitors differs between right and left colorectal cancer due to the distinct molecular mechanisms underlying each type of cancer. Right-sided tumors have mutations in the DNA mismatch repair pathway, leading to a flat histology, while left-sided tumors have chromosomal instability pathway-related mutations, resulting in polypoid-like morphology. The immune microenvironment also varies between the two types of cancer, with more immune infiltration observed in right-sided tumors. These differences result in varying responses to EGFR inhibitors, with right-sided tumors showing better clinical benefit compared to left-sided tumors.', 'The clinical benefit of EGFR inhibitors differs in right and left colorectal cancer primarily due to the distinct molecular characteristics of tumors in these locations. Left-sided colorectal cancers (LCC) often have mutations in genes like KRAS, APC, and p53, which are involved in the chromosomal instability pathway. These mutations can make LCC more responsive to EGFR inhibitors. In contrast, right-sided colorectal cancers (RCC) frequently exhibit mutations in the DNA mismatch repair pathway and have a different set of dominant gene mutations, such as BRAF and KRAS, which may contribute to a lower responsiveness to EGFR inhibitors. Additionally, the presence of these mutations often leads to a mutual exclusion with APC gene mutations, further influencing the effectiveness of EGFR inhibitors.', 'The clinical benefit of EGFR inhibitors differs in right and left colorectal cancer due to the differences in molecular characteristics and histology between these tumor entities. Right-sided colorectal cancer (RCRC) commonly exhibits mutations in the DNA mismatch repair pathway and has a flat histology, while left-sided colorectal cancer (LCRC) is characterized by chromosomal instability pathway-related mutations and a polypoid-like morphology. LCRC patients benefit more from adjuvant chemotherapies and targeted therapies such as anti-EGFR therapy, while RCRC patients do not respond well to conventional chemotherapies but show promising results with immunotherapies due to their high antigenic load.', 'The clinical benefit of EGFR inhibitors is different in right and left colorectal cancer because of the differences in the expression of EGFR in these tumors. EGFR is overexpressed in approximately 70% of right-sided colorectal cancers, but only in approximately 40% of left-sided cancers. This difference in EGFR expression may explain why EGFR inhibitors have been shown to be more effective in right-sided colorectal cancer than in left-sided cancer.', 'The clinical benefit of EGFR inhibitors in colorectal cancer (CRC) can differ between right-sided (RCC) and left-sided colon cancer (LCC) due to their distinct molecular characteristics and histology. RCC is commonly characterized by mutations in the DNA mismatch repair pathway, which often results in a flat histology, while LCC exhibits chromosomal instability pathway-related mutations, such as KRAS, APC, PIK3CA, and p53. These genetic differences can lead to variations in the immune microenvironment and gene expression profiles between RCC and LCC. Specifically, immune infiltration is more common in RCC than LCC, and there are 360 differentially expressed genes between the two types, with BRAF and KRAS gene mutations being dominant in RCC and APC gene mutation being dominant in LCC. These mutations show a strong mutual exclusion pattern, suggesting different molecular mechanisms at play. EGFR inhibitors have been shown to be more effective in treating left-sided CRC, which may be due to the higher prevalence of EGFR-activating mutations and lower frequency of RAS mutations in LCC compared to RCC. Additionally, the higher immune infiltration in RCC may also contribute to the differential response to EGFR inhibitors, as these drugs can modulate the immune system. Overall, the distinct molecular features of RCC and LCC can help explain the observed differences in the clinical benefit of EGFR inhibitors.', 'The clinical benefit of EGFR inhibitors is different in right and left colorectal cancer because of the different molecular characteristics and histology of tumors in the proximal colon (right side) and distal colon (left side). In the right-sided tumors, mutations in the DNA mismatch repair pathway are commonly observed; and these tumors generally have a flat histology. In the left-sided tumors, chromosomal instability pathway-related mutations, such as KRAS, APC, PIK3CA, p53 mutations are observed and these tumors demonstrate polypoid-like morphology.', 'The clinical benefit of EGFR inhibitors differs between right and left colorectal cancer due to the distinct molecular characteristics of each tumor type. Right-sided colon cancer (RCC) has a higher frequency of KRAS mutations, which are associated with resistance to EGFR inhibitors. In contrast, left-sided colon cancer (LCC) has a higher frequency of APC and PIK3CA mutations, which do not confer resistance to EGFR inhibitors. Therefore, LCC patients benefit more from adjuvant chemotherapies such as 5-FU-based regimes and targeted therapies like anti-EGFR therapy, while RCC patients may require different treatment strategies, such as immunotherapies, due to their unique molecular profile.', 'The clinical benefit of EGFR inhibitors differs in right and left colorectal cancer because the molecular mechanisms and genetic mutations present in the two types of cancer are distinct, with right-sided tumors commonly exhibiting DNA mismatch repair pathway mutations and left-sided tumors showing chromosomal instability pathway-related mutations.', 'Tumors in the proximal colon (right side) and distal colon (left side) exhibit different molecular characteristics. In the right-sided tumors, mutations in the DNA mismatch repair pathway are commonly observed; and these tumors generally have a flat histology. In left- sided tumors, chromosomal instability pathway-related mutations, such as KRAS, APC, PIK3CA, p53 mutations are observed. The mutation frequency of RCC was generally higher than that of LCC.', 'Right-sided colon cancers (RCC) and left-sided colon cancers (LCC) have distinct molecular characteristics. RCC more commonly have BRAF and KRAS mutations, which are associated with resistance to EGFR inhibitors. In contrast, LCC more frequently have APC mutations and lower rates of KRAS/BRAF mutations, making them more likely to respond to EGFR inhibition.\\n\\nThe different mutation profiles in RCC vs LCC lead to differences in their sensitivity to EGFR-targeted therapies. The higher prevalence of KRAS and BRAF mutations in RCC renders many of these tumors intrinsically resistant to EGFR inhibitors, resulting in lower efficacy. Conversely, the molecular profile of LCC, with more frequent APC mutations and lower KRAS/BRAF mutation rates, makes these tumors more susceptible to growth inhibition by EGFR-targeted agents.\\n\\nIn summary, the sidedness of colorectal cancer correlates with different underlying mutations that influence responsiveness to EGFR inhibitor therapy. The greater prevalence of EGFR inhibitor resistance mutations in RCC is a major factor leading to inferior clinical outcomes with these agents compared to LCC.', 'The clinical benefit of EGFR inhibitors differs between right and left colorectal cancer primarily due to the distinct molecular characteristics of tumors in these locations. Left-sided colorectal cancers (LCC) often have mutations in genes like KRAS, APC, and PIK3CA, which are associated with the chromosomal instability pathway. These mutations can make LCC more responsive to EGFR inhibitors. In contrast, right-sided colorectal cancers (RCC) frequently exhibit mutations in the DNA mismatch repair pathway and have a higher mutation burden, including BRAF mutations, which can lead to resistance against EGFR inhibitors. Thus, the molecular differences significantly influence the effectiveness of EGFR inhibitors in treating right versus left-sided colorectal cancers', 'The clinical benefit of EGFR inhibitors is different in right and left colorectal cancer due to the differences in molecular characteristics and histology between the two sides of the colon. Right-sided tumors, which commonly have mutations in the DNA mismatch repair pathway and a flat histology, are less responsive to EGFR inhibitors. On the other hand, left-sided tumors, which often have chromosomal instability pathway-related mutations and a polypoid-like morphology, are more likely to respond to EGFR inhibitors.', 'The clinical benefit of EGFR inhibitors may be different in right and left colorectal cancer due to the different molecular characteristics and histology of the tumors. In right-sided tumors, which are more commonly associated with DNA mismatch repair pathway mutations, EGFR inhibitors may not be as effective as they target a different pathway. In contrast, left-sided tumors, which are more commonly associated with chromosomal instability pathway-related mutations, may respond better to EGFR inhibitors as they target a similar pathway.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe clinical benefit of EGFR inhibitors is different in right and left colorectal cancer due to differences in the molecular characteristics of these two types of cancer. Right-sided colorectal cancers tend to have a different genetic profile compared to left-sided cancers, which affects the response to EGFR inhibitors.\n\nResearch has shown that right-sided colorectal cancers are more likely to have mutations in the BRAF gene, microsatellite instability (MSI), and mutations in the PIK3CA gene, which are associated with a poorer response to EGFR inhibitors. In contrast, left-sided colorectal cancers are more likely to have KRAS mutations, which are associated with a better response to EGFR inhibitors.\n\nStudies have also shown that the sidedness of the tumor (right vs. left) is a strong predictor of the response to anti-EGFR therapy. Patients with left-sided tumors tend to have a better response to EGFR inhibitors, while patients with right-sided tumors have a poorer response.\n\nThe exact mechanisms underlying these differences are not fully understood, but it is thought that the differences in genetic mutations and molecular pathways between right and left colorectal cancers contribute to the varying response to EGFR inhibitors.\n\nSource: Recent developments in the treatment of metastatic colorectal cancer.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer effectively recalls key points found in the reference answers, such as the difference in genetic profiles between right and left colorectal cancers, including mutations in BRAF, MSI, PIK3CA, and KRAS. It also mentions the impact of sidedness on response to EGFR inhibitors, which aligns with multiple references. However, it does not explore the immune microenvironment differences or specific details about histological differences provided in some references.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer stays focused on the molecular differences affecting EGFR inhibitor efficacy without introducing irrelevant details. It accurately highlights relevant mutations (BRAF, MSI, PIK3CA, KRAS) and their implications for treatment response.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer avoids significant repetition, succinctly covering genetic profiles, sidedness, and differing responses. While it reinforces the theme of molecular differences, it does so without redundant phrasing.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured and clear, using plain language to explain complex concepts. The logical flow from genetic profiles to clinical implications enhances readability."
    },
    {
        "Question": "Can Connexin hemi channels be used for drug delivery?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nCan Connexin hemi channels be used for drug delivery?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['yes,  pore forming channels such as connexin can potentiially be used as a drug delivery system.', 'Yes, Connexin hemi channels can be used for drug delivery.', 'Yes, connexin hemichannels can be used as a conduit for the delivery of therapeutic agents into cells', 'Yes, Connexin hemichannels can be used for drug delivery, as shown by the delivery of polymeric macromolecules via gap junctions.', 'Yes, Connexin hemi-channels can be employed for drug delivery.', 'Yes,, Connexin hemichannels can be used for drug delivery.', 'Yes, Connexin hemi channels have been proposed as a potential route for drug delivery due to their ability to form open channels in the cell membrane, allowing for the passage of molecules, including drugs, into and out of the cell.', 'Yes, Cx43 channels are highly permeable to small molecules and macromolecules, making them attractive targets for delivering drugs directly into the cytoplasm.', 'Yes, Connexin hemichannels can be used for drug delivery due to their ability to allow the passage of molecules up to 1,000 Da.', 'Yes, Connexin hemi channels can be used for drug delivery due to their permeability to small molecules and macromolecules.', 'Yes, Connexin hemichannels can be used for drug delivery due to their ability to allow for the non-selective passage of molecules up to 1,000 Da.', 'Yes, Connexin hemichannels can be utilized for drug delivery.', 'yes, Connexin hemichannels, due to their permeability to small molecules and macromolecules, can be utilized for delivering drugs directly into the cytoplasm.', 'Yes, the permeability of Cx43 channels to small molecules and macromolecules makes them highly attractive targets for delivering drugs directly into the cytoplasm.', 'Yes, Connexin hemi channels can be used for drug delivery due to their ability to create transitory plasma membrane permeability changes, allowing for the non-selective passage of molecules up to 1,000 Da.', 'Yes, Connexin hemi channels can be used for drug delivery due to their high permeability to small molecules and macromolecules, allowing for direct delivery of drugs into the cytoplasm.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, Connexin hemichannels can be used for drug delivery. According to the provided data, Connexin hemichannels can lead to transitory plasma membrane permeability changes, allowing for the non-selective passage of molecules up to 1,000 Da (Source: Table: Relations, id: 24). This suggests that Connexin hemichannels can be used as a drug delivery system for hydrophilic substances, such as those used in photodynamic therapy in cancer treatment (Source: Table: Relations, id: 14).\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer captures all the necessary information from the reference answers, including the ability of Connexin hemichannels to facilitate drug delivery and the specific detail about the passage of molecules up to 1,000 Da. It also provides additional context with examples of potential applications, such as photodynamic therapy in cancer treatment.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise and includes relevant details without unnecessary information. It specifically mentions the molecular weight limit (1,000 Da) and an application (photodynamic therapy), which are pertinent to the question. However, it could be slightly more concise.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each point is distinct and contributes to the overall understanding without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to read. It uses clear and concise language, making it accessible to the reader. The inclusion of specific examples enhances its clarity and readability."
    },
    {
        "Question": "Pasteurization kills Mycobacterium tuberculosis from infected cattle.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nPasteurization kills Mycobacterium tuberculosis from infected cattle.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes, Mycobacterium bovis is eliminated by pasteurization.', 'Yes, pasteurization kills Mycobacterium tuberculosis from infected cattle']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, pasteurization is mentioned as a process that kills bacteria, including Mycobacterium bovis, in milk, making it safe for human consumption (Source: Entity 8, Description: \"A process that involves heating milk to kill bacteria, including Mycobacterium bovis, and is used to eliminate the risk of tuberculosis transmission via milk.\").\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer correctly recalls the necessary information that pasteurization kills Mycobacterium bovis, which aligns with the reference answers. It also provides additional context from a source, enhancing the recall.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and only includes relevant information about pasteurization and its effect on Mycobacterium bovis (the bacteria associated with tuberculosis in cattle). No irrelevant details are reported.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of the same information. The answer clearly states the key point once and supports it with a source.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, easily readable, and fluent. The inclusion of the source adds clarity without disrupting the flow."
    },
    {
        "Question": "TAK-994 is developed for which disease?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nTAK-994 is developed for which disease?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['TAK-994 is an oral orexin receptor 2-selective agonist that was developed and tested for narcolepsy type 1.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nI don't see any information in the provided data tables about TAK-994.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "1",
        "Information Recall Explanation": "The answer fails to recall any necessary information about TAK-994, as it claims no information was found.",
        "Information Precision Score": "2",
        "Information Precision Explanation": "While the answer does not include any irrelevant information about TAK-994 (since it states nothing was found), it also does not provide any precise information to answer the question.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition of information, as the answer does not provide any information in the first place.",
        "Readability Score": "4",
        "Readability Explanation": "The answer is clear, grammatically correct, and easy to understand, despite not providing the required information."
    },
    {
        "Question": "Is high blood pressure a clinical biomarker of response to Bevacizumab in advanced colorectal cancer patients?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs high blood pressure a clinical biomarker of response to Bevacizumab in advanced colorectal cancer patients?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Bevacizumab-induced hypertension during the first-line treatment of mCRC is an independent prognostic factor, also adopting a time-dependency correction.  In TRIBE and TRIBE-2 study populations (N = 1175), patients experiencing ≥ G2 HTN during first-line bevacizumab administration showed longer Progression free survival  (median: 14.7 versus 10.3 months, p < 0.001) and Overall survival (median: 31.7 versus 24.2 months, p < 0.001).', 'Yes, high blood pressure can be a clinical biomarker of response to Bevacizumab in advanced colorectal cancer patients. Studies have shown that patients who develop hypertension during Bevacizumab treatment have a better overall survival and progression-free survival compared to those who do not develop hypertension. However, it is important to note that the relationship between hypertension and response to Bevacizumab is complex and may depend on various factors, such as the severity of hypertension and the timing of its development. Further research is needed to confirm these findings and establish the clinical utility of hypertension as a biomarker for Bevacizumab response in colorectal cancer patients.', 'Yes, high blood pressure (hypertension) has been identified as a potential clinical biomarker of response to Bevacizumab in advanced colorectal cancer patients. Studies have shown that Bevacizumab-related hypertension is associated with improved outcomes such as increased objective response rate, prolonged progression-free survival, and overall survival in patients receiving Bevacizumab-based chemotherapy for metastatic colorectal cancer. The occurrence of hypertension during Bevacizumab treatment has been linked to better treatment responses and clinical benefits in these patients.', 'High blood pressure (hypertension) has been associated with improved outcomes in patients with advanced colorectal cancer (mCRC) treated with Bevacizumab. Studies have shown that the occurrence of Bevacizumab-induced hypertension is associated with increased overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Additionally, grade 2 hypertension has been identified as an independent prognostic factor for longer PFS and OS. However, it is important to note that hypertension is also a major adverse event associated with Bevacizumab treatment. Therefore, while hypertension may represent a clinical biomarker for response to Bevacizumab, it must be carefully managed to ensure patient safety.', 'Yes, according to several studies, high blood pressure (hypertension) induced by Bevacizumab, a drug used to treat advanced colorectal cancer, has been identified as a potential clinical biomarker of response to the treatment. Patients who develop grades 2-3 hypertension while on Bevacizumab have been found to have a higher response rate, longer progression-free survival, and better overall survival compared to those who do not develop hypertension. However, more large prospective trials are required to confirm its predictive role.', 'Yes, high blood pressure may be a clinical biomarker of response to Bevacizumab in advanced colorectal cancer patients. A retrospective analysis of 107 patients treated with Bevacizumab-containing chemotherapy regimens found that the development of hypertension (≥grade 1) was associated with improved progression-free survival and overall survival compared to normotensive patients. However, this finding needs to be confirmed in prospective studies.', 'Yes, high blood pressure (hypertension) has been identified as a clinical biomarker of response to Bevacizumab in advanced colorectal cancer patients. Studies have shown that patients who develop grades 2-3 hypertension during Bevacizumab treatment have better overall survival and progression-free survival compared to those who do not develop hypertension. This suggests that Bevacizumab-related hypertension may serve as a predictive marker for the effectiveness of Bevacizumab treatment in colorectal cancer patients.', 'Yes. Pooled data from clinical trials, cohort studies and meta-analyses indicate that high blood pressure is a clinical biomarker of response to Bevacizumab in advanced colorectal cancer patients.', 'High blood pressure has been suggested as a potential biomarker of response to bevacizumab in some studies, but its role is still under investigation and not fully understood. Some research suggests that patients who develop hypertension during treatment with bevacizumab may have better outcomes, such as longer progression-free survival or overall survival. However, the relationship between blood pressure changes and clinical benefit is complex and can vary among individuals. More studies are needed to determine whether high blood pressure can serve as a reliable biomarker of response to bevacizumab in advanced colorectal cancer patients.', 'High blood pressure (HTN) may be a clinical biomarker of response to Bevacizumab in advanced colorectal cancer patients. Studies have shown that patients who developed HTN during treatment with Bevacizumab had significantly prolonged overall survival compared to normotensive patients. Additionally, increasing levels of vasoactive peptides, which are associated with hypertension, have been linked to improved tumor response and time to tumor progression in metastatic colorectal cancer patients treated with Bevacizumab-containing regimens. These findings suggest that HTN may be a useful biomarker for predicting treatment response to Bevacizumab in advanced colorectal cancer patients. However, further prospective studies are needed to confirm these observations and establish the clinical utility of HTN as a biomarker of response to Bevacizumab.', 'Yes, bevacizumab-related hypertension may represent a clinical biomarker for response and improved outcomes in patients with metastatic colorectal cancer. Several studies have shown that the occurrence of hypertension during bevacizumab treatment is associated with increased objective response rates, prolonged progression-free survival, and overall survival compared to patients who do not develop hypertension.', 'Yes, high blood pressure has been identified as a clinical biomarker of response to bevacizumab in advanced colorectal cancer patients. Studies have shown that patients who develop hypertension during treatment with bevacizumab have significantly prolonged overall survival compared to normotensive patients. This suggests that bevacizumab-induced hypertension may serve as a biomarker for clinical benefit in colorectal cancer patients treated with bevacizumab.', 'Yes, high blood pressure (hypertension, HTN) is a clinical biomarker of response to Bevacizumab in advanced colorectal cancer (CRC) patients. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) and is commonly used in the first-line treatment of metastatic CRC (mCRC). The development of hypertension is a known side effect of Bevacizumab, and studies have shown that patients with mCRC who experience hypertension during Bevacizumab treatment have a better prognosis.\\n\\nIn two large clinical trials, TRIBE and TRIBE-2, patients with mCRC who experienced grade 2 or higher hypertension (G2 HTN) during first-line Bevac', 'High blood pressure induced by Bevacizumab during the first-line treatment of metastatic colorectal cancer has been identified as an independent prognostic factor. Patients who experience grade 2 or higher hypertension during Bevacizumab treatment have shown longer progression-free survival (PFS) and overall survival (OS) compared to those who do not experience such hypertension. This suggests that high blood pressure may serve as a clinical biomarker of response to Bevacizumab in advanced colorectal cancer patients.', 'Yes, high blood pressure is a clinical biomarker of response to Bevacizumab in advanced colorectal cancer patients.Bevacizumab-induced hypertension (HTN) during the first-line treatment of metastatic colorectal cancer (mCRC) is an independent prognostic factor, also adopting a time-dependency correction.Therefore, high blood pressure is a clinical biomarker of response to Bevacizumab in advanced colorectal cancer patients.', 'Yes, high blood pressure (hypertension) appears to be a clinical biomarker of response to Bevacizumab in advanced colorectal cancer patients. According to the TRIBE and TRIBE-2 study populations, patients who developed grade 2 or higher hypertension during first-line treatment with Bevacizumab had longer progression-free survival (PFS) and overall survival (OS) compared to those who did not. Specifically, the median PFS was 14.7 months versus 10.3 months, and the median OS was 31.7 months versus 24.2 months, both statistically significant findings.', 'Yes, high blood pressure can serve as a clinical biom marker for response to bevacisib in advanced coloreceptive cancer patients. This is because bevacisib can cause changes in blood pressure and lead to cardiovascular events, making it important for physiological monitoring in advanced cancer. ', 'Yes, high blood pressure (≥G2 HTN) during first-line bevacizumab administration is a clinical biomarker of response in advanced colorectal cancer patients. The TRIBE and TRIBE-2 study populations showed that patients who experienced ≥G2 HTN had longer progression-free survival (PFS) and overall survival (OS) compared to those who did not.', 'Yes, high blood pressure (hypertension) appears to be a clinical biomarker of response to Bevacizumab in advanced colorectal cancer patients. Studies like TRIBE and TRIBE-2 have shown that patients who developed grade 2 or higher hypertension during treatment had longer progression-free survival and overall survival compared to those who did not develop significant hypertension. This suggests that hypertension could be an indicator of better treatment response to Bevacizumab', 'yes, high blood pressure (hypertension) appears to be a clinical biomarker of response to Bevacizumab in advanced colorectal cancer patients. According to the TRIBE and TRIBE-2 study populations, patients who developed grade 2 or higher hypertension during first-line treatment with Bevacizumab had longer progression-free survival (PFS) and overall survival (OS) compared to those who did not. Specifically, the median PFS was 14.7 months versus 10.3 months, and the median OS was 31.7 months versus 24.2 months, both statistically significant findings.', 'Yes, high blood pressure (hypertension, HTN) is a clinical biomarker of response to Bevacizumab in advanced colorectal cancer (CRC) patients. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), which is overexpressed in many types of cancer, including CRC. Bevacizumab inhibits the formation of new blood vessels, which can slow or stop the growth of tumors.\\n\\nIn CRC patients receiving Bevacizumab as part of first-line treatment for metastatic disease, the development of hypertension (HTN) has been shown to be a predictive biomarker of response. A study published in the Journal of Clinical Oncology found that CRC patients who developed grade 2 or higher HTN during Bevacizumab treatment had significantly longer progression-free survival (PFS) and overall survival (OS) compared to those who did not develop HTN (14.7 versus 10.3 months for PFS, and 31.7 versus 24.2 months for OS). This association between HTN and response to Bev', 'Bevacizumab-associated high blood pressure (grades 2-3) was associated with better progression-free survival and with improved PFS in patients with metastatic colorectal cancer treated with chemotherapy.', 'High blood pressure (HTN) has been identified as a potential clinical biomarker of response to Bevacizumab in advanced colorectal cancer patients. In the TRIBE and TRIBE-2 studies, patients who experienced ≥G2 HTN during first-line Bevacizumab administration had longer progression-free survival (PFS) and overall survival (OS) compared to those who did not experience ≥G2 HTN. This suggests that HTN may be a useful biomarker for predicting response to Bevacizumab in this patient population. However, further research is needed to validate these findings and determine the underlying mechanisms.', 'Yes, high blood pressure (hypertension) has been identified as a clinical biomarker of response to Bevacizumab in advanced colorectal cancer patients. Retrospective studies and a pooled analysis of prospective randomized trials have shown that patients who develop grade 2 or higher hypertension during treatment with Bevacizumab have longer progression-free survival (PFS) and overall survival (OS) compared to those who do not develop hypertension. This association remains significant even after correcting for time-dependency and considering pre-existing hypertension. Therefore, monitoring and managing blood pressure in patients receiving Bevacizumab may provide valuable prognostic information and guide treatment decisions.', 'High blood pressure (HTN) during first-line treatment with bevacizumab is an independent prognostic factor for longer progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC), according to a study that included the TRIBE and TRIBE-2 trial populations. Patients who experienced grade 2 or higher HTN during bevacizumab treatment had significantly better PFS and OS compared to those without hypertension, suggesting that Bevacizumab-induced HTN may be associated with improved clinical outcomes in mCRC patients.', 'High blood pressure (HTN) may be a clinical biomarker of response to Bevacizumab in advanced colorectal cancer patients. A pooled analysis of two randomized studies found that patients experiencing ≥G2 HTN during first-line Bevacizumab administration had longer progression-free survival (PFS) and overall survival (OS) compared to those who did not experience ≥G2 HTN. The association with OS retained statistical significance after correcting for time-dependency and was confirmed in a multivariable model including HTN as a time-dependent variable. Moreover, patients with pre-existing HTN did not show any difference in PFS and OS compared to those without pre-existing HTN. These findings suggest that Bevacizumab-induced HTN may be a prognostic factor for clinical outcome in mCRC patients.', 'Yes, bevacizumab-induced hypertension (HTN) during first-line treatment of metastatic colorectal cancer (mCRC) is an independent prognostic factor. Patients experiencing grade 2 or higher HTN during first-line bevacizumab administration showed significantly longer progression-free survival and overall survival compared to those without HTN. This suggests that bevacizumab-induced HTN may serve as a clinical biomarker of response to bevacizumab in advanced colorectal cancer patients.', 'Yes, high blood pressure (hypertension) has been identified as a clinical biomarker of response to Bevacizumab in advanced colorectal cancer patients. Studies have shown that patients who experience grade 2 or higher hypertension during first-line treatment with Bevacizumab have longer progression-free survival (PFS) and overall survival (OS) compared to those who do not develop hypertension. This suggests that the development of hypertension may be indicative of a positive response to Bevacizumab therapy in these patients.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, hypertension (high blood pressure) is indeed associated with Bevacizumab treatment in advanced colorectal cancer patients. In fact, there are several relations in the data that indicate a connection between Bevacizumab treatment and hypertension.\n\nFor example, relation 15 states that \"Liver metastasis is a risk factor for increased blood pressure in patients treated with bevacizumab.\" This suggests that the presence of liver metastasis, which is a common site of metastasis for colorectal cancer, may increase the risk of high blood pressure in patients treated with Bevacizumab.\n\nAdditionally, relation 43 states that \"Arterial hypertension is caused by the inhibition of the vascular endothelial growth factor-related pathway by bevacizumab.\" This suggests that Bevacizumab's mechanism of action, which involves inhibiting the VEGF pathway, may contribute to the development of high blood pressure in some patients.\n\nHowever, it is essential to note that the data does not provide a clear answer to whether high blood pressure is a clinical biomarker of response to Bevacizumab in advanced colorectal cancer patients. While there may be an association between Bevacizumab treatment and hypertension, it is unclear whether high blood pressure is a reliable indicator of treatment response or outcome.\n\nFurther research is needed to fully understand the relationship between Bevacizumab treatment, hypertension, and clinical outcomes in advanced colorectal cancer patients.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer mentions references to hypertension and Bevacizumab treatment but fails to include critical information from the reference answers, such as the association between Bevacizumab-induced hypertension and improved survival outcomes (e.g., progression-free survival, overall survival). It also misses key studies like TRIBE and TRIBE-2, which are central to the reference answers.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer does not include irrelevant information, but it lacks precision in addressing the specific question about hypertension as a biomarker of response to Bevacizumab. It focuses more on the association between Bevacizumab and hypertension rather than its role as a clinical biomarker.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. It introduces different aspects of the relationship between Bevacizumab and hypertension (e.g., liver metastasis, VEGF pathway inhibition) without redundancy.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-structured and easy to follow. The language is clear and fluent, though it could benefit from more direct evidence from the reference answers to strengthen its argument."
    },
    {
        "Question": "What is the significance of Acute pancreatitis-induced splanchnic vein thrombosis",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the significance of Acute pancreatitis-induced splanchnic vein thrombosis\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Deep Venous Thrombosis in Acute Pancreatitis Is Associated with High Mortality.', 'Acute pancreatitis-induced splanchnic vein thrombosis (APISVT) is a serious complication of acute pancreatitis that can lead to poor prognosis, including severe gastrointestinal hemorrhage, bowel ischemic necrosis, and liver failure. The pathogenesis of APISVT is multifactorial and centered on local and systemic inflammation. The management of APISVT involves the treatment of underlying acute pancreatitis and its complications, but there is no consensus guideline on the use of anticoagulation in this setting. Literature suggests the use of anticoagulation in the presence of portal vein thrombosis with or without superior mesenteric vein thrombosis and extrasplanchnic vessel involvement. However, the significance of APISVT lies in its potential to improve outcomes for patients with acute pancreatitis by prevent', '7.6% of patients with acute pancreatitis develop splanchnic vein thrombosis (SVT) with a 40% risk of extension into the portal vein. This is a serious complication.', 'Acute pancreatitis-induced splanchnic vein thrombosis is a potentially severe complication that can lead to poor prognosis, including severe gastrointestinal hemorrhage, bowel ischemic necrosis, and liver failure.', 'Acute pancreatitis-induced splanchnic vein thrombosis is a prognostic indicator in patients with acute pancreatitis, being a critical factor for the development of serious gastrointestinal complications, and can predict increased intensive care unit stay and death, especially in severe cases of necrotizing pancreatitis.', 'Acute pancreatitis-induced splanchnic vein thrombosis is a well-known vascular complication of acute pancreatitis, particularly in the severe form of the disease and pancreatic necrosis.', 'Acute pancreatitis-induced splanchnic vein thrombosis (APISVT) is a potentially severe complication of acute pancreatitis, which may cause poor prognosis, such as severe gastrointestinal hemorrhage, bowel ischemic necrosis and liver failure.', 'Acute pancreatitis-induced splanchnic vein thrombosis is significant due to its potential to cause severe complications such as gastrointestinal hemorrhage, bowel ischemic necrosis, and liver failure, leading to poor prognosis.', 'The splanchnic vein thrombosis that occurs in acute pancreatitis is associated with high mortality.', 'Acute pancreatitis-induced splanchnic vein thrombosis is an important sequela complication of acute pancreatitis, which may cause poor prognosis, such as severe gastrointestinal hemorrhage, bowel ischemic necrosis, and liver failure.', 'Acute pancreatitis-induced splanchnic vein thrombosis (APISVT) is significant because it can lead to severe complications such as gastrointestinal hemorrhage, bowel ischemic necrosis, and liver failure. These complications can worsen the prognosis and increase the mortality risk associated with acute pancreatitis', 'Acute pancreatitis-induced splanchnic vein thrombosis is significantly associated with high mortality in acute pancreatitis.', 'Acute pancreatitis-induced splanchnic vein thrombosis (APISVT) is a serious complication of acute pancreatitis that can lead to poor prognosis, severe gastrointestinal hemorrhage, bowel ischemic necrosis, and liver failure.', 'Splanchnic vein thrombosis (SVT) is a well-recognised though little-studied complication in acute pancreatitis (AP) Acute pancreatitis-induced splanchnic artery thromBosis (APISVT) may cause poor prognosis, such as gastrointestinal hemorrhage, bowel ischemic necrosis and liver failure.', 'Acute pancreatitis-induced splanchnic vein thrombosis (APISVT) is an important and potentially life-threatening complication of acute pancreatitis. It may lead to poor prognosis, including severe gastrointestinal hemorrhage, bowel ischemic necrosis, and liver failure.', 'Acute pancreatitis-induced splanchnic vein thrombosis (APISVT) is significant because it can lead to severe complications such as gastrointestinal hemorrhage, bowel ischemic necrosis, and liver failure. These complications can worsen the prognosis and increase the mortality rate in patients with acute pancreatitis', 'Acute pancreatitis-induced splanchnic vein thrombosis (APISVT) is an important complication of acute pancreatitis. It can lead to poor prognosis, including severe gastrointestinal hemorrhage, bowel ischemic necrosis, and liver failure. Splanchnic vein thrombosis (SVT) is a potentially severe complication of pancreatitis.', 'Acute pancreatitis-induced splanchnic vein thrombosis is associated with high mortality, indicating that it is a significant complication that can lead to severe consequences.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAcute pancreatitis-induced splanchnic vein thrombosis (APISVT) is a serious complication of acute pancreatitis, characterized by the formation of blood clots in the splanchnic veins. The splanchnic veins are a group of veins that drain blood from the abdominal organs, including the pancreas, spleen, and intestines.\n\nThe significance of APISVT lies in its potential to cause severe complications, including:\n\n1. **Poor prognosis**: APISVT is associated with a high risk of mortality, with mortality rates ranging from 10% to 30%.\n2. **Severe gastrointestinal hemorrhage**: Blood clots in the splanchnic veins can lead to bowel ischemia and necrosis, resulting in severe gastrointestinal hemorrhage.\n3. **Liver failure**: Thrombosis in the splanchnic veins can also lead to liver failure, which can be life-threatening.\n4. **Bowel ischemia and necrosis**: Blood clots in the splanchnic veins can cause bowel ischemia and necrosis, leading to severe abdominal pain, nausea, and vomiting.\n5. **Increased risk of complications**: APISVT can increase the risk of complications, including sepsis, multi-organ failure, and death.\n\nThe pathogenesis of APISVT is not fully understood, but it is thought to be related to the inflammatory response and coagulation cascade activation that occurs in acute pancreatitis. Several factors contribute to the development of APISVT, including:\n\n1. **Inflammation**: The inflammatory response in acute pancreatitis can lead to the activation of coagulation factors and the formation of blood clots.\n2. **Coagulation cascade activation**: The coagulation cascade is activated in acute pancreatitis, leading to the formation of blood clots.\n3. **Hypercoagulability**: Acute pancreatitis can lead to hypercoagulability, which increases the risk of blood clots forming in the splanchnic veins.\n\nThe diagnosis of APISVT is typically made using imaging studies, such as computed tomography (CT) scans or magnetic resonance imaging (MRI). Treatment of APISVT typically involves anticoagulation therapy to prevent further clot formation and promote recanalization of the affected veins. However, the optimal treatment approach for APISVT is still a topic of debate, and further research is needed to determine the most effective treatment strategy.\n\nIn summary, APISVT is a serious complication of acute pancreatitis that can lead to severe gastrointestinal hemorrhage, liver failure, bowel ischemia, and increased risk of complications. The pathogenesis of APISVT is related to inflammation, coagulation cascade activation, and hypercoagulability, and treatment typically involves anticoagulation therapy.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers all key aspects of Acute pancreatitis-induced splanchnic vein thrombosis (APISVT) mentioned in the reference answers. These include complications (poor prognosis, severe gastrointestinal hemorrhage, liver failure, bowel ischemia and necrosis), pathogenesis (inflammation, coagulation cascade activation, hypercoagulability), diagnostic methods (CT, MRI), and treatment (anticoagulation therapy). The answer provides all the necessary information.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is mostly precise with minimal irrelevant information. However, it includes minor details such as 'nausea and vomiting' under bowel ischemia and necrosis, which, while related, are not central to the main points about APISVT's significance as per the reference answers. Overall, it stays focused on key points.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer avoids major repetition but does reiterate the concept of 'blood clots in the splanchnic veins' in multiple sections (complications and pathogenesis). However, the repetition is not excessive and serves to reinforce key concepts.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to follow. It uses clear headings (e.g., 'Poor prognosis') to organize information logically. The language is professional yet accessible, making it highly readable."
    },
    {
        "Question": "Is gout a very common inflammatory arthritis, which is caused by hyperbilirubinemia?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs gout a very common inflammatory arthritis, which is caused by hyperbilirubinemia?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['No, gout is not caused by hyperbilirubinemia. Gout is an inflammatory arthritis caused by the deposition of monosodium urate (MSU) crystals. Hyperbilirubinemia refers to an elevated level of bilirubin in the blood and is not a known cause of gout. Gout is primarily associated with elevated levels of uric acid in the blood, which leads to the formation of MSU crystals in the joints and tissues.', 'No, gout is not caused by hyperbilirubinemia. Gout is a common form of inflammatory arthritis that develops due to hyperuricemia (elevated levels of uric acid in the blood). The buildup of uric acid can lead to the formation of urate crystals in joints, fluids, and tissues within the body, causing painful gout flares and potentially leading to joint damage over time. Hyperbilirubinemia, on the other hand, refers to elevated bilirubin levels in the blood and is not directly related to the development of gout.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nNo.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "1",
        "Information Recall Explanation": "The answer 'No' does not provide any necessary information about gout or hyperbilirubinemia. It fails to recall or report key facts such as gout being caused by hyperuricemia and the formation of MSU crystals, or that hyperbilirubinemia is unrelated to gout.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer 'No' is extremely precise—it directly answers the question with no irrelevant details. However, its precision comes at the cost of lacking explanatory depth.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition in the answer. It is concise and does not repeat any information.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is very readable and fluent due to its simplicity and brevity. It clearly communicates the response without ambiguity."
    },
    {
        "Question": "What receptors are targeted by Retatrutide?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat receptors are targeted by Retatrutide?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Retatrutide is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, Retatrutide targets the following receptors:\n\n* Glucose-dependent insulinotropic polypeptide (GIP) receptors\n* Glucagon-like peptide 1 (GLP-1) receptors\n* Glucagon receptors\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately reports all the necessary information from the reference answers, listing all three targeted receptors (GIP, GLP-1, and glucagon receptors).",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information. It directly addresses the question with the exact receptors mentioned in the reference.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of the same information. Each receptor is listed clearly and only once.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is easily readable and fluent. The information is presented in a clear, bullet-point format, making it straightforward to understand."
    },
    {
        "Question": "What is the mechanism by which the microbiota module the effectiveness of chemotherapy?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the mechanism by which the microbiota module the effectiveness of chemotherapy?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The gut microbiota influences both local and systemic inflammation. Inflammation contributes to development, progression, and treatment of cancer. \\n In preclinical models, disruption of the microbiota impairs the response of subcutaneous tumors to CpG-oligonucleotide immunotherapy and platinum chemotherapy.', \"The mechanism by which the microbiota modulates the effectiveness of chemotherapy involves several key mechanisms, including: , 1. Translocation: The gut microbiota can translocate chemotherapeutic drugs from the gut lumen to the systemic circulation, thereby affecting their bioavailability and efficacy., 2. Metabolism: The gut microbiota can metabolize chemotherapeutic drugs, converting them into active or inactive metabolites, which can affect their efficacy and toxicity., 3. Immune modulation: The gut microbiota can modulate the immune system's response to cancer and chemotherapy, affecting the efficacy of treatment and the development of side effects., 4. Production of bioactive molecules: The gut microbiota can produce bioactive molecules that can affect the activity of chemotherapeutic drugs, such as antibiotics, anticancer agents\", '5-fluorouracil (5-FU) significantly reduced the gut microbiota diversity. The presence of Bifidobacteria could contribute to the therapeutic success of 5-FU.\\n\\nConclusion: The responses seem to be a little too specific to the examples in the provided contexts. \\n\\nThe questions seem to just ask for a summary of the provided contexts. For example, the first question could have been answered with \"Hirschsprung disease is a multifactorial disorder, involving RET, GDNF, EDNRB, EDN3, and SOX10\". The fourth question could have been answered with \"Renal sympathetic denervation reduces blood pressure and heart rate\". The second and third questions are more interesting, but they are still narrowly focused on one particular point of the provided contexts.\\n\\nI suspect that if you try a few of these examples on a real test,', 'The microbiota can modulate the effectiveness of chemotherapy by directly interacting with the drugs, altering their pharmacokinetics and pharmacodynamics. Additionally, the microbiota can influence the host response through immunomodulation, impacting the overall efficacy and toxicity of anti-cancer treatments. This modulation can affect drug metabolism, bioaccumulation, and immunological effects, ultimately influencing the response to chemotherapy and other cancer therapies.', \"The microbiota can modulate the effectiveness of chemotherapy by influencing the host immune response. The gut microbiota plays a crucial role in the regulation of the immune system, and alterations in the microbiota can affect the efficacy of chemotherapy. For example, the presence of certain bacteria in the gut can promote the growth of cancer cells, while others can inhibit their growth. Additionally, the microbiota can influence the host's response to chemotherapy by modulating the expression of genes involved in drug metabolism and transport. Furthermore, the microbiota can also affect the distribution and pharmacokinetics of chemotherapeutic drugs in the body, leading to variations in their efficacy and toxicity. Therefore, the gut microbiota can have a significant impact on the effectiveness of chemotherapy, and modulating the microbiota through fecal microbiota transplantation or other means may be a promising strategy for improving chemotherapy outcomes.\", 'The microbiota can modulate the effectiveness of chemotherapy by modulating the pharmacokinetics and pharmacodynamics of the compounds used, thus varying the real response and therefore the efficacy of the oncological treatment.', '1. Modulation of the tumour microenvironment: Gut microbiota can inhibit tumour growth by modulating the tumour microenvironment. \\n2. Production of bioactive metabolites: Gut microbiota can also produce bioactive metabolites, such as short chain fatty acids, that have anti-tumour effects.\\n3. Modulation of drug metabolism: Gut microbiota can affect drug metabolism by activating or inhibiting drug metabolizing enzymes.\\n4. Modulation of immune responses: Gut microbiota can also modulate immune responses, including the activation of immune cells and the production of cytokines.\\n5. Regulation of intestinal permeability: Gut microbiota can regulate intestinal permeability, which can affect the absorption and distribution of chemotherapeutic drugs.', \"The microbiota modulates the effectiveness of chemotherapy through various mechanisms including immunomodulation, which involves altering the immune system's response to cancer cells; xenometabolism, which refers to the transformation of chemotherapeutic drugs by microbial metabolism affecting their bioavailability, bioactivity, or toxicity; and alteration of community structure, where changes in the composition of microbial communities can impact drug efficacy and patient response to treatment.\", 'The microbiota can modulate the effectiveness of chemotherapy through several mechanisms including translocation, immunomodulation, metabolism, enzymatic degradation, and reduced diversity and ecological variation. These mechanisms can either facilitate drug efficacy, abrogate or compromise anticancer effects, or mediate toxicity. Gut bacteria are particularly intimately linked to the pharmacological effects of chemotherapies and novel targeted immunotherapies. The gut microbiota can now be targeted to improve efficacy and reduce the toxicity of current chemotherapy agents.', 'The microbiota can modulate the effectiveness of chemotherapy through various mechanisms. These include influencing the tumor microenvironment, affecting the pharmacokinetics and pharmacodynamics of chemotherapeutic drugs, and modulating the immune response. Additionally, the composition of the microbiota can impact the efficacy and toxicity of chemotherapy.', 'The gut microbiota modulates the effectiveness of chemotherapy through three key mechanisms: microbial ecocline, catalysis of microbial enzymes, and immunoregulation. Targeting the gut microbiota through dietary interventions, probiotics, and strain-engineered interventions can improve the efficacy and reduce the toxicity of chemotherapy agents.', 'The exact mechanisms by which the gut microbiota modulates the efficacy of chemotherapeutic agents are not yet fully understood, but several proposed pathways exist. One mechanism involves the metabolic transformation of chemotherapeutics by microbial enzymes, which can either inactivate or activate these drugs within the intestinal lumen. For example, some bacteria possess enzymes that can convert prodrugs into their active form, enhancing their therapeutic effect. Conversely, other bacterial species may be capable of metabolizing active drugs to less potent forms or even rendering them inactive, thereby reducing their efficacy. Additionally, microbial metabolites, such as short-chain fatty acids (SCFAs) and bile acids, can influence the expression of drug transporters in intestinal cells, which can affect the absorption and bioavailability of chemotherapeutic agents. The microbiota also plays a role in immune system modulation, and its composition can impact how the body responds to chemotherapy by altering the tumor microenvironment and systemic immunity.', 'The microbiota modulates the effectiveness of chemotherapy by affecting the pharmacokinetics and pharmacodynamics of the compounds used, thus varying the real response and therefore the efficacy of the oncological treatment.', 'The gut microbiota can modulate the effectiveness of chemotherapy through several mechanisms, including: , 1. Translocation: The gut microbiota can translocate certain chemotherapeutic drugs from the gut lumen to the systemic circulation, enhancing their efficacy., 2. Immunomodulation: The gut microbiota can influence the host immune response to chemotherapy, either by promoting or suppressing immune cell activity., 3. Metabolism: The gut microbiota can metabolize chemotherapeutic drugs, converting them into active or inactive metabolites that may affect their efficacy and toxicity., 4. Enzymatic degradation: Certain gut bacteria can produce enzymes that degrade chemotherapeutic drugs, reducing their efficacy., 5. Reduced diversity and ecological variation: An imbalance of the gut microbiota,', '\\nThe microbiota can impact chemotherapy effectiveness through multiple mechanisms, including metabolic interactions (e.g., converting prodrugs into active forms or detoxifying drugs), immune system modulation (e.g., promoting cytokine production), and drug resistance (e.g., producing enzymes that deactivate chemotherapy agents). The exact mechanisms and their relative importance are complex and still being studied.', 'The gut microbiota can modulate the effectiveness of chemotherapy through several mechanisms:\\n\\n1. Direct interaction with the chemotherapeutic drugs, changing their chemical structure and affecting their activity and local concentration.\\n\\n2. Modulating the pharmacokinetics and pharmacodynamics of the chemotherapeutic compounds, thus varying the response and efficacy of the treatment. \\n\\n3. Stimulating host immune response through immunomodulation, which can indirectly impact the efficacy of chemotherapy.\\n\\n4. Influencing tumor biology, including cell proliferation, invasion, and metastasis, which can affect overall survival and tumor recurrence after treatment.\\n\\n5. Certain taxa in the microbiota have been shown to specifically modulate the anti-tumor efficacy of various chemotherapies when present or depleted.\\n\\nIn summary, the gut microbiota interacts with chemotherapeutic drugs both directly and indirectly via modulation of host response, significantly impacting the pharmacological effects and overall effectiveness of chemotherapy in cancer treatment.', 'The gut microbiota can modulate the effectiveness of chemotherapy through various mechanisms. One mechanism is the metabolism of chemotherapeutic drugs by gut bacteria, which can alter their pharmacokinetics and pharmacodynamics. Additionally, the gut microbiota can influence the immune response to chemotherapy, affecting the tumor microenvironment and the efficacy of treatment.', 'The gut microbiota influences both local and systemic inflammation. Inflammation contributes to development, progression, and treatment of cancer.', 'The microbiota modulate the effectiveness of chemotherapy by influencing both local and systemic inflammation, which in turn affects the development, progression, and treatment of cancer.', \"The microbiota can influence the effectiveness of chemotherapy by modulating local and systemic inflammation. This inflammation plays a role in the development, progression, and treatment of cancer. Disruption of the microbiota can impair the response of tumors to immunotherapy and chemotherapy, such as CpG-oligonucleotide immunotherapy and platinum chemotherapy. The gut microbiota's impact on inflammation can affect the tumor microenvironment and the body's immune response to treatment, ultimately influencing the outcomes of cancer therapy.\", 'The microbiota modulates the effectiveness of chemotherapy by altering the metabolite profile, increasing the levels of toxins, and disrupting the tumor microenvironment.', \"The gut microbiota modulates the effectiveness of chemotherapy by influencing systemic inflammation, which plays a crucial role in the development, progression, and treatment of cancer. When the microbiota is disrupted, it impairs the body's inflammatory response, which is essential for the effectiveness of treatments like CpG-oligonucleotide immunotherapy and platinum chemotherapy. This interaction highlights the importance of maintaining a healthy microbiota to support optimal responses to cancer therapies.\", 'Disruption of the microbiota by antibiotic treatment impairs the response of subcutaneous tumors to CpG-oligonucleotide immunotherapy and platinum chemotherapy.\\nThe mechanisms underlying microbiota modulation of chemotherapy response likely involve increased antigenic presentation and improved intratumoral T-cell infiltration.', 'Overall, Retritylated proteins serve as receptors for various signaling pathways, enabling cells to respond to environmental changes and interact with other cells in specific ways. These receptors play crucial roles in cellular communication and signaling, contributing to the diversity and complexity of living organisms. ', 'The gut microbiota can influence both local and systemic inflammation, which contributes to the development, progression, and treatment of cancer. Specifically, disruption of the microbiota has been shown to impair the response of subcutaneous tumors to CpG-oligonucleotide immunotherapy and platinum chemotherapy. However, the specific mechanisms by which the microbiota modulate the effectiveness of chemotherapy are not fully understood and require further research.', \"The microbiota can modulate the effectiveness of chemotherapy by influencing the body's immune response and inflammation levels. Certain bacteria in the gut can metabolize drugs, affecting their efficacy and toxicity. Additionally, a healthy microbiota can help maintain the integrity of the gut barrier, reducing systemic inflammation and potentially improving the body's overall response to chemotherapy\", 'The gut microbiota influences both local and systemic inflammation. Inflammation contributes to development, progression, and treatment of cancer. disruption of the microbiota impairs the response of subcutaneous tumors to CpG-oligonucleotide immunotherapy and platinum chemotherapy.', \"The gut microbiota plays a crucial role in modulating the effectiveness of chemotherapy by influencing both local and systemic inflammation. Inflammation is a key factor in the development, progression, and treatment of cancer. When the microbiota is disrupted, it can impair the body's inflammatory response, which is necessary for the effectiveness of treatments like CpG-oligonucleotide immunotherapy and platinum chemotherapy. Essentially, a healthy and balanced microbiota helps to maintain the right level of inflammation needed to support the therapeutic effects of cancer treatments.\", 'The gut microbiota, which refers to the collection of microorganisms that reside in the gastrointestinal tract, has been shown to play a role in modulating the effectiveness of chemotherapy. The exact mechanism by which the microbiota affects chemotherapy response is not fully understood, but several potential pathways have been proposed:\\n\\n1. Metabolic interactions: The gut microbiota can metabolize chemotherapy drugs, either by breaking them down into less active metabolites or by converting them into more active forms. For example, the bacterium Clostridium perfringens can convert the chemotherapy drug irinotecan into its active metabolite SN-38, which can increase its toxicity.\\n\\n2. Immune system modulation: The gut microbiota can influence the activity of immune cells, which can impact chemotherapy response. For example, some bacteria can promote the production of regulatory T cells, which can suppress the immune response and reduce the effectiveness of chemotherapy.\\n\\n3. Intestinal barrier function: The gut microbiota can affect the integrity of the intestinal barrier, which can impact the absorption and distribution of chemotherapy drugs. For example, some bacteria', '45 species of gut microbiota were found to be significantly different between responder and non-responder mice. Lactobacillus johnsonii strain N6.2, Alistipes shahii strain WB2340, and Bifidobacterium pseudolongum subsp. globosum strain WB1109 were found to enhance the effectiveness of chemotherapy through modulation of DNA damage response and cell death pathways.', 'The microbiota modulates the effectiveness of chemotherapy by influencing both local and systemic inflammation. Inflammation plays a role in the development, progression, and treatment of cancer, and the gut microbiota can impact this process.', \"The gut microbiota can influence the effectiveness of chemotherapy through several mechanisms. One way is by modulating the host's immune response to chemotherapeutic agents. Certain bacterial species can stimulate the immune system, leading to an enhanced response to chemotherapy. Conversely, other bacteria can suppress the immune response, reducing the effectiveness of chemotherapy. , Another mechanism by which the microbiota can affect chemotherapy is through metabolic processes. Gut bacteria can metabolize chemotherapeutic drugs, altering their bioavailability and pharmacokinetics. For example, some bacteria can convert irinotecan, a topoisomerase inhibitor used in colorectal cancer treatment, into its active metabolite, SN-38, thereby enhancing its cytotoxicity. , Furthermore, the microbiota can affect the intestinal epithelial barrier function, which is critical for maintaining gut homeostasis and preventing the translocation\", 'The gut microbiota influences both local and systemic inflammation, which plays a significant role in the development, progression, and treatment of cancer. Disruption of the microbiota can impair the response of tumors to treatments like CpG-oligonucleotide immunotherapy and platinum chemotherapy. This suggests that a healthy and balanced microbiota is crucial for effective cancer treatment outcomes.', 'The microbiota modulates the effectiveness of chemotherapy by influencing the functions of myeloid-derived cells in the tumor microenvironment. Disruption of the microbiota impairs the response of tumor-infiltrating myeloid-derived cells to chemotherapy, resulting in deficient production of reactive oxygen species and cytotoxicity. An intact commensal microbiota is necessary for optimal responses to chemotherapy.', \"The microbiota can influence the effectiveness of chemotherapy by modulating both local and systemic inflammation. Disruption of the microbiota has been shown to impair the response of subcutaneous tumors to CpG-oligonucleotide immunotherapy and platinum chemotherapy. The gut microbiota, in particular, can affect the host's immune system and influence the tumor microenvironment. Certain bacteria can enhance the immune response to chemotherapy, while others can suppress it. Additionally, chemotherapy itself can alter the composition of the gut microbiota, further impacting its ability to modulate the effectiveness of treatment. Therefore, understanding the complex interactions between the microbiota and chemotherapy is crucial for developing more effective cancer therapies.\", 'The gut microbiota influences both local and systemic inflammation. Inflammation contributes to development, progression, and treatment of cancer, and the gut microbiota influences both local and systemic inflammation.', 'The mechanism by which the microbiota modulates the effectiveness of chemotherapy is through its influence on myeloid-derived cell functions in the tumor microenvironment. The commensal bacteria interact with these cells, leading to changes in cytokine production and reactive oxygen species (ROS) generation. The reduced ability of tumor-infiltrating myeloid cells to respond to therapy in antibiotics-treated or germ-free mice results in lower cytokine production and tumor necrosis after CpG-oligonucleotide treatment, and deficient ROS and cytotoxicity production after chemotherapy. Therefore, an intact commensal microbiota is necessary for optimal responses to cancer therapy by modulating myeloid-derived cell functions in the tumor microenvironment.', \"The microbiota can modulate the effectiveness of chemotherapy by affecting the body's immune response and inflammation levels. Certain microbes can enhance the immune system's ability to attack tumor cells, while others might reduce inflammation, which can alter how effectively chemotherapy drugs work. For example, some bacteria can metabolize the drugs, affecting their potency and side effects\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe mechanism by which the microbiota modulates the effectiveness of chemotherapy is complex and multifaceted. According to the provided data tables, the microbiota can influence chemotherapy effectiveness through several key mechanisms:\n\n1.  **Immunomodulation**: The microbiota can modulate the host immune system, which plays a crucial role in the effectiveness of chemotherapy. Certain bacteria can stimulate or suppress the immune system, affecting the body's ability to respond to cancer cells.\n2.  **Xenometabolism**: The microbiota can alter the metabolism of chemotherapy drugs, affecting their bioavailability, bioactivity, or toxicity. This can result in reduced drug efficacy or increased toxicity.\n3.  **Alteration of community structure**: Changes in the gut microbiota composition can influence the host's response to chemotherapy. For example, an imbalance of the gut microbiota, known as dysbiosis, can lead to reduced chemotherapy effectiveness.\n4.  **Microbial ecocline**: The microbiota can affect the gut environment, influencing the growth and activity of cancer cells. This can impact the effectiveness of chemotherapy by altering the tumor microenvironment.\n5.  **Enzymatic degradation**: Certain bacteria can break down chemotherapy drugs, reducing their effectiveness.\n6.  **Modulation of the tumor microenvironment**: The microbiota can influence the tumor microenvironment, affecting the growth and spread of cancer cells. This can impact the effectiveness of chemotherapy by altering the tumor's response to treatment.\n\nThese mechanisms highlight the complex interplay between the microbiota, the host, and chemotherapy drugs. The microbiota can either enhance or inhibit the effectiveness of chemotherapy, depending on its composition and the specific mechanisms involved.\n\nIn addition, the data tables suggest that the microbiota can be targeted to improve chemotherapy effectiveness. This can be achieved through various strategies, including:\n\n*   **Fecal microbiota transplantation (FMT)**: Transplanting fecal microbiota from healthy individuals into patients can restore a balanced gut microbiota, potentially improving chemotherapy effectiveness.\n*   **Probiotics**: Supplementing with specific probiotic bacteria can modulate the gut microbiota, enhancing chemotherapy effectiveness.\n*   **Prebiotics**: Prebiotics can stimulate the growth of beneficial bacteria, promoting a balanced gut microbiota and improving chemotherapy effectiveness.\n*   **Dietary interventions**: Modifying the diet to promote a balanced gut microbiota can also enhance chemotherapy effectiveness.\n\nOverall, the microbiota plays a crucial role in modulating the effectiveness of chemotherapy, and targeting the microbiota may provide new opportunities for improving treatment outcomes.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer excels in Information Recall by comprehensively covering all necessary mechanisms by which the microbiota modulates chemotherapy effectiveness, including immunomodulation, xenometabolism, alteration of community structure, microbial ecocline, enzymatic degradation, and modulation of the tumor microenvironment. It also includes additional strategies like FMT, probiotics, prebiotics, and dietary interventions for targeting the microbiota.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise, focusing solely on the mechanisms and strategies related to microbiota's role in chemotherapy effectiveness without including irrelevant information. Each point is clearly and directly relevant to the question asked.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no unnecessary repetition in the answer. Each mechanism and strategy is presented once, clearly and succinctly, making the information dense yet easy to follow.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is highly readable and fluent. The information is logically organized, with mechanisms and strategies presented in a clear, numbered list. The language is straightforward and free from jargon, making it accessible to a broad audience."
    },
    {
        "Question": "What is Tagraxofusp?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is Tagraxofusp?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Tagraxofusp (or SL-401) is a recombinant molecule composed of human interleukin-3 that binds CD123 on neoplastic cells fused to a truncated diphtheria toxin (DT). It is a  is a first-in-class drug targeting CD123 approved for treatment of blastic plasmacytoid dendritic cell neoplasm.', 'Tagraxofusp is a first-in-class drug targeting CD123 approved for treatment of blastic plasmacytoid dendritic cell neoplasm.', 'Tagraxofusp is a CD123-directed cytotoxin composed of human interleukin-3 fused to a truncated diphtheria toxin.', 'Tagraxofusp is a bispecific antibody that targets both CD3 and CD20 antigens on cancer cells. It is being developed for the treatment of B-cell malignancies, including non-Hodgkin lymphoma and chronic lymphocytic leukemia.', 'Tagraxofusp (SL-401) is a CD123-directed cytotoxin composed of interleukin-3 (IL-3) and diphtheria toxin.', 'Tagraxofusp is an intravenously administered CD123-directed cytotoxin consisting of the fusion of interleukin-3 with a truncated diphtheria toxin payload.', 'Tagraxofusp (SL-401) is a CD123-targeted therapy consisting of interleukin-3 fused to a truncated diphtheria toxin payload.', 'Tagraxofusp (tagraxofusp-erzs) is an intravenously administered CD123-directed cytotoxin. It is composed of human interleukin-3 and a truncated diphtheria toxin payload. Tagraxofusp is used for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).', 'Tagraxofusp is a CD123-targeted therapy consisting of interleukin-3 fused to a truncated diphtheria toxin payload.', 'Tagraxofusp is a recombinant cytotoxin which consists of human interleukin-3 fused to a truncated diphtheria toxin, approved for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).', '\\n Tagraxofusp (brand name Elzonris) is a targeted cancer therapy that specifically targets a protein called CD123 and is approved by the US FDA for the treatment of adults and children with blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive form of non-Hodgkin lymphoma. It is a recombinant cytotoxin that consists of human interleukin-3 fused to a truncated diphtheria toxin.', 'Tagraxofusp (SL-401) is a CD123-targeted therapy consisting of human interleukin-3 fused to a truncated diphtheria toxin payload. It is a recombinant cytotoxin approved for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and pediatric patients 2 years and older.', 'Tagraxofusp is a CD123-targeted immunotoxin that has been approved by the FDA for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). It consists of the ligand for CD123, interleukin 3, conjugated to a truncated diphtheria toxin payload.', 'Tagraxofusp (or SL-401) is a recombinant molecule composed of human interleukin-3 that binds CD123 on neoplastic cells fused to a truncated diphtheria toxin (DT).', 'Tagraxofusp is an oral, small molecule, targeted therapy for the treatment of adults with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).', 'Tagraxofusp is a recombinant molecule composed of human interleukin-3 that binds CD123 on neoplastic cells fused to a truncated diphtheria toxin.', 'Tagraxofusp is a first-in-class drug targeting CD123 approved for treatment of blastic plasmacytoid dendritic cell neoplasm, consisting of the ligand for CD123, interleukin 3, fused to a truncated diphtheria toxin.', 'Tagraxofusp is a recombinant fusion protein designed to target CD123-positive cells that express the interleukin-3 receptor. It consists of interleukin 3 (IL-3) conjugated with diphtheria toxin, which is a cytotoxic protein.', 'Tagraxofusp is a recombinant molecule composed of human interleukin-3 (IL-3) that binds CD123 on neoplastic cells fused to a truncated diphtheria toxin (DT). It is a first-in-class drug targeting CD123, approved for treatment of blastic plasmacytoid dendritic cell neoplasm.', \"Tagraxofusp is a targeted therapy drug that combines interleukin-3 with a truncated diphtheria toxin. It specifically targets CD123 on cancer cells, and it's used primarily to treat blastic plasmacytoid dendritic cell neoplasm, a rare type of blood cancer\", 'Tagraxofusp is a recombinant molecule composed of human interleukin-3 that binds CD123 on neoplastic cells fused to a truncated diphtheria toxin (DT).', 'Tagraxofusp is a CD123-targeting drug that is used to treat blastic plasmacytoid dendritic cell neoplasm. It consists of the ligand for CD123, interleukin 3.', 'Tagraxofusp, also known as SL-401, is a first-in-class therapeutic agent that combines human interleukin-3 with a truncated diphtheria toxin. It specifically targets CD123 on cancer cells and is approved for treating blastic plasmacytoid dendritic cell neoplasm.', 'Tagraxofusp, also known as SL-401, is a recombinant drug that targets CD123 on neoplastic cells. It consists of interleukin-3 fused to a truncated diphtheria toxin payload. The drug is approved for the treatment of blastic plasmacytoid dendritic cell neoplasm and is the first-in-class drug targeting CD123.', \"Tagraxofusp, also known as SL-401, is a first-in-class drug that targets CD123. It's made up of a recombinant molecule combining human interleukin-3, which binds to CD123 on neoplastic cells, with a truncated diphtheria toxin. This drug is approved for treating blastic plasmacytoid dendritic cell neoplasm.\", 'Tagraxofusp (or SL-401) is a recombinant molecule composed of human interleukin-3 that binds CD123 on neoplastic cells fused to a truncated diphtheria toxin (DT). It is a CD123-targeting drug approved for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) and other CD123-positive myeloid malignancies.', 'Tagraxofusp is a first-in-class drug targeting CD123 approved for treatment of blastic plasmacytoid dendritic cell neoplasm. It is a recombinant molecule composed of human interleukin-3 fused to a truncated diphtheria toxin payload.', 'Tagraxofusp is a CD123-targeting drug consisting of interleukin-3 (IL-3) fused to a truncated diphtheria toxin (DT). IL-3 binds to CD123 expressed on neoplastic cells, allowing the targeted delivery of the cytotoxic DT payload.', 'Tagraxofusp is a targeted therapy drug that combines interleukin-3 with a truncated diphtheria toxin. It specifically targets CD123 on cancer cells, and is primarily used to treat blastic plasmacytoid dendritic cell neoplasm, a rare type of blood cancer', 'Tagraxofusp, also known as SL-401, is a CD123-targeting drug composed of human interleukin-3 fused to a truncated diphtheria toxin payload. It is a first-in-class drug approved for the treatment of blastic plasmacytoid dendritic cell neoplasm.', 'Tagraxofusp is a CD123-targeting drug that consists of the ligand for CD123, interleukin 3.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nTagraxofusp, also known as Elzonris, is a CD123-targeted cytotoxin that has been approved by the US Food and Drug Administration (FDA) for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and children aged 2 years and older. It is a recombinant fusion protein that consists of interleukin-3 (IL-3) fused to a truncated diphtheria toxin payload. This combination allows the drug to selectively target and kill cancer cells that express CD123, a protein that is overexpressed in BPDCN. Tagraxofusp works by binding to CD123 on the surface of cancer cells, translocating the diphtheria toxin into the cytosol, and causing cell death.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers all essential aspects of Tagraxofusp as per the reference answers. It mentions the drug's alternative name (Elzonris), its mechanism as a CD123-targeted cytotoxin, its composition (recombinant fusion protein with IL-3 and truncated diphtheria toxin), its FDA approval for BPDCN in adults and children, and its mechanism of action (targeting CD123 and causing cell death). This aligns well with the detailed reference answers provided.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and avoids including irrelevant information. It sticks to key points: the drug's target, structure, approval status, and therapeutic use. There is no extraneous detail that deviates from the core description of Tagraxofusp.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer is concise and does not repeat the same information in different ways. Each piece of information is presented clearly and only once, such as the drug's mechanism of action, its composition, and its clinical application.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to follow. The sentences are logically connected, and the vocabulary is appropriately technical yet accessible. The description of the drug's mechanism is particularly clear and demonstrates high readability."
    },
    {
        "Question": "What is the epidemiology of breast cancer in men?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the epidemiology of breast cancer in men?\n\nHere are some reference answers:\n\n**Reference Answers:**\n[\"The epidemiology of breast cancer in men is similar to that of female breast cancer. However, male breast cancer accounts for less than 1% of all cancers in men and less than 1% of all breast cancers. Despite its rarity, the incidence of male breast cancer has been increasing over the past 25 years. The major risk factors for the development of male breast cancer include advancing age, hormonal imbalance, radiation exposure, and a family history of breast cancer. BRCA2 gene mutations are the most common genetic risk factor for male breast cancer. Male breast cancer is often diagnosed at a later stage than female breast cancer, with higher-grade tumors and lower estrogen receptor positivity. The incidence of lobular breast cancer is rare in men, but Paget's disease and papillary carcinoma occur more frequently in men than in women. Localized breast cancer is the most common stage at diagnosis for both men\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, breast cancer in men is a rare type of cancer that affects the breast tissue, accounting for less than 1% of all breast cancer cases. It is associated with increased longevity, obesity, testicular diseases and tumors, and germline mutations of BRCA2. \n\nA systematic review and meta-analysis were conducted to evaluate the risk of breast cancer in transgender individuals, but the results are not specified in the provided data. \n\nThe incidence of breast cancer in men is not explicitly stated in the provided data, but it is mentioned that men have a lower risk of breast cancer than women. \n\nThe treatment of breast cancer in men is not discussed in the provided data, but it is mentioned that breast cancer is a type of cancer that can be associated with RET amplification and other genetic alterations.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 2,
        "Information Recall Explanation": "The answer covers some key points about male breast cancer but misses several crucial details from the reference answers, such as the increasing incidence, major risk factors (e.g., advancing age, hormonal imbalance, radiation exposure, family history), and the specifics about tumor characteristics (higher-grade tumors, lower estrogen receptor positivity). The mention of RET amplification is irrelevant to the epidemiology question.",
        "Information Precision Score": 2,
        "Information Precision Explanation": "The answer includes some irrelevant details (e.g., RET amplification, treatment, and transgender individuals' meta-analysis) that are not pertinent to the epidemiology of male breast cancer. These detract from the precision of the response and do not align with the reference answers.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. Each point is introduced once without redundancy.",
        "Readability Score": 3,
        "Readability Explanation": "The answer is somewhat readable but suffers from abrupt shifts and tangential information (e.g., transgender individuals' meta-analysis and RET amplification). This disrupts the flow and clarity, making it less fluent than it could be."
    },
    {
        "Question": "What disease can be treatment with Bulevirtide?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat disease can be treatment with Bulevirtide?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Bulevirtide can be used for chronic hepatitis D virus infection.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBulevirtide is a treatment for Chronic Hepatitis D (CHD), a severe form of viral hepatitis caused by the hepatitis D virus (HDV). It is also used to treat Hepatitis B virus (HBV) and Hepatitis D virus (HDV) coinfection.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer correctly identifies Bulevirtide as a treatment for Chronic Hepatitis D (CHD) and mentions the hepatitis D virus (HDV). However, it includes an incorrect claim about treating Hepatitis B virus (HBV), which is not supported by the reference answer. This detracts from full recall accuracy.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer introduces an irrelevant claim about treating Hepatitis B virus (HBV), which is not mentioned in the reference. This reduces precision, despite accurately mentioning Chronic Hepatitis D (CHD) and HDV.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information. It provides a clear and concise description without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, easily readable, and fluent. It conveys the information clearly and effectively."
    },
    {
        "Question": "Which initial chemotherapy regimen is the most appropriate in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhich initial chemotherapy regimen is the most appropriate in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Neoadjuvant mFOLFOXIRI regimens improved pCR rate and survival outcome, reduced the rate of distant metastasis and anastomotic fistula when comparing with propensity-score matched controls of mFOLFOX6 neoadjuvant chemotherapy.', 'In Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients, the most appropriate initial chemotherapy regimen often includes cycles of induction chemotherapy, such as FOLFIRINOX or fluorouracil, leucovorin, and oxaliplatin, followed by chemoradiotherapy to improve pathological complete response rates and facilitate the delivery of chemotherapy before surgery.', 'The initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is a combination of chemoradiotherapy, FOLFOX, and CAPOX.', 'The most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is induction chemotherapy followed by chemoradiotherapy (CRT) and consolidation chemotherapy. The specific regimen can vary, including options such as CapeOx (capecitabine and oxaliplatin), FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin), or 5-fluorouracil and leucovorin with or without oxaliplatin. The choice of regimen may depend on factors such as patient characteristics, tumor stage, and potential side effects.', 'The optimal initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is still not established. However, FOLFOXIRI (5-fluorouracil, leucovorin, oxaliplatin, and irinotecan) appears to be a promising option as suggested by some studies. The decision should be individualized and discussed with patients.', \"The choice of initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients depends on various factors such as patient's overall health, potential toxicities, and the risk of distant metastasis. Some studies have shown promising results with FOLFOXIRI as the initial chemotherapy regimen in TNT, while others have used TEGAFIRI or CAPOX. However, it is important to note that these studies are still ongoing and their safety and feasibility need to be further evaluated. In Japan, a phase II trial is currently underway to evaluate the safety and activity of a TNT strategy including SCRT, intensified consolidation treatment with FOLFOXIRI and delayed surgery. After protocol amendment, the treatment seems feasible without safety concern. Ultimately, the most appropriate initial chemotherapy regimen in TNT for locally advanced rectal cancer patients will depend on the results of ongoing clinical trials and individual patient characteristics.\", 'Based on the provided information, both CAPEOX (capecitabine plus oxaliplatin) and FOLFIRINOX appear to be effective induction chemotherapy regimens as part of total neoadjuvant therapy (TNT) for locally advanced rectal cancer.\\n\\nCAPEOX is mentioned in several studies as the induction chemotherapy given prior to chemoradiotherapy and consolidation chemotherapy. FOLFIRINOX is also noted to have established efficacy, significantly increasing 3-year disease-free survival when used as neoadjuvant therapy.\\n\\nThe most appropriate regimen may depend on individual patient factors and institutional protocols. However, both CAPEOX and FOLFIRINOX seem to be valid options for induction chemotherapy in the TNT approach for locally advanced rectal cancer patients, with the goal of improving pathologic complete response rates and facilitating delivery of systemic therapy.', 'The most appropriate initial chemotherapy regimen in total neoadjuvant therapy (TNT) for locally advanced rectal cancer patients is a combination of fluoropyrimidine-based chemotherapy, such as capecitabine or 5-fluorouracil (5-FU), with oxaliplatin (FOLFOX or CAPOX). This regimen has been shown to improve tumor response rates and increase the likelihood of achieving a complete pathological response. It is important to note that the choice of chemotherapy regimen may vary depending on individual patient factors and institutional protocols.', 'The most appropriate chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is mFOLFOXIRI.', 'mFOLFOXIRI', 'Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients, the most appropriate initial chemotherapy regimen is mFOLFOXIRI neoadjuvant chemotherapy, which has shown improved pCR rate, survival outcome, and reduced the rate of distant metastasis and anastomotic fistula compared to other regimens.', 'In Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients, the mFOLFOXIRI regimen has shown promising results, including improved pathological complete response (pCR) rates, better survival outcomes, reduced distant metastasis rates, and lower incidences of anastomotic fistulas compared to other regimens like mFOLFOX6.', 'The most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer appears to be the neoadjuvant mFOLFOXIRI regimen. This regimen has shown to improve the pathological complete response (pCR) rate and survival outcomes, as well as reduce the rate of distant metastasis and anastomotic fistula compared to mFOLFOX6, according to studies with propensity-score matched controls.', 'mFOLFOXIRI is the most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients.', 'The most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is mFOLFOXIRI.', 'The most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is mFOLFOXIRI. This regimen has been shown to improve pCR rate and survival outcome, reduce the rate of distant metastasis and anastomotic fistula when compared with mFOLFOX6 neoadjuvant chemotherapy.', 'In Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer, the most appropriate initial chemotherapy regimen can vary based on specific patient factors and treatment goals. However, regimens like mFOLFOXIRI have shown promising results in improving the pathological complete response (pCR) rate and survival outcomes, as well as reducing the rate of distant metastasis and anastomotic fistula compared to mFOLFOX6. This makes mFOLFOXIRI a strong candidate for initial chemotherapy in TNT settings', 'According to a randomized phase III trial published in The Lancet Oncology in 2018, the most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is mFOLFOXIRI (oxaliplatin, leucovorin, irinotecan, and fluorouracil) followed by short-course radiotherapy (SCRT) and delayed surgery, as compared to the standard of care, which is preoperative radiotherapy (PRT) followed by surgery. The study found that the mFOLFOXIRI-SCRT-surgery arm had a higher pathological complete response (pCR) rate (34% vs 16%) and a lower rate of distant metastases (11% vs 19%) than the PRT-surgery arm. However, the overall survival and local recurrence rates were similar between the two arms. It is essential to note that the decision to use TNT should be individualized based on patient factors and multidisciplinary team discussion.', 'In Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients, the most appropriate initial chemotherapy regimen could be preoperative induction or consolidation with a range of options such as FOLFOXIRI, FOLFOX, or CAPEOX. However, the decision should be individualized based on patient and tumor characteristics and clinician experience.', 'The most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is mFOLFOXIRI. This regimen has been shown to improve pathological complete response (pCR) rates and survival outcomes, as well as reduce the risk of distant metastasis and anastomotic fistula, compared to other neoadjuvant chemotherapy regimens such as FOLFOX or CAPEOX. The mFOLFOXIRI regimen has become a new standard of care for locally advanced rectal cancer patients undergoing TNT.', 'The neoadjuvant mFOLFOXIRI regimen is most appropriate in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients, as it has shown improved pathological complete response rate and survival outcomes, along with reduced rates of distant metastasis and anastomotic fistula.', 'The most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is mFOLFOXIRI (modified FOLFOXIRI). This regimen has been shown to improve the pathological complete response (pCR) rate, reduce the rate of distant metastasis, and improve survival outcomes compared to other regimens, such as mFOLFOX6. However, it is important to consider individual patient factors and discuss treatment options with a multidisciplinary team to determine the most suitable regimen for each patient.', 'The most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is the modified FOLFOXIRI (mFOLFOXIRI), which has been demonstrated to improve pathological complete response rate and survival outcomes compared with propensity-score matched controls receiving mFOLFOX6 neoadjuvant chemotherapy. Additionally, mFOLFOXIRI reduces the rates of distant metastasis and anastomotic fistula.', 'The choice of initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is still a matter of debate. However, a recent study found that neoadjuvant mFOLFOXIRI chemotherapy improved pathological complete response rate, survival outcome, and reduced distant metastasis and anastomotic fistula rates compared to propensity-score matched controls of mFOLFOX6 neoadjuvant chemotherapy. This suggests that mFOLFOXIRI could be a more appropriate initial chemotherapy regimen in TNT for locally advanced rectal cancer patients. However, it is important to consider the higher incidence of grade III and/or IV nausea and/or vomiting associated with mFOLFOXIRI. Further studies are needed to confirm these findings and establish the optimum combination, sequence, or duration of TNT.', 'Based on the provided information, FOLFOXIRI appears to be the most appropriate initial chemotherapy regimen for Total Neoadjuvant Therapy (TNT) in patients with locally advanced rectal cancer. The abstracts mention that FOLFOXIRI is a potential chemotherapy option in the neoadjuvant setting, and that neoadjuvant mFOLFOXIRI regimens improved pathologic complete response (pCR) rate, survival outcomes, and reduced distant metastasis and anastomotic fistula rates compared to mFOLFOX6 neoadjuvant chemotherapy.', 'The most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients includes options like FOLFOXIRI, FOLFOX, or CAPEOX, with mFOLFOXIRI showing improved outcomes in some studies.', 'The most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is mFOLFOXIRI (modified FOLFOXIRI). This regimen has been shown to improve pathological complete response (pCR) rates, survival outcomes, and reduce the rate of distant metastasis and anastomotic fistula compared to other regimens like mFOLFOX6. Therefore, mFOLFOXIRI is recommended as the preferred choice for initial chemotherapy in TNT for locally advanced rectal cancer patients.', 'The most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is FOLFOXIRI.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the data, the most commonly used initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab. This regimen has been shown to improve progression-free survival and overall survival in patients with locally advanced rectal cancer. However, the optimal regimen may vary depending on individual patient factors, such as performance status, comorbidities, and tumor characteristics.\n\nAccording to the data, FOLFOXIRI plus bevacizumab has been used in several clinical trials, including the TRIBE study, which demonstrated improved progression-free survival and overall survival compared to FOLFIRI plus bevacizumab. Additionally, FOLFOXIRI plus bevacizumab has been shown to be effective in patients with RAS and BRAF wild-type tumors.\n\nOther chemotherapy regimens, such as FOLFIRI, FOLFOX, and CAPOX, have also been used in TNT for locally advanced rectal cancer, but FOLFOXIRI plus bevacizumab appears to be the most commonly used and effective regimen.\n\nIt is essential to note that the choice of chemotherapy regimen should be individualized based on the patient's specific characteristics and medical history, and should be discussed with a healthcare provider or oncologist.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "3",
        "Information Recall Explanation": "The answer correctly identifies FOLFOXIRI as a commonly used regimen in TNT for locally advanced rectal cancer, aligning with the reference answers. However, it inaccurately includes bevacizumab, which is not mentioned in the references. Additionally, the answer misses other relevant regimens like mFOLFOXIRI, which is prominently cited in the references.",
        "Information Precision Score": "2",
        "Information Precision Explanation": "The answer introduces bevacizumab, which is irrelevant to the references and thus lowers precision. Despite correctly noting FOLFOXIRI, the inclusion of unspecified clinical trials (e.g., TRIBE study) and non-reference drugs dilutes the precision.",
        "Information Repetition Score": "4",
        "Information Repetition Explanation": "The answer does not excessively repeat the same information. However, it redundantly emphasizes the effectiveness of FOLFOXIRI plus bevacizumab across different sentences.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured, logically organized, and easily understandable. The language is clear and professional, making it highly readable."
    },
    {
        "Question": "In what part of the cell would a SNARE Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) be found",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIn what part of the cell would a SNARE Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) be found\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (R-SNAREs) mainly promoted the assembly of the SNARE complex to drive the final membrane fusion step of membrane transport', 'Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) can be found in various parts of the cell, including the plasma membrane, endoplasmic reticulum, Golgi apparatus, and synaptic vesicles. They are involved in mediating membrane fusion and play a crucial role in intracellular vesicle trafficking, neurotransmitter release, and other cellular processes.', 'Astrocytes, the most abundant glial cells in the central nervous system (CNS), sense synaptic activity and respond through the release of gliotransmitters, a process mediated by intracellular Ca. In these cells, SNARE Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) are found on vesicles membranes and contribute to the docking and fusion of vesicles with the cell membrane, allowing the release of gliotransmitters to the extracellular space.', 'Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) would be found in nerve terminals, synaptic vesicles, and in nerve terminals.', 'SNAREs are found in the plasma membrane of neuronal presynaptic terminals.', 'SNAREs (Soluble N-ethylmaleimide-sensitive factor attachment protein receptors) are specialized proteins, involved in the process of vesicle fusion in a cell. They are typically located in the plasma membrane and vesicle membrane.', 'A SNARE Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) would be found in presynaptic terminals and perisynaptic astrocytic processes.', '\\nSNAREs are transmembrane proteins found in various organelles and vesicles involved in vesicle trafficking and secretion, such as synaptic vesicles, endoplasmic reticulum (ER), Golgi apparatus, and lysosomes. In synapses, SNAREs are located in both presynaptic and postsynaptic membranes.', 'SNARE proteins are primarily found in nerve terminals, synaptic vesicles, endosomes, and the astrocytic plasma membrane.', 'SNAREs are found in the trans-Golgi network.', 'SNARE soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) are transmembrane proteins found in the endosomal/lysosomal system.', 'SNAREs are found in the plasma membrane and vesicles.', 'SNAREs are found in nerve terminals and synaptic vesicles.', 'Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) are found in the membrane.', 'SNAREs are found in the plasma membrane of cells.', 'Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) would be found in secretory vesicles.', 'SNAREs are found in the plasma membrane of the cell, where they play a crucial role in membrane fusion and transport.', \"SNARE proteins are located in the cell's membranes, including those of synaptic vesicles and the plasma membrane.\", 'The SNARE Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) are found in the cell membrane.', 'SNAREs are typically found in the membranes of cells where they play a crucial role in the process of membrane fusion.', 'SNAREs are found in the cell membrane.', 'SNARE proteins are primarily found in the cytoplasm of cells, where they play a crucial role in membrane fusion and intracellular transport processes.', 'SNAREs, including Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs), are found in the Golgi apparatus and endoplasmic reticulum of the cell.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data provided, SNAREs are associated with the following cellular components:\n\n* VESICLE TRAFFICKING (relation id 13, rank 19)\n* VESICLE SNARES (relation id 11, rank 20)\n* SNARES (relation id 12, rank 20)\n* SNARE COMPLEX (relation id 19, rank 11)\n* SNARE (relation id 32, rank 5)\n* SNARE PROTEINS (relation id 30, rank 6)\n* SNARE (relation id 33, rank 10)\n\nBased on this information, it appears that SNAREs are involved in various cellular processes, including vesicle trafficking, membrane fusion, and protein transport. However, their specific location within the cell is not explicitly stated in the provided data.\n\nHowever, based on general knowledge, SNAREs are typically found on the surface of vesicles, such as synaptic vesicles, endosomes, and lysosomes, as well as on the plasma membrane and other organelle membranes. They play a crucial role in facilitating the fusion of vesicles with target membranes, allowing for the transport of molecules between different cellular compartments.\n\nTherefore, while the provided data does not specify the exact location of SNAREs within the cell, it is generally accepted that they are found on the surface of various cellular membranes and vesicles.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer mentions the general locations of SNAREs (vesicles, plasma membrane, organelle membranes) and their role in membrane fusion, which aligns with the reference answers. However, it lacks specific details like synaptic vesicles, endoplasmic reticulum, Golgi apparatus, and nerve terminals that are present in the reference answers.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise in stating where SNAREs are typically found and their role in cellular processes, without including irrelevant information. However, it could be more specific about certain organelles as seen in the reference answers.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. It clearly differentiates between the provided data and general knowledge, maintaining a good flow without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to read. It logically separates the analysis of provided data from general knowledge, making it clear and understandable."
    },
    {
        "Question": "Relevance of tumoral microbiome.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nRelevance of tumoral microbiome.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The tumoral microbiome (TM) has been linked to cancer prognosis and is garnering progressively greater consideration as an essential facet of the tumor microenvironment that regulates tumor proliferation and affects cancer prognosis. The TM plays an important role in the formation of the tumor microenvironment, regulation of local immunity, and modification of tumor cell biology, and directly affects the efficacy of drug treatment for tumors. Recent studies have begun to highlight the diverse and tumor-specific microbiomes across multiple cancer types. New evidence suggests that microbes are also present in many tumors, though the scope of how they affect tumor biology and clinical outcomes is in its early stages. In cancer patients, the clinical response to checkpoint-based immunotherapy is associated with the composition and functional quality of the host microbiome. Our study suggests novel microbiome-specific/derived biomarkers for checkpoint immunotherapy response prediction and prognosis in lung cancer.', 'The tumoral microbiome, which refers to the specific microorganisms residing in and around tumor tissues, plays a significant role in cancer development and progression. This is particularly relevant in obesity-associated malignancies such as colorectal, gastric, and liver cancers. Dysbiosis, or the imbalance of these gut microorganisms, can alter metabolite profiles and increase levels of carcinogenic toxins like Bacteroides fragilis toxin and colibactin, which contribute to oncogenesis—the process of tumor formation. Understanding the relationship between the gut microbiome and tumor development can help in creating targeted therapies and improving treatment responsiveness.', 'The tumoral microbiome refers to the microorganisms and their secreted bioactive metabolites that are present within the tumor microenvironment. These microorganisms and their metabolites can contribute to the initiation and progression of cancer by modulating the immune response, promoting inflammation, and altering the metabolic profile of the tumor. Additionally, the tumoral microbiome can impact cancer treatment responsiveness by affecting drug metabolism and drug resistance. Therefore, understanding the tumoral microbiome is crucial for developing precision cancer therapeutics that target microorganisms or their secreted bioactive metabolites.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe tumoral microbiome, also known as the tumor microbiome, refers to the community of microorganisms that live within and around a tumor. Research has shown that the tumoral microbiome plays a crucial role in cancer development and progression, as well as in the response to cancer therapies.\n\nStudies have identified various microorganisms that are associated with different types of cancer, including colorectal cancer, breast cancer, and lung cancer. The tumoral microbiome has been shown to influence cancer progression through several mechanisms, including:\n\n1. Modulating the immune system: The tumoral microbiome can modulate the immune system, either by suppressing or enhancing the immune response, which can affect the growth and spread of cancer cells.\n2. Producing metabolites: The tumoral microbiome can produce metabolites that can affect the tumor microenvironment, promoting or inhibiting cancer growth and progression.\n3. Interacting with cancer cells: The tumoral microbiome can interact with cancer cells, influencing their behavior and survival.\n4. Modulating chemotherapy and radiation therapy: The tumoral microbiome can affect the efficacy of chemotherapy and radiation therapy, either by enhancing or reducing their effectiveness.\n\nThe tumoral microbiome has also been shown to be a potential biomarker for cancer diagnosis and prognosis. For example, certain microorganisms have been associated with poor prognosis in colorectal cancer patients.\n\nIn terms of relevance, the tumoral microbiome has significant implications for cancer treatment and management. Understanding the composition and function of the tumoral microbiome can help identify new therapeutic targets and strategies for cancer treatment. Additionally, the tumoral microbiome may be used as a biomarker for monitoring cancer progression and response to treatment.\n\nSome of the key findings related to the tumoral microbiome include:\n\n* The tumoral microbiome is composed of a diverse community of microorganisms, including bacteria, viruses, and fungi.\n* The tumoral microbiome is influenced by the host's genetic and environmental factors, such as diet, lifestyle, and exposure to antibiotics.\n* The tumoral microbiome can be altered by cancer therapies, such as chemotherapy and radiation therapy.\n* The tumoral microbiome can affect the efficacy of cancer therapies and the development of resistance to treatment.\n* The tumoral microbiome has been associated with poor prognosis in various types of cancer, including colorectal cancer.\n\nOverall, the tumoral microbiome is a complex and dynamic ecosystem that plays a crucial role in cancer development and progression. Further research is needed to fully understand the mechanisms by which the tumoral microbiome influences cancer and to explore its potential as a biomarker and therapeutic target.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer comprehensively covers the relevance of the tumoral microbiome, mentioning its role in cancer development, progression, and therapy response. It also includes details on mechanisms (immune modulation, metabolite production, interaction with cancer cells, and therapy modulation) and potential uses as biomarkers. This aligns well with the reference answers.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise and stays focused on the tumoral microbiome, avoiding irrelevant details. It directly addresses how the microbiome affects cancer and therapy, mirroring the key points from the reference answers without straying into unrelated topics.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer avoids repetition, presenting information in a structured manner with clear, distinct points. Each section of the answer builds on the previous one without redundant statements, similar to the reference answers.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-written, logically organized, and easy to follow. It uses clear language and transitions smoothly between points, making it highly readable and understandable, much like the reference answers."
    },
    {
        "Question": "What disease is treated with Teplizumab?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat disease is treated with Teplizumab?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Teplizumab is a CD3-directed monoclonal antibody that was approved for type 1 diabetes (T1D) and was shown to delay the onset of Stage 3 T1D in adults and pediatric patients 8 years of age and older with Stage 2 T1D, based on results of a clinical trial in high-risk relatives of individuals with T1D.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nTeplizumab is a medication used to treat Type 1 Diabetes Mellitus (T1DM). It is a disease-modifying therapy that targets the immune system to delay the onset of clinical type 1 diabetes in high-risk individuals and preserve beta-cell function in patients with new-onset type 1 diabetes.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer captures all the necessary information from the reference answer, including that Teplizumab is used to treat Type 1 Diabetes Mellitus (T1DM), its role as a disease-modifying therapy, and its ability to delay the onset of clinical type 1 diabetes in high-risk individuals while preserving beta-cell function.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information. It focuses solely on Teplizumab's indication for Type 1 Diabetes Mellitus and its mechanism of action in delaying onset and preserving beta-cell function.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each point is clearly stated without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, easily readable, and fluent. It uses clear and concise language to convey the information effectively."
    },
    {
        "Question": "Is Trifluridine/Tipiracil a preferential treatment over Regorafenib in elderly colorectal cancer patients?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs Trifluridine/Tipiracil a preferential treatment over Regorafenib in elderly colorectal cancer patients?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Although no difference in overall survival was found between the two drugs in adjusted analysis using propensity score, regorafenib showed favorable survival in patients aged <65 years, whereas trifluridine/tipiracil was favored in patients aged ≥65 years in the subgroup analysis', 'Trifluridine/tipiracil is a preferential treatment over regorafenib in elderly colorectal cancer patients, as shown in clinical trials and real-world studies. In a phase III randomized controlled trial, trifluridine/tipiracil demonstrated superior overall survival and progression-free survival compared to placebo in patients with metastatic colorectal cancer who had been previously treated with standard chemotherapies. Additionally, a cost-effectiveness analysis showed that trifluridine/tipiracil is more clinically and cost-effective than regorafenib, with better outcomes at reduced costs. In real clinical practice, a retrospective study found that the effectiveness results of standard clinical practice are lower than those described in clinical trials and the literature, but trifluridine/tipiracil has a better toxicity profile compared to regorafenib. Therefore, trifl', 'A recent study suggested that Trifluridine/Tipiracil and Regorafenib have comparable efficacy and safety in elderly patients with refractory metastatic colorectal cancer (mCRC)', \"Trifluridine/Tipiracil (TAS-102) is generally preferred over Regorafenib as a treatment option for elderly colorectal cancer patients due to its favorable safety profile and efficacy in this population. Clinical studies have shown that TAS-102 provides significant survival benefits and manageable side effects compared to Regorafenib, making it a more suitable choice for elderly patients with colorectal cancer. However, the choice between these two treatments should be individualized based on factors such as patient's overall health, treatment goals, and potential drug interactions.\", \"There is no definitive answer to this question, as the choice of treatment for elderly colorectal cancer patients should be individualized based on the patient's overall health, comorbidities, and personal preferences. Both Trifluridine/Tipiracil and Regorafenib are approved treatment options for patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild type, an anti-EGFR therapy.\\n\\nA phase III clinical trial (RECOURSE) compared Trifluridine/Tipiracil to placebo in patients with metastatic colorectal cancer who had been previously treated with standard chemotherapy and found a significant improvement in overall survival and progression-free survival.\\n\\nAnother phase III clinical trial (CORRECT) compared Regorafenib to placebo in patients with metastatic colorectal cancer who had been previously treated with standard chemotherapy and found a significant improvement in overall survival.\\n\\nA retrospective study of 102 elderly patients with metastatic colorectal cancer who received Trifluridine/Tipiracil or Regorafenib as third-line treatment found that Trifluridine/Tipiracil was associated with a trend towards better overall survival compared to Regorafenib (median 7.1 vs 5.3 months, p=0.057). However, this study was not randomized and had a small sample size.\\n\\nTherefore, it is not possible to say that Trifluridine/Tipiracil is a preferential treatment over Regorafenib in elderly colorectal cancer patients based on the current evidence. It is important to consider the individual patient's characteristics and to discuss the potential benefits and risks of each treatment option with the patient.\", 'Trifluridine/tipiracil (FTD/TPI) is not clearly preferable over regorafenib in older patients with metastatic colorectal cancer. Both have similar efficacy and tolerability.', 'Based on the available literature, Trifluridine/Tipiracil (FTD/TPI) appears to be a more cost-effective treatment option compared to Regorafenib in elderly patients with refractory metastatic colorectal cancer. The study showed that FTD/TPI had a lower expected cost per patient and a lower cost-effectiveness ratio compared to Regorafenib. Additionally, FTD/TPI can be safely administered while maintaining efficacy in patients who are ineligible for Regorafenib due to comorbidities. However, it is important to consider individual patient factors and preferences when making treatment decisions.', 'According to a subgroup analysis of a clinical trial, in elderly colorectal cancer patients (aged ≥65 years), Trifluridine/Tipiracil (FTD/TPI) was found to have better disease control and tumor response compared to Regorafenib. However, in the adjusted analysis using propensity score, there was no significant difference in overall survival between the two drugs. In patients aged <65 years, Regorafenib showed favorable survival, while FTD/TPI was favored in patients aged ≥65 years. Therefore, the choice of treatment between FTD/TPI and Regorafenib in elderly colorectal cancer patients should be individualized based on factors such as age, overall health, and other clinical considerations.', 'Yes, Trifluridine/Tipiracil (FTD/TPI) is favored as a treatment over Regorafenib in elderly colorectal cancer patients aged ≥65 years. The subgroup analysis showed that Trifluridine/Tipiracil had a more favorable survival outcome in this age group, with a hazard ratio (HR) of 0.78 (95% CI, 0.59-1.03), indicating a lower risk of death compared to Regorafenib.', 'Yes, patients treated with FTD/TPI had better tumor response and disease control than patients treated with regorafenib', 'Yes, Trifluridine/Tipiracil is a preferential treatment over Regorafenib in elderly colorectal cancer patients based on the favorable survival outcomes observed in patients aged ≥65 years.', 'Yes, Trifluridine/Tipiracil (FTD/TPI) appears to be a more favorable treatment option for elderly colorectal cancer patients, specifically those aged 65 years and older, as it showed better survival outcomes in this age group compared to Regorafenib', 'Although no difference in overall survival was found between the two drugs in adjusted analysis using propensity score, regorafenib showed favorable survival in patients aged <65 years, whereas trifluridine/tipiracil was favored in patients aged ≥65 years in the subgroup analysis.', 'yes, Trifluridine/Tipiracil (FTD/TPI) appears to be a more favorable treatment option for elderly colorectal cancer patients aged 65 years and older. In the subgroup analysis, Trifluridine/Tipiracil showed better survival outcomes in this age group with a hazard ratio (HR) of 0.78, which suggests a lower risk of death compared to Regorafenib.', \"According to a subgroup analysis of a clinical trial, Trifluridine/Tipiracil (FTD/TPI) was found to have better tumor response and disease control in elderly colorectal cancer patients (aged ≥65 years) compared to Regorafenib. However, in an adjusted analysis using propensity score, there was no significant difference in overall survival between the two drugs in the overall population. In the subgroup analysis, Regorafenib showed favorable survival in patients aged <65 years, while FTD/TPI was favored in patients aged ≥65 years. Therefore, the choice of treatment between FTD/TPI and Regorafenib may depend on the patient's age and other clinical factors. It is always recommended to consult with a healthcare provider for personalized treatment recommendations.\", 'Regorafenib and trifluridine/tipiracil hydrochloride (TFTD) are novel antitumor agents for patients with refractory metastatic colorectal cancer. In this study, we report the survival benefits of TFTD and Regorafenib in elderly frail patients with metastatic colorectal cancer.', 'Yes, Trifluridine/Tipiracil is preferred for patients aged 65 and above.', 'yes, trifluridine/tipiracil is favored in patients aged ≥65 years for treating colorectal cancer, as it showed better survival rates in this age group compared to regorafenib.', 'Based on the available evidence, Trifluridine/Tipiracil (FTD/TPI) may be a preferential treatment over Regorafenib in elderly colorectal cancer patients. A retrospective cohort study showed that FTD/TPI had better tumor response and disease control rates compared to Regorafenib in patients with refractory metastatic colorectal cancer. Subgroup analysis also suggested that early use of FTD/TPI may have clinical benefits in second- or third-line therapy. However, further studies are needed to confirm these findings and identify predictive biomarkers to guide treatment selection.', 'According to the retrospective study conducted at a tertiary oncology center, Trifluridine/Tipiracil (FTD/TPI) appears to be a preferential treatment over Regorafenib in elderly colorectal cancer patients. In the subgroup analysis of patients aged ≥65 years, FTD/TPI showed better overall survival compared to Regorafenib, with an adjusted hazard ratio of 0.78 (95% CI, 0.59-1.03). This suggests that in elderly patients with metastatic colorectal cancer refractory to standard chemotherapy, FTD/TPI may be a better treatment option than Regorafenib. However, it is important to note that this study has limitations as an observational study and further research is needed to confirm these findings.', 'Yes, Trifluridine/Tipiracil (FTD/TPI) appears to be a preferential treatment over Regorafenib in elderly colorectal cancer patients aged ≥65 years. While regorafenib showed favorable survival in patients aged <65 years, FTD/TPI was favored in patients aged ≥65 years based on the subgroup analysis. Additionally, patients treated with FTD/TPI had better tumor response and disease control compared to those treated with regorafenib.', 'Yes, trifluridine/tipiracil (FTD/TPI) is favored in patients aged ≥65 years for treating colorectal cancer, as indicated by the subgroup analysis showing better survival outcomes in this age group compared to regorafenib.', 'Based on the subgroup analysis, Trifluridine/Tipiracil (FTD/TPI) is favored as a treatment option over Regorafenib in elderly colorectal cancer patients (aged ≥65 years). The analysis showed that FTD/TPI had better tumor response and disease control in this age group. Although there was no significant difference in overall survival between the two drugs in the adjusted analysis, FTD/TPI showed a favorable survival trend in elderly patients compared to Regorafenib. Therefore, FTD/TPI may be considered as a preferential treatment for elderly colorectal cancer patients.', 'Yes, Trifluridine/Tipiracil (FTD/TPI) is a preferential treatment over Regorafenib in elderly colorectal cancer patients, as it has been shown to have better tumor response and disease control.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the answer to your question is that Trifluridine/Tipiracil may be a preferential treatment over Regorafenib in elderly colorectal cancer patients, especially when considering the safety profile and effectiveness.\n\nFrom the Relations table, we can see that Trifluridine/Tipiracil is used to treat refractory metastatic colorectal cancer in elderly patients (Relation 18), and it has been shown to have a survival benefit in patients with unresectable colorectal cancer when compared to the best supportive care (Relation 1).\n\nAdditionally, the Sources table mentions a study (Source 3) that discusses the use of Trifluridine/Tipiracil and Regorafenib in older patients with metastatic colorectal cancer, and it highlights the importance of considering the age of the patient when choosing the best therapy. The study suggests that Trifluridine/Tipiracil may be a better option for older patients due to its safety profile and effectiveness.\n\nHowever, it's essential to note that the answer is not definitive, as the data does not provide a direct comparison between Trifluridine/Tipiracil and Regorafenib in elderly patients. Further research and clinical trials would be necessary to confirm the preferential treatment status of Trifluridine/Tipiracil over Regorafenib in this patient population.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer captures the key points from the reference answers, mentioning the preferential treatment status of Trifluridine/Tipiracil in elderly patients based on safety and effectiveness. However, it misses some detailed findings like the subgroup analysis showing better survival outcomes in patients aged ≥65 years.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer focuses on pertinent information regarding the comparison of Trifluridine/Tipiracil and Regorafenib, with no irrelevant details. However, it could explicitly include the hazard ratio (HR) and age-specific subgroup data for better precision.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer avoids repetition and presents information concisely, covering safety, effectiveness, and the need for further research without redundancy.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is clearly written and logically structured, making it easy to follow. However, integrating statistical details like the HR could enhance completeness without significantly impacting readability."
    },
    {
        "Question": "What is the function of Diphthamide?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the function of Diphthamide?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Diphthamide is a post-translationally modified histidine residue of eukaryotic TRANSLATION ELONGATION FACTOR2 (eEF2),', 'Diphthamide is involved in the synthesis and function of translation in human development, cancer, and infectious diseases.', 'Diphthamide serves as the only target for diphtheria toxin and Pseudomonas aeruginosa exotoxin A, providing protection against ribosome-inactivating proteins (RIPs) and promoting the accuracy of translation elongation factor 2 (eEF-2) during protein synthesis.', 'Diphthamide is a post-translationally modified histidine residue found in eukaryotic elongation factor-2 (eEF-2). It plays a crucial role in protein synthesis by ensuring the fidelity of mRNA translation. Diphthamide is essential for normal physiological functions and is uniquely targeted by ADP-ribosylating toxins, such as diphtheria toxin, in bacterial pathogenesis. Loss of diphthamide can lead to hypersensitivity to certain toxins and activation of specific cellular pathways, making it a key target for various therapeutic strategies and a critical factor in cellular protection against ribosome-inactivating proteins.', 'Diphthamide is a protein that is involved in the regulation of protein function in cells. It is a protein that is able to disrupt protein-protein interactions and is a direct protein target for thalidomide teratogenicity and antitumor activity of immunomodulatory drugs (IMiDs).', 'Diphthamide is a unique post-translationally modified histidine residue that serves as the only target for diphtheria toxin and Pseudomonas aeruginosa exotoxin A, and it also plays a role in promoting the accuracy of eEF-2 performance during translation.', 'Diphthamide is a unique post-translationally modified histidine residue that is required for and serves as the site of ADP-ribosylation.', 'Diphthamide serves as the only target for diphtheria toxin and Pseudomonas aeruginosa exotoxin A, provides protection against ricin, and promotes the accuracy of elongation factor 2 (eEF-2) performance during protein synthesis translation.', 'Diphthamide is a post-translational modification of elongation factor 2 (eEF2) that is found in all eukaryotes. It is a highly conserved modification of archaeal and eukaryal translation elongation factor 2 (EF2) and yet why cells need EF2 to contain diphthamide is unclear', 'Diphthamide is a conserved modification in archaeal and eukaryal translation elongation factor 2 (EF2). Its name refers to the target function for diphtheria toxin, the regulation of diphthamide, and importantly, its ill-defined biological role.', 'Diphthamide is a post-translational modification of histidine that occurs in archaeal and eukaryotic translation elongation factor 2 (eEF2). This modification serves as the target for ADP-ribosylation by diphtheria toxin, which inhibits protein synthesis and can be lethal to cells.', 'Diphthamide is a modified histidine residue which is uniquely present in archaeal and eukaryotic elongation factor 2 (EF-2), an essential GTPase responsible for catalyzing the coordinated translocation of tRNA and mRNA through the ribosome.', 'Diphthamide, a unique post-translationally modified histidine residue, serves as the sole target for diphtheria toxin and Pseudomonas aeruginosa exotoxin A. It is also involved in the ADP-ribosylation process and plays a role in protecting against ricin. Furthermore, diphthamide promotes the accuracy of eEF-2 performance during translation.', 'Diphthamide functions as a post-translational modification on eukaryotic translation elongation factor eEF2, essential for its proper activity in protein synthesis.', 'Diphthamide is involved in the ADP-ribosylation of eukaryotic elongation factor 2 (eEF2).', '* Diphthamide plays a role in protein biosynthesis by acting as a target for diphtheria toxin.\\n* Diphthamide enhances the efficiency of transcription, but not translation elongation.\\n* Diphthamide is a key component of the elongation factor eEF2 that helps protein synthesis.\\n* Diphthamide functions as a specific modification of the side chain of a histidine residue of eukaryotic elongation factor 2 that is necessary for the activity of diphtheria toxin.\\n* Diphthamide is a post-translational modification of the histidine residue in position 715 of eukaryotic translation elongation factor 2 (eEF2).', 'Diphthamide catalyzes the ADP-ribosylation of a post-translationally modified histidine on eukaryotic elongation factor 2 (eEF2).', 'Diphthamide is a post-translationally modified histidine residue of eukaryotic TRANSLATION ELONGATION FACTOR2 (eEF2) and is synthesized via a complex, multi-enzyme pathway.', '1. Diphthamide is involved in the activation of eEF2 kinase (calcium/calmodulin-dependent protein kinase III) that phosphorylates eEF2, preventing its interaction with ribosomes.\\n2. Diphthamide is also responsible for binding of the diphtheria toxin and Pseudomonas exotoxin A to eEF2.', 'Diphthamide is involved in the ADP-ribosylation of a post-translationally modified histidine on eukaryotic elongation factor 2 (eEF2), which is crucial for protein synthesis.', 'Diphthamide is a modified histidine residue on eukaryotic translation elongation factor 2 (eEF2) that plays a role in the ADP-ribosylation process. This modification is crucial for the proper functioning of eEF2 during protein synthesis.', 'Diphthamide is a post-translational modification of eukaryotic translation elongation factor 2 (EEF2). Its function is to contribute to the functionality of the translational machinery, regulating growth and translation elongation. Loss of diphthamide impairs translational fidelity, leading to increased rates of ribosomal frameshifting and premature termination.', 'Diphthamide is a post-translationally modified histidine residue of eukaryotic TRANSLATION ELONGATION FACTOR2 (eEF2) It is synthesized via a complex, multi-enzyme pathway. It catalyzes the ADP-ribosylation of a post\\xa0translationally\\xa0modified histidine (diphthamide) on eukarian elongation factor 2 (EEF2)', 'Diphthamide is a post-translationally modified histidine residue found on eukaryotic translation elongation factor 2 (eEF2). It is synthesized via a complex, multi-enzyme pathway and is conserved across eukaryotes.', 'Diphthamide is a post-translational modification of eukaryotic elongation factor 2 (eEF2). Its function is to catalyze the ADP-ribosylation of a post-translationally modified histidine on eEF2.', 'Diphthamide is a post-translationally modified histidine residue of eukaryotic TRANSLATION ELONGATION FACTOR2 (eEF2). Its function is to regulate the activity of eEF2, which is involved in the process of protein synthesis.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nDiphthamide is a post-translationally modified histidine residue found in the translation elongation factor 2 (eEF2) protein. It is a unique modification that is conserved in all eukaryotes and archaebacteria. The function of diphthamide is not entirely clear, but it is believed to play a role in maintaining translational fidelity by preventing spurious frameshifting during translation elongation.\n\nStudies have shown that loss of diphthamide leads to increased resistance to certain translation inhibitors, such as sordarin, and increased frameshifting at non-programmed sites during translation elongation. Additionally, ribosome profiling of yeast and mammalian cells lacking diphthamide reveals increased ribosomal drop-off during elongation, suggesting that diphthamide helps to maintain the fidelity of translocation during translation elongation.\n\nDiphthamide is also the target of ADP-ribosylating toxins, such as diphtheria toxin and Pseudomonas aeruginosa exotoxin A, which inhibit translation by ADP-ribosylating the diphthamide residue on eEF2. However, the presence of diphthamide is not essential for cell viability, and its function has not been fully resolved.\n\nOverall, while the exact function of diphthamide is still unclear, it is thought to play a role in maintaining the fidelity of translation elongation and preventing frameshifting, and its modification is a target for certain bacterial toxins.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers the key aspects of diphthamide, including its presence as a post-translationally modified histidine residue in eEF2, its conservation across eukaryotes and archaebacteria, its role in translational fidelity, and its role as a target for ADP-ribosylating toxins. It also mentions the effects of diphthamide loss, such as increased resistance to translation inhibitors and ribosomal drop-off, which are detailed in the reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and sticks to relevant information about diphthamide. It avoids irrelevant details and focuses on its functional roles (e.g., translational fidelity) and biological significance (e.g., toxin target). There are no extraneous facts that deviate from the topic.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer presents information concisely without repetition. Each point about diphthamide—its structural nature, functional roles, and implications of its loss—is discussed once, efficiently contributing to a clear understanding.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured and easy to follow. The sentences are clear and logically ordered, making the explanation fluent and accessible. Technical terms are appropriately introduced and explained, enhancing comprehension."
    },
    {
        "Question": "Without immunization, rabies is a lethal disease.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWithout immunization, rabies is a lethal disease.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Rabies lethality is close to 100% without immunization.', 'Rabies is a zoonotic disease caused primarily by the rabies virus (RABV) and is considered fatal without vaccination or treatment. The RABV infects the central nervous system, leading to symptoms such as fever, headache, fatigue, nausea, and ultimately progressing to more severe neurological signs like seizures, paralysis, and encephalitis. Without immunization through vaccination or post-exposure prophylaxis, rabies is almost always fatal once clinical symptoms appear.', 'Yes, without immunization, rabies is almost always a lethal disease. Rabies is a viral encephalitis that is statistically 100% fatal if left untreated. However, rabies is also one of the few infectious diseases that can be prevented through vaccination, providing almost 100% protection if administered early enough after exposure.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, that's correct. According to the data, rabies is a lethal zoonotic disease that is transmitted to humans primarily through dog bites. The data also mentions that rabies is responsible for an estimated 60,000 annual fatalities worldwide.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "2",
        "Information Recall Explanation": "The answer correctly confirms that rabies is lethal without immunization and adds context about zoonotic transmission via dog bites and global fatalities. However, it misses key details from the reference answers, such as the 100% fatality rate without vaccination, the role of post-exposure prophylaxis, and the progression of neurological symptoms.",
        "Information Precision Score": "3",
        "Information Precision Explanation": "The answer provides relevant information about rabies transmission and fatalities but includes some non-essential details (e.g., global fatality numbers) that were not requested in the original question. The core idea (lethality without immunization) is accurate but slightly diluted.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat the same information. It succinctly states the key points without redundancy.",
        "Readability Score": "4",
        "Readability Explanation": "The answer is clear and fluent, with no grammatical issues. However, structuring the information to match the reference answers' precision (e.g., emphasizing the near 100% fatality rate) could improve readability further."
    },
    {
        "Question": "What is the target of Divarasib?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the target of Divarasib?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Divarasib is a KRAS G12C inhibitor.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe target of Divarasib is the KRAS G12C mutation.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately reports the target of Divarasib as the KRAS G12C mutation, which aligns perfectly with the reference answer ('Divarasib is a KRAS G12C inhibitor.').",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is concise and directly addresses the question without including any irrelevant information.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information; it clearly states the target once.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is clear, fluent, and easily understandable."
    },
    {
        "Question": "What is the appropriate treatment in HER2Neu amplificated refractory advanced colorectal cancer patients?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the appropriate treatment in HER2Neu amplificated refractory advanced colorectal cancer patients?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Tucatinib plus trastuzumab had clinically meaningful anti-tumour activity and favourable tolerability', '1) HER2Neu amplification occurs in approximately 2-5% of colorectal cancer patients. 2) Chemotherapy with standard agents such as oxaliplatin or irinotecan and fluoropyrimidines remains the first-line treatment in HER2Neu amplified refractory advanced colorectal cancer. 3) Trastuzumab, an anti-HER2Neu monoclonal antibody, has shown promising results in combination with standard chemotherapy in patients with HER2Neu amplified metastatic colorectal cancer.', 'In HER2Neu amplified refractory advanced colorectal cancer patients, appropriate treatments may include targeted therapies such as trastuzumab deruxtecan, dual HER2-targeted therapy with pertuzumab plus trastuzumab, or the combination of trastuzumab and lapatinib. These treatments have shown promising activity and tolerability in patients with HER2-positive metastatic colorectal cancer who have developed resistance to standard therapies. Additionally, novel targeted treatments under development, such as anti-ERBB2 therapeutic strategies, may also be considered as potential options for these patients.', 'The appropriate treatment for HER2Neu amplified refractory advanced colorectal cancer patients is trastuzumab (Herceptin).', 'The appropriate treatment in HER2Neu amplified refractory advanced colorectal cancer patients includes the use of neratinib, trastuzumab deruxtecan, and trastuzumab.', '-In HER2Neu amplificated refractory advanced colorectal cancer patients, anti-HER2 therapies have shown promising activity. \\n-Anti-HER2 therapies include trastuzumab and lapatinib, and these should be considered as potential therapeutic options in this specific patient population. \\n-Currently, there are no formal recommendations for the use of anti-HER2 therapies in refractory colorectal cancer, and further studies are needed to establish the optimal treatment approach.', 'The appropriate treatment in HER2Neu amplificated refractory advanced colorectal cancer patients is the combination of pyrotinib and trastuzumab.', 'HER2Neu amplification is a molecular alteration that can lead to resistance to anti-EGFR monoclonal antibodies (mAbs) in colorectal cancer (CRC). Recent evidence suggests that anti-ERBB2 therapeutic strategies, such as trastuzumab deruxtecan, are active in patients with ERBB2-positive metastatic CRC and could potentially represent a new standard-of-care. Pyrotinib is a promising new candidate for salvage therapy in patients with HER2-positive metastatic CRC who have developed resistance to trastuzumab and lapatinib. Dual HER2-targeted therapy with pertuzumab plus trastuzumab is also an option for patients with heavily pretreated, HER2-amplified metastatic CRC. Rechallenge with anti-EGFR inhibitors, in case of persistent or recovery of RAS-wildness, and targeted approach of specific mutations (BRAF inhibitors), amplifications (anti-Her2 treatment), or fusion proteins (NTRK inhibitors) can be guided by the use of next-generation sequencing (NGS).', 'The appropriate treatment in HER2Neu amplificated refractory advanced colorectal cancer patients is the combination of trastuzumab and lapatinib.', 'Currently, the optimal treatment in HER2Neu amplificated refractory advanced colorectal cancer patients is not well established. Targeted therapy for patients with HER2/neu amplification in refractory mCRC is still being evaluated. HER2/neu amplification occurs in a minority of patients with refractory mCRC (2-6%), and data on treatment of HER2/neu amplified mCRC is still limited. However, several studies are underway to evaluate the role of anti-HER2/neu agents (trastuzumab or trastuzumab deruxtecan) in this subgroup.', 'For patients with advanced colorectal cancer and HER2Neu amplification who have not responded to prior treatments, recommended therapies include tucatinib plus trastuzumab, trastuzumab deruxtecan, pyrotinib and trastuzumab, or neratinib combined with cetuximab.', 'Trastuzumab plus erlotinib is the standard of care for HER2-amplified, treatment-refractory metastatic colorectal cancer.', 'The appropriate treatment for HER2Neu amplified refractory advanced colorectal cancer (mCRC) remains an area of active research and debate. While the HERACLES trial did not meet its primary endpoint of objective response rate, the combination of pertuzumab and trastuzumab deruxtecan demonstrated promising disease control rates and progression-free survival in this patient population. Additionally, a real-world study found that regorafenib plus PD-1 inhibitor therapy was effective in refractory microsatellite stable mCRC with ERBB2/ERBB3 mutation. However, there is currently no standard of care for HER2Neu amplified refractory advanced colorectal cancer patients. Clinical trials are ongoing to further evaluate the safety and efficacy of these and other treatment regimens in this population.', 'Cetuximab plus bevacizumab is an effective treatment for HER2Neu amplified refractory advanced colorectal cancer patients.', 'The appropriate treatment for HER2Neu amplified refractory advanced colorectal cancer patients may include combination targeted therapy with agents such as trastuzumab and lapatinib, which have shown activity in other HER2-positive malignancies. Additionally, enrollment in clinical trials exploring novel HER2-targeted therapies or combinatorial strategies could offer potential benefits for these patients who are resistant to standard treatments.', 'Trastuzumab deruxtecan showed promising and durable activity in HER2-positive metastatic colorectal cancer refractory to standard treatment, with a safety profile consistent with that reported in previous trastuzumab deruxtecan trials.', 'The appropriate treatment for HER2Neu amplified refractory advanced colorectal cancer patients would be regorafenib plus PD-1 inhibitor therapy, as this combination has shown promising efficacy in a real-world study. Patients with ERBB2/ERBB3 mutation may be the preferred population for this combination regimen.', 'The recommended treatments for HER2Neu amplificated refractory advanced colorectal cancer patients are trastuzumab deruxtecan, neratinib, and tucatinib plus trastuzumab.', 'For patients with HER2-amplified metastatic colorectal cancer refractory to standard treatment, anti-HER2 targeted therapies have shown promising activity. Potential treatment options include:\\n\\n- Dual HER2-targeted therapy with trastuzumab plus pertuzumab\\n- Trastuzumab deruxtecan \\n- Combination of trastuzumab and lapatinib\\n- Pyrotinib (for patients resistant to trastuzumab and lapatinib)\\n\\nRecent evidence suggests anti-HER2 strategies could potentially represent a new standard of care in this patient population. However, secondary resistance to HER2-targeted agents can occur in most cases.', 'In HER2neu amplificated refractory advanced colorectal cancer patients, the appropriate treatment option is the combination of HER2-targeted therapy with chemotherapy. This can include the use of trastuzumab, a monoclonal antibody targeting HER2, in combination with chemotherapy agents such as 5-fluorouracil (5-FU) or oxaliplatin. The addition of trastuzumab to chemotherapy has shown improved outcomes in HER2-positive colorectal cancer patients, including increased response rates and prolonged survival. However, further studies are needed to determine the optimal treatment regimen and the role of other HER2-targeted agents in this patient population.', 'Tucatinib plus trastuzumab had clinically meaningful anti-tumour activity and favourable tolerability. This treatment is the first US Food and Drug Administration-approved anti-HER2 regimen for metastatic colorectal cancer and is an important new treatment option for chemotherapy-refractory HER2-positive metastatic colorectal cancer.', 'It is currently assumed that patients who have received standard chemotherapy and have no evidence of recurrent disease should be treated with targeted therapy alone. In particular, HER2-positive patients who have received chemotherapy and have a good performance status should be treated with a combination of targeted therapy and chemotherapy.', 'Tucatinib plus trastuzumab had clinically meaningful anti-tumour activity and favourable tolerability, making it the appropriate treatment in HER2Neu amplificated refractory advanced colorectal cancer patients.', 'Tucatinib plus trastuzumab has shown clinically meaningful anti-tumour activity and favorable tolerability in patients with HER2-positive metastatic colorectal cancer refractory to chemotherapy. This treatment regimen is the first FDA-approved anti-HER2 therapy for metastatic colorectal cancer, providing an important new treatment option for patients with this condition.', 'The most appropriate treatment in HER2Neu amplificated refractory advanced colorectal cancer patients is tucatinib plus trastuzumab.', \"The appropriate treatment for HER2-positive refractory advanced colorectal cancer patients is the combination of tucatinib and trastuzumab. This regimen has shown clinically meaningful anti-tumor activity and is well-tolerated. It's significant as it's the first FDA-approved anti-HER2 therapy for metastatic colorectal cancer, offering a new treatment option for those with chemotherapy-refractory disease.\", 'The recommended treatment for HER2Neu amplificated refractory advanced colorectal cancer patients is Tucatinib plus trastuzumab.', 'Tucatinib plus trastuzumab has clinically meaningful anti-tumour activity and favourable tolerability in HER2Neu amplificated refractory advanced colorectal cancer patients. This treatment is the first US Food and Drug Administration-approved anti-HER2 regimen for metastatic colorectal cancer and is an important new treatment option for chemotherapy-refractory HER2-positive metastatic colorectal cancer.', ' The appropriate treatment for advanced coloreCTal cancer with H ER-pos and SCFV translocation is a multidrug approach involving the use of monoclonal antibodies, antibody-drug conjugates, and immune checkpoint inhibitors. ideal_answer: The appropriate treatment for advanced coloreCTal cancer with H ER-pos and SCFV translocation is a multidrug approach involving the use of monoclonal antibodies, antibody-drug conjugates, and immune checkpoint inhibitors. This approach combines the targeted elimination of cancer cells with the activation of the immune system to recognize and eliminate tumor cells. ', 'Tucatinib plus trastuzumab is the appropriate treatment in HER2Neu amplificated refractory advanced colorectal cancer patients.', 'The appropriate treatment for HER2Neu amplified refractory advanced colorectal cancer patients is a combination of tucatinib and trastuzumab. This regimen has shown clinically meaningful anti-tumor activity and is well-tolerated, making it a significant new option for patients whose cancer has not responded to chemotherapy', 'Tucatinib plus trastuzumab is the first US Food and Drug Administration-approved anti-HER2 regimen for metastatic colorectal cancer and is an important new treatment option for chemotherapy-refractory HER2-positive metastatic colorectal cancer.', \"The appropriate treatment for HER2-positive refractory advanced colorectal cancer patients is the combination of tucatinib and trastuzumab. This regimen has shown clinically meaningful anti-tumor activity and is well-tolerated. It's also the first FDA-approved anti-HER2 therapy specifically for metastatic colorectal cancer, making it a significant new option for patients who have not responded to chemotherapy.\", 'The appropriate treatment for HER2Neu amplificated refractory advanced colorectal cancer patients is tucatinib (a small molecule HER2 inhibitor) in combination with trastuzumab (a monoclonal antibody against HER2). This treatment was recently approved by the US Food and Drug Administration for this specific patient population who have previously received chemotherapy. This is the first approved anti-HER2 regimen for metastatic colorectal cancer.', 'The new treatment option for refractory HER2-positive metastatic colorectal cancer is Tucatinib plus trastuzumab. It is a US Food and Drug Administration-approved anti-HER2 regimen for metastatic colorectal cancer.', 'The appropriate treatment for HER2-positive, metastatic colorectal cancer patients who have not responded to chemotherapy is Tucatinib plus trastuzumab, which is the first US Food and Drug Administration-approved anti-HER2 regimen for this condition.', 'HER2 amplification and/or activating mutations are present in 4% of metastatic colorectal cancers. To date, there are no approved therapies for HER2-positive metastatic colorectal cancer. Tucatinib plus trastuzumab is the first US Food and Drug Administration-approved anti-HER2 regimen for metastatic colorectal cancer.', 'For patients with HER2Neu amplified refractory advanced colorectal cancer, the combination of Tucatinib and Trastuzumab is a clinically meaningful and FDA-approved treatment option.', 'The appropriate treatment for HER2Neu amplified, chemotherapy-refractory advanced colorectal cancer patients is the combination of tucatinib plus trastuzumab. This regimen has demonstrated clinically meaningful anti-tumor activity and favorable tolerability in this patient population. It is the first US Food and Drug Administration-approved anti-HER2 regimen for metastatic colorectal cancer, making it an important new treatment option for these patients.', 'The appropriate treatment for HER2-positive refractory advanced colorectal cancer patients is tucatinib plus trastuzumab. This regimen has shown clinically meaningful anti-tumor activity and favorable tolerability.', 'The appropriate treatment in HER2Neu amplificated refractory advanced colorectal cancer patients is the combination of tucatinib and trastuzumab. This treatment has shown clinically meaningful anti-tumor activity and favorable tolerability, making it the first FDA-approved anti-HER2 regimen for metastatic colorectal cancer. It is an important new treatment option for patients with chemotherapy-refractory HER2-positive metastatic colorectal cancer.', 'The FDA approved combination of trastuzumab and pertuzumab for use in metastatic breast cancer has shown promising results in HER2-positive refractory advanced colorectal cancer patients, with an objective response rate (ORR) of 38% and a disease control rate (DCR) of 76.9%. This treatment regimen is currently being evaluated for its safety and efficacy in larger clinical trials, making it a potential new option for patients with HER2-positive metastatic colorectal cancer who have progressed on standard chemotherapy regimens.', \"The study suggests that tucatinib plus trastuzumab has clinically meaningful anti-tumor activity and favorable tolerability in patients with HER2Neu amplificated refractory advanced colorectal cancer. This treatment is the first US Food and Drug Administration-approved anti-HER2 regimen for metastatic colorectal cancer and is an important new treatment option for chemotherapy-refractory HER2-positive metastatic colorectal cancer. Therefore, it would be appropriate to consider tucatinib plus trastuzumab as a treatment option for these patients. However, it is essential to consider each patient's individual circumstances and potential risks and benefits when making treatment decisions.\", 'Tucatinib plus trastuzumab is an appropriate treatment option for HER2-positive metastatic colorectal cancer patients who are refractory to chemotherapy.', 'The appropriate treatment for HER2Neu amplificated refractory advanced colorectal cancer patients is the combination of tucatinib and trastuzumab. This treatment has shown clinically meaningful anti-tumour activity and favorable tolerability. It is the first FDA-approved anti-HER2 regimen for metastatic colorectal cancer and provides an important new treatment option for patients who have not responded to chemotherapy.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided tables and sources, the treatment for HER2Neu amplified refractory advanced colorectal cancer patients is a topic of ongoing research and development.\n\nAccording to the tables, several clinical trials and studies have investigated the use of HER2-targeted therapies in patients with HER2-amplified metastatic colorectal cancer. Some of these studies have shown promising results, including:\n\n* The HERACLES-A trial, which demonstrated that dual HER2 blockade with trastuzumab and lapatinib led to inhibition of tumor growth in patient-derived xenografts of HER2-amplified metastatic colorectal cancer.\n* The MyPathway trial, which showed that pertuzumab plus trastuzumab had a potential overall survival benefit for patients with HER2-amplified, treatment-refractory metastatic colorectal cancer.\n* The DESTINY-CRC01 trial, which is investigating the use of trastuzumab deruxtecan (DS-8201) in patients with HER2-amplified metastatic colorectal cancer.\n\nBased on these studies, it appears that HER2-targeted therapies, such as trastuzumab, lapatinib, pertuzumab, and trastuzumab deruxtecan, may be effective in treating HER2-amplified refractory advanced colorectal cancer patients. However, more research is needed to confirm these findings and to determine the optimal treatment strategy for this patient population.\n\nIn summary, the appropriate treatment for HER2Neu amplified refractory advanced colorectal cancer patients is likely to involve HER2-targeted therapies, such as trastuzumab, lapatinib, pertuzumab, and trastuzumab deruxtecan. However, further research is needed to confirm the efficacy and safety of these treatments and to determine the optimal treatment strategy for this patient population.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "4",
        "Information Recall Explanation": "The answer captures key points from the reference answers, mentioning HER2-targeted therapies such as trastuzumab, lapatinib, pertuzumab, and trastuzumab deruxtecan. It also references notable studies (HERACLES-A, MyPathway, DESTINY-CRC01). However, it does not mention newer approved treatments like tucatinib plus trastuzumab, which is highlighted in many reference answers.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer is mostly precise, focusing on HER2-targeted therapies and relevant clinical trials without straying into irrelevant details. However, the omission of tucatinib plus trastuzumab, despite being FDA-approved in this setting, slightly reduces precision.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat the same information unnecessarily. Each point is distinct and contributes to a cohesive summary of the treatment landscape.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand. It presents complex medical information clearly and logically, making it accessible to the intended audience."
    },
    {
        "Question": "What is a basket trial?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is a basket trial?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The phase II basket trial in oncology is a novel design that enables the simultaneous assessment of treatment effects of one anti-cancer targeted agent in multiple cancer types.', 'A basket trial is a type of clinical trial that tests the effects of an investigational drug on multiple diseases or conditions that share certain characteristics, for example, the presence of a particular gene mutation.', 'A basket trial is a type of clinical trial in which eligibility is based on the presence of a specific genomic alteration, irrespective of cancer type.', 'A basket trial is a type of clinical trial for which eligibility is based on the presence of a specific genomic alteration, irrespective of cancer type.', 'A basket trial is a clinical study that enrolls participants with diverse tumor types but with a common molecular target.', 'A basket trial is a type of clinical trial in which a single intervention is investigated in multiple patient subgroups, or \"baskets,\" based on specific molecular alterations or biomarkers, irrespective of cancer type.', '\\nA basket trial is a type of clinical trial that evaluates the effectiveness of a single drug or treatment across multiple types of cancer or diseases that have a common genetic mutation or biomarker, rather than targeting a specific cancer type.', 'A basket trial is a type of clinical trial that tests the effectiveness of a single drug or therapeutic approach on multiple diseases or conditions, based on the presence of specific molecular characteristics or biomarkers, rather than the location or type of disease.', 'A basket trial is a type of clinical trial in which a new treatment is tested on various types of cancer, regardless of their location in the body.', 'A basket trial is a clinical trial that treats patients with similar types of cancer using different treatments, and it is used to compare the efficacy of different treatments.', '\\nA basket trial is a type of clinical trial that evaluates the effectiveness of a targeted therapy in patients with different types of cancer who share a common genetic mutation or biomarker, rather than limiting the trial to a specific type of cancer.', 'Basket trials are increasingly used for the simultaneous evaluation of a new treatment in various patient subgroups under one overarching protocol.', 'simultaneous evaluation of a new treatment in various patient subgroups under one overarching protocol', 'Basket trials are used to evaluate new drug or treatment efficacy in heterogeneous patient populations.', 'A basket trial is a novel study design that allows for the evaluation of a new treatment in multiple patient subgroups or different types of cancer under one overarching protocol.', 'A basket trial is a novel design that enables the simultaneous assessment of treatment effects of one anti-cancer targeted agent in multiple cancer types.', 'A basket trial is a type of clinical trial design that allows for the simultaneous evaluation of a new treatment in various patient subgroups under one overarching protocol.', 'A basket trial evaluates a new treatment in various patient subgroups under one overarching protocol.', 'A basket trial is a novel study design that allows for the evaluation of a single targeted therapy across multiple cancer types simultaneously.', 'A basket trial is a type of clinical trial that tests how well a new drug works on multiple, different types of cancer that all share a specific genetic mutation. It allows researchers to evaluate the effectiveness of the drug across various cancer types under one overarching study protocol', 'A basket trial is a design for simultaneously evaluating a new treatment in various patient subgroups under one overarching protocol.', 'A basket trial is a type of clinical trial that evaluates the effectiveness of a new treatment in various patient subgroups under one overarching protocol. In oncology, a phase II basket trial allows for the simultaneous assessment of treatment effects of one anti-cancer targeted agent in multiple cancer types.', 'A basket trial is a type of clinical trial that evaluates the efficacy of a single treatment in multiple patient subgroups.', 'Basket trials are increasingly used for the simultaneous evaluation of a new treatment in various patient subgroups under one overarching protocol. The phase II basket trial in oncology is a novel design that enables the simultaneous assessment of treatment effects of one anti-cancer targeted agent in multiple cancer types.', 'A basket trial is a clinical trial design that enables the simultaneous evaluation of a new treatment in various patient subgroups with different cancer types under one overarching protocol.', 'A basket trial is a type of clinical trial that evaluates the effectiveness of a new treatment in multiple patient subgroups under one overarching protocol.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nA basket trial is a type of clinical trial design that evaluates the effectiveness of a single treatment across multiple patient populations, or \"baskets,\" based on the presence of a specific molecular alteration or biomarker, rather than traditional histology-based approaches. In a basket trial, patients are grouped into baskets according to their tumor type, and the treatment is tested in each basket to identify which patients are most likely to benefit from it. This design allows for the evaluation of a treatment in multiple cancer types simultaneously, which can be more efficient and cost-effective than running multiple separate trials. Basket trials are often used in oncology to evaluate targeted therapies for specific genetic alterations or biomarkers, and they have the potential to revolutionize cancer treatment by identifying effective therapies for patients based on their individual molecular characteristics.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer thoroughly covers all essential aspects of a basket trial, including its design, purpose, grouping criteria ('baskets'), and its application in oncology. It matches well with the reference answers, noting the evaluation of a single treatment across multiple patient populations based on molecular alterations or biomarkers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and focuses strictly on the concept of basket trials. It avoids any irrelevant details, sticking to the core definition and applications without straying into unrelated clinical trial types or unnecessary elaborations.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each sentence contributes new and distinct details about basket trials, from their design to their benefits and specific use cases in oncology.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is exceptionally clear and fluent. It logically progresses from defining a basket trial to explaining its structure and advantages, making it easy to understand even for readers unfamiliar with clinical trial designs."
    },
    {
        "Question": "What are atypical symptoms of gluten allergy?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are atypical symptoms of gluten allergy?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Atypical symptoms of gluten allergy, such as celiac disease, can include peripheral neuropathy, cerebellar ataxia, laryngospasm, enamel defects, aphthous stomatitis, neuromuscular symptoms, skin rash, insomnia, abnormal taste, impaired memory, and concentration, among others. These symptoms may not be the typical gastrointestinal manifestations commonly associated with gluten-related disorders like diarrhea, weight loss, and abdominal pain. It is important to consider a wide range of symptoms when diagnosing gluten allergies to ensure proper treatment and management.', \"While celiac disease (CD) is an immune reaction to gluten, not all individuals with CD present with classic symptoms such as diarrhea, bloating, and abdominal pain. Some people with CD may have atypical symptoms, which can include:\\n\\n1. Fatigue and weakness\\n2. Weight loss or weight gain\\n3. Iron-deficiency anemia\\n4. Bone or joint pain\\n5. Depression or anxiety\\n6. Tingling or numbness in the hands and feet\\n7. Skin rashes or itching\\n8. Neurological symptoms such as seizures, migraines, or neuropathy\\n9. Dental enamel defects or tooth discoloration\\n10. Infertility or menstrual irregularities\\n\\nIt's essential to note that these symptoms can also be caused by other medical conditions, and a diagnosis of CD should be confirmed through blood tests and intestinal biopsy.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, atypical symptoms of gluten allergy can include:\n\n* Irritability (mentioned in relation to atypical coeliac disease)\n* Anaemia (mentioned in relation to atypical coeliac disease)\n* Rickets (mentioned in relation to atypical coeliac disease)\n* Dermatitis herpetiformis (mentioned in relation to atypical coeliac disease)\n* Alopecia (mentioned in relation to atypical coeliac disease)\n* Intussusception (mentioned in relation to atypical coeliac disease)\n* Extreme thrombocytosis and severe anemia (mentioned in relation to a case report of celiac disease presenting atypically)\n* Non-gastrointestinal symptoms such as numbness in hands and feet, marked thinness, and electrolyte imbalance (mentioned in relation to a case report of celiac disease presenting atypically)\n\nIt's worth noting that these symptoms may not be exhaustive, and atypical symptoms of gluten allergy can vary widely from person to person.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers a range of atypical symptoms but misses some key ones mentioned in the reference answers, such as peripheral neuropathy, cerebellar ataxia, and enamel defects. However, it includes several relevant symptoms like anemia, dermatitis herpetiformis, and alopecia.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer lists specific symptoms without unnecessary details, but it includes 'Intussusception,' which is a very rare and less typical symptom, potentially making it less precise compared to the reference answers.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each symptom is mentioned only once, and the response is concise.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-structured and easy to read. The bullet-point format enhances readability, though the mention of 'extreme thrombocytosis and severe anemia' could be phrased more fluently."
    },
    {
        "Question": "Is transdermal glyceryl trinitrate effective for stroke?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs transdermal glyceryl trinitrate effective for stroke?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['No. Transdermal glyceryl trinitrate is not effective for stroke treatment.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the effectiveness of transdermal glyceryl trinitrate (GTN) for stroke is inconclusive. \n\nThe RIGHT-2 trial, a multicenter, randomized, sham-controlled, blinded-endpoint, phase 3 trial, investigated the effect of transdermal GTN in patients with ultra-acute presumed stroke. The trial found no difference in the modified Rankin Scale (mRS) between the GTN group and the sham group at day 90 and day 365. However, subgroup analyses suggested that GTN may be associated with a worse outcome in patients with intracerebral hemorrhage and a better outcome in patients with a mimic diagnosis.\n\nAnother study, Prehospital transdermal glyceryl trinitrate for ultra-acute ischaemic stroke: data from the RIGHT-2 randomised sham-controlled ambulance trial, found that GTN did not improve clinical outcomes in patients with ischaemic stroke.\n\nTherefore, the current evidence suggests that transdermal glyceryl trinitrate may not be effective for stroke, but further research is needed to confirm these findings.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer provides information from studies (RIGHT-2 trial and another related study) that closely align with the reference answer, which states that transdermal glyceryl trinitrate is not effective for stroke treatment. The answer also acknowledges the need for further research, which is not part of the reference answer but is not incorrect.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer includes details from specific studies, which is precise, but it slightly strays from the direct simplicity of the reference answer by discussing subgroup analyses and mimic diagnoses. While these are not irrelevant, they are more detailed than necessary compared to the reference.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information unnecessarily. Each point is distinct and contributes relevant details without redundancy.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-structured and fluent, making it easy to follow. It could be slightly simpler to better match the directness of the reference answer, but it remains clear and accessible."
    },
    {
        "Question": "What is the mechanism by which the microbiota modulates the effectiveness of immunotherapy?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the mechanism by which the microbiota modulates the effectiveness of immunotherapy?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The microbiota may affect tumor immunity by regulating the host immune system and tumor microenvironment. Some bacteria help fight tumors by activating immunity, while some bacteria mediate immunosuppression to help cancer cells escape from the immune system.', 'The mechanism by which the microbiota modulates the effectiveness of immunotherapy is not fully understood, but several interlacing mechanisms have been proposed. The gut microbiota can activate pattern recognition receptors, such as Toll-like receptors, which can stimulate the immune system and enhance the activity of immune cells. The gut microbiota can also engage in molecular mimicry, where they produce molecules that mimic those produced by cancer cells, leading to an immune response against the cancer cells. Additionally, the gut microbiota can impact the metabolism of drugs and nutrients, which can affect the efficacy of chemotherapy and immunotherapy. Furthermore, the gut microbiota can modulate the activity of immune cells, such as T-cells and dendritic cells, which play a crucial role in the immune response against cancer. Overall, the gut microbiota', '1) The microbiota influences the systemic immune system and the presence of Bacteroides fragilis in the gut enhances the efficacy of anti-PD1 checkpoint inhibitor therapy in mice and humans.\\n2) The microbiota influences local inflammation of the tumor and the presence of Bacteroides thetaiotaomicron is associated with increased CD8 T cell activity in the tumor microenvironment, leading to better treatment responses in mice treated with anti-CTLA-4 and anti-PD1 antibodies.', \"The gut microbiota modulates the effectiveness of immunotherapy by influencing antitumor immunity through metabolites that impact local and systemic immune responses, reprogramming the tumor microenvironment's immunity, affecting both anti-tumor and pro-tumor immune responses, regulating the overall efficacy of cancer immunotherapies, and enhancing the activity of immunotherapies through microbially derived vitamins and modulation of costimulatory pathways.\", 'The microbiota modulates the effectiveness of immunotherapy through several mechanisms, including:1. Modulation of the immune system: The microbiota can modulate the immune system by altering the composition of immune cells and cytokines, which can affect the efficacy of immunotherapy.2. Production of anti-tumor factors: The microbiota can produce anti-tumor factors, such as bacteriocins, that can enhance the effectiveness of immunotherapy.3. Modulation of the gut barrier: The microbiota can modulate the gut barrier, which can affect the delivery of immunotherapy to the tumor site.4. Inflammation: The microbiota can modulate inflammation, which can affect the efficacy of immunotherapy.5. Metabolism: The microbiota can modulate the metabolism of immunotherapy, which can affect its efficacy.', 'The mechanism by which the microbiota modulates the effectiveness of immunotherapy is through general immunomodulation, increasing cells that specifically respond to antigens of both microbial and tumor origin, metabolism, and degradation (utilization) of drug compounds. Additionally, the metabolite butyrate of the gut microbiota facilitates the efficacy of anti-PD-1 immunotherapy by modulating TCR signaling of cytotoxic CD8 T cells. Furthermore, favorable microbiota modulation is associated with increased intratumoral infiltration of CD8+ effector T cells. Molecular mimicry between melanoma and Bifidobacterium-derived epitopes may favor activation of cross-reactive T cells, and downregulation of the PD-L2-RGMb pathway is a specific mechanism by which the gut microbiota can promote responses to PD-1 checkpoint blockade.', 'The microbiota is able to influence the systemic and anti-tumor immune response in the host by activating dendritic cells and by stimulating the T helper 1 (Th1) response. A microbial signature is needed for the proper activation of these cells and for the effective production of the pro-inflammatory cytokine interferon-gamma (IFN-γ) in the peripheral blood of cancer patients undergoing immune checkpoint blockade.', \"The gut microbiota can modulate the effectiveness of immunotherapy by affecting both anti-tumor and pro-tumor immune responses, reprogramming the tumor microenvironment's immunity, and engaging innate and/or adaptive immune cells. They can also produce metabolites that spread from the gut and impact local and systemic antitumor immune response, promoting immunotherapy efficiency. Additionally, the gut microbiota can shift to a 'favorable' one through various modifications, leading to more pronounced responses and better clinical outcomes when combined with immunotherapy treatment. The efficacy of cancer immunotherapies that manipulate costimulatory and coinhibitory pathways has also been correlated with the gut microbiota. Commensal microorganisms can signal immune cells, potentially impacting costimulation.\", 'The gut microbiota can affect both anti-tumor and pro-tumor immune responses, and further modulate the efficacy of cancer immunotherapy, particularly in the context of therapy with ICIs. The gut microbiota reprogram the immunity of the tumor microenvironment (TME) by engaging innate and/or adaptive immune cells. One of the primary modes by which the gut microbiota modulate antitumor immunity is by means of metabolites, which are small molecules that could spread from their initial location of the gut and impact local and systemic antitumor immune response to promote ICI efficiency.', '\\nThe microbiota can modulate the effectiveness of immunotherapy through several interrelated mechanisms, including activation of pattern recognition receptors (PRRs), production of metabolites that influence immune responses, and impact on the gut barrier. These processes can either enhance or suppress immune responses, ultimately affecting the response to immunotherapy.', \"The microbiota modulates the effectiveness of immunotherapy through mechanisms such as general immunomodulation, increasing cells that respond to both microbial and tumor antigens, affecting metabolism and drug compound degradation. Specifically, it downregulates the PD-L2-RGMb pathway, thereby promoting responses to PD-1 checkpoint blockade. Microbes alter immunotherapy's efficacy and toxicity by modifying host immune responses, with favorable microbiota modulation associated with increased CD8+ effector T cell infiltration into tumors. The gut microbiota metabolite butyrate enhances anti-PD-1 therapy efficacy by modulating cytotoxic CD8 T cell TCR signaling.\", 'The gut microbiota can modulate antitumor immunity and affect the efficacy of cancer immunotherapies, especially immune checkpoint inhibitors (ICIs). Deciphering the underlying mechanisms reveals that the gut microbiota reprogram the immunity of the tumor microenvironment (TME) by engaging innate and/or adaptive immune cells. Notably, one', \"The gut microbiota can influence the effectiveness of immunotherapy through several mechanisms, including activation of pattern recognition receptors, molecular mimicry, and impact of metabolites. Preclinical and preliminary clinical studies have shown that favorable microbiota modulation is associated with increased intratumoral infiltration of CD8+ effector T cells, which is often associated with enhanced intratumoral activity of T-helper type 1 cells and dendritic cells and a lower density of immunosuppressive cells. This suggests that the microbiota can modulate the immune system's response to tumors by altering the composition and activation state of immune cells within the tumor microenvironment. Furthermore, metabolites produced by the gut microbiota can also impact local and systemic antitumor immune responses, providing a potential mechanism for developing rational microbiota-based therapeutic strategies to augment the efficacy of immunotherapy.\", 'The gut microbiota can modulate the host immune system through the microbiota-gut-brain axis. Modulation of the gut microbiota induced by immunotherapy may partially underlie the efficacy of the treatment. The composition of the gut microbiota may affect the efficacy and toxicity of cancer immunotherapy. Manipulation of the gut microbiota through antibiotics, probiotics, prebiotics, or fecal transplantation has been investigated to improve the efficacy and mitigate toxicity of anticancer drugs. DeepGeni, a deep generalized interpretable autoencoder, has been proposed to improve the generalizability and interpretability of microbiome profiles in predicting responsiveness to cancer immunotherapy.', 'The gut microbiota plays a crucial role in the modulation of the effectiveness of immunotherapy. The gut microbiota can influence the success of immunotherapy through several mechanisms, including:1. Modulation of the immune system: The gut microbiota can modulate the immune system by altering the composition of immune cells and cytokines, which can affect the efficacy of immunotherapy.2. Production of metabolites: The gut microbiota can produce metabolites that can modulate the activity of immunotherapy, such as the anti-tumor effects of cytokines.3. Inflammation: The gut microbiota can contribute to inflammation, which can reduce the effectiveness of immunotherapy.4. Antibiotic-induced disruption: Antibiotics can disrupt the gut microbiota, leading to reduced efficacy of immunotherapy.5. Microbiota-derived signals: The gut microbiota can produce signals that can modulate the activity of immunotherapy, such as the production of short-chain fatty acids.Overall, the gut microbiota plays a crucial role in the modulation of the effectiveness of immunotherapy, and modulating the gut microbiota may be a promising strategy for improving the success rate of immunotherapy in patients with cancer.', 'The mechanisms by which the gut microbiota influences the effectiveness of immunotherapy are not fully understood, but several key pathways have been proposed. These include: 1. Modulation of immune responses through activation or suppression of various immune cells such as T cells and dendritic cells. 2. Production of metabolites that can influence the tumor microenvironment, including short-chain fatty acids (SCFAs) like butyrate, which have anti-inflammatory effects. 3. Alteration of the intestinal barrier function, potentially leading to increased permeability and translocation of bacteria or their products into the systemic circulation, thereby affecting distant sites such as tumors. 4. Induction of antigen presentation by microbial components, which can prime the immune system to recognize tumor-associated antigens more effectively. 5. Regulation of cytokine production, which can influence the balance between pro-inflammatory and anti-inflammatory responses. 6. Shaping of the systemic inflammatory response.', 'The microbiota can modulate the effectiveness of immunotherapy through several mechanisms, including activation of pattern recognition receptors, molecular mimicry, and the impact of metabolites. These mechanisms influence the activity of immune cells, leading to increased intratumoral infiltration of CD8+ effector T cells, enhanced intratumoral activity of T-helper type 1 cells and dendritic cells, and a lower density of immunosuppressive cells.', 'The mechanism by which the microbiota modulates the effectiveness of immunotherapy is through general immunomodulation, an increase in cells that specifically respond to antigens of both microbial and tumor origin, metabolism, degradation (utilization) of drug compounds, and downregulation of the PD-L2-RGMb pathway. Additionally, the metabolite butyrate of the gut microbiota facilitates the efficacy of anti-PD-1 immunotherapy by modulating TCR signaling of cytotoxic CD8 T cells.', '\\nThe microbiota can modulate the effectiveness of immunotherapy through multiple interrelated mechanisms, including activation of pattern recognition receptors (PRRs) on immune cells, molecular mimicry between bacterial antigens and tumor antigens, and shaping of the gut microenvironment to promote the recruitment and activation of immune cells. These processes can enhance or suppress the immune response to cancer and ultimately affect the response to immunotherapy.', 'The gut microbiota modulates the effectiveness of immunotherapy through several mechanisms:\\n\\n1. The microbiota produces metabolites like small molecules that can spread systemically and impact local and systemic antitumor immune responses, promoting the efficiency of immune checkpoint inhibitors (ICIs).\\n\\n2. The microbiota reprograms the immunity of the tumor microenvironment by engaging innate and/or adaptive immune cells, affecting both anti-tumor and pro-tumor immune responses. \\n\\n3. Shifting the gut microbiota composition to a favorable one through various modifications can lead to more pronounced responses and better clinical outcomes when combined with ICI treatment.\\n\\n4. Microbially-derived vitamins can potentially enhance the activity of immunotherapies in cancer through immune-interactive mechanisms.\\n\\n5. Commensal microorganisms signal immune cells in ways that impact costimulatory and coinhibitory pathways, which correlates with the efficacy of cancer immunotherapies targeting those pathways.\\n\\nIn summary, the gut microbiota crucially regulates the host immune response and boosts the efficacy of immunotherapy by modulating the tumor microenvironment, producing beneficial metabolites, and interacting with immune cells and pathways.', 'The mechanism by which the microbiota modulates the effectiveness of immunotherapy is not fully understood, but several mechanisms have been proposed. One mechanism is through the production of metabolites by the microbiota that can directly or indirectly affect immune cell function and tumor growth. Another mechanism is through the modulation of the gut barrier function, which can influence the trafficking of immune cells to the tumor microenvironment. Additionally, the microbiota can interact with the host immune system and influence the response to immunotherapy through the activation of specific immune pathways.', 'The microbiota, which refers to the collection of microorganisms that reside in the human body, has been shown to play a role in modulating the effectiveness of immunotherapy, which is a type of cancer treatment that harnesses the power of the immune system to fight cancer cells.\\n\\nThe microbiota can affect the immune system in several ways, which can impact the response to immunotherapy. Here are some mechanisms by which the microbiota modulates the effectiveness of immunotherapy:\\n\\n1. Shaping the gut microbiome: The gut is home to a diverse community of microorganisms, and studies have shown that the gut microbiome can influence the immune system. Certain bacteria in the gut, such as Bifidobacterium and Lactobacillus, have been shown to promote the production of immune cells called regulatory', 'The microbiota modulates the effectiveness of immunotherapy by influencing tumor immunity through regulation of the host immune system and tumor microenvironment. Some bacteria activate immunity to fight tumors, while others mediate immunosuppression, aiding cancer cells in evading the immune system. This dual role of the microbiota highlights its impact on shaping the immune response to cancer and the outcomes of immunotherapy treatments.', 'The microbiota modulates the effectiveness of immunotherapy by altering the metabolite profile and levels of toxins, such as Bacteroides fragilis toxin and colibactin and cytolethal distending toxin, which are responsible for oncogenesis. Dysbiosis of the gut microbiota can also impair the response of subcutaneous tumors to CpG-oligonucleotide immunotherapy and platinum chemotherapy.', \"The microbiota can influence the effectiveness of immunotherapy by interacting with the host's immune system and the tumor microenvironment. Some bacteria in the microbiota can enhance the immune response against tumors, potentially improving the effectiveness of immunotherapy. Conversely, other bacteria might suppress the immune system, aiding cancer cells in evading immune detection. This dual role of the microbiota means that its composition can be crucial in determining the outcome of immunotherapy treatments.\", 'The microbiota modulates the effectiveness of immunotherapy by regulating the host immune system and tumor microenvironment, where some bacteria activate immunity to fight tumors, while others mediate immunosuppression to help cancer cells evade the immune system.', 'The microbiota modulates the effectiveness of immunotherapy through several mechanisms. One mechanism is that the microbiota regulates the host immune system and tumor microenvironment. For example, some bacteria activate immunity to fight tumors, while others mediate immunosuppression to help cancer cells escape the immune system. Another mechanism is that the microbiota modulates the response to PD-1 blockade immunotherapy.', 'The efficacy of trans-diaresyl trinities, also known as trans-diaresyl glycogen trinities, for preventing or treating strokes is not well understood, and there is limited research specifically addressing this topic. ', 'The microbiota can modulate the effectiveness of immunotherapy by regulating the host immune system and tumor microenvironment. Some bacteria can activate immunity and help fight tumors, while others can mediate immunosuppression and help cancer cells escape from the immune system.', 'The microbiota can influence the effectiveness of immunotherapy primarily by interacting with the immune system and the tumor microenvironment. Certain bacteria in the microbiota can enhance the immune response against tumors, potentially increasing the effectiveness of immunotherapy. Conversely, other bacteria might suppress immune functions, which could reduce the efficacy of immunotherapy by helping cancer cells evade immune detection. This interaction between the microbiota and the immune system is key to understanding how changes in gut bacteria could either boost or hinder the success of cancer treatments like immunotherapy', \"The microbiota can influence the effectiveness of immunotherapy by interacting with the host's immune system and the tumor microenvironment. Certain bacteria in the microbiota can enhance the immune response against tumors, potentially improving the outcomes of immunotherapy. Conversely, other bacteria might suppress the immune system, aiding cancer cells in evading immune detection. This dual role of the microbiota in either activating immunity or mediating immunosuppression is crucial in determining the success of immunotherapy treatments.\", 'Some bacterial species activate the host immune response, some mediate immunosuppression. The mechanism is not yet clear but it is postulated to involve the production of antitumor and immunostimulatory metabolites, modulation of the differentiation and function of immune cells, direct antitumor activity, modulation of drug metabolism, and direct interaction with tumor cells.', 'The gut microbiota modulates the response to cancer immunotherapy. The gut microbiota may modulate the host immune system and tumor microenvironment. Some bacteria may help fight tumors by activating the host immune system, while others mediate immunosuppression to help cancer cells escape from the immune system.', \"The microbiota affects the efficacy of immunotherapy by interacting with the host's immune system and the tumor microenvironment. Certain bacteria can enhance tumor immunity by stimulating immune responses, while others may promote immunosuppression, aiding cancer cells in evading immune detection.\", 'The microbiota can influence the effectiveness of immunotherapy by regulating the host immune system and the tumor microenvironment. Some bacteria within the microbiota can activate the immune system to help fight tumors, while others may mediate immunosuppression, allowing cancer cells to evade immune detection. This interaction between the microbiota and the immune system plays a crucial role in the success of immunotherapy treatments.', 'The microbiota can modulate the effectiveness of immunotherapy by influencing the host immune system and the tumor microenvironment. Certain bacteria can activate immunity and enhance the anti-tumor response, while others can mediate immunosuppression and help cancer cells evade the immune system. The composition of the gut microbiota can serve as biomarkers to predict the prognosis of immunotherapy and may be used to develop interventions that improve treatment outcomes.', \"The microbiota can modulate the effectiveness of immunotherapy by regulating the host immune system and tumor microenvironment. Certain bacteria can activate the immune system, enhancing the body's ability to fight tumors. These bacteria can stimulate the production of immune cells, such as T cells and natural killer cells, which can recognize and destroy cancer cells. On the other hand, some bacteria can mediate immunosuppression, helping cancer cells to evade the immune system. These bacteria can suppress the activity of immune cells, inhibit the production of cytokines, and promote the formation of immunosuppressive cells, such as regulatory T cells and myeloid-derived suppressor cells. By modulating the balance between immune activation and immunosuppression, the microbiota can significantly affect the response to immunotherapy. For example, certain microbiota profiles have been associated with improved outcomes in patients receiving checkpoint inhibitor therapy, while other profiles have been linked to resistance or toxicity. Therefore, understanding the role of the microbiota in modulating tumor immunity is crucial for optimizing the effectiveness of immunotherapy and improving patient outcomes.\", 'The gut microbiota modulates the effectiveness of immunotherapy through various mechanisms. It can affect the host immune system and tumor microenvironment, thereby influencing the response to cancer treatment. Some bacteria have been shown to activate immune responses, enhancing the anti-tumor effects of immunotherapy. Conversely, certain microbes can mediate immunosuppression, allowing cancer cells to evade the immune system and leading to poor therapeutic outcomes. , The composition of the gut microbiota has been linked to the efficacy and adverse reactions of tumor immunotherapy. Specific characteristics in the intestinal microbiota may serve as biomarkers for predicting treatment prognosis or even act as \"immune potentiators\" to assist immunotherapy. , Microbial interventions, such as transplantation and the use of engineered bacteria, have demonstrated potential in improving the sensitivity of immunotherapy and reducing side effects. As research advances in gene', 'The microbiota modulates the effectiveness of immunotherapy by regulating the host immune system and tumor microenvironment, with certain bacteria activating immunity to fight tumors, while others mediate immunosuppression to help cancer cells evade the immune system.', 'The microbiota can influence the effectiveness of immunotherapy primarily by interacting with the immune system. Certain bacteria in the gut can enhance the immune response, making the body more responsive to immunotherapy treatments. These bacteria do this by promoting the maturation and activation of immune cells like T cells, which are crucial for attacking cancer cells. Conversely, other bacteria might suppress immune responses, which can decrease the effectiveness of immunotherapy. Thus, the composition of the microbiota can play a significant role in how well immunotherapy works', 'The microbiota modulates the effectiveness of immunotherapy through multiple mechanisms. Firstly, certain bacteria can activate the immune system and enhance the anti-tumor response. Secondly, the microbiota can influence the composition and function of immune cells in the tumor microenvironment. Lastly, the microbiota can affect the metabolism of immunotherapy drugs, potentially impacting their efficacy.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, the microbiota modulates the effectiveness of immunotherapy through several mechanisms:\n\n1. **Modulation of the immune system**: The gut microbiota influences the immune system, affecting the efficacy of immunotherapies, particularly in the context of immune checkpoint inhibitors (ICIs). The microbiota can modulate the immune response, either enhancing or suppressing it, which can impact the effectiveness of immunotherapy.\n2. **Production of metabolites**: The gut microbiota produces various metabolites that can influence the immune system and modulate the effectiveness of immunotherapy. For example, certain metabolites can enhance the efficacy of ICIs or reduce their toxicity.\n3. **Alteration of the tumor microenvironment**: The gut microbiota can alter the tumor microenvironment, making it more or less conducive to the growth of cancer cells. This can impact the effectiveness of immunotherapy by affecting the tumor's ability to evade the immune system.\n4. **Regulation of the gut-lung axis**: The gut-lung axis is a bidirectional communication network between the gut microbiota and the lungs. The gut microbiota can influence the lung microbiota, which can, in turn, impact the effectiveness of immunotherapy in lung cancer.\n5. **Modulation of the gut-brain axis**: The gut microbiota can influence the brain-gut axis, which can impact the immune system and modulate the effectiveness of immunotherapy.\n6. **Production of cytokines and chemokines**: The gut microbiota can produce cytokines and chemokines that can modulate the immune response and impact the effectiveness of immunotherapy.\n7. **Alteration of the gut epithelial barrier**: The gut microbiota can alter the gut epithelial barrier, which can impact the absorption of nutrients and the translocation of pathogens, which can, in turn, affect the effectiveness of immunotherapy.\n8. **Modulation of the host's metabolic profile**: The gut microbiota can influence the host's metabolic profile, which can impact the effectiveness of immunotherapy by affecting the host's energy metabolism and immune function.\n\nThese mechanisms are supported by various studies, including preclinical and clinical trials, which have shown that the gut microbiota can modulate the effectiveness of immunotherapy in different types of cancer, including colorectal, lung, and melanoma.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers a broad range of mechanisms through which the microbiota modulates immunotherapy effectiveness, including immune system modulation, metabolite production, tumor microenvironment alteration, and more. However, it does not specifically mention certain details found in the reference answers, such as molecular mimicry or the role of specific bacterial species like Bacteroides fragilis.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer includes relevant mechanisms, but some points like 'gut-lung axis' and 'gut-brain axis' are less directly related to the core mechanisms of immunotherapy modulation, potentially introducing minor irrelevance. More focused details from the reference answers, such as specific metabolites (e.g., butyrate) or pathways (e.g., PD-L2-RGMb), could improve precision.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer presents distinct mechanisms without significant repetition, but the explanations for some mechanisms (e.g., immune modulation and cytokine production) slightly overlap in concept without adding new details.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clearly organized into numbered points, and written in fluent, accessible language. Each mechanism is logically introduced and explained, making the content easy to follow."
    },
    {
        "Question": "What is the results of diphthamide deficiency?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the results of diphthamide deficiency?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Diphthamide deficiency syndrome is a novel human developmental disorder and ribosomopathy. It is s an autosomal recessive disorder associated with developmental delay, abnormal head circumference (microcephaly or macrocephaly), short stature, and congenital heart disease', 'Diphthamide deficiency results in reduced selenocysteine incorporation into selenoproteins, decreased selenite sensitivity, pre-disposition to oxidative stress, altered tRNA-synthetase and selenoprotein transcript levels, hypersensitivity to oxidative stress, and increased selenite tolerance.', 'Diphthamide deficiency can cause severe developmental defects, embryonic lethality or profound NDDs with multisystem involvement, deregulated selenoprotein expression, oxidative stress, and increased selenite tolerance.', 'Diphthamide deficiency results in reduced selenocysteine incorporation into selenoproteins, altered tRNA-synthetase and selenoprotein transcript levels, hypersensitivity to oxidative stress, and increased selenite tolerance.', 'Diphthamide deficiency results in reduced selenocysteine incorporation into selenoproteins, altered tRNA-synthetase and selenoprotein transcript levels, hypersensitivity to oxidative stress, and increased selenite tolerance. It also leads to deregulated selenoprotein expression, oxidative stress, NFkB activation, and increased selenite tolerance in cells. In patients, diphthamide deficiency is associated with developmental delay, abnormal head circumference, short stature, and congenital heart disease.', 'Diphthamide deficiency results in reduced selenocysteine incorporation into selenoproteins, altered tRNA-synthetase and selenoprotein transcript levels, hypersensitivity to oxidative stress, and increased cell death.', 'Diphthamide deficiency is associated with increased incidence of urogenital infections, characterized by tympanitis, urethritis, and epididymitis. Post-diphthamide dermatitis and photophobia as well as intellectual disability and behavioral problems also have been described.', '\\n Diphthamide deficiency leads to resistance to diphtheria toxin and Pseudomonas aeruginosa exotoxin A, but also causes hypersensitivity to TNF-mediated apoptosis, embryonic lethality in mice, and neurodevelopmental delays with multisystem abnormalities and miscarriages in humans.', 'Diphthamide deficiency is associated with developmental delay, short stature, and sparse hair syndrome (DEDSSH/DPH1 syndrome).', 'Diphthamide deficiency is a rare genetic disorder that affects protein synthesis in cells. The symptoms of this disorder can vary widely, but most affected individuals have developmental delays, intellectual disability, and short stature. Some may also have sparse hair, a small head size (microcephaly), and heart defects.\\n\\nIn terms of the results of diphthamide deficiency, studies have shown that this disorder can lead to a variety of health problems. One study found that individuals with diphthamide deficiency have an increased risk of developing certain types of cancer, including liver cancer and leukemia. This may be due to the fact that diphthamide is involved in the regulation of cell growth and division.\\n\\nAnother study found that diphthamide deficiency can also affect the immune system,', 'Diphthamide deficiency results in developmental delay, short stature, and sparse hair syndrome (DEDSSH/DPH1 syndrome).', 'The results of diphthamide deficiency include developmental delay, short stature, sparse hair syndrome, abnormal head circumference (microcephaly or macrocephaly), congenital heart disease, and differential regulation of hepatocellular carcinogenesis.', 'Diphthamide deficiency results in a severe neurodevelopmental disorder called Diphthamide-deficiency syndrome (DPH1 syndrome or Loucks-Innes syndrome). It is associated with developmental delay, abnormal head circumference (microcephaly or macrocephaly), short stature, sparse hair, and congenital heart disease.', 'Diphthamide deficiency is associated with developmental delay, abnormal head circumference (microcephaly or macrocephaly), short stature, and congenital heart disease.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nDiphthamide deficiency is associated with a range of symptoms and conditions, including:\n\n* Intellectual disability and developmental abnormalities\n* Seizures\n* Craniofacial and morphological phenotypes\n* Reduced selenocysteine incorporation into selenoproteins\n* Altered tRNA-synthetase and selenoprotein transcript levels\n* Hypersensitivity to oxidative stress\n* Increased selenite tolerance\n* Reduced translation elongation rate in hepatocytes\n* Liver damage with fatty accumulation\n* Increased p53-mediated pericentral hepatocyte death\n* Reduced compensatory proliferation\n* Decreased incidence of DEN-induced pericentral-derived HCC\n* Increased tumor loads associated with KRT19-positive periportal-like cell expansion in mice\n* Favorable arterial wall remodeling\n* Lower arterial stiffness\n* Reduced mechanical wall stiffness in aorta rings from p16-3MR mice\n* Increased NO bioavailability\n* Reduced cellular- and mitochondrial-related oxidative stress\n* Increased endothelial function\n* Favorable arterial wall remodeling\n\nThese effects are due to the critical role of diphthamide in UGA-SECIS decoding, which is necessary for selenoprotein expression and translation elongation. Diphthamide deficiency affects the translation of proteins involved in the TORC1 pathway, leading to a range of downstream effects on cellular metabolism and function.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers a broad range of symptoms and conditions associated with diphthamide deficiency, including developmental, metabolic, and cellular effects. It also includes some unique details not mentioned in the reference answers, such as effects on liver damage and arterial wall remodeling. However, it misses some key clinical features like abnormal head circumference (microcephaly or macrocephaly) and congenital heart disease, which are consistently mentioned in the reference answers.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "While the answer provides detailed information, some details seem irrelevant to diphthamide deficiency or are overly specific (e.g., arterial wall remodeling, NO bioavailability, mechanical wall stiffness in aorta rings from p16-3MR mice). These points are not well-supported by the reference answers and may distract from the core symptoms and mechanisms of the disorder.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not significantly repeat the same information, but some related themes (e.g., oxidative stress, selenoprotein expression) are mentioned multiple times in slightly different contexts. Overall, repetition is minimal.",
        "Readability Score": 3,
        "Readability Explanation": "The answer is well-structured with bullet points, but the inclusion of highly technical details (e.g., TORC1 pathway, UGA-SECIS decoding) without sufficient context may hinder readability. The flow is logical, but the balance between clarity and detail could be improved."
    },
    {
        "Question": "What is the cause of Sydenham's chorea?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the cause of Sydenham's chorea?\n\nHere are some reference answers:\n\n**Reference Answers:**\n[\"Sydenham's chorea is caused by an autoimmune response after a group A beta-hemolytic streptococcal (GABHS) infection.\", \"Sydenham's chorea is an autoimmune disorder that can develop after a group A beta-hemolytic streptococcal (GABHS) infection, such as strep throat or scarlet fever. The infection triggers an immune response that mistakenly attacks the basal ganglia, a structure in the brain that controls movement, leading to the symptoms of Sydenham's chorea.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the cause of Sydenham's chorea is associated with a Group A beta-hemolytic streptococcal (GABHS) infection.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "4",
        "Information Recall Explanation": "The answer correctly identifies the cause of Sydenham's chorea as being associated with a Group A beta-hemolytic streptococcal (GABHS) infection. However, it lacks details about the autoimmune response and the involvement of the basal ganglia, which are mentioned in the more detailed reference answer.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information. It succinctly states the key cause without unnecessary details.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition of information in the answer. It is concise and to the point.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is easily readable, fluent, and clearly communicates the cause of Sydenham's chorea."
    },
    {
        "Question": "What are active ingredients of Xultophy pill?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are active ingredients of Xultophy pill?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Xultophy is a fixed ratio combination of basal insulin degludec and glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, the active ingredients of Xultophy are insulin degludec and liraglutide.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer correctly identifies both active ingredients of Xultophy: insulin degludec and liraglutide, matching the reference answer exactly.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information beyond the two active ingredients mentioned in the reference.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each active ingredient is mentioned once without redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is clear, concise, and easily understandable, making it highly readable and fluent."
    },
    {
        "Question": "Should UGT1A1 alteration be routinely determined in colorectal cancer patients?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nShould UGT1A1 alteration be routinely determined in colorectal cancer patients?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['An examination of more UGT1A loci, except for UGT1A1*6 and UGT1A1*28, was not helpful to improve the predictive value of irinotecan-based toxicity and efficacy.', 'The question of whether UGT1A1 alteration should be routinely determined in colorectal cancer patients is a complex one. On the one hand, identifying patients with the UGT1A1*28 allele could help prevent severe neutropenia and potentially life-threatening side effects associated with irinotecan treatment. This could lead to improved outcomes and reduced healthcare costs. However, the cost of genetic testing and the potential for false negatives or false positives must also be considered. Additionally, the clinical utility of UGT1A1 genotyping is still uncertain, and there is a lack of prospective studies examining the effectiveness of modifying irinotecan regimens based on UGT1A1 genotype. Therefore, it is unclear whether UGT1A1 alteration should be routinely determined in colorectal cancer patients. Further research is needed to determine the benefits and harms of UGT1', 'UGT1A1 alteration should be routinely determined in colorectal cancer patients, especially those undergoing treatment with irinotecan, as it can help predict the risk of severe toxicity such as neutropenia. Identifying UGT1A1 alterations can guide personalized dosing strategies and improve treatment outcomes by reducing the likelihood of adverse reactions to irinotecan therapy.', 'Yes, UGT1A1 alteration should be routinely determined in colorectal cancer patients. UGT1A1 is a critical enzyme involved in the metabolism of many chemotherapeutic agents, including capecitabine and oxaliplatin, which are commonly used in the treatment of colorectal cancer. UGT1A1 alterations have been associated with altered drug metabolism and response, and may impact treatment outcomes. Therefore, determining UGT1A1 status in colorectal cancer patients may help guide personalized treatment strategies and improve patient outcomes.', 'No. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group found that the evidence is currently insufficient to recommend for or against the routine use of UGT1A1 genotyping in patients with metastatic colorectal cancer who are to be treated with irinotecan, with the intent of modifying the dose as a way to avoid adverse drug reactions (severe neutropenia).', 'Yes, a UGT1A1 test should be performed in colorectal cancer patients prior to treatment with irinotecan.', 'The determination of UGT1A1 alteration in colorectal cancer patients is not currently a routine test. However, it may be considered in certain cases, such as patients with metastatic disease who are being considered for irinotecan-based chemotherapy. This is because UGT1A1 alterations can lead to an increased risk of irinotecan-induced toxicity. However, the clinical utility of UGT1A1 testing in colorectal cancer patients is still a topic of ongoing research and debate. It is important to consult with a healthcare provider to determine the most appropriate course of action for an individual patient.', 'No, UGT1A1 alteration should not be routinely determined in colorectal cancer patients.', \"According to the current guidelines from the Food and Drug Administration (FDA) of the United States, UGT1A1 alteration should be routinely determined in colorectal cancer patients receiving irinotecan, a chemotherapy drug commonly used in the treatment of colorectal cancer. However, the clinical significance of UGT1A1 testing in colorectal cancer patients receiving other chemotherapy agents, such as 5-fluorouracil (5-FU), is less clear and requires further investigation. Therefore, it is recommended to consult with a healthcare provider or a genetic counselor to determine if UGT1A1 genotyping is appropriate for a specific patient's situation. In summary, UGT1A1 alteration should be routinely determined in colorectal cancer patients receiving irinotecan, but the decision to test for UGT1A1 alteration in patients receiving other chemotherapy agents is still a subject of debate among healthcare professionals.\", 'Determining UGT1A1 alterations might be helpful in predicting irinotecan toxicity in colorectal cancer patients, but their clinical relevance in gastric cancer patients is currently unclear.', 'Based on the available evidence, it is recommended that UGT1A1 alteration should be routinely determined in colorectal cancer patients receiving irinotecan-based therapy. This can help to determine the optimal dose of irinotecan and prevent hematologic and digestive toxicities, especially in patients who are homozygous for the UGT1A1*28 allele. However, it is important to note that testing for UGT1A1 alteration does not improve treatment efficacy, and its clinical utility remains uncertain due to the lack of prospective studies examining treatment options based on UGT1A1 genotype. Nevertheless, given the potential benefits and minimal harm associated with UGT1A1 testing, it is recommended as a routine practice in colorectal cancer patients receiving irinotecan-based therapy.', 'Based on the current evidence, routine determination of UGT1A1 alteration in colorectal cancer patients is recommended. UGT1A1 polymorphisms, such as UGT1A1*28 and UGT1A1*6, have been associated with increased risk of irinotecan-induced toxicity, including severe hematological toxicity. Several studies have shown that patients with the UGT1A1*28 7/7 genotype have a higher risk of hematological toxicity, increased hospitalization rates, and lower overall survival when treated with irinotecan. Therefore, determining UGT1A1 alteration can help identify patients who may be at higher risk of adverse effects from irinotecan therapy and guide personalized treatment decisions.', 'Yes, UGT1A1 alteration should be routinely determined in colorectal cancer patients. The presence of the UGT1A1*28 allele is associated with a higher risk of adverse effects and reduced efficacy of irinotecan-based therapy. Routine genotyping of UGT1A1 can help to identify patients who are at risk of adverse effects and optimize their treatment.', 'Yes, UGT1A1 alteration should be routinely determined in colorectal cancer patients because it is associated with aggressive behavior of the cancer and it is a marker of poor prognosis.', \"Yes, routine determination of UGT1A1 alterations is recommended for colorectal cancer patients who are candidates for treatment with irinotecan-based chemotherapy. This is because genetic polymorphisms in the UGT1A1 gene can significantly affect a patient's ability to metabolize and tolerate irinotecan, leading to increased toxicity or reduced efficacy of the drug. The most common polymorphism, UGT1A1*28, has been associated with decreased glucuronidation activity and an increased risk of severe neutropenia when standard doses of irinotecan are used. Patients who are heterozygous for this allele or have other variants known to affect drug metabolism may benefit from dose reduction or alternative treatment strategies to optimize safety and efficacy.\", \"According to the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN), no, UGT1A1 alteration should not be routinely determined in colorectal cancer patients. However, some healthcare providers and institutions may offer this testing on a case-by-case basis for patients with a history of severe toxicity or those receiving high-dose irinotecan. It is recommended to consult with a healthcare provider or a genetic counselor to determine if UGT1A1 genotyping is appropriate for a specific patient's situation.\", 'Answer: The routine determination of UGT1A1 alteration in colorectal cancer patients is recommended to assess the risk of irinotecan-induced toxicities and guide personalized treatment decisions.', 'The decision of whether to routinely determine UGT1A1 alterations in colorectal cancer patients for predicting irinotecan-based toxicity and efficacy is still a subject of debate in the medical community. While the UGT1A1*6 and UGT1A1*28 variants have been associated with irinotecan-induced toxicity, the clinical utility of routinely testing for these variants is not yet clear.\\n\\nA meta-analysis published in the Journal of Clinical Oncology in 2019 found that UGT1A1*6 and UGT1A1*28 variants were significantly associated with increased risk of irinotecan-induced neutropenia and diarrhea, but the clinical significance of this finding is still uncertain. The authors', 'Yes, UGT1A1 alteration should be routinely determined in colorectal cancer patients because it is associated with aggressive behavior and poor outcome.', 'Yes, UGT1A1 alteration should be routinely determined in colorectal cancer patients.The UGT1A1 gene is a potential biomarker for colorectal cancer diagnosis and prognosis.The UGT1A1 gene is a potential biomarker for colorectal cancer diagnosis and prognosis.The UGT1A1 gene is a potential biomarker for colorectal cancer diagnosis and prognosis.The UGT1A1 gene is a potential biomarker for colorectal cancer diagnosis and prognosis.The UGT1A1 gene is a potential biomarker for colorectal cancer diagnosis and prognosis.The UGT1A1 gene is a potential biomarker for colorectal cancer diagnosis and prognosis.The UGT1A1 gene is a potential biomarker for colorectal cancer diagnosis and prognosis.The UGT1A1 gene is a potential biomarker for colorectal cancer diagnosis and prognosis.The UGT1A1 gene is a potential biomarker for colorectal cancer diagnosis and prognosis.The UGT1A1 gene is a potential biomarker for colorectal cancer diagnosis and prognosis.The UGT1A1 gene is a potential biomarker for colorectal cancer diagnosis and prognosis.The UGT1A1 gene is a potential biomarker for colorectal cancer diagnosis and prognosis.The UGT1A1 gene is a potential biomarker for colorectal cancer diagnosis and prognosis.The UGT1A1 gene is a potential biomarker for colorectal cancer diagnosis and prognosis.The UGT1A1 gene is a potential biomarker for colorectal cancer diagnosis and prognosis.The UGT1A1 gene is a potential biomarker for colorectal cancer diagnosis and prognosis.The UGT1', 'Yes, determining UGT1A1 alterations should be routinely done in colorectal cancer patients, especially considering the impact of UGT1A1*6 and UGT1A1*28 on the toxicity and efficacy of irinotecan-based treatments. The examination of other UGT1A loci beyond these two does not significantly improve the predictive value for these outcomes.', 'Yes, UGT1A1 alteration should be determined in all coloreectal cancer patients. This is because UGTP is an essential co-factor for the synthesis of viral hemagens, which are used as a proxy for viral infection. UGTP is also involved in the metabolism of various drugs, including those used in the treatment of coloreectal cancer. ', 'Yes, UGT1A1 alteration should be routinely determined in colorectal cancer patients.', \"The UGT1A1*6 and UGT1A1*28 alterations have been shown to be predictive of irinotecan-based toxicity and efficacy in colorectal cancer patients. However, an examination of other UGT1A loci did not improve the predictive value. Therefore, it may not be necessary to routinely determine UGT1A1 alterations other than *6 and *28 in colorectal cancer patients. It is important to note that this is a complex issue and the decision to test for UGT1A1 alterations should be individualized based on the patient's specific circumstances and the availability of alternative treatment options.\", 'Yes, determining UGT1A1 alterations should be considered routinely in colorectal cancer patients, especially before administering irinotecan-based chemotherapy. This is because variations in the UGT1A1 gene, particularly UGT1A1*28, can significantly affect how a patient metabolizes irinotecan, potentially leading to increased toxicity. Testing for these genetic variations can help tailor treatment plans to individual patients, enhancing both the efficacy and safety of the therapy', 'yes, determining UGT1A1 alterations should be routinely done in colorectal cancer patients, especially considering the impact of UGT1A1*6 and UGT1A1*28 on the toxicity and efficacy of irinotecan-based treatments. The examination of additional UGT1A loci beyond these two does not significantly improve the predictive value for irinotecan-related outcomes.', 'The decision of whether to routinely determine UGT1A1 alterations in colorectal cancer patients for predicting irinotecan-based toxicity and efficacy is still a subject of debate in the medical community. While the UGT1A1*6 and UGT1A1*28 variants have been associated with increased risk of irinotecan-induced toxicity, particularly neutropenia and diarrhea, the clinical utility of routine UGT1A1 genotyping is not yet established.\\n\\nA meta-analysis published in the Journal of Clinical Oncology in 2019 found that UGT1A1 genotyping could improve the prediction of irinotecan-induced toxicity, particularly in Asian populations. However, the authors noted that the clinical significance of this finding is still uncertain, as the majority of studies included in the meta-analysis were retrospective and had small sample sizes.\\n\\nIn a 2020 review published in the Journal of Gastrointestinal Oncology, the authors concluded that UGT1A1 genotyping should be considered in patients with a history of severe ir', 'No, UGT1A1 alteration should not be routinely determined in colorectal cancer patients, as it does not significantly improve the predictive value of irinotecan-based toxicity and efficacy.', 'Yes, determining UGT1A1 alterations should be a standard practice for colorectal cancer patients.', 'Based on the provided snippet, routine determination of UGT1A1 alterations beyond UGT1A1*6 and UGT1A1*28 may not significantly improve the prediction of irinotecan-based toxicity and efficacy in colorectal cancer patients. This suggests that testing for these specific alleles could be sufficient for risk stratification and personalized treatment planning. However, it is important to note that this conclusion is based on the examination of certain UGT1A loci only and may not exclude the potential relevance of other UGT1A alterations. Therefore, further research is needed to comprehensively evaluate the clinical utility of UGT1A1 genotyping in colorectal cancer management.', 'no, examining more UGT1A loci beyond UGT1A1*6 and UGT1A1*28 does not improve the predictive value of irinotecan-based toxicity and efficacy in colorectal cancer patients.', 'Yes, UGT1A1 alteration should be routinely determined in colorectal cancer patients.UGT1A1 is a critical enzyme involved in the metabolism of many drugs, including chemotherapeutics, and genetic variations in UGT1A1 have been associated with altered drug metabolism and response. Therefore, determining UGT1A1 alterations in colorectal cancer patients may help guide personalized medicine approaches, including drug selection and dosing.Additionally, UGT1A1 has been implicated in the development and progression of colorectal cancer, and alterations in UGT1A1 may be associated with poorer prognosis. Therefore, determining UGT1A1 alterations in colorectal cancer patients may help identify patients at high risk of recurrence or metastasis.In summary, UGT1A1 alteration should be routinely determined in colorectal cancer patients to help guide personalized medicine approaches and improve patient outcomes.', 'The study suggests that UGT1A1*6 and UGT1A1*28 are associated with an increased risk of severe neutropenia in Chinese patients with metastatic colorectal cancer (mCRC) treated with irinotecan-based chemotherapy. However, the study also found that examining more UGT1A loci did not improve the predictive value of irinotecan-based toxicity and efficacy. Therefore, it is unclear whether UGT1A1 alteration should be routinely determined in colorectal cancer patients. Further research is needed to confirm these findings and determine the clinical utility of UGT1A1 genotyping in this patient population.', 'Based on the provided information, it appears that examining additional UGT1A loci beyond UGT1A1*6 and UGT1A1*28 does not significantly improve the predictive value of irinotecan-based toxicity and efficacy in colorectal cancer patients. Therefore, routine determination of UGT1A1 alterations may not be necessary for all colorectal cancer patients receiving irinotecan treatment. However, it is important to note that this conclusion is based on the specific studies mentioned and does not rule out the potential value of genetic testing in certain clinical contexts or patient populations. For personalized medicine approaches, further research is needed to determine if other genetic markers or combinations thereof could provide more accurate predictions of irinotecan response and toxicity.', 'Based on the provided information, examining more UGT1A loci beyond UGT1A1*6 and UGT1A1*28 was not helpful in improving the predictive value of irinotecan-based toxicity and efficacy in colorectal cancer patients. Therefore, routine determination of UGT1A1 alterations beyond *6 and *28 does not appear to be beneficial for guiding irinotecan therapy in this patient population. The abstract suggests focusing on UGT1A1*6 and *28 variants is sufficient. However, more context and additional studies would be needed to make a definitive recommendation on routine UGT1A1 testing in colorectal cancer.', 'Yes, routine determination of UGT1A1 alteration should be considered in colorectal cancer patients. Although additional UGT1A loci beyond UGT1A1*6 and UGT1A1*28 do not improve the predictive value of irinotecan-based toxicity and efficacy, UGT1A1 alterations can still have clinical implications. UGT1A1 polymorphisms are associated with variable drug metabolism and can affect the response to irinotecan, a commonly used chemotherapy drug in colorectal cancer. Therefore, determining UGT1A1 alterations can help guide treatment decisions and optimize patient outcomes.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the data provided, it appears that UGT1A1 alterations, particularly the UGT1A1*28 polymorphism, are associated with increased risk of toxicity and reduced efficacy of irinotecan-based chemotherapy in colorectal cancer patients. However, the evidence is not uniform across all studies, and the predictive value of UGT1A1 testing for toxicity and efficacy is not consistently demonstrated.\n\nSome studies suggest that UGT1A1*28 is a significant predictor of severe neutropenia and diarrhea in patients receiving irinotecan-based chemotherapy (e.g., studies 12, 13, and 16). Other studies have found associations between UGT1A1 polymorphisms and clinical outcomes, such as response rates and progression-free survival (e.g., studies 14 and 15).\n\nHowever, not all studies have found a significant association between UGT1A1 polymorphisms and toxicity or efficacy (e.g., study 17). Additionally, some studies have suggested that other UGT1A1 polymorphisms, such as UGT1A1*6, may also be associated with toxicity and efficacy (e.g., studies 12 and 13).\n\nGiven the variability in the evidence, it is not clear whether UGT1A1 alteration should be routinely determined in all colorectal cancer patients. However, it may be beneficial to consider UGT1A1 testing in patients who are receiving irinotecan-based chemotherapy, particularly those with a history of severe toxicity or those who are at high risk of toxicity. This could help guide dose adjustments and minimize the risk of adverse events.\n\nIn conclusion, while the evidence is not uniform, UGT1A1 testing may be a useful tool in the management of colorectal cancer patients receiving irinotecan-based chemotherapy, particularly in those at high risk of toxicity. However, further research is needed to fully elucidate the role of UGT1A1 testing in this context.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers the key points from the reference answers, including the association of UGT1A1 alterations with irinotecan toxicity and efficacy, variability in studies, and the potential clinical utility of testing in high-risk patients. However, it does not explicitly mention the lack of improvement from examining additional UGT1A loci beyond *6 and *28, which is a significant point in some reference answers.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise and avoids irrelevant details, focusing on the role of UGT1A1 alterations in irinotecan-based chemotherapy. There is minimal inclusion of unnecessary or extraneous information.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat information unnecessarily, maintaining a clear flow from discussing the evidence variability to clinical recommendations, without redundancy.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-structured, coherent, and easy to follow. It presents complex information in a clear manner, though slightly more technical details could impact readability for a non-specialist audience."
    },
    {
        "Question": "Please list sources of orthobiologics",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nPlease list sources of orthobiologics\n\nHere are some reference answers:\n\n**Reference Answers:**\n[\"Orthobiologics  are derived from patient's own tissues, such as blood, bone marrow, and adipose tissue to prepare platelet-rich plasma (PRP), bone marrow concentrate, Stem cells and adipose tissue concentrate.\", '- The most common orthobiologic sources are bone marrow aspirates (BMA), which contains mesenchymal stem cells (MSCs) and platelets.\\n- Adipose tissue is also a great source of MSCs\\n- Blood products like platelet-rich plasma (PRP) and umbilical cord blood (UCB) are also commonly used.\\n- Other sources of orthobiologics can be:\\n    + Peripheral blood\\n    + Amniotic fluid\\n    + Amniotic membrane\\n    + Placental tissue\\n    + Synovial tissue\\n    + Bone tissue', 'Sources of orthobiologics can be bone marrow aspirate concentrate, bone marrow concentrate, platelet-rich plasma, amniotic membrane products, expert opinion, bone marrow aspirate, bone marrow, and adipose-derived mesenchymal stromal cells.', 'Sources of orthobiologics include platelet-rich plasma (PRP), connective tissue progenitor cells derived from bone marrow and adipose tissue, purified cytokines and small peptides, bone autograft, bone allograft, demineralized bone matrix, bone graft substitutes, bone marrow aspirate concentrate, bone morphogenetic proteins, platelet-derived growth factor, parathyroid hormone, vitamin D, calcium, osseous hollow fillers, extracellular matrix substances, hyaluronic acid, gene therapies, Wnt inhibitors, autologous and allogenic cell therapies, and mesenchymal stem cells.', 'Orthobiologics are biological products derived from living organisms, such as bacteria, fungi, or plants, that are used to treat or prevent diseases. Examples of orthobiologics include:1. Platelet-rich plasma (PRP)2. Bone marrow-derived mesenchymal stem cells (BM-MSCs)3. Growth factors (e.g. platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and transforming growth factor-beta (TGF-β))4. Hyaluronic acid (HA)5. Collagen6. Fibrin glue7. Bone morphogenetic proteins (BMPs)8. Osteogenic and chondrogenic factors9. Stem cells10. Growth factors and cytokinesThese biological products have been used in various applications, including:1. Orthopedic and musculoskeletal disorders2. Cardiovascular diseases3. Neurological disorders4. Wound healing5. Cancer6. Ophthalmic disorders7. Dermatological disorders8. Gastrointestinal disorders9. Respiratory disorders10. Urological disordersIn addition, there are several biomarkers that have been identified for the diagnosis and monitoring of tuberculosis, including:1. Exhaled nitric oxide (NO)2. Carbon dioxide (CO2)3. Volatile organic compounds (VOCs) in breath4. Urinary biomarkers (e.g. urea, creatinine, and uric acid)5. Blood biomarkers (e.g. C-reactive protein, interleukin-6, and tumor necrosis factor-alpha)These biomarkers can be used in various applications, including:1. Diagnosis of active pulmonary tuberculosis2. Monitoring of treatment response3. Detection of latent tuberculosis infection4.', 'Sources of orthobiologics include whole blood, bone marrow, and adipose tissue.', 'Platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), adipose-derived mesenchymal stromal cells, amniotic membrane products, and umbilical cord-derived cells are sources of orthobiologics.', 'Orthobiologics are biologically-derived materials intended to promote bone formation and union. They can be derived from various sources, including:\\n\\n* Bone autograft\\n* Bone allograft\\n* Demineralized bone matrix\\n* Bone graft substitutes\\n* Bone marrow aspirate concentrate\\n* Platelet-rich plasma\\n* Bone morphogenetic proteins\\n* Platelet-derived growth factor\\n* Parathyroid hormone\\n* Vitamin D and calcium\\n* Hyaluronic acid\\n* Adipose tissue\\n* Expanded mesenchymal stem cells\\n* Autologous blood products\\n* Wnt inhibitors\\n* Systemic treatments\\n* Autologous and allogenic cell therapies\\n* Bone marrow\\n* Mesenchymal stem cells (MSCs)\\n* Osseous hollow fillers\\n* Extracellular matrix (ECM) substances\\n* Bone marrow aspirate (BMA)\\n* Bone marrow aspirate concentrate (BMAC)\\n\\nIt is important to note that the use of orthobiologics is increasing, with hyaluronic acid and platelet-rich plasma being the most commonly used. Leukocyte-rich platelet-rich plasma is the most popular orthobiologic in muscle, ligament, tendon, and labral injuries, whereas bone marrow aspirate concentrate is most popular for focal articular cartilage injuries.', 'Orthobiologic agents, including platelet-rich plasma, connective tissue progenitor cells derived from bone marrow, adipose, and other tissues, and purified cytokines and small peptides, have tremendous potential to target deficiencies in soft-tissue healing. Other orthobiologics include bone autograft, bone allograft, demineralized bone matrix, bone graft substitutes, bone marrow aspirate concentrate, bone morphogenetic proteins, platelet-derived growth factor, parathyroid hormone, vitamin D and calcium, osseous hollow fillers, extracellular matrix (ECM) substances, bone morphogenetic protein-2 (BMP-2), bone marrow aspirate (BMA), bone marrow aspirate concentrate (BMAC), mesenchymal stem cells (MSCs), hyaluronic acid, gene therapies, Wnt inhibitors, and a variety of systemic treatments.', 'Orthobiologics are derived from blood, bone marrow, and adipose tissue.', 'The principal sources of orthobiologics are:, 1) Platelet-rich plasma (PRP), 2) Bone marrow concentrate (BMC), 3) Adipose tissue concentrate (ATC), 4) Purified cytokines and small peptides, 5) Exosomes, 6) Gene therapy approaches', 'Orthobiologics can be derived from a variety of sources, including: , 1. Bone marrow aspirate concentrate, 2. Adipose tissue (also known as fat tissue), 3. Platelet-rich plasma (PRP), which can be further categorized into leukocyte-rich and leukocyte-poor types, 4. Amniotic membrane products, 5. Umbilical cord-derived cells, 6. Hyaluronic acid, 7. Expanded mesenchymal stem cells, 8. Tissue sources such as knee synovium, shoulder subacromial bursa, bone marrow aspirate, and anterior cruciate ligament injury effusion fluid and stump tissue (for point-of-care harvest and application).', 'Sources of orthobiologics include bone autograft, bone allograft, demineralized bone matrix, bone graft substitutes, bone marrow aspirate concentrate, platelet-rich plasma, bone morphogenetic proteins, platelet-derived growth factor, parathyroid hormone, and vitamin D and calcium.', 'The main sources of orthobiologics are:, Decellularized bovine heart extracellular matrix as an alternative source of macrobiotics, Biomaterials, Chondrocytes, Collagenic scaffolds from extracellular matrix, Chondrocytes grown in vitro on scaffolds from extracellular matrix, C', \"Orthobiologics can be derived from various sources within the human body, including: 1. Platelet-Rich Plasma (PRP): PRP is obtained by spinning a sample of the patient's own blood in a centrifuge to separate and concentrate the platelets. The concentrated platelets contain growth factors that can promote healing when injected into an injured area. 2. Bone Marrow Aspirate: This procedure involves extracting bone marrow from the pelvis or other suitable bones and using it as a source of mesenchymal stem cells (MSCs), which have the potential to differentiate into various cell types including osteoblasts (bone-forming cells) and chondrocytes (cartilage-forming cells). 3. Adipose Tissue: Similar to bone marrow aspiration, adipose tissue can be harvested from areas such as the abdomen or thighs and processed to isolate MSCs.\", 'Orthobiologics include bone autograft, bone allograft, demineralized bone matrix, bone graft substitutes, bone marrow aspirate concentrate, platelet-rich plasma, bone morphogenetic proteins, platelet-derived growth factor, parathyroid hormone, and vitamin D and calcium.', \"Sources of orthobiologics include: , 1. Autologous cells from the patient's own body (e.g., platelet-rich plasma, bone marrow concentrate, adipose tissue concentrate), 2. Donor cells from a donor's body (e.g., allogenic stem cells), 3. Stem cells derived from embryonic tissues (e.g., embryonic stem cells), 4. Synthetic biomaterials (e.g., polylactic acid, polyglycolic acid), 5. Biologic scaffolds (e.g., collagen, fibrin), 6. Tissue-engineered constructs (e.g., tissue-engineered skin substitutes), 7. Cell-based therapies (e.g., chondrocyte implantation, mesenchymal stem cell therapy), 8.\", 'Platelet-rich plasma (PRP), bone marrow concentrate (BMC), and adipose tissue concentrate (ATC) are sources of orthobiologics.', 'Sources of orthobiologics include:\\n\\n1. Platelet-rich plasma (PRP)\\n2. Bone marrow aspirate (BMA) and bone marrow aspirate concentrate (BMAC) \\n3. Adipose tissue\\n4. Mesenchymal stem cells (MSCs)\\n5. Bone autograft and allograft\\n6. Demineralized bone matrix\\n7. Bone morphogenetic proteins (BMPs)\\n8. Hyaluronic acid\\n9. Platelet-derived growth factor (PDGF)\\n10. Parathyroid hormone\\n11. Vitamin D and calcium\\n12. Extracellular matrix (ECM) substances\\n13. Gene therapies\\n14. Wnt inhibitors', \"Orthobiologics are derived from patient's own tissues, such as blood, bone marrow, and adipose tissu\", \"Orthobiologics are derived from a patient's own tissues and can be obtained from the following sources:\\n\\n1. Blood: Platelet-rich plasma (PRP) is prepared from a patient's own blood by spinning it in a centrifuge to separate the platelets and growth factors from the other components.\\n\\n2. Bone marrow: Bone marrow aspirate (BMA) is obtained by withdrawing a small amount of bone marrow from the hip or iliac crest using a needle and syringe. The aspirate is then processed to isolate the stem cells and growth factors.\\n\\n3. Adipose tissue: Adipose tissue, also known as fat tissue, can be harvested from areas such as the abdomen, thighs, or buttocks using liposuction. The tissue is then\", 'The main sources of orthobiologics are: , 1) Autologous chondrocytes, , 2) Allograft chondrocytes, , 3) Unconditioned mesenchymal stem cells, , 4) Conditioned mesenchymal stem cells, , 5) Peripheral blood mononuclear cells and , 6)', 'Platelet-Rich Plasma, bone marrow aspirate, bone marrow, adipose tissue to prepare platelet-rich plasma, stem cells, and adipose tissue can be sources of orthobiologics.', \"Sources of orthobiologics include the patient's own tissues, such as blood for platelet-rich plasma (PRP), bone marrow for bone marrow aspirate, and adipose tissue for adipose tissue concentrate. These orthobiologics are derived from autologous sources to aid in the treatment of various musculoskeletal conditions and injuries.\", 'There are several sources of orthobiologics, including:1. Platelet-rich plasma (PRP)2. Bone marrow aspirate3. Stem cells4. Adipose tissue concentrate5. Growth factors6. Hyaluronic acid7. Platelet-rich fibrin (PRF)8. Bone marrow-derived mesenchymal stem cells (BM-MSCs)9. Adipose-derived stem cells (ADSCs)10. Umbilical cord blood-derived mesenchymal stem cells (UC-MSCs)', \"Orthobiologics are derived from patient's own tissues, such as blood, bone marrow, and adipose tissue to prepare platelet-rich plasma (PRP), bone marrow concentrate, and adipose tissue concentrate, respectively.\", 'Sources of orthobiologics include adipose tissue, bone marrow, stem cells, and blood.', \"Orthobiologics are derived from a patient's own tissues and include:\\n\\n* Platelet-rich plasma (PRP) from blood\\n* Bone marrow concentrate from bone marrow\\n* Adipose tissue concentrate from adipose tissue.\", 'Orthobiologics can be sourced from various tissues in your own body. Common sources include:\\n\\n1. **Blood** - for creating Platelet-Rich Plasma (PRP).\\n2. **Bone marrow** - used to extract stem cells and create bone marrow concentrate.\\n3. **Adipose (fat) tissue** - used to derive adipose tissue concentrate rich in stem cells.\\n\\nThese autologous sources are utilized to help accelerate healing in bone, cartilage, and soft tissue injuries', \"Orthobiologics are cellular and biochemical substances derived from a patient's own body that are used to promote healing in orthopedic procedures. Here are some sources of orthobiologics:\\n\\n1. Bone marrow: Bone marrow aspirate (BMA) and bone marrow concentrate (BMC) are obtained through a bone marrow aspiration or bone marrow biopsy. BMA contains a high concentration of mesenchymal stem cells (MSCs), growth factors, and cytokines. BMC is a concentrated form of BMA that contains a higher number of MSCs.\\n\\n2. Adipose tissue: Adipose tissue, also known as fat tissue, is a rich source of MSCs. Adipose tissue can be harvested through liposuction, and the MSCs can be isolated and used for orthopedic procedures.\\n\\n3. Platelets: Platelet-rich plasma (PRP) is obtained by separating platelets from a patient's own blood. PRP contains a high concentration of growth factors, such as platelet-derived growth factor (PDGF) and transforming growth factor\", '- Blood derived orthobiologics include: Platelet Rich Plasma (PRP), Concentrated Bone Marrow Aspirate (CBMA), White Blood Cell-Rich Plasma (WBC-PRP), White Blood Cell-Rich Fibrinogen (WBC-RF), Bone Marrow Mononuclear Cells (BM-MNC), Red Blood Cell-Rich Plasma (RBC-PRP), Platelet Poor Plasma (PPP), and Platelet-Rich Fibrin Matrix (PRFM).\\n- Adipose-derived orthobiologics include: Stromal Vascular Fraction (SVF), Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSC), Lipogems, and Adipose-Derived Stem Cells (ADSC).', \"Orthobiologics are derived from patient's own tissues, such as blood, bone marrow, and adipose tissue. The sources of orthobiologics include platelet-rich plasma (PRP), bone marrow concentrate, and adipose tissue concentrate.\", \"Orthobiologics are derived from a patient's own tissues. The sources include blood, bone marrow, and adipose tissue, which are used to prepare platelet-rich plasma (PRP), bone marrow concentrate, and adipose tissue concentrate, respectively.\", 'Sources of orthobiologics are adipose tissue, bone marrow, and blood.', \"Orthobiologics are derived from the patient's own tissues. Common sources include blood, bone marrow, and adipose tissue, which are used to prepare platelet-rich plasma, bone marrow concentrate, and adipose tissue concentrate respectively.\", \"Sources of orthobiologics include patient's own tissues such as blood, bone marrow, and adipose tissue. Platelet-rich plasma (PRP) can be prepared from blood, bone marrow concentrate can be prepared from bone marrow, and adipose tissue concentrate can be prepared from adipose tissue.\", \"Orthobiologics are substances that are derived from the body's own tissues or cells and are used to promote healing and regeneration in the musculoskeletal system. Some common sources of orthobiologics include:\\n\\n1. Platelet-rich plasma (PRP): This is a concentrated form of platelets that are obtained from the patient's own blood. PRP contains growth factors and other substances that can stimulate tissue repair and regeneration.\\n\\n2. Bone marrow aspirate concentrate (BMAC): This is a concentrated form of bone marrow that is obtained from the patient's own bone. BMAC contains stem cells and other substances that can promote tissue repair and regeneration.\\n\\n3. Adipose-derived stem cells (ADSCs): These are stem cells that are obtained from the patient's own fat tissue. ADSCs can differentiate into various cell types and have the potential to promote tissue repair and regeneration.\\n\\n4. Amniotic membrane: This is a tissue that is obtained from the\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided tables, the following are sources of orthobiologics:\n\n1. Bone Marrow (entities #2, #11, #13, #14, #21, #28)\n2. Platelet-rich Plasma (entities #5, #17, #18, #20, #21, #25, #27)\n3. Bone Marrow Aspirate (entities #2, #14, #20, #22, #25, #28)\n4. Bone Marrow Concentrate (entities #2, #14, #20, #22, #25, #28)\n5. Adipose Tissue (entities #20, #22, #25, #28)\n6. Bone Marrow Aspirate Concentrate (entities #2, #14, #20, #22, #25, #28)\n7. Autologous Biological Preparations (entities #22, #25)\n8. Umbilical Cord-Derived Cells (entities #13)\n9. Amniotic Membrane Products (entities #13)\n10. Adipose-Derived Mesenchymal Stromal Cells (entities #13)\n11. Bone Graft Substitutes (entities #15)\n12. Demineralized Bone Matrix (entities #15)\n13. Bone Graft (entities #15)\n14. Platelet-Derived Growth Factor (entities #15)\n15. Bone Morphogenetic Proteins (entities #15)\n16. Parathyroid Hormone (entities #15)\n17. Vitamin D and Calcium (entities #15)\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer lists a comprehensive range of sources for orthobiologics, including bone marrow, platelet-rich plasma, adipose tissue, and other derivatives like bone marrow aspirate concentrate and amniotic membrane products. It covers most of the key sources mentioned in the reference answers but misses some specifics like hyaluronic acid and certain types of stem cells.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and includes only relevant information without venturing into unrelated topics. Each listed source is directly relevant to orthobiologics, as confirmed by the reference answers.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "There is minor repetition with terms like 'bone marrow aspirate' and 'bone marrow aspirate concentrate,' which are closely related but listed separately. However, the answer avoids significant redundancy and each listed item adds distinct value.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-structured and easy to read, with each source clearly enumerated and logically grouped. The use of numerical listing enhances readability, though slight improvement could be made by grouping similar items (e.g., bone marrow-related terms) under subheadings."
    },
    {
        "Question": "Are advanced directives an expression of the patient's wishes for future care in case they become cognitively impaired or find themselves in critical condition?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nAre advanced directives an expression of the patient's wishes for future care in case they become cognitively impaired or find themselves in critical condition?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes. Advance care directives are important for documenting treatment preferences in patient care planning.', \"Yes, advanced directives serve as an expression of the patient's wishes for future care in case they become cognitively impaired or find themselves in critical condition.\", \"Yes, advanced directives are an expression of the patient's wishes for future care in case they become cognitively impaired or find themselves in critical condition.\", \"Yes, advance directives are an expression of the patient's wishes for future care in case they become cognitively impaired or find themselves in critical condition.\", \"Yes, advanced directives are legal documents describing the patient's wishes for medical treatment in future scenarios where they are unable to make decisions for themselves.\", \"Yes. Advance directives are legal documents that express a patient's wishes for future medical care in case they become unable to make their own decisions.\", \"An advance directive is a document in writing that expresses a patient's wishes for future medical care in the event that they become cognitively impaired or find themselves in critical condition. It is a legal document that can be used to guide the care of the patient in the event that they are unable to express their wishes.\", \"Yes, advanced directives are documents that express a patient's wishes for future care in case they become cognitively impaired or find themselves in critical condition.\", \"Advanced directives are documents that express a patient's wishes for their future medical care in case they become unable to communicate their decisions due to cognitive impairment or critical illness. These directives can include instructions on the use of life-sustaining treatments, pain management, and organ donation, among others. By completing an advanced directive, patients can ensure that their preferences are respected and avoid potential disagreements among family members or healthcare providers. Advanced directives can also help alleviate some of the burden on surrogate decision-makers, who may struggle with making decisions on behalf of a loved one. Overall, advanced directives provide patients with greater autonomy and control over their medical care, even in the event that they are unable to communicate their wishes.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, advanced directives are a document that outlines a patient's wishes and preferences for future medical treatment in the event that they become incapacitated or unable to communicate their wishes. They are a way for patients to express their values, goals, and preferences for care in advance, ensuring that their autonomy and decision-making capacity are respected if they are unable to make decisions for themselves.\n\nAdvanced directives can include information such as:\n\n* Preferences for life-sustaining treatments, such as CPR, mechanical ventilation, or artificial nutrition and hydration\n* Wishes regarding pain management and symptom control\n* Desires for end-of-life care, including hospice care or palliative care\n* Designation of a healthcare proxy or surrogate decision-maker\n* Instructions for specific medical treatments or procedures\n\nBy having an advanced directive in place, patients can ensure that their wishes are respected and their care is aligned with their values and goals, even if they are unable to communicate their preferences at the time of treatment.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer covers all essential aspects of advanced directives, including their purpose, types of preferences they can include (e.g., life-sustaining treatments, pain management, hospice care), and the designation of a healthcare proxy. It aligns well with the reference answers, which also emphasize the expression of patient wishes in cases of incapacity.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include irrelevant information. It clearly and concisely describes the function and components of advanced directives without straying from the topic.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no unnecessary repetition in the answer. Each point is mentioned once, clearly, and serves a distinct purpose in the explanation. The bulleted list efficiently organizes related information without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is highly readable and fluent. The language used is straightforward and professional. The bulleted list improves comprehension by breaking down detailed components logically, making it easy for the reader to follow."
    },
    {
        "Question": "Which drugs were tested in the CodeBreaK 300 clinical trial?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhich drugs were tested in the CodeBreaK 300 clinical trial?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Phase III CodeBreaK 300 showed EGFR inhibitor panitumumab plus KRAS G12C inhibitor sotorasib resulted in longer progression-free survival than standard treatment in Refractory Colorectal Cancer with Mutated KRAS G12C.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nI don't see a mention of the CodeBreaK 300 clinical trial in the provided data tables.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "1",
        "Information Recall Explanation": "The answer fails to recall any information about the drugs tested in the CodeBreaK 300 clinical trial, which is the key piece of information requested in the question.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise in stating that no mention of the CodeBreaK 300 clinical trial was found in the provided data tables. It does not include irrelevant details.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat any information; it succinctly communicates the lack of relevant data in the provided tables.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is clear and easily understandable, with no grammatical issues or complex jargon."
    },
    {
        "Question": "Is surgical resection an appropriate treatment over immunotherapy in MSI-H locally advanced rectal cancer patients?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs surgical resection an appropriate treatment over immunotherapy in MSI-H locally advanced rectal cancer patients?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Immunotherapy with organ preservation are the preferred treatment over surgical resection in locally advanced rectal cancer patients with MSI-H', 'Surgical resection is not necessarily the most appropriate treatment for MSI-H locally advanced rectal cancer patients. Immunotherapy, specifically neoadjuvant therapy with immune checkpoint inhibitors (ICIs), has shown promising results in treating MSI-H/dMMR rectal cancer. ICIs are more active in treatment-naïve patients than in patients with refractory MSI-H/dMMR metastatic colorectal cancer, and they have been shown to be effective in achieving complete clinical and pathological responses in locally advanced MSI-H/dMMR rectal cancer patients. Additionally, neoadjuvant treatment with ICIs has the potential to preserve organ function and fertility in young patients. Therefore, it is reasonable to consider neoadjuvant immunotherapy as a viable alternative to surgical resection for MSI-H locally advanced rectal cancer patients. However, clinical trials are', 'No, surgical resection is not an appropriate treatment over immunotherapy in MSI-H locally advanced rectal cancer patients.', \"In MSI-H locally advanced rectal cancer patients, neoadjuvant immunotherapy, particularly immune checkpoint inhibitors, has shown promising results in terms of efficacy and safety. Surgical resection following neoadjuvant immunotherapy may be considered as a treatment strategy, especially when there is a good response to immunotherapy leading to tumor downsizing or achieving a pathological complete response (pCR). The decision between surgical resection and immunotherapy should be individualized based on factors such as tumor response to immunotherapy, patient's overall health status, and treatment goals. Further studies and clinical trials are ongoing to determine the optimal treatment approach for MSI-H locally advanced rectal cancer patients.\", 'No, neoadjuvant PD-1 blockade had high efficacy and led to a high rate of CR in LARC patients with dMMR/MSI-H.', 'While surgical resection is a good treatment option for MSI-H locally advanced rectal cancer patients, immunotherapy is preferred because the latter has been proven to provide more benefits to patients in the long term', 'No, surgical resection may not be the most appropriate treatment for MSI-H locally advanced rectal cancer (LARC) patients. Recent studies suggest that neoadjuvant immunotherapy (NAICI) treatment, such as monoimmunotherapy with PD-1 inhibitor, can have favorable overall response rate (ORR) and pathological complete response (pCR) rate, as well as relatively low incidences of immune-related adverse events (irAEs) and serious adverse events (srAEs) for patients with dMMR/MSI-H LARC. Additionally, a case report showed that a patient with LARC and MSI-H achieved pCR and complete radical resection after being treated with neoadjuvant chemotherapy (TNT) with nivolumab. The NICHE trial also pioneered the use of NAICI treatment in LARC, and recent reports from several phase II studies have demonstrated satisfactory tumor downsizing in CRC. However, further studies are needed to confirm the long-term efficacy and safety of immunotherapy in MSI-H LARC patients.', 'No. Due to the special features of biologics in MSI-H/dMMR CRC patients, this subgroup of patients achieved little treatment efficacy from chemoradiotherapy but benefited from immune checkpoint inhibitors (ICIs).', 'No, surgical resection is not an appropriate treatment over immunotherapy in MSI-H locally advanced rectal cancer patients because the latter one showed better outcome in recent studies.', 'No, immunotherapy has shown high efficacy in MSI-H locally advanced rectal cancer patients.', 'Surgical resection is currently the standard of care for locally advanced rectal cancer, including those that are MSI-H. However, recent studies have shown that neoadjuvant treatment with immune checkpoint inhibitors (ICIs) can be highly effective in MSI-H locally advanced rectal cancer patients, resulting in a complete clinical and pathological response. While these results are promising, it is important to note that they come from case reports and small studies, and further research is needed to establish the role of ICIs in the treatment of MSI-H locally advanced rectal cancer. Additionally, organ-preservation strategies should be evaluated in clinical trials. Therefore, while surgical resection remains the standard of care, immunotherapy may be a promising alternative for MSI-H locally advanced rectal cancer patients.', 'The use of surgical resection as a treatment for MSI-H locally advanced rectal cancer patients should be considered in conjunction with immunotherapy. While immunotherapy has shown promising results in achieving complete clinical and pathological responses, surgical resection remains an important component of treatment to ensure complete removal of the tumor and assess the extent of disease. The combination of neoadjuvant immunotherapy followed by surgical resection may offer the best outcomes for these patients, allowing for organ preservation and potentially avoiding the need for chemoradiation therapy in the future.', 'No. Surgical resection is not an appropriate treatment over immunotherapy in locally advanced MSI-H locally advanced rectal cancer patients.', 'In conclusion, while surgery remains the standard of care for localized rectal cancers, emerging data suggests that neoadjuvant immunotherapy may be a safe and effective treatment option for select patients with mismatch repair-deficient or microsatellite instability-high tumors. For these individuals, particularly those who achieve clinical complete response to immunotherapy, close surveillance without immediate surgical intervention could potentially offer a less invasive approach with comparable outcomes. However, larger studies are needed to fully understand the long-term benefits and risks of this strategy.', 'No, immunotherapy is a more appropriate treatment for MSI-H locally advanced rectal cancer patients.', 'No, surgical resection is not necessarily an appropriate treatment over immunotherapy in MSI-H locally advanced rectal cancer patients. While surgical resection remains the standard of care due to the high likelihood of achieving a pathologic complete response (pCR) with neoadjuvant therapy, immune checkpoint inhibitors (ICIs) have shown promising results in this population, particularly in metastatic disease. In fact, ongoing clinical trials are investigating the role of ICIs in combination with neoadjuvant therapy in MSI-H locally advanced rectal cancer patients to determine if they can improve outcomes beyond surgery alone. Therefore, the decision to choose between surgical resection and immunotherapy in MSI-H locally advanced rectal cancer patients should be made on a case-by-case basis, taking into account factors such as tumor stage, patient preferences, and the availability of clinical trials.', 'No, surgical resection alone is not the most appropriate treatment for MSI-H locally advanced rectal cancer (LARC) patients. The evidence suggests that these patients benefit more from neoadjuvant immune checkpoint inhibitors (ICIs) compared to standard chemoradiotherapy followed by surgery.\\n\\nKey points:\\n- MSI-H/dMMR LARC patients achieve little benefit from standard chemoradiotherapy but respond well to ICIs\\n- Neoadjuvant ICI treatment before surgery leads to better systemic immune function, increased antigenic exposure, and improved long-term memory induction\\n- Several phase II studies have shown that neoadjuvant ICI results in satisfactory tumor downsizing in MSI-H LARC\\n- Neoadjuvant PD-1 inhibitor monotherapy has favorable response rates, pathologic complete response rates, and acceptable safety in MSI-H LARC\\n\\nTherefore, while surgery remains an important component of treatment, the evidence supports using neoadjuvant immunotherapy first in MSI-H LARC patients, rather than upfront surgical resection alone. The combination of neoadjuvant ICIs followed by surgery appears to be the preferred approach for improved outcomes in this molecular subset of rectal cancer.', 'Based on the provided context, surgical resection is the standard treatment for locally advanced rectal cancer. However, in patients with dMMR/MSI-H locally advanced rectal cancer who achieve a complete pathological response (cCR) during neoadjuvant immunotherapy, adopting immunotherapy as a curative-intent treatment might be considered as an alternative option. This approach requires longer follow-up and larger cohorts to verify its effectiveness.', 'No, patients with locally advanced colorectal cancer (LACRC) have a high risk of recurrence and metastasis, although neoadjuvant therapy may provide some benefit.', 'Surgical resection is proposed as a new organ-preservation strategy for patients with MSI-H/dMMR low LARC, as patients with high microsatellite instability/deficient mismatch repair (MSI-H/dMMR) LACRC may receive little benefit from neoadjuvant chemoradiotherapy or neoadjuvant chemotherapy. In locally advanced colorectal cancer (LACRC), neoadjuvant therapy may offer some benefit, but the choice between surgical resection and immunotherapy should be carefully evaluated based on individual patient characteristics and treatment response.', 'Surgical resection is an appropriate treatment over immunotherapy in MSI-H locally advanced rectal cancer patients.The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 1250 mg/m2.Initial chemotherapy regimen with FOLFOX is the most appropriate in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients.HER2Neu amplificated refractory advanced colorectal cancer patients should be treated with Trastuzumab emtansine.Watch-and-wait policy after neoadjuvant therapy is a cost-effective policy for locally advanced rectal cancer patients.Trifluridine/Tipiracil is a preferential treatment over Regorafenib in elderly colorectal cancer patients.', 'In the case of patients with MSI-H/dMMR locally advanced rectal cancer (LARC), surgical resection might still be considered a primary treatment option. This is because these patients typically receive little benefit from neoadjuvant chemoradiotherapy (nCRT) or neoadjuvant chemotherapy (nCT), which are common pre-surgical treatments aimed at reducing tumor size and spread. Since MSI-H/dMMR tumors have a unique genetic profile that makes them less responsive to these therapies, focusing on surgical options could be more beneficial. However, exploring immunotherapy as a part of the treatment strategy is also advisable, given its potential effectiveness in targeting the specific genetic abnormalities present in MSI-H/dMMR cancers.', 'Yes, resection is proposed in MSI-H locally advanced rectal cancer patients to improve outcomes.', 'The document does not provide enough information to make a direct comparison between surgical resection and immunotherapy in MSI-H locally advanced rectal cancer patients. However, it does mention that patients with locally advanced colorectal cancer (LACRC) have a high risk of recurrence and metastasis, and that neoadjuvant therapy may provide some benefit. It also states that patients with high microsatellite instability/deficient mismatch repair (MSI-H/dMMR) LACRC receive little benefit from neoadjuvant chemoradiotherapy (nCRT) or neoadjuvant chemotherapy (nCT). The document also proposes a new organ-preservation strategy for patients with MSI-H/dMMR low LARC. Further research and studies are needed to determine the most appropriate treatment for MSI-H locally advanced rectal cancer patients.', 'For MSI-H locally advanced rectal cancer patients, surgical resection might be more beneficial compared to immunotherapy alone. This is because these patients typically show poor response to conventional neoadjuvant therapies like chemoradiotherapy, which are often used before immunotherapy. Surgical resection directly removes the tumor, which can be more effective in managing the disease in these specific cases', 'Our team also proposes a new organ-preservation strategy for patients with MSI-H/dMMR low LARC. Patients with locally advanced colorectal cancer (LACRC) have a high risk of recurrence and metastasis, although neoadjuvant therapy may provide some benefit. Patients with high microsatellite instability/deficient mismatch repair (MSI-H/dMMR) LACRC receive little benefit from neoadjuvant chemoradiotherapy (nCRT) or neoadjuvant chemotherapy (nCT).', \"In the case of patients with MSI-H/dMMR locally advanced rectal cancer (LARC), surgical resection might be more appropriate than relying solely on immunotherapy. This is because these patients typically receive little benefit from neoadjuvant chemoradiotherapy (nCRT) or neoadjuvant chemotherapy (nCT), which are common pre-surgical treatments aimed at shrinking the tumor and making surgery more effective. Since the effectiveness of these therapies is limited in MSI-H/dMMR patients, moving directly to surgical resection could be a more effective strategy. However, the potential role of immunotherapy in this context should also be considered, especially given its promising results in other MSI-H/dMMR cancer settings. It's important to tailor the treatment plan to the specific needs and response patterns of the patient.\", 'Based on current evidence, surgical resection is still considered the primary treatment for locally advanced rectal cancer (LARC) with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors. While immunotherapy has shown promising results in other types of cancer, its role in MSI-H/dMMR LARC is still being investigated.\\n\\nA study published in the Journal of Clinical Oncology in 2021 found that neoadjuvant chemotherapy (nCT) and chemoradiotherapy (nCRT) did not significantly improve pathological complete response (pCR) rates in MSI-H/dMMR LARC patients compared to surgery alone. The study also found that patients who received nCT or nCRT had higher rates of surgical complications and longer hospital stays.\\n\\nAnother study published in the Annals of Surgical Oncology in 2020 found that neoadjuvant immunotherapy did not significantly improve pCR rates or overall survival in MSI-H/dMMR LARC patients compared to surgery alone.\\n\\nHowever,', 'Based on the provided snippets, surgical resection may not be the most appropriate treatment for MSI-H locally advanced rectal cancer patients. The snippets mention that patients with high microsatellite instability/deficient mismatch repair (MSI-H/dMMR) LACRC receive little benefit from neoadjuvant chemoradiotherapy (nCRT) or neoadjuvant chemotherapy (nCT), suggesting that these therapies may not be effective in this patient population. Additionally, the snippets propose a new organ-preservation strategy for these patients, which suggests that surgical resection may not be necessary or beneficial. Immunotherapy, on the other hand, may be a more appropriate treatment option for these patients, as it can target the cancer cells specifically and has shown promise in treating MSI-H/dMMR colorectal cancer.', 'no, surgical resection may not be the most appropriate treatment over immunotherapy for MSI-H locally advanced rectal cancer patients. These patients typically receive little benefit from neoadjuvant chemoradiotherapy or neoadjuvant chemotherapy, suggesting that alternative treatments such as immunotherapy could be more beneficial.', 'Surgical resection is the standard treatment for locally advanced rectal cancer. However, in patients with MSI-H (microsatellite instability-high) locally advanced rectal cancer, immunotherapy has shown promising results. The use of immune checkpoint inhibitors, such as pembrolizumab and nivolumab, has been approved by the FDA for the treatment of MSI-H metastatic colorectal cancer. There is growing interest in using immunotherapy as neoadjuvant therapy for MSI-H locally advanced rectal cancer, which may change the current approaches to treatment. Further research and clinical trials are needed to determine the optimal treatment strategy for these patients.', 'Surgical resection is an appropriate treatment over immunotherapy in MSI-H locally advanced rectal cancer patients.The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 1250 mg/m2.Initial chemotherapy regimen with FOLFOX is the most appropriate in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients.HER2Neu amplificated refractory advanced colorectal cancer patients should be treated with Trastuzumab plus chemotherapy.Watch-and-wait policy after neoadjuvant therapy is a cost-effective policy for locally advanced rectal cancer patients.Tucatinib plus trastuzumab is a preferential treatment over Regorafenib in elderly colorectal cancer patients.', 'Surgical resection may not be the most appropriate treatment for MSI-H locally advanced rectal cancer patients, as neoadjuvant immunotherapy (nIT) has shown promising results in this patient population. The KEYNOTE-016 trial and CheckMate-142 trial demonstrated that immune checkpoint inhibitors (ICIs) are effective in treating MSI-H/dMMR metastatic colorectal cancer (mCRC), and the FDA has approved nivolumab and pembrolizumab for this indication. Additionally, the NICHE trial is currently investigating the use of nIT for CRC. While surgical resection may still have a role in certain cases, immunotherapy may offer a more effective and less invasive treatment approach for MSI-H locally advanced rectal cancer patients.', 'Surgical resection is currently considered the standard of care for localized colorectal cancers, including those with high microsatellite instability/deficient mismatch repair (MSI-H/dMMR). While immunotherapy has shown promising results in metastatic MSI-H/dMMR tumors, there is limited data on its use as an alternative to surgical resection in the locally advanced setting. Therefore, based on current evidence, surgical intervention remains the primary treatment approach for localized MSI-H/dMMR LACRC patients, with immunotherapy being explored primarily in metastatic or unresectable disease scenarios.', 'Based on the information provided, patients with high microsatellite instability/deficient mismatch repair (MSI-H/dMMR) locally advanced colorectal cancer (LACRC) receive little benefit from standard neoadjuvant chemoradiotherapy (nCRT) or neoadjuvant chemotherapy (nCT). The authors propose a new organ-preservation strategy for patients with MSI-H/dMMR low LARC, which suggests that surgical resection may not be the most appropriate treatment for these patients compared to alternative approaches like immunotherapy. However, more details would be needed to definitively determine the optimal treatment strategy.', 'No, patients with MSI-H/dMMR locally advanced rectal cancer receive little benefit from traditional treatments like neoadjuvant chemoradiotherapy or chemotherapy, suggesting that alternative treatments such as immunotherapy might be more appropriate.', \"In patients with MSI-H locally advanced rectal cancer, surgical resection is the standard treatment approach. However, immunotherapy can be considered as an additional treatment option in certain cases, such as those with unresectable tumors or those who have a high risk of recurrence or metastasis despite surgery. The decision to use immunotherapy should be made on a case-by-case basis, taking into account the patient's overall health, tumor characteristics, and response to other treatments.\", 'Surgical resection is generally considered the primary treatment for locally advanced rectal cancer (LARC) patients with MSI-H/dMMR. However, immunotherapy may be an option for patients who have not responded to surgery or who have recurrent disease.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data tables, I do not have direct information on the comparative effectiveness of surgical resection versus immunotherapy in MSI-H locally advanced rectal cancer patients. However, I can provide some relevant information from the tables that might be useful in answering this question.\n\nFrom the Relations table, I found the following associations:\n\n* MSI-H/dMMR rectal cancer is associated with immune checkpoint inhibitors (relation id: 15, keywords: \"association\").\n* Immunotherapy is used to treat rectal cancer (relation id: 29, keywords: \"treatment\").\n* Rectal cancer with MSI-H/dMMR tumors is more susceptible to immune checkpoint inhibitors (relation id: 15, keywords: \"association\").\n\nThese associations suggest that immunotherapy may be a viable treatment option for MSI-H locally advanced rectal cancer patients.\n\nHowever, I did not find any direct comparisons between surgical resection and immunotherapy in the provided data tables. Therefore, I cannot provide a definitive answer to the question of whether surgical resection is an appropriate treatment over immunotherapy in MSI-H locally advanced rectal cancer patients.\n\nIt's worth noting that clinical trials and studies have investigated the effectiveness of immunotherapy in MSI-H colorectal cancer, including rectal cancer. These studies have shown promising results, with some patients achieving complete or partial responses to immunotherapy. However, the optimal treatment approach for MSI-H locally advanced rectal cancer patients remains a topic of ongoing research and debate.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer provides relevant associations from the data tables, such as the link between MSI-H/dMMR rectal cancer and immune checkpoint inhibitors, and the use of immunotherapy for rectal cancer. However, it lacks specific data or references to clinical trials or studies comparing surgical resection with immunotherapy, which would enhance recall.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise, focusing only on the information available in the provided data tables without adding irrelevant details. It clearly states the limitations of the data and does not extrapolate beyond what is given.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each point is made clearly and concisely without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, easy to follow, and written in clear, fluent English. The explanation is logical and the limitations are clearly stated, making it very readable."
    },
    {
        "Question": "Is One-carbon (1C)  metabolism associated with folate?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs One-carbon (1C)  metabolism associated with folate?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['One-carbon (1C) metabolism, mediated by the folate cofactor, supports multiple physiological processes. These include biosynthesis (purines and thymidine), amino acid homeostasis (glycine, serine, and methionine), epigenetic maintenance, and redox defense.', '1C metabolism is associated with folate as it provides methyl group donors and the related intermediate metabolites for biosynthesis of amino acids, nucleic acids, and phospholipids.', 'Yes, one-carbon (1C) metabolism is associated with folate.', 'Yes, One-carbon (1C) metabolism is associated with folate.', '1C metabolism is a network of biochemical reactions that transfer 1-carbon groups. Folate is a co-factor that participates in this network.', 'Yes, One-carbon (1C) metabolism is associated with folate, as it is a folate-dependent pathway essential for various metabolic processes.', 'Yes, One-carbon (1C) metabolism is a metabolic network that is centered on folate, a B vitamin.', '5-MTHF levels, a measure of folate status, were investigated in association with OCM-related metabolites in this study, suggesting a relationship between folate and 1C metabolism.', 'Yes, folate plays a crucial role in one-carbon metabolism.', 'Yes, folate is an essential cofactor in the one-carbon (1C) metabolic pathway and participates in amino acid metabolism.', 'Yes, One-carbon (1C)  metabolism is associated with folate.', 'Yes, the one-carbon (1C) metabolic pathway is associated with folate.', 'Yes, One-carbon (1C) metabolism is associated with folate as folate is an essential cofactor in the one-carbon metabolic pathway.', 'Yes, one-carbon (1C) metabolism is closely associated with folate. Folate acts as a key cofactor in this metabolic pathway, helping to transfer one-carbon units necessary for various critical processes including DNA and RNA synthesis', 'Yes, Folate (FA) is an essential cofactor in the one-carbon (1C) metabolic pathway and participates in amino acid metabolism.', 'yes, one-carbon (1C) metabolism is closely associated with folate. Folate is an essential cofactor in the 1C metabolic pathway, where it helps in the transfer of 1C units necessary for nucleotide biosynthesis and other critical cellular processes.', 'Yes, folate is closely associated with one-carbon metabolism.', 'Yes, folate is an essential cofactor in the one-carbon (1C) metabolic pathway and participates in amino acid metabolism, purine and thymidylate synthesis, and DNA methylation.', 'yes, one-carbon (1C) metabolism is closely associated with folate, which is an essential cofactor in this metabolic pathway.', 'Yes. Folate (FA) is an essential cofactor in the one-carbon (1C) metabolic pathway and participates in amino acid metabolism.', 'Yes, folate is an essential cofactor in the one-carbon (1C) metabolic pathway and is crucial for its function.', 'Yes, One-carbon (1C) metabolism is associated with folate, as it is an essential cofactor in the pathway and plays a role in amino acid metabolism.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, one-carbon (1C) metabolism is closely associated with folate. Folate plays a central role in 1C metabolism, mediating the transfer of one-carbon units, which are essential for various cellular processes, including nucleotide synthesis, methylation, and amino acid homeostasis. The folate cycle is a key component of 1C metabolism, and disruptions in this cycle can have significant effects on overall 1C metabolism.\n\nIn fact, the relations table shows that folate is mentioned as a key component or involved in 1C metabolism in 23 entries, and the description of folate metabolism in the entities table highlights its central role in one-carbon metabolism, including nucleotide and amino acid biosynthesis, antioxidant regeneration, and epigenetic regulation.\n\nAdditionally, the sources table contains several studies that discuss the relationship between folate and 1C metabolism, including the role of folate in one-carbon metabolism, its importance in DNA synthesis and repair, and its impact on epigenetic regulation.\n\nTherefore, based on the data provided, it is clear that one-carbon metabolism is closely associated with folate.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively recalls all necessary information regarding the association between one-carbon (1C) metabolism and folate. It includes details about the central role of folate in mediating the transfer of one-carbon units, its impact on various cellular processes, and references to supporting evidence from tables (relations, entities, sources). This covers the breadth of information provided in the reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and avoids irrelevant information. It focuses solely on the relationship between 1C metabolism and folate, detailing specific roles and impacts without straying into unrelated topics. The mention of supporting evidence (relations table, entities table, sources table) is pertinent to reinforcing the argument.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does a good job of avoiding direct repetition, but there is some redundancy in emphasizing the 'close association' between 1C metabolism and folate multiple times ('closely associated', 'central role', 'key component'). While this reinforces the point, it could be slightly streamlined.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is highly readable and fluent. The structure is clear, with a logical flow from the initial assertion to supporting details and concluding remarks. The language is concise and avoids jargon that might hinder understanding. The use of intermediate explanations (e.g., 'mediating the transfer of one-carbon units') enhances readability."
    },
    {
        "Question": "What type of drug is administered to the mother for the prevention of lung immaturity when a preterm delivery is anticipated?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat type of drug is administered to the mother for the prevention of lung immaturity when a preterm delivery is anticipated?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Corticosteroids administered to the mother accelerate development of immature lung in premature babies intra utero.', 'Corticosteroids are the drug administered to the mother for the prevention of lung immaturity when a preterm delivery is anticipated.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, the type of drug administered to the mother for the prevention of lung immaturity when a preterm delivery is anticipated is a corticosteroid. Specifically, the corticosteroids mentioned in the data as being used for this purpose are betamethasone and dexamethasone.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer correctly identifies corticosteroids as the type of drug administered to the mother for the prevention of lung immaturity in preterm deliveries. It goes beyond the reference answers by specifying betamethasone and dexamethasone, indicating a thorough recall of relevant information.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise, focusing solely on the relevant information about the drugs used (corticosteroids, specifically betamethasone and dexamethasone) without including any irrelevant details.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. It clearly states the type of drug and provides additional specific examples without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easily understandable. It clearly communicates the necessary information in a concise manner without any ambiguity."
    },
    {
        "Question": "Is Depatuxizumab mafodotin effective for glioblastoma?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs Depatuxizumab mafodotin effective for glioblastoma?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['No. Depatuxizumab mafodotin does improve survival of glioblastoma patients.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data tables, Depatuxizumab mafodotin appears to have shown limited effectiveness for glioblastoma. \n\nIn the EORTC 1410/INTELLANCE 2 trial, Depatuxizumab mafodotin did not provide a definitive overall survival benefit in patients with EGFR-amplified glioblastoma (median OS 18.9 vs 18.7 months, HR 1.02, 95% CI 0.82-1.26). However, progression-free survival was longer for Depatuxizumab mafodotin than placebo (median 8.0 vs 6.3 months; HR 0.84, 95% CI 0.70-1.01). \n\nAdditionally, a phase III randomized clinical trial found that Depatuxizumab mafodotin did not improve overall survival in patients with EGFR-amplified newly diagnosed glioblastoma. \n\nIt's worth noting that Depatuxizumab mafodotin was associated with ocular dose-limiting toxicity and no impact on health-related quality of life and neurological functioning in the EORTC 1410/INTELLANCE 2 trial.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer includes detailed information from clinical trials, specifically mentioning the EORTC 1410/INTELLANCE 2 trial and a phase III trial, which aligns with the reference answer's implication of limited effectiveness. Specific metrics like median OS, HR, and 95% CI are also included.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer is precise, focusing on the effectiveness of Depatuxizumab mafodotin without straying into unrelated topics. However, it includes slightly more detail about progression-free survival and toxicity than strictly necessary to answer the question.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat the same information; each point is unique and contributes to the overall understanding of the drug's efficacy in glioblastoma.",
        "Readability Score": "4",
        "Readability Explanation": "The answer is well-structured and fluent; however, some technical terms like 'EGFR-amplified' and 'HR 0.84' may require prior knowledge to fully understand, slightly affecting readability for a general audience."
    },
    {
        "Question": "Is the use of Bevacizumab indicated after progression to a previous regimen with Bevacizumab in advanced colorectal cancer patients?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs the use of Bevacizumab indicated after progression to a previous regimen with Bevacizumab in advanced colorectal cancer patients?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['These results from a large, prospective, observational study suggest that continued vascular endothelial growth factor inhibition with bevacizumab beyond initial PD could play an important role improving the overall success of therapy for patients who have metastastic colorectal cancer', 'The use of bevacizumab after progression to a previous regimen with bevacizumab in advanced colorectal cancer patients is not clearly established. A retrospective single-center study suggested that the use of bevacizumab combined with chemotherapy in this patient population can result in high disease control rates. However, the selection of patients may have influenced the results, and further research is necessary to confirm these findings. In contrast, clinical data and in vitro studies suggest that a previous anti-VEGF therapy may decrease the efficacy of anti-EGFR therapy in metastatic colorectal cancer. Therefore, it is uncertain whether bevacizumab is indicated after progression to a previous regimen with bevacizumab in advanced colorectal cancer patients, and further research is needed to determine its efficacy in this setting.', 'Yes, the results of this study suggest that re-introduction of bevacizumab may still result in clinically meaningful benefits in some patients with advanced colorectal cancer.', 'The use of Bevacizumab after progression on a previous regimen with Bevacizumab may still be indicated in advanced colorectal cancer patients, as it has shown benefits in combination with other agents or regimens in late-line or salvage therapy, potentially improving patient outcomes and survival rates. However, the decision to continue Bevacizumab therapy after progression should be carefully evaluated based on individual patient factors, treatment history, and response to prior therapies.', 'The use of Bevacizumab after progression to a previous regimen with Bevacizumab in advanced colorectal cancer patients is not indicated. According to the document, adding bevacizumab to second-line regimen after failing a bevacizumab-containing regimen does not indicate any benefit. Instead, it suggests that patients may develop addiction to anti-vascular endothelial growth factor (VEGF) agents in these cases.', \"According to the guidelines by the National Comprehensive Cancer Network (NCCN), the use of Bevacizumab after progression to a previous regimen with Bevacizumab is not recommended in advanced colorectal cancer patients. However, in some clinical trials, Bevacizumab has shown activity in patients who have previously received Bevacizumab, and its use in this setting is being investigated in ongoing clinical trials. Therefore, the decision to continue Bevacizumab in this setting should be made on an individual basis, taking into account the patient's overall clinical condition and the potential risks and benefits of continued treatment. In summary, the answer is both yes and no, depending on the specific context and recommendations from a healthcare provider.\", 'No, the use of Bevacizumab is not indicated after progression to a previous regimen with Bevacizumab in advanced colorectal cancer patients. The study mentioned in the context evaluated the efficacy and adverse events of Bevacizumab in colorectal cancer patients. It showed that the median time to progression (TTP) was not significantly different between combination therapy with mFOLFOX6 or FOLFIRI. However, the TTP of Bevacizumab first-line treatment was significantly longer than that of second-line treatment. Therefore, Bevacizumab is recommended for first-line therapy of advanced or metastatic colorectal cancer, but its use after progression to a previous regimen with Bevacizumab is not supported by the available evidence.', 'The question posed is whether the use of bevacizumab is indicated after progression to a previous regimen containing bevacizumab in advanced colorectal cancer (CRC) patients. While there are limited data on this specific scenario, clinical practice and expert opinions suggest that for some patients with metastatic CRC who have progressed on a prior bevacizumab-containing regimen, reintroduction of bevacizumab in combination with chemotherapy may still provide benefit. This is based on the premise that despite initial progression, these patients may respond differently to subsequent treatments due to factors such as tumor heterogeneity and the potential for different mechanisms of resistance. However, decisions regarding retreatment should take into account individual patient characteristics, including disease status, response to previous therapy, overall health, and treatment goals. It is important to note that further research is needed to better understand the role of bevacizumab in this context and to establish clear guidelines for its use after progression on a prior', 'The use of bevacizumab after progression to a previous regimen with bevacizumab in advanced colorectal cancer patients is not clearly established. While some studies suggest that continuing bevacizumab therapy can improve survival outcomes in patients with metastatic colorectal cancer who have progressed on previous treatment, other studies have found inconclusive results regarding the efficacy of bevacizumab in this setting. Additionally, the safety profile of continued bevacizumab use has been shown to be manageable but requires careful monitoring for potential side effects. Ultimately, the decision to use bevacizumab after progression to a previous regimen should be individualized and take into account factors such as patient performance status, tumor burden, and other relevant clinical variables. It is important to consult with a qualified healthcare professional to determine the best course of treatment for each patient.', \"Yes, based on the results of the BOND-2 study, the use of Bevacizumab is indicated after progression to a previous regimen with Bevacizumab in advanced colorectal cancer patients who have received at least 6 months of prior Bevacizumab-containing therapy. However, the decision to continue Bevacizumab in this setting should still be made on an individual basis, taking into account the patient's overall clinical condition and the potential risks and benefits of continued treatment. It is always recommended to consult with a healthcare provider for personalized treatment recommendations.\", 'Yes, the use of bevacizumab is indicated after progression on a previous bevacizumab-containing regimen in advanced colorectal cancer patients. Studies have shown that continuing anti-VEGF therapy with bevacizumab in second-line treatment, even after progression on a bevacizumab-containing first-line regimen, can provide survival benefits. Bevacizumab may be added to first, second, and third-line chemotherapy for palliative treatment of metastatic colorectal cancer, with data indicating increased patient survival, good response rates, and low toxicity. The benefit of maintaining bevacizumab or switching to other anti-VEGF agents like aflibercept after first-line progression suggests an ongoing dependence on VEGF inhibition in these patients.', 'The use of bevacizumab after progression to a previous regimen with bevacizumab is not indicated in advanced colorectal cancer patients. Bevacizumab has shown efficacy as a first-line treatment in combination with chemotherapy, but its benefit as a second-line therapy after progression is limited. Alternative treatment options should be considered in patients who have progressed on bevacizumab-based regimens.', 'Yes, the use of Bevacizumab after progression in advanced colorectal cancer patients is indicated. The study suggests that continuing vascular endothelial growth factor inhibition with Bevacizumab beyond initial progression of the disease (PD) could significantly improve the overall success of the therapy for patients with metastatic colorectal cancer (mCRC).', 'Yes, the use of bevacisubab is often indicated after progression to a previous regimen with bevacisubab in advanced coloreectal cancer (CRC) patients. This is because bevacisubab, being a monoclonal antibody, can specifically recognize and bind to human epidermal growth factor receptor (EGFP) on the surface of cancer cells. This recognition and binding can lead to the activation of the complement system, resulting in the selective destruction of cancer cells. ', \"The study suggests that continued use of bevacizumab beyond initial progression in patients with metastatic colorectal cancer (mCRC) may improve overall success of therapy. However, further research is needed to confirm these findings and to determine the optimal duration and timing of bevacizumab therapy in this patient population. It is important to consider the potential risks and benefits of continued bevacizumab therapy on a case-by-case basis and in consultation with the patient's healthcare team.\", 'Yes, the use of bevacizumab beyond progression in advanced colorectal cancer patients can be beneficial. Continuing bevacizumab treatment even after initial progression has shown to potentially improve outcomes, as suggested by observational studies. This approach involves maintaining the inhibition of vascular endothelial growth factor, which can help in managing the disease more effectively', 'yes, the use of bevacizumab might be indicated even after progression in advanced colorectal cancer patients. The study suggests that \"continued vascular endothelial growth factor inhibition with bevacizumab beyond initial PD (progressive disease) could play an important role in improving the overall success of therapy for patients who have mCRC (metastatic colorectal cancer).\" This indicates potential benefits of continuing bevacizumab treatment beyond the initial progression of the disease.', \"The results of a large, prospective, observational study suggest that continued use of Bevacizumab after progression to a previous regimen with Bevacizumab may play an important role in improving the overall success of therapy for advanced colorectal cancer patients. However, the use of Bevacizumab after progression is not currently approved by regulatory agencies for this indication, and the decision to continue treatment with Bevacizumab in this setting should be made on an individual basis by the treating healthcare provider in light of the patient's clinical circumstances and preferences. It is always recommended to consult the prescribing information and discuss with a healthcare provider for the most up-to-date and personalized treatment recommendations.\", 'The study suggests that continued use of bevacizumab beyond initial progression may improve overall success of therapy for advanced colorectal cancer patients. However, the optimal duration and timing of bevacizumab therapy requires further investigation. It is not clear whether bevacizumab is indicated after progression to a previous regimen with bevacizumab. Patients should discuss the potential benefits and risks with their healthcare provider to determine the most appropriate treatment plan for their individual situation.', 'Yes, the use of Bevacizumab is indicated after progression to a previous regimen with Bevacizumab in advanced colorectal cancer patients. A large observational study (BRiTE) showed that continuing Bevacizumab treatment beyond initial disease progression (BBP) was strongly and independently associated with improved survival in patients with metastatic colorectal cancer (mCRC). The study reported a longer-than-expected overall survival of 25.1 months in patients who received Bevacizumab. The results suggest that continued vascular endothelial growth factor inhibition with Bevacizumab could play an important role in improving the overall success of therapy for patients with mCRC.', 'Yes, the use of Bevacizumab is indicated after progression to a previous regimen with Bevacizumab in advanced colorectal cancer patients based on these study results. Continued treatment with Bevacizumab beyond initial disease progression may contribute to improved overall success rates and play an important role in therapy for metastatic colorectal cancer (mCRC) patients.', 'Yes, the use of Bevacizumab beyond first progression (BBP) is indicated in advanced colorectal cancer (CRC) patients. The BRiTE study, a large observational cohort study, demonstrated that BBP was strongly and independently associated with improved overall survival (OS) in metastatic CRC patients who had previously been untreated and experienced disease progression. Median OS rates were 12.6, 19.9, and 31.8 months in the no post-PD treatment, no-BBP, and BBP groups, respectively. Multivariate analyses further confirmed these findings, indicating that BBP significantly improved survival compared to no BBP (HR, 0.48; P < .001). Hypertension requiring medication was the only bevacizumab-related safety event observed more frequently in the BBP group. Therefore, continued vascular endothelial growth factor inhibition with Bevacizum', 'Yes, the results from a large, prospective, observational study suggest that continued vascular endothelial growth factor inhibition with bevacizumab beyond initial disease progression could play an important role in improving the overall success of therapy for patients who have metastatic colorectal cancer.', \"The use of Bevacizumab may be indicated after progression to a previous regimen with Bevacizumab in advanced colorectal cancer patients. Results from a large, prospective, observational study suggest that continued vascular endothelial growth factor (VEGF) inhibition with Bevacizumab beyond initial progression could improve the overall success of therapy for patients with metastatic colorectal cancer (mCRC). However, the decision to continue Bevacizumab should be individualized based on factors such as the patient's overall health, treatment goals, and potential risks and benefits.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the use of Bevacizumab after progression to a previous regimen with Bevacizumab in advanced colorectal cancer patients is indicated. \n\nThe data from relation 2 \"BEVACIZUMAB-CONTAINING REGIMEN\",\"COLORECTAL CANCER\" states that \"Bevacizumab-containing regimens improve the efficacy of treatment in colorectal cancer.\" \n\nAdditionally, relation 10 \"BEVACIZUMAB\",\"DISEASE PROGRESSION\" states that \"The continuation of bevacizumab after disease progression offers a survival benefit.\"\n\nHowever, the data also indicates that the effectiveness of Bevacizumab may be limited by drug resistance and side effects (entity 2 \"BEVACIZUMAB\",\"CHEMICAL\" states that \"A monoclonal antibody used in various indications to suppress tumor growth through anti-angiogenesis, but its efficacy is limited by drug resistance and side effects.\").\n\nTherefore, while the use of Bevacizumab after progression to a previous regimen with Bevacizumab in advanced colorectal cancer patients is indicated, it is essential to consider the potential limitations of the treatment.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer captures key points from the reference answers, such as the indication of Bevacizumab after progression and the potential survival benefits. However, it misses some nuanced details from the references, such as the variability in patient response and the need for individualized treatment decisions.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise in stating the indication of Bevacizumab and its limitations (drug resistance and side effects). It does not include irrelevant information, but could be more detailed about the specific conditions under which Bevacizumab is beneficial.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. Each point is presented clearly and concisely without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand. The information is presented in a logical sequence, making it highly readable."
    },
    {
        "Question": "Please list the psychoactive drugs used to treat mental health disorders.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nPlease list the psychoactive drugs used to treat mental health disorders.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['LSD, Psilocybin, MDMA, and Ketamine have been studied preclinically and clinically to treat mental health disorders', 'Psychoactive drugs used to treat mental health disorders can be ketamine, psychedelics, ayahuasca, psilocybin, modafinil, by modulation of certain neurochemical pathways, cathinones, and antidepressants.', 'The psychoactive drugs used to treat mental health disorders include ketamine, psilocybin, ayahuasca, MDMA, LSD, modafinil, cannabidiol, and psychedelics.', 'Psychoactive drugs used to treat mental health disorders include ketamine, psilocybin, ayahuasca, MDMA, LSD, modafinil, cannabidiol, and antidepressants.', 'Psychoactive drugs used to treat mental health disorders include stimulants, nonstimulants, selective serotonin reuptake inhibitors, antipsychotics, antiepileptics/mood stabilizers/lithium, anxiolytics (BDZ), antidepressants, neuroleptic drugs, anxiolytics, and hypnotics. The most frequently used psychoactive drugs are benzodiazepines.', 'The psychoactive drugs used to treat mental health disorders are stimulants, nonstimulants, selective serotonin reuptake inhibitors, antipsychotics, antiepileptics/mood stabilizers/lithium, anxiolytics, central sympatholytics, and benzodiazepines.', '\\nAntidepressants (SSRIs, SNRIs, TCAs, MAOIs), anxiolytics (benzodiazepines, buspirone, azapirones), antipsychotics (FGAs, SGAs), mood stabilizers (lithium, valproic acid, carbamazepine), and antimanic agents (olanzapine, risperidone, quetiapine) are examples of psychoactive drugs used to treat mental health disorders.', 'Psychoactive drugs like MDMA, ketamine, psilocybin, ayahuasca, and LSD are used in treating mental health disorders.', 'The following psychoactive drugs are used to treat mental health disorders:, 1. MDMA, 2. ketamine, 3. psilocybin, 4. LSD, 5. psilocybin, 6. MDMA, 7. ketamine, 8. psilocybin, 9. LSD, 1', 'The psychoactive drugs commonly used to treat mental health disorders include antidepressants, antipsychotics, mood stabilizers, anxiolytics, and stimulants.', 'The psychoactive drugs used to treat mental health disorders include: , 1. Cannabis (CBD and THC), 2. Psychoactive mushrooms (psilocybin), 3. MDMA (ecstasy), 4. Molly (MDMA and psilocybin), 5. Ayahuasca, 6.', 'The psychoactive drugs used to treat mental health disorders are stimulants, nonstimulants, selective serotonin reuptake inhibitors, antipsychotics, antiepileptics/mood stabilizers/lithium, anxiolytics (BDZ), antidepressants, antipsychotics, mood stabilizers, and anxiolytics.', 'Psychoactive drugs used to treat mental health disorders include:\\n\\n1. Stimulants (for ADHD)\\n2. Non-stimulants (for ADHD) \\n3. Selective serotonin reuptake inhibitors (SSRIs) (for anxiety and depression)\\n4. Antipsychotics\\n5. Antiepileptics/mood stabilizers/lithium\\n6. Anxiolytics (benzodiazepines)\\n7. Hypnotics/sedatives\\n8. Antidepressants\\n9. Central sympatholytics (e.g. clonidine)', 'Ketamine, esketamine, psilocybin, and psychedelics are psychoactive drugs used to treat mental health disorders.', 'Psychoactive drugs used to treat mental health disorders include MDMA, ketamine, esketamine, psilocybin, and other psychedelic substances. These drugs have shown promise in targeting fear, anxiety pathways, and depressive disorders, offering new treatment options for various mental health conditions.', 'The psychoactive drugs mentioned for treating mental health disorders include MDMA, ketamine, esketamine, and psilocybin. These substances have been researched for their potential to alleviate symptoms of disorders such as chronic posttraumatic stress disorder (PTSD) and depressive disorders.', 'The psychoactive drugs used to treat mental health disorders include ketamine, psilocybin, esketamine, and MDMA.', 'Psychoactive drugs like MDMA, ketamine, and psilocybin have been shown to specifically target and decrease fear and anxiety pathways in the brain.', 'Psychoactive drugs used to treat mental health disorders include Ketamine, Psilocybin, MDMA, esketamine, psychedelics, esketamine, MDMA-assisted, and MDMA-assisted psychotherapy.', 'The psychoactive drugs used to treat mental health disorders include MDMA, ketamine, esketamine, and psilocybin. These drugs have been shown to specifically target and decrease fear and anxiety pathways in the brain.', 'The psychoactive drugs used to treat mental health disorders include MDMA, ketamine, psilocybin, and esketamine. These substances have shown promise in targeting and alleviating symptoms of various mental health conditions, such as depression and anxiety', 'Psychoactive drugs such as MDMA, ketamine, and psilocybin have been shown to specifically target and decrease fear and anxiety pathways in the brain.', 'The psychoactive drugs mentioned for treating mental health disorders include MDMA, ketamine, esketamine, and psilocybin. These substances have been researched for their potential to alleviate symptoms of disorders such as chronic posttraumatic stress disorder (PTSD) and depression.', '1. Selective Serotonin Reuptake Inhibitors (SSRIs): Commonly prescribed for depression, anxiety disorders, and post-traumatic stress disorder (PTSD). Examples include fluoxetine (Prozac), sertraline (Zoloft), and paroxetine (Paxil).\\n\\n2. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): Used to treat depression, anxiety disorders, and PTSD. Examples include venlafaxine (Effexor) and duloxetine (Cymbalta).\\n\\n3. Tricyclic Antidepressants (TCAs): Used to treat depression, anxiety disorders, and chronic pain. Examples include amitriptyline (Elavil) and imipramine (Tofranil).\\n\\n4. Monoamine Oxidase Inhibitors (MAOIs): Used to treat depression, anxiety disorders, and PTSD. Examples include phenelzine (Nardil) and tranylcypromine (Parnate).\\n\\n5. Benzodiazepines: Used to treat anxiety disorders and insomnia', '1. Ketamine and esketamine are anesthetics that have been increasingly used to treat depressive disorders. 2. Lithium and valproate are commonly used to treat mood disorders such as bipolar disorder and depression. 3. Certain benzodiazepines such as clonazepam and lorazepam are often used to treat anxiety disorders. 4. Olanzapine and quetiapine are commonly used to treat schizophrenia and other psychotic disorders. 5. Methylphenidate and amphetamine are used to treat attention deficit hyperactivity disorder. 6. Psilocybin and LSD are psychoactive substances that are currently being investigated for their potential therapeutic use in various mental health disorders.', 'The psychoactive drugs used to treat mental health disorders include ketamine, esketamine, MDMA, and psilocybin.', 'Psychoactive drugs used for treating mental health disorders include MDMA, ketamine, psilocybin, and esketamine.', 'Psychoactive drugs used to treat mental health disorders include MDMA, ketamine, and psilocybin.', 'Psychoactive drugs used to treat mental health disorders include:MDMA (3,4-methylenedioxymethamphetamine)KetaminePsilocybinLSD (Lysergic acid diethylamide)DMT (N,N-Dimethyltryptamine)AyahuascaSalvia divinorumGHB (Gamma-hydroxybutyric acid)KetamineMethoxetamineDXM (Death-cap mushroom)AMT (Alpha-methyltryptamine)', 'Ketamine, psilocybin, MDMA, and esketamine can be used to treat mental health disorders.', 'Psychoactive drugs that have been used to treat mental health disorders include:\\n\\n1. Ketamine and esketamine for depressive disorders\\n2. Psilocybin for treating mental disorders such as anxiety and depression\\n3. MDMA for treating chronic PTSD\\n\\nThese dissociative and psychedelic substances have been shown to specifically target and decrease fear and anxiety pathways in the brain. Recent research has brought advances in using these drugs in psychotherapeutic settings for various mental health conditions.', 'Psychoactive drugs such as MDMA, ketamine, and psilocybin are used to treat mental health disorders, specifically targeting symptoms like fear, anxiety, and depressive disorders.', 'Psychoactive drugs used to treat mental health disorders include ketamine, esketamine, MDMA, and psilocybin.', 'Ketamine and esketamine are psychoactive drugs used to treat mental health disorders, specifically depressive disorders.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data tables, the following psychoactive drugs are used to treat mental health disorders:\n\n1. MDMA (3,4-methylenedioxymethamphetamine)\n2. Psilocybin\n3. Ketamine\n4. LSD (not explicitly mentioned in the data tables, but mentioned in the text as a psychedelic drug)\n5. Cannabidiol (mentioned as a psychoactive substance used to treat psychotic disorders)\n6. Modafinil (mentioned as a psychoactive substance used to treat psychotic disorders)\n7. Psychedelic compounds (general category, not a specific drug)\n\nThese psychoactive substances are used to treat various mental health conditions, including post-traumatic stress disorder (PTSD), depression, anxiety disorders, obsessive-compulsive disorder (OCD), and psychotic disorders.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers a broad range of psychoactive drugs used in mental health treatment, including MDMA, Psilocybin, Ketamine, LSD, Cannabidiol, Modafinil, and general psychedelic compounds. However, it misses some categories like antidepressants (SSRIs, SNRIs, etc.), anxiolytics, antipsychotics, and mood stabilizers mentioned in the reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise, listing explicitly the psychoactive drugs and their applications without including irrelevant information. The mention of 'general psychedelic compounds' is slightly broad but still relevant.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat information and presents each drug and its use clearly and concisely.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, easily readable, and fluent, with clear enumeration of items and their applications."
    },
    {
        "Question": "List of attenuated viral vaccines still in use.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nList of attenuated viral vaccines still in use.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Some examples of attenuated viral vaccines still in use include the measles, mumps, and rubella (MMR) vaccine, the oral polio vaccine (OPV), the yellow fever vaccine, the varicella (chickenpox) vaccine, and the rotavirus vaccine.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided tables, the following attenuated viral vaccines are still in use:\n\n1. Measles-containing vaccine (MCV)\n2. MMR (Measles, Mumps, and Rubella) vaccine\n3. JYNNEOS (live-attenuated, nonreplicating vaccine against monkeypox virus)\n4. MMRV (Measles, Mumps, Rubella, and Varicella-Zoster virus vaccine)\n5. Varicella vaccine (live attenuated vaccine against Varicella-Zoster virus)\n6. MVA-BN (live attenuated vaccine against smallpox)\n7. Live attenuated vaccines against other diseases such as poliomyelitis, smallpox, and others are not explicitly listed but are mentioned in the table as examples of successful vaccines that have been used to eradicate or control diseases.\n\nNote that the effectiveness and safety of attenuated viral vaccines can vary, and their use may be subject to specific regulations and guidelines in different regions.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers most of the key attenuated viral vaccines mentioned in the reference answer (MMR, varicella, poliomyelitis) and adds additional examples (JYNNEOS, MVA-BN, MCV). However, it misses the yellow fever and rotavirus vaccines, which are included in the reference.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer includes relevant vaccines but also adds some less common or region-specific examples (e.g., JYNNEOS for monkeypox) which may not be universally recognized as standard attenuated viral vaccines. The note about effectiveness and safety is somewhat redundant given the question's focus on listing vaccines.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not repeat information excessively, but the mention of 'live attenuated vaccines against other diseases' vaguely overlaps with the listed examples (e.g., poliomyelitis is already implied in the reference answer).",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clearly listed, and easy to read. The note at the end is a helpful addition without disrupting clarity."
    },
    {
        "Question": "What was tested in the PATCH-Trauma trial?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat was tested in the PATCH-Trauma trial?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage (The PATCH-Trauma study) compared TXA, initiated prehospital and continued in hospital over 8\\u2009hours, with placebo in patients with severe trauma at risk of acute traumatic coagulopathy.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe PATCH-Trauma trial tested the effectiveness of prehospital administration of tranexamic acid (TXA) in patients with severe trauma and suspected trauma-induced coagulopathy.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer correctly identifies the intervention (TXA) and the patient population (severe trauma with suspected coagulopathy). However, it omits details about the continuation of treatment in-hospital over 8 hours and the comparison with placebo, which are key components of the PATCH-Trauma trial mentioned in the reference answer.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and stays on topic, focusing solely on the essential elements of the trial—TXA administration and the patient group. There is no irrelevant information included.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer provides a concise response without repeating the same information. Each piece of information is stated once and clearly.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is easily readable and fluent. It uses clear and straightforward language to convey the key points of the trial without ambiguity."
    },
    {
        "Question": "What is the most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['capecitabine was administered daily at a dose of 1650 mg/m(2) during the entire course of radiation therapy', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients has been studied in clinical trials. A phase I trial evaluated the safety and efficacy of capecitabine given twice daily during pelvic irradiation in patients with resectable rectal cancer. The maximum tolerated dose (MTD) was reached at a dose level of 2000 mg m(-2) day(-1), but dose escalation was ceased at 1800 mg m(-2) day(-1) after reaching MTD. A phase II trial evaluated the feasibility and efficacy of concurrent radiotherapy and capecitabine in rectal cancer patients. The recommended dose for further evaluation was established at capecitabine 825 mg/m(2) bid, administered without break during a conventional radiotherapy period of about ', '825 mg/m^2^ twice daily on days 1-38 of chemoradiotherapy for neoadjuvant treatment of locally advanced rectal cancer patients.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 825 mg.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is typically around 825 mg/m² twice daily. This dose has been commonly used in various studies in combination with radiotherapy and other chemotherapy agents like oxaliplatin or irinotecan. The specific dosing regimen may vary slightly depending on the study protocol, but the dose range of capecitabine used in these treatments is generally consistent around 825 mg/m² twice daily.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 1250 mg/m2 per day for 2 weeks followed by 5-fluorouracil (5-FU) 400 mg/m2 per day for 5 days, with a total of 6 cycles.', '825 mg/m2, twice daily, administered continuously, during radiotherapy, and until 1 week after the last fraction of radiotherapy.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 825 mg/m2 twice-daily. This dose is recommended in multiple studies and has been shown to be effective and well-tolerated in combination with radiotherapy and other chemotherapy agents.', 'Capecitabine was administered orally at a dose of 825 mg/m(2) twice-daily concomitantly every day during pelvic irradiation.', '\\nAnswer: 825 mg/m² twice daily on days 1-14 of radiotherapy, as recommended by the National Comprehensive Cancer Network (NCCN) guidelines for colorectal cancer. Alternatively, daily 1600 mg/m² (2 cycles, separated by a 7-day rest) as determined in a phase I study. Consult with a healthcare provider for personalized treatment recommendations.', '825 mg/m² twice daily during radiotherapy and at weekends is considered the most appropriate dose of capecitabine for concurrent treatment in neoadjuvant therapy of locally advanced rectal cancer patients.', 'The most suitable dose of capecitabine for concurrent use with radiotherapy in neoadjuvant therapy for locally advanced rectal cancer is either 825 mg/m(2) twice daily or 900 mg/m(2) twice daily, depending on the specific trial and patient tolerance.', 'The recommended dose for phase II evaluation is capecitabine 825 mg/m(2) bid, administered without break during a conventional radiotherapy period of about 6 weeks.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 825 mg/m^2^ bid, administered without break during a conventional radiotherapy period of about 6 weeks. This dosage was determined based on the results of a phase I trial that established the feasibility of concurrent radiotherapy and capecitabine and defined the maximum-tolerated dose (MTD) in patients with rectal cancer. The recommended dose for further evaluation is capecitabine 825 mg/m^2^ bid, which showed acceptable toxicity and promising response rates in preoperative chemoradiation based on RT at 45 Gy in 25 daily fractions over 5 weeks with continuous daily oral capecitabine at 650 mg m^2^ b.i.d. days 1-35 and weekly IV irinotecan at', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 825 mg/m2 twice daily, given on the days of radiotherapy, with a maximum daily dose of 1650 mg/m2.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 1,600 mg/m2.', 'The optimal dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer has been studied, and various doses have been used in clinical trials. However, there is no definitive consensus on the ideal dose due to differences in study designs, patient populations, and treatment regimens. In some studies, capecitabine was administered at a dose of 800 mg/m² orally twice daily during radiotherapy, while others have used doses ranging from 625 to 1,250 mg/m² per day. The choice of dose should be based on the balance between efficacy and toxicity, as well as individual patient factors such as performance status, comorbidities, and tolerance to treatment. Clinical judgment and guidelines from expert panels can provide guidance in selecting an appropriate capecitabine dose for each patient undergoing neoadjuvant chemoradiotherapy for rectal cancer.', 'The appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients has not been definitively established. However, a phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer found that the maximum tolerated dose (MTD) of capecitabine was 625 mg/m(2) bid, given concurrently with weekly irinotecan and pelvic radiotherapy. The MTD was determined based on the incidence of dose-limiting toxicities, primarily diarrhea. However, larger phase II trials are needed to confirm the efficacy and safety of this dose and schedule.', 'Based on the information provided, the most commonly used dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 825 mg/m2 twice daily, administered continuously or on days 1-14 and 22-35 of radiotherapy. Some key findings:\\n\\n- Capecitabine 825 mg/m2 twice daily for 7 days/week was found to be an effective and tolerable continuous dosing regimen. \\n- Capecitabine 825 mg/m2 twice daily on days 1-14 and 22-35 was used in combination with oxaliplatin and radiotherapy in one study.\\n- Several studies used capecitabine at 825 mg/m2 twice daily concomitantly with radiotherapy.\\n\\nWhile some variations in dosing schedules exist, capecitabine 825 mg/m2 twice daily, either continuously or on select days concurrent with radiotherapy, appears to be a standard neoadjuvant regimen for locally advanced rectal cancer based on the provided abstracts.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 825 mg/m² delivered orally twice daily for the duration of radiotherapy.', 'Capecitabine was administered daily at a dose of 1650 mg/m(2) during the entire course of radiation therapy.', '1650 mg/m(2)', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 1650 mg/m² administered daily throughout the course of radiation therapy.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 1650 mg/m(2) daily.', 'The most appropriate dose of capecitabine for concurrent treatment with radiotherapy in neoadjuvant therapy of locally advanced rectal cancer patients is 1650 mg/m² daily. This dosage is administered throughout the entire course of radiation therapy.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 1650 mg/m(2).', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 1650 mg/m2 daily during the entire course of radiation therapy.', 'The most appropriate dose of capecitabine when used concurrently with radiotherapy for neoadjuvant therapy in patients with locally advanced rectal cancer is 1650 mg/m² daily throughout the entire course of radiation therapy', 'capecitabine was administered daily at a dose of 1650 mg/m(2) during the entire course of radiation therapy.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 1650 mg/m² per day, administered orally during the entire course of radiation therapy. This dose has been shown to improve pathological complete response rates and decrease local recurrence rates in clinical trials. However, the specific dose and duration of capecitabine and radiotherapy may vary based on individual patient factors and the discretion of the treating healthcare provider. It is always recommended to consult with a healthcare professional for personalized treatment recommendations.', '1650 mg/m(2) daily during the entire course of radiation therapy.', '1650 mg/m(2) of capecitabine is the most appropriate dose for concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients.', 'Preoperative concomitant radiation therapy with oral capecitabine for locally advanced rectal cancer is feasible and safe. It is well tolerated. The most suitable dose of capecitabine is 825 mg/m2 twice daily every day during the entire course of radiation therapy.', 'The most appropriate dose of capecitabine for concurrent use with radiation in neoadjuvant therapy for locally advanced rectal cancer is 1650 mg/m(2) daily.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 1650 mg/m(2) daily for 14 days.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients has not been definitively established. The standard dose of capecitabine used in clinical practice is 1650 mg/m(2) per day, which is the dose used in the landmark phase III trial that demonstrated the efficacy and safety of capecitabine in this setting. However, some studies have suggested that a lower dose of capecitabine (e.g., 1250 mg/m(2) per day) may be equally effective and less toxic. The choice of dose should be individualized based on patient factors, such as age, performance status, and comorbidities, as well as the radiation dose and fractionation scheme used.', 'The most appropriate dose of capecitabine for concurrent treatment with radiotherapy in neoadjuvant therapy of locally advanced rectal cancer patients is 1650 mg/m(2) daily during the entire course of radiation therapy.', 'In the study mentioned, the most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients was 1650 mg/m(2) administered daily during the entire course of radiation therapy.', 'The most appropriate dose of capecitabine for concurrent treatment with radiotherapy in neoadjuvant therapy of locally advanced rectal cancer patients is generally considered to be 1650 mg/m² per day, as this dosage has been used effectively in clinical trials and aligns with current guidelines.', 'Based on the study, the most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer is 1650 mg/m2 daily during the entire course of radiation therapy. This dosage was used in a prospective Phase II trial and was found to have low toxicity while achieving encouraging rates of tumor downstaging and sphincter preservation. However, further studies may be needed to confirm these findings and establish this dose as the standard.', 'Based on the information provided, capecitabine was administered daily at a dose of 1650 mg/m(2) during the entire course of radiation therapy for neoadjuvant treatment of locally advanced rectal cancer patients.', 'The most appropriate dose of capecitabine for concurrent treatment with radiotherapy in neoadjuvant therapy of locally advanced rectal cancer patients is 1650 mg/m(2) daily.', 'The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 1650 mg/m(2) administered daily during the entire course of radiation therapy.', '1650 mg/m(2) is the most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, the most commonly recommended dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 825 mg/m^2 twice daily on radiotherapy days.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer correctly identifies the commonly recommended dose of capecitabine (825 mg/m^2 twice daily) but does not mention alternative doses or variations in schedules that are also referenced in the reference answers, such as 1650 mg/m^2 daily.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is concise and directly addresses the question by specifying the dose and administration schedule without including irrelevant details.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times; it presents the necessary details in a single statement.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is clear, easily understandable, and well-structured, making it highly readable."
    },
    {
        "Question": "Is Tako-Tsubo syndrome is an irreversible form of an acute stress-related cardiomyopathy?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs Tako-Tsubo syndrome is an irreversible form of an acute stress-related cardiomyopathy?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Tako-Tsubo syndrome is an reversible form of an acute stress-related cardiomyopathy', 'No, Tako-Tsubo syndrome is a reversible form of an acute stress-related cardiomyopathy.', 'No. Tako-Tsubo syndrome is a reversible form of an acute stress-related cardiomyopathy.', 'No, Tako-Tsubo syndrome is not an irreversible form of an acute stress-related cardiomyopathy.', 'No, Tako-Tsubo syndrome is a reversible condition.', 'No, Tako-Tsubo cardiomyopathy (TC) is a recognized clinical syndrome characterized by reversible cardiomyopathy with a distinctive left ventricular apical ballooning appearance.', 'No', 'No, Tako-Tsubo syndrome, also known as Takotsubo cardiomyopathy, is a reversible form of acute stress-related cardiomyopathy characterized by transient left ventricular dysfunction.', 'No, Takotsubo syndrome is a reversible form of an acute stress-related cardiomyopathy.', 'No, Tako-Tsubo syndrome is a recognized clinical syndrome characterized by reversible cardiomyopathy', 'Takotsubo cardiomyopathy is a reversible cardiomyopathy with a distinctive left ventricular apical ballooning appearance. It is a rare cause of acute left ventricular dysfunction in the absence of obstructive coronary disease.', 'Tako-Tsubo syndrome, also known as stress cardiomyopathy, is typically reversible.', 'no, Tako-Tsubo syndrome, also known as Takotsubo cardiomyopathy, is a reversible form of cardiomyopathy.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nNo, Tako-Tsubo syndrome is typically a reversible form of an acute stress-related cardiomyopathy. According to the data, it is characterized by transient left ventricular dysfunction that usually resolves within weeks.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer correctly states that Tako-Tsubo syndrome is reversible, which is consistent with all reference answers. Additionally, it provides extra detail about the transient nature of left ventricular dysfunction and its typical resolution time, enhancing the recall of necessary information.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer precisely addresses the question without including irrelevant details. It focuses on the reversibility and transient dysfunction of Tako-Tsubo syndrome, which is directly relevant to the query.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. It succinctly states the reversibility and adds a brief, relevant detail about the condition's transient nature without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is clear, fluent, and easy to understand. It uses straightforward language and a logical structure, making it highly readable."
    },
    {
        "Question": "New treatments in multiple sclerosis.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nNew treatments in multiple sclerosis.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['New approaches to treatment for MS include gut microbiome modification, fumarates, interferons, and biologicals.', 'New treatments in multiple sclerosis are interferons, glatiramer acetate, teriflunomide, sphingosine 1-phosphate receptor modulators, fumarates, cladribine, and 3 types of monoclonal antibodies. One additional DMT, ocrelizumab, is approved for primary progressive multiple sclerosis.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided tables, the following are some new treatments in multiple sclerosis:\n\n1. **Fingolimod**: A sphingosine 1-phosphate receptor immunomodulator approved in Europe for treating multiple sclerosis in patients with highly active disease or rapidly evolving severe relapsing-remitting MS.\n2. **Glatiramer acetate**: A disease-modifying therapy commonly used to treat multiple sclerosis.\n3. **Teriflunomide**: A disease-modifying therapy approved for the treatment of multiple sclerosis.\n4. **Dimethyl fumarate**: A disease-modifying therapy used to treat multiple sclerosis.\n5. **Natalizumab**: A high-efficacy disease-modifying therapy used to treat multiple sclerosis.\n6. **Alemtuzumab**: A disease-modifying therapy for multiple sclerosis.\n7. **Ocrelizumab**: A medication used to treat multiple sclerosis, which works by reducing the frequency of relapses and slowing the progression of the disease.\n8. **Cladribine**: A disease-modifying therapy used to treat multiple sclerosis.\n9. **Bulevirtide**: A medication used to treat autoimmune liver injury.\n10. **Interferon-beta**: A disease-modifying therapy commonly used to treat multiple sclerosis.\n11. **Rituximab**: A high-efficacy disease-modifying treatment for multiple sclerosis that is administered via infusion.\n12. **Monoclonal antibodies**: A class of medications used to treat multiple sclerosis, which work by targeting specific proteins in the immune system.\n\nThese treatments are mentioned in the provided tables as being used to treat multiple sclerosis, although the exact mechanisms of action and efficacy may vary.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "4",
        "Information Recall Explanation": "The answer provides a comprehensive list of new treatments for multiple sclerosis, including several mentioned in the reference answers (e.g., fumarates, interferons, monoclonal antibodies, cladribine, and ocrelizumab). However, it includes 'Bulevirtide,' which is irrelevant as it is used for autoimmune liver injury, not MS.",
        "Information Precision Score": "3",
        "Information Precision Explanation": "Most of the treatments listed are relevant to multiple sclerosis, but the inclusion of 'Bulevirtide' detracts from precision, as it is not a treatment for MS. Additionally, the mechanisms of action are briefly mentioned, but some descriptions are somewhat generic (e.g., 'disease-modifying therapy').",
        "Information Repetition Score": "4",
        "Information Repetition Explanation": "The answer avoids significant repetition, with each treatment listed only once. However, phrases like 'disease-modifying therapy' and 'used to treat multiple sclerosis' are repeated frequently, which slightly affects the score.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured and fluent, with each treatment clearly listed and described. The language is straightforward and easy to follow, making it highly readable."
    },
    {
        "Question": "Is UGT1A1 implicated in Crigler–Najjar syndrome?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs UGT1A1 implicated in Crigler–Najjar syndrome?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes. Crigler-Najjar syndrome is a rare disorder of bilirubin metabolism caused by uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1) mutations characterized by hyperbilirubinemia and jaundice.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, the UGT1A1 gene is implicated in Crigler-Najjar syndrome. The UGT1A1 gene encodes the enzyme bilirubin UDP-glucuronosyltransferase, which is responsible for converting unconjugated bilirubin into a water-soluble form that can be excreted from the body. Mutations in the UGT1A1 gene can lead to Crigler-Najjar syndrome, a rare genetic disorder characterized by an inability to eliminate bilirubin, resulting in elevated levels of unconjugated bilirubin in the blood and potential neurological damage.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer correctly recalls all necessary information from the reference answers and provides additional context about the UGT1A1 gene's function and the consequences of its mutations in Crigler-Najjar syndrome. It covers the enzyme's role in bilirubin metabolism and the syndrome's hallmark features (hyperbilirubinemia and neurological risks).",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise, focusing only on relevant details without any extraneous information. It directly addresses the implication of UGT1A1 in Crigler-Najjar syndrome, the genetic basis, and the biochemical and clinical consequences of the mutation.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information. Each piece of information is presented clearly once, with logical flow connecting the gene, its function, the mutation, and the resulting disorder.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is highly readable and fluent. The sentences are well-structured, and the technical concepts are explained in a clear and accessible manner."
    },
    {
        "Question": "Should PDYD polymorphism determination be routinely performed in patients with colorectal cancer patients?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nShould PDYD polymorphism determination be routinely performed in patients with colorectal cancer patients?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Prospective DPYD genotyping was feasible in routine clinical practice, and DPYD genotype-based dose reductions improved patient safety of fluoropyrimidine treatment.', 'The question of whether PDYD polymorphism determination should be routinely performed in patients with colorectal cancer is a complex one. The literature suggests that DPD deficiency, which is caused by genetic variations in the DPYD gene, is a significant risk factor for severe toxicities associated with 5-fluorouracil (5-FU) therapy. However, the current methods for determining DPD status are not yet suitable for routine clinical practice. While complete genotyping of the DPYD gene would be ideal, it is not currently feasible for routine use. Prospective genotyping for specific polymorphisms, such as the exon 14-skipping and 2846A>T-polymorphisms, may reduce the risk of serious toxic events by about 25%. However, the cost-effectiveness of such screening methods would need to be evaluated before they could be widely implemented in', 'The routine determination of PDYD polymorphism in patients with colorectal cancer is not currently a standard practice. However, further research and clinical studies may provide insights into the potential relevance and impact of PDYD polymorphism in the management and treatment of colorectal cancer patients. It is advisable to consult with a healthcare provider or genetic counselor for personalized recommendations regarding genetic testing and its implications in colorectal cancer care.', 'Yes, PDYD polymorphism determination should be routinely performed in patients with colorectal cancer, particularly those with high-risk stage II resected colorectal cancer enrolled in the TOSCA trial. The presence of the PDYD polymorphism has been associated with improved response to capecitabine and oxaliplatin in these patients.', \"There is currently no consensus on the routine determination of PDYD polymorphism in colorectal cancer patients. The clinical utility of this test is still under investigation and its use should be based on individual patient's needs and the availability of resources. It is recommended to consult with a healthcare provider to determine the most appropriate course of action.\", 'No, according to current guidelines from major cancer organizations such as the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO), routine PDYD polymorphism determination is not recommended in patients with colorectal cancer. However, some experts suggest that PDYD genotyping may be considered in certain situations, such as in patients with a history of severe fluoropyrimidine toxicity or in those receiving high-dose fluoropyrimidine therapy. Therefore, the decision to perform PDYD polymorphism determination should be made on a case-by-case basis in consultation with a healthcare provider.', 'This question is too specific and does not reflect the scope of the study. PDYD polymorphisms are not associated with colorectal cancer in general. The study focuses on a specific subset of colorectal cancer patients, and even for that subset, PDYD polymorphism determination is not routinely recommended, but rather it is suggested as an optional tool to improve clinical management of patients with stage II/III disease.', \"Currently, there is no consensus on routine PDYD polymorphism determination in colorectal cancer patients. The decision to perform such testing should be made on a case-by-case basis, taking into account factors such as the patient's medical history, treatment goals, and availability of alternative treatment options. However, it is important for healthcare providers to be aware of the potential for fluoropyrimidine-induced cardiotoxicity and to consider alternative regimens, such as s-MOX, in patients who have experienced this toxicity or who have abnormalities in the DYPD gene.\", 'Based on the current evidence, there is no strong recommendation for routine PDYD polymorphism determination in patients with colorectal cancer. The available studies have focused on other gene polymorphisms such as p53 and IRS-2, and there is limited data on the association between PDYD polymorphism and colorectal cancer. Further research is needed to determine the clinical significance and utility of PDYD polymorphism determination in colorectal cancer patients.', 'Yes, PDYD polymorphism determination should be routinely performed in patients with colorectal cancer. The XPD Lys751Gln and XRCC1 Arg399Gln polymorphisms have been associated with increased sensitivity to oxaliplatin-based chemotherapy in colorectal cancer patients.', 'Yes, determining dihydropyrimidine dehydrogenase (DPYD) polymorphisms should be considered routine practice for patients with colorectal cancer who are candidates for fluoropyrimidine-based chemotherapy. This is because DPYD plays a crucial role in the metabolism of these drugs and genetic variations can significantly impact both drug efficacy and toxicity. By identifying individuals with variants that may lead to reduced or absent enzyme activity, clinicians can adjust treatment plans accordingly, potentially avoiding severe adverse reactions while optimizing therapeutic outcomes.', 'The question of whether PDYD polymorphism determination should be routinely performed in patients with colorectal cancer is a topic of ongoing debate. Some argue that genetic testing for DPYD variants can help identify patients who are at risk of developing severe side effects from fluoropyrimidine chemotherapy, such as 5-FU and capecitabine. This could potentially spare patients from experiencing life-threatening adverse reactions and reduce the need for costly and time-consuming medical interventions. However, others argue that the frequency of DPYD variants is relatively low, and the cost and time required for genetic testing may not be justified for all patients with colorectal cancer. Moreover, there are still concerns about the accuracy and reproducibility of current genotyping methods, and the clinical utility of genetic testing in this setting remains uncertain. Therefore, it is crucial to weigh the potential benefits and', 'Yes, complete genotyping of the encoding DPYD gene is desirable, in the interest of drug safety, before treatment is started.', 'The determination of the PDYD polymorphism should not be routinely performed in patients with colorectal cancer. Although polymorphisms in certain genes, such as p53 and hMLH1, have been shown to play a role in the pathogenesis of colorectal cancer, there is currently insufficient evidence to support the routine use of PDYD polymorphism determination in clinical practice. Further research is needed to establish the clinical significance and prognostic value of PDYD polymorphism in colorectal cancer patients.', 'Yes, DPYD genotyping is feasible in routine clinical practice, and DPYD genotype-based dose reductions improved patient safety of fluoropyrimidine treatment.', 'Yes, determining DPYD polymorphisms should be routinely performed in patients with colorectal cancer as it can help predict the risk of severe toxicity from fluoropyrimidine treatment and guide personalized dose adjustments to improve patient safety and treatment outcomes.', 'PDYD polymorphism determination should not be routinely performed in patients with colorectal cancer.The PDYD gene encodes a protein involved in the regulation of the immune response and is associated with the risk of colorectal cancer. However, the clinical utility of PDYD genotyping in colorectal cancer patients is still unclear.The clinical utility of PDYD genotyping in colorectal cancer patients is still unclear.The PDYD gene encodes a protein involved in the regulation of the immune response and is associated with the risk of colorectal cancer. However, the clinical utility of PDYD genotyping in colorectal cancer patients is still unclear.The PDYD gene encodes a protein involved in the regulation of the immune response and is associated with the risk of colorectal cancer. However, the clinical utility of PDYD genotyping in colorectal cancer patients is still unclear.The PDYD gene encodes a protein involved in the regulation of the immune response and is associated with the risk of colorectal cancer. However, the clinical utility of PDYD genotyping in colorectal cancer patients is still unclear.The PDYD gene encodes a protein involved in the regulation of the immune response and is associated with the risk of colorectal cancer. However, the clinical utility of PDYD genotyping in colorectal cancer patients is still unclear.The PDYD gene encodes a protein involved in the regulation of the immune response and is associated with the risk of colorectal cancer. However, the clinical utility of PDYD genotyping in colorectal cancer patients is still unclear.The PDYD gene encodes a protein involved in the regulation of the immune response and is associated with the risk of colorectal cancer. However, the clinical utility of PDYD genotyping in colorectal cancer patients is still unclear.The PDYD gene encodes a protein involved in the regulation of the immune response and is', 'Yes, PDYD polymorphism determination should be routinely performed in patients with colorectal cancer. This is because genetic variants in the DPYD gene can lead to severe toxicity in patients treated with fluoropyrimidine. As mentioned, \"Prospective DPYD genotyping was feasible in routine clinical practice, and DPYD genotype-based dose reductions improved patient safety of fluoropyrimidine treatment.\" This indicates that knowing a patient\\'s DPYD genotype can help tailor their treatment plan to reduce the risk of severe side effects and enhance treatment safety.', 'Yes, DPYD polymorphism determination should be routinely performed in patients with colorectal cancer to improve patient safety of fluoropyrimidine treatment.', 'Yes, PDYD polymorphism determination should be routinely performed in patients with colorectal cancer before they start receiving Fluorouracil (FP) treatment.', 'Yes, in summary, polypeptide diversity analysis (PDYD) is a valuable technique for characterizing coloreactal cancer and should be considered for routine use in clinical oncology. It allows for the assessment of genetic, epigenetic, and biological diversity within a tumor population, providing valuable insights into cancer progression and response to treatment. ', 'Yes, DPYD polymorphism determination should be routinely performed in patients with colorectal cancer patients.', 'Yes, DPYD polymorphism determination should be routinely performed in patients with colorectal cancer to improve patient safety during fluoropyrimidine treatment.', 'Yes, determining DPYD polymorphism should be routinely performed in patients with colorectal cancer before starting fluoropyrimidine-based chemotherapy. This is because certain genetic variants in the DPYD gene can lead to severe toxicity in patients treated with fluoropyrimidines. Identifying these variants through genotyping can help tailor the treatment dose to improve safety and efficacy for the patient', 'yes, PDYD polymorphism determination should be routinely performed in patients with colorectal cancer. This is because genetic variants in the DPYD gene can lead to severe toxicity in patients treated with fluoropyrimidine. Prospective DPYD genotyping has been shown to be feasible in routine clinical practice, and using the genotype to guide dose adjustments can significantly improve patient safety.', 'Yes, DPYD polymorphism determination should be routinely performed in patients with colorectal cancer who are planned to receive fluoropyrimidine treatment. The presence of certain genetic variants in the DPYD gene can result in extremely severe and early onset toxicity in these patients. Prospective DPYD genotyping has been shown to be feasible in routine clinical practice, and DPYD genotype-based dose reductions have been shown to improve patient safety of fluoropyrimidine treatment. By identifying patients who are at risk for severe toxicity, healthcare providers can take steps to minimize the risk of adverse events and optimize treatment outcomes.', \"yes, PDYD polymorphism determination should be routinely performed in patients with colorectal cancer to improve patient safety by allowing for dose adjustments of fluoropyrimidine treatment based on the patient's genetic profile.\", 'Yes, PDYD polymorphism determination should be routinely performed in patients with colorectal cancer. PDYD genetic variants are associated with severe toxicity in patients treated with fluoropyrimidines, which are commonly used in colorectal cancer treatment. Prospective genotyping for PDYD polymorphisms allows for dose individualization and reduces the risk of severe fluoropyrimidine-related toxicity. Implementing PDYD genotype-guided dosing as a standard of care can improve patient safety and treatment outcomes.', 'PDYD polymorphism determination should not be routinely performed in patients with colorectal cancer.The PDYD gene encodes a protein involved in the biosynthesis of the amino acid proline. The PDYD polymorphism is associated with altered proline metabolism, which may have implications for cancer development and progression. However, the clinical utility of PDYD polymorphism determination in colorectal cancer patients is not well established.The clinical utility of PDYD polymorphism determination in colorectal cancer patients is not well established.The PDYD polymorphism is associated with altered proline metabolism, which may have implications for cancer development and progression. However, the clinical utility of PDYD polymorphism determination in colorectal cancer patients is not well established.', 'Yes, PDYD (dihydropyrimidine dehydrogenase) polymorphism determination should be routinely performed in colorectal cancer patients treated with fluoropyrimidines. The abstract describes a prospective study that demonstrated reduced severe toxicity in patients who received genotype-guided dosing of fluoropyrimidines based on PDYD variants. Specifically, DPYD*2A and c.1679T>G carriers benefited from a 50% initial dose reduction, while c.1236G>A and c.2846A>T carriers may require a larger dose reduction of 50%. Given that fluoropyrimidines are commonly used anticancer agents, the implementation of PDYD genotype-guided individualized dosing should be considered a new standard of care to improve patient safety and treatment outcomes.', 'Yes, DPYD polymorphism determination should be considered for routine performance in patients with colorectal cancer who are candidates for fluoropyrimidine treatment such as 5-fluorouracil or capecitabine. This is because genetic variants in the dihydropyrimidine dehydrogenase (DPYD) gene have been associated with an increased risk of severe and potentially life-threatening toxicity, particularly when patients carry certain DPYD alleles that result in reduced enzyme activity. By identifying these polymorphisms before initiating treatment, clinicians can adjust the fluoropyrimidine dose to reduce the likelihood of severe toxic effects, thereby improving patient safety and outcomes.', 'Yes, prospective DPYD genotyping was feasible in routine clinical practice, and DPYD genotype-based dose reductions improved patient safety of fluoropyrimidine treatment.', 'Yes, prospective DPYD genotyping should be routinely performed in colorectal cancer patients treated with fluoropyrimidines (FP). DPYD genetic variants are associated with extremely severe, early-onset FP toxicity. Prospective DPYD genotyping is feasible in routine clinical practice, and DPYD genotype-based FP dose reductions improve patient safety.', 'Yes, determining DPYD polymorphism should be routinely performed in colorectal cancer patients to improve patient safety by allowing for dose adjustments of fluoropyrimidine treatment based on genetic predisposition to toxicity.', 'Yes, DPYD polymorphism determination should be routinely performed in patients with colorectal cancer. Host genetic variants in the DPYD gene have been found to be associated with severe toxicity in patients treated with fluoropyrimidine drugs. Prospective DPYD genotyping has been shown to be feasible in routine clinical practice and has led to improved patient safety by allowing for genotype-based dose reductions. Therefore, routine DPYD polymorphism determination can help identify patients who are at higher risk of toxicity and guide personalized treatment strategies.', 'Yes, PDYD polymorphism determination should be routinely performed in patients with colorectal cancer patients to identify those who may be at risk for severe toxicity from fluoropyrimidine-based chemotherapy.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the answer to this question is not a simple yes or no. However, I can provide some insights based on the information available.\n\nDPYD polymorphisms, particularly the c.1129-5923C > G and c.1896 T > C variants, have been associated with an increased risk of fluoropyrimidine-related toxicities in colorectal cancer patients. These polymorphisms can lead to reduced DPD enzyme activity, which can result in increased levels of 5-fluorouracil (5-FU) and its active metabolites, leading to toxicity.\n\nStudies have shown that patients with these polymorphisms may experience severe neutropenia, diarrhea, and other adverse events when treated with fluoropyrimidine-based chemotherapy. For example, a study published in the Journal of Clinical Oncology found that patients with the DPYD c.1896 T > C variant had a significantly increased risk of severe neutropenia (OR = 8.42, 95% CI 0.88-80.56, P = 0.052).\n\nHowever, another study published in the Journal of Clinical Oncology found that the utility of DPYD polymorphism testing in predicting irinotecan-induced toxicity was limited, and that UGT1A1 polymorphisms were more strongly associated with toxicity.\n\nA cost-utility analysis conducted in the U-PGx PREPARE study found that pharmacogenomic-guided treatment based on DPYD and/or UGT1A1 genomic variants may be a cost-saving option compared to the standard-of-care intervention among patients with colorectal cancer.\n\nBased on these findings, it appears that DPYD polymorphism determination may be useful in identifying patients at increased risk of fluoropyrimidine-related toxicities, particularly those with the c.1129-5923C > G and c.1896 T > C variants. However, the utility of routine testing is still a topic of debate, and more research is needed to fully understand the benefits and limitations of this approach.\n\nIn conclusion, while DPYD polymorphism determination may be a useful tool in identifying patients at increased risk of fluoropyrimidine-related toxicities, it is not yet clear whether routine testing should be performed in all patients with colorectal cancer. Further studies are needed to determine the clinical utility and cost-effectiveness of this approach.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "4",
        "Information Recall Explanation": "The answer recalls a significant amount of relevant information, including specific DPYD polymorphisms (c.1129-5923C > G and c.1896 T > C), their association with fluoropyrimidine-related toxicities, and references to studies and cost-utility analyses. However, it misses some nuances present in the reference answers, such as the feasibility of routine genotyping or alternative opinions on the topic.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer is precise, focusing on DPYD polymorphisms and their clinical implications without straying into irrelevant details. The specific variants, study references, and cost-utility analysis are all directly relevant to the question. However, it could be more precise by not mentioning irinotecan-induced toxicity (which is somewhat off-topic).",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat the same information unnecessarily. Each point is distinct and contributes to the overall argument without redundancy. Only relevant details about DPYD polymorphisms and their impact are included.",
        "Readability Score": "4",
        "Readability Explanation": "The answer is well-structured and fluent, making it easy to follow. The use of specific examples and study citations enhances clarity. However, the conclusion could be slightly more concise to improve readability further."
    },
    {
        "Question": "What is the function of the sodium leak channel (NALCN)?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the function of the sodium leak channel (NALCN)?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The sodium leak channel (NALCN) is widely express in the CNS  has multiple functions including the regulation of neuronal excitability, maintaining resting membrane potential, pacemaking of dopaminergic neuron (DAN) subpopulations and is a key regulator of cancer metastasis and nonmalignant cell dissemination.', 'NALCN is a Na leak channel that is voltage-independent and functions as a critical mediator of basal excitability, and thus its function in the myometrium is to modulate the basal excitability.', 'The function of the sodium leak channel (NALCN) is to regulate excitability and neuromodulation of specific neurons, such as brainstem chemosensory neurons, and control breathing responses to CO2 stimulation.', 'The function of the sodium leak channel (NALCN) is to form the background Na(+) leak conductance and control neuronal excitability, as well as regulate excitability and neuromodulation of RTN neurons and CO2-stimulated breathing.', 'NALCN is a sodium leak channel permeable to divalent cations that plays an important role in the control of neuronal excitability, thereby participating in the regulation of respiratory rhythm and probably in the development of neuropathic pain.', 'The function of the sodium leak channel (NALCN) is to regulate excitability of brainstem chemosensory neurons and breathing.', 'The sodium leak channel (NALCN) gene encodes a sodium leak channel that plays an important role in the regulation of the resting membrane potential and the control of neuronal excitability.', 'Sodium leak channel (NALCN) is a voltage-independent ion channel that generates a tonic inward Na(+) leak current, which results in depolarization of neurons and neuronal hyperexcitability.', 'The sodium leak channel (NALCN) is responsible for the major background sodium conductance in neurons. It regulates neuronal excitability linked to respiration, locomotion, and circadian rhythm. Mutations in NALCN can cause severe neurological disorders and early death.', 'The sodium leak channel (NALCN) is a non-selective ion channel that is activated by M3 muscarinic receptors in pancreatic beta-cells. It forms a subthreshold sodium conductance that controls the resting membrane potentials of neurons.', 'The sodium leak channel (NALCN) is a critical regulator of Na+ homeostasis and plays a critical role in maintaining cellular excitability in a variety of physiological settings. The NLCN is highly permeable to Na+ ions and simultaneously permeable to H+ ions, and it is located in the plasma membrane of cells. The', 'The sodium leak channel (NALCN) is a sodium leak channel that plays an important role in the regulation of the resting membrane potential and the control of neuronal excitability.', 'The function of the sodium leak channel (NALCN) is to regulate neuronal excitability and control breathing by generating \"leak\" sodium currents.', 'Sodium leak channel (NALCN) is widely expressed in the central nervous system and regulates neuronal excitability.', 'The sodium leak channel (NALCN) is a critical regulator of Na+ and water homeostasis in neurons and cancer cells and plays a role in many physiological and pathological settings.', 'The function of the sodium leak channel (NALCN) is to regulate neuronal excitability, maintain proper resting membrane potential, and mediate sodium leak currents.', 'The sodium leak channel (NALCN) functions as a regulator of neuronal excitability, pacemaking in dopaminergic neurons, nerve-resting conductance, excitability, maintenance of proper resting membrane potential, and as a key regulator of cancer metastasis and nonmalignant cell dissemination.', 'The sodium leak channel (NALCN) is a non-selective cation channel that is important for maintaining proper resting membrane potential in neurons.', 'Sodium leak channel (NALCN) regulates neuronal excitability.', 'The function of the sodium leak channel (NALCN) is to regulate nerve-resting conductance and excitability, maintain proper resting membrane potential, and mediate sodium leak currents in various cell types, including dopaminergic neurons and cancer cells.', 'The sodium leak channel (NALCN) helps regulate the resting membrane potential in neurons by allowing a small, continuous flow of sodium ions into the cell. This activity is crucial for maintaining neuronal excitability and proper functioning of the nervous system', 'The sodium leak channel (NALCN) is widely expressed in the central nervous system and regulates neuronal excitability.', 'The sodium leak channel (NALCN) regulates neuronal excitability and maintains proper resting membrane potential in the central nervous system. It also plays a role in the pacemaking of dopaminergic neurons and is involved in the regulation of cancer metastasis and nonmalignant cell dissemination.', 'NALCN is a member of the GPCR-activated NALCN channelosome that is involved in the regulation of resting membrane potential and excitability in neurons. NALCN is a key regulator of metastasis and nonmalignant cell dissemination.', 'The sodium leak channel (NALCN) is crucial for regulating nerve-resting conductance and excitability, maintaining proper resting membrane potential, and playing a significant role in pacemaking of dopaminergic neurons. It also influences cancer metastasis and nonmalignant cell dissemination.', 'The sodium leak channel (NALCN) is a sodium-coupled chloride channel that is widely expressed in the central nervous system and regulates neuronal excitability.', 'The sodium leak channel (NALCN) mediates sodium leak currents and is crucial for maintaining the proper resting membrane potential in cells. This helps regulate nerve-resting conductance and excitability, particularly in the central nervous system.', 'The sodium leak channel (NALCN) mediates sodium leak currents and plays a crucial role in maintaining proper resting membrane potential, regulating neuronal excitability, and controlling metastasis and nonmalignant cell dissemination.', 'Sodium leak channel (NALCN) is widely expressed in the central nervous system and regulates neuronal excitability. We tested the role of the sodium leak channel, NALCN, in pacemaking of dopaminergic neuron (DAN) subpopulations from adult male and female mice.', 'The sodium leak channel (NALCN) regulates neuronal excitability and resting membrane potential by mediating sodium leak currents. It is important for maintaining proper resting conductance in neurons.', 'The sodium leak channel (NALCN) is crucial for regulating the resting membrane potential in neurons. It mediates a sodium leak current that helps maintain the excitability of neurons, influencing various physiological processes such as pacemaking in dopaminergic neurons and overall neuronal activity', 'The sodium leak channel (NALCN) regulates neuronal excitability by mediating sodium leak currents and maintaining proper resting membrane potential.', 'The sodium leak channel (NALCN) regulates neuronal excitability in the central nervous system.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe sodium leak channel (NALCN) plays a crucial role in regulating the resting membrane potential and controlling neuronal excitability. It is a non-selective cation channel that allows sodium ions to leak into neurons, influencing their excitability and rhythmic behaviors. The NALCN channel is essential for the maintenance of the resting membrane potential in neurons, and its dysfunction has been associated with various neurological disorders, including Rett syndrome, Lennox-Gastaut syndrome, and epilepsy.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers the key functions of NALCN, such as regulating resting membrane potential and neuronal excitability, and it mentions its role in neurological disorders. However, it misses some details like its involvement in pacemaking of dopaminergic neurons, control of breathing responses, and cancer metastasis, which are mentioned in the reference answers.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise and focuses on relevant information about NALCN without including unnecessary details. It sticks to the core functions and implications of NALCN in neuronal activity and disorders.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each point is clearly stated without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand. It communicates complex biological concepts clearly and effectively."
    },
    {
        "Question": "Cancer risk in transgender individuals.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nCancer risk in transgender individuals.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Transgender people have higher rates of HIV and HPV infection rates, and are thus at higher risk of cancer associated with these viruses. They might also be at higher risk of cancer associated with hormone replacement. Barriers to screening and treatment might translate into worse outcomes.', 'Cancer risk in transgender individuals may be influenced by several factors, including hormone therapy, which can alter risks associated with sex hormones. Additionally, transgender and gender-diverse people often face higher rates of tobacco and alcohol use, and higher prevalence of HPV and HIV infections, which can further affect their cancer risk. Barriers such as discrimination and lack of culturally sensitive care can also hinder access to cancer screening and treatment, potentially leading to poorer outcomes.', 'Transgender and gender-diverse individuals face a higher risk of certain cancers compared to cisgender individuals. This increased risk is attributed to several factors:\\n\\n1. Higher prevalence of tobacco and alcohol use\\n2. Higher rates of HPV and HIV infections, which are associated with certain cancers\\n3. Altered cancer risk due to hormone therapy, as the risk of certain cancers differs between men and women and is influenced by sex hormone exposure\\n4. Lower adherence to cancer screening programs\\n\\nAdditionally, transgender individuals face barriers in accessing appropriate cancer care due to discrimination, discomfort with gender-labeled oncological services, stigma, and lack of cultural sensitivity among healthcare providers. These findings suggest that the cancer care needs of transgender and gender-diverse individuals are not being adequately addressed.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, cancer risk in transgender individuals is a complex and multifaceted issue. According to the data, cancer risk in transgender individuals can be influenced by various factors, including hormone therapy, gender-affirming surgery, and genetic predisposition.\n\nOne study (Source ID: 14) suggests that gender-affirming hormonal treatment (HT) in transgender people is considered safe in general, but the question regarding long-term risk on sex hormone-related cancer remains. The study notes that the cancer risk may be altered in transgender people receiving HT, particularly for certain types of cancer that differ between men and women, such as breast cancer.\n\nAnother study (Source ID: 15) highlights the importance of cancer screening and prevention in transgender individuals, particularly those who have undergone gender-affirming hormone therapy. The study notes that transgender individuals may be at higher risk for certain types of cancer, including prostate cancer, and recommends that healthcare providers be aware of these risks and provide appropriate screening and prevention recommendations.\n\nA study (Source ID: 16) examines the cancer risk in transgender adolescents and young adults, particularly those with a family history of cancer or hereditary cancer syndrome. The study notes that there is a lack of information on cancer risk counseling in transgender individuals with a family history of cancer, and highlights the importance of addressing this gap in care.\n\nA study (Source ID: 17) discusses the relationship between inflammation-driven colorectal cancer and inflammatory bowel disease (IBD), and notes that patients with IBD have a higher risk of developing colorectal cancer.\n\nA study (Source ID: 20) examines the incidence of prostate cancer in male-to-female transgender individuals and notes that these individuals are at risk for prostate cancer, particularly those who have undergone hormone therapy for gender affirmation. The study highlights the importance of awareness and screening for prostate cancer in this population.\n\nA study (Source ID: 21) provides a review of the existing literature on prostate cancer in transgender women, and notes that the risk of prostate cancer in this population is lower than in cisgender men, but diagnosis and treatment can be more nuanced.\n\nOverall, the data suggest that cancer risk in transgender individuals is influenced by various factors, including hormone therapy, genetic predisposition, and other health conditions. Healthcare providers should be aware of these risks and provide appropriate screening and prevention recommendations to transgender individuals.\n\nIn terms of specific cancer types, the data suggest that:\n\n* Prostate cancer is a significant risk for male-to-female transgender individuals, particularly those who have undergone hormone therapy for gender affirmation.\n* Breast cancer is a risk for transgender women, particularly those who have undergone hormone therapy for gender affirmation.\n* Colorectal cancer is a risk for individuals with inflammatory bowel disease (IBD), and may be influenced by other factors such as genetic predisposition.\n* Cancer risk in transgender adolescents and young adults with a family history of cancer or hereditary cancer syndrome is not well understood and requires further research.\n\nIt is essential to note that these findings are based on a limited number of studies and more research is needed to fully understand the cancer risk in transgender individuals.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers multiple aspects of cancer risk in transgender individuals, including hormone therapy, genetic predisposition, and specific cancer types (prostate, breast, colorectal). It references several studies (Source IDs 14, 15, 16, 17, 20, 21) to support its points. However, it misses some broader social determinants of risk mentioned in the reference answers, such as higher rates of HPV/HIV, tobacco/alcohol use, and barriers to screening due to discrimination.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer includes relevant information about cancer risk factors but also introduces less directly relevant details, such as the link between colorectal cancer and inflammatory bowel disease (IBD), which is not a primary focus of the reference answers. The inclusion of Source ID 17, which discusses IBD and colorectal cancer, feels tangential to the main topic of transgender cancer risk.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not repeat information excessively. However, it reiterates the importance of hormone therapy and screening across different sections without adding new insights each time.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clearly written, and logically organized. It uses bullet points for specific cancer types, enhancing readability. The language is fluent and accessible."
    },
    {
        "Question": "Does Lenvatinib plus pembrolizumab improve prognosis of advanced hepatocellular carcinoma?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nDoes Lenvatinib plus pembrolizumab improve prognosis of advanced hepatocellular carcinoma?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['No. Lenvatinib plus pembrolizumab did not improve overall survival and progression-free survival versus lenvatinib plus placebo of advanced hepatocellular carcinoma patients.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, there is no direct evidence that Lenvatinib plus Pembrolizumab improves the prognosis of advanced hepatocellular carcinoma (HCC). However, the data does mention that Lenvatinib is used in combination with Pembrolizumab for the treatment of renal cell carcinoma (ID: 24, Relation ID: 24). \n\nA study (ID: 13, Source ID: 57) mentions that Regorafenib is used to treat HCC, and another study (ID: 10, Source ID: 57) suggests that Regorafenib primes tumor cells to BH3-mimetic-induced cell death, allowing BCL-xL inhibition with A-1331852 or other strategies based on BCL-xL degradation to enhance Regorafenib efficacy, offering a novel approach for HCC treatment. However, this does not directly relate to the combination of Lenvatinib and Pembrolizumab.\n\nAnother study (ID: 12, Source ID: 12) discusses the management of adverse events associated with tyrosine kinase inhibitors, including Lenvatinib, for the treatment of advanced HCC.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "3",
        "Information Recall Explanation": "The answer partially addresses the question by stating that there is no direct evidence for Lenvatinib plus Pembrolizumab improving HCC prognosis. However, it diverts to discussing Regorafenib and unrelated studies, which do not directly answer the question. The reference answer clearly states that the combination did not improve outcomes in advanced HCC.",
        "Information Precision Score": "2",
        "Information Precision Explanation": "The answer includes irrelevant information about Regorafenib and unrelated studies (e.g., renal cell carcinoma), which do not pertain to the question. The precision is compromised as the focus strays from the central question.",
        "Information Repetition Score": "4",
        "Information Repetition Explanation": "There is minimal repetition in the answer. Each point is introduced once, though some of the points are not relevant to the question.",
        "Readability Score": "4",
        "Readability Explanation": "The answer is well-structured and fluent, making it easy to read. However, the inclusion of off-topic information slightly detracts from overall clarity."
    },
    {
        "Question": "What molecular subtypes of colon cancer are associated to smoking?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat molecular subtypes of colon cancer are associated to smoking?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Cigarette smoking are associated with the MSI-high, CIMP-positive, and BRAF mutation-positive colorectal cancer subtypes.', 'Smoking is associated with three molecular subtypes of colorectal cancer, which are MSI-high, CIMP-positive, and BRAF mutation-positive. In a study conducted by the National Cancer Institute, it was found that current smoking showed higher odds ratios for MSI-high compared to MSS, BRAF-mutated compared to BRAF-wild type, KRAS-wt compared to KRAS-mut, and CIMP-high compared to CIMP-low/negative CRC. Additionally, smoking seemed more strongly associated with sessile serrated pathway CRC than with traditional pathway CRC. No association was observed between alcohol consumption and molecular subtypes of colon cancer.', 'Smoking has been associated with various molecular subtypes of colon cancer, including high CpG island methylator phenotype (CIMP), BRAF mutation, microsatellite instability (MSI) high, P53 mutation, and KRAS wild-type colorectal cancer. Additionally, heavier smokers have a higher risk of CRC subtypes that are CIMP positive and MSI high, suggesting a potential involvement of smoking in the development of colorectal tumors via the serrated pathway. These associations highlight the impact of smoking on the molecular characteristics and subtypes of colon cancer.', 'Smoking is associated with a higher risk of developing colon cancer, particularly in the proximal colon. The molecular subtypes of colon cancer associated with smoking are:1. Proximal colon adenocarcinoma: Smoking is associated with a higher risk of developing proximal colon adenocarcinoma, which is the most common subtype of colon cancer.2. Right-sided colon adenocarcinoma: Smoking is associated with a higher risk of developing right-sided colon adenocarcinoma, which is less common than proximal colon adenocarcinoma.3. Mucinous adenocarcinoma: Smoking is associated with a higher risk of developing mucinous adenocarcinoma, which is a rare subtype of colon cancer.4. Adenocarcinoma in situ: Smoking is associated with a higher risk of developing adenocarcinoma in situ, which is a precancerous condition that can progress to invasive colon cancer.5. Microsatellite instability-high (MSI-H) colon cancer: Smoking is associated with a higher risk of developing MSI-H colon cancer, which is a subtype of colon cancer that is characterized by high levels of genomic instability.6. TP53 mutation: Smoking is associated with a higher risk of developing TP53 mutation, which is a common mutation in colon cancer that is associated with poor prognosis.7. KRAS mutation: Smoking is associated with a higher risk of developing KRAS mutation, which is a common mutation in colon cancer that is associated with poor prognosis.8. BRAF mutation: Smoking is associated with a higher risk of developing BRAF mutation, which is a common mutation in colon cancer that is associated with poor prognosis.9. PIK3CA mutation: Smoking is associated with a higher risk of developing PIK3CA mutation, which is a common mutation in colon cancer that is associated with poor prognosis.10. APC mutation: Smoking is associated with a higher risk of developing APC mutation, which is a common mutation in colon cancer that is associated with poor prognosis.', 'Smoking was strongly associated with the risk of CRC, characterized by high CpG island methylator phenotype, BRAF mutation, or high microsatellite instability.', '370 papers reported positive correlations between cigarette smoke and microsatellite instability (MSI) or CpG island methylator phenotype (CIMP) in colorectal carcinogenesis. In addition, smoking has been positively associated to the EGFR mutation and negatively to the KRAS mutation, BRAF mutation and the presence of the MET receptor.', \"Smoking is associated with molecular subtypes of colon cancer including 'BRAF mutation', 'CIMP-positive CRC', 'KRAS wild type', 'Rectal cancer', 'KRAS wild type CRC', 'high microsatellite instability', 'colorectal neoplasms type II', and 'Type II tumors'.\", 'Smoking is associated with an increased risk of colon cancer with high CpG island methylator phenotype (CIMP), BRAF mutation, and high microsatellite instability (MSI). Heavier smokers have a particularly higher risk of CRC subtypes that are CIMP positive and MSI high in combination. Smoking cessation is associated with a lower risk of CIMP-high colorectal cancer. Additionally, cigarette smoking is associated with increased risks of rectal cancer and MSI-H CRC. Smokers have an approximately 2-fold higher risk of KRAS wild-type colorectal cancer than never smokers in an Asian population. SNP associations observed for colon cancer include VEGFA rs2010963 with CIMP+ colon tumors, FLT1 rs4771249 and rs7987649 with TP53, FLT1 rs3751397, rs7337610, rs7987649, and rs9513008 and KDR rs10020464, rs11941492, and rs12498529 with MSI+ and CIMP+/KRAS2-mutated tumors.', 'Smoking is associated with the risk of CRC, characterized by high CpG island methylator phenotype, BRAF mutation, or high microsatellite instability, but not characterized by KRAS or TP53 mutations.', '\\nAnswers: CIMP-high, BRAF mutations, and neuroendocrine tumors (rare but aggressive subtypes) have been associated with smoking in molecularly defined subtypes of colon cancer, according to a recent study published in Cancer Epidemiology Biomarkers Prevention. However, smoking cessation has been associated with a lower risk of CIMP-high colon cancer. The association between smoking and colon cancer subtypes with MSI-high tumors is less clear.', 'Smoking was associated with differential risk of CRC subtypes defined by molecular characteristics. Heavier smokers had particularly higher risk of CRC subtypes that were CIMP positive and MSI high in combination, suggesting that smoking may be involved in the development of colorectal tumors via the serrated pathway.', 'Smoking is associated with the microsatellite instability-high (MSI-high), CpG island methylator phenotype (CIMP)-positive, and BRAF mutation-positive subtypes of colon cancer. These subtypes are thought to arise via the serrated pathway of colorectal carcinogenesis, which is characterized by abnormal methylation of DNA and mutations in the BRAF gene. The association between smoking and these molecular subtypes suggests that epigenetic modification may be involved in smoking-related colon carcinogenesis.', 'Smoking is associated with differential risk of colorectal cancer (CRC) subtypes defined by molecular characteristics. Heavier smokers have a particularly higher risk of CRC subtypes that are CIMP-positive (CpG island methylator phenotype) and MSI-high (microsatellite instability), suggesting that smoking may be involved in the development of colorectal tumors via the serrated pathway.', 'Smoking has been associated with an increased risk of colon cancer, and the molecular subtypes of colon cancer that are most strongly associated with smoking are the microsatellite instability-high (MSI-H) and the p53 mutant subtypes.', 'Smoked colorectal cancer patients have an increased risk of being diagnosed with adenomatous polyps and adenocarcinomas compared to non-smokers. This smoking-associated increased risk of colorectal cancer is associated with the molecular subtypes: microsatellite-stable and -unstable, and with the smoking index.', 'The molecular subtypes of colorectal cancer (CRC) that have been associated with smoking include those characterized by microsatellite instability-high (MSI-H), CpG island methylator phenotype-high (CIMP-H), BRAF mutation, and KRAS wild type. These molecular features are more commonly found in tumors from smokers and may be related to the increased risk of colorectal cancer associated with tobacco use.', 'Smoking is associated with high CpG island methylator phenotype (RR 1.42; 95% CI 1.20-1.67; number of studies [n] = 4), BRAF mutation (RR 1.63; 95% CI 1.23-2.16; n = 4), or high microsatellite instability (RR 1.56; 95% CI 1.32-1.85; n = 8) in colon cancer.', 'Smoking is strongly associated with the risk of CRC, characterized by high CpG island methylator phenotype, BRAF mutation, or high microsatellite instability.', 'Based on the provided information, smoking is associated with the following molecular subtypes of colorectal cancer (CRC):\\n\\n1. CRC with high CpG island methylator phenotype (CIMP-high)\\n2. CRC with BRAF mutation\\n3. CRC with high microsatellite instability (MSI-high)\\n4. CRC with CIMP-high and MSI-high in combination\\n5. CRC with P53 mutation (exons 4 to 8)\\n6. CRC with KRAS wild-type\\n\\nHowever, smoking does not appear to be significantly associated with CRC characterized by KRAS or TP53 mutations. Additionally, smoking cessation was associated with a lower risk of CIMP-high CRC but not CIMP-low/CIMP-negative CRC.', 'Smoking is associated with differential risk of colorectal cancer (CRC) subtypes defined by molecular characteristics. Heavier smokers have a particularly higher risk of CRC subtypes that are CIMP positive and MSI high in combination, suggesting that smoking may be involved in the development of colorectal tumors via the serrated pathway.', 'According to recent studies, cigarette smoking has been associated with three molecular subtypes of colon cancer:\\n\\n1. Microsatellite instability-high (MSI-H) subtype: This subtype is characterized by high levels of mutations in microsatellite regions due to defects in DNA mismatch repair. Smoking has been found to increase the risk of developing MSI-H colon cancer, possibly through its effects on DNA repair pathways.\\n\\n2. CpG island methylator phenotype (CIMP)-positive subtype: This subtype is characterized by global DNA hypermethylation, particularly in CpG islands. Smoking has been found to increase the risk of developing CIMP-positive colon cancer, possibly through its effects on DNA methylation pathways.\\n\\n3. BRAF mut', 'MSI-high, CIMP-positive, and BRAF mutation-positive', 'Smoked adenocarcinoma of the colon and rectum belong to the group of molecular subtypes of colon cancer, which is associated with smoking-related factors such as environmental tobacco smoke and oxidative stress.', 'Cigarette smoking is associated with the BRAF mutation-positive and CIMP-positive molecular subtypes of colon cancer.', 'Cigarette smoking has been associated with the MSI-high, CIMP-positive, and BRAF mutation-positive subtypes of colorectal cancer.', 'The molecular subtypes of colon cancer associated with smoking are:The molecular subtypes of colon cancer associated with smoking are:The molecular subtypes of colon cancer associated with smoking are:The molecular subtypes of colon cancer associated with smoking are:The molecular subtypes of colon cancer associated with smoking are:', 'Cigarette smoking is associated with specific molecular subtypes of colorectal cancer, namely MSI-high, CIMP-positive, and those with BRAF mutations. These subtypes are characterized by distinct genetic and epigenetic alterations that can influence the behavior and treatment response of the cancer.', '3 subtypes of colon cancer have been associated to cigarette smoking. These are: MSI-high, CIMP-positive, and BRAF mutation-positive.', 'Overall, the most common molecular subtypes of colon cancer associated with smoking are nicotine-induced colon cancer (NIPC) and smoking-associated colorec cancer (SAC). These subtypes are characterized by specific genetic, epigenetic, and environmental factors that contribute to their development and progression. ', 'Cigarette smoking was associated with the MSI-high, CIMP-positive, and BRAF mutation-positive colorectal cancer subtypes.', 'According to recent studies, cigarette smoking has been associated with three molecular subtypes of colon cancer:\\n\\n1. Microsatellite instability-high (MSI-H) subtype: This subtype is characterized by high levels of mutations in microsatellite regions due to defects in DNA mismatch repair. Smoking has been found to increase the risk of developing MSI-H colon cancer, possibly through its effects on DNA repair pathways.\\n\\n2. CpG island methylator phenotype (CIMP)-positive subtype: This subtype is characterized by global DNA hypermethylation, particularly in CpG islands. Smoking has been found to increase the risk of developing CIMP-positive colon cancer, possibly through its effects on DNA methylation pathways.\\n\\n3. BRAF mutation-positive subtype: This subtype is characterized by mutations in the BRAF gene, which is involved in the MAPK signaling pathway. Smoking has been found to increase the frequency of BRAF mutations in colon cancer, possibly through its effects on oxidative stress and DNA damage.\\n\\nOverall, smoking appears to contribute', '3 molecular subtypes of colon cancer have been associated to smoking: MSI-high (microsatellite instability), CIMP-positive (CpG island methylator phenotype) and BRAF mutation-positive.', 'MSI-high, CIMP-positive, and BRAF mutation-positive colon cancer subtypes are associated with smoking.', 'Cigarette smoking is linked to the MSI-high, CIMP-positive, and BRAF mutation-positive subtypes of colorectal cancer.', 'Based on the snippet provided, cigarette smoking is associated with three molecular subtypes of colorectal cancer (CRC): MSI-high, CIMP-positive, and BRAF mutation-positive. MSI-high CRCs have a high frequency of microsatellite instability due to deficient DNA mismatch repair. CIMP-positive CRCs exhibit a high level of CpG island methylation, which can lead to the silencing of tumor suppressor genes. BRAF mutation-positive CRCs have activating mutations in the BRAF gene, leading to constitutive activation of the MAPK/ERK signaling pathway and promoting cancer cell growth and survival. These subtypes are often found in serrated polyps, a type of precancerous colon polyp that can progress to CRC. Therefore, smoking cessation is crucial in preventing the development and progression of CRC.', 'Cigarette smoking is associated with specific molecular subtypes of colorectal cancer, namely MSI-high, CIMP-positive, and BRAF mutation-positive subtypes.', 'Cigarette smoking is associated with the MSI-high, CIMP-positive, and BRAF mutation-positive subtypes of colorectal cancer. These findings suggest that smoking may contribute to epigenetic modifications and play a role in the development of these specific molecular subtypes of colon cancer.', 'The molecular subtypes of colon cancer associated with smoking are:MSI-high, CIMP-positive, and BRAF mutation-positive', 'The study found that cigarette smoking is associated with three molecular subtypes of colorectal cancer, namely MSI-high, CIMP-positive, and BRAF mutation-positive tumors. These subtypes are characterized by specific genetic alterations, such as high levels of microsatellite instability (MSI-high), promoter methylation of tumor suppressor genes (CIMP-positive), and mutations in the BRAF gene. The study suggests that smoking may play a role in the development of these subtypes through epigenetic modifications, which can alter the expression of genes involved in cell growth and differentiation.', 'MSI-High (Microsatellite Instability High) colorectal cancer is characterized by a high rate of genetic instability due to defects in DNA mismatch repair genes, which can lead to an accumulation of mutations and tumor formation. CIMP (CpG Island Methylator Phenotype) positive tumors are associated with hypermethylation of promoter regions, leading to the silencing of tumor suppressor genes. BRAF mutation-positive colorectal cancers have a specific genetic alteration in the BRAF gene, which is involved in the MAPK/ERK signaling pathway and can lead to uncontrolled cell growth.', 'Smoking is associated with the MSI-high, CIMP-positive, and BRAF mutation-positive colorectal cancer subtypes.', 'Cigarette smoking is associated with specific molecular subtypes of colorectal cancer, specifically those that are MSI-high, CIMP-positive, and have BRAF mutations.', 'Cigarette smoking is associated with the MSI-high, CIMP-positive, and BRAF mutation-positive subtypes of colorectal cancer. This means that individuals who smoke cigarettes are more likely to develop these specific molecular subtypes of colon cancer.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the Relations table, there is no direct association between smoking and molecular subtypes of colon cancer. However, there are some indirect associations. \n\nThe Consensus Molecular Subtypes (CMS) classification of colon cancer is mentioned in the Relations table, but there is no specific mention of smoking as a factor associated with any of the CMS subtypes.\n\nHowever, smoking is associated with an increased risk of colorectal cancer in general, and some studies suggest that smoking may be associated with specific molecular subtypes of colon cancer, such as CMS4, which is characterized by a high degree of tumor heterogeneity and a poor prognosis.\n\nIt's worth noting that the Relations table does not provide a comprehensive list of all molecular subtypes of colon cancer or their associations with various risk factors, including smoking.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "2",
        "Information Recall Explanation": "The answer fails to recall the well-documented associations between smoking and specific molecular subtypes of colon cancer (e.g., MSI-high, CIMP-positive, BRAF mutation-positive) mentioned in the reference answers. It vaguely suggests an association with CMS4, which is not supported by the majority of references provided.",
        "Information Precision Score": "3",
        "Information Precision Explanation": "While the answer is cautious and avoids incorrect assertions, it lacks precision by not directly addressing the well-established associations cited in the references. The mention of CMS4 is an imprecise assumption since it is not validated by the references.",
        "Information Repetition Score": "4",
        "Information Repetition Explanation": "The answer does not repeat information unnecessarily. It clearly differentiates between direct and indirect associations without redundancy.",
        "Readability Score": "4",
        "Readability Explanation": "The answer is clearly written and logically structured, making it easy to follow. However, the lack of direct relevance to the referenced associations slightly affects its overall clarity."
    },
    {
        "Question": "What part of the cell is mitophagy associated with?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat part of the cell is mitophagy associated with?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Mitophagy, or selective autophagy of mitochondria, is an essential pathway to preserve mitochondrial homeostasis by clearing up damaged mitochondria', 'Mitophagy is associated with \"mitochondria\".', 'Mitophagy is associated with the selective autophagic clearance of flawed or damaged mitochondria within the cell, ensuring the maintenance of a healthy mitochondrial pool and cellular homeostasis.', 'Mitophagy is associated with the outer mitochondrial membrane 20 (Tomm20), a mitochondrial translocase that, when ubiquitinated, promotes mitophagy.', 'Mitochondrial autophagy is associated with the removal of defective mitochondria from the cell by internalisation into autophagosomes which fuse with lysosomes.', 'Mitophagy is a selective form of autophagy, where damaged or dysfunctional mitochondria are targeted and degraded by the autophagosome.', 'Mitophagy is associated with lysosomes, where defective mitochondria are internalized into autophagosomes that fuse with lysosomes for degradation.', 'Mitophagy is a selective autophagy of mitochondria, can efficiently degrade, remove and recycle the malfunctioning or damaged mitochondria, and is crucial for quality control.', 'Mitophagy is a specific type of autophagy that involves the selective elimination of damaged or dysfunctional mitochondria via autophagosomes and lysosomes, a process that is critical for mitochondrial quality control.', 'Mitophagy is associated with mitochondria, involving their encapsulation into autophagosomes for delivery to lysosomes for degradation.', 'Mitophagy is associated with the lysosomes, which are responsible for the degradation of damaged or superfluous mitochondria.', 'Mitophagy is associated with the outer membrane of mitochondria (OMM).', 'Mitophagy is associated with mitochondria.', 'Mitochondrial dysfunction is targeted for degradation in the lysosomes by mitophagy.', 'Mitophagy is a selective form of autophagy that specifically targets damaged or dysfunctional mitochondria for degradation and recycling. It is a quality control mechanism associated with maintaining a healthy mitochondrial pool within the cell.', 'Mitophagy is associated with the elimination of damaged mitochondria and maintenance of mitochondrial homeostasis. It is a process that occurs within the cell, specifically targeting and removing dysfunctional or damaged mitochondria.', 'Mitophagy is an essential physiological process that eliminates damaged mitochondria via lysosomes.', 'Mitophagy is associated with mitochondria, which are organelles within eukaryotic cells. Mitophagy is a process by which cells selectively remove and recycle damaged or dysfunctional mitochondria through the autophagy-lysosome pathway. This process helps to maintain mitochondrial quality control and homeostasis.', 'Mitophagy is a process by which cells selectively remove and burn their own mitochondria. It is a conserved mechanism that all eukaryotes use to remove damaged mitochondria.', 'Mitophagy is associated with mitochondria through autophagic machinery to maintain mitochondrial quality control and homeostasis.', 'Mitophagy is associated with the process of selectively clearing damaged or dysfunctional mitochondria through autophagic machinery to maintain mitochondrial quality control and homeostasis within the cell.', 'Mitophagy is associated with the mitochondria.', 'Mitophagy is associated with mitochondria, the part of the cell responsible for energy production. It specifically targets damaged or dysfunctional mitochondria, clearing them out to maintain cellular health and efficiency.', 'Mitophagy is associated with the clearance of damaged mitochondria via lysosomes.', 'Mitophagy is an essential pathway responsible for preserving mitochondrial homeostasis through the clearance of damaged mitochondria.', ' Mitophory are primarily associated with the organelle membrane of eukaryotes, where they play a crucial role in the degradation of misfolded proteins and the maintenance of cellular integrity. ', 'Mitophagy is associated with lysosomes.', \"Mitophagy is a process associated with the elimination of damaged or dysfunctional mitochondria through autophagic machinery, which is a part of the cell's quality control and homeostasis maintenance mechanism.\", 'Mitophagy is associated with mitochondria, the part of the cell responsible for energy production. It specifically targets damaged or dysfunctional mitochondria for degradation to maintain cellular health', 'Mitophagy is associated with mitochondria, which are organelles within eukaryotic cells. Mitophagy is a process by which cells selectively remove and recycle damaged or dysfunctional mitochondria through the autophagy-lysosome pathway. This helps to maintain mitochondrial quality control and homeostasis.', 'Mitophagy refers to selective autophagy of mitochondria, which plays a crucial role in preserving mitochondrial homeostasis by clearing up damaged or dysfunctional mitochondria.', 'Mitophagy is associated with the mitochondria, which are the powerhouses of the cell.', 'Mitophagy is associated with the mitochondria, targeting them for degradation.', 'Mitophagy is associated with mitochondria, specifically targeting damaged or dysfunctional mitochondria for degradation to maintain cellular health.', 'Mitophagy is associated with the mitochondria, which are critical cellular energy resources and central to the life of the neuron. Mitophagy selectively clears damaged or dysfunctional mitochondria through autophagic machinery to maintain mitochondrial quality control and homeostasis.', 'Mitophagy is associated with mitochondria. It is the selective autophagy of damaged or dysfunctional mitochondria to maintain mitochondrial homeostasis and quality control.', 'Mitophagy is associated with the lysosomes, which are responsible for the degradation of damaged or dysfunctional mitochondria.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nMitophagy is associated with the mitochondria, specifically the process of degrading and recycling damaged or dysfunctional mitochondria.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer correctly identifies mitophagy's association with mitochondria and specifies the process of degrading and recycling damaged or dysfunctional mitochondria. However, it does not mention related structures like lysosomes or autophagosomes, which are part of the process as indicated in some reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise, focusing solely on the key aspects of mitophagy—association with mitochondria and the process of degradation and recycling. There is no irrelevant information included.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information. It succinctly presents the core idea without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is clear, concise, and easily understandable. The sentence is well-structured and flows smoothly, making it highly readable."
    },
    {
        "Question": "What is the association between statins and stroke?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the association between statins and stroke?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['\\n The association between statins and stroke is complex and varies by factors such as race and baseline cholesterol levels. While statins have been shown to reduce the incidence of stroke in high-risk populations, including those with a history of cardiovascular disease, the evidence for a benefit in primary prevention is less clear. Some studies have suggested that statins may increase the risk of hemorrhagic stroke, although the evidence is not conclusive. More research is needed to fully understand the relationship.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, there is a relationship between statins and stroke. Specifically, statins have been associated with a lower risk of hemorrhagic stroke (HS) in patients with a first cerebrovascular event, but may increase the risk of HS in patients with a history of ischemic stroke or transient ischemic attack.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer mentions the association between statins and stroke, and specifically discusses hemorrhagic stroke (HS) risk. However, it does not cover other aspects mentioned in the reference answers, such as the variability by race and baseline cholesterol levels, or the unclear evidence for primary prevention.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise in stating the relationship between statins and hemorrhagic stroke, and clearly distinguishes between patients with a first cerebrovascular event and those with a history of ischemic stroke. It avoids including irrelevant information.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each point is clearly and concisely stated once.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is easily readable and fluent, with clear and concise language that effectively communicates the key points."
    },
    {
        "Question": "What channel is targeted by VX-548?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat channel is targeted by VX-548?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['VX-548 is an oral, highly selective inhibitor of NaV1.8 that is studied for control of acute pain.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the Relations table, VX-548 is a selective inhibitor of Na(V)1.8 voltage-gated sodium channel.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer correctly identifies VX-548 as a selective inhibitor of the Na(V)1.8 voltage-gated sodium channel, which matches the reference answer.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise and directly addresses the question without including any irrelevant information.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat any information; it succinctly states the relevant fact once.",
        "Readability Score": "4",
        "Readability Explanation": "The answer is clear and fluent, though the mention of 'Relations table' may slightly distract from the directness of the information provided."
    },
    {
        "Question": "What is the most effective drug for oxaliplatin-induced neuropathy?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the most effective drug for oxaliplatin-induced neuropathy?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Duloxetine, a serotonin and norepinephrine reuptake inhibitor, is the best-established treatment for painful chemotherapy-induced peripheral neuropathy (CIPN).  Despite intense investigation at the preclinical and clinical levels, no treatment can be suggested for the prevention of Oxaliplatin-induced peripheral neurotoxicity (OIPN), and only limited evidence for the efficacy of duloxetine in the treatment setting has been provided.', 'Oxaliplatin-induced neuropathy (OIN) is a side effect of oxaliplatin chemotherapy treatment and the FDA has not approved a specific treatment for this condition. However, various clinical trials have investigated agents such as vitamin B12, B6, B1, calcium and magnesium infusions, and duloxetine. Based on the available literature, duloxetine 30 mg or 60 mg orally once daily appears to be the most effective drug.', 'Amifostine is the most effective drug for oxaliplatin-induced neuropathy.', 'The most effective drugs for treating oxaliplatin-induced neuropathy include pregabalin, duloxetine, and oxycodone, with mexiletine, omeprazole, and Calmangafodipir also showing effectiveness.', 'There is currently no single \"most effective\" drug for oxaliplatin-induced neuropathy, as treatment options are often individualized based on the severity of symptoms and patient preferences. However, duloxetine and pregabalin are commonly used medications for managing neuropathic pain associated with oxaliplatin-induced neuropathy. Other treatments may include tricyclic antidepressants, opioids, or topical agents. Additionally, there is ongoing research into potential neuroprotective agents that may prevent or reduce the severity of oxaliplatin-induced neuropathy.', 'The most effective drug for oxaliplatin-induced neuropathy is donepezil. Donepezil has been shown to effectively attenuate oxaliplatin-induced inhibition of neurite outgrowth and ameliorate peripheral neuropathy in both in vitro and in vivo models. It does not inhibit the anti-tumor activity of oxaliplatin and may be useful for managing oxaliplatin-induced peripheral neuropathy.', \"The most effective drugs for treating oxaliplatin-induced neuropathy are those that target specific mechanisms of nerve damage and pain perception, such as gabapentinoids (like gabapentin or pregabalin), which work by inhibiting voltage-dependent calcium channels to reduce the release of neurotransmitters involved in pain signaling. Other medications used include duloxetine, a serotonin-norepinephrine reuptake inhibitor that has been shown to be effective for managing chemotherapy-induced neuropathic pain. Additionally, tricyclic antidepressants like amitriptyline and selective serotonin reuptake inhibitors (SSRIs) can also be used off-label for their analgesic effects in treating neuropathy. It is important to note that the choice of medication should be individualized based on a patient's specific symptoms, overall health status, and potential drug interactions.\", 'Amifostine at the dose of 25 mg/kg provided the best protection against oxaliplatin-induced neuropathy.', 'There are several drugs that have been studied for their potential in treating oxaliplatin-induced neuropathy, including pregabalin, duloxetine, oxycodone, and riluzole. However, the most effective drug for oxaliplatin-induced neuropathy is still unknown, as different studies have shown varying results. A systematic review and meta-analysis of available studies would be necessary to determine the most effective drug for this condition.', 'Based on the provided information, several drugs have shown potential in preventing or treating oxaliplatin-induced neuropathy in preclinical and clinical studies:\\n\\n1. Amifostine: Reduced nociception induced by oxaliplatin in mice, with 25 mg/kg providing the best protection.\\n\\n2. Rutin and Quercetin: Prevented painful peripheral neuropathy induced by oxaliplatin in mice. \\n\\n3. Ibudilast: Prevented the development of tactile allodynia and memory impairments caused by oxaliplatin in an animal study.\\n\\n4. Mangafodipir: Suggested to prevent and/or relieve oxaliplatin-induced neuropathy in cancer patients.\\n\\n5. Carbamazepine: Demonstrated prevention of oxaliplatin-induced sensory neuropathy greater than grade 1 in a clinical study.\\n\\nHowever, the information provided does not clearly indicate which drug is the most effective. More comparative clinical studies would be needed to determine the relative efficacy of these agents in preventing or treating oxaliplatin-induced neuropathy in humans.', 'The most effective drug for oxaliplatin-induced neuropathy is currently not established. However, several drugs have shown potential in alleviating neuropathic symptoms. These include duloxetine, pregabalin, gabapentin, and amifostine. Further research is needed to determine the optimal treatment approach for oxaliplatin-induced neuropathy.', 'Duloxetine is the best-established treatment for painful chemotherapy-induced peripheral neuropathy (CIPN).', 'Duloxetine is the most effective drug for oxaliplatin-induced neuropathy, according to a systematic review and meta-analysis published in the Journal of Clinical Oncology in 2019. The review analyzed data from 11 randomized controlled trials involving 1,225 patients with chemotherapy-induced peripheral neuropathy (CIPN) caused by oxaliplatin. The study found that duloxetine significantly reduced the severity and incidence of CIPN compared to placebo or standard care. Other drugs that have shown some effectiveness in managing oxaliplatin-induced neuropathy include gabapentin, pregabalin, and amitriptyline, but duloxetine appears to be the most effective.', 'Duloxetine, a serotonin and norepinephrine reuptake inhibitor, is considered the best-established treatment for painful chemotherapy-induced peripheral neuropathy (CIPN), including oxaliplatin-induced neuropathy. It has shown efficacy in managing neuropathic pain associated with oxaliplatin treatment.', 'Duloxetine is currently the best-established treatment for painful chemotherapy-induced peripheral neuropathy (CIPN) caused by oxaliplatin. However, the evidence for its efficacy in the treatment setting is limited.', 'The most effective drug for managing oxaliplatin-induced neuropathy is duloxetine. It has been shown to help reduce the pain associated with this type of chemotherapy-induced peripheral neuropathy (CIPN)', \"Duloxetine is the best-established treatment for painful chemotherapy-induced peripheral neuropathy (CIPN), including that caused by oxaliplatin. However, it's important to note that there is only limited evidence for its efficacy in this specific treatment setting.\", 'Duloxetine is the most effective drug for oxaliplatin-induced neuropathy, according to a systematic review and meta-analysis published in the Journal of Clinical Oncology in 2019. The review analyzed data from 11 randomized controlled trials involving 1,212 patients with chemotherapy-induced peripheral neuropathy (CIPN) caused by oxaliplatin. The study found that duloxetine significantly reduced the severity and incidence of CIPN compared to placebo or standard care. Other drugs that have shown some effectiveness in managing oxaliplatin-induced neuropathy include gabapentin, pregabalin, and amitriptyline, but their efficacy is less well-established than that of duloxetine.', 'The most effective drug for oxaliplatin-induced neuropathy is duloxetine, a serotonin and norepinephrine reuptake inhibitor. Duloxetine has been shown to have limited evidence for its efficacy in the treatment setting for painful chemotherapy-induced peripheral neuropathy (CIPN), including oxaliplatin-induced neuropathy. However, it is important to note that the evidence is limited and further research is needed to fully establish its effectiveness.', 'Currently, there is limited evidence for the efficacy of duloxetine in the treatment of oxaliplatin-induced neuropathy. Duloxetine, a serotonin and norepinephrine reuptake inhibitor, is the best-established treatment for painful chemotherapy-induced peripheral neuropathy (CIPN). However, it is only effective in little more than half of patients, and our ability to predict patient response remains incompletely understood. Further research is needed to identify more effective treatments for oxaliplatin-induced neuropathy.', 'The most effective drug for oxaliplatin-induced neuropathy is duloxetine, a serotonin and norepinephrine reuptake inhibitor. Duloxetine has been shown to prevent and reverse mechanical hyperalgesia associated with oxaliplatin-induced peripheral neuropathy in preclinical studies. However, its efficacy in clinical settings is limited, with only about 50% of patients responding to the treatment. The neuroendocrine stress axis-dependence of duloxetine analgesia has been demonstrated in preclinical models, suggesting that stress may impact response to duloxetine. Further research is needed to identify additional effective treatments for oxaliplatin-induced neuropathy.', 'Duloxetine, a serotonin and norepinephrine reuptake inhibitor, is the best-established treatment for painful chemotherapy-induced peripheral neuropathy (CIPN), although only limited evidence for its efficacy has been provided.', 'The most effective drug for oxaliplatin-induced neuropathy is duloxetine, a serotonin and norepinephrine reuptake inhibitor. Duloxetine has been shown to be the best-established treatment for painful chemotherapy-induced peripheral neuropathy (CIPN).']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided tables, the most effective drug for oxaliplatin-induced neuropathy appears to be Duloxetine. \n\nDuloxetine has been studied in several clinical trials and has been found to potentially prevent oxaliplatin-induced peripheral neuropathy and has been used to treat neuropathic pain associated with oxaliplatin-induced peripheral neuropathy. It has been recommended by the American Society of Clinical Oncology for the management of oxaliplatin-induced peripheral neuropathy.\n\nOther drugs that have been studied for their potential to prevent or treat oxaliplatin-induced neuropathy include carbamazepine, amifostine, and exenatide. However, the effectiveness of these drugs is not as well established as Duloxetine.\n\nIt's worth noting that the effectiveness of a drug can depend on various factors, including the individual patient's response, the severity of the neuropathy, and the specific treatment regimen being used. Therefore, it's essential to consult with a healthcare professional to determine the best course of treatment for a specific patient.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer correctly identifies Duloxetine as the most effective drug for oxaliplatin-induced neuropathy, which is supported by the reference answers. It also mentions other drugs like carbamazepine, amifostine, and exenatide, which are referenced in some of the provided answers. However, it misses some other drugs mentioned in the reference answers, such as pregabalin and gabapentin, which are also significant in the context of this condition.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer focuses on Duloxetine and other relevant drugs without including irrelevant information. It clearly states the effectiveness of Duloxetine and briefly mentions other options without going into unnecessary detail, maintaining a high level of precision.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. It presents the information about Duloxetine and other drugs concisely and clearly, without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand. It provides a clear and logical flow of information, making it highly readable."
    },
    {
        "Question": "What is Microcoring used for",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is Microcoring used for\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Microcoring (MCT)  is  used skin treatments such as scarless skin removal or treatment of enlarged pores. This minimally invasive technique involves creating controlled damage in cutaneous tissue to induce neocollagenesis and neoelastogenesis. MCT involves hollow microneedles capable of removing excess tissue without inducing scar formation.', 'Microcoring is used for dermal treatment to the lower face and perioral region.', 'Microcoring is used for skin rejuvenation, treatment of pores, addressing concerns of enlarged pores, serving as a rejuvenation approach, enabling scarless skin removal, treating skin laxity, and facilitating transdermal delivery of macromolecules.', 'Microcoring technology is primarily used for treating pores, rejuvenating the skin, and lifting and tightening facial tissues.', 'Microcoring is a technology used for scarless skin removal without the use of thermal energy. It involves the use of a modified, hollow hypodermic needle to safely remove skin cores without leaving a scar. Microcoring has been found to be effective in skin rejuvenation, with benefits such as skin tightening and an increase in skin thickness observed in clinical trials.', 'Microcoring is a technique used to create small, hollow, cylindrical cavities in tissue. It is commonly used in botulinum injections to create microcores that may serve as a delivery system for therapeutic agents.', 'Microcoring is used for the treatment of supraumbilical lipomatosis.', 'Microcoring is used for skin rejuvenation, scarless skin removal, and treatment of pores.', 'Microcoring is used for skin rejuvenation.', 'Microcoring is a minimally invasive procedure used for the treatment of various conditions, including chronic pain, spinal cord injury, and neurodegenerative diseases.', 'Microcoring is used for skin rejuvenation. It involves removing tiny cores of skin to promote skin tightening and potentially increase skin thickness, which can help in improving the overall appearance of the skin', 'MCT treatment of human skin is safe and well tolerated. Although further studies on efficacy are required to evaluate the full potential of MCT in skin rejuvenation, early findings such as skin tightening and increase in skin thickness are encouraging.', 'Microcoring is used for skin rejuvenation. It has shown promising early results, including skin tightening and an increase in skin thickness, suggesting its potential for improving the appearance and health of the skin.', ' Microcoring is used for skin rejuvenation, specifically to tighten the skin and increase its thickness.', 'Microcoring is used for skin rejuvenation, including effects like skin tightening and increasing skin thickness.', 'Microcoring is used for the treatment of various medical conditions, including cancer, cardiovascular disease, and neurological disorders.', 'Microcoring is used for skin rejuvenation and skin tightening.', 'Microcoring treatment (MCT) is used for skin rejuvenation. Early findings suggest it may help with skin tightening and increasing skin thickness, although further studies are needed to fully evaluate its potential in this area.', 'Microcoring is used for skin rejuvenation, as it has shown promising early results such as skin tightening and increased skin thickness.', 'Microcoring is a treatment used for skin rejuvenation, which involves the use of micro-needles to create micro-channels in the skin. This treatment is safe and well-tolerated, and early findings suggest that it can lead to skin tightening and an increase in skin thickness.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, Microcoring technology is mentioned as a treatment option for abdominal skin (Relation id: 25) and is also used to treat facial wrinkles (Relation id: 26).\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "2",
        "Information Recall Explanation": "The answer mentions two specific applications (abdominal skin treatment and facial wrinkles) but misses many other key uses of Microcoring highlighted in the reference answers, such as skin rejuvenation, scarless skin removal, and pore treatment.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer provides precise information about two specific applications without including irrelevant details, but it lacks broader context present in the reference answers.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat any information and succinctly addresses the two distinct uses without redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is clear, concise, and easy to understand, with no grammatical or structural issues."
    },
    {
        "Question": "What symptoms can be expected in women suffering from endometriosis?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat symptoms can be expected in women suffering from endometriosis?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Women suffering from endometriosis may experience the following symptoms:\\n\\n1. Pelvic pain, especially during menstruation\\n2. Painful periods (dysmenorrhea)\\n3. Pain during sex (dyspareunia)\\n4. Painful urination or bowel movements during menstruation\\n5. Heavy menstrual bleeding\\n6. Infertility\\n7. Fatigue\\n8. Bloating or constipation\\n9. Nausea or vomiting during menstruation\\n10. Spotting or bleeding between periods (menorrhagia)\\n11. Chronic pelvic pain, which may be continuous or worsen during menstruation\\n12. Anxiety and depression due to the physical and emotional impact of the condition.\\n\\nNote that not all women with endometriosis will experience all of these symptoms, and some may not have any symptoms at all. The severity of symptoms can also vary from woman to woman.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, women suffering from endometriosis may experience a range of symptoms, including:\n\n1. Pelvic pain: A common symptom of endometriosis, characterized by chronic pain in the lower abdomen.\n2. Dysmenorrhea: Painful menstrual cramps that can be a symptom of endometriosis.\n3. Infertility: Endometriosis can lead to infertility in some women.\n4. Heavy or irregular menstrual bleeding: Women with endometriosis may experience heavy or irregular menstrual bleeding.\n5. Painful intercourse: Painful sex is a common symptom of endometriosis.\n6. Bowel or urinary symptoms: Endometriosis can cause symptoms such as constipation, diarrhea, or urinary frequency.\n7. Abdominal bloating: Some women with endometriosis may experience abdominal bloating.\n8. Fatigue: Endometriosis can cause fatigue in some women.\n9. Depression and anxiety: Endometriosis has been linked to an increased risk of depression and anxiety.\n10. Infrequent or prolonged menstrual periods: Women with endometriosis may experience infrequent or prolonged menstrual periods.\n\nIt's worth noting that not all women with endometriosis will experience all of these symptoms, and the severity of the symptoms can vary widely from woman to woman.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer captures all major symptoms mentioned in the reference answers, such as pelvic pain, dysmenorrhea, infertility, heavy menstrual bleeding, painful intercourse, bowel or urinary symptoms, fatigue, depression, and anxiety. It also notes variability in symptoms among women, aligning well with the reference.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer is precise in listing symptoms but includes minor additions like 'infrequent or prolonged menstrual periods' which, while plausible, are not explicitly mentioned in the reference. The focus remains largely on relevant symptoms.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition in the provided symptoms. Each symptom is listed once with clear and distinct descriptions.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured, fluent, and easy to read. Each symptom is clearly enumerated and described concisely. The note about variability in symptoms enhances readability."
    },
    {
        "Question": "What is the mechanism of action of Mirvetuximab Soravtansine?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the mechanism of action of Mirvetuximab Soravtansine?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Mirvetuximab soravtansine is an antibody-drug conjugate (ADC), which is comprised of a folate receptor α (FRα) directed antibody conjugated to a microtubule inhibitor via a cleavable linker.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nMirvetuximab Soravtansine is an antibody-drug conjugate (ADC) that targets the folate receptor alpha (FRα). The mechanism of action of Mirvetuximab Soravtansine involves the following steps:\n\n1. Binding to FRα: Mirvetuximab Soravtansine binds to the FRα protein on the surface of cancer cells, specifically ovarian cancer cells that overexpress FRα.\n2. Internalization: The ADC is internalized by the cancer cells through receptor-mediated endocytosis, which involves the FRα protein.\n3. Release of the payload: The ADC is then broken down, releasing the cytotoxic payload, DM4, a maytansinoid, which is a potent inhibitor of microtubule assembly.\n4. Inhibition of microtubule assembly: DM4 inhibits microtubule assembly, leading to cell cycle arrest and apoptosis (cell death).\n\nMirvetuximab Soravtansine is specifically designed to target FRα-positive ovarian cancer cells, which are often resistant to traditional chemotherapy. By delivering the cytotoxic payload directly to the cancer cells, Mirvetuximab Soravtansine aims to reduce the side effects associated with traditional chemotherapy and improve treatment outcomes for patients with FRα-positive ovarian cancer.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer thoroughly covers the mechanism of action of Mirvetuximab Soravtansine, including binding to FRα, internalization, payload release, and microtubule inhibition. It also provides additional context about its specificity for FRα-positive ovarian cancer cells and potential benefits, which enhances understanding.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and focuses solely on the mechanism of action and relevant details such as the cytotoxic payload (DM4) and its effects. There is no irrelevant information included.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information. Each point is clearly and concisely stated without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, using a numbered list for clarity, and is written in a fluent and easily understandable manner. The technical terms are appropriately explained, making it accessible to a broader audience."
    },
    {
        "Question": "Is watch-and-wait policy after neoadjuvant therapy a cost-effective policy for locally advanced rectal cancer patients?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs watch-and-wait policy after neoadjuvant therapy a cost-effective policy for locally advanced rectal cancer patients?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Using current multi-institutional recurrence estimates, we observed comparable cancer-specific survival, superior quality-adjusted survival, and decreased costs with Watch and Wait compared with upfront Total Mesorectal Excision.', 'Yes, the watch-and-wait policy after neoadjuvant therapy is likely a cost-effective policy for locally advanced rectal cancer patients. A study published in the Journal of Clinical Oncology found that the watch-and-wait policy resulted in comparable oncologic outcomes and reduced costs compared to upfront total mesorectal excision (TME) surgery. The study included 292 patients with locally advanced rectal cancer, and found that the mean costs per patient were significantly lower for the watch-and-wait subgroup (€6713) compared to the TME subgroup (€17,108) during a two-year follow-up period. Additionally, the study found that the overall survival rate was high in both groups, with no significant difference in metastasis-free survival or disease-free survival between the two groups. These findings suggest that the watch-and-wait policy can be a cost-effect', 'Yes, a watch-and-wait policy after neoadjuvant therapy can be a cost-effective policy for locally advanced rectal cancer patients, as it can decrease costs related to unnecessary surgery.', 'The watch-and-wait strategy after neoadjuvant therapy in locally advanced rectal cancer has shown to offer similar oncological outcomes compared to surgery, along with excellent results in quality of life and cost outcomes, especially for low rectal cancer cases. This approach can be considered cost-effective for eligible patients, providing comparable outcomes while potentially avoiding the morbidity and costs associated with surgery.', 'Yes, the watch-and-wait policy is a cost-effective approach', 'Yes, the watch-and-wait (WW) policy after neoadjuvant therapy is a cost-effective policy for locally advanced rectal cancer patients, as it offers similar oncological outcomes to the surgical group and excellent results in quality of life and cost outcomes, especially for low rectal cancer.', 'Yes, according to a cost-utility analysis using a Markov decision analytic model, the watch-and-wait policy (WW) after neoadjuvant therapy is a cost-effective policy for locally advanced rectal cancer patients. The study found that WW saves costs and provides better health outcomes, with an incremental cost-effectiveness ratio (ICER) of -75,486.75 € and an additional 2.04 quality-adjusted life years (QALYs) gained, when compared to standard resection (SR). The study also compared WW to robotic rectal resection (RRR) and found that WW dominates both SR and RRR in terms of cost and effectiveness. However, the study noted significant uncertainty due to the high utility value assigned to clinical complete response (cCR) after neoadjuvant therapy in the RRR alternative.', 'Yes, Watch-and-wait policy after neoadjuvant therapy is a cost-effective policy for locally advanced rectal cancer patients with complete clinical response.', 'Yes, the watch-and-wait policy is cost-effective for these patients.', 'The \"watch and wait\" policy, also known as active surveillance or expectant management, is an emerging treatment strategy for selected patients with locally advanced rectal cancer who achieve a clinical complete response (cCR) after neoadjuvant chemoradiotherapy. While this approach avoids the morbidity associated with radical surgery, it is still under investigation and considered experimental by some medical institutions. The cost-effectiveness of watch and wait compared to standard surgical resection for LARC patients remains unclear. Some studies have suggested that watch and wait may be a cost-effective option due to shorter hospital stays, fewer complications, and better quality of life associated with avoiding major surgery. However, these findings are based on limited data and need further validation through larger prospective trials. Additionally, the long-term oncological outcomes and costs related to potential local recurrences or distant metastases in watch and wait patients require careful consideration.', 'Watch-and-wait policy after neoadjuvant therapy may be a cost-effective policy for locally advanced rectal cancer patients, as it has been shown to offer comparable cancer-specific survival, superior quality-adjusted survival, and reduced cost compared with upfront surgery in some studies. However, more research is needed to confirm the clinical efficacy and cost effectiveness of this approach compared with surgery in rectal cancer.', \"Yes, according to some studies. A study published in the Journal of Gastrointestinal Surgery found that the watch-and-wait (W&W) policy after neoadjuvant therapy is a cost-effective policy for locally advanced rectal cancer patients, estimating the incremental cost-effectiveness ratio per quality-adjusted life year (QALY) to be gained from patients reaching a clinical complete response (cCR) to chemoradiotherapy. However, it's important to note that further researches on patient screening, strategy improvement, evaluation optimization, and risk control during implementation are necessary. Encouraging doctor-patient shared decision-making, adequate patient communication and informed consent, and careful design and practice of clinical research are also necessary.\", 'Yes, the watch-and-wait strategy in locally advanced rectal cancer offers similar oncological outcomes compared to the surgical group and excellent results in quality of life and cost outcomes, especially for low rectal cancer.', 'Yes, using current multi-institutional recurrence estimates, we observed comparable cancer-specific survival, superior quality-adjusted survival, and decreased costs with WW compared with upfront TME.', 'Yes, the watch-and-wait policy after neoadjuvant therapy is considered a cost-effective strategy for locally advanced rectal cancer patients, as it has shown comparable cancer-specific survival, superior quality-adjusted survival, and decreased costs compared to upfront total mesorectal excision (TME) in cases where surgical salvage rates are low.', 'Yes, the watch-and-wait (WW) policy after neoadjuvant therapy is a cost-effective policy for locally advanced rectal cancer patients. The findings indicate that WW leads to decreased costs while maintaining comparable cancer-specific survival and providing superior quality-adjusted survival compared to upfront total mesorectal excision (TME). Upfront TME tends to be preferred only when surgical salvage rates are low.', 'Yes, the watch-and-wait policy is associated with superior quality-adjusted survival, comparable cancer-specific survival, and decreased costs for locally advanced rectal cancer patients undergoing neoadjuvant therapy. However, upfront TME should be considered when surgical salvage rates are low.', 'Yes, the watch-and-wait (WW) policy after neoadjuvant therapy for locally advanced rectal cancer patients is generally cost-effective. It has been observed to offer comparable cancer-specific survival rates and superior quality-adjusted survival, along with decreased costs compared to immediate total mesorectal excision (TME). However, the preference for upfront TME might increase if the rates of successful surgical salvage are low', 'yes, the watch-and-wait (WW) policy after neoadjuvant therapy is a cost-effective policy for locally advanced rectal cancer patients. According to the study, this approach not only shows comparable cancer-specific survival rates but also leads to superior quality-adjusted survival and decreased costs compared to upfront total mesorectal excision (TME). The text mentions, \"we observed comparable cancer-specific survival, superior quality-adjusted survival, and decreased costs with WW compared with upfront TME.\" This indicates that WW is a financially and medically viable option when surgical salvage rates are adequate.', 'According to a study published in the Journal of Clinical Oncology, watch-and-wait (WW) policy after neoadjuvant therapy is a cost-effective policy for locally advanced rectal cancer patients. The study compared the costs and outcomes of watch-and-wait (WW) and upfront surgery (TME) for locally advanced rectal cancer patients. The study found that WW resulted in comparable cancer-specific survival, superior quality-adjusted survival, and decreased costs compared to upfront TME. However, upfront TME was preferred when surgical salvage rates were low. Overall, the study suggests that WW policy after neoadjuvant therapy is a cost-effective and clinically beneficial approach for locally advanced rectal cancer patients.', 'Yes, the watch-and-wait (WW) policy after neoadjuvant therapy is a cost-effective policy for locally advanced rectal cancer patients. According to a decision-analytic model, the WW strategy offers comparable cancer-specific survival, superior quality-adjusted survival, and reduced costs compared to upfront total mesorectal excision (TME). In the study, WW was found to be dominant relative to both low anterior resection and abdominoperineal resection, with cost savings of $28,500 and $32,100 respectively. The incremental quality-adjusted life-years (QALY) were also higher for the WW strategy. However, upfront TME was preferred when the rate of surgical salvage was low. These findings suggest that the WW policy can be a cost-effective alternative for locally advanced rectal cancer patients who have achieved a clinical complete response to neoadjuvant therapy.', 'The Watch and Wait (WW) policy, which involves close surveillance without immediate surgical intervention following neoadjuvant therapy for locally advanced rectal cancer, has been found to be comparable in terms of cancer-specific survival but offers superior quality-adjusted survival and lower costs compared to upfront Total Mesorectal Excision (TME). However, when the rate of successful surgical salvage after WW is low, upfront TME may become a more preferred option due to its higher success rate in achieving local control.', 'The study suggests that a watch-and-wait (WW) policy after neoadjuvant chemoradiotherapy (CRT) is a cost-effective strategy for locally advanced rectal cancer patients. The WW approach offers comparable cancer-specific survival, superior quality-adjusted survival, and reduced costs compared to upfront total mesorectal excision (TME). In the base case analysis, WW resulted in cost savings of $28,500 and $32,100 compared to low anterior resection and abdominoperineal resection, respectively, along with improved quality-adjusted life-years. These findings were consistent across various sensitivity analyses. However, it is essential to note that WW remains a dominant strategy only if the rate of surgical salvage does not fall below 73%. Thus, the watch-and-wait policy after neoadjuvant therapy could be considered a cost-effective approach for managing locally advanced rectal cancer patients.', 'Yes, based on the provided information, a watch-and-wait approach for locally advanced rectal cancer patients after neoadjuvant therapy was found to have comparable cancer-specific survival, superior quality-adjusted survival, and decreased costs compared to upfront total mesorectal excision (TME) surgery. However, upfront TME was preferred when surgical salvage rates were low.', 'Based on current multi-institutional recurrence estimates, the watch-and-wait (WW) policy after neoadjuvant therapy has been found to be a cost-effective approach for locally advanced rectal cancer patients. This approach has shown comparable cancer-specific survival, superior quality-adjusted survival, and decreased costs compared to upfront total mesorectal excision (TME). However, it is important to consider the surgical salvage rates when deciding between WW and upfront TME. If the surgical salvage rates are low, upfront TME may be preferred.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data tables, there are multiple studies that have investigated the cost-effectiveness of watch-and-wait policy after neoadjuvant therapy for locally advanced rectal cancer patients.\n\nStudy 5 (Cost analysis of a watch-and-wait approach in patients with a complete clinical response to chemoradiotherapy for rectal cancer) found that the total cost of surveillance over a 5-year period for patients in the watch-and-wait pathway was $45,246, which was significantly lower than the cost of an ultra-low anterior resection/loop ileostomy/closure of loop and routine postoperative surveillance, which was $87,473.\n\nStudy 6 (Cost Effectiveness of Watch and Wait Versus Resection in Rectal Cancer Patients with Complete Clinical Response to Neoadjuvant Chemoradiation) found that the watch-and-wait policy dominated both abdominoperineal resection (APR) and low anterior resection (LAR) at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year (QALY). This suggests that the watch-and-wait policy is a cost-effective option for patients with locally advanced rectal cancer who achieve a complete clinical response to neoadjuvant chemoradiation.\n\nStudy 7 (Quality of Life in Rectal Cancer Patients After Chemoradiation: Watch-and-Wait Policy Versus Standard Resection - A Matched-Controlled Study) found that patients who underwent watch-and-wait policy had better quality of life outcomes compared to those who underwent standard resection.\n\nHowever, it is essential to note that these studies have some limitations and that more research is needed to confirm the cost-effectiveness of the watch-and-wait policy for locally advanced rectal cancer patients.\n\nIn conclusion, based on the provided data, the watch-and-wait policy after neoadjuvant therapy appears to be a cost-effective option for locally advanced rectal cancer patients, especially for those who achieve a complete clinical response to neoadjuvant chemoradiation. However, further studies are needed to confirm these findings and to determine the optimal patient selection criteria for the watch-and-wait policy.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer effectively captures multiple key studies (Study 5, Study 6, Study 7) to support the cost-effectiveness of the watch-and-wait policy, including concrete figures and outcomes such as cost savings and quality-adjusted life-years (QALYs). The acknowledgment of study limitations and the need for further research is also noted, aligning with many reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The response is precise and focused on the cost-effectiveness of the watch-and-wait policy, providing specific cost figures and outcomes from the cited studies. No irrelevant information is included.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "No repetition is observed; each point is distinct and contributes uniquely to the argument for cost-effectiveness, supported by different studies and metrics.",
        "Readability Score": 5,
        "Readability Explanation": "The response is well-structured, with clear and fluent language, making it easy to follow. Paragraph transitions are logical, and the conclusion succinctly summarizes the findings without redundancy."
    },
    {
        "Question": "Are senolytics used to treat cardiovascular disease?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nAre senolytics used to treat cardiovascular disease?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes, senolytics have therapeutic potential in cardiovascular disease.', 'Senolytics have been tested in cardiovascular studies targeting senescence.', 'Yes, senolytics are used to treat cardiovascular disease, as they have shown promise in improving various age-related cardiovascular conditions in preclinical studies.', 'Yes, senolytics are used to treat cardiovascular disease.', 'Yes, the study and use of senolytics has increased, representing a promising field for finding accessible and safe therapies for cardiovascular disease (CVD) treatment', 'Senolytics are used to treat cardiovascular disease.', 'Not currently, but there is research and therapeutic potential in using senolytics to treat cardiovascular disease.', 'Senolytics may be used to treat cardiovascular disease by targeting senescent cells which can contribute to the pathogenesis of cardiovascular disease.', 'Yes, senolytics are used to treat cardiovascular disease. They target and eliminate senescent cells, which can contribute to the development and progression of age-related cardiovascular diseases.', 'Yes, senolytics are being explored as a treatment option for cardiovascular disease.', 'yes, senolytics like quercetin and dasatinib are being explored as treatments for age-related cardiovascular diseases, representing a promising field for developing new therapies.', 'Yes, senolytics are being explored as a promising therapeutic option for the treatment of cardiovascular diseases, particularly those related to aging.', 'Yes, senolytics are being explored as a potential treatment for cardiovascular disease.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, senolytics are being researched as a potential treatment for cardiovascular disease (CVD). Senolytics are a class of drugs that selectively target and eliminate senescent cells, which are cells that have reached the end of their lifespan and can contribute to aging and age-related diseases, including CVD.\n\nSeveral studies have shown that senescent cells play a role in the development and progression of CVD, including atherosclerosis, heart failure, and cardiac arrhythmias. Senolytic therapy has been shown to improve cardiovascular function and reduce the severity of CVD in preclinical models.\n\nSome senolytic compounds, such as Dasatinib, Quercetin, and Fisetin, have been shown to reduce senescent cell populations and improve cardiovascular function in animal models of CVD. These compounds work by inhibiting the activity of pathways that promote senescence and induce apoptosis in senescent cells.\n\nClinical trials are currently underway to evaluate the safety and efficacy of senolytic therapy for the treatment of CVD. These trials are investigating the use of senolytic compounds in patients with heart failure, atherosclerosis, and other CVDs.\n\nOverall, while senolytics are still in the early stages of research, they hold promise as a potential treatment for cardiovascular disease.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers all necessary aspects of the question. It mentions that senolytics are being researched for CVD, explains what senolytics are, their mechanism of action, their potential impact on various cardiovascular conditions, and references preclinical and clinical evidence. This matches well with the reference answers that highlight therapeutic potential, research status, and mechanism.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include irrelevant information. It focuses specifically on senolytics and their role in CVD, providing details about senescent cells, examples of senolytic compounds (Dasatinib, Quercetin, Fisetin), and ongoing clinical trials. No extraneous details are included.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer avoids repetition. Each piece of information is presented clearly and concisely without redundancy. The explanation flows logically from the definition of senolytics to their application in CVD, with no unnecessary reiteration.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is highly readable and fluent. It is well-structured, with a logical progression of ideas. The language is clear and accessible, making it easy to understand the scientific concepts without oversimplifying."
    },
    {
        "Question": "What is the cause of Brazilian spotted fever?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the cause of Brazilian spotted fever?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Brazilian spotted fever is caused by Rickettsia rickettsii.', 'The cause of Brazilian spotted fever is Rickettsia rickettsii.', 'Brazilian spotted fever is a tick-borne disease caused by a bacterium named Rickettsia rickettsii.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBrazilian spotted fever is caused by the bacterium Rickettsia rickettsii.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately identifies 'Rickettsia rickettsii' as the cause of Brazilian spotted fever, which aligns perfectly with all reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is concise and only includes the necessary information about the causative agent ('Rickettsia rickettsii') without any irrelevant details.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information and clearly states the cause once without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand, making it highly readable."
    },
    {
        "Question": "Can Nitrofurantoin cause Lung Injury?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nCan Nitrofurantoin cause Lung Injury?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes. Nitrofurantoin can cause a spectrum of lung injuries, from acute hypersensitivity reactions that might be fatal to chronic reactions involving fibrosis.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, Nitrofurantoin can cause lung injury. The data shows that there are several entities related to Nitrofurantoin-induced lung injury, including:\n\n* Nitrofurantoin-induced pulmonary toxicity\n* Nitrofurantoin-induced lung injury\n* Nitrofurantoin-induced interstitial pneumonitis\n* Nitrofurantoin-induced chronic lung disease\n* Nitrofurantoin-induced pulmonary fibrosis\n* Pulmonary toxicity caused by nitrofurantoin\n* Nitrofurantoin-stimulated oxidant production in pulmonary endothelial cells\n\nThese entities are listed in the \"Entities\" table with a rank of 1-8, indicating that they are significant and well-documented conditions associated with Nitrofurantoin use.\n\nFurthermore, the \"Sources\" table contains several articles and case reports that describe the pulmonary toxicity of Nitrofurantoin, including:\n\n* A case report of a 51-year-old woman who developed lung fibrosis after long-term use of Nitrofurantoin (Source 20)\n* A case report of a 47-year-old woman with an acute pulmonary reaction to Nitrofurantoin (Source 23)\n* A review of the literature on Nitrofurantoin-induced pulmonary toxicity (Source 23)\n* A study showing that Nitrofurantoin can stimulate oxidant production in pulmonary endothelial cells, leading to lung injury (Source 22)\n\nOverall, the data suggests that Nitrofurantoin can cause lung injury, and that this is a well-documented and significant side effect of the medication.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers the spectrum of lung injuries caused by Nitrofurantoin, including acute and chronic reactions, and provides specific examples and references. It exceeds the reference answer by detailing the various types of lung injuries and supporting evidence.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is highly precise with relevant details about the types of lung injuries and supporting case reports. However, the inclusion of 'Nitrofurantoin-stimulated oxidant production in pulmonary endothelial cells' might be slightly tangential, as it delves into mechanisms rather than clinical presentations.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not repeat information unnecessarily, but there is some redundancy in listing multiple entities that essentially describe similar lung injuries (e.g., 'Nitrofurantoin-induced pulmonary toxicity' vs. 'Pulmonary toxicity caused by nitrofurantoin'). However, this is balanced by the additional context provided.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clear, and fluent. The use of bullet points for entities and sources enhances readability, making it easy to follow. The flow from general statement to specific examples is logical and effective."
    },
    {
        "Question": "What is the first-line treatment for BRAF mutated advanced colorectal cancer patients?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the first-line treatment for BRAF mutated advanced colorectal cancer patients?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The current standard therapies for first-line treatment of BRAF-mutated mCRC are chemotherapy with bevacizumab as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab in patients with a good performance status. FOLFOXIRI plus bevacizumab is a feasible treatment option for those patients who meet the inclusion criteria of the present study, irrespective of baseline clinical characteristics and RAS or BRAF mutational status', 'The first-line treatment for BRAF mutated advanced colorectal cancer patients includes bevacizumab, chemotherapy, and chemotherapy\\u2009+\\u2009bevacizumab.', 'The first-line treatment for BRAF-mutated advanced colorectal cancer patients typically involves a combination of chemotherapy with bevacizumab, such as the FOLFOXIRI regimen, which includes 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan, along with bevacizumab. This treatment approach has shown efficacy in improving outcomes for these patients, regardless of their RAS and BRAF mutational status. Additionally, FOLFOXIRI plus bevacizumab is considered a preferred first-line treatment option for clinically selected patients with right-sided metastatic colorectal cancer.', 'The first-line treatment for BRAF mutated advanced colorectal cancer patients is chemotherapy, which includes cytotoxic chemotherapy plus bevacizumab.', 'The first-line treatment for BRAF mutated advanced colorectal cancer patients would be a combination of BRAF, MEK, and EGFR inhibitors.', 'The first-line treatment for BRAF mutated advanced colorectal cancer patients is a fluoropyrimidine-based cytotoxic regimen in combination with bevacizumab.', 'The first-line treatment for BRAF mutated advanced colorectal cancer patients is chemotherapy with bevacizumab as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab in patients with a good performance status.', 'Triplet chemotherapy (FOLFOXIRI) + bevacizumab regimen is indicated as first-line treatment of BRAF-mutated metastatic colorectal cancer (mCRC).', 'The first-line treatment for BRAF mutated advanced colorectal cancer patients has been a subject of intense debate and research. A triplet regimen, which consists of BRAF inhibitor, MEK inhibitor and EGFR inhibitor has shown to provide promising results for patients with BRAF-mutant advanced colorectal cancer in comparison to conventional doublet chemotherapy.', 'The first-line treatment for BRAF mutated advanced colorectal cancer patients typically involves a combination of chemotherapy and targeted therapy. The current standard therapies include fluoropyrimidine-based cytotoxic regimen with bevacizumab, or FOLFOXIRI plus bevacizumab in patients with good performance status. Recently, combination strategies involving mitogen-activated protein kinase (MAPK) pathway blockade have shown promising results for the treatment of patients with BRAF V600E-mutated mCRC. The largest study to date is the Binimetinib, Encorafenib, And Cetuximab cOmbiNed to treat BRAF-mutant ColoRectal Cancer (BEACON CRC) study, which has provided strong clinical evidence for BRAF and epidermal growth factor receptor inhibition with the combination of encorafenib plus cetuximab.', 'The standard first-line treatment for BRAF mutated advanced colorectal cancer (mCRC) typically involves combination chemotherapy with or without targeted therapy, such as bevacizumab or cetuximab. For patients with wild-type RAS and BRAF mutations, the addition of anti-EGFR antibodies like cetuximab to standard chemotherapy has shown improved outcomes compared to chemotherapy alone. However, for those with BRAF V600E mutation specifically, response rates to these treatments are generally lower, and more recent data suggest that a combination therapy including BRAF inhibitors (e.g., encorafenib) along with anti-EGFR antibodies may provide better outcomes in the first-line setting. It is important to note that treatment options can vary based on individual patient characteristics, disease stage, and molecular profiling results.', 'The first-line treatment for BRAF mutated advanced colorectal cancer patients is not well established, as there are limited data and no consensus on the optimal approach. However, a phase II study known as NIVACOR is currently investigating the combination of triplet chemotherapy (FOLFOXIRI) with bevacizumab and nivolumab in patients with mCRC RAS/BRAF mutated, regardless of microsatellite status. The primary endpoint of the study is the overall response rate, and secondary endpoints include overall survival, safety, time to progression, and duration of response. Additionally, translational studies are being conducted to evaluate tumor mutational burden and genetic alterations by circulating free DNA (cfDNA) obtained from plasma samples. The trial is currently open to enrollment.', 'The current standard first-line treatment for BRAF-mutated metastatic colorectal cancer (mCRC) patients is FOLFOXIRI (5-fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab, especially for patients with a good performance status. Triplet chemotherapy (FOLFOXIRI) plus bevacizumab is indicated as a preferred option for these patients, irrespective of their RAS mutational status.', 'The first-line treatment for BRAF-mutated advanced colorectal cancer patients typically involves a combination of cytotoxic chemotherapy and an antiangiogenic antibody, such as bevacizumab.', \"The current standard first-line treatment for BRAF mutated advanced colorectal cancer (mCRC) patients is chemotherapy with either 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) or capecitabine and irinotecan (XELOXI), both in combination with the anti-EGFR antibody panitumumab or cetuximab. However, patients with BRAF mutations should not receive anti-EGFR therapy as it has been shown to be ineffective and may even worsen outcomes. Therefore, the choice of chemotherapy regimen and anti-EGFR antibody should be based on other factors such as patient's performance status, prior chemotherapy, and RAS mutational status. Bevacizum\", 'chemotherapy with bevacizumab as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab', 'Chemotherapy with bevacizumab as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab is the first-line treatment for BRAF mutated advanced colorectal cancer patients.', 'The current standard first-line treatment for BRAF-mutated advanced colorectal cancer patients involves chemotherapy with bevacizumab, along with a combination of 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab, especially in patients with a good performance status. FOLFOXIRI plus bevacizumab is considered a feasible treatment option for eligible patients, regardless of baseline clinical characteristics and RAS or BRAF mutational status.', 'The first-line treatment for BRAF-mutated advanced colorectal cancer (mCRC) typically includes chemotherapy combined with bevacizumab, specifically using regimens like 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab, especially in patients with good performance status. This approach is feasible for patients who meet specific study inclusion criteria, regardless of their RAS or BRAF mutational status.', 'The current standard therapies for first-line treatment of BRAF-mutated mCRC include chemotherapy with bevacizumab and 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab in patients with a good performance status.', 'Chemotherapy with bevacizumab, 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab is the first-line treatment for BRAF mutated advanced colorectal cancer patients.', 'The first-line treatment for BRAF mutated advanced colorectal cancer patients is chemotherapy with bevacizumab as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab.', 'The first-line treatment for BRAF-mutated advanced colorectal cancer typically includes chemotherapy combined with bevacizumab, specifically using regimens like FOLFOXIRI (5-fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab, especially in patients with good performance status', 'The first-line treatment for BRAF-mutated advanced colorectal cancer (mCRC) typically includes chemotherapy combined with bevacizumab. Specifically, regimens such as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab are used, especially in patients who have a good performance status. This approach is feasible for patients who meet specific study inclusion criteria, regardless of their RAS or BRAF mutational status.', \"The current standard first-line treatment for BRAF mutated advanced colorectal cancer patients is a combination of chemotherapy with bevacizumab (a monoclonal antibody that targets vascular endothelial growth factor) and either 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) or 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI), depending on the patient's performance status and other factors. This treatment is recommended for patients with a good performance status, as FOLFOXIRI plus bevacizumab is a feasible treatment option for those who meet the inclusion criteria, irrespective of baseline clinical characteristics and RAS or BRAF mutational status. However, the median overall survival is shorter in patients with RAS-mutation-positive or BRAF-mutation-positive tumors compared to those with RAS and BRAF wild-type tumors (25.6 months vs. 37.1 months vs. 13.4 months, respectively).\", '1. Chemotherapy with bevacizumab and 2. FOLFOXIRI plus bevacizumab in patients with good performance status are the first-line treatment options for BRAF-mutated metastatic colorectal cancer.', 'The first-line treatment for advanced colorectal cancer patients with a BRAF mutation includes FOLFOXIRI combined with bevacizumab, or chemotherapy alongside bevacizumab, incorporating drugs like 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan.', 'The first-line treatment for BRAF mutated advanced colorectal cancer (mCRC) patients includes chemotherapy with bevacizumab and 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab. This combination therapy has been found to be a feasible treatment option for mCRC patients with a good performance status, regardless of their baseline clinical characteristics or RAS or BRAF mutational status. However, it is important to note that the median overall survival (OS) for BRAF-mutation-positive subgroups is shorter compared to RAS and BRAF wild-type subgroups. The OS for BRAF-mutation-positive patients is 13.4 months (95% CI 8.2-24.1), while for RAS and BRAF wild-type subgroups,', 'The first-line treatment for BRAF-mutated advanced colorectal cancer includes chemotherapy with bevacizumab and a regimen of 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan, known as FOLFOXIRI, particularly for patients with good performance status.', 'The current standard first-line treatment for BRAF-mutated advanced colorectal cancer patients is chemotherapy with bevacizumab, as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab in patients with a good performance status.', 'The first-line treatment for BRAF mutated advanced colorectal cancer typically involves chemotherapy with bevacizumab, as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab in patients with a good performance status. However, recent clinical research has shown promising results for combination strategies involving mitogen-activated protein kinase (MAPK) pathway blockade, such as the Binimetinib, Encorafenib, And Cetuximab cOmbiNed to treat BRAF-mutant Colorectal Cancer (BEACON CRC) study. This study provided strong clinical evidence to support BRAF and epidermal growth factor receptor inhibition with the combination of encorafenib plus cetuximab in BRAF V600E-mutated mCRC. As', 'The first-line treatment for BRAF mutated advanced colorectal cancer patients is chemotherapy with bevacizumab, FOLFOXIRI plus bevacizumab, and bevacizumab.', 'The current standard first-line treatment options for BRAF-mutated metastatic colorectal cancer (mCRC) are:\\n\\n1. Chemotherapy with bevacizumab \\n2. FOLFOXIRI (5-fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab in patients with a good performance status\\n\\nFOLFOXIRI plus bevacizumab is a feasible treatment option for eligible patients irrespective of baseline clinical characteristics and RAS or BRAF mutational status. However, patients with BRAF mutations have worse overall survival compared to those with RAS mutations or RAS/BRAF wild-type.', 'The first-line treatment for BRAF-mutated advanced colorectal cancer includes chemotherapy with bevacizumab, and specifically the regimen of 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab for patients with good performance status.', 'The current standard first-line treatment for BRAF-mutated advanced colorectal cancer patients is chemotherapy with bevacizumab, as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab. This treatment regimen has shown improved overall survival compared to other treatment options.', 'The first-line treatment for BRAF mutated advanced colorectal cancer patients is chemotherapy with bevacizumab, as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab in patients with a good performance status.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the first-line treatment for BRAF mutated advanced colorectal cancer patients is chemotherapy plus bevacizumab.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer correctly identifies chemotherapy plus bevacizumab as a first-line treatment, which aligns with several reference answers. However, it misses specific details such as the FOLFOXIRI regimen and the importance of patient performance status, which are mentioned in the reference answers.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise in stating the treatment as chemotherapy plus bevacizumab without including irrelevant information. However, it could be more precise by specifying the chemotherapy regimen (e.g., FOLFOXIRI).",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information. It is concise and to the point.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is clear, concise, and easily understandable. It effectively communicates the key point without unnecessary complexity."
    },
    {
        "Question": "List the causes of Restrictive cardiomyopathy (RCM)",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nList the causes of Restrictive cardiomyopathy (RCM)\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Three of the leading causes of Restrictive Cardiomyopathy RCM include cardiac amyloidosis, cardiac sarcoidosis, and cardiac hemochromatosis.', 'The causes of Restrictive Cardiomyopathy (RCM) include: , 1. Mutations in genes that govern the contractile function of the cardiomyocytes, such as FLNC, TTN, and CRYAB., 2. Cardiac amyloidosis, a condition where abnormal proteins accumulate in the heart tissue., 3. Cardiac sarcoidosis, a condition where inflammatory cells accumulate in the heart tissue., 4. Cardiac hemochromatosis, a condition where excess iron accumulates in the heart tissue., 5. Other genetic mutations, such as those affecting the desmin and familial amyloidosis genes., 6. Unknown causes, as the genetic etiology of RCM is not yet fully understood.', 'Cardiac amyloidosis, cardiac sarcoidosis, hypertrophic, restrictive cardiomyopathy, amyloidosis, Cardiac troponin mutations, RCM mutants are incorporated into reconstituted myofilaments, and restrictive cardiomyopathies can be causes of Restrictive cardiomyopathy (RCM).', 'The causes of Restrictive cardiomyopathy (RCM) include cardiac sarcoidosis, cardiac hemochromatosis, cardiac amyloidosis, mutations in TTN, Cardiac troponin mutations, and amyloidosis.', 'The causes of Restrictive cardiomyopathy (RCM) include Cardiac sarcoidosis, Cardiac hemochromatosis, Cardiac amyloidosis, Cardiac troponin mutations, mutations in FLNC, amyloidosis, mutations in TTN, and Sarcomere protein gene mutations.', 'Restrictive cardiomyopathy (RCM) can be caused by various factors, including genetic mutations in sarcomeric genes, infiltrative diseases such as amyloidosis, storage diseases like Fabry disease and glycogen storage diseases, and radiation therapy. Other potential causes include idiopathic or unknown etiology, endomyocardial fibrosis, and certain medications or toxins.', 'Restrictive cardiomyopathy (RCM) is caused by a number of factors including viral infection, idiopathic cardiomyopathy, familial restrictive cardiomyopathy, and hypertrophic cardiomyopathy.', 'The known causes of Restrictive Cardiomyopathy (RCM) include mutations in sarcomere protein genes, desmin gene, familial amyloidosis genes, and specific genetic variants in filamin C (FLNC) and titin (TTN) genes. Additionally, RCM can be caused by certain diseases such as cardiac amyloidosis, cardiac sarcoidosis, and cardiac hemochromatosis.', 'The causes of Restrictive cardiomyopathy (RCM) are cardiac sarcoidosis, cardiac hemochromatosis, cardiac amyloidosis, Cardiac troponin mutations, mutations in TTN, Sarcomere protein gene mutations, Mutations in FLNC, and amyloidosis.', 'Restrictive cardiomyopathy (RCM) can result from various local and systemic disorders. The main causes include:\\n\\n1. Mutations in genes encoding sarcomeric proteins such as cardiac troponin I (TNNI3), cardiac troponin T (TNNT2), tropomyosin (TPM1), myosin light chain 3 (MYL3), and myosin light chain 2 (MYL2).\\n\\n2. Mutations in genes encoding cytoskeletal and Z-line-associated proteins like myopalladin (MYPN). \\n\\n3. Familial forms of RCM are mainly caused by mutations in sarcomere proteins and share a common genetic etiology with other inherited cardiomyopathies.\\n\\n4. Other local and systemic disorders (not specified in the given information).', 'The causes of Restrictive Cardiomyopathy (RCM) include mutations in sarcomeric proteins, genetic variants in sarcomeric or cytoskeletal genes, such as MYH7, and other genetic causes that are yet to be determined. Additionally, RCM can be secondary to infiltrative diseases (e.g., amyloidosis, sarcoidosis), endomyocardial diseases (e.g., endomyocardial fibrosis, Loeffler syndrome), storage diseases (e.g., Fabry disease, Gaucher disease), radiation therapy, and certain medications (e.g., anthracyclines).', 'Restrictive cardiomyopathy (RCM) is caused by a number of conditions, including obstructive cardiomyopathy, hypertrophic cardiomyopathy, and myocarditis.', 'Cardiac amyloidosis, cardiac sarcoidosis, and cardiac hemochromatosis are causes of Restrictive cardiomyopathy (RCM).', 'The causes of Restrictive cardiomyopathy (RCM) include cardiac amyloidosis, cardiac sarcoidosis, and cardiac hemochromatosis.', 'Overall, the causes of restrictive cardiomyopathy are multifactorial, involving complex interactions between genetic, environmental, and other factors. ', 'RCM is caused by multiple factors which include genetic cardiac diseases such as:\\n- Glycogen storage diseases (GSD)\\n- Mitochondrial cardiomyopathies\\n- Desmin-related myopathies\\n- Neuromuscular diseases\\n- Amyloidosis\\n- Sarcoidosis\\n- Hemochromatosis\\n- Carcinoid heart disease\\n- Radiation therapy\\n- Malignancy\\n- Hypereosinophilia', 'The main causes of Restrictive cardiomyopathy include cardiac amyloidosis, cardiac sarcoidosis, and cardiac hemochromatosis.', 'The causes of Restrictive cardiomyopathy (RCM) are cardiac amyloidosis, cardiac sarcoidosis, and cardiac hemochromatosis.', 'The major causes of restrictive cardiomyopathy (RCM) mentioned in the text are:\\n\\n1. Cardiac amyloidosis\\n2. Cardiac sarcoidosis\\n3. Cardiac hemochromatosis', 'The major causes of Restrictive cardiomyopathy (RCM) include cardiac amyloidosis, cardiac sarcoidosis, and cardiac hemochromatosis, each requiring specific interventions.', 'The causes of Restrictive cardiomyopathy (RCM) include cardiac amyloidosis, cardiac sarcoidosis, cardiac hemochromatosis, endomyocardial fibrosis, idiopathic restrictive cardiomyopathy, and infiltrative diseases such as Gaucher disease and Fabry disease.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data tables, the following are the causes of Restrictive Cardiomyopathy (RCM):\n\n1. **Cardiac Amyloidosis**: A type of restrictive cardiomyopathy caused by the deposition of amyloid fibrils in the heart muscle, leading to restrictive cardiomyopathy.\n2. **Cardiac Sarcoidosis**: A type of restrictive cardiomyopathy caused by the deposition of granulomatous tissue in the heart muscle.\n3. **Cardiac Hemochromatosis**: A type of restrictive cardiomyopathy caused by the accumulation of iron in the heart muscle.\n4. **Filamin C (FLNC) mutations**: Mutations in the FLNC gene have been linked to restrictive cardiomyopathy.\n5. **Transthyretin Amyloidosis (ATTR)**: A type of restrictive cardiomyopathy caused by the deposition of transthyretin protein in the heart muscle.\n6. **Wild-type Systemic Senile Amyloidosis**: A type of restrictive cardiomyopathy caused by the deposition of amyloid fibrils in the heart muscle.\n7. **Genetic mutations in cardiac sarcomere protein genes**: Mutations in genes such as cardiac troponin T (TNNT2), cardiac troponin I (TNNI3), beta-myosin heavy chain (MYH7), and alpha-actin (ACTC) have been linked to restrictive cardiomyopathy.\n8. **Restrictive Cardiomyopathy with idiopathic cause**: Some cases of restrictive cardiomyopathy have an unknown or idiopathic cause.\n\nNote that this list may not be exhaustive, as the provided data tables may not contain all possible causes of Restrictive Cardiomyopathy.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "4",
        "Information Recall Explanation": "The answer covers most of the key causes listed in the reference answers, including cardiac amyloidosis, cardiac sarcoidosis, cardiac hemochromatosis, and genetic mutations (FLNC, sarcomere protein genes). It also introduces additional causes like transthyretin amyloidosis and wild-type systemic senile amyloidosis, which are not commonly mentioned in the reference answers but are relevant. The acknowledgment of idiopathic cases is also noted. However, it misses a few causes like storage diseases (e.g., Fabry disease) and conditions such as endomyocardial fibrosis.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is highly precise, focusing solely on the causes of RCM without including irrelevant information. Each listed cause is directly related to RCM, and the descriptions are concise and accurate.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each cause is listed once with a clear and distinct explanation, making it easy to follow.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured and highly readable. Each cause is presented in a numbered list with a brief but clear description. The language is fluent and easy to understand, and the note at the end adds context without disrupting the flow."
    },
    {
        "Question": "Trends of acute epiglottitis in children.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nTrends of acute epiglottitis in children.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Mortality due to epiglottitis in children has decreased since the adoption of the Haemophilus influenza Type b vaccination (Hib) in pediatric populations.', 'The trend in mortality from acute epiglottitis in children has decreased following the widespread adoption of the Haemophilus influenzae Type b (Hib) vaccination.', 'The trends in mortality due to acute epiglottitis in children have decreased significantly after the adoption of the Haemophilus influenza Type b vaccination (Hib) in pediatric populations.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, the incidence of acute epiglottitis in children has shown a significant decline in recent years, particularly after the introduction of Haemophilus influenzae type b (Hib) vaccination. \n\nA study from northern Finland (Relation ID: 15) reported a sharp decline in the incidence of acute epiglottitis among children after the introduction of conjugate Hib vaccination in 1986, from 7.6 cases per 100,000 individuals per year to 0 cases per 100,000 individuals per year. \n\nAnother study from England (Relation ID: 16) also observed a decline in the number of pediatric cases of epiglottitis following the introduction of Hib vaccines, although the numbers were still lower than those reported before vaccine availability. \n\nThese findings suggest that the widespread use of Hib vaccination has been effective in reducing the incidence of acute epiglottitis in children. However, it's worth noting that there was a corresponding increase in the number of adult cases of epiglottitis after vaccination of children, as reported in the study from northern Finland (Relation ID: 15). \n\nOverall, the data suggest that the incidence of acute epiglottitis in children has declined significantly in recent years, likely due to the introduction of Hib vaccination.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers the main point concerning the decline in acute epiglottitis in children due to Hib vaccination, which matches the reference answers. However, it also includes additional information (e.g., specific studies from Finland and England, and the increase in adult cases) that was not present in the reference answers, which slightly deviates from pure recall.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise in discussing the impact of Hib vaccination on acute epiglottitis in children. However, it includes some additional details (e.g., specific studies and adult case trends) that, while relevant, are not part of the reference answers and may be considered slightly off-topic for a strictly recall-based evaluation.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. Each point is introduced clearly and contributes to the overall understanding without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to follow. The sentences are clear, and the logical flow of information is maintained throughout."
    },
    {
        "Question": "Is Omaveloxolone effective for Friedreich Ataxia?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs Omaveloxolone effective for Friedreich Ataxia?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes. Omaveloxolone is effective and approved for Friedreich Ataxia.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nOmaveloxolone is a medication that has been approved by the FDA for the treatment of Friedreich's Ataxia (FA) in adults and adolescents aged 16 years and older. It is an orally active, small molecule semi-synthetic triterpenoid drug that increases antioxidant activity, which is being developed by Reata Pharmaceuticals, Inc. for the treatment of FA.\n\nAccording to clinical trial data, omaveloxolone has been shown to improve neurological function and slow the progression of FA in patients. In a phase 2 clinical trial (the MOXIe study), patients treated with omaveloxolone showed a significant improvement in the modified Friedreich's Ataxia Rating Scale (mFARS) score compared to placebo. The mFARS score is a measure of the severity of FA symptoms.\n\nAdditionally, a propensity-matched comparison of omaveloxolone treatment to FA natural history data showed that omaveloxolone provided persistent benefit over 3 years when compared to an untreated, matched cohort from the Friedreich's Ataxia Clinical Outcome Measures Study (FACOMS). At each year, patients in the omaveloxolone group experienced a smaller change from baseline in mFARS score than matched FACOMS patients.\n\nOmaveloxolone has also been shown to be generally safe and well-tolerated, with transient reversible increases in aminotransferase levels being the most common adverse effect.\n\nOverall, the available evidence suggests that omaveloxolone is effective for the treatment of Friedreich's Ataxia, improving neurological function and slowing disease progression.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer provides comprehensive details about omaveloxolone, including its approval status, mechanism of action, clinical trial results (MOXIe study), comparison with natural history data (FACOMS), and safety profile. All necessary information is reported.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is focused solely on omaveloxolone and its efficacy for Friedreich's Ataxia. No irrelevant information is included.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer presents clear and concise information without repeating the same points unnecessarily.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand. It logically flows from one point to another, making it highly readable."
    },
    {
        "Question": "What non-colonic tumors are associated with Lynch syndrome?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat non-colonic tumors are associated with Lynch syndrome?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Following colorectal cancer, carriers of MMR gene mutations had the following 10-year risk of cancers in other organs: kidney, renal pelvis, ureter, and bladder (2%, 95% confidence interval [CI] = 1% to 3%); small intestine, stomach, and hepatobiliary tract (1%, 95% CI = 0.2% to 2%); prostate (3%, 95% CI = 1% to 5%); endometrium (12%, 95% CI = 8% to 17%); breast (2%, 95% CI = 1% to 4%); and ovary (1%, 95% CI = 0% to 2%). They were at elevated risk compared with the general population: cancers of the kidney, renal pelvis, and ureter (SIR = 12.54, 95% CI = 7.97 to 17.94), urinary bladder (SIR = 7.22, 95% CI = 4.08 to 10.99), small intestine (SIR = 72.68, 95% CI = 39.95 to 111.29), stomach (SIR = 5.65, 95% CI = 2.32 to 9.69), and hepatobiliary tract (SIR = 5.94, 95% CI = 1.81 to 10.94) for both sexes; cancer of the prostate (SIR = 2.05, 95% CI = 1.23 to 3.01), endometrium (SIR = 40.23, 95% CI = 27.91 to 56.06), breast (SIR = 1.76, 95% CI = 1.07 to 2.59), and ovary (SIR = 4.19, 95% CI = 1.28 to 7.97).', 'Lynch syndrome (LS) is a genetic condition that increases the risk of developing various types of cancer, including colonic and endometrial cancer. In addition to these, several other malignancies are associated with LS, although less commonly. The following non-colonic tumors have been linked to Lynch syndrome: , 1. Ovarian cancer: Studies suggest that women with a family history of Lynch syndrome have an increased risk of developing ovarian cancer., 2. Stomach cancer: Individuals with LS are at higher risk of developing gastric cancer, particularly those with a family history of gastric or colorectal cancer., 3. Urinary tract cancer (UTUC): Lynch syndrome is associated with an increased risk of UTUC, including kidney and ureteral cancer., 4. Pancreatic cancer: Some studies suggest that individuals with LS may have a higher risk of developing pancreatic cancer', 'LS has been associated with various non-colonic malignancies. The main tumors in LS are:\\n\\n1. Colon cancer and other intestinal tumors\\n2. Uterine cancer\\n3. Ovarian cancer\\n4. Urothelial tumors, which include ureter and renal pelvis cancers\\n5. Pancreatic cancer\\n6. Stomach cancer\\n7. Small bowel cancer\\n8. Skin cancer\\n9. Central nervous system tumors', 'Endometrial, glioblastoma, colorectal, sarcomas, endometrial carcinomas, small intestine, ovarian, and brain malignancies are non-colonic tumors associated with Lynch syndrome.', 'Non-colonic tumors associated with Lynch syndrome (hereditary nonpolyposis colorectal cancer - HNPCC) include endometrial carcinoma, stomach cancer, ovarian carcinoma, urinary tract carcinoma (renal pelvis and ureter), biliary system cancer, breast cancer, prostate cancer, uterine cervix cancer, brain tumors, skin cancer, and upper urinary tract tumors. These extracolonic tumors are part of the spectrum of cancers seen in individuals with Lynch syndrome, highlighting the importance of comprehensive surveillance and management strategies for affected individuals.', 'Turcot syndrome is a rare genetic disorder characterized by the presence of multiple colon polyps and a primary brain tumor, typically glioblastoma multiforme. In addition to colon polyps, Turcot syndrome can also be associated with other non-colonic tumors, including glioblastoma multiforme, ovarian cancer, and breast cancer. The association between Turcot syndrome and these non-colonic tumors is thought to be due to shared genetic mutations, such as those in the mismatch repair genes, which are responsible for maintaining genomic stability.', '\"The non-colonic tumors associated with Lynch syndrome include glioblastoma, biliary duct cancers, small intestine, ovarian, endometrial, upper urinary tract, and gastric cancers.\"', 'Non-colonic tumors associated with Lynch syndrome include those that are found in the endometrium, ovaries, stomach, small intestine, pancreas, upper urinary tract, biliary tract, brain, skin, and sebaceous glands. Among these tumors, endometrial and ovarian cancers are the most frequent in women. The association with the skin tumors is called Muir-Torre syndrome, which is characterized by the presence of multiple sebaceous neoplasms and one or more keratoacanthomas, in association with visceral malignancies, particularly colorectal, urologic, and gastrointestinal cancers.', 'Non-colonic tumors associated with Lynch syndrome include glioblastoma, biliary duct cancers, upper urinary tract, small intestine, ovarian, gastric, endometrial, and breast carcinoma with medullary features.', 'Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC), is an autosomal dominant genetic condition that is associated with a high risk of colorectal cancer or other extracolonic tumors. These extracolonic tumors include adenocarcinoma of the endometrium, stomach, ovarian carcinoma, carcinoma of the urinary tract, small intestine, brain tumors, and skin cancer.\\n\\nIn HNPCC, endometrial carcinoma (EC) is the most common extracolonic tumor, followed by cancers of the stomach, small bowel, urinary tract (renal pelvis and ureter), biliary system, and ovary. In women, breast and endometrial cancer are the most frequent extracolonic manifestations, while in men, prostate and stomach cancer are the most frequent.\\n\\nUpper urinary tract tumors rank third (5%) after colon (63%) and endometrial (9%) cancer within the group of HNPCC related tumors. Endometrial and ovarian cancers are common extracolonic tumors in this syndrome.\\n\\nCRC and endometrial carcinoma were associated with a greater probability of detecting pathogenic mutations in mismatch repair genes, with MSH2 involvement predominating.\\n\\nPatients inheriting this predisposition are susceptible to colorectal, endometrial and other extracolonic tumors.', 'A variety of extracolonic tumors may be encountered in HNPCC, including cancers of the endometrium, stomach, small bowel, urinary tract (renal pelvis and ureter), biliary system and ovary.', '\\nEndometrial, ovarian, gastric, small intestine, ureter and renal pelvis, pancreatic, bile duct, liver, brain (glioma), and skin (melanoma) tumors are associated with Lynch syndrome (also known as hereditary non-polyposis colorectal cancer).', 'Lynch syndrome II or extracolonic cancers that are particularly associated with Lynch syndrome are carcinomas of the stomach, endometrium, biliary and pancreatic systems, and urinary tract.', 'Lynch syndrome is associated with several non-colonic tumors including endometrial, upper urinary tract, small intestine, ovarian, gastric, biliary duct cancers, and glioblastoma.', 'Lynch syndrome (LS) is a common genetic syndrome characterized by pathogenic mutations of DNA mismatch repair genes resulting in a hereditary predisposition to cancer. While typically associated with colonic and endometrial cancer, LS additionally influences the development of many other malignancies. The Amsterdam II and Revised Bethesda Guidelines are the established clinical criteria for diagnosing LS.', 'Non-colonic tumors associated with Lynch syndrome include endometrial, stomach, small bowel, pancreas, biliary tract, ovary, kidney, brain, skin (sebaceous adenomas and keratoacanthomas), and urinary tract cancers. The Revised Bethesda Guidelines recommend considering Lynch syndrome in patients with these tumors, particularly if they are young at diagnosis or have a family history of cancer.', 'Lynch syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC), is associated with an increased risk of several non-colonic tumors. These include endometrial cancer, ovarian cancer, gastric cancer, small bowel cancer, urinary tract cancer (including urothelial carcinoma), pancreatic cancer, and sebaceous gland tumors. Therefore, individuals with Lynch syndrome should undergo regular surveillance and screening for these malignancies to detect them at an early stage.', 'Lynch syndrome is a hereditary cancer syndrome that is associated with non-colonic tumors, including endometrial, ovarian, stomach, small bowel, urinary tract, and brain tumors.', 'Non-polyposis colorectal carcinoma (Lynch syndrome) is among the most common hereditary cancers in man. It is characterized by an increased risk of developing colorectal cancer, often at a young age, and sometimes accompanied by other types of tumors such as endometrial, ovarian, stomach, small intestine, pancreas, biliary tract, urinary tract, brain, skin, or prostate cancers. The syndrome is named after Henry T. Lynch, who first described the condition in 1964.', 'Lynch syndrome is associated with a high risk of colorectal cancer or other extracolonic tumors (adenocarcinoma of endometrium, stomach, ovarian carcinoma, carcinoma of urinary tract, small intestine, brain tumors and skin cancer).', 'Lynch syndrome is a genetic condition that increases the risk of developing colorectal cancer, as well as several other types of cancer. In addition to colonic tumors, Lynch syndrome has been associated with the following non-colonic tumors: , 1. Endometrial cancer: Lynch syndrome is associated with an increased risk of endometrial cancer in both men and women., 2. Ovarian cancer: Women with Lynch syndrome have a higher risk of developing ovarian cancer compared to the general population., 3. Gastric cancer: Some studies suggest that individuals with Lynch syndrome may be at increased risk of developing gastric cancer., 4. Small bowel cancer: There is evidence to suggest that individuals with Lynch syndrome may be at higher risk of developing small bowel cancer compared to the general population., 5. Urinary tract cancer: Some studies have found an increased risk of urinary tract cancer in individuals with Lynch syndrome', 'Glioblastoma, biliary duct cancers, upper urinary tract, small intestine, ovarian, gastric, endometrial, and endometrial carcinomas are non-colonic tumors associated with Lynch syndrome.', '\\nEndometrial, ovarian, gastric, small intestine, ureter and renal pelvis, and brain (rarely)', 'The most common extracolonic tumors associated with Lynch syndrome (hereditary nonpolyposis colorectal cancer, HNPCC) are:\\n\\n1. Endometrial cancer (most common in women)\\n2. Ovarian cancer \\n3. Stomach cancer\\n4. Small bowel cancer\\n5. Urinary tract cancers (renal pelvis and ureter)\\n6. Biliary tract cancer\\n7. Breast cancer\\n8. Prostate cancer (in men)\\n9. Brain tumors\\n10. Skin cancer\\n\\nOther less common extracolonic manifestations include cancers of the uterine cervix and pancreas.', 'In addition to colon cancer and endometrial cancer, Lynch syndrome is also associated with an increased risk of several non-colonic tumors, including ovarian cancer, gastric cancer, small intestine cancer, urinary tract cancer, pancreatic cancer, and sebaceous gland tumors.', 'Following colorectal cancer, carriers of MMR gene mutations had the following 10-year risk of cancer', 'Lynch syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC), is associated with an increased risk of developing several types of cancer besides colorectal cancer. These include:\\n\\n1. Endometrial cancer (cancer of the lining of the uterus)\\n2. Ovarian cancer (cancer of the ovaries)\\n3. Gastric cancer (cancer of the stomach)\\n4. Pancreatic cancer (cancer of the pancreas)\\n5. Ureteral cancer (cancer of the tubes that carry urine from the kidneys to the bladder)\\n6. Renal pelvis cancer (cancer of the center of the kidney)\\n7. Small intestine cancer (cancer of the small int', 'kidney, renal pelvis, ureter, and bladder', 'Endometrium, prostate, bladder, kidney, breast, and ovary are non-colonic tumors associated with Lynch syndrome.', 'Non-colonic tumors associated with Lynch syndrome include cancers of the kidney, renal pelvis, ureter, bladder, small intestine, stomach, hepatobiliary tract, prostate, endometrium, breast, and ovary. Carriers of MMR gene mutations have an elevated risk of developing these cancers compared to the general population, with varying levels of risk observed for each type of cancer.', 'Non-colonic tumors associated with Lynch syndrome include endometrial cancer, ovarian cancer, and urinary tract cancer.', 'Lynch syndrome, associated with mutations in mismatch repair (MMR) genes, significantly increases the risk of several non-colonic cancers. These include cancers of the kidney, renal pelvis, ureter, urinary bladder, small intestine, stomach, hepatobiliary tract, prostate, endometrium, breast, and ovary. The elevated risks are quantified with substantial increases in standardized incidence ratios (SIRs), indicating a higher incidence compared to the general population. For example, the SIR for small intestine cancer is notably high at 72.68, and for endometrial cancer, it is 40.23.', 'The non-colonic tumors associated with Lynch syndrome are prostate, endometrium, breast, ovary, kidney, bladder, small intestine, and stomach.', 'The following non-colonic tumors have been associated with Lynch syndrome: kidney, renal pelvis, ureter and bladder (1-3%); small intestine, stomach and hepatobiliary tract (0.2-2%); prostate (3%); endometrium (8-17%); breast (1-4%); and ovary (0-2%). Compared with the general population, patients with Lynch syndrome had elevated risks of these tumors. The exact figures of risk and SIR were provided in the question.', 'Non-colonic tumors associated with Lynch syndrome include prostate, endometrium, breast, bladder, ovary, kidney, renal pelvis, and ureter.', 'Lynch syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC), is associated with an increased risk of developing certain non-colonic tumors. These include cancers of the kidney, renal pelvis, ureter, and bladder (2% 10-year risk), small intestine, stomach, and hepatobiliary tract (1% 10-year risk), prostate (3% 10-year risk), endometrium (12% 10-year risk), breast (2% 10-year risk), and ovary (1% 10-year risk). These risks are elevated compared to the general population.', 'Individuals with Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC), are at increased risk for several types of non-colonic cancers. These include cancers of the endometrium, ovary, stomach, small intestine, hepatobiliary tract, kidney, renal pelvis, ureter, and bladder. Additionally, there is an elevated risk for prostate and breast cancers', 'Lynch syndrome, associated with mutations in MMR genes, significantly increases the risk of several non-colonic cancers. These include cancers of the kidney, renal pelvis, ureter, urinary bladder, small intestine, stomach, hepatobiliary tract, prostate, endometrium, breast, and ovary. The elevated risks are reflected in the substantially higher standardized incidence ratios (SIRs) for these cancers compared to the general population. For example, the SIR for small intestine cancer is remarkably high at 72.68, and for endometrial cancer, it is 40.23, indicating a much greater likelihood of these cancers in individuals with Lynch syndrome.', \"Lynch syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC), is associated with an increased risk of developing several types of cancer besides colorectal cancer. These include:\\n\\n1. Endometrial cancer (cancer of the lining of the uterus)\\n2. Ovarian cancer (cancer of the ovaries)\\n3. Gastric cancer (cancer of the stomach)\\n4. Pancreatic cancer (cancer of the pancreas)\\n5. Ureteral cancer (cancer of the tubes that carry urine from the kidneys to the bladder)\\n6. Renal pelvis cancer (cancer of the center of the kidney)\\n7. Small intestine cancer (cancer of the small intestine)\\n8. Bile duct cancer (cancer of the tubes that carry bile from the liver and gallbladder)\\n9. Brain cancer (cancer of the brain or central nervous system)\\n10. Skin cancer (melanoma)\\n\\nIt's essential to note that while individuals with Lynch syndrome have\", 'Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC), is associated with an increased risk of non-colonic tumors. These include cancers of the kidney, renal pelvis, and ureter, urinary bladder, small intestine, stomach, hepatobiliary tract, prostate, endometrium, breast, and ovary. The risk of these cancers is elevated compared to the general population.', 'Lynch syndrome is associated with an increased risk of cancers in the endometrium, ovary, kidney, renal pelvis, ureter, bladder, small intestine, stomach, hepatobiliary tract, prostate, and breast.', 'Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC), is a genetic condition that increases the risk of developing various types of cancer, including non-colonic tumors. The snippets provided suggest that carriers of MMR gene mutations associated with Lynch syndrome have an elevated risk of developing cancers in several organs, including the kidney, renal pelvis, ureter, bladder, small intestine, stomach, hepatobiliary tract, prostate, endometrium, breast, and ovary. Therefore, non-colonic tumors associated with Lynch syndrome include cancers of the kidney, urinary bladder, small intestine, stomach, hepatobiliary tract, prostate, endometrium, breast, and ovary.', 'Individuals with Lynch syndrome are at an increased risk for several types of non-colonic tumors, including cancers of the kidney, renal pelvis, ureter, urinary bladder, small intestine, stomach, hepatobiliary tract, prostate, endometrium, breast, and ovary.', 'Non-colonic tumors associated with Lynch syndrome include tumors of the kidney, renal pelvis, ureter, bladder, small intestine, stomach, hepatobiliary tract, prostate, endometrium, breast, and ovary.', 'Lynch syndrome, caused by germline mutations in DNA mismatch repair (MMR) genes, is associated with an increased risk of various non-colonic tumors. The abstract provided presents the risks of primary cancers other than colorectal cancer following a diagnosis of colorectal cancer in mutation carriers. According to this research, carriers of MMR gene mutations who have already had a colorectal cancer are at an increased risk of developing various non-colonic tumors, including kidney, renal pelvis, ureter, and bladder; small intestine, stomach, and hepatobiliary tract; prostate; endometrium; breast; and ovary cancers. These individuals had a 10-year risk of 2% for kidney, renal pelvis, ureter, and bladder cancers; 1% for small intestine, stomach, and hepatobiliary tract cancers; 3%', 'Carriers of MMR gene mutations, particularly those with Lynch syndrome, have an increased risk of developing certain cancers beyond colorectal cancer. These include kidney, renal pelvis, and ureter tumors; small intestine, stomach, and hepatobiliary tract cancers; prostate cancer in men; endometrial cancer in women; breast cancer; and ovarian cancer. Compared to the general population, individuals with Lynch syndrome are at significantly elevated risk for these non-colonic tumors, with standardized incidence ratios (SIRs) ranging from 1.76 for breast cancer to as high as 72.68 for small intestine cancer.', 'Carriers of MMR gene mutations had the following 10-year risk of cancers in other organs: kidney, renal pelvis, ureter, and bladder (2%, 95% confidence interval [CI] = 1% to 3%); small intestine, stomach, and hepatobiliary tract (1%, 95% CI = 0.2% to 2%); prostate (3%, 95% CI = 1% to 5%); endometrium (12%, 95% CI = 8% to 17%); breast (2%, 95% CI = 1% to 4%); and ovary (1%, 95% CI = 0% to 2%). They were at elevated risk compared with the general population: cancers of the kidney, renal pelvis, and ureter (SIR = 12.54, 95% CI = 7.97 to 17.94), urinary bladder (SIR = 7.22, 95% CI = 4.08 to 10.99), small intestine (SIR = 72.68, 95% CI = 39.95 to 111.29), stomach (SIR = 5.65, 95% CI = 2.32 to 9.69), and hepatobiliary tract (SIR = 5.94, 95% CI = 1.81 to 10.94) for both sexes; cancer of the prostate (SIR = 2.05, 95% CI = 1.23 to 3.01), endometrium (SIR = 40.23, 95% CI = 27.91 to 56.06), breast (SIR = 1.76, 95% CI = 1.07 to 2.59), and ovary (SIR = 4.19, 95% CI = 1.28 to 7.97).', 'Non-colonic tumors associated with Lynch syndrome are prostate, endometrium, breast, bladder, ovary, kidney, renal pelvis, and ureter.', 'According to the information provided, carriers of MMR gene mutations (Lynch syndrome) following colorectal cancer are at elevated risk compared to the general population for the following non-colonic tumors:\\n\\n- Kidney, renal pelvis, and ureter cancers\\n- Urinary bladder cancer \\n- Small intestine cancer\\n- Stomach cancer\\n- Hepatobiliary tract cancer\\n- Prostate cancer (in males)\\n- Endometrial cancer (in females) \\n- Breast cancer (in females)\\n- Ovarian cancer (in females)\\n\\nThe risk is particularly high for cancers of the small intestine, endometrium, kidney/renal pelvis/ureter, and urinary bladder.', 'Individuals with Lynch syndrome, due to mutations in MMR genes, are at increased risk for several non-colonic tumors. These include cancers of the kidney, renal pelvis, ureter, bladder, small intestine, stomach, hepatobiliary tract, prostate, endometrium, breast, and ovary.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the non-colonic tumors associated with Lynch syndrome include:\n\n* Endometrial cancer\n* Ovarian cancer\n* Small bowel cancer\n* Gastric cancer\n* Pancreatic cancer\n* Transitional cell carcinoma of the ureter and renal pelvis\n* Brain tumors\n* Urothelial cancer\n* Skin tumors\n\nThese associations are based on the information provided in the \"Relations\" table, where the source entity is \"Lynch Syndrome\" and the target entity is one of the above-mentioned non-colonic tumors.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "4",
        "Information Recall Explanation": "The answer covers most of the non-colonic tumors associated with Lynch syndrome as referenced in the provided data, such as endometrial cancer, ovarian cancer, small bowel cancer, gastric cancer, and urothelial cancer. However, it misses some specific details like the increased risk of prostate and breast cancers, and some other less common associations like biliary tract cancers.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer lists only the relevant non-colonic tumors associated with Lynch syndrome without including any irrelevant information. It directly addresses the question without straying from the topic.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each non-colonic tumor is mentioned only once, making the response concise and clear.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured and easy to read. Each tumor type is clearly listed, and the explanation at the end provides context for the information, enhancing readability."
    },
    {
        "Question": "Is Durvalumab effective for locally advanced cervical cancer?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs Durvalumab effective for locally advanced cervical cancer?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Durvalumab concurrent with chemoradiotherapy was well tolerated in participants with locally advanced cervical cancer, however it did not significantly improve progression-free survival in a biomarker unselected, all-comers population.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data provided, there is a study (id: 10) that investigated the effectiveness of Durvalumab in combination with chemoradiotherapy for locally advanced cervical cancer. The study, titled \"Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial\", found that the addition of Durvalumab to chemoradiotherapy did not significantly improve progression-free survival in a biomarker-unselected, all-comers population. However, the study did not provide a clear answer to the effectiveness of Durvalumab for locally advanced cervical cancer.\n\nTo provide a more definitive answer, I would need to look at other sources outside of the provided data. However, based on the information available, it appears that the study did not find a significant benefit of Durvalumab in this specific context.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer mentions the key findings from the study, including the lack of significant improvement in progression-free survival and the fact that it was a biomarker-unselected, all-comers population. However, it does not explicitly state that Durvalumab was well tolerated, which is part of the reference answer.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer focuses on the relevant information from the study and does not include irrelevant details. It directly addresses the effectiveness of Durvalumab in the specified context without straying from the topic.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. It succinctly presents the findings and acknowledges the limitations of the provided data without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is clearly written, well-structured, and easy to understand. It flows logically from the study findings to the conclusion, making it highly readable."
    },
    {
        "Question": "What clinical conditions influence the prognostic after the liver metastasis resection from colorectal cancer patients?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat clinical conditions influence the prognostic after the liver metastasis resection from colorectal cancer patients?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Seven factors were found to be significant and independent predictors of poor long-term outcome by multivariate analysis: positive margin (p = 0.004), extrahepatic disease (p = 0.003), node-positive primary (p = 0.02), disease-free interval from primary to metastases <12 months (p = 0.03), number of hepatic tumors >1 (p = 0.0004), largest hepatic tumor >5 cm (p = 0.01), and carcinoembryonic antigen level >200 ng/ml (p = 0.01).', 'Based on the provided abstracts, several clinical conditions have been identified as influencing the prognosis after liver metastasis resection from colorectal cancer patients. These include: , 1. **ally:) |201): age (< 65 vs > = 65 years), , 2. lymph node metastases of the primary tumor (> 3 lymph nodes), , 3. metastasis number (< 3 vs > = 3 tumors), , 4. maximal tumor dimension (< 3 vs > = 3 cm), , 5. presence of extrahepatic tumor, , 6. hepatic resection margin (<1 mm), , 7. number of hepatic metastases (> = 3 lesions within the liver), , 8. glutamine-oxaloacetic transaminase (GOT) preoperative level (> = 42 mg/dl), and , 9. coexisting medical diseases. , These clinical conditions have been identified as influencing the prognosis after liver metastasis resection from colorectal cancer patients, and may be useful for future studies on', '1. T stage (Tumor invasion): AST·MLR index was found to be significantly correlated with T stage, higher Dukes stage and presence of lymph node metastasis.\\n2. Presence of liver metastasis: AST·MLR index and operation injury condition were both found to be significantly correlated with presence of liver metastasis.\\n3. Sex: AST·MLR index was found to be significantly correlated with sex (OR=2.92, 95% CI=2.16-3.95, p<0.001).\\n4. GLUT-1 expression: GLUT-1 expression was also found to be significantly correlated with the presence of lymph node metastasis, T stage, higher Dukes stage and presence of liver metastasis.', 'The prognostic after liver metastasis resection in colorectal cancer patients can be influenced by the number of metastases, preoperative CEA level, lymph node metastasis, tumor differentiation, and time to recurrence. Among these, regional lymph node metastatic status was found to be a significant prognostic factor by multivariate analysis.', 'Extrahepatic disease, inadequate resection margin, secondary tumors, rectal cancer, differentiation grade, frailty, disease, and centrally located liver metastasis can influence the prognostic after the liver metastasis resection from colorectal cancer patients.', 'The prognosis after liver metastasis resection in colorectal cancer patients is influenced by several clinical conditions. These include the number and size of liver metastases, the presence of extrahepatic disease, the type of primary tumor, the serum CEA concentration, the resection of liver metastases, the presence of abdominal carcinomatosis, and the use of chemotherapy and intervention treatment. The resection of liver metastases is a favorable prognostic factor, and the longer survival is observed in patients with fewer than four lesions, with lesions smaller than 4 cm, without extra-hepatic disease, with lesions that appeared more than two years after the resection of a stage I or II colorectal cancer and whose CEA level is normal. The role of neoadjuvant and adjuvant chemotherapy is still debated.', 'Clinical conditions that influence the prognostic after the liver metastasis resection from colorectal cancer patients include:1. Presence of liver metastases at the time of initial diagnosis2. Presence of distant metastases at the time of initial diagnosis3. Presence of liver metastases at the time of resection4. Presence of distant metastases at the time of resection5. Presence of liver metastases in the absence of distant metastases6. Presence of distant metastases in the absence of liver metastases7. Presence of liver metastases in the presence of distant metastases8. Presence of distant metastases in the presence of liver metastases9. Presence of liver metastases in the absence of distant metastases10. Presence of distant metastases in the absence of liver metastases11. Presence of liver metastases in the presence of distant metastases12. Presence of distant metastases in the presence of liver metastases13. Presence of liver metastases in the absence of distant metastases14. Presence of distant metastases in the absence of liver metastases15. Presence of liver metastases in the presence of distant metastases16. Presence of distant metastases in the presence of liver metastases17. Presence of liver metastases in the absence of distant metastases18. Presence of distant metastases in the absence of liver metastases19. Presence of liver metastases in the presence of distant metastases20. Presence of distant metastases in the presence of liver metastases21. Presence of liver metastases in the absence of distant metastases22. Presence of distant metastases in the absence of liver metastases23. Presence of liver metastases in the presence of distant metastases24. Presence of distant metastases in the presence', 'The clinical conditions that influence the prognostic after the liver metastasis resection from colorectal cancer patients include extrahepatic disease, inadequate resection margin, preoperative frailty, synchronous disease, centrally located liver metastasis, differentiation grade, age < 65 years, and T3 stage.', '5-year overall survival for resected liver metastases is reported to be 24–58%. There are several conditions that influence the prognosis of the patients after liver metastasis resection. Patients with good performance status, primary tumor resected, negative surgical margins, small tumor burden, few lymph nodes metastasis, lower preoperative carcinoembryonic antigen level and adjuvant chemotherapy treatment are associated with a better prognosis.', 'Clinical conditions that influence the prognostic after the liver metastasis resection from colorectal cancer patients include:1. Synchronous vs metachronous metastases2. Male vs female gender3. Age of the patient4. Presence of synchronous primary disease5. Presence of metachronous primary disease6. Colon vs rectal primary disease7. Presence of liver metastases at the time of surgery', '\"Inadequate resection margin, preoperative frailty, extrahepatic disease, centrally located liver metastasis, synchronous disease, T3 stage, differentiation grade, and age < 65 years are clinical conditions that influence the prognostic after the liver metastasis resection from colorectal cancer patients.\"', 'The prognosis after liver metastasis resection in colorectal cancer patients is influenced by several clinical conditions, including the number of hepatic metastases, surgical margin, serum CEA concentration, number and size of liver metastases, distribution of liver metastases, extrahepatic invasion, primary tumor resection, type of primary tumor, and signs of disseminated disease or hepatic lymph node metastases. Favorable patient selection criteria for liver resection include medical fitness for hepatectomy, radical resection of the primary colorectal lesion, metastatic tumors anatomically confined within the liver, no signs of disseminated disease or hepatic lymph node metastases, four or fewer metastatic tumors, and resection margins of 10 mm or greater. In multivariate analysis, the resection of liver metastases, serum CEA concentration, number and size of liver metastases have been identified as prognostic factors.', 'The prognosis after liver metastasis resection in colorectal cancer patients can be influenced by several clinical conditions, including the number of hepatic metastases, surgical margin, extra-hepatic disease, CEA level, size and distribution of liver metastases, and type of primary tumor. Patients with fewer metastatic nodules, clear surgical margins, normal CEA levels, smaller and fewer liver metastases, and no extra-hepatic disease tend to have a better prognosis. Additionally, the resection of liver metastases, serum CEA concentration, and number and size of liver metastases have been identified as prognostic factors in multivariate analysis.', 'Several clinical conditions are associated with the curative resection and prognosis in patients with stage IV colorectal cancer. Surgical resection remains the standard therapy for patients with colorectal liver metastases. Among these conditions, pre- and postoperative management plays a key role. In particular, the current article highlights the importance of liver transplantation in very advanced cases of subacute liver failure due to insufficient functional liver parenchyma and toxicity of chemotherapy. The analysis of the data of patients who underwent total laparoscopic or laparoscopy-assisted simultaneous resection of primary colorectal cancer and liver metastases in a hospital between December 2008 and December 2016 has also been presented to understand the possible benefits and risks of these procedures.', \"Factors such as preoperative frailty, synchronous disease, having more than four metastases, APRI and TBS scores, being younger than 65, the primary tumor's location and stage, the number of examined lymph nodes, resection margin adequacy, and the central location of liver metastasis significantly influence prognosis after liver metastasis resection in colorectal cancer patients.\", 'In summary, nine clinical factors influence the prognostic of liver metastasis resection in colorectal cancer patients: age (<65 vs. ≥65 years), lymph node metastases of primary tumor (>3 nodes), number of metastatic tumors (<3 vs. ≥3), maximal tumor dimension (<3 vs. ≥3 cm), presence of extrahepatic tumor, hepatic resection margin (<1 mm), number of liver metastases (≥3 lesions within the liver), preoperative GOT level (≥42 mg/dl), and coexisting medical diseases.', 'The prognosis of patients with colorectal cancer who undergo liver metastasis resection is influenced by several clinical conditions. In multivariate analysis, a hepatic resection margin <1 mm and the number of hepatic metastases ≥3 are independent factors that negatively impact survival. Other prognostic factors include the presence of more than three lymph node metastases in the primary tumor, more than two liver lesions, and extrahepatic tumor. The timing of liver resection for synchronous metastases does not affect survival. The prognosis after treatment of any recurrence is best after accomplishing a repeated R0 situation, regardless of the location of the recurrence. These factors can help guide care strategies and monitoring for colorectal cancer patients with liver metastasis.', 'The prognostic after liver metastasis resection in colorectal cancer patients can be influenced by the number of metastases, preoperative CEA level, lymph node metastasis, tumor differentiation, and time to recurrence.', 'Clinical conditions that influence the prognostic after the liver metastasis resection from colorectal cancer patients include:1. Presence of liver metastasis at the time of initial diagnosis2. Presence of distant metastasis at the time of initial diagnosis3. Presence of liver metastasis at the time of resection4. Presence of distant metastasis at the time of resection5. Presence of liver metastasis in the absence of distant metastasis6. Presence of distant metastasis in the absence of liver metastasis', 'Clinical conditions that influence the prognostic after the liver metastasis resection from colorectal cancer patients include synchronous liver metastasis and tumor recurrence.', \"1) Liver metastases originating from the left-sided colorectal cancers have a significantly better prognosis than metastases from right-sided colorectal cancers.\\n2) Metachronous liver metastases are associated with a better prognosis than synchronous liver metastases.\\n3) The prognosis is worse in patients with extrahepatic metastases, especially when such metastases have a higher Dukes' grade.\\n4) The prognosis in patients with only hepatic metastases is better than that in patients with non-hepatic metastases.\", 'The prognostic of liver metastasis resection in colorectal cancer patients is influenced by several clinical factors: age (< 65 vs. >/= 65 years), lymph node metastases of the primary tumor, number and size of metastatic lesions, presence of extrahepatic tumors, hepatic resection margin width, GOT preoperative level, and coexisting medical diseases.', 'The prognosis of colorectal cancer (CRC) patients after liver metastasis resection is influenced by several clinical conditions. A study using data from the SEER database found that age, number and size of liver metastases, and lymph node status of the primary tumor are important prognostic factors. In a national registry study in Sweden, lymph node status, multiple sites of metastasis, high ASA grade, and postoperative complications after resection of the primary tumor were identified as risk factors for worse survival. Another retrospective analysis of patients treated at the Liaoning Cancer Hospital and Institute in China found that the degree of tumor differentiation, number and size of metastases, and proximity to major vessels are significant prognostic factors. In a study of patients who experienced recurrence following hepatectomy for CRC metastases, shorter time to recurrence, node-positive primary tumor, and more than one site of recurrence were associated with worse outcomes. These studies suggest that a comprehensive assessment of multiple clinical factors is necessary to accurately predict the prognosis of CRC patients after liver metastasis resection.', 'The prognosis after liver metastasis resection in colorectal cancer patients is influenced by several clinical conditions. The number of hepatic metastases and the surgical margin are the most important prognostic factors. Patients with four or more metastatic nodules in the liver have a poor prognosis. Other prognostic factors include the size of the lesions, the presence of extra-hepatic disease, the time interval between the resection of the primary tumor and the appearance of liver metastases, and the level of carcinoembryonic antigen (CEA). The resection of liver metastases is a favorable prognostic factor. The role of neoadjuvant and adjuvant chemotherapy is still debated.', 'According to the studies, several clinical conditions influence the prognosis after liver metastasis resection from colorectal cancer patients. These include: , 1. Lymph node status: Positive lymph nodes are associated with poor prognosis., 2. Multiple sites of metastasis: Presence of multiple metastases is a negative prognostic factor., 3. High ASA grade: Patients with high American Society of Anesthesiologists (ASA) grades have a higher risk of mortality., 4. Postoperative complications after primary tumor resection: Complications during primary tumor surgery are associated with poor prognosis., 5. Hepatic resection margin <1 mm: A narrow hepatic resection margin is a negative prognostic factor., 6. Number of hepatic metastases ≥3: Presence of three or more hepatic metastases is associated with poor prognosis., 7. Age > 65 years: Older patients have a higher risk of mortality., 8. Elevated preoperative GOT levels: High glutamine-oxaloacetic transaminase (GOT) levels are associated with poor', 'Inadequate resection margin, preoperative frailty, synchronous disease, extrahepatic disease, centrally located liver metastasis, T3 stage, age < 65 years, and APRI are the clinical conditions that influence the prognostic after the liver metastasis resection from colorectal cancer patients.', \"Based on the provided information, several key clinical factors influence the prognosis after liver metastasis resection in colorectal cancer patients:\\n\\n1. Number and size of liver metastases: Patients with fewer than 4 metastases and lesions smaller than 4 cm have better prognosis.\\n\\n2. Resection margins: Clear surgical margins of at least 10 mm are associated with improved survival. \\n\\n3. Presence of extrahepatic metastases: Metastatic disease confined to the liver has better outcomes than cancer spread to other organs.\\n\\n4. Preoperative CEA levels: Normal carcinoembryonic antigen levels before surgery are a positive prognostic factor.\\n\\n5. Timing of metastases: Metachronous metastases appearing more than 2 years after primary colorectal tumor resection have better prognosis than synchronous metastases.\\n\\n6. Chemotherapy: Neoadjuvant chemotherapy to downsize metastases and adjuvant chemotherapy after resection may improve outcomes, although still debated.\\n\\n7. Patient health and liver function: The patient must be medically fit to tolerate major liver resection surgery.\\n\\nIn summary, key prognostic determinants include the number, size, and distribution of metastases, evidence of extrahepatic spread, tumor biology markers like CEA, and the patient's overall health status and liver function. Optimal outcomes depend on carefully selecting patients with favorable clinical characteristics.\", '1. Positive margin 2. Extrahepatic disease 3. Node-positive primary 4. Disease-free interval from primary to metastases <12 months 5. Number of hepatic tumors >1 6. Largest hepatic tumor >5 cm 7. Carcinoembryonic antigen level >200 ng/ml', 'There is a study identifying factors that predict poor long-term outcomes in colorectal cancer patients who have undergone liver metastasis resection. Seven significant and independent predictors of poor prognosis were identified through multivariate analysis. These factors include positive margin, extrahepatic disease, node-positive primary, disease-free interval from primary to metastases being less than 12 months, having more than one hepatic tumor, the largest hepatic tumor being larger than 5 cm, and carcinoembryonic antigen level being greater than 200 ng/ml. These clinical conditions, therefore, influence the prognosis of colorectal cancer patients after liver metastasis resection.', 'The clinical conditions that influence the prognostic after the liver metastasis resection from colorectal cancer patients are disease-free interval less than 1 year and extrahepatic disease.', 'Extrahepatic disease, positive margin, and node-positive primary are clinical conditions that influence the prognostic after liver metastasis resection from colorectal cancer patients.', 'The clinical conditions that influence the prognostic after liver metastasis resection from colorectal cancer patients are:1. Positive margin2. Extrahepatic disease3. Node-positive primary4. Disease-free interval from primary to metastases <12 months5. Number of hepatic tumors >16. Largest hepatic tumor >5 cm7. Carcinoembryonic antigen level >200 ng/ml', 'The prognosis after liver metastasis resection in colorectal cancer patients is influenced by several clinical conditions. These include having a positive margin, presence of extrahepatic disease, node-positive primary, a short disease-free interval from primary to metastases (less than 12 months), having more than one hepatic tumor, the largest hepatic tumor being larger than 5 cm, and a high carcinoembryonic antigen level (greater than 200 ng/ml). These factors were identified as significant and independent predictors of poor long-term outcomes.', 'Seven factors were found to be significant and independent predictors of poor long-term outcome by multivariate analysis: positive margin, extrahepatic disease, node-positive primary, disease-free interval from primary to metastases <12 months, number of hepatic tumors >1, largest hepatic tumor >5 cm, and carcinoembryonic antigen level >200 ng/ml.', '7 clinical factors can influence the prognosis of the patients after the resection of colorectal cancer liver metastasis. The factors include a positive margin, extrahepatic disease, node-positive primary, disease-free interval from primary to metastases less than 12 months, number of hepatic tumors greater than 1, largest hepatic tumor greater than 5 cm, and carcinoembryonic antigen level greater than 200 ng/ml.', 'The seven significant and independent predictors of poor long-term outcome after liver metastasis resection from colorectal cancer patients are: positive margin, extrahepatic disease, node-positive primary, disease-free interval from primary to metastases <12 months, number of hepatic tumors >1, largest hepatic tumor >5 cm, and carcinoembryonic antigen level >200 ng/ml. These factors can influence the prognosis after liver metastasis resection', 'filtering of genes, pathway analysis, and clinical evaluation are essential for assessing the progestic outcomes after the resection of liver metastasis in colorectal cancer patients. By identifying the genes and pathways that influence the development and progression of colorectal cancer, researchers can gain insights into the factors that impact the progenostic after the resection of liver metastasis. This information can be used to develop more accurate and targeted therapeutic strategies for colorectal cancer.', 'Seven factors were found to be significant and independent predictors of poor long-term outcome in colorectal cancer patients who underwent liver metastasis resection: positive margin, extrahepatic disease, node-positive primary, disease-free interval from primary to metastases <12 months, number of hepatic tumors >1, largest hepatic tumor >5 cm, and carcinoembryonic antigen level >200 ng/ml.', 'The prognosis after liver metastasis resection in colorectal cancer patients is influenced by several factors. These include having a positive margin, presence of extrahepatic disease, node-positive primary cancer, a short disease-free interval of less than 12 months from primary to metastases, having more than one hepatic tumor, the largest hepatic tumor being over 5 cm, and a carcinoembryonic antigen level greater than 200 ng/ml. These factors are significant predictors of a poor long-term outcome', 'The prognosis after liver metastasis resection in colorectal cancer patients is influenced by several clinical conditions, including positive margin, extrahepatic disease, node-positive primary, disease-free interval from primary to metastases less than 12 months, number of hepatic tumors greater than 1, largest hepatic tumor greater than 5 cm, and carcinoembryonic antigen level greater than 200 ng/ml.', 'The prognosis after liver metastasis resection in colorectal cancer patients is influenced by several clinical conditions. These include having a positive margin, presence of extrahepatic disease, node-positive primary, a short disease-free interval from primary to metastases (less than 12 months), having more than one hepatic tumor, the largest hepatic tumor being larger than 5 cm, and a high carcinoembryonic antigen level (greater than 200 ng/ml). These factors are significant and independent predictors of poor long-term outcomes.', '1) Positive margin of the tumor (p = 0.004)\\n2) Extrahepatic disease (p = 0.003)\\n3) Node-positive primary (p = 0.02)\\n4) Disease-free interval from primary to metastases <12 months (p = 0.03)\\n5) Number of hepatic tumors >1 (p = 0.0004)\\n6) Largest hepatic tumor >5 cm (p = 0.01)\\n7) Carcinoembryonic antigen level >200 ng/ml (p = 0.01)', 'The seven factors found to be significant and independent predictors of poor long-term outcome after liver metastasis resection from colorectal cancer patients are: positive margin, extrahepatic disease, node-positive primary, disease-free interval from primary to metastases <12 months, number of hepatic tumors >1, largest hepatic tumor >5 cm, and carcinoembryonic antigen level >200 ng/ml.', 'The prognosis after liver metastasis resection in colorectal cancer patients is significantly influenced by seven factors: positive margin, presence of extrahepatic disease, node-positive primary, a short disease-free interval from primary to metastases of less than 12 months, having more than one hepatic tumor, the largest hepatic tumor being over 5 cm, and a carcinoembryonic antigen level greater than 200 ng/ml.', 'The prognosis after liver metastasis resection from colorectal cancer patients is influenced by seven clinical conditions: positive margin, extrahepatic disease, node-positive primary, disease-free interval <12 months, number of hepatic tumors >1, largest hepatic tumor >5 cm, and carcinoembryonic antigen level >200 ng/ml. These conditions can be used in a preoperative scoring system to predict outcome, with patients having up to two criteria having a favorable prognosis. Patients with three or more criteria may be considered for experimental adjuvant trials.', 'Seven significant factors influence long-term outcomes after liver metastasis resection in colorectal cancer patients: 1) Positive margin, 2) Extrahepatic disease, 3) Node-positive primary, 4) Disease-free interval <12 months, 5) >1 hepatic tumor, 6) Largest hepatic tumor >5 cm, and 7) CEA level >200 ng/ml. These clinical conditions can help predict prognosis and inform treatment decisions.', 'The clinical conditions that influence the prognosis after liver metastasis resection from colorectal cancer patients include positive margin, presence of extrahepatic disease, node-positive primary, a short disease-free interval from primary to metastases, multiple hepatic tumors, large size of the largest hepatic tumor, and high carcinoembryonic antigen levels.', 'The prognosis after liver metastasis resection from colorectal cancer patients is influenced by several clinical conditions including a positive surgical margin, presence of extrahepatic disease, node-positive primary, disease-free interval from primary to metastases less than 12 months, number of hepatic tumors greater than 1, largest hepatic tumor greater than 5 cm, and carcinoembryonic antigen level greater than 200 ng/ml.', 'The clinical conditions that influence the prognostic after the liver metastasis resection from colorectal cancer patients are:* Positive margin* Extrahepatic disease* Node-positive primary* Disease-free interval from primary to metastases <12 months* Number of hepatic tumors >1* Largest hepatic tumor >5 cm* Carcinoembryonic antigen level >200 ng/ml', 'The seven significant independent predictors of poor long-term outcome after liver metastasis resection from colorectal cancer include positive margin, extrahepatic disease, node-positive primary, disease-free interval less than 12 months, number of hepatic tumors over one, largest hepatic tumor over five centimeters, and a carcinoembryonic antigen level above 200 ng/ml. These clinical conditions can predict prognosis after surgery and inform treatment decisions.', 'Based on the provided snippet, seven clinical conditions have been identified as significant and independent predictors of poor long-term outcome after liver metastasis resection from colorectal cancer patients. These factors include: , 1. Positive margin, 2. Extrahepatic disease, 3. Node-positive primary, 4. Disease-free interval from primary to metastases <12 months, 5. Number of hepatic tumors >1, 6. Largest hepatic tumor >5 cm, 7. Carcinoembryonic antigen level >200 ng/ml , These clinical conditions can help predict the prognosis of patients undergoing liver metastasis resection and inform treatment decisions.', 'Seven clinical conditions are found to be significant and independent predictors of poor long-term outcome after the liver metastasis resection from colorectal cancer patients: positive margin, extrahepatic disease, node-positive primary, disease-free interval from primary to metastases <12 months, number of hepatic tumors >1, largest hepatic tumor >5 cm, and carcinoembryonic antigen level >200 ng/ml.', 'According to the provided information, several clinical factors significantly influence the prognosis after liver metastasis resection in colorectal cancer patients:\\n\\n1. Positive surgical margins\\n2. Presence of extrahepatic disease \\n3. Node-positive primary colorectal tumor\\n4. Short disease-free interval from primary tumor to liver metastases (<12 months)\\n5. Multiple liver tumors (>1)\\n6. Large size of the largest liver tumor (>5 cm)\\n7. High pre-operative carcinoembryonic antigen (CEA) level (>200 ng/ml)\\n\\nThese factors were found to be independent predictors of poor long-term outcomes after liver metastasis resection in colorectal cancer patients based on a multivariate analysis. The prognosis is worse when there is more extensive metastatic disease, incomplete resection, and risk factors like high CEA levels.', 'Several factors significantly influence the prognosis after liver metastasis resection in colorectal cancer patients. These include the presence of a positive margin, extrahepatic disease, node-positive primary, a short disease-free interval from primary to metastases, multiple hepatic tumors, large size of the largest hepatic tumor, and high carcinoembryonic antigen levels.', 'The clinical conditions that influence the prognosis after liver metastasis resection from colorectal cancer patients include a positive margin, presence of extrahepatic disease, node-positive primary, disease-free interval from primary to metastases less than 12 months, more than one hepatic tumor, largest hepatic tumor greater than 5 cm, and carcinoembryonic antigen level greater than 200 ng/ml, as these factors were found to be significant and independent predictors of poor long-term outcome.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided tables, the clinical conditions that influence the prognostic after the liver metastasis resection from colorectal cancer patients include:\n\n1. Extrahepatic invasion (Table 1, id=8, relation id=1)\n2. Primary tumor resection (Table 1, id=8, relation id=1)\n3. Liver metastasis resection (Table 1, id=8, relation id=1)\n4. Type of primary tumor (Table 1, id=8, relation id=1)\n5. Serum CEA concentration (Table 1, id=8, relation id=1)\n6. Number and size of liver metastases (Table 1, id=8, relation id=1)\n7. Distribution of liver metastases (Table 1, id=8, relation id=1)\n8. Synchronous liver metastasis (Table 1, id=14, relation id=20)\n9. Disease-free interval between initial and repeat hepatectomy (Table 1, id=15, relation id=25)\n10. Number of hepatic lesions (> 1) (Table 1, id=15, relation id=25)\n11. Size of hepatic lesions (>/= 5 cm) (Table 1, id=15, relation id=25)\n12. Presence of extrahepatic disease (Table 1, id=15, relation id=25)\n13. Carcinoembryonic antigen level (Table 1, id=6, relation id=18)\n14. Lymphovascular invasion (Table 1, id=14, relation id=20)\n15. Ki67 (Table 1, id=14, relation id=20)\n16. Mismatch Repair (MMR) (Table 1, id=14, relation id=20)\n17. N stage (Table 1, id=14, relation id=20)\n18. R0 resection (Table 1, id=15, relation id=25)\n19. Blood transfusion (Table 1, id=15, relation id=25)\n20. Adjuvant chemotherapy after initial hepatectomy (Table 1, id=15, relation id=25)\n\nThese clinical conditions are associated with the prognosis of patients with colorectal liver metastases after liver metastasis resection, and some of them are independent risk factors for postoperative survival.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers a wide range of clinical conditions that influence prognosis after liver metastasis resection, including extrahepatic invasion, primary tumor resection, serum CEA concentration, and more. However, it misses some key factors mentioned in the reference answers, such as positive margin (p = 0.004), node-positive primary (p = 0.02), and disease-free interval from primary to metastases <12 months (p = 0.03).",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer lists many relevant clinical conditions but also includes some less commonly cited factors like Ki67 and Mismatch Repair (MMR), which are not prominently featured in the reference answers. This slightly dilutes the precision.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information and presents each clinical condition distinctly without redundancy.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-structured and clearly lists each clinical condition. The use of table references (e.g., 'Table 1, id=8, relation id=1') slightly disrupts readability, but the overall flow remains good."
    },
    {
        "Question": "What is Lennox-Gastaut syndrome?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is Lennox-Gastaut syndrome?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Lennox-Gastaut syndrome is a severe early onset, rug-resistant developmental and epileptic encephalopathy with slow spike and wave on EEG (DEE-SSW) composing about 1-2% of epilepsy patients', 'Lennox-Gastaut syndrome is a severe form of childhood-onset epilepsy that is characterized by multiple types of seizures, intellectual disability, and behavioral problems. It is one of the most difficult epilepsy syndromes to treat and is frequently resistant to treatment with standard antiepilepsy drugs.', 'Lennox-Gastaut syndrome is a severe childhood epilepsy disorder characterized by encephalopathy and multiple, often intractable, seizure types.', 'Lennox-Gastaut syndrome is a severe form of epilepsy that begins in childhood and is characterized by multiple types of seizures, intellectual disability, and behavioral problems.', 'Lennox-Gastaut syndrome is a severe drug-resistant developmental and epileptic encephalopathy with slow spike and wave on EEG (DEE-SSW) composing about 1-2% of epilepsy patients.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nLennox-Gastaut syndrome (LGS) is a rare and severe form of epilepsy that begins in childhood, typically between the ages of 1 and 8 years. It is characterized by a triad of symptoms:\n\n1. Multiple types of seizures, including tonic, atonic, and atypical absence seizures, which are often resistant to treatment.\n2. Intellectual disability or cognitive impairment.\n3. A specific electroencephalogram (EEG) pattern showing bursts of slow spike-and-wave complexes or generalized paroxysmal fast activity.\n\nLGS is considered a catastrophic epileptic encephalopathy, meaning that it affects the brain's electrical activity and can lead to significant cognitive and behavioral problems. The syndrome is often associated with a poor prognosis, and individuals with LGS may experience a range of comorbidities, including sleep disturbances, behavioral problems, and physical disabilities.\n\nThe exact cause of LGS is often unknown, but it is thought to be related to abnormalities in brain development and function. Some potential underlying causes of LGS include genetic mutations, structural brain abnormalities, and infections or injuries to the brain.\n\nTreatment for LGS is often challenging, and individuals with the syndrome may require a combination of medications, dietary therapies, and other interventions to manage their seizures and improve their quality of life. Despite these efforts, the long-term outcome for individuals with LGS is generally poor, with many experiencing persistent seizures, cognitive decline, and significant disability.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer includes all key elements from the reference answers, such as the severe nature of LGS, childhood onset, multiple seizure types, intellectual disability, EEG patterns, drug resistance, and poor prognosis. It also adds detailed information about the triad of symptoms, comorbidities, potential causes, and treatment challenges, which are not explicitly mentioned in all reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include irrelevant information. Every point made is directly relevant to the description of LGS, its symptoms, causes, and treatment. There is no extraneous detail that detracts from the focus on the syndrome.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no unnecessary repetition in the answer. Each piece of information is presented clearly and concisely without redundancies. The answer flows logically from one point to the next without reiterating the same idea.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to read. It uses clear and concise language, and the information is organized into distinct sections (such as the triad of symptoms, causes, and treatment), making it accessible to the reader. The use of bullet points for the triad of symptoms enhances clarity."
    },
    {
        "Question": "What is the prevalence of neurofibromatosis?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the prevalence of neurofibromatosis?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Neurofibromatosis is a common genetic disorder that affects the growth and development of nerve tissue. It is typically inherited in an autosomal dominant pattern and there are 2 main subtypes: neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2). The prevalence of NF1 is approximately 1 in 3,000 births, while NF2 is less common with a prevalence of approximately 1 in 25,000 births.', 'Neurofibromatosis (NF) is a group of three distinct genetic conditions affecting the nervous system, characterized by non-cancerous tumors. The prevalence of NF1 is approximately 1 in 3,500, NF2 is approximately 1 in 25,000, and schwannomatosis is approximately 1 in 40,000. NF1 is the most common type of NF and is characterized by café au lait spots, neurofibromas, scoliosis, and headaches. NF2 presents with early-onset hearing loss, cataracts, tinnitus, and muscle atrophy. Schwannomatosis often presents in early adulthood with widespread pain, numbness, or tingling. There is no known prevention or cure, but surgery, radiation, and chemotherapy may be used to manage symptoms.', 'The prevalence of neurofibromatosis varies by type:\\n\\nNeurofibromatosis type 1 (NF1) is the most common, with a birth incidence of about 1 in 2,500 to 1 in 3,000. \\n\\nNeurofibromatosis type 2 (NF2) is less common, with an incidence of about 1 in 25,000 to 1 in 33,000 births.\\n\\nSchwannomatosis is the rarest, with an incidence of about 1 in 40,000 to 1 in 60,000 births.\\n\\nAll types affect males and females equally across all races and ethnicities. The neurofibromatoses are considered rare genetic disorders based on these prevalence figures.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, the prevalence of Neurofibromatosis Type 1 (NF1) is estimated to be approximately 1 in 4,088, based on a study conducted in the Finnish population (Source: Prevalence of neurofibromatosis type 1 in the Finnish population). \n\nAdditionally, a study from the UK family genetic register service estimated the prevalence of NF1 to be 1 in 4,560 (Source: Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service).\n\nIt's worth noting that the prevalence of NF1 can vary depending on the population being studied and the criteria used for diagnosis. However, these estimates provide a general idea of the prevalence of NF1 in different populations.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "3",
        "Information Recall Explanation": "The answer provides prevalence data for NF1 but does not mention NF2 or schwannomatosis, which are also part of the broader neurofibromatosis spectrum. The reference answers include prevalence details for all three, making the answer incomplete.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer focuses on NF1 prevalence and cites specific studies, avoiding irrelevant information. However, the specificity of the data could be improved by acknowledging the broader context (NF2 and schwannomatosis).",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "No repetition is observed. The answer efficiently presents two studies on NF1 prevalence without redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is clear, well-structured, and fluently written. It logically presents the data and includes caveats about population variability, enhancing readability."
    },
    {
        "Question": "What is the key transcription factor for melanocyte development and differentiation?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the key transcription factor for melanocyte development and differentiation?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Certain transcription factors have vital roles in lineage development, including the specification of cell types and control of differentiation. Microphthalmia-associated transcription factor (MITF) is a key transcription factor for melanocyte development and differentiation. MITF regulates the expression of numerous pigmentation genes to promote melanocyte differentiation, as well as fundamental genes for maintaining cell homeostasis, including genes encoding proteins involved in apoptosis (eg, BCL2) and the cell cycle (eg, CDK2).', 'The key transcription factor for melanocyte development and differentiation is Microphthalmia-associated transcription factor (MITF). MITF regulates the expression of numerous pigmentation genes to promote melanocyte differentiation, as well as fundamental genes for maintaining cell homeostasis, including genes encoding proteins involved in apoptosis and the cell cycle. Loss-of-function mutations of MITF cause Waardenburg syndrome type IIA, which includes pigmentation defects, while MITF activation can lead to melanoma development. Additionally, other transcription factors such as SOX10, MEF2C, and PAX3 also play crucial roles in melanocyte development and differentiation by interacting with MITF or controlling its expression.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe key transcription factor for melanocyte development and differentiation is Microphthalmia-associated transcription factor (MITF). MITF is a master regulator of the melanocyte lineage and plays a crucial role in melanocyte development, survival, and differentiation. It regulates the expression of genes involved in melanin production, cell cycle regulation, and apoptosis, and is essential for the proper development of melanocytes.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer correctly identifies MITF as the key transcription factor for melanocyte development and differentiation, and mentions its role in regulating melanin production, cell cycle regulation, and apoptosis. However, it lacks some details present in the reference answers, such as the specific genes involved (e.g., BCL2, CDK2) and the association with Waardenburg syndrome type IIA and melanoma.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include irrelevant information. It focuses solely on MITF and its roles in melanocyte development and differentiation, without straying into unnecessary details or unrelated topics.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. It succinctly covers MITF's roles without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to read. The sentences are clear and logically connected, making the information accessible."
    },
    {
        "Question": "What is the cause of Phenylketonuria (PKU)?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the cause of Phenylketonuria (PKU)?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase (PAH) gene that result in deficiencies in phenylalanine (Phe) metabolism.', 'Phenylketonuria (PKU) is a metabolic and genetic disorder caused by the deficiency of the phenylalanine hydroxylase enzyme (PAH), resulting in the accumulation of phenylalanine (Phe) in organs, which further leads to its toxic effects on the brain.', 'Phenylketonuria (PKU) is caused by a mutation in the PAH gene, which encodes the enzyme phenylalanine hydroxylase that metabolizes the amino acid phenylalanine.', 'Phenylketonuria (PKU) is caused by a deficiency of phenylalanine hydroxylase, leading to impaired phenylalanine metabolism.', 'Phenylketonuria (PKU) is an autosomal recessive disorder caused by mutations in the phenylalanine hydroxylase (PAH) gene, leading to deficient enzyme activity and an accumulation of phenylalanine in the body.', 'Phenylketonuria (PKU) is a metabolic disorder caused by mutations in the gene encoding for the hepatic enzyme phenylalanine hydroxylase (PAH), which leads to an accumulation of phenylalanine in the blood (Phe) and its derivative products in body tissues.', \"PKU is caused by mutations in the PAH gene, leading to a deficiency in phenylalanine hydroxylase, and it's inherited in an autosomal recessive manner.\", 'Phenylketonuria (PKU) is caused by a defect in the PAH gene, which impairs the conversion of phenylalanine (Phe) to tyrosine.', 'Phenylketonuria (PKU) is a rare genetic disorder in which the body cannot process phenylalanine (Phe), an amino acid necessary for normal growth and development, which can lead to an accumulation of this harmful substance in the brain. This disorder is caused by a defect in the enzyme PAH (phenylalanine hydroxylase) that converts Phe to tyrosine.', 'Phenylketonuria (PKU) is an autosomal recessive disorder caused by mutations in the phenylalanine hydroxylase (PAH) gene, which leads to deficient enzyme activity and elevation of phenylalanine in body fluids.', 'Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by deficiency of phenylalanine hydroxylase.', 'Phenylketonuria (PKU) is caused by mutations in the PAH gene, which leads to deficiencies in phenylalanine (Phe) metabolism and results in toxically elevated levels of Phe accumulation in plasma and organs such as the brain, causing irreversible intellectual disability.', 'Phenylketonuria (PKU) is caused by deficiencies in phenylalanine metabolism, particularly due to mutations in the phenylalanine hydroxylase gene.', 'Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase (PAH) gene, leading to deficiencies in phenylalanine metabolism.', 'Mutations in the phenylalanine hydroxylase (PAH) gene are the cause of Phenylketonuria (PKU).', 'Phenylketonuria (PKU) is caused by deficiencies in phenylalanine (Phe) metabolism, specifically mutations in the phenylalanine hydroxylase (PAH) gene. These mutations result in toxically elevated levels of Phe accumulation in plasma and organs such as the brain, leading to irreversible intellectual disability.', 'Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase (PAH) gene, which leads to a deficiency in the enzyme responsible for metabolizing the amino acid phenylalanine. This results in high levels of phenylalanine in the blood, which can be harmful to the brain and other organs', 'Phenylketonuria (PKU) is an inborn error of metabolism characterized by deficiencies in phenylalanine (Phe) metabolism due to a mutation in the phenylalanine hydroxylase (PAH) gene. This deficiency leads to the accumulation of Phe and its metabolites in the blood, causing damage to the brain.', 'The cause of Phenylketonuria (PKU) is a deficiency in phenylalanine (Phe) metabolism due to mutations in the phenylalanine hydroxylase (PAH) gene.', 'Phenylketonuria (PKU) is caused by mutations in the PAH gene, leading to deficiencies in metabolizing phenylalanine.', 'PKU is caused by mutations in the PAH gene, leading to deficient phenylalanine metabolism, high Phe levels in plasma and organs, resulting in intellectual disabilities.', 'Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase (PAH) gene, leading to deficient Phe metabolism and toxic accumulation in plasma and organs like the brain, resulting in intellectual disability.', 'Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase (PAH) gene, which leads to deficiencies in phenylalanine metabolism.', 'Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase (PAH) gene, leading to deficiencies in phenylalanine metabolism and resulting in toxically elevated levels of phenylalanine accumulation in plasma and organs such as the brain, which can cause irreversible intellectual disability.', 'Phenylketonuria (PKU) is an inborn error caused by deficiencies in phenylalanine (Phe) metabolism.', 'The main cause of Phenylketonuria (PKU) is mutations in the phenylalanine hydroxylase (PAH) gene, leading to deficiencies in phenylalanine metabolism and resulting in elevated levels of Phe accumulation that causes irreversible intellectual disability.', 'Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase (PAH) gene, which result in deficiencies in phenylalanine (Phe) metabolism. This leads to toxically elevated levels of Phe accumulation in plasma and organs such as the brain, resulting in irreversible intellectual disability.', 'Phenylketonuria (PKU) is caused by deficiencies in phenylalanine metabolism and mutations in the phenylalanine hydroxylase (PAH) gene.', 'Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase (PAH) gene. These mutations lead to deficiencies in phenylalanine metabolism, resulting in toxic accumulation of phenylalanine in the blood and organs like the brain. The elevated phenylalanine levels can cause intellectual disability if untreated.', 'Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase (PAH) gene, which leads to deficiencies in phenylalanine metabolism, resulting in toxically elevated levels of phenylalanine accumulation in plasma and organs such as the brain, and ultimately causing irreversible intellectual disability.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nPhenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase (PAH) gene, which is responsible for encoding the enzyme phenylalanine hydroxylase. This enzyme plays a crucial role in the metabolism of the amino acid phenylalanine, converting it into tyrosine. Mutations in the PAH gene lead to a deficiency of this enzyme, resulting in the accumulation of phenylalanine in the body, which can cause a range of health problems, including intellectual disability, seizures, and behavioral problems if left untreated.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately recalls all necessary information about the cause of PKU, including the specific gene (PAH), the enzyme (phenylalanine hydroxylase), its role in metabolizing phenylalanine, and the consequences of its deficiency (accumulation of phenylalanine leading to health problems such as intellectual disability, seizures, and behavioral problems).",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information. It focuses solely on the genetic and metabolic details of PKU and its effects, which are all pertinent to the question asked.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each piece of information is presented once and contributes to a coherent explanation of the cause of PKU.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is highly readable and fluent. The sentences are well-structured, and the information flows logically from the genetic defect to the metabolic consequence and its clinical implications."
    },
    {
        "Question": "Which disease is treated with nirsevimab?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhich disease is treated with nirsevimab?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Nirsevimab can be used for treatment of respiratory syncytial virus disease.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, the disease treated with nirsevimab is Respiratory Syncytial Virus (RSV) infection, specifically for the prevention of RSV-associated lower respiratory tract infections in infants.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer fully recalls all the necessary information from the reference answers, including the treatment of respiratory syncytial virus (RSV) and its specific application for preventing RSV-associated lower respiratory tract infections in infants.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise, directly addressing the disease treated with nirsevimab without including any irrelevant details or digressions.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition in the answer; it clearly states the information just once without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured and easily readable, with clear and fluent language that makes the information accessible."
    },
    {
        "Question": "Why does rectal cancer have worse prognosis than other colon tumors?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhy does rectal cancer have worse prognosis than other colon tumors?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Rectal cancer differs respect to colon cancer in etiology, carcinogenesis, pathology, genetics, anatomy and treatment response, surgical topography, procedures and multimodal treatment', 'Rectal cancer has a worse prognosis compared to other colon tumors due to several factors. One reason is that rectal cancers tend to have higher rates of TOPO1 expression and Her2/neu amplification, which are associated with more aggressive tumor behavior. Additionally, rectal cancers often present at a more advanced stage, making them harder to treat. The proximity of the rectum to otherical200, as well as the distinct venous drainage systems, may also contribute to the development of pulmonary metastases, which are associated with poorer prognosis. Furthermore, rectal cancer patients who undergo pulmonary metastasectomy (PM) have worse prognosis if they have a history of liver metastasis, multiple pulmonary metastases, or abnormal preoperative CEA levels. These factors combined may contribute to the worse prognosis of rectal cancer compared to other colon tumors.', 'The prognosis of rectal cancer is worse than other colon cancers because rectal cancer is associated with anal cancer and their biologic features and treatment approaches are different.', 'Rectal cancer has worse prognosis than other colon tumors due to its proximity to the anus, which makes surgical resection more challenging and increases the risk of local recurrence. However, in the case of recurrence, rectal cancer has a better prognosis than colon cancer.', 'Overall survival in rectum was better than that of colon. Our findings support this hypothesis that prognosis of CRC varies with tumor site. Rectal cancer was associated with worse relapse-free survival and overall survival compared with left-sided colon cancer in patients with colorectal liver metastases who underwent hepatic resection.', 'Rectal cancer has a worse prognosis than other colon tumors due to its higher incidence of TDs. TDs are tumor deposits that occur in the rectum and are associated with poorer prognosis. The incidence of TDs is higher in rectal cancer than in colonic cancer, and this may contribute to the poorer prognosis of rectal cancer.', '\"Our study revealed significant differences between RCC, LCC and rectal cancers not only at somatic but also at proteomic level that may have therapeutic relevance in these highly complex and heterogeneous tumors.\"\\n\\n\"Twenty percent of right-sided colon cancer recurrences exhibited peritoneal dissemination, 42% of left-sided colon cancer recurrences were liver metastases, and 33% of rectal cancer recurrences were local recurrences.\"\\n\\n\"This study suggests that TDs have a negative impact on the prognosis in rectal cancer.\"', '1. The anatomical location makes rectal cancer detection and surgical intervention more difficult.\\n2. Rectal cancer is often at an advanced stage at the time of diagnosis, due to an absence of symptoms in the early stages of the disease.\\n3. There is a higher proportion of unfavorable histological subtypes, such as mucinous adenocarcinoma, signet-ring cell carcinoma, and undifferentiated carcinoma.\\n4. The rectum has a greater lymphatic vessel density, which contributes to the higher rate of lymph node metastases in rectal cancer.\\n5. A decreased number of tumor-infiltrating CD8(+) T-cells and upregulation of regulatory T-cells in the rectal mucosa promote tumor progression.\\n6. High Treg to T CD8 cell ratio, higher IL-17', 'Rectal cancer has a worse prognosis than other colon tumors due to the presence of tumor deposits (TDs) in the rectum. TDs are associated with a higher risk of recurrence and poorer overall survival in rectal cancer patients. The reason for this difference in outcomes is not well understood, but it is thought to be related to the unique biology of the rectum and the presence of TDs. Historically, management of patients with rectal cancer has been different than for left-sided colon cancer, and these patient subgroups respond differently to biological therapies. It has been suggested that TDs may have a worse prognosis in rectal cancer compared with colonic cancer.', 'Rectal cancer was associated with worse relapse-free survival and overall survival compared with left-sided colon cancer in patients with colorectal liver metastases who underwent hepatic resection. Our study revealed significant differences between RCC, LCC, and rectal cancers not only at somatic but also at proteomic level that may have therapeutic relevance in these highly complex and heterogeneous tumors.', 'Rectal cancer has worse prognosis compared to other colon tumors due to several factors. Rectal cancer is often diagnosed at a later stage as it is more difficult to detect and symptoms may not appear until the cancer has advanced. Additionally, rectal cancer is more likely to invade surrounding tissues and organs, and has a higher risk of lymph node metastasis. Treatment options for rectal cancer are also more complex and may result in long-term side effects, such as bowel dysfunction and sexual dysfunction. Furthermore, rectal cancer is more resistant to chemotherapy and radiation therapy compared to other colon tumors. All these factors contribute to a worse prognosis for rectal cancer compared to other colon tumors.', 'Rectal cancer has a worse prognosis compared to other colon tumors due to several factors, including its anatomical location, which makes it more difficult to surgically remove with clear margins, and its higher likelihood of lymph node involvement and metastasis. Additionally, rectal cancers may be less responsive to certain treatments, such as chemotherapy and radiation therapy, compared to other colon tumors.', 'Colon cancer patients with larger tumors did not have a higher risk of recurrence, but rectal cancer patients with larger tumors had a significantly worse prognosis.\\n\\n\\nThe given question is a combination of two questions; it first asks why rectal cancer has worse prognosis than other colon tumors and then combines it with a statement that tumor size was not associated with higher recurrence risk for colon cancer patients (P = 0.098). \\n\\nThe provided answer only focuses on the first part of the question and states that rectal cancer patients with larger tumors had a significantly worse prognosis. However, it does not provide any information about the reason why rectal cancer has worse prognosis than other colon tumors. \\n\\nTherefore, the answer is not correct.', 'Rectal cancer is associated with worse prognosis due to factors such as higher likelihood of recurrence, distinct patterns of metastasis, and differences in tumor biology compared to other colon tumors. Studies have shown that rectal cancer patients experience worse relapse-free survival and overall survival rates, with specific challenges including a higher rate of local recurrences and different prognostic implications based on tumor location within the colorectal region.', 'Rectal cancer has a poorer prognosis than other colon cancers due to higher TOPO1 expression and Her2/neu amplification, more advanced stages at presentation, distinct venous drainage contributing to pulmonary metastases, and worse outcomes for patients who undergo PM with liver metastasis history or multiple lung tumors.', 'According to the studies, rectal cancer has a worse prognosis than left-sided colon cancer and right-sided colon cancer. The reasons for this are not entirely clear, but some factors may contribute to this difference. One study found that rectal cancer had a higher rate of multiple-site recurrence and a lower surgical resection rate for recurrence compared to left-sided colon cancer. This suggests that rectal cancer may be more aggressive and harder to treat than other colon tumors. Additionally, the anatomy of the rectum may make it more difficult to achieve complete surgical removal of the tumor, leading to higher recurrence rates and worse outcomes. Further research is needed to fully understand the reasons for this difference in prognosis.', 'Rectal cancer has worse prognosis than other colon tumors due to its proximity to the anus, which makes surgical resection more challenging and increases the risk of local recurrence.', 'Rectal cancer has a worse prognosis than other colon tumors due to its higher incidence of TDs. TDs are tumor deposits that occur in the rectum and have been associated with poorer prognosis in rectal cancer patients. The presence of TDs in rectal cancer is associated with a higher risk of recurrence and death compared to colonic cancer. This is thought to be due to the fact that TDs are more aggressive and have a higher risk of metastasis than primary tumors in the colon. Additionally, TDs are more common in right-sided colon cancers than in left-sided colon or rectal cancers, which may also contribute to the poorer prognosis of rectal cancer.', 'Rectal cancer does not have worse prognosis than other colon tumors. Recent studies show that patients with advanced right-sided colon cancers have a worse prognosis than those with left-sided colon or rectal cancers. In stages IIIC and IV, rectal cancer patients had better survival than colon cancer patients, by about 3 months.', 'Rectal cancer is the disease that affects the most distal part of the large bowel. \\nIn rectal cancer the tumor is generally more proximal, meaning it is closer to the anus.\\nBecause of the position of the tumor in the rectal cancer patient, surgeries are more complicated than in colon cancer patient.\\n\\nThe most complicated surgeries are rectal surgery in low rectal cancer patients that are often associated with permanent stoma and a poor quality of life.\\n\\nThe higher risk of recurrence in rectal cancer is due to more advanced stage at diagnosis and to the use of neoadjuvant chemotherapy that increases the risk of anastomotic leakage.\\n\\nThe prognosis of rectal cancer is worse than that of colon cancer because of the local invasion and metastatic dissemination.\\n\\nTumor size was not associated with higher recurrence risk because it is not one', 'Rectal cancer has a worse prognosis than other colon tumors due to differences in tumor biology, microsatellite instability, molecular markers, higher rates of TOPO1 expression and Her2/neu amplification leading to more aggressive behavior, history of liver metastasis, multiple metastases, abnormal preoperative carcinoembryonic antigen levels, and different prognostic factors for pulmonary metastasectomy based on anatomic differences.', 'Rectal cancer has been observed to have a worse prognosis compared to other colon cancers, including right-sided and left-sided colon cancers. This was found to be true even after accounting for differences in background mortality. When examining recurrence-free survival (RFS) and overall survival (OS) after primary surgery and recurrence, rectal cancer was associated with worse RFS compared to right-sided and left-sided colon cancers. Among patients with recurrence, rectal cancer was associated with better OS compared to right-sided colon cancer, but worse OS compared to left-sided colon cancer. A cohort study in Fars province, southern Iran, found that patients with right-sided colon tumors had lower overall survival (OS) and cancer-related survival (CRS) at 60 months after diagnosis compared to patients with left-sided colon or rectal tumors. The localization of the primary tumor was found to be an independent prognostic indicator for OS and CRS. These findings suggest that tumor location is an important factor to consider in the prognosis and treatment of colorectal cancer.', \"Rectal cancer has a worse prognosis than other colon tumors due to several factors. One of the main reasons is that rectal cancer is often diagnosed at a later stage, as it may not cause symptoms until it has grown or spread. Additionally, the rectum is located in a confined space, which can make it more difficult to surgically remove the cancer and increase the risk of recurrence. The rectum also has a rich lymphatic and vascular network, which can facilitate the spread of cancer cells to other parts of the body. Furthermore, the treatment of rectal cancer often involves a combination of surgery, radiation, and chemotherapy, which can have significant side effects and impact the patient's quality of life.\", 'Rectal cancer has been shown to have a worse prognosis compared to other colon tumors, but the reasons for this are not fully understood. One possible explanation is that rectal cancer has distinct molecular characteristics and responds differently to biological therapies compared to other colon cancers. Additionally, management of patients with metastatic colon and rectal cancers has historically been similar, with patients often grouped together in clinical trials. However, recent studies have demonstrated that right-sided colon cancers have higher rates of microsatellite instability and aberrant activation of the EGFR pathway, while rectal cancers have higher rates of TOPO1 expression and Her2/neu amplification. These molecular variations among right-sided colon, left-sided colon, and rectal tumors may contribute to differences in clinical behavior and should be considered when selecting treatment regimens and stratifying patients for future clinical trials.', '\"Our study revealed significant differences between RCC, LCC and rectal cancers not only at somatic but also at proteomic level that may have therapeutic relevance in these highly complex and heterogeneous tumors.\"\\n\\n\"Twenty percent of right-sided colon cancer recurrences exhibited peritoneal dissemination, 42% of left-sided colon cancer recurrences were liver metastases, and 33% of rectal cancer recurrences were local recurrences.\"\\n\\n\"Rectal cancer was associated with worse relapse-free survival and overall survival compared with left-sided colon cancer in patients with colorectal liver metastases who underwent hepatic resection.\"\\n\\n\"TD-positive pN1a-b patients had significantly worse outcomes whereas TDs did not affect outcomes in pN2a-b patients. This study suggests that TDs have a negative impact on the prognosis in rectal cancer.\"', \"Rectal cancer has a worse prognosis than other colon tumors for several reasons:\\n\\n1. Location: The rectum's confined location in the pelvis makes it harder to surgically remove tumors with adequate margins, increasing the risk of local recurrence.\\n\\n2. Lymph node involvement: Rectal cancers are more likely to spread to regional lymph nodes due to the rectum's extensive lymphatic drainage, significantly lowering 5-year survival rates. \\n\\n3. Metastasis: The rectum's venous drainage bypasses the liver and drains into the inferior vena cava, enabling metastasis to the lungs and other organs. Distant metastases are associated with very poor survival.\\n\\n4. Treatment challenges: The rectum's location limits surgical options and increases complication risks. Radiation therapy, often used for rectal cancer, can increase acute toxicity.\\n\\n5. Late detection: Rectal cancers may be detected at later stages due to their location, leading to poorer survival outcomes.\\n\\nIn summary, rectal cancer's location, propensity for metastasis, treatment limitations, and often later stage at diagnosis contribute to its generally worse prognosis compared to colon cancer.\", 'Rectal cancer patients have a worse prognosis than other colon tumors due to local recurrence after rectal cancer resection, adherence of the primary tumour in rectal cancer to an adjacent organ, and a significant correlation between positive p53 expression and worse disease-free survival. Rectal cancers also show significantly more immunohistochemical expression of p53 and may involve more nuclear beta-catenin in the APC/beta-catenin pathway than colon cancers.', \"According to the abstract, rectal cancer (RC) does not have a worse prognosis than colon cancer (CC). In fact, CC patients had higher short-term mortality rates compared to RC patients. The study found that complications were more frequent in RC patients, but they had a lesser impact on survival outcomes. Specifically, the 30-day and 90-day mortality rates were lower for RC patients (6.7% and 9.5%, respectively) compared to CC patients (1.5% and 5.2%, respectively). Therefore, it is not accurate to conclude that rectal cancer has a worse prognosis than other colon tumors based on this study's findings.\", '1. Rectal cancer has a higher rate of local recurrence than colon cancer. 2. Rectal cancer has a higher rate of distant metastasis than colon cancer. 3. Rectal cancer has a higher rate of lymph node metastasis than colon cancer. 4. Rectal cancer has a higher rate of peritoneal metastasis than colon cancer. 5. Rectal cancer has a higher rate of liver metastasis than colon cancer. 6. Rectal cancer has a higher rate of lung metastasis than colon cancer. 7. Rectal cancer has a higher rate of bone metastasis than colon cancer. 8. Rectal cancer has a higher rate of brain metastasis than colon cancer. 9. Rectal cancer has a higher rate of adrenal metastasis than colon cancer. 10. Rectal cancer has a higher rate of other metastasis than colon cancer. 11. Rectal cancer has a higher rate of recurrence than colon cancer. 12. Rectal cancer has a higher rate of death than colon cancer. 13. Rectal cancer has a higher rate of complications than colon cancer. 14. Rectal cancer has a higher rate of adverse events than colon cancer. 15. Rect', \"Rectal cancer has been found to have worse prognosis compared to other colon tumors due to differences in molecular carcinogenesis, pathology, surgical topography and procedures, and multimodal treatment. These differences can result in distinct treatment responses and outcomes between colon and rectal cancers. Rectal cancer's proximity to the anus and pelvic cavity can make surgical removal more challenging, potentially leading to increased risk of positive margins and local recurrence. Additionally, rectal cancer may require radiation therapy, which can have long-term side effects impacting quality of life. These factors, combined with rectal cancer's unique biology and molecular characteristics, contribute to its generally worse prognosis compared to other colon tumors.\", 'Rectal cancer does not have worse prognosis than other colon tumors. However, recent studies show that patients with advanced right-sided colon cancers have a worse prognosis than those with left-sided colon or rectal cancers. The differences in molecular biology among right-sided colon, left-sided colon, and rectal cancers should be further studied to account for disparities in clinical outcomes.', 'Rectal cancer has a worse prognosis than other colon tumors due to differences in molecular carcinogenesis, pathology, surgical topography, and multimodal treatment response.', 'The prognosis of rectal cancer is worse than other colon tumors due to several factors, including:1. Higher incidence of lymph node involvement: Rectal cancer has a higher incidence of lymph node involvement compared to colon cancer, which can lead to poorer prognosis.2. Higher risk of distant metastasis: Rectal cancer has a higher risk of distant metastasis compared to colon cancer, which can also contribute to poorer prognosis.3. Different tumor biology: Rectal cancer has a different tumor biology compared to colon cancer, with a higher proportion of poorly differentiated tumors and a higher risk of microsatellite instability.4. Different treatment approaches: The treatment approach for rectal cancer is different compared to colon cancer, with a higher proportion of surgery and radiation therapy, and a lower proportion of chemotherapy.5. Different prognostic factors: The prognostic factors for rectal cancer are different compared to colon cancer, with a higher proportion of lymph node involvement and a lower proportion of tumor location.6. Different patient population: The patient population for rectal cancer is different compared to colon cancer, with a higher proportion of older patients and a higher risk of comorbidities.7. Different treatment outcomes: The treatment outcomes for rectal cancer are different compared to colon cancer, with a higher risk of treatment failure and a lower risk of long-term survival.8. Different molecular biology: The molecular biology of rectal cancer is different compared to colon cancer, with a higher proportion of genetic alterations and a higher risk of microsatellite instability.9. Different clinical presentation: The clinical presentation of rectal cancer is different compared to colon cancer, with a higher proportion of symptoms and a higher risk of advanced disease at diagnosis.10. Different pathological features: The pathological features of rectal cancer are different compared to colon cancer, with a higher proportion of poorly differentiated tumors and a higher risk of lymph node involvement.In conclusion, the prognosis of rectal cancer is worse than other colon tumors due to several factors, including higher incidence of lymph node invol', 'Rectal cancer often has a worse prognosis than other colon tumors due to several factors. Firstly, its anatomical location in the pelvis makes surgical removal more challenging, increasing the risk of incomplete resection and local recurrence. Additionally, rectal cancer is more likely to spread to lymph nodes and distant organs compared to tumors located higher up in the colon. The text also highlights differences in \"molecular carcinogenesis, pathology, surgical topography and procedures, and multimodal treatment\" between colon and rectal cancers, which can contribute to variations in treatment response and overall outcomes.', \"Rectal cancer has a worse prognosis than other colon tumors due to several factors. Firstly, the anatomical location of the rectum makes it more difficult to access and remove tumors, often requiring more complex surgical procedures. Secondly, the dense lymphatic network in the rectum can lead to a higher risk of metastasis and recurrence. Additionally, the molecular carcinogenesis and genetics of rectal cancer may differ from those of other colon tumors, potentially affecting treatment response and overall survival rates. Finally, the multimodal treatment approach for rectal cancer may involve more aggressive chemotherapy and radiation therapy, which can have significant side effects and impact the patient's quality of life.\", 'Rectal cancers are diagnosed at later stages than other colon cancers, are more likely to have positive surgical margins and present in a setting of a poorer nutritional status.', 'Rectal cancer has a worse prognosis than other colon tumors due to its unique characteristics, such as the presence of lymph node metastases at the time of diagnosis, the difficulty in achieving clear resection margins during surgery, and the higher risk of local recurrence. Additionally, rectal cancer often presents at a more advanced stage, which can lead to a poorer outcome. \\n\\nPlease provide your answer in a concise and clear manner. \\nPlease note that the answer should be based on the provided context and should not exceed 200 words. \\nPlease use proper grammar and spelling. \\nPlease avoid using jargon or technical terms that may be unfamiliar to a non-expert. \\nPlease provide a clear and concise answer that is easy to understand. \\nPlease note that the answer should be based on the provided context and should not exceed 200 words. \\nPlease use proper grammar and spelling. \\nPlease avoid using jargon or technical terms that may be unfamiliar to a non-expert. \\nPlease provide a clear and concise answer that is easy to understand. \\nPlease note that the answer should be based on the provided context and should not exceed 200 words. \\nPlease use proper grammar and spelling. \\nPlease avoid using jargon or technical terms that may be unfamiliar', 'Many apparent differences exist in aetiology, genetics, anatomy, and treatment response between colon cancer (CC) and rectal cancer (RC). Obvious differences exist in molecular carcinogenesis, pathology, surgical topography, and procedures, which contribute to the worse prognosis of rectal cancer compared to other colon tumors.', 'Rectal cancer (RC) has been shown to have worse prognosis compared to other colon tumors due to several factors, including differences in molecular carcinogenesis, pathology, surgical topography and procedures, and multimodal treatment. Rectal cancer is often diagnosed at a later stage, which can contribute to a worse prognosis. Additionally, the rectum has a richer lymphatic network compared to the colon, which can lead to a higher risk of lymph node metastasis. Furthermore, the rectum is in close proximity to other organs, such as the prostate and vagina, which can make surgical resection more challenging and increase the risk of complications. The standard treatment for rectal cancer also differs from that of colon cancer, with rectal cancer often requiring a combination of surgery, radiation therapy, and chemotherapy. These differences in treatment can also contribute to a worse prognosis for rectal cancer compared to other colon tumors.', \"Rectal cancer often has a worse prognosis than colon cancer because of its anatomical location and the complexity involved in its surgical treatment. The rectum's proximity to other organs and structures can make it more challenging to achieve clear surgical margins, which is crucial for reducing the risk of recurrence. Additionally, rectal cancer is more likely to involve local lymph nodes and spread to nearby tissues, further complicating treatment and potentially worsening outcomes\", 'Rectal cancer has a worse prognosis compared to other colon tumors due to several factors, including differences in aetiology, genetics, anatomy, and treatment response. These differences can lead to variations in molecular carcinogenesis, pathology, surgical topography and procedures, and multimodal treatment. Additionally, rectal cancer is often diagnosed at a later stage and may be less responsive to certain treatments, such as chemotherapy and radiation therapy.', 'Rectal cancer often has a worse prognosis than other colon tumors due to several factors. Firstly, its anatomical location in the pelvis makes surgical removal more complex and challenging, increasing the risk of incomplete resection and local recurrence. Additionally, rectal cancer is more likely to spread to lymph nodes and distant organs compared to tumors located higher up in the colon. The proximity to other organs and structures also complicates the application of effective radiation therapy and surgical techniques. These factors collectively contribute to the generally poorer outcomes seen in rectal cancer cases compared to other colon cancers.', 'Rectal cancer has a worse prognosis than other colon tumors due to a combination of factors, including the anatomical location of the tumor, the unique biology of rectal cancer, and the higher incidence of local recurrence. The primary tumor can adhere to adjacent organs, which is associated with a poor prognosis, resulting in a low 9% 5-year survival rate. Rectal cancer is also more likely to recur locally due to the implantation of cancer cells in the surroundings, and the involvement of the rectum and anus can lead to obstructive symptoms, perforation, and fistulae, all of which increase the risk of death. Rectal cancer has also been found to have more mutations in the APC gene and is more likely to have nuclear beta-catenin expression, which is associated with a poor prognosis.', 'Rectal cancer has worse prognosis than other colon tumors.\\n\\nRectal cancer is more often diagnosed in its locally advanced stages, making it more difficult to treat and resulting in a worse prognosis. The anatomical proximity of the rectum to pelvic organs can result in tumor invasion into these organs, complicating surgery and decreasing the chance of complete surgical resection. Radiotherapy is a common treatment for rectal cancer, and the proximity of the rectum to other sensitive organs can cause more frequent treatment-related toxicity than in colon cancer, affecting quality of life.\\n\\nReferences:\\n[1] http://www.ncbi.nlm.nih.gov/pubmed/27120406\\n[2] http://www.ncbi.nlm.nih.gov/pubmed/26968280\\n[3]', 'Rectal cancer has a worse prognosis than other colon tumors due to several factors. Firstly, rectal cancer is more likely to spread to nearby lymph nodes, which can make it more difficult to treat. Secondly, rectal cancer is often diagnosed at a later stage, as it can be difficult to detect due to its location. Finally, rectal cancer is more likely to recur after treatment, which can lead to a worse prognosis.', 'Rectal cancer has a worse prognosis than other colon tumors due to several factors:\\n- Rectal cancer has a higher incidence of nuclear beta-catenin, which may indicate a different role of the APC/beta-catenin pathway in rectal cancer.\\n- Rectal cancers show a higher expression of p53, which is associated with worse disease-free survival.\\n- Rectal cancer may involve different oncogenesis mechanisms than colon cancer, suggesting a different biological behavior.\\n- Rectal cancer has a higher frequency of liver metastases and local recurrence, which can lead to a worse prognosis.\\n- Rectal cancer patients have a lower 5-year survival rate compared to colon cancer patients.', 'Rectal cancer often has a worse prognosis than other colon tumors due to its unique molecular carcinogenesis, challenging surgical anatomy, differences in pathological features, and variability in response to multimodal treatments. **PROVE** These factors contribute to the complexity of managing rectal cancer effectively. The anatomical location of the rectum within the pelvis makes surgical resection more difficult compared to other parts of the colon, increasing the risk of incomplete removal and local recurrence. Additionally, rectal cancers may have distinct genetic mutations and molecular profiles that affect their behavior and response to treatment differently than colon cancers located elsewhere. This can influence both treatment strategies and outcomes. Furthermore, achieving clear margins during surgery is critical for prognosis, and this is more challenging in rectal cancer due to its proximity to other organs and structures. Lastly, rectal cancer requires a multidisciplinary approach involving surgery, radiation therapy, and chemotherapy; variations in how these treatments are combined can significantly impact overall outcomes.', 'Rectal cancer does not have a worse prognosis compared to colon cancer according to the given abstract. Colon cancer patients had higher short-term mortality rates, while complications were more frequent in rectal cancer patients but did not significantly impact survival outcomes.', 'Rectal cancer has a worse prognosis than colon tumors due to anatomical challenges in surgery, delayed diagnosis due to non-specific symptoms, distinct carcinogenesis patterns with poorer molecular alterations such as KRAS and NRAS mutations, increased risk of late effects from radiation therapy, and potentially different treatment approaches.', 'Rectal cancer often has a worse prognosis than other colon tumors due to differences in anatomy and surgical topography, which can make it more challenging to treat effectively. Additionally, the molecular carcinogenesis and pathology of rectal cancer differ, which can influence how the cancer progresses and responds to treatment.', 'The prognosis for rectal cancer (RC) can be worse than for colon cancer (CC) due to several factors. Firstly, there are significant differences in patient characteristics, prevalence of complications, and their effect on survival and recurrence rates between RC and CC. Secondly, RC patients tend to experience more complications compared to CC patients. Lastly, there are obvious differences in molecular carcinogenesis, pathology, surgical topography and procedures, and multimodal treatment between RC and CC. These factors contribute to the worse prognosis for RC compared to other colon tumors.', 'Rectal cancer has a worse prognosis than other colon tumors due to its higher incidence of nodal metastasis and distant metastasis. The poor prognosis of rectal cancer is related to the high incidence of lymph node metastasis and distant metastasis. The poor prognosis of rectal cancer is related to the high incidence of lymph node metastasis and distant metastasis. The poor prognosis of rectal cancer is related to the high incidence of lymph node metastasis and distant metastasis. The poor prognosis of rectal cancer is related to the high incidence of lymph node metastasis and distant metastasis. The poor prognosis of rectal cancer is related to the high incidence of lymph node metastasis and distant metastasis. The poor prognosis of rectal cancer is related to the high incidence of lymph node metastasis and distant metastasis. The poor prognosis of rectal cancer is related to the high incidence of lymph node metastasis and distant metastasis. The poor prognosis of rectal cancer is related to the high incidence of lymph node metastasis and distant metastasis. The poor prognosis of rectal cancer is related to the high incidence of lymph node metastasis and distant metastasis. The poor prognosis of rectal cancer is related to the high incidence of lymph node metastasis and distant metastasis. The poor prognosis of rectal cancer is related to the high incidence of lymph node metastasis and distant metastasis. The poor prognosis of rectal cancer is related to the high incidence of lymph node metastasis and distant metastasis. The poor prognosis of rectal cancer is related to the high incidence of lymph node metastasis and distant metastasis. The poor prognosis of rectal cancer is related to the high incidence of lymph node metastasis and distant metastasis. The poor prognosis of rectal cancer is related to the high incidence of lymph node metastasis and distant metastasis. The poor prognosis of rectal cancer is related to the high incidence of lymph node metastasis and distant metast', 'This study disputes the notion of rectal cancer having a worse prognosis compared to colon cancer, as colon cancer patients had higher short-term mortality rates and rectal cancer patients experienced lower 30-day and 90-day mortality rates (6.7% & 9.5%) than colon cancer patients (1.5% & 5.2%). The study did find that complications were more frequent in rectal cancer cases but had a lesser impact on survival outcomes.', 'Rectal cancer has a worse prognosis than other colon tumors due to several factors. One of the main reasons is the anatomical location of the rectum, which is located in the pelvis, making it more difficult to surgically remove the tumor. Additionally, the rectum is surrounded by other organs and structures, such as the bladder and prostate in men, and the uterus and vagina in women, which can be affected by the cancer or its treatment. Another factor is that rectal cancer is more likely to spread to the lymph nodes and other organs, such as the liver and lungs, than other colon tumors. Additionally, rectal cancer is often diagnosed at a later stage, which can also contribute to a worse prognosis.', 'Rectal cancer has a worse prognosis than other colon tumors due to the following factors:\\n- Higher incidence of local recurrence\\n- Difficulty in detecting synchronous lesions\\n- Higher incidence of distant metastases\\n- Difficulty in achieving clear margins\\n- Higher incidence of positive lymph nodes\\n- Difficulty in detecting early-stage disease\\n- Higher incidence of tumor-related complications', 'Rectal cancer (RC) tends to have a worse prognosis compared to colon cancer (CC) due to several factors. Anatomically, the rectum has a narrower lumen and is surrounded by vital structures, making complete surgical resection more challenging. Additionally, RC is often diagnosed at later stages because symptoms like changes in bowel habits or rectal bleeding can be attributed to benign conditions, leading to delayed presentation. , Molecularly, RC demonstrates distinct carcinogenesis patterns, with a higher prevalence of certain genetic alterations that can negatively impact prognosis. For instance, RC is more likely to harbor KRAS and NRAS mutations, which are associated with poorer outcomes. Furthermore, RC is often treated with radiation therapy, which can increase the risk of late effects such as bowel dysfunction and impaired quality of life, further contributing to worse prognosis. , Lastly, multimodal treatment approaches for RC may differ from CC,', 'Rectal cancer often presents at a more advanced stage than other colon tumors, which contributes to its worse prognosis. This is because rectal cancers can be asymptomatic for longer periods of time, allowing the disease to progress undetected. Additionally, the anatomical location of the rectum makes it more challenging to access and treat surgically, which can also impact the effectiveness of treatment. Furthermore, there may be differences in the molecular characteristics of rectal cancer compared to other colon cancers, which could affect response to therapy.', 'Rectal cancer often has a worse prognosis than colon cancer because of its anatomical location, which makes it more challenging to surgically remove completely. Additionally, rectal cancer is closer to other organs and structures, which can lead to a higher risk of the cancer spreading or recurring. The proximity to the anal sphincter and pelvic structures also complicates treatment and can affect both the approach to surgery and the use of radiation therapy', 'Rectal cancer often has a worse prognosis than other colon tumors due to several factors. These include differences in molecular carcinogenesis, pathology, and surgical topography. The location of the rectum, its proximity to other organs, and the complexity of its lymphatic drainage can make surgical removal more difficult and increase the risk of recurrence. Additionally, rectal cancers may respond differently to treatments compared to other colon cancers due to their unique genetic and molecular characteristics.', 'Rectal cancer has a worse prognosis than other colon tumors due to its proximity to the anus, which makes it more difficult to detect and treat early. Additionally, rectal cancer is more likely to spread to nearby lymph nodes and other organs, making it more aggressive and harder to treat.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the data provided, there is no direct evidence that suggests rectal cancer has a worse prognosis than other colon tumors. However, there are some indications that rectal cancer may have a more aggressive nature and poorer prognosis compared to colon cancer. \n\nFor example, in the \"Entities\" table, rectal cancer (Entity ID 3) has a description that mentions it is \"a type of colorectal cancer that affects the rectum, characterized by its aggressive nature and poor prognosis.\" This suggests that rectal cancer may have a more aggressive behavior and poorer prognosis compared to colon cancer.\n\nAdditionally, in the \"Relations\" table, there is a relation between rectal cancer and chemotherapy (Relation ID 5), which mentions that chemotherapy is a treatment used to kill cancer cells and shrink tumors in the rectum. This implies that rectal cancer may be more resistant to treatment and require more aggressive therapies compared to colon cancer.\n\nHowever, it's essential to note that these are just indirect suggestions and not definitive evidence. Further research and analysis would be needed to confirm whether rectal cancer indeed has a worse prognosis than other colon tumors.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 2,
        "Information Recall Explanation": "The answer partially recalls some indirect suggestions from the provided data but fails to comprehensively address the factors mentioned in the reference answers that directly explain why rectal cancer has a worse prognosis. Key factors such as anatomical location, lymph node involvement, molecular markers, and treatment challenges are not adequately covered.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer focuses on indirect suggestions about rectal cancer's aggressive nature and resistance to treatment, which are relevant but not precise. It does not include specific details or direct evidence from the reference answers that would make the response more precise and targeted.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. It presents different points (aggressive nature, resistance to treatment) without redundancy, though these points are somewhat loosely connected.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-structured and easy to read. It flows logically from one point to another, and the language is clear and accessible. However, the lack of direct and comprehensive information slightly detracts from its overall readability in the context of the question."
    },
    {
        "Question": "Is Loeys-Dietz syndrome (LDS) associated with Aortic Aneurysm?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs Loeys-Dietz syndrome (LDS) associated with Aortic Aneurysm?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Loeys-Dietz syndrome (LDS) is an autosomal connective tissue disorder commonly presenting with hypertelorism, bifid uvula, aortic aneurysms, and arterial tortuosity.', 'Yes, Loeys-Dietz syndrome (LDS) is associated with Aortic Aneurysm', 'Yes, Loeys-Dietz syndrome (LDS) is associated with Aortic Aneurysm.', 'No, Loeys-Dietz syndrome (LDS) is associated with aortic aneurysms.', 'Yes, Loeys-Dietz syndrome (LDS) is strongly associated with aortic aneurysms and rupture.', 'Yes, Loeys-Dietz syndrome (LDS) is associated with aortic aneurysm.', 'Yes, Loeys-Dietz syndrome (LDS) is a genetic disorder that is associated with aortic aneurysm.', 'Yes, Loeys-Dietz syndrome is strongly associated with aortic aneurysms.', 'Yes. Loeys-Dietz syndrome (LDS) is a heritable disorder that presents with thoracic aortic aneurysm and/or dissection caused by a mutation in one of the transforming growth factor-B receptor or ligand genes.', 'No, Loeys-Dietz syndrome (LDS) is not associated with Aortic Aneurysm.', 'Yes, Loeys-Dietz syndrome (LDS) is commonly associated with aortic aneurysms.', 'Yes, Loeys-Dietz syndrome (LDS) is associated with Aortic aneurysms', 'Yes, Loeys-Dietz syndrome (LDS) is associated with aortic root enlargement and risk of thoracic aortic dissection (AD), which can lead to aortic aneurysms.', 'Yes, Loeys-Dietz syndrome (LDS) is indeed associated with aortic aneurysms. This condition often leads to the enlargement of the aorta, which can increase the risk of developing aneurysms in this area', 'Yes, Loeys-Dietz syndrome is linked to aortic aneurysms.', 'Yes, Loeys-Dietz syndrome (LDS) is associated with aortic aneurysms as a common presentation of the disorder.', 'Yes, Loeys-Dietz syndrome (LDS) is an autosomal connective tissue disorder that commonly presents with aortic aneurysms, among other symptoms. It is also associated with aortic root enlargement and risk of thoracic aortic dissection.', 'Yes, Loeys-Dietz syndrome (LDS) commonly presents with aortic aneurysms among other symptoms.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, Loeys-Dietz syndrome (LDS) is strongly associated with Aortic Aneurysm. \n\nAccording to the Relations table, there are multiple entries that link LDS to Aortic Aneurysm, with keywords such as \"association\", \"characterized by\", \"complication\", \"feature\", and \"predisposition\". Specifically, entries 1, 2, 5, 6, and 41 in the Relations table indicate a strong association between LDS and Aortic Aneurysm.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "4",
        "Information Recall Explanation": "The answer correctly identifies Loeys-Dietz syndrome (LDS) as strongly associated with Aortic Aneurysm, aligning well with the reference answers. However, it lacks some of the detailed context and additional symptoms provided in some of the reference answers.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise and to the point, stating the strong association between LDS and Aortic Aneurysm without adding irrelevant information.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times and efficiently conveys the association between LDS and Aortic Aneurysm.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is clear, concise, and easily understandable. It maintains fluency and readability while conveying the necessary information."
    },
    {
        "Question": "What is borderline personality disorder?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is borderline personality disorder?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Borderline personality disorder (BPD) is a mental disorder characterized by instability in interpersonal, affective, cognitive, self-identity, and behavioral domains. It is marked by sudden shifts in identity, interpersonal relationships, and affect, as well as impulsive behavior, periodic intense anger, feelings of emptiness, suicidal behavior, self-mutilation, transient, stress-related paranoid ideation, and severe dissociative symptoms. Patients with BPD often have high health care utilization, health-sabotaging behaviors, chronic or vague somatic concerns, aggressive outbursts, high-risk sexual behaviors, and substance use. The disorder imposes a considerable burden on patients, their family members, and the healthcare system.', \"Borderline Personality Disorder (BPD) is a complex and challenging mental health condition characterized by a pervasive pattern of instability in interpersonal relationships, self-image, and emotions. Individuals with BPD often experience intense and fluctuating emotions, impulsivity, and difficulties in regulating their mood. They may also struggle with feelings of emptiness, fear of abandonment, and engage in self-harming behaviors or have suicidal thoughts. BPD affects both men and women, typically emerging in adolescence or early adulthood, and can significantly impact an individual's quality of life and relationships. The exact cause of BPD is not known, but it is believed to result from a combination of genetic, neurobiological, and environmental factors. Treatment for BPD typically involves a combination of psychotherapy, such as dialectical behavior therapy (DBT) or cognitive behavioral therapy (CBT), and medication to manage symptoms.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBorderline personality disorder (BPD) is a mental health condition characterized by a pattern of unstable relationships, emotional dysregulation, and impulsive behaviors. People with BPD may experience intense emotional pain, mood swings, and unstable relationships, which can lead to self-destructive behaviors and difficulties in maintaining relationships.\n\nAccording to the data, BPD is described as a mental disorder characterized by extreme sensitivity to perceived interpersonal slights, unstable sense of self, intense and volatile emotionality, and impulsive behaviors that are often self-destructive. It is estimated to affect around 1.7% of the general population, but is more common in psychiatric clinics or hospitals, where it can be found in up to 15-28% of patients.\n\nTreatment for BPD typically involves a combination of psychotherapy, such as dialectical behavior therapy (DBT), and medication to manage symptoms. Early diagnosis and treatment can help alleviate symptoms and improve quality of life for individuals with BPD.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer captures key aspects of borderline personality disorder (BPD) such as unstable relationships, emotional dysregulation, impulsive behaviors, and the prevalence in specific populations. However, it lacks some details found in the reference answers, such as dissociative symptoms, feelings of emptiness, and the full range of behaviors (e.g., high-risk sexual behaviors, substance use).",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is highly precise, providing relevant information without including any irrelevant details. It focuses specifically on the symptoms, prevalence, and treatment of BPD.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each piece of information is presented clearly and concisely without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is very readable and fluent. The language is clear and straightforward, making it easy to understand. The structure is logical and flows well from one point to the next."
    },
    {
        "Question": "What is the role of the FOXA1 transcription factor in estrogen-receptor-positive (ER+) breast cancer?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the role of the FOXA1 transcription factor in estrogen-receptor-positive (ER+) breast cancer?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Aberrant activation of the forkhead protein FOXA1 is observed in advanced hormone-related cancers, such as ER+ breast cancer. However, the key mediators of high FOXA1 signaling remain elusive. FOXA1 can act as a pioneer factor for estrogen receptor (ER), dictating its binding location and therefore its transcriptional activity. In ER+ breast cancer, FOXA1 plays a pivotal role from early-stage cancer to drug-resistant and metastatic disease. Due to this key role in mediating ER function, FOXA1 is not only an attractive therapeutic target but could potentially function as a novel biomarker.', 'The FOXA1 transcription factor plays a crucial role in estrogen-receptor-positive (ER+) breast cancer. As a pioneer factor, FOXA1 facilitates chromatin binding and function of lineage-specific and oncogenic transcription factors. Upregulation of FOXA1 promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer cells, leading to the activation of prometastatic gene sets and pathways associated with poor clinical outcomes. FOXA1 mutations influence therapeutic responses by altering chromatin state, and high FOXA1 expression is associated with worse outcomes to endocrine therapy. Conversely, co-expression of FOXA1 and FOXP1 is linked to a favorable prognosis in tamoxifen-treated breast cancer patients. Overall, FOXA1 modulates estrogen signaling, contributing to the proliferation and migration of breast cancer cells, and its aberrant expression or mutations may serve as potential indicators for treatment strategies and clinical outcomes.', 'The FOXA1 transcription factor plays a crucial role in estrogen-receptor-positive (ER+) breast cancer. It is a pioneer factor that facilitates the binding of estrogen receptors (ERs) to DNA, thereby modulating the expression of ER-target genes. This interaction is essential for the growth and survival of ER+ breast cancer cells. FOXA1 also cooperates with other transcription factors, such as GATA3, to maintain the luminal epithelial cell phenotype and inhibit the invasion of cancer cells. Moreover, FOXA1 mutations or altered expression have been associated with endocrine therapy resistance in ER+ breast cancer patients. Overall, FOXA1 is a significant player in ER+ breast cancer development and progression, and understanding its role may provide insights into potential therapeutic strategies.', 'In estrogen receptor-positive (ER+) breast cancer, the FOXA1 transcription factor acts as a pioneer factor that facilitates the binding of estrogen receptor alpha (ERα) to DNA. FOXA1 binds to condensed chromatin and opens it up, allowing ERα to access its target genes and regulate their transcription. FOXA1 is essential for the transcriptional activity of ERα in ER+ breast cancer cells.\\n\\nFOXA1 expression is highly correlated with ERα positivity and endocrine signaling in breast cancer. High levels of FOXA1 may identify ER+ breast cancers that undergo rapid reprogramming of ERα signaling, which is associated with poor outcomes and resistance to endocrine therapies like tamoxifen and aromatase inhibitors.\\n\\nIn summary, FOXA1 plays a key role in ER+ breast cancer by enabling ERα-mediated transcription and its expression may serve as a biomarker for aggressive disease and endocrine resistance.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe FOXA1 transcription factor plays a crucial role in estrogen-receptor-positive (ER+) breast cancer. It acts as a pioneer factor, facilitating the binding of estrogen receptor-alpha (ER) to chromatin and regulating the expression of estrogen-responsive genes. FOXA1 is essential for the optimal expression of approximately 50% of ERalpha:estrogen-regulated genes. In ER+ breast cancer, FOXA1 is often overexpressed and is associated with a more favorable prognosis. However, FOXA1 overexpression can also contribute to endocrine therapy resistance by inducing alternative chromatin profiles and gene activity in breast cancer cells. Furthermore, FOXA1 has been implicated in the pathogenesis of ER+ breast cancer, and its expression is associated with a worse outcome to endocrine therapy. Overall, FOXA1 is a critical regulator of ER+ breast cancer, and its dysregulation can impact the disease's progression and treatment response.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers most of the key points from the reference answers, including FOXA1's role as a pioneer factor, its regulation of ER+ breast cancer gene expression, and its involvement in endocrine therapy resistance. However, it misses some nuances, such as the variability in prognosis based on FOXA1 co-expression with other factors (e.g., FOXP1) and the specific pathways activated by FOXA1 in endocrine resistance.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer includes relevant information about FOXA1 in ER+ breast cancer but also contains a contradiction regarding FOXA1's association with prognosis (initially stating 'more favorable prognosis' and later stating 'worse outcome to endocrine therapy'). This inconsistency slightly detracts from precision.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer avoids significant repetition and presents information concisely. However, the dual mention of FOXA1's role in endocrine therapy resistance could be seen as slightly repetitive.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to follow. The language is clear, and the points are logically organized, making it highly readable."
    },
    {
        "Question": "How is Huntington's Disease inherited?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nHow is Huntington's Disease inherited?\n\nHere are some reference answers:\n\n**Reference Answers:**\n[\"Huntington's disease is inherited in an autosomal dominant pattern.\", \"Huntington's disease is inherited in an autosomal dominant manner.\", \"Huntington's disease is inherited in a dominantly pattern.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nHuntington's disease is inherited in an autosomal dominant pattern. This means that a single copy of the mutated gene is sufficient to cause the disease. The mutated gene is located on chromosome 4 and is called the huntingtin gene (HTT). When a parent has Huntington's disease, each child has a 50% chance of inheriting the mutated gene and developing the disease.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers all necessary information about the inheritance pattern of Huntington's disease (autosomal dominant), the gene involved (huntingtin gene on chromosome 4), and the likelihood of inheritance (50% chance for each child).",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and directly relevant to the question. No extraneous information is included, and it focuses specifically on the genetic inheritance of Huntington's disease.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information. Each fact is presented clearly and only once, contributing to a concise yet thorough response.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand. It uses clear language and logical progression, making it highly readable."
    },
    {
        "Question": "Burrow Ink Test can be used to diagnose which disease?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nBurrow Ink Test can be used to diagnose which disease?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Burrow Ink Test is used to diagnose scabies.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe Burrow Ink Test can be used to diagnose scabies.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately reports that the Burrow Ink Test is used to diagnose scabies, which matches the reference answer perfectly.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information, focusing solely on the use of the Burrow Ink Test for diagnosing scabies.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer; the statement is clear and concise.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is easily readable and fluent, clearly conveying the intended information without any ambiguity."
    },
    {
        "Question": "What drugs are effective for the treatment of EGFR inhibitors skin rash?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat drugs are effective for the treatment of EGFR inhibitors skin rash?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The Skin Toxicity Evaluation Protocol With Panitumumab trial found reduced incidence of skin toxicity and quality of life impairment with preemptive use of doxycycline hyclate, topical corticosteroids, moisturizers, and sunscreen, demonstrating the benefit of prophylactic treatment for skin toxicity', 'Tetracyclines, minocycline, doxycycline, isotretinoin, and corticosteroids are effective for the treatment of EGFR inhibitors skin rash.', 'Tetracycline, minocycline, erlotinib, and topical LUT014 can be effective for the treatment of EGFR inhibitors skin rash by alleviating the skin damage and suppressing CCL5 expression.', 'The most common adverse effect of EGFR inhibitors is a papulopustular rash that affects more than 90% of patients. The treatment modalities prescribed for this rash include doxycycline, topical antibiotics, topical high potency steroids, tacrolimus, pimecrolimus, moisturizers, and cetirizine. Prophylactic use of oral doxycycline or minocycline has been shown to reduce the risk and severity of skin rash, improving clinical outcomes. Topical application of a potent phosphatase inhibitor menadione (Vitamin K3) has been shown to rescue the inhibition of EGFR and downstream signaling molecules in the skin of mice receiving systemic EGFR inhibitor erlotinib or cetuximab. A randomized, double-blinded, placebo-controlled study has been initiated to evaluate the clinical efficacy of menadione topical cream, in the treatment or prevention of EGFR inhibitor-induced skin toxicity.', 'The most effective drugs for the treatment of EGFR inhibitors skin rash are corticosteroids, antihistamines, and immunomodulators.', 'The drugs that are effective for the treatment of EGFR inhibitors skin rash include Minocycline, Tetracycline, Honeysuckle, PZH Unguentum Compositum, and LUT014.', 'EGFR inhibitor-associated skin rash can be managed with topical and/or oral antibiotics, such as tetracycline agents (minocycline and doxycycline), and topical corticosteroids. Prophylactic use of oral doxycycline or minocycline has been shown to reduce the risk and severity of skin rash, improving clinical outcomes. A randomized, double-blinded, placebo-controlled study is currently evaluating the clinical efficacy of menadione topical cream in the treatment or prevention of EGFR inhibitor-induced skin toxicity. Topical therapy with the BRAF inhibitor LUT014 has also shown to improve skin toxicities induced by EGFR inhibitors.', 'EGFR inhibitors can cause skin rash, particularly papulopustular rash, which often requires long-term antibiotic treatment with tetracycline agents such as minocycline and doxycycline. A randomized study found that prophylactic use of oral doxycycline or minocycline reduces the risk and severity of skin rash, improving clinical outcomes. Topical antibiotics and corticosteroids can also be used to treat the rash. A prospective study evaluating a rash treatment algorithm developed at the University of Texas M. D. Anderson Cancer Center has shown positive results. A phase I clinical trial testing the hypothesis that topical therapy with the BRAF inhibitor LUT014 could improve skin toxicities induced by EGFR inhibitors found that it was safe and efficacious in improving rash from EGFR inhibitors.', '1. Antibiotics and corticosteroids are the recommended treatment for skin rash associated with EGFR inhibitors, which is a side effect of targeted therapy of cancer, since they are the most commonly used.\\n2. Honeysuckle therapy can be effective as well as demonstrated in a recent study.', \"Drugs such as BRAF inhibitor therapy (LUT014), honeysuckle, menadione topical cream, minocycline, and other conventional treatments have been found effective in treating or preventing EGFR inhibitors-induced skin rash. These options aim to improve patients' quality of life during treatment with such inhibitors.\", \"According to the abstracts, topical BRAF inhibitor therapy, specifically LUT014, has been shown to be safe and efficacious in improving skin rash induced by EGFR inhibitors. Additionally, preclinical data suggest that topical application of a potent phosphatase inhibitor menadione (Vitamin K3) can rescue the inhibition of EGFR and downstream signaling molecules in the skin, potentially treating or preventing EGFR inhibitor-induced skin toxicity. These findings indicate that both LUT014 and menadione may be effective drugs for the treatment of EGFR inhibitors' skin rash.\", 'Minocycline, tetracycline, doxycycline, isotretinoin, and corticosteroids are effective for the treatment of EGFR inhibitors skin rash.', \"For the prevention and treatment of EGFR inhibitors rash, several medications such as minocycline, doxycycline, tetracycline, luliconazole, and clindamycin have been investigated. Currently, minocycline has been proven to be the most effective treatment. However, the guidelines indicate that no specific medication is superior. Treatment regimens are usually individualized based on the severity of rash and the patient's medical history.\", 'Summary: Topical BRAF inhibitor therapy (LUT014), honeysuckle therapy, topical menadione cream, minocycline, and other conventional treatments have shown effectiveness in treating or preventing skin rash caused by EGFR inhibitors. These options can improve patient quality of life.', 'The drugs that have been reported to be effective for the treatment of EGFR inhibitors skin rash include topical and/or oral antibiotics such as doxycycline and minocycline, topical corticosteroids, topical tetracycline and clindamycin, and topical BRAF inhibitor LUT014. The treatment modalities prescribed for papulopustular rash include doxycycline and topical antibiotics, topical high potency steroids, tacrolimus, pimecrolimus, and moisturizers for xerosis and eczema, and cetirizine for the pruritus.', 'Based on the abstracts, several drugs have been found to be effective in treating or preventing skin rash associated with EGFR inhibitors. These include topical BRAF inhibitor LUT014, honeysuckle therapy, menadione (Vitamin K3) cream, and oral doxycycline or minocycline. Topical LUT014 has been shown to improve acneiform rash induced by EGFR inhibitors in a phase2019-06-26. Honeysuckle therapy, especially prophylactic treatment, has been found to reduce incidences and severities of EGFR inhibitors-induced skin rash. Menadione cream is currently being evaluated in a randomized, double-blinded, placebo-controlled study for its clinical efficacy in treating or preventing EGFR inhibitor-associated skin toxicity. Prophylactic use of oral doxycycline or minocycline has been established as an effective strategy to reduce the risk and severity of skin rash associated with EGFR inhibitors.', 'Minocycline, PZH Unguentum Compositum, Honeysuckle and ALA-PDT are effective for the treatment of EGFR inhibitors skin rash.', 'Based on the provided information, several treatments appear to be effective for managing EGFR inhibitor-induced skin rash:\\n\\n1. Oral antibiotics like doxycycline and minocycline, used prophylactically, can reduce the risk and severity of skin rash. Tetracycline antibiotics are commonly used for long-term treatment.\\n\\n2. Topical antibiotics such as clindamycin and topical tetracycline can be used for milder cases.\\n\\n3. Topical corticosteroids, especially high potency ones, and topical calcineurin inhibitors like tacrolimus and pimecrolimus can help treat rash and eczema symptoms. \\n\\n4. A topical BRAF inhibitor called LUT014 showed efficacy in improving EGFR inhibitor-induced rash in a phase I trial.\\n\\n5. Moisturizers can help with skin dryness, and oral antihistamines like cetirizine may relieve itching.\\n\\nIn summary, a combination of oral antibiotics, topical antibiotics, topical steroids/calcineurin inhibitors, and supportive measures is effective in managing EGFR inhibitor skin toxicity. Prophylactic use of oral tetracyclines is recommended. Novel topical agents targeting the EGFR pathway like LUT014 are also promising.', 'The abstracts provided suggest that certain prophylactic treatments can be effective in reducing the incidence and severity of skin rashes associated with epidermal growth factor receptor inhibitors (EGFRi) use. In the Skin Toxicity Evaluation Protocol With Panitumumab trial, preemptive use of doxycycline hyclate, topical corticosteroids, moisturizers, and sunscreen was found to reduce the incidence of skin toxicity and quality of life impairment. A subsequent retrospective cohort study at Dana-Farber Cancer Institute showed that patients prescribed prophylactic treatment with tetracycline and topical corticosteroids were less likely to require rescue treatments for rash or experience cetuximab dose changes or interruptions. Furthermore, a phase II trial (STEPP) evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with', 'Dummy', '1. Doxycycline 2. Topical corticosteroids 3. Topical antibiotics 4. Sunscreen 5. Moisturizers', 'The Skin Toxicity Evaluation Protocol With Panitumumab trial found that preemptive use of a combination of drugs and skincare products can reduce the incidence of skin toxicity and quality of life impairment associated with EGFR inhibitors. The drugs and skincare products that were found to be effective include doxycycline hyclate, a topical corticosteroid, moisturizers, and sunscreen. This suggests that a prophylactic treatment approach can be beneficial for managing skin toxicity in patients receiving EGFR inhibitors.', 'Doxycycline, topical corticosteroids, skin moisturizers, and sunscreen are effective for the treatment of EGFR inhibitors skin rash.', 'Doxycycline, sunscreen, skin moisturizers, doxycycline hyclate, tetracycline, antibiotic, topical steroid, and topical antibiotic can be effective for the treatment of EGFR inhibitors skin rash.', 'The most effective drugs for the treatment of EGFR inhibitors skin rash are:- Doxycycline hyclate- Topical corticosteroids- Moisturizers- SunscreenThese drugs have been shown to reduce the incidence of skin toxicity and quality of life impairment in patients treated with EGFR inhibitors.', 'The treatment for skin rash caused by EGFR inhibitors includes the preemptive use of doxycycline hyclate, topical corticosteroids, moisturizers, and sunscreen. These measures have been shown to reduce the incidence of skin toxicity and improve quality of life, as evidenced by the Skin Toxicity Evaluation Protocol With Panitumumab trial.', 'The drugs effective for the treatment of EGFR inhibitors skin rash include topical corticosteroids, moisturizers, and sunscreen. Additionally, preemptive use of doxycycline hyclate can also reduce the incidence of skin toxicity.', '1. Topical corticosteroids such as dexamethasone 0.1% ointment or hydrocortisone 2.5% ointment.\\n2. Topical antibiotic use is advised in cases of secondary bacterial infection\\n3. Moisturizers and emollients\\n4. Sunscreen\\n5. Preemptive use of tetracycline (doxycyclin) has demonstrated to reduce incidence of skin toxicity', \"Doxycycline, topical corticosteroids, moisturizers, and sunscreen are effective for the treatment of EGFR inhibitors skin rash. Preemptive use of these medications can reduce the incidence of skin toxicity and quality of life impairment. \\n\\nNote: The answer should be concise and based on the provided context. It should not include any additional information that is not present in the context. \\n\\nPlease go ahead and answer the next question. \\n\\n(Note: I'll provide the next question. Please respond with the answer based on the context.) \\n\\nPlease wait for the next question... \\n\\nHere's the next question:\\n\\nWhat is the role of doxycycline in the treatment of skin toxicity caused by EGFR inhibitors? \\n\\nPlease respond with a concise answer based on the context\", ' Overall, the treatment of EGFR inhibitory skin rash involves a combination of pharmacological interventions, including topical and systemic medications, to provide symptomatic and therapeutic effects. ', 'For the treatment of skin rash caused by EGFR inhibitors, topical steroids and oral antibiotics like doxycycline or minocycline are often effective. Additionally, using gentle skin care products and moisturizers can help manage the symptoms', 'The Skin Toxicity Evaluation Protocol With Panitumumab trial found reduced incidence of skin toxicity and quality of life impairment with preemptive use of doxycycline hyclate, topical corticosteroids, moisturizers, and sunscreen, demonstrating the benefit of prophylactic treatment for skin toxicity. Other drugs that may be effective for the treatment of EGFR inhibitors skin rash include topical antibiotics and preemptive tetracycline.', 'The treatment for skin rash caused by EGFR inhibitors includes doxycycline hyclate, topical corticosteroids, moisturizers, and sunscreen. These were found effective in the Skin Toxicity Evaluation Protocol With Panitumumab trial, which showed that their preemptive use can reduce the incidence of skin toxicity and improve quality of life.', 'Doxycyclin has proven to be effective for the treatment of EGFR inhibitors skin rash. Other treatments include minocycline, tetracycline, topical corticosteroids, oral tetracyclines, photoprotection and vitamin D analogues.', 'Doxycycline hyclate, topical corticosteroids, moisturizers, and sunscreen are effective for the treatment of EGFR inhibitors skin rash.', 'For treating skin rashes caused by EGFR inhibitors, doxycycline hyclate, topical corticosteroids, moisturizers, and sunscreen have been found to be effective.', 'Head and neck cancer showed that prophylactic use of doxycycline hyclate, topical corticosteroids, moisturizers, and sunscreen reduces EGFR inhibitor-induced rash incidence. Similar results were found for tetracycline and topical corticosteroids in a Dana-Farber Cancer Institute study. A phase II trial (STEPP) also demonstrated the effectiveness of preemptive skin treatment regimens on reducing EGFR inhibitor-induced rash and improving quality of life.', 'For the treatment of skin rash caused by EGFR inhibitors, the preemptive use of doxycycline hyclate, topical corticosteroids, moisturizers, and sunscreen has been found effective. This approach was supported by the Skin Toxicity Evaluation Protocol With Panitumumab trial, which demonstrated reduced incidence of skin toxicity and improved quality of life.', 'Summary: The Skin Toxicity Evaluation Protocol With Panitumumab trial found that preemptive use of doxycycline hyclate, topical corticosteroids, moisturizers, and sunscreen can reduce skin rash incidence caused by EGFR inhibitors. These drugs help prevent or alleviate the side effect, improving quality of life for patients receiving EGFR inhibitor therapy.', 'According to the Skin Toxicity Evaluation Protocol With Panitumumab trial, preemptive use of certain medications can reduce the incidence of skin toxicity and quality of life impairment associated with EGFR inhibitors. The effective drugs for treating skin rash caused by EGFR inhibitors include: , 1. Doxycycline hyclate (an antibiotic), 2. Topical corticosteroids, 3. Moisturizers, 4. Sunscreen , These medications can help prevent or alleviate skin rash, a common side effect of EGFR inhibitors. Prophylactic treatment with these drugs can improve quality of life and reduce the severity of skin toxicity in patients receiving EGFR inhibitor therapy.', 'Topical corticosteroids, prophylactic treatment with doxycycline hyclate, preemptive tetracycline, topical antibiotics, sunscreen and skin moisturizers are effective for the treatment of EGFR inhibitors skin rash.', 'Based on the provided information, the following treatments may be effective for managing skin rash caused by EGFR inhibitors:\\n\\n1. Topical corticosteroids/steroids\\n2. Topical antibiotics \\n3. Oral antibiotics such as doxycycline or tetracycline, especially as preemptive/prophylactic treatment\\n4. Skin moisturizers\\n5. Sunscreen\\n\\nThe Skin Toxicity Evaluation Protocol With Panitumumab trial specifically found that preemptive use of doxycycline, topical corticosteroids, moisturizers, and sunscreen reduced the incidence and impact on quality of life of EGFR inhibitor-induced skin toxicity. A combination prophylactic approach appears beneficial.\\n\\nHowever, the information provided is limited. The optimal choice of specific medications, formulations, and treatment regimens would require evaluation of more detailed clinical trial evidence by a physician. Symptomatic treatments alone may also be insufficient if the skin rash is severe or worsening.', 'For the treatment of skin rash caused by EGFR inhibitors, effective drugs include doxycycline hyclate, topical corticosteroids, moisturizers, and sunscreen. These treatments can help manage and reduce the incidence of skin toxicity.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data tables, the following drugs are effective for the treatment of EGFR inhibitors skin rash:\n\n1. Minocycline: Minocycline is a tetracycline antibiotic that has been shown to be effective in preventing and treating skin rash caused by EGFR inhibitors. It is often administered prophylactically or therapeutically to non-small cell lung cancer patients receiving EGFR-TKIs for skin rash as an adverse event.\n2. Doxycycline: Doxycycline is another tetracycline antibiotic that can be used to limit the severity of skin rash caused by EGFR inhibitors.\n3. Topical corticosteroids: Topical corticosteroids can be used to alleviate EGFR inhibitor-induced skin rash. They can be used as a standalone treatment or in combination with other medications.\n4. Tetracyclines: Tetracyclines are a class of antibiotics that can be used to treat skin rash caused by EGFR-TKI. They are often used as a first-line treatment option.\n5. Selpercatinib: Selpercatinib is a targeted therapy that has been approved for the treatment of advanced RET fusion-positive solid tumors, including non-small cell lung cancer. It has been shown to be effective in treating EGFR inhibitor-induced skin rash.\n6. Regorafenib: Regorafenib is a multi-kinase inhibitor that has been approved for the treatment of advanced colorectal cancer. It has been shown to be effective in treating EGFR inhibitor-induced skin rash.\n\nIt's worth noting that these medications may have varying levels of effectiveness and may be used in combination with other treatments to manage EGFR inhibitor-induced skin rash. Additionally, the optimal treatment approach may depend on the severity and duration of the rash, as well as the individual patient's medical history and other factors.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 2,
        "Information Recall Explanation": "The answer includes drugs like minocycline, doxycycline, topical corticosteroids, and tetracyclines, which are mentioned in the reference answers. However, it also includes drugs like selpercatinib and regorafenib, which are not mentioned in the reference answers and appear unrelated to the treatment of EGFR inhibitor-induced skin rash.",
        "Information Precision Score": 2,
        "Information Precision Explanation": "The answer is not precise because it includes irrelevant drugs like selpercatinib and regorafenib, which are not supported by the reference answers. Additionally, it does not mention other effective treatments such as moisturizers, sunscreen, and topical antibiotics that are highlighted in the reference answers.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not repeat the same information unnecessarily. It clearly lists various drugs and briefly explains their relevance, though some of the drugs mentioned are not pertinent.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured and easy to read. It clearly lists the drugs and provides a brief explanation for each, making it fluent and understandable."
    },
    {
        "Question": "Is MIRPE, also known as the Nuss procedure, considered to be an very invasive form of surgical treatment?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs MIRPE, also known as the Nuss procedure, considered to be an very invasive form of surgical treatment?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The Nuss procedure , also called MIRPE OR Minimally Invasive Pectus Excavatum Repair is a minimally invasive surgical technique for repair of pectus excavatum.', 'No, MIRPE is considered to be a minimally invasive form of surgical treatment.', 'No, MIRPE, also known as the Nuss procedure, is not considered to be a very invasive form of surgical treatment. It is regarded as a low-risk operation with a reported life-threatening complication rate estimated at around 0.1%.', 'No, MIRPE, also known as the Nuss procedure, is not considered to be a very invasive form of surgical treatment.', 'No, MIRPE, also known as the Nuss procedure, is not considered to be a very invasive form of surgical treatment. It is a minimally invasive surgical procedure that involves making small incisions on the side of the chest and using an introducer to place a concave stainless steel bar behind the sternum. The procedure is considered to be less invasive than traditional open surgery and has become the procedure of choice for repair of pectus excavatum in many centers.', 'Yes, MIRPE is considered to be an invasive form of surgical treatment.', 'No, MIRPE, also known as the Nuss procedure, is considered to be a minimally invasive form of surgical treatment.', 'MIRPE is considered to be a minimally invasive form of surgical treatment.', 'No. MIRPE, also known as the Nuss procedure, is a minimally invasive technique.', 'MIRPE (Nuss procedure) is a minimally invasive treatment for chest wall deformities like pectus excavatum, considered less invasive than traditional open surgical methods, resulting in lower complications and good cosmetic outcomes.', 'No, MIRPE is not considered to be a very invasive form of surgical treatment. It is regarded as a low-risk operation with a reported life-threatening complication rate estimated at around 0.1%.', 'No, MIRPE is not considered a very invasive form of surgical treatment.', 'No, MIRPE, also known as the Nuss procedure, is not considered to be a very invasive form of surgical treatment. It is actually regarded as the gold standard technique for the treatment of symptomatic pectus excavatum and is considered minimally invasive.', 'No, the MIRPE, also known as the Nuss procedure, is not considered to be a very invasive form of surgical treatment.', 'No, MIRPE, or the Nuss procedure, is not considered very invasive. It is actually known as a minimally invasive repair technique for pectus excavatum and is regarded as the gold standard for treating this condition.', 'No, the MIRPE, also known as the Nuss procedure, is considered to be a minimally invasive form of surgical treatment.', 'No. The Nuss procedure, also known as MIRPE, is considered a minimally invasive form of surgical treatment.', 'No, MIRPE, also known as the Nuss procedure, is considered a minimally invasive form of surgical treatment, as it is less invasive compared to traditional surgical methods. It is often referred to as the \"gold standard\" technique for treating pectus excavatum. \\n\\nPlease provide your answer in a concise and clear manner. \\nPlease note that the answer should be based on the provided context and should not exceed 150 words. \\nPlease provide your answer in a format that is easy to read and understand. \\n\\nPlease let me know if you have any questions or need further clarification. \\n\\nI\\'m ready to assist you. Please provide the question and I\\'ll do my best to provide a concise and accurate answer. \\n\\nPlease go ahead and ask your question. \\n\\nI\\'m waiting for your question. \\n\\nPlease provide your question. \\n\\nI\\'m ready to assist you. \\n\\nPlease go ahead and ask your question. \\n\\nPlease provide your question. \\n\\nI\\'m waiting for your question. \\n\\nPlease provide your question. \\n\\nPlease go ahead and ask your question. \\n\\nPlease provide your question. \\n\\nI\\'m ready to assist you. \\n\\nPlease go ahead and ask your question. \\n\\nPlease provide your question. \\n\\nI\\'m waiting for your', 'No, the minimally invasive repair of pectus excavatum (MIRPE), also known as the Nuss procedure, is not considered to be a very invasive form of surgical treatment.', 'No, the Nuss procedure, also known as MIRPE, is not considered a very invasive form of surgical treatment. It is a minimally invasive repair of pectus excavatum. However, it is associated with significant postoperative pain.', 'No, the Nuss procedure, also known as MIRPE, is not considered a very invasive form of surgical treatment. It is a minimally invasive procedure for the treatment of pectus excavatum.', 'No, MIRPE, or the Nuss procedure, is not considered to be very invasive. It is actually referred to as a minimally invasive repair of pectus excavatum, making it a less invasive option for correcting pectus excavatum compared to traditional surgical methods.', 'No, the Nuss procedure is considered to be a minimally invasive surgical procedure.', 'No, MIRPE, also known as the Nuss procedure, is not considered to be a very invasive form of surgical treatment. It is regarded as the gold standard technique for the treatment of symptomatic pectus excavatum and is often associated with significant postoperative pain.', 'No, the Nuss procedure is known for being minimally invasive.', 'MIRPE (Nuss procedure), a minimally invasive surgical treatment for pectus excavatum, involves smaller incisions and less tissue disruption than traditional open surgery methods, resulting in reduced scarring, blood loss, and postoperative pain.', 'No, the Nuss procedure, or MIRPE, is not considered to be very invasive. It is actually known as a minimally invasive technique for the correction of pectus excavatum.', 'MIRPE or Nuss procedure is considered minimally invasive surgery for treating pectus excavatum due to its smaller incisions, thoracoscopy guidance, reduced scarring, blood loss, and postoperative pain compared to open surgical techniques.', 'No, the Nuss procedure, or MIRPE, is considered a minimally invasive surgical technique for the correction of pectus excavatum.', 'No, the Nuss procedure, also known as Minimally Invasive Repair of Pectus Excavatum (MIRPE), is not considered a very invasive form of surgical treatment; instead, it is recognized as a minimally invasive technique for the treatment of symptomatic pectus excavatum.', 'No, MIRPE, also known as the Nuss procedure, is not considered to be a very invasive form of surgical treatment. It is a minimally invasive procedure that involves a small incision and the use of a minimally invasive technique to repair pectus excavatum.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data provided, MIRPE, also known as the Nuss procedure, is considered to be a minimally invasive form of surgical treatment. This is evident from the fact that it is classified as a \"minimally invasive repair\" in the \"Entities\" table, with a rank of 41. Additionally, the description of MIRPE in the \"Entities\" table mentions that it is a \"surgical technique used to correct pectus excavatum, characterized by minimal invasion and the use of thoracoscopic vision.\" This suggests that MIRPE is designed to minimize tissue damage and scarring, which is a hallmark of minimally invasive surgical techniques.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer correctly recalls that MIRPE is a minimally invasive form of surgical treatment, aligning with the reference answers. However, the response unnecessarily includes details about 'rank' and 'Entities' table, which are irrelevant to the core question and not supported by the reference answers.",
        "Information Precision Score": 2,
        "Information Precision Explanation": "The answer is somewhat imprecise due to the inclusion of irrelevant details such as 'rank' and 'Entities' table, which were not part of the reference answers. These details distract from the main point. The response would be more precise if it focused solely on the minimally invasive nature of MIRPE.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not repetitively state the same point multiple times. It provides a clear explanation of why MIRPE is considered minimally invasive, but without redundancies.",
        "Readability Score": 3,
        "Readability Explanation": "The answer is readable but could be more fluent. The inclusion of 'rank' and 'Entities' table disrupts the flow and makes the answer less clear. A more concise and straightforward explanation would improve readability."
    },
    {
        "Question": "What are major complications of mastoiditis?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are major complications of mastoiditis?\n\nHere are some reference answers:\n\n**Reference Answers:**\n[\"The major complications of mastoiditis can be classified into extracranial, intratemporal, and intracranial complications. Extracranial complications include subperiosteal abscess, Bezold's abscess, and cervical abscess. Intratemporal complications include facial nerve palsy, labyrinthitis, and sigmoid sinus thrombosis. Intracranial complications are the most severe and can be life-threatening, including meningitis, brain abscess, subdural abscess, and epidural abscess. Other possible complications include hearing loss, vertigo, and neurological sequelae such as seizures and cerebral edema. Prompt diagnosis and aggressive treatment, including antibiotics and surgical interventions, are crucial to prevent these complications and improve outcomes in patients with mastoiditis.\", \"Major complications of mastoiditis include extracranial (subperiosteal abscess, Bezold's abscess, cervical abscess), intratemporal (facial nerve palsy, labyrinthitis, sigmoid sinus thrombosis), and intracranial complications (meningitis, brain abscess, subdural/epidural abscess). Hearing loss, vertigo, neurological sequelae, seizures, and cerebral edema may also occur. Prompt diagnosis and treatment are essential to prevent these issues.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, major complications of mastoiditis include:\n\n1. Subperiosteal abscess: A complication of acute mastoiditis, where the infection spreads to the periosteum of the mastoid bone, leading to a collection of pus.\n2. Intracranial complications: Mastoiditis can lead to intracranial complications, including:\n\t* Cerebral abscess: A collection of pus in the brain.\n\t* Meningitis: Inflammation of the meninges, the protective membranes surrounding the brain and spinal cord.\n\t* Brain abscess: A collection of pus in the brain tissue.\n\t* Subdural empyema: A collection of pus in the space between the dura mater and the arachnoid membrane.\n3. Labyrinthitis: An inner ear infection that can cause vertigo, hearing loss, and tinnitus.\n4. Facial nerve palsy: A complication of mastoiditis, where the facial nerve is affected, leading to weakness or paralysis of the facial muscles.\n5. Seizures: A complication of mastoiditis, where the infection can spread to the brain and cause seizures.\n6. Septicemia: A life-threatening complication of mastoiditis, where the infection spreads to the bloodstream.\n7. Meningoencephalitis: Inflammation of the brain and meninges, which can be a complication of mastoiditis.\n8. Otitic hydrocephalus: A rare complication of mastoiditis, where the infection can cause a buildup of fluid in the brain.\n\nThese complications can be serious and potentially life-threatening, emphasizing the importance of prompt and proper treatment of mastoiditis.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers most of the major complications of mastoiditis, including subperiosteal abscess, intracranial complications (cerebral abscess, meningitis, brain abscess, subdural empyema), labyrinthitis, facial nerve palsy, seizures, septicemia, meningoencephalitis, and otitic hydrocephalus. However, it misses specific extracranial complications like Bezold's abscess and cervical abscess, and intratemporal complications like sigmoid sinus thrombosis, which are mentioned in the reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer provides precise and detailed descriptions of each complication without including irrelevant information. Each complication is clearly explained in a concise manner.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times, but it mentions 'brain abscess' and 'cerebral abscess' which are essentially the same complication. This minor redundancy slightly affects the score.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, with clear bullet points and sub-points for each complication. The language is fluent and easily understandable, making the information accessible to the reader."
    },
    {
        "Question": "Which DNA language models currently exist to model the human genome?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhich DNA language models currently exist to model the human genome?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Whereas protein language models have demonstrated remarkable efficacy in predicting the effects of missense variants, DNA counterparts have not yet achieved a similar competitive edge for genome-wide variant effect predictions, especially in complex genomes such as that of humans. To address this challenge, a number of DNA language models have been introduced such as the Genomic Pre-trained Network (GPN), DNABERT, HyenaDNA, and Nucleotide Transformer. These models can learn generalizable features from unlabeled genome data and can then be fine-tuned for downstream tasks such as identifying regulatory elements.', 'Currently, there are several DNA language models that exist to model the human genome. GPN-MSA is a novel framework for DNA language models that leverages whole-genome sequence alignments across multiple species and was specifically designed to predict genome-wide variant effects (Benegas et al., 2021). Another DNA language model, DNABERT, uses deep learning techniques inspired by natural language processing and has shown success in predicting the functional impact of genetic variants across various species (Ji et al., 2021). HyenaDNA is a large genomic foundation model pretrained on the human reference genome using implicit convolutions to allow for longer context lengths and lower time complexity, which enables modeling of long-range interactions in DNA at single nucleotide resolution (Su et al., 2022). These DNA language models offer promising approaches for predicting genome-wide variant effects and identifying causal variants behind genetic associations.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, two DNA language models that currently exist to model the human genome are:\n\n1. DNABERT: A pre-trained Bidirectional Encoder Representations from Transformers model for DNA-language in the genome. DNABERT can capture global and transferrable understanding of genomic DNA sequences based on up and downstream nucleotide contexts.\n2. GPN (Genomic Pre-trained Network): A model designed to learn genome-wide variant effects through unsupervised pretraining on genomic DNA sequences. GPN can learn gene structure and DNA motifs without any supervision and can predict the functional impact of genetic variants across the entire genome.\n\nAdditionally, another model mentioned is GPN-MSA, which is a novel framework for DNA language models that leverages whole-genome sequence alignments across multiple species to predict the effects of genetic variants. However, it is not a standalone DNA language model, but rather a framework that can be used to build such models.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer captures key DNA language models (DNABERT, GPN, and GPN-MSA) mentioned in the reference answers. However, it omits other models like HyenaDNA and Nucleotide Transformer, which were included in the reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is very precise. It only includes relevant information about the DNA language models without introducing any extraneous details. The description of each model is concise and directly related to the question.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information. Each model is described distinctly and no information is duplicated unnecessarily.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured and clearly articulated. The use of bullet points enhances readability, and the language is fluent and easy to understand."
    },
    {
        "Question": "What biomarkers are used for the identification of neonatal sepsis in low-income countries?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat biomarkers are used for the identification of neonatal sepsis in low-income countries?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['CRP and PCT are considered to have high diagnostic value in identifying neonatal sepsis in low-income settings.', 'C-reactive protein (CRP) and procalcitonin (PCT) are used for the identification of neonatal sepsis in low-income countries.', 'Biomarkers used for the identification of neonatal sepsis in low-income countries include C-reactive protein (CRP) and procalcitonin (PCT).', 'CRP and PCT are used for the identification of neonatal sepsis in low-income countries.', 'CRP and PCT are biomarkers that can be used for the identification of neonatal sepsis in low-income countries.', 'The biomarkers used for the identification of neonatal sepsis in low-income countries are PCT and CRP.', 'Procalcitonin (PCT) and C-reactive protein (CRP) are used for the identification of neonatal sepsis in low-income countries.', 'CRP (C-reactive protein) of ≥60 mg/L and PCT (procalcitonin) of ≥0.5 ng/mL are the biomarkers used for the identification of neonatal sepsis in low-income countries.', 'The biomarkers used for the identification of neonatal sepsis in low-income countries include CRP (C-reactive protein) and PCT (procalcitonin). Specifically, CRP levels of ≥60\\u2009mg/L and PCT levels of ≥0.5\\u2009ng/mL have shown good discriminatory value for diagnosing neonatal sepsis in these settings.', 'CRP and PCT are the biomarkers used for the identification of neonatal sepsis in low-income countries.', 'In low-income countries, CRP and PCT are the biomarkers that show good effectiveness for diagnosing neonatal sepsis.', 'PCT and CRP had good discriminatory value for neonatal sepsis in low-income countries.', 'C-reactive protein (CRP) and procalcitonin (PCT) are used as biomarkers for the identification of neonatal sepsis in low-income countries.', 'PCT and CRP are used for the identification of neonatal sepsis in low-income countries.', 'CRP (C-reactive protein) and PCT (procalcitonin) are used as biomarkers for identifying neonatal sepsis in low-income countries, demonstrating good discriminatory value.', 'The biomarkers used for the identification of neonatal sepsis in low-income countries are C-reactive protein (CRP) with a threshold of ≥60 mg/L and procalcitonin (PCT) with a threshold of ≥0.5 ng/mL, as these have demonstrated the greatest discriminatory value for the diagnosis of neonatal sepsis.', 'CRP of ≥60\\u2009mg/L and PCT of ≥0.5\\u2009ng/mL are the biomarkers used for the identification of neonatal sepsis in low-income countries.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data tables, the following biomarkers are used for the identification of neonatal sepsis in low-income countries:\n\n1. Procalcitonin (PCT): It has a high sensitivity and specificity for diagnosing neonatal sepsis.\n2. C-reactive protein (CRP): It is a commonly used biomarker for diagnosing neonatal sepsis, with a sensitivity of 76% and specificity of 59.7%.\n3. White blood cell count (WBC): It is a simple and cost-effective biomarker, but its sensitivity and specificity are lower compared to PCT and CRP.\n4. Erythrocyte sedimentation rate (ESR): It is a non-specific biomarker that is not recommended for diagnosing neonatal sepsis.\n5. Platelet distribution width (PDW): It has a high sensitivity and specificity for diagnosing neonatal sepsis, with an area under the receiver operating characteristic curve (AUC) of 0.86.\n6. Mean platelet volume (MPV): It has a moderate sensitivity and specificity for diagnosing neonatal sepsis, with an AUC of 0.81.\n7. Red cell distribution width (RDW): It has a moderate sensitivity and specificity for diagnosing neonatal sepsis, with an AUC of 0.76.\n\nThese biomarkers can be used in combination to improve the accuracy of diagnosis in low-income countries where resources may be limited.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer mentions several biomarkers (PCT, CRP, WBC, ESR, PDW, MPV, RDW), which goes beyond the biomarkers listed in the reference answers (only CRP and PCT). However, it omits specific thresholds for CRP (≥60 mg/L) and PCT (≥0.5 ng/mL) mentioned in some reference answers. The inclusion of non-recommended biomarkers like ESR also affects recall negatively.",
        "Information Precision Score": 2,
        "Information Precision Explanation": "The answer includes biomarkers (e.g., ESR, WBC) that are not mentioned in the reference answers or are explicitly stated as non-specific (ESR). The inclusion of less relevant details like AUC values for PDW, MPV, and RDW, which are not mentioned in the references, further reduces precision.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times, though it lists multiple biomarkers with varying levels of detail, which avoids repetition.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-structured, clearly listing each biomarker with its associated diagnostic properties (sensitivity, specificity, AUC). However, the inclusion of less relevant details slightly impacts readability as it detracts from the key points."
    },
    {
        "Question": "What is the mechanism of action of Mirikizumab?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the mechanism of action of Mirikizumab?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Mirikizumab is a humanized IgG4 monoclonal antibody against the p19 subunit of IL-23.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the mechanism of action of Mirikizumab is to selectively inhibit the activity of interleukin-23 (IL-23). Mirikizumab is a monoclonal antibody that targets the p19 subunit of IL-23, which is a cytokine that plays a key role in the immune system and is involved in the pathogenesis of various inflammatory and autoimmune diseases, including ulcerative colitis.\n\nAccording to the data, Mirikizumab works by modulating the biological pathways involved in resistance to antitumor necrosis factor and Janus kinase inhibitors, and by downregulating transcripts associated with ulcerative colitis disease activity.\n\nThe data also suggests that Mirikizumab induces a distinct molecular healing pathway associated with IL-23 inhibition, which is characterized by changes in gene expression that correlate with clinical, endoscopic, and molecular healing in ulcerative colitis.\n\nTherefore, the mechanism of action of Mirikizumab can be summarized as:\n\n* Selective inhibition of interleukin-23 (IL-23)\n* Modulation of biological pathways involved in resistance to antitumor necrosis factor and Janus kinase inhibitors\n* Downregulation of transcripts associated with ulcerative colitis disease activity\n* Induction of a distinct molecular healing pathway associated with IL-23 inhibition.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer comprehensively covers all necessary details about the mechanism of action of Mirikizumab. It mentions the selective inhibition of IL-23, the targeting of the p19 subunit, modulation of biological pathways, downregulation of transcripts, and induction of a molecular healing pathway. All these points are accurately reported, matching the reference answer while expanding with additional relevant details.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer is precise and mostly relevant, focusing on the mechanism of action of Mirikizumab. However, it includes slightly more details than the reference answer, such as the broader implications in inflammatory diseases and ulcerative colitis, which, while useful, could be considered additional rather than strictly necessary for explaining the mechanism of action.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat the same information. Each point is distinct and contributes to a full understanding of the mechanism of action without redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand. The use of bullet points at the end helps clarify the summary of the mechanism, enhancing readability."
    },
    {
        "Question": "What clinical indications does the self-expanding colon stent have in colorectal cancer patients?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat clinical indications does the self-expanding colon stent have in colorectal cancer patients?\n\nHere are some reference answers:\n\n**Reference Answers:**\n[\"This technique can be used in the palliation of malignant colorectal obstruction, as a bridge to elective surgery for resectable colorectal cancers, palliation of extracolonic malignant obstruction, and for nonmalignant etiologies such as anastomotic strictures, Crohn's disease, radiation therapy, and diverticular diseases\", \"According to the abstracts, self-expanding metallic stents (SEMS) have several clinical indications in colorectal cancer patients. These include: , 1. Palliation of malignant colorectal obstruction: SEMS can relieve obstruction and improve quality of life., 2. Bridge to elective surgery for resectable colorectal cancers: SEMS can be used to decompress the bowel, allowing for elective surgery instead of emergency surgery with colostomy., 3. Palliation of extracolonic malignant obstruction: SEMS can also be used to relieve obstruction caused by extracolonic malignancies., 4. Non-malignant etiologies such as anastomotic strictures, Crohn's disease, radiation therapy, and diverticular diseases. , Overall, SEMS provide a safe and effective minimally invasive treatment option for colorectal cancer patients with malignant obstruction, offering advantages over emergency surgery, including shorter hospitalization, reduced morbidity, and improved quality of life.\", '1. It is used in palliative treatment of patients with obstructing colorectal cancer to relieve bowel obstruction\\n2. It can be used as a bridge to surgery, allowing for colonic decompression and bowel preparation prior to surgery\\n3. In emergency situations, it can be used to bypass a malignant obstruction\\n4. It is used for chemotherapy drug delivery by drug-loaded membrane coated stents\\n5. It can be used to prevent anastomotic leakage and/or avoid protective stoma', 'The self-expanding colon stent has clinical indications in colorectal cancer patients for the management of obstruction, perforation, bleeding, and fistula. However, it is not recommended to use self-expanding metallic stent as a palliative treatment for obstruction in patients treated or being considered for treatment with antiangiogenic agents such as bevacizumab due to the high risk of perforation.', \"The self-expanding colon stent is used in the treatment of colorectal cancer, particularly in cases where the cancer has caused a blockage in the colon. The stent is inserted into the colon to expand the blocked area, allowing for the passage of stool and relieving symptoms such as abdominal pain, bloating, and constipation. The use of self-expanding colon stents is typically reserved for patients who are not candidates for surgery or those who require palliative care. The stent can be inserted using a variety of methods, including endoscopy, fluoroscopy, or a combination of both. The procedure is generally well-tolerated, with a low risk of complications. However, stent placement may not be suitable for all patients, and careful consideration of the individual patient's condition and medical history is necessary before proceeding with the procedure.\", 'Self-expanding colon stents have been used in colorectal cancer patients for the treatment of obstructive large bowel cancers. The clinical indications for the use of self-expanding colon stents in colorectal cancer patients include malignant colorectal stenosis, which is a common complication of colorectal cancer. The self-expanding colon stent is a minimally invasive procedure that can be used to relieve obstruction in patients with colorectal cancer, improving their quality of life and reducing the risk of complications such as bowel obstruction, perforation, and ischemia.', 'Self-expanding colon stents are indicated for acute large bowel obstruction in colorectal cancer patients with distal malignant obstruction due to the possibility of irreversible obstruction and colonic ischemia. They are also used for palliation of incurable colorectal cancer and to provide bowel decompression before an elective resection of the tumor, as well as a bridge to resection.', 'The self-expanding colon stent has clinical indications in colorectal cancer patients for \"malignant colorectal obstruction, malignant colonic obstruction, left-sided colonic obstruction, bridge to surgery, acute colonic decompression, palliative treatment, palliation of malignant colorectal obstruction, and palliation of extracolonic malignant obstruction\".', 'The self-expanding colon stent is used for achieving acute colonic decompression in obstructed colorectal cancer. It offers nonoperative, immediate, and effective colon decompression and allows bowel preparation for an elective oncologic resection. It is particularly beneficial for high-risk surgical patients and candidates for laparoscopic resection with complete obstruction, as emergency surgery can be avoided in more than 90% of patients. Additionally, it provides effective palliation of malignant colonic obstruction, although it carries risks of delayed complications. It can also be used in selected patients with benign colonic strictures. However, the feasibility of endoscopic resection for synchronous early colon cancer after placement of self-expandable metallic stents for malignant colorectal obstruction is unknown.', \"The self-expanding colon stent is used in colorectal cancer patients for achieving acute colonic decompression in obstructed colorectal cancer, allowing bowel preparation for an elective oncologic resection. It is particularly beneficial for high-risk surgical patients and candidates for laparoscopic resection with complete obstruction, as emergency surgery can be avoided in more than 90% of patients. Additionally, it offers effective palliation of malignant colonic obstruction, although it carries risks of delayed complications. It can also be used in selected patients with benign colonic strictures. The procedure is typically performed by experienced endoscopists with a high technical success rate and low procedural complication rate. However, it is not a curative treatment for colorectal cancer and regular follow-up and monitoring are required to assess the stent's effectiveness and to manage any potential complications.\", '1) As a palliation in advanced colorectal cancer 2) As a bridge to surgery for malignant colonic obstruction', \"The self-expanding colon stent has four main clinical indications in colorectal cancer patients: 1) Palliation of malignant colorectal obstruction by relieving blockages and improving quality of life, 2) Bridge to elective surgery for resectable cancers by decompressing the bowel, allowing for planned surgeries instead of emergencies with colostomy, 3) Palliation of extracolonic malignant obstruction caused by non-colorectal cancer blockages and 4) Non-malignant etiologies such as anastomotic strictures, Crohn's disease, radiation therapy, and diverticular diseases. It is a safe and effective minimally invasive treatment option that offers shorter hospitalization, reduced morbidity, and improved quality of life compared to emergency surgery.\", 'The self-expanding colon stent has two main clinical indications in colorectal cancer patients. Firstly, it can be used as a bridge to surgery, where it is inserted to alleviate symptoms of obstruction and enable elective surgical resection at a later date. This approach reduces the need for emergency surgery, which is associated with higher rates of complications, colostomy creation, and mortality compared to elective surgery. Secondly, colonic stents can be used for palliative treatment in patients who are not suitable for or do not wish to undergo surgical resection. The stent provides symptomatic relief from obstruction, improves quality of life, and may reduce the need for colostomy creation. However, complications such as stent re-occlusion, migration, and perforation can occur, highlighting the importance of good preparation, adequate staffing, backup systems, and informed consent. The current evidence on long-term prognosis for bridge to', 'The self-expanding colon stent has clinical indications in colorectal cancer patients for the management of obstruction, perforation, bleeding, and fistula.', 'Self-expanding colon stents have been used in colorectal cancer patients for the treatment of obstructive large bowel cancers. The clinical indications for the use of self-expanding colon stents in colorectal cancer patients include malignant colorectal stenosis, which is a common complication of colorectal cancer. The self-expanding colon stent is a minimally invasive procedure that can be used to relieve obstruction in patients with colorectal cancer, improving their quality of life and survival.', 'The self-expanding colon stent is indicated for palliation and as a bridge to elective surgery in patients with obstructive colorectal cancers. It can reduce the risk of early complications, mortality, stoma creation rate, and shorten hospital stay.', \"Self-expanding metallic stents (SEMS) have three main clinical indications in colorectal cancer patients: 1. Palliation of malignant colorectal obstruction to relieve blockage and improve quality of life, 2. Bridge to elective surgery for resectable cancers by reducing complications, mortality, stoma creation rate, and hospital stay duration, and 3. Palliation of extracolonic malignant obstruction in non-malignant etiologies such as strictures, Crohn's disease, radiation therapy, or diverticular diseases. Overall, SEMS are considered a safe and effective treatment for colorectal cancer-related obstructions, offering advantages over surgery in specific indications.\", 'The self-expanding colon stent is clinically indicated in colorectal cancer patients for the palliative treatment of obstructive primary advanced colorectal cancer. Its advantages over emergency surgery with colostomy include avoidance of colostomy, relief of obstruction, shorter hospitalization, and better quality of life. Additionally, stent placement can be used as a bridge to surgery, allowing for a shorter duration of hospitalization, lower postoperative complications, colostomy rates, and mortality rates compared to emergency surgery. However, it is important to note that despite recent studies reporting low complication rates related to colonic stents, complications can still occur, highlighting the importance of good preparation, adequate staffing, backup systems, and informed consent. The long-term prognosis of patients with bridge to surgery purposes is currently not well-established, with ongoing clinical research needed.', 'Self-expanding colon stents are used in colorectal cancer patients for achieving acute colonic decompression in obstructed colorectal cancer, offering nonoperative, immediate, and effective colon decompression and allowing bowel preparation for an elective oncologic resection. They are particularly beneficial for high-risk surgical patients and candidates for laparoscopic resection with complete obstruction, as emergency surgery can be avoided in more than 90% of patients. Colonic stent placement also offers effective palliation of malignant colonic obstruction, although it carries risks of delayed complications. When performed by experienced endoscopists, the technical success rate is high with a low procedural complication rate. Despite concerns of tumor seeding following endoscopic colorectal stent placement, no difference exists in oncologic long-term survival between patients who undergo stent placement followed by elective resection and those undergoing emergency bowel resection. Colorectal stents have also been used in selected patients with benign colonic strictures.', \"According to the abstracts, self-expanding metallic stents (SEMS) have several clinical indications in colorectal cancer patients. These include palliation of malignant colorectal obstruction, bridge to elective surgery for resectable colorectal cancers, and palliation of extracolonic malignant obstruction. Additionally, SEMS can be used for non-malignant etiologies such as anastomotic strictures, Crohn's disease, radiation therapy, and diverticular diseases. The stents can also provide feasible outcomes for patients with obstructive unresectable colorectal cancer as palliative treatment. Overall, the indications highlight the versatility of SEMS in managing various aspects of colorectal cancer, including malignant obstruction, surgical preparation, and symptom relief.\", 'The self-expanding colon stent is used for malignant colorectal obstruction and malignant colonic obstruction in colorectal cancer patients.', 'Based on the provided information, self-expanding colon stents have two main clinical indications in colorectal cancer patients:\\n\\n1. As a bridge to surgery: In patients with acute colonic obstruction due to colorectal cancer, stent placement can achieve immediate decompression and allow for bowel preparation before an elective oncologic resection. This is especially beneficial for high-risk surgical patients and those requiring laparoscopic resection.\\n\\n2. For palliation: In patients with incurable colorectal cancer, stent placement offers effective palliation of malignant colonic obstruction and its associated symptoms. It can improve quality of life when curative treatment is not possible.\\n\\nThe technical success rate of stent placement is high with a low procedural complication rate when performed by experienced endoscopists. Long-term oncologic outcomes are comparable between patients undergoing stent placement followed by elective resection and those undergoing emergency bowel resection.', \"The self-expanding metal stent (SEMS) has several clinical indications in colorectal cancer patients. It is recommended for palliation in patients with colonic obstruction from incurable colorectal cancer or extracolonic malignancy, providing effective and safe decompression. SEMS also serves as a bridge to surgery in high-risk patients, allowing them to undergo elective surgery instead of emergency procedures. , Additionally, SEMS can be used in the management of nonmalignant etiologies such as anastomotic strictures, Crohn's disease, radiation therapy, and diverticular diseases. However, the use of SEMS in patients receiving antiangiogenic agents like bevacizumab is not recommended due to the high risk of perforation. , The decision to use SEMS should involve careful clinical evaluation, considering the patient's condition, the type and stage of cancer, and potential risks and benefits.\", \"1. Palliation of malignant colorectal obstruction, 2. Bridge to elective surgery for resectable colorectal cancers, 3. Palliation of extracolonic malignant obstruction, 4. Nonmalignant etiologies such as anastomotic strictures, Crohn's disease, radiation therapy, and diverticular diseases\", \"The self-expanding colon stent (SEMS) is a technique that can be used in various clinical scenarios for colorectal cancer patients. Based on recent evidence, SEMS is recommended for palliation in patients with colonic obstruction from incurable colorectal cancer or extracolonic malignancy. It can also be used as a bridge to surgery in patients who are at a high surgical risk, allowing for elective surgery to be performed in a more stable condition. Additionally, SEMS may be utilized for nonmalignant etiologies such as anastomotic strictures, Crohn's disease, radiation therapy, and diverticular diseases. Therefore, SEMS can play a crucial role in the management of colorectal cancer and related conditions, providing symptom relief and improving clinical outcomes.\", \"The self-expanding colon stent is clinically indicated for palliation of malignant colorectal obstruction, as a bridge to elective surgery for resectable colorectal cancers, palliation of extracolonic malignant obstruction, and for nonmalignant etiologies such as anastomotic strictures, Crohn's disease, radiation therapy, and diverticular diseases.\", 'Colorectal self-expanding metal stents (SEMS) can be used for malignant colorectal obstruction, colonic obstruction, palliation of extracolonic malignant obstruction, colonic obstruction from incurable colorectal cancer or extracolonic malignancy, for nonmalignant etiologies such as anastomotic strictures, palliation of malignant colorectal obstruction, as a bridge to elective surgery for resectable colorectal cancers, and also as a bridge to surgery.', \"The self-expanding colon stent (SECS) is a palliative treatment option for patients with incurable colorectal cancer or extracolonic malignancy causing colonic obstruction. SECS has been shown to be effective in improving symptoms and quality of life in these patients. The clinical indications for SECS in colorectal cancer patients include:Palliation of malignant colorectal obstruction: SECS can be used to relieve symptoms such as abdominal pain, nausea, and vomiting in patients with incurable colorectal cancer.Bridge to surgery: SECS can be used as a bridge to elective surgery for resectable colorectal cancers, allowing patients to undergo surgical resection while avoiding the risks associated with palliative surgery.Palliation of extracolonic malignant obstruction: SECS can be used to relieve symptoms in patients with extracolonic malignancies such as pancreatic or lung cancer that are causing colonic obstruction.Nonmalignant etiologies: SECS can be used to treat nonmalignant etiologies such as anastomotic strictures, Crohn's disease, radiation therapy, and diverticular diseases.\", \"The self-expanding metal stent (SEMS) in colorectal cancer patients is used for several clinical indications. It can be utilized for palliation in cases of malignant colorectal obstruction when the cancer is incurable. It's also recommended as a bridge to surgery for those with resectable colorectal cancers who are at high surgical risk. This approach helps manage the obstruction and improves the patient's condition before they undergo definitive surgery.\", 'The self-expanding colon stent has clinical indications in colorectal cancer patients for the palliation of malignant colorectal obstruction, as a bridge to elective surgery for resectable colorectal cancers, and for the palliation of extracolonic malignant obstruction.', \"The self-expanding colon stent is used for the palliation of patients with colonic obstruction from incurable colorectal cancer or extracolonic malignancy. It is also used as a bridge to surgery in those who are a high surgical risk, for palliation of extracolonic malignant obstruction, and in patients with nonmalignant etiologies such as anastomotic strictures, Crohn's disease, radiation therapy, and diverticular diseases.\", ' Overall, self-expanding colon stenting is a viable treatment option for colorectal cancer patients with appropriate clinical indications. ', \"The clinical indications that the self-expanding colon stent has in colorectal cancer patients include palliation of malignant colorectal obstruction, palliation of extracolonic malignant obstruction, bridge to elective surgery for resectable colorectal cancers, Crohn's disease, and anastomotic strictures.\", \"Self-expanding colon stents (SEMS) are recommended for palliation of colonic obstruction in patients with incurable colorectal cancer or extracolonic malignancy. Additionally, SEMS can be used as a bridge to surgery in high surgical risk patients with resectable colorectal cancers. SEMS are also used for palliation of nonmalignant etiologies such as anastomotic strictures, Crohn's disease, radiation therapy, and diverticular diseases.\", 'Self-expanding colon stents are used in colorectal cancer patients primarily for two purposes: as a palliative treatment for those with incurable colorectal cancer causing obstruction, and as a bridge to surgery for those who are high surgical risks, allowing time to stabilize and optimize their condition before undergoing potentially curative surgery', 'Self-expanding colon stents (SEMS) are used in colorectal cancer patients for palliative treatment of obstructive symptoms caused by the cancer. They are typically used in patients who are not candidates for surgery or when surgery is not immediately available. Clinical indications for colon stent placement in colorectal cancer patients include alleviating bowel obstruction, improving stool passage, and enhancing quality of life. Stenting can help avoid or postpone the need for surgical intervention, particularly in individuals with advanced or metastatic disease. SEMS are recommended for the palliation of patients with colonic obstruction from incurable colorectal cancer or extracolonic malignancy and also as a bridge to surgery in those who are a high surgical risk.', 'The self-expanding metal stent (SEMS) is used in colorectal cancer patients primarily for two reasons: as a palliative measure in cases of colonic obstruction from incurable colorectal cancer or extracolonic malignancy, and as a bridge to surgery for those who are considered high surgical risk. This allows for temporary relief from symptoms and stabilization before more definitive surgical treatment can be undertaken.', \"The self-expanding colon stent is used in patients with malignant colorectal obstruction (1) for palliation, (2) as a bridge to elective surgery, (3) for the palliation of extracolonic malignant obstruction and (4) for nonmalignant etiologies such as anastomotic strictures, Crohn's disease, radiation therapy, and diverticular diseases.\", \"The self-expanding colon stent (SEMS) has clinical indications in colorectal cancer patients for palliation of malignant colorectal obstruction, as a bridge to elective surgery for resectable colorectal cancers, palliation of extracolonic malignant obstruction, and for nonmalignant etiologies such as anastomotic strictures, Crohn's disease, radiation therapy, and diverticular diseases.\", \"Self-expanding colon stents are used for palliating malignant colorectal obstruction, serving as a bridge to surgery in resectable cases, palliating extracolonic malignancies' obstruction, and treating nonmalignant conditions like anastomotic strictures and complications from Crohn's disease, radiation therapy, and diverticular diseases.\", \"The self-expanding colon stent (SEMS) has several indications for colorectal cancer patients: palliation in advanced cases with obstruction; a bridge to surgery for high-risk patients; management of nonmalignant strictures, Crohn's disease, radiation therapy, and diverticular diseases. However, it is not recommended for patients on antiangiogenic agents like bevacizumab due to perforation risk. The use should consider individual patient factors and the type/stage of cancer with potential benefits weighed against risks.\", \"Self-expanding colon stents (SEMS) are used for palliation in patients with nonresectable or extracolonic malignancies causing colonic obstructions, as a bridge to surgery for high-risk resectable colorectal cancers, and for alleviating nonmalignant strictures including anastomotic strictures, Crohn's disease, radiation therapy effects, and diverticular diseases. SEMS aims to improve patient quality of life by relieving obstructions while reducing surgical risks in some cases.\", 'The self-expanding colon stent (SEMS) is recommended for use in colorectal cancer patients primarily for two clinical indications: as a palliative measure in patients with colonic obstruction from incurable colorectal cancer or extracolonic malignancy, and as a bridge to surgery for those who are at high surgical risk.', 'The self-expanding metallic stent in colorectal cancer patients is clinically indicated for the palliation of malignant colorectal obstruction, as a bridge to elective surgery for resectable colorectal cancers, and for palliation of extracolonic malignant obstruction. However, it is not recommended for patients treated or being considered for treatment with antiangiogenic agents such as bevacizumab due to the high risk of perforation.', 'The self-expanding colon stent has been used in colorectal cancer patients for palliation of obstructive symptoms, and it has been shown to be effective in relieving symptoms and improving quality of life in patients with advanced colorectal cancer. The stent is particularly useful in patients with obstructive symptoms due to tumor invasion or adhesions, and it can be used in combination with chemotherapy to improve treatment outcomes. Additionally, the stent can be used in patients with rectal cancer to relieve symptoms and improve quality of life in patients with advanced rectal cancer.', \"The self-expanding colon stent has four primary clinical indications for colorectal cancer patients: 1) Palliation of malignant colorectal obstruction in those with advanced or extracolonic cancers, 2) Bridge to surgery in high-risk patients, 3) Management of non-malignant conditions like strictures and Crohn's disease, and 4) Palliation for extracolonic malignancies causing bowel obstructions. The stent aims to relieve blockages while minimizing complications such as perforation or bleeding.\", \"The self-expanding colon stent has clinical indications in colorectal cancer patients for the palliation of malignant colorectal obstruction, as a bridge to elective surgery for resectable colorectal cancers, palliation of extracolonic malignant obstruction, and for nonmalignant etiologies such as anastomotic strictures, Crohn's disease, radiation therapy, and diverticular diseases. It is also recommended for the palliation of patients with colonic obstruction from incurable colorectal cancer or extracolonic malignancy and as a bridge to surgery in those who are a high surgical risk.\", \"The self-expanding colon stent (SEMS) has several clinical indications for colorectal cancer patients. According to recent evidence, SEMS is recommended for palliation in patients with colonic obstruction from incurable colorectal cancer or extracolonic malignancy. It serves as a bridge to surgery for resectable colorectal cancers in individuals who are high surgical risks. Furthermore, SEMS is also used for nonmalignant etiologies such as anastomotic strictures, Crohn's disease, radiation therapy, and diverticular diseases. The primary objective of using SEMS in these clinical scenarios is to alleviate malignant colorectal obstruction and improve the patient's quality of life while potentially reducing surgical risks.\", 'The self-expanding colon stent is/are/can be used in palliation of malignant colorectal obstruction, as a bridge to elective surgery for resectable colorectal cancers, and for palliation of extracolonic malignant obstruction.', 'The main clinical indications for self-expanding colon stents in colorectal cancer patients are:\\n\\n1. Palliation of malignant colorectal obstruction in patients with incurable colorectal cancer or extracolonic malignancy. The stent helps relieve the obstruction and associated symptoms.\\n\\n2. As a bridge to elective surgery in colorectal cancer patients who are at high surgical risk. The stent allows relief of the obstruction before definitive surgical treatment.\\n\\n3. Treatment of complications related to colorectal cancer such as colonic perforations. \\n\\n4. Addressing issues with previously placed colonic stents, like tumor ingrowth or overgrowth, stent fracture or migration.', 'The self-expanding colon stent is used for palliation in patients with incurable colorectal cancer causing obstruction, and as a bridge to surgery for those who are high surgical risks.', 'The self-expanding colon stent (SEMS) is clinically indicated in colorectal cancer patients for the palliation of malignant colorectal obstruction, as a bridge to elective surgery for resectable colorectal cancers, and for the palliation of patients with colonic obstruction from incurable colorectal cancer or extracolonic malignancy, particularly in those who are at high surgical risk.', \"The self-expanding colon stent has clinical indications in colorectal cancer patients for palliation of malignant colorectal obstruction, as a bridge to elective surgery for resectable colorectal cancers, palliation of extracolonic malignant obstruction, and for nonmalignant etiologies such as anastomotic strictures, Crohn's disease, radiation therapy, and diverticular diseases.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data tables, the self-expanding colon stent has the following clinical indications in colorectal cancer patients:\n\n1. **Relief of malignant colonic obstruction**: The stent is used to relieve obstruction caused by colorectal cancer, allowing for the passage of stool and relieving symptoms (e.g., abdominal pain, constipation, and vomiting).\n2. **Bridge to surgery**: The stent is used as a bridge to surgery in cases of malignant large bowel obstruction, allowing for the relief of obstruction and potential cure of the disease.\n3. **Palliation of malignant colonic obstruction**: The stent offers palliation of malignant colonic obstruction, improving quality of life and relieving symptoms.\n4. **Decompression of the colon**: The stent is used to decompress the colon in patients with large bowel obstruction, allowing for bowel preparation for elective surgery.\n5. **Treatment of colonic obstruction**: The stent is used to treat colonic obstruction, including cases caused by colorectal cancer.\n\nThese indications are supported by various studies and clinical trials, including:\n\n* \"Colorectal stenting offers nonoperative, immediate, and effective colon decompression and allows bowel preparation for an elective oncologic resection.\" (Source: Update on the indications and use of colonic stents)\n* \"Colonic stenting is used as a bridge to surgery in cases of malignant large bowel obstruction, allowing for the relief of obstruction and potential cure of the disease.\" (Source: Implications of genetic testing in the management of colorectal cancer)\n* \"Self-expanding metal stents are used as a palliative treatment for malignant colorectal obstruction.\" (Source: Treatment of patients with metastatic colorectal cancer and poor performance status: current evidence and challenges)\n\nNote that these indications are based on the provided data tables and may not be an exhaustive list of all possible clinical indications for self-expanding colon stents in colorectal cancer patients.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "4",
        "Information Recall Explanation": "The answer captures most of the key clinical indications for self-expanding colon stents in colorectal cancer patients, including relief of malignant obstruction, bridge to surgery, palliation, and decompression. However, it misses some additional indications mentioned in the references, such as palliation of extracolonic malignant obstruction and use in non-malignant etiologies like strictures or Crohn's disease.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The information provided is relevant and avoids extensive irrelevant details, but some redundancy is observed (e.g., mentions of decompression/relief of obstruction overlap with other points).",
        "Information Repetition Score": "3",
        "Information Repetition Explanation": "There is some repetition in the answer, such as the overlapping indications for decompression (point 4) and relief of obstruction (point 1), which could be streamlined. Additionally, 'treatment of colonic obstruction' (point 5) is somewhat redundant with prior items.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-organized, clearly worded, and easy to follow. Supporting evidence is appropriately cited, enhancing clarity and trustworthiness."
    },
    {
        "Question": "List the cells which have CD21 on the surface.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nList the cells which have CD21 on the surface.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['CD21 is produced by B cells and follicular dendritic cells, where it binds cleavage products of the C3 complement protein.', 'B cells have CD21 on the surface.', 'B cells, follicular dendritic cells, T lymphocytes, lymphocytes, external ocular tissues, similar to other MALT, the T cell lines Jurkat, Ramos are cells that have CD21 on the surface.', 'CD21 is expressed on the surface of B cells and follicular dendritic cells.', 'The cells which have CD21 on the surface are follicular dendritic cells, B lymphocytes, and B cells.', 'CD21 is a cell surface protein that is expressed on the surface of B cells.', 'B lymphocytes, T cells, B cells, memory B cells, follicular dendritic cells, external ocular tissues, CD19+ CD10- CD27- CD21lo B cells, and lymphocytes have CD21 on the surface.', 'CD21, also known as CR2, is primarily expressed on the surface of mature B cells and follicular dendritic cells.', 'CD21 is found on the surface of B cells and follicular dendritic cells.', 'B lymphocytes and follicular dendritic cells have CD21 on the surface.', 'CD21 is primarily expressed on B lymphocytes and follicular dendritic cells, but has also been reported on T cells.', 'The cells which have CD21 on the surface are follicular dendritic cells and B lymphocytes.', 'B cells and follicular dendritic cells have CD21 on their surface.', 'Follicular dendritic cells, complement receptor 2, CD81, CD19, and B cells can be cells which have CD21 on the surface.', 'The cells which have CD21 on the surface are follicular dendritic cells and B cells.', 'Cells which have CD21 on the surface include follicular dendritic cells, B cells, complement receptor 2, CD81, CD19, activated B cells, CD21(+) CD27(+) memory B cells, and classical B2 cells.', 'CD21 is found on the surface of B cells and follicular dendritic cells', 'CD21 is a protein found on the surface of B cells and follicular dendritic cells (FDCs).', 'B cells and follicular dendritic cells have CD21 on the surface.', 'The cells which have CD21 on the surface are B cells and follicular dendritic cells.', 'CD21, also known as complement receptor 2, is produced by and found on the surface of B cells and follicular dendritic cells.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the cells that have CD21 on the surface are:\n\n* B-lymphocytes\n* Follicular dendritic cells\n* T cells (in some cases, particularly in the presence of Epstein-Barr virus nuclear antigen-2 (EBNA2))\n* Jurkat cells (a type of T cell line)\n* CD21(LOW) B cells (a subset of B cells with a unique phenotype)\n* B cells in patients with myasthenia gravis (specifically, AchR specified B cells)\n\nNote that the surface expression of CD21 can vary depending on the context and the presence of certain factors, such as EBNA2.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively lists cells with CD21 surface expression, including B-lymphocytes, follicular dendritic cells, T cells, Jurkat cells, CD21(LOW) B cells, and B cells in myasthenia gravis patients. It also notes context-dependent variations, aligning well with the reference answers.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise, focusing on CD21-expressing cells with relevant contextual details (e.g., EBNA2 influence). While highly accurate, the inclusion of specific conditions (e.g., myasthenia gravis) slightly deviates from the general focus of the reference answers.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information. Each cell type or condition is mentioned once, and the answer is concise.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clearly itemized, and uses fluent language. The note about context-dependent variations enhances clarity without compromising readability."
    },
    {
        "Question": "Do PPIs increase the risk of gastric cancer?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nDo PPIs increase the risk of gastric cancer?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Proton pump inhibitors have been associated with a higher risk of gastric cancer.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, the answer is yes. A population-based cohort study using the UK Clinical Practice Research Datalink found that new users of proton pump inhibitors (PPIs) had a 45% increased risk of gastric cancer compared to new users of histamine-2 receptor antagonists (H2RAs). The number needed to harm was estimated to be 2121 and 1191 for five and 10 years after treatment initiation, respectively. The risk increased with cumulative duration, cumulative omeprazole equivalents, and time since treatment initiation.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer provides all necessary information regarding the association between PPIs and gastric cancer. It includes details from a specific study (UK Clinical Practice Research Datalink), statistical measures (45% increased risk, number needed to harm), and factors like cumulative duration and omeprazole equivalents.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise, focusing solely on the risk of gastric cancer associated with PPIs. It does not include any irrelevant information.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information. Each piece of data provided is unique and contributes to the understanding of the topic.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is readable and fluent but could be slightly improved by simplifying some of the statistical terms (e.g., 'number needed to harm') for broader accessibility."
    },
    {
        "Question": "Can enhancers act as promoters?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nCan enhancers act as promoters?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['It is generally assumed that there is a clear distinction between promoters, which initiate transcription, and enhancers, which control the spatiotemporal expression. However, studies have unexpectedly shown that regulatory elements can have both enhancer and promoter functions.\\nFor example, some enhancers (mainly bidirectional) can act as weak promoters, producing overlapping spatiotemporal expression. Conversely, bidirectional promoters often act as strong enhancers, while unidirectional promoters generally cannot.', 'Enhancers and promoters are cis-regulatory elements in the genome that regulate target gene transcription. While traditionally considered distinct, recent evidence suggests that there is overlap between their functions. Some enhancers, particularly bidirectional ones, can act as weak promoters, producing overlapping spatio-temporal expression. Conversely, some promoters, especially bidirectional ones, can function as strong enhancers. The balance between enhancer and promoter activity is reflected in the levels and directionality of enhancer RNA (eRNA) transcription, which is likely an inherent sequence property of the elements themselves. These observations suggest that enhancers and promoters may lie on a spectrum of transcriptional regulation, rather than being strictly separate entities. However, more research is needed to fully understand the mechanisms and implications of this relationship.', 'While enhancers and promoters have distinct canonical functions, there is evidence that enhancers can sometimes act as weak promoters in addition to their primary role of augmenting transcription from target promoters:\\n\\n- Some enhancers are transcribed, producing enhancer RNAs (eRNAs), before activating their target promoter. This suggests enhancers can directly recruit transcriptional machinery.\\n\\n- Certain DNA elements have been found to possess both enhancer and promoter activity, blurring the line between the two.\\n\\n- Enhancers and promoters share some features like transcription factor binding, open chromatin, and transcriptional activity.\\n\\nSo while enhancers mainly serve to boost transcription from promoters, they can occasionally act as weak promoters themselves. The boundary between enhancers and promoters is not always clear cut, with some overlap in their functions and characteristics. However, their primary roles remain distinct, with promoters directly initiating transcription and enhancers mainly augmenting promoter activity.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, there is evidence that enhancers can act as promoters in certain contexts. \n\nA study mentioned in the \"Sources\" table (entry 20) proposes a model where promoters and enhancers are considered a single class of functional element, with a unified architecture for transcription initiation. This suggests that enhancers can have both enhancer and promoter functions, and can drive transcription initiation.\n\nAdditionally, another study (entry 131) states that \"Intragenic enhancers can act as alternative tissue-specific promoters.\" This implies that enhancers can function as promoters in specific tissues or contexts.\n\nHowever, it is worth noting that the relationship between enhancers and promoters is complex, and enhancers are typically thought to act at a distance from the promoter to enhance gene expression, rather than directly initiating transcription.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately recalls the necessary information from the reference answers, highlighting the dual functions of enhancers and promoters, and providing specific examples and studies that support this overlap.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include irrelevant information. It focuses on the key points about the dual functionality of enhancers and promoters, and the complexity of their relationship.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. Each point made is distinct and contributes to a comprehensive understanding of the topic.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is easily readable and fluent. The information is presented in a clear and logical manner, making it accessible to the reader."
    },
    {
        "Question": "How is pain treated in patients with Ehlers-Danlos Syndrome?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nHow is pain treated in patients with Ehlers-Danlos Syndrome?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Treatment of pain in Ehlers-Danlos Syndrome patients requires a multidisciplinary approach which includes physical therapy, psychotherapy, pharmacotherapy and interventional pain procedures such as trigger point injections, peripheral nerve block, radiofrequency ablation and peripheral nerve stimulation.', 'Pain in patients with Ehlers-Danlos Syndrome is treated using a multidisciplinary approach that includes physical therapy, psychotherapy, pharmacotherapy, and interventional pain procedures such as trigger point injections, peripheral nerve block, radiofrequency ablation, and peripheral nerve stimulation.', 'Since Ehlers-Danlos Syndrome (EDS) associated chronic pain is multifactorial in origin, treatment requires a multidisciplinary approach which includes physical therapy, psychotherapy, pharmacotherapy and interventional pain procedures such as trigger point injections, peripheral nerve block, radiofrequency ablation and peripheral nerve stimulation.', 'Pain in patients with Ehlers-Danlos Syndrome (hEDS) is treated using a multidisciplinary approach. This includes physical therapy, psychotherapy, pharmacotherapy, and interventional pain procedures. The interventional procedures may include trigger point injections, peripheral nerve block, radiofrequency ablation, and peripheral nerve stimulation.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nPain management in patients with Ehlers-Danlos Syndrome (EDS) is a complex and multifaceted process that often requires a multidisciplinary approach. The treatment of pain in EDS patients involves a combination of pharmacological, non-pharmacological, and lifestyle modifications. \n\nAccording to the provided data, patients with EDS often experience chronic pain, which can be managed through various treatments, including medications, physical therapy, occupational therapy, cognitive behavioral therapy, and pain self-management sessions. \n\nSome medications used to alleviate pain in EDS patients include duloxetine, which has been found to alleviate oxaliplatin-induced peripheral neuropathy by regulating p53-mediated apoptosis. Thrombomodulin alfa has also been shown to prevent oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity.\n\nPhysical therapy and occupational therapy can help improve joint mobility, strength, and function, reducing pain and discomfort. Cognitive behavioral therapy and pain self-management sessions can also help patients cope with chronic pain and develop coping strategies.\n\nIt's worth noting that there is a lack of controlled clinical trials or good clinical practice recommendations for the management of chronic pain in EDS patients, and more research is needed to better understand the underlying mechanisms of pain in EDS and to develop effective treatment strategies.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers a broad range of treatments including pharmacological, non-pharmacological, and lifestyle modifications, which aligns well with the reference answers. It mentions physical therapy, cognitive behavioral therapy, and medications, but lacks specific interventional pain procedures like the reference answers do (e.g., trigger point injections, peripheral nerve block, etc.).",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer includes relevant information about pain management in EDS, but it also introduces details about specific medications (duloxetine, thrombomodulin alfa) and their mechanisms, which are not part of the reference answers and are somewhat tangential to the core question. This detracts from focus on EDS-specific pain treatments.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. Each section introduces a new aspect of pain management, though some points could be more concise (e.g., the explanation of medication mechanisms could be shortened).",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-structured and fluent, with clear transitions between sections. However, the inclusion of detailed pharmacological mechanisms slightly disrupts readability for a general audience."
    },
    {
        "Question": "Is Patisiran used for Transthyretin Cardiac Amyloidosis?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs Patisiran used for Transthyretin Cardiac Amyloidosis?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes. Patisiran can be used for Transthyretin Cardiac Amyloidosis']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, Patisiran is used to treat Transthyretin Cardiac Amyloidosis. According to the provided data, Patisiran is mentioned in the following relations:\n\n* \"Patisiran is used to treat Transthyretin Amyloidosis, which is caused by amyloid fibrils\" (relation 21)\n* \"Patisiran is used to treat hereditary transthyretin cardiac amyloidosis\" (relation 22)\n* \"Patisiran is a RNA-interfering drug effective in the treatment of ATTRh amyloidosis\" (relation 15)\n* \"Patisiran is a disease-modifying drug used to treat advanced heart failure with hereditary transthyretin cardiac amyloidosis\" (description of entity 11)\n\nAdditionally, Patisiran is also mentioned in several articles in the \"Sources\" section, which describe its use in treating Transthyretin Cardiac Amyloidosis, including:\n\n* \"Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy\"\n* \"Patisiran for advanced heart failure with hereditary transthyretin cardiac amyloidosis\"\n* \"Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis\"\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer includes all the necessary information about Patisiran's use in treating Transthyretin Cardiac Amyloidosis. It references specific relations and sources, providing a comprehensive overview.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information. Each statement is directly related to Patisiran's use for Transthyretin Cardiac Amyloidosis.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not repeat the exact information multiple times, but there is some overlap in the mentions of Patisiran's use for Transthyretin Cardiac Amyloidosis. However, this does not detract from the overall clarity.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured and easy to read. The use of bullet points and clear references to sources enhance the readability and fluency of the answer."
    },
    {
        "Question": "What are the molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer patients?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are the molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer patients?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Despite promising preclinical results, anti-angiogenic monotherapies led only to mild clinical benefits. The minimal benefits could be secondary to primary or acquired resistance, through the activation of alternative mechanisms that sustain tumor vascularization and growth. Mechanisms of resistance are categorized into VEGF-dependent alterations, non-VEGF pathways and stromal cell interactions. Resistance observed in several tumor types through alternative angiogenic \"escape\" pathways contributes to restoration of tumor growth and may induce progression, enhancement of invasion, and metastasis. Therefore, activation of major compensatory angiogenic pathways, sustaining tumor angiogenesis during VEGF blockade contributing to the recurrence of tumor growth overcome antiangiogenic strategies.', 'The molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer patients are not well understood. However, a study has suggested that germline polymorphisms in the degradation process may predict efficacy of cetuximab in patients with metastatic colorectal cancer (mCRC). The study found that UBE2M rs895374 was significantly associated with progression-free survival in cetuximab-treated patients, but not in bevacizumab-treated patients. Additionally, a recurrent focal amplification on chromosome 13q12.2 has been identified as a mechanism of resistance to bevacizumab therapy. This amplicon frequently emerges later during the clinical course of disease and is associated with more advanced stages. The minimally amplified region contains the gene POLR1D, which impacts cell proliferation and results in upregulation of VEGFA', 'Bevacizumab resistance is a major problem in advanced colorectal cancer patients that undergo first-line FOLFOX-bevacizumab treatment. Two main mechanisms are associated with this resistance: RAS mutations, especially KRAS mutations, which appear in a high percentage of patients, and MSI-high (Microsatellite Instability High) which is related to lower survival but not common in patients.', 'Secondary resistance to Bevacizumab in advanced colorectal cancer patients can be attributed to molecular mechanisms such as VEGF upregulation, Bevacizumab target mutation, and alteration of the tumor microenvironment. One specific mechanism is the upregulation of VEGF, which can be induced by Bevacizumab treatment, leading to resistance. Additionally, changes in the tumor microenvironment, such as extracellular matrix stiffening, can also contribute to Bevacizumab resistance.', 'E-selectin, cetuximab, PRSS, and VEFGR2 can be molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer patients.', 'The molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer patients include the upregulation of alternative pro-angiogenic signaling pathways, such as fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF), and the recruitment of pro-angiogenic bone marrow-derived cells, such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs). Additionally, hypoxia-induced adaptations within the tumor microenvironment, such as the upregulation of hypoxia-inducible factor 1-alpha (HIF-1α) and the promotion of epithelial-mesenchymal transition (EMT), can contribute to resistance. Genetic alterations within the tumor cells themselves, such as mutations in the PI3K/Akt/mTOR and RAS/RAF/MEK/ERK signaling pathways, can also promote tumor cell survival and proliferation, even in the presence of Bevacizumab.', 'Secondary resistance to bevacizumab in advanced colorectal cancer patients is mediated by the physical tumor microenvironment. ECM remodeling triggers lipid metabolic cross-talk between colon cancer cells and HSCs, leading to the development of a bevacizumab-resistant phenotype. This mechanism of resistance represents a major hurdle limiting bevacizumab efficacy, highlighting the importance of identifying a mechanism of antiangiogenic therapy resistance.', 'The molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer patients include alterations in the tumor microenvironment, such as extracellular matrix stiffening and the activation of hepatic stellate cells, which provide fuel for mCRC cells in the liver. Additionally, changes in the RAS status from wild type to mutant type and back can contribute to acquired resistance to anti-EGFR antibody drugs during treatment. Furthermore, PRSS expression levels are negatively associated with the sensitivity of cancer cells to cetuximab, as PRSS can cleave cetuximab, leading to resistance. Lastly, the emergence of a 13q12.2 amplicon under bevacizumab treatment is associated with therapy resistance.', '1. The increased expression of VEGF and/or increased activity of VEGFR2, bypassing the inhibitory effect of bevacizumab. 2. The activation of alternative angiogenic pathways, including FGF2, angiopoietin and interleukin 8. 3. An increase in intratumoral hypoxia, which has been associated with the activation of the Akt and NFkB pathways. 4. The enhanced invasiveness of tumor cells, including increased MMP activity. 5. The increased secretion of exosomes and the transfer of resistance factors.', 'Secondary resistance to Bevacizumab in advanced colorectal cancer patients is associated with molecular mechanisms such as ECM remodeling, lipid metabolic cross-talk between colon cancer cells and HSCs, and physical tumor heterogeneity.', 'The molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer patients include extracellular matrix stiffening, which drives resistance by stimulating hepatic stellate cells to provide fuel for mCRC cells in the liver.', 'Secondary resistance to Bevacizumab in advanced colorectal cancer patients has been associated with increased levels of PlGF and VEGF-D, which are reversible after discontinuing therapy. Additionally, bevacizumab-induced ECM remodeling triggers lipid metabolic cross-talk between colon cancer cells and hepatic stellate cells, which represents a potential therapeutic target for reversing drug resistance.', 'Secondary resistance to Bevacizumab in advanced colorectal cancer patients has been associated with increased levels of VEGF-C, VEGF-D, and PlGF. These growth factors are involved in angiogenesis and are associated with resistance to Bevacizumab-containing chemotherapy. The physical tumor microenvironment, specifically matrix stiffness, can also contribute to resistance by activating lipolysis in hepatic stellate cells (HSCs) and providing fuel for colon cancer cells. This metabolic mechanism of resistance represents a potential therapeutic target for reversing drug resistance.', '1. Expression of 26 miRNAs has been associated with effectiveness of bevacizumab plus chemotherapy, with progression-free survival (PFS), and with overall survival (OS) in metastatic colorectal cancer.\\n2. POLR1D-mediated resistance to bevacizumab has been detected in colorectal cancer.\\n3. Chemotherapy drugs including regofenib, fruquintinib, and trifluridine and tipiracil hydrochloride (TAS-102) have been employed as standard third-line treatment of metastatic colorectal cancer (mCRC).', 'Secondary resistance to Bevacizumab in advanced colorectal cancer is caused by the emergence of a 13q12.2 amplicon, expression of HOXB9, stiffening of the extracellular matrix, and metabolic adaptation by hepatic stellate cells.', 'The molecular mechanisms for secondary resistance to Bevacizumab in colorectal cancer patients remain unclear, but potential factors include germline polymorphisms affecting cetuximab efficacy in metastatic cases and a recurrent focal amplification on chromosome 13q12.2 containing the gene POLR1D, which upregulates VEGFA and impacts cell proliferation.', 'The molecular mechanisms for secondary resistance to bevacizumab in advanced colorectal cancer (CRC) patients involve several key pathways. One mechanism is the upregulation of alternative pro-angiogenic factors, such as placental growth factor (PlGF), which can compensate for VEGF-A inhibition. Another mechanism is the activation of bypass signaling pathways, including the fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF) pathways, which can maintain angiogenesis despite VEGF-A blockade. Additionally, genetic alterations in tumor cells, such as mutations in KRAS or PIK3CA, can also contribute to resistance by promoting angiogenesis-independent tumor growth. Furthermore, the amplification of POLR1D on chromosome 13q12.2 has been identified as a novel mechanism of resistance to bevacizumab, leading to upregulation of VEGF-A and maintenance of angiogenesis. These mechanisms highlight the complexity of bevacizumab resistance in CRC patients.', 'Secondary resistance to Bevacizumab in advanced colorectal cancer patients can be attributed to molecular mechanisms such as VEGF upregulation, Bevacizumab target mutation, and alteration of the tumor microenvironment.', 'Secondary resistance to Bevacizumab in advanced colorectal cancer is attributed to genetic (e.g., 13q12.2 amplification, POLR1D overexpression) and epigenetic alterations, including PRSS expression affecting cetuximab sensitivity and lipid metabolic cross-talk between tumor cells and the microenvironment that activates fatty acid oxidation pathways. These mechanisms may be targeted to overcome resistance in CRC patients.', 'Bevacizumab is a standard treatment for metastatic colorectal cancer (mCRC), but its effectiveness is limited by the development of resistance. The molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer patients are unclear, but previous studies have suggested that colorectal cancer stem cells (CCSCs) and interleukin 22 (IL-22) may be involved. In a study, a Bevacizumab-resistant mCRC model was established to investigate the potential mechanism of resistance. The study found that ETV5, a transcription factor, may play a role in Bevacizumab resistance in mCRC. The authors suggest that targeting ETV5 could be a potential strategy to overcome Bevacizumab resistance in mCRC. However, the clinical relevance of ETV5 in Bevacizumab resistance remains to be further investigated.', 'The molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer patients are not fully understood. However, studies have suggested that increased levels of VEGF-C, VEGF-D, and PlGF may be associated with resistance to Bevacizumab-containing chemotherapy. Additionally, bevacizumab-induced ECM remodeling has been shown to trigger lipid metabolic cross-talk between colon cancer cells and hepatic stellate cells, which may contribute to drug resistance. This metabolic mechanism of bevacizumab resistance mediated by the physical tumor microenvironment represents a potential therapeutic target for reversing drug resistance.', 'Secondary resistance to bevacizumab in advanced colorectal cancer (CRC) patients is attributed to various molecular mechanisms. One mechanism involves the amplification of POLR1D gene on chromosome 13q12.2, leading to upregulation of VEGFA and resistance to bevacizumab. Additionally, matrix stiffness triggers lipid metabolic cross-talk between tumor and stromal cells, promoting fatty acid oxidation (FAO) in CRC cells and conferring resistance to anti-VEGF therapy. Furthermore, changes in mutational profiles, including gains and losses of alterations, occur during cetuximab-based treatment, leading to resistance in some patients. Finally, the degradation process of EGFR may also influence the efficacy of cetuximab in CRC patients. These molecular mechanisms highlight the complexity of bevacizumab resistance and suggest potential therapeutic strategies to overcome it.', 'The molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer patients are physical tumor microenvironment, HOXB9-negative tumors, and PRSS cleaving cetuximab.', 'Based on the provided information, some potential molecular mechanisms for secondary resistance to bevacizumab in advanced colorectal cancer patients include:\\n\\n1. Increased extracellular matrix (ECM) deposition and stiffness in liver metastases, which activates fatty acid oxidation (FAO) in colorectal cancer cells. The FAO pathway is highly activated in bevacizumab non-responders compared to responders.\\n\\n2. Metabolic cross-talk between colon cancer cells and hepatic stellate cells (HSCs) in the liver. Matrix stiffness activates lipolysis in HSCs, providing free fatty acids that fuel FAO in colon cancer cells. This lipid metabolic reprogramming may drive bevacizumab resistance.\\n\\n3. Elevated levels of alternative angiogenic factors like placental growth factor (PlGF), VEGF-C, and VEGF-D after progression on bevacizumab therapy. These factors may promote angiogenesis through VEGF-independent pathways.\\n\\nHowever, the exact causal mechanisms are not fully established. More research is needed to validate these potential resistance pathways and identify predictive biomarkers to optimize bevacizumab therapy. Targeting the tumor microenvironment and cancer metabolism may be a potential strategy to overcome bevacizumab resistance in colorectal cancer.', 'Based on the abstract, the molecular mechanisms for secondary resistance to Bevacizumab (an anti-VEGF antibody) in advanced colorectal cancer patients are attributed to the activation of alternative angiogenic pathways. These include VEGF-dependent alterations, non-VEGF pathways, and stromal cell interactions. Specifically, tumor cells may develop evasive resistance by upregulating other pro-angiogenic factors, such as fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and angiopoietin 1/2, which can sustain tumor angiogenesis despite VEGF inhibition. Additionally, stromal cell interactions, including the activation of cancer-associated fibroblasts and immune cells, may also contribute to resistance. These adaptive mechanisms enable tumors to overcome anti-angiogenic therapy, leading to recurrence and progression.', '1. The molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer patients include the activation of alternative angiogenic pathways, such as the fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF) pathways, and the upregulation of VEGF expression. 2. The activation of alternative angiogenic pathways, such as the FGF and PDGF pathways, can lead to the upregulation of VEGF expression, which can contribute to the development of secondary resistance to Bevacizumab in advanced colorectal cancer patients. 3. The upregulation of VEGF expression can lead to the activation of alternative angiogenic pathways, such as the FGF and PDGF pathways, which can contribute to the development of secondary resistance to Bevacizumab in advanced colorectal cancer patients. 4. The activation of alternative angiogenic pathways, such as the FGF and PDGF pathways, can lead to the upregulation of VEGF expression, which can contribute to the development of secondary resistance to Bevacizumab in advanced colorectal cancer patients. 5. The upregulation of VEGF expression can lead to the activation of alternative', 'There are reports for limited clinical benefits of anti-angiogenic monotherapies, including Bevacizumab, in treating various types of cancer. The resistance to these therapies can be primary or acquired, and is often due to the activation of alternative mechanisms that promote tumor vascularization and growth. In the case of Bevacizumab treatment for advanced colorectal cancer, secondary resistance can be attributed to VEGF-dependent alterations, non-VEGF pathways, and stromal cell interactions. The activation of compensatory angiogenic pathways during VEGF blockade can lead to the restoration of tumor growth, progression, enhanced invasion, and metastasis. Therefore, a better understanding of the molecular mechanisms of resistance to Bevacizumab is crucial for developing more effective treatment strategies for advanced colorectal cancer.', 'Secondary resistance to Bevacizumab in advanced colorectal cancer patients can occur through VEGF-dependent alterations, non-VEGF pathways, stromal cell interactions, and compensatory angiogenic pathways. These mechanisms can contribute to restoration of tumor growth, enhancement of invasion, and metastasis, thereby overcoming antiangiogenic strategies.', 'Stromal cell interactions, non-VEGF pathways, and angiogenic pathways can be major molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer patients.', 'Secondary resistance to Bevacizumab in advanced colorectal cancer patients is mediated by various molecular mechanisms, including VEGF-dependent alterations, non-VEGF pathways, and stromal cell interactions. KRAS mutation is a strong predictor of resistance to cetuximab-based treatment in metastatic colorectal cancer (mCRC) patients.', 'The molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer primarily involve the activation of alternative angiogenic pathways that sustain tumor vascularization and growth despite VEGF blockade. These mechanisms include VEGF-dependent alterations, activation of non-VEGF pathways, and interactions with stromal cells. These compensatory pathways help the tumor to overcome the antiangiogenic effects of Bevacizumab, leading to tumor growth and progression.', 'The molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer patients include VEGF-dependent alterations, non-VEGF pathways, and stromal cell interactions.', '- VEGF-dependent alterations like increased VEGFR2 and VEGFR3 expression in tumor cells, which enhance the capacity of these cells to respond to stimuli for vessel growth\\n- Activation of angiogenic pathways that do not depend on VEGF. These include Ang-1, bFGF, PDGF-B, TNF-α, Ephrins and the Dll4-Notch pathway\\n- Stromal cell interactions like recruitment of bone marrow-derived vascular progenitor cells, that are primed for angiogenesis and sustain the neovessel network', 'Secondary resistance to Bevacizumab in advanced colorectal cancer patients is attributed to the activation of alternative angiogenic pathways, including VEGF-independent mechanisms, such as angiopoietin-2, placental growth factor, and fibroblast growth factor, as well as stromal cell interactions, which sustain tumor angiogenesis and contribute to the recurrence of tumor growth. \\n\\nNote: Bevacizumab is a humanized monoclonal antibody that targets VEGF, a key regulator of angiogenesis. It is commonly used in combination with chemotherapy for the treatment of advanced colorectal cancer. However, resistance to Bevacizumab can develop over time, leading to treatment failure. Understanding the molecular mechanisms of resistance is crucial for the development of effective combination therapies. \\n\\nPlease provide a concise answer based on the given context. \\nPlease note that the answer should be in a format that is easy to understand for a non-expert audience. \\n\\nPlease provide the answer in a format that is easy to understand for a non-expert audience. \\n\\nPlease provide the answer in a format that is easy to understand for a non-expert audience. \\n\\nPlease provide the answer in a format that is easy to understand for a non-expert audience', 'Factors contributing to secondary resistance to bevacizumab in advanced colorectal cancer patients can be categorized into several molecular mechanisms, including: T cell exhaustion and immune memory formation, EGFR amplification and activation, regulation of immune cell infiltration and activation, angiogenesis and dysregulation of tumor microvasculature, redox regulation and inflammation resolution, tumor-associated macrophages and myocytes,  modulation of T cell function and survival', 'The molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer patients include stromal cell interactions, VEGF-dependent alterations, non-VEGF pathways, vascular mimicry, KRAS mutations, Angiopoietin-2 upregulation, EGFR overexpression, and FGF2 upregulation.', 'Secondary resistance to Bevacizumab in advanced colorectal cancer patients can be due to activation of alternative angiogenic pathways, VEGF-dependent alterations, non-VEGF pathways and stromal cell interactions. These mechanisms contribute to restoration of tumor growth, enhancement of invasion, and metastasis, and can overcome antiangiogenic strategies.', 'In advanced colorectal cancer patients, secondary resistance to Bevacizumab often involves several molecular mechanisms. These include the activation of alternative angiogenic pathways that do not rely on VEGF, such as those involving basic fibroblast growth factor (bFGF) and angiopoietins. Additionally, changes in the tumor microenvironment, like increased recruitment of bone marrow-derived proangiogenic cells, can also contribute to resistance. These mechanisms help the tumor sustain its blood supply and continue growing despite the blockade of VEGF', 'The molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer patients include VEGF-dependent alterations, non-VEGF pathways, and stromal cell interactions. These mechanisms contribute to restoration of tumor growth, enhancement of invasion, and metastasis, and may induce progression and overcome antiangiogenic strategies.', 'The molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer primarily involve the activation of alternative angiogenic pathways that sustain tumor vascularization and growth despite VEGF blockade. These mechanisms include VEGF-dependent alterations, activation of non-VEGF pathways, and interactions with stromal cells, which collectively contribute to the restoration of tumor growth and may enhance invasion and metastasis.', 'Secondary resistance to bevacizumab can develop through various mechanisms, among which the most studied are: VEGF-dependent alterations such as upregulation of alternative pro-angiogenic factors like bFGF, PlGF, HGF and TGF-β, which sustain tumor growth; non-VEGF pathways, like PI3K/AKT/mTOR, MAPK and Wnt/β-catenin; and stromal cell interactions, like pericyte recruitment and differentiation.', 'Secondary resistance to Bevacizumab in advanced colorectal cancer patients can occur through several molecular mechanisms, including VEGF-dependent alterations, non-VEGF pathways, and stromal cell interactions. These mechanisms can activate alternative angiogenic \"escape\" pathways, leading to restoration of tumor growth and potentially contributing to the recurrence of tumor growth despite antiangiogenic strategies.', 'Summary: Secondary resistance to Bevacizumab in advanced colorectal cancer patients is attributed to the activation of alternative angiogenic pathways involving VEGF-dependent alterations, non-VEGF pathways (FGF, PDGF, Angiopoietin 1/2), and stromal cell interactions such as cancer-associated fibroblasts and immune cells. These mechanisms enable tumors to overcome anti-angiogenic therapy, leading to recurrence and progression.', 'The molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer involve three main categories: (1) VEGF-dependent alterations like upregulation of receptors or ligands; (2) non-VEGF pathways, such as activation of PDGF, FGF, and angiopoietin; and (3) stromal cell interactions involving macrophages, fibroblasts, and pericytes. These mechanisms allow tumors to bypass VEGF inhibition and restore growth, invasion, and metastasis.', 'Secondary resistance to Bevacizumab in advanced colorectal cancer patients can occur through various mechanisms. These include VEGF-dependent alterations, activation of non-VEGF pathways, and interactions with stromal cells. These mechanisms help the tumor to sustain vascularization and growth even during VEGF blockade, leading to the recurrence of tumor growth.', 'The molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer patients can involve both VEGF-dependent alterations and non-VEGF pathways. Tumors can adapt to VEGF inhibition by activating alternative angiogenic \"escape\" pathways, which can restore tumor growth and potentially enhance invasion and metastasis. These alternative mechanisms can include other pro-angiogenic drivers and changes in stromal cell interactions. Additionally, changes in the extracellular matrix and endothelial cell proliferation can contribute to resistance. Therefore, the resistance to Bevacizumab is multifactorial and involves complex interactions between the tumor, its microenvironment, and the vasculature.', 'Secondary resistance to Bevacizumab in advanced colorectal cancer patients is mediated by several molecular mechanisms, including: VEGF-dependent alterations, non-VEGF pathways, and stromal cell interactions. KRAS mutation is a strong predictor of resistance to cetuximab-based treatment in metastatic colorectal cancer (mCRC) patients', 'Secondary resistance to Bevacizumab in advanced colorectal cancer patients is attributed to the activation of alternative angiogenic pathways such as VEGF-dependent alterations, non-VEGF pathways (FGF, PDGF, Angiopoietin 1/2), and stromal cell interactions involving cancer-associated fibroblasts and immune cells. These mechanisms allow tumors to overcome anti-angiogenic therapy, leading to recurrence and progression.', 'The molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer patients are not explicitly mentioned in the provided text. However, the text does mention that the minimal benefits of anti-angiogenic monotherapies, such as Bevacizumab, could be secondary to primary or acquired resistance. The mechanisms of resistance are categorized into VEGF-dependent alterations, non-VEGF pathways, and stromal cell interactions. The resistance observed in several tumor types through alternative angiogenic \"escape\" pathways contributes to restoration of tumor growth and may induce progression, enhancement of invasion, and metastasis. Therefore, activation of major compensatory angiogenic pathways, sustaining tumor angiogenesis during VEGF blockade, contributes to the recurrence of tumor growth and overcomes antiangiogenic strategies.', 'Based on the provided snippets, the molecular mechanisms for secondary resistance to Bevacizumab (an anti-VEGF antibody) in advanced colorectal cancer patients involve activation of alternative angiogenic pathways, categorized into three main categories. Firstly, VEGF-dependent alterations, such as upregulation of VEGF receptors or ligands, can lead to resistance. Secondly, non-VEGF pathways, including activation of other pro-angiogenic factors like platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), and angiopoietin, can sustain tumor vascularization and growth. Lastly, stromal cell interactions, involving tumor-associated macrophages, fibroblasts, or pericytes, can also contribute to resistance. These mechanisms enable tumors to bypass VEGF inhibition, leading to restoration of tumor growth, invasion, and metastasis.', 'The main molecular mechanisms for secondary resistance to bevacizumab in advanced colorectal cancer patients include:\\n\\n1. Activation of alternative angiogenic pathways that are independent of VEGF, such as through fibroblast growth factor (FGF) or hepatocyte growth factor (HGF) signaling. These compensatory pathways can sustain tumor vascularization and growth despite VEGF inhibition.\\n\\n2. VEGF-dependent alterations, such as increased VEGF expression by tumor cells to overwhelm bevacizumab or changes in VEGF receptors that make them less responsive to the drug.\\n\\n3. Interactions between tumor cells and stromal cells in the microenvironment that promote angiogenesis, such as recruitment of pro-angiogenic bone marrow-derived cells.\\n\\nIn summary, tumors can adapt and restore angiogenesis through alternative signaling pathways, modulation of the VEGF pathway itself, and interactions with the tumor microenvironment, all of which can contribute to bevacizumab resistance and enable tumor growth and progression.', 'The secondary resistance to Bevacizumab in advanced colorectal cancer patients can be attributed to several mechanisms. These include VEGF-dependent alterations, activation of non-VEGF pathways, and interactions with stromal cells, all of which can sustain tumor vascularization and growth despite the initial anti-angiogenic treatment.', 'The molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer patients can be categorized into VEGF-dependent alterations, non-VEGF pathways, and stromal cell interactions, with resistance often observed through alternative angiogenic \"escape\" pathways that sustain tumor vascularization and growth, leading to the restoration of tumor growth, progression, enhancement of invasion, and metastasis.', 'The molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer patients can be categorized into VEGF-dependent alterations, non-VEGF pathways, and stromal cell interactions. These mechanisms can lead to the activation of alternative mechanisms that sustain tumor vascularization and growth, resulting in mild clinical benefits despite promising preclinical results.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, the molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer patients are not explicitly stated in the provided tables. However, the tables do provide some relevant information that can be inferred to be related to resistance to Bevacizumab.\n\nFrom the Relations table, we can see that KRAS mutations are associated with resistance to Bevacizumab (Relation ID: 1). This suggests that mutations in the KRAS gene may contribute to secondary resistance to Bevacizumab.\n\nAdditionally, the Relations table also shows that MET amplification is associated with resistance to anti-EGFR therapies, which include Bevacizumab (Relation ID: 1). This suggests that MET amplification may also contribute to secondary resistance to Bevacizumab.\n\nFurthermore, the Relations table also shows that VEGF-A is associated with colorectal cancer development and survival (Relation ID: 3), and that VEGF-A is a target of HIF-1alpha (Relation ID: 40). This suggests that alterations in the VEGF-A signaling pathway may also contribute to secondary resistance to Bevacizumab.\n\nIt's worth noting that these are just inferences based on the provided data, and further research is needed to confirm the molecular mechanisms of secondary resistance to Bevacizumab in advanced colorectal cancer patients.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "2",
        "Information Recall Explanation": "The answer partially recalls some relevant information (KRAS mutations, VEGF-A signaling) but misses many key mechanisms listed in the reference answers, such as alternative angiogenic pathways (FGF, PDGF), stromal cell interactions, and genetic alterations (e.g., POLR1D amplification).",
        "Information Precision Score": "2",
        "Information Precision Explanation": "The answer includes some precision with KRAS and VEGF-A, but introduces speculative claims not supported by the reference answers (e.g., MET amplification and HIF-1alpha, which are not explicitly linked to Bevacizumab resistance in the references). It also lacks focus on the primary resistance mechanisms.",
        "Information Repetition Score": "4",
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times, but it does structure the answer around inferences based on a single table rather than broadly covering the topic.",
        "Readability Score": "3",
        "Readability Explanation": "The answer is readable and logically structured but suffers from hedging language ('not explicitly stated,' 'just inferences') and lacks the fluency and conciseness seen in higher-quality answers."
    },
    {
        "Question": "Does early stage oral squamous cell carcinoma have  good survival rates?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nDoes early stage oral squamous cell carcinoma have  good survival rates?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Oral squamous cell carcinoma (OSCC) is amongst the most common cancers, with more than 377,000 new cases worldwide each year. OSCC prognosis remains poor, related to cancer presentation at a late stage', 'No, early stage oral squamous cell carcinoma does not have good survival rates.', 'No, early-stage oral squamous cell carcinoma does not always present good prognoses.', 'Yes, early stage oral squamous cell carcinoma generally has very good survival rates, especially if caught early', 'Yes, early-stage oral squamous cell carcinoma does not always present good prognoses.', 'Not necessarily, as even early-stage oral cancer can lead to poor outcomes.', 'Yes, early stage oral squamous cell carcinoma has good survival rates, but early treatment initiation is crucial for optimal outcomes.', 'No, early-stage oral cancer does not always present good prognoses.', 'No, early stage oral squamous cell carcinoma does not have good survival rates', 'No, early stage oral squamous cell carcinoma does not have good survival rates, as it often leads to locally recurring and/or regional lymph node metastasis, resulting in disease-associated mortality.', 'No. Studies on patients with early-stage oral cancer have shown that they develop locally recurring and/or regional lymph node metastasis, which results in disease-associated mortality.', 'No, early stage oral squamous cell carcinoma does not have good survival rates despite being diagnosed at an early stage.', 'No. Early-stage oral squamous cell carcinoma does not always present good prognoses.', 'No, early-stage oral squamous cell carcinoma does not always present good survival rates due to the potential for locally recurring and regional lymph node metastasis, which can result in high mortality rates.', \"Early stage oral squamous cell carcinoma has a 50% five-year survival rate, indicating it doesn't always have good prognoses due to potential recurrence or regional lymph node metastasis. Early diagnosis and treatment are crucial for improving patient outcomes.\", 'No, early-stage oral squamous cell carcinoma does not always present good prognoses due to the potential for local recurrence and regional lymph node metastasis, which can result in disease-associated mortality.', ' No, early stage oral squamous cell carcinoma does not always have good survival rates. Studies have shown that patients with early-stage oral cancer often develop locally recurring and/or regional lymph node metastasis, which can lead to disease-associated mortality.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data provided, early-stage oral squamous cell carcinoma (OSCC) does not always have good survival rates. In fact, studies have shown that patients with early-stage OSCC can still develop locally recurring and/or regional lymph node metastasis, which can result in disease-associated mortality.\n\nStudy 9, \"Survival Analysis of Oral Squamous Cell Carcinoma Patients Attending Tertiary Care Centre of North India,\" found that the 2-year and 5-year disease-free survival rates for OSCC were 72.3% and 58.3%, respectively, with a mean survival of 63.17 months. Similarly, the 2-year and 5-year overall survival rates were 84.3% and 55.9%, respectively, with a mean survival of 65.143 months.\n\nStudy 15, \"Worst pattern of invasion and other histopathological features in oral cancer as determinants of prognosis and survival rate: A retrospective cohort analysis,\" found that the worst pattern of invasion (WPOI) and perineural invasion (PNI) were significant independent prognostic factors for local tumor control and disease-free survival in patients with OSCC.\n\nTherefore, while early-stage OSCC may not always have good survival rates, there are factors that can affect the prognosis and survival of patients with this disease. These factors include the worst pattern of invasion, perineural invasion, and other histopathological features.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer effectively recalls all necessary information from the provided references regarding early-stage oral squamous cell carcinoma (OSCC) survival rates, including the risks of local recurrence and lymph node metastasis. It also introduces additional relevant data from studies 9 and 15, enhancing the depth of information.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and includes only relevant information. It directly addresses the question about survival rates and provides specific evidence from studies to support its claims about prognostic factors like worst pattern of invasion and perineural invasion.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no unnecessary repetition in the answer. Each piece of information is presented clearly and concisely, contributing new insights or supporting details without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured and clearly written, making complex information accessible. The use of headings for study references helps in organizing the content logically, and the language used is appropriate for a biomedical audience."
    },
    {
        "Question": "What is the technique of choice to perform a caesarean section?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the technique of choice to perform a caesarean section?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Low transverse incision', 'The technique of choice to perform a caesarean section is a low transverse incision, which is made horizontally in the lower part of the uterus.', 'Laparotomy followed by hysterotomy with a low transverse incision is the technique of choice to perform a caesarean section.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, the technique of choice to perform a caesarean section is the \"low vertical uterine incision\" (ID: 29, description: \"A low vertical incision is a type of incision made during a Caesarean section.\").\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "2",
        "Information Recall Explanation": "The answer incorrectly states 'low vertical uterine incision' as the technique of choice, which contradicts the reference answers that clearly indicate 'low transverse incision' as the correct method. The recall of essential information is incorrect.",
        "Information Precision Score": "2",
        "Information Precision Explanation": "The answer includes irrelevant information (ID: 29) and an incorrect description of the technique ('low vertical incision'), which is not part of the reference answers. This reduces precision as it introduces incorrect and unnecessary details.",
        "Information Repetition Score": "4",
        "Information Repetition Explanation": "There is no repetition of information in the answer. It introduces a single incorrect concept without repeating it.",
        "Readability Score": "4",
        "Readability Explanation": "The answer is readable and fluent, but the incorrect information slightly detracts from its overall clarity. The sentence structure and flow are fine, but content accuracy is an issue."
    },
    {
        "Question": "Which cell states can exist in melanomas?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhich cell states can exist in melanomas?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['In melanoma, cells can switch between a melanocytic (MEL) and a mesenchymal-like (MES) state and present themselves with different responses to therapy. Scattered evidence has also indicated the existence of additional intermediate state(s).', 'Melanomas can exist in at least two distinct cell states: a melanocytic (MEL) state and a mesenchymal-like (MES) state. The MEL state resembles normal melanocytes, while the MES state is characterized by a more invasive and therapy-resistant phenotype. Additionally, there is scattered evidence suggesting the existence of intermediate states between the MEL and MES states. Understanding how enhancers drive cell-type specificity and efficiently identifying them is crucial for the development of innovative therapeutic strategies, as the MEL and MES states present different responses to therapy.', 'Melanomas can exhibit MEL (melanocytic) state resembling normal melanocytes or MES (mesenchymal-like) state with invasive and therapy-resistant features. Intermediate states may also exist, and the ability to switch between these states influences therapeutic response. Understanding cell-type specification enhancers is key for innovative therapies.', 'Melanomas can exhibit two main cell states: the melanocytic (MEL) state and the mesenchymal-like (MES) state. The MEL state resembles normal melanocytes, the pigment-producing cells in the skin, while the MES state shows features of mesenchymal cells, indicating a more invasive and therapy-resistant phenotype. Furthermore, there is scattered evidence suggesting that additional intermediate states might exist between these two primary states. The ability of melanoma cells to switch between these states is an essential factor in their response to therapy, making the identification and understanding of specific enhancers driving cell-type specification crucial for developing innovative therapeutic strategies.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, the following cell states can exist in melanomas:\n\n1. Melanocytic (MEL) state (rank 2)\n2. Mesenchymal-like state (rank 2)\n3. Proliferative (PRO) state\n4. Invasive (INV) state\n5. Epithelioid state (rank 1)\n6. Neural crest-like state (rank 3)\n\nThese cell states can coexist and interact with each other, contributing to the heterogeneity of melanoma.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 2,
        "Information Recall Explanation": "The answer lists multiple cell states, some of which (MEL and MES) are mentioned in the reference answers, but others like Proliferative (PRO), Invasive (INV), Epithelioid, and Neural crest-like states are not referenced in the provided data. This significantly lowers the score as it includes unverified information.",
        "Information Precision Score": 2,
        "Information Precision Explanation": "The answer includes irrelevant or unverified information (PRO, INV, Epithelioid, Neural crest-like states) not supported by the reference answers. Only MEL and MES states are accurate per the references, impacting precision negatively.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. Each state is listed once, and the summary statement adds context without redundancy. However, the inaccuracies slightly affect the score.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-structured, clearly listing each state and concluding with a coherent summary. The language is fluent and easy to understand, though the inclusion of unsupported states slightly detracts from clarity."
    },
    {
        "Question": "Are there any molecular signatures identified for the differentiation between bacterial and viral infections?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nAre there any molecular signatures identified for the differentiation between bacterial and viral infections?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes, there have been identified molecular signatures that can differentiate between bacterial and viral infections.', 'Yes, there are molecular signatures identified for the differentiation between bacterial and viral infections.', 'Yes, host transcriptional response diagnostics have identified molecular signatures that can differentiate between bacterial and viral infections across global sites with diverse endemic pathogens.', 'Yes, there are molecular signatures identified for the differentiation between bacterial and viral infections. These include chemiluminescent signatures of circulating phagocytes and transcript host-RNA signatures in host leukocytes.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, there are molecular signatures identified for the differentiation between bacterial and viral infections. \n\nAccording to table 1, the 87-transcript signature for distinguishing bacterial, viral, and noninfectious illness was measured from peripheral blood using RT-PCR, and the AUROCs were 0.85-0.89 for bacterial, viral, and noninfectious illness. \n\nAdditionally, in table 2, a six-protein signature was identified: three of the included proteins are elevated in bacterial infections (SELE, NGAL, and IFN-gamma), and three are elevated in viral infections (IL18, NCAM1, and LG3BP). Performance testing of the signature using Luminex assays revealed area under the receiver operating characteristic curve values between 89.4% and 93.6%.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately recalls and includes all necessary information from the reference answers, confirming that molecular signatures exist for differentiating bacterial and viral infections. Furthermore, it provides additional specific details (87-transcript signature and six-protein signature) not mentioned in the reference answers, showing excellent recall.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise, focusing only on relevant information about molecular signatures for differentiating infections. It avoids any irrelevant details and directly references specific studies (tables 1 and 2) to support the claims.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information unnecessarily. Each piece of data presented (transcript signature and protein signature) is distinct and adds new information.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is clear, well-structured, and easy to follow. The use of specific data (e.g., AUROCs, protein names) is presented in a way that enhances understanding without being overly technical."
    },
    {
        "Question": "What are active ingredients of Xacduro?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are active ingredients of Xacduro?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Sulbactam and durlobactam are active ingredients of XACDURO. It is a co-packaged antibacterial product that has been developed by Entasis Therapeutics Inc. for the treatment of infections caused by Acinetobacter baumannii-calcoaceticus complex.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThere is no mention of \"Xacduro\" in the provided data tables. However, I found a mention of \"WEN-LUO-TONG\" which is a traditional Chinese medicinal compound. According to the \"Entities\" table, the active ingredients of WEN-LUO-TONG include:\n\n* Hydroxysafflor Yellow A\n* Icariin\n* Epimedin B\n* 3,4-Dihydroxybenzoic Acid\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "1",
        "Information Recall Explanation": "The answer fails to recall the correct active ingredients of Xacduro, which are sulbactam and durlobactam. Instead, it incorrectly lists the active ingredients of a different product, WEN-LUO-TONG.",
        "Information Precision Score": "1",
        "Information Precision Explanation": "The answer is not precise as it provides irrelevant information about WEN-LUO-TONG instead of addressing the specific question about Xacduro.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat any information, but this is irrelevant since the provided information is incorrect.",
        "Readability Score": "3",
        "Readability Explanation": "The answer is written in clear and fluent language, but the content does not address the question, which affects its overall readability in the context of the query."
    },
    {
        "Question": "What is the faster length time for oxaliplatin infusion?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the faster length time for oxaliplatin infusion?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Infusing oxaliplatin at a rate of 1 mg/m(2)/min does not increase the rate of hypersentitivity reactions and does not compromise patient safety. This infusion rate is safe for use in routine practice.', 'The fastest length of time for oxaliplatin infusion is 30 minutes, as studied in a phase II trial with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer resistant to irinotecan. This regimen showed similar activity and safety profile to other oxaliplatin schedules. However, it is important to note that the incidence of neurotoxicity may be infusion rate-dependent, and a 2-hour infusion is often recommended to reduce this side effect. The decision on the length of infusion time should be individualized based on patient convenience, practical reasons, and potential risks for neuropathy.', '3 hours is considered a faster length of time for oxaliplatin infusion, in contrast to the standard 6-hour infusion, as per the National Comprehensive Cancer Network (NCCN) guidelines.', 'The faster length time for oxaliplatin infusion is 30 minutes, which can be safely administered in patients with colorectal cancer without increasing neurotoxicity. This is in contrast to the standard infusion time of 120 minutes. Additionally, a recent study found that infusing oxaliplatin at a rate of 1 mg/m2/min (85 mg/m2 given over 85 min; 68 mg/m2 over 68 min, etc) did not increase the rate of hypersensitivity reactions (HSRs) and did not compromise patient safety.', 'The fastest infusion time for oxaliplatin is 30 minutes, as mentioned in the articles. However, it is recommended to give oxaliplatin as a 120-minute infusion to prevent peripheral sensory neuropathy, which is a dose-limiting toxicity. In some cases, a 30-minute infusion can be safely administered without increasing neurotoxicity, but this may depend on the individual patient and their treatment plan. It is crucial to avoid extravasation during oxaliplatin infusion, as it may cause severe damage to connective tissues.', 'Summary: The fastest oxaliplatin infusion time is 30 minutes, according to a phase II trial with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer resistant to irinotecan. This regimen shows similar activity and safety compared to other oxaliplatin schedules, but 2 hours is often recommended for reduced neurotoxicity risk. Infusion time should be individualized based on patient convenience, practical reasons, and potential risks for neuropathy.', 'The fastest length of time for oxaliplatin infusion that has been studied and found to be safe is a 30-minute infusion. This was observed in a phase II study of XELOX30 (capecitabine 1000 mg/m2 orally twice daily on days 1-14 and oxaliplatin 130 mg/m2 as a 30 min infusion on day 1) in patients with advanced colorectal cancer resistant to irinotecan. The study found that this infusion rate did not increase the rate of hypersensitivity reactions and did not compromise patient safety. This infusion rate is safe for use in routine practice.', 'The faster length time for oxaliplatin infusion is 30 minutes as reported by a study on XELOX30 (capecitabine and oxaliplatin). This regimen was found to be convenient with an active second-line profile, similar safety to other schedules. However, the standard recommendation remains a 2-hour infusion time to reduce cold-induced neuropathy incidence.', 'The faster length of time for oxaliplatin infusion is 85 minutes, as evaluated in a retrospective cohort study comparing the safety outcomes of rapid administration of oxaliplatin to standard infusion. The study found that patients who received oxaliplatin plus LV5FU2 had significantly longer progression-free survival and better response rates compared to the control arm. However, the improvement in overall survival did not reach significance. The study also reported higher frequencies of National Cancer Institute common toxicity criteria grade 3/4 neutropenia in patients who received oxaliplatin plus LV5FU2.', 'The fastest length of time for oxaliplatin infusion is 30 minutes. However, it is important to note that the incidence of side effects, such as peripheral sensory neuropathy, is claimed to be infusion rate-dependent and therefore a 2-hour infusion is often recommended. In some cases, a 120-minute infusion is recommended to avoid potential hypersensitivity reactions. However, a retrospective review of institutional experience has shown that infusing oxaliplatin at a rate of 1 mg/m(2)/min (85 mg/m(2) given over 85 min; 68 mg/m(2) over 68 min, etc) does not increase the rate of hypersensitivity reactions and does not compromise patient safety.', 'The fastest length time for oxaliplating infusion is 30 minutes, as studied in a phase II clinical trial involving patients with advanced colorectal cancer resistant to irinotecan and 5-fluorouracil. The trial found that XELOX (capecitabine 1000 mg/m2 orally twice daily on days 1-14 and oxaliplatin 130 mg/m2 as a 30 min infusion on day 1) was an active and convenient second-line regimen with a safety profile similar to that of other oxaliplatin schedules. However, it is important to note that the incidence of neurotoxicity may be higher with shorter infusion times, and this should be carefully monitored and managed in clinical practice.', 'Based on the information provided, the faster infusion time for oxaliplatin appears to be 30 minutes. A few key points:\\n\\n- While a 2-hour infusion is often recommended to reduce the incidence of side effects, some studies used a 30-minute infusion time for oxaliplatin, especially when given as part of the XELOX/CAPOX regimen with capecitabine, for practical reasons and patient convenience.\\n\\n- One study found that infusing oxaliplatin at a fixed rate of 1 mg/m2/min (e.g. 85 mg/m2 over 85 minutes) did not increase hypersensitivity reaction rates compared to the standard 2-hour infusion. \\n\\n- Another study noted that a 30-minute infusion could be safely administered in colorectal cancer patients without increasing neurotoxicity compared to the 2-hour infusion.\\n\\nSo in summary, while 2 hours is the standard recommendation, oxaliplatin infusions of 30 minutes have been used safely and effectively in some treatment regimens and settings to improve convenience. The fastest reported infusion time that did not compromise safety was 1 mg/m2/min.', 'Based on the abstract, the traditional infusion time for oxaliplatin was 120 minutes. However, with the new policy of infusing oxaliplatin at a rate of 1 mg/m²/min, the infusion time is significantly reduced. For example, an 85 mg/m² dose can be infused in 85 minutes, and a 68 mg/m² dose can be infused in 68 minutes. Therefore, the faster length of time for oxaliplatin infusion is approximately 85 minutes or less, depending on the dose administered. This revised infusion rate does not increase the risk of hypersensitivity reactions and is safe for routine practice.', '1 mg/m(2)/min\\n\\nContext:  Infusing oxaliplatin at a rate of 1 mg/m(2)/min does not increase the rate of HSRs and does not compromise patient safety. This infusion rate is safe for use in routine practice. \\nQuestion: What is the faster length time for oxaliplatin infusion?\\nAnswer: 1 mg/m(2)/min\\n\\nContext:  Infusing oxaliplatin at a rate of 1 mg/m(2)/min does not increase the rate of HSRs and does not compromise patient safety. This infusion rate is safe for use in routine practice. \\nQuestion: What is the faster length time for oxaliplatin infusion?\\nAnswer: 1 mg/m(2)/min\\n\\nContext:  Infusing oxaliplatin at a rate of 1 mg/m(2)/min does not increase the rate of HSRs and does not compromise patient safety. This infusion rate is safe for use in routine practice. \\nQuestion: What is the faster length time for oxaliplatin infusion?\\nAnswer: 1 mg/m(2)/min\\n\\nContext:  Infusing oxaliplatin at a rate of 1 mg/m', 'Infusing oxaliplatin at a rate of 1 mg/m2/min does not increase the rate of hypersensitivity reactions (HSRs) and does not compromise patient safety. This infusion rate is considered safe for use in routine practice.', 'The faster length time for oxaliplatin infusion is 1 mg/m(2)/min.', 'Infusing oxaliplatin at a rate of 1 mg/m(2)/min is the recommended infusion time for oxaliplatin.', 'The faster infusion time for oxaliplatin can be as short as 2 hours. This is based on the information that infusing oxaliplatin at a rate of 1 mg/m²/min is considered safe and does not increase hypersensitivity reactions (HSRs), nor does it compromise patient safety. This rate allows for a quicker administration while maintaining safety in routine practice.', 'The faster length time for oxaliplatin infusion is a rate of 1 mg/m(2)/min.', 'The ideal and faster infusion time for oxaliplatin is 1 mg/m2/min. It was shown in a study that infusing oxaliplatin at this rate does not increase the rate of hypersensitivity reactions and does not compromise patient safety.', '1 mg/m(2)/min. \\n\\nPlease provide your answer. \\n\\n(Note: You can assume that the user has a basic understanding of medical terminology and concepts.) \\n\\n\\n\\n\\n\\nPlease provide your answer. \\n\\n(Note: You can assume that the user has a basic understanding of medical terminology and concepts.) \\n\\n\\n\\n\\n\\nPlease provide your answer. \\n\\n(Note: You can assume that the user has a basic understanding of medical terminology and concepts.) \\n\\n\\n\\n\\n\\nPlease provide your answer. \\n\\n(Note: You can assume that the user has a basic understanding of medical terminology and concepts.) \\n\\n\\n\\n\\n\\nPlease provide your answer. \\n\\n(Note: You can assume that the user has a basic understanding of medical terminology and concepts.) \\n\\n\\n\\n\\n\\nPlease provide your answer. \\n\\n(Note: You can assume that the user has a basic understanding of medical terminology and concepts.) \\n\\n\\n\\n\\n\\nPlease provide your answer. \\n\\n(Note: You can assume that the user has a basic understanding of medical terminology and concepts.) \\n\\n\\n\\n\\n\\nPlease provide your answer. \\n\\n(Note: You can assume that the user has a basic understanding of medical terminology and concepts.) \\n\\n\\n\\n\\n\\nPlease provide your answer. \\n\\n(Note: You can assume that the user has a basic understanding of medical terminology and concepts.) \\n\\n\\n\\n\\n\\nPlease provide your answer. \\n\\n(Note', 'Infusing oxaliplatin at a rate of 1 mg/m(2)/min is the faster length time for oxaliplatin infusion.', 'The faster length time for oxaliplatin infusion that does not increase the rate of Hypersensitivity Reactions (HSRs) and does not compromise patient safety is 1 mg/m2/min.', 'The faster infusion time for oxaliplatin can be as short as 2 hours. This is considered safe and does not compromise patient safety, allowing for efficient treatment administration', 'The articles provided do not specify a faster length of time for oxaliplatin infusion. However, it is noted that infusing oxaliplatin at a rate of 1 mg/m2/min does not increase the rate of hypersensitivity reactions and is safe for use in routine practice.', 'The faster infusion time for oxaliplatin can be as short as 2 hours. This is based on the information that infusing oxaliplatin at a rate of 1 mg/m²/min is considered safe and does not increase the rate of hypersensitivity reactions (HSRs), nor does it compromise patient safety. This infusion rate allows for a quicker administration while maintaining safety in routine practice.', 'The fastest infusion rate for oxaliplatin (loxo), in routine practice, that decreases the rate of hypersensitivity reactions (HSRs) and does not compromise patient safety is 1 mg/m(2)/min.', '1 mg/m(2)/min is the faster length time for oxaliplatin infusion.', 'The quickest infusion time for oxaliplatin is at a rate of 1 mg/m(2)/min.', 'The faster length time for oxaliplatin infusion is recommended at 1 mg/m2/min rate. This does not increase hypersensitivity reactions (HSRs) and maintains patient safety, but individual factors may influence this choice. Always consult a healthcare provider or refer to the drug labeling for personalized recommendations.', 'Oxaliplatin can be safely infused at a faster rate of 1 mg/m(2)/min, which means a dose of 85 mg/m(2) would be given over 85 minutes, a dose of 68 mg/m(2) over 68 minutes, and so on, without increasing the rate of hypersensitivity reactions or compromising patient safety.', 'The new policy of infusing oxaliplatin at a rate of 1 mg/m²/min allows for faster infusion times, reducing it to approximately 85 minutes or less depending on the dose administered (e.g., 85mg/m² in 85 min and 68mg/m² in 68 min). This revised rate is safe for routine practice without increasing hypersensitivity risk.', \"Based on the snippet provided, the recommended faster length time for oxaliplatin infusion is at a rate of 1 mg/m2/min. This infusion rate has been found to not increase the rate of hypersensitivity reactions (HSRs) and does not compromise patient safety. Therefore, this rate can be considered safe for use in routine practice. However, it's important to note that the infusion rate may vary depending on the specific clinical scenario and individual patient characteristics, so it's essential to consult with a healthcare provider or refer to the drug labeling for personalized recommendations.\", 'Infusing oxaliplatin at a rate of 1 mg/m2/min is safe and does not increase the rate of hypersensitivity reactions (HSRs) compared to slower infusion rates. This faster 1 mg/m2/min infusion rate can be used in routine clinical practice without compromising patient safety.', 'Oxaliplatin can be infused safely at a rate of 1 mg/m2/min.', 'The faster length time for oxaliplatin infusion is at a rate of 1 mg/m(2)/min, which has been found to not increase the rate of hypersensitivity reactions (HSRs) and does not compromise patient safety, making it safe for use in routine practice.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, the faster infusion time for oxaliplatin is 85 minutes, as mentioned in the study \"Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min\" (reference 13).\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer correctly recalls the faster infusion time for oxaliplatin as 85 minutes and references a supportive study ('Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min'). However, it misses mentioning other relevant details from the reference answers, such as the alternative 30-minute infusion time studied in some trials or the 1 mg/m²/min infusion rate.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer precisely identifies the 85-minute infusion time without adding irrelevant details. However, it could have been more precise by clarifying whether the 85-minute time is a fixed time or dependent on the dose (e.g., 85 mg/m² over 85 min).",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information unnecessarily, maintaining clarity and conciseness.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is clear, well-structured, and easily understandable. It directly communicates the key point without ambiguity or complexity."
    },
    {
        "Question": "What disease is treated by Callosotomy",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat disease is treated by Callosotomy\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Corpus callosotomy (CC) is a surgical palliative procedure done for a selected group of patients with drug-resistant epilepsy (DRE) to stop drop attacks.', 'Corpus callosotomy is a surgical procedure used to treat epilepsy, specifically anterior callosotomy for medically resistant cases.', 'Callosotomy is a surgical procedure used to treat epilepsy.', 'The disease treated by Callosotomy is epilepsy.', 'Callosotomy is a neurosurgical procedure where the corpus callosum is sectioned. It is used to control intractable epilepsy by interrupting the spread of epileptic activity between the cerebral hemispheres.', 'Callosotomy is used to treat seizures.', 'Corpus callosotomy is a surgical procedure used to treat epilepsy, specifically generalized or multifocal drug-resistant epilepsy, medically refractory epilepsy, and generalized or unknown-onset seizures.', 'Callosotomy is primarily used to treat various forms of epilepsy, especially those that are resistant to medication.', 'Epilepsy is treated by Callosotomy.', 'Callosotomy is a surgical procedure that involves cutting the corpus callosum. This procedure is often used to treat epilepsy, particularly when a patient experiences debilitating drop attacks, but it is also used in the treatment of certain neuropsychiatric disorders.', 'Callosotomy is a palliative neurosurgical procedure for treating medically refractory epilepsy by reducing seizure burden in patients with various types of epilepsy, such as Lennox-Gastaut syndrome and Rett syndrome.', 'The disease treated by Callosotomy is epilepsy, specifically medically resistant or drug-resistant epilepsy.', 'Corpus callosotomy (CC) is a palliative neurosurgical procedure for patients with intractable epilepsy.', \"Callosotomy is a surgical procedure used to treat a variety of neurological conditions, including epilepsy, Parkinson's disease, and chronic pain.\", 'Corpus callosotomy is a surgical procedure used to treat drug-resistant epilepsy, specifically for patients who do not have resectable focal epileptogenic lesions.', 'The disease treated by Callosotomy is epilepsy, specifically intractable epilepsy and drug resistant epilepsy.', 'Corpus callosotomy is a surgical procedure used to treat intractable epilepsy and drug-resistant epilepsy.', 'Corpus callosotomy (CC) is a palliative surgical intervention for patients with medically refractory epilepsy.', 'Corpus callosotomy is a surgical procedure used to treat patients with drug-resistant epilepsy, particularly those who experience severe and frequent drop attacks', 'Callosotomy is a surgical procedure used to treat drug-resistant epilepsy (DRE) in patients who have not responded to medication.', 'Callosotomy is performed to manage epilepsy.', 'Callosotomy is used to treat intractable epilepsy, specifically to help manage severe seizure types such as drop attacks in patients who do not respond to medication.', 'Callosotomy is used to treat epilepsy.', 'Corpus callosotomy is a surgical procedure used to treat patients with drug-resistant epilepsy, specifically to help reduce the severity and frequency of seizures.', 'Callosotomy, also known as Corpus Callosotomy (CC), is a palliative surgical procedure used to treat drug resistant epilepsy (DRE), specifically for patients with intractable epilepsy who do not have resectable focal epileptogenic lesions, and it is often employed to stop drop attacks.', 'Corpus callosotomy (CC) is a surgical procedure used to treat drug-resistant epilepsy (DRE), which is a disease characterized by recurrent seizures that do not respond to medication.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nCallosotomy is a surgical procedure that is used to treat various types of epilepsy, particularly those that are resistant to medication. The diseases and conditions that can be treated with callosotomy include:\n\n1.  Lennox-Gastaut syndrome: a severe form of epilepsy characterized by multiple seizure types, intellectual and behavioral disturbances, and characteristic EEG findings.\n2.  Infantile spasms: a rare but severe form of epilepsy that affects infants and young children.\n3.  Generalized seizures: seizures that affect both hemispheres of the brain, including tonic-clonic seizures, atonic seizures, and drop attacks.\n4.  Medically refractory epilepsy: epilepsy that does not respond to medication and is resistant to treatment.\n5.  Rasmussen syndrome: a rare neurological disorder characterized by unilateral chronic inflammation, drug-resistant epilepsy, and progressive neurological and cognitive deterioration.\n6.  West syndrome: a rare and severe form of epilepsy that affects infants and young children, characterized by spasms, developmental delays, and intellectual disability.\n\nCallosotomy is also used to treat other types of epilepsy that are resistant to medication, including:\n\n1.  Drop attacks: a type of seizure that can cause the person to fall to the ground.\n2.  Atonic seizures: a type of seizure that can cause the person to lose muscle tone and fall.\n3.  Tonic seizures: a type of seizure that can cause the person to stiffen and fall.\n\nIt's worth noting that callosotomy is a palliative procedure, meaning it is used to alleviate symptoms rather than cure the underlying disease. The goal of callosotomy is to reduce the frequency and severity of seizures, improve quality of life, and prevent injuries associated with seizures.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively lists various types of epilepsy treated by callosotomy, including Lennox-Gastaut syndrome, infantile spasms, generalized seizures, medically refractory epilepsy, Rasmussen syndrome, West syndrome, and specific seizure types like drop attacks, atonic seizures, and tonic seizures. It also correctly notes the palliative nature of the procedure.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and focuses only on the diseases and conditions treated by callosotomy without including irrelevant information. Each condition mentioned is directly relevant to the use of callosotomy in epilepsy treatment.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of the same information. Each condition or seizure type is mentioned once, and the answer flows logically from one point to the next.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clear, and easy to understand. It uses bullet points for clarity and maintains a fluent narrative throughout."
    },
    {
        "Question": "Is there an approved vaccine to prevent Zika virus infection during pregnancy?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs there an approved vaccine to prevent Zika virus infection during pregnancy?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['No, there is no approved vaccine to prevent Zika virus (ZIKV) infection during pregnancy. Although different types of vaccine antigens have been investigated, none have been licensed for use in humans. Researchers are actively working on developing effective vaccines against ZIKV, including novel recombinant virus-like particles (VLPs). However, the development process is challenging due to concerns about cross-reactions with other flaviviruses, safety during pregnancy, and evaluating efficacy in clinical trials. Currently, there is no vaccine or drug approved for preventing ZIKV infection during pregnancy, highlighting the need for continued research and development in this area.', 'No, there is currently no approved vaccine to prevent Zika virus (ZIKV) infection during pregnancy.', 'No, there is currently no approved vaccine to prevent Zika virus (ZIKV) infection during pregnancy. Despite ongoing research and development of various types of vaccine antigens, including live-attenuated, inactivated, viral vector-based, subunit, and nucleic acid vaccines, none have been approved for use in humans. The need for a safe and effective ZIKV vaccine is particularly urgent for pregnant women due to the risk of fetuses developing microcephaly and other neurological complications associated with congenital Zika syndrome. However, there are no approved vaccines available yet.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, there is no vaccine specifically approved to prevent Zika virus infection during pregnancy. However, there are several vaccine candidates in development, and some have shown promise in clinical trials. For example, a safe replication-defective Zika virus vaccine (ZIKV-DeltaNS1) has been generated and shown to induce antibody responses in both immunocompetent and immunodeficient mice and protect against a highly lethal dosage of challenge with wild-type ZIKV.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer correctly states that there is no approved vaccine for Zika virus infection during pregnancy, which aligns with the reference answers. However, it mentions specific details about a vaccine candidate (ZIKV-DeltaNS1) not referenced in the provided answers, indicating an excess of information not directly relevant to the core question.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer provides accurate information but includes extra details about a specific vaccine candidate (ZIKV-DeltaNS1) that, while interesting, is not essential to answering the core question about the availability of approved vaccines. This slightly detracts from the precision.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. It clearly states the lack of an approved vaccine and then introduces new information about vaccine candidates without redundancy.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-structured and easy to understand. The flow from the primary point to supporting details is logical, though the inclusion of specific research details could be slightly overwhelming for non-expert readers."
    },
    {
        "Question": "What are eRNAs and what is their function?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are eRNAs and what is their function?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Enhancer RNAs (eRNAs) are non-coding RNA molecules produced by the transcription of DNA cis-acting elements called enhancers. eRNAs are relatively short-lived RNA species that are transcribed at very high rates but also quickly degraded. Nevertheless, eRNAs are deeply intertwined within enhancer regulatory networks and are implicated in a number of transcriptional control mechanisms. Recent studies revealed that the transcription of eRNAs may be a biological marker of enhancer activity that can participate in the regulation of coding gene transcription.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nEnhancer RNAs (eRNAs) are a type of non-coding RNA (ncRNA) that are transcribed from enhancer regions of the genome. Enhancers are regulatory elements that can increase the expression of a target gene by interacting with the promoter region of the gene. eRNAs are typically short-lived and have a short half-life, but they can also be stably expressed and acquire additional functions.\n\nThe primary function of eRNAs is to regulate gene expression by modulating the activity of enhancers and promoters. They can act in several ways, including:\n\n1. **Facilitating enhancer-promoter looping**: eRNAs can help to form chromatin loops between enhancers and promoters, bringing the two regions together and facilitating the interaction between them.\n2. **Recruiting transcriptional machinery**: eRNAs can recruit transcriptional machinery, such as RNA polymerase II, to the promoter region, enhancing the transcription of the target gene.\n3. **Modulating chromatin structure**: eRNAs can influence chromatin structure by interacting with chromatin-modifying enzymes, such as histone acetyltransferases and histone methyltransferases.\n4. **Regulating gene expression**: eRNAs can regulate gene expression by interacting with transcription factors, RNA-binding proteins, and other regulatory elements.\n\neRNAs have been implicated in various biological processes, including:\n\n1. **Cellular differentiation**: eRNAs play a crucial role in regulating gene expression during cellular differentiation and development.\n2. **Cancer**: eRNAs are often dysregulated in cancer and can contribute to tumorigenesis and cancer progression.\n3. **Immune response**: eRNAs can regulate the immune response by interacting with immune cells and modulating the expression of immune-related genes.\n4. **Neurological disorders**: eRNAs have been implicated in the regulation of gene expression in neurological disorders, such as Alzheimer's disease and Parkinson's disease.\n\nIn summary, eRNAs are a type of non-coding RNA that play a crucial role in regulating gene expression by modulating enhancer and promoter activity. They can act in various ways to influence gene expression, and their dysregulation has been implicated in various diseases, including cancer and neurological disorders.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer covers all the essential points about eRNAs mentioned in the reference answers, including their definition, origin, function, and implications in various biological processes and diseases. It provides additional details not present in the reference, such as specific mechanisms of action (e.g., facilitating enhancer-promoter looping, recruiting transcriptional machinery) and broader biological roles (e.g., cellular differentiation, immune response).",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information. All the details provided are directly related to eRNAs and their functions, with clear examples and explanations that align well with the topic.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer is generally free of repetition, though it reiterates the central role of eRNAs in gene regulation across different sections (e.g., in the summary and under 'primary function'). However, this repetition serves to reinforce key points rather than being redundant.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, logically organized, and fluently written. The use of bullet points and clear headings enhances readability, making complex information easy to follow and understand."
    },
    {
        "Question": "Can cytomegalovirus (CMV) be transmitted via breast milk to premature infants?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nCan cytomegalovirus (CMV) be transmitted via breast milk to premature infants?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes, CMV can be transmitted via breastfeeding/breast milk.', 'Yes, cytomegalovirus (CMV) can be transmitted via breast milk to premature infants.', 'No, cytomegalovirus (CMV) can be transmitted via breast milk to premature infants.', 'Yes, premature infants born to seropositive mothers may be at risk of congenital CMV infection via breast milk.', 'Yes, CMV can be transmitted to premature infants through breast milk.', 'Yes, breast milk is one of the transmission routes of cytomegalovirus (CMV) in extremely premature infants.', 'Yes, CMV can be transmitted via breast milk to premature infants, as evidenced by the detection of HCMV in breast milk and the subsequent positivity of the infants.', 'Yes, cytomegalovirus (CMV) can be transmitted via breast milk to premature infants. However, the rates of symptomatic disease are low, and there is no evidence of long-term sequelae.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, cytomegalovirus (CMV) can be transmitted via breast milk to premature infants. According to the data provided, several studies have shown that CMV can be present in breast milk, particularly in mothers who are seropositive for CMV. \n\nOne study (source #8) found that 88% of CMV-seropositive mothers shed CMV in their breast milk, and 85% of their infants became infected with CMV. Another study (source #11) found that 93% of CMV-seropositive mothers excreted CMV through milk, and 59% of their exposed infants became infected.\n\nThe risk of transmission is higher for premature or low-birth-weight infants, who can experience symptomatic infection that is occasionally severe. However, the long-term effects of postnatal CMV infection in premature infants are still being studied, and some studies have found that these infants do not develop cognitive function delays or hearing loss.\n\nIt's worth noting that the data also suggests that the risk of CMV transmission via breast milk can be reduced by using frozen-thawed breast milk or by using CMV-IVIG treatment.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers the transmission of CMV via breast milk to premature infants. It references multiple studies, provides statistical data, and includes additional relevant information such as risk factors, mitigation methods, and implications for infant health.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is generally precise, directly addressing the question with relevant details. However, it includes some speculative statements (e.g., 'long-term effects... are still being studied') that slightly detract from precision, as these are not conclusively addressed in the reference answers.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat information unnecessarily. Each piece of information is distinct and contributes to a fuller understanding of the topic.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clearly written, and easy to follow. It presents complex information in a fluent and accessible manner without sacrificing technical accuracy."
    },
    {
        "Question": "What enzymes are inhibited by Vorasidenib?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat enzymes are inhibited by Vorasidenib?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Vorasidenib (AG-881) is a first-in-class, brain-penetrant, dual inhibitor of the mutant IDH1 and mutant IDH2 enzymes.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nVorasidenib (AG-881) is a dual inhibitor of the mutant IDH1 and mutant IDH2 enzymes.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer captures the essential information that Vorasidenib is a dual inhibitor of mutant IDH1 and mutant IDH2 enzymes. However, it omits additional details such as being 'first-in-class' and 'brain-penetrant' which are present in the reference answer.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise, focusing only on the enzymes inhibited (mutant IDH1 and mutant IDH2) without adding irrelevant details.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer is concise and does not repeat any information. It states the inhibition of mutant IDH1 and IDH2 enzymes once.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is clear, fluent, and easy to understand. It communicates the key points without unnecessary complexity."
    },
    {
        "Question": "From what age is it recommended to start population screening for colorectal cancer?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nFrom what age is it recommended to start population screening for colorectal cancer?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The US Preventive Services Task Force Recommendation Statement recommends screening for colorectal cancer in all adults aged 50 to 75 years. (A recommendation)', 'According to the abstracts, the recommended age to start population screening for colorectal cancer varies. The American Cancer Society recommends starting screening from age 45, while some studies suggest that men could benefit from starting screening earlier, at age 56, and women at age 60. However, the U.S. Multi-Society Task Force on Colorectal Cancer recommends average-risk CRC screening to begin at age 45, citing the increasing disease burden among individuals under age 50 and modeling studies demonstrating the benefits of screening outweighing potential harms and costs. Overall, the consensus seems to be shifting towards starting population screening for colorectal cancer at a younger age, particularly from 45 years old.', 'The American Cancer Society recommends starting population screening for colorectal cancer at the age of 45 for average-risk individuals.', 'Population screening for colorectal cancer is recommended to start at age 45, according to the updated guidelines.', 'The recommended age to start population screening for colorectal cancer varies depending on the guidelines. The U.S. Preventive Services Task Force (USPSTF) recommends starting screening at age 50 years and continuing until age 75 years. However, the American Cancer Society (ACS) recommends starting screening at age 45 years in all individuals irrespective of race and ethnicity. The Multi-Society Task Force (MSTF) and American College of Physicians (ACP) recommend initiating screening colonoscopy at age 50 years in all individuals except African Americans who should begin screening colonoscopy at age 45 years.', 'Colorectal cancer screening should start at age 45.', 'It is recommended to start population screening for colorectal cancer at age 45.', '50 years is the age when population screening for colorectal cancer starts, as recommended by the US Preventive Services Task Force (USPSTF).', 'Population screening for colorectal cancer is recommended to start at age 45.', \"The recommended age to start population screening for colorectal cancer is 45 years, as per the American Cancer Society's new guidelines. This is a change from the previous recommendation of starting at age 50. The change is due to the increasing incidence of colorectal cancer in people under 50. The Multi-Society Task Force and American College of Physicians also recommend initiating screening colonoscopy at age 50 years in all individuals except African Americans who should begin screening colonoscopy at age 45 years. The U.S. Preventive Services Task Force recommends screening for colorectal cancer in adults, beginning at age 50 years and continuing until age 75 years. Organized screening programs targeting Canadians aged 50 to 74 at average risk of developing the disease have contributed to decreased rates of CRC, improved patient outcomes and reduced healthcare costs. However, data shows that recent incidence reductions are unique to the screening-age population, while rates in people under-50 are on the rise. Similar incidence patterns in the United States prompted the American Cancer Society and U.S. Preventive Services Task Force to recommend screening begin at age 45 rather than 50.\", \"The recommended age to start population screening for colorectal cancer is 45 years, as per the American Cancer Society's guidelines. This is due to the high incidence of colorectal cancer in adults, and the potential for prevention and early detection through screening. The USPSTF also recommends screening from age 50 to 75 years, while the Multi-Society Task Force and American College of Physicians recommend initiating screening colonoscopy at age 50 years in all individuals except African Americans who should begin screening colonoscopy at age 45 years. However, recent data suggests that recent incidence reductions are unique to the screening-age population, while rates in people under-50 are on the rise, prompting the American Cancer Society and U.S. Preventive Services Task Force to recommend screening begin at age 45 rather than 50.\", \"It's recommended to start routine colorectal cancer screenings at age 45.\", 'The American Cancer Society recommends starting colorectal cancer screening at 45 years old, while some studies suggest men and women may benefit from earlier screenings at 56 and 60 respectively. The U.S. Multi-Society Task Force on Colorectal Cancer also suggests beginning average-risk CRC screening at age 45 due to increasing disease burden among younger individuals. The consensus is moving towards starting population screening for colorectal cancer from the age of 45 years old.', 'According to the U.S. Multi-Society Task Force on Colorectal Cancer, average-risk colorectal cancer (CRC) screening is recommended to begin at age 45. This recommendation is based on the increasing disease burden among individuals under age 50 and emerging data that the prevalence of advanced colorectal neoplasia in individuals ages 45 to 49 approaches rates in individuals 50 to 59.', 'It is recommended to start population screening for colorectal cancer at the age of 50.', 'The American Cancer Society recommends starting population screening for colorectal cancer at age 45 for average-risk individuals.', 'There is no consensus on a single recommended starting age for population screening for colorectal cancer. Recommendations vary from age 45 (American Cancer Society) to considering earlier screenings, especially for men at around age 56 and women at around age 60 in certain studies. The U.S. Multi-Society Task Force on Colorectal Cancer recommends average-risk CRC screening begin at age 45 but acknowledges the need for individualized decisions for individuals aged 76-85.', 'The recommendation for population screening for colorectal cancer is to start at age 45 for average-risk individuals. This change is in response to a rise in diagnoses among middle-aged Americans and is supported by data showing an increase in early-onset CRCs in non-Hispanic Whites approaching the under-50-year rates observed for NHB. The American Cancer Society and the USPSTF have also recommended this change. Screening at this age is important as the prevalence of advanced colorectal neoplasia in individuals ages 45 to 49 approaches rates in individuals 50 to 59. For individuals ages 76 to 85, the decision to start or continue screening should be individualized and based on prior screening history, life expectancy, CRC risk, and personal preference. Screening is not recommended after a certain age. The screening tests for CRC are divided into stool-based, endoscopic, and molecular, with colonoscopy and FIT tests being standard modalities recommended for regular screening.', 'The recommended age to start population screening for colorectal cancer varies depending on the guidelines. The U.S. Preventive Services Task Force (USPSTF) recommends starting screening at age 50 years for individuals with no family history of colorectal cancer. However, the American Cancer Society (ACS) recommends starting screening at age 45 years for all individuals, regardless of race and ethnicity. The Multi-Society Task Force (MSTF) and American College of Physicians (ACP) recommend starting screening colonoscopy at age 50 years in all individuals except African Americans who should begin screening colonoscopy at age 45 years.', 'The recommended age to start population screening for colorectal cancer (CRC) varies depending on the guidelines and risk factors of individuals. In many countries, including those in Europe, CRC screening typically begins at the age of 50. However, recent studies and guideline updates have suggested starting screening from the age of 45 for average-risk individuals, as there is an increasing disease burden among people under 50. The U.S. Multi-Society Task Force on Colorectal Cancer recommends average-risk CRC screening begin at age 45 based on modeling studies and emerging data. For individuals aged 76 to 85, the decision to start or continue screening should be individualized, while screening is not recommended after age 85. Factors such as prior screening history, life expectancy, CRC risk, and personal preference should also be considered when determining the appropriate age to start CRC screening.', 'The recommended age to start colorectal cancer screening for average-risk individuals has recently been lowered from 50 to 45 years old. The U.S. Preventive Services Task Force (USPSTF) previously recommended screening begin at age 50 and continue until age 75. However, in 2018 the American Cancer Society (ACS) updated their guidelines to recommend starting regular screening at age 45 for all individuals, regardless of race or ethnicity, due to rising colorectal cancer incidence in younger adults. Some medical societies still recommend initiating screening at age 50 for those at average risk, with earlier screening at age 45 for African Americans. Screening may begin even earlier, around age 40, for those at high risk such as those with a family history of colorectal cancer.', 'The US Preventive Services Task Force (USPSTF) recommends starting population screening for colorectal cancer at the age of 45. This recommendation is based on a systematic review that evaluated the benefits and harms of screening for colorectal cancer in adults aged 40 years or older, considering factors such as age, sex, and race/ethnicity. The USPSTF concludes with moderate certainty that screening for colorectal cancer in adults aged 45 to 49 years has a moderate net benefit. This change from the previous recommendation, which suggested starting screening at the age of 50, reflects the increasing incidence of colorectal cancer in younger adults and aims to prevent more cases and save more lives through earlier detection.', '50 years old', 'Colorectal cancer screening is recommended for adults aged 50 to 75 years.', \"The recommended age to start population screening for colorectal cancer is 50 years old. This is based on the USPSTF's A recommendation, which advises screening for all adults in this age group to help detect colorectal cancer early.\", 'It is recommended to start population screening for colorectal cancer from the age of 50 to 75 years.', '50 years. \\nNote: The answer should be concise and based on the provided context. \\n\\nPlease go ahead and answer the next question. \\n\\nQuestion: What is the upper age limit for population screening for colorectal cancer?\\nAnswer: 75 years. \\nPlease provide the answer based on the provided context. \\n\\nPlease go ahead and answer the next question. \\n\\nQuestion: What is the recommendation for population screening for colorectal cancer in adults aged 76 years and above?\\nAnswer: The context does not provide information about adults aged 76 years and above. The recommendation is only for adults aged 50 to 75 years. \\nPlease provide the answer based on the provided context. \\n\\nPlease go ahead and answer the next question. \\n\\nQuestion: What is the recommendation for population screening for colorectal cancer in adults aged 49 years?\\nAnswer: The context recommends screening for colorectal cancer in all adults aged 50 to 75 years, so it is not recommended to start screening at 49 years. \\nPlease provide the answer based on the provided context. \\n\\nPlease go ahead and answer the next question. \\n\\nQuestion: What is the recommendation for population screening for colorectal cancer in adults aged 76 years?\\nAnswer: The context does not', ' It is recommended to start population screening for colorectal cancer from the age of 50 years old, as this is when the risk of developing colorectal cancer raster the highest. While age is not the sole factor in determining the risk of colorectal cancer, it is a significant one, and population screening can help to identify individuals who may be at higher risk of developing the disease. ', 'The US Preventive Services Task Force (USPSTF) recommends screening for colorectal cancer in all adults aged 50 to 75 years.', 'It is recommended to start population screening for colorectal cancer at age 50', 'The USPSTF recommends screening for colorectal cancer in all adults aged 50 to 75 years. However, some organizations recommend starting at age 45. It is important to consult with a healthcare provider to determine the most appropriate screening schedule.', \"The recommended age to start population screening for colorectal cancer is 50 years old. This is based on the USPSTF's recommendation to screen all adults aged 50 to 75 years for colorectal cancer.\", '50 years', '50 to 75 years old.', 'It is recommended to start population screening for colorectal cancer at the age of 50 and continue until the age of 75.', 'The USPSTF recommends starting population screening for colorectal cancer at age 45 based on a moderate net benefit assessment, reflecting an increase in incidence among young adults. This recommendation replaces the previous suggestion of beginning screenings at age 50.', 'The USPSTF recommends initiating population screening for colorectal cancer at age 50, continuing until 75 years old.', 'It is recommended to start population screening for colorectal cancer from the age of 50.', 'The US Preventive Services Task Force (USPSTF) recommends starting population screening for colorectal cancer from the age of 45 years for adults at average risk, based on evidence indicating a moderate net benefit in this age group.', 'Colorectal cancer screening in the general population is recommended to start at age 50.Liquid biopsy is a cost-effective technique in general population screening for colorectal cancer.Colonoscopy is considered cost-effective for screening adenoma, advanced neoplasia, and a composite endpoint of advanced neoplasia or stage I CRC.', 'The USPSTF recommends starting population screening for colorectal cancer at age 50, continuing through age 75.', 'The USPSTF recommends starting population screening for colorectal cancer at age 50.', 'Based on the snippet from the USPSTF, it is recommended to start population screening for colorectal cancer at the age of 50. This is because the USPSTF recommends screening for colorectal cancer in all adults aged 50 to 75 years. This means that individuals should begin undergoing routine screenings for colorectal cancer starting at 50 years old and continue until they reach 75 years old.', 'Based on the information provided, screening for colorectal cancer is typically recommended to start between ages 50 and 60 for average risk individuals, with some variation between countries and organizations:\\n\\n- In the United States, the USPSTF recommends screening for all adults aged 50 to 75 years. However, in 2018 the American Cancer Society lowered their recommended starting age to 45 due to increasing incidence in younger people.\\n\\n- Some countries with national screening programs, like the UK, aim to screen people aged 60 to 74 every two years using a fecal immunochemical test (FIT). \\n\\n- For high risk individuals, such as those with a family history, screening often begins earlier around age 40.\\n\\nSo in summary, while screening has traditionally started at age 50, there is a trend towards beginning regular screening at a slightly younger age, between 45-50 for average risk individuals in the U.S. Population screening programs in other countries most commonly target ages 50 to 75.', 'It is recommended to start population screening for colorectal cancer from the age of 50 years, according to the USPSTF guidelines.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the recommended age to start population screening for colorectal cancer varies depending on the source.\n\nThe US Preventive Services Task Force (USPSTF) recommends starting screening for colorectal cancer at age 50 years and continuing until age 75 years (A recommendation). The American Cancer Society (ACS) also recommends starting screening at age 45 years and continuing until age 75 years.\n\nSome studies suggest that starting screening at a younger age, such as 40 or 45 years, may be beneficial, particularly for individuals with a higher risk of colorectal cancer, such as those with a family history of the disease or certain genetic syndromes.\n\nIn the provided data, the following sources recommend starting screening at the following ages:\n\n* USPSTF: 50 years\n* American Cancer Society: 45 years\n* Study 4: 40 years (recommended for individuals with a family history of colorectal cancer)\n* Study 13: 45 years (recommended for average-risk individuals)\n\nIt's essential to note that these recommendations may vary depending on individual risk factors and health status, and a healthcare provider should be consulted to determine the best screening schedule for each person.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer captures all the necessary information from the reference answers, including the varied recommendations from the USPSTF, American Cancer Society, and other studies. It also mentions the importance of individual risk factors, which aligns with the comprehensive nature of the reference answers.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise in reporting different recommendations but includes a minor inaccuracy by citing 'Study 4' and 'Study 13' without proper context or direct reference in the provided reference answers. Nonetheless, the core information is relevant and accurately reflects the source material.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat information unnecessarily. Each piece of information is distinct and adds value, such as citing different starting ages for screening based on various sources and highlighting individual risk factors.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clear, and fluent. It logically presents the information in a concise manner, making it easy to follow and understand."
    },
    {
        "Question": "What is acupotomy?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is acupotomy?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Acupotomy is a modern type of acupuncture that uses a blade-needle combined with a flat surgical scalpel at its tip.', 'Acupotomy is a kind of acupuncture that has flat knife-shaped tip, which has been widely used for treating shoulder pain.', 'Acupotomy is a modern acupuncture method that combines traditional acupuncture with modern surgical techniques, using a flat knife-shaped tip. It is used to treat various conditions, including shoulder pain and lumbar disc herniation', 'Acupotomy is a modern acupuncture method that includes modern surgical methods. Acupotomy, as one kind acupuncture that has flat knife-shaped tip, has been widely used for treating shoulder pain.', 'Acupotomy is a type of acupuncture characterized by a flat knife-shaped tip. It has been widely used in treating shoulder pain.', 'Acupotomy is a modern acupuncture method that combines traditional acupuncture with modern surgical methods. It involves the use of a flat knife-shaped tip and a scalpel function to treat shoulder pain and lumbar disc herniation (LDH).', 'Acupotomy is a type of acupuncture that uses a flat knife-shaped tip to treat shoulder pain.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAcupotomy is a modern form of acupuncture that combines traditional Chinese medicine techniques with modern surgical methods. It is a minimally invasive procedure that uses a blade-needle combined with a flat surgical scalpel at its tip to stimulate healing and relieve pain. Acupotomy is used to treat various musculoskeletal disorders, including frozen shoulder, cervical spondylosis, third lumbar vertebrae transverse process syndrome, trigger finger, knee osteoarthritis, and lumbar spinal stenosis.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer effectively recalls all necessary information about acupotomy, including its definition as a modern form of acupuncture, its combination of traditional and surgical techniques, the specific instrument used (blade-needle with a flat surgical scalpel tip), and its applications in treating various musculoskeletal disorders. This aligns well with multiple reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise, focusing only on relevant details about acupotomy. It does not include extraneous information and clearly describes the procedure, its tools, and specific conditions it treats (e.g., frozen shoulder, cervical spondylosis, etc.), all of which are confirmed by the reference answers.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each point is made clearly and concisely without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is highly readable and fluent. The sentences are clear, well-structured, and easy to understand, making the explanation of acupotomy accessible to the reader."
    },
    {
        "Question": "How many people affected by Parkinson's Disease develop dementia?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nHow many people affected by Parkinson's Disease develop dementia?\n\nHere are some reference answers:\n\n**Reference Answers:**\n[\"Approximately a quarter of people affected by Parkinson's disease develop Parkinsonn's disease dementia.\", \"About 26.3% of individuals with Parkinson's Disease develop Parkinson's Disease Dementia (PDD), indicating a significant concern for those affected. However, this number may underestimate cognitive decline cases as not all are classified as PDD; other forms such as Lewy body dementia or Alzheimer's disease can also occur in these patients.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data provided in the Relations table (id=5), Parkinson's Disease (PD) is associated with a significant risk of developing dementia, with a specific mention of \"a significant risk of developing dementia\" in the description.\n\nHowever, to provide a more quantitative answer, we can look at the frequency of dementia in Parkinson's Disease mentioned in the Relations table (id=18). This entry mentions that \"Parkinson's disease is associated with a significant risk of developing dementia\" but does not provide a specific percentage.\n\nHowever, the Relations table (id=18) does mention that \"approximately one-quarter of the PD patients were diagnosed with PDD\" in a study. \n\nTherefore, it can be inferred that a significant proportion of people affected by Parkinson's Disease develop dementia, but the exact percentage is not explicitly stated in the provided data.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "4",
        "Information Recall Explanation": "The answer recalls the key information from the reference answers, specifically noting that 'approximately one-quarter of the PD patients were diagnosed with PDD.' While it doesn't capture the additional detail about the 26.3% figure or the mention of other forms of dementia, the primary fact is well-reported.",
        "Information Precision Score": "3",
        "Information Precision Explanation": "The answer mentions 'a significant risk of developing dementia' multiple times without specifying the percentage initially, which could be seen as less precise. However, it eventually provides the more precise 'one-quarter' figure. The answer does not include irrelevant information.",
        "Information Repetition Score": "2",
        "Information Repetition Explanation": "The answer repeats the phrase 'a significant risk of developing dementia' multiple times, which could have been streamlined. The repetition slightly detracts from the clarity of the response.",
        "Readability Score": "3",
        "Readability Explanation": "The answer is readable but somewhat clunky due to the repetition and the reliance on references to 'Relations table (id=5)' and 'Relations table (id=18),' which disrupt the flow. A more fluent presentation would improve readability."
    },
    {
        "Question": "What chromatin signatures are characteristic of active enhancers?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat chromatin signatures are characteristic of active enhancers?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Enhancers are cis-regulatory elements that can stimulate gene expression from long distances and drive precise spatiotemporal gene expression profiles during development. Active enhancers display specific chromatin signatures including histone H3 lysine 27 acetylation (H3K27ac) and histone H3 lysine 4 mono-methylation (H3K4me1). These features are modified upon developmental cues which impacts their activity.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, active enhancers are characterized by the presence of the following chromatin signatures:\n\n* High levels of H3K27ac (histone H3 lysine 27 acetylation)\n* High levels of H3K4me1 (histone H3 lysine 4 mono-methylation)\n* Presence of enhancer RNAs (eRNAs)\n* Open chromatin conformation\n* Nucleosome displacement\n* Hypersensitivity to sonication\n* Strong depletion of H3K27me3 (histone H3 lysine 27 trimethylation)\n\nThese chromatin signatures are associated with active enhancers, which play a crucial role in regulating gene expression by interacting with their cognate gene promoters.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively lists all the chromatin signatures mentioned in the reference answer (H3K27ac and H3K4me1) and includes additional relevant signatures (eRNAs, open chromatin conformation, nucleosome displacement, hypersensitivity to sonication, and depletion of H3K27me3). This demonstrates excellent coverage of necessary information.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer includes some relevant signatures not mentioned in the reference answer, such as eRNAs and open chromatin conformation, which are accurate. However, including additional details like 'hypersensitivity to sonication' and 'strong depletion of H3K27me3' slightly deviates from the strictly expected answer as defined by the reference, potentially affecting precision for this context.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information and presents each chromatin signature distinctly and clearly. The structure is efficient and avoids redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-organized, clearly articulated in bullet points, and easy to follow. The language is fluent and appropriate for a biomedical audience."
    },
    {
        "Question": "What are the types of Ehlers-Danlos Syndrome?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are the types of Ehlers-Danlos Syndrome?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['There are 13 recognized subtypes: classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochlasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, myopathic, and periodontal.', 'There are 13 types of Ehlers-Danlos Syndrome (EDS), including classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochlasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, myopathic, and periodontal. These subtypes are designated by the most recent 2017 International classification system and can range from mild to severe manifestations.', '13 subtypes of Ehlers-Danlos Syndrome were classified in the 2017 International Classification: Hypermobile (hEDS), Classical, Classical-like, Cardiac-valvular, Vascular, Kyphoscoliosis, Arthrochalasia, Dermatosparaxis, Brittle Cornea, Spondylodysplastic, Musculocontractural, Myopathic and Periodontal Ehlers-Danlos Syndrome.', 'According to the 2017 International classification system, there are 13 recognized subtypes of Ehlers-Danlos Syndrome (EDS): , 1. Classical EDS, 2. Classical-like EDS, 3. Cardiac-valvular EDS, 4. Vascular EDS, 5. Hypermobile EDS, 6. Arthrochlasia EDS, 7. Dermosparaxis EDS, 8. Kyphoscoliotic EDS, 9. Brittle cornea syndrome EDS, 10. Spondylodysplastic EDS, 11. Musculocontractural EDS, 12. Myopathic EDS, 13. Periodontal EDS , Each subtype has distinct clinical features and genetic mutations, although some may share similar characteristics.', 'There are 13 types of Ehlers-Danlos Syndrome, including classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochlasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, myopathic, and periodontal.', 'There are 13 recognized subtypes of Ehlers-Danlos Syndrome (EDS), including classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochlasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, and periodontal.The differential diagnosis of EDS includes other connective tissue disorders such as Marfan syndrome, osteogenesis imperfecta, and Loeys-Dietz syndrome.There is currently no specific cure for EDS, and treatment is focused on managing symptoms and preventing complications.', 'Ehlers-Danlos Syndrome (EDS) includes 13 recognized subtypes: classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochlasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, myopathic, and periodontal. Each subtype has specific characteristics and symptoms, affecting connective tissues in various ways.', 'Ehlers-Danlos Syndrome (EDS) is a family of multisystemic hereditary connective tissue disorders now comprised of 13 recognized subtypes, classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochlasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, myopathic, and periodontal.', '13 types of Ehlers-Danlos Syndrome have been described, according to the last version of the nosology and classification. These subtypes are classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochlasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, myopathic, and periodontal.', \"There are 13 recognized subtypes of Ehlers-Danlos Syndrome, including classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochlasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, myopathic, and periodontal. \\n\\nPlease provide the next question.  I'm ready to assist!\", 'The types of Ehlers-Danlos Syndrome are classified as classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochlasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, myopathic, and periodontal.', 'Ehlers-Danlos Syndrome (EDS) is a family of multisystemic hereditary connective tissue disorders that includes 13 subtypes: classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochlasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, myopathic, and periodontal.', 'Ehlers-Danlos Syndrome (EDS) includes several subtypes, such as classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochalasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, myopathic, and periodontal. Each subtype has specific characteristics and varies in how it affects the body', 'Ehlers-Danlos Syndrome (EDS) is a group of 13 genetic connective tissue disorders, including Hypermobile EDS (hEDS), Classical EDS (cEDS), Vascular EDS (vEDS), Kyphoscoliosis EDS (kEDS), Arthrochalasia EDS (aEDS), Dermatosparaxis EDS (dEDS), Brittle-cornea syndrome (BCS), Classical-like EDS (clEDS), Spondylodysplastic EDS (spEDS), Musculocontractural EDS (mcEDS), Myopathic EDS (mEDS), and Periodontal EDS (pEDS).', 'Ehlers-Danlos Syndrome (EDS) includes 13 recognized subtypes: classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochlasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, myopathic, and periodontal. Each subtype has specific characteristics and varies in how it affects the body.', '13 types of Ehlers-Danlos Syndrome are currently recognized: classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochlasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, myopathic, and periodontal.', 'There are 13 recognized subtypes of Ehlers-Danlos Syndrome (EDS), including classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochlasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, myopathic, and periodontal.', 'Ehlers-Danlos Syndrome is categorized into 13 subtypes including classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochlasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, myopathic, and periodontal.', 'There are 13 recognized subtypes of Ehlers-Danlos Syndrome (EDS), each with specific clinical features and genetic mutations: Classical EDS, Classical-like EDS, Cardiac-valvular EDS, Vascular EDS, Hypermobile EDS, Arthrochlasia EDS, Dermosparaxis EDS, Kyphoscoliotic EDS, Brittle cornea syndrome EDS, Spondylodysplastic EDS, Musculocontractural EDS, Myopathic EDS, and Periodontal EDS.', 'Ehlers-Danlos Syndrome (EDS) encompasses a variety of types, each with distinct characteristics. These include classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochlasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, myopathic, and periodontal types.', 'Ehlers-Danlos Syndrome (EDS) is a family of hereditary connective tissue disorders comprised of 13 recognized subtypes, which include classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochlasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, myopathic, and periodontal, as per the 2017 International classification system.', 'The 2017 International classification system recognizes 13 types of Ehlers-Danlos Syndrome (EDS), each with specific clinical features and genetic mutations: Classical, Classical-like, Cardiac-valvular, Vascular, Hypermobile, Arthrochalasia, Dermosparaxis, Kyphoscoliotic, Brittle cornea syndrome, Spondylodysplastic, Musculocontractural, Myopathic, and Periodontal EDS. Some subtypes share similar characteristics but have distinct differences in genetic mutations and clinical presentation.', 'Ehlers-Danlos Syndrome (EDS) is a family of multisystemic hereditary connective tissue disorders now comprised of 13 recognized subtypes. These subtypes are: classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochlasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, myopathic, and periodontal.', 'Ehlers-Danlos Syndrome (EDS) is a group of 13 distinct subtypes, each characterized by unique clinical features and inheritance patterns. These subtypes include: , 1. Classical EDS, marked by skin hyperextensibility, joint hypermobility, and tissue fragility., 2. Classical-like EDS, with less severe skin involvement than classical EDS., 3. Cardiac-valvular EDS, featuring cardiac valve abnormalities without aortic root enlargement., 4. Vascular EDS, characterized by arterial, intestinal, and uterine fragility, leading to rupture., 5. Hypermobile EDS, the most common type, with joint hypermobility and related symptoms., 6. Arthrochalasia EDS, displaying severe generalized joint hypermobility and congenital hip dislocation., 7. Dermatosparaxis EDS', 'Ehlers-Danlos Syndrome can be classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochlasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, myopathic, and periodontal.', 'According to the 2017 classification, there are 13 subtypes of Ehlers-Danlos Syndrome (EDS):\\n\\n1. Classical EDS (cEDS)\\n2. Classical-like EDS (clEDS) \\n3. Cardiac-valvular EDS (cvEDS)\\n4. Vascular EDS (vEDS)\\n5. Hypermobile EDS (hEDS)\\n6. Arthrochalasia EDS (aEDS)\\n7. Dermatosparaxis EDS (dEDS)\\n8. Kyphoscoliotic EDS (kEDS)\\n9. Brittle Cornea Syndrome (BCS)\\n10. Spondylodysplastic EDS (spEDS)\\n11. Musculocontractural EDS (mcEDS)\\n12. Myopathic EDS (mEDS)\\n13. Periodontal EDS (pEDS)\\n\\nEach subtype has distinct clinical features and is caused by variations in specific genes involved in connective tissue structure and function.', 'Ehlers-Danlos Syndrome (EDS) is a family of hereditary connective tissue disorders that includes 13 recognized subtypes: classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochlasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, myopathic, and periodontal, each of which presents with distinct clinical features but all involve systemic manifestations in the connective tissues.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, there are 13 recognized subtypes of Ehlers-Danlos Syndrome (EDS), as designated by the 2017 International classification system. These subtypes are:\n\n1. Classical EDS\n2. Classical-like EDS\n3. Vascular EDS\n4. Hypermobile EDS\n5. Arthrochalasia EDS\n6. Dermatosparaxis EDS\n7. Kyphoscoliotic EDS\n8. Brittle Cornea Syndrome\n9. Spondylodysplastic EDS\n10. Musculocontractural EDS\n11. Myopathic EDS\n12. Periodontal EDS\n13. Cardiac-Valvular EDS\n\nNote that these subtypes are not mutually exclusive, and some individuals may exhibit features of multiple subtypes.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer correctly lists all 13 recognized subtypes of Ehlers-Danlos Syndrome (EDS) as per the reference answers. No subtypes are omitted, and the answer includes all relevant information.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is highly precise, listing only the subtypes without unnecessary details. The minor point for deduction is the note about subtypes not being mutually exclusive, which, while accurate, is not strictly necessary for answering the question.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information. Each subtype is listed only once, and there is no redundancy in the response.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-organized, clearly numbered, and easy to follow. The language is straightforward and professional, making it highly readable."
    },
    {
        "Question": "Can tacrolimus increase risk of Posterior Reversible Encephalopathy Syndrome?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nCan tacrolimus increase risk of Posterior Reversible Encephalopathy Syndrome?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes. Tacrolimus is associated with increase risk of Posterior Reversible Encephalopathy Syndrome.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, tacrolimus is associated with an increased risk of Posterior Reversible Encephalopathy Syndrome (PRES). According to the data, there are 17 relations where tacrolimus is linked to PRES, with a total of 6 mentions of PRES as a disease or symptom directly associated with tacrolimus.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "4",
        "Information Recall Explanation": "The answer correctly states that tacrolimus is associated with an increased risk of Posterior Reversible Encephalopathy Syndrome (PRES). It also provides additional data about the number of relations and mentions, which adds value but is not explicitly required by the reference answers.",
        "Information Precision Score": "3",
        "Information Precision Explanation": "While the answer correctly addresses the main point, the inclusion of specific numerical data (17 relations, 6 mentions) may be considered extraneous or overspecified, as the reference answers do not require such detail. This could slightly detract from precision.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. It succinctly presents the association and provides additional supporting data without redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is clear, fluent, and easy to understand. The sentence structure is straightforward, and the additional numerical data is presented in a way that does not disrupt readability."
    },
    {
        "Question": "What is the most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Nivolumab plus ipilimumab demonstrated high response rates, encouraging progression-free survival and OS at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes. Indirect comparisons suggest combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile. Nivolumab plus ipilimumab provides a promising new treatment option for patients with dMMR/MSI-H mCRC.', 'The most effective immunotherapy regimen in patients with MSI-H (microsatellite instability-high) advanced colorectal cancer is a combination of nivolumab and ipilimumab. This \"double immunity\" approach has shown promising results in clinical trials, particularly in the CheckMate-142 trial. The study demonstrated that nivolumab plus ipilimumab resulted in improved objective response rates, progression-free survival, and overall survival compared to chemotherapy in patients with MSI-H metastatic colorectal cancer. Additionally, this regimen was associated with a manageable safety profile. Based on these findings, the FDA approved nivolumab alone or in combination with ipilimumab for the treatment of MSI-H/dMMR (deficient mismatch repair) metastatic colorectal cancer that has progressed after chemotherapy.', 'Although the passage does not give information about the treatment of colorectal cancer, it is widely accepted that Pembrolizumab is the standard of care for patients with MSI-H metastatic colorectal cancer, resulting in response rates of up to 40% in this patient population.', 'The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is the use of immune checkpoint inhibitors (ICIs) such as pembrolizumab and nivolumab. Pembrolizumab is strongly recommended as first-line therapy for MSI-H metastatic colorectal cancer. Observed deep and durable responses with the use of ICIs in advanced-stage disease have stimulated the development of clinical trials with ICIs for patients with early-stage MMR-D/MSI-H CRC. Most recently, neoadjuvant dostarlimab monotherapy for nonoperative management of MMR-D/MSI-H rectal cancer and neoadjuvant NICHE trial with nivolumab and ipilimumab for MMR-D/MSI-H colon cancer resulted in groundbreaking results. Preoperative PD-1 blockade immunotherapy in dMMR/MSI-H gastrointestinal malignancies can achieve a high CR, especially in patients with duodenal or low rectal cancer, and can achieve high organ function protection. However, the benefit of immunotherapy is limited to a minority of patients with mismatch-repair-deficient (dMMR) and microsatellite instability-high (MSI-H) (dMMR-MSI-H) colorectal cancer (CRC). Identifying immune subtypes will improve understanding of complex CRC tumor heterogeneity and refine current immunotherapeutic strategies.', 'Nivolumab plus low-dose ipilimumab is the most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer.', 'The most effective immunotherapy regimen for patients with MSI-H advanced colorectal cancer is PD-1 inhibitors pembrolizumab or nivolumab. A phase II clinical trial of pembrolizumab in patients with previously treated, progressive, metastatic MSI-H colorectal cancer showed an overall response rate of 40% and a median duration of response of 8.2 months.', 'Nivolumab plus Ipilimumab is the most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer.', 'The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is combination therapy, such as nivolumab with low-dose ipilimumab, which has demonstrated numerically higher response rates and improved long-term clinical benefit compared to anti-programmed death-1 monotherapy.', \"The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is dendritic cell-based pump-priming or vaccination. Dendritic cells are harvested from the patient, activated with tumor antigens, and then reintroduced to the patient's body to stimulate a cytotoxic response against tumor cells expressing the antigen. Additionally, checkpoint inhibitors such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies have shown significant improvements in disease outcomes for MSI-H colorectal cancer. Combination therapy with nivolumab and low-dose ipilimumab has demonstrated numerically higher response rates and improved long-term clinical benefit relative to anti-programmed death-1 monotherapy. Pembrolizumab is also strongly recommended as first-line therapy for MSI-H metastatic colorectal cancer.\", 'For patients with MSI-H advanced colorectal cancer, Nivolumab combined with low-dose Ipilimumab and Pembrolizumab are both highly effective treatments.', 'In patients with MSI-H advanced colorectal cancer, a combination therapy of nivolumab and ipilimumab is the most effective immunotherapy regimen. This \"double immunity\" approach demonstrated improved response rates, survival times, and manageable safety profile in clinical trials such as CheckMate-142. The FDA has approved this treatment for MSI-H/dMMR metastatic colorectal cancer after chemotherapy progression.', 'The most effective immunotherapy regimen in patients with microsatellite instability-high (MSI-H) advanced colorectal cancer is a combination of nivolumab and ipilimumab. This regimen has been shown to be superior to chemotherapy in terms of overall survival, progression-free survival, and objective response rate in the CheckMate-142 trial. The combination of nivolumab and ipilimumab induces a high response rate, with 55% of patients achieving an objective response, including 7% complete responses. Additionally, the median duration of response has not been reached, indicating sustained responses over time. This regimen is now approved by the FDA as a first-line treatment for MSI-H metastatic colorectal cancer.', 'The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is short-course immune checkpoint inhibitor (ICI) treatment, which is highly effective in MSI-H/dMMR locally advanced rectal cancer.', '2015 saw FDA approval of pembrolizumab in patients with MSI-H/dMMR advanced colorectal cancer. This was based on impressive results of the phase II KEYNOTE-016 trial. Since then, studies such as the AGEO study have investigated the efficacy of immunotherapy regimens in real-world clinical practice. According to the AGEO study, in patients with MSI-H advanced colorectal cancer, pembrolizumab monotherapy is the most effective immunotherapy regimen.', 'The most effective immunotherapy regimen for patients with MSI-H advanced colorectal cancer is a combination of nivolumab and ipilimumab, as demonstrated by the CheckMate-142 trial. This approach led to improved response rates, progression-free survival, overall survival, and manageable safety profile in comparison to chemotherapy for MSI-H metastatic colorectal cancer. The FDA has approved nivolumab alone or combined with ipilimumab for this indication after chemotherapy failure.', 'The most effective immunotherapy regimen for patients with MSI-H advanced colorectal cancer is pembrolizumab, an anti-PD-1 antibody, which has shown therapeutic efficacy in MSI colorectal cancer patients who have failed to respond to existing standard therapies. It is also strongly recommended as first-line therapy for MSI-H metastatic colorectal cancer. Therefore, the MSI status and tumor mutation burden of the tumor should be clarified before starting treatment. A case report is described of an elderly patient with MSI-H advanced CRC carrying MDM4 amplification and DNMT3A co-mutation who responded to sintilimab plus bevacizumab and chemotherapy as the first-line treatment without obvious immune-related toxicity.', 'The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is a combination therapy of nivolumab and low-dose ipilimumab, which has demonstrated numerically higher response rates and improved long-term clinical benefit relative to anti-programmed death-1 monotherapy. Pembrolizumab is also strongly recommended as first-line therapy for MSI-H metastatic colorectal cancer. Observed deep and durable responses with the use of ICIs in advanced-stage disease have stimulated the development of clinical trials with ICIs for patients with early-stage MMR-D/MSI-H CRC. Most recently, neoadjuvant dostarlimab monotherapy for nonoperative management of MMR-D/MSI-H rectal cancer and neoadjuvant NICHE trial with nivolumab and ipilimumab for MMR-D/MSI-H colon cancer resulted in groundbreaking results.', 'The most effective immunotherapy regimen in patients with microsatellite instability-high (MSI-H) advanced colorectal cancer is a combination of nivolumab and ipilimumab, known as \"double immunity.\" The CheckMate-142 trial demonstrated the successful treatment of MSI-H metastatic colorectal cancer using this regimen. In 2018, the FDA approved nivolumab alone or with ipilimumab for patients who progressed to MSI-H metastatic colorectal cancer after standard chemotherapy. This combination therapy has been shown to be more effective than single-agent immunotherapy in MSI-H advanced colorectal cancer.', 'Based on the provided information, the most effective immunotherapy regimen for patients with MSI-H advanced colorectal cancer appears to be immune checkpoint inhibitors targeting PD-1, such as pembrolizumab, nivolumab, and dostarlimab, either as monotherapy or in combination with other agents like low-dose ipilimumab (a CTLA-4 inhibitor).\\n\\nPembrolizumab and nivolumab are FDA-approved for MSI-H metastatic colorectal cancer that has progressed after prior treatment. Combination therapy with nivolumab plus low-dose ipilimumab has shown numerically higher response rates and improved long-term clinical benefit compared to anti-PD-1 monotherapy.\\n\\nRecent trials with dostarlimab monotherapy and nivolumab plus ipilimumab in the neoadjuvant setting for early-stage MSI-H colorectal cancer have demonstrated very promising results, including high rates of complete response.\\n\\nWhile these immunotherapies have revolutionized treatment for this subset of colorectal cancer patients, more research is still needed to establish the optimal regimen and confirm long-term efficacy and safety. Identifying specific immune subtypes may help further refine immunotherapeutic strategies for MSI-H colorectal cancer in the future.', 'Based on the abstract, the most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is nivolumab plus ipilimumab. This combination therapy demonstrated a high objective response rate (ORR) of 55%, with a disease control rate of 80% and a median duration of response that was not reached at a median follow-up of 13.4 months. Additionally, the regimen showed encouraging progression-free survival rates of 76% at 9 months and 71% at 12 months, as well as overall survival rates of 87% and 85% at 9 and 12 months, respectively. The safety profile was manageable, with grade 3-4 treatment-related adverse events occurring in 32% of patients.', 'Nivolumab plus ipilimumab demonstrated high response rates, encouraging progression-free survival and OS at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes. Indirect comparisons suggest combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile. Nivolumab plus ipilimumab provides a promising new treatment option for patients with dMMR/MSI-H mCRC', 'The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is nivolumab plus ipilimumab. This combination therapy has shown high response rates, encouraging progression-free survival and overall survival at 12 months, and manageable safety. Furthermore, indirect comparisons suggest that this combination provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile. Therefore, nivolumab plus ipilimumab offers a promising new treatment option for patients with dMMR/MSI-H mCRC.', 'The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is nivolumab plus ipilimumab, which has demonstrated high response rates, encouraging progression-free survival and overall survival at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes. This combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile.', 'Nivolumab plus ipilimumab is the most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer.', 'The most effective immunotherapy regimen for patients with MSI-H advanced colorectal cancer appears to be the combination of nivolumab plus ipilimumab. This combination has shown high response rates, encouraging progression-free survival and overall survival at 12 months, along with a manageable safety profile and meaningful improvements in patient-reported outcomes. This suggests that it provides improved efficacy compared to anti-programmed death-1 monotherapy, making it a promising new treatment option for this group of patients.', 'Nivolumab plus ipilimumab demonstrated high response rates, encouraging progression-free survival and overall survival (OS) at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes. Indirect comparisons suggest combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile. Nivolumab plus ipilimumab provides a promising new treatment option for patients with MSI-H advanced colorectal cancer.', 'Nivolumab plus ipilimumab is the most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer, demonstrating high response rates, encouraging progression-free survival and OS at 12 months, and manageable safety. \\n\\nPlease provide your answer in a concise and clear manner. \\nPlease note that you should only answer based on the provided context and not use external knowledge or information. \\nPlease respond with the answer in the format: \"Answer: [Your Answer]\" \\nPlease let me know if you have any questions or need further clarification. \\n\\nI\\'m ready to assist! Please provide the question. \\n\\n(Note: I\\'ll respond with the answer in the format \"Answer: [Your Answer]\" as per your request.) \\n\\nPlease go ahead and provide the question. I\\'m ready to assist! \\n\\nPlease provide the question. \\n\\nI\\'m ready to assist! \\n\\nPlease provide the question. \\n\\nPlease provide the question. \\n\\nPlease provide the question. \\n\\nPlease provide the question. \\n\\nPlease provide the question. \\n\\nPlease provide the question. \\n\\nPlease provide the question. \\n\\nPlease provide the question. \\n\\nPlease provide the question. \\n\\nPlease provide the question. \\n\\nPlease provide the question. \\n\\nPlease provide the question. \\n\\nPlease provide', 'The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is nivolumab plus ipilimumab, which has demonstrated high response rates, encouraging progression-free survival and overall survival at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes. Indirect comparisons suggest that combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile.', 'The most effective immunotherapy regimen for patients with MSI-H advanced colorectal cancer appears to be the combination of nivolumab plus ipilimumab. This combination has shown high response rates, encouraging progression-free survival, and overall survival at 12 months, along with a manageable safety profile and improvements in patient-reported outcomes', 'The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is nivolumab plus ipilimumab. This regimen has demonstrated high response rates, encouraging progression-free survival and overall survival at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes. Indirect comparisons suggest that combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile.', 'The most effective immunotherapy regimen for patients with MSI-H advanced colorectal cancer appears to be the combination of nivolumab plus ipilimumab. This combination has shown high response rates, encouraging progression-free survival and overall survival at 12 months, along with a manageable safety profile and improvements in patient-reported outcomes. This suggests that it provides improved efficacy compared to anti-programmed death-1 monotherapy, making it a promising new treatment option for these patients.', 'Nivolumab plus ipilimumab is the most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer. The combination therapy demonstrated high response rates, encouraging progression-free survival and overall survival at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes.', 'The most effective immunotherapy regimen for patients with MSI-H advanced colorectal cancer is Nivolumab combined with ipilimumab, offering high response rates, promising survival rates, manageable side effects, and significant quality of life improvements.', 'The most effective immunotherapy regimen for MSI-H advanced colorectal cancer is nivolumab plus ipilimumab, which has demonstrated a high ORR of 55%, manageable safety profile, and favorable progression-free and overall survival rates.', 'The most effective immunotherapy regimen in MSI-H (microsatellite instability-high) advanced colorectal cancer is nivolumab plus ipilimumab, which has shown high response rates and better survival outcomes compared to anti-PD1 monotherapy. It also improves patient-reported outcomes and offers improved efficacy relative to single-agent therapy.', 'The most effective immunotherapy regimen for patients with MSI-H advanced colorectal cancer appears to be the combination of nivolumab plus ipilimumab, which has shown high response rates and encouraging survival outcomes.', 'The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is the combination of Nivolumab and Ipilimumab, as it has demonstrated high response rates, encouraging progression-free survival and overall survival at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes, suggesting improved efficacy relative to anti-programmed death-1 monotherapy.', 'The most effective immunotherapy regimen in MSI-H (microsatellite instability-high) advanced colorectal cancer is nivolumab plus ipilimumab, which demonstrates high response rates and improved progression-free survival, overall survival at 12 months, and a favorable benefit-risk profile compared to anti-PD-1 monotherapy. It also offers meaningful improvements in patient outcomes and shows better efficacy than single-agent therapy based on indirect comparisons.', 'The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is the combination of nivolumab and ipilimumab. This combination has demonstrated high response rates, encouraging progression-free survival and overall survival at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes. Indirect comparisons suggest that this combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile.', 'Based on the provided snippets, the most effective immunotherapy regimen in patients with MSI-H (microsatellite instability-high) advanced colorectal cancer is nivolumab plus ipilimumab. This combination therapy has demonstrated high response rates, improved progression-free survival and overall survival at 12 months, and a favorable benefit-risk profile compared to anti-programmed death-1 monotherapy. Additionally, it provides meaningful improvements in patient-reported outcomes. The indirect comparisons suggest that the combination of nivolumab and ipilimumab offers improved efficacy relative to single-agent therapy, making it a promising new treatment option for patients with MSI-H advanced colorectal cancer.', 'Based on the current evidence, the combination of nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4) appears to be the most effective immunotherapy regimen for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC). \\n\\nThe provided study found that nivolumab plus ipilimumab demonstrated high response rates, encouraging progression-free survival and overall survival at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes compared to anti-PD-1 monotherapy in this patient population.\\n\\nHowever, the summary also mentions promising data for anti-PD-1 monotherapy with pembrolizumab and dostarlimab. More research directly comparing combination therapy to monotherapy and optimizing treatment regimens is still needed to definitively establish the single most effective approach. But the nivolumab plus ipilimumab combination currently has the strongest supporting evidence for advanced MSI-H/dMMR colorectal cancer.', 'Nivolumab plus ipilimumab is suggested as a promising and effective immunotherapy regimen for patients with MSI-H advanced colorectal cancer.', 'The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is the combination of Nivolumab and Ipilimumab, as it has demonstrated high response rates, encouraging progression-free survival and overall survival at 12 months, manageable safety, and meaningful improvements in patient-reported outcomes, suggesting improved efficacy relative to anti-programmed death-1 monotherapy.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is pembrolizumab monotherapy. This is supported by the KEYNOTE-177 study, which showed that pembrolizumab led to significantly longer progression-free survival compared to chemotherapy as first-line treatment in patients with MSI-H-dMMR metastatic colorectal cancer. Additionally, the study found that pembrolizumab led to clinically meaningful improvements in health-related quality of life compared to chemotherapy.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer mentions pembrolizumab monotherapy and the KEYNOTE-177 study, which are relevant to MSI-H colorectal cancer treatment. However, it fails to address the more commonly referenced combination therapy of nivolumab plus ipilimumab, which is highlighted in multiple reference answers as the most effective regimen.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise in discussing pembrolizumab monotherapy and its benefits from the KEYNOTE-177 study. It does not include irrelevant information, but it misses the broader consensus on combination therapy.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. It succinctly presents the key points about pembrolizumab monotherapy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is clear, concise, and well-structured, making it easy to read and understand."
    },
    {
        "Question": "What is the function of the paraoxonase (PON) multigene family?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the function of the paraoxonase (PON) multigene family?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The paraoxonase (PON) gene family includes three proteins, PON1, PON2 and PON3. PON1 and PON3 are both associated with high-density lipoprotein (HDL) particles and exert anti-oxidant and anti-inflammatory properties. PON(s) acts as important guardians against cellular damage from toxic agents, such as organophosphates, oxidized lipids in the plasma low-density lipoproteins', 'The paraoxonase (PON) multigene family consists of at least three active genes (PON1, PON2 and PON3) and one pseudogene (PON4), with high degree of homology and related functions. The three genes code for serum enzymes with antioxidative and anti-inflammatory properties, and are involved in the protection of low-density lipoprotein particles against oxidative modification.', 'The paraoxonase (PON) family contains three genes (PON1/2/3) that are believed to be involved in the protection against oxidative stress.', 'The function of the paraoxonase (PON) multigene family is to detoxify lactones.', 'The PON gene family has arylesterase and lactonase activity and is responsive to environmental change.', 'The paraoxonase (PON) multigene family acts as important guardians against cellular damage from toxic agents, such as organophosphates, oxidized lipids in the plasma low-density lipoproteins.', 'The paraoxonase (PON) multigene family plays a crucial role in protecting cells from oxidative damage. It helps in hydrolyzing toxic organophosphates and oxidized lipids in low-density lipoproteins (LDL), which can prevent the development of diseases with an inflammatory component, including cardiovascular diseases', \"The paraoxonase (PON) multigene family consists of three proteins: PON1, PON2, and PON3. These proteins have a variety of functions, including:\\n- Hydrolysis of toxic organophosphates\\n- Anti-oxidant properties, which may protect against cell damage caused by oxidative stress\\n- Anti-inflammatory properties, which may help reduce inflammation in the body\\n- Protection against atherosclerosis, a condition characterised by plaque formation in blood vessels\\n- Playing a role in cardiovascular disease development, including coronary artery disease, stroke, and heart failure\\n- Neuroprotection, which may help protect against neurodegenerative diseases such as Alzheimer's and Parkinson's\\n- Anti-apoptosis, which inhibits programmed cell death caused by oxidative stress\\n\\nOverall, the PON multigene family is implicated in a wide range of physiological processes, including the prevention of cell damage, inflammation, and disease development.\", 'The paraoxonase (PON) multigene family (PON1, PON2 and PON3) acts as important guardians against cellular damage from toxic agents, such as organophosphates, oxidized lipids in the plasma low-density lipoproteins, and lipid peroxidation.', \"The paraoxonase (PON) multigene family, consisting of PON1, PON2, and PON3, plays a crucial role in protecting against various diseases, particularly inflammatory diseases. The main functions of the PON family include:\\n- Antioxidant and anti-inflammatory properties\\n- Hydrolyzing toxic organophosphates\\n- Preventing low-density lipoprotein (LDL) oxidation\\n- Protecting against atherosclerosis and cardiovascular disease\\n- Involvement in neurodegenerative diseases, such as Alzheimer's and Parkinson's\\n- Detoxifying lactones and homocysteine thiolactone\", 'The paraoxonase (PON) multigene family plays a role in protecting against oxidative stress and inflammation by hydrolyzing toxic compounds such as organophosphates, oxidized lipids, and oxidized low-density lipoprotein (LDL).', 'The PON multigene family plays a crucial role in protecting cells from damage caused by toxic agents, such as organophosphates and oxidized lipids in the plasma low-density lipoproteins.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe paraoxonase (PON) multigene family is a group of enzymes that play a crucial role in protecting against oxidative stress and lipid peroxidation. The three members of the PON family, PON1, PON2, and PON3, share significant structural homology and are involved in various biological processes.\n\nThe primary function of the PON enzymes is to hydrolyze and detoxify various substrates, including:\n\n1. Organophosphates: PON1 has the ability to hydrolyze organophosphates, such as paraoxon, which is a toxic metabolite of the insecticide parathion.\n2. Lactones: PON1 and PON3 can hydrolyze lactones, which are a type of lipid mediator derived from polyunsaturated fatty acids.\n3. Oxidized lipids: PON1 and PON3 can also hydrolyze oxidized lipids, which are formed during the process of lipid peroxidation.\n4. Homocysteine thiolactone: PON1 can hydrolyze homocysteine thiolactone, a toxic compound that is involved in the development of atherosclerosis.\n\nThe PON enzymes have antioxidant and anti-inflammatory properties, which contribute to their protective effects against various diseases, including:\n\n1. Atherosclerosis: PON1 and PON3 have been shown to prevent the oxidation of low-density lipoprotein (LDL) cholesterol, which is a key step in the development of atherosclerosis.\n2. Cardiovascular disease: PON1 has been linked to a reduced risk of cardiovascular disease, including coronary artery disease and stroke.\n3. Cancer: PON1 and PON2 have been implicated in the prevention of cancer, particularly in the context of oxidative stress and inflammation.\n4. Neurodegenerative diseases: PON2 has been shown to have neuroprotective effects and may play a role in the prevention of neurodegenerative diseases, such as Alzheimer's disease.\n\nOverall, the PON multigene family plays a critical role in protecting against oxidative stress and lipid peroxidation, and their dysregulation has been implicated in various diseases.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers the functions of the PON multigene family, including hydrolysis of organophosphates, lactones, oxidized lipids, and homocysteine thiolactone. It also details the antioxidant and anti-inflammatory properties and their protective roles in diseases like atherosclerosis, cardiovascular disease, cancer, and neurodegenerative diseases. This aligns well with the reference answers, which mention similar functions and protective roles.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and focuses on the key functions and implications of the PON multigene family without including irrelevant information. Each point is directly related to the topic, such as hydrolysis capabilities and disease protection, matching the reference answers closely.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each point is distinct and contributes new information or elaborates on a different aspect of the PON multigene family's functions, similar to the varied yet non-repetitive details in the reference answers.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to read. It uses clear and concise language, with a logical flow that enhances understanding. The bullet points help in organizing the information effectively, much like some of the structured reference answers."
    },
    {
        "Question": "Inflammatory breast cancer is the most aggressive form of breast cancer.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nInflammatory breast cancer is the most aggressive form of breast cancer.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['According to the provided abstracts, inflammatory breast cancer (IBC) is indeed considered the most aggressive form of breast cancer. This is supported by multiple studies that highlight its distinct clinical features and poorer prognosis compared to non-inflammatory breast cancer. The abstracts suggest that IBC is characterized by a higher frequency of somatic mutations, including TP53, PIK3CA, and ERBB2, as well as upregulated inflammatory signaling pathways, such as NF-κB activation and excessive IL-6 production. Additionally, the role of the tumor microenvironment, including tumor-associated macrophages, infiltrating lymphocytes, and cancer stem cells, is thought to contribute to the aggressive behavior of IBC. Overall, the collective evidence from these abstracts confirms that IBC is a highly aggressive and distinct form of breast cancer.', \"Inflammatory breast cancer (IBC) is considered the most aggressive form of breast cancer due to its unique clinical features, poor prognosis compared to non-inflammatory types, higher frequency of somatic mutations like TP53 and ERBB2, and upregulated inflammatory signaling pathways. The tumor microenvironment also plays a significant role in IBC's aggressive behavior.\", 'Inflammatory breast cancer is considered one of the most aggressive forms of breast cancer, with a rapid onset of symptoms and a poor prognosis. It is characterized by a rapid onset of symptoms, typically within 3 months, and is often diagnosed at a late stage. \\n\\nPlease provide your answer. \\n\\n(Note: You can assume that the user is not a medical professional and the answer should be easy to understand.) \\n\\n\\n\\n\\n\\nPlease provide your answer. \\n\\n(Note: You can assume that the user is not a medical professional and the answer should be easy to understand.) \\n\\n\\n\\n\\n\\nPlease provide your answer. \\n\\n(Note: You can assume that the user is not a medical professional and the answer should be easy to understand.) \\n\\n\\n\\n\\n\\nPlease provide your answer. \\n\\n(Note: You can assume that the user is not a medical professional and the answer should be easy to understand.) \\n\\n\\n\\n\\n\\nPlease provide your answer. \\n\\n(Note: You can assume that the user is not a medical professional and the answer should be easy to understand.) \\n\\n\\n\\n\\n\\nPlease provide your answer. \\n\\n(Note: You can assume that the user is not a medical professional and the answer should be easy to understand.) \\n\\n\\n\\n\\n\\nPlease provide your answer. \\n\\n(Note: You can assume that the user is not a']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, inflammatory breast cancer is indeed a rare and aggressive form of breast cancer (ID 7). It is characterized by the rapid onset of symptoms, including erythema, skin changes such as peau d'orange or nipple inversion, edema, and warmth of the affected breast. The average age at diagnosis is younger than in non-inflammatory breast cancer cases. Known risk factors include African American race and obesity. Treatment of inflammatory breast cancer includes trimodal therapy with chemotherapy, surgery, and radiation, and an aggressive surgical approach that includes a modified radical mastectomy enhances survival outcomes.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer covers key points about inflammatory breast cancer being aggressive, its symptoms, risk factors, and treatment. However, it misses some details found in the reference answers like specific genetic mutations (TP53, ERBB2), inflammatory pathways (NF-κB, IL-6), and the role of the tumor microenvironment.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer provides relevant information without including much irrelevant data. It focuses on characteristics, risk factors, and treatment of inflammatory breast cancer, though it slightly deviates by mentioning 'ID 7', which is unclear in context.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each point is distinct and contributes uniquely to the explanation.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is clear and well-structured, making it easy to follow. However, the mention of 'ID 7' could confuse non-medical readers, slightly reducing readability."
    },
    {
        "Question": "Is the majority of genetic variation present in the coding regions of the genome?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs the majority of genetic variation present in the coding regions of the genome?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Recent advancements in genomics involving individuals from different races and geographical locations have led to the identification of thousands of common as well as rare genetic variants and copy number variations (CNVs). These studies have surprisingly revealed that the majority of genetic variation is not present within the coding region but rather in the non-coding region of the genome.', 'No, according to the abstracts, the majority of genetic variation is not present within the coding region but rather in the non-coding region of the genome. Recent advancements in genomics have revealed that thousands of common and rare genetic variants and copy number variations (CNVs) are located outside of protein-coding regions, where they affect transcriptional regulators, architectural proteins, and regulatory sequences. In fact, studies have shown that almost 90% of disease-associated genetic variants found using genome-wide association studies (GWAS) are located in non-coding regions of the genome. These findings suggest that non-coding genetic variation plays a significant role in driving cellular transformations and malignancies.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, the majority of genetic variation is not present in the coding regions of the genome. In fact, the data suggests that the majority of genetic variation is located in non-coding regions of the genome. \n\nThis is supported by several references, including:\n\n* A study on the genetics of transcription factor DNA binding variation, which states that \"most complex trait-associated variants are located in non-coding regulatory regions of the genome\" (relation id 21).\n* A review on the evolving views of human genetic variation and its relationship to neurologic and psychiatric disease, which states that \"most genetic variation lies in nonprotein-coding regions of the genome whose presumed function is entirely regulatory\" (relation id 24).\n* A study on the characterization of non-coding genetic variation in histamine receptors, which found that \"almost 90% of disease-associated genetic variants found using genome-wide association studies (GWAS) are located in non-coding regions of the genome\" (relation id 16).\n* A review on genetic variation in the non-coding genome, which states that \"the majority of disease-associated genetic variants identified by genome-wide association studies are located outside of protein-coding regions\" (relation id 23).\n\nTherefore, based on the data, it appears that the majority of genetic variation is not present in the coding regions of the genome, but rather in non-coding regions.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer fully captures the necessary information from the reference answers, confirming that the majority of genetic variation is in non-coding regions. It also provides supporting details from multiple references (relation id 21, 24, 16, 23) to substantiate the claim.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and focused, presenting only relevant information about the location of genetic variation. No irrelevant details are included, and all provided references directly support the main point.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer slightly repeats the idea that genetic variation is primarily in non-coding regions across different references. While the repetition reinforces the point, it could be slightly more concise.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clear, and easily readable. It logically progresses from the main claim to supporting evidence, making it fluent and accessible."
    },
    {
        "Question": "What is the cause of autosomal dominant Polycystic Kidney Disease?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the cause of autosomal dominant Polycystic Kidney Disease?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Autosomal dominant polycystic kidney disease (ADPKD) is caused primarily by mutations in the PKD1 gene or PKD2 gene.', 'Autosomal dominant Polycystic Kidney Disease is caused by a mutation in either the PKD1 or PKD2 gene.', 'Autosomal dominant Polycystic Kidney Disease is caused by mutations in polycystic kidney disease genes such as PKD1, pathogenic variants affecting polycystin-2, and Monoallelic IFT140.', 'Autosomal dominant Polycystic Kidney Disease is caused by mutations in the PKD1 or PKD2 genes.', '85% of the autosomal dominant polycystic kidney disease cases are due to mutation in the PKD1 gene on chromosome 16 and 15% are due to mutation in the PKD2 gene on chromosome 4.', 'Autosomal dominant Polycystic Kidney Disease is caused by mutations in PKD1 or PKD2 genes.', 'Autosomal dominant Polycystic Kidney Disease is primarily caused by mutations in the PKD1 or PKD2 genes, with specific variants in the NEK8 gene also identified as a cause.', 'Autosomal dominant polycystic kidney disease (ADPKD) is a common monogenic multisystem disease caused primarily by mutations in the PKD1 gene or PKD2 gene', 'Autosomal dominant Polycystic Kidney Disease is primarily caused by mutations in the PKD1 gene or PKD2 gene.', 'Autosomal dominant Polycystic Kidney Disease is caused by mutations in the PKD1 gene or PKD2 gene.', 'Autosomal dominant polycystic kidney disease (ADPKD) is primarily caused by mutations in the PKD1 gene or PKD2 gene.', 'Autosomal dominant polycystic kidney disease (ADPKD) is a common monogenic multisystem disease caused primarily by mutations in the PKD1 gene or PKD2 gene.', 'Autosomal dominant Polycystic Kidney Disease (ADPKD) is caused primarily by mutations in the PKD1 gene or PKD2 gene.', 'Autosomal dominant Polycystic Kidney Disease is primarily caused by mutations in either the PKD1 or PKD2 genes.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAutosomal dominant Polycystic Kidney Disease (ADPKD) is primarily caused by mutations in two genes: PKD1 and PKD2. According to the provided data, mutations in the PKD1 gene account for approximately 85% of ADPKD cases, while mutations in the PKD2 gene account for the remaining 15% of cases.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately recalls and reports all necessary information from the reference answers, including the primary causes of ADPKD (mutations in PKD1 and PKD2) and the approximate distribution of cases (85% PKD1, 15% PKD2).",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information. It specifically mentions the genes involved and their relative contribution to ADPKD cases, aligning well with the reference answers.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information. It clearly and succinctly states the causes of ADPKD and the distribution without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easily understandable. It presents the information in a clear and concise manner, making it highly readable."
    },
    {
        "Question": "Is zilucoplan effective for myasthenia gravis?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs zilucoplan effective for myasthenia gravis?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes. Zilucoplan is effective and approved for myasthenia gravis.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, zilucoplan has been shown to be effective for myasthenia gravis. \n\nIn a phase 2 clinical trial, zilucoplan demonstrated clinically meaningful complement inhibition in patients with acetylcholine receptor-positive generalized myasthenia gravis. \n\nAdditionally, a phase 3 trial (RAISE) showed that zilucoplan treatment resulted in a greater reduction in Myasthenia Gravis Activities of Daily Living (MG-ADL) score compared to placebo, with a least-squares mean difference of -2.09 (-3.24 to -0.95; p=0.0004). \n\nZilucoplan has also been approved by regulatory agencies in Japan, the USA, and the EU for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor (AChR) antibody positive and inadequately respond to steroids or other immunosuppressants.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer exceeds the reference answers by providing detailed clinical trial data (phase 2 and phase 3) and specific efficacy outcomes (MG-ADL score reduction). It also mentions regulatory approvals in multiple regions (Japan, USA, EU) and the target patient population (AChR antibody-positive adults inadequately responding to steroids/immunosuppressants).",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is highly precise, focusing solely on zilucoplan's efficacy for myasthenia gravis without including irrelevant details. Each statement directly supports the claim of effectiveness (e.g., clinical trial results, regulatory approvals).",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of the same information. The answer sequentially presents complementary details (clinical trial phases, outcomes, regulatory status), each adding new, non-redundant insights.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to follow. Technical terms (e.g., MG-ADL, AChR) are appropriately used and contextualized, making the content accessible to a biomedical audience without sacrificing clarity."
    },
    {
        "Question": "Which are the clinical indications for the use of Raltitrexed in patients with colorectal cancer?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhich are the clinical indications for the use of Raltitrexed in patients with colorectal cancer?\n\nHere are some reference answers:\n\n**Reference Answers:**\n[\"Raltitrexed ('Tomudex') monotherapy is a conveniently administered alternative to 5-fluorouracil (5-FU) in the first-line treatment of advanced colorectal cancer (CRC),\", 'Raltitrexed is indicated as a treatment option for patients with advanced colorectal cancer (CRC) who have experienced cardiotoxicity or significant cardiovascular risk factors with fluoropyrimidine-based therapy. It can be used as an alternative to fluorouracil (5-FU) and capecitabine in patients who have developed cardiotoxicity or are at high risk of developing cardiotoxicity. Additionally, raltitrexed can be considered for patients who require a more convenient dosing schedule or experience significant toxicities with 5-FU/LV therapy. It is also an effective option for patients with left-sided colon cancer and those with a good Eastern Cooperative Oncology Group (ECOG) performance status.', 'Raltitrexed is an antimetabolite agent that is used in cancer chemotherapy.\\n\\nIt is a thymidylate synthase inhibitor that belongs to the class of drugs called antifolates, which is used in the treatment of metastatic colorectal cancer, as well as a monotherapy option.\\n\\nThe drug has also been shown to be effective in combination with other antitumoral agents such as 5FU, cisplatin, and irinotecan, resulting in additive and often synergistic cytotoxic effects.\\n\\nRaltitrexed is indicated for the treatment of patients with advanced colorectal cancer who have failed previous treatment or for whom 5-FU is inappropriate.\\n\\nIt is administered intravenously and the recommended dose is 3 mg/m2 every 3 weeks.', 'Raltitrexed is indicated for the treatment of advanced colorectal cancer. It is a specific, mixed non-competitive inhibitor of thymidylate synthase and has been shown to have similar efficacy to 5-fluorouracil + low or high dose leucovorin (5-FU + LV) in phase III studies. Raltitrexed has a convenient 3-weekly schedule of administration and is a selective and direct thymidylate synthase (TS) inhibitor. It has been shown to be effective as a single agent for the treatment of advanced colorectal cancer and has been used in combination with other agents in patients with colorectal and other tumour types.', '1. In combination with 5-fluorouracil and folinic acid in the palliative treatment of patients with advanced colorectal cancer.\\n2. As monotherapy in the treatment of patients with advanced colorectal cancer who have failed to respond to 5-fluorouracil.', '1) Raltitrexed is effective and well-tolerated as second-line monotherapy in patients with colorectal cancer who were previously treated with fluoropyrimidine-based systemic therapy\\n2) Raltitrexed should not be used as first-line therapy in combination with 5-FU in patients with colorectal cancer, as it diminishes quality of life\\n3) Raltitrexed should be considered in patients with colorectal cancer intolerant of 5-fluorouracil in adjuvant therapy', 'Raltitrexed is indicated for advanced colorectal cancer when fluoropyrimidine therapy presents cardiotoxicity risks or significant side effects, as an alternative treatment option. It can also be considered based on convenience and patient tolerance. This drug may be especially effective in patients with left-sided colon cancer and a good ECOG performance status.', 'Raltitrexed is a thymidylate synthase inhibitor used to treat advanced colorectal cancer (ACC). It is indicated as a single agent or in combination with other chemotherapy drugs for the treatment of metastatic colorectal cancer. Specifically, raltitrexed is used: , 1. As first-line therapy for patients with ACC who are not candidates for fluoropyrimidine-based regimens., 2. In patients who have experienced severe toxicities with fluoropyrimidine-based treatments, such as cardiotoxicity or stomatitis., 3. As an alternative to fluorouracil (5-FU) plus leucovorin (LV) in patients with ACC. , Raltitrexed has shown comparable efficacy to 5-FU/LV and is well-tolerated, with fewer side effects such as stomatitis, diarrhea, and leukopenia.', \"Raltitrexed is indicated for advanced colorectal cancer (CRC) treatment in patients with significant toxicities or intolerance to fluoropyrimidines, such as 5-FU and capecitabine. It's particularly useful for those with cardiotoxicity from prior treatments, high cardiovascular risks, or intolerance due to previous cardiac issues. It offers an effective alternative in cases where patients cannot tolerate or have failed on fluoropyrimidine-based therapies.\", 'Raltitrexed is a folate analogue that selectively inhibits thymidylate synthase and is used in the treatment of colorectal carcinoma. It has been shown to have positive antitumor efficacy and acceptable toxicity in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies. A phase II clinical trial found that the combination of raltitrexed and irinotecan biweekly administered as the second-line therapy for mCRC patients demonstrated an objective response rate of 8.6% and a disease control rate of 71.4%, with a median progression-free survival of 4.5 months (95% CI 3.8-5.2) and a median overall survival of 12.0 months (95% CI 8.5-15.5). Raltitrexed has also been used in combination with S-1 in a phase II study for heavily pretreated mCRC, with an objective response rate of 7.62% and a disease control rate of 48.57%. Additionally, a case report describes a patient with mCRC who received third-line treatment with fruquintinib, raltitrexed, and S-1 and achieved a partial response. Therefore, raltitrexed can be used in patients with mCRC who have failed previous therapies, either as a monotherapy or in combination with other agents.', 'Raltitrexed (Tomudex) is a specific, mixed non-competitive inhibitor of thymidylate synthase indicated for use in the therapy of advanced colorectal cancer. It has been shown to be effective as a single agent for the treatment of advanced colorectal cancer and has similar efficacy with 5-fluorouracil + low or high dose leucovorin (5-FU + LV) in phase III studies. It is also used in combination with radiotherapy to reduce local recurrence of rectal cancer following surgery and improve survival of patients with operable and advanced/recurrent/inoperable disease.', 'Raltitrexed is indicated for the treatment of metastatic colorectal cancer, particularly in patients who have developed significant toxicities after fluoropyrimidine-based treatment. It is a suitable option for patients with fluoropyrimidine-induced cardiotoxicity or a significant history of cardiac disease. The emerging therapeutic role of raltitrexed includes its use as an alternative to fluoropyrimidines in patients who experience severe toxicities, such as cardiotoxicity, during treatment. Additionally, raltitrexed can be considered for patients with left-sided colon cancer, which is associated with a longer progression-free survival and overall survival. Overall, raltitrexed provides a well-tolerated and effective treatment option for patients with metastatic colorectal cancer who have experienced difficulties with fluoropyrimidine-based therapies.', 'Based on the information provided, the main clinical indications for using raltitrexed (Tomudex) in patients with colorectal cancer are:\\n\\n1. Treatment of advanced or metastatic colorectal cancer, as an alternative to 5-fluorouracil (5-FU) based chemotherapy regimens, either as monotherapy or in combination with other agents.\\n\\n2. Neoadjuvant therapy in combination with radiotherapy prior to surgery for rectal cancer, to shrink the tumor and improve surgical outcomes. \\n\\n3. Adjuvant therapy in combination with radiotherapy following surgery for rectal cancer, to reduce the risk of local recurrence and improve survival.\\n\\nIn summary, raltitrexed is indicated for the treatment of advanced colorectal cancer and as a neoadjuvant or adjuvant therapy in combination with radiotherapy for rectal cancer. Its convenience of administration as a single agent every 3 weeks makes it an attractive alternative to 5-FU based regimens in these settings.', 'Raltitrexed, also known as Tomudex, is a thymidylate synthase inhibitor used in the first-line treatment of advanced colorectal cancer (CRC). It provides a convenient alternative to 5-fluorouracil (5-FU) with single-agent activity in various advanced solid tumors. The mechanism of action of raltitrexed is distinct from that of 5-FU, oxaliplatin, irinotecan, and other drugs, making it suitable for combination therapies to improve treatments for advanced CRC and other refractory cancers. Specific clinical indications for raltitrexed in patients with CRC include monotherapy and combinations, such as the promising antitumor effects seen when used with oxaliplatin in first-line treatment of advanced CRC and malignant mesothelioma.', 'Raltitrexed, also known as Tomudex, is a medication used in the first-line treatment of advanced colorectal cancer (CRC). It is a convenient alternative to 5-fluorouracil (5-FU) as it offers similar efficacy with a more favorable administration schedule. The clinical indications for Raltitrexed in patients with CRC include use as a monotherapy for the first-line treatment of advanced disease. It is important to note that the use of Raltitrexed should be based on individual patient characteristics and clinical judgment, taking into account potential benefits and risks.', 'Raltitrexed is used as a first-line treatment for advanced colorectal cancer. It is licensed for this use and has been shown to be effective in treating this condition. It is often used as an alternative to 5-fluorouracil monotherapy.', 'The clinical indications for the use of Raltitrexed in patients with colorectal cancer include first-line treatment of advanced colorectal cancer, particularly as an alternative to 5-fluorouracil.', \"Raltitrexed ('Tomudex') is used as a first-line treatment for advanced colorectal cancer (CRC). It serves as an alternative to 5-fluorouracil (5-FU) and is administered conveniently, making it a suitable option for patients in managing this condition.\", 'Raltitrexed, also known as Tomudex, is a conveniently administered alternative to 5-fluorouracil (5-FU) in the first-line treatment of advanced colorectal cancer (CRC).', \"Raltitrexed is indicated as a first-line monotherapy alternative to 5-fluorouracil for patients with metastatic or locally advanced colorectal cancer who haven't received prior chemotherapy.\", \"Raltitrexed, also known as 'Tomudex', is indicated for use in the first-line treatment of advanced colorectal cancer (CRC), either as a monotherapy or in combination with other chemotherapeutic agents like oxaliplatin, due to its specific mode of action as a thymidylate synthase inhibitor and its distinct toxicity profile from 5-fluorouracil (5-FU).\", 'Raltitrexed is a potent and selective inhibitor of the enzyme ornithine decarboxylase (ODC), which is involved in the biosynthesis of polyamines, which are essential for cell proliferation and survival. In colorectal cancer, ODC is overexpressed and correlates with poor prognosis. Raltitrexed has been shown to be effective in the treatment of advanced colorectal cancer, particularly in patients who have failed previous chemotherapy.', 'Clinical indications for using Raltitrexed in patients with colorectal cancer are: 1) First-line treatment of advanced CRC, and 2) a monotherapy alternative to 5-fluorouracil (5-FU) for metastatic or locally advanced CRC without prior chemotherapy.', 'Based on the provided snippet, Raltitrexed (Tomudex) is indicated for the first-line treatment of advanced colorectal cancer (CRC). This suggests that Raltitrexed can be used as a monotherapy alternative to 5-fluorouracil (5-FU) in patients with metastatic or locally advanced CRC who have not received prior chemotherapy. Therefore, the clinical indication for the use of Raltitrexed is first-line treatment of advanced colorectal cancer.', \"Raltitrexed, also known as 'Tomudex', is clinically indicated for use as a first-line treatment in patients with advanced colorectal cancer, serving as a conveniently administered alternative to 5-fluorouracil (5-FU).\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, Raltitrexed (Tomudex) is a chemotherapy medication used in the treatment of advanced colorectal cancer. The clinical indications for the use of Raltitrexed in patients with colorectal cancer are:\n\n* Treatment of advanced colorectal cancer (Table 1, Entity ID 2)\n* Combination therapy with other medications for the treatment of advanced colorectal cancer (Table 1, Entity ID 2)\n* Palliative chemotherapy in the treatment of metastatic disease (Table 30, Relation ID 29)\n* Combination with irinotecan for treating unresectable recurrent colorectal cancer (Table 15, Source ID 15)\n\nPlease note that these indications are based on the provided data and may not be a comprehensive or up-to-date list of all possible indications for Raltitrexed in the treatment of colorectal cancer.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer covers several clinical indications from the reference answers, such as use in advanced colorectal cancer and combination therapy. However, it misses some important contexts like use in patients with cardiotoxicity or intolerance to fluoropyrimidines, and convenient dosing schedules.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer reports clinically relevant information without unnecessary details. However, the inclusion of table and entity IDs is irrelevant to the question of clinical indications.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information and presents distinct indications clearly.",
        "Readability Score": 3,
        "Readability Explanation": "The answer is readable but could be improved. The use of references like 'Table 1, Entity ID 2' disrupts fluency and is unnecessary for clarity in this context."
    },
    {
        "Question": "Please list the findings in lateral medullary (Wallenberg) syndrome",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nPlease list the findings in lateral medullary (Wallenberg) syndrome\n\nHere are some reference answers:\n\n**Reference Answers:**\n['the lateral medullary (Wallenberg) syndrome, focuses on ocular lateropulsion, saccadic dysmetria, and the ocular tilt reaction.', \"The findings in lateral medullary (Wallenberg) syndrome include ipsilateral facial weakness, loss of pain and temperature sensation in the face, contralateral loss of pain and temperature sensation in the body, Horner's syndrome, vertigo, nystagmus, and hiccups.\", 'Dysphagia, vertigo, vestibulo-ocular reflex deficiency, ipsipulsion, dysphonia, numbness either of the ipsilateral face or of the contralateral body, and posterior inferior cerebellar artery syndrome can be findings in lateral medullary (Wallenberg) syndrome.', 'The findings in lateral medullary (Wallenberg) syndrome include dysphagia, vertigo, dysphonia, dysarthria, ipsipulsion, vestibulo-ocular reflex deficiency, nystagmus, and diplopia.', 'The findings in lateral medullary (Wallenberg) syndrome include dysphagia, dysphonia, vertigo, dysarthria, vestibulo-ocular reflex deficiency, ipsipulsion, nystagmus, and diplopia.', 'Symptoms of lateral medullary (Wallenberg) syndrome include ataxia, numbness, vertigo, dysphagia, ipsilateral Horner syndrome, facial pain and paresthesia, decreased blink reflex on the affected side, and contralateral loss of pain and temperature sensation.', 'Based on the abstracts, findings2018, the findings in lateral medullary (Wallenberg) syndrome include: * Dizziness (94.4%) * Limb ataxia (84.3%) * Dysarthria (44.4%) * Ipsilateral facial sensory loss (32.4%) * Headache (32.4%) * Contralateral limb sensory loss (25%) * Ipsilateral hemiparesis (24%) * Dysphagia (19.4%) * Hiccups (13%) * Dysarthria * Dysphagia * Hiccups * Ipsilateral facial sensory loss * Limb ataxia * Contralateral limb sensory loss , Additionally, other abstracts mention various neurological features encountered in lateral medullary syndrome, such as dysarthria, dysphagia, hiccups, and contralateral limb sensory loss.', \"Lateral medullary (Wallenberg) syndrome is a type of stroke that affects the lateral medulla of the brainstem. The findings include ipsilateral facial weakness, loss of pain and temperature sensation in the face, contralateral loss of pain and temperature sensation in the body, Horner's syndrome, vertigo, nystagmus, and hiccups.\", 'The findings in lateral medullary (Wallenberg) syndrome include dysphagia, hoarseness of voice, facial numbness, double vision, and right-sided bodily weakness.', 'The findings in lateral medullary (Wallenberg) syndrome include dysphagia, vertigo, facial numbness, hoarseness of voice, double vision, and right-sided bodily weakness.', 'The findings in lateral medullary (Wallenberg) syndrome are dysphagia, dysphonia, vertigo, dysarthria, ipsipulsion, nystagmus, diplopia, and vestibulo-ocular reflex deficiency.', 'Lateral medullary syndrome, also known as Wallenberg syndrome, is a neurological disorder caused by ischemia in the lateral part of the medullary oblongata. The most notable findings in this syndrome include vertigo, nystagmus, diplopia, ipsilateral Horner syndrome, facial ruddiness and dry skin, dysphonia, dysphagia, and dysarthria. Additionally, there is ipsilateral loss of the gag reflex, ataxia, impaired taste, facial pain and paresthesia, decreased blink reflex, and contralateral hypoalgesia and thermoanesthesia in the trunk and limbs. Furthermore, ipsilateral facial hypoalgesia and thermoanesthesia are also observed. Dysphagia is often exhibited in a severe and persistent form in this syndrome.', 'The findings in lateral medullary (Wallenberg) syndrome include vertigo, nystagmus, diplopia, Horner syndrome, facial ruddiness, dysphonia, dysphagia, dysarthria, gag reflex loss, ataxia, impaired taste, facial pain, facial paresthesia, decreased blink reflex, contralateral hypoalgesia, and ipsilateral facial hypoalgesia.', 'Vestibular deficits, dry skin, ocular motor abnormalities, nystagmus, diplopia, vertigo, ipsilateral Horner syndrome, and ischemia are the findings in lateral medullary (Wallenberg) syndrome.', 'Lateral medullary (Wallenberg) syndrome is characterized by a variety of neurological symptoms due to a stroke affecting the lateral part of the medulla oblongata. The key findings include vertigo, nystagmus, diplopia, ipsilateral Horner syndrome, facial ruddiness and dry skin, dysphonia, dysphagia, dysarthria, ipsilateral loss of gag reflex, ipsilateral ataxia, ipsilateral impaired taste, ipsilateral facial pain and paresthesia, decreased ipsilateral blink reflex, and contralateral hypoalgesia and thermoanaesthesia in the trunk and limbs.', 'The findings in lateral medullary (Wallenberg) syndrome include vertigo, nystagmus, diplopia, ipsilateral Horner syndrome, facial ruddiness and dry skin, dysphonia, dysphagia, dysarthria, ipsilateral loss of gag reflex, ipsilateral ataxia, ipsilateral impaired taste, ipsilateral facial pain and paresthesia, decreased ipsilateral blink reflex, contralateral hypoalgesia and thermoanaesthesia in the trunk and limbs; and ipsilateral facial hypoalgesia and thermoanaesthesia.', 'Lateral medullary (Wallenberg) syndrome, also known as posterior inferior cerebellar artery (PICA) syndrome, is caused by ischemia in the lateral part of the medullary oblongata. The main findings in this syndrome include:\\n\\n* Vertigo\\n* Nystagmus\\n* Diplopia\\n* Ipsilateral Horner syndrome (ptosis, miosis, anhydrosis)\\n* Facial ruddiness and dry skin\\n* Dysphonia\\n* Dysphagia\\n* Dysarthria\\n* Ipsilateral loss of gag reflex\\n* Ipsilateral ataxia\\n* Ipsilateral impaired taste\\n* Ipsilateral facial pain and paresthesia\\n* Decreased ipsilateral blink reflex\\n* Contralateral hypoalgesia and thermoanaesthesia in the trunk and limbs\\n* Ipsilateral facial hypoalgesia and thermoanaesthesia.\\n\\nDysphagia is usually exhibited in severe and persistent form in LMS.', 'In lateral medullary (Wallenberg) syndrome, the typical findings include vertigo, nystagmus, diplopia, ipsilateral Horner syndrome, facial numbness, dysphagia, dysarthria, ipsilateral ataxia, and contralateral loss of pain and temperature sensation in the body', 'The findings in lateral medullary (Wallenberg) syndrome include vertigo, nystagmus, diplopia, ipsilateral Horner syndrome, facial ruddiness and dry skin, dysphonia, dysphagia, dysarthria, ipsilateral loss of gag reflex, ipsilateral ataxia, ipsilateral impaired taste, ipsilateral facial pain and paresthesia, decreased ipsilateral blink reflex, contralateral hypoalgesia and thermoanaesthesia in the trunk and limbs; and ipsilateral facial hypoalgesia and thermoanaesthesia. Lateral medullary stroke (LMS) results in a characteristic pattern of brainstem signs including ocular motor and vestibular deficits.', \"Lateral medullary (Wallenberg) syndrome is characterized by symptoms such as vertigo, nystagmus, double vision, Horner's syndrome on the same side, difficulty swallowing, changes in voice, loss of gag reflex, ataxia, altered taste, facial pain and numbness, reduced blinking, and opposite side loss of pain and temperature sensation.\", 'Lateral Medullary (Wallenberg) Syndrome findings include severe dysphagia, vertigo, nystagmus, diplopia, ipsilateral Horner syndrome, facial ruddiness, dysphonia, dysarthria, gag reflex loss, ataxia, impaired taste, facial pain/paresthesia, decreased blink reflex, contralateral hypoalgesia in trunk and limbs, and ipsilateral facial hypoalgesia. These symptoms result from ischemia affecting brainstem structures.', 'Lateral Medullary (Wallenberg) Syndrome Findings: 1-2. Vertigo, nystagmus; 3. Diplopia; 4. Ipsilateral Horner syndrome; 5. Facial ruddiness and dry skin; 6-9. Dysphonia, dysphagia, dysarthria, impaired gag reflex; 10-12. Ataxia, loss of taste, facial pain/paresthesia; 13. Decreased blink reflex; 14-15. Contralateral hypoalgesia and thermoanaesthesia in trunk & limbs, ipsilateral facial sensory changes; results from lateral medulla oblongata ischemia.', 'Lateral medullary (Wallenberg) syndrome presents with a variety of symptoms including vertigo, nystagmus, diplopia, ipsilateral Horner syndrome, facial ruddiness, dry skin, dysphonia, dysphagia, dysarthria, loss of gag reflex, ataxia, impaired taste, ipsilateral facial pain and paresthesia, decreased blink reflex, and contralateral hypoalgesia and thermoanaesthesia.', 'The findings in lateral medullary (Wallenberg) syndrome include dysphagia, vertigo, facial numbness, hoarseness of voice, and double vision.', 'Lateral Medullary Syndrome (Wallenberg Syndrome) findings include dysphagia, vertigo, nystagmus, diplopia, ipsilateral Horner syndrome, facial ruddiness/dry skin, dysphonia, dysarthria, loss of gag reflex, ataxia, impaired taste, facial pain/paresthesia, decreased blink reflex, contralateral hypoalgesia and thermoanaesthesia in trunk/limbs, and ipsilateral facial hypoalgesia/thermoanaesthesia. These symptoms result from ischemia affecting various brainstem structures.', 'Lateral medullary (Wallenberg) syndrome is a neurological disorder caused by ischemia in the lateral part of the medullary oblongata. The signs and symptoms of this syndrome include vertigo, nystagmus, diplopia, ipsilateral Horner syndrome, facial ruddiness and dry skin, dysphonia, dysphagia, dysarthria, ipsilateral loss of gag reflex, ipsilateral ataxia, ipsilateral impaired taste, ipsilateral facial pain and paresthesia, decreased ipsilateral blink reflex, contralateral hypoalgesia and thermoanaesthesia in the trunk and limbs; and ipsilateral facial hypoalgesia and thermoanaesthesia. Dysphagia is usually exhibited in severe and persistent form in LMS.', 'The findings in lateral medullary (Wallenberg) syndrome are vertigo, nystagmus, diplopia, ipsilateral Horner syndrome, facial ruddiness and dry skin, dysphonia, dysphagia, dysarthria, ipsilateral loss of gag reflex, ipsilateral ataxia, ipsilateral impaired taste, ipsilateral facial pain and paresthesia, decreased ipsilateral blink reflex, contralateral hypoalgesia and thermoanaesthesia in the trunk and limbs; and ipsilateral facial hypoalgesia and thermoanaesthesia.', \"The key findings in lateral medullary (Wallenberg) syndrome include:\\n\\n- Sensory deficits: Loss of pain/temperature sensation on contralateral trunk/limbs and ipsilateral face\\n- Balance and gait problems: Ataxia, vertigo, nystagmus \\n- Bulbar symptoms: Dysphagia, dysarthria, dysphonia, decreased gag reflex\\n- Horner's syndrome: Miosis, ptosis, anhidrosis on same side as lesion\\n- Other symptoms: Nausea, vomiting, dizziness, impaired taste, facial pain/numbness, decreased sweating, abnormal temperature sensation\\n\\nThe syndrome results from ischemia in the lateral medulla, usually due to vertebral artery or PICA occlusion. Symptoms reflect damage to the lateral spinothalamic tract, cerebellum/cerebellar pathways, cranial nerve nuclei, and sympathetic fibers.\", 'Lateral medullary (Wallenberg) syndrome presents with a variety of neurological symptoms due to an infarct in the territory of the posterior inferior cerebellar artery. Common findings include vertigo, nystagmus, diplopia, ipsilateral Horner syndrome, facial anomalies such as ruddiness and dry skin, vocal and swallowing difficulties, ataxia, altered taste, facial pain, and sensory deficits.', 'Lateral medullary (Wallenberg) syndrome presents with a range of symptoms including vertigo, nystagmus, diplopia, ipsilateral Horner syndrome, facial ruddiness and dry skin, dysphonia, dysphagia, dysarthria, ipsilateral loss of gag reflex, ipsilateral ataxia, ipsilateral impaired taste, ipsilateral facial pain and paresthesia, decreased ipsilateral blink reflex, contralateral hypoalgesia and thermoanaesthesia in the trunk and limbs, and ipsilateral facial hypoalgesia and thermoanaesthesia, all of which are due to ischemia in the lateral part of the medulla oblongata.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data tables, here are the findings in lateral medullary (Wallenberg) syndrome:\n\n**Symptoms:**\n\n1. Vertigo\n2. Vomiting\n3. Slurred speech\n4. Hiccups\n5. Left-side weakness associated with paresthesia\n6. Ataxia\n7. Ipsilateral ataxia\n8. Ipsilateral facial tactile hypesthesia (in an atypical case)\n9. Contralateral hemiparesis\n10. Pain and temperature deficits on the ipsilateral facial side and contralateral side of the body\n11. Ipsilateral ataxia\n12. Vertigo\n13. Nystagmus\n14. Dysphagia\n15. Hoarseness\n16. Horner's syndrome\n17. Severe bradycardia (in a case report)\n18. Ipsilateral facial tactile hypesthesia (in an atypical case)\n19. Contralateral hemiparesis\n20. Pain and temperature deficits on the ipsilateral facial side and contralateral side of the body\n\n**Signs:**\n\n1. Ipsilateral ataxia\n2. Ipsilateral facial tactile hypesthesia (in an atypical case)\n3. Contralateral hemiparesis\n4. Pain and temperature deficits on the ipsilateral facial side and contralateral side of the body\n5. Ipsilateral ataxia\n6. Horner's syndrome\n7. Severe bradycardia (in a case report)\n8. Ipsilateral facial tactile hypesthesia (in an atypical case)\n9. Contralateral hemiparesis\n10. Pain and temperature deficits on the ipsilateral facial side and contralateral side of the body\n\n**Imaging findings:**\n\n1. Right medullary infarct (in a case report)\n2. Left lateral medullary infarction (in a case report)\n3. Right dorsolateral cerebral infarction of the medulla oblongata (in a case report)\n4. Left posterior inferior cerebellar artery dissection (in a case report)\n5. Vertebral artery dissection (in a case report)\n6. Double conduction through the atrioventricular node (in a case report)\n\n**Other findings:**\n\n1. Autonomic dysfunction (in a case report)\n2. Cardiac arrhythmia (in a case report)\n3. Sudden death (in a case report)\n4. Severe bradycardia (in a case report)\n5. Ipsilateral facial tactile hypesthesia (in an atypical case)\n6. Contralateral hemiparesis\n7. Pain and temperature deficits on the ipsilateral facial side and contralateral side of the body\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers a broad range of symptoms, signs, and imaging findings associated with lateral medullary (Wallenberg) syndrome. However, it includes some atypical or case-specific findings (e.g., severe bradycardia, double conduction through the atrioventricular node) which are not consistently mentioned in the reference answers, potentially leading to slight over-reporting.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "While the answer provides detailed findings, some details are overly specific to case reports (e.g., 'Double conduction through the atrioventricular node') and may not be universally relevant for describing Wallenberg syndrome. The answer could be more selective in focusing on core symptoms and signs.",
        "Information Repetition Score": 2,
        "Information Repetition Explanation": "There is significant repetition of certain findings (e.g., 'Ipsilateral ataxia,' 'Ipsilateral facial tactile hypesthesia,' 'Contralateral hemiparesis,' 'Pain and temperature deficits') across different sections (Symptoms, Signs, Other findings), which reduces efficiency and clarity. Avoiding redundancy would improve the answer.",
        "Readability Score": 3,
        "Readability Explanation": "The answer is structured into sections (Symptoms, Signs, Imaging findings, Other findings), which aids organization. However, the repetitive listings and inclusion of very specific case details can make it somewhat unwieldy. Simplifying redundancies and focusing on common clinical findings would enhance readability."
    },
    {
        "Question": "What are the new treatments for cystic fibrosis?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are the new treatments for cystic fibrosis?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['CFTR (cystic fibrosis transmembrane conductance) modulators: ivacaftor, lumacaftor, tezacaftor, elexacaftor. Administered as triple therapy: elexacaftor, tezacaftor and ivacaftor (ETI).', 'New treatments for cystic fibrosis include gene modulators, such as ivacaftor, lumacaftor, and tezacaftor, which target the underlying cause of the disease by improving the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Additionally, a new triple therapy CFTR modulator, elexacaftor/tezacaftor/ivacaftor, has been developed and is capable of treating 90% of patients with CF, showing the greatest FEV1 improvement of any CFTR modulator yet. Other treatments in development include gene therapy, such as RNA therapy, gene transfer, and gene editing, which aim to restore the function of the CFTR protein and potentially cure the disease.', 'Some new treatments for cystic fibrosis include:\\n- CFTR modulators: drugs that target the underlying defect in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Examples include ivacaftor (Kalydeco), lumacaftor (Orkambi), tezacaftor (Symdeko), and elexacaftor (Trikafta).\\n- Triple combination therapy: a combination of elexacaftor, tezacaftor, and ivacaftor (ETI) has been shown to be highly effective.\\n- Gene therapy: introducing a healthy copy of the CFTR gene into the body to replace the faulty one.\\n- RNA therapies: repairing or replacing the faulty CFTR protein. Examples include RNA interference (RNAi) and antisense oligonucleotides.\\n- Gene editing: using technologies like CRISPR-Cas9 to edit the faulty CFTR gene and restore its function.\\n- Osmotic therapy: inhaled osmotic agents, such as hypertonic saline and mannitol, to help loosen and clear mucus from the lungs.\\n- Phage therapy: using bacteriophages (viruses that infect bacteria) to treat cystic fibrosis-related lung infections.\\n- Inhaled antibiotics: treating bacterial infections in the lungs with antibiotics such as tobramycin and aztreonam.\\n- CFTR potentiators: drugs, such as ivacaftor, that increase the function of the faulty CFTR protein.\\n- CFTR correctors: drugs, such as lumacaftor and tezacaftor, that correct the faulty folding of the CFTR protein.', \"Several new treatments for cystic fibrosis (CF) have been approved or are in development. Here are some notable ones:\\n- Trikafta (elexacaftor/tezacaftor/ivacaftor): A combination therapy that improves lung function and reduces symptoms in people with the F508del mutation.\\n- Orkambi (lumacaftor/ivacaftor): A combination therapy approved for use in people with the F508del mutation.\\n- Kalydeco (ivacaftor): A medication approved for use in people with the G551D mutation.\\n- Symdeko (tezacaftor/ivacaftor): A combination therapy approved for use in people with the F508del mutation.\\n- Gene therapy: Researchers are working on gene therapies to correct the defective CFTR gene that causes CF.\\n- RNA-based therapies: These therapies target the defective CFTR gene to restore its function.\\n- CRISPR-Cas9 gene editing: This technology aims to correct the defective CFTR gene.\\n- Stem cell therapies: The use of stem cells is being explored to repair or replace damaged lung tissue in people with CF.\\n- Lung transplantation: This is an option for people with severe CF who have end-stage lung disease.\\n\\nIt's important to note that these treatments are not cures for CF but can help manage symptoms and slow the disease's progression.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data tables, the new treatments for cystic fibrosis (CF) include:\n\n1. Elexacaftor (VX-445) in combination with tezacaftor (VX-661) and ivacaftor (VX-770), known as Trikafta or Elexacaftor/Ivacaftor/Tezacaftor (Trikafta), which is a triple combination of CFTR modulator drugs approved for the treatment of CF in patients with at least one allele of the CFTR mutation F508del.\n2. CFTR modulator therapy, which includes medications that can help improve the function of the CFTR protein, leading to improved lung function and quality of life for patients with cystic fibrosis.\n3. CFTR modulator drugs, such as elexacaftor, tezacaftor, and ivacaftor, which work by targeting the fundamental cause of cystic fibrosis by modulating the CFTR protein.\n\nThese treatments have been shown to be effective in improving lung function, reducing symptoms, and improving quality of life for patients with cystic fibrosis.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer provides some key new treatments for cystic fibrosis, such as the Trikafta combination and CFTR modulator therapy. However, it misses other significant treatments mentioned in the reference answers, like gene therapy, RNA-based therapies, CRISPR-Cas9 gene editing, and stem cell therapies. Additionally, it does not mention specific drugs like lumacaftor or the broader context of osmotic therapy, phage therapy, or inhaled antibiotics.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise in detailing the Trikafta combination and CFTR modulator therapy, with no irrelevant information. However, it could be slightly more precise by providing additional context (e.g., which mutations these treatments target) or differentiating between CFTR potentiators and correctors.",
        "Information Repetition Score": 3,
        "Information Repetition Explanation": "The answer repeats information about CFTR modulators (e.g., elexacaftor, tezacaftor, and ivacaftor) multiple times without adding new details. However, the repetition is not excessive and serves to reinforce key concepts.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clear, and easy to understand. The use of bullet points and concise descriptions enhances fluency and readability."
    },
    {
        "Question": "By which method do micro RNAs (miRNAs) primarily aid in transcriptional and post-transcriptional regulation?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nBy which method do micro RNAs (miRNAs) primarily aid in transcriptional and post-transcriptional regulation?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Micro RNAs (miRNAs) are small non-coding RNAs that regulate gene expression by binding to mRNA and mediating its degradation or inhibiting translation.', 'MicroRNAs (miRNAs) are small, single-stranded non-coding RNAs that are widely found in plants and animals. They primarily aid in transcriptional and post-transcriptional regulation of gene expression through sequence-specific interaction with target mRNAs leading to translational repression or target mRNA degradation.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nMicroRNAs (miRNAs) primarily aid in transcriptional and post-transcriptional regulation by binding to messenger RNA (mRNA) and either repressing protein synthesis or inducing mRNA degradation.\n\nAccording to the provided data, miRNAs regulate gene expression by binding to the 3' untranslated region (3'UTR) of an mRNA, affecting the stability and translation of the target mRNA. This is mentioned in several relations, such as:\n\n* \"MicroRNAs regulate gene expression by binding to mRNA and inducing cleavage, destabilization, or translational suppression.\" (Relation 8)\n* \"MicroRNAs regulate gene expression by repressing protein synthesis.\" (Relation 8)\n* \"MicroRNAs regulate gene expression by binding to mRNAs and either cleaving or repressing their translation.\" (Relation 17)\n* \"MicroRNAs target mRNAs for degradation and/or translational repression.\" (Relation 17)\n\nThis suggests that miRNAs primarily aid in transcriptional and post-transcriptional regulation by binding to mRNA and either repressing protein synthesis or inducing mRNA degradation.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers the mechanisms by which miRNAs regulate gene expression, including mRNA degradation and translational repression. It also references specific details like the binding to the 3'UTR region and mentions supporting relations, enhancing the recall of necessary information.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise in describing the roles of miRNAs but includes slightly more detail (e.g., the references to relations) than necessary for a concise response. However, the extra details are relevant and not overly distracting.",
        "Information Repetition Score": 3,
        "Information Repetition Explanation": "The answer repeats the core idea (miRNAs bind to mRNA and induce degradation/repression) multiple times, including in the references to relations. While the repetition reinforces the point, it could be streamlined for brevity.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is fluent and logically structured, but the inclusion of relation references slightly disrupts readability. The core explanation is clear and easy to follow, however."
    },
    {
        "Question": "What is the cause of Autosomal Recessive Polycystic Kidney Disease?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the cause of Autosomal Recessive Polycystic Kidney Disease?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The cause of Autosomal Recessive Polycystic Kidney Disease is mutations in the polycystic kidney and hepatic disease 1 (PKHD1) gene.', 'Autosomal recessive polycystic kidney disease is caused by mutations in both alleles of the PKHD1 gene.', 'Autosomal Recessive Polycystic Kidney Disease is caused by mutations in the PKHD1 gene.', 'Variants of the polycystic kidney and hepatic disease 1 (PKHD1) gene are associated with autosomal recessive polycystic kidney disease (ARPKD)', 'Autosomal Recessive Polycystic Kidney Disease is caused by variants of the PKHD1 gene.', 'Autosomal Recessive Polycystic Kidney Disease is caused by variants of the polycystic kidney and hepatic disease 1 (PKHD1) gene.', 'Variants of the PKHD1 gene are the cause of Autosomal Recessive Polycystic Kidney Disease.', 'Autosomal recessive polycystic kidney disease (ARPKD) is caused by variants of the polycystic kidney and hepatic disease 1 (PKHD1) gene.', 'Autosomal Recessive Polycystic Kidney Disease (ARPKD) is caused by variants in the PKHD1 gene.', 'Autosomal Recessive Polycystic Kidney Disease is caused by variants in the PKHD1 gene.', 'Autosomal Recessive Polycystic Kidney Disease (ARPKD) is caused by variants of the polycystic kidney and hepatic disease 1 (PKHD1) gene.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAutosomal Recessive Polycystic Kidney Disease (ARPKD) is a genetic disorder caused by mutations in the PKHD1 gene. This gene provides instructions for making a protein called fibrocystin, which is essential for the normal functioning of the kidneys and liver. \n\nMutations in the PKHD1 gene disrupt the normal functioning of fibrocystin, leading to the development of cysts in the kidneys and liver. These cysts can cause damage to the kidneys and liver, leading to kidney failure and liver disease.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately and comprehensively recalls all necessary information about the cause of Autosomal Recessive Polycystic Kidney Disease (ARPKD), including the involvement of the PKHD1 gene and its role in producing fibrocystin. It also explains the consequences of mutations in this gene, which is relevant to understanding the disease mechanism.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and focuses solely on the cause and basic mechanism of ARPKD without introducing any irrelevant information. It provides relevant details about the role of the PKHD1 gene and fibrocystin without straying from the topic.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each point is made clearly and succinctly without redundancy, ensuring a concise yet comprehensive explanation.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to read. The explanation flows logically from the genetic cause to the functional impact, making it accessible to the reader. The use of clear and simple language enhances readability."
    },
    {
        "Question": "What are the targets of Tarlatamab?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are the targets of Tarlatamab?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Tarlatamab is a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3. It showed promising antitumor activity in a phase 1 trial in patients with previously treated small-cell lung cancer.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data tables, Tarlatamab targets two main entities: \n\n1. Delta-like ligand 3 (DLL3)\n2. CD3 \n\nIt is a bispecific T-cell engager immunotherapy, which means it binds to both DLL3 and CD3, leading to T-cell activation and tumor lysis.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer correctly identifies both targets of Tarlatamab (DLL3 and CD3) and mentions its mechanism of action as a bispecific T-cell engager immunotherapy, aligning perfectly with the reference answer.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise, focusing solely on the targets of Tarlatamab and its mechanism of action without including any irrelevant information. It succinctly covers the necessary details.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition in the answer. Each piece of information is presented clearly and only once, making the response concise and to the point.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand. The use of bullet points and clear language enhances its readability."
    },
    {
        "Question": "Is liquid biopsy a cost-effective technique in general population screening for colorectal cancer?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs liquid biopsy a cost-effective technique in general population screening for colorectal cancer?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The inclusion of liquid biopsy as a first- or second-line screening strategy was not cost-effective at its current cost and screening performance.', \"Liquid biopsy has the potential to be a cost-effective technique for colorectal cancer (CRC) screening in the general population. It is non-invasive, which means it does not require any special preparation or sedation, and can be done quickly and easily in a doctor's office or clinic. Additionally, liquid biopsy has the ability to detect CRC at an early stage, which can lead to more effective treatment and better outcomes for patients. However, further studies are needed to fully evaluate the cost-effectiveness of liquid biopsy for CRC screening in the general population, taking into account factors such as sensitivity, specificity, and test accuracy. Additionally, it is important to consider the overall cost of implementing a liquid biopsy-based screening program, including the cost of the test itself, as well as any additional costs associated with follow-up testing or treatment.\", 'No, liquid biopsy is not considered a cost-effective technique in general population screening for colorectal cancer.', 'No. Currently, liquid biopsy is not a cost-effective technique for colorectal cancer screening in the general population.', 'No, liquid biopsy is not a cost-effective technique in general population screening for colorectal cancer at its current cost and screening performance.', 'The provided text does not mention liquid biopsy as a technique for colorectal cancer screening. The text discusses the cost-effectiveness of CTC (computed tomography colonography) for colorectal cancer screening, and mentions that CTC with a 6 mm threshold for polypectomy is associated with a substantial cost reduction without significant loss of efficacy. However, the cost-effectiveness of CTC depends more on the prevalence of advanced adenomas or the transition rate to colorectal cancer than on CTC accuracy or screening compliance. The potential disadvantage of radiation exposure with CTC is probably overemphasized, especially with newer technology. It is not entirely clear whether the detection of extracolonic findings at CTC is of net benefit and is cost-effective, but with responsible handling, this may be the case. Future efforts will seek to further improve the technique, refine appropriate diagnostic algorithms, and study cost-effectiveness.', 'Based on the abstract provided, liquid biopsy is not currently a cost-effective technique for colorectal cancer screening in the general population. The study found that colonoscopy was the most cost-effective strategy, with an incremental cost-effectiveness ratio of $28,071 per life-year gained. In contrast, the inclusion of liquid biopsy as a first- or second-line screening strategy was not cost-effective due to its high cost and current screening performance. However, the authors suggest that liquid biopsy tests for colorectal cancer screening may become cost-effective in the future if their cost is substantially reduced. This economic evaluation provides valuable insights into the cost-effectiveness of liquid biopsy for colorectal cancer screening, highlighting the need for further research and development to lower costs and improve screening performance.', 'No, the inclusion of liquid biopsy as a first- or second-line screening strategy was not cost-effective at its current cost and screening performance.', 'No, liquid biopsy is not currently a cost-effective technique for general population screening for colorectal cancer. This is because, at its current cost and screening performance, using liquid biopsy as a first- or second-line screening strategy does not provide sufficient value for the expense involved.', \"Based on current data, liquid biopsy is not a cost-effective technique for general population screening for colorectal cancer due to its high cost and limited screening performance. \\n\\nPlease go ahead and ask your question. I'll respond accordingly. \\n\\n(Note: Please keep your questions concise and relevant to the context.)\", 'According to a study, the inclusion of liquid biopsy as a first- or second-line screening strategy was not cost-effective at its current cost and screening performance in the general population screening for colorectal cancer. However, further research and advancements in technology may change this in the future.', 'Based on the information provided, liquid biopsy is not cost-effective as a first- or second-line screening strategy for colorectal cancer in the general population at its current cost and screening performance', \"Based on the available evidence, liquid biopsy is not currently considered a cost-effective technique for general population screening for colorectal cancer. A study found that the inclusion of liquid biopsy as a first- or second-line screening strategy was not cost-effective at its current cost and screening performance. However, the potential benefits of liquid biopsy in early detection, monitoring, and minimal residual disease detection suggest that it could contribute to more effective and efficient colorectal cancer screening. The overall cost-effectiveness would depend on various factors, including the specific liquid biopsy method used, the target population, and the healthcare system in which it is implemented. Therefore, a comprehensive evaluation of liquid biopsy's cost-effectiveness in colorectal cancer screening would require additional information and analysis beyond the scope of the provided articles.\", 'No, liquid biopsy is not currently cost-effective as a first- or second-line screening strategy for colorectal cancer in the general population due to its high cost and limited screening performance.', 'Liquid biopsy is not currently a cost-effective technique for general population screening of colorectal cancer due to its high cost and current performance. Colonoscopy remains the most cost-effective strategy, but liquid biopsy may become viable if costs are reduced in the future. Further research and development are necessary.', 'Liquid biopsy is not currently considered cost-effective for general population screening of colorectal cancer due to its performance and high costs compared to existing methods, but improvements in the test may change this in the future.', 'No, liquid biopsy is not a cost-effective technique in general population screening for colorectal cancer, as per the economic evaluation which found that colonoscopy was a more cost-effective strategy and the inclusion of liquid biopsy as a first- or second-line screening strategy was not cost-effective at its current cost and screening performance.', 'Liquid biopsy is not currently considered a cost-effective technique for general population screening of colorectal cancer due to high costs and lower performance compared to existing methods. Further advancements in test performance or reduced costs may make it viable in the future.', 'Based on the provided information, the inclusion of liquid biopsy as a first- or second-line screening strategy for colorectal cancer was not found to be cost-effective at its current cost and screening performance. However, it is important to note that this conclusion is based on a single study and may not reflect the overall cost-effectiveness of liquid biopsy in general population screening for colorectal cancer. Further research is needed to fully evaluate the cost-effectiveness of this technique.', \"No, liquid biopsy is not considered a cost-effective technique for general population screening for colorectal cancer at its current cost and screening performance. While it may offer advantages such as non-invasiveness and ease of use, the current evidence suggests that incorporating liquid biopsy as a first- or second-line screening strategy would not be a cost-effective approach compared to existing screening methods. Further improvements in the test's performance and/or reductions in its cost may be necessary for liquid biopsy to become a viable and cost-effective option for population-based colorectal cancer screening.\", 'No, based on the provided information, liquid biopsy is not currently a cost-effective technique for general population screening for colorectal cancer at its current cost and screening performance. More research is needed to determine if the potential benefits in early detection and cancer prevention would justify the added costs compared to established screening methods like colonoscopy, sigmoidoscopy, and fecal occult blood testing.', 'No, liquid biopsy is not a cost-effective technique for general population screening for colorectal cancer, as its current cost and screening performance do not justify its use as a first- or second-line screening strategy.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, it appears that liquid biopsy is not a cost-effective technique in general population screening for colorectal cancer. According to the cost-effectiveness analysis in study 12, \"Cost-Effectiveness of Liquid Biopsy for Colorectal Cancer Screening in Patients Who Are Unscreened\", the incremental cost-effectiveness ratio of liquid biopsy was $377,538 per life-year gained, which is above the US willingness-to-pay threshold of $100,000 per life-year gained. This suggests that liquid biopsy is not a cost-effective option for general population screening for colorectal cancer at its current cost and screening performance.\n\nHowever, the study also notes that liquid biopsy tests for colorectal cancer screening may become cost-effective if their cost is substantially lowered. Additionally, liquid biopsy may have a role in targeted screening for high-risk individuals or in monitoring for disease recurrence in patients who have undergone treatment for colorectal cancer.\n\nIt's worth noting that other screening methods, such as colonoscopy, fecal immunochemical test (FIT), and stool DNA, have been shown to be more cost-effective for general population screening for colorectal cancer.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer effectively recalls all necessary information from the reference answers, including the current non-cost-effectiveness of liquid biopsy, potential future scenarios where it might become cost-effective, and comparisons to other screening methods. The inclusion of specific data (incremental cost-effectiveness ratio and willingness-to-pay threshold) enhances the recall accuracy.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer maintains high precision by focusing strictly on the topic of liquid biopsy's cost-effectiveness for colorectal cancer screening. It avoids irrelevant details and provides targeted, meaningful information derived from the references.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no unnecessary repetition in the answer. Each piece of information is presented once and logically flows into the next point, making the content concise yet comprehensive.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is highly readable and fluent. The sentences are well-structured, the terminology is appropriate, and the logical flow makes it easy to follow. The use of specific data points and clear transitions enhances overall readability."
    },
    {
        "Question": "What causes Mucormycosis?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat causes Mucormycosis?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Mucormycosis is a serious and invasive fungal infection caused by Mucorales fungi.', 'Mucormycosis is caused by filamentous molds within the Class Zygomycetes and Order Mucorales.', 'Mucormycosis is caused by the mucormycetes group of molds, which are filamentous molds within the Class Zygomycetes and Order Mucorales.', 'Mucormycosis is caused by a group of fungi belonging to the order Mucorales.', 'Mucormycosis is caused by a fungal infection, particularly by fungi of the family Mucoraceae, and is often seen as a side effect in post-COVID-19 patients.', 'Mucormycosis is caused by a ubiquitous saprophytic filamentous fungus that belongs to the class Zygomycosis, specifically from the family Mucoraceae.', 'Fungi of the family Mucoraceae causes Mucormycosis.', 'Mucormycosis is a serious, life-threatening fungal infection caused by the exposure to mucorales.', 'Mucormycosis is caused by fungi of the family Mucoraceae.', 'Mucormycosis is caused by fungi belonging to the family Mucoraceae.', 'Mucormycosis is caused by fungi of the family Mucoraceae, which are ubiquitous saprophytic filamentous fungi that belong to the class Zygomycosis.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nMucormycosis is caused by a group of molds that belong to the order Mucorales. These molds are found in the environment, such as in soil, decaying vegetation, and organic matter. The spores of these molds can enter the human body through inhalation, direct skin inoculation by trauma or ingestion, and result in pulmonary, cutaneous, and gastrointestinal mucormycosis in immunocompromised hosts.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer provides comprehensive information about the causes of mucormycosis, including the specific group of molds (order Mucorales), their environmental sources, and the various routes of entry into the human body (inhalation, direct skin inoculation, ingestion). This aligns well with the reference answers and includes additional context about environmental sources and routes of infection, enhancing the completeness of the information.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and directly addresses the question without including any irrelevant information. It focuses on the causative agents (Mucorales molds), their environmental presence, and the pathways of infection, all of which are pertinent to understanding mucormycosis.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. Each piece of information provided is distinct and contributes to a fuller understanding of the topic without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured and easily readable, with clear and fluent language. It logically presents the information, making it accessible to readers without compromising scientific accuracy."
    },
    {
        "Question": "When was the first case of human monkey pox diagnosed?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhen was the first case of human monkey pox diagnosed?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The first case of human monkeypox was diagnosed in September 1970 in the Democratic Republic of the Congo.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the text in source #2, the first human case of monkeypox was detected in the Democratic Republic of the Congo in 1970.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately recalls all the necessary information from the reference answer, including the year (1970) and the location (Democratic Republic of the Congo).",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise in reporting the key details, but it does leave out the specific month (September) mentioned in the reference answer, which slightly detracts from precision.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information; it succinctly states the facts without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is clear, concise, and fluently written, making it easy to understand."
    },
    {
        "Question": "Does chromatin accessibility affect CRISPR-Cas9 efficiency?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nDoes chromatin accessibility affect CRISPR-Cas9 efficiency?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['While many studies consider DNA sequences of CRISPR target sites as the primary determinant for CRISPR-Cas9 mutagenesis efficiency and mutation profiles, increasing evidence reveals the substantial role of chromatin context. Indeed, results across different organisms have shown that Cas9-mediated editing is more efficient in open chromatin regions (euchromatin) than in closed ones (heterochromatin).', 'Yes, chromatin accessibility significantly affects CRISPR-Cas9 efficiency. The abstracts collectively demonstrate that gene editing is more efficient in euchromatin (open chromatin) than in heterochromatin (closed chromatin). This correlation is observed in various cell lines and organisms, including HEK293T cells, HeLa cells, human fibroblasts, and zebrafish embryos. The studies show that chromatin openness positively correlates with CRISPR-Cas9 mutagenesis efficiency, whereas closed chromatin regions exhibit reduced editing efficiency. These findings are consistent across different experimental settings, including in vitro and in vivo systems. Furthermore, modulating chromatin accessibility using transactivation or targeting proximal dsgRNAs can enhance Cas9 editing efficiency in vivo. Therefore, considering chromatin accessibility is crucial for optimizing CRISPR-Cas9 gene editing outcomes.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, chromatin accessibility can significantly affect CRISPR-Cas9 efficiency. Studies have shown that chromatin structure and accessibility can influence the ability of CRISPR-Cas9 to edit the genome. Nucleosomes, the basic units of chromatin, can impede Cas9 binding and cleavage, and chromatin remodeling can restore Cas9 access. Open chromatin regions tend to have higher CRISPR-Cas9 editing efficiency, while closed chromatin regions can hinder the process. Enhancers and promoters with high chromatin accessibility tend to be more active and responsive to CRISPR-Cas9. The presence of certain histone modifications, such as H3K27ac, can also indicate chromatin accessibility and influence CRISPR-Cas9 efficiency.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer effectively captures all necessary information regarding chromatin accessibility's impact on CRISPR-Cas9 efficiency. It mentions the influence of nucleosomes, chromatin remodeling, open versus closed chromatin regions, and specific histone modifications like H3K27ac, aligning well with the reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include irrelevant information. It focuses solely on how chromatin accessibility affects CRISPR-Cas9 efficiency, touching on nucleosomes, chromatin remodeling, and histone modifications—all of which are relevant to the topic.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information. Each sentence introduces a new aspect of how chromatin accessibility impacts CRISPR-Cas9 efficiency, ensuring a clear and concise progression of ideas.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured and easily readable. The sentences are fluent, logically connected, and free of jargon that could impede understanding, making the explanation accessible to a broad audience."
    },
    {
        "Question": "What diseases are included in the differential diagnosis of Ehlers-Danlos Syndrome?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat diseases are included in the differential diagnosis of Ehlers-Danlos Syndrome?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The differential diagnosis of Ehlers-Danlos Syndrome includes hypermobility spectrum disorders, Marfan syndrome, Loey-Dietz syndrome, Cutis laxa syndromes, autosomal dominant polycystic kidney disease, osteogenesis Imperfecta Type 1,cfibromyalgia, depression, and chronic fatigue syndrome.', 'The diseases included in the differential diagnosis of Ehlers-Danlos Syndrome are Marfan syndrome, autosomal dominant polycystic kidney disease, Cutis laxa syndromes, osteogenesis Imperfecta Type 1, fibromyalgia, depression, chronic fatigue syndrome, and hypermobility spectrum disorders.', 'The diseases included in the differential diagnosis of Ehlers-Danlos Syndrome are Marfan Syndrome, Cutis Laxa Syndromes, Osteogenesis Imperfecta Type 1, autosomal dominant polycystic kidney disease, fibromyalgia, depression, chronic fatigue syndrome, and hypermobility spectrum disorders.', 'The differential diagnosis of Ehlers-Danlos Syndrome includes autosomal dominant polycystic kidney disease, fibromyalgia, osteogenesis Imperfecta Type 1, depression, chronic fatigue syndrome, hypermobility spectrum disorders, Marfan syndrome, and Cutis laxa syndromes.', 'Ehlers-Danlos Syndrome is a group of disorders that affect the connective tissues supporting the skin, bones, blood vessels, and other organs. Its differential diagnosis includes hypermobility spectrum disorders, Marfan syndrome, Loey-Dietz syndrome, Cutis laxa syndromes, autosomal dominant polycystic kidney disease, osteogenesis Imperfecta Type 1, fibromyalgia, depression, and chronic fatigue syndrome.', \"The differential diagnosis of Ehlers-Danlos Syndrome (EDS) includes hypermobility spectrum disorders, Marfan syndrome, Loey-Dietz syndrome, Cutis laxa syndromes, autosomal dominant polycystic kidney disease, osteogenesis Imperfecta Type 1, fibromyalgia, depression, and chronic fatigue syndrome. \\n\\nPlease go ahead and ask your question. I'll provide a concise answer based on the given context. \\n(Note: You can ask a question, and I'll respond accordingly. If you want to ask another question, feel free to do so!) \\n\\nPlease go ahead and ask your question!  I'm ready to help!\", 'The diseases included in the differential diagnosis of Ehlers-Danlos Syndrome are \"Autosomal dominant polycystic kidney disease,\" \"Fibromyalgia,\" \"Hypermobility spectrum disorders,\" \"Marfan syndrome,\" \"Osteogenesis Imperfecta Type 1,\" \"Depression,\" \"Chronic fatigue syndrome,\" and \"Cutis laxa syndromes\".', 'The differential diagnosis of Ehlers-Danlos Syndrome (EDS) includes hypermobility spectrum disorders, Marfan syndrome, Loey-Dietz syndrome, Cutis laxa syndromes, autosomal dominant polycystic kidney disease, osteogenesis Imperfecta Type 1, fibromyalgia, depression, and chronic fatigue syndrome.', 'The differential diagnosis of Ehlers-Danlos Syndrome includes hypermobility spectrum disorders, Marfan syndrome, Loey-Dietz syndrome, Cutis laxa syndromes, autosomal dominant polycystic kidney disease, osteogenesis Imperfecta Type 1, fibromyalgia, depression, and chronic fatigue syndrome.', 'The differential diagnosis for Ehlers-Danlos Syndrome includes hypermobility spectrum disorders, Marfan syndrome, Loey-Dietz syndrome, Cutis laxa syndromes, autosomal dominant polycystic kidney disease, osteogenesis Imperfecta Type 1, fibromyalgia, depression, and chronic fatigue syndrome.', 'The differential diagnosis of Ehlers-Danlos Syndrome (EDS) includes several conditions that may present with similar symptoms. These conditions are hypermobility spectrum disorders, Marfan syndrome, Loey-Dietz syndrome, Cutis laxa syndromes, autosomal dominant polycystic kidney disease, osteogenesis Imperfecta Type 1, fibromyalgia, depression, and chronic fatigue syndrome.', 'The diseases included in the differential diagnosis of Ehlers-Danlos Syndrome (EDS) are hypermobility spectrum disorders, Marfan syndrome, Loey-Dietz syndrome, Cutis laxa syndromes, autosomal dominant polycystic kidney disease, osteogenesis Imperfecta Type 1, fibromyalgia, depression, and chronic fatigue syndrome, all of which share some clinical features with EDS but are distinct conditions.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the following diseases are included in the differential diagnosis of Ehlers-Danlos Syndrome:\n\n1. Marfan syndrome\n2. Loey-Dietz syndrome\n3. Cutis laxa syndromes\n4. Autosomal dominant polycystic kidney disease\n5. Osteogenesis imperfecta Type 1\n6. Fibromyalgia\n7. Depression\n8. Chronic fatigue syndrome\n9. Hypermobile spectrum disorders\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer includes all the necessary diseases mentioned in the reference answers for the differential diagnosis of Ehlers-Danlos Syndrome (EDS). This includes Marfan syndrome, Loey-Dietz syndrome, Cutis laxa syndromes, autosomal dominant polycystic kidney disease, osteogenesis imperfecta Type 1, fibromyalgia, depression, chronic fatigue syndrome, and hypermobile spectrum disorders.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer does not include any irrelevant information. It strictly lists the conditions relevant to the differential diagnosis of EDS as provided in the reference answers.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "Each condition is listed only once without any repetition. The answer is concise and avoids redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is presented in a clear, bullet-point format, making it easy to read and understand. The use of a numbered list enhances readability and allows for quick identification of each condition included in the differential diagnosis."
    },
    {
        "Question": "What is the mechanism of action of Nemolizumab?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the mechanism of action of Nemolizumab?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Nemolizumab is an interleukin-31 receptor alpha antagonist that down-regulates key pathways in the pathogenesis of prurigo nodularis.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nNemolizumab is a humanized monoclonal antibody that targets the interleukin-31 receptor A (IL-31RA) subunit. It works by inhibiting the IL-31 signaling pathway, which is involved in the pathogenesis of atopic dermatitis and pruritus. By blocking the IL-31 receptor, nemolizumab suppresses the production of IL-31, a cytokine that contributes to the development of pruritus and inflammation in atopic dermatitis.\n\nThe exact mechanism of action of nemolizumab is as follows:\n\n1. Nemolizumab binds to the IL-31RA subunit, preventing IL-31 from binding to its receptor.\n2. This blocks the IL-31 signaling pathway, which is involved in the production of inflammatory cytokines and the activation of immune cells.\n3. The inhibition of IL-31 signaling leads to a reduction in the production of pro-inflammatory cytokines, such as IL-4, IL-5, and IL-13, which contribute to the development of atopic dermatitis and pruritus.\n4. The reduction in pro-inflammatory cytokines leads to a decrease in inflammation and pruritus in the skin.\n\nOverall, the mechanism of action of nemolizumab is to inhibit the IL-31 signaling pathway, which leads to a reduction in inflammation and pruritus in atopic dermatitis.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer provides a detailed explanation of the mechanism of action of Nemolizumab, including its target (IL-31RA), the signaling pathway it inhibits, and the downstream effects on inflammation and pruritus. However, it does not explicitly mention prurigo nodularis, which is referenced in the provided answer. The answer covers most of the necessary information but slightly deviates from the reference.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise, detailing the specific actions of Nemolizumab without including irrelevant information. It focuses on the IL-31 signaling pathway and its implications for atopic dermatitis and pruritus. However, the inclusion of atopic dermatitis, while scientifically relevant, slightly deviates from the reference, which focuses solely on prurigo nodularis.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not repeat information unnecessarily. Each point adds new details about the mechanism of action of Nemolizumab, contributing to a comprehensive understanding without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured and clearly written, with numbered points that enhance comprehension. The language is fluent and technical terms are appropriately explained, making it accessible to a biomedical audience."
    },
    {
        "Question": "What type of colorectal cancer screening is the most cost-effective for general population?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat type of colorectal cancer screening is the most cost-effective for general population?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['colonoscopy was the preferred, or cost-effective, strategy with an incremental cost-effectiveness ratio of $28\\u202f071 per life-year gained.', 'Colonoscopy every 10 years is the most cost-effective primary screening strategy for colorectal cancer in the general population, according to a decision tree modeling study. The study compared five common and effective CRC screening modalities in average-risk 40-year olds versus deferring screening until 50 (standard of care) under a limited societal perspective. Flexible sigmoidoscopy, FOBT, and FIT all dominated the current standard of care, while colonoscopy and FIT-DNA were cost-effective. Regardless of screening modality, CRC screening at 40 years old is cost-effective with increased QALYs compared to current screening initiation at 50 years old, with flexible sigmoidoscopy being the most preferred option. Therefore, consideration should be given for a general recommendation to start screening at age 40 for average risk individuals.', 'The most cost-effective colorectal cancer screening strategy for the general population is not definitively established, as it depends on various factors such as the specific population, healthcare system, and available resources. However, several studies suggest that flexible sigmoidoscopy, fecal occult blood testing (FOBT), and fecal immunochemical testing (FIT) are cost-effective screening options. In particular, flexible sigmoidoscopy has been found to be the most favorable intervention by net monetary benefit in some studies. It is important to note that the cost-effectiveness of a screening strategy can vary depending on the context-specific parameters and the framework of the cost-effectiveness analysis. Therefore, it is recommended to adopt a reference-based methodology for economic evaluation studies to make the results more comparable.', 'Colorectal cancer screening is a cost-effective method for reducing colorectal cancer incidence and mortality in the general population. The most cost-effective method is likely to be a combination of screening tests, such as fecal occult blood test (FOBT) and flexible sigmoidoscopy (FS). These tests have been shown to be effective in reducing colorectal cancer incidence and mortality, and they are relatively inexpensive compared to other screening methods. Additionally, risk-stratification based on genetic and phenotypic factors can help identify individuals who are at high risk for colorectal cancer and target screening efforts accordingly. Overall, colorectal cancer screening is a valuable investment in public health, as it can save lives and reduce healthcare costs in the long run.', 'The most cost-effective colorectal cancer screening strategy for the general population is likely to be a combination of flexible sigmoidoscopy and faecal occult blood test (FOBT) every 5 years. This approach has been shown to be highly effective in reducing colorectal cancer incidence and mortality, while also being cost-effective compared to other screening strategies.', 'According to a systematic review, colorectal cancer (CRC) screening techniques such as flexible sigmoidoscopy, fecal occult blood test (FOBT), and fecal immunochemical test (FIT) have been found to be cost-effective compared to no-screening. Among these, flexible sigmoidoscopy had the lowest incremental cost-effectiveness ratio (ICER) of $PPP -16265/quality-adjusted life-year (QALY). However, the cost-effectiveness of various screening techniques may vary depending on context-specific parameters and the framework of the cost-effectiveness analysis. It is important to adopt a reference-based methodology for economic evaluation studies to make them comparable.', 'According to a systematic review, colorectal cancer (CRC) screening techniques such as flexible sigmoidoscopy, fecal occult blood test (FOBT), and fecal immunochemical test (FIT) have been found to be cost-effective compared to no screening. However, the cost-effectiveness of various screening techniques may vary depending on the context-specific parameters and the framework of the cost-effectiveness analysis. A one-time colonoscopy at age 60 may also be a more cost-effective method for some individuals. It is important to adopt a reference-based methodology for economic evaluation studies to make them comparable.', 'Colonoscopy every 10 years is the most cost-effective primary colorectal cancer (CRC) screening strategy in the general population according to a decision tree modeling study. Flexible sigmoidoscopy, fecal occult blood test (FOBT), and fecal immunochemical tests (FIT) were more effective than standard care, while colonoscopy and FIT-DNA were cost-effective. Screening at 40 years old is recommended for average risk individuals as it increases QALYs compared to starting at 50 years old, with flexible sigmoidoscopy being the most preferred option.', 'Colonoscopy every 10 years is considered the most cost-effective CRC screening strategy for the general population, achieving nearly half of the reduction in CRC mortality obtainable with colonoscopy every 10 years. The combination of annual FOBT plus sigmoidoscopy every 5 years is also cost-effective but less effective than colonoscopy every 10 years. Compliance rates significantly affect incremental CE ratios, and mathematical modeling used to inform clinical guidelines needs to take this into account.', 'A systematic review of cost-effectiveness analyses of colorectal cancer screening in Europe suggests that fecal occult blood testing (FOBT) has shown to be cost-effective in most European countries. However, the review points out that most studies have not evaluated optimal screening intervals and may therefore have overestimated the cost-effectiveness of screening.', 'Colonoscopy and flexible sigmoidoscopy are cost-effective strategies for colorectal cancer (CRC) screening in the general population, with colonoscopy having an incremental cost-effectiveness ratio of $28,071 per life-year gained, while flexible sigmoidoscopy has a cost-utility of $32,284 per person and offers the greatest net monetary benefit among all screening modalities assessed. Both procedures are considered cost-effective options for CRC screening.', 'The most cost-effective colorectal cancer (CRC) screening strategy in a general population is a subject of multiple cost-effectiveness analyses, and the results can vary depending on regional epidemiology, available screening strategies, and local healthcare systems. However, several studies suggest that some screening methods are more cost-effective than others. Fecal immunochemical tests (FIT) and colonoscopy are frequently reported as cost-effective options. For instance, in a systematic review, CRC screening with colonoscopy and FIT was found to be cost-effective compared to no screening. Another study found that, under the assumption of perfect adherence, annual mSEPT9 screening resulted in more quality-adjusted life-years gained and averted more CRC cases and deaths than annual FIT screening, but it led to a higher rate of colonoscopy referrals. Ultimately, the choice of the most cost-effective CRC screening strategy should consider factors such as effectiveness, harms, cost, screening interval, patient preferences, and test availability.', 'The most cost-effective colorectal cancer screening strategy for the general population is not definitively established, as it depends on various factors such as the specific population, healthcare system, and available resources. However, several studies suggest that flexible sigmoidoscopy, fecal immunochemical test (FIT), and fecal occult blood test (FOBT) are cost-effective screening strategies. The American Cancer Society recommends a combination of FOBT and flexible sigmoidoscopy, while some experts believe that a one-time colonoscopy at age 60 may be a more cost-effective method. A systematic review found that all colorectal cancer screening techniques were cost-effective compared to no-screening methods, but the cost-effectiveness of the various screening techniques mainly depended on context-specific parameters and was highly affected by the framework of the cost-effectiveness analysis.', 'The most cost-effective colorectal cancer screening strategy for the general population is colonoscopy every 10 years. This method reduces mortality at relatively low incremental costs. However, if compliance rates are low, annual fecal occult blood testing (FOBT) becomes a more cost-effective option. Flexible sigmoidoscopy every 5 or 10 years is less cost-effective than the other two screening methods. These conclusions are based on computer models of a Markov process that compare the cost-effectiveness of fecal occult blood testing, flexible sigmoidoscopy, and colonoscopy by using U.S. vital statistics, cancer statistics, published data on the sensitivity, specificity, and efficacy of various screening techniques, and Medicare reimbursement data for costs.', 'Based on the abstracts provided, colonoscopy is the most cost-effective strategy for colorectal cancer screening in the general population. According to the first abstract, colonoscopy had an incremental cost-effectiveness ratio of $28,071 per life-year gained, making it a cost-effective strategy. The inclusion of liquid biopsy as a first- or second-line screening strategy was not cost-effective at its current cost and screening performance. In contrast, the second abstract compared the cost-effectiveness of faecal immunochemical test (FIT) vs. colonoscopy and found that colonoscopy detected more adenomas and advanced lesions or cancer than FIT, with an incremental cost-effectiveness ratio ranging from $3,489 to $922,762 depending on the outcome measured. Overall, colonoscopy is the most cost-effective strategy for colorectal cancer screening in the general population.', 'colonoscopy was the preferred, or cost-effective, strategy with an incremental cost-effectiveness ratio of $28\\u202f071 per life-year gained', 'A comparison of colonoscopy and FIT (fecal immunochemical test) as strategies for colorectal cancer screening in the general population suggests that colonoscopy is a cost-effective strategy for colorectal cancer screening, particularly when considering adenoma, advanced neoplasia, and a composite endpoint of advanced neoplasia or stage I CRC. Compared to FIT, colonoscopy is the preferred or cost-effective strategy, with an incremental cost-effectiveness ratio of $28,071 per life-year gained. Therefore colonoscopy is the most cost-effective type of colorectal cancer screening for the general population.', 'Colonoscopy is considered the most cost-effective strategy for colorectal cancer screening in the general population. It is preferred due to its effectiveness in screening for adenoma, advanced neoplasia, and a composite endpoint of advanced neoplasia or stage I CRC, with an incremental cost-effectiveness ratio of $28,071 per life-year gained.', 'Colonoscopy is the most cost-effective strategy for colorectal cancer screening in the general population.', 'Screening for colorectal cancer in the general population can be done using different methods, including fecal occult blood testing, flexible sigmoidoscopy, and colonoscopy. Colonoscopy is considered the most cost-effective strategy for colorectal cancer screening in the general population.', 'Colonoscopy is considered to be the most cost-effective strategy for colorectal cancer screening in the general population. This was found in multiple studies, including one from 2023 which reported that colonoscopy was the preferred, or cost-effective, strategy with an incremental cost-effectiveness ratio of $28,071 per life-year gained. Another study from 2014 found that when compared to FIT, colonoscopy is considered cost-effective for screening adenoma, advanced neoplasia, and a composite endpoint of advanced neoplasia or stage I CRC.', 'Colonoscopy is considered the most cost-effective strategy for colorectal cancer screening in the general population. It has an incremental cost-effectiveness ratio of $28,071 per life-year gained, making it a preferred choice compared to other methods like FIT (fecal immunochemical test)', 'Colonoscopy is considered the most cost-effective strategy for colorectal cancer screening in the general population. This is based on a comparison to fecal immunochemical testing (FIT) where colonoscopy was found to be cost-effective for screening adenoma, advanced neoplasia, and a composite endpoint of advanced neoplasia or stage I colorectal cancer. The incremental cost-effectiveness ratio for colonoscopy was $28,071 per life-year gained.', 'Colonoscopy is recognized as the most cost-effective strategy for colorectal cancer screening in the general population, with an incremental cost-effectiveness ratio of $28,071 per life-year gained.', 'Summary: Colonoscopy is the most cost-effective strategy for colorectal cancer screening in the general population, with an incremental cost-effectiveness ratio of $28,071 per life-year gained according to one abstract. The inclusion of liquid biopsy was not found to be cost-effective at its current cost and performance. Comparing colonoscopy vs. faecal immunochemical test (FIT), colonoscopy detects more adenomas, advanced lesions, or cancer than FIT with a varying incremental cost-effectiveness ratio.', 'The most cost-effective type of colorectal cancer screening for the general population is colonoscopy, as it has an incremental cost-effectiveness ratio of $28,071 per life-year gained, according to an economic evaluation comparing no screening and five colorectal cancer screening strategies including colonoscopy, liquid biopsy, liquid biopsy following nonadherence to colonoscopy, stool DNA, and fecal immunochemical test.', 'Based on the provided information, colonoscopy appears to be the most cost-effective colorectal cancer screening strategy for the general population. The summary states that modeling studies suggest fecal occult blood testing (FOBT) every 1-2 years, sigmoidoscopy every 5 years with FOBT every 2-3 years, and colonoscopy every 10 years are all considered cost-effective compared to no screening. However, the additional evidence specifically highlights that colonoscopy was found to be cost-effective compared to no screening and even compared to FIT (fecal immunochemical testing, a type of FOBT), with an incremental cost-effectiveness ratio of $28,071 per life-year gained. So while all three main screening strategies are cost-effective, colonoscopy seems to be the preferred choice from a cost-effectiveness perspective for average-risk individuals.', 'The most cost-effective type of colorectal cancer screening for the general population is colonoscopy, as it is the preferred strategy with an incremental cost-effectiveness ratio of $28,071 per life-year gained, and is particularly effective for screening adenoma, advanced neoplasia, and stage I colorectal cancer.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data tables, the cost-effectiveness of colorectal cancer screening strategies varies depending on the specific population, adherence rates, and assumptions made in the economic evaluations. However, the data suggests that the following strategies are considered cost-effective:\n\n1. **Annual or biennial fecal immunochemical tests (FIT)**: Several studies (e.g., [5, 12, 16]) indicate that annual or biennial FIT is cost-effective or cost-saving compared to colonoscopy every 10 years.\n2. **Colonoscopy every 10 years**: This strategy is considered cost-effective in some studies (e.g., [6, 12]) and is often recommended as a cost-effective option for the general population.\n3. **Flexible sigmoidoscopy every 5 years**: This strategy is also considered cost-effective in some studies (e.g., [6, 12]) and may be a good option for populations with high adherence rates.\n\nIt is essential to note that the cost-effectiveness of these strategies can vary depending on factors such as:\n\n* Adherence rates: Higher adherence rates can make a strategy more cost-effective.\n* Test performance characteristics: The sensitivity and specificity of the screening test can impact its cost-effectiveness.\n* Comparator strategies: The cost-effectiveness of a strategy can depend on the comparator used (e.g., no screening, other screening strategies).\n* Population characteristics: The cost-effectiveness of a strategy may vary depending on the population being screened (e.g., age, risk factors).\n\nIn general, the most cost-effective strategy for the general population is likely to be a combination of a non-invasive test (e.g., FIT) with a more invasive test (e.g., colonoscopy) for individuals with positive results or high-risk characteristics.\n\nPlease consult the original studies and references for more detailed information and specific recommendations.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers multiple cost-effective screening strategies (FIT, colonoscopy, and flexible sigmoidoscopy) and mentions factors affecting cost-effectiveness, such as adherence rates and test performance. However, it could have explicitly cited colonoscopy as the most cost-effective in line with the majority of the reference answers.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer avoids irrelevant details and sticks to discussing cost-effective strategies and their variables. However, it doesn't prioritize colonoscopy as the most cost-effective despite many references supporting this, which slightly affects precision.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information redundantly. Each point is distinct and contributes to understanding the topic without unnecessary duplication.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, uses clear and concise language, and logically organizes the information, making it easy to read and understand."
    },
    {
        "Question": "Is Cri du Chat syndrome (CdCS) a genetic syndrome caused by deletions in the long arm of chromosome 5",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs Cri du Chat syndrome (CdCS) a genetic syndrome caused by deletions in the long arm of chromosome 5\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Cri du Chat syndrome (CdCS) is a genetic syndrome caused by deletions in the short arm of chromosome 5', 'No, Cri du Chat syndrome (CdCS) is a genetic disorder caused by deletions in the short arm (p) of chromosome 5.', 'No, Cri du Chat syndrome (CdCS) is a genetic syndrome caused by deletions in the short arm of chromosome 5, not the long arm.', 'No, Cri du Chat syndrome (CdCS) is a genetic syndrome caused by deletions in the short arm of chromosome 5.', 'No, Cri du Chat syndrome (CdCS) is not caused by deletions in the long arm of chromosome 5. It is caused by a partial deletion of the short arm (5p) of chromosome 5.', 'No, Cri du Chat syndrome (CDCS) is caused by deletions in the short arm of chromosome 5.', \"No, it's caused by deletions on the short arm of chromosome 5.\", 'Cri du Chat syndrome (CdCS) is caused by deletions in the short arm of chromosome 5 (5p-), not the long arm, with an incidence ranging from 1:15,000 to 1:50,000 live births. It presents with a high-pitched monochromatic cry and various clinical features such as microcephaly, facial abnormalities, and severe psychomotor and mental retardation. Diagnosis can be confirmed through karyotype or FISH analysis.', 'No, Cri du Chat syndrome (CdCS) is caused by deletions in the short arm of chromosome 5.', 'No. Cri du Chat syndrome (CDCS) is caused by a deletion in the short arm of chromosome 5 (5p).', 'No, Cri du Chat syndrome (CdCS) is a genetic syndrome caused by deletions in the short arm of chromosome 5', 'Yes, Cri du Chat syndrome (CdCS) is a genetic syndrome caused by deletions in the short arm of chromosome 5.', 'No, Cri-du-chat syndrome (CdCS) is not a genetic syndrome caused by deletions in the long arm of chromosome 5.', 'No, Cri du Chat syndrome (CdCS) is a genetic syndrome caused by deletions in the short arm of chromosome 5 (5p-).', 'No, Cri-du-chat syndrome is not caused by deletions in the long arm of chromosome 5. It is caused by deletions in the short arm of chromosome 5, specifically designated as 5p-', 'No, Cri du Chat syndrome (CdCS) is caused by a partial deletion of the short arm (5p) of chromosome 5, not the long arm.', 'No, Cri-du-chat syndrome is caused by deletions in the short arm of chromosome 5 (5p-).', 'No, Cri-du-chat syndrome (CdCS) is not caused by deletions in the long arm of chromosome 5. It is caused by deletions in the short arm of chromosome 5.', \"No, it's caused by deletions in the short arm of chromosome 5.\", 'No, Cri-du-chat syndrome is caused by deletions in the short arm of chromosome 5, not the long arm.', 'No, Cri du Chat syndrome is caused by deletions in the short arm of chromosome 5.', 'No, Cri-du-chat syndrome (CdCS) is not caused by deletions in the long arm of chromosome 5, but rather it is a genetic disorder caused by deletions in the short arm of chromosome 5, as confirmed by karyotype testing.', 'No, Cri du Chat syndrome (CdCS) is not caused by deletions in the long arm of chromosome 5. It is caused by deletions in the short arm of chromosome 5 (5p-), which are greater than 10 Mb.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nNo, Cri du Chat syndrome (CdCS) is a genetic disorder caused by deletions in the short arm of chromosome 5, not the long arm.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer correctly recalls that Cri du Chat syndrome (CdCS) is caused by deletions in the short arm of chromosome 5, not the long arm, which aligns with all reference answers. No necessary information is missing.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer precisely states the correct genetic cause of CdCS without including any irrelevant information. It directly addresses the question without straying from the topic.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. It is concise and to the point, stating the cause of CdCS clearly in one go.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is easily readable and fluent. It is well-structured, grammatically correct, and uses simple language to convey the information."
    },
    {
        "Question": "Mortality in schizophrenia.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nMortality in schizophrenia.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Mortality rates are significantly higher among individuals with schizophrenia compared to the general population. Studies have shown that people with schizophrenia die 15-20 years prematurely, with a standardized mortality ratio (SMR) of around 2.5. The leading causes of death in schizophrenia include suicide, cardiovascular disease, respiratory infections, and accidents. Comorbidities such as2021), and aggravating or attenuating factors is essential to reduce this gap.', 'Mortality rates in schizophrenia are two- to three-fold higher than those of the general population, corresponding to a 10-25-year reduction in life expectancy. Natural deaths account for about 60% of the excess mortality, with ischemic heart disease being a common cause. Suicide is also a significant cause of death, with a rate of 10-20%. The overall PYLL (potential years of life lost) of people with schizophrenia is 18.4 years, with suicide having the largest PYLL (31.2 years) among all causes of mortality. Long-lasting negative health habits, disease- and treatment-related metabolic disorders, and consequent increased frequencies of cardiovascular diseases may contribute to the high death rates.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, mortality in schizophrenia is a significant concern. The entity \"SCHIZOPHRENIA\" (ID: 4) is associated with high mortality rates, with a rank of 24 out of 22 entities. This suggests that schizophrenia is a serious condition with significant health implications.\n\nThe relations table shows that physical comorbidity (ID: 3) may contribute to excess mortality in schizophrenia (ID: 4). This is consistent with the idea that co-occurring medical conditions can increase the risk of mortality in individuals with schizophrenia.\n\nFurthermore, the relations table also shows that lifestyle factors (ID: 2) can influence the risk of schizophrenia, which may indirectly impact mortality rates. Additionally, risk-enriched cohorts (ID: 6) and premature mortality (ID: 7) are also associated with schizophrenia, suggesting that individuals with schizophrenia may be at higher risk of premature death.\n\nOverall, the data suggests that mortality in schizophrenia is a complex issue influenced by multiple factors, including physical comorbidity, lifestyle factors, and risk-enriched cohorts.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "3",
        "Information Recall Explanation": "The answer touches on some relevant points such as physical comorbidity, lifestyle factors, and risk-enriched cohorts contributing to mortality in schizophrenia. However, it misses key details from the reference answers, such as the standardized mortality ratio (SMR), leading causes of death (e.g., suicide, cardiovascular disease), and the potential years of life lost (PYLL).",
        "Information Precision Score": "3",
        "Information Precision Explanation": "The answer avoids irrelevant information and focuses on factors related to schizophrenia mortality. However, it lacks precision in specifying the exact causes and quantifiable data (e.g., SMR, PYLL) that are critical for understanding the severity and nature of mortality in schizophrenia.",
        "Information Repetition Score": "4",
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. Each point is introduced clearly and builds upon the previous one without redundancy.",
        "Readability Score": "4",
        "Readability Explanation": "The answer is well-structured and fluent, making it easy to follow. The use of phrases like 'Furthermore' and 'Overall' helps in maintaining a logical flow. However, the occasional technical terms without explanation (e.g., 'risk-enriched cohorts') might slightly hinder readability for a non-specialist audience."
    },
    {
        "Question": "Is ICD-10 encoding sensitive for capturing paediatric sepsis?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs ICD-10 encoding sensitive for capturing paediatric sepsis?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['No, the current ICD-10 encoding for paediatric sepsis does have high sensitivity.', 'No, ICD-10 encoding is not sensitive for capturing paediatric sepsis.', 'No, the ICD-10 system is not sensitive for capturing paediatric sepsis.', 'No, ICD-10 encoding is not sensitive for capturing paediatric sepsis. The sensitivity of ICD-10 coding abstraction for sepsis in children is only 60% and for sepsis with organ dysfunction is 35%.', 'No, ICD-10 coding may underestimate the true prevalence of paediatric sepsis', 'No, the sensitivity of ICD-10 coding abstraction was low for capturing paediatric sepsis.', 'No, ICD-10 coding is not sensitive for capturing paediatric sepsis. The sensitivity of ICD-10 coding abstraction was 60% for sepsis and 35% for sepsis with organ dysfunction, using an explicit abstraction strategy.', 'No, ICD-10 coding is not very sensitive for capturing pediatric sepsis, as it has a sensitivity of only 60% for sepsis and even lower for sepsis with organ dysfunction at 35% using an explicit abstraction strategy.', 'No, the sensitivity of ICD-10 coding abstraction for capturing pediatric sepsis is relatively low, as indicated by a sensitivity of 60% for sepsis and 35% for sepsis with organ dysfunction using an explicit abstraction strategy.', 'No, the sensitivity of ICD-10 coding abstraction for capturing pediatric sepsis is relatively low, with a sensitivity of 60% for sepsis and 35% for sepsis with organ dysfunction using an explicit abstraction strategy, indicating that it may severely underestimate the true prevalence of the disease.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the table, the sensitivity of ICD-10 coding abstraction for sepsis in children was found to be 60% (95%-CI 57-63) in a population-based study. This suggests that ICD-10 coding may not be highly sensitive for capturing pediatric sepsis, as it missed approximately 40% of cases.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer captures the essential point that ICD-10 encoding is not highly sensitive for pediatric sepsis, with a specific sensitivity figure (60%) and confidence interval (95%-CI 57-63) sourced from a population-based study. However, it misses mentioning the lower sensitivity (35%) for sepsis with organ dysfunction, which is present in most of the reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and sticks to the relevant information about the sensitivity of ICD-10 encoding for pediatric sepsis. No irrelevant details are included.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. The points made are concise and not redundant.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is clear, fluent, and easily understandable. The use of statistics and clear language aids in conveying the message effectively."
    },
    {
        "Question": "Is Amivantamab used for non–small-cell lung cancer?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs Amivantamab used for non–small-cell lung cancer?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes. Amivantamab is approved for treatment of patients with Non-Small Cell Lung Cancer with EGFR Exon 20 insertion mutations.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, Amivantamab is used to treat non-small cell lung cancer (NSCLC). It is a bispecific antibody that targets the epidermal growth factor receptor (EGFR) and mesenchymal epithelial transition factor (MET) for the treatment of NSCLC with EGFR exon 20 insertion mutations.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer correctly recalls that Amivantamab is used for non-small cell lung cancer (NSCLC) and specifically mentions its approval for patients with EGFR exon 20 insertion mutations. This aligns perfectly with the reference answer.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer provides precise and relevant information about Amivantamab's mechanism of action as a bispecific antibody targeting EGFR and MET, which is directly relevant to its use in NSCLC. No irrelevant details are included.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information. It clearly states the use of Amivantamab in NSCLC and its target mechanisms without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand. It presents the information in a clear and concise manner, making it highly readable."
    },
    {
        "Question": "Do very elderly stage III colorectal cancer patients present clinical benefit from oxaliplatin-based adjuvant chemotherapy?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nDo very elderly stage III colorectal cancer patients present clinical benefit from oxaliplatin-based adjuvant chemotherapy?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes, adjuvant FOLFOX4 maintains its efficacy and safety ratio in selected elderly patients with colorectal cancer', 'Studies suggest that very elderly (≥70 or ≥75 years) patients with Stage III colon cancer can benefit from oxaliplatin-based adjuvant chemotherapy, despite increased toxicity and early treatment cessation. A study in Asia found similar efficacy without significant increase in toxicity in older patients (≥65) compared to younger patients. Another study in Australia demonstrated a persistent survival benefit for the addition of oxaliplatin to fluoropyrimidine as adjuvant treatment for Stage III colon cancer in elderly patients, although with increased hospital admissions and early chemotherapy cessation. A population-based cohort study in Ontario, Canada found that patients aged ≥70 years had a higher risk of developing peripheral neuropathy with oxaliplatin-based regimens. Finally, an analysis of four data sets in the US found that adjuvant chemotherapy was associated with a survival benefit for patients ≥75 years with Stage III colon cancer, although the incremental benefit of oxaliplatin over non-oxaliplatin-containing regimens was inconsistent.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, there is evidence to suggest that very elderly stage III colorectal cancer patients may not benefit from oxaliplatin-based adjuvant chemotherapy. \n\nA study (Reference 3) found that patients aged >/= 70 years at the time of cancer diagnosis who were treated with oxaliplatin had a significant risk of developing peripheral neuropathy. Another study (Reference 9) demonstrated that elderly patients receiving oxaliplatin were more likely to cease treatment early and require hospital admission, but still showed a survival benefit from the addition of oxaliplatin to a fluoropyrimidine. However, the benefit was modest and the study noted that the addition of oxaliplatin provided an overall survival benefit for patients < 70 years, but not for patients >/= 70 years.\n\nAnother study (Reference 8) found that patients aged >/= 70 years had a worse prognosis than non-Hispanic white patients, despite adjusting for confounding factors.\n\nTherefore, based on these studies, it appears that very elderly stage III colorectal cancer patients may not present a significant clinical benefit from oxaliplatin-based adjuvant chemotherapy, and may even be at a higher risk of adverse effects. However, more research is needed to confirm this finding.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "4",
        "Information Recall Explanation": "The answer captures key points from the reference answers, including the risks (peripheral neuropathy, early treatment cessation, hospital admissions) and the inconsistent survival benefit for elderly patients (≥70 years). However, it misses some nuances, such as the similar efficacy found in an Asian study for patients ≥65 years and the overall survival benefit in certain elderly populations.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer is largely precise, focusing on the risks and modest benefits of oxaliplatin for elderly patients. However, it slightly misrepresents the reference answers by stating that the benefit is absent for patients ≥70 years, whereas some studies still suggest a survival benefit, albeit inconsistent.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat information unnecessarily. Each point is distinct and contributes to the overall argument without redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured, clear, and logically flows from one point to the next. The language is concise and easy to follow."
    },
    {
        "Question": "What is the rationale behind treating melanoma with immunotherapy?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the rationale behind treating melanoma with immunotherapy?\n\nHere are some reference answers:\n\n**Reference Answers:**\n[\"The rationale behind treating melanoma with immunotherapy is that melanoma is a highly immunogenic cancer, meaning the immune system can recognize and attack it. Key points:\\n\\n1. Melanoma cells express tumor-specific antigens that immune cells can target.\\n\\n2. Melanomas often have lymphocytic infiltrates, showing the immune system does react to the cancer. \\n\\n3. Melanoma patients can respond to immunotherapies like immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1), which take the brakes off the immune response.\\n\\n4. Adoptive cell transfer using a patient's own anti-tumor T cells extracted from the tumor can lead to responses.\\n\\n5. Melanoma has multiple mechanisms of immune evasion that immunotherapies can counteract.\\n\\nIn summary, melanoma's immunogenicity and evidence that boosting anti-tumor immunity with immunotherapies can lead to clinical responses provides a strong rationale for this treatment approach. Harnessing the immune system allows specific targeting of melanoma cells.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nImmunotherapy is a type of treatment that uses the body's immune system to fight cancer, including melanoma. The rationale behind treating melanoma with immunotherapy is based on the understanding that melanoma is an immunogenic cancer, meaning it can be recognized and targeted by the immune system.\n\nMelanoma cells have several characteristics that make them susceptible to immunotherapy:\n\n1. **Tumor antigens**: Melanoma cells express tumor antigens, which are proteins or other molecules that can be recognized by the immune system as foreign. These antigens can be targeted by the immune system to attack and destroy cancer cells.\n2. **High mutational burden**: Melanoma cells have a high mutational burden, meaning they have many genetic mutations that can be recognized by the immune system as foreign. This can trigger an immune response against the cancer cells.\n3. **Immunogenicity**: Melanoma cells can stimulate an immune response, which can lead to the activation of immune cells, such as T cells and natural killer cells, that can attack and destroy cancer cells.\n\nImmunotherapy for melanoma typically involves the use of checkpoint inhibitors, which block the interaction between cancer cells and immune cells, allowing the immune system to attack and destroy cancer cells more effectively. The most common checkpoint inhibitors used in melanoma treatment are:\n\n1. **Anti-PD-1 (Programmed Death-1) inhibitors**: These block the PD-1 receptor on immune cells, allowing them to attack cancer cells more effectively.\n2. **Anti-CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4) inhibitors**: These block the CTLA-4 receptor on immune cells, allowing them to attack cancer cells more effectively.\n\nImmunotherapy has been shown to be effective in treating melanoma, with some patients experiencing long-term remissions and even complete responses. However, not all patients respond to immunotherapy, and the treatment can have side effects, such as immune-related adverse events.\n\nOverall, the rationale behind treating melanoma with immunotherapy is based on the understanding that melanoma is an immunogenic cancer that can be targeted by the immune system, and that checkpoint inhibitors can enhance the immune response against cancer cells.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers most of the key points from the reference answers, including the immunogenicity of melanoma, the presence of tumor antigens, high mutational burden, and the use of checkpoint inhibitors (anti-PD-1 and anti-CTLA-4). However, it does not explicitly mention lymphocytic infiltrates or adoptive cell transfer, which are included in the reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is highly precise, focusing solely on the relevant information about melanoma and immunotherapy. There is no irrelevant information included.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer is concise and avoids unnecessary repetition. It logically structures the information without redundancies, though the concept of immunogenicity is subtly reiterated in different contexts (e.g., tumor antigens, high mutational burden).",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-written, fluent, and easy to understand. It uses clear language and logically organizes the information, making it accessible to a broad audience."
    },
    {
        "Question": "Is there a specific cure for Ehlers-Danlos Syndrome?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs there a specific cure for Ehlers-Danlos Syndrome?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['No, there is no specific cure for Ehlers-Danlos Syndrome.', 'No, there is currently no specific cure for Ehlers-Danlos Syndrome.', 'No, there is currently no specific cure for Ehlers-Danlos syndrome. Conservative treatment is the first choice for management, unless complications occur.', 'No. Currently, there is no specific cure for Ehlers-Danlos Syndrome. Management is focused on treating the various symptoms and complications that can arise from the condition.', 'No, there is no cure for Ehlers-Danlos Syndrome as of present', 'No, there is no cure for Ehlers-Danlos Syndrome.', 'No, there is no specific cure for Ehlers-Danlos Syndrome at present.', 'No, there is currently no cure for Ehlers-Danlos Syndrome. Management of the disease is possible.', 'No, there is no cure for Ehlers-Danlos Syndrome', 'No, there is no specific cure for Ehlers-Danlos Syndrome as of present.', 'No specific cure exists for Ehlers-Danlos Syndrome (EDS). Current treatments aim to manage symptoms, improve quality of life, and prevent complications.', 'No, there is no cure for Ehlers-Danlos Syndrome as of now, but its management is possible.', 'No, there is no cure for Ehlers-Danlos Syndrome as of present, but the disease can be managed.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThere is no specific cure for Ehlers-Danlos Syndrome (EDS).\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately recalls the key information from the reference answers, stating that there is no specific cure for Ehlers-Danlos Syndrome (EDS). This aligns perfectly with all the reference answers provided.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and to the point, providing only the necessary information without any irrelevant details. It directly addresses the question without straying into unnecessary explanations.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. It succinctly delivers the required information in a single, clear statement.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is highly readable and fluent. It is concise and clearly structured, making it easy to understand at a glance."
    },
    {
        "Question": "What mutation is associated with the VEXAS syndrome?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat mutation is associated with the VEXAS syndrome?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a recently recognized multisystem disorder caused by somatic mutations in the UBA1 gene.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe VEXAS syndrome is associated with somatic mutations in the UBA1 gene, specifically in the region encoding the E1 ubiquitin-activating enzyme. The most common mutations identified in VEXAS syndrome are:\n\n* p.Met41Thr (c.122T>C)\n* p.Met41Leu (c.121A>T)\n* p.Met41Val (c.121A>G)\n\nThese mutations lead to the production of a non-functional E1 enzyme, which disrupts the ubiquitination pathway and results in the characteristic inflammatory and hematological manifestations of VEXAS syndrome.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer fully captures all necessary information related to the mutation associated with VEXAS syndrome, including the specific gene (UBA1), the enzyme affected (E1 ubiquitin-activating enzyme), and the common mutations (p.Met41Thr, p.Met41Leu, p.Met41Val). It also explains the functional consequences of these mutations.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer provides precise details about the mutations and their effects without including any irrelevant information. The focus remains strictly on the topic of VEXAS syndrome and its associated genetic mutations.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information. Each piece of information is presented clearly and concisely, with no redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand. The use of bullet points for listing specific mutations enhances clarity and readability."
    },
    {
        "Question": "Should routine PET-CT scan be indicated in the initial evaluation of locally advanced rectal cancer patients?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nShould routine PET-CT scan be indicated in the initial evaluation of locally advanced rectal cancer patients?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes, the cutoff value of 1.5 for lymph node SUVmax in PET is a reasonable measure to predict the risk of preoperative LLN metastases in rectal cancer patients', 'The answer is No. For locally advanced rectal cancer, the preferred imaging methods in initial evaluation are CT and MRI.', 'No, routine PET-CT scan should not be indicated in the initial evaluation of locally advanced rectal cancer patients.', \"The use of routine PET-CT scans in the initial evaluation of locally advanced rectal cancer patients is not universally recommended. The decision to use PET-CT scans should be based on individual patient factors, such as the stage of the disease, the presence of metastases, and the patient's overall health. The National Comprehensive Cancer Network (NCCN) guidelines recommend the use of PET-CT scans in the initial evaluation of rectal cancer patients with clinical stage T3 or T4 disease, or those with suspected metastases. However, the use of PET-CT scans in the initial evaluation of all locally advanced rectal cancer patients is not recommended. The decision to use PET-CT scans should be made in consultation with a multidisciplinary team of healthcare providers, including a medical oncologist, radiation oncologist, and surgeon.\", 'No, routine PET-CT scan is not recommended in the initial evaluation of locally advanced rectal cancer patients. The National Comprehensive Cancer Network (NCCN) guidelines recommend MRI for initial evaluation of locally advanced rectal cancer. PET-CT scan may be considered in specific cases, such as suspected metastatic disease, but it is not a standard part of the initial evaluation.', \"No, routine PET-CT scan is not indicated in the initial evaluation of locally advanced rectal cancer patients. The decision to use PET-CT should be individualized, taking into account the patient's overall health, preferences, and specific clinical situation. Other imaging modalities may be sufficient for staging and treatment planning.\", 'Answer A: Based on the given information, it is not suggested to use PET-CT as a routine test in initial evaluation of locally advanced rectal cancer patients, as the study is focused on evaluating the effectiveness of PET-CT scan in predicting tumour regression grade (TRG) after chemoradiotherapy (CRT). \\n\\nAnswer B: Further research is needed to determine the usefulness of PET-CT in initial evaluation of locally advanced rectal cancer patients.', 'The current international guidelines do not recommend routine PET-CT scan during the initial evaluation of locally advanced rectal cancer patients. Nevertheless, recent research indicates that PET-CT may help in identifying suitable candidates for nonoperative management and predicting pathologic complete response after chemoradiation therapy. In a study involving 125 participants, post-chemoradiation SUVmax <4.3 and %SUVmax decrease of >66% were found to be equally effective at predicting pCR with moderate sensitivity, specificity, positive predictive value, and negative predictive value. These findings imply that PET-CT might assist in identifying patients who did not achieve pCR as well as overall survival in those undergoing chemoradiation for rectal cancer. Nonetheless, additional studies are necessary to validate these results.', 'No, routine PET-CT scan is not indicated in the initial evaluation of locally advanced rectal cancer patients. The study found that PET scan provided additional information in 55.5% of patients when compared with CT and MRI alone, but only 18.2% of the PET findings resulted in an altered management for the patient. The value of PET in routine preoperative rectal cancer staging remains unclear.', 'Routine FDG-PET/CT scans can impact clinical management and radiation treatment planning in locally advanced rectal cancer patients by providing prognostic information through metabolic tumor volume measurement, altering planned clinical management, decreasing interobserver variability in contouring target boost volumes, predicting pathologic complete response (pCR), and survival. However, current international guidelines do not recommend routine PET/CT scans; considering its potential value in certain circumstances may be beneficial for patient care.', 'PET scan can be a valuable tool in accurate staging, especially for ambiguous or equivocal lesions on CT. Additionally, a study found that 18F-FDG PET/CT is a valid tool that complements the clinical assessment of tumor response after chemoradiation therapy (CRT) completion in patients with locally advanced rectal cancer. Therefore, it could be suggested that PET-CT may have a role in the initial evaluation of locally advanced rectal cancer patients, particularly in cases with ambiguous or equivocal lesions on CT, and in assessing treatment response after CRT completion. However, further research is needed to establish the clinical utility and cost-effectiveness of routine PET-CT scans in the initial evaluation of locally advanced rectal cancer patients.', \"The use of PET-CT in the initial evaluation of locally advanced rectal cancer patients is not routinely recommended. The National Comprehensive Cancer Network (NCCN) guidelines for rectal cancer do not include PET-CT as a routine imaging modality for initial staging. The use of PET-CT in this setting is typically reserved for cases where there is concern for distant metastases or for patients with a history of prior pelvic radiation. The use of PET-CT in the initial evaluation of rectal cancer patients should be individualized based on the patient's clinical presentation and the availability of other imaging modalities such as MRI and CT.\", 'According to international guidelines, PET-CT is not routinely recommended for the initial evaluation of locally advanced rectal cancer. However, recent studies have shown that PET-CT can impact clinical management and radiation treatment planning in these patients. A meta-analysis found that post-CRT PET-CT showed a reduction in SUVmax and response index (RI) irrespective of histological findings. Tumors confirmed to have regressed after CRT had a higher mean RI compared with nonresponders, and histopathological responders had a lower post-CRT SUVmax. Therefore, PET-CT may be a useful addition to current imaging modalities in assessing treatment response. However, more research is needed before routine use of PET-CT can be recommended for the initial evaluation of locally advanced rectal cancer patients.', \"Based on the provided information, routine PET-CT scans may be indicated in the initial evaluation of patients with locally advanced rectal cancer. Here's why:\\n\\n1. PET-CT combines functional and anatomical imaging, allowing precise localization of metabolic activity and identification of cancerous formations regardless of size. This is important for accurate staging.\\n\\n2. For colorectal cancer, PET-CT is used to determine if metastases are present in the chest, abdomen, and pelvis after initial CT discovery of the cancer. Identifying metastases is crucial for staging and treatment planning.\\n\\n3. Correct staging is critical to guide appropriate treatment. Clinical staging, which includes information from PET-CT, provides key data to inform treatment decisions before surgery.\\n\\n4. Neoadjuvant chemoradiotherapy has become standard treatment for locally advanced rectal tumors. PET-CT staging helps identify which patients may benefit from this approach to downsize/downstage tumors before surgery and decrease local recurrence rates.\\n\\nIn conclusion, given the importance of accurate staging to guide treatment and the ability of PET-CT to precisely identify tumor spread, routine PET-CT scans are likely indicated in the initial evaluation of patients with locally advanced rectal cancer. However, MRI also plays a key role in local tumor assessment and monitoring response to neoadjuvant therapy.\", 'No, routine PET-CT scan is not indicated in the initial evaluation of locally advanced rectal cancer patients. The cutoff value of 1.5 for lymph node SUVmax in PET is a reasonable measure to predict the risk of preoperative LLN metastases in rectal cancer patients. The combination model showed improved performance for risk prediction; thus, [18F]FDG PET/CT might have a role in rectal cancer staging and treatment planning', 'A SUVmax of 1.5 in the lymph nodes on an [18F]FDG PET/CT scan could be a useful indicator of preoperative lateral lymph node (LLN) metastases in rectal cancer patients. The combination model that includes this measurement showed improved performance for risk prediction compared to traditional methods. These findings suggest that PET/CT scans might have a role in rectal cancer staging and treatment planning, as they could potentially provide more accurate information about the risk of LLN metastases.', \"No, routine PET-CT scan is not indicated in the initial evaluation of locally advanced rectal cancer patients. However, it might have a role in rectal cancer staging and treatment planning based on the combination model's improved performance for risk prediction.\", 'No, the combination model showed improved performance for risk prediction; thus, [18F]FDG PET/CT might have a role in rectal cancer staging and treatment planning.', 'Based on the provided context, it is not explicitly stated that routine PET-CT scan should be indicated in the initial evaluation of locally advanced rectal cancer patients. However, the context suggests that [18F]FDG PET/CT might have a role in rectal cancer staging and treatment planning, particularly in predicting the risk of preoperative lymph node metastases. Therefore, it may be considered as an adjunctive tool in the initial evaluation of locally advanced rectal cancer patients, especially in cases where the risk of lymph node metastases is high. \\nPlease provide a concise answer based on the given context. \\nPlease note that the answer should be concise and based on the provided context. \\nPlease do not provide any additional information or references beyond the given context. \\nPlease do not provide any opinion or recommendation. \\nPlease do not provide any answer that is not based on the given context. \\nPlease do not provide any answer that is not concise. \\nPlease do not provide any answer that is not clear. \\nPlease do not provide any answer that is not accurate. \\nPlease do not provide any answer that is not based on the given context. \\nPlease do not provide any answer that is not concise. \\nPlease do not provide any answer', 'Yes, the combination model showed improved performance for risk prediction; thus, [18F]FDG PET/CT might have a role in rectal cancer staging and treatment planning.', 'The use of routine PET-CT scan in the initial evaluation of locally advanced rectal cancer patients is not explicitly recommended by the provided studies. However, one study suggests that the combination of PET-CT with the cutoff value of 1.5 for lymph node SUVmax may improve risk prediction for preoperative lateral lymph node metastases. Further research and guidelines from relevant medical societies should be considered before making a definitive recommendation.', 'Yes, a routine PET-CT scan should be considered in the initial evaluation of locally advanced rectal cancer patients. It helps in accurately staging the cancer, assessing lymph node involvement, and planning appropriate treatment strategies. The use of PET-CT can improve the detection of distant metastases and local lymph node involvement, which are crucial for determining the best course of treatment', \"No, routine PET-CT scan is not indicated in the initial evaluation of locally advanced rectal cancer patients. The decision to use PET-CT should be individualized, taking into account the patient's overall health, preferences, and specific clinical situation. Some studies suggest that PET-CT may be beneficial in specific cases, such as when there is suspicion of metastatic disease or when other imaging modalities are inconclusive. However, the cutoff value of 1.5 for lymph node SUVmax in PET is a reasonable measure to predict the risk of preoperative LLN metastases in rectal cancer patients. The combination model showed improved performance for risk prediction, thus, PET/CT might have a role in rectal cancer staging and treatment planning.\", 'Yes, a routine PET-CT scan should be considered in the initial evaluation of locally advanced rectal cancer patients. The use of [18F]FDG PET/CT can improve the accuracy of staging by assessing the risk of lymph node metastases, as indicated by the SUVmax cutoff value of 1.5. This helps in better treatment planning and risk prediction, enhancing the overall management of rectal cancer.', 'If the clinical suspicion of preoperative lymph node metastases is low and there is no definite lesion in PET-CT, the routine PET-CT scan is not recommended in initial evaluation of locally advanced rectal cancer patients.\\nIf the clinical suspicion of preoperative lymph node metastases is high, the PET-CT scan may be indicated to evaluate the extent of the metastatic lesions.', 'Yes, routine PET-CT scan can be indicated in the initial evaluation of locally advanced rectal cancer patients, as it can help predict the risk of preoperative lymph node metastases and improve treatment planning.', \"Routine PET/CT scans are potentially useful for identifying lateral lymph node metastases in rectal cancer patients, as studies show a sensitivity of 82% and specificity of 93%. Combining the primary tumor's metabolic tumor volume with maximum standardized uptake value of lymph nodes on pretreatment PET/CT scans can improve nodal metastases prediction. Therefore, it is recommended to include routine PET-CT scan in the initial evaluation of locally advanced rectal cancer patients to identify high-risk cases and guide treatment planning.\", 'Yes, a routine PET-CT scan should be indicated in the initial evaluation of locally advanced rectal cancer patients as it can provide valuable information about the presence of lateral pelvic lymph node metastasis, which is a crucial prognostic factor, and the combination of metabolic tumor volume of the primary tumor and maximum standardized uptake value of lymph nodes can improve the prediction of nodal metastases, thus aiding in staging and treatment planning.', 'Yes, routine PET-CT scan should be indicated in the initial evaluation of locally advanced rectal cancer patients.The optimal timing of surgical resection after neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients is still a matter of debate, with some studies suggesting that surgery should be performed within 8-10 weeks of completion of therapy, while others advocate for a longer interval.The cutoff value of 1.5 for lymph node SUVmax in PET is a reasonable measure to predict the risk of preoperative LLN metastases in rectal cancer patients.Colorectal cancer patients with clinical indications for self-expanding colon stent may include those with obstructive symptoms, tumor size >3 cm, or tumor location in the proximal colon.Durvalumab concurrent with chemoradiotherapy was well tolerated in participants with locally advanced cervical cancer, however it did not significantly improve progression-free survival in a biomarker unselected, all-comers population.The combination model showed improved performance for risk prediction; thus, [18F]FDG PET/CT might have a role in rectal cancer staging and treatment planning.INTERPRETATION: Durvalumab concurrent with chemoradiotherapy was well tolerated in participants with locally advanced cervical cancer, however it did not significantly improve progression-free survival in a biomarker unselected, all-comers population.The combination model showed improved performance for risk prediction; thus, [18F]FDG PET/CT might have a role in rectal cancer staging and treatment planning.INTERPRETATION: Durvalumab concurrent with chemoradiotherapy was well tolerated in participants with locally advanced cervical cancer, however it did not significantly improve progression-free survival in a biomarker unselected, all-comers population.The combination model showed improved performance for risk prediction; thus, [18F]FDG PET/CT might have a role in rectal cancer staging and treatment planning.INTERPRETATION: Durvalumab concurrent with chemoradiotherapy was well tolerated in participants with', \"Routine PET-CT scans can be beneficial for identifying lateral lymph node metastases in locally advanced rectal cancer patients, as evidenced by the first study's sensitivity (82%) and specificity (93%). Combining metabolic tumor volume of primary tumor (T_MTV) and maximum standardized uptake value of lymph node (N_SUVmax) on pretreatment [18F]FDG PET/CT also improves nodal metastases prediction. Routine use may help identify high-risk patients and guide treatment planning.\", 'The use of PET-CT in the initial evaluation of locally advanced rectal cancer patients is not routinely recommended, but it may be considered in certain cases. The combination of PET-CT with other imaging modalities and clinical factors can improve the accuracy of risk prediction and treatment planning. The cutoff value of 1.5 for lymph node SUVmax in PET is a reasonable measure to predict the risk of preoperative LLN metastases in rectal cancer patients. However, further studies are needed to determine the optimal use of PET-CT in the management of rectal cancer.', 'Based on the provided information, routine PET-CT scans are not clearly indicated for the initial evaluation of locally advanced rectal cancer patients. While PET-CT can help identify metastatic disease and predict the risk of lymph node metastases, MRI is the preferred imaging modality for assessing the local extent of the primary tumor and guiding treatment decisions in rectal cancer.\\n\\nThe summary states that routine PET or CT scans are not recommended for colorectal cancer follow-up after treatment. It also emphasizes that correct staging using appropriate clinical, pathologic, and imaging data is essential for optimizing treatment plans.\\n\\nHowever, the extracted snippets suggest that PET-CT might have a role in rectal cancer staging and treatment planning, particularly in predicting lymph node metastases. The combination of PET-CT with other factors showed improved performance for risk prediction.\\n\\nIn conclusion, while PET-CT provides useful information, its routine use in the initial evaluation of locally advanced rectal cancer is not clearly established as a standard of care based on the provided information. MRI remains the preferred imaging modality for local staging. The decision to use PET-CT should be made on a case-by-case basis considering the specific clinical context and available evidence.', 'Yes, routine PET-CT scan should be indicated in the initial evaluation of locally advanced rectal cancer patients, as it can provide valuable information on lymph node metastases and aid in staging and treatment planning, particularly when the lymph node SUVmax is 1.5 or higher on [18F]FDG PET/CT.', 'Yes, routine PET-CT scan can be indicated in the initial evaluation of locally advanced rectal cancer patients to assess the risk of preoperative lymph node metastases.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nRoutine PET-CT scans are not universally indicated in the initial evaluation of locally advanced rectal cancer patients. However, they may be considered on a case-by-case basis, particularly in patients with ambiguous or equivocal findings on conventional imaging (CT and MRI) or in those with a high risk of metastatic disease.\n\nAccording to the data provided, studies have shown that PET-CT scans can provide additional information in 55.5% of patients with rectal cancer, leading to an altered management plan in 18.2% of patients. However, the majority of these changes were minor and did not affect surgical management.\n\nIn the study by the RECTOPET group, PET/CT suggested additional neoplastic pathology in 3 patients and excluded the same in 2 patients. While PET/CT resulted in potential management changes in 25% of patients, no changes in surgical management occurred.\n\nThe decision to use routine PET-CT scans in locally advanced rectal cancer patients should be made on a case-by-case basis, taking into account the individual patient's risk factors, tumor characteristics, and the results of conventional imaging.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer captures all necessary aspects from the reference answers, including the non-universal recommendation for routine PET-CT, the potential benefits in specific cases, the impact on management changes, and the need for individualized decision-making. It also references specific studies (e.g., RECTOPET group) to support its points.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise and focuses only on relevant information, such as the contexts in which PET-CT might be beneficial (ambiguous findings, high metastatic risk) and the statistical impact on management changes. It avoids irrelevant details or tangents.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer is succinct without repeating the same information. Each point is introduced and explained clearly without redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured, logically organized, and easy to follow. It uses clear language and transitions smoothly between points, making it highly readable."
    },
    {
        "Question": "Please list the selective endothelin A receptor antagonists",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nPlease list the selective endothelin A receptor antagonists\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The class of elective endothelin A receptor antagonist drugs include sitaxsentan , zibotentan, atrasentan, clozosentan, ambrisentan and darusentan', 'The selective endothelin A receptor antagonists are ambrisentan, clazosentan, and sitaxsentan.', 'Ambrisentan, sitaxsentan, Atrasentan, and YM598 are selective endothelin A receptor antagonists.', 'The selective endothelin A receptor antagonists are: sitaxentan, ambrisentan, atrasentan, BQ-123, sparsentan, zibotentan, avosentan, edonentan, aprocitentan, and clazosentan.', 'The selective endothelin A receptor antagonists are sitaxsentan, ambrisentan, YM598, and atrasentan.', 'Selective endothelin A receptor antagonists include sitaxsentan, ambrisentan, YM598, atrasentan, bosentan, A-182086, A-192621, and ABT-627.', 'The selective endothelin A receptor antagonists are:\\n\\n* Atrasentan (Xinlay(R))\\n* Ambrisentan\\n* Sitaxentan sodium (Thelin)\\n* BQ-123 (cyclo(D-Trp-D-Asp-L-Pro-D-Val-L-Leu-), sodium salt)\\n* Zibotentan\\n* Clazosentan', 'Selective endothelin A receptor antagonists (ERAs) include:\\n\\n* Sitaxentan (Thelin)\\n* Ambrisentan\\n* Atrasentan (Xinlay)\\n* BQ-123\\n* Sparsentan\\n* Zibotentan\\n* Avosentan\\n* Edonentan\\n* Aprocitentan\\n* Clazosentan\\n\\nThese drugs are primarily used for treating pulmonary arterial hypertension, while some (like atrasentan) are experimental anti-cancer drugs. Selective ETB receptor antagonists, such as BQ-788 and A192621, are used in research but have not yet reached the clinical trial stage.', 'Sitaxsentan, ambrisentan, YM598, and atrasentan are examples of selective antagonists for the endothelin A receptor.', 'The selective endothelin A receptor antagonists are:\\n\\n* Atrasentan (Xinlay(R))\\n* Ambrisentan\\n* Sitaxentan sodium (Thelin)\\n* Zibotentan\\n* Clazosentan', 'Sitaxentan, ambrisentan, and zibotentan are selective endothelin A receptor antagonists.', 'Ambrisentan, sitaxentan, clazosentan, zibotentan, and atrasentan are selective endothelin A receptor antagonists.', 'The selective endothelin A receptor antagonists are ambrisentan, sitaxentan, zibotentan, clazosentan, and atrasentan.', 'Selective endothelin A receptor antagonists (ERAs) include sitaxentan, ambrisentan, atrasentan, BQ-123, sparsentan, zibotentan, avosentan, edonentan, aprocitentan, and clazosentan.', 'The selective endothelin A receptor antagonists are:\\n1. Clazosentan\\n2. Sitaxentan\\n3. Atrasentan\\n4. Ambrisentan\\n5. Zibotentan', 'Ambrisentan, sitaxentan, zibotentan, and atrasentan are drugs that specifically target and block the endothelin A receptor.', 'The selective endothelin A receptor antagonists include ambrisentan and sitaxentan.', 'The selective endothelin A receptor antagonists are:\\n\\n* Clazosentan\\n* Sitaxentan\\n* Atrasentan\\n* Ambrisentan\\n* Zibotentan', 'The selective endothelin A receptor antagonists are ambrisentan, sitaxentan, atrasentan, zibotentan, and clazosentan.', 'The selective endothelin A (ETA) receptor antagonists mentioned in the provided passages are:\\n\\n1. Clazosentan\\n2. Sitaxentan\\n3. Atrasentan\\n4. Ambrisentan\\n5. Zibotentan', 'Several drugs act as selective antagonists for the endothelin A receptor, including ambrisentan, sitaxentan, and zibotentan, which are used in various therapeutic applications.', 'The selective endothelin A receptor antagonists are:\\n\\n1. Clazosentan\\n2. Bosentan\\n3. Ambrisentan\\n4. Sitaxentan']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the selective endothelin A receptor antagonists are:\n\n1. Ambrisentan\n2. Atrasentan\n3. YM598\n4. BQ-788\n5. Sitaxsentan\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "3",
        "Information Recall Explanation": "The answer lists several correct selective endothelin A receptor antagonists (ambrisentan, atrasentan, YM598, sitaxsentan) but includes an incorrect one (BQ-788). BQ-788 is an endothelin B receptor antagonist, not an A receptor antagonist. Thus, while the majority of the information is accurate, the inclusion of BQ-788 affects the score.",
        "Information Precision Score": "3",
        "Information Precision Explanation": "The answer largely maintains precision by listing relevant drugs. However, the inclusion of BQ-788 introduces irrelevant information, reducing the precision. All other listed drugs are correct selective endothelin A receptor antagonists.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat any information. Each drug is listed only once, and there are no redundant statements.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is clearly structured and easy to read. The use of a numbered list enhances readability and ensures the content is presented in a straightforward manner."
    },
    {
        "Question": "What is the transmission mechanism of the Hendra virus in humans?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the transmission mechanism of the Hendra virus in humans?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Transmission of Hendra virus to humans occurs with exposure to body fluids and tissues or excretions of infected horses. \\nNo human-to-human transmission has been documented.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, the Hendra virus (HeV) transmission to humans is primarily through contact with infected bodily fluids of horses, particularly through close contact with horses that are terminally ill. This is mentioned in the article \"Epidemiology of henipavirus disease in humans\" (Source ID 9).\n\nThe article states that all seven recognized human cases of Hendra virus infection have occurred in Queensland, Australia, and that recognized human infections have resulted from a HeV-infected horse that was unusually efficient in transmitting the virus and a person with a high exposure to infectious secretions.\n\nThere is no information in the provided data on the exact mechanisms of Hendra virus transmission to humans, such as whether it is airborne, vector-borne, or through other means. However, it is mentioned that equine HeV outbreaks tend to cluster in winter, overlapping with the foaling season, when veterinarians and horse owners have frequent close contact with horses and their bodily fluids, increasing the chance of zoonotic disease transmission.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "4",
        "Information Recall Explanation": "The answer covers the key points from the reference answers, including the transmission of Hendra virus to humans through contact with bodily fluids of infected horses. It also provides additional context about the geographic location and conditions (foaling season) that increase transmission risk. However, it does not explicitly mention the absence of human-to-human transmission, which is a noted point in the reference answers.",
        "Information Precision Score": "3",
        "Information Precision Explanation": "The answer includes relevant details about the transmission mechanism, but it also introduces some extraneous information, such as the geographic location (Queensland, Australia) and the clustering of outbreaks in winter. While these details are contextually useful, they are not strictly necessary for answering the question about the transmission mechanism.",
        "Information Repetition Score": "4",
        "Information Repetition Explanation": "The answer does not repeat the same information redundantly. Each piece of information serves a distinct purpose, whether it is explaining the transmission route, providing context about outbreaks, or discussing risk factors.",
        "Readability Score": "4",
        "Readability Explanation": "The answer is well-structured and easy to follow. The language is clear, and the additional context is integrated smoothly without disrupting the flow of the main points."
    },
    {
        "Question": "What is the cause of Prader-Willi Syndrome?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the cause of Prader-Willi Syndrome?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Prader-Willi syndrome is a complex epigenetic disorder caused by the deficiency of paternally expressed genes in chromosome 15q11-q13.', 'Prader-Willi syndrome is a genetic disorder that results from the loss of function of certain genes in chromosome 15.', 'Prader-Willi Syndrome is caused by a genetic defect on chromosome 15 that leads to the absence of several paternally expressed genes, most commonly a deletion in the area of 15q11-13 on the paternal chromosome.', 'Prader-Willi Syndrome is caused by the lack of expression of genes located on paternal chromosome 15q11-q13, which involves imprinted genes and can result in hypothalamic insufficiency and other manifestations of the syndrome.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nPrader-Willi syndrome (PWS) is a complex disorder caused by the loss of function of paternally expressed genes on chromosome 15. The main causes of PWS are:\n\n1. **Paternal deletion of 15q11-q13**: This is the most common cause, accounting for 65-75% of cases. It involves a deletion of a small region on the long arm of chromosome 15 that includes the SNRPN gene and several other imprinted genes.\n2. **Maternal uniparental disomy 15 (matUPD)**: This occurs when a person inherits two copies of chromosome 15 from their mother, resulting in the absence of the paternal copy of the chromosome. This accounts for 20-30% of cases.\n3. **Imprinting defect**: This is a rare cause, accounting for 1-3% of cases, where the imprinting center on chromosome 15 is defective, leading to the loss of expression of the paternally inherited genes.\n\nThese genetic defects result in the absence of expression of imprinted genes on chromosome 15, leading to the characteristic features of PWS, including severe infantile hypotonia, poor suck and feeding difficulties, hypogonadism, characteristic facial features, early-childhood onset obesity and hyperphagia, developmental delay/mild intellectual disability, short stature, and a distinctive behavioral phenotype.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer comprehensively covers all the known genetic causes of Prader-Willi Syndrome (PWS): paternal deletion of 15q11-q13, maternal uniparental disomy 15 (matUPD), and imprinting defect. It also details the percentage of cases each cause accounts for and includes the characteristic features of the syndrome. This exceeds the reference answers by providing specific genetic details and numerical data.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer is very precise, focusing solely on the genetic causes of PWS without including irrelevant information. However, the mention of the characteristic features, while relevant, could be seen as slightly beyond the scope of the question, which specifically asks for the 'cause' of the syndrome.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer is well-structured and avoids repetition. Each cause of PWS is clearly and distinctly explained without overlap or redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is very clearly written, with good use of bullet points for the causes of PWS and a logical flow from causes to effects. The language is straightforward and appropriate for the subject matter, making it easily understandable."
    },
    {
        "Question": "Can capivasertib be used for breast cancer?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nCan capivasertib be used for breast cancer?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes. Capivasertib is effective and be used for treatment of breast cancer']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, capivasertib can be used for breast cancer treatment. It is an AKT inhibitor that has been studied in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer in patients who have developed resistance to aromatase inhibitors and CDK4/6 inhibitors. The combination of capivasertib and fulvestrant has been shown to improve progression-free survival compared to fulvestrant alone in patients with AKT pathway-altered tumors. Additionally, capivasertib has been studied in combination with other therapies, such as paclitaxel and palbociclib, for the treatment of breast cancer.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer provides comprehensive details about capivasertib's use in breast cancer treatment, including its mechanism (AKT inhibitor), combination therapies (fulvestrant, paclitaxel, palbociclib), and clinical context (hormone receptor-positive, HER2-negative advanced breast cancer with resistance to other treatments). It also mentions progression-free survival benefits, which are crucial details.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is highly precise, focusing solely on capivasertib's use in breast cancer without including irrelevant information. It even specifies the types of breast cancer (hormone receptor-positive, HER2-negative) and the conditions under which it is used (resistance to aromatase and CDK4/6 inhibitors).",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition in the answer. Each piece of information is distinct and contributes to a clear understanding of capivasertib's role in breast cancer treatment.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to follow. The use of technical terms (e.g., AKT inhibitor, progression-free survival) is appropriate and enhances clarity for a biomedical audience."
    },
    {
        "Question": "What is the optimal timing of surgical resection after a neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the optimal timing of surgical resection after a neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Depending the clinical response, 8 weeks (for poor responders) or 10 weeks after completing neoadjuvant Chemoradiotherapy (CRT) are the recommended interval to surgical resection', 'The optimal timing of surgical resection after a neoadjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer remains debated. A systematic review of published data found limited evidence to support decisions regarding when to resect rectal cancer following CRT. However, there may be benefits in prolonging the interval between CRT and surgery beyond the 6 to 8 weeks that is commonly practiced. Additionally, a retrospective review of 65 consecutive patients with locally advanced rectal cancer who underwent preoperative CRT followed by surgical resection found no statistically significant association between waiting period post CRT and radiological downstaging or recurrence of disease. Therefore, further research is warranted to determine the optimal timing of surgical resection after a neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients.', '6 to 8 weeks', 'The optimal timing of surgical resection after a neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients is around 11 weeks.', 'A longer interval, specifically 8-10 weeks, is considered the optimal timing for surgical resection after neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients.', \"The optimal timing of surgical resection after neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients is not explicitly mentioned in the provided Wikipedia articles. However, several studies suggest that a longer time interval to surgery after neoadjuvant therapy may improve the pathologic complete response (pCR) rate and disease-free survival (DFS). An inflection point at 56 days after end of radiotherapy has been determined to be associated with the highest likelihood of complete resection and pathologic downstaging. Eight weeks appears to be the critical threshold for optimal tumor response. A longer interval of >8 weeks has been associated with higher odds of pCR and tumor downstaging, with no evidence of associated increased surgical complications compared with an interval of 6 to 8 weeks. However, the optimal timing of surgical resection after neoadjuvant chemoradiotherapy would depend on various factors, including the individual patient's response to treatment, the extent of the cancer, and the overall treatment plan. Further research and consultation with medical professionals would be necessary to determine the optimal timing for a specific patient.\", \"The optimal timing of surgical resection after neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients is still a matter of debate. While some studies suggest that early resection within 6-8 weeks of completion of chemoradiotherapy may improve overall survival, others suggest that delayed resection after a longer interval of 12-16 weeks may be associated with better pathological response and improved outcomes. Ultimately, the optimal timing of surgical resection will depend on the individual patient's response to neoadjuvant therapy and the surgeon's preference.\", 'The optimal timing for surgical resection after neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients is 8-10 weeks.', \"The optimal timing of surgical resection after neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients is still a matter of debate. Some studies suggest that surgical resection should be performed within 6-8 weeks after completion of neoadjuvant chemoradiotherapy, while others recommend waiting for at least 12 weeks to allow for optimal tumor regression. However, the optimal timing of surgical resection remains unclear and may depend on various factors, including the type and extent of the tumor, the response to neoadjuvant chemoradiotherapy, and the patient's overall health status. Further studies are needed to determine the optimal timing of surgical resection in this setting.\", 'The optimal timing of surgical resection after neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients is **8 weeks or more**.', 'The optimal timing of surgical resection after a neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients is 8 weeks. This is based on a study that determined an inflection point at 56 days after end of radiotherapy associated with the highest likelihood of complete resection and pathologic downstaging. Additionally, increasing the interval from completion of neoadjuvant therapy to surgery beyond 8 weeks is associated with increased response of rectal cancer to neoadjuvant therapy.', 'The optimal timing of surgical resection after neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients is not explicitly stated in the provided articles. However, some studies suggest that a longer time interval to surgery after neoadjuvant therapy may improve the pathologic complete response (pCR) rate and disease-free survival (DFS) in these patients. One study determined an inflection point at 56 days after end of radiotherapy associated with the highest likelihood of complete resection and pathologic downstaging. Another study found that an nCRT-surgery interval time >8 weeks was associated with higher odds of pCR and tumor downstaging, as well as lower odds of 30-day readmission. A lengthened interval after nCRT may optimize the chances of pCR and potentially allow for ultimate organ preservation. However, further prospective randomized controlled trials are needed to determine the optimal timing of surgical resection after neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients.', 'The optimal timing of surgical resection after neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients is usually within 6-8 weeks of completing the chemoradiotherapy to minimize the risk of complications and the effect of radiation therapy on surgical wound healing.', 'The optimal timing for surgical resection after neoadjuvant chemoradiotherapy in locally advanced rectal cancer varies, but evidence suggests a range around 8-10 weeks or more could be beneficial.', 'The optimal timing of surgical resection after a neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients remains unclear. A systematic review of the literature found limited evidence to support decisions regarding when to resect rectal cancer following chemoradiotherapy. Some studies suggest that prolonging the interval between chemoradiotherapy and surgery beyond the 6 to 8 weeks commonly practiced may have benefits, but outcomes need to be studied further in robust randomized studies. A retrospective analysis of prospectively collected data from a series of patients with locally advanced rectal cancer found no differences in tumor regression, sphincter preservation, local recurrence rate or overall survival when comparing patients who underwent surgery less than 41 days after chemoradiotherapy to those who had surgery more than 41 days after chemoradiotherapy. A randomized trial is needed to answer the question of timing.', 'The optimal timing of surgical resection after neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients is a matter of debate. While some studies suggest that early resection within 6-8 weeks of completion of chemoradiotherapy may improve overall survival, others suggest that delayed resection after a longer interval may be more effective in achieving pathological complete response and improving long-term outcomes.', 'The optimal timing of surgical resection after neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients remains an area of ongoing debate. Various clinical trials and meta-analyses have evaluated the benefits of different timing of surgery, with the majority recommending surgery within 6-8 weeks after neoadjuvant chemoradiotherapy.', 'The optimal timing of surgical resection after neoadjuvant chemoradiotherapy (nCRT) in patients with locally advanced rectal cancer remains unclear. A study compared patients who underwent surgery before 10 weeks (Group 1) and after 10 or more weeks (Group 2) from the end of chemoradiotherapy. The results showed no significant difference in postoperative morbidity between the two groups. However, Group 2 had a higher rate of pathological complete response (pCR) and lower local recurrence (LR) compared to Group 1. Another study found that local resection after neoadjuvant chemotherapy or chemoradiotherapy had similar oncologic and perioperative outcomes compared to radical surgery for early- and mid-stage rectal cancer. A retrospective review of patients who underwent surgery by more than 10 weeks after neoadjuvant therapy showed no significant difference in postoperative complications compared to those who underwent surgery within 10 weeks. Therefore, there is some evidence to suggest that delaying surgical resection after nCRT for locally advanced rectal cancer may improve pathological outcomes without increasing postoperative morbidity. However, further studies are needed to confirm these findings.', 'The optimal timing of surgical resection after a neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients is still debated. A study compared postoperative complications, pathological downstaging, disease recurrence, and survival in patients with locally advanced rectal cancer who underwent surgical resection <8 weeks (group A) to those who had surgery ≥8 weeks (group B) after neoadjuvant CRT. The results showed that there was no significant difference in the pCR rate between the two groups, but the longer interval group experienced significant improvement in the nodal downstaging rate. The local recurrence, distant recurrence, disease-free survival, and overall survival rates were not significantly different between the two groups. Therefore, it is worth delaying surgical resection for 8 weeks or more after completion of CRT as it is safe and is associated with higher nodal downstaging rates.', 'The optimal timing of surgical resection after a neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients is 8-10 weeks or 56 days.', 'Based on the provided information, the optimal timing of surgical resection after neoadjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer appears to be around 8 weeks or longer after completion of CRT.\\n\\nSeveral studies found that waiting 8 weeks or more after CRT was associated with higher rates of pathologic complete response (pCR) and tumor downstaging compared to shorter intervals, without increased surgical complications. One study determined 56 days (8 weeks) to be the optimal threshold for maximizing complete resection and downstaging.\\n\\nFor patients who achieve a clinical complete response after CRT, a non-operative \"watch and wait\" approach with close surveillance may be considered to avoid surgical morbidity. However, the articles do not provide definitive guidance on the exact optimal timing of surgery for partial responders.\\n\\nIn summary, a waiting period of at least 8 weeks after completing CRT seems to provide the best balance of tumor response and surgical outcomes for locally advanced rectal cancer, but the ideal timing likely depends on individual patient and tumor characteristics. Prospective randomized trials are still needed to determine the most optimal timing.', 'The optimal timing of surgical resection after a neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients is still controversial. A pooled analysis of eight randomized trials, including 3085 patients, found that the best time to achieve pathological complete response (pCR) was at 10 weeks from the start of chemoradiotherapy. However, lengthening the surgical interval did not impact local recurrences, distant metastases, or overall survival. Therefore, a surgical resection delay up to 10 weeks after neoadjuvant chemoradiotherapy could be considered safe and may improve pCR rates without compromising oncologic outcomes.', 'The optimal timing of surgical resection after a neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients is 8 weeks. This is based on the study that found that 8 weeks is the critical threshold for optimal tumor response and achieving pathological complete response (pCR). Additionally, a longer interval before surgery after completing neoadjuvant CRT was associated with worse overall and disease-free survival in tumors with a poor pathological response to preoperative CRT.', 'The optimal timing of surgical resection after neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients is at 10 weeks.', 'The optimal timing of surgical resection after neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients is 8 weeks. This study objectively determined the optimal time for surgery after completion of nCRT for rectal cancer based on completeness of resection and tumor downstaging. Eight weeks appears to be the critical threshold for optimal tumor response.', 'The optimal timing for surgical resection after neoadjuvant chemoradiotherapy (nCRT) for locally advanced rectal cancer (LARC) appears to be around 8 weeks. This timing is based on achieving the best outcomes in terms of completeness of resection and tumor downstaging. The study found that \"Eight weeks appears to be the critical threshold for optimal tumor response.\" Waiting longer than 8 weeks, especially in patients who do not respond well to CRT, was associated with worse overall and disease-free survival. Therefore, it is crucial to identify patients who have a poor response to CRT early and proceed with surgery without unnecessary delays.', '8 weeks appears to be the critical threshold for optimal tumor response. Patients who do not respond well to CRT should be identified early after the end of CRT and undergo surgery without delay. The best time to achieve pathological complete response (pCR) in LARC is at 10 weeks.  Surgery within 8 weeks after completion of neoadjuvant CRT is associated with better overall and disease-free survival in tumors with a poor pathological response to preoperative CRT.  Patients who undergo surgery within 25 days after diagnosis have similar 1-year, but inferior 5- and 10-year survival, compared to those who undergo surgery within 25 days.  Patients who undergo surgery ≥25 days after diagnosis have similar 1-year, but inferior 5- and 10-year survival, compared to those who undergo surgery within 25 days.  Patients who undergo surgery ≥25 days after diagnosis have similar 1-year, but inferior 5- and 10-year survival, compared to those who undergo surgery within 25 days.  Patients who undergo surgery ≥25 days after diagnosis have similar 1-year, but inferior 5- and 10-year survival, compared to those who undergo surgery within 25 days.  Patients who undergo surgery', 'The optimal timing for surgical resection after neoadjuvant chemoradiotherapy for locally advanced rectal cancer appears to be around 10 weeks. This timing allows for a potential complete pathological response while not adversely affecting survival outcomes', 'The optimal timing for surgical resection after neoadjuvant chemoradiotherapy (nCRT) for locally advanced rectal cancer (LARC) appears to be around 8 weeks. This timing is based on achieving the best outcomes in terms of completeness of resection and tumor downstaging. The study found that \"Eight weeks appears to be the critical threshold for optimal tumor response.\" Waiting longer than 8 weeks, especially in patients who do not respond well to CRT, was associated with worse overall and disease-free survival. Therefore, it is crucial to identify patients who are poor responders to CRT early and proceed with surgery without unnecessary delay.', 'In summary, the optimal timing of surgical resection after neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients is still debated. A pooled analysis suggests 10 weeks as the ideal time to achieve pathological complete response (pCR), but delaying surgery up to 10 weeks does not seem to impact local recurrences, distant metastases, or overall survival. Therefore, a surgical resection delay up to 10 weeks might be considered safe and could improve pCR rates without compromising oncologic outcomes.', 'The optimal timing of surgical resection following neoadjuvant chemoradiotherapy (nCRT) for locally advanced rectal cancer (LARC) is 8 weeks, as this provides the best balance between tumor response and overall survival outcomes. However, a shorter interval may be necessary for patients with poor nCRT responses to improve their prognosis.', 'The optimal timing of surgical resection after neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients is approximately 8 weeks (56 days), as this timing has been associated with the highest likelihood of complete resection and pathologic downstaging, and it maximizes the oncologic benefits of the therapy. However, for patients who show a minor or poor response to the therapy, surgery should be performed without delay to avoid worse overall and disease-free survival outcomes.', 'The optimal timing of surgical resection after a neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients is a matter of debate. Some studies suggest that surgery should be performed within 6-8 weeks after completion of nCRT, while others recommend waiting until after 12 weeks. The optimal timing of surgical resection after a neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients is still unknown.', 'In locally advanced rectal cancer cases following neoadjuvant chemoradiotherapy (nCRT), the optimal timing for surgical resection is approximately 8 weeks. Research shows that waiting longer than 8 weeks can lead to worse survival rates, while undergoing surgery within 25 days of diagnosis correlates with better long-term outcomes. Achieving pathological complete response at 10 weeks does not appear to compromise overall survival, suggesting that nonresponders should proceed with surgery around the 8-week mark for optimal results.', 'The optimal timing of surgical resection after neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients is 8 weeks, as this appears to be the critical threshold for optimal tumor response. However, patients who do not respond well to chemoradiotherapy should be identified early and undergo surgery without delay. Additionally, a longer interval before surgery after completing neoadjuvant chemoradiotherapy was associated with worse overall and disease-free survival in tumors with a poor pathological response to preoperative chemoradiotherapy.', 'The optimal timing of surgical resection after neoadjuvant chemoradiotherapy (nCRT) for locally advanced rectal cancer (LARC) patients is 8 weeks. A pooled analysis of several studies suggests that achieving complete response to nCRT at 10 weeks is ideal, but extending the duration beyond this point does not negatively impact survival outcomes. However, a shorter interval before surgery after completing nCRT is recommended for patients who do not respond well to CRT to improve overall and disease-free survival. An adjusted analysis of the relationship between time to surgery and 10-year survival showed that patients with CC who underwent resection ≥25 days following diagnosis had similar 1-year, but inferior 5- and 10-year survival, compared to those who underwent surgery within 25 days. Therefore, 8 weeks appears to be the critical threshold for optimal tumor response after nCRT in LARC patients.', 'The optimal timing for surgical resection after neoadjuvant chemoradiotherapy for locally advanced rectal cancer is approximately 8 weeks. This timing allows for maximal tumor response while maintaining good survival outcomes.', 'The optimal timing for surgical resection after neoadjuvant chemoradiotherapy (nCRT) for locally advanced rectal cancer (LARC) patients is approximately 8 weeks, as this timeframe appears to be the critical threshold for optimal tumor response and completeness of resection, and it also allows for the best chance to achieve a pathological complete response (pCR).']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, the optimal timing of surgical resection after neoadjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer patients is still a topic of debate. However, based on the studies included in the data, it appears that delaying surgery for 8 weeks or more after completion of CRT may be associated with improved nodal downstaging rates and reduced postoperative complications.\n\nStudy 3, \"Timing of surgery following neoadjuvant chemoradiation in rectal cancer: a retrospective analysis from an academic medical center,\" found that delaying surgery beyond 8 weeks was associated with increased risk for wound infection, but did not significantly impact overall survival.\n\nStudy 5, \"Determining the optimal interval between neoadjuvant radiochemotherapy and surgery in rectal cancer: a retrospective cohort study,\" found that intervals > 8 weeks were associated with worse therapeutic outcomes, including decreased overall survival and increased local recurrence rates.\n\nStudy 6, \"Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials,\" found that the cumulative pCR rate increased significantly when the interval between CRT and surgery lengthened, with 95% of pCR events within 10 weeks from CRT.\n\nStudy 14, \"Optimal timing of surgery after neoadjuvant chemoradiation therapy in locally advanced rectal cancer,\" found that delaying surgery for 8 weeks or more after completion of CRT was associated with higher nodal downstaging rates, but did not significantly impact local recurrence, distant recurrence, disease-free survival, or overall survival.\n\nOverall, while the optimal timing of surgical resection after neoadjuvant CRT for locally advanced rectal cancer patients is still a topic of debate, delaying surgery for 8 weeks or more may be associated with improved nodal downstaging rates and reduced postoperative complications. However, further research is needed to confirm these findings and establish the optimal timing of surgery after CRT.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately recalls key information from the provided studies, including the debate around the optimal timing of surgery, the benefits of an 8-week or longer interval, and specific findings from studies 3, 5, 6, and 14. It captures the variability in outcomes such as nodal downstaging rates, postoperative complications, and pCR rates.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise in its discussion of the 8-week interval and its effects, though it briefly mentions risks like wound infection (from Study 3) and worse therapeutic outcomes (from Study 5) without elaborating on whether these are common or outlier findings. It could better contextualize these findings within the broader debate.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer avoids direct repetition but frequently reiterates the point about the 8-week or longer interval being associated with improved outcomes (nodal downstaging, complications), which is slightly redundant. The summary at the end could be more concise.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, logically flows from one study's findings to the next, and maintains clarity throughout. The conclusion ties the information together effectively without sacrificing readability."
    },
    {
        "Question": "Is Kagami-Ogata associated with a deletion in chromosome 14",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs Kagami-Ogata associated with a deletion in chromosome 14\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Kagami-Ogata syndrome is a rare genetic imprinting disorder involving the 14q32.2 genomic location of chromosome 14.', 'Yes, Kagami-Ogata syndrome is associated with a deletion in chromosome 14', 'No, Kagami-Ogata is not associated with a deletion in chromosome 14.', 'Yes, Kagami-Ogata syndrome is associated with a deletion in chromosome 14.', 'Yes, Kagami-Ogata syndrome is associated with a deletion in chromosome 14q32.', 'Yes, Kagami-Ogata syndrome is associated with a microdeletion in the distal long arm of chromosome 14 (14q32).', 'Yes, Kagami-Ogata syndrome (KOS) is associated with abnormalities in chromosome 14, specifically involving the 14q32.2 genomic location. This can include deletions or other disruptions in the genomic imprinting of this area, leading to the characteristic features and symptoms of the syndrome.', 'Yes, Kagami-Ogata syndrome is often associated with deletions or other abnormalities in the 14q32.2 region of chromosome 14, which affects the normal imprinting process', 'Summary: Kagami-Ogata syndrome involves the 14q32.2 genomic location of chromosome 14 but does not specifically mention a deletion. It refers to an imprinting disorder affecting chromosome 14, suggesting regulation or expression issues rather than a physical deletion.', 'Kagami-Ogata syndrome is a rare genetic imprinting disorder involving the 14q32.2 genomic location of chromosome 14, but it is not specifically associated with a deletion in chromosome 14.', 'Yes, Kagami-Ogata syndrome involves abnormalities at the 14q32.2 genomic location of chromosome 14, which can include deletions.', 'Yes, Kagami-Ogata syndrome is associated with a deletion in chromosome 14, specifically at the 14q32.2 genomic location.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, yes, Kagami-Ogata syndrome is associated with a deletion in chromosome 14. \n\nIn the \"Entities\" table, there are several entries related to Kagami-Ogata syndrome, including:\n\n* Entry 5, \"KAGAMI-OGATA SYNDROME\", mentions a \"microdeletion in the chr14q32 imprinted domain\" as a characteristic of the disorder.\n* Entry 8, \"KAGAMI-OGATA SYNDROME (KOS14)\", also mentions a \"microdeletion in the chr14q32 imprinted domain\".\n* Entry 12, \"CHROMOSOME 14Q32.2\", mentions that microdeletions in this region are associated with Kagami-Ogata syndrome.\n* Entry 13, \"14Q32.2\", mentions that this region is involved in the genetic etiology of Kagami-Ogata syndrome.\n* Entry 24, \"CHROMOSOME 14Q32 DOMAIN\", mentions that this region is involved in the genomic imprinting process and is associated with Kagami-Ogata syndrome.\n\nAdditionally, in the \"Relations\" table, entry 86, \"CHR14Q32 MICRODELETION\", mentions that the chr14q32 microdeletion is associated with Kagami-Ogata syndrome.\n\nTherefore, based on the provided data, it appears that Kagami-Ogata syndrome is associated with a deletion in chromosome 14, specifically in the 14q32.2 region.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer provides comprehensive information by referencing multiple entries from the 'Entities' and 'Relations' tables, confirming the association of Kagami-Ogata syndrome with a deletion in chromosome 14, specifically at the 14q32.2 region. This aligns well with the reference answers.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer is precise and focused, detailing the specific genomic location (14q32.2) and the type of deletion (microdeletion). However, it slightly elaborates on the context by mentioning 'genomic imprinting process' and 'characteristic of the disorder', which, while relevant, are not strictly necessary for the question.",
        "Information Repetition Score": "4",
        "Information Repetition Explanation": "The answer reiterates the association between Kagami-Ogata syndrome and the 14q32.2 deletion multiple times (in different entries). While this reinforces the point, it could be seen as slightly repetitive. The repetition is, however, contextual and not overly excessive.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured, clear, and fluent. It logically presents the evidence and concludes with a summary that ties everything together effectively. The use of bullet points and clear transitions enhances readability."
    },
    {
        "Question": "Are children affected by multiple sclerosis?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nAre children affected by multiple sclerosis?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes, children can be affected by multiple sclerosis (MS). While MS is more common in adults, it can also occur in children and adolescents before the age of 18. This is known as pediatric MS (PMS) and accounts for 3-5% of the general population of patients with MS. The incidence of pediatric MS is relatively rare, affecting 0.2 to 0.64/100,000 subjects, and cases with MS onset before age 10-12 years account for less than 1% of all MS cases. However, 2.7 to 10.5% of all MS cases worldwide are seen in children <18 years of age, with a strong female preponderance. The first episode of central nervous system (CNS) symptoms with a presumed inflammatory demyelinating cause is defined as clinically isolated syndrome (CIS) in children, and 34% of patients with CIS develop childhood onset multiple sclerosis (MS).', 'Children are affected by multiple sclerosis, known as Pediatric MS, with approximately 3-10% of patients developing the disease before the age of 16.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, children can be affected by multiple sclerosis (MS). Pediatric multiple sclerosis (PMS) is a rare form of MS that affects children and adolescents under the age of 18. It is estimated that PMS accounts for 3-5% of all MS cases. Children with PMS may experience similar symptoms to adults, including numbness, weakness, vision problems, and difficulty with coordination and balance. However, the disease course and prognosis of PMS can differ from that of adult-onset MS. PMS is often characterized by a milder course, but it can still lead to significant disability at an early age.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers essential information from the reference answers, such as the existence of pediatric multiple sclerosis (PMS), the age group affected (under 18), and the estimated percentage of MS cases (3-5%). It also adds valuable information about symptoms and disease course differences. However, it misses some details from the reference answers, like the incidence rate (0.2 to 0.64/100,000 subjects), cases before age 10-12 (<1%), and CIS in children (34% develop MS).",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and focuses on relevant information about pediatric MS without including any irrelevant details. It provides a clear and concise overview of the condition, distinguishing between PMS and adult-onset MS in terms of symptoms and disease course.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information. Each sentence contributes new and relevant details about pediatric MS, ensuring clarity and conciseness.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-written, fluent, and easy to understand. It uses straightforward language and maintains a logical flow, making it accessible to readers without compromising on the medical accuracy."
    },
    {
        "Question": "What are the current approaches for gene therapy for Phenylketonuria (PKU)?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are the current approaches for gene therapy for Phenylketonuria (PKU)?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The current approaches for gene therapy for Phenylketonuria (PKU) include recombinant viral (AdV, AAV, and LV) and non-viral (naked DNA or LNP-mRNA) vector delivery methods, combined with gene addition, genome, gene or base editing, and gene insertion or replacement']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, the current approaches for gene therapy for Phenylketonuria (PKU) include:\n\n1. **Adeno-associated virus (AAV)-mediated CRISPR/Cas9 gene editing**: This approach involves using AAV vectors to deliver CRISPR/Cas9 machinery to the liver, where it can edit the Pah gene to correct the genetic defect causing PKU. This approach has been shown to be effective in mouse models of PKU (Source 17: \"AAV-Mediated CRISPR/Cas9 Gene Editing in Murine Phenylketonuria\").\n2. **Gene therapy using recombinant adenoviral vectors**: This approach involves using recombinant adenoviral vectors to deliver the human PAH cDNA to the liver, where it can restore normal PAH activity and normalize serum phenylalanine levels. This approach has been shown to be effective in mouse models of PKU (Sources 20-22: \"Gene therapy for phenylketonuria\").\n3. **Gene therapy using gene editing tools such as CRISPR/Cas9**: This approach involves using CRISPR/Cas9 to edit the Pah gene to correct the genetic defect causing PKU. This approach has been shown to be effective in mouse models of PKU (Source 17: \"AAV-Mediated CRISPR/Cas9 Gene Editing in Murine Phenylketonuria\").\n4. **Gene therapy using gene transfer**: This approach involves using gene transfer techniques to introduce the normal PAH gene into the liver, where it can restore normal PAH activity and normalize serum phenylalanine levels. This approach has been shown to be effective in mouse models of PKU (Sources 20-22: \"Gene therapy for phenylketonuria\").\n5. **Gene therapy using gene editing tools such as base editing**: This approach involves using base editing tools to correct the genetic defect causing PKU by making precise changes to the Pah gene. This approach has been shown to be effective in mouse models of PKU (Source 19: \"State-of-the-art 2023 on gene therapy for phenylketonuria\").\n6. **Gene therapy using RNA interference (RNAi)**: This approach involves using RNAi to silence the expression of the mutated Pah gene, thereby reducing the levels of phenylalanine in the blood. This approach has been shown to be effective in mouse models of PKU (Source 18: \"An Overview of Traditional and Novel Therapeutic Options for the Management of Phenylketonuria\").\n\nThese are the current approaches for gene therapy for PKU, and further research is needed to determine their efficacy and safety in humans.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer provides a comprehensive list of current approaches for gene therapy for PKU, including AAV-mediated CRISPR/Cas9, recombinant adenoviral vectors, gene editing tools, gene transfer, base editing, and RNA interference. It also mentions mouse models, which adds context to the efficacy of these approaches. However, it does not explicitly mention non-viral vector methods like naked DNA or LNP-mRNA, which are part of the reference answer.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is generally precise, focusing on the specific techniques and methods for gene therapy in PKU. Each approach is clearly described, and the explanations are relevant. However, some redundancy occurs with CRISPR/Cas9 and base editing being mentioned separately, even though they are related gene-editing tools.",
        "Information Repetition Score": 3,
        "Information Repetition Explanation": "There is some repetition in the answer, particularly with gene editing tools (CRISPR/Cas9, base editing) and gene transfer techniques (adenoviral vectors and gene transfer). These could have been consolidated to avoid redundancy. For example, points 1, 3, and 5 all discuss gene editing with slight variations in wording, which is somewhat repetitive.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured and highly readable. Each approach is listed clearly and explained in a fluent manner. The use of numbered points and consistent formatting enhances readability. The language is clear and accessible to a biomedical audience."
    },
    {
        "Question": "What disease can be treated with Trofinetide?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat disease can be treated with Trofinetide?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Trofinetide is approved for Rett syndrome.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, Trofinetide is a medication used to treat Rett syndrome, a serious and debilitating neurodevelopmental condition.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer accurately reports that Trofinetide is used to treat Rett syndrome, which matches the reference answer perfectly.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer provides only the relevant information about Trofinetide's use for Rett syndrome with no extraneous details.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The information is stated clearly once without repetition.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand, with no grammatical or syntactical issues."
    },
    {
        "Question": "Which is the most reliable liquid biopsy technique after complete resection of  colorectal cancer metastases?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhich is the most reliable liquid biopsy technique after complete resection of  colorectal cancer metastases?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Among all liquid biopsy methods (cell-free DNA, exosomes and circulating tumor cells), circulating tumor cells showed the best diagnostic performance', \"The most reliable liquid biopsy technique after complete resection of colorectal cancer metastases is still under investigation. However, a study has shown that pre-surgery circulating tumor DNA (ctDNA) levels are positively correlated with tumor burden and have predictive value for relapse in patients with metastatic colorectal cancer following resection. Additionally, another study has demonstrated that circulating tumor cell (CTC) subcategorization based on morphological differences leads to nuanced results between the subtypes, emphasizing the heterogeneity within the CTC classification. Furthermore, integrating morphology and time-based analysis alongside standard CTC enumeration can provide greater insight into the pathophysiology of mCRC by highlighting the complexity of the disease across a patient's treatment. Liver transplantation for liver-confined unresectable colorectal cancer liver metastases is emerging as a valid surgical option in selected patients, and clearance\", 'Liquid biopsy techniques are currently being investigated as a promising method for monitoring minimal residual disease (MRD) in cancer patients, particularly in colorectal cancer (CRC) after complete resection of metastases. The most reliable liquid biopsy technique, however, is still a subject of ongoing research and debate.', 'Liquid biopsy, particularly circulating tumor DNA (ctDNA), is the most reliable technique after complete resection of colorectal cancer metastases.', 'Circulating tumor DNA (ctDNA) is the most reliable liquid biopsy technique after complete resection of colorectal cancer metastases. It has been shown to be highly predictive of early disease recurrence in surgically resected colorectal cancer, and is superior to carcinoembryonic antigen (CEA) in detecting residual disease and early recurrence. Additionally, pre-surgery ctDNA levels are positively correlated with tumor burden and have predictive value for relapse. Positive ctDNA has been found to precede radiologic and clinical evidence of recurrence by a median of 3 months. Furthermore, in patients with metastatic colorectal cancer (mCRC), detection of ctDNA following curative intent therapies is a surrogate for microscopic residual disease.', 'The most reliable liquid biopsy technique after complete resection of colorectal cancer metastases is still under investigation. However, a recent study has shown that perioperative circulating tumor DNA (ctDNA) levels are positively correlated with tumor burden and have predictive value for relapse in patients with colorectal liver metastases. Additionally, pre-surgery ctDNA, cfDNA, and CEA levels have been shown to have predictive value for relapse in this patient population. Therefore, perioperative liquid biopsy techniques, including ctDNA analysis, may be useful for postoperative surveillance and outcome prediction in patients with colorectal cancer metastases.', 'Based on the meta-analysis provided, all liquid biopsy methods, including circulating tumor cells (CTCs), exosomes, and cell-free DNA (cfDNA), demonstrated high diagnostic value for colorectal cancer (CRC) detection. However, when comparing their performance after complete resection of CRC metastases, it is essential to consider the specific clinical context and purpose of the liquid biopsy. , For detecting residual or recurrent disease, CTCs seem to be the most reliable technique among those studied, as they showed the best diagnostic performance with a pooled sensitivity of 0.82 (95% CI 0.79-0.85) and specificity of 0.97 (95% CI 0.95-0.99). Higher sensitivity implies that CTCs are more likely to detect residual or recurrent cancer compared to other liquid biopsy methods, while high specificity reduces', 'Circulating tumor cells (CTCs) have demonstrated the best diagnostic performance among all liquid biopsy methods. CTC-based liquid biopsy is likely the most reliable technique for monitoring colorectal cancer metastases after complete resection. This method can provide real-time information about the presence of residual tumor cells in the body, helping to detect potential recurrence early and guiding more effective personalized treatment strategies.', 'Circulating tumor cells (CTCs) are the most reliable liquid biopsy technique after complete resection of colorectal cancer metastases, as they showed the best diagnostic performance among all liquid biopsy methods.', 'The most reliable liquid biopsy technique after complete resection of colorectal cancer metastases is CTCs.', 'The most reliable liquid biopsy technique for detecting minimal residual disease after complete resection of colorectal cancer metastases is the CellSearch method for enumeration of circulating tumor cells (CTCs). This method has been validated and approved by the FDA as a useful prognostic method for metastatic breast, colon, and prostate cancer. However, it is important to note that detecting ctDNA in blood samples can be challenging due to the presence of wild type DNA from white blood cells, and pre-analytical considerations such as preventing or delaying white cell lysis, using cell stabilization tubes, and performing a double centrifugation step can help improve ctDNA detection. Plasma is better than serum for ctDNA recovery, and ctDNA or cfDNA can be extracted from plasma fractions using commercially available kits. The analysis of ctDNA after extraction requires the use of various amplification and sequencing methods, which can be separated into two main groups: untargeted approaches (e.g., whole genome or whole exome sequencing) and targeted approaches (e.g., sequencing of ctDNA based on mutational hotspots for the cancer of interest). Targeted approaches can amplify ctDNA through polymerase chain reactions (PCR) or digital PCR, which is especially important given the low levels of DNA circulating in the bloodstream and the small proportion of ctDNA in the total cell-free DNA extracted.', 'Among all liquid biopsy methods, CTCs (Circulating Tumor Cells) showed the best diagnostic performance after complete resection of colorectal cancer metastases. This makes CTCs the most reliable technique in this specific scenario.', 'There are several liquid biopsy methods for the detection of circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA). Among all these techniques, CTCs showed the best diagnostic performance for prognosis and treatment response of patients with colorectal cancer metastases after complete resection.', 'CTCs is the most reliable liquid biopsy technique after complete resection of colorectal cancer metastases.', 'In the context of complete resection of colorectal cancer metastases, circulating tumor cells (CTCs) show higher reliability for detecting residual or recurrent disease than exosomes and cell-free DNA (cfDNA), with a pooled sensitivity of 0.82 and specificity of 0.97.', \"Based on the available research, Circulating Tumor Cells (CTCs) are currently considered the most reliable liquid biopsy technique for monitoring colorectal cancer metastases after complete resection due to their ability to detect minimal residual disease and predict clinical outcomes. This minimally invasive method analyzes tumor-derived components from bodily fluids, providing valuable information about the tumor's characteristics and response to treatment.\", \"The question asks for the most reliable liquid biopsy technique for monitoring colorectal cancer (CRC) metastases after complete resection. Based on the context, Circulating Tumor Cells (CTCs) have demonstrated the best diagnostic performance among all liquid biopsy methods. , Liquid biopsies are minimally invasive tests that analyze various tumor-derived components from bodily fluids. Among these, CTCs have gained attention as a promising tool for cancer detection and monitoring. CTCs are cancer cells that shed into the bloodstream from primary or metastatic tumors and can be detected and analyzed to provide valuable information about the tumor's characteristics, evolution, and response to treatment. , Several studies have shown that CTC analysis can detect minimal residual disease, predict clinical outcomes, and monitor tumor dynamics in real-time, making it a potentially valuable tool for post-treatment surveillance of CRC metastases. Therefore,\", 'CTCs (Circulating Tumor Cells) showed the best diagnostic performance among all liquid biopsy methods after complete resection of colorectal cancer metastases.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the most reliable liquid biopsy technique after complete resection of colorectal cancer metastases is not explicitly stated. However, we can analyze the data to identify the most promising liquid biopsy method.\n\nAccording to the Relations table (id=16), liquid biopsy can detect exosomes, which are small vesicles released by cells that can carry genetic material and proteins. Exosomes are present in the peripheral blood of cancer patients, including those with colorectal cancer (id=30). Liquid biopsy can analyze exosomes to detect biomarkers for cancer diagnosis and monitoring (id=16).\n\nAnother promising liquid biopsy method is the analysis of circulating tumor DNA (ctDNA) (id=17). ctDNA is released from primary tumors into the bloodstream and can be detected through liquid biopsy (id=31). The presence of ctDNA in the blood can be used to monitor tumor progression and recurrence (id=18).\n\nThe data also suggests that the combination of liquid biopsy methods may provide more accurate results. A meta-analysis of various liquid biopsy methods (id=8) found that the overall performance of all liquid biopsy methods had a pooled sensitivity of 0.77, specificity of 0.89, and area under the curve (AUC) of 0.9004.\n\nBased on this analysis, the most reliable liquid biopsy technique after complete resection of colorectal cancer metastases is likely a combination of exosome analysis and ctDNA detection. However, more research is needed to confirm this and to determine the optimal liquid biopsy method for this specific scenario.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer mentions exosomes and ctDNA as potential methods, but it misses key points from the reference answers, such as the superior diagnostic performance of Circulating Tumor Cells (CTCs) and specific clinical studies supporting their reliability. The mention of meta-analysis (id=8) is vague and not specific enough compared to the detailed references provided.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise in discussing exosomes and ctDNA without adding irrelevant information. However, it inaccurately concludes that a combination of exome and ctDNA is the most reliable, which does not align with the reference answers that clearly favor CTCs.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. It introduces different concepts (exosomes, ctDNA, combination methods) without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clear, and fluent. It logically presents the analysis and conclusion without confusing language or awkward phrasing."
    },
    {
        "Question": "Where is the tumor of follicular infundibulum usually found?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhere is the tumor of follicular infundibulum usually found?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Tumor of follicular infundibulum is usually found in the skin', 'Dilated pores of Winer are follicular cysts that arise from the infundibulum of the hair follicle and usually occur on the trunk and extremities.', 'The tumor of follicular infundibulum is usually found in the head, neck, and trunk.', 'Tumor of follicular infundibulum is usually found as a benign adnexal tumor on the head and neck.', 'The tumor of follicular infundibulum is usually found in the head and neck region, particularly on the face.', 'Tumor of the follicular infundibulum is usually found in the head, neck, and trunk.', 'The tumor of follicular infundibulum is usually found on the head and neck.', 'Follicular infundibuloma is a benign neoplasm arising from the hair follicle infundibulum and it is commonly located on the face, particularly around the eyes and nose.', 'The tumor of the follicular infundibulum is usually found in the head, neck, and trunk.', 'Tumor of follicular infundibulum is usually found on the head and neck.', 'The tumor of follicular infundibulum, also known as trichilemmal cyst or pilar cyst, is most commonly found on the scalp.', '- Tumor of follicular infundibulum (TFI) is a benign neoplasm that arises from the infundibular portion of the hair follicle, \\n- it is mostly found on the scalp, forehead, nose, ears and cheeks', 'The tumor of the follicular infundibulum is typically found on the head, neck, face, or scalp.', 'The tumor of follicular infundibulum (TFI) is commonly found on head and neck, but can also occur on upper trunk or uncommonly at other locations such as buttock, vulva, or anterior neck. Diagnosis typically requires histopathological examination for confirmation.', 'The tumor of follicular infundibulum is usually found in the head.', 'Tumors of the follicular infundibulum are benign cutaneous adnexal tumors that most commonly present as dome-shaped or cystic papules on the scalp, face, or trunk.', 'The tumor of follicular infundibulum (TFI) is commonly found on the head and neck or upper trunk but can also occur at uncommon locations like the buttock, vulva, or anterior neck. Diagnosis typically requires histopathological examination for accurate identification.', 'The tumor of follicular infundibulum is usually found on the scalp', 'The tumor of follicular infundibulum is usually found in the scalp.', 'The tumor of the follicular infundibulum is usually found on the scalp, particularly within a nevus sebaceus, as described in the case of the 63-year-old male with multiple tumors.', 'The tumor of follicular infundibulum is usually found on the scalp.', 'The tumor of the follicular infundibulum (TFI) is usually found on the scalp. This is evident from the description of a 63-year-old male with multiple tumors, including TFI, arising within a nevus sebaceus on the posterior scalp.', 'The tumor of follicular infundibulum is usually found on the scalp, specifically on the posterior scalp.', 'Scalp follicular infundibulum, also known as infundibuloma, is a tumor that develops from the infundibulum (upper portion) of the hair follicle, thus it is usually found on the scalp.', \" The tumor of follicular infarction, commonly known as a 'malignant melanoma', is usually found on the skin, typically on the face, ears, and hands. It is less commonly found on the soles of the feet or within the oral cavity.\", 'The tumor of the follicular infundibulum (TFI) is a rare benign neoplasm that typically arises in the skin, specifically within a nevus sebaceus on the scalp.', 'The tumor of the follicular infundibulum is usually found on the scalp', 'The tumor of follicular infundibulum (TFI) usually arises from the infundibulum of a hair follicle located within the dermis.', 'The tumor of follicular infundibulum is usually found on the scalp, specifically in the follicular infundibulum, which is the area where the hair follicle meets the skin.', 'The tumor of the follicular infundibulum is typically found on the scalp, particularly in the posterior region.', 'The tumor of the follicular infundibulum (TFI) is usually found on the scalp, as evidenced by case reports involving patients with TFI occurring in this area.', \"The tumor of follicular infundibulum (TFI) is commonly found on the scalp where there are abundant hair follicles. It may arise within a nevus sebaceus in this area, and its association with microneedling indicates that it's related to these structures.\", 'The tumor of the follicular infundibulum is usually found on the scalp.', 'The tumor of follicular infundibulum is usually found in the head and neck.', 'The tumor of follicular infundibulum (TFI) is commonly found on the scalp, as evidenced by case reports involving patients with multiple skin lesions in this area.', 'The tumor of follicular infundibulum, also known as infundibuloma or isthmicoma, is usually found on the head and neck region, presenting as flat, keratotic papules. These skin lesions are typically solitary.', 'The tumor of the follicular infundibulum (TFI) is usually found on the scalp, as it is a rare benign neoplasm that arises within the follicular infundibulum, a part of the hair follicle predominantly located in this area.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe tumor of the follicular infundibulum (TFI) is usually found in the head and neck area. According to the relations table, the TFI is associated with the \"HEAD AND NECK AREA\" entity with a rank of 60. Additionally, it is also mentioned in the entities table that the TFI is a type of tumor that occurs in the follicular infundibulum, which is a part of the hair follicle, and it is often located in the head and neck area.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately recalls the key information from the reference answers, stating that the tumor of follicular infundibulum is usually found in the 'head and neck area', which matches several reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include irrelevant information. It specifically mentions the 'head and neck area' and adds relevant details about the follicular infundibulum being part of the hair follicle.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no unnecessary repetition in the answer. The key point is stated clearly once, and additional details are provided without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, concise, and easy to understand. The use of clear language and logical flow enhances readability."
    },
    {
        "Question": "Mechanisms that explain irritable bowel syndrome.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nMechanisms that explain irritable bowel syndrome.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Underlying mechanisms that could lead to irritable bowel syndrome include genetic factors (most notably an identified mutation of SCN5A); post-infectious changes, chronic infections and disturbances in the intestinal microbiota; low-grade mucosal inflammation, immune activation, and altered intestinal permeability; disordered bile salt metabolism (in 10-20% of cases with diarrhoea); abnormalities in serotonin metabolism; and alterations in brain function, which could be primary or secondary factors.', 'The pathophysiological mechanisms that explain irritable bowel syndrome (IBS) are complex and multifactorial. While the exact causes of IBS are still not fully understood, several factors have been implicated, including:1. Gastrointestinal motility and sensory dysfunction: IBS is characterized by altered gastrointestinal motility and sensory abnormalities, including hypersensitivity to food, pain, and distension.2. Visceral hypersensitivity: Visceral hypersensitivity, or increased sensitivity to internal organ stimuli, is a key feature of IBS. This can lead to abdominal pain, bloating, and other symptoms.3. Inflammation: Inflammation is a common feature of IBS, and may contribute to symptoms such as abdominal pain, bloating, and diarrhea.4. Gut microbiota dysbiosis: Dysbiosis, or an imbalance of the gut microbiota, has been linked to IBS. This can lead to changes in gut permeability, inflammation, and other symptoms.5. Psychological factors: Psychological factors, such as stress, anxiety, and depression, can also contribute to IBS symptoms.6. Genetic predisposition: Genetic factors may also play a role in the development of IBS, as some individuals may be more susceptible to the condition due to their genetic makeup.7. Other factors: Other factors that may contribute to IBS include food intolerances, hormonal changes, and medication use.', 'Several mechanisms have been proposed to explain irritable bowel syndrome (IBS), a complex and multifactorial disorder. These mechanisms include:\\n- Visceral hypersensitivity: increased gut sensitivity to stimuli, causing abdominal pain and discomfort\\n- Altered gut motility: changes in food movement through the digestive system, leading to constipation or diarrhoea\\n- Dysbiosis: alterations in gut microbiota, impacting gut functions and its interaction with the brain\\n- Inflammation: low-grade gut inflammation contributing to abdominal pain and bloating\\n- Brain-gut axis dysfunction: abnormal brain-gut communication, altering gut functions and causing symptoms\\n- Neurotransmitter imbalance: serotonin and other neurotransmitter imbalances affecting gut function\\n- Genetic factors: genetic variations impacting gut function and causing IBS symptoms\\n- Epigenetic factors: environmental influences on gene expression, contributing to IBS symptoms\\n- Food intolerances: adverse reactions to certain foods, exacerbating IBS symptoms\\n- Stress and anxiety: psychological factors affecting gut function and IBS symptoms\\n- Altered bile salt metabolism: changes in bile salt processing, contributing to diarrhoea in some IBS patients\\n- Mast cell activation: activation of gut mast cells, causing abdominal pain and diarrhoea\\n\\nThese mechanisms often overlap, and multiple factors typically contribute to IBS development in individuals.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nIrritable Bowel Syndrome (IBS) is a multifactorial disorder characterized by abdominal pain, discomfort, and changes in bowel habits, without any structural or metabolic abnormalities. The pathophysiology of IBS is complex and involves various mechanisms, including:\n\n1. **Visceral hypersensitivity**: Increased sensitivity of the nerves in the gut, leading to exaggerated pain perception.\n2. **Altered gut motility**: Abnormal movement of food through the digestive system, leading to constipation, diarrhea, or a combination of both.\n3. **Gut microbiota imbalance**: Alterations in the composition of the gut microbiome, which can lead to changes in the production of short-chain fatty acids, inflammation, and immune system activation.\n4. **Mucosal immune activation**: Increased inflammation and immune system activation in the gut, leading to symptoms such as abdominal pain and changes in bowel habits.\n5. **Increased intestinal permeability**: Abnormalities in the gut lining, allowing toxins and undigested food particles to pass through and trigger inflammation and immune system activation.\n6. **Dysregulation of the brain-gut axis**: Abnormal communication between the central nervous system and the enteric nervous system, leading to changes in gut function and symptoms.\n7. **Epigenetic factors**: Changes in gene expression and epigenetic markers, such as histone modification and DNA methylation, which can influence the development of IBS.\n8. **Genetic predisposition**: Family history and genetic mutations, such as the SCN5A mutation, which may contribute to the development of IBS.\n9. **Psychosocial factors**: Stress, anxiety, and depression, which can exacerbate IBS symptoms and contribute to the development of the disorder.\n10. **Food intolerance**: Sensitivity to certain foods, such as gluten or lactose, which can trigger symptoms in some individuals.\n\nThese mechanisms are not mutually exclusive, and IBS is likely the result of a combination of factors. Further research is needed to fully understand the pathophysiology of IBS and to develop effective treatments.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer covers all key mechanisms of IBS as highlighted in the reference answers, including visceral hypersensitivity, altered gut motility, gut microbiota imbalance, mucosal immune activation, increased intestinal permeability, dysregulation of the brain-gut axis, epigenetic factors, genetic predisposition, psychosocial factors, and food intolerance. It also mentions the multifactorial nature of IBS, aligning well with the reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and concise, providing relevant details for each mechanism without including extraneous information. Each point is directly related to the pathophysiology of IBS, matching the criteria for precision.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each mechanism is presented distinctly without overlap, ensuring clarity and efficiency in conveying the information.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured and clearly articulated, with logical flow and appropriate use of medical terminology. The bullet-point format enhances readability and makes the information easily digestible."
    },
    {
        "Question": "What is the cause of Rett Syndrome?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the cause of Rett Syndrome?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Rett Syndrome is caused by mutations of the X-linked gene encoding methyl-CpG-binding protein 2 (MECP2).', 'Rett Syndrome is caused by a mutation in the MECP2 gene.', 'Rett syndrome is primarily caused by mutations of methyl CpG-binding protein 2 (MeCP2).', 'Rett syndrome is caused by mutations in the MECP2 gene.', 'Mutations in the X-linked MECP2 gene cause Rett Syndrome.', 'Rett Syndrome is primarily caused by mutations in the MECP2 gene located on the Xq28 chromosome.', 'Rett syndrome is a genetic disorder caused by mutations of the methyl CpG-binding protein 2 (MeCP2) gene.', 'Rett Syndrome is caused by mutations in the MECP2 gene.', 'Rett syndrome is caused by mutations in the X-linked MECP2 gene, encoding MeCP2 protein.', 'Mutations in the gene encoding methyl-CpG-binding protein 2 cause Rett syndrome.', 'Mutations of the X-linked gene encoding methyl-CpG-binding protein 2 (MECP2) cause classical forms of Rett syndrome in girls.', 'Rett syndrome is caused by mutations in the gene encoding the transcription factor Methyl CpG Binding Protein 2 (MECP2).', 'Mutations of the X-linked gene encoding methyl-CpG-binding protein 2 (MECP2) cause classical forms of Rett syndrome (RTT) in girls.', 'Rett Syndrome is caused by mutations in the X-linked gene encoding methyl-CpG-binding protein 2 (MECP2).', 'Rett Syndrome (RTT) is a neurodevelopmental disorder affecting girls, it is caused by mutations in the X-linked gene encoding methyl-CpG-binding protein 2 (MECP2)', 'The cause of Rett Syndrome is mutations of the X-linked gene encoding methyl-CpG-binding protein 2 (MECP2).', 'Rett Syndrome is primarily caused by mutations in the MECP2 gene, which is located on the X chromosome.', 'Rett Syndrome is caused by mutations in the X-linked gene MECP2, which encodes the methyl-CpG-binding protein 2.', 'Rett Syndrome is caused by mutations of the X-linked gene encoding methyl-CpG-binding protein 2 (MECP2), which is responsible for classical forms of the disease in girls.', 'Rett Syndrome is caused by mutations in the MECP2 gene, which is located on the X chromosome.', 'Rett Syndrome is caused by mutations of the X-linked gene encoding methyl-CpG-binding protein 2 (MECP2), which typically affects girls and results in severe cognitive and physical impairments.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nRett Syndrome is caused by mutations in the MECP2 gene, which encodes the methyl-CpG binding protein 2 (MeCP2). These mutations can lead to a loss of function of the MeCP2 protein, resulting in the characteristic symptoms of Rett Syndrome. The MECP2 gene is located on the X chromosome and is responsible for encoding the MeCP2 protein, which plays a crucial role in brain development and function. Mutations in MECP2 can lead to a range of symptoms, including intellectual disability, loss of speech, and physical and motor impairments.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer accurately recalls all necessary information about the cause of Rett Syndrome, including the specific gene (MECP2), the protein it encodes (MeCP2), the location of the gene (X chromosome), and the functional consequences of mutations (loss of function leading to characteristic symptoms). This aligns perfectly with the reference answers, which frequently mention these details.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer precisely reports the cause of Rett Syndrome without including any irrelevant information. It focuses solely on the genetic mutation, its location, and the protein it affects, as well as the resultant symptoms, which are all directly related to the question.",
        "Information Repetition Score": "4",
        "Information Repetition Explanation": "The answer does mention the MECP2 gene and the MeCP2 protein more than once, but it serves to clarify their relationship rather than simply repeating the same information. However, there is a slight repetition in stating the role of the protein and the gene's location, which could be streamlined.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is highly readable and fluent. It clearly conveys complex genetic information in a structured manner, making it easy to understand. Each sentence logically follows the previous one, building a coherent explanation."
    },
    {
        "Question": "What is the use of P85-Ab?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the use of P85-Ab?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['P85-Ab is a promising novel biomarker for nasopharyngeal carcinoma screening.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, P85-Ab is a biomarker for nasopharyngeal carcinoma with higher sensitivity and specificity than the standard two-antibody method.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "4",
        "Information Recall Explanation": "The answer accurately recalls the key role of P85-Ab as a biomarker for nasopharyngeal carcinoma, which aligns with the reference answer. However, it misses mentioning its 'promising novel' aspect, which is present in the reference.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer focuses solely on the relevant information about P85-Ab being a biomarker for nasopharyngeal carcinoma and its performance compared to the standard method. No irrelevant details are included.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat any information. It succinctly presents the facts about P85-Ab in a single statement.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is clear, concise, and easy to understand. The sentence structure is fluent, making it highly readable."
    },
    {
        "Question": "What are the indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are the indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Lack of difference in the incidence of cholinergic syndrome observed in irinotecan-treated patients suggests atropinediphenoxylate and hyoscyamine may both be effective prophylactic option', 'Based on the abstracts provided, the indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan are not explicitly stated. However, some insights can be gained from the studies. , In one study, female sex and high irinotecan dose (≥175 mg) were identified as significant predictors of cholinergic syndrome. This suggests that dose reduction or alternative dosing regimens may be considered in these patient populations. , Another study found that coadministration of cytotoxic chemotherapeutic agents with irinotecan increased the risk of cholinergic syndrome, implying that careful selection and sequencing of chemotherapy agents may help mitigate this risk. , The case report highlighted the potential benefit of loperamide in alleviating abdominal pain associated with irinotecan-induced cholinergic syndrome. While anticholinergic drugs were not effective in this patient, the combination of loperamide and atropine resulted in symptom relief. This suggests that loperamide may be a useful adjunctive therapy for managing acute cholinergic syndrome secondary to ir', 'Irinotecan, a plant alkaloid used in cancer treatment, causes adverse reactions, especially when administered at higher doses, in combination with other drugs or in patients with low cholinesterase activity. \\nThe preventive strategy relies mainly on the administration of anticholinergics such as atropine or glycopyrrolate, preferably by infusion, before the administration of irinotecan. \\nFor the management of severe toxicities, high doses of atropine are recommended and it is necessary to follow a monitoring plan of heart rate and QTc interval.', 'A retrospective study aimed to identify predictive factors for the development of irinotecan-related cholinergic syndrome in order to improve the quality of life of patients undergoing chemotherapy. The study enrolled 150 cancer patients who underwent chemotherapy, which included irinotecan, in their outpatient chemotherapy center between October 2014 and January 2017. The results showed that scopolamine butylbromide was effective in preventing irinotecan-related cholinergic syndrome. The only risk factor associated with irinotecan-related cholinergic syndrome was the irinotecan dose (≥ 150 mg/m2), and the incidence of cholinergic syndrome in patients with this risk factor was 75%. Therefore, prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan include administering anticholinergics, such as atropine sulfate or scopolamine butylbromide, and adjusting the irinotecan dose. A study on the incidence of CPT-11 (irinotecan) related cholinergic symptoms in cancer patients found that high-dose CPT-11 administration was a significant risk factor for the appearance of cholinergic symptoms. The cholinergic syndrome is caused by the inhibition of the acetylcholinesterase (AChE) enzyme by irinotecan or its metabolites, leading to an accumulation of acetylcholine and subsequent symptoms. The study also explores the potential of phytochemicals found in Phyllanthus emblica (amla) as an alternative treatment for cancer to target and inhibit the Top1 protein and identify a non-inhibitor for AChE. Prophylactic treatments for acute cholinergic syndrome secondary to irinotecan include scopolamine butylbromide.', 'Atropine-diphenoxylate, hyoscyamine, scopolamine, and atropine can be indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan.', 'The indicated prophylaxis treatment for acute cholinergic syndrome secondary to irinotecan is atropine.', 'Prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan include atropine sulfate or scopolamine butylbromide.', 'The indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan include atropine-diphenoxylate, hyoscyamine, scopolamine butylbromide, scopolamine, and atropine.', '25 mg of pyridostigmine administered orally three times a day is the prophylaxis treatment of choice for acute cholinergic syndrome secondary to irinotecan.', 'Prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan include anticholinergic agents such as loperamide and atropine.', 'The indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan include atropine for cholinergic symptoms.', 'The indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan include atropine for cholinergic symptoms and preventive antiemetic treatment.', 'Summary: There is no specific indicated prophylaxis treatment for acute cholinergic syndrome secondary to irinotecan, but studies suggest that loperamide combined with anticholinergic drugs may be effective in alleviating symptoms and reducing severity. Further research is needed to establish a standard treatment protocol.', 'Based on the provided abstracts, the indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan are: , 1. Atropine: Anticholinergic drugs like atropine can be used to alleviate symptoms of cholinergic syndrome., 2. Loperamide: A case report suggests that loperamide, an opioid receptor agonist, may improve abdominal pain attributed to irinotecan-induced cholinergic syndrome when administered before irinotecan infusion. , It is essential to identify patients at high risk of developing cholinergic syndrome, such as females and those receiving higher doses of irinotecan (≥175 mg). Prophylactic administration of these medications may help alleviate symptoms and improve the quality of life in cancer patients undergoing chemotherapy with irinotecan.', 'The indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan are atropine and pralidoxime.', 'Prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan include atropine sulfate, scopolamine butylbromide, and hyoscyamine.', 'The indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan are atropine-diphenoxylate and hyoscyamine.', '320 mg of atropine sulfate, administered intravenously on day 1 of the irinotecan therapy. If no response is observed, up to 1,200 mg (3 doses of 400 mg administered at intervals of at least 30 minutes) may be given to the patient. The prophylactic treatment is highly recommended in case of increased risks for developing cholinergic syndrome, such as decreased liver function.', 'Summary: There is no specific prophylaxis treatment indicated for acute cholinergic syndrome secondary to irinotecan, but loperamide combined with anticholinergic drugs like scopolamine or atropine may be beneficial in alleviating symptoms. Further studies are needed to confirm this finding and establish a standard prophylaxis treatment.', 'According to the information provided, atropine is indicated for treating cholinergic symptoms associated with irinotecan therapy. The abstract mentions that concomitant treatments included atropine specifically for managing cholinergic symptoms.', 'Based on the abstract, the indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan are atropine-diphenoxylate and hyoscyamine. The study found no significant difference in the incidence of cholinergic syndrome between these two anticholinergic agents, suggesting that both may be effective prophylactic options. Additionally, the authors mention that scopolamine and atropine could also be potential premedications for preventing irinotecan-related cholinergic syndrome, although further studies are needed to compare their efficacy.', 'Both atropine-diphenoxylate and hyoscyamine may be effective prophylactic options for preventing acute cholinergic syndrome in patients receiving irinotecan. A study found no significant difference in the incidence of cholinergic syndrome between the two treatment groups, indicating that both may be equally efficacious. Therefore both atropine-diphenoxylate and hyoscyamine are indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan.', 'Atropine-diphenoxylate and hyoscyamine are both indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan.', 'Hyoscyamine and atropine-diphenoxylate can be effective prophylactic options for acute cholinergic syndrome secondary to irinotecan.', 'The indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan are hyoscyamine and atropinediphenoxylate.', 'The main treatment options for cholinergic syndrome secondary to irinotecan include atropine and glycopyrrolate. While atropine is the drug of choice to reverse bradycardia and hypotension, glycopyrrolate is the drug of choice for the treatment of excessive cholinergic symptoms. Other options include diphenhydramine and scopolamine, which are not as recommended.', \"Atropinediphenoxylate and hyoscyamine are both effective prophylactic options for acute cholinergic syndrome secondary to irinotecan. \\n\\nPlease go ahead and ask your question. I'll respond accordingly. \\n\\n(Note: Please keep your questions concise and relevant to the context.)\", 'Lack of difference in the incidence of cholinergic syndrome observed in irinotecan-treated patients suggests atropine, diphenoxylate and hyoscyamine may both be effective prophylactic options.', 'The indicated prophylactic treatments for acute cholinergic syndrome secondary to irinotecan are atropinediphenoxylate and hyoscyamine. Both of these options appear to be effective based on the similar incidence of cholinergic syndrome observed in irinotecan-treated patients', 'The indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan are atropinediphenoxylate and hyoscyamine.', '* Atropine: The first step in the prophylaxis of acute cholinergic syndrome is the administration of atropine. This anticholinergic drug acts by inhibiting the stimulation of the muscarinic receptor. It should be started prophylactically at low doses in patients that are going to start treatment with irinotecan and then the dose should be progressively increased.\\n* Physostigmine: It is an anticholinesterase drug that could be used as a third-line drug in the management of cholinergic syndrome. Physostigmine is used only when atropine is no longer effective. The doses should be carefully titrated to avoid excess of cholinergic stimulation.', 'The indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan are hyoscyamine, atropinediphenoxylate, atropine, and diphenoxylate.', 'Both atropine-diphenoxylate and hyoscyamine are effective in preventing acute cholinergic syndrome secondary to irinotecan, with no significant difference in their efficacy. These two treatments can be considered as indicated prophylaxis options for this condition.', 'The indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan are atropine-diphenoxylate and hyoscyamine. A study found no difference in the incidence of cholinergic syndrome between patients treated with either of these agents, suggesting both are effective prophylactic options. However, a larger, randomized study is needed to confirm these findings and compare these agents with other potential premedications such as scopolamine and atropine.', \"Summary: The indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan include atropine-diphenoxylate and hyoscyamine. Both agents showed comparable effectiveness in preventing the condition, but further studies are needed to compare scopolamine and atropine's efficacy as potential premedications for this purpose.\", 'Atropine-diphenoxylate and hyoscyamine may both be effective prophylactic options for preventing cholinergic syndrome in patients treated with irinotecan, as suggested by the lack of difference in incidence of cholinergic syndrome observed between patients receiving these treatments.', 'Based on the snippet provided, atropine-diphenoxylate and hyoscyamine are both suggested as effective prophylactic options for preventing acute cholinergic syndrome secondary to irinotecan treatment. The incidence of cholinergic syndrome did not differ between patients treated with either of these two prophylaxis treatments, indicating their comparable efficacy in preventing this adverse effect. Therefore, both atropine-diphenoxylate and hyoscyamine can be considered as indicated prophylaxis treatments for acute cholinergic syndrome resulting from irinotecan use.', 'hyoscyamine and atropinediphenoxylate can be the indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan.', 'Based on the information provided, the indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan include:\\n\\n1. Aggressive early use of antidiarrheal medications such as loperamide or atropine at the first onset of loose stools to manage the potentially life-threatening late diarrhea. \\n\\n2. Close monitoring for signs of respiratory depression, which cannot be reversed by atropine.\\n\\n3. Mechanical ventilation if respiratory failure occurs, until the cholinergic crisis resolves on its own.\\n\\nThe abstract also suggests that atropine-diphenoxylate and hyoscyamine may both be effective prophylactic options for preventing irinotecan-induced cholinergic syndrome.', 'Atropinediphenoxylate and hyoscyamine are indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan', '1. Atropinediphenoxylate 2. Hyoscyamine\\n\\nYou are given a context and a question, and you should provide a concise answer based on the context']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, the indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan are:\n\n1. Atropine-diphenoxylate: This medication is a combination of atropine and diphenoxylate, which is used to prevent the cholinergic syndrome associated with irinotecan infusion. Studies have shown that atropine-diphenoxylate is effective in reducing the incidence of cholinergic syndrome in patients receiving irinotecan.\n2. Scopolamine butylbromide: This is a competitive antagonist of muscarinic acetylcholine receptors, which can help prevent the cholinergic syndrome associated with irinotecan. Studies have shown that scopolamine butylbromide is effective in reducing the incidence of cholinergic syndrome in patients receiving irinotecan.\n3. Atropine: This medication can be used as a premedication to prevent the cholinergic syndrome associated with irinotecan infusion.\n4. Loperamide: This medication can be used to alleviate symptoms of cholinergic syndrome, including abdominal pain and diarrhea. It works by inhibiting the release of acetylcholine and prostaglandins, which can help reduce the symptoms of cholinergic syndrome.\n5. Hyoscyamine: This medication is another anticholinergic agent that can be used to prevent the cholinergic syndrome associated with irinotecan infusion.\n\nIt is essential to note that these treatments may not completely eliminate the risk of cholinergic syndrome, and patients should be closely monitored for symptoms during and after irinotecan treatment.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively lists all the indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan, including atropine-diphenoxylate, scopolamine butylbromide, atropine, loperamide, and hyoscyamine. It also notes the need for close monitoring, which aligns with the reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and reports only relevant information without any extraneous details. Each mentioned treatment is directly related to the prophylaxis of acute cholinergic syndrome secondary to irinotecan, as supported by the reference answers.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information. Each treatment is presented once with clarity, and there is no unnecessary redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluently written, and easy to understand. The information is presented in a clear and coherent manner, making it highly readable."
    },
    {
        "Question": "What is the function of FAM134B (also called JK-1, RETREG1)?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the function of FAM134B (also called JK-1, RETREG1)?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['FAM134B (also called JK-1, RETREG1), a member of the family with sequence similarity 134, was originally discovered as an oncogene in esophageal squamous cell carcinoma. However, its most famous function is that of an ER-phagy-regulating receptor', 'FAM134B, also known as JK-1 or RETREG1, is a selective ER-phagy receptor that regulates the size and shape of the endoplasmic reticulum.', 'FAM134B, also known as JK-1 or RETREG1, is a reticulophagy receptor that regulates turnover of the endoplasmic reticulum (ER) by selective phagocytosis.', '1) FAM134B is required for autophagic degradation of mitochondria, also known as mitophagy.\\n2) FAM134B promotes mitochondrial elongation and fragmentation.\\n3) FAM134B has been identified as a biomarker for poor prognosis in various cancers including breast cancer, ovarian cancer, gastric cancer, renal cancer, and liver cancer.', 'FAM134B, also known as JK-1 or RETREG1, is an endoplasmic reticulum (ER)-phagy receptor that facilitates ER-phagy during ER stress. It has been identified as an oncogene in esophageal squamous cell carcinoma.', 'FAM134B, also called JK-1, RETREG1, is best known for its function as an ER-phagy-regulating receptor.', 'FAM134B (also called JK-1, RETREG1) is an ER-phagy-regulating receptor.', 'FAM134B, also known as JK-1 or RETREG1, functions as an ER-phagy-regulating receptor. It facilitates ER-phagy during endoplasmic reticulum (ER) stress and its upregulation inhibits ER stress-related degradation protein expression.', 'FAM134B is an ER-phagy-regulating receptor that facilitates ER-phagy during ER stress, and it also inhibits autophagy of HCC cells by reducing the expression of ER stress-related degradation proteins. Additionally, it has been linked to oncogenesis and intervertebral disc degeneration. \\n\\nPlease provide the next question.  If you want to ask a question, please let me know.  If you want to provide more context, please let me know.  If you want to clarify any part of the context, please let me know.  If you want to stop, please let me know.  If you want to ask for help, please let me know.  If you want to ask for feedback, please let me know.  If you want to ask for guidance, please let me know.  If you want to ask for resources, please let me know.  If you want to ask for a summary, please let me know.  If you want to ask for a review, please let me know.  If you want to ask for a clarification, please let me know.  If you want to ask for a confirmation, please let me know.  If you want to ask for a suggestion', 'FAM134B, the initial endoplasmic reticulum (ER)-phagy receptor identified, facilitates ER-phagy during ER stress.', 'FAM134B, also known as JK-1 or RETREG1, is the first identified endoplasmic reticulum (ER)-phagy receptor. It plays a crucial role in facilitating ER-phagy, a process that helps maintain cellular homeostasis by degrading and recycling unnecessary or dysfunctional components of the ER, especially during ER stress', 'FAM134B (also called JK-1, RETREG1) was originally discovered as an oncogene in esophageal squamous cell carcinoma. However, its most famous function is that of an ER-phagy-regulating receptor.', 'FAM134B, also known as JK-1 or RETREG1, is an ER-phagy-regulating receptor. It plays a crucial role in facilitating ER-phagy during endoplasmic reticulum (ER) stress. It was originally discovered as an oncogene in esophageal squamous cell carcinoma.', 'FAM134B (also called JK-1, RETREG1) is an endoplasmic reticulum (ER)-phagy receptor that facilitates ER-phagy during ER stress. It was originally discovered as an oncogene in esophageal squamous cell carcinoma, but its most well-known function is regulating ER-phagy.', 'FAM134B (JK-1, RETREG1) is an ER-phagy receptor that degrades damaged ER components, maintaining cellular homeostasis during ER stress.', 'FAM134B, also known as JK-1 or RETREG1, is known to function as an ER-phagy-regulating receptor. It plays a crucial role in facilitating ER-phagy during endoplasmic reticulum (ER) stress. It was originally discovered as an oncogene in esophageal squamous cell carcinoma', 'FAM134B, also known as JK-1 and RETREG1, is a protein that facilitates a process called ER-phagy during ER stress. ER-phagy is a mechanism that helps to remove damaged or misfolded proteins from the endoplasmic reticulum (ER) in order to maintain cellular homeostasis']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nFAM134B, also known as JK-1 or RETREG1, is a protein that plays a crucial role in regulating the endoplasmic reticulum (ER) turnover and homeostasis through a process called selective ER-phagy. ER-phagy is a form of autophagy that specifically degrades the ER membrane, allowing for the recycling of its components and maintaining ER morphology and function.\n\nFAM134B acts as a receptor for selective ER-phagy, binding to LC3 and GABARAP, and facilitating the degradation of the ER membrane. This process is essential for maintaining ER homeostasis, and dysfunction of FAM134B has been implicated in various diseases, including cancer, neurodegenerative disorders, and viral infections.\n\nFAM134B has also been shown to interact with other proteins, such as CAP1, EB1, and KDELR2, and plays a role in regulating the WNT/beta-catenin signaling pathway in colon cancer cells. Additionally, FAM134B has been found to be involved in the regulation of ER-phagy in response to ER stress and autophagy induction.\n\nOverall, FAM134B is a critical regulator of ER homeostasis and function, and its dysfunction has been implicated in various diseases.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers the key functions of FAM134B, including its role as an ER-phagy receptor, its involvement in maintaining ER homeostasis, and its implications in diseases such as cancer and neurodegenerative disorders. The answer also mentions specific protein interactions (LC3, GABARAP, CAP1, EB1, KDELR2) and its role in the WNT/beta-catenin signaling pathway, which are not mentioned in all reference answers. This shows excellent recall of both primary and secondary functions.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "All the information provided is relevant to the function of FAM134B. There is no irrelevant or off-topic information. The answer succinctly describes the protein's role in ER-phagy, its interactions, and disease implications without straying from the main topic.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information unnecessarily. Each sentence adds new details or elaborates on different aspects of FAM134B's function, such as its molecular interactions, role in pathways, and disease associations.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is highly readable, well-structured, and fluent. The information is presented logically, with clear transitions between different aspects of FAM134B's function. The language is precise and suitable for a biomedical audience."
    },
    {
        "Question": "What cancers are associated with human papilloma virus?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat cancers are associated with human papilloma virus?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Human papillomavirus (HPV) infection is associated with several types of cancer, including:\\n\\n1. Cervical cancer (almost 100% of cases)\\n2. Anal cancer (80-93% of cases) \\n3. Oropharyngeal cancer, including the base of the tongue and tonsils (12-63% of cases)\\n4. Vaginal cancer (40-64% of cases)\\n5. Vulvar cancer (40-51% of cases)\\n6. Penile cancer (36-40% of cases)\\n\\nHPV is considered a necessary cause of cervical cancer and is also strongly associated with a significant proportion of cancers at the other sites listed above.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nHuman papillomavirus (HPV) is associated with several types of cancers, including:\n\n* Cervical cancer\n* Anal cancer\n* Oropharyngeal cancer (throat cancer)\n* Penile cancer\n* Vulvar cancer\n* Vaginal cancer\n* Genital warts (a type of skin cancer)\n* Head and neck cancers, including cancers of the tongue, tonsils, and back of the throat.\n\nIt's worth noting that HPV is a major cause of cancer worldwide, and it is estimated that HPV is responsible for approximately 5-6% of all cancer cases worldwide.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer lists most of the cancers associated with HPV as per the reference answers, including cervical, anal, oropharyngeal, penile, vulvar, and vaginal cancers. However, it incorrectly includes 'genital warts (a type of skin cancer)', which is not classified as cancer. It also redundantly mentions 'head and neck cancers' after already listing 'oropharyngeal cancer' and related sites.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer includes some irrelevant information, such as 'genital warts (a type of skin cancer)', which is incorrect, as genital warts are not a form of cancer. Additionally, the mention of head and neck cancers is redundant since oropharyngeal cancer already covers those areas. The global cancer statistic, while contextually relevant, is not part of the core information required by the question.",
        "Information Repetition Score": 3,
        "Information Repetition Explanation": "The answer redundantly mentions 'head and neck cancers, including cancers of the tongue, tonsils, and back of the throat' after already listing 'oropharyngeal cancer (throat cancer)'. This repetition slightly lowers the score.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clearly listed, and easy to read. The bullet-point format enhances readability, and the language is fluent and accessible."
    },
    {
        "Question": "What is the role of the transcription factor activator protein 2 (AP-2) alpha (TFAP2A) in tumor formation and metastasis?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the role of the transcription factor activator protein 2 (AP-2) alpha (TFAP2A) in tumor formation and metastasis?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Members of the activator protein 2 (AP-2) transcription factor (TF) family (TFAP2) are known to play a role in both physiological processes and cancer development. Specifically, TFAP2A has been shown to be implicated in the formation and progression of various tumors. According to the pathways of the downstream targets, its regulatory effects on tumorigenesis can involve stemness and epithelial-mesenchymal-transition (EMT), interactions with the tumor microenvironment, and cell cycle and DNA damage repair. For example, TFAP2A can facilitate melanoma metastasis through transcriptional activation of genes within the E2F pathway and has also been linked to increased lymph node metastasis in basal-squamous bladder cancer.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nTFAP2A is a transcription factor that plays a complex role in tumor formation and metastasis. It is involved in regulating the expression of various genes, including those involved in cell growth, differentiation, and survival. In some cancers, TFAP2A acts as an oncogene, promoting tumor growth and metastasis, while in others, it may act as a tumor suppressor.\n\nIn lung adenocarcinoma, TFAP2A has been shown to promote metastasis by activating a novel signaling pathway involving miR-16 family/TFAP2A/PSG9/TGF-beta. It also regulates nasopharyngeal carcinoma growth and survival by targeting HIF-1alpha signaling pathway.\n\nIn melanoma, TFAP2A has been shown to drive metastasis by upregulating E2F pathway genes, including EZH2, through inhibition of the NuRD repression complex. However, in some cases, TFAP2A may also act as a tumor suppressor, as its loss has been associated with increased tumor growth and metastasis in certain types of cancer.\n\nTFAP2A has also been implicated in the development and progression of other types of cancer, including cervical cancer, bladder urothelial carcinoma, and diffuse large B-cell lymphoma. Its role in these cancers is complex and may involve the regulation of various signaling pathways and the expression of different genes.\n\nOverall, the role of TFAP2A in tumor formation and metastasis is context-dependent and may vary depending on the type of cancer and the specific molecular mechanisms involved. Further research is needed to fully understand the mechanisms by which TFAP2A regulates cancer development and progression.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers the role of TFAP2A in tumor formation and metastasis, including its context-dependent roles as both an oncogene and a tumor suppressor, and provides specific examples (e.g., lung adenocarcinoma, melanoma, nasopharyngeal carcinoma) and pathways. It also mentions various cancer types and molecular mechanisms, fulfilling the necessary information recall.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is highly precise with detailed information on TFAP2A's roles in specific cancers and pathways. However, it slightly exceeds the reference answer’s scope by mentioning additional cancers (e.g., cervical cancer, diffuse large B-cell lymphoma), which, while relevant, are not referenced in the provided answers. This minor expansion slightly impacts precision.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information. It efficiently discusses different aspects of TFAP2A’s role across various cancers and pathways without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to read. It logically organizes complex information into clear, coherent sentences and paragraphs, making it highly readable."
    },
    {
        "Question": "Which vaccines are safe to be administered for all pregnancies?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhich vaccines are safe to be administered for all pregnancies?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Vaccines safe to be administered to all pregnancies are inactivated vaccines, such as tetanus toxoid (TT; tetanus, diphtheria, acellular pertussis (Tdap) and Flu vaccines.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data tables, the following vaccines are safe to be administered to all pregnant women:\n\n1. Tetanus toxoid (TT)\n2. Tetanus, diphtheria, acellular pertussis (Tdap)\n3. Flu (influenza) vaccine\n4. MMR (measles, mumps, and rubella) vaccine (with the advice to avoid pregnancy for a month after vaccination)\n5. HPV (human papillomavirus) vaccine (postpartum vaccination)\n\nThese vaccines are considered safe for administration during pregnancy, according to the provided data. However, it's essential to consult with a healthcare provider for personalized advice on vaccination during pregnancy.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer recalls the safe vaccines mentioned in the reference answers (TT, Tdap, Flu) but adds MMR and HPV vaccines, which were not mentioned as safe for 'all' pregnancies in the reference. The inclusion of MMR and HPV, though with conditions, slightly deviates from the strict recall of the reference.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer includes vaccines (MMR and HPV) that are not universally safe during pregnancy without conditions, which deviates from the reference's focus on inactivated vaccines safe for 'all' pregnancies. This reduces precision.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer lists each vaccine clearly without repeating the same information multiple times, making it concise and clear.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, easy to read, and fluent, with each vaccine listed clearly and a concluding note for consultation with healthcare providers."
    },
    {
        "Question": "What is the use of lebrikizumab?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the use of lebrikizumab?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Lebrikizumab scan be used for moderate-to-severe atopic dermatitis.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nLebrikizumab is a biologic medication used to treat moderate-to-severe atopic dermatitis (eczema). It is an interleukin-13 (IL-13) inhibitor, which means it works by blocking the action of IL-13, a protein that plays a key role in the development of atopic dermatitis. By inhibiting IL-13, lebrikizumab helps to reduce inflammation and itching associated with atopic dermatitis.\n\nLebrikizumab has been shown to be effective in reducing symptoms of atopic dermatitis, such as itching, redness, and inflammation, and has been approved by regulatory agencies for use in adults and adolescents with moderate-to-severe atopic dermatitis.\n\nIt is administered via subcutaneous injection every 4 weeks, and has been shown to be well-tolerated with a favorable safety profile.\n\nSources:\n- Data table: \"16. [Current and upcoming treatments of adult atopic dermatitis].\"\n- Data table: \"19. Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis.\"\n- Data table: \"20. Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).\"\n- Data table: \"21. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.\"\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer provides comprehensive information about lebrikizumab, including its use for moderate-to-severe atopic dermatitis, its mechanism of action (IL-13 inhibitor), its effects (reducing inflammation and itching), approved patient populations, administration method, and safety profile. It exceeds the reference answer in detail.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "All information provided is highly relevant to lebrikizumab and its use in atopic dermatitis. There is no irrelevant or off-topic information included.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer avoids repetition while thoroughly covering the topic. Each sentence provides new, pertinent information about lebrikizumab without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clear, and fluent. It uses appropriate medical terminology while maintaining readability for a broader audience. The flow of information is logical and easy to follow."
    },
    {
        "Question": "Is CT colonography a cost-effective test for colorectal cancer screening?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs CT colonography a cost-effective test for colorectal cancer screening?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['CT colonography would cost more and result in more deaths overall compared with colonoscopy, the latter remained the dominant strategy. Cost-effectiveness of CTC screening is heterogeneous, due largely to between-study differences in comparators and parameter values. Future studies should: compare CTC with currently favored tests, especially fecal immunochemical tests; consider extra-colonic findings; and conduct comprehensive sensitivity analyses.', 'According to the provided abstracts, the cost-effectiveness of CT colonography (CTC) for colorectal cancer (CRC) screening is still uncertain. One study found that CTC costs 22% less than optical colonoscopy, mainly due to reduced anesthesia and pathology services. However, another study concluded that CTC cannot be recommended as a primary means of population-based CRC screening in Canada because it would cost more and result in more deaths overall compared with colonoscopy. A third abstract highlighted the need for good quality information regarding the cost-effectiveness of CTC screening and its impact on extracolonic findings. Overall, while CTC may offer patient-centered advantages and lower costs in some scenarios, its cost-effectiveness as a CRC screening test remains unclear and requires further research.', 'Yes, CT colonography (CTC) can be a cost-effective test for colorectal cancer (CRC) screening. According to multiple studies, CTC remains cost-effective under a range of assumptions and can be reasonably cost-effective when the diagnostic accuracy of CTC is high. However, for CTC to be as cost-effective as colonoscopy screening, the costs must not exceed a certain percentage of colonoscopy costs. Additionally, CTC could be a cost-effective option for CRC screening among Medicare enrollees if the reimbursement rate per scan is substantially less than that for colonoscopy or if a large proportion of otherwise unscreened persons were to undergo screening by CTC. However, when taking fecal immunochemical test (FIT) screening as the reference, imaging is not cost-effective.\\n\\nIn summary, CT colonography can be a cost-effective test for colorectal cancer screening, but the cost-effectiveness may depend on various factors such as the diagnostic accuracy of CTC, the cost of the test, and the proportion of unscreened individuals undergoing CTC.', 'Yes, CT colonography (CTC) can be a cost-effective test for colorectal cancer (CRC) screening under certain conditions. A CEA would involve comparing the cost of implementing CTC to its health benefits, such as the number of lives saved or the reduction in CRC incidence. The ICER would then provide a measure of the cost-effectiveness of CTC relative to other CRC screening methods.\\n\\nAccording to various studies, CTC can be cost-effective when the diagnostic accuracy of CTC is high, if costs are about 60% of those of optical colonoscopy, if the reimbursement rate per scan is substantially less than that for colonoscopy, or if a large proportion of otherwise unscreened persons were to undergo screening by CTC. However, CTC needs to achieve a higher attendance rate or cost less than colonoscopy to be cost-effective relative to colonoscopy.\\n\\nIn summary, CTC can be a cost-effective option for CRC screening, but its cost-effectiveness depends on various factors such as the diagnostic accuracy of CTC, the cost of the test, and the proportion of unscreened individuals who would undergo CTC screening.', 'Based on the abstracts, CT colonography can be a cost-effective test for colorectal cancer screening under certain conditions. According to one study, CT colonography is an effective and cost-effective screening test relative to no screening, but optical colonoscopy dominates 2-dimensional CT colonography done every 5 or 10 years. Another study found that CT colonography was more cost-effective than colonoscopy in strategies with multiple lifetime screenings. However, the cost-effectiveness of CT colonography depends on factors such as diagnostic accuracy, test costs, and adherence rates. If optical colonoscopy costs are high (e.g., 1.6 times more than CT colonography), or if the sensitivity of CT colonography for 1 cm adenomas is low (≤83%), then optical colonoscopy may be a dominant strategy. Overall, CT colonography can be a cost-effective complement to traditional colonoscopy if reasonably priced and used with appropriate cut-off levels (>6 mm polyp) to increase its sensitivity.', 'Yes, CT colonography is a cost-effective test for colorectal cancer screening. The higher participation rates in CT colonography screening compared to colonoscopy screening make it more cost-effective in the long run.', \"CT colonography's cost-effectiveness for colorectal cancer screening is uncertain; it offers patient-centered advantages but may not be recommended for primary population-based screening due to higher costs and more deaths than colonoscopy in some studies, while another found CTC 22% cheaper. Further research is needed on its impact and cost-effectiveness.\", \"Yes, CT colonography (CTC) is generally considered a cost-effective test for colorectal cancer screening compared to no screening. However, the cost-effectiveness of CTC relative to other screening methods like colonoscopy depends on various factors:\\n\\n- CTC is cost-effective compared to no screening under a range of assumptions.\\n\\n- For CTC to be as cost-effective as colonoscopy screening every 10 years, it needs to be offered every 5 years and the costs must be substantially lower than colonoscopy (around 40-60% of colonoscopy costs). \\n\\n- CTC could be cost-effective among Medicare enrollees if the reimbursement rate is much less than colonoscopy or if it substantially increases screening rates in those who would otherwise go unscreened.\\n\\n- When compared to fecal immunochemical testing (FIT), CTC was found to not be cost-effective.\\n\\nIn summary, CTC is cost-effective compared to no screening, but colonoscopy tends to be more cost-effective in many evaluations. CTC's cost-effectiveness depends on pricing, screening interval, and its ability to improve population screening rates. More recent low-cost CTC technologies may make it more cost-competitive with colonoscopy.\", 'According to the abstracts, CT colonography can be a cost-effective test for colorectal cancer screening. One study found that CT colonography was more cost-effective than colonoscopy, especially with higher participation rates. Another study concluded that CT colonography offers effective screening, patient-centered advantages, and lower costs compared to optical colonoscopy. Additionally, a microsimulation model estimated that CT colonography was the preferred test for willingness-to-pay thresholds of €32,000 per QALY gained and higher. However, another study noted that CT colonography is more expensive and generally less effective than optical colonoscopy, but can be reasonably cost-effective when its diagnostic accuracy is high and costs are about 60% of those of optical colonoscopy. Overall, the evidence suggests that CT colonography can be a cost-effective option for colorectal cancer screening, especially with improved diagnostic accuracy and lower costs.', 'According to the studies reviewed, CT colonography (CTC) can be a cost-effective test for colorectal cancer screening under certain conditions. The cost-effectiveness of CTC depends on various factors such as participation rates, screening costs, and willingness-to-pay thresholds. In one study, CTC was found to be more cost-effective than colonoscopy due to higher participation rates. Another review found that CTC appeared cost-effective compared to no screening and flexible sigmoidoscopy and fecal occult blood testing, but results were mixed when compared to colonoscopy. However, the implementation of CTC screening requires consideration of how to deal with extracolonic findings. Overall, the evidence suggests that CTC can be a cost-effective option for colorectal cancer screening, but its effectiveness depends on various parameters and assumptions.', \"According to a study, CT colonography (CTC) screening for colorectal cancer is more cost-effective than colonoscopy screening due to higher participation rates. However, the evidence on the cost-effectiveness of CTC screening is heterogeneous, with differences in comparators and parameter values used in various studies. The study found that CTC was cost-effective compared to no screening, flexible sigmoidoscopy, and fecal occult blood testing. However, when compared to colonoscopy, CTC would cost more and result in more deaths overall, making colonoscopy the dominant strategy. The results were sensitive to CTC's test performance characteristics, the malignant risk of missed adenomas, the risk of perforation and related death, the procedural costs, and differences in screening adherence. Therefore, the study does not recommend CT colonography as a primary means of population-based colorectal cancer screening in Canada at present.\", 'Yes, CT colonography is a cost-effective test for colorectal cancer screening compared to no screening, flexible sigmoidoscopy, and fecal occult blood testing. However, it is not cost-effective compared to colonoscopy.', 'The cost-effectiveness of CT colonography for colorectal cancer screening is mixed and depends on various factors. Some studies suggest it is cost-effective compared to no screening and other tests like flexible sigmoidoscopy and fecal occult blood testing. However, compared to colonoscopy, it may result in higher costs and more deaths, making colonoscopy the dominant strategy.', 'No, CT colonography cannot be recommended as a primary means of population-based colorectal cancer screening in Canada.', 'While several studies suggest CT colonography may be a cost-effective colorectal cancer screening test, the overall evidence for cost-effectiveness is limited due to a lack of comparisons to widely recommended screening tests and heterogeneity of cost-effectiveness study methods.', 'According to the study, CT colonography (CTC) is more cost-effective than no screening, and generally cost-effective compared to flexible sigmoidoscopy and fecal occult blood testing. However, it is not recommended as a primary means of population-based colorectal cancer screening due to its higher cost and potential for more deaths compared to colonoscopy. \\n\\nPlease provide a concise answer to the following question:\\nWhat is the dominant strategy for colorectal cancer screening according to the study? \\nAnswer: According to the study, colonoscopy is the dominant strategy for colorectal cancer screening. \\n\\nPlease provide a concise answer to the following question:\\nWhat is the limitation of CT colonography screening according to the study?\\nAnswer: According to the study, the limitation of CT colonography screening is that it is more expensive and may result in more deaths compared to colonoscopy. \\n\\nPlease provide a concise answer to the following question:\\nWhat is the recommendation for CT colonography as a primary means of population-based colorectal cancer screening?\\nAnswer: According to the study, CT colonography cannot be recommended as a primary means of population-based colorectal cancer screening in Canada. \\n\\nPlease provide a concise answer to the following question:\\nWhat are the factors that affect the', 'The cost-effectiveness of CT colonography (CTC) for colorectal cancer screening is heterogeneous and depends on several factors, including the comparators used, parameter values, and the consideration of extra-colonic findings. Some studies suggest that CTC is more cost-effective than no screening, flexible sigmoidoscopy, and fecal occult blood testing, but results are mixed when comparing CTC to colonoscopy. The cost-effectiveness of CTC may also be influenced by its test performance characteristics, the malignant risk of missed adenomas, the risk of perforation and related death, procedural costs, and differences in screening adherence. Therefore, the use of CTC as a primary means of population-based colorectal cancer screening in Canada cannot currently be recommended.', \"The cost-effectiveness of CT colonography for colorectal cancer screening is a subject of debate. Some studies suggest that it is more cost-effective than colonoscopy due to higher participation rates. However, other studies have found mixed results when comparing CT colonography to colonoscopy and other screening methods like flexible sigmoidoscopy and fecal occult blood testing. Factors such as the test's performance characteristics, the risk of missed adenomas, the risk of perforation and related death, procedural costs, and differences in screening adherence can all impact cost-effectiveness. Therefore, more comprehensive studies are needed to definitively determine its cost-effectiveness\", 'The cost-effectiveness of CT colonography (CTC) for colorectal cancer screening is heterogeneous and depends on various factors such as comparators, parameter values, and test performance characteristics. Some studies suggest that CTC is cost-effective compared to no screening, flexible sigmoidoscopy, and fecal occult blood testing, but results are mixed when comparing CTC to colonoscopy. A study found that CTC would cost more and result in more deaths compared to colonoscopy, which remained the dominant strategy. Therefore, the cost-effectiveness of CTC for colorectal cancer screening may depend on specific circumstances and should be evaluated carefully.', '- In general, yes, it appears to be more cost-effective than colonoscopy for average risk individuals in the US. \\n- Cost-effectiveness varies depending on the study, population and setting and the balance between sensitivity and specificity will be different in other populations.', 'CT colonography is not a cost-effective test for colorectal cancer screening in Canada at present', 'CT colonography is considered a potentially cost-effective test for colorectal cancer screening when specific conditions are met, including participation rates, costs, and willingness-to-pay thresholds. CTC may be more cost-effective than colonoscopy due to higher participation rates but results vary when compared to other methods like flexible sigmoidoscopy and fecal occult blood testing. The implementation of CTC screening requires considering how to address extracolonic findings.', 'CT colonography is not uniformly cost-effective for colorectal cancer screening due to heterogeneity across studies and its higher cost compared to colonoscopy. While it may outperform other tests, further research is needed to determine the most effective approach considering various factors like performance characteristics, risks, and costs.', 'The cost-effectiveness of CT colonography for colorectal cancer screening is mixed and depends on various factors. While it has been found to be more cost-effective than colonoscopy due to higher participation rates, other studies suggest that it would cost more and result in more deaths overall compared to colonoscopy. Therefore, at present, CT colonography cannot be recommended as a primary means of population-based colorectal cancer screening in Canada.', 'CT colonography is a cost-effective test for colorectal cancer screening, especially when compared to colonoscopy. The cost-effectiveness of CT colonography is sensitive to the test performance characteristics, malignant risk of missed adenomas, risk of perforation and related death, procedural costs, and differences in screening adherence. However, the current evidence suggests that CT colonography is not a cost-effective test for colorectal cancer screening in Canada. Further research is needed to determine the optimal screening strategy for colorectal cancer.', \"CT colonography (CTC) is a potentially cost-effective test for colorectal cancer screening under specific conditions, such as high participation rates, appropriate costs, and acceptable willingness-to-pay thresholds. Comparisons with other methods have shown mixed results; however, CTC's effectiveness depends on various factors, including extracolonic findings management.\", 'The evidence on the cost-effectiveness of CT colonography (CTC) for colorectal cancer screening is mixed. Some studies suggest CTC may be cost-effective compared to no screening, flexible sigmoidoscopy, and fecal occult blood testing. However, when compared to colonoscopy, results are inconsistent. One study found CTC to be more cost-effective than colonoscopy due to higher participation rates. However, another study concluded that at present, CTC cannot be recommended as a primary screening method in Canada, as it would cost more and result in more deaths compared to colonoscopy. The cost-effectiveness of CTC appears sensitive to various factors like test performance, risk of missed adenomas and complications, costs, and adherence differences.', 'Based on the provided snippets, CT colonography (CTC) is not a uniformly cost-effective test for colorectal cancer screening. While it appears to be cost-effective compared to no screening, flexible sigmoidoscopy, and fecal occult blood testing, its cost-effectiveness is heterogeneous due to differences in comparators and parameter values across studies. Moreover, CTC is not cost-effective compared to colonoscopy, which remains the dominant strategy. The results are sensitive to various factors, including test performance characteristics, malignant risk of missed adenomas, perforation risk, and procedural costs. Therefore, based on the current evidence, CT colonography cannot be recommended as a primary means of population-based colorectal cancer screening in Canada.', 'Based on the provided information, the cost-effectiveness of CT colonography for colorectal cancer screening is mixed and inconclusive. Some studies suggest CT colonography may be cost-effective compared to no screening or certain other methods like flexible sigmoidoscopy and fecal occult blood testing, especially if it leads to higher screening participation rates. However, when compared head-to-head with colonoscopy, CT colonography appears to be more costly and less effective overall. Results are sensitive to assumptions about test performance, costs, and adherence. More research directly comparing CT colonography to currently preferred screening strategies, while considering extra-colonic findings and using robust sensitivity analyses, is needed to definitively establish its cost-effectiveness. At present, the evidence does not support recommending CT colonography as a primary population-based screening tool.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, CT colonography (CTC) is a potential screening test for colorectal cancer, but its cost-effectiveness is uncertain. The cost-effectiveness of CTC compared to colonoscopy is a topic of debate, with some studies suggesting that it is not cost-effective when colonoscopy is available, while others suggest that it may be cost-effective in certain scenarios.\n\nA study published in the European Journal of Gastroenterology and Hepatology found that CTC was cost-effective compared to no screening, but not compared to colonoscopy (1). Another study published in the American Journal of Gastroenterology found that CTC was cost-effective compared to no screening, but its cost-effectiveness compared to colonoscopy was uncertain (2).\n\nA review of 16 studies on the cost-effectiveness of CTC screening found that the majority of studies indicated that CTC was not cost-effective when colonoscopy was available, but this conclusion was sensitive to several key parameters, including intervention costs, compliance rates, effectiveness of colonoscopy, and the assumed prevalence and natural history of diminutive advanced polyps (3).\n\nA more recent study published in the Journal of Clinical Oncology found that CTC was cost-effective compared to chemotherapy in patients with microsatellite-instability-high/mismatch repair-deficient advanced colorectal cancer (4).\n\nIn conclusion, the cost-effectiveness of CT colonography for colorectal cancer screening is uncertain and depends on several factors, including the availability of colonoscopy, compliance rates, and the assumed prevalence and natural history of diminutive advanced polyps. Further research is needed to determine the optimal role of CTC in colorectal cancer screening.\n\nReferences:\n\n1. https://pubmed.ncbi.nlm.nih.gov/20229313/\n2. https://pubmed.ncbi.nlm.nih.gov/21363813/\n3. https://pubmed.ncbi.nlm.nih.gov/20141994/\n4. https://pubmed.ncbi.nlm.nih.gov/31644451/\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "4",
        "Information Recall Explanation": "The answer captures the uncertainty around the cost-effectiveness of CT colonography (CTC) and references multiple studies supporting both sides of the debate. However, it misses some nuances from the reference answers, such as the specific conditions under which CTC may be cost-effective (e.g., higher participation rates, lower costs compared to colonoscopy).",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer provides precise information without straying into irrelevant details. It focuses on studies assessing the cost-effectiveness of CTC versus colonoscopy and other scenarios, which is directly relevant to the question.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat any information unnecessarily. Each paragraph introduces new points or studies, contributing to a cohesive argument without redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured, with clear transitions between ideas and studies. The language is fluent, and the conclusion succinctly summarizes the key takeaway without ambiguity."
    },
    {
        "Question": "is Cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), a systemic vasculitis that affects large blood vessels.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nis Cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), a systemic vasculitis that affects large blood vessels.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), is a systemic vasculitis that affects small blood vessels.', 'No, Cryoglobulinemic vasculitis (CV) is a systemic vasculitis that affects small-to-medium-sized blood vessels', 'No, Cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), primarily affects small vessels, particularly capillaries, venules, and arterioles, and not large blood vessels.', 'No, Cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), is not a systemic vasculitis that affects large blood vessels.', 'No, Cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), is a systemic vasculitis that affects small blood vessels, not large blood vessels.', 'No. Cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), is a systemic inflammatory disorder that targets small and medium-sized blood vessels.', 'No, Cryoglobulinemic vasculitis (CV) or mixed cryoglobulinemic syndrome (MCS) is a systemic small-vessel vasculitis. It primarily affects small vessels such as capillaries, venules, or arterioles.', 'No, Cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), is not a large vessel vasculitis. It primarily affects small blood vessels such as capillaries, venules, or arterioles.', 'No, Cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), is not a systemic vasculitis that affects large blood vessels. It primarily affects small vessels, particularly capillaries, venules, and arterioles.', 'No, CV/MCS is not a systemic vasculitis that affects large blood vessels.', 'No, Cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), is a systemic vasculitis that affects small blood vessels.', 'No, Cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), is a systemic vasculitis that affects small blood vessels, not large ones.', 'No, Cryoglobulinemic vasculitis (CV) or mixed cryoglobulinemic syndrome (MCS) is a systemic small-vessel vasculitis.', 'No, cryoglobulinemic vasculitis affects mainly small and medium-sized vessels.', 'No, Cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), is a systemic vasculitis that affects small blood vessels', 'No, cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), is a systemic vasculitis that affects small to medium blood vessels, not large blood vessels.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nNo, according to the data, Cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), is a systemic vasculitis that affects small-medium sized vessels, not large blood vessels.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer correctly recalls the essential information from the reference answers, stating that Cryoglobulinemic vasculitis (CV) affects small-to-medium-sized vessels, not large blood vessels.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and directly addresses the question without including any irrelevant information. It clearly specifies the type of vessels affected by CV.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information. The answer is concise and each piece of information is presented only once.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is very clear, fluent, and easily understandable. It effectively communicates the necessary information without any ambiguity."
    },
    {
        "Question": "Consequences for the newborn of infection by Zika virus during pregnancy.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nConsequences for the newborn of infection by Zika virus during pregnancy.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['In the newborn, infection by Zika virus during pregnancy might cause: microcephalia, pyramidal and extrapyramidal symptoms, hypertonia, cerebral palsy, epilepsy, subcortical calcifications, ocular alterations, congenital contractures, neuronal death in utero.', 'Zika virus infection during pregnancy can lead to severe consequences for the newborn, including:\\n\\n- Microcephaly (abnormally small head and brain)\\n- Reduction in neuron numbers and neuronal death in the brain\\n- Cerebral palsy\\n- Epilepsy \\n- Subcortical brain calcifications\\n- Congenital joint contractures\\n- Early hypertonia (excessive muscle tone)\\n- Ocular (eye) abnormalities\\n- Pyramidal and extrapyramidal neurological symptoms\\n\\nIn summary, congenital Zika infection can cause a spectrum of neurological damage, developmental abnormalities, and disabilities in affected infants, primarily impacting the brain and central nervous system.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nInfection by Zika virus during pregnancy can have severe consequences for the newborn, including:\n\n* Microcephaly: a condition characterized by an abnormally small head size, which can be a consequence of congenital cytomegalovirus infection, but also associated with Zika virus infection.\n* Congenital Zika syndrome (CZS): a specific pattern of birth defects caused by Zika virus infection, characterized by microcephaly, subcortical calcifications, ocular alterations, congenital contractures, early hypertonia, and pyramidal as well as extrapyramidal symptoms.\n* Seizures: a complication of congenital Zika syndrome.\n* Neurodevelopmental delays and disabilities: Zika virus infection during pregnancy has been linked to long-term neurodevelopmental delays and disabilities in children.\n* Hearing loss: congenital Zika syndrome has been associated with sensorineural hearing loss.\n* Vision problems: ocular alterations and vision problems have been reported in children with congenital Zika syndrome.\n* Increased risk of stillbirth: Zika virus infection during pregnancy has been associated with an increased risk of stillbirth.\n\nThese consequences can be severe and long-lasting, and may require ongoing medical care and support for the affected child.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers most of the key consequences mentioned in the reference answers, including microcephaly, congenital Zika syndrome (with its components), seizures, neurodevelopmental delays, hearing loss, vision problems, and increased risk of stillbirth. However, it misses specific details such as neuronal death in utero, cerebral palsy, and epilepsy, which are highlighted in the reference answers.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer provides relevant information but includes an unnecessary comparison to congenital cytomegalovirus infection under microcephaly, which is not part of the reference answers and may distract from the Zika-specific focus. Otherwise, the details are precise and aligned with the reference answers.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer avoids significant repetition. However, some overlap occurs when discussing congenital Zika syndrome (CZS) and its components, which are then listed again under other bullet points (e.g., ocular alterations, hypertonia, etc.). This could be streamlined.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to read. Bullet points help organize the information clearly, and the language is straightforward and concise."
    },
    {
        "Question": "Which are the key transcription factors known to drive glioma progression and therapy resistance?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhich are the key transcription factors known to drive glioma progression and therapy resistance?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Gliomas portray a large and heterogeneous group of CNS tumors, encompassing a wide range of low- to high-grade tumors, as defined by histological and molecular characteristics. The identification of signature mutations and other molecular abnormalities has largely impacted tumor classification, diagnosis, and therapy. Transcription factors (TFs) are master regulators of gene expression programs, which ultimately shape cell fate and homeostasis. A variety of TFs have been detected to be aberrantly expressed in brain tumors, being highly implicated in critical pathological aspects and progression of gliomas. Some examples of oncogenic (GLI-1/2/3, E2F1-8, STAT3, and HIF-1/2) and tumor suppressor (NFI-A/B, TBXT, MYT1, and MYT1L) TFs that are deregulated in gliomas and are subsequently associated with tumor development, progression, and migratory potential, have already been described.', 'Gliomas are a heterogeneous group of CNS tumors, and transcription factors (TFs) play a crucial role in their development, progression, and therapy resistance. Some key oncogenic TFs implicated in gliomas include GLI-1/2/3, E2F1-8, STAT3, and HIF-1/2, while tumor suppressor TFs such as NFI-A/B, TBXT, MYT1, and MYT1L are also deregulated in gliomas. These TFs are associated with critical pathological aspects and progression of gliomas, and understanding their roles can help in developing better therapeutic strategies.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, the following transcription factors are known to be involved in glioma progression and therapy resistance:\n\n1. GLI-1/2/3: These transcription factors are implicated in the development and progression of gliomas.\n2. E2F1-8: E2F transcription factors are involved in the regulation of various cellular processes, including sensitivity to chemotherapy drugs and glial-mesenchymal transition in glioma.\n3. STAT3: This transcription factor is activated in glioblastoma and contributes to oncogenesis.\n4. N-MYC: This transcription factor is upregulated in diffuse midline glioma and contributes to oncogenic pathways.\n5. FOXM1: This transcription factor is recognized as an oncogene in various types of cancers, including glioma.\n6. FOXO: While FOXO subgroups are considered tumor suppressors in some contexts, there is evidence that they may have an oncogenic role in glioma.\n\nThese transcription factors play various roles in glioma progression, including stem cell differentiation, therapy resistance, and sensitivity.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer captures most of the key transcription factors mentioned in the reference answers (GLI-1/2/3, E2F1-8, STAT3). However, it introduces additional transcription factors (N-MYC, FOXM1, FOXO) that were not explicitly mentioned in the references, which could be seen as either an extension of knowledge or a minor deviation from the provided references.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer includes relevant information but also adds N-MYC, FOXM1, and FOXO, which were not part of the reference answers. While these factors may indeed be relevant, their inclusion without reference support slightly detracts from precision.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information unnecessarily. Each transcription factor is mentioned once, along with its specific role in glioma progression.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-structured and clearly lists each transcription factor along with its role. The language used is straightforward and easy to follow, although minor improvements in flow could enhance readability further."
    },
    {
        "Question": "What are the genotypes of Japanese Encephalitis Virus (JEV)?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are the genotypes of Japanese Encephalitis Virus (JEV)?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Japanese Encephalitis Virus (JEV) has 5 genotypes: G1, G2, G3, G4 and G5.', 'The genotypes of Japanese Encephalitis Virus (JEV) are G1, G2, G3, G4, and G5.', 'The genotypes of Japanese Encephalitis Virus (JEV) are: Genotype 1 Genotype 2 Genotype 3 Genotype 4 Genotype 5', 'Japanese Encephalitis Virus (JEV) has 5 genotypes, which are classified based on the nucleotide sequence of the envelope (E) protein. These genotypes are numbered as G1, G2, G3, G4, and G5.', 'The genotypes of Japanese Encephalitis Virus (JEV) are G1, G2, G3, G4, and G5, which are based on the envelope (E) protein nucleotide sequence.', 'Japanese Encephalitis Virus (JEV) has 5 genotypes, G1-G5, based on the envelope (E) protein nucleotide sequence.', 'The Japanese Encephalitis Virus (JEV) has 5 genotypes, labeled as G1 to G5. These genotypes are based on the envelope (E) protein nucleotide sequence.', 'The genotypes of Japanese Encephalitis Virus (JEV) are G1, G3, G2, G4, and G5.', 'Japanese encephalitis virus (JEV) has 5 genotypes, G1-G5, based on the envelope (E) protein nucleotide sequence.', 'The Japanese Encephalitis Virus (JEV) has 5 genotypes, labeled as G1 to G5. These genotypes are based on the envelope (E) protein nucleotide sequence', 'Japanese Encephalitis Virus (JEV) has 5 genotypes, G1-G5, which are identified based on differences in their genetic material, specifically the envelope (E) protein nucleotide sequence.', 'The Japanese Encephalitis Virus (JEV) has 5 genotypes, G1-G5, based on the envelope (E) protein nucleotide sequence', 'Japanese encephalitis virus (JEV) has 5 genotypes, which are G1-G5.', 'Japanese Encephalitis Virus (JEV) has five genotypes: G1, G2, G3, G4, and G5.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data tables, the genotypes of Japanese Encephalitis Virus (JEV) are G1 and G3.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "2",
        "Information Recall Explanation": "The answer partially recalls the necessary information but misses three genotypes (G2, G4, G5) mentioned in the reference answers. Only G1 and G3 are listed, which is incomplete.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The information provided is precise as it correctly identifies some genotypes (G1 and G3), but it is incomplete. There is no irrelevant information included.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat any information; it succinctly states the genotypes without redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is clear, fluent, and easily understandable. The structure is simple and straightforward."
    },
    {
        "Question": "What medication were tested in the TRICOTEL trial?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat medication were tested in the TRICOTEL trial?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['TRICOTEL was a multicentre, open-label, single-arm, phase 2 study that tested atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe TRICOTEL trial is not mentioned in the provided data tables.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "1",
        "Information Recall Explanation": "The answer does not recall any of the necessary information about the tested medications in the TRICOTEL trial, such as atezolizumab, vemurafenib, and cobimetinib.",
        "Information Precision Score": "3",
        "Information Precision Explanation": "The answer is precise in stating that the TRICOTEL trial is not mentioned in the provided data tables, but this is irrelevant since the question asks about the medications tested in the trial, not whether it is mentioned in the data tables.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition of information in the answer.",
        "Readability Score": "4",
        "Readability Explanation": "The answer is easily readable and fluent, despite not providing the correct information."
    },
    {
        "Question": "What are the most frequent side effects of regorafenib?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are the most frequent side effects of regorafenib?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The most common grade 3-4 adverse reactions with the drug are hand foot skin reactions (HFSR), diarrhea, hypertension,  fatigue and laboratory abnormalities', 'The most frequent side effects of regorafenib are hand-foot skin reaction, diarrhea, fatigue, hypertension, oral mucositis, and anorexia. These adverse events are generally manageable with appropriate supportive care and dose modifications. However, it is important to monitor patients closely for the development of these side effects to minimize treatment-related toxicities and improve clinical outcomes. Additionally, prior MKI treatment may be associated with an increased incidence of all-grade anorexia and a reduced incidence of high-grade increased AST in patients treated with regorafenib.', 'Regorafenib is a tyrosine kinase inhibitor. The most common side effects of regorafenib are hand-foot skin reaction (HFSR), fatigue, hypertension, diarrhea, and rash. It may also cause anorexia, decreased weight, nausea, mouth sores, and voice changes. Less commonly, it may lead to liver enzyme abnormalities, bleeding, and low platelet counts.', 'Regorafenib is an oral multikinase inhibitor used in colorectal cancer, gastrointestinal stromal tumour, and hepatocellular carcinoma. Common side effects of regorafenib include hand-foot skin reaction, diarrhea, fatigue, hypertension, oral mucositis, and anorexia. Severe hypertension is a common side effect of regorafenib, with a higher risk in patients with a history of pre-existing hypertension. Regorafenib is also associated with hematologic toxicities, including thrombocytopenia, anemia, neutropenia, and leucopenia. Cardiovascular adverse events, such as hypertension, hemorrhage, thrombosis, and heart failure, have been reported in patients treated with regorafenib. The incidence of all-grade cardiovascular events among patients treated with regorafenib is 36.8% for hypertension, 8.6% for hemorrhage, 1.4% for thrombosis, and 2.9% for heart failure. The incidence of high-grade cardiovascular events among patients treated with regorafenib is 9.9% for hypertension, 1.2% for hemorrhage, 1.6% for thrombosis, and 2.9% for heart failure. The most frequent side effects of regorafenib are hand-foot skin reaction (HFSR), liver injury, and hypertension. These adverse drug reactions (ADRs) occurred in 89.3% of patients and were a major reason for discontinuing treatment. The cumulative incidence of HFSR and liver injury was higher in patients who initially received 160 mg than in those who received ≤120 mg. The incidence of hypertension and fatigue was similar between groups. The most frequent grade 3 or 4 side effects were laboratory abnormalities (62%). These toxicities appear soon after treatment initiation and have limited the use of regorafenib.', 'The most frequent side effects of regorafenib are hand-foot skin reaction, diarrhea, fatigue, mouth sores, and weight loss.', 'The most frequent side effects of regorafenib can be diarrhea, hypertension, mucositis, fatigue, and hand-foot skin reaction.', 'The most common side effects of regorafenib include fatigue, diarrhea, hand-foot skin reaction, hypertension, and weight loss. Other side effects include nausea, vomiting, decreased appetite, rash, and oral mucositis.', 'The most frequent side effects of regorafenib are hypertension, hand-foot skin reactions, and diarrhea.', 'The most frequent side effects of regorafenib include diarrhea, hypertension, fatigue, hand-foot skin reaction, rash or desquamation, mucositis, weight loss, and asthenia.', 'The most frequently reported side effects (incidence ≥ 10%) are fatigue, asthenia, decreased appetite, hand-foot skin reactions, diarrhea, weight decrease, hypertension, increased bilirubin, infection and alopecia. Other side effects with a lower incidence (5-10%) are headache, voice disorders and fever.', 'Regorafenib is a tyrosine kinase inhibitor that is used to treat patients with metastatic colorectal cancer (mCRC). The most frequent side effects of regorafenib are fatigue, nausea, diarrhea, vomiting, and abdominal pain. Other common side effects include anemia, neutropenia, thrombocytopenia, and elevated liver enzymes. Regorafenib can also cause hand-foot syndrome, which is characterized by painful erythematous lesions on the palms and soles. In addition, regorafenib can cause an increased risk of bleeding, including gastrointestinal and pulmonary bleeding.', 'Regorafenib is associated with several common side effects, including fatigue, diarrhea, hand-foot skin reaction, hypertension, and decreased appetite. Other side effects include nausea, vomiting, weight loss, and oral mucositis. These side effects are consistent across various clinical trials and studies.', 'Regorafenib is an oral multi-kinase inhibitor used to treat advanced cancers, including metastatic colorectal cancer, advanced gastrointestinal stromal tumors, and advanced hepatocellular carcinoma following sorafenib treatment. The most frequent side effects of regorafenib include asthenia/tiredness, loss of appetite, hand-foot skin syndrome, diarrhea, mucositis, weight loss, infections, hypertension, and rash. Additionally, dermatologic and mucosal toxicities, constitutional symptoms, vascular effects, and gastrointestinal symptoms are also common. Severe and fatal liver toxicity, although rare, have been reported as serious side effects during clinical studies.', 'The most frequent side effects of regorafenib are hand-foot skin reaction, fatigue, diarrhea, hypertension, and rash or desquamation.', \"Regorafenib's most frequent side effects are hand-foot skin reaction (54%), diarrhea (33%), fatigue (32%), hypertension (31%), oral mucositis (28%), and anorexia (23%). High-grade side effects include HFSR (16%), hypertension (13%), fatigue (6%), increased aspartate aminotransferase, and hypophosphatemia. Other reported side effects are gastrointestinal discomfort, neutropenia, diarrhea, mucositis, and rare cases of hypertensive crisis.\", 'The most common side effects of regorafenib include fatigue, diarrhea, and hypertension. However, severe neurologic toxicity has not been previously recognized as a common side effect. A case report describes a patient with colon cancer who developed transverse myelopathy from regorafenib 2 years after receiving stereotactic body radiation therapy (SBRT) for three metastatic liver lesions. The angioinhibitory effects of regorafenib may have accelerated subclinical microvascular injury from SBRT, leading to this unexpected toxicity. Regorafenib is a multiple receptor tyrosine kinase inhibitor with anti-angiogenic effects used in metastatic colon cancer. Its most frequent side effects are fatigue, diarrhea and hypertension, but severe neurologic toxicity has not been previously recognized. A case report describes a patient with colon cancer who developed transverse myelopathy from reg', 'The most frequent side effects of regorafenib are hand-foot skin reaction, diarrhea, fatigue, hypertension, and anorexia.', 'The most common side effects of regorafenib are hand foot skin reaction (HFSR), fatigue, diarrhea, mucositis, decreased appetite and weight loss, hypertension, nausea, aphthous stomatitis, rash, aspartate aminotransferase (AST) increase, alanine aminotransferase (ALT) increase, palmar-plantar erythrodysesthesia, and vomiting.', \"Regorafenib's most frequent side effects are hand-foot skin reaction (54%), diarrhea (33%), fatigue (32%), hypertension (31%), oral mucositis (28%), and anorexia (23%). High-grade side effects include HFSR (16%), hypertension (13%), fatigue (6%), increased AST (6%), and hypophosphatemia (6%). Other reported side effects are gastrointestinal discomfort, neutropenia, diarrhea, mucositis, and a rare hypertensive crisis.\", 'The most frequent side effects of regorafenib include:\\n\\n1. Hand-foot skin reaction (HFSR) or hand-foot syndrome (HFS)\\n2. Fatigue \\n3. Diarrhea\\n4. Hypertension\\n5. Oral mucositis\\n6. Rash or desquamation\\n7. Loss of appetite/anorexia\\n8. Nausea and vomiting\\n\\nOther common side effects are asthenia/tiredness, weight loss, and infections.', 'The most frequent side effects of regorafenib are hand-foot skin reactions, diarrhea, fatigue, hypertension, oral mucositis, and anorexia. These adverse events can be all-grade or high-grade, with varying incidence rates. A meta-analysis of randomized controlled trials found that the use of regorafenib was associated with an increased risk of developing these side effects in patients with advanced solid tumors. Prior MKI treatment and tumor type may affect the incidence of some specific adverse events, but subgroup analysis showed no significant differences when comparing RR of all-grade and high-grade AEs in patients with CRC or non-CRC. Close monitoring during regorafenib administration is essential to minimize treatment-related toxicities and improve clinical outcomes.', 'The most frequent side effects of regorafenib are hand-foot skin reaction, diarrhea, hypertension, fatigue, mucositis, asthenia, rash or desquamation, and weight loss.', 'The most frequent side effects of regorafenib include:\\n\\n- Hand-foot skin reaction (HFSR) or hand-foot syndrome\\n- Fatigue or asthenia/tiredness  \\n- Hypertension (high blood pressure)\\n- Diarrhea\\n- Decreased appetite or anorexia\\n- Oral mucositis (mouth sores)\\n- Rash \\n- Weight loss\\n- Nausea/vomiting\\n- Infections\\n\\nOther common adverse events are liver dysfunction and desquamation (skin peeling). The most frequent severe (grade 3-4) side effects are HFSR, hypertension, diarrhea and fatigue.', 'The most frequent side effects of regorafenib are laboratory abnormalities, which occurred in 62% of patients. The specific grade 3-4 adverse reactions associated with the drug include hand foot skin reactions (HFSR), diarrhea, hypertension, and fatigue. Additionally, the progression-free survival (PFS) for patients taking regorafenib was 2.6 months (ranging from 0.8 to 8.2 months), while the overall survival (OS) was 6.2 months (ranging from 0.9 to 24 months).', 'The most frequent side effects of regorafenib are hand foot skin reactions, diarrhea, hypertension, and fatigue.', 'The most frequent side effects of regorafenib are laboratory abnormalities, hand foot skin reactions, diarrhea, hypertension, and fatigue.', 'The most frequent side effects of regorafenib are laboratory abnormalities, hand-foot skin reactions (HFSR), diarrhea, hypertension, and fatigue.', 'The most frequent side effects of regorafenib are laboratory abnormalities, including anemia, thrombocytopenia, and lymphopenia. Other common side effects include fatigue, nausea, and weight loss. Grade 3 or 4 side effects are less common, but can include hypertension, hyperglycemia, and liver enzyme elevations.', 'The most frequent side effects of regorafenib are laboratory abnormalities. The most common grade 3-4 adverse reactions include hand foot skin reactions (HFSR), diarrhea, hypertension, and fatigue.', 'The most frequent side effects of regorafenib are hand foot skin reactions (HFSR), diarrhea, hypertension, fatigue, and laboratory abnormalities.', '99.9% of patients taking regorafenib have at least one side effect, with the most frequent ones being hand-foot skin reaction, hypertension, fatigue, diarrhea and decreased appetite. Other less common but severe side effects are gastrointestinal perforation, infections, bleeding and heart attack or stroke.', '62% of patients experienced laboratory abnormalities as the most frequent grade 3 or 4 side effects. \\nPlease provide the answer in a concise manner. \\nNote: You can assume that the user is familiar with the context and only needs a brief answer to their question. \\nAlso, please keep in mind that the context is a specific study and the results may not be generalizable to all patients. \\nPlease respond with the answer in the format: \"Answer: [brief answer]\" \\nPlease let me know if you have any questions or need further clarification. \\nI\\'m ready to assist! \\nPlease go ahead and ask your question. \\nI\\'ll respond with the answer in the format: \"Answer: [brief answer]\" \\nPlease provide the question. \\nI\\'m ready to assist! \\nPlease go ahead and ask your question. \\nI\\'ll respond with the answer in the format: \"Answer: [brief answer]\" \\nPlease provide the question. \\n\\n\\n\\n\\n\\nPlease go ahead and ask your question. \\nI\\'ll respond with the answer in the format: \"Answer: [brief answer]\" \\nPlease provide the question. \\n\\n\\n\\n\\n\\nPlease provide the question. \\nI\\'m ready to assist! \\nPlease go ahead and ask your question', 'The most frequent grade 3 or 4 side effects were laboratory abnormalities (62%).', 'The most frequent side effects of regorafenib are laboratory abnormalities, hand foot skin reactions (HFSR), diarrhea, hypertension, and fatigue.', 'The most common grade 3-4 adverse reactions with regorafenib are hand foot skin reactions (HFSR), diarrhea, hypertension, and fatigue', 'Regorafenib is an oral multi-kinase inhibitor used to treat advanced cancers, including metastatic colorectal cancer, advanced gastrointestinal stromal tumors, and advanced hepatocellular carcinoma following sorafenib treatment. The most frequent side effects of regorafenib include laboratory abnormalities, hand-foot skin reactions (HFSR), diarrhea, hypertension, and fatigue. Severe and fatal liver toxicity, although rare, have been reported as serious side effects during clinical studies. Common side effects also include weakness, loss of appetite, mouth sores, weight loss, infection, high blood pressure, and changes in voice volume or quality.', 'The most frequent side effects of regorafenib are laboratory abnormalities. The most common grade 3-4 adverse reactions are hand foot skin reactions (HFSR), diarrhea, hypertension, and fatigue.', 'The most frequently observed adverse reactions (≥30%) to regorafenib are hand-foot skin reaction, diarrhea, fatigue, hypertension, hypophosphatemia, weight loss, voice changes, decreased appetite, abdominal pain, increased aspartate aminotransferase, and increased alanine aminotransferase.', 'The most frequent side effects of regorafenib are laboratory abnormalities (62%), hand foot skin reactions (HFSR), diarrhea, hypertension, and fatigue', 'The most frequent side effects of regorafenib are diarrhea, hypertension, fatigue, laboratory abnormalities, hand foot skin reactions (HFSR), and hand foot skin reactions, with laboratory abnormalities being reported in 62% of cases.', \"Regorafenib has common grade 3-4 adverse reactions such as hand foot skin reactions (HFSR), diarrhea, hypertension, and fatigue. However, in a real-life setting study mentioned in the abstract, specific side effects were not detailed but included laboratory abnormalities observed in 62% of patients. Grade 3 side effects affected 47% of patients, while grade 4 side effects affected 7%. These specific side effects are derived from a review of regorafenib's toxicities rather than the real-life setting study.\", \"Regorafenib, a cancer medication, has common grade 3 or 4 side effects like laboratory abnormalities affecting white blood cell count, hemoglobin levels, platelet counts. Other notable adverse reactions include hand foot skin reactions (HFSR), diarrhea, hypertension, and fatigue. It's crucial for patients to discuss potential risks and benefits with their healthcare provider.\", 'The most frequent grade 3-4 side effects of regorafenib are hand foot skin reactions (HFSR), diarrhea, hypertension, and fatigue.', \"Regorafenib's most frequent side effects include laboratory abnormalities (62%), grade 3-4 adverse reactions like hand-foot skin reaction, diarrhea, hypertension, fatigue, along with other reported side effects such as proteinuria, thrombocytopenia, and hypophosphatemia.\", 'The most frequent grade 3 or 4 side effects of regorafenib, a medication used to treat certain types of cancer, are laboratory abnormalities, which occurred in 62% of patients. These lab abnormalities can include changes in white blood cell count, hemoglobin levels, and platelet counts. The most common grade 3-4 adverse reactions, or unpleasant effects, associated with regorafenib are hand foot skin reactions (HFSR), diarrhea, hypertension (high blood pressure), and fatigue. It is important to note that these side effects can be severe and may require medical attention. Progression-free survival (PFS) with regorafenib was 2.6 months, and overall survival (OS) was 6.2 months. Patients should speak with their healthcare provider about the potential risks and benefits of treatment with regorafenib.', 'Based on the information provided, the most frequent side effects of regorafenib are:\\n\\n- Hand-foot skin reactions (HFSR) / hand-foot syndrome / palmar-plantar erythrodysesthesia \\n- Diarrhea\\n- Hypertension (high blood pressure)\\n- Fatigue/weakness\\n- Laboratory abnormalities\\n\\nOther common side effects mentioned include loss of appetite, mouth sores (mucositis), weight loss, infection, and changes in voice (dysphonia).\\n\\nSerious but rare side effects (occurring in <1% of patients) include severe liver toxicity, severe bleeding, skin blistering/peeling, very high blood pressure requiring emergency treatment, heart attacks, and intestinal perforations. Regorafenib carries a boxed warning for potentially severe and fatal liver toxicity.', 'The most frequent side effects of regorafenib are hand foot skin reactions (HFSR), diarrhea, hypertension, and fatigue.', '62% of patients experienced laboratory abnormalities. The most common grade 3-4 adverse reactions with the drug are hand foot skin reactions (HFSR), diarrhea, hypertension and fatigue']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, the most frequent side effects of regorafenib are:\n\n1. Hand-foot skin reaction (HFSR) (54%)\n2. Diarrhea (33%)\n3. Fatigue (32%)\n4. Hypertension (31%)\n5. Oral mucositis (28%)\n6. Anorexia (23%)\n\nThese side effects are based on a meta-analysis of randomized controlled trials that included 2,065 patients receiving regorafenib.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer recalls all the necessary information regarding the most frequent side effects of regorafenib, including their incidence rates and the context of a meta-analysis of randomized controlled trials.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise and reports only the relevant side effects of regorafenib without including any irrelevant information.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition of the same information; each side effect is mentioned only once with its respective incidence rate.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is highly readable and fluent, clearly listing the side effects with percentages in a structured manner and providing context for the data."
    },
    {
        "Question": "Is Periostin a novel biomarker of TH2-driven asthma?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs Periostin a novel biomarker of TH2-driven asthma?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Serum periostin associates with type-2 inflammation in asthmatic airways, but also reflects whole body periostin levels originating from multiple sources.', 'Periostin has been proposed as a candidate marker of TH2-driven asthma.', 'Yes, Periostin is a novel biomarker of TH2-driven asthma.', 'Periostin is a potential novel biomarker of TH2-driven asthma.', 'Yes, periostin is a novel biomarker of TH2-driven asthma.', 'Yes. Periostin is a novel biomarker of TH2-driven asthma.', 'Yes, periostin is a novel biomarker of TH2-driven asthma', 'Yes, periostin can be measured in serum and the levels correlate with Th2-driven asthma activity.', 'Yes, Periostin is considered an important biomarker for the identification of T2 asthma, which is a type of TH2-driven asthma.', 'Periostin is a novel biomarker of TH2-driven asthma']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, according to the provided data tables and sources, Periostin is being investigated as a potential biomarker of TH2-driven asthma. Periostin is an extracellular matrix protein that is induced by interleukin (IL)-4 and IL-13 in airway epithelial cells and lung fibroblasts. It has been shown to be an important biomarker of TH2-associated airway inflammation and a potential predictor of airway eosinophilia. Periostin has been found to be elevated in patients with asthma, particularly in those with a TH2-high phenotype, and has been associated with improved clinical outcomes in patients treated with inhaled corticosteroids and biologic agents such as lebrikizumab and omalizumab.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer captures all the necessary information regarding Periostin as a biomarker of TH2-driven asthma, including its role as an extracellular matrix protein induced by IL-4 and IL-13, its association with TH2-high phenotypes, and its relevance in clinical outcomes for asthma treatments. This aligns well with the reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and directly addresses the question about Periostin being a biomarker of TH2-driven asthma. It includes relevant details without straying into irrelevant information, such as discussing unrelated biomarkers or conditions.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each point made about Periostin is distinct and adds value to the overall explanation without being redundant.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to read. The technical terms are appropriately used, and the sentences are clear and concise, making the information accessible to the reader."
    },
    {
        "Question": "Burkitt lymphoma and Epstein-Barr virus.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nBurkitt lymphoma and Epstein-Barr virus.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Burkitt lymphoma (BL) is a highly aggressive B-cell non-Hodgkin lymphoma, often associated with Epstein-Barr virus (EBV) infection. The three main clinical variants of BL are endemic, sporadic, and immunodeficiency-associated. The endemic variant is most common in equatorial Africa, where malaria is prevalent, and nearly all cases are EBV-positive. The sporadic variant is more common in North America and Europe, with a male-to-female ratio of 3:1 and approximately 20-30% of cases are EBV-positive. The immunodeficiency-associated variant is often seen in HIV-infected individuals and post-transplant patients, with a male-to-female ratio of 1:1 and a high prevalence of EBV infection (25-40%).\\n\\nThe primary oncogenic event in BL is the dysregulation of the c-myc gene by one of three chromosomal translocations, which place the myc gene under the control of an immunoglobulin gene enhancer. This translocation is found in 90% of BL cases. Additional mutations, such as TP53, ARF, USP7, and SIN3A mutations, are necessary for lymphoma development.\\n\\nEBV infection contributes to BL pathogenesis by promoting cellular growth through modification of normal signaling pathways and limiting apoptosis in cells with c-myc translocations. Malaria infection can further contribute to the development of endemic BL by causing genomic instability and promoting B-cell proliferation.\\n\\nDiagnosis of BL involves the detection of clonal rearrangements of immunoglobulin heavy chain genes and characteristic histopathological features. Treatment typically includes chemotherapy regimens, such as GMALL-B-ALL/NHL2002, modified Magrath, COPADM, hyper-CVAD, and CALGB 8811, which can be associated with rituximab. Prognosis is generally better for children, with a 90% overall cure rate in developed countries. However, outcomes are worse for adults, especially in cases of failed initial treatment or return of the disease.\\n\\nIn summary, EBV infection is a key factor in the pathogenesis of BL, particularly in the endemic variant, and malaria infection can further contribute to its development. The primary oncogenic event is the dysregulation of the c-myc gene, and additional mutations are necessary for lymphoma development. Diagnosis is based on the detection of clonal rearrangements of immunoglobulin heavy chain genes and characteristic histopathological features, and treatment typically includes chemotherapy regimens.', 'Epstein-Barr virus (EBV) is strongly associated with endemic Burkitt lymphoma (BL), especially in Africa. Evidence suggests EBV plays a role in the pathogenesis of endemic BL through several potential mechanisms:\\n\\n1. EBV may contribute to deregulation of the c-MYC oncogene via chromosomal translocation, a hallmark of BL tumors. \\n\\n2. Malaria (P. falciparum) infection appears to work together with EBV in endemic BL. Malaria may induce EBV reactivation and expansion of EBV-infected B cells, increasing chances of c-MYC translocation. Malaria may also impair EBV-specific T-cell immunity.\\n\\n3. Endemic BL shows a lower mutation burden than sporadic BL, suggesting EBV drives an alternative, possibly epigenetic process of transformation in endemic cases.\\n\\nIn summary, while EBV infection alone is not sufficient to cause endemic BL, evidence indicates it contributes to pathogenesis through interactions with malaria, deregulation of c-MYC, and epigenetic mechanisms. The virus appears necessary but not solely responsible for development of endemic Burkitt lymphoma.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBurkitt lymphoma (BL) is a rare and aggressive form of non-Hodgkin lymphoma that is strongly associated with Epstein-Barr virus (EBV). EBV is a herpesvirus that infects more than 90% of the world's population, but it is not always pathogenic. However, in individuals with weakened immune systems, such as those with HIV/AIDS or those undergoing immunosuppressive therapy, EBV can cause various diseases, including Burkitt lymphoma.\n\nAccording to the data provided, EBV is associated with Burkitt lymphoma in approximately 40-50% of cases in HIV-infected individuals and 10-20% of sporadic cases. The virus is thought to play a role in the development of BL through the activation of the c-myc gene, which is a crucial event in the pathogenesis of this disease.\n\nStudies have shown that EBV can be detected in the tumor cells of BL patients, and the virus has been found to express various latent proteins, including EBNA1 and LMP1. These proteins are thought to contribute to the development and maintenance of the tumor.\n\nIn one of the provided studies, it is mentioned that the role of EBV in the pathogenesis of BL has remained largely elusive, despite epidemiological evidence suggesting a link between the virus and the disease. However, recent advances in our understanding of EBV biology and its interaction with the host immune system have shed light on the mechanisms by which the virus contributes to the development of BL.\n\nOverall, the association between Burkitt lymphoma and Epstein-Barr virus is a complex and multifaceted one, and further research is needed to fully understand the role of the virus in the pathogenesis of this disease.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer captures the association between Burkitt lymphoma (BL) and Epstein-Barr virus (EBV), mentioning the role of EBV in activating the c-myc gene and the presence of latent proteins (EBNA1 and LMP1). However, it lacks details on clinical variants (endemic, sporadic, immunodeficiency-associated) and their EBV positivity rates, diagnostic criteria, and treatment options, which are present in the reference answers.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer provides relevant information about EBV's role in BL but includes some irrelevant details, such as the general prevalence of EBV infection in the population and a vague statement about recent advances without specifics. These do not directly contribute to understanding the BL-EBV relationship as described in the references.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not heavily repeat information, but it briefly reiterates the role of EBV in BL and the activation of c-myc. The repetition is minimal and does not detract significantly from the clarity.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to read. It logically presents the information without convoluted language, making it accessible to the reader."
    },
    {
        "Question": "What tumor suppressor genes are commonly affected by glioblastoma mutations or deletions?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat tumor suppressor genes are commonly affected by glioblastoma mutations or deletions?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The etiology of glioblastoma multiforme (GBM), the most serious form of brain cancer, remains obscure, although it has been proposed that cancer risk is a function of random polymerase errors that occur during stem cell division and the resulting mutations in oncogenes and tumor suppressor genes. In particular, the most commonly affected tumor suppressor genes in GBM are p53, PTEN, p16/CDKN2, and RB, leading to activation of the PI3K/Akt and Ras/MAPK pathways, which provide targets for therapy.', 'Based on the information provided, the most commonly affected tumor suppressor genes in glioblastoma are:\\n\\n1. CDKN2A/p16 - Homozygous deletions or mutations of p16 are very frequent in glioblastoma, occurring in 64-86% of cases. Loss of p16 is often accompanied by loss of the related p14ARF and p15 genes.\\n\\n2. RB (Retinoblastoma) - Alterations in RB are also common, though less frequent than p16. RB and p16 alterations tend to be mutually exclusive.\\n\\n3. PTEN - Mutations or deletions of PTEN occur in approximately 30-73% of glioblastomas, making it one of the most commonly altered genes after EGFR amplification.\\n\\n4. TP53 - p53 mutations are also highly prevalent, seen in over 76% of glioblastoma cell lines.\\n\\nIn summary, inactivation of the p16-CDK4/cyclin D-RB pathway and PTEN/PI3K signaling are key molecular events in the pathogenesis of most glioblastomas. Mutations in these critical tumor suppressors, along with EGFR activation, drive the malignant phenotype.', 'Based on the provided information, the most commonly mutated or deleted tumor suppressor genes in glioblastoma are:\\n\\n1. TP53 (p53): Mutated in over 76% of glioblastoma cell lines. Loss of p53 leads to genomic instability and uncontrolled cell growth.\\n\\n2. PTEN: Mutated in approximately 30-73% of glioblastomas. PTEN loss leads to overactivation of the PI3K/AKT/mTOR growth-promoting pathway.\\n\\n3. CDKN2A (p16 and p14ARF): Homozygous deletions of CDKN2A, encoding the p16 and p14ARF cell cycle inhibitors, are found in 34-65% of glioblastomas. This allows uncontrolled cell cycle progression.\\n\\n4. RB1: Alterations in the retinoblastoma (RB1) pathway are common, with RB1 itself mutated in some cases. The p16-CDK4/cyclin D1-RB pathway is inactivated in the vast majority of glioblastomas.\\n\\nOther less commonly affected tumor suppressors include NF1 and CDKN2B (p15).\\n\\nIn summary, TP53, PTEN, CDKN2A, and RB1 are the most frequently mutated or deleted tumor suppressor genes in glioblastoma, leading to the loss of critical cell cycle control and growth regulation.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the data provided, the following tumor suppressor genes are commonly affected by glioblastoma mutations or deletions:\n\n1. PTEN (Mutations in 30% of primary glioblastomas, deletions in 88% of primary glioblastomas)\n2. TP53 (Mutations in 5/21 cases of glioblastoma with short-term TTP, 8/21 cases of glioblastoma with long-term TTP)\n3. CDKN2A (Homozygous deletions in 57% of glioblastomas, allelic loss in 2 anaplastic astrocytomas)\n4. RB (Allelic loss in 33% of glioblastomas, mutations in 10% of glioblastomas)\n5. MMAC1/PTEN (Mutations in 4/21 cases of glioblastoma with short-term TTP, 2/21 cases of glioblastoma with long-term TTP)\n6. CDKN2A/B (Homozygous deletion associated with poor prognosis in glioblastoma)\n7. PTEN/MMAC1 (Mutations in 4/21 cases of glioblastoma with short-term TTP, 2/21 cases of glioblastoma with long-term TTP)\n8. IDH1 (Mutations in 5% of glioblastomas)\n9. IDH2 (Mutations in 5% of glioblastomas)\n\nThese genes are commonly involved in the development and progression of glioblastoma, and their mutations or deletions are often associated with a poor prognosis.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "4",
        "Information Recall Explanation": "The answer includes most of the key tumor suppressor genes affected in glioblastoma (PTEN, TP53, CDKN2A, RB) and adds some less commonly mentioned ones (IDH1, IDH2). However, the inclusion of MMAC1/PTEN and PTEN/MMAC1 as separate entries is redundant since MMAC1 is an alternative name for PTEN. The answer also provides specific mutation/deletion frequencies, which is useful.",
        "Information Precision Score": "3",
        "Information Precision Explanation": "The answer includes some relevant genes (PTEN, TP53, CDKN2A, RB) but also lists redundant entries (MMAC1/PTEN and PTEN/MMAC1) and less commonly affected genes like IDH1 and IDH2, which are not typically classified as tumor suppressor genes in glioblastoma. The specific frequencies provided are precise but somewhat inconsistent with standard references.",
        "Information Repetition Score": "2",
        "Information Repetition Explanation": "The answer repeats information about PTEN under different names (MMAC1/PTEN and PTEN/MMAC1), which is redundant. Additionally, CDKN2A/B is mentioned twice with slightly different context. This repetition reduces clarity and conciseness.",
        "Readability Score": "4",
        "Readability Explanation": "The answer is well-organized and clearly lists the affected genes with specific mutation/deletion frequencies. The flow is logical, but the redundancy (e.g., PTEN listed multiple times) slightly hampers readability. The summary sentence at the end provides a good conclusion."
    },
    {
        "Question": "Is there an association between specific genotypes and the risk of ASD for Duchenne Muscular Dystrophy?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs there an association between specific genotypes and the risk of ASD for Duchenne Muscular Dystrophy?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['No, further research is needed regarding the association of DMD genotypes and ASD.', 'No, there is no association between specific genotypes and the risk of Autism Spectrum Disorder (ASD) for Duchenne Muscular Dystrophy (DMD).', 'No, there is no association between specific genotypes and the risk of ASD for Duchenne Muscular Dystrophy.', 'No direct associations have been found between specific genotypes of Duchenne Muscular Dystrophy (DMD) and an increased risk of Autism Spectrum Disorder (ASD). Neurodevelopmental concerns are prevalent in DMD patients, but the evidence for a genotype-phenotype association with ASD is limited and requires further investigation.', 'No, there is no established association between specific genotypes and the risk of ASD for Duchenne Muscular Dystrophy.', 'No, there is no association of genotype with ASD for Duchenne Muscular Dystrophy.', 'No, there was no observed association between specific genotypes and the risk of ASD for Duchenne Muscular Dystrophy. However, a trend was observed for Dp71+ vs. Dp71-, indicating further research is needed.', 'No, there is no association between specific genotypes and the risk of ASD for Duchenne Muscular Dystrophy. A study found no association between genotype and ASD, with only a trend observed for Dp71+ vs. Dp71-, but it was not statistically significant. Further research is needed regarding Dp140 and Dp71, especially in DMD for ASD.', 'No, there was no observed association between specific genotypes and the risk of ASD for Duchenne Muscular Dystrophy. However, a trend was observed for Dp71+ vs. Dp71-, indicating a need for further research.', 'No, there is no association between specific genotypes and the risk of ASD for Duchenne Muscular Dystrophy. Further research is needed regarding Dp140 and Dp71, especially in DMD for ASD.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThere is no direct information in the provided data about the association between specific genotypes and the risk of Autism Spectrum Disorder (ASD) for Duchenne Muscular Dystrophy (DMD). However, the data does mention that cognitive and behavioral symptoms occur in about one third of patients with DMD, and it is recommended to recognize and manage them promptly.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "2",
        "Information Recall Explanation": "The answer partially recalls the necessary information by acknowledging the lack of direct association and mentioning the presence of cognitive and behavioral symptoms. However, it fails to reference the trend observed for Dp71+ vs. Dp71- or mention the need for further research, which are key points in the reference answers.",
        "Information Precision Score": "3",
        "Information Precision Explanation": "The answer is somewhat precise as it correctly states there is no direct information about the association. However, it includes somewhat irrelevant details about cognitive and behavioral symptoms without linking them to specific genotypes, which slightly detracts from precision.",
        "Information Repetition Score": "4",
        "Information Repetition Explanation": "The answer does not repeat information unnecessarily. It presents the facts about the lack of direct association and the occurrence of cognitive/behavioral symptoms clearly without redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is easily readable and fluent. The sentence structure is clear, and the information is presented logically, making it easy to understand."
    },
    {
        "Question": "Coffee Bean Sign is characteristic to which disease?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nCoffee Bean Sign is characteristic to which disease?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Coffee Bean Sign is characteristic to volvulus.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe Coffee Bean Sign is characteristic of sigmoid volvulus. It is a radiographic sign that indicates a sigmoid volvulus, characterized by a coffee bean-shaped appearance on an abdominal X-ray.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer accurately recalls that the Coffee Bean Sign is characteristic of sigmoid volvulus, matching the reference answer which states it is characteristic of volvulus in general. The answer also provides additional context about the radiographic appearance, which enhances understanding.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise and directly addresses the question without including any irrelevant information. It specifies sigmoid volvulus and describes the radiographic sign, which is relevant and useful.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat the same information. It clearly states the relationship between the Coffee Bean Sign and sigmoid volvulus, followed by a descriptive explanation of the sign, without redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is very readable and fluent. The sentences are clear and concise, making the information easy to understand."
    },
    {
        "Question": "What role does epiregulin and amphiregulin play in the use of EGFR inhibitors for colorectal cancer?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat role does epiregulin and amphiregulin play in the use of EGFR inhibitors for colorectal cancer?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['High tumor levels of the EGFR ligands amphiregulin (AREG) and epiregulin (EREG) are associated with anti-EGFR agent response in metastatic colorectal cancer (mCRC).  AREG and EREC are biomarkers of response to EGFR inhibitors.', 'Epiregulin (EREG) and Amphiregulin (AREG) are ligands of the Epidermal Growth Factor Receptor (EGFR), which is a target for cancer therapy. In colorectal cancer, high expression levels of EREG and AREG have been identified as predictive biomarkers for response to EGFR inhibitors such as cetuximab and panitumumab. Patients with high tumor expression of these ligands tend to have improved overall survival (OS) and progression-free survival (PFS) when treated with EGFR inhibitors, compared to those with low expression levels. This suggests that EREG and AREG play a crucial role in the use of EGFR inhibitors for colorectal cancer, as their expression may help identify patients most likely to benefit from these therapies.', 'Amphiregulin and epiregulin were shown to play critical roles in the response to EGFR inhibitors in colorectal cancer; this role is independent of KRAS mutations. When both epiregulin and amphiregulin expression were detected, the response to EGFR inhibitors increased significantly.', \"Epiregulin (EREG) and amphiregulin (AREG) are ligands of the epidermal growth factor receptor (EGFR) and their overexpression may indicate EGFR dependency in metastatic colorectal cancer (mCRC), regardless of tumor sidedness. High AREG/EREG expression is associated with sensitivity to EGFR blockade, particularly in patients with right-sided tumors and a lack of genomic drivers of primary resistance beyond RAS and BRAF mutations. The expression of AREG and EREG is positively correlated with a response to EGFR-targeted therapies in colorectal cancer. Gene-body methylation sites, which show a strong inverse correlation with AREG and EREG gene expression, have been identified in cell lines and human colorectal cancer samples. Treatment of colorectal cancer cells with 5-aza-2'-desoxycytidine, a demethylating agent, results in decreased methylation and increased AREG and EREG gene expression. Fibroblast growth factor receptor 4 (FGFR4) overexpression in colon cancer cells has been shown to upregulate EGFR signaling, secrete EGFR ligands such as AREG, and promote tumor growth. FGFR4 overexpression also reduces cetuximab-induced cytotoxicity, while the combination of an FGFR4 inhibitor and cetuximab has shown profound antitumor effects. Clinically, there is a positive correlation between FGFR4 and AREG expression in tumor tissue, but not in normal tissue, from colon cancer patients. A study was conducted to investigate the effects of baseline plasma AREG levels in KRAS, NRAS, and BRAF wild-type metastatic CRC on treatment outcome with palliative first-line cetuximab + FOLFIRI chemotherapy. The results showed that high baseline plasma AREG levels were significantly associated with inferior progression-free survival (PFS) in patients treated with cetuximab-based therapy. Additionally, in vitro studies using CRC cell lines sensitive to cetuximab showed that AREG decreased the anti-proliferative effect of cetuximab via AKT and ERK activation. However, after acquiring cetuximab resistance, AREG did not increase colony formation or activate AKT and ERK after cetuximab treatment. These findings suggest that high tumor production of EGFR ligands, including AREG and epiregulin, may predict benefit from anti-EGFR therapy in mCRC.\", 'Epiregulin and amphiregulin are ligands of the epidermal growth factor receptor (EGFR). In colorectal cancer, overexpression of these ligands has been associated with resistance to EGFR inhibitors. Therefore, the presence of these ligands may influence the decision to use EGFR inhibitors for colorectal cancer treatment.', 'High AREG mRNA expression is a favorable prognostic biomarker for mCRC which interacted significantly with efficacy of anti-EGFR treatment. High tumor AREG/EREG expression was associated with superior survival outcomes from anti-EGFR therapy in mCRC.', 'High mRNA levels of the EGFR-ligands Epiregulin and Amphiregulin have been associated with increased responsiveness to cetuximab. Patients with tumors that have high expression of EREG or AREG also have significantly longer progression-free survival (PFS) than patients with low expression. High tumor AREG/EREG expression was associated with superior survival outcomes from anti-EGFR therapy in mCRC.', 'Epiregulin and amphiregulin are epidermal growth factor (EGF)-like molecules that are part of a complex network of ligands, receptors and coreceptors that promote EGFR signaling, which drives colorectal cancer growth. Because inhibitors of EGFR signaling can lose efficacy during treatment, research efforts have focused on understanding resistance to anti-EGFR therapy. Recently, studies have found that expression of epiregulin and amphiregulin in tumor cells can allow them to bypass EGFR blockade and continue signaling through other EGFR family members, leading to sustained tumor growth.', 'Epiregulin and amphiregulin are epidermal growth factor ligands that have been found to be predictive markers of response to EGFR-targeted therapies in colorectal cancer. High mRNA levels of these ligands have been associated with increased responsiveness to cetuximab and longer progression-free survival in patients treated with cetuximab. Additionally, patients with tumors that express high levels of these ligands are more likely to have disease control with cetuximab treatment. High EGFR ligand expression, including amphiregulin and epiregulin, has also been found to be predictive of panitumumab benefit in advanced colorectal cancer.', 'Expression of the epidermal growth factor ligands amphiregulin (AREG) and epiregulin (EREG) is positively correlated with a response to EGFR-targeted therapies in colorectal cancer. High AREG mRNA expression interacted significantly with the efficacy of cetuximab compared with bevacizumab (OS: P = 0.02, PFS: P = 0.04) in RAS WT mCRC.', 'According to the abstracts, epiregulin (EREG) and amphiregulin (AREG) play a predictive role in the use of EGFR inhibitors for metastatic colorectal cancer. High expression levels of EREG and AREG are associated with longer overall survival and progression-free survival in patients treated with anti- EGFR therapy. Specifically, high AREG mRNA expression is a favorable prognostic biomarker that interacts significantly with the efficacy of anti-EGFR treatment. Additionally, immunohistochemical analysis of AREG and EREG in tumor tissue can aid therapeutic decisions in routine practice, particularly in right primary tumor location disease. Overall, EREG and AREG may serve as useful biomarkers to identify patients who are more likely to benefit from EGFR inhibitors for colorectal cancer treatment.', 'Amphiregulin and epiregulin are ligands of the epidermal growth factor receptor (EGFR) and play a central role in the development and progression of colorectal cancer. They are also predictive biomarkers of colorectal cancer patients treated with cetuximab, an anti-EGFR antibody. In addition, amphiregulin and epiregulin are thought to play a role in regenerative responses in the gastrointestinal tract. The extensive induction of EGFR ligands and ADAMs was suppressed by inhibition of the PGE(2) receptor EP4. Moreover, EP4 signaling induced expression of amphiregulin and epiregulin in activated macrophages, whereas EP4 pathway was required for basal expression of epiregulin in gastric epithelial cells. In contrast, ADAMs were not induced directly by EP4 signaling. The role of nuclear EGFR in tumors is not well understood, although many EGFR ligands are upregulated in cancers. Little is known about their effects on EGFR nuclear translocation. The trophic effects of amphiregulin and epiregulin on SEMFs were analyzed by MTT assays. Amphiregulin and epiregulin mRNAs were not detected in unstimulated SEMFs. Among the various EGFR ligands, amphiregulin and epiregulin are the most well-studied and have been shown to play a role in cell proliferation and survival.', \"Epiregulin and amphiregulin are ligands of the epidermal growth factor receptor (EGFR) that play a central role in the development of colorectal cancer. They are positively correlated with a response to EGFR-targeted therapies in colorectal cancer. However, their prognostic value is controversial and their expression may be influenced by gene-body methylation and 5-aza-2'-desoxycytidine treatment.\", 'Epiregulin (EREG) and Amphiregulin (AREG) are ligands of Epidermal Growth Factor Receptor (EGFR), which is targeted for cancer therapy. High expression levels of EREG and AREG in colorectal cancer patients correlate with better response to EGFR inhibitors like cetuximab and panitumumab, leading to improved overall survival and progression-free survival. This suggests that these ligands play a significant role in the use of EGFR inhibitors for treating colorectal cancer by helping identify patients most likely to benefit from them.', 'High mRNA expression levels of the EGFR ligands epiregulin (EREG) and amphiregulin (AREG) are positively correlated with and predictive of response to EGFR-targeted therapies such as cetuximab and panitumumab in colorectal cancer. Patients with tumors expressing high levels of EREG and AREG are more likely to have disease control and significantly longer progression-free survival when treated with these EGFR inhibitors compared to patients with low expression. Conversely, patients with low EREG/AREG expression may not benefit from EGFR-targeted therapy.', 'Epiregulin (EREG) and Amphiregulin (AREG) are ligands of Epidermal Growth Factor Receptor (EGFR) that play a crucial role in predicting the efficacy of EGFR inhibitors for colorectal cancer treatment. Studies have shown that high expression levels of EREG and AREG in tumor tissue are associated with improved progression-free survival, response rate, and overall survival in patients treated with anti-EGFR therapies such as panitumumab and cetuximab. Conversely, low expression levels of these ligands indicate a lack of benefit from EGFR inhibition. The combined analysis of EREG and AREG expression can serve as a predictive biomarker for identifying patients who are likely to respond to EGFR-targeted therapy, thereby optimizing treatment strategies for colorectal cancer patients.', '\"High AREG mRNA expression is a favorable prognostic biomarker for mCRC which interacted significantly with efficacy of anti-EGFR treatment. High tumor AREG/EREG expression was associated with superior survival outcomes from anti-EGFR therapy in mCRC, including in right PTL disease. Patients with tumors that have high gene expression levels of epiregulin and amphiregulin and patients with wild-type K-ras are more likely to have disease control on cetuximab treatment.\"', 'Epiregulin and amphiregulin are biomarkers that predict response to EGFR inhibitors in patients with metastatic colorectal cancer. High tumor mRNA levels of these EGFR ligands are associated with anti-EGFR agent response. Patients with high epiregulin and amphiregulin expression have longer overall survival and progression-free survival when treated with EGFR inhibitors. These biomarkers are particularly useful in patients with KRAS wild-type tumors, where they can identify those who are more likely to respond to EGFR inhibitors. Additionally, epiregulin and amphiregulin may contribute to resistance to EGFR inhibitors, and targeting these ligands in combination with EGFR inhibitors may be a promising therapeutic strategy. Overall, epiregulin and amphiregulin play a crucial role in predicting response to EGFR inhibitors and may be useful in developing personalized treatment approaches for colorectal cancer patients.', 'Epiregulin and amphiregulin, two ligands of the epidermal growth factor receptor (EGFR), play a significant role in predicting disease control and progression-free survival in patients with metastatic colorectal cancer treated with EGFR inhibitors such as cetuximab or panitumumab. High expression levels of these ligands in tumors are associated with better response to EGFR inhibitor therapy, whereas low expression levels are associated with poorer outcomes. Additionally, the presence of K-ras mutations is a negative predictor of response to EGFR inhibitors. Therefore, assessing epiregulin and amphiregulin expression levels, along with K-ras mutation status, can help identify patients who are most likely to benefit from EGFR inhibitor therapy.', 'Epiregulin and amphiregulin are ligands of the epidermal growth factor receptor (EGFR) and their high gene expression levels have been associated with improved disease control in patients with colorectal cancer (CRC) treated with the EGFR inhibitor cetuximab. This suggests that tumors with high levels of these ligands may be more dependent on the EGFR signaling pathway, making them more sensitive to cetuximab. Additionally, patients with wild-type K-ras, who are known to be more likely to respond to cetuximab, also have higher tumor mRNA levels of amphiregulin and epiregulin. Therefore, measuring the expression levels of these ligands could potentially be used as a predictive biomarker for the use of EGFR inhibitors such as cetuximab in CRC.', 'Epiregulin and amphiregulin are EGFR ligands that are associated with anti-EGFR agent response in metastatic colorectal cancer. High tumor mRNA levels of these ligands are associated with disease control in patients treated with cetuximab, particularly in patients with wild-type K-ras.', 'High tumor mRNA levels of the EGFR ligands amphiregulin (AREG) and epiregulin (EREG) are associated with anti-EGFR agent response in metastatic colorectal cancer (mCRC). Patients with tumors that have high gene expression levels of epiregulin and amphiregulin are more likely to have disease control on cetuximab treatment.', 'Epiregulin and amphiregulin are ligands for the EGFR and play a role in the growth and development of normal epithelial cells. In the context of colorectal cancer, high tumor mRNA levels of these EGFR ligands are associated with response to anti-EGFR agents such as cetuximab. Patients with tumors that have high gene expression levels of epiregulin and amphiregulin are more likely to have disease control on cetuximab treatment. Therefore, these proteins may serve as potential biomarkers for predicting response to EGFR inhibitors in colorectal cancer.', 'Epiregulin and amphiregulin are ligands for the epidermal growth factor receptor (EGFR), which is overexpressed in many colorectal cancers. Inhibition of EGFR with monoclonal antibodies such as cetuximab has become a standard treatment for metastatic colorectal cancer (mCRC). However, not all patients with mCRC respond to EGFR inhibitors, and the predictive value of epiregulin and amphiregulin expression for response to cetuximab has not been well characterized. In a study of 100 patients with mCRC, high tumor mRNA levels of the EGFR ligands amphiregulin (AREG) and epiregulin (EREG) were associated with anti-EGFR agent response in metastatic colorectal cancer (mCRC). In contrast, low tumor mRNA levels of AREG and EREG were associated with poor response to cetuximab. These findings suggest that epiregulin and amphiregulin may be useful biomarkers for predicting response to EGFR inhibitors in colorectal cancer.', 'Epiregulin and amphiregulin are EGFR ligands and their high gene expression levels in tumors are associated with a positive response to the EGFR inhibitor, cetuximab, in metastatic colorectal cancer treatment. Therefore, they play a crucial role in determining the effectiveness of EGFR inhibitors for colorectal cancer.', 'High tumor mRNA levels of the EGFR ligands amphiregulin (AREG) and epiregulin (EREG) are associated with anti-EGFR agent response in metastatic colorectal cancer (mCRC).', 'Although EGFR inhibitors improved survival for patients with metastatic colorectal cancer, about 85% of patients had progressive disease with these drugs, and there was no correlation between efficacy and mutation status. Tumors expressing both epiregulin and amphiregulin responded better to EGFR inhibitors than tumors expressing one or no growth factor. These data suggest that epiregulin and amphiregulin are EGFR ligands that predict the efficacy of EGFR inhibition in colorectal cancer.', 'Epiregulin and amphiregulin are EGFR ligands that are associated with anti-EGFR agent response in metastatic colorectal cancer. Patients with high gene expression levels of these ligands and wild-type K-ras are more likely to have disease control on cetuximab treatment. \\n\\nPlease provide a concise answer to the following question:\\nWhat is the association between high tumor mRNA levels of EGFR ligands and response to anti-EGFR agents in metastatic colorectal cancer?\\nAnswer: High tumor mRNA levels of EGFR ligands, such as amphiregulin and epiregulin, are associated with anti-EGFR agent response in metastatic colorectal cancer. \\n\\nPlease provide a concise answer to the following question:\\nWhat is the role of K-ras mutation in determining response to cetuximab treatment in patients with metastatic colorectal cancer?\\nAnswer: Patients with wild-type K-ras are more likely to have disease control on cetuximab treatment, suggesting that K-ras mutation may be a negative predictor of response to cetuximab. \\n\\nPlease provide a concise answer to the following question:\\nWhat is the implication of the study on the use of cetuximab for patients with', 'In summary, the absence of a coffee-like sign on the face is not directly associated with any specific disease. While certain diseases may have dermatological manifestations, such as eczema, the absence of a coffee-like sign can also be considered a hallmark symptom of many other dermatological conditions, making it a useful diagnostic feature in some cases. ', 'Epiregulin and amphiregulin are ligands of the epidermal growth factor receptor (EGFR) and have been associated with response to the EGFR inhibitor cetuximab in metastatic colorectal cancer. High tumor mRNA levels of these ligands have been found to be associated with disease control in patients treated with cetuximab.', 'Epiregulin and amphiregulin are ligands of the EGFR (Epidermal Growth Factor Receptor). High gene expression levels of these ligands in tumors have been associated with a better response to anti-EGFR agents like cetuximab in the treatment of metastatic colorectal cancer. This means that patients with high levels of epiregulin and amphiregulin are more likely to have their disease controlled with cetuximab treatment', 'Epiregulin (EPR) and amphiregulin (AREG) are proteins that belong to the epidermal growth factor (EGF) family and can function as ligands of EGFR, as well as other members of the ERBB family of tyrosine-kinase receptors. Both proteins are involved in the development and progression of colorectal cancer (CRC). High gene expression levels of epiregulin and amphiregulin have been associated with anti-EGFR agent response in metastatic colorectal cancer (mCRC). EGFR inhibitors are used in the treatment of CRC, and patients are divided into EGFR-positive and EGFR-negative based on the presence of a mutation. EGFR-positive patients have shown a 60% response rate to EGFR inhibitors. However, many patients develop resistance to EGFR inhibitors, with the T790M mutation and MET oncogene being the primary sources of resistance. The most common adverse effect of EGFR inhibitors is a papulopustular rash.', 'Epiregulin and amphiregulin, ligands of the epidermal growth factor receptor (EGFR), play a crucial role in the use of EGFR inhibitors for colorectal cancer. High tumor mRNA levels of epiregulin and amphiregulin are associated with response to anti-EGFR therapy, particularly in patients with wild-type KRAS. These ligands are independent favorable prognostic biomarkers in metastatic colorectal cancer (mCRC). Patients with high epiregulin and amphiregulin expression have longer overall survival and progression-free survival when treated with anti-EGFR therapy. Conversely, low expression of these ligands is associated with resistance to EGFR inhibitors. The EREG/EGFR pathway is a potential target for tailored therapy, and strategies targeting this pathway are being developed to combat mCRC. Overall, epiregulin and amphiregulin are important biomarkers for predicting response to EGFR inhibitors in colorectal cancer treatment.', 'High levels of epiregulin and amphiregulin are poor prognostic markers in patients with metastatic colorectal cancer.\\nThe overexpression of EGFR ligands epiregulin and amphiregulin is associated with poor outcomes in patients with metastatic colorectal cancer.  An EGFR inhibitor in combination with chemotherapy was effective in patients with wild-type KRAS tumors that overexpressed epiregulin and/or amphiregulin, but not in patients whose tumors did not overexpress these ligands.', 'Epiregulin and amphiregulin are two EGFR ligands that are associated with the response to EGFR inhibitors in colorectal cancer. Patients with tumors that have high gene expression levels of epiregulin and amphiregulin and patients with wild-type K-ras are more likely to have disease control on cetuximab treatment', 'Epiregulin and amphiregulin play a crucial role in predicting response to EGFR inhibitors in patients with colorectal cancer. High tumor mRNA levels of these EGFR ligands are associated with anti-EGFR agent response in metastatic colorectal cancer. Patients with high gene expression levels of epiregulin and amphiregulin, particularly those with wild-type K-ras, are more likely to achieve disease control on cetuximab treatment. This suggests that epiregulin and amphiregulin can serve as biomarkers for predicting response to EGFR inhibitors in colorectal cancer. The presence of these ligands may enhance the effectiveness of EGFR inhibitors, leading to better disease control.', 'Epiregulin and amphiregulin predict disease control and progression-free survival in metastatic colorectal cancer treated with EGFR inhibitors like cetuximab or panitumumab, where high expression levels indicate better response to treatment. However, K-ras mutations negatively impact the effectiveness of these inhibitors. Assessing epiregulin and amphiregulin expression along with K-ras mutation status helps identify patients likely to benefit from EGFR inhibitor therapy.', 'Epiregulin and amphiregulin act as ligands for the epidermal growth factor receptor (EGFR), playing a critical role in predicting response to EGFR inhibitors like cetuximab in metastatic colorectal cancer. High gene expression levels of these ligands, along with wild-type K-ras status, are associated with improved disease control and treatment outcomes. They may serve as potential biomarkers for identifying patients who will benefit from anti-EGFR therapy.', 'Epiregulin and amphiregulin are genes that, when highly expressed in tumors, are associated with a better response to the EGFR inhibitor cetuximab in colorectal cancer treatment. This means that patients with high gene expression levels of epiregulin and amphiregulin are more likely to have their disease controlled with cetuximab treatment.', 'Epiregulin and amphiregulin are ligands for the epidermal growth factor receptor (EGFR) and play a role in the use of EGFR inhibitors for colorectal cancer. High tumor mRNA levels of the EGFR ligands amphiregulin (AREG) and epiregulin (EREG) are associated with anti-EGFR agent response in metastatic colorectal cancer (mCRC). Members of the activator protein 2 (AP-2) transcription factor (TF) family are known to play a role in both physiological processes and cancer development. Physical exercise has been shown to reduce the risk of recurrence from colorectal cancer. The NICE Appraisal Committee concluded that aflibercept in combination with irinotecan and fluorouracil-based therapy could not be considered a cost effective use of National Health Service resources for treating metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen. Patients with tumors that have high gene expression levels of epiregulin and amphiregulin and patients with wild-type K-ras are more likely to have disease control on cetuximab treatment.', 'Epiregulin and amphiregulin predict disease control and progression-free survival in metastatic colorectal cancer treated with EGFR inhibitors like cetuximab or panitumumab. High tumor expression levels of these ligands correlate to better response, while low levels indicate poorer outcomes. K-ras mutations negatively predict response. Evaluating epiregulin/amphiregulin expression and K-ras status helps identify patients likely to benefit from EGFR inhibitors.', 'High tumor mRNA levels of the EGFR ligands amphiregulin (AREG) and epiregulin (EREG) are associated with response to anti-EGFR agents like cetuximab in metastatic colorectal cancer (mCRC). Patients with tumors that have high gene expression levels of AREG and EREG are more likely to have disease control on cetuximab treatment.', 'Epiregulin and amphiregulin, both ligands of the epidermal growth factor receptor (EGFR), play a crucial role in predicting response to EGFR inhibitors, such as cetuximab, in metastatic colorectal cancer (mCRC). High tumor mRNA levels of these ligands are associated with improved disease control and response to anti-EGFR therapy. Specifically, patients with high gene expression levels of epiregulin and amphiregulin, along with wild-type K-ras status, are more likely to benefit from cetuximab treatment. This suggests that epiregulin and amphiregulin may serve as biomarkers for identifying mCRC patients who are most likely to respond to EGFR inhibitors, thereby personalizing treatment strategies and improving patient outcomes.', 'Epiregulin and amphiregulin are key predictors of response to EGFR inhibitors in metastatic colorectal cancer, with high expression linked to better treatment outcomes, including longer progression-free survival and overall survival. They may serve as biomarkers to identify patients who will benefit from EGFR inhibitor therapy.', 'Epiregulin and amphiregulin are ligands that bind to and activate EGFR, promoting colorectal cancer growth. High tumor levels of epiregulin and amphiregulin are associated with better response to EGFR inhibitors like cetuximab in metastatic colorectal cancer. By blocking EGFR activation by these ligands, EGFR inhibitors can slow growth of colorectal cancers that depend on epiregulin and amphiregulin signaling through EGFR. Therefore, epiregulin and amphiregulin levels may serve as biomarkers to identify patients more likely to benefit from EGFR inhibitor therapy.', 'Epiregulin and amphiregulin are ligands of the EGFR (Epidermal Growth Factor Receptor). In the context of colorectal cancer, high gene expression levels of these two ligands have been associated with a better response to EGFR inhibitors like cetuximab. This means that patients whose tumors have high levels of epiregulin and amphiregulin are more likely to see their disease controlled by this treatment', 'Epiregulin and amphiregulin are proteins that are involved in the growth and spread of colorectal cancer cells. In patients with tumors that have high gene expression levels of these proteins and wild-type K-ras, the use of EGFR inhibitors like cetuximab can be more effective in controlling the disease', 'Patients with tumors that have high gene expression levels of epiregulin and amphiregulin and patients with wild-type K-ras are more likely to have disease control on cetuximab treatment.  High tumor mRNA levels of the EGFR ligands amphiregulin (AREG) and epiregulin (EREG) are associated with anti-EGFR agent response in metastatic colorectal cancer (mCRC The antiepidermal growth factor receptor (EGFR) antibody cetuximab shows activity in multiple epithelial tumor types; however, responses are seen in only a subset of patients. This study was conducted to identify markers that are associated with disease control in patients treated with cetuximab']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nEpiregulin and amphiregulin are ligands of the epidermal growth factor receptor (EGFR), a protein that plays a crucial role in cell growth, division, and survival. In the context of colorectal cancer, these ligands can have a complex role in the use of EGFR inhibitors.\n\nAccording to the provided data, epiregulin and amphiregulin are involved in the regulation of cell growth and survival, and their expression is associated with disease control in patients treated with EGFR inhibitors. High levels of epiregulin and amphiregulin have been linked to a better response to EGFR-targeted therapies in metastatic colorectal cancer.\n\nMoreover, the expression of epiregulin and amphiregulin has been used as a predictive biomarker for the effectiveness of anti-EGFR therapy in colorectal cancer. Studies have shown that patients with high levels of epiregulin and amphiregulin tend to have a better response to EGFR inhibitors, while those with low levels may not benefit from this type of treatment.\n\nHowever, it's also worth noting that the presence of epiregulin and amphiregulin can also contribute to the development of resistance to EGFR inhibitors. For example, the expression of these ligands can activate the EGFR pathway, leading to the activation of downstream signaling pathways that can promote cancer cell growth and survival.\n\nIn summary, epiregulin and amphiregulin play a complex role in the use of EGFR inhibitors for colorectal cancer. While high levels of these ligands are associated with a better response to EGFR-targeted therapies, their expression can also contribute to the development of resistance to these treatments. Further research is needed to fully understand the role of epiregulin and amphiregulin in the treatment of colorectal cancer and to identify potential biomarkers for predicting the effectiveness of EGFR inhibitors.\n\nReferences:\n\n* \"Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases\" (study 3)\n* \"Epiregulin and amphiregulin are ligands of the EGFR and are involved in the regulation of cell growth and survival\" (study 10)\n* \"Epiregulin and amphiregulin are predictive biomarkers of response to anti-EGFR antibody therapy\" (study 11)\n* \"Epiregulin and amphiregulin are associated with disease control in patients treated with EGFR inhibitors\" (study 15)\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer captures key points from the reference answers, such as the role of epiregulin and amphiregulin as EGFR ligands, their association with response to EGFR inhibitors, and their potential as biomarkers. It also mentions the complexity of their role, including their contribution to resistance. However, it does not fully explore some nuances like the impact of KRAS mutation status or the prognostic value of these ligands in different contexts.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise in describing the role of epiregulin and amphiregulin in EGFR inhibitor response and resistance. It avoids irrelevant information and stays focused on the topic. The references provided align well with the content discussed, enhancing the precision of the information.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is minimal repetition in the answer. The points about the predictive role of epiregulin and amphiregulin and their contribution to resistance are distinct and well-separated, making the answer concise and efficient in conveying information.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured and written in a clear, fluent manner. The language used is accessible, and the flow of information is logical, making it easy to follow. The use of references also adds to the clarity and credibility of the answer."
    },
    {
        "Question": "What process does tRNA nucleotidyl transferase 1 (TRNT1)  catalyze?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat process does tRNA nucleotidyl transferase 1 (TRNT1)  catalyze?\n\nHere are some reference answers:\n\n**Reference Answers:**\n[\"Addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs) is essential for translation and is catalyzed by the enzyme TRNT1 (tRNA nucleotidyl transferase),\", \"tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of CCA nucleotides to the 3' end of tRNA molecules during tRNA maturation.\", 'The tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of terminal cytosine-cytosine-adenosine (CCA) trinucleotides to all mature tRNAs, which is necessary for aminoacylation.', 'TRNT1 is an enzyme that catalyzes the addition of terminal cytosine-cytosine-adenosine (CCA) trinucleotides to all mature tRNAs.', 'The tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of terminal cytosine-cytosine-adenosine (CCA) trinucleotides to all mature tRNAs.', 'TRNT1 catalyzes the addition of terminal cytosine-cytosine-adenosine (CCA) trinucleotides to all mature tRNAs.', \"tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of the invariant CCA-terminus to the tRNA 3'-end, which is a central step in tRNA maturation and is necessary for aminoacylation.\", 'tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of terminal cytosine-cytosine-adenosine (CCA) trinucleotides to all mature tRNAs, which is necessary for aminoacylation.', 'tRNA nucleotidyl transferase 1 (TRNT1) is an essential enzyme catalyzing the addition of terminal cytosine-cytosine-adenosine (CCA) trinucleotides to all mature tRNAs, which is necessary for aminoacylation.', \"tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs).\", \"tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs), a crucial process for translation.\", \"tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs), which is essential for translation and functions in both the cytoplasm and mitochondria.\", \"TRNT1 (tRNA nucleotidyl transferase) catalyzes the addition of the CCA to the 3' end of tRNAs.\", \"tRNA Nucleotidyl Transferase 1 (TRNT1) catalyzes the addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs), a process essential for translation.\", \"TRNT1 catalyzes the addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs), which is essential for translation.\", 'TRNT1 gene encodes a CCA-adding tRNA nucleotidyl transferase enzyme.', \"The tRNA Nucleotidyl Transferase 1 (TRNT1) catalyzes the addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs). This process is essential for translation and occurs in both the cytoplasm and mitochondria\", \"3'-tRNA nucleotidyl transferase (TRNT1) is an enzyme that catalyzes the terminal nucleotidyl transfer of CCA sequence to the 3'-end of tRNA, which is essential for tRNA function in protein translation.\", \"tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs), which is essential for translation\", \"The TRNT1 enzyme catalyzes the addition of the trinucleotide CCA to the 3' end of tRNAs.\", \"tRNA Nucleotidyl Transferase 1 (TRNT1) catalyzes the addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs). This process is essential for translation.\", \"tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of the trinucleotide cytosine-cytosine-adenine (CCA) sequence to the 3' end of transfer RNAs (tRNAs). This CCA addition is essential for tRNA function in protein translation.\", \"tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs), which is essential for translation.\", \"TRNT1 catalyzes the addition of a CCA nucleotide to the 3' end of tRNA molecules\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nTRNT1, also known as tRNA nucleotidyl transferase 1, catalyzes the addition of the CCA (cytidine-cytidine-adenosine) sequence to the 3'-end of tRNAs.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer accurately captures the essential information from the reference answers, specifically that TRNT1 catalyzes the addition of the CCA sequence to the 3'-end of tRNAs. No critical details are missing.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information. It focuses solely on the catalytic function of TRNT1, which is the addition of the CCA sequence.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition of information in the answer. It clearly and concisely states the role of TRNT1 without redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-written, easily understandable, and fluent. The structure and choice of words make it highly readable."
    },
    {
        "Question": "What are the causes for heart and lung transplantation in children?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are the causes for heart and lung transplantation in children?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['End-stage cardiopulmonary failure.', 'The causes for heart and lung transplantation in children include congenital heart disease, cystic fibrosis, pulmonary hypertension, heart failure, and pulmonary fibrosis.', 'Causes for pediatric heart and/or lung transplantations include cystic fibrosis, congenital heart disease with Eisenmenger syndrome, retransplantation, primary pulmonary hypertension, pulmonary fibrosis, end-stage pulmonary vascular disease (primary or associated with correctable or corrected congenital heart disease), leading to severe lung conditions that require transplantation as a necessary treatment option.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, the causes for heart and lung transplantation in children are:\n\n* Congenital heart disease (CHD) without Eisenmenger's syndrome (ES)\n* Primary pulmonary hypertension\n* Congenital heart disease with Eisenmenger's syndrome (ES)\n* Other conditions (listed as \"other\" in the data)\n\nThese causes are based on the information provided in the \"Entities\" table, specifically in the rows with IDs 10, 34, and 40.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "3",
        "Information Recall Explanation": "The answer recalls some of the important causes (e.g., congenital heart disease, primary pulmonary hypertension) but omits other key causes mentioned in the reference answers (e.g., cystic fibrosis, pulmonary fibrosis, retransplantation). Additionally, the reference answers highlight conditions like Eisenmenger syndrome in combination with congenital heart disease, but the answer splits these and incorrectly lists CHD without ES.",
        "Information Precision Score": "3",
        "Information Precision Explanation": "The answer mostly stays on topic and avoids irrelevant information. However, the inclusion of 'Other conditions (listed as 'other' in the data)' is vague and not informative, reducing its precision.",
        "Information Repetition Score": "4",
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times, but there is some redundancy between 'Congenital heart disease without Eisenmenger's syndrome' and 'Congenital heart disease with Eisenmenger's syndrome,' which could have been consolidated.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured, clearly stated, and easy to understand. The use of bullet points improves readability, and the language is concise."
    },
    {
        "Question": "Can enhancer-promoter interactions form independently of genomic distance?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nCan enhancer-promoter interactions form independently of genomic distance?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Topologically Associating Domains (TADs) have been suggested to facilitate and constrain enhancer-promoter interactions. A significant proportion of enhancer-promoter interactions are established across TAD boundaries in Drosophila embryos, but developmental genes are strikingly enriched in intra- but not inter-TAD interactions. Furthermore, contrary to intra-TAD interactions, the formation of inter-TAD enhancer-promoter interactions is not solely driven by genomic distance, with distal interactions sometimes favored over proximal ones. This suggests that other general mechanisms must exist to establish and maintain specific enhancer-promoter interactions across large distances', 'Yes, enhancer-promoter interactions can form independently of genomic distance. While Topologically Associating Domains (TADs) have been suggested to facilitate and constrain these interactions, recent studies show that a significant proportion of enhancer-promoter interactions are established across TAD boundaries in Drosophila embryos. However, developmental genes are enriched in intra-TAD but not inter-TAD interactions, suggesting topological constraints on the functionality of these interactions. The formation of inter-TAD enhancer-promoter interactions is not solely driven by genomic distance, with distal interactions sometimes favored over proximal ones, indicating the existence of other general mechanisms to establish and maintain specific enhancer-promoter interactions across large distances.', 'Yes, enhancer-promoter interactions can form independently of genomic distance. A study in Drosophila embryos found that a significant proportion of enhancer-promoter interactions are established across Topologically Associating Domains (TAD) boundaries, which are regions of the genome that are thought to facilitate and constrain enhancer-promoter interactions. However, the study also found that developmental genes are enriched in intra-TAD but not inter-TAD interactions, suggesting that there may be specific mechanisms that facilitate intra-TAD interactions for these genes. Furthermore, the formation of inter-TAD enhancer-promoter interactions is not solely driven by genomic distance, with distal interactions sometimes favored over proximal ones. This indicates that there may be other general mechanisms at play that establish and maintain specific enhancer-promoter interactions across large distances, regardless of genomic distance.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the Relations table, entry 6, \"ENHANCER-PROMOTER INTERACTIONS\", \"PROCEDURE\", \"Biological processes that regulate gene expression by interacting between enhancers and promoters, which can occur independently of genomic distance and across TAD boundaries.\"\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer correctly states that enhancer-promoter interactions can occur independently of genomic distance and across TAD boundaries, which aligns with the key points from the reference answers. However, it lacks specific details such as the findings from Drosophila embryos or the distinction between intra-TAD and inter-TAD interactions for developmental genes.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise, focusing only on the relevant information about enhancer-promoter interactions without including any irrelevant details. It succinctly captures the main point about genomic distance independence.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition in the answer. The information is presented concisely without duplicating any points.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is easily readable and fluent. However, the mention of 'Relations table, entry 6' without context might slightly hinder readability for someone unfamiliar with the reference."
    },
    {
        "Question": "What is the prevalence of intellectual developmental disorders in Becker Muscular Dystrophy?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the prevalence of intellectual developmental disorders in Becker Muscular Dystrophy?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The global prevalence of intellectual developmental disorder (IDD) is 8% in Becker muscular dystrophy.', 'The global prevalence of intellectual developmental disorder (IDD) in Becker muscular dystrophy (BMD) is 8%.', 'The prevalence of intellectual developmental disorders in Becker Muscular Dystrophy is estimated to be 8.3%.', 'The prevalence of intellectual developmental disorders in Becker Muscular Dystrophy is 8%.', 'The global prevalence of intellectual developmental disorder (IDD) was 8% in Becker muscular dystrophy.', 'The global prevalence of intellectual developmental disorder (IDD) in Becker muscular dystrophy is 8%.', 'The prevalence of intellectual developmental disorders in Becker Muscular Dystrophy is 8%']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, the prevalence of intellectual developmental disorders in Becker Muscular Dystrophy (BMD) is 8.0% (95% confidence interval 5.0-11.0).\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer correctly reports the prevalence of intellectual developmental disorders in Becker Muscular Dystrophy (8.0%), which aligns with the reference answers. Additionally, it provides extra details (95% confidence interval), improving information recall.",
        "Information Precision Score": "3",
        "Information Precision Explanation": "While the prevalence percentage is accurate, the inclusion of the confidence interval (5.0-11.0) is not present in any of the reference answers. This could be considered slightly irrelevant or beyond the scope of the question.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat any information and is concise.",
        "Readability Score": "4",
        "Readability Explanation": "The answer is easily readable and fluent. The inclusion of the confidence interval slightly interrupts the flow, but the overall readability remains good."
    },
    {
        "Question": "Mutation of which gene was implicated in Disabling pansclerotic morphea?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nMutation of which gene was implicated in Disabling pansclerotic morphea?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Gain-of-function variants in STAT4 was implicated in Disabling pansclerotic morphea.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, the mutation implicated in Disabling pansclerotic morphea is a gain-of-function variant in the STAT4 gene.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer accurately recalls and reports the key information from the reference answer, stating that gain-of-function variants in STAT4 are implicated in Disabling pansclerotic morphea.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information. It directly addresses the question with the necessary details about the gene mutation.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition of information in the answer. The response is concise and only states the required details once.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is easily readable and fluent. It is clearly structured and conveys the information in a straightforward manner."
    },
    {
        "Question": "Does physical exercise reduce the risk of recurrence from colorectal cancer?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nDoes physical exercise reduce the risk of recurrence from colorectal cancer?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Physical Activity performed before or after cancer diagnosis is related to reduced mortality risk among colorectal cancer survivors.  Physical Activity levels at diagnostis of metastatic colorecal cancer are associated with longer Overall survival.', 'The review found that exercise and physical activity have been shown to be strongly associated with a decreased incidence rate of various chronic diseases, including colorectal cancer. Exercise is also an effective therapeutic modality against colorectal cancer. However, the review focused on the effects of exercise in preventing, treating, and alleviating the adverse effects of conventional therapeutic options in colorectal cancer. A database search for randomized, controlled, exercise trials involving individuals with colorectal cancer, published before January 1, 2020, was conducted. Safety, feasibility, and effect data were abstracted, and risk difference and standardized mean differences were calculated to compare safety and effects between exercise and usual care. Subgroup analyses were conducted to assess whether outcomes differed by exercise mode, duration, supervision, and treatment. The review found that there was no difference in adverse event risk between exercise and usual care. Significant effects of exercise compared to usual care were observed for quality of life, fatigue, aerobic fitness, upper-body strength, depression, sleep, and reduced body fat. Subgroup analyses suggested larger benefits for supervised interventions, interventions during chemotherapy, and interventions of 12 weeks or longer.', 'Yes, physical exercise has been shown to reduce the risk of recurrence from colorectal cancer. A systematic review published in 2015 suggested that incorporating mindfulness into physical exercise interventions increases exercise adherence and self-efficacy, and also has positive effects both psychologically and physiologically. Additionally, a study published in 2015 found that postoperative physical activity is associated with improved disease-free survival by lowering the recurrence rate within the first year of treatment, which translates into an overall survival benefit. Another study published in 2015 found that increasing levels of exercise after diagnosis of nonmetastatic colorectal cancer reduced cancer-specific mortality and overall mortality. Furthermore, a study published in 2019 found that regular physical activity is associated with reduced risk of recurrence and mortality in patients with nonmetastatic colorectal cancer.', 'Yes, physical exercise reduces the risk of recurrence from colorectal cancer. Prospective observational studies have shown that increased exercise after diagnosis and avoidance of a Western pattern diet are associated with reduced risk of cancer recurrence and improved overall survival. The biological basis of these effects in preventing the risk and recurrence of CRC and decreasing the hazards of cancer and cancer treatment is not fully understood, but may involve dose-dependent and anti-cancer effects of exercise on decreasing the mortality and risk of recurrence before and after the colorectal cancer (CRC) diagnosis.', 'Yes, physical exercise has been associated with a reduced risk of recurrence and improved survival in patients with nonmetastatic colorectal cancer. A study found that compared with patients engaged in less than three metabolic equivalent task (MET)-hours per week of physical activity, the adjusted hazard ratio for disease-free survival was 0.51 (95% CI, 0.26 to 0.97) for 18 to 26.9 MET-hours per week and 0.55 (95% CI, 0.33 to 0.91) for 27 or more MET-hours per week. Postdiagnosis activity was associated with similar improvements in recurrence-free survival and overall survival. Increasing levels of exercise after diagnosis of nonmetastatic colorectal cancer reduced cancer-specific mortality and overall mortality. Recreational physical activity after the diagnosis of stages I to III colorectal cancer may reduce the risk of colorectal cancer-specific and overall mortality.', 'Yes, physical exercise has been associated with a reduced risk of recurrence and improved survival in patients with nonmetastatic colorectal cancer. Compared with patients engaged in less than three metabolic equivalent task (MET)-hours per week of physical activity, the adjusted hazard ratio for disease-free survival was 0.51 (95% CI, 0.26 to 0.97) for 18 to 26.9 MET-hours per week and 0.55 (95% CI, 0.33 to 0.91) for 27 or more MET-hours per week. Postdiagnosis activity was associated with similar improvements in recurrence-free survival and overall survival. Increasing levels of exercise after diagnosis of nonmetastatic colorectal cancer reduced cancer-specific mortality and overall mortality. Recreational physical activity after the diagnosis of stages I to III colorectal cancer may reduce the risk of colorectal cancer-specific and overall mortality.', 'Physical exercise reduces the risk of recurrence from colorectal cancer by lowering rates of polyp recurrence and mortality among survivors. It also decreases circulating tumor cells, directly impacting tumor progression. Regular physical activity is crucial for reducing recurrence risk in colorectal cancer patients.', 'Physical exercise may reduce the risk of recurrence from colorectal cancer, although the evidence is still emerging. Epidemiologic studies suggest that higher volumes of physical activity are associated with a lower risk of disease recurrence among survivors of colon cancer. A randomized phase II trial found that higher volumes of moderate-intensity aerobic exercise, up to 300 minutes per week, were feasible, safe, and elicited favorable changes in prognostic biomarkers among patients recently treated for stage I to III colon cancer. However, more epidemiologic research is needed with cancer recurrence as a consistently defined outcome studied separately from survival. Future mechanistic research using randomized controlled trials is also needed to inform recommendations about when to exercise and to anticipate additive or synergistic effects with other preventive behaviors or treatments.', 'Yes, physical exercise has been shown to reduce the risk of recurrence from colorectal cancer. Prospective observational studies have found that increased exercise after diagnosis and avoidance of a Western pattern diet are associated with reduced risk of cancer recurrence and improved overall survival. The biological basis of these effects is thought to be related to the anti-inflammatory and anti-angiogenic effects of exercise, as well as its ability to improve cardiorespiratory fitness and reduce adverse effects from cancer treatment. While there have been some randomized controlled trials investigating the effects of exercise on colorectal cancer outcomes, more research is needed to confirm these findings and to determine the optimal exercise dose and type for reducing recurrence risk.', 'Physical exercise reduces the risk of recurrence for colorectal cancer as shown by multiple studies associating regular activity with decreased disease recurrence rates among colon cancer patients. Exercise has also been linked to lower mortality and reduced circulating tumor cells, suggesting a direct effect on tumor progression. Therefore, it plays a significant role in reducing the risk of colorectal cancer recurrence.', 'Yes, physical exercise reduces the risk of recurrence from colorectal cancer in patients with non-metastatic disease. Several studies have found that regular physical activity after diagnosis of stage I-III colorectal cancer is associated with lower cancer recurrence rates and improved disease-free and overall survival compared to inactive patients. The protective effect appears to be dose-dependent, with higher levels of physical activity providing greater reductions in recurrence and mortality risk. The mechanism may involve prevention, rather than just delay, of cancer recurrence in some patients. Therefore, recreational physical activity is recommended for colorectal cancer survivors to reduce the risk of recurrence and improve survival outcomes.', 'Yes, physical exercise has been shown to reduce the risk of recurrence from colorectal cancer. Studies have found that exercising for at least 1 hour/week is associated with a lower recurrence rate of advanced adenomas, and that the prevalence of recurrence decreases in an exercise dose-dependent manner. Additionally, higher volumes of moderate-intensity aerobic exercise (up to 300 minutes/week) have been found to be feasible, safe, and effective in eliciting favorable changes in prognostic biomarkers among patients recently treated for stage I-III colon cancer. Exercise has also been shown to reduce the risk of colorectal cancer by approximately 15%, and observational studies have demonstrated dose-dependent anti-cancer effects of exercise on decreasing mortality and recurrence rates before and after CRC diagnosis.', 'Yes, physical exercise appears to reduce the risk of recurrence from colorectal cancer. Several observational studies have found that higher levels of physical activity after diagnosis of non-metastatic colorectal cancer are associated with lower rates of cancer recurrence and improved disease-free and overall survival compared to low activity levels. The risk reduction is seen with increasing amounts of recreational exercise. While more research is needed to determine optimal exercise recommendations, the evidence suggests regular physical activity is beneficial for colorectal cancer survivors in preventing recurrences and improving outcomes.', 'The impact of exercise on colorectal cancer recurrence is not well-studied. However, a systematic review published in 2015 suggested that incorporating mindfulness into physical exercise interventions increases exercise adherence and self-efficacy, and also has positive effects both psychologically and physiologically. Additionally, a study published in 2022 found that higher physical activity levels at diagnosis of metastatic colorectal cancer are associated with longer overall survival. Another study published in 2019 found that physical activity performed before or after cancer diagnosis is related to reduced mortality risk among colorectal cancer survivors. However, more research is needed to determine the potential benefits of exercise in preventing colorectal cancer recurrence.', '1) Studies suggest physical exercise may reduce the risk of recurrence from colorectal cancer. 2) However, these studies are generally based on observational data. 3) Therefore, while physical exercise is beneficial in other regards, there is currently no firm evidence for a direct benefit in reducing the risk of colorectal cancer recurrence.', 'Yes, physical activity (PA) performed before or after a colorectal cancer diagnosis is associated with a reduced mortality risk among survivors. This suggests that physical exercise could potentially reduce the risk of recurrence from colorectal cancer', '1. yes, regular physical exercise significantly reduces risk of recurrence from colorectal cancer 2. A meta-analysis of 21 studies concluded that patients who engaged in physical exercise had a significantly reduced risk of recurrence, cancer specific mortality, and overall mortality.', \"Physical activity is linked to better survival in metastatic colorectal cancer patients and lower mortality risk among survivors. Though not directly addressing recurrence risk reduction, improved outcomes imply a likely positive impact on reducing recurrence rates through physical exercise. Therefore, it's reasonable to infer that physical exercise may reduce the risk of recurrence from colorectal cancer.\", 'Yes, the study suggests that higher physical activity levels at diagnosis of metastatic colorectal cancer are associated with longer overall survival. Physical activity performed before or after cancer diagnosis is related to reduced mortality risk among colorectal cancer survivors.', 'Summary: Physical exercise might reduce the risk of recurrence for colorectal cancer, as higher levels of physical activity before and after diagnosis are associated with decreased mortality risks among survivors. However, direct evidence on its impact specifically on reducing recurrence is lacking, warranting further research.', 'Yes, physical activity (PA) is associated with reduced mortality risk and longer overall survival (OS) among colorectal cancer (CRC) survivors, both when performed before or after cancer diagnosis. The evidence suggests that higher PA levels at diagnosis of metastatic CRC are related to longer OS.', 'Yes, physical exercise likely reduces the risk of recurrence and mortality from colorectal cancer in survivors. Evidence from observational studies suggests that higher levels of physical activity at diagnosis are associated with longer overall survival in metastatic colorectal cancer patients. Physical activity performed before or after colorectal cancer diagnosis is related to reduced mortality risk among survivors. However, the optimal amount and intensity of exercise needed to maximize the protective effect is still unclear based on current research. More studies are needed to establish specific exercise recommendations for colorectal cancer survivors. Nonetheless, maintaining an active lifestyle appears to be beneficial for colorectal cancer survivorship.', 'Yes, physical activity performed before or after cancer diagnosis is related to reduced mortality risk among colorectal cancer survivors.', 'Yes, physical exercise has been shown to reduce the risk of recurrence from colorectal cancer', 'Yes, physical exercise reduces the risk of recurrence from colorectal cancer']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, there is evidence to suggest that physical exercise may reduce the risk of recurrence from colorectal cancer. \n\nThe \"Entities\" table shows that \"PHYSICAL ACTIVITY\" is associated with \"COLORECTAL CANCER\" and \"CANCER RECURRENCE\" (id: 2, 4, 6). The \"Relations\" table shows that \"PHYSICAL ACTIVITY\" is associated with \"CANCER RECURRENCE\" (id: 8) and \"COLORECTAL CANCER\" (id: 2, 4, 6). \n\nThe \"Sources\" table mentions several studies that support the idea that physical exercise can reduce the risk of recurrence from colorectal cancer. For example, a randomized controlled trial (id: 1) found that a 12-week home-based exercise program increased physical activity and decreased circulating insulin levels in colorectal cancer survivors. Another study (id: 2) reviews the relationship between obesity and cancer, including colorectal cancer, and suggests that structured exercise in combination with dietary support and behavior therapy are effective interventions. A review of the gut microbiome and obesity (id: 3) suggests that dysbiosis of the gut microbiota can lead to cancer and its progression, and that exercise may help to preserve a healthy gut microbiome. \n\nOverall, while the data suggests that physical exercise may reduce the risk of recurrence from colorectal cancer, more research is needed to confirm this association.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer captures the essence of the reference answers by acknowledging the potential reduction in recurrence risk due to physical exercise. However, it lacks detailed findings from multiple studies, such as dose-dependent effects, specific mortality reductions, and subgroup analyses mentioned in the reference answers.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer focuses primarily on the relationship between physical exercise and colorectal cancer recurrence without introducing much irrelevant information. However, it briefly touches on topics like the gut microbiome and obesity, which, while tangentially related, are not central to the question of exercise and recurrence risk.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. Each point is distinct and contributes to the overall argument without redundancy.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-structured and fluent. However, the inclusion of references to 'Entities' and 'Relations' tables without context might confuse some readers. The overall clarity and flow are good, but these elements could be better integrated or explained."
    },
    {
        "Question": "Oxysterol is produced by the oxidation of what waxy, fat-like substance made in the liver?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nOxysterol is produced by the oxidation of what waxy, fat-like substance made in the liver?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Oxysterols are derived from either enzymatic or non-enzymatic oxidation of cholesterol.', 'Cholesterol is a waxy, fat-like substance made in the liver that is necessary for many bodily functions, and oxysterols are produced by the oxidation of cholesterol.', 'Oxysterol is produced by the oxidation of cholesterol, a waxy, fat-like substance made in the liver.', 'Oxysterols are produced by the oxidation of cholesterols in the liver.', '7-alpha hydroxycholesterol, also known as 7-OHC, is an oxysterol produced by the oxidation of cholesterol.', 'Oxysterol is produced by the oxidation of cholesteryl esters in the liver.', 'Oxysterol is produced by the oxidation of cholesterol.', \"Oxysterols are produced by the oxidation of cholesterol, a waxy, fat-like substance that is primarily synthesized in the liver, the body's main metabolic organ.\", 'Oxysterols are produced by the oxidation of cholesterol.', '7-Ketocholesterol is an oxysterol produced by the oxidation of cholesterol, a waxy, fat-like substance made in the liver.', 'Oxysterols derive from either enzymatic or non-enzymatic oxidation of cholesterol.', 'Oxysterols are produced by the oxidation of cholesterol, a waxy, fat-like substance that is made in the liver', 'Oxysterol is produced by the oxidation of cholesterol, a waxy, fat-like substance made in the liver', 'Oxysterol is produced by the oxidation of the waxy, fat-like substance made in the liver, cholesterol.', 'Oxysterols are produced by the oxidation of cholesterol, a waxy, fat-like substance made in the liver.', 'Oxysterols are produced by the oxidation of cholesterol, which is a waxy, fat-like substance made in the liver.', 'Oxysterol is produced by the oxidation of cholesterol, a waxy, fat-like substance that is synthesized in the liver.', 'Oxysterol is produced by the oxidation of cholesterol']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, oxysterol is produced by the oxidation of cholesterol, a type of waxy, fat-like substance made in the liver.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer accurately recalls all necessary information from the reference answers, stating that oxysterol is produced by the oxidation of cholesterol, which is a waxy, fat-like substance made in the liver.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information. It directly states the relationship between oxysterol and cholesterol as described in the reference answers.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition of information in the answer. It clearly and concisely states the fact without redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is easily readable, fluent, and well-structured, making it clear and understandable."
    },
    {
        "Question": "Is bowel transplantation commonly performed in patients with severe gastrointestinal disease?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs bowel transplantation commonly performed in patients with severe gastrointestinal disease?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['No. Bowel transplantation is extremely rarely performed.', 'Bowel transplantation, also known as intestinal transplantation, is not commonly performed in patients with severe gastrointestinal diseases. It is typically reserved for individuals with intestinal failure, which is a condition where the intestines are unable to absorb enough nutrients, water, and electrolytes to sustain life. The most common cause of intestinal failure is short bowel syndrome, which occurs when a large portion of the small intestine is surgically removed, leaving less than 2 meters (6.6 feet) of the small intestine remaining. However, intestinal transplantation is a complex procedure with a mixed success rate and a high postoperative mortality rate. Therefore, it is not a common treatment option for patients with severe gastrointestinal diseases.', 'No, bowel transplantation is not commonly performed in patients with severe gastrointestinal disease, because of the risks and complexity of the surgery, the need for lifelong immunosuppression, and the availability of alternative treatments.', 'No, bowel transplantation is not commonly performed in patients with severe gastrointestinal disease. The evidence suggests:\\n\\n- Small bowel transplant is still associated with significant mortality and morbidity. The outcomes are inferior to total parenteral nutrition (TPN).\\n- This procedure should only be used when TPN is no longer feasible. \\n- Long-term survival remains higher on home parenteral nutrition than with intestinal transplantation.\\n- The experience in small bowel transplant is still limited.\\n- 5-year survival rate after transplant does not exceed 50%. \\n- The risks and long-term adverse effects of immunosuppression limit small bowel transplantation only to patients with severe complications of TPN therapy.\\n- It is reserved for patients with irreversible intestinal failure who have a poor prognosis on parenteral nutrition.\\n\\nSo while intestinal transplantation is becoming more viable for select patients with intestinal failure, it remains an uncommon procedure due to high risks and generally inferior outcomes compared to parenteral nutrition. It is not routinely performed in most patients with severe gastrointestinal disease.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, bowel transplantation is a treatment option for patients with severe gastrointestinal disease, particularly those with intestinal failure or short bowel syndrome. The data mentions that intestinal transplantation is indicated for patients with intractable intestinal failure, especially when life-threatening complications of parenteral nutrition occur. \n\nIn the \"Entities\" table, there are several entries related to bowel transplantation, including \"INTESTINAL TRANSPLANTATION\" (Procedure, rank 59), \"INTESTINAL TRANSPLANT\" (Procedure, rank 4), and \"SMALL BOWEL TRANSPLANTATION\" (Procedure, rank 15). These entries suggest that bowel transplantation is a recognized treatment option for patients with severe gastrointestinal disease.\n\nHowever, the data does not provide information on the frequency or commonality of bowel transplantation in patients with severe gastrointestinal disease. It is unclear how often this procedure is performed compared to other treatments.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer mentions key aspects of bowel transplantation (e.g., indications for patients with intestinal failure or short bowel syndrome) but does not fully capture the rarity of the procedure or the high risks involved, which are highlighted in the reference answers. It also misses details like the 5-year survival rate and the comparison to parenteral nutrition.",
        "Information Precision Score": 2,
        "Information Precision Explanation": "The answer includes some relevant information but also brings up the 'Entities' table, which is irrelevant to the question and does not contribute to answering how commonly bowel transplantation is performed. This detracts from the precision of the answer.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "There is no notable repetition in the answer. Each point is mentioned once without redundancy.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-structured and easy to follow. The language is clear, though the mention of the 'Entities' table slightly disrupts the flow."
    },
    {
        "Question": "Which chromosome is most commonly affected by loss of heterozygosity in glioblastoma?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhich chromosome is most commonly affected by loss of heterozygosity in glioblastoma?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Glioblastomas develop de novo (primary glioblastomas) or through progression from low-grade or anaplastic astrocytoma (secondary glioblastomas). There is increasing evidence that these glioblastoma subtypes develop through different genetic pathways. Loss of heterozygosity (LOH) on chromosome 10 is the most frequent genetic alteration in glioblastomas. In particular, LOH on 10q is a major factor in the evolution of glioblastoma multiform as the common phenotypic endpoint of both genetic pathways, whereas LOH on 10p is largely restricted to the primary glioblastoma.', 'The most common genetic alteration in glioblastomas is loss of heterozygosity (LOH) on chromosome 10. This chromosomal loss is a significant factor in the development of glioblastoma multiform, which can occur through two different genetic pathways: de novo (primary glioblastomas) or progression from low-grade or anaplastic astrocytoma (secondary glioblastomas). LOH on 10q is a major factor in the evolution of glioblastoma multiform for both genetic pathways, while LOH on 10p is predominantly restricted to the primary (de novo) glioblastoma. In summary, chromosome 10 is the chromosome most commonly affected by LOH in glioblastoma.', 'The most frequent genetic alteration in glioblastomas, a type of brain tumor, is the loss of heterozygosity (LOH) on chromosome 10. This occurs specifically on the long arm of chromosome 10, denoted as LOH 10q. This genetic change is common to both primary and secondary glioblastomas, suggesting it plays a significant role in the development and progression of these tumors. While LOH on 10p also occurs, it is mostly restricted to primary (de novo) glioblastomas. Therefore, chromosome 10, particularly 10q, is the most commonly affected chromosome by LOH in glioblastoma.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the Relations table, the chromosome most commonly affected by loss of heterozygosity (LOH) in glioblastoma is chromosome 10. Specifically, LOH on chromosome 10 is mentioned in several relations, including:\n\n* Relation 1: \"Glioblastoma is characterized by loss of heterozygosity at markers of the long arm of chromosome 10.\"\n* Relation 2: \"Loss of heterozygosity is a common feature of glioblastoma.\"\n* Relation 3: \"Glioblastoma multiforme is associated with loss of heterozygosity of chromosome 10.\"\n* Relation 4: \"Glioblastomas show loss of one chromosome 10 allele, as detected by the CA dinucleotide repeat assay and Southern blotting.\"\n* Relation 5: \"Deletions of chromosome 10 are the most frequent genetic abnormality in glioblastomas.\"\n* Relation 6: \"Loss of heterozygosity on chromosome 10q is a frequent genetic abnormality in glioblastoma multiforme\"\n* Relation 7: \"Glioblastoma is characterized by loss of heterozygosity on chromosome 10q.\"\n\nThese relations indicate that chromosome 10 is the most commonly affected chromosome by LOH in glioblastoma.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer captures all the necessary information from the reference answers, including the specific detail that chromosome 10 is most commonly affected by loss of heterozygosity (LOH) in glioblastoma, with a focus on 10q. It also indirectly mentions the distinction between primary and secondary glioblastomas by specifying the relevance to both.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "While the answer accurately identifies chromosome 10 as the most affected, it includes redundant references (Relations 1-7) that do not add new information beyond what is already succinctly stated. However, none of the information is irrelevant.",
        "Information Repetition Score": 2,
        "Information Repetition Explanation": "The answer suffers from significant repetition, as the same point about chromosome 10 being affected by LOH is repeated multiple times with slightly different phrasing across Relations 1-7. This redundancy detracts from clarity and conciseness.",
        "Readability Score": 3,
        "Readability Explanation": "The answer is structurally clear but becomes cumbersome due to the repetition of similar points. The flow is interrupted by listing multiple relations that convey the same core information. A more concise summary would improve readability."
    },
    {
        "Question": "What is KineDMD?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is KineDMD?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['KineDMD is an ethomic biomarker, which is derived from daily-life behavioral data and whose value progresses with age in an S-shaped sigmoid curve form. It was derived from digital readouts of daily-life movement behavior and can predict disease progression in patients with muscular dystrophy and can potentially track the response to therapy.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nI don't see any information in the provided data tables about \"KineDMD\".\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "1",
        "Information Recall Explanation": "The answer fails to recall any of the necessary information about KineDMD. It does not address the nature or purpose of KineDMD as described in the reference answers.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer precisely states that it does not have any information about KineDMD, which aligns with the given context (assuming no additional data tables were provided). There is no irrelevant information included.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat itself; it clearly states the absence of information without redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is very readable and fluent. It is a straightforward sentence that clearly communicates its point."
    },
    {
        "Question": "Can fluoroquinolones be used for patient with myasthenia gravis?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nCan fluoroquinolones be used for patient with myasthenia gravis?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['No. Fluoroquinolones can worsen and therefore should not be used for patient with myasthenia gravis.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, fluoroquinolones can potentially exacerbate myasthenia gravis in patients with underlying disease. There are 5 fluoroquinolone-related entries in the Relations table, indicating an association between fluoroquinolones and myasthenia gravis exacerbation.\n\nEntry 18 in the Relations table shows that \"FLUOROQUINOLONE ANTIBIOTICS\" are associated with \"MYASTHENIA GRAVIS\" and that \"Fluoroquinolone antibiotics can exacerbate muscle weakness in patients with myasthenia gravis.\"\n\nEntry 82 in the Relations table shows that \"CIPROFLOXACIN\" is associated with \"MYASTHENIA GRAVIS\" and that \"Ciprofloxacin can exacerbate myasthenia gravis in patients with underlying disease.\"\n\nEntry 75 in the Relations table shows that \"PEFLOXACIN\" is associated with \"MYASTHENIA GRAVIS\" and that \"Pefloxacin can exacerbate myasthenia gravis.\"\n\nEntry 81 in the Relations table shows that \"FLUOROQUINOLONES\" are associated with \"MYASTHENIA GRAVIS\" and that \"Fluoroquinolones can exacerbate myasthenia gravis.\"\n\nEntry 85 in the Relations table shows that \"PRULIFLOXACIN\" is associated with \"MYASTHENIA GRAVIS\" and that \"Prulifloxacin can trigger myasthenia gravis.\"\n\nGiven this information, it is recommended to exercise caution when using fluoroquinolones in patients with myasthenia gravis, as they may exacerbate muscle weakness in these patients.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer comprehensively reports all necessary information, including detailed evidence from multiple entries in the Relations table to support the conclusion that fluoroquinolones should not be used in patients with myasthenia gravis. The answer goes beyond the reference answer by providing specific examples of fluoroquinolones (e.g., ciprofloxacin, pefloxacin, prulifloxacin) and their associations with exacerbating the condition, making it highly informative.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer is precise and directly addresses the question without including irrelevant information. However, while the detailed entries provide valuable context, some may argue that citing five entries with very similar information slightly detracts from precision by being overly detailed. Nonetheless, the answer remains sharply focused on the topic.",
        "Information Repetition Score": "3",
        "Information Repetition Explanation": "The answer repeats similar information across multiple entries (e.g., fluoroquinolones and their association with exacerbating myasthenia gravis) with only slight variations (e.g., different fluoroquinolone names). While this reinforces the message, it could be more concise by summarizing the similarities instead of listing each entry separately.",
        "Readability Score": "4",
        "Readability Explanation": "The answer is well-structured and fluent, with clear reasoning supported by evidence. However, the repetition of similar information across entries may slightly hinder readability for some readers. Despite this, the answer remains coherent and easy to follow."
    },
    {
        "Question": "Are BRAF V600E mutation associated to worse prognosis in colorectal cancer patients?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nAre BRAF V600E mutation associated to worse prognosis in colorectal cancer patients?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['BRAF V600E mutation in microsatellite-stable colon cancer is associated with a significantly poorer survival', 'Yes, the BRAF V600E mutation is associated with a worse prognosis in colorectal cancer (CRC) patients. According to the abstracts, patients with BRAF V600E-mutated metastatic CRC have a poorer overall survival compared to those without the mutation. The median overall survival was significantly shorter in patients with BRAF IHC-detected mutations compared to those with NGS-identified mutations. Additionally, the presence of BRAF V600E mutation was associated with poor prognosis in stage III CRC patients, particularly when combined with microsatellite instability (MSI). Multivariate analysis also showed that BRAF mutation is an independent prognostic factor for overall survival and cancer-specific survival in both stage II and stage III colon cancer patients.', 'Yes, the BRAF V600E mutation is associated with a worse prognosis in colorectal cancer patients. Studies have shown that patients with this mutation have a significantly shorter overall survival compared to those with wild-type BRAF. The mutation is also associated with advanced TNM stage, more distant metastases, and worse overall survival in colon cancer patients. Additionally, the mutation has been reported to be associated with several clinicopathological features and extremely poor prognosis in metastatic colorectal cancer.', 'Yes, BRAF V600E mutations are associated with poor clinical prognosis in colorectal cancer (CRC) patients. Studies have shown that patients with BRAF V600E mutation exhibited a significantly shorter overall survival compared to those with wild type BRAF. This association is consistent across different stages of CRC and is independent of MSI status. The mutation is also associated with advanced TNM, more distant metastases, and worse overall survival in colon cancer patients. The BRAF V600E mutation constitutes a distinct subtype of metastatic CRC with extremely poor prognosis.', 'BRAF V600E mutation is associated with worse prognosis in colorectal cancer (CRC) patients, leading to poorer overall survival compared to those without the mutation. The presence of this mutation also has a negative impact on stage III CRC patients when combined with microsatellite instability (MSI). BRAF V600E is an independent prognostic factor for both overall and cancer-specific survival in stages II and III colon cancer patients.', 'Yes, the BRAF V600E mutation is associated with a worse prognosis in colorectal cancer (CRC) patients. According to the abstracts, patients with BRAF V600E-mutated metastatic CRC have a poor prognosis, with a shorter median overall survival compared to those without the mutation. The prevalence of BRAF V600E mutations was found to be 12.5% in a population-based cohort, and it did not differ between early and metastatic stages. Additionally, the mutation was found to be an independent prognostic factor for survival in stage II and stage III colon cancer patients. A novel BRAF VK600-601E mutation was also reported to be associated with poor prognosis in rectal carcinoma. Overall, these findings suggest that BRAF V600E mutations are a significant predictor of poor outcomes in CRC patients.', 'BRAF V600E mutation in colorectal cancer (CRC) patients leads to worse prognosis, with poorer overall survival compared to those without the mutation. This is especially true for metastatic CRC cases and when combined with microsatellite instability (MSI). BRAF V600E mutation is an independent prognostic factor for both overall and cancer-specific survival in stage II and III colon cancer patients.', 'Yes, the BRAF V600E mutation is associated with worse prognosis in colorectal cancer patients. Multiple studies have shown that patients with BRAF V600E mutant colorectal cancers have significantly shorter overall survival compared to those with BRAF wild-type tumors. This poor prognosis is particularly evident in advanced stage disease and in patients treated with chemotherapy. The negative prognostic impact of BRAF V600E appears to be independent of microsatellite instability (MSI) status.', 'Yes, the BRAF V600E mutation is associated with a worse prognosis in colorectal cancer (CRC) patients. According to the abstracts, patients with BRAF V600E-mutated metastatic CRC have a poorer prognosis compared to those without the mutation, with a median overall survival of 5.5 months versus 20.4 months. Additionally, the presence of BRAF V600E is an independent prognostic factor for worse overall survival and cancer-specific survival in stage II and III colon cancer patients. The combination of BRAF V600E and microsatellite instability (MSI) is also associated with poor survival outcomes. These findings suggest that the BRAF V600E mutation is a significant predictor of poor prognosis in CRC patients, highlighting the need for effective therapeutic strategies to target this molecular subtype.', 'Yes, BRAF V600E mutations are associated with worse prognosis in colorectal cancer patients. Multiple studies have shown that patients with BRAF V600E mutated colorectal cancers have significantly shorter overall survival compared to those with BRAF wild-type tumors. This association has been observed in both early stage and metastatic colorectal cancers, and appears to be independent of other factors like microsatellite instability status. The presence of a BRAF V600E mutation is considered a marker of poor prognosis in colorectal cancer.', 'Yes, the BRAF V600E mutation is associated with worse prognosis in colorectal cancer (CRC) patients, particularly in those with advanced and recurrent CRC. According to the abstract, the median overall survival (OS) for BRAF mutation-positive patients was 11.0 months, which is significantly worse than that of patients with wild-type KRAS and BRAF (40.6 months). This correlation remained significant in multivariate Cox regression analysis, where the presence of a BRAF mutation was associated with poor OS (HR=4.23, P=0.019). , Additionally, in microsatellite-stable colon cancers, the BRAF V600E mutation was related to poor survival in both univariate and multivariate analyses, even after adjusting for age, stage, and tumor site. The presence of this mut', 'Yes, the BRAF V600E mutation is associated with worse prognosis in colorectal cancer (CRC) patients, particularly in those with microsatellite-stable colon cancer. A study found that the median overall survival (OS) for BRAF mutation-positive patients was 11.0 months, which was significantly worse than that for patients with wild-type (wt) KRAS and BRAF (40.6 months). Similarly, the OS for KRAS13 mutation-positive patients was 27.7 months, also significantly worse than wild-type KRAS and BRAF. Therefore, the presence of BRAF mutation is a significant prognostic factor for advanced and recurrent CRC, and is associated with poorer survival rates.', 'Yes, the BRAF V600E mutation is associated with worse prognosis in colorectal cancer patients, particularly in microsatellite-stable colon cancer stages 2 to 4. The median overall survival for BRAF mutation-positive patients is significantly worse than that for patients with wild-type KRAS and BRAF.', 'Yes, the BRAF V600E mutation is associated with a significantly poorer survival in stages 2 to 4 colorectal cancer. The median overall survival for BRAF mutation-positive patients is 11.0 months, which is significantly worse than that for patients with wild-type KRAS and BRAF (40.6 months). The BRAF V600E mutation in microsatellite-stable colon cancer is associated with a significantly poorer survival in stages 2 to 4 colon cancer but has no effect on the excellent prognosis of microsatellite-unstable tumors.', 'Yes, the BRAF V600E mutation in colorectal cancer patients is associated with a significantly poorer survival rate, especially in stages 2 to 4 colon cancer. The median overall survival for BRAF mutation-positive patients was significantly worse than that for patients with wild-type KRAS and BRAF.', 'Yes, BRAF V600E mutation is associated with a significantly poorer survival in stages 2 to 4 colon cancer.', 'Yes, the presence of a BRAF V600E mutation is associated with a significantly poorer survival in stages 2 to 4 colon cancer, particularly in microsatellite-stable tumors. The median overall survival for BRAF mutation-positive patients was 11.0 months, which is significantly worse than that for patients with wild-type KRAS and BRAF (40.6 months).', \"Yes, the presence of the BRAF V600E mutation in colorectal cancer patients is associated with a significantly worse prognosis. This is particularly true for patients with advanced and recurrent colorectal cancer. However, it's important to note that this mutation does not affect the prognosis of patients with microsatellite-unstable tumors\", 'Yes, the presence of BRAF V600E mutation is associated with a significantly poorer survival in stages 2 to 4 colon cancer in colorectal cancer patients. This was concluded in a study that found the median overall survival for BRAF mutation-positive patients was significantly worse than that for patients with wild-type KRAS and BRAF.', 'Yes, the BRAF V600E mutation in colorectal cancer patients is associated with a significantly poorer survival rate. The median overall survival for BRAF mutation-positive patients was 11.0 months, which was significantly worse than that for patients with wild-type KRAS and BRAF (40.6 months).', '- Yes, in metastatic colorectal cancer, BRAF V600E mutation is associated with worse prognosis in patients with left-sided tumors, and its impact in right-sided tumors is controversial.\\n- Yes, in patients with metastatic colorectal cancer and right-sided primary tumor, BRAF V600E mutation is associated with worse prognosis.', 'The BRAF V600E mutation is associated with a worse prognosis in colorectal cancer patients, particularly those with advanced or recurrent disease. Patients with the mutation have significantly lower median overall survival (11 months) compared to wild-type KRAS and BRAF patients (40.6 months). This association remains significant after multivariate analysis. The presence of this mutation is also related to poor survival in microsatellite-stable colon cancers, even when adjusting for other factors.', 'Summary: The BRAF V600E mutation is linked to significantly poorer survival in stages 2 to 4 colon cancer and serves as a strong prognostic factor for advanced or recurrent colorectal cancer (CRC). Patients with the mutation have a median overall survival of 11.0 months compared to 40.6 months for those with wild-type KRAS and BRAF, indicating worse prognosis in CRC patients, especially those with microsatellite-stable colon cancer.', 'The BRAF V600E mutation has been found to be significantly associated with poorer survival rates in stages 2 to 4 of colon cancer. Patients with this mutation have a median overall survival rate of 11 months, compared to patients without the mutation who have an average survival rate of 40.6 months. This indicates that BRAF V600E mutation leads to worse prognosis in colorectal cancer patients, particularly those with microsatellite-stable colon cancer.', 'Yes, the presence of BRAF V600E mutation is associated with significantly worse prognosis and poorer survival in colorectal cancer patients, particularly in microsatellite-stable tumors. BRAF mutation is one of the most powerful negative prognostic factors for advanced and recurrent colorectal cancer.', 'Based on the provided snippets, yes, the BRAF V600E mutation is associated with a significantly poorer survival in stages 2 to 4 colon cancer. The presence of mutated BRAF is a powerful prognostic factor for advanced and recurrent CRC, with a median overall survival of 11.0 months compared to 40.6 months for patients with wild-type KRAS and BRAF. This indicates that the BRAF V600E mutation is associated with a worse prognosis in colorectal cancer patients, particularly in microsatellite-stable colon cancer.', 'Yes, BRAF V600E mutations are associated with worse prognosis in colorectal cancer patients, particularly in those with microsatellite-stable tumors. The presence of mutated BRAF is one of the most powerful negative prognostic factors for advanced and recurrent colorectal cancer. Patients with BRAF V600E mutations have significantly shorter overall survival compared to those with wild-type BRAF. However, BRAF V600E does not appear to impact the excellent prognosis of patients with microsatellite-unstable colorectal tumors.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nYes, the data suggests that BRAF V600E mutation is associated with a worse prognosis in colorectal cancer patients. This is evident from the relations table, where it is mentioned that BRAF V600E mutation is associated with poorer overall survival (OS) and progression-free survival (PFS) in various studies (e.g., relations 52, 53, 64, 65, 92). Additionally, the entities table shows that BRAF V600E mutation is associated with a poor prognosis in colorectal cancer patients, with a median OS of 23.1 months compared to 49.9 months in non-V600E mutation patients (relation 16). Furthermore, the studies listed in the sources table also support this association, with BRAF V600E mutation being a negative prognostic factor in stage IV colorectal cancer (relation 18) and associated with worse OS in MSI-H metastatic colorectal cancer (relation 19).\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer provides multiple pieces of evidence supporting the association between BRAF V600E mutation and worse prognosis in colorectal cancer patients, including references to poorer overall survival (OS) and progression-free survival (PFS). It also mentions specific studies and data points (e.g., median OS of 23.1 months vs. 49.9 months). However, it does not cover all aspects mentioned in the reference answers, such as the impact of microsatellite instability (MSI) or the association with advanced TNM stages.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise, focusing on the association of BRAF V600E mutation with worse prognosis without including irrelevant details. It uses specific data points and study references to support its claims, which enhances its precision. However, some of the references (e.g., relations 52, 53, 64, 65, 92) are not fully explained, which could slightly affect precision.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. It presents different pieces of evidence (e.g., OS, PFS, specific study results) to support the claim without redundancy.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-structured and fluent, making it easy to read. However, the use of references like 'relations 52, 53, 64, 65, 92' and 'relation 16' without further context could slightly impede readability for those unfamiliar with the source material."
    },
    {
        "Question": "Circular RNAs (circRNAs) are a distinct family of RNAs, how are they derived?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nCircular RNAs (circRNAs) are a distinct family of RNAs, how are they derived?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Most of the circRNAs reported to date originate from back splicing of a pre-mRNA.', 'Circular RNAs (circRNAs) are a novel category of covalently-closed non-coding RNAs mainly derived from the back-splicing of exons or introns of protein-coding genes.', 'Circular RNAs (circRNAs) are derived from precursor mRNA (pre-mRNA) through a process called backsplicing, where a downstream splice site is covalently linked to an upstream splice site, resulting in a circular RNA molecule.', 'Circular RNAs (circRNAs) are generated by back-splicing and have a single-stranded continuous circular structure.', 'Circular RNAs (circRNAs) are derived from pre-mRNA through a process known as back-splicing. This process results in a single-stranded continuous circular structure that is highly stable and conserved', \"3 Types of circRNAs are known, which are derived from different biogenetic mechanisms:\\n1. Circular RNA exons that are generated by exon-skipping;\\n2. Circular intron lariats (ciRNAs), which result from the ligation of a 3'-hydroxyl to a 5'-phosphate during spliceosome function; and\\n3. EcircRNAs, which are generated by direct back-splicing.\", 'Circular RNAs (circRNAs) are derived from pre-mRNA back splicing, which results in a single-stranded continuous circular structure', 'Circular RNAs (circRNAs) are derived from pre-mRNA back splicing. They are a distinct family of RNAs known for their considerable stability and conservation.', 'Circular RNAs (circRNAs) are derived from back-splicing of pre-mRNA, forming a single-stranded continuous circular structure. They are a distinct family of RNAs and are produced from exonic regions, termed canonical circRNAs.', 'Circular RNAs (circRNAs) are derived from pre-mRNA back splicing with considerable stability and conservation.', 'Circular RNAs (circRNAs) are derived from pre-mRNA back splicing. This process creates a continuous, single-stranded circular structure', 'Circular RNAs (circRNAs) are derived by a process called back-splicing, which results in a single-stranded continuous circular structure', 'Circular RNAs (circRNAs) are produced by back-splicing and influence the interactive RNA network by microRNA and protein sponging']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nCircular RNAs (circRNAs) are derived from precursor messenger RNA (pre-mRNA) through a process called back-splicing, which is a non-canonical splicing mechanism. In back-splicing, the 5' end of an upstream exon is covalently linked to the 3' end of a downstream exon, resulting in a circularized RNA molecule. This process is distinct from the conventional splicing mechanism, where the 5' splice site is connected to a downstream 3' splice site.\n\nThere are two main models of circRNA biogenesis: the lariat or exon skipping model and the direct back-splicing model. In the lariat model, canonical splicing occurs before back-splicing, whereas in the direct back-splicing model, the circRNA is generated first.\n\nBack-splicing is facilitated by the presence of specific sequences, such as reverse complementary sequences in the flanking introns and trans-acting factors, including splicing regulatory factors and RNA-binding factors. The exact mechanisms of circRNA biogenesis are still being researched and are not fully understood.\n\nIt is worth noting that circRNAs can also be derived from other sources, such as:\n\n* Lariat-derived intronic circRNAs: These are formed from introns that are retained in the mature RNA molecule.\n* Sub-exonic circRNAs: These are formed from exons that are not fully included in the mature RNA molecule.\n* Intron circles: These are formed from introns that are retained in the mature RNA molecule.\n* TricRNAs: These are formed from three exons that are joined together in a circular manner.\n\nOverall, the biogenesis of circRNAs is a complex process that involves multiple mechanisms and factors, and more research is needed to fully understand the details of this process.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer provides a comprehensive explanation of how circRNAs are derived, covering the process of back-splicing, the two main models of circRNA biogenesis, and additional sources of circRNAs. It aligns well with the reference answers and even adds more detail, such as the lariat or exon skipping model and direct back-splicing model, as well as other sources like lariat-derived intronic circRNAs, sub-exonic circRNAs, intron circles, and tricRNAs.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include irrelevant information. It focuses on the derivation of circRNAs and provides detailed, relevant mechanisms and factors involved in their biogenesis. All the information is pertinent to the question asked.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. Each point is distinct and contributes new details about the process of circRNA biogenesis. The explanation is concise and avoids redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand. It logically progresses from one point to another, making it highly readable. The use of bullet points for additional sources of circRNAs enhances clarity and readability."
    },
    {
        "Question": "Transgender identity and mortality.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nTransgender identity and mortality.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Transgender people might have higher mortality than their cisgender counterparts.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided tables, there are several data points related to transgender identity and mortality. \n\nTransgender individuals have higher rates of mortality compared to non-transgender individuals, as mentioned in relation #14 (\"TRANSGENDER IDENTITY\", \"MORTALITY\"). The study by \"Transgender Identity and Suicide Attempts and Mortality in Denmark\" (relation #10) found that transgender individuals had a significantly higher risk of suicide attempts and mortality compared to non-transgender individuals, with a standardized suicide attempt rate of 498 per 100,000 person-years and a standardized suicide mortality rate of 75 per 100,000 person-years.\n\nAnother study, \"Analysis of Mortality Among Transgender and Gender Diverse Adults in England\" (relation #11), found that transgender and gender diverse individuals had elevated mortality rates compared to cisgender individuals, with a mortality rate of 528.11 deaths per 100,000 person-years for transfeminine individuals and 325.86 deaths per 100,000 person-years for transmasculine individuals.\n\nThese findings suggest that transgender individuals may face higher mortality risks compared to non-transgender individuals, and further research is needed to understand the underlying causes of this disparity.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer provides detailed information from multiple studies regarding transgender identity and mortality, including specific rates and comparisons to non-transgender individuals. It covers the key points from the reference answers and expands with additional data.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer focuses on relevant data and studies about transgender mortality without including irrelevant details. The specific rates and comparisons are directly related to the question.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not repeat the same information unnecessarily. Each piece of data or study mentioned adds new information to the discussion about transgender mortality.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clear, and easy to read. The information flows logically, and the sentences are fluent and coherent."
    },
    {
        "Question": "Which genetic alteration is most commonly associated with the classical subtype of glioblastoma?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhich genetic alteration is most commonly associated with the classical subtype of glioblastoma?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Despite all of the progress in understanding its molecular biology and pathogenesis, glioblastoma (GBM) is one of the most aggressive types of cancer, and without an efficient treatment modality at the moment, it remains largely incurable. Nowadays, it is known that epidermal growth factor receptor (EGFR) amplification is one of the most commonly associated genetic alterations of the classical subtype of glioblastoma. However, targeted therapies against this type of receptor have not yet shown a clear clinical benefit.', 'The classical subtype of glioblastoma is most commonly associated with epidermal growth factor receptor (EGFR) gene amplification, occurring in 40-60% of cases. Despite EGFR overexpression contributing to the aggressive nature of GBM and numerous clinical trials for targeted therapies, no significant benefits have been reported due to resistance factors such as tumor heterogeneity, alternative pathways, and blood-brain barrier. Further understanding of these mechanisms is crucial for effective treatment strategies.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the genetic alteration most commonly associated with the classical subtype of glioblastoma is EGFR amplification.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately recalls the key information from the reference answers, stating that EGFR amplification is the most commonly associated genetic alteration in the classical subtype of glioblastoma.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and directly addresses the question without including any irrelevant details or digressions.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information and succinctly provides the required detail in a single statement.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is clear, concise, and easily understandable, making it highly readable."
    },
    {
        "Question": "What is PUL-2 in Duchenne Muscular Dystrophy?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is PUL-2 in Duchenne Muscular Dystrophy?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['PUL 2.0 is the performance of upper limb 2.0 (PUL) and is widely used to assess upper limb function in DMD patients.', 'The Performance of Upper Limb 2.0 (PUL-2) in Duchenne Muscular Dystrophy is a widely used assessment tool for evaluating upper limb function in patients with this condition.', 'The Performance of Upper Limb version 2.0 (PUL 2.0) is a widely used tool to assess upper limb function in Duchenne Muscular Dystrophy patients.', 'PUL-2 is a clinical scale for assessing the performance of the upper limb in patients with Duchenne muscular dystrophy.', 'The Performance of Upper Limb version 2.0 (PUL 2.0) is increasingly used in Duchenne Muscular Dystrophy (DMD) to study longitudinal functional changes of motor upper limb function in ambulant and non-ambulant patients.', 'PUL-2 is a component of the Performance of Upper Limb 2.0 (PUL) assessment tool, which is used to evaluate upper limb function in patients with Duchenne Muscular Dystrophy (DMD).', 'The performance of upper limb 2.0 (PUL) is a widely used assessment tool to evaluate upper limb function in Duchenne Muscular Dystrophy (DMD) patients.', 'PUL-2, or Performance of Upper Limb 2.0, is a tool used to assess upper limb function in patients with Duchenne Muscular Dystrophy (DMD).', 'The performance of upper limb 2.0 (PUL) is widely used to assess upper limb function in Duchenne Muscular Dystrophy.', 'The performance of upper limb 2.0 (PUL) is widely used to assess upper limb function in DMD patients.', 'PUL-2, or Performance of Upper Limb 2.0, is a standardized assessment tool used to evaluate upper limb function in Duchenne Muscular Dystrophy (DMD) patients', 'The performance of upper limb 2.0 in Duchenne Muscular Dystrophy is an assessment tool used to evaluate upper limb function in DMD patients.', 'PUL 2.0 or Performance of Upper Limb 2.0 is a tool used to assess the function of the upper limbs in patients with Duchenne Muscular Dystrophy (DMD).', 'PUL (Performance of Upper Limb) 2.0 is a widely used assessment tool to evaluate upper limb function in patients with Duchenne Muscular Dystrophy (DMD).', 'PUL 2.0 (Performance of Upper Limb 2.0) is a functional assessment tool used to evaluate upper limb function in patients with Duchenne muscular dystrophy (DMD). It measures the ability to perform various upper limb tasks and helps track disease progression and treatment effects in DMD.', 'PUL-2, or Performance of the Upper Limb 2.0, is a measure used to assess upper limb function in patients with Duchenne Muscular Dystrophy.', 'The performance of upper limb 2.0 (PUL) is widely used to assess upper limb function in DMD patients']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, PUL-2, also known as the \"PUL 2.0\" or \"Upper Limb 2.0\", is a tool or assessment used to evaluate upper limb function in patients with Duchenne Muscular Dystrophy (DMD). This is mentioned in the \"Relations\" table, where it is associated with the entity \"Duchenne Muscular Dystrophy\" and described as \"DMD patients are assessed using the PUL to evaluate upper limb function.\"\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately reports that PUL-2 is a tool used to evaluate upper limb function in Duchenne Muscular Dystrophy (DMD) patients. This aligns with the reference answers, which uniformly describe PUL-2 as an assessment tool for upper limb function in DMD.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information. It focuses solely on the purpose and use of PUL-2 in the context of DMD, which matches the key points from the reference answers.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information. It clearly and concisely defines PUL-2 and its application in DMD patients, avoiding redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, easily readable, and fluent. It clearly communicates the key points about PUL-2 without unnecessary complexity or ambiguity."
    },
    {
        "Question": "What is the mechanism of action of Mezigdomide?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the mechanism of action of Mezigdomide?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Mezigdomide is a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal activity in multiple myeloma.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data tables, the mechanism of action of Mezigdomide is not explicitly stated in the \"Mechanism of Action\" table. However, the relation between Mezigdomide and Multiple Myeloma is described in the Relations table, where it is stated that Mezigdomide has \"potent antiproliferative and tumoricidal activity in preclinical models of multiple myeloma\" and \"enhanced autonomous cell-killing activity in multiple myeloma cells and promising immunomodulatory and antitumor activity in patients with multiple myeloma.\"\n\nA more detailed description of Mezigdomide's mechanism of action can be found in the Sources table, where it is stated that Mezigdomide is a \"cereblon E3 ligase modulator\" and that it works by \"redirecting the ubiquitin-proteasome system (UPS) to reduce or eliminate proteins or survival factors key to malignant pathobiology, multiple myeloma (MM) in particular.\"\n\nThis suggests that Mezigdomide works by modulating the activity of the cereblon E3 ligase complex, which is involved in the ubiquitination and degradation of proteins. By targeting this pathway, Mezigdomide may be able to selectively kill cancer cells, such as those found in multiple myeloma, while sparing normal cells.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately recalls the mechanism of action of Mezigdomide, as described in the reference answer. It details how Mezigdomide modulates the cereblon E3 ligase complex, enhances antiproliferative and tumoricidal activity, and targets the ubiquitin-proteasome system, which are all key points mentioned in the reference.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise and focuses on the mechanism of action without including irrelevant information. However, it slightly elaborates on preclinical models and patient activity, which, while related, are not strictly necessary for explaining the mechanism.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information. It presents the mechanism of action clearly and then elaborates on implications, ensuring each point is distinct and informative.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-written, fluent, and easy to understand. It logically organizes information, making the complex mechanism of action accessible."
    },
    {
        "Question": "What is the average median survival for advanced colorectal cancer patients?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the average median survival for advanced colorectal cancer patients?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Median OS was roughly stable for patients diagnosed between 2004 and 2012 (22.6 months) but since has steadily improved for those diagnosed in 2013 to 2015 (28.8 months), and 2016 to 2019 (32.4 months)', 'According to the abstracts, the average median survival for advanced colorectal cancer patients varies from study to study. In one study, the median overall survival was reported to be nearly 2 years (20 months). Another study found a median survival of 18 months with a range of 12-18 months. A third study reported a median survival of 24 months in untreated advanced colorectal cancer patients. Overall, the median survival for advanced colorectal cancer patients appears to range from approximately 18-24 months, with some studies reporting longer or shorter median survivals depending on the specific patient population and treatment regimens used.', 'Advanced or metastatic colorectal cancer is a deadly disease with poor prognosis. Median survival for such patients is around 22-24 months, however, with novel therapeutic interventions, its been improved slightly.', 'The average median survival is close to 15 months and in best-case scenario approximately 40 months.', 'The average median survival for advanced colorectal cancer patients is 25 months, with hepatic metastases showing a median survival of 7 months and current patients having an expected median survival of 20 months.', \"The average median survival for advanced colorectal cancer patients is not explicitly stated in the provided Wikipedia articles. However, the articles mention that the five-year survival rate in the United States was around 65% in 2014, and the individual likelihood of survival depends on factors such as the stage of the cancer, the ability to remove the cancer surgically, and the person's overall health. The articles also discuss various treatment options for colorectal cancer, including surgery, radiation therapy, chemotherapy, and targeted therapy, as well as the importance of early detection and prevention through lifestyle changes and regular screenings.\\n\\nBased on the provided articles, the median survival time for patients with inoperable liver metastases from colorectal cancer is 7.4 to 11 months. Systemic chemotherapy produces a modest improvement to 12 months, while regional chemotherapy produces a further improvement to 15 to 17 months. The median survival time after diagnosis of metastases is almost comparable with 17 months. The median survival time was 6 months in the entire cohort, 16 months, 7.5 months, 8.5 months for all patients, 11 months for patients with solitary hepatic tumour, and 7.5 months for those with multiple tumours. Combined with regimens such as FOLFOX or FOLFIRI, median survival rates have been increased to an average of 23 months. The 1Y-PFS was 28.5% (median survival time (MST): 7.4 months), 1Y-OS was 76.6% (MST not reached), 3Y-PFS was 5.5% (MST: 7.4 months), and 3Y-OS was 26.4% (MST: 25.2 months).\", 'The average median survival for advanced colorectal cancer patients is 20 months. The addition of ramicurumab to second-line therapy significantly improved median overall survival. Immunotherapy has shown promise in GI malignancies, with the combination of pembrolizumab and chemotherapy extending median survival in patients with advanced colorectal cancer to 21 months. KRAS gene mutation is a poor prognostic factor in colorectal cancer patients, and advanced age and high TNM stage are independent risk factors for postoperative outcome in early-stage colorectal cancer patients. Class II and III obesity is associated with a modestly increased risk of disease recurrence and death in colorectal cancer patients. Fluorouracil has been the mainstay of chemotherapy for advanced colorectal cancer for over 40 years, and its use has been shown to prolong time to disease progression and survival in these patients.', 'The average median survival for advanced colorectal cancer patients is 25 months.', 'The median survival for advanced colorectal cancer patients is 12-18 months.', 'The average median survival time for advanced colorectal cancer patients is approximately 15 months. This is based on the data from several studies that report median survival times ranging from 6 to 25 months. It is important to note that the survival time can vary depending on the stage of the disease, the treatment regimen, and other patient-specific factors.', \"The average median survival for advanced colorectal cancer patients is around 65% in the United States, according to 2014 data. However, survival rates can vary significantly and depend on various factors, including the stage of the cancer, the effectiveness of treatment, and the patient's overall health. Median survival time for patients with inoperable liver metastases from colorectal cancer is 7.4 to 17 months. When combined with regimens such as FOLFOX or FOLFIRI, median survival rates have been increased to an average of 23 months.\", 'The median time to worsening of the ECOG performance-status score from 0 or 1 to 2 or more was 9.3 months in the combination group and 6.3 months in the FTD-TPI group (hazard ratio, 0.54; 95% CI, 0.43 to 0.67).', 'The average median survival for advanced colorectal cancer patients is approximately 20-24 months based on various studies; however, the median overall survival has increased over time due to advancements in treatment strategies.', \"The average median survival for advanced colorectal cancer patients, based on the abstracts provided, appears to be around 7 months. This estimate comes from a review of the natural history of disseminated colorectal cancer, which states that the overall median survival rate of patients with hepatic metastases from colorectal primary cancer is approximately 7 months. However, it's important to note that many patients survive for three years and some even live for more than ten years without any specific treatment. This variability in survival times underscores the complex nature of colorectal cancer and the importance of personalized medical approaches.\", 'The average median survival for advanced colorectal cancer patients is 20 months.The addition of ramicurumab to second line therapy significantly improved median overall survival.KRAS gene mutation in colorectal cancer patients is closely associated with poor prognosis.Obesity is a risk factor for poor overall survival in patients with colorectal cancer.EGFR, primary tumor site, and multiple metastases of tumor are independent risk factors for poor overall survival in patients with colorectal cancer.Fluorouracil has been the mainstay of chemotherapy for advanced colorectal cancer for over 40 years and is effective in prolonging time to disease progression and survival.', 'The average median survival for advanced colorectal cancer patients is between 12-20 months, however, this can vary based on many factors such as patient demographics, disease presentation, treatment response, and comorbidities.', 'The average median survival for advanced colorectal cancer patients is approximately 20-24 months, but has shown improvement over time due to advancements in treatment strategies. However, exact values can vary between studies and patient groups.', 'Based on the information provided, the median survival time for patients with advanced colorectal cancer, specifically those with liver metastases, ranges from approximately 6 to 17 months without treatment or with systemic chemotherapy alone. Some key findings:\\n\\n- Without treatment, median survival is around 7.4 to 11 months\\n- With systemic chemotherapy, median survival improves modestly to around 12 months  \\n- Regional chemotherapy can further improve median survival to 15-17 months\\n- More recent combination regimens like FOLFOX or FOLFIRI have increased median survival to around 23 months on average\\n\\nSo in summary, median survival for advanced colorectal cancer with liver metastases is quite poor, typically under 1.5 years, but modern chemotherapy regimens have improved this to almost 2 years. The exact median survival depends on the specific treatment approach.', 'According to the abstracts provided, the average median survival for advanced colorectal cancer patients varies depending on the specific study and population. However, based on the information presented, it can be concluded that: * The median overall survival for metastatic colorectal cancer is nearly 2 years (Abstract 1). * Median survival in advanced colorectal cancer patients treated with 5-fluorouracil (5FU) and leucovorin (LV) is between 12 and 18 months, with a specific study reporting a median survival of 18 months (Abstract 3). * The median survival for advanced CRC reported in clinical trials now approaches 2 years (Abstract 4). * In untreated advanced colorectal cancer patients, the median survival was found to be 24 months (range 16-42) (Abstract 5). , Overall, the average median survival for advanced colorectal cancer patients appears to be around 18-24 months.', 'Based on the provided information, the median survival time for patients with advanced or metastatic colorectal cancer ranges from approximately 6 to 25 months, depending on factors such as extent of metastases and treatment received.\\n\\nWithout treatment, median survival is around 7.5 to 11 months. Systemic chemotherapy modestly improves median survival to about 12 months. More aggressive treatments like regional chemotherapy or combined chemotherapy regimens (e.g. FOLFOX, FOLFIRI) can extend median survival further to 15-17 months or even up to 23-25 months in some cases.\\n\\nHowever, even with treatment, 5-year survival rates remain low, ranging from under 5% to 31%. Advanced colorectal cancer is rarely curable, although treatments can prolong survival. Median survival is highly variable based on individual patient and cancer characteristics.', 'The average median survival for advanced colorectal cancer (CRC) patients cannot be precisely determined from the provided text, as it presents data on overall survival (OS) improvements over time at a single institution, the University of Texas M.D. Anderson Cancer Center (UTMDACC). However, some key points can help approximate an answer: , 1. Median OS for de novo metastatic CRC patients at UTMDACC was 22.6 months for those diagnosed between 2004 and 2012., 2. For patients diagnosed from 2013 to 2015, the median OS improved to 28.8 months, and further increased to 32.4 months for those diagnosed from 2016 to 2019. , Considering these figures, a rough estimate of the average median survival for advanced CRC patients may fall between 22.6 and 32.4 months, with an understanding', 'The average median survival for patients with advanced colorectal cancer has slightly improved over the years. For those diagnosed between 2004 and 2012, the median overall survival (OS) was 22.6 months. However, there has been a steady increase in survival for more recently diagnosed patients. Those diagnosed between 2013 and 2015 had a median OS of 28.8 months, while those diagnosed between 2016 and 2019 experienced a further improvement in survival, with a median OS of 32.4 months. Therefore, on average, the median survival for advanced colorectal cancer patients is around 27-32 months, based on the most recent data.', 'The average median survival for advanced colorectal cancer patients is 32.4 months.', 'The average median survival for advanced colorectal cancer patients has been roughly stable for those diagnosed between 2004 and 2012 at 22.6 months, but has shown a steady improvement for those diagnosed in 2013 to 2015 (28.8 months) and 2016 to 2019 (32.4 months).', 'The average median survival for advanced colorectal cancer patients has steadily improved over the years. For patients diagnosed between 2004 and 2012, the median overall survival (OS) was roughly stable at 22.6 months. However, for those diagnosed in 2013 to 2015, the median OS improved to 28.8 months, and for those diagnosed in 2016 to 2019, the median OS further improved to 32.4 months.', 'The average median survival for advanced colorectal cancer patients has been improving, with it being 22.6 months for those diagnosed between 2004 and 2012, 28.8 months for those diagnosed between 2013 and 2015, and 32.4 months for those diagnosed between 2016 and 2019.', 'The average median survival for advanced colorectal cancer patients has steadily improved over time, with the median OS being 22.6 months for those diagnosed between 2004 and 2012, 28.8 months for those diagnosed in 2013 to 2015, and 32.4 months for those diagnosed in 2016 to 2019.', '30 months is the average median survival for advanced colorectal cancer patients, however it can vary based on several factors such as patient age, general health status, treatment response and presence of metastatic disease.', \"22.6 months for patients diagnosed between 2004 and 2012, 28.8 months for those diagnosed in 2013 to 2015, and 32.4 months for those diagnosed in 2016 to 2019. \\n\\nPlease go ahead and ask your question. I'll do my best to provide a concise answer. \\n\\n(Note: Please keep your question related to the context provided.)\", \" In summary, advanced colorectal cancer patients have varied survival outcomes depending on the extent and location of the disease, the patient's age, overall health status, and the effectiveness of available treatment options. Improvements in early detection and prompt initiation of appropriate chemoradiation regimens can help improve patient outcomes and reduce the need for extensive surgery and associated morbidity. \", 'Median OS was roughly stable for patients diagnosed between 2004 and 2012 (22.6 months) but since has steadily improved for those diagnosed in 2013 to 2015 (28.8 months), and 2016 to 2019 (32.4 months.', 'The average median survival for advanced colorectal cancer patients has improved over time. For patients diagnosed between 2004 and 2012, the median OS was 22.6 months, while for those diagnosed in 2013 to 2015, it was 28.8 months, and for those diagnosed in 2016 to 2019, it was 32.4 months.', 'The average median survival for advanced colorectal cancer patients has been improving over the years. For patients diagnosed between 2004 and 2012, the median overall survival (OS) was about 22.6 months. This improved to 28.8 months for those diagnosed between 2013 and 2015, and further increased to 32.4 months for those diagnosed between 2016 and 2019', 'The average median survival for advanced colorectal cancer patients is around 65% in the United States, according to 2014 data. However, the median overall survival for patients diagnosed between 2004 and 2012 was 22.6 months, but it has steadily improved for those diagnosed in 2013 to 2015 (28.8 months) and 2016 to 2019 (32.4 months).', 'The average median survival for advanced colorectal cancer patients has improved from 22.6 months between 2004 and 2012 to 28.8 months for those diagnosed in 2013 to 2015, and further improved to 32.4 months for those diagnosed in 2016 to 2019', 'In summary, based on the provided data, the average median overall survival (OS) of advanced colorectal cancer patients has improved over time from approximately 22.6 months between 2004 and 2012 to around 32.4 months for those diagnosed between 2016 and 2019. The weighted average median survival for the entire period is about 28.0 months.', 'The median overall survival (OS) for patients diagnosed with advanced colorectal cancer has been improving over the years. For those diagnosed between 2004 and 2012, it was roughly 22.6 months. It improved to 28.8 months for those diagnosed between 2013 and 2015, and further improved to 32.4 months for those diagnosed between 2016 and 2019.', 'The average median overall survival (OS) of advanced colorectal cancer patients has improved over time: 22.6 months for diagnoses between 2004 and 2012, 28.8 months for those diagnosed between 2013 and 2015, and 32.4 months for those diagnosed between 2016 and 2019. The average median survival across these periods is approximately 28.0 months.', 'The median overall survival (OS) for advanced colorectal cancer patients has improved over time:\\n\\n- For those diagnosed between 2004 and 2012, median OS was roughly stable at 22.6 months\\n- For those diagnosed from 2013 to 2015, median OS improved to 28.8 months  \\n- Most recently, for patients diagnosed between 2016 to 2019, the median OS further increased to 32.4 months\\n\\nIn summary, the average median survival for advanced colorectal cancer patients diagnosed in recent years is around 32 months, representing a substantial improvement compared to earlier time periods.', 'Based on the provided snippets, it appears that the question refers to the median overall survival (OS) of advanced colorectal cancer patients. The snippets suggest a steady improvement in median OS over time. , The median OS was roughly stable at 22.6 months for patients diagnosed between 2004 and 2012. However, for those diagnosed between 2013 and 2015, the median OS improved to 28.8 months, and further increased to 32.4 months for patients diagnosed between 2016 and 2019. , To calculate the average median survival, we can take a weighted average of these values based on the number of years in each period. Assuming equal weights, the average median OS would be approximately (22.6 + 28.8 + 32.4) / 3 = 28.0 months. , Therefore, the average median survival for advanced colorectal cancer patients is roughly 28.0 months.', 'The average median survival for advanced colorectal cancer patients is 32.4 months, 28.8 months, and 22.6 months for the years 2016 to 2019, 2013 to 2015, and 2004 to 2012 respectively.', 'Based on the provided information, the median overall survival for patients with advanced colorectal cancer has been improving in recent years:\\n\\nFor patients diagnosed between 2004 and 2012, median overall survival was around 22.6 months. \\n\\nFor those diagnosed from 2013 to 2015, median overall survival increased to 28.8 months.\\n\\nMost recently, for patients diagnosed between 2016 and 2019, the median overall survival further improved to 32.4 months.\\n\\nSo in summary, while advanced colorectal cancer remains difficult to cure, treatment advances have extended median survival from under 2 years to nearly 3 years over the past 15 years. However, individual prognosis still depends on factors like extent of disease, treatment options, and overall health.', 'The average median survival for advanced colorectal cancer patients has been improving over the years. It was roughly stable at 22.6 months for patients diagnosed between 2004 and 2012, improved to 28.8 months for those diagnosed in 2013 to 2015, and further improved to 32.4 months for those diagnosed in 2016 to 2019.', '32.4 months\\n\\nContext: The median OS was 22.6 months for patients diagnosed between 2004 and 2012, 28.8 months for those diagnosed in 2013 to 2015, and 32.4 months for those diagnosed in 2016 to 2019.\\nQuestion: What is the average median survival for advanced colorectal cancer patients?\\nAnswer: 32.4 months\\n\\nContext: The median OS was 22.6 months for patients diagnosed between 2004 and 2012, 28.8 months for those diagnosed in 2013 to 2015, and 32.4 months for those diagnosed in 2016 to 2019.\\nQuestion: What is the average median survival for advanced colorectal cancer patients?\\nAnswer: 32.4 months\\n\\nContext: The median OS was 22.6 months for patients diagnosed between 2004 and 2012, 28.8 months for those diagnosed in 2013 to 2015, and 32.4 months for those diagnosed in 2016 to 2019.\\nQuestion: What is the average median survival for advanced colorectal cancer patients?\\nAnswer: 32.4 months\\n\\nContext:']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, the median survival rate for patients with advanced colorectal cancer varies depending on the stage and treatment. However, based on the data, we can see that the median survival rate for patients with stage IV colorectal cancer is around 25.1 months, as mentioned in study 5, \"Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)\".\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 2,
        "Information Recall Explanation": "The answer mentions a specific median survival rate of 25.1 months from a study, but it does not align with the comprehensive reference data provided, which indicates improvements from 22.6 to 32.4 months over different years. The reference answers suggest a more detailed and nuanced understanding of survival rates.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer is precise in citing a specific study and survival rate, but it lacks alignment with the broader reference data, which could lead to potential inaccuracies. The precision could be improved by referencing the detailed time-based improvements.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. It succinctly presents the data from the specified study without redundancy.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is clear and well-structured, making it easy to read and understand. It effectively conveys the information without unnecessary complexity, though it could benefit from a more comprehensive context."
    },
    {
        "Question": "What is the function of the mTORC1 kinase?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the function of the mTORC1 kinase?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The mammalian target of rapamycin (mTOR) is one of the most important signaling pathways that regulate nutrient sensing, cell growth, metabolism, and aging. The mTOR pathway, particularly mTOR complex 1 (mTORC1), has been shown to control aging, lifespan, and healthspan through the regulation of protein synthesis, autophagy, mitochondrial function, and metabolic health.', 'The mammalian target of rapamycin complex 1 (mTORC1) kinase plays a crucial role in the regulation of protein and lipid synthesis, autophagy, mitochondrial function and metabolism.\\nDeregulation of mTORC1 has been implicated in a variety of metabolic diseases.', 'mTORC1 transduces anabolic signals to stimulate protein synthesis and inhibits autophagy.', 'The mTORC1 kinase plays a key role in the regulation of cell growth and metabolism. It regulates multiple cellular processes, including protein translation and autophagy.', 'mTORC1 is a protein kinase that plays a central role in regulating cell growth and metabolism in response to various environmental cues, including nutrient availability, energy status, and growth factor signaling.', 'mTORC1 is a protein kinase complex involved in nutrient sensing, growth factor signaling, and cellular energy balance, and its activation promotes cell growth, proliferation, and survival. mTORC1 is implicated in various pathological states, including cancer and metabolic disorders.', 'The mTORC1 kinase is a nutrient-sensing kinase that regulates cell growth in response to nutritional status, particularly by controlling protein synthesis, autophagy, mitochondrial function, and metabolic health. It functions as a molecular sensor for amino acids, linking the cellular demand to the nutritional supply.', 'mTOR complex 1 (mTORC1) regulates cell growth in response to nutritional status and controls aging, lifespan, and healthspan through the regulation of protein synthesis, autophagy, mitochondrial function, and metabolic health.', 'The mTORC1 kinase is a key regulator of cell growth and metabolism. It is activated in response to nutrient availability and growth factors, and phosphorylates and activates key downstream effectors, including the translation initiation factor 4E-BP1, the cell cycle regulator S6K1, and the transcription factor FOXO1. mTORC1 also regulates autophagy and mitochondrial function, and is a key regulator of aging and lifespan.', 'The mTORC1 kinase regulates cell growth in response to nutritional status. It also controls aging, lifespan, and healthspan through the regulation of protein synthesis, autophagy, mitochondrial function, and metabolic health.', 'The mTORC1 kinase regulates cell growth in response to nutritional status. It is one of the most important signaling pathways that regulate nutrient sensing, cell growth, metabolism, and aging. The mTOR pathway, particularly mTOR complex 1 (mTORC1), has been shown to control aging, lifespan, and healthspan through the regulation of protein synthesis, autophagy, mitochondrial function, and metabolic health.', 'The mTORC1 kinase is a major nutrient sensor and regulator of cell growth, proliferation, and metabolism. mTORC1 mediates cellular response to nutrients and hormones and is the central regulator of anabolic metabolism. mTORC1 integrates various signals to orchestrate a physiological program that allows cells to grow and divide.', 'mTORC1 is a nutrient-sensing kinase that regulates cell growth in response to nutritional status. It plays a key role in controlling cell growth, proliferation, differentiation, metabolism, and survival, ultimately contributing to the physiological development and functions of various organs, including the kidney.', 'The mTORC1 kinase, part of the mTOR signaling pathway, plays a crucial role in regulating cell growth in response to nutritional status. It controls various biological processes including protein synthesis, autophagy, mitochondrial function, and metabolic health. This kinase is also involved in nutrient sensing, cell growth, metabolism, and aging', 'The mammalian target of rapamycin (mTOR) complex 1 (mTORC1) regulates cell growth in response to nutritional status.', 'mTORC1 kinase regulates cell growth based on nutritional status, controlling protein synthesis, autophagy, mitochondrial function, and metabolic health; it influences aging, lifespan, and organ development and functions.', 'The mTORC1 kinase, or mechanistic target of rapamycin complex 1, regulates cell growth in response to nutritional status. It plays key roles in controlling cell growth, proliferation, differentiation, metabolism, and survival. It also contributes to the physiological development and functions of various organs. Additionally, it has been shown to control aging, lifespan, and healthspan through the regulation of protein synthesis, autophagy, mitochondrial function, and metabolic health.', 'The mTORC1 kinase is a nutrient-sensing kinase that regulates cell growth in response to nutritional status. It plays a key role in controlling protein synthesis, autophagy, mitochondrial function, and metabolic health, thereby contributing to aging, lifespan, and healthspan.', 'The mTORC1 kinase is a key regulator of cell growth and metabolism. It is activated in response to nutrient availability and growth factors, and regulates protein synthesis, autophagy, and mitochondrial function. The mTOR pathway is also involved in aging and lifespan regulation.', 'mTORC1 kinase regulates cell growth by controlling protein synthesis, autophagy, mitochondrial function, and metabolic health in response to nutritional status. It influences aging, lifespan, and healthspan, as well as contributes to the development and functions of various organs like the kidney.', 'The mTOR complex 1 (mTORC1) kinase regulates cell growth, metabolism, and aging in response to nutrient availability. It controls protein synthesis, autophagy, mitochondrial function, and metabolic health, thereby contributing to lifespan and healthspan.', 'Based on the provided snippets, the function of mTORC1 (mechanistic target of rapamycin complex 1) kinase is to regulate cell growth in response to nutritional status. Specifically, it controls protein synthesis, autophagy, mitochondrial function, and metabolic health, ultimately influencing aging, lifespan, and healthspan. Additionally, mTORC1 plays a key role in the regulation of cell growth, proliferation, differentiation, metabolism, and survival, contributing to the physiological development and functions of various organs, including the kidney.', 'The mTORC1 kinase is a key player in the regulation of cell growth, metabolism, and aging. It controls these processes by responding to nutrient availability and other cellular signals. Specifically, mTORC1 regulates protein synthesis, autophagy, mitochondrial function, and metabolic health. By doing so, it contributes to the physiological development and functions of various organs, including the kidney.', 'mTORC1 kinase regulates cell growth by controlling protein synthesis, autophagy, and metabolism in response to nutritional status, maintaining cellular homeostasis and overall health, particularly in the kidney and heart.', 'mTORC1 (mammalian target of rapamycin complex 1) is a protein kinase complex that functions as a central regulator of cell growth, metabolism, and aging in response to nutrient availability and other environmental cues. When activated by sufficient nutrients and growth factors, mTORC1 promotes anabolic processes such as protein synthesis, lipid synthesis, and cell proliferation, while inhibiting catabolic processes like autophagy. This allows cells to grow and divide when resources are plentiful. Conversely, mTORC1 is inhibited under starvation conditions to conserve resources. By controlling these fundamental cellular processes, mTORC1 plays a key role in physiological development, metabolic regulation, and age-related pathologies.', 'The mTORC1 kinase plays a crucial role in regulating cell growth in response to nutritional status. It controls various processes such as protein synthesis, autophagy, mitochondrial function, and metabolic health. It also has a significant role in aging, lifespan, and healthspan', 'The mTORC1 kinase is a key regulator of the mTOR signaling pathway, which plays a crucial role in controlling nutrient sensing, cell growth, metabolism, and aging. Specifically, mTORC1 regulates protein synthesis, autophagy, mitochondrial function, and metabolic health, ultimately influencing aging, lifespan, and healthspan']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe mTORC1 kinase is a critical component of the mechanistic target of rapamycin (mTOR) pathway, which plays a central role in regulating cell growth, proliferation, and metabolism. mTORC1 is a protein complex that integrates inputs from nutrients, energy status, and growth factors to regulate various cellular processes.\n\nThe primary function of mTORC1 is to promote anabolic processes, including:\n\n1. **Protein synthesis**: mTORC1 regulates the translation of mRNA into proteins by phosphorylating and activating key regulators of mRNA translation, such as S6K1 and 4E-BP1.\n2. **Ribosome biogenesis**: mTORC1 promotes the synthesis of ribosomal RNA and proteins, which are essential for protein synthesis.\n3. **Glycolysis and lipogenesis**: mTORC1 regulates the expression of genes involved in glycolysis and lipogenesis, which are critical for energy production and storage.\n4. **Autophagy**: mTORC1 inhibits autophagy, a process by which cells recycle damaged or dysfunctional organelles and proteins.\n5. **Cell growth and proliferation**: mTORC1 promotes cell growth and proliferation by regulating the expression of genes involved in cell cycle progression and DNA synthesis.\n\nmTORC1 is activated by growth factors, such as insulin and amino acids, and inhibited by nutrient deprivation, energy stress, and hypoxia. Dysregulation of mTORC1 has been implicated in various diseases, including cancer, diabetes, and autoimmune disorders.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers all the major functions of mTORC1 kinase as indicated in the reference answers, including protein synthesis, autophagy, cell growth and proliferation, and its role in metabolism (glycolysis and lipogenesis). It also mentions the regulatory inputs (nutrients, energy status, growth factors) and the implications of mTORC1 dysregulation in diseases.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and focuses only on the functions and regulatory mechanisms of mTORC1 kinase without including any irrelevant information. Each point is directly related to the role and regulation of mTORC1.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each point is distinct and adds new information about the function and regulation of mTORC1 kinase.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clearly organized into bullet points, and written in a fluent and easily understandable manner. The use of numbered points enhances readability and comprehension."
    },
    {
        "Question": "Has statin use been associated with a higher risk of dementia?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nHas statin use been associated with a higher risk of dementia?\n\nHere are some reference answers:\n\n**Reference Answers:**\n[\"No, there is no strong evidence to suggest that statin use is associated with a higher risk of dementia. In fact, some studies have found that statin use may be linked to a reduced risk of dementia, particularly among patients with stroke. However, it's important to note that the relationship between statins and dementia risk is complex and may depend on various factors such as the type and duration of statin use, age, sex, and other health conditions. Further research is needed to fully understand the potential benefits and risks of statin use in relation to dementia.\", \"According to a systematic review and meta-analysis of observational studies, statin use is not associated with a higher risk of dementia or Alzheimer's disease. In fact, the study found that statin use was associated with a decreased risk of both dementia and Alzheimer's disease. This reduction in risk was similar for both lipophilic and hydrophilic statins, but high-potency statins showed a greater efficacy in reducing dementia risk compared to low-potency statins. These findings suggest that statin treatment does not carry a neurocognitive risk and may even have a potential favorable role in reducing the risk of dementia. However, randomized clinical trials are needed to further explore this potential neuroprotective effect.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the data, there is no clear evidence to suggest that statin use has been associated with a higher risk of dementia. In fact, several studies have found that statin use may be associated with a lower risk of dementia. For example, one study found that statin use was associated with a 21% lower risk of dementia in patients with stroke (study 18). Another study found that statin use was associated with a 22% lower risk of dementia in patients with hypercholesterolemia (study 19). Additionally, a meta-analysis of observational studies found that statin use was associated with a 20% lower risk of dementia (study 16). However, it's essential to note that these findings are based on observational studies, and more research is needed to confirm these associations.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer effectively covers key points from the reference answers, including the lack of association between statin use and higher dementia risk, and the potential reduction in dementia risk with statin use. It also includes specific study examples (studies 18, 19, and 16) to support these claims.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise and focuses on the relevant information about statin use and dementia risk. It does not include irrelevant details. However, it could briefly mention the complexity of the relationship (e.g., factors like type and duration of statin use) as noted in the reference answers.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information unnecessarily. Each piece of information serves to build a coherent argument without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to follow. The use of specific examples and clear language enhances readability."
    },
    {
        "Question": "Is DNA methylation always associated with gene silencing?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs DNA methylation always associated with gene silencing?\n\nHere are some reference answers:\n\n**Reference Answers:**\n[\"DNA methylation is frequently described as a 'silencing' epigenetic mark, and indeed this function of 5-methylcytosine was originally proposed in the 1970s. Now, thanks to improved genome-scale mapping of methylation, we can evaluate DNA methylation in different genomic contexts: transcriptional start sites with or without CpG islands, in gene bodies, at regulatory elements, and at repeat sequences. The emerging picture is that the function of DNA methylation seems to vary with context, and the relationship between DNA methylation and transcription is more nuanced than we realized at first. For example, in the standard model, methylation in gene promoters has received the most attention since it is generally associated with transcriptional silencing. In contrast, recent studies in human tissues reveal that methylation of the region downstream of the transcription start site is highly informative of gene expression. Also, in some cell types and specific genes, it has been found that methylation of the first intron is linked with gene expression. Therefore, improving our understanding of the functions of DNA methylation is necessary for interpreting changes in this mark that are observed in diseases such as cancer.\", \"DNA methylation is not always associated with gene silencing. While it is true that DNA methylation is frequently described as a 'silencing' epigenetic mark, recent studies have shown that its function varies with context. Improved genome-scale mapping of methylation has allowed for a more nuanced understanding of the relationship between DNA methylation and transcription. For example, methylation in gene bodies, regulatory elements, and repeat sequences can have positive associations with gene expression. Additionally, recent studies in human tissues have found that methylation downstream of the transcription start site and in the first intron, a gene feature typically rich in enhancers, is linked with gene expression. Therefore, DNA methylation should not be solely considered as a mark of gene silencing, but rather as a more complex mechanism of epigenetic regulation.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, DNA methylation is not always associated with gene silencing. While it is true that DNA methylation is frequently described as a \"silencing\" epigenetic mark, the relationship between DNA methylation and transcription is more nuanced than previously thought.\n\nAs stated in the data, \"The emerging picture is that the function of DNA methylation seems to vary with context, and the relationship between DNA methylation and transcription is more nuanced than we realized at first.\" (Source: Functions of DNA methylation: islands, start sites, gene bodies and beyond.)\n\nIn fact, the data suggests that DNA methylation can also be associated with active gene expression in certain contexts. For example, some genes that are hypermethylated are still expressed at low or undetectable levels, while others are moderately expressed despite being hypermethylated. (Source: DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status.)\n\nAdditionally, the data highlights that the function of DNA methylation can vary depending on the genomic context, such as transcriptional start sites with or without CpG islands, gene bodies, regulatory elements, and repeat sequences. (Source: Functions of DNA methylation: islands, start sites, gene bodies and beyond.)\n\nTherefore, while DNA methylation is often associated with gene silencing, it is not a universal rule, and its relationship with gene expression can be context-dependent.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer effectively captures the key points from the reference answers, including the nuanced relationship between DNA methylation and gene silencing, the context-dependent nature of methylation effects, and examples of methylation associated with gene expression.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include irrelevant information. It focuses on the context-dependent outcomes of DNA methylation and avoids digressing into unrelated topics.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer avoids significant repetition, although it does reiterate the nuanced nature of DNA methylation's role, which is necessary for clarity but slightly redundant.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand. It presents complex information in a clear and accessible manner."
    },
    {
        "Question": "Are there any digital biomarkers for Duchenne Muscular Dystrophy?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nAre there any digital biomarkers for Duchenne Muscular Dystrophy?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes, digital biomarkers have been developed for Duchenne Muscular Dystrophy.', 'Yes, there are digital biomarkers for Duchenne Muscular Dystrophy.', 'Yes. Bayesian optimization, machine learning algorithms and movement behavioral fingerprints are used as digital biomarkers for Duchenne Muscular Dystrophy.', 'Yes, a digital biomarker called the KineDMD ethomic biomarker has been developed for Duchenne Muscular Dystrophy. It is derived from daily-life behavioral data and can predict disease progression.', 'Yes, the KineDMD ethomic biomarker is a digital biomarker for Duchenne Muscular Dystrophy.', \"Yes, there is a digital biomarker for Duchenne Muscular Dystrophy. It's called the KineDMD ethomic biomarker, which is derived from daily-life behavioral data.\", 'Yes, wearable full-body motion tracking of activities of daily living is a digital biomarker for Duchenne Muscular Dystrophy that can predict disease trajectory', 'Yes, the KineDMD ethomic biomarker is a digital biomarker for Duchenne Muscular Dystrophy. It is derived from daily-life movement behavior and can predict disease progression in patients with muscular dystrophy and can potentially track the response to therapy']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided tables, there are several digital biomarkers mentioned for Duchenne Muscular Dystrophy (DMD). \n\nOne example is the \"KINEDMD ETHOMIC BIOMARKER\" (id: 14), which is described as a \"behavioral biomarker developed using machine learning algorithms to track disease progression in patients with Duchenne muscular dystrophy\".\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer correctly identifies the KineDMD ethomic biomarker as a digital biomarker for Duchenne Muscular Dystrophy (DMD) and mentions its use of machine learning algorithms to track disease progression. However, it does not cover other mentioned digital biomarkers like Bayesian optimization or wearable full-body motion tracking.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise, focusing specifically on the KineDMD ethomic biomarker without including any irrelevant information. It directly addresses the question without straying from the topic.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition in the answer. It clearly and concisely presents the information about the KineDMD ethomic biomarker without redundancies.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is easily readable and fluent. The sentence structure is clear, and the information is presented in a straightforward manner."
    },
    {
        "Question": "How should Insulin icodec be administered?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nHow should Insulin icodec be administered?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Insulin icodec is administered as once weekly injection.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, Insulin icodec can be administered subcutaneously (under the skin) as a once-weekly basal insulin analog.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer reports all necessary information, including the frequency (once-weekly) and the method of administration (subcutaneously).",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer is mostly precise but includes additional details (basal insulin analog) that, while correct, are not strictly necessary to answer the question about administration.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat any information; each detail is mentioned only once.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is easily readable and fluent, with clear and concise language."
    },
    {
        "Question": "Is FOLFIRI plus Aflibercept a cost-effective treatment in patients with advanced colorectal caner?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs FOLFIRI plus Aflibercept a cost-effective treatment in patients with advanced colorectal caner?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Compared with FOLFIRI treatment, aflibercept combined with FOLFIRI for the second-line treatment of mCRC patients has better efficacy, worse safety, and is not cost-effective', 'According to the abstracts, the cost-effectiveness of FOLFIRI plus aflibercept in patients with advanced colorectal cancer is uncertain. One study found that adding AFL or RAM to FOLFIRI in the second line of mCRC treatment was not cost-effective in the Japanese health care system, and AFL was more cost-effective than RAM. Another study concluded that combining pharmacological costs of drugs with the measure of efficacy represented by progression-free survival (PFS), aflibercept in combination with FOLFIRI is a cost-effective second-line treatment for patients with mCRC. However, a rapid health technology assessment found that compared with FOLFIRI, aflibercept combined with FOLFIRI had no cost-effectiveness advantage in mCRC patients receiving second-line treatment. Overall, the evidence suggests that the cost-effectiveness of FOLFIRI plus aflibercept is uncertain and may depend on the specific healthcare system and patient population.', 'FOLFIRI plus aflibercept is not cost-effective in patients with advanced colorectal cancer.', 'No, FOLFIRI plus Aflibercept is not a cost-effective treatment in patients with advanced colorectal cancer.', 'No, FOLFIRI plus Aflibercept is not considered a cost-effective treatment in patients with advanced colorectal cancer.', 'The cost-effectiveness of FOLFIRI plus Aflibercept in patients with advanced colorectal cancer is not definitively established and may vary depending on the healthcare system and specific circumstances. Some studies suggest that it may not be a cost-effective use of resources, while others suggest that it may be an efficient strategy. The incremental cost-effectiveness ratios reported in the literature range from 19,836,504 to 41,947,989 per quality-adjusted life-year (QALY) gained. The National Institute for Health and Care Excellence (NICE) in the UK concluded that FOLFIRI plus Aflibercept could not be considered a cost-effective use of National Health Service resources for treating metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen. However, other studies have found that it may be a cost-effective second-line treatment for patients with metastatic colorectal cancer.', 'Yes, aflibercept plus FOLFIRI is a cost-effective treatment in patients with advanced colorectal cancer. The addition of aflibercept to FOLFIRI resulted in a small but statistically significant increase in overall survival in a phase III clinical trial. This treatment combination is a useful option for patients with metastatic colorectal cancer previously treated with oxaliplatin-containing regimens. However, the cost-effectiveness of this treatment regimen should be carefully evaluated in clinical practice settings.', 'According to the cost-effectiveness analysis, FOLFIRI plus Aflibercept is a cost-effective treatment in patients with advanced colorectal cancer. The Euros 38,931/LYG obtained with this combination is considered efficient from the National Health System perspective. However, it is important to note that this analysis is based on specific healthcare system and cost parameters, and may not be directly applicable to other settings.', 'According to a cost-effectiveness analysis, FOLFIRI plus aflibercept is not considered a cost-effective use of National Health Service resources for treating metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen. However, another study found that aflibercept in combination with FOLFIRI is a cost-effective second-line treatment for patients with mCRC. It is important to note that cost-effectiveness can vary depending on the healthcare system and specific cost considerations.', 'Yes, FOLFIRI plus Aflibercept is a cost-effective treatment in patients with advanced colorectal cancer.', 'Summary: The cost-effectiveness of FOLFIRI plus Aflibercept in patients with advanced colorectal cancer varies across studies, regions, and treatment lines, making it uncertain overall. Some studies found it to be a cost-effective option, while others did not.', 'According to the abstracts provided, the cost-effectiveness of FOLFIRI plus aflibercept in patients with advanced colorectal cancer is uncertain. In Japan, adding AFL or RAM to FOLFIRI in second-line treatment was not found to be cost-effective. However, a European study suggested that aflibercept in combination with FOLFIRI had the lowest cost per month of progression-free survival gained (€45,811). Another study concluded that aflibercept plus FOLFIRI could not be considered a cost-effective use of National Health Service resources for treating metastatic colorectal cancer. A rapid health technology assessment found that aflibercept combined with FOLFIRI had no cost-effectiveness advantage in mCRC patients receiving second-line treatment. Overall, the evidence suggests that the cost-effectiveness of FOLFIRI plus aflibercept is uncertain and may vary depending on the healthcare system and region.', 'Yes, FOLFIRI plus Aflibercept is a cost-effective treatment in patients with advanced colorectal cancer. In a cost-effectiveness analysis, Euros 38,931/LYG was obtained with aflibercept in combination with FOLFIRI versus FOLFIRI alone.', 'Based on a study done by the University of Toronto, FOLFIRI plus Aflibercept is not cost-effective for patients with advanced colorectal cancer.', 'In summary, the cost-effectiveness of FOLFIRI plus Aflibercept in patients with advanced colorectal cancer varies across studies and regions; some show it to be cost-effective while others do not, indicating uncertainty about its overall value.', 'Based on the information provided, the cost-effectiveness of FOLFIRI plus aflibercept for advanced colorectal cancer is mixed. Some studies suggest it is cost-effective:\\n\\n- One study found aflibercept plus FOLFIRI had the lowest cost per month of progression-free survival (PFS) at €4581, and concluded it was cost-effective as a second-line treatment.\\n\\n- Another reported an incremental cost-effectiveness ratio of €38,931 per life-year gained with aflibercept plus FOLFIRI vs FOLFIRI alone, deeming it an efficient second-line strategy. \\n\\nHowever, other analyses indicate it may not be cost-effective:\\n\\n- A UK analysis reported incremental cost-effectiveness ratios of £54,368-£92,089 per quality-adjusted life year (QALY) for aflibercept plus FOLFIRI. The appraisal committee concluded it could not be considered cost-effective.\\n\\n- In Japan, aflibercept plus FOLFIRI was found not cost-effective compared to FOLFIRI alone, with an incremental cost-effectiveness ratio of ¥19,836,504 (US$179,678) per QALY.\\n\\nIn summary, while some studies support the cost-effectiveness of aflibercept plus FOLFIRI, others suggest it exceeds commonly accepted willingness-to-pay thresholds. The cost-effectiveness likely varies between healthcare systems and patient populations.', 'Based on the abstracts, the cost-effectiveness of FOLFIRI plus Aflibercept in patients with advanced colorectal cancer is controversial. In Japan, adding AFL or RAM to FOLFIRI was not found to be cost-effective. However, in another study, combining pharmacological costs with progression-free survival (PFS) suggested that aflibercept in combination with FOLFIRI was a cost-effective second-line treatment for patients with metastatic colorectal cancer. Additionally, a rapid health technology assessment concluded that aflibercept combined with FOLFIRI had no cost-effectiveness advantage compared to FOLFIRI alone in mCRC patients receiving second-line treatment. Overall, the evidence suggests that FOLFIRI plus Aflibercept may not be a cost-effective treatment for advanced colorectal cancer patients.', \"Based on the information provided, the cost-effectiveness of FOLFIRI plus aflibercept for treating advanced colorectal cancer is unclear and debated. A few studies found it to be cost-effective, with one reporting it had the lowest cost per month of progression-free survival compared to other regimens. However, other analyses determined it was not cost-effective, with incremental cost-effectiveness ratios per quality-adjusted life-year that were quite high from a health system perspective. The UK's NICE concluded aflibercept plus FOLFIRI could not be considered a cost-effective use of National Health Service resources for metastatic colorectal cancer. So while aflibercept plus FOLFIRI provides a survival benefit, its high cost raises questions about its overall cost-effectiveness. More research is likely needed to determine if the efficacy gains justify the added expense in different health care settings.\", 'According to the studies, FOLFIRI plus Aflibercept is not considered a cost-effective treatment for patients with metastatic colorectal cancer. The incremental cost-effectiveness ratio (ICER) was estimated to be £54,368 per quality-adjusted life-year (QALY) in one study, and ¥19,836,504 (approximately US $179,678) per QALY in another study, which exceeds the willingness-to-pay threshold in both cases. This suggests that the additional cost of Aflibercept is not justified by its marginal health benefits. Therefore, FOLFIRI plus Aflibercept cannot be considered a cost-effective treatment option for patients with advanced colorectal cancer.', \"FOLFIRI plus Aflibercept is not a cost-effective treatment for patients with advanced colorectal cancer. The NICE Appraisal Committee determined that the combination of aflibercept with irinotecan and fluorouracil-based therapy is not a cost-effective use of National Health Service resources for treating metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen. This is due to the treatment's worse safety profile and higher cost compared to FOLFIRI alone, without a significant improvement in efficacy. Similar conclusions were reached in the Japanese healthcare system, where adding AFL or RAM to FOLFIRI in the second line of mCRC treatment was not cost-effective.\", 'No, adding AFL or RAM to FOLFIRI in the second line of mCRC treatment was not cost-effective in the Japanese health care system.', 'Based on the available evidence, FOLFIRI plus Aflibercept is not considered a cost-effective treatment for patients with advanced colorectal cancer. The National Institute for Health and Care Excellence (NICE) in the UK has concluded that Aflibercept in combination with FOLFIRI is not recommended for the treatment of metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen. Similarly, a study in the Japanese healthcare system found that adding Aflibercept or Ramucirumab to FOLFIRI in the second line of treatment for metastatic colorectal cancer was not cost-effective.', 'No, aflibercept plus FOLFIRI is not cost-effective in patients with advanced colorectal cancer.', 'No, FOLFIRI plus Aflibercept is not a cost-effective treatment for patients with advanced colorectal cancer. This conclusion is based on evaluations by the NICE Appraisal Committee and within the Japanese health care system.', 'Yes. The FOLFIRI plus Aflibercept combination regimen is considered cost-effective, when compared to FOLFIRI alone, in patients with advanced colorectal cancer.', \"According to the NICE guidance TA307, FOLFIRI plus Aflibercept is not a cost-effective treatment for patients with metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen. Additionally, the Japanese health care system also found that adding AFL or RAM to FOLFIRI in the second line of mCRC treatment was not cost-effective.  Therefore, the answer is no, FOLFIRI plus Aflibercept is not a cost-effective treatment in patients with advanced colorectal cancer.  However, it is important to note that the efficacy of FOLFIRI plus Aflibercept is better compared to FOLFIRI treatment alone.  Therefore, the decision to use this treatment should be made after careful consideration of the patient's individual circumstances and the availability of alternative treatments.  Patients should discuss their treatment options with their healthcare provider to determine the best course of treatment for their specific situation\", 'In summary, adding FOLF(5-FUorylotin) to the standard treatment of advanced colorectal cancer improves overall survival and may be considered cost-effective in certain patients. ', 'No, FOLFIRI plus Aflibercept is not considered a cost-effective treatment in patients with advanced colorectal cancer. This is based on the conclusions of the National Institute for Health and Care Excellence (NICE) in the UK, as well as studies in the Japanese health care system. These studies have found that adding Aflibercept to FOLFIRI in the second line of treatment for metastatic colorectal cancer (mCRC) is not cost-effective. Additionally, a study published in 2013 found that aflibercept in combination with irinotecan and fluorouracil-based therapy could not be considered a cost-effective use of National Health Service resources for treating mCRC that is resistant to or has progressed after an oxaliplatin-containing regimen.', 'No, the combination of FOLFIRI and Aflibercept is not considered a cost-effective treatment for patients with advanced colorectal cancer. This conclusion is based on various studies and assessments, including those conducted by the National Health Service and the Japanese health care system', 'No, FOLFIRI plus Aflibercept is not considered a cost-effective treatment in patients with advanced colorectal cancer. This conclusion is based on the results of a cost-effectiveness analysis (CEA) study which found that adding Aflibercept to FOLFIRI in the second line of mCRC treatment was not cost-effective in the Japanese health care system. Additionally, a study published by the National Institute for Health and Care Excellence (NICE) in the UK found that aflibercept in combination with irinotecan and fluorouracil-based therapy could not be considered a cost effective use of National Health Service resources for treating metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen.', 'Yes, FOLFIRI plus aflibercept is a cost-effective treatment option for patients with advanced colorectal cancer.', 'No, FOLFIRI plus Aflibercept is not a cost-effective treatment in patients with advanced colorectal cancer', \"FOLFIRI plus Aflibercept is not a cost-effective treatment for metastatic colorectal cancer due to high incremental costs and low health benefits, exceeding the willingness-to-pay threshold in both studies. The therapy's additional cost does not justify its marginal advantages for patients with advanced colorectal cancer.\", 'FOLFIRI plus Aflibercept is not considered cost-effective for treating advanced colorectal cancer due to its poor safety profile, high costs, and lack of significant benefit compared to FOLFIRI alone. Both NICE guidance TA307 and Japanese healthcare system findings support this conclusion.', 'No, FOLFIRI plus Aflibercept is not a cost-effective treatment in patients with advanced colorectal cancer. Both in the Japanese health care system and according to the NICE Appraisal Committee, this combination could not be considered a cost effective use of resources for treating metastatic colorectal cancer.', 'Short Summary: FOLFIRI plus Aflibercept is not considered a cost-effective treatment for advanced colorectal cancer due to its high costs, poorer safety profile, and no significant improvement in efficacy compared to alternative treatments such as FOLFIRI alone, according to NICE guidance TA307. This conclusion applies across healthcare systems.', 'No, FOLFIRI plus aflibercept is not considered a cost-effective treatment for patients with advanced or metastatic colorectal cancer that has progressed after an oxaliplatin-containing regimen, based on the evidence provided. Multiple studies concluded that adding aflibercept to FOLFIRI in the second-line setting was not cost-effective compared to FOLFIRI alone, despite potentially improved efficacy, due to worse safety and higher costs.', 'No, FOLFIRI plus aflibercept is not considered a cost-effective treatment for patients with advanced colorectal cancer. According to NICE guidance TA307, the combination therapy was deemed not cost-effective for treating metastatic colorectal cancer that has progressed after an oxaliplatin-containing regimen. Similarly, in the Japanese healthcare system, adding aflibercept to FOLFIRI in the second-line treatment of mCRC patients was also found to be not cost-effective. While the combination therapy may have better efficacy compared to FOLFIRI alone, its worse safety profile and higher costs outweigh any potential benefits, making it not a recommended or cost-effective treatment option.', 'No, aflibercept in combination with irinotecan and fluorouracil-based therapy is not considered a cost effective use of National Health Service resources for treating metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen.', \"No, based on the provided information, FOLFIRI plus aflibercept does not appear to be a cost-effective treatment for patients with advanced or metastatic colorectal cancer, despite improving efficacy compared to FOLFIRI alone. The high cost of aflibercept raises concerns about the cost-effectiveness of this combination. Some health systems, such as the UK's NHS, have concluded it is not a cost-effective use of resources and do not recommend it. Studies in China and Japan have also found adding aflibercept to FOLFIRI is not cost-effective in their health care systems for second-line treatment of metastatic colorectal cancer.\", 'No, FOLFIRI plus Aflibercept is not considered a cost-effective treatment for patients with advanced colorectal cancer.', 'No, FOLFIRI plus Aflibercept is not cost-effective in patients with advanced colorectal cancer', 'No, FOLFIRI plus Aflibercept is not a cost-effective treatment in patients with advanced colorectal caner']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the data provided, we can analyze the cost-effectiveness of FOLFIRI plus Aflibercept in patients with advanced colorectal cancer.\n\nFrom the Relations table, we can see that FOLFIRI plus Aflibercept is used to treat metastatic colorectal cancer (MCRC) and has been shown to increase overall survival in patients with MCRC (Relation 7). However, the cost-effectiveness of this treatment is not explicitly stated in the data.\n\nFrom the Sources table, we can find some information on the cost-effectiveness of FOLFIRI plus Aflibercept. In Source 3, the TRIBE study is mentioned, which compared FOLFOXIRI plus bevacizumab with FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. The study found that FOLFOXIRI plus bevacizumab had a higher overall survival rate compared to FOLFIRI plus bevacizumab.\n\nHowever, we cannot directly determine the cost-effectiveness of FOLFIRI plus Aflibercept from the provided data. We can only infer that FOLFIRI plus Aflibercept may be a cost-effective treatment option for patients with advanced colorectal cancer, but further analysis and evaluation are needed to confirm this.\n\nIt is worth noting that the cost-effectiveness of a treatment is not only determined by its efficacy but also by its cost. Therefore, to determine the cost-effectiveness of FOLFIRI plus Aflibercept, we would need to consider the costs of the treatment, including the cost of the drugs, hospitalization, and other related expenses, as well as the benefits of the treatment, including the increase in overall survival and quality of life.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "3",
        "Information Recall Explanation": "The answer attempts to recall information about FOLFIRI plus Aflibercept's use in metastatic colorectal cancer and mentions the TRIBE study. However, it fails to address the direct cost-effectiveness question comprehensively, missing key points from the reference answers that highlight mixed or negative cost-effectiveness findings across different healthcare systems.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer is precise in discussing the treatment's efficacy and the need for cost considerations but lacks specific cost-effectiveness data. It avoids irrelevant details but misses the opportunity to directly address the cost-effectiveness metrics provided in the reference answers.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. Each point is made clearly and distinctly, contributing to the overall flow of the response without redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured, clear, and fluent. It logically progresses from discussing efficacy to the need for cost considerations, making it easy to follow and understand."
    },
    {
        "Question": "Please list some treatment options for bone marrow edema syndrome,",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nPlease list some treatment options for bone marrow edema syndrome,\n\nHere are some reference answers:\n\n**Reference Answers:**\n['BME can be related to trauma or a variety of non-traumatic diseases, and current treatment modalities include non-steroidal anti-inflammatory drugs (NSAIDS), bisphosphonates, denosumab, extracorporeal shockwave therapy (ESWT), the vasoactive prostacyclin analogue iloprost, zoledronic acid, and surgical decompression.', 'Based on the abstracts provided, some treatment options for bone marrow edema syndrome (BMES) include: , 1. Symptomatic treatment, 2. Extracorporeal shock waves therapy (ESWT), 3. Pulsed electromagnetic fields (PEFs), 4. Hyperbaric oxygen (HBO), 5. Vitamin D, 6. Iloprost, 7. Bisphosphonates, 8. Denosumab, 9. Surgery, including core decompression (CD), 10. Conservative measures such as non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, and restricted weight bearing. , These treatment options aim to alleviate pain, reduce bone marrow edema, and promote the natural course of the disease. The choice of treatment may depend on the etiology of BMES, severity of symptoms, and patient-specific factors.', 'Some treatment options for bone marrow edema syndrome include bisphosphonates, iloprost, vitamin D, denosumab, surgery, core decompression, symptomatic treatment, and pulsed electromagnetic fields (PEFs).', 'Treatment options for bone marrow edema syndrome include symptomatic treatment, extracorporeal shock waves therapy (ESWT), pulsed ultrasound, and core decompression.', 'Treatment options for bone marrow edema syndrome include symptomatic treatment, extracorporeal shock waves therapy (ESWT), pulsed electromagnetic fields (PEFs), hyperbaric oxygen (HBO), vitamin D, iloprost, bisphosphonates, denosumab, and surgery.', 'Treatment options for bone marrow edema syndrome (BMES) include: 1. Symptomatic relief, 2. Extracorporeal shock waves therapy (ESWT), 3. Pulsed electromagnetic fields (PEFs), 4. Hyperbaric oxygen (HBO), 5. Vitamin D supplementation, 6. Iloprost, 7. Bisphosphonates, 8. Denosumab, 9. Surgery like core decompression (CD), and 10. Conservative measures such as NSAIDs, analgesics, restricted weight bearing. The choice of treatment may depend on BMES cause, symptom severity, and patient factors.', 'Based on the abstracts, some treatment options for bone marrow edema syndrome (BMES) include: , 1. Symptomatic treatment, 2. Extracorporeal shock waves therapy (ESWT), 3. Pulsed electromagnetic fields (PEFs), 4. Hyperbaric oxygen (HBO), 5. Vitamin D, 6. Iloprost, 7. Bisphosphonates, 8. Denosumab, 9. Surgery, 10. Conservative treatment, including non-steroidal anti-inflammatory drugs (NSAIDs) and/or analgesics and/or restricted weight bearing., 11. Core decompression (CD) , These treatments aim to relieve pain, reduce bone marrow edema, and shorten the duration of the disease.', 'Treatment options for bone marrow edema syndrome are iloprost, bisphosphonates, vitamin D, denosumab, surgery, core decompression, symptomatic treatment, extracorporeal shock waves therapy (ESWT), pulsed electromagnetic fields (PEFs), and hyperbaric oxygen (HBO).', 'Treatment options for bone marrow edema syndrome include NSAIDS, bisphosphonates, denosumab, extracorporeal shockwave therapy (ESWT), the vasoactive prostacyclin analogue iloprost, and surgical decompression.', 'Zoledronic acid, extracorporeal shock wave therapy, iloprost, extracorporeal shockwave therapy, denosumab, shock wave therapy, bisphosphonates, and physical therapy can be treatment options for bone marrow edema syndrome.', 'Treatment options for bone marrow edema syndrome include non-steroidal anti-inflammatory drugs (NSAIDS), bisphosphonates, denosumab, extracorporeal shockwave therapy (ESWT), the vasoactive prostacyclin analogue iloprost, surgical decompression, and a single dose of zoledronic acid.', 'Some treatment options for bone marrow edema syndrome include iloprost, extracorporeal shockwave therapy, surgical decompression, zoledronic acid, bisphosphonates, and denosumab.', 'Treatment options for bone marrow edema syndrome include non-steroidal anti-inflammatory drugs (NSAIDs), bisphosphonates, denosumab, extracorporeal shockwave therapy (ESWT), the vasoactive prostacyclin analogue iloprost, and surgical decompression. Additionally, single-dose therapy with zoledronic acid has also been reviewed as a treatment option', 'Treatment options for bone marrow edema syndrome (BMES) include:\\n\\n* Non-steroidal anti-inflammatory drugs (NSAIDS)\\n* Bisphosphonates\\n* Denosumab\\n* Extracorporeal shockwave therapy (ESWT)\\n* Vasoactive prostacyclin analogue iloprost\\n* Surgical decompression\\n* Single-dose therapy of zoledronic acid\\n\\nThese treatments have been shown to improve pain, function, and edema changes in BMES.', 'Sure, treatment options for bone marrow edema syndrome include non-steroidal anti-inflammatory drugs (NSAIDS), bisphosphonates, denosumab, extracorporeal shockwave therapy (ESWT), the vasoactive prostacyclin analogue iloprost, and surgical decompression. Some specific therapies include intravenous iloprost therapy and single-dose zoledronic acid treatment', 'Treatment options for bone marrow edema syndrome include non-steroidal anti-inflammatory drugs (NSAIDS), bisphosphonates, denosumab, extracorporeal shockwave therapy (ESWT), the vasoactive prostacyclin analogue iloprost, surgical decompression, and a single-dose therapy of zoledronic acid.', 'Some treatment options for bone marrow edema syndrome include non-steroidal anti-inflammatory drugs (NSAIDS), bisphosphonates, denosumab, extracorporeal shockwave therapy (ESWT), the vasoactive prostacyclin analogue iloprost, and surgical decompression', 'Treatment options for bone marrow edema syndrome include bisphosphonates, denosumab, iloprost, surgical decompression, zoledronic acid, NSAIDs, ESWT, and extracorporeal shockwave therapy (ESWT).', 'Treatment options for bone marrow edema syndrome include:\\n\\n1. Non-steroidal anti-inflammatory drugs (NSAIDS)\\n2. Bisphosphonates such as zoledronic acid \\n3. Denosumab\\n4. Extracorporeal shockwave therapy (ESWT)\\n5. Iloprost, a vasoactive prostacyclin analogue\\n6. Surgical decompression', 'Based on the provided snippets, some treatment options for Bone Marrow Edema Syndrome (BMES) include: , 1. Non-steroidal anti-inflammatory drugs (NSAIDS), 2. Bisphosphonates, 3. Denosumab, 4. Extracorporeal Shockwave Therapy (ESWT), 5. Iloprost, a vasoactive prostacyclin analogue, 6. Surgical decompression, 7. Single-dose therapy of Zoledronic Acid , These treatment options aim to alleviate pain, improve function, reduce edema changes, and potentially prevent follow-up surgery in patients with BMES.', 'Treatment options for bone marrow edema syndrome can be zoledronic acid, extracorporeal shockwave therapy (ESWT), iloprost, bisphosphonates, denosumab, and surgical decompression.', 'Based on the provided information, some treatment options for bone marrow edema syndrome include:\\n\\n1. Non-steroidal anti-inflammatory drugs (NSAIDs)\\n2. Bisphosphonates, such as zoledronic acid \\n3. Denosumab\\n4. Extracorporeal shockwave therapy (ESWT)\\n5. Iloprost, a vasoactive prostacyclin analogue\\n6. Surgical decompression\\n\\nThe optimal treatment depends on the underlying cause and severity of the bone marrow edema syndrome. Conservative therapies like NSAIDs, bisphosphonates, and ESWT are often tried first. Iloprost and surgical options may be considered for more severe or refractory cases.', 'Treatment options for bone marrow edema syndrome include non-steroidal anti-inflammatory drugs (NSAIDS), bisphosphonates, denosumab, extracorporeal shockwave therapy (ESWT), the vasoactive prostacyclin analogue iloprost, and surgical decompression.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, here are some treatment options for bone marrow edema syndrome:\n\n1. **Corticosteroid therapy**: Corticosteroids, such as prednisolone, are used to reduce inflammation and swelling in the bone marrow.\n2. **Iloprost infusion therapy**: Iloprost, a prostacyclin analogue, is used to improve blood flow and reduce inflammation in the bone marrow.\n3. **Bisphosphonate therapy**: Bisphosphonates, such as zoledronic acid, are used to reduce bone resorption and alleviate symptoms.\n4. **Denosumab therapy**: Denosumab, a monoclonal antibody, is used to inhibit bone resorption and reduce inflammation.\n5. **Extracorporeal shock wave therapy (ESWT)**: ESWT is a non-invasive treatment that uses shock waves to stimulate healing and reduce pain.\n6. **Hyperbaric oxygen (HBO) therapy**: HBO therapy involves breathing pure oxygen in a pressurized chamber to promote healing and reduce inflammation.\n7. **Pulsed electromagnetic fields (PEFs)**: PEFs are used to stimulate healing and reduce pain.\n8. **Symptomatic treatment**: This includes pain management and physical therapy to alleviate symptoms.\n9. **Surgery**: In some cases, surgery may be necessary to relieve pressure on the bone marrow or to repair damaged tissue.\n\nPlease note that these treatment options may vary depending on the severity and location of the bone marrow edema syndrome, as well as the individual patient's overall health and medical history. It's essential to consult a healthcare professional for a personalized treatment plan.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer includes a mix of correct and incorrect treatment options for bone marrow edema syndrome. It correctly lists iloprost, bisphosphonates, denosumab, ESWT, PEFs, and surgery, but includes corticosteroid therapy and hyperbaric oxygen (HBO) therapy, which are not widely referenced in the provided reference answers for this condition. The answer could be more comprehensive by including NSAIDs, vitamin D, and core decompression, which are frequently mentioned in the reference answers.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise in describing the mechanisms of action for many of the treatments (e.g., iloprost improving blood flow, bisphosphonates reducing bone resorption). However, it includes corticosteroids and HBO therapy, which may not be accurate or commonly referenced for bone marrow edema syndrome, detracting from precision.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each treatment is listed once with a brief description.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clear, and fluent. It uses bullet points for easy readability and provides concise descriptions of each treatment option."
    },
    {
        "Question": "What is the immediate treatment after a sexual assault?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the immediate treatment after a sexual assault?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The immediate treatment after a sexual assault includes ensuring the victim\\'s safety and privacy, treating physical injuries, and preventing unwanted pregnancy and sexually transmitted infections (STIs). This may involve administering emergency contraception, prophylaxis for bacterial and viral STIs, and offering post-exposure prophylaxis for human immunodeficiency virus (HIV) infection in high-risk cases. Additionally, psychological support and risk assessment for self-harm or suicide should be provided. The healthcare provider should also collect evidence for a \"rape kit\" if trained to do so, while being sensitive to the victim\\'s emotional well-being. Overall, the goal of immediate treatment is to address the victim\\'s physical and emotional needs, prevent long-term health consequences, and provide support during this traumatic experience.', \"The immediate treatment after a sexual assault typically involves:\\n\\n1. Providing emergency contraception to prevent pregnancy\\n2. Giving preventative medication for common sexually transmitted infections like chlamydia, gonorrhea, trichomoniasis, bacterial vaginosis, HIV, and hepatitis B\\n3. Collecting forensic evidence using a rape kit, which includes gathering the victim's clothing, swabbing for evidence, plucking hairs, scraping under fingernails, and documenting the victim's account, medical history and emotional state\\n\\nShort-term treatment may also include benzodiazepines for acute anxiety, antidepressants for PTSD, depression and panic attacks, and EMDR therapy. The forensic evidence from the rape kit can assist with criminal investigation and prosecution of the assailant.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the immediate treatment after a sexual assault involves several steps, which are outlined in the table for \"Sexual Assault Treatment Units (SATUS)\" (entity ID 4). \n\nThe description for SATUS states: \"Medical facilities that provide care and support for victims of sexual assault.\"\n\nThe table for \"Post-exposure prophylaxis, STI testing and factors associated with follow-up attendance: a review of 4159 cases of acute post-sexual assault medical care\" (source ID 10) provides further details on the immediate treatment after a sexual assault. \n\nAccording to this study, the immediate treatment after a sexual assault includes:\n\n1. Emergency contraception (administered to 53.8% of cases)\n2. Post-exposure prophylaxis (PEP) for chlamydia (given in 75.1% of cases) and HIV (given in 11.0% of cases)\n3. Hepatitis B vaccination (initiated in 53.7% of cases)\n4. Medical services, including STI testing and treatment, were provided in 75.8% of cases.\n\nIt's essential to note that these findings are based on a specific study and may not be representative of all cases of sexual assault. The immediate treatment after a sexual assault may vary depending on the individual circumstances and the healthcare provider's professional judgment.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers most of the key aspects of immediate treatment after sexual assault, including emergency contraception, post-exposure prophylaxis for STIs and HIV, hepatitis B vaccination, and STI testing/treatment. However, it misses some important elements like psychological support, forensic evidence collection ('rape kit'), and risk assessment for self-harm/suicide mentioned in the reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is highly precise, sticking strictly to the data points from the referenced study without including any irrelevant information. It clearly distinguishes between study-specific findings (e.g., percentages) and general observations about variability in care.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each point is clearly and concisely presented without redundancy.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is generally well-structured and clear but could be slightly improved by presenting the information more directly (e.g., listing treatments in bullet points like the reference answers). The use of statistics (e.g., '53.8% of cases') is helpful but might slightly disrupt readability for some readers."
    },
    {
        "Question": "What is the potential role of the tumor microenvironment and factors like stem cells in contributing to the recurrence of glioblastoma?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the potential role of the tumor microenvironment and factors like stem cells in contributing to the recurrence of glioblastoma?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Glioblastoma (GBM) tumor microenvironment (TME) is a highly heterogeneous and complex system, which in addition to cancer cells, consists of various resident brain and immune cells as well as cells in transit through the tumor such as marrow-derived immune cells. The TME is a dynamic environment that is heavily influenced by alterations in cellular composition, cell-to-cell contact, and cellular metabolic products as well as other chemical factors, such as pH and oxygen levels. Emerging evidence suggests that GBM cells - especially glioma stem cells (GSCs) - appear to reprogram the TME, and hijack microenvironmental elements to facilitate rapid proliferation, invasion, migration, and survival thus generating treatment resistance and recurrence.', 'According to the abstracts, the tumor microenvironment and factors like stem cells play a crucial role in contributing to the recurrence of glioblastoma. The microenvironment provides essential support for the aberrant growth of tumor stem cells, which are believed to contribute to therapeutic resistance and tumor recurrence. Growth factors derived from the tumor microenvironment can promote the proliferation of glioblastoma-derived stem-like cells (GDSCs). Additionally, the bidirectional crosstalk between glioma stem cells (GSCs) and their niche may also promote angiogenesis, invasion, proliferation, and stemness of GSCs, leading to recurrence. Furthermore, cancer stem cells can manipulate host immunity and create a self-advantageous microenvironment for themselves to regrow, ultimately contributing to cancer recurrence. Understanding the interactions between tumor stem cells and the microenvironment is essential to develop innovative therapies and diagnoses to achieve glioblastoma eradication.', 'The tumor microenvironment (TME) of glioblastoma (GBM) is a complex and dynamic system that contributes to the aggressive growth, invasion, and recurrence of this deadly brain cancer. The TME is composed of various cell types, including cancer cells, resident brain cells, immune cells, and stem cells. Emerging evidence suggests that GBM cells can reprogram the TME to facilitate their own growth, survival, and migration, thereby promoting treatment resistance and recurrence. Glioma stem cells (GSCs), a subpopulation of cancer cells with stem-like properties, play a critical role in this process by continuously interacting with the TME and promoting disease progression. Therefore, understanding the mechanisms underlying the cross-talk between GSCs and the TME is crucial for developing new therapeutic strategies to prevent GBM recurrence.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe tumor microenvironment (TME) plays a crucial role in the development and progression of glioblastoma, and it is a key contributor to the recurrence of this aggressive brain tumor. The TME is composed of various cell types, including glioma stem cells (GSCs), which are thought to be responsible for glioblastoma recurrence. The TME provides a complex network of interactions between GSCs and other cell types, including vascular cells, immune cells, and neural precursor cells, that promote tumor growth, invasion, and resistance to therapy.\n\nGSCs are a subpopulation of glioblastoma cells that possess stem-like properties, including self-renewal, differentiation, and the ability to initiate tumor formation. They are thought to be responsible for the recurrence of glioblastoma due to their ability to evade standard treatments and persist in the TME. The TME provides a supportive niche for GSCs, which includes a hypoxic microenvironment, angiogenesis, and the presence of growth factors and cytokines that promote GSC survival and proliferation.\n\nThe TME also plays a role in the maintenance of GSCs through various mechanisms, including:\n\n1. Hypoxia: The TME is characterized by low oxygen levels, which activate hypoxia-inducible factors (HIFs) that promote GSC survival and proliferation.\n2. Angiogenesis: The formation of new blood vessels in the TME provides a source of oxygen and nutrients for GSCs, promoting their growth and survival.\n3. Growth factors and cytokines: The TME releases various growth factors and cytokines that promote GSC survival, proliferation, and migration.\n4. Immune evasion: The TME can suppress immune responses against GSCs, allowing them to evade immune surveillance and persist in the TME.\n\nIn addition to GSCs, other cell types in the TME, such as vascular cells, immune cells, and neural precursor cells, also contribute to glioblastoma recurrence. For example:\n\n1. Vascular cells: The TME contains a complex network of blood vessels that provide oxygen and nutrients to GSCs, promoting their growth and survival.\n2. Immune cells: Immune cells, such as microglia and T cells, can be recruited to the TME and promote GSC survival and proliferation.\n3. Neural precursor cells: Neural precursor cells can be recruited to the TME and contribute to the formation of new GSCs.\n\nOverall, the TME plays a critical role in the recurrence of glioblastoma by providing a supportive niche for GSCs and other cell types that promote tumor growth, invasion, and resistance to therapy. Targeting the TME and GSCs may provide new therapeutic strategies for the treatment of glioblastoma.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers all essential aspects of the tumor microenvironment (TME) and glioma stem cells (GSCs) in contributing to glioblastoma recurrence. It mentions key components like hypoxia, angiogenesis, growth factors, cytokines, and immune evasion, as well as interactions with other cell types such as vascular cells, immune cells, and neural precursor cells. The details align well with the reference answers.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is highly precise, focusing on relevant details without including irrelevant information. However, there is a minor overlap in discussing GSCs and their supportive niche, which slightly affects precision. The answer could be slightly more concise in avoiding redundant emphasis on the supportive role of the TME for GSCs.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer is mostly free of repetition, but there is some overlap in the discussion of the TME's supportive niche for GSCs (e.g., hypoxia, angiogenesis, and growth factors are mentioned multiple times in slightly different contexts). The repetition is minimal and does not significantly detract from the overall quality.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to follow. The use of bullet points for listing mechanisms enhances clarity, and the transitions between ideas are smooth. The language is technical but appropriate for the subject matter, making it highly readable."
    },
    {
        "Question": "Is there an association between specific genotypes and the risk of ADHD for Duchenne Muscular Dystrophy?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs there an association between specific genotypes and the risk of ADHD for Duchenne Muscular Dystrophy?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes, ADHD might be associated with the Dp71 genotype in DMD.', 'Yes, there is an association between specific genotypes and the risk of ADHD for Duchenne Muscular Dystrophy, with mutations predicted to affect dystrophin isoforms expressed in the brain being linked to a higher risk of ADHD.', 'Yes, there is an association between specific genotypes and the risk of ADHD for Duchenne Muscular Dystrophy.', 'Yes, there is an association between specific genotypes and the risk of ADHD for Duchenne Muscular Dystrophy. ADHD might be associated with the Dp71 genotype in DMD.', 'Yes, ADHD might be associated with the Dp71 genotype in Duchenne Muscular Dystrophy (DMD).', 'Yes, there is an association between specific genotypes and the risk of ADHD for Duchenne Muscular Dystrophy. The Dp71 genotype in DMD has been linked to an increased risk of ADHD', 'Yes. ADHD might be associated with the Dp71 genotype in DMD.', 'Yes, there is an association between specific genotypes and the risk of ADHD for Duchenne Muscular Dystrophy. The Dp71 genotype in DMD might be associated with ADHD.', 'Yes, there is an association between specific genotypes and the risk of ADHD for Duchenne Muscular Dystrophy']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThere is no data in the provided tables to support an association between specific genotypes and the risk of ADHD for Duchenne Muscular Dystrophy.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "1",
        "Information Recall Explanation": "The answer fails to recall the key information presented in the reference answers, which consistently affirm an association between specific genotypes (particularly Dp71) and ADHD risk in Duchenne Muscular Dystrophy (DMD). Instead, it incorrectly states there is no data to support this association.",
        "Information Precision Score": "3",
        "Information Precision Explanation": "The answer is precise in its statement about the lack of data in the provided tables, avoiding irrelevant details. However, it contradicts established findings, which affects its overall precision in addressing the question.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition of information in the answer, making it concise on this criterion.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is clear, fluent, and easy to understand, meeting high standards for readability."
    },
    {
        "Question": "Is vemurafenib–cobimetinib promising for craniopharyngioma?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs vemurafenib–cobimetinib promising for craniopharyngioma?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes. Vemurafenib–cobimetinib showed promising for craniopharyngioma']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, vemurafenib-cobimetinib combination therapy appears to be promising for treating papillary craniopharyngiomas, particularly those with BRAF V600E mutations. \n\nAccording to a study mentioned in the sources, vemurafenib-cobimetinib combination therapy resulted in a durable objective partial response or better in 15 out of 16 patients with papillary craniopharyngiomas who had not undergone previous radiation therapy. The median reduction in tumor volume was 91%, and the median progression-free survival was 87% at 12 months.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer provides detailed information about the vemurafenib-cobimetinib combination therapy for craniopharyngioma, including specific outcomes such as median reduction in tumor volume and progression-free survival rates. This aligns well with the reference answer, confirming the promising nature of the therapy.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer focuses specifically on the efficacy of vemurafenib-cobimetinib for papillary craniopharyngiomas, particularly those with BRAF V600E mutations, and includes relevant statistics from a study. No irrelevant information is included.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information. Each piece of information provided is unique and adds value to the understanding of the therapy's effectiveness.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clear, and easy to understand. The flow of information is logical, and the language used is appropriate for a biomedical evaluation."
    },
    {
        "Question": "What is the molecular mechanism by which Bacteroides Fragilis is associated to colorectal cancer development?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the molecular mechanism by which Bacteroides Fragilis is associated to colorectal cancer development?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['B. fragilis (BFT) had a higher abundance in the tumor samples than in healthy tissues, and this bacterium may lead to CRC by making changes in cellular signaling pathways and genes, including the WNT/Beta-catenin pathway.  Intestinal inflammation is mediated by BFT, as yet the only known virulence factor of ETBF. Recent experimental evidence demonstrating that ETBF-driven colitis promotes colon tumorigenesis has generated interest in the potential contribution of ETBF to human colon carcinogenesis', 'The molecular mechanism by which Bacteroides Fragilis (ETBF) is associated with colorectal cancer (CRC) development involves the activation of signal transducers and activators of transcription (STAT)3. ETBF interacts with epithelial cells, leading to STAT3 activation, which in turn activates regulatory T-cells (Tregs). This reduces interleukin (IL)-2 levels, promoting the generation of T-helper (Th17) cells and increasing IL-17 production. IL-17 induces early intestinal inflammation, cancer cell survival, and proliferation, ultimately activating the STAT3 pathway. Additionally, ETBF degrades E-cadherin, altering signaling pathways and upregulating spermine oxidase, leading to carcinogenesis and irreversible DNA damage. Long noncoding RNA BFAL1 also plays a role in mediating ETBF-induced CRC by activating the RHEB/mTOR pathway. Furthermore, ETBF induces stemness in CRC cells by upregulating histone demethylase JMJD2B, which epigenetically regulates core', '20% of colorectal cancers show frameshift mutations in the K-RAS gene. The bacterial genome contains a region with homology to the K-RAS gene, that harbors a frameshift mutation in polyp-forming strains of B. fragilis. This bacterial mutation is thought to result in the expression of a truncated, constitutively active K-RAS protein and to play a role in the development of colorectal cancer in patients with pre-existing K-RAS mutations.', 'Bacteroides fragilis (B. fragilis) is a bacterium found in the human gut that is typically considered to have anti-inflammatory effects. However, a subtype of B. fragilis, known as enterotoxigenic B. fragilis (ETBF), produces an enterotoxin called B. fragilis toxin (BFT) that can lead to asymptomatic chronic infections and colonic tumor formation. ETBF has been associated with colorectal cancer (CRC) through a molecular mechanism involving the activation of signal transducers and activators of transcription (STAT)3, which is triggered by the interaction between epithelial cells and BFT. This activation of STAT3 leads to an increase in the levels of interleukin (IL)-17 due to the generation of T-helper (Th17) cells and a reduction in the amount of IL-2 due to the activation of regulatory T-cell (Tregs). The enterotoxin BFT has also been shown to trigger the expression of cyclooxygenase (COX)-2, which releases prostaglandin E2 (PGE2) and contributes to inflammation and the control of cell proliferation, leading to the development of CRC.', 'Bacteroides Fragilis is associated with colorectal cancer development through the production of a metalloprotease toxin, BFT, which induces DNA damage and inflammation in colonic epithelial cells.', 'The results of these studies indicate that SMO is a source of bacteria-induced ROS directly associated with tumorigenesis and could serve as a unique target for chemoprevention. These findings support a role for Fn and ETBF in potentiating tumorigenesis via the induction of a cancer stem cell-like transit-amplifying and enterocyte population and the disruption of CTL cytotoxic function. Taken together, BF mono-colonization of GF mice might prevent CAC via the TLR4 signal pathway.', 'Bacteroides fragilis is associated with colorectal cancer development through its production of Bacteroides fragilis toxin (BFT), also known as fragilysin. BFT is a zinc-dependent metallopeptidase that damages the intestinal mucosa and triggers disease-related signaling mechanisms. BFT induces E-cadherin cleavage, interleukin-8 secretion, and epithelial cell proliferation, which can lead to chronic colitis and increased colon tumorigenesis. BFT also damages the colonic epithelial barrier by inducing cleavage of the zonula adherens protein E-cadherin and initiating a cell signaling response characterized by inflammation and c-Myc-dependent pro-oncogenic hyperproliferation. Additionally, B. fragilis can lead to tumorigenesis by changing signaling pathways, including the WNT/-catenin pathway. The recent observation of ETBF-bearing biofilms in colon biopsies from humans with colon cancer susceptibility loci strongly suggests that ETBF is a driver of colorectal cancer.', 'Bacteroides fragilis is associated with colorectal cancer development through the production of the Bacteroides fragilis toxin, which induces inflammation and tumorigenesis.', 'B. fragilis had a higher abundance in the tumor samples than in healthy tissues, and this bacterium may lead to CRC by making changes in cellular signaling pathways and genes. The protective role against tumor formation provided by B. fragilis is associated with inhibition of expression of the chemokine receptor CCR5 in the colon. Taken together, BF mono-colonization of GF mice might prevent CAC via the TLR4 signal pathway.', 'Bacteroides Fragilis is the most common bacterium associated with colorectal cancer, which was found in 100% of colorectal cancer patients.  The enterotoxigenic Bacteroides fragilis (ETBF) produces a potent metalloprotease toxin that can stimulate the proliferation and invasion of colon cancer cells. ETBF is also capable of inducing DNA damage in the colonic epithelial cells. ETBF strains can increase the severity of colitis and promote tumor formation in the colon of mice.\\nThe enterotoxigenic Bacteroides fragilis (ETBF) causes increased proliferation and decreased apoptosis in epithelial cells.', 'Bacteroides fragilis (B. fragilis) has been identified as a potential promoter of tumorigenesis through the alteration of signaling pathways. The abundance of B. fragilis increased significantly in intestinal mucosa of colitis-associated cancer (CAC) mice, and finally, B. fragilis was found to be associated with colorectal cancer development.', 'Bacteroides Fragilis (BF) is a commensal bacterium in the human colon, but under dysbiotic conditions, the enterotoxigenic BF (ETBF) can cause diarrhea, anaerobic bacteremia, inflammatory bowel disease, and colorectal cancer. The primary virulence factor of ETBF is B. fragilis toxin (BFT), a zinc-dependent metallopeptidase that damages the intestinal mucosa and triggers disease-related signaling mechanisms. BFT induces E-cadherin cleavage, interleukin-8 secretion, and epithelial cell proliferation, leading to chronic colitis in mice and increased colon tumorigenesis in multiple intestinal neoplasia mice. Additionally, BFT is related to inflammatory bowel disease and colon cancer by triggering nuclear activation with potential oncogene expression. The recent observation of ETBF-bearing biofilms in colon biopsies from humans with colon cancer susceptibility loci suggests that ETBF is a driver of colorectal cancer. BF can also lead to tumorigenesis by changing signaling pathways, including the WNT/-catenin pathway.', 'Bacteroides Fragilis (BF) is a commensal bacterium in the human colon, but under dysbiotic conditions, the enterotoxigenic BF (ETBF) can cause diarrhea, anaerobic bacteremia, inflammatory bowel disease, and colorectal cancer. The primary virulence factor of ETBF is B. fragilis toxin (BFT), a zinc-dependent metallopeptidase that damages the intestinal mucosa and triggers disease-related signaling mechanisms. BFT induces E-cadherin cleavage, interleukin-8 secretion, and epithelial cell proliferation, leading to chronic colitis in mice and increased colon tumorigenesis in multiple intestinal neoplasia mice. BFT also changes signaling pathways, including the WNT/-catenin pathway, and triggers nuclear activation with potential oncogene expression, which is related to inflammatory bowel disease and colon cancer. The recent observation of ETBF-bearing biofilms in colon biopsies from humans with colon cancer susceptibility loci suggests that ETBF is a driver of colorectal cancer.', 'Bacteroides Fragilis (ETBF) is associated with colorectal cancer development through activating STAT3 pathways, promoting Th17 cell generation and IL-17 production causing inflammation and carcinogenesis; degrading E-cadherin which alters signaling pathways leading to morphology changes; and mediating ETBF-related carcinogenesis via the RHEB/mTOR pathway.', 'The molecular mechanisms by which Bacteroides Fragilis (BF) is associated with colorectal cancer (CRC) development involve several pathways. In one mechanism, Enterotoxigenic Bacteroides fragilis (ETBF) promotes tumor growth through the upregulation of a long non-coding RNA, BFAL1, which activates the RHEB/mTOR pathway by competitively sponging microRNAs miR-155-5p and miR-200a-3p. In another mechanism, ETBF induces stemness in CRC cells by upregulating histone demethylase JMJD2B through the TLR4-NFAT5 pathway, leading to the demethylation of H3K9me3 on the NANOG promoter and increased expression of core stemness transcription factors. Conversely, Bacteroides fragilis has also been shown to restrict colitis-associated cancer by negatively regulating the NLRP3 axis through the production of short-chain fatty acids, such as butyrate.', 'Bacteroides Fragilis is associated with colorectal cancer development through its enterotoxin-1 (BFT-1) which promotes proliferation of colorectal cancer via CCL3-related molecular pathways, including NF-κB and TRAF-6.', 'Bacteroides Fragilis infections can induce colitis and colorectal cancer in susceptible hosts.  They are associated with a higher incidence of colonic adenomas.\\nBacteroides fragilis produces a zinc metalloprotease, BFT, which plays a crucial role in these effects. BFT can induce activation of a non-canonical NF-kB pathway in colon epithelial cells, leading to the production of pro-inflammatory cytokines and growth factors that ultimately result in activation of colonic epithelial cells. The long-term activation of these epithelial cells can contribute to the development of colitis and colorectal cancer.', 'Bacteroides Fragilis (ETBF) contributes to colorectal cancer development through STAT3 pathway activation, promoting Tregs and Th17 cells, inducing early inflammation and cell survival/proliferation, triggering IL-6 production, degrading E-cadherin, altering signaling pathways that upregulate spermine oxidase, and mediating carcinogenesis via the RHEB/mTOR pathway.', 'Enterotoxigenic Bacteroides fragilis (ETBF) produces a toxin called B. fragilis toxin (BFT) or fragilysin. BFT is a zinc-dependent metallopeptidase that cleaves the zonula adherens protein E-cadherin in the colonic epithelium. This leads to increased intestinal permeability, inflammation, and c-Myc-dependent epithelial cell proliferation. BFT also triggers other pro-oncogenic signaling pathways like WNT/β-catenin and induces secretion of pro-inflammatory cytokines like IL-8. Through these mechanisms, ETBF and BFT are thought to promote the development of colorectal cancer.', 'The molecular mechanisms by which Bacteroides fragilis, specifically enterotoxigenic B. fragilis (ETBF), contributes to colorectal cancer (CRC) development involve several pathways. ETBF produces a toxin that triggers chronic intestinal inflammation and tissue injury, leading to CRC. The toxin activates cyclooxygenase-2, releasing PGE2, which induces inflammation and controls cell proliferation. This leads to the activation of STAT3, which promotes cancer cell survival and proliferation. Additionally, ETBF degrades E-cadherin, altering signaling pathways that upregulate spermine oxidase, promoting carcinogenesis and irreversible DNA damage. Furthermore, a lncRNA called BFAL1 is highly expressed in CRC tissues and mediates ETBF-induced carcinogenesis by activating the Ras/RHEB/mTOR pathway. Overall, ETBF colonization in the intestinal tract contributes to the development of CRC through multiple mechanisms.', '\"Enterotoxigenic Bacteroides fragilis (ETBF) has been implicated in colorectal carcinogenesis through the actions of its toxin, B. fragilis toxin (BFT). A reduction in E-cadherin expression in response to ETBF treatment was not restored by blocking Stat3. We found that treatment of colorectal cancer cell lines with live cultures of ETBF had the equivalent effect on IL-8 expression as the use of purified toxin, and this may be a more representative model of ETBF-mediated colorectal carcinogenesis.\"', 'Enterotoxigenic Bacteroides fragilis (ETBF) strains secrete a toxin called fragilysin or B. fragilis toxin (BFT), a zinc-dependent metalloprotease. BFT is the key virulence factor linking B. fragilis to colorectal cancer development through several mechanisms:\\n\\n1. BFT cleaves the adherens junction protein E-cadherin, disrupting the intestinal epithelial barrier and triggering inflammation. \\n\\n2. BFT binding to epithelial receptors activates cell signaling pathways that cause increased cell proliferation, likely in a c-Myc-dependent manner. This hyperproliferation has pro-oncogenic effects.\\n\\n3. BFT induces secretion of pro-inflammatory cytokines like IL-8 from epithelial cells, promoting chronic inflammation.\\n\\n4. BFT may alter signaling in pathways like WNT/β-catenin that are often dysregulated in colorectal cancer.\\n\\nIn summary, BFT from ETBF strains damages the colonic epithelium, induces inflammation, and directly promotes proliferation and oncogenic signaling. This creates a tumor-promoting microenvironment that, over time, can lead to colorectal cancer development, likely in conjunction with other genetic and environmental risk factors. The ability of ETBF to form biofilms in the colon may enable sustained BFT delivery to the epithelium.', \"Bacteroides Fragilis, a gut bacterium, contributes to colorectal cancer (CRC) development through various molecular mechanisms. It produces enterotoxin, which promotes cell proliferation, inhibits apoptosis, and induces inflammation, leading to tumorigenesis. The toxin activates the WNT/β-catenin pathway, altering cellular signaling and gene expression. Additionally, B. Fragilis induces the production of interleukin-17 (IL-17), which promotes inflammation and tumorigenesis. The bacterium also modulates the immune response, suppressing anti-tumor immunity and promoting a pro-tumorigenic microenvironment. Furthermore, B. Fragilis influences the gut microbiome, altering the balance of microbial populations and promoting the growth of other pathogenic bacteria. The bacterium's polysaccharide A (PSA) inhibits the expression of the chemokine receptor CCR5, which is involved in the recruitment of immune cells to the tumor site. Overall, B. Fragilis contributes to CRC development by inducing inflammation, modulating the immune response, and altering the gut microbiome.\", 'Based on the abstract, the molecular mechanism by which Bacteroides fragilis is associated with colorectal cancer (CRC) development involves changes in cellular signaling pathways and genes. Specifically, the high level of enterotoxigenic B. fragilis has a significant relationship with the high expression of AXIN, CTNNB1, and BCL2 genes, which are involved in CRC. The WNT/β-catenin pathway, in particular, is altered by B. fragilis, leading to tumorigenesis. Additionally, the toxin produced by enterotoxigenic B. fragilis, bft-1, may also play a role in inducing inflammatory diarrhea and promoting colon tumorigenesis. Overall, the molecular mechanism involves the dysregulation of cellular signaling pathways and genes, potentially contributing to CRC development. Further research is needed to fully understand the molecular mechanisms by which B. fragilis regulates cellular signaling pathways and its impact on CRC.', 'Bacteroides fragilis, particularly the enterotoxigenic variant (ETBF), is associated with the development of colorectal cancer (CRC). The molecular mechanism by which B. fragilis contributes to CRC involves changes in signaling pathways, with a focus on the WNT/β-catenin pathway. This bacterium is more abundant in tumor samples compared to healthy tissues. ETBF produces B. fragilis toxin (BFT), which mediates intestinal inflammation and promotes colitis, a condition known to increase the risk of colon cancer. Recent experimental evidence suggests that ETBF-driven colitis can foster colon tumorigenesis, highlighting the potential role of ETBF in human colon carcinogenesis.', 'Bacteroides Fragilis is associated with colorectal cancer development by changing signaling pathways, specifically the WNT/β-catenin pathway, through its virulence factor BFT. BFT leads to intestinal inflammation and promotes colon tumorigenesis by inducing ectodomain cleavage of E-cadherin in colonic epithelial cells, consequently leading to cell rounding, epithelial barrier disruption, and the secretion of IL-8. This inflammation promotes tumorigenesis in mice via IL-17A-mediated inflammation.', 'B. fragilis had a higher abundance in the tumor samples than in healthy tissues, and this bacterium may lead to CRC by making changes in cellular signaling pathways and genes. Bacteroides fragilis can lead to tumorigenesis by changing signaling pathways, including the WNT/β-catenin pathway.', 'Bacteroides fragilis has been associated with colorectal cancer development through its ability to produce capsular polysaccharide, which is protective against phagocytosis and stimulates abscess formation. Additionally, B. fragilis has been shown to induce regulatory T cells and suppress pro-inflammatory T helper 17 cells in the gut mucosa. Recent studies have also suggested that B. fragilis may lead to colorectal cancer by changing cellular signaling pathways and genes, including the WNT/β-catenin pathway. Furthermore, the virulence factor of enterotoxigenic B. fragilis (ETBF), BFT, has been shown to mediate intestinal inflammation and promote colon tumorigenesis. However, further research is needed to confirm these findings and elucidate the exact molecular mechanism by which B. fragilis is associated with colorectal cancer development.', 'Bacteroides fragilis is associated with colorectal cancer development through the WNT/β-catenin signaling pathway.', 'Bacteroides Fragilis is associated with colorectal cancer development by altering signaling pathways, including the WNT/β-catenin pathway. This bacterium is found in higher abundance in tumor samples and can lead to changes in cellular signaling pathways and genes. Additionally, it mediates intestinal inflammation through BFT, a known virulence factor, promoting colon tumorigenesis.', 'Intestinal inflammation is mediated by BFT, a virulence factor of ETBF. Recent evidence suggests that ETBF-driven colitis promotes colon tumorigenesis. Bacteroides fragilis has a higher abundance in tumor samples than in healthy tissues and may lead to CRC by altering cellular signaling pathways and genes. Specifically, Bacteroides fragilis can induce tumorigenesis by modulating the WNT/β-catenin pathway.', '1) B. fragilis induces the expression of miR-21 in host cells, which can increase the resistance of cancer cells to apoptosis.\\n2) B. fragilis-derived enterotoxin induces DNA damage in host cells, thereby increasing genomic instability, which is a driving force of carcinogenesis.', 'Bacteroides fragilis changes signaling pathways, including the WNT/β-catenin pathway, leading to tumorigenesis. It also promotes colon tumorigenesis by inducing intestinal inflammation through its virulence factor BFT. \\n\\nNote: The answer should be concise and based on the provided context. It should not include any external information or references.  If the question is unclear or ambiguous, you can ask for clarification.  If the question is not answerable based on the provided context, you can say so.  You should not provide any opinion or make any assumptions.  Your answer should be based on the facts provided in the context.  You should not provide any external references or citations.  Your answer should be in a neutral tone.  You should not use any jargon or technical terms that are not defined in the context.  You should not provide any information that is not supported by the context.  You should not provide any information that is not relevant to the question.  You should not provide any information that is not accurate based on the context.  You should not provide any information that is not clear based on the context.  You should not provide any information that is not concise based on the context', 'Overall, the molecular mechanism by which Bacteria species, including E. coli, is associated with colorectal cancer development is complex and multifaceted, involving a combination of bacterial virulases, cell signaling pathways, and tissue microenvironments. While the primary role of E. coli in colorectal cancer development remains an active area of research, it is clear that bacteriophages and other bacterial factors play a crucial role in promoting cancer progression and treatment resistance in colorectal cancer patients. Integrating bacterial-directed therapies into colorectal cancer management strategies has the potential to improve outcomes and reduce the need for toxic chemotherapies and their side effects. However, careful consideration of potential bacterial-directed therapies in colorectal cancer patients is required to minimize the risk of exacerbating local tissue injury and promoting systemic toxicity.', 'Bacteroides fragilis can contribute to the development of colorectal cancer by altering cellular signaling pathways, including the WNT/β-catenin pathway. This bacterium is found in higher abundance in tumor samples compared to healthy tissues. Additionally, a virulence factor of B. fragilis known as BFT can mediate intestinal inflammation, which has been shown to promote colon tumorigenesis', 'Bacteroides fragilis has been associated with colorectal cancer (CRC) development through molecular mechanisms involving changes in cellular signaling pathways and genes. This bacterium, which is more abundant in tumor samples than in healthy tissues, produces Bacteroides fragilis toxin (BFT) which mediates intestinal inflammation. Recent experimental evidence suggests that ETBF-driven colitis promotes colon tumorigenesis, indicating a potential contribution to human colon carcinogenesis. Additionally, B. fragilis has been shown to lead to tumorigenesis by changing signaling pathways, including the WNT/β-catenin pathway.', 'Bacteroides fragilis, a commensal bacterium, has been implicated in colorectal cancer (CRC) development. The molecular mechanism involves the production of enterotoxin, which promotes cell proliferation, inflammation, and tumorigenesis. The enterotoxin activates the WNT/β-catenin pathway, leading to the upregulation of genes involved in cell proliferation and tumorigenesis. Additionally, the enterotoxin induces the production of pro-inflammatory cytokines, such as IL-17, which promotes inflammation and tumorigenesis. The enterotoxin also inhibits the production of anti-inflammatory cytokines, such as IL-10, which normally suppresses inflammation. Furthermore, B. fragilis has been shown to induce the production of reactive oxygen species (ROS), which can damage DNA and promote tumorigenesis. The bacterium also alters the expression of genes involved in cell adhesion, migration, and invasion, promoting the development of CRC. Overall, the molecular mechanism by which B. fragilis is associated with CRC development involves the production of enterotoxin, which promotes inflammation, cell proliferation, and tumorigenesis.', '16S rRNA gene sequences of Bacteroides Fragilis (BF) were identified in both normal and cancer tissues. The BF strain (enterotoxigenic Bacteroides Fragilis, EBF) that causes diarrhea was associated with colorectal cancer development. However, non-diarrheal BF strains were also detected in cancer tissues and not in normal tissues. The enterotoxin gene bft is responsible for the association of EBF to CRC development. EBF bft interacts with epithelial cells and activates epithelial β-catenin, a key molecule involved in CRC development.', 'Bacteroides Fragilis is associated with colorectal cancer development through its ability to alter signaling pathways, particularly the WNT/β-catenin pathway, and by increasing the abundance of the bacterium in tumor samples compared to healthy tissues. Additionally, BFT, a virulence factor of ETBF, has been shown to mediate intestinal inflammation, which can promote colon tumorigenesis', 'Bacteroides Fragilis, a type of gut bacteria, contributes to colorectal cancer development by altering cellular signaling pathways and genes. Specifically, it affects the WNT/β-catenin pathway, leading to tumorigenesis. The bacterium is more abundant in tumor samples than in healthy tissues, suggesting its role in cancer development. The enterotoxigenic B. fragilis (ETBF) strain, which produces the virulence factor BFT, mediates intestinal inflammation, promoting colon tumorigenesis. ETBF-driven colitis creates a favorable environment for cancer development. The molecular mechanisms underlying this process involve changes in cellular signaling pathways and genes, ultimately leading to the transformation of normal colonic epithelial cells into cancerous cells.', 'Bacteroides fragilis can lead to tumorigenesis by changing signaling pathways, including the WNT/β-catenin pathway. B. fragilis had a higher abundance in the tumor samples than in healthy tissues, and this bacterium may lead to CRC by making changes in cellular signaling pathways and genes. Intestinal inflammation is mediated by BFT, as yet the only known virulence factor of ETBF. Recent experimental evidence demonstrating that ETBF-driven colitis promotes colon tumorigenesis has generated interest in the potential contribution of ETBF to human colon carcinogenesis.', 'Bacteroides Fragilis is associated with colorectal cancer (CRC) development through alterations in cellular signaling pathways, particularly the WNT/β-catenin pathway. The high expression of AXIN, CTNNB1, and BCL2 genes in enterotoxigenic B. fragilis contributes to CRC, and bft-1 toxin may induce inflammatory diarrhea and promote colon tumorigenesis. Further research is needed for a comprehensive understanding of the molecular mechanisms involved.', 'Bacteroides Fragilis is associated with colorectal cancer development due to alterations in cellular signaling pathways like WNT/β-catenin, primarily driven by enterotoxigenic B. fragilis producing the virulence factor BFT which promotes inflammation and colon tumorigenesis.', 'Bacteroides fragilis is associated with colorectal cancer development through its ability to change signaling pathways, including the WNT/β-catenin pathway. This bacterium is found in higher abundance in tumor samples than in healthy tissues. It can lead to colorectal cancer by altering cellular signaling pathways and genes. Additionally, intestinal inflammation, which can promote colon tumorigenesis, is mediated by BFT, a known virulence factor of B. fragilis.', 'Bacteroides Fragilis is associated with colorectal cancer development by changing signaling pathways, specifically the WNT/β-catenin pathway. This is mediated by BFT, the only known virulence factor of Enterotoxigenic Bacteroides Fragilis (ETBF), which leads to intestinal inflammation and promotes colon tumorigenesis.', 'Bacteroides Fragilis contributes to colorectal cancer development by modifying cellular signaling pathways, including WNT/β-catenin, and producing virulence factors such as BFT from enterotoxigenic strains, which induce inflammation and promote tumor growth.', 'Bacteroides fragilis can lead to colorectal cancer development by altering cellular signaling pathways, including the WNT/β-catenin pathway. B. fragilis produces a toxin called B. fragilis toxin (BFT), which is a key virulence factor. BFT mediates intestinal inflammation and colitis, which can promote colon tumorigenesis. The altered cellular signaling and inflammatory environment driven by B. fragilis and its toxin are thought to be the main mechanisms contributing to colorectal cancer development.', 'The molecular mechanism by which Bacteroides fragilis (B. fragilis) is associated with colorectal cancer (CRC) development involves altering cellular signaling pathways, including the WNT/β-catenin pathway. B. fragilis has a higher abundance in tumor samples compared to healthy tissues and can lead to CRC by modifying cellular signaling pathways and genes. The enterotoxigenic B. fragilis (ETBF) produces a virulence factor called Bacteroides fragilis toxin (BFT), which mediates intestinal inflammation and promotes colon tumorigenesis. This suggests that ETBF may contribute to human colon carcinogenesis, highlighting the potential role of B. fragilis in CRC development through its influence on cellular signaling pathways and gene expression.', 'Bacteroides fragilis is associated with colorectal cancer development through its only known virulence factor, BFT, which mediates intestinal inflammation. This inflammation can promote colon tumorigenesis. Additionally, B. fragilis has a higher abundance in tumor samples compared to healthy tissues and may lead to CRC by altering cellular signaling pathways and genes. Specifically, it can modify the WNT/β-catenin pathway, contributing to tumorigenesis.', 'Bacteroides fragilis colonizes the gut epithelium, producing enterotoxins that activate the WNT/β-catenin pathway, leading to the upregulation of genes that promote cell proliferation and survival, ultimately disrupting normal cellular signaling and contributing to the development of colorectal cancer. The key steps involved in this mechanism include B. fragilis colonization and enterotoxin production, activation of the WNT/β-catenin pathway, upregulation of specific genes, promotion of cell proliferation and survival, and disruption of normal cellular signaling.', 'Bacteroides fragilis, particularly the enterotoxigenic strain (ETBF), is associated with colorectal cancer development through the actions of B. fragilis toxin (BFT), its main virulence factor. BFT mediates intestinal inflammation and colitis, which can promote colon tumorigenesis.\\n\\nSpecifically, B. fragilis and BFT can lead to colorectal tumorigenesis by inducing changes in important cell signaling pathways involved in cell growth and proliferation, such as the WNT/β-catenin pathway. B. fragilis is found at higher abundance in colorectal tumor samples compared to healthy tissues.\\n\\nSo in summary, B. fragilis, especially toxin-producing strains, appears to contribute to colorectal cancer development by causing chronic inflammation and colitis and by altering cell signaling pathways in the colon that regulate cell growth, leading to increased proliferation. The key molecular links are the B. fragilis toxin, induction of inflammatory pathways, and dysregulation of growth-regulating cell signaling cascades like WNT/β-catenin.', 'Bacteroides Fragilis is associated with colorectal cancer development through its ability to alter cellular signaling pathways, particularly the WNT/β-catenin pathway. This alteration can lead to tumorigenesis. Additionally, Bacteroides Fragilis can cause intestinal inflammation, which can further promote colon tumorigenesis', 'Bacteroides fragilis can lead to tumorigenesis by changing signaling pathways, including the WNT/β-catenin pathway.   B. fragilis had a higher abundance in the tumor samples than in healthy tissues, and this bacterium may lead to CRC by making changes in cellular signaling pathways and genes Intestinal inflammation is mediated by BFT, as yet the only known virulence factor of ETBF. Recent experimental evidence demonstrating that ETBF-driven colitis promotes colon tumorigenesis has generated interest in the potential contribution of ETBF to human colon carcinogenesis']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, Bacteroides Fragilis is associated with colorectal cancer development through several molecular mechanisms, including:\n\n1. **Production of Bacteroides fragilis toxin (BFT)**: BFT is a virulence factor produced by Bacteroides fragilis that can induce E-cadherin cleavage, interleukin-8 secretion, and epithelial cell proliferation, leading to colitis and tumorigenesis (Source 15).\n2. **Modulation of the mucosal immune response**: Bacteroides fragilis can modulate the mucosal immune response, leading to chronic inflammation and increased risk of colorectal cancer (Source 1, 2, 14).\n3. **Alteration of signaling pathways**: Bacteroides fragilis can alter signaling pathways, including the WNT/β-catenin pathway, which is involved in colorectal carcinogenesis (Source 16).\n4. **Production of reactive metabolites**: Bacteroides fragilis can produce reactive metabolites, such as secondary bile salts, hydrogen sulfide, and trimethylamine-N-oxide (TMAO), which can promote inflammation and cancer development (Source 12).\n5. **Inhibition of autophagy**: Bacteroides fragilis can inhibit autophagy, a process that helps to remove damaged or dysfunctional cellular components, leading to the accumulation of damaged cells and increased risk of cancer (Source 13).\n\nThese mechanisms are supported by various studies, including in vitro, in vivo, and human studies, and suggest that Bacteroides fragilis plays a significant role in the development of colorectal cancer.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers several key mechanisms by which Bacteroides Fragilis is associated with colorectal cancer development, including the production of BFT, modulation of the immune response, alteration of signaling pathways, production of reactive metabolites, and inhibition of autophagy. However, it does not mention some other pathways referenced in the source materials, such as the STAT3 pathway or the involvement of long noncoding RNA BFAL1.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer is generally precise but includes reactive metabolites and inhibition of autophagy, which are not explicitly mentioned in the reference answers. This could be considered minor deviations from the reference content.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information unnecessarily. Each point is distinct and clearly outlined.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-structured and easy to follow. The bullet points enhance clarity, though some technical terms could benefit from brief definitions to improve accessibility."
    },
    {
        "Question": "Where in the body would the globus pallidus be found?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhere in the body would the globus pallidus be found?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The globus pallidus is found deep within the brain', 'The globus pallidus can be found in the basal ganglia, thalamus, and putamen.', 'The globus pallidus would be found in the basal ganglia.', 'Globus pallidus is one of the components of the basal ganglia, located deep within the brain. It is responsible for the regulation of motor control and movement.', 'The globus pallidus is located in the basal ganglia.', 'The globus pallidus is found in the basal ganglia.', 'The globus pallidus is a part of the basal ganglia, which is a group of nuclei located deep within the cerebral hemispheres of the brain.', 'The globus pallidus is found in the basal ganglia of the brain.', 'The globus pallidus is a structure found in the brain.', 'The globus pallidus is found in the brain.', 'The globus pallidus is located in the brain, specifically in regions such as the substantia nigra and nucleus accumbens.', 'The globus pallidus would be found in the brain.', 'The globus pallidus is located in the brain.', 'The globus pallidus is found in the brain. It is part of the basal ganglia, which is involved in the control of voluntary motor movements.', 'The globus pallidus is a structure in the brain']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe globus pallidus is a structure in the brain, specifically located in the basal ganglia, which is a group of structures involved in movement control and cognition. It is situated in the forebrain, near the thalamus and the substantia nigra, and is a key component of the basal ganglia circuitry.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately recalls all necessary information about the location of the globus pallidus, including its specific placement in the basal ganglia, its proximity to the thalamus and substantia nigra, and its role in the basal ganglia circuitry.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer provides precise information without any irrelevant details. It clearly states the location and role of the globus pallidus, aligning well with the reference answers.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information. Each piece of information is presented once and contributes to a comprehensive understanding of the globus pallidus.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is written in a clear, fluent, and easily understandable manner. The sentence structure is logical, and the terms used are appropriately defined within the context."
    },
    {
        "Question": "What is the approximate prevalence of autoimmune diseases?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the approximate prevalence of autoimmune diseases?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['There is an approximate incidence of 10% autoimmune diseases affecting the general population.', \"Autoimmune diseases affect approximately 10% of the population, with a higher prevalence in females (about 64% of diagnosed individuals are female). Some of the most common autoimmune diseases, such as Sjögren's syndrome, systemic lupus erythematosus, and systemic sclerosis, are often associated with each other.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, it is not possible to determine the approximate prevalence of autoimmune diseases as a whole, as the data only provides information on various autoimmune diseases and conditions, but not on the overall prevalence of autoimmune diseases.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "1",
        "Information Recall Explanation": "The answer fails to recall the key information from the reference answers, which clearly state the approximate prevalence of autoimmune diseases (10%). Instead, it incorrectly claims that the information is not available.",
        "Information Precision Score": "3",
        "Information Precision Explanation": "The answer does not include irrelevant information, staying focused on the topic of prevalence. However, it incorrectly interprets the available data, missing the key point about prevalence.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition of information in the answer. The response is concise and avoids redundancy.",
        "Readability Score": "4",
        "Readability Explanation": "The answer is written in a clear and fluent manner, making it easy to understand. However, the inaccuracy of the content slightly detracts from its overall readability."
    },
    {
        "Question": "What is the role of Isocitrate dehydrogenase (IDH) mutations in glioma?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the role of Isocitrate dehydrogenase (IDH) mutations in glioma?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Isocitrate dehydrogenase (IDH) is a key rate-limiting enzyme in the Krebs cycle that plays an important role in energy metabolism. In recent years, it has been found that IDH mutations are closely related to the occurrence and development of glioma, and it is a notable potential therapeutic target. First, IDH mutations can produce high levels of 2-hydroxyglutaric acid (2-HG), thereby inhibiting glioma stem cell differentiation. At the same time, IDH mutations can upregulate vascular endothelial growth factor (VEGF) to promote the formation of the tumor microenvironment. In addition, IDH mutations can also induce high levels of hypoxia-inducible factor-1α (HIF-1α) to promote glioma invasion. Ultimately, these changes will lead to the development of glioma. Finally, in addition to affecting gliomas directly, mutations in IDH can also alter their immune microenvironment and can change immune-cell function in direct and indirect ways. Currently, a large number of IDH inhibitors and vaccines have entered clinical trials, representing progress in the treatment of glioma patients.', 'Isocitrate dehydrogenase (IDH) mutations play a crucial role in the development and progression of glioma, a type of brain cancer. IDH mutations are commonly observed in lower-grade gliomas and secondary glioblastomas. These mutations lead to the production of 2-hydroxyglutarate, an oncometabolite that inhibits glioma stem cell differentiation and promotes the formation of the tumor microenvironment. IDH mutations also upregulate vascular endothelial growth factor (VEGF) and induce high levels of hypoxia-inducible factor-1α (HIF-1α), promoting glioma invasion. Additionally, IDH mutations alter the immune microenvironment and change immune-cell function, making them a potential therapeutic target. IDH mutations are a favorable prognostic factor for human glioma and can be used as a biomarker for differential diagnosis and subclassification. Targeting IDH mutations with inhibitors and vaccines has shown promise in treating glioma patients. Overall, IDH mutations are a key driver of gliomagenesis and a promising target for glioma therapy.', 'Isocitrate dehydrogenase (IDH) mutations play a significant role in glioma, a type of brain tumor. These mutations can lead to increased levels of 2-hydroxyglutaric acid (2-HG), which inhibits the differentiation of glioma stem cells. Additionally, IDH mutations can upregulate vascular endothelial growth factor (VEGF), promoting the formation of the tumor microenvironment. Furthermore, IDH mutations can induce high levels of hypoxia-inducible factor-1α (HIF-1α), which contributes to glioma invasion. These changes ultimately lead to the development of glioma. IDH mutations can also affect the immune microenvironment of gliomas, altering immune-cell infiltration and function by modulating immune-checkpoint gene expression and chemokine secretion. Currently, a number of IDH inhibitors and vaccines are in clinical trials, representing progress in the treatment of glioma patients.', 'IDH mutations play a crucial role in the development and progression of glioma, a type of brain cancer. These mutations lead to the production of high levels of 2-hydroxyglutaric acid (2-HG), which inhibits glioma stem cell differentiation. Additionally, IDH mutations upregulate vascular endothelial growth factor (VEGF), promoting the formation of the tumor microenvironment, and induce high levels of hypoxia-inducible factor-1α (HIF-1α), promoting glioma invasion. Furthermore, IDH mutations alter the immune microenvironment, modulating immune-checkpoint gene expression and chemokine secretion, which affects immune-cell infiltration and function. These changes ultimately contribute to the development of glioma. The diagnostic and therapeutic implications of IDH mutations are significant, with potential as a biomarker for disease diagnosis and monitoring, and as a target for treatment strategies, including IDH inhibitors and vaccines, which are currently in clinical trials.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nIsocitrate dehydrogenase (IDH) mutations play a crucial role in the development and progression of glioma. IDH mutations are found in approximately 70-80% of grade II/III gliomas and the majority of secondary glioblastomas, but only 10% of primary glioblastomas. These mutations are early and common events in the development of astrocytomas, oligodendrogliomas, and oligoastrocytomas. \n\nIDH mutations confer a neomorphic enzyme activity that converts alpha-ketoglutarate to an oncometabolite D-2-hydroxyglutarate (2-HG), which impacts cellular epigenetics and metabolism. IDH mutations are associated with a favorable prognosis and are a major prognostic marker for overall and progression-free survival in grade II-IV gliomas. Mutated IDH has an altered catalytic activity that results in the accumulation of 2-HG, which inhibits glioma stem cell differentiation.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers key aspects of IDH mutations in glioma, including prevalence, the production of 2-HG, impact on cellular processes, and prognostic significance. However, it misses details on the roles of VEGF and HIF-1α, and the immune microenvironment alterations mentioned in the reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and focuses on relevant information about IDH mutations in glioma without including irrelevant details. Each point made is directly related to the topic.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not repeat information unnecessarily. However, the mention of 2-HG accumulation could be seen as slightly repetitive, as it is discussed in two different contexts (epigenetics/ metabolism and stem cell differentiation).",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clear, and fluent. The information is presented in a logical sequence, making it easy to follow and understand."
    },
    {
        "Question": "Is there an association between specific genotypes and the risk of neurodevelopmental disorders for Becker Muscular Dystrophy?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs there an association between specific genotypes and the risk of neurodevelopmental disorders for Becker Muscular Dystrophy?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes, in Becker Muscular Dystrophy, Dp140 and Dp71 could be associated with developmental disorders.', 'Yes. In BMD, Dp140+ vs. Dp140- and Dp71+ vs. Dp71- were associated with developmental disorders with a PR of 0.11 (0.04, 0.34) and 0.22 (0.07, 0.67), respectively.', 'Yes, there is an association between specific genotypes and the risk of neurodevelopmental disorders for Becker Muscular Dystrophy. Particularly, Dp140 and Dp71 genotypes could be linked to these disorders.', 'Yes, in Becker Muscular Dystrophy (BMD), specific genotypes such as Dp140 and Dp71 could be associated with developmental disorders.', 'Yes. Certain genotypes, such as Dp140 and Dp71, are associated with an increased risk of neurodevelopmental disorders in Becker Muscular Dystrophy.', 'Yes, there is an association between specific genotypes and the risk of neurodevelopmental disorders for Becker Muscular Dystrophy. The genes Dp140 and Dp71 are associated with developmental disorders in BMD', 'Yes, specific genotypes such as Dp140 and Dp71 have been associated with an increased risk of neurodevelopmental disorders in individuals with Becker Muscular Dystrophy.', 'Yes, in Becker Muscular Dystrophy (BMD), the dystrophin isoforms Dp140 and Dp71 could be associated with developmental disorders.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, there is limited information on the association between specific genotypes and the risk of neurodevelopmental disorders for Becker Muscular Dystrophy (BMD). However, the data suggests that there may be an association between the Dp140 and Dp71 genotypes and the risk of intellectual developmental disorder (IDD) in BMD.\n\nA systematic review and meta-analysis of observational studies found that the prevalence of IDD in BMD was 8.0% (95% CI 5.0-11.0), and the number of isoforms affected (Dp140 and/or Dp71) was strongly and negatively associated with the prevalence of IDD in DMD. However, in BMD, there was no association for Dp140(+) /Dp71(+) versus Dp140(-) /Dp71(+) genotypes.\n\nAnother study found that the Dp140+ vs. Dp140- genotype was associated with developmental disorders in BMD, with a prevalence ratio (PR) of 0.11 (0.04, 0.34). Additionally, the Dp71+ vs. Dp71- genotype was associated with IDD in DMD, with a PR of 0.47 (0.36, 0.63).\n\nWhile these findings suggest a possible association between specific genotypes and the risk of neurodevelopmental disorders in BMD, further research is needed to confirm these results and to better understand the relationship between genotype and phenotype in BMD.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer provides detailed information about the association between Dp140 and Dp71 genotypes and neurodevelopmental disorders in BMD, including prevalence ratios and study findings. However, it does not fully capture the direct associations mentioned in some reference answers, such as the specific PR values for Dp71 in BMD.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise, focusing on the association between specific genotypes and neurodevelopmental disorders in BMD. It avoids irrelevant details and stays on topic. However, it includes some discussion about DMD, which is not directly relevant to the question.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. Each point is made clearly and concisely.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to read. It presents complex information clearly and logically."
    },
    {
        "Question": "What medication are included in the Juvisync pill?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat medication are included in the Juvisync pill?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Juvisync pill included sitagliptin and simvastatin.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe Juvisync pill includes two medications: Sitagliptin and Simvastatin.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer correctly identifies both medications included in the Juvisync pill (sitagliptin and simvastatin) as per the reference answer.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer provides only the relevant information about the medications in Juvisync without including any extraneous details.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition of information in the answer; each medication is mentioned only once.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is clear, concise, and easy to read, with proper punctuation and grammar."
    },
    {
        "Question": "Is fish intake a protective factor against colorectal cancer?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs fish intake a protective factor against colorectal cancer?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Individuals in the highest (vs. lowest) category of fish consumption had a significantly reduced risk of CRC (SRR 0.94, 95%CI 0.89-0.99). In dose-response meta-analysis, a 50-g increment in the daily consumption of fish was associated with a statistically significant 4% reduction in CRC risk (SRR 0.96, 95%CI 0.92-0.99)', 'Fish intake has been inversely associated with colorectal cancer risk in several studies. A case-control study in Sweden found that canned fish consumption was lower among cases than among controls, and an inverse association was found between canned fish consumption and CRC risk. A cohort study in Sweden found that higher intake of long-chain omega-3 polyunsaturated fatty acids, which are abundant in fish, was associated with a lower risk of colorectal cancer in women. A meta-analysis of 41 studies found that fish consumption was associated with a lower risk of colorectal cancer. However, a cohort study in the United States found no association between fish intake and colorectal cancer risk. Overall, the evidence suggests that fish intake may be a protective factor against colorectal cancer, but more research is needed to confirm this association.', 'Yes, fish intake has been shown to be a protective factor against colorectal cancer. Studies have consistently found that higher consumption of fish, particularly fatty fish, is associated with a lower risk of colorectal cancer. The mechanisms by which fish consumption protects against colorectal cancer are thought to involve the n-3 polyunsaturated fatty acids found in fish, which have anti-inflammatory and antioxidant effects in the colon. Additionally, adherence to a Mediterranean-style diet, which includes high levels of fish consumption, has been shown to be protective against colorectal and breast cancer.', 'Yes, fish intake is a protective factor against colorectal cancer, as indicated by multiple observational studies and meta-analyses showing an inverse association between fish consumption and colorectal cancer risk.', 'Yes, fish intake is inversely associated with colorectal cancer risk, with a 12% decrease in risk found in a meta-analysis. This association is supported by multiple observational and clinical studies, which suggest that fish consumption may have a protective effect against colorectal cancer. The protective effect is thought to be due to the high content of n-3 polyunsaturated fatty acids, such as eicosapentaenoic acid and docosahexaenoic acid, in some fish.', 'Yes, fish intake is a protective factor against colorectal cancer. Multiple studies have found that increased fish consumption is inversely associated with colorectal cancer risk. A meta-analysis found that fish consumption decreased the risk of colorectal cancer by 12%. Other studies have also found that high fish intake is associated with a decreased risk of colorectal cancer, which has been linked to the high content of n-3 polyunsaturated fatty acids (PUFAs) in some fish.', 'Fish intake is linked to reduced colorectal cancer (CRC) risk according to multiple studies. Moderate fish consumption and n-3 fatty acids from fish show inverse associations with CRC incidence, suggesting fish consumption provides protection against the disease.', 'Yes, fish intake is a protective factor against colorectal cancer. A number of studies have found an inverse relationship between fish consumption and the risk of developing colorectal cancer. For example, a case-control study in Eastern Europe found that increased fish intake was associated with a lower risk of colorectal cancer, even after adjusting for potential confounders such as demographic characteristics, body mass index, smoking status, and physical activity. Similarly, a prospective cohort study in the United States found that men who consumed fish at least once a week had a lower risk of colorectal cancer than those who rarely or never consumed fish. The protective effect of fish consumption on colorectal cancer risk may be due to the presence of long-chain n-3 fatty acids, which have been shown to have anti-inflammatory and antiproliferative effects in laboratory and animal studies. However, more research is needed to confirm these findings and to understand the underlying mechanisms', 'Yes, fish intake is a protective factor against colorectal cancer. This is based on a long-term prospective study that found intakes of fish and long-chain n-3 fatty acids from fish may decrease the risk for colorectal cancer. Additionally, a case-control study found that higher freshwater fish and sea fish intake is inversely associated with colorectal cancer risk among Chinese population.', 'Fish intake is linked to reduced colorectal cancer (CRC) risk, according to various studies. Moderate fish consumption and n-3 fatty acid intake from fish are associated with lower CRC incidence. Fish consumption of once a week or more might protect against CRC. Overall, these findings suggest that eating fish may have protective effects against the development of colorectal cancer.', 'Yes, fish intake appears to be a protective factor against colorectal cancer. Several epidemiological studies and meta-analyses have found an inverse association between fish consumption and colorectal cancer risk. The protective effect may be attributed to the high content of n-3 polyunsaturated fatty acids (PUFAs), particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), in some fish. These PUFAs are thought to suppress the proliferation of colorectal mucosa and inhibit the development of colorectal cancer. Overall, the evidence suggests that increasing fish intake may have a preventive effect on colorectal cancer risk.', 'Based on the abstracts provided, it appears that fish intake is indeed a protective factor against colorectal cancer. The first study found an inverse association between fish intake and colorectal cancer risk, with a multivariate relative risk of 0.63 for the highest versus lowest category of fish intake. Similarly, the second study found a significant reduction in colorectal cancer risk at moderate fish intake (one or two servings per week), with an odds ratio of 0.70. The third study also suggested a protective effect of fish consumption against colorectal cancer, although the association was not statistically significant. Overall, the evidence suggests that consuming fish may decrease the risk of developing colorectal cancer.', 'According to the meta-analysis, yes, fish intake is a protective factor against colorectal cancer (CRC). The study found that individuals who consumed more fish had a significantly reduced risk of CRC. Specifically, those in the highest category of fish consumption had a 6% lower risk of CRC compared to those in the lowest category. Additionally, for every 50g increase in daily fish consumption, there was a 4% reduction in CRC risk. The study suggests that dietary recommendations for cancer prevention should take into account the evidence from epidemiological and preclinical studies that increasing fish consumption may be effective in preventing CRC.', 'Yes, fish intake appears to be a protective factor against colorectal cancer (CRC). According to a study, individuals who consumed fish at higher levels had a significantly reduced risk of CRC compared to those who consumed less fish. In a dose-response meta-analysis, a 50-g increase in daily fish consumption was associated with a statistically significant 4% reduction in CRC risk. Therefore, increasing fish intake may help lower the risk of developing colorectal cancer.', 'Yes, fish intake is a protective factor against colorectal cancer. A 50-g increment in daily fish consumption is associated with a 4% reduction in colorectal cancer risk.', 'The evidence is not conclusive to establish a causal relationship between fish intake and a reduced risk of colorectal cancer. While some studies suggest a protective effect, others show no association or even a positive correlation. The potential benefits of fish consumption should be weighed against the risks associated with contaminants such as mercury and polychlorinated biphenyls (PCBs). More research is needed to better understand the relationship between fish consumption and colorectal cancer risk, and to determine the optimal amount and type of fish intake for cancer prevention.', 'Yes, fish intake has been shown to be a protective factor against colorectal cancer. In a meta-analysis of 17 cohort studies, individuals in the highest category of fish consumption had a significantly reduced risk of colorectal cancer compared to those in the lowest category. Additionally, a 50-g increment in daily fish consumption was associated with a 4% reduction in colorectal cancer risk. The protective effect of fish intake was observed in both men and women, and across all sub-sites of the colon and rectum. The mechanism by which fish intake reduces colorectal cancer risk is not fully understood, but may involve the omega-3 fatty acids and other nutrients found in fish.', 'Yes, fish intake is a protective factor against colorectal cancer. Higher fish consumption significantly reduces the risk of colorectal cancer, and a 50-g daily increase in fish consumption is associated with a 4% reduction in colorectal cancer risk.', \"Yes, according to the study, individuals with higher fish consumption had a significantly reduced risk of colorectal cancer (CRC). A 50-g increment in daily fish consumption was associated with a 4% reduction in CRC risk. \\n\\nPlease go ahead and ask your question. I'll respond accordingly. \\n\\n(Note: You can ask a question, and I'll provide an answer based on the given context. You can also ask follow-up questions based on my previous response.)\", 'Yes, fish intake is a protective factor against colorectal cancer. A study found that individuals in the highest category of fish consumption had a significantly reduced risk of colorectal cancer compared to those in the lowest category. Additionally, a dose-response meta-analysis found that a 50-g increment in the daily consumption of fish was associated with a statistically significant 4% reduction in colorectal cancer risk.', 'Yes, fish intake is indeed a protective factor against colorectal cancer. Studies have shown that individuals who consume more fish have a significantly reduced risk of developing this type of cancer. Specifically, a 50-gram increase in daily fish consumption is associated with a 4% reduction in colorectal cancer risk', 'Yes, fish intake is considered to be a protective factor against colorectal cancer. A study found that individuals in the highest category of fish consumption had a significantly reduced risk of colorectal cancer compared to those in the lowest category. Additionally, a dose-response meta-analysis found that a 50-g increment in the daily consumption of fish was associated with a statistically significant 4% reduction in colorectal cancer risk.', 'Yes, fish intake is a protective factor against colorectal cancer. Individuals in the highest category of fish consumption had a significantly reduced risk of CRC, and a 50-g increment in the daily consumption of fish was associated with a statistically significant 4% reduction in CRC risk', 'Fish intake is a protective factor against colorectal cancer (CRC). A meta-analysis found that individuals with higher fish consumption had a 6% lower risk of CRC, and for every 50g increase in daily fish consumption, there was a 4% reduction in CRC risk. The study suggests incorporating this information into dietary recommendations for cancer prevention.', 'In summary, consuming more fish has been shown to lower the risk of colorectal cancer (CRC), with each 50g increase in daily intake associated with a 4% reduction in CRC risk according to the meta-analysis data and observed dose-response relationship.', 'Yes, fish intake is a protective factor against colorectal cancer. Individuals in the highest category of fish consumption had a significantly reduced risk of CRC. Also, a 50-g increment in the daily consumption of fish was associated with a statistically significant 4% reduction in CRC risk.', 'Yes, fish intake is a protective factor against colorectal cancer. Individuals in the highest category of fish consumption had a significantly reduced risk of colorectal cancer (CRC) compared to those in the lowest category. A 50-g increment in daily fish consumption was associated with a 4% reduction in CRC risk.', 'Yes, fish intake has been shown to be a protective factor against colorectal cancer. In a meta-analysis of 17 cohort studies, individuals in the highest category of fish consumption had a significantly reduced risk of colorectal cancer compared to those in the lowest category. Specifically, a 50-g increment in daily fish consumption was associated with a 4% reduction in colorectal cancer risk. The protective effect of fish intake was observed in both men and women and across all sub-sites of the colon and rectum. The mechanism by which fish intake reduces colorectal cancer risk is not fully understood, but may involve the omega-3 fatty acids and other nutrients found in fish.', 'In summary, based on a meta-analysis, increased fish intake is associated with reduced colorectal cancer risk by 6% for those consuming more fish compared to the lowest category of consumers. For every 50g increase in daily consumption, there was an observed 4% decrease in CRC risk, suggesting that dietary recommendations may benefit from considering higher fish consumption as a potential preventative measure against colorectal cancer.', 'Yes, fish intake appears to be a protective factor against colorectal cancer (CRC). Individuals in the highest category of fish consumption had a significantly reduced risk of CRC compared to those in the lowest category (SRR 0.94, 95%CI 0.89-0.99). Additionally, a dose-response meta-analysis found that a 50-gram increment in daily fish consumption was associated with a statistically significant 4% reduction in CRC risk (SRR 0.96, 95%CI 0.92-0.99).', 'Based on the provided snippets, the answer is yes, fish intake appears to be a protective factor against colorectal cancer (CRC). The data suggests that individuals who consume higher amounts of fish have a significantly reduced risk of CRC. Specifically, a daily increment of 50g in fish consumption is associated with a 4% reduction in CRC risk. This finding is supported by the statistically significant dose-response relationship observed in the meta-analysis. These results suggest that moderate fish consumption may be a useful strategy for reducing the risk of colorectal cancer.', 'Yes, fish intake appears to be a protective factor against colorectal cancer. A meta-analysis found that individuals in the highest category of fish consumption had a significantly reduced risk of colorectal cancer compared to those in the lowest category (SRR 0.94, 95% CI 0.89-0.99). The dose-response analysis showed that each 50g increment in daily fish consumption was associated with a statistically significant 4% reduction in colorectal cancer risk (SRR 0.96, 95% CI 0.92-0.99).']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the answer is yes, fish intake appears to be a protective factor against colorectal cancer. The data from various studies, including cohort studies and case-control studies, suggest that high fish intake is associated with a reduced risk of colorectal cancer. Specifically, the data indicate that:\n\n* Fish consumption is inversely associated with colorectal cancer risk (e.g., study 1, study 3, study 6, study 10, study 11)\n* High intake of fish and long-chain n-3 polyunsaturated fatty acids (PUFAs) from fish may decrease the risk of colorectal cancer (e.g., study 3, study 10)\n* Fish and fish n-3 PUFAs may have a protective effect against colorectal cancer (e.g., study 9)\n* High intake of fish and fish n-3 PUFAs is associated with reduced risk of distal colon cancer (e.g., study 11)\n\nHowever, it is essential to note that the evidence is not uniform across all studies, and some studies found no association or a weak association between fish intake and colorectal cancer risk (e.g., study 8, study 16). Additionally, the mechanisms by which fish intake may exert its protective effect against colorectal cancer are not fully understood and require further investigation.\n\nOverall, while the data suggest that fish intake may be a protective factor against colorectal cancer, more research is needed to confirm these findings and to understand the underlying mechanisms.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "4",
        "Information Recall Explanation": "The answer captures most of the essential information from the reference answers, including the inverse association between fish intake and colorectal cancer risk, the role of n-3 PUFAs, and the variability in study findings. However, it could more explicitly mention specific metrics like the 4% reduction in risk per 50g increment, which is recurrent in the references.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise and does not include irrelevant information. It directly addresses the question by focusing on the protective effect of fish intake against colorectal cancer and acknowledges conflicting evidence without digressing.",
        "Information Repetition Score": "4",
        "Information Repetition Explanation": "The answer avoids unnecessary repetition but does reiterate the inverse association between fish intake and colorectal cancer risk in slightly different ways. However, this is done to emphasize key points rather than redundant details.",
        "Readability Score": "4",
        "Readability Explanation": "The answer is well-structured and fluent, making it easy to read. However, the use of parenthetical references (e.g., 'study 1, study 3') could be slightly improved for smoother readability by integrating these references more seamlessly into the text."
    },
    {
        "Question": "What is the exposome?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the exposome?\n\nHere are some reference answers:\n\n**Reference Answers:**\n[\"The exposome, defined as the totality of an individual's exposures over the life course. The concept of the Exposome is a compilation of diseases and one's lifetime exposure to chemicals, whether the exposure comes from environmental, dietary, or occupational exposures; or endogenous chemicals that are formed from normal metabolism, inflammation, oxidative stress, lipid peroxidation, infections, and other natural metabolic processes such as alteration of the gut microbiom\", 'The exposome is defined as the totality of exposures received by an individual from conception to death. The exposome comprises all environmental (non-genetic) factors that can change the gene expression, function or structure. The exposure can be physical (e.g. temperature, altitude), chemical (e.g. metals, organic compounds), biological (e.g. bacteria, parasites, viruses) or psychosocial (e.g. social environment, behaviour, education). It is important to know that, as the genome, the exposome is individual and specific for every person.', 'The exposome is the cumulative measure of environmental influences and associated biological responses throughout the lifespan, including those from the environment, diet, behaviour, and endogenous processes.', 'The exposome integrates the variety and accumulation of exposures (external and internal) to which an individual is submitted to from conception to death. The exposome is the cumulative measure of environmental influences and associated biological responses throughout the lifespan, including those from the environment, diet, behaviour, and endogenous processes.', 'The exposome is the analogue to the genome, from an environmental exposure perspective; research on the exposome is a new field that has gained momentum only since 2011.', 'The exposome integrates the variety and accumulation of exposures (external and internal) to which an individual is submitted to from conception to death.', 'The exposome refers to the measure of all the exposures of an individual in a lifetime and how those exposures relate to health. It includes everything from environmental pollutants, diet, lifestyle, and behavior to genetics and the microbiome.', \"The exposome is the totality of an individual's environmental exposures, including dietary, occupational, and endogenous exposures, from conception onward, complementing the genome.\", \"The exposome is the totality of an individual's exposures over the life course.\", \"The term 'exposome' was proposed to reflect a life-course of environmental influences beginning in-utero and proceeding right through childhood to adulthood.\", 'The exposome is a comprehensive concept of the entire set of exposures encountered by a human individual in its life-time. It includes internal and external exposures in the broadest sense, for example physical, chemical, biological, social, and psychological factors.', \"The exposome is the totality of an individual's exposures over the life course, including environmental, dietary, occupational, and endogenous exposures.\", \"The exposome is the totality of an individual's exposures over their life course, beginning from conception onwards. It encompasses all non-genetic exposures from environmental, dietary, occupational sources as well as endogenous chemicals produced by normal metabolism, inflammation, oxidative stress, lipid peroxidation, infections, and other natural metabolic processes such as alteration of the gut microbiome. The exposome concept complements the genome and provides a new paradigm in environmental health sciences to assess the comprehensive impact of exposures on health.\", 'The exposome is a concept that encompasses the totality of human environmental exposures from conception onwards, complementing the genome. It includes lifetime exposure to chemicals from environmental, dietary, or occupational sources, as well as endogenous chemicals formed from normal metabolism, inflammation, oxidative stress, lipid peroxidation, infections, and other natural metabolic processes such as alterations in the gut microbiome.', 'The exposome is a comprehensive measure of all environmental influences an individual is exposed to from conception to adulthood, including pollutants, lifestyle, diet, and other health-shaping factors.', \"The exposome is a concept that refers to the cumulative exposure to environmental factors throughout an individual's lifetime, starting from in-utero development and continuing through childhood and adulthood\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe exposome is a comprehensive concept that refers to the total environmental exposure to various factors throughout an individual's lifetime, which can impact human health. It encompasses all external exposures from the environment, diet, behavior, societal influences, and infections, as well as cumulative biological responses to exposures and endogenous processes.\n\nThe exposome includes three main domains:\n\n1. **General external exposome**: This refers to measurable population-level exposures such as air pollution, meteorological factors, and other environmental factors that affect the general population.\n2. **Specific external exposome**: This includes individual-level exposures, such as lifestyle factors, obtained from questionnaires or other sources.\n3. **Internal exposome**: This encompasses multiple biological responses to external factors, detected through molecular and omics analyses.\n\nThe exposome is a dynamic and life-course concept, meaning that it changes over an individual's lifetime and can be influenced by various factors, including socioeconomic status, lifestyle choices, and environmental exposures.\n\nThe exposome has been proposed as a new paradigm to study the impact of the environment on health, complementing the genome in understanding the causes of chronic diseases. It has the potential to provide a more comprehensive understanding of the role of environmental risk factors in disease etiology and to inform prevention and public health policies.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers all necessary aspects of the exposome as reflected in the reference answers. It includes definitions, domains (general external, specific external, internal), and the dynamic nature of the exposome over a lifetime. It also mentions the exposome's role in disease etiology and public health, aligning well with the references.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include irrelevant information. It focuses exactly on the exposome, its domains, and its implications, without straying into unrelated topics. Each point is relevant to the concept of the exposome.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no unnecessary repetition in the answer. Each section introduces new and relevant information about the exposome, from its definition to its domains and broader implications. The flow is logical and avoids redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured and easy to follow. The use of bullet points for the domains of the exposome enhances clarity. The language is clear and fluent, making complex concepts accessible without sacrificing depth."
    },
    {
        "Question": "What is the gold standard for a diagnosis of narcolepsy?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the gold standard for a diagnosis of narcolepsy?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The gold standard for diagnosing narcolepsy is a combination of overnight polysomnography (PSG) followed by a multiple sleep latency test (MSLT). PSG is used to rule out other sleep disorders, while the MSLT assesses daytime sleepiness and the presence of sleep-onset REM periods, which are characteristic of narcolepsy. Measuring cerebrospinal fluid hypocretin-1 levels can provide additional diagnostic information.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nThe gold standard for a diagnosis of narcolepsy is a polysomnography (PSG) recording, which is a comprehensive sleep study that records various physiological activities during sleep, such as brain waves, muscle activity, and heart rate. This is according to table 15.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 2,
        "Information Recall Explanation": "The answer mentions polysomnography (PSG) as the gold standard, but it omits critical components such as the multiple sleep latency test (MSLT) and the potential role of cerebrospinal fluid hypocretin-1 levels. Therefore, it partially captures the necessary information.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer focuses on PSG, which is relevant to narcolepsy diagnosis, but it does not include irrelevant information. However, it misses other relevant diagnostic tests, slightly affecting precision.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. It succinctly describes PSG without redundancy.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is easily readable and fluent, with a clear description of PSG. However, the reference to 'table 15' without context slightly detracts from clarity."
    },
    {
        "Question": "Which receptor tyrosine kinase is commonly mutated or amplified in pediatric glioma cases?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhich receptor tyrosine kinase is commonly mutated or amplified in pediatric glioma cases?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Pediatric high-grade glioma (pHGG), including both diffuse midline glioma (DMG) and non-midline tumors, continues to be one of the deadliest oncologic diagnoses. Targeted therapy options aimed at key oncogenic receptor tyrosine kinase (RTK) drivers using small-molecule RTK inhibitors have been extensively studied, but the absence of proper in vivo modeling that recapitulates pHGG biology has historically been a research challenge. Over 20% of pHGG have been found in sequencing studies to have alterations in platelet derived growth factor-alpha (PDGFRA), making growth factor modeling and inhibition via targeted tyrosine kinases a promising research direction.', 'Receptor tyrosine kinase (RTK) alterations are commonly found in pediatric high-grade glioma (pHGG), including diffuse midline glioma (DMG) and non-midline tumors. Sequencing studies have revealed that over 20% of pHGG cases have alterations in platelet derived growth factor-alpha (PDGFRA). This has made growth factor modeling and inhibition via targeted tyrosine kinases a significant area of interest in pHGG research. The challenge in this field has been the lack of proper in vivo modeling that accurately represents pHGG biology.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, the receptor tyrosine kinase that is commonly mutated or amplified in pediatric glioma cases is PDGFRA (Platelet-Derived Growth Factor Receptor Alpha).\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer fully captures the key point from the reference answers, which is that PDGFRA is commonly mutated or amplified in pediatric glioma cases. It accurately references the specific receptor tyrosine kinase mentioned in the references.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is concise and directly addresses the question without including any irrelevant information. It focuses solely on the receptor tyrosine kinase (PDGFRA) relevant to pediatric glioma.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information. It states the key fact (PDGFRA involvement in pediatric glioma) once clearly and succinctly.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is highly readable, clear, and fluent. It uses straightforward language and proper terminology, making it easy to understand."
    },
    {
        "Question": "Can procalcitonin be used as a predictor for mortality in paediatric sepsis?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nCan procalcitonin be used as a predictor for mortality in paediatric sepsis?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes, procalcitonin can be used as a predictor for mortality in paediatric sepsis.', 'Yes, Procalcitonin can be used as a predictor for mortality in paediatric sepsis.', 'Yes, serum procalcitonin on admission can predict mortality in paediatric sepsis', 'Yes, procalcitonin can be used as a predictor for mortality in paediatric sepsis, when combined with clinical evaluation', 'Yes, procalcitonin can be used as a predictor for mortality in paediatric sepsis']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, it appears that procalcitonin can be used as a predictor for mortality in paediatric sepsis. \n\nProcalcitonin levels are elevated in sepsis, and the higher the level of procalcitonin, the higher the risk of mortality. Studies have shown that procalcitonin levels can predict septic shock and mortality in children. \n\nFor example, in one study, the area under the receiver operating characteristic curve (AUC) for procalcitonin to predict septic shock was 0.91 (95% CI: 0.83-0.97), and the AUC for procalcitonin to predict mortality was 0.80 (95% CI: 0.69-0.88). \n\nAnother study found that procalcitonin levels were significantly associated with mortality in children with sepsis, with an odds ratio of 3.26 (95% CI: 1.16-9.16) for mortality in children with lactate levels greater than 36 mg/dL.\n\nTherefore, procalcitonin can be used as a predictor for mortality in paediatric sepsis, and it may be useful in early risk stratification of pediatric sepsis.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer provides a comprehensive response to the question, including not only the affirmative answer but also supporting details such as the association between procalcitonin levels and mortality risk, specific study results (AUC values, odds ratio), and the utility of procalcitonin in early risk stratification. This exceeds the basic recall demonstrated in the reference answers by adding contextual evidence.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer is precise and focused on the role of procalcitonin in predicting mortality in paediatric sepsis. However, it includes slightly more granular detail (e.g., specific AUC values and odds ratios) than the reference answers, which might be considered beyond the scope of a simple yes/no question. Nonetheless, this detail enhances the precision without introducing irrelevant information.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. Each piece of information builds upon the previous one to support the conclusion without redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured, fluent, and easy to read. It logically progresses from the basic assertion to supporting evidence and concludes with a clear statement of utility. The use of specific examples (studies) is integrated smoothly into the narrative."
    },
    {
        "Question": "What is the race with the highest incidence of colorectal cancer?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the race with the highest incidence of colorectal cancer?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Black Americans demonstrating the highest incidence and mortality from this disease', 'The race with the highest incidence of colorectal cancer is African Americans, particularly African American females. This was found in a study that analyzed data from the Surveillance, Epidemiology, and End Results Registry (SEER) of individuals aged 45-79 years from 2000-2017. The results showed that while the incidence of colorectal cancer decreased for both males and females during the study period, African Americans had the least decline in incidence. Moreover, African American females had the highest risk for colorectal cancer compared to other females or males from different racial groups, and they also had the poorest 5-year survival rate among females. This highlights the need for targeted interventions and screening strategies to reduce the burden of colorectal cancer in this population.', 'Black Americans have the highest incidence of colorectal cancer (CRC) compared to other racial/ethnic groups in the United States. This is supported by multiple studies and sources, including a 2016 report stating that CRC incidence was higher among Blacks (42.5 per 100,000) than Whites (38.0), Latinos (31.7) and Asians (30.0). Additionally, a 2012 study found that after a mean follow-up of 10.8 years, CRC incidence was the highest in African-Americans (annualized rate = 0.14%) compared to Whites, Native Americans, Asian/Pacific Islanders, and Hispanics. A 2021 study also found that Black Americans have a higher risk of CRC incidence and mortality compared to other groups.', 'Black Americans have the highest incidence of colorectal cancer (CRC) compared to other racial and ethnic groups in the United States. This is consistent across various studies and sources, which show that CRC incidence and mortality rates are significantly higher in Black Americans compared to non-Hispanic Whites, Hispanics, Asian/Pacific Islanders, and Native Americans. The disparity in CRC incidence and mortality rates between Black Americans and other racial and ethnic groups is likely due to a combination of genetic, environmental, and socioeconomic factors. It is important to continue researching and addressing these disparities to improve CRC outcomes for all populations.', 'African Americans have the highest incidence of colorectal cancer in the United States, with a younger mean age at diagnosis and greater proportion of proximal cancers compared to whites. Survival rates are also lower for African Americans with this type of cancer. Socioeconomic, lifestyle, and healthcare factors do not fully explain the racial disparity, suggesting other etiologic factors may be important in Black American populations.', 'The race with the highest incidence of colorectal cancer is African Americans (AAs). This racial group has been consistently shown to have higher rates of colorectal cancer incidence and mortality compared to other races in the United States. The disparity between AAs and Non-Hispanic Whites (NHWs) is multifactorial, including genetic, environmental, and societal factors. Some studies suggest that interventions such as increasing screening utilization rates among AAs to match NHWs can help reduce this incidence disparity. Additionally, research has identified unique genetic and epigenetic changes in AA colorectal cancers, which could lead to more precise approaches to colorectal cancer care for this population. Despite these findings, there is still a need for a better understanding of the etiologic factors contributing to the higher incidence and mortality rates of colorectal cancer among African Americans.', 'The race with the highest incidence of colorectal cancer is non-Hispanic Black service members, but this study observed similar rates of colorectal cancer for all races and ethnicities after adjusting for age.', 'Colorectal cancer is the third most common cancer diagnosed in both men and women in the United States and is the second leading cause of cancer death. According to the most recent data, African Americans had the highest incidence rate among all races.', 'Summary: African Americans have the highest incidence of colorectal cancer in the United States with a younger mean age at diagnosis and lower survival rates compared to whites. Socioeconomic, lifestyle, and healthcare factors do not fully explain this disparity.', 'The race with the highest incidence of colorectal cancer is African Americans, who have the highest colorectal cancer incidence and mortality rates of any U.S. racial/ethnic group. This disparity exists despite efforts to promote awareness and screening, and is not fully explained by established risk factors or socioeconomic status. In fact, researchers are actively seeking to understand other etiologic factors that may contribute to this health disparity. Additionally, African Americans with colorectal cancer tend to be diagnosed at a younger age and have more proximal cancers compared to whites, further highlighting the need for targeted interventions to reduce this health disparity.', 'According to the provided information, African Americans have the highest incidence rates of colorectal cancer compared to other racial and ethnic groups in the United States. The data consistently shows that colorectal cancer incidence is significantly higher in African Americans than in non-Hispanic whites, Hispanics, Asian/Pacific Islanders, and other racial groups. African Americans are about 20% more likely to get colorectal cancer and 40% more likely to die from it than most other groups.', 'The race with the highest incidence of colorectal cancer (CRC) in the United States is Black Americans. This was observed across all age groups, with no decrease in incidence seen in any age group in 2016. The disparity in CRC incidence and mortality between racial and ethnic groups appears to be multifactorial, with structured societal issues, abnormal environmental factors, and cancer-specific immune and genetic changes contributing to the observed differences. Although acquiring additional knowledge into the science behind these disparities is crucial for developing interventions that reduce both CRC incidence and mortality, current evidence suggests that prevention through CRC screening has been effective in mitigating the disparity, but only before CRC has developed.', 'The race with the highest incidence of colorectal cancer (CRC) is Black Americans. This has been consistently observed across different age groups. The incidence of CRC among Black Americans is persistently higher compared to other racial groups, making them the most affected demographic in terms of CRC occurrence.', ' Africans, certain genetic, lifestyle, and clinical factors may contribute to a higher incidence of colorectal cancer in specific populations, but the overall risk is influenced by a complex interplay of various factors and may vary among individuals within each population. Early diagnosis and prompt initiation of appropriate cancer treatments are essential for reducing morbidity and improving outcomes. ', 'Black Americans have the highest incidence and mortality rate from colorectal cancer (CRC) compared to other racial groups. This was observed across all age groups.', 'Summary: Black Americans have the highest incidence of colorectal cancer (CRC) in the United States across all age groups. The disparity is multifactorial and includes societal issues, environmental factors, and immune or genetic changes. While prevention through screening mitigates disparities before CRC develops, further research is needed to understand these differences fully.', 'Summary: Black Americans exhibit the highest incidence and mortality rates from colorectal cancer (CRC) compared to other races in the United States. This highlights a significant health disparity, emphasizing the need for targeted interventions and increased awareness about CRC screening and prevention among this population.', 'According to the provided information, Black Americans have the highest incidence of colorectal cancer compared to other racial groups. The passages state that \"Black Americans demonstrat[e] the highest incidence and mortality from this disease\" and \"blacks continued to have the highest incidence of CRC for every age group.\"', 'Based on the provided snippets, it is clear that Black Americans have the highest incidence and mortality from colorectal cancer (CRC). The data indicates that Blacks continued to have the highest incidence of CRC for every age group. Therefore, the answer to the question is that Blacks or African Americans have the highest incidence of colorectal cancer. This highlights a significant health disparity in the US, emphasizing the need for targeted interventions and increased awareness about CRC screening and prevention in this population.', 'According to the provided information, Black Americans have the highest incidence of colorectal cancer compared to other racial groups. The abstracts state that \"Black Americans demonstrat[e] the highest incidence and mortality from this disease\" and \"blacks continued to have the highest incidence of CRC for every age group.\"']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, the racial group with the highest incidence of colorectal cancer is African Americans. This is mentioned in several relations, including:\n\n* Relation 2: \"African Americans have the highest incidence and mortality rates of colorectal cancer in the United States.\"\n* Relation 3: \"Blacks have a higher incidence of colorectal cancer compared to other racial groups.\"\n* Relation 4: \"Whites have a lower incidence and mortality rate of colorectal cancer compared to African-Americans.\"\n* Relation 5: \"African-Americans have higher incidence and mortality rates from colorectal cancer compared to non-African-Americans\"\n\nThis is also supported by the data in the Entities table, where entity 14, \"AFRICAN AMERICANS\", has a rank of 31, indicating that it is the racial group with the highest incidence of colorectal cancer compared to other racial groups.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer effectively captures the key point from the reference answers: African Americans have the highest incidence of colorectal cancer. It references multiple relations and even mentions supporting data from an Entities table, which indicates thorough recall of the necessary information.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise in identifying African Americans as the group with the highest incidence. However, it slightly strays by mentioning 'Whites have a lower incidence' and 'non-African-Americans,' which, while contextually correct, are not as directly relevant as the main point for this specific question.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer repeats the core idea that African Americans have the highest incidence across multiple relations, but this repetition serves to reinforce the point rather than being redundant. The phrasing varies enough to avoid monotony.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is clear and well-structured. It uses bullet points for relations, making the information easy to follow, and the inclusion of the Entities table adds a layer of comprehensiveness without detracting from fluency."
    },
    {
        "Question": "LRP6 is a member of what  superfamily of cell-surface receptors?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nLRP6 is a member of what  superfamily of cell-surface receptors?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['LRP6 is a member of the low-density lipoprotein receptor superfamily of cell-surface receptors', 'LRP6 (low-density lipoprotein receptor-related protein 6) is a member of the LDL receptor superfamily that plays an important role in regulating the Wnt/β-catenin signaling pathway.', 'LRP6 is a member of the low-density lipoprotein receptor (LDLR) superfamily of cell-surface receptors.', 'LRP6 is a member of the low-density lipoprotein receptor superfamily of cell-surface receptors.', 'LRP6 is a member of the low-density lipoprotein receptor superfamily.', 'LRP6 is a member of the low-density lipoprotein (LDL) receptor superfamily of cell-surface receptors.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nLRP6 is a member of the low-density lipoprotein receptor superfamily of cell-surface receptors.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer accurately identifies LRP6 as a member of the low-density lipoprotein receptor superfamily, which is consistent with all reference answers.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information, focusing solely on the superfamily membership of LRP6.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information unnecessarily; it provides a clear and concise statement about LRP6's superfamily.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is straightforward and easy to understand, with no grammatical errors or awkward phrasing."
    },
    {
        "Question": "List of major risks of intrauterine device.",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nList of major risks of intrauterine device.\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Risks of using IDU for contraception are unwanted pregnancy, anemia, heavy bleeding, infection, PID, perforation, IUD expulsion, and deleterious effect on vaginal microbial environment.', 'The major risks associated with intrauterine devices (IUDs) include perforation of the uterus, pregnancy, and pelvic inflammatory disease. Perforation of the uterus is rare but potentially fatal and can occur during insertion or later. Pregnancy with an IUD in place is associated with an increased risk of spontaneous abortion, ectopic pregnancy, and sepsis during pregnancy. Pelvic inflammatory disease is more common in IUD users than in users of oral contraceptives and diaphragms, and can lead to serious complications such as infertility. Additionally, IUD use is associated with increased blood loss during menstruation. It is important for healthcare providers to consider these risks when recommending and inserting IUDs and to inform patients of the potential complications.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the following are major risks associated with intrauterine devices (IUDs):\n\n1. **Expulsion**: The risk of IUD expulsion is higher for younger women compared to older women, especially for copper-bearing IUDs.\n2. **Perforation**: Although rare, IUD perforation can occur, which may lead to complications such as infection, bleeding, or damage to surrounding tissues.\n3. **Infection**: IUDs can increase the risk of infection, particularly in women with a history of pelvic inflammatory disease (PID) or other sexually transmitted infections (STIs).\n4. **Pregnancy**: IUDs are effective in preventing pregnancy, but there is a small risk of pregnancy occurring despite the presence of an IUD.\n5. **Adverse effects on vaginal environment**: Copper IUDs can alter the vaginal environment by increasing the concentration of inflammatory anaerobes and decreasing the concentration of lactobacilli, which may lead to adverse effects on reproductive health.\n\nIt's essential to note that while these risks exist, IUDs are generally considered a safe and effective form of contraception when used correctly and under the guidance of a healthcare provider.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers most of the major risks of IUDs mentioned in the reference answers, including expulsion, perforation, infection, pregnancy, and adverse effects on the vaginal environment. However, it misses some specific details such as the increased risk of ectopic pregnancy, spontaneous abortion, and sepsis, as well as the mention of anemia and heavy bleeding.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and focuses solely on the major risks associated with IUDs without including irrelevant information. Each point is clearly articulated and directly relates to the question.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information. Each risk is mentioned only once, and the answer flows logically from one point to the next.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is very readable and fluent. The use of bullet points makes it easy to follow, and each risk is explained clearly and concisely. The concluding note adds context without disrupting the flow."
    },
    {
        "Question": "What are episignatures?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are episignatures?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Episignatures are unique genomic DNA methylation patterns that can be used for diagnostic testing and as disease biomarkers in genetic syndromes.', 'Episignatures are distinct, highly sensitive, and specific biomarkers that represent unique genomic DNA methylation patterns.', 'Episignatures are distinct, highly sensitive, and specific biomarkers that have recently been applied in clinical diagnosis of genetic syndromes.', 'Episignatures are a type of epigenetic signature that refers to specific patterns of DNA methylation and histone modifications that are associated with certain genetic disorders.', 'Episignatures are unique genomic DNA methylation patterns that have been associated with a growing number of genetic syndromes. They can be used for diagnostic testing and as disease biomarkers.', 'Episignatures are unique genomic DNA methylation patterns.', 'Episignatures are unique genomic DNA methylation patterns associated with certain genetic syndromes. They can be used for diagnostic testing and as disease biomarkers.', 'Episignatures are unique genomic DNA methylation patterns that can be used for diagnostic testing and as disease biomarkers.', 'Episignatures refer to unique genomic DNA methylation patterns that have been associated with a growing number of genetic syndromes. These episignatures can be used for diagnostic testing and as disease biomarkers.', 'Episignatures are unique genomic DNA methylation patterns. They are associated with various genetic syndromes and can be used for diagnostic testing and as disease biomarkers', 'Episignatures refer to unique genomic DNA methylation patterns that have been associated with certain genetic syndromes. These episignatures can be used for diagnostic testing and as disease biomarkers.', 'Episignatures are unique genomic DNA methylation patterns that are associated with genetic syndromes and can be used for diagnostic testing and as disease biomarkers', 'Episignatures are genomic DNA methylation patterns that are associated with specific diseases, such as Duchenne Muscular Dystrophy. These patterns can be used for diagnostic testing and as disease biomarkers.', 'Episignatures are unique genomic DNA methylation patterns that have been associated with a growing number of genetic syndromes. These DNA methylation patterns can be used for diagnostic testing and as disease biomarkers.', 'Episignatures are unique genomic DNA methylation patterns that can be used for diagnostic testing and as disease biomarkers']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nEpisignatures are a concept related to the exposome, which refers to the totality of environmental exposures encountered by an individual from conception to death. Episignatures are essentially the unique patterns or signatures of environmental exposures and their associated biological responses that are present in an individual's body at a particular point in time or across their lifetime.\n\nIn the context of exposome research, episignatures are used to describe the complex and dynamic interactions between environmental exposures and biological systems, resulting in unique molecular, cellular, or physiological changes. These signatures can be thought of as a \"fingerprint\" of an individual's exposure history and can be used to predict disease risk, identify potential health outcomes, and develop personalized medicine approaches.\n\nEpisignatures can be measured using various \"omics\" technologies, such as genomics, transcriptomics, proteomics, metabolomics, and epigenomics, which allow researchers to assess the impact of environmental exposures on an individual's biological systems. By analyzing episignatures, researchers can gain insights into the underlying mechanisms of disease and develop new strategies for disease prevention and treatment.\n\nIn the context of the provided data tables, episignatures are mentioned in relation to the exposome, specifically in the following entries:\n\n* \"Episignatures\" is mentioned in the \"Entities\" table (id = 77) as a concept related to the exposome.\n* \"Episignatures\" is also mentioned in the \"Relations\" table (id = 110) as a component of the exposome, related to the study of exposure-phenotype interaction.\n\nOverall, episignatures are an important concept in exposome research, allowing researchers to better understand the complex relationships between environmental exposures and human health.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "2",
        "Information Recall Explanation": "The answer does not accurately recall the key details provided in the reference answers, which focus on episignatures as unique genomic DNA methylation patterns associated with genetic syndromes for diagnostic and biomarker purposes. Instead, the answer incorrectly associates episignatures with the exposome and environmental exposures.",
        "Information Precision Score": "1",
        "Information Precision Explanation": "The answer includes irrelevant information about the exposome and environmental exposures, which is not aligned with the reference answers. This major deviation from the expected topic makes the answer imprecise.",
        "Information Repetition Score": "3",
        "Information Repetition Explanation": "The answer does not repeat the same information but instead repeatedly emphasizes the incorrect association with exposome research, which detracts from the actual topic of episignatures.",
        "Readability Score": "4",
        "Readability Explanation": "The answer is well-structured and fluent, making it easy to read. However, the clarity of the content is compromised by the inaccurate focus on the exposome rather than the correct definition of episignatures."
    },
    {
        "Question": "Is chemotherapy an effective treatment for patients with advance colorectal cancer and poor performance status (ECOG/PS >1)",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs chemotherapy an effective treatment for patients with advance colorectal cancer and poor performance status (ECOG/PS >1)\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Treatment with chemotherapy was associated with longer median overall survival across Performance Status (PS) groups. Exploratory analysis based on comorbidity score and tumor burden subgroups demonstrated a consistently positive overall survival association with treatment. Benefit was observed where poor overall survival was attributable to medical comorbidities and to tumor burden. Chemotherapy might benefit selected metastatic colorectal cancer (mCRC) patients with poor PS. With up-front dose reduction and close monitoring for toxicity, the risk of serious adverse events is minimized.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, there is limited information available on the effectiveness of chemotherapy for patients with advanced colorectal cancer and poor performance status (ECOG/PS >1). However, we can look at some relevant studies and data points that may provide some insights.\n\nStudy 1: \"The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4\" (Source 9)\n\n* This study retrospectively analyzed 240 consecutive patients with metastatic colorectal cancer who started first-line chemotherapy at their institution.\n* The study found that patients with ECOG PS 3/4 who received chemotherapy had a median survival of 6.8 months, which was not significantly different from those who received best supportive care (BSC) alone.\n* However, the study also found that patients with ECOG PS 3/4 who received upfront dose-reduced therapy had a lower rate of treatment-related hospitalization and a similar rate of Grade 3/4 toxicities compared to those who received full-dose therapy.\n\nStudy 2: \"Survival impact of optimal treatment for elderly patients with colorectal cancer: A real-world study\" (Source 4)\n\n* This study retrospectively analyzed 150 patients with colorectal cancer older than 65 years who were diagnosed in their institution between 2010 and 2018.\n* The study found that patients with ECOG PS 0/1 who received optimal treatment had a median overall survival (mOS) of 27.63 months, while those with ECOG PS 3/4 had a mOS of 6.8 months.\n* However, the study also found that the addition of oxaliplatin to chemotherapy did not benefit patients with ECOG PS 3/4.\n\nStudy 3: \"ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials\" (Source 5)\n\n* This study pooled data from five clinical trials of 5-FU-based treatment for metastatic colorectal cancer.\n* The study found that patients with ECOG PS 0 had a lower probability of serious adverse events, fatal adverse events, high-grade anemia, and high-grade nausea/vomiting compared to those with ECOG PS 1.\n* The study also found that patients with ECOG PS 0 had better overall and progression-free survival compared to those with ECOG PS 1.\n\nBased on these studies, it appears that chemotherapy may have some benefits for patients with advanced colorectal cancer and poor performance status (ECOG/PS >1), particularly if they receive upfront dose-reduced therapy. However, the evidence is limited, and further research is needed to confirm these findings. Additionally, the decision to use chemotherapy in these patients should be made on an individual basis, taking into account their overall health, performance status, and preferences.\n\nIn summary, while there is some evidence to suggest that chemotherapy may be beneficial for patients with advanced colorectal cancer and poor performance status (ECOG/PS >1), the evidence is limited, and more research is needed to confirm these findings.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer provides a thorough overview of studies related to chemotherapy in advanced colorectal cancer patients with poor performance status. However, it misses mentioning the consistent positive overall survival association and benefits observed where poor survival was due to comorbidities or tumor burden, as highlighted in the reference answer.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise and focuses on relevant studies without straying into unrelated topics. The studies cited are directly applicable to the question, though some details from the reference answer (e.g., impact of up-front dose reduction) could have been more explicitly mentioned.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat information unnecessarily. Each study mentioned contributes unique insights without redundancy, and the conclusion succinctly summarizes the findings without reiterating points excessively.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clearly written, and easy to follow. Each study is introduced and explained logically, and transitions between sections are smooth, enhancing readability."
    },
    {
        "Question": "How does Pamrevlumab work?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nHow does Pamrevlumab work?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Pamrevlumab (FG-3019) is a fully human monoclonal antibody that binds to connective tissue growth factor (CTGF) and can be used for non-ambulatory patients with Duchenne Muscular Dystrophy.', 'Pamrevlumab is a monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), which is involved in fibrosis and tumor growth. By blocking CTGF, pamrevlumab may help to reduce fibrosis and slow tumor progression.', 'Pamrevlumab is a human monoclonal antibody that binds to connective tissue growth factor (CTGF) and attenuates progression of idiopathic pulmonary fibrosis.', 'Pamrevlumab is an anti-connective tissue growth factor therapy that binds to connective tissue growth factor (CTGF) and has shown potential in attenuating progression of idiopathic pulmonary fibrosis.', 'Pamrevlumab is a fully recombinant human monoclonal antibody against CTGF. It has shown efficacy in idiopathic pulmonary fibrosis.', 'Pamrevlumab, also known as FG-3019, is a fully human monoclonal antibody that targets connective tissue growth factor (CTGF). The antibody works by binding to CTGF, which is a protein that plays a role in the formation of fibrosis or scarring in muscles. By binding to CTGF, pamrevlumab is thought to inhibit the activity of the protein, reducing the formation of fibrosis and potentially slowing the progression of Duchenne muscular dystrophy (DMD). The antibody has been studied in non-ambulatory patients with DMD, a group that often experiences significant muscle deterioration and fibrosis. Pamrevlumab may have the potential to improve muscle function and quality of life in these patients, although further research is needed to confirm its safety and efficacy.', 'Pamrevlumab is a fully human monoclonal antibody that binds to connective tissue growth factor (CTGF), a secreted glycoprotein that has a central role in the process of fibrosis. It is in Phase III development for treatment of DMD and other diseases, with the aim of slowing, stopping, or reversing progression of fibrosis.', 'Pamrevlumab is a fully human monoclonal antibody that binds to connective tissue growth factor (CTGF).', 'Pamrevlumab works by binding to the connective tissue growth factor (CTGF). As a fully human monoclonal antibody, it targets this specific protein to exert its effects.', 'Pamrevlumab is a monoclonal antibody that targets CTGF, a key regulator of fibrosis and muscle damage in Duchenne muscular dystrophy (DMD). It works by binding to CTGF, reducing the formation of fibrotic tissue in muscles, potentially preserving muscle function and slowing disease progression.', 'Pamrevlumab (FG-3019) is a fully human monoclonal antibody that binds to and inhibits connective tissue growth factor (CTGF).', 'Pamrevlumab, a fully human monoclonal antibody, works by targeting and binding to connective tissue growth factor (CTGF). CTGF is a key regulator of fibrosis and muscle degeneration, which are hallmarks of Duchenne muscular dystrophy (DMD). By inhibiting CTGF, pamrevlumab aims to reduce the excessive deposition of extracellular matrix proteins that leads to fibrosis and muscle damage in DMD patients. This may help to preserve muscle function and slow down disease progression. In non-ambulatory patients with DMD, pamrevlumab has shown potential to improve muscle strength and function, and reduce muscle inflammation and damage.', 'Pamrevlumab, a fully human monoclonal antibody, works by specifically binding to connective tissue growth factor (CTGF). This binding action inhibits the activity of CTGF, which plays a role in fibrosis and tissue scarring. By blocking the effects of CTGF, Pamrevlumab aims to reduce muscle fibrosis and improve muscle function in patients with Duchenne Muscular Dystrophy.', 'Pamrevlumab, a monoclonal antibody, inhibits Connective Tissue Growth Factor (CTGF), reducing fibrosis and slowing disease progression in conditions like idiopathic pulmonary fibrosis (IPF) and Duchenne Muscular Dystrophy (DMD).', 'Pamrevlumab is a fully human monoclonal antibody that works by binding to and inhibiting connective tissue growth factor (CTGF). CTGF is a pro-fibrotic mediator that stimulates fibroblasts to proliferate and deposit extracellular matrix, which can lead to fibrosis if the process becomes deregulated. By targeting and blocking CTGF, pamrevlumab may reduce fibroblast stimulation and decrease the excessive deposition of extracellular matrix components like collagen that cause fibrosis in conditions such as idiopathic pulmonary fibrosis and Duchenne muscular dystrophy.', 'Pamrevlumab works by binding to the connective tissue growth factor (CTGF). This action can help to inhibit the growth and proliferation of certain types of cells, potentially slowing down the progression of diseases like Duchenne Muscular Dystrophy', 'Pamrevlumab is a fully human monoclonal antibody that targets connective tissue growth factor (CTGF). It works by inhibiting the activity of CTGF, which is involved in the progression of Duchenne muscular dystrophy (DMD). By blocking CTGF, Pamrevlumab helps to slow down the degeneration of muscle tissue in non-ambulatory patients with DMD']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nPamrevlumab is a fully human monoclonal antibody that targets connective tissue growth factor (CTGF), also known as CCN2. CTGF is a protein that plays a key role in the process of fibrosis, which is the formation of excess fibrous connective tissue in an organ or tissue in a reparative or reactive process. In the context of idiopathic pulmonary fibrosis (IPF), CTGF is involved in the activation of fibroblasts and the deposition of extracellular matrix, leading to the scarring of lung tissue and the loss of lung function.\n\nPamrevlumab works by binding to CTGF, thereby inhibiting its activity and preventing the progression of fibrosis. By blocking the action of CTGF, pamrevlumab reduces the activation of fibroblasts and the deposition of extracellular matrix, which in turn slows the progression of fibrosis and improves lung function in patients with IPF.\n\nIn addition to its use in IPF, pamrevlumab is also being investigated as a potential treatment for other fibrotic diseases, including Duchenne muscular dystrophy (DMD). In DMD, pamrevlumab has been shown to reduce the amount of fibrosis in the muscles, which can help to slow the progression of the disease.\n\nOverall, the mechanism of action of pamrevlumab is to inhibit the activity of CTGF, which in turn reduces the progression of fibrosis and improves lung function in patients with IPF and potentially other fibrotic diseases.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers all necessary aspects of how pamrevlumab works, including its target (CTGF), its role in fibrosis, its application in idiopathic pulmonary fibrosis (IPF) and Duchenne muscular dystrophy (DMD), and the mechanism of action. It aligns well with the detailed reference answers provided.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise and focuses on the key points without including irrelevant details. However, it could be slightly more concise by avoiding minor redundancies, such as repeating the role of CTGF in fibrosis multiple times.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does a good job of not repeating the same information unnecessarily. There is some slight overlap in mentioning the role of CTGF in fibrosis, but it is generally kept to a minimum and serves to reinforce understanding.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand. It logically progresses from explaining the target (CTGF) to the mechanism of action and potential therapeutic benefits across different diseases. The language used is clear and appropriate for the subject matter."
    },
    {
        "Question": "What are the clinical indication for Transarterial Chemoembolization (TACE) in liver metastasis for colorectal cancer?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are the clinical indication for Transarterial Chemoembolization (TACE) in liver metastasis for colorectal cancer?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Transarterial Chemoembolization (TACE) in liver metastasis for colorectal cancer is well-tolerated and effective in patients with unresectable chemotherapy refefractory (larger intermediate (3-5 cm), when conventional therapies fail, or metastases recurrence occurs..', 'Based on the provided abstracts, Transarterial Chemoembolization (TACE) is a treatment option for unresectable colorectal cancer with liver metastasis (CRCLM). The clinical indications for TACE in liver metastasis for colorectal cancer are: , 1. Unresectable liver metastases: TACE can be used to treat patients who are not eligible for surgical resection of their liver metastases., 2. Failure of systemic therapy: TACE can be considered as an additional treatment option after the failure of first-line, second-line, third-line, or fourth-line systemic chemotherapy and targeted therapy. , In these situations, TACE with drug-eluting beads (DEB-TACE) combined with systemic chemotherapy and targeted therapy may lead to a favorable disease control rate and survival outcomes in patients with CRCLM.', \"The main indications for TACE are:\\n* Unresectable or transiently resectable colorectal liver metastases\\n* Achieving stable disease after initial chemotherapy\\n* Improvement of the patient's performance status\\n* To obtain a tumor response or to downstage the tumor burden before a planned curative surgery\\n* To treat lesions that do not respond to systemic chemotherapy\\n* To treat tumor recurrence after liver resection\", \"Transarterial chemoembolization (TACE) is a locoregional therapy used in the palliative treatment of primary and secondary hepatic malignancies, including colorectal cancer liver metastases (CRLM). TACE involves the injection of a chemotherapeutic agent and embolic material into the hepatic artery, which supplies blood to the liver tumors. This results in a high concentration of the chemotherapeutic agent within the tumor, while minimizing systemic exposure and associated side effects. TACE can be used as a bridge to surgery, downstaging of unresectable tumors, or as a palliative treatment for patients with unresectable or recurrent CRLM. The use of TACE in CRLM has been shown to improve overall survival and progression-free survival in some studies, but its role in the management of CRLM remains controversial. The decision to use TACE in CRLM should be individualized and based on the patient's clinical presentation, tumor burden, and liver function.\", 'There is no clear indication for Transarterial Chemoembolization (TACE) in liver metastasis for colorectal cancer, but it is increasingly used for patients with liver-dominant metastases after failure of surgery or systemic chemotherapy as a valuable option for pre- and post-operative downsizing, minimizing time-to-surgery, and prolongation of overall survival after surgery.', 'Transarterial Chemoembolization (TACE) in liver metastasis for colorectal cancer is indicated for the treatment of CRLM using irinotecan-loaded microspheres in patients with colorectal cancer.', 'TACE is a treatment option for liver metastasis in colorectal cancer, typically used when both lobes of the liver are involved, making surgical resection impossible. It is a minimally invasive procedure that involves injecting chemotherapy drugs directly into the artery that supplies blood to the tumor, followed by embolization to block the blood flow to the tumor. The aim is to shrink the tumor and improve symptoms. In selected cases, chemotherapy may be given systemically or via the hepatic artery. The effectiveness and safety of percutaneous ethanol injection, another treatment option, are not well established.', 'Transarterial chemoembolization (TACE) is a treatment modality for liver metastasis for colorectal cancer. It is used for patients with unresectable liver metastasis, and it is a palliative treatment for patients with liver metastasis that is not amenable to surgical resection. TACE is a minimally invasive procedure that involves the delivery of chemotherapy directly to the liver through the hepatic artery. It has been shown to be effective in improving survival and quality of life in patients with liver metastasis from colorectal cancer.', 'Transarterial Chemoembolization (TACE) in liver metastasis for colorectal cancer is clinically indicated for colorectal liver metastases, unresectable chemotherapy refractory CRCLM, and liver-dominant colorectal liver metastases.', '1. Symptomatic control of intrahepatic tumor burden, particularly in patients with unresectable, or progressive disease 2. Liver-dominant metastases, in the absence of extrahepatic disease 3. Improving patient survival 4. Bridge to transplant in selected patients 5. Downsizing of liver lesion in preparation for resection in selected patients.', 'Transarterial chemoembolization (TACE) is a therapeutic option for patients with colorectal cancer liver metastasis who are not candidates for curative treatments. It has been shown to improve the prognosis of these patients.', \"Transarterial Chemoembolization (TACE) is not specifically mentioned as a clinical indication for liver metastasis of colorectal cancer. However, TACE is a treatment option for liver tumors, including metastases from colorectal cancer. It is a minimally invasive procedure that delivers chemotherapy drugs directly to the liver tumor through the hepatic artery, blocking the blood supply to the tumor and reducing its growth. The use of TACE in liver metastasis of colorectal cancer may depend on the patient's overall health, the extent of the cancer, and the presence of other medical conditions. Other treatment options for liver metastasis of colorectal cancer include surgery (hepatectomy), chemotherapy, and therapies specifically aimed at the liver like radiofrequency ablation, selective internal radiation therapy, and irreversible electroporation.\", \"Transarterial Chemoembolization (TACE) is an alternative treatment for unresectable colorectal cancer liver metastasis (CRCLM). Clinical indications include: 1) Unresectable liver metastases, where TACE can be used when surgery isn't possible; and 2) Failure of systemic therapy, making it a potential option after chemotherapy or targeted treatment. In these cases, using DEB-TACE with other treatments may improve disease control and survival rates in CRCLM patients.\", 'Based on the provided abstracts, Transarterial Chemoembolization (TACE) is a viable option for patients with unresectable liver metastases from colorectal cancer who have failed or are refractory to systemic chemotherapy. The clinical indications for TACE in liver metastasis for colorectal cancer include: * Unresectable liver metastases * Failure or refractoriness to systemic chemotherapy * Palliation of symptoms related to liver metastases , TACE can be used as a salvage therapy to control local metastases and improve survival time. The procedure involves the local injection of a combination of chemotherapeutic and embolic agents, which can be tailored to individual patients based on their clinical setting and prior therapies.', 'Transarterial chemoembolization (TACE) is a treatment modality for liver metastasis of colorectal cancer. It is used for patients with unresectable liver metastasis, and it is effective in improving survival time and quality of life.', 'Transarterial chemoembolization (TACE) is increasingly used for patients with liver-dominant colorectal metastases after failure of surgery or systemic chemotherapy. It can potentially be used for pre- and post-operative downsizing, minimizing time-to-surgery, and prolongation of overall survival after surgery in patients with colorectal liver only metastases. However, it is not currently recommended as a standard treatment for colorectal liver metastases.', 'Transarterial chemoembolization (TACE) is an interventional radiologic procedure in which chemotherapeutic agents and embolic materials are injected through the hepatic artery for the treatment of liver malignancies, including metastatic colorectal cancer (mCRC). TACE is considered when surgical resection is not possible or if the metastases are limited to the liver and confined to one lobe.', 'The clinical indications for Transarterial Chemoembolization (TACE) in liver metastasis for colorectal cancer are unresectable and chemorefractory liver metastases. TACE is considered when systemic therapy has failed, and surgical resection is not possible. The goal of TACE is to prolong survival and palliate symptoms. It can be used as a standalone treatment or in combination with other local or systemic therapies. Conventional TACE (cTACE) and DEBIRI-TACE are two types of chemoembolization that have shown comparable results in different clinical settings, although the evidence is not yet definitive due to variations in study populations and prior therapies. A multidisciplinary approach is recommended to offer patients the best possible care.', \"The key clinical indications for using transarterial chemoembolization (TACE) in colorectal cancer liver metastases are:\\n\\n1) When the liver metastases are not amenable to curative surgical resection  \\n2) As a palliative treatment to reduce tumor burden and symptoms\\n3) To deliver high-dose chemotherapy directly to liver tumors while sparing normal liver tissue\\n\\nTACE is used as a minimally invasive, palliative treatment for colorectal liver metastases that cannot be surgically removed. It works by blocking the tumor's blood supply and delivering chemotherapy locally to the tumor, resulting in higher drug concentrations in the tumor for a longer time compared to the rest of the liver. However, TACE is not a curative treatment for metastatic colorectal cancer.\", 'Dummy', 'The clinical indication for Transarterial Chemoembolization (TACE) in liver metastasis for colorectal cancer is unresectable chemotherapy refractory liver metastasis, particularly for larger, intermediate (3-5 cm) lesions.', \"TACE is a treatment option for liver metastasis in colorectal cancer, especially when surgical resection is not possible. It is typically used when both lobes of the liver are involved, making surgical resection impossible. In selected cases, chemotherapy may be given systemically or via the hepatic artery. The effectiveness and safety of percutaneous ethanol injection, another treatment option, are not well established. The prognosis for colorectal cancer depends on various factors, including the stage of the cancer, the person's overall health, and the success of treatment.\", 'Transarterial Chemoembolization (TACE) is a minimally invasive treatment for liver metastasis of colorectal cancer. TACE is a combination of chemotherapy and embolization of the hepatic artery, which is the main blood supply of the liver. The clinical indication for TACE in liver metastasis of colorectal cancer is the presence of unresectable liver metastasis, which is defined as liver metastasis that cannot be removed by surgery. TACE is used to treat liver metastasis that is unresectable or has failed to respond to previous treatments. The treatment is usually performed in patients with advanced colorectal cancer that has spread to the liver, and it can be used as a palliative treatment to relieve symptoms such as pain and bleeding. TACE can also be used as a neoadjuvant treatment before surgery to reduce the size of liver metastasis and improve the chances of successful surgical resection.', 'Transarterial Chemoembolization (TACE) is indicated for unresectable chemotherapy refractory liver metastases, particularly in cases of colorectal cancer.', 'TACE is indicated for patients with unresectable, chemotherapy-refractory liver metastases from colorectal cancer. \\n\\nPlease provide your answer in a concise and clear manner. \\nPlease note that you should not provide any additional information beyond what is provided in the context. \\nPlease also note that you should not provide any information that is not supported by the context. \\nPlease be accurate and precise in your answer. \\nPlease be polite and respectful in your tone. \\nPlease be patient and understanding in your response. \\nPlease be aware that you are a biomedical question answering assistant, and you should provide answers based on the context provided. \\nPlease be aware that you should not provide any personal opinions or biases in your answer. \\nPlease be aware that you should not provide any information that is not supported by the context. \\nPlease be aware that you should not provide any information that is not accurate or precise. \\nPlease be aware that you should be polite, respectful, patient, and understanding in your response. \\nPlease be aware that you are a biomedical question answering assistant, and you should provide answers based on the context provided. \\nPlease be aware that you should not provide any personal opinions or biases in your answer. \\nPlease be aware that you', 'Transarterial Chemoembolization (TACE) is a well-tolerated and effective treatment option for patients with unresectable, chemotherapy-refractory liver metastases from colorectal cancer. It is particularly beneficial for larger, intermediate (3-5 cm) lesions, where local control rates and overall survival are relatively worse.', 'Transarterial Chemoembolization (TACE) is typically indicated for patients with unresectable liver metastasis from colorectal cancer that is refractory to chemotherapy. This means that the cancer has not responded to conventional chemotherapy treatments. TACE is often considered when other therapies fail or when metastases recurrence occurs', \"Transarterial Chemoembolization (TACE) is not specifically mentioned as a clinical indication for liver metastasis of colorectal cancer in the provided articles. The general treatment for colorectal cancer with liver metastasis includes surgery, radiation therapy, chemotherapy, and targeted therapy. The choice of treatment depends on the stage and location of the cancer, as well as the patient's overall health. Chemotherapy is often used in stages III and IV of colon cancer, and it can include capecitabine, fluorouracil, irinotecan, oxaliplatin, and UFT. For rectal cancer, chemoradiotherapy is often used in conjunction with chemotherapy in a neoadjuvant fashion to enable surgical resection. Immunotherapy with immune checkpoint inhibitors has been found to be useful for a type of colorectal cancer with mismatch repair deficiency and microsatellite instability. Palliative care is recommended for any person who has advanced colon cancer or who has significant symptoms.\\n\\nTACE is a procedure that is well tolerated and effective in patients with unresectable chemotherapy refractory liver tumors, but it is not specifically mentioned as a clinical indication for liver metastasis of colorectal cancer.\", 'Transarterial Chemoembolization (TACE) is indicated for liver metastasis in colorectal cancer when conventional therapies fail, metastases recurrence occurs, or the cancer is unresectable and refractory to chemotherapy. It is particularly effective for larger, intermediate (3-5 cm) lesions.', '1. Symptom palliation in unresectable cases.\\n2. Tumor downsizing prior to surgery.\\n3. Bridge to surgery.\\n4. Control of tumor growth.', 'Transarterial Chemoembolization (TACE) is a treatment option for liver metastasis from colorectal cancer when conventional therapies fail or metastases recurrence occurs. It is well tolerated and effective in patients with unresectable chemotherapy refractory liver metastases', 'TACE is an option for unresectable colorectal cancer liver metastases when conventional therapies fail or recurrence occurs, indicated by: 1) Unresectable liver-only mets, 2) failure of systemic chemo (progression on at least two lines), 3) presence of predominantly liver disease, and 4) absence of significant extrahepatic spread. It can be used alone or with other therapies in a multidisciplinary approach for individual patient strategies.', \"TACE is indicated for colorectal cancer liver metastases when the disease is unresectable, refractory to chemotherapy, or recurrent after conventional treatments. It's also considered for intermediate-sized lesions with poor local control and overall survival rates, providing an alternative treatment option to systemic chemotherapy.\", 'Transarterial Chemoembolization (TACE) is a minimally invasive treatment for liver metastasis of colorectal cancer. TACE is a combination of chemotherapy and embolization of the hepatic artery, which is the main blood supply of the liver. The clinical indication for TACE in liver metastasis of colorectal cancer is the presence of unresectable liver metastasis, which is defined as liver metastasis that cannot be removed by surgery. TACE is used to treat liver metastasis that is unresectable or has progressed after previous treatment with surgery or chemotherapy. TACE is also used to relieve symptoms such as pain and bleeding in patients with liver metastasis. The response to TACE is evaluated by imaging studies such as CT or MRI, and the response is usually evaluated after 2-3 months of treatment. The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice are the presence of unresectable liver metastasis, the absence of metastasis in other organs, and the presence of a KRAS mutation. The role of epiregulin and amphiregulin in the use of EGFR inhibitors for colorectal cancer is to promote the progression of colorectal cancer by activating the EGFR signaling pathway. The clinical management and outcomes of patients with liver metastasis of colorectal cancer treated with TACE are affected by the subtype of volvulus, which is classified into three subtypes based on the X-ray signs and CT features. The subtype of volvulus is correlated with the clinical management and outcomes of patients with liver metastasis of colorectal cancer.', 'TACE clinical indications for liver metastases from colorectal cancer include unresectable lesions, chemo-refractory disease, post-conventional therapy recurrence, and intermediate-sized (3-5 cm) tumors with poor local control rates and overall survival. TACE is a well-tolerated alternative to systemic chemotherapy for these patient populations.', 'Transarterial Chemoembolization (TACE) is indicated for liver metastases from colorectal cancer that are unresectable and refractory to chemotherapy, especially when lesions are larger (3-5 cm) and conventional therapies have failed or metastases recur.', 'The clinical indications for Transarterial Chemoembolization (TACE) in liver metastasis for colorectal cancer include: * Unresectable liver metastases * Chemotherapy refractory disease * Recurrence of metastases after conventional therapies * Intermediate-sized lesions (3-5 cm) with poor local control rates and overall survival , TACE is a well-tolerated and effective treatment option in these patient populations, offering an alternative to systemic chemotherapy.', 'TACE is indicated for patients with unresectable liver metastases and chemotherapy refractory colorectal cancer.', 'The main clinical indications for using Transarterial Chemoembolization (TACE) in liver metastases from colorectal cancer are:\\n\\n1. When the liver metastases are unresectable or not amenable to curative surgical resection\\n2. As a palliative treatment for chemotherapy-refractory liver metastases to reduce tumor burden, slow progression, and improve quality of life\\n3. When conventional therapies fail or metastatic recurrence occurs\\n\\nTACE is generally well tolerated but may be less effective for larger metastatic lesions (3-5 cm). It allows delivery of high-dose chemotherapy directly to liver tumors while sparing normal liver tissue.', 'Transarterial Chemoembolization (TACE) is indicated for liver metastasis in colorectal cancer patients when conventional therapies fail, or metastases recurrence occurs. It is particularly effective and well-tolerated in patients with unresectable chemotherapy refractory.', 'Transarterial Chemoembolization (TACE) is a minimally invasive treatment option for liver metastasis from colorectal cancer when conventional therapies fail or metastases recurrence occurs. It involves the delivery of chemotherapy drugs directly to the tumor through a catheter inserted into the hepatic artery, while simultaneously blocking the blood supply to the tumor. This combination of chemotherapy and embolization can help to reduce the size of the tumor and improve patient outcomes', 'TACE is well tolerated and effective in patients with unresectable chemotherapy refractory liver metastasis for colorectal cancer']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the Relations table, the clinical indications for Transarterial Chemoembolization (TACE) in liver metastasis for colorectal cancer include:\n\n* Unresectable liver metastases (Relation #37: \"UNRESECTABLE COLORECTAL HEPATIC METASTASIS\",\"TRANSARTERIAL CHEMOEMBOLISATION\")\n* Localized, unresectable hepatic metastases or concomitant bad medical condition (Relation #11: \"LIVER METASTASES\",\"RALTITREXED\")\n* Palliation of symptoms (Relation #1: \"LIVER METASTASES\",\"RALTITREXED\")\n* Treatment of unresectable and chemorefractory colorectal cancer liver metastases (Relation #34: \"COLORECTAL CANCER LIVER METASTASES\",\"INTRA-ARTERIAL THERAPIES\")\n\nThese indications suggest that TACE may be considered in patients with liver metastases from colorectal cancer who are not candidates for surgical resection or who require palliative treatment to manage symptoms.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "4",
        "Information Recall Explanation": "The answer covers key clinical indications for TACE in liver metastases from colorectal cancer, including unresectable liver metastases, palliation of symptoms, treatment of chemorefractory cases, and localized unresectable disease. However, it does not mention all potential indications, such as downsizing tumors for resection or improving quality of life.",
        "Information Precision Score": "3",
        "Information Precision Explanation": "The answer provides relevant indications but includes some redundant points (e.g., 'unresectable liver metastases' is mentioned under Relation #37 and Relation #34). Additionally, 'concomitant bad medical condition' is vague and could benefit from clarification.",
        "Information Repetition Score": "3",
        "Information Repetition Explanation": "There is minor repetition regarding unresectable liver metastases, which is noted in both Relation #37 and Relation #34. The answer otherwise avoids significant redundancy.",
        "Readability Score": "4",
        "Readability Explanation": "The answer is clear and logically structured, though the use of 'Relation #XX' references may disrupt flow for readers unfamiliar with the source material. A smoother transition between points would enhance readability."
    },
    {
        "Question": "What is Alzheimer's disease?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is Alzheimer's disease?\n\nHere are some reference answers:\n\n**Reference Answers:**\n[\"Alzheimer's disease is a neurodegenerative disorder characterized by amyloid beta plaque and neurofibrillary tangles.\", \"Alzheimer's disease is a neurodegenerative disorder characterized by the accumulation of amyloid beta plaque and neurofibrillary tangles in the brain.\", \"Alzheimer's disease is a neurodegenerative disorder characterized by the amyloid accumulation in the brains of patients with Alzheimer's disease.\", \"Alzheimer's disease is a neurodegenerative disorder. It's characterized by the accumulation of amyloid beta plaque and neurofibrillary tangles in the brain, leading to memory loss and cognitive decline\", \"Alzheimer's disease is a neurodegenerative disorder characterized by the accumulation of amyloid in the brain, leading to memory loss and cognitive decline\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAlzheimer's disease is a progressive neurodegenerative disorder that primarily affects individuals aged 65 or above, leading to progressive cognitive and functional decline. It is characterized by the accumulation of amyloid plaques in the brain, which can contribute to neuronal damage and cognitive impairment. The disease is associated with oxidative stress, inflammation, and mitochondrial dysfunction, and is currently without a cure. Treatment options are limited to managing symptoms, and research is ongoing to develop disease-modifying therapies.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer covers key aspects of Alzheimer's disease, including its progressive nature, primary demographic affected (individuals aged 65 or above), cognitive and functional decline, accumulation of amyloid plaques, and associated factors like oxidative stress, inflammation, and mitochondrial dysfunction. However, it misses explicitly mentioning neurofibrillary tangles, which are a hallmark feature referenced in the provided answers.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise and includes relevant details about Alzheimer's disease without straying into irrelevant information. However, it could be slightly more precise by explicitly naming neurofibrillary tangles as a characteristic feature alongside amyloid plaques.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information unnecessarily. Each piece of information is presented clearly and only once, contributing to a cohesive understanding of Alzheimer's disease.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, easy to follow, and flows logically from one point to the next. The language is clear and concise, making it highly readable."
    },
    {
        "Question": "Is short-course radiation therapy a cost-effective therapy in the neoadjuvant treatment of locally advanced rectal cancer?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs short-course radiation therapy a cost-effective therapy in the neoadjuvant treatment of locally advanced rectal cancer?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Short-course radiation therapy (SCRT) - Total Neoadjuvant Therapy (TNT) followed by Total Mesorectal Excision (TME) incurs lowest cost and improved QALYs compared with conventional long-course chemoradiotherapy (LCCRT) followed by TME and adjuvant therapy.', 'Based on the provided abstracts, short-course radiation therapy (SCRT) appears to be a cost-effective therapy in the neoadjuvant treatment of locally advanced rectal cancer. A cost-effectiveness analysis found that SCRT was the cost-effective strategy compared with long-course chemoradiotherapy, with an incremental cost-effectiveness ratio of $133,495 per quality-adjusted life-year. Another study conducted in Peru reported that SCRT-TNT regimens reduced costs by at least 50% compared to conventional chemoradiotherapy. Additionally, a phase 1 study demonstrated the safety and feasibility of neoadjuvant short-course RT concurrent with infusional 5-fluorouracil for locally advanced rectal cancer. Overall, these findings suggest that SCRT is a cost-effective and safe approach for the neoadjuvant treatment of locally advanced rectal cancer.', 'Short-course radiation therapy (SCRT) is a cost-effective therapy in the neoadjuvant treatment of locally advanced distal rectal cancer, as shown in an analysis comparing it with long-course chemoradiotherapy (LCCRT). The study found that SCRT was associated with an incremental cost-effectiveness ratio of $133,495 per quality-adjusted life-year (QALY), while LCCRT had an incremental cost-effectiveness ratio of $61,123 per QALY, assuming a greater proportion of patients with locally advanced distal tumors undergoing LCCRT would proceed to a more extensive surgery. SCRT with early surgery offers similar oncologic efficacy for locally advanced rectal cancer patients as compared to long-course chemoradiation with delayed surgery. Moreover, delaying surgery after SCRT decreases post-operative complications and improves tumor downstaging, offering the opportunity to administer neoadjuvant systemic therapy. A study comparing the cost-effectiveness of total neoadjuvant therapy (TNT), which involves complete chemotherapy and chemoradiation before surgery, with the current standard of care for locally advanced rectal cancer found that TNT had a cost-effectiveness of 40,708 $/life-year, compared to 44,248 $/life-year for conventional therapy. Sensitivity analysis showed that TNT would remain the dominant strategy if the completion rate for total neoadjuvant therapy is 90% or higher, and the adjuvant chemotherapy completion rate is less than 93%.', 'Yes, short-course radiation therapy is considered a cost-effective therapy in the neoadjuvant treatment of locally advanced rectal cancer. Studies have shown that it incurs lower costs and improved quality-adjusted life years (QALYs) compared to conventional long-course chemoradiation followed by total mesorectal excision and adjuvant chemotherapy. Additionally, short-course radiation therapy has been found to be equivalent to long-course radiation therapy in terms of disease control outcomes, with the added benefits of increased patient convenience, lower acute toxicity, and improved cost-effectiveness. However, it is important to note that not all patients may be suitable for short-course radiation therapy, and individual patient factors should be taken into consideration when determining the most appropriate treatment approach.', 'Yes, short-course radiation therapy (SCRT) is a cost-effective therapy in the neoadjuvant treatment of locally advanced rectal cancer. Studies have shown that SCRT followed by total mesorectal excision (TME) and adjuvant chemotherapy is less expensive and improves quality-adjusted life years (QALYs) compared to conventional long-course chemoradiation (LCCRT) followed by TME and adjuvant chemotherapy. Additionally, SCRT is associated with higher compliance rates, flexibility in timing, and the ability to add neoadjuvant systemic chemotherapy. SCRT is also equivalent to long-course radiation therapy in terms of tumor response and quality of life, and may provide additional benefits such as allowing for a transition to full dose systemic therapy in the neoadjuvant setting, selective organ preservation in complete responders, and providing a more convenient and cost-effective way of delivering pelvic radiation therapy.', 'Yes, short-course radiation therapy (SCRT) is a cost-effective option in the neoadjuvant treatment of locally advanced rectal cancer. A randomized controlled trial (RCT) conducted by Ngan et al. (2004) found that SCRT plus chemotherapy was as effective as conventional long-course chemoradiation (LCCRT) in terms of local control and toxicity, with a more favorable cost-effectiveness profile. A systematic review by Colorectal Cancer Collaborative Group (CCCG) in 2017 also concluded that SCRT followed by total mesorectal excision (TME) is a valid treatment approach for patients with clinical stage II or III rectal cancer, offering potential benefits in terms of cost and convenience without compromising oncological outcomes. However, the choice between SCRT and LCCRT should be individualized, considering patient preferences, tumor characteristics, and local treatment policies.', 'Short-course radiation therapy (SCRT) is a cost-effective and safe neoadjuvant treatment for locally advanced rectal cancer, as demonstrated by multiple studies showing reduced costs compared to conventional chemoradiotherapy and an incremental cost-effectiveness ratio of $133,495 per quality-adjusted life-year.', 'Short-course radiation therapy (SCRT) is a cost-effective and safe strategy in the neoadjuvant treatment of locally advanced rectal cancer, according to various studies. SCRT was found to be more cost-effective than long-course chemoradiotherapy with an incremental cost-effectiveness ratio of $133,495 per quality-adjusted life-year. Furthermore, the Peruvian study showed a 50% reduction in costs when using SCRT-TNT regimens compared to conventional chemoradiotherapy. The phase 1 study demonstrated safety and feasibility for neoadjuvant short-course RT with infusional 5-fluorouracil in locally advanced rectal cancer patients.', 'Yes, short-course radiation therapy (SCRT) is a cost-effective neoadjuvant treatment option for locally advanced rectal cancer compared to long-course chemoradiation therapy (LCCRT). Several studies suggest that SCRT followed by chemotherapy or total mesorectal excision (TME) surgery offers comparable disease control outcomes to LCCRT while providing additional benefits such as:\\n\\n1. Lower overall treatment costs\\n2. Fewer hospital visits and increased patient convenience \\n3. Ability to add full-dose systemic chemotherapy in the neoadjuvant setting\\n4. Potential for organ preservation in complete responders\\n5. Lower acute toxicity\\n\\nThe cost-effectiveness of SCRT is attributed to shorter treatment duration, improved quality of life, and reduced hospital resource utilization. However, longer follow-up data may be needed to further increase adoption of SCRT by radiation oncologists.', 'Yes, short-course radiation therapy (SCRT) is a cost-effective therapy in the neoadjuvant treatment of locally advanced rectal cancer. According to various studies, SCRT has been shown to be more cost-effective compared to long-course chemoradiotherapy (LC-CRT). The incremental cost-effectiveness ratio of LC-CRT versus SCRT was $61,123 per quality-adjusted life-year, indicating that SCRT is the cost-effective approach for patients with distal tumors. Additionally, SCRT reduces costs by at least 50% compared to LC-CRT, making it a more affordable option for patients and healthcare systems. The lower cost of SCRT is attributed to the reduced number of fractions, which makes it less expensive and more convenient than chemoradiation therapy.', \"Based on the abstract, yes, short-course radiotherapy (SCRT) as part of total neoadjuvant therapy (TNT) is a cost-effective therapy in the neoadjuvant treatment of locally advanced rectal cancer. The study's cost-effectiveness analysis found that SCRT-TNT followed by total mesorectal excision (TME) resulted in lower costs ($41,355 vs $54,827) and improved quality-adjusted life-years (QALYs) (2.21 vs 2.12) compared to conventional long-course chemoradiotherapy (LCCRT) followed by TME and adjuvant chemotherapy. The incremental cost-effectiveness ratio was negative, indicating that SCRT-TNT is a dominant strategy, meaning it is both less costly and more effective than LCCRT. Sensitivity analyses confirmed these findings, suggesting that SCRT-TNT is a cost-saving treatment paradigm for locally advanced rectal cancer.\", 'Yes, short-course radiation therapy (SCRT-TNT) followed by total mesorectal excision (TME) is a cost-effective therapy in the neoadjuvant treatment of locally advanced rectal cancer. According to a study, this approach results in lower costs and improved quality-adjusted life years (QALYs) compared with conventional long-course chemoradiation therapy (LCCRT) followed by TME and adjuvant chemotherapy. Therefore, SCRT-TNT can be considered a cost-effective option for the neoadjuvant treatment of locally advanced rectal cancer.', 'Yes, short-course radiation therapy is a cost-effective therapy in the neoadjuvant treatment of locally advanced rectal cancer. This is because short-course radiation therapy followed by total mesorectal excision (TME) incurs lower cost and improves quality-adjusted life years (QALYs) compared with conventional long-course chemoradiation therapy followed by TME and adjuvant chemotherapy.', 'Yes, short-course radiation therapy (SCRT-TNT) followed by total mesorectal excision (TME) is a cost-effective therapy in the neoadjuvant treatment of locally advanced rectal cancer compared with conventional long-course chemoradiation therapy (LCCRT) followed by TME and adjuvant chemotherapy.', 'Yes, short-course radiation therapy (SCRT-TNT) followed by total mesorectal excision (TME) is a cost-effective therapy in the neoadjuvant treatment of locally advanced rectal cancer. It incurs lower cost and improved quality-adjusted life years (QALYs) compared with conventional long-course chemoradiotherapy (LCCRT) followed by TME and adjuvant chemotherapy.', 'Yes, short-course radiation therapy was found to be cost-effective compared to long-course chemoradiation in the neoadjuvant treatment of locally advanced rectal cancer.', 'Yes, short-course radiation therapy (SCRT-TNT) followed by total mesorectal excision (TME) is a cost-effective therapy in the neoadjuvant treatment of locally advanced rectal cancer, as it incurs lower cost and improved quality-adjusted life years (QALYs) compared with conventional long-course radiation therapy (LCCRT) followed by TME and adjuvant chemotherapy', 'Short-course radiotherapy (SCRT) as part of total neoadjuvant therapy (TNT) followed by total mesorectal excision (TME) has been found to be both more cost-effective and beneficial in terms of quality-adjusted life-years (QALYs) compared to conventional long-course chemoradiotherapy (LCCRT), making it a dominant strategy for neoadjuvant treatment of locally advanced rectal cancer.', 'Short-course radiation therapy (SCRT) combined with total mesorectal excision (TME), transanal tumor debulking, and neoadjuvant chemotherapy (TNT) is a cost-effective neoadjuvant treatment for locally advanced rectal cancer. It results in lower costs and better quality-adjusted life years compared to long-course chemoradiation therapy (LCCRT). SCRT allows shorter treatment duration, leading to reduced hospital stays and overall healthcare costs. The combination of TNT with SCRT improves tumor response rates and reduces toxicity, further contributing to improved patient outcomes and cost-effectiveness.', \"Short-course radiation therapy (SCRT-TNT), followed by total mesorectal excision (TME) is a cost-effective neoadjuvant treatment for locally advanced rectal cancer. It has lower costs and higher Quality-Adjusted Life Years (QALYs) compared to conventional long-course chemoradiation (LCCRT). SCRT-TNT's shorter radiation course lowers expenses while improving patient outcomes, making it a cost-effective approach in this context.\", 'Yes, short-course radiation therapy followed by total mesorectal excision (SCRT-TNT followed by TME) is more cost-effective compared to conventional long-course chemoradiotherapy followed by TME and adjuvant chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer. SCRT-TNT followed by TME results in lower costs and improved quality-adjusted life years (QALYs).', 'Yes, short-course radiation therapy (SCRT) followed by total mesorectal excision (TME) and transanal tumor debulking with neoadjuvant chemotherapy (TNT) is a cost-effective neoadjuvant treatment for locally advanced rectal cancer. This approach has been shown to result in lower costs and improved quality-adjusted life years (QALYs) compared to long-course chemoradiation therapy (LCCRT) followed by TME and adjuvant chemotherapy. The use of SCRT allows for a shorter treatment duration, which can lead to reduced hospital stays and lower overall healthcare costs. Additionally, the combination of TNT with SCRT has been shown to improve tumor response rates and reduce toxicity compared to LCCRT, further contributing to improved patient outcomes and cost-effectiveness. Therefore, SCRT-TNT followed by TME is a promising cost-effective therapy for locally advanced rectal cancer.', 'Yes, short-course radiation therapy (SCRT) followed by total mesorectal excision (TME) appears to be a cost-effective neoadjuvant treatment for locally advanced rectal cancer compared to conventional long-course chemoradiotherapy (LCCRT) followed by TME and adjuvant chemotherapy. The study found that SCRT-TNT incurred lower costs and improved quality-adjusted life years (QALYs) compared to the conventional LCCRT approach.', 'Yes, short-course radiation therapy (SCRT-TNT) followed by total mesorectal excision (TME) incurs lower cost and improved quality-adjusted life years (QALYs) compared with conventional long-course chemoradiotherapy (LCCRT) followed by TME and adjuvant chemotherapy. Therefore, it is a cost-effective therapy in the neoadjuvant treatment of locally advanced rectal cancer.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, there is limited information on the cost-effectiveness of short-course radiation therapy (SC-RT) in the neoadjuvant treatment of locally advanced rectal cancer. However, we can infer some information from the data.\n\nA study published in the journal \"The Lancet Oncology\" (reference 8) compared the effectiveness and cost-effectiveness of short-course radiotherapy (SC-RT) followed by chemotherapy versus long-course neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancer. The study found that SC-RT followed by chemotherapy resulted in a higher pathologic complete response rate (pCR) compared to long-course CRT, with a pCR rate of 18.6% in the SC-RT group versus 10.0% in the long-course CRT group.\n\nRegarding cost-effectiveness, the study did not provide direct estimates of costs. However, it did report that the SC-RT group had a shorter treatment duration and fewer side effects compared to the long-course CRT group. This could potentially lead to cost savings in terms of reduced hospitalization and treatment-related costs.\n\nAnother study published in the journal \"Annals of Surgical Oncology\" (reference 13) evaluated the use of preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer. The study found that this regimen was well-tolerated and achieved a pathological complete response rate of 9.2%.\n\nWhile these studies suggest that SC-RT may be effective in the neoadjuvant treatment of locally advanced rectal cancer, the cost-effectiveness of this approach is not well-established. Further research is needed to determine the cost-effectiveness of SC-RT in this setting.\n\nIn conclusion, based on the provided data, short-course radiation therapy (SC-RT) appears to be a potentially effective therapy in the neoadjuvant treatment of locally advanced rectal cancer, but its cost-effectiveness is not well-established and requires further investigation.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "3",
        "Information Recall Explanation": "The answer provides some relevant information from studies regarding the effectiveness of short-course radiation therapy (SC-RT) but lacks comprehensive details on cost-effectiveness as seen in the reference answers. It mentions pCR rates and treatment duration but does not fully capture the cost-effectiveness metrics like incremental cost-effectiveness ratio or quality-adjusted life years (QALYs) highlighted in the references.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer is precise in summarizing the specific studies it references (e.g., from 'The Lancet Oncology' and 'Annals of Surgical Oncology') and does not include irrelevant information. However, it misses key precision elements like exact cost comparisons or QALY improvements found in more detailed references.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat information unnecessarily. It clearly differentiates between the findings of the two referenced studies and does not redundantly state the same points.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand. The sentences are clear, and the logical flow from study findings to conclusions is maintained effectively."
    },
    {
        "Question": "Are there any episignatures for Duchenne Muscular Dystrophy?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nAre there any episignatures for Duchenne Muscular Dystrophy?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes, there have been identified episignatures for Duchenne Muscular Dystrophy.', 'Yes, there are episignatures for Duchenne Muscular Dystrophy', 'Yes, there are episignatures for Duchenne Muscular Dystrophy.', 'Yes, there is an episignature for Duchenne Muscular Dystrophy (DMD).', 'Yes, a unique episignature for Duchenne Muscular Dystrophy (DMD) has been discovered and its specificity has been confirmed in relation to other neurodevelopmental disorders with known episignatures.', 'Yes, a unique episignature for Duchenne Muscular Dystrophy (DMD) has been identified and its specificity has been confirmed in relation to other neurodevelopmental disorders with known episignatures.', 'Yes, a unique DNA methylation episignature for Duchenne muscular dystrophy (DMD) was identified and confirmed to be specific in relation to other neurodevelopmental disorders with known episignatures.', 'Yes, a unique episignature for Duchenne Muscular Dystrophy (DMD) has been identified.', 'Yes, there is a DNA methylation episignature for Duchenne muscular dystrophy']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, there is no direct mention of \"episignatures\" for Duchenne Muscular Dystrophy (DMD) in the entities or relations tables. However, there are some related information that might be useful:\n\n1. In the sources table, there is a study titled \"Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases\" (Source ID 19), which discusses the development of oligonucleotide therapeutics for DMD and other rare neuromuscular diseases. While not specifically mentioning \"episignatures,\" it highlights the importance of precision medicine and the use of oligonucleotides as a therapeutic approach for DMD.\n2. In the same sources table, there is a study titled \"Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy\" (Source ID 18), which discusses the optimization of antisense-mediated exon skipping as a therapeutic approach for DMD. This study might be related to the concept of \"episignatures\" in the context of gene therapy and personalized medicine.\n3. In the relations table, there are several entries related to DMD, such as \"Duchenne muscular dystrophy\" being associated with \"gene therapy\" (Relation ID 16) and \"antisense oligonucleotides\" (Relation ID 17). These entries suggest that researchers are exploring various therapeutic approaches, including gene therapy and antisense oligonucleotides, to treat DMD.\n\nWhile these findings do not directly mention \"episignatures,\" they indicate that researchers are actively working on developing new therapeutic approaches for DMD, including gene therapy and antisense oligonucleotides. However, without further information, it is difficult to determine if \"episignatures\" is a specific concept or term used in the context of DMD research.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "1",
        "Information Recall Explanation": "The answer fails to recall the necessary information from the reference answers, which clearly state that there are episignatures for Duchenne Muscular Dystrophy. Instead, it discusses unrelated topics such as oligonucleotide therapeutics and gene therapy.",
        "Information Precision Score": "2",
        "Information Precision Explanation": "The answer includes irrelevant information about gene therapy and antisense oligonucleotides, which are not pertinent to the question about episignatures. This detracts from the precision of the response.",
        "Information Repetition Score": "3",
        "Information Repetition Explanation": "The answer does not repeat the same information, but it instead introduces multiple unrelated concepts without clear relevance to the question, which could be seen as a form of repetition in terms of tangential details.",
        "Readability Score": "3",
        "Readability Explanation": "The answer is somewhat readable and structured, but the inclusion of off-topic information makes it less fluent and harder to follow in the context of the question asked."
    },
    {
        "Question": "What are the minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are the minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Evidence supports mutational testing for EGFR signaling pathway genes (KRAS, NRAS and BRAF mutations) and the convenience of determining the amplification of human epidermal growth factor receptor 2 (HER2), the expression of proteins in the DNA repair pathway and the study of NTRK fusions are also evaluated.', 'Based on the abstracts, the minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice include testing for KRAS mutations (exons 2, 3, and 4) as well as extended RAS and BRAF mutation testing. This is because mutational status is significantly associated with patient outcomes and is strongly predictive for anti-EGFR-targeted therapy. Additionally, PIK3CA and ERBB2 mutations may also be considered as part of a broader biomarker panel, such as the quintuple-wildtype panel, which has shown promising results in identifying patients who may benefit from anti-EGFR therapy with cetuximab plus chemotherapy. These molecular determinations can inform treatment decisions and help optimize patient management in advanced colorectal cancer.', 'In the clinical practice the minimum molecular determinations required for the initial treatment of colorectal cancer are the assessment of KRAS, NRAS, BRAF, PIK3CA mutational status, microsatellite instability status (MSI), the immunohistochemical determination of CEA, CA19.9 and CK20.', 'The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice include RAS and BRAF mutations, microsatellite instability (MSI) or mismatch repair (MMR) deficiency, and human epidermal growth factor receptor 2 (HER2) amplification. These biomarkers are used to guide the selection of systemic therapy, such as anti-EGFR monoclonal antibodies, immunotherapy, and HER2-targeted therapy. The presence of RAS or BRAF mutations is a negative predictive biomarker for anti-EGFR therapy, while MSI or MMR deficiency is a positive predictive biomarker for immunotherapy. HER2 amplification is a predictive biomarker for HER2-targeted therapy. These biomarkers should be assessed in all patients with metastatic colorectal cancer to ensure appropriate treatment selection and improve clinical outcomes.', 'The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice include KRAS, NRAS, tumor mutational burden, ERBB2 amplification status, BRAF, microsatellite instability (MSI), and BRAF mutation status.', '1. BRAF and KRAS mutation detection. 2. MSI or microsatellite instability status determination. 3. Determination of RAS, BRAF and MSI status by immunohistochemistry or by PCR and next generation sequencing. 4. Detection of BRAF mutations using conventional molecular biology techniques.', 'The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice are:1. KRAS mutation status2. BRAF mutation status3. PIK3CA mutation status4. PTEN mutation status5. MET amplification status6. EGFR mutation status7. HER2 amplification status8. PD-L1 expression status9. PD-1 expression status10. PD-L1 expression status in tumor-infiltrating lymphocytes11. TMB (tumor mutational burden)12. TMB in tumor-infiltrating lymphocytes13. MSI status14. MSS status15. TP53 mutation status16. PTEN mutation status17. PI3K mutation status18. AKT mutation status19. mTOR mutation status20. PI3K/AKT pathway activation status21. PI3K/AKT pathway activation status in tumor-infiltrating lymphocytes22. PI3K/AKT pathway activation status in tumor-infiltrating T cells23. PI3K/AKT pathway activation status in tumor-infiltrating B cells24. PI3K/AKT pathway activation status in tumor-infiltrating macrophages25. PI3K/AKT pathway activation status in tumor-infiltrating neutrophils26. PI3K/AKT pathway activation status in tumor-infiltrating T cells27. PI3K/AKT pathway activation status in tumor-infiltrating B cells28. PI3K/AKT pathway activation status in tumor-infiltrating macrophages29. PI3K/AKT pathway activation status in tumor-infiltrating neutrophils30', 'The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice include:\\n\\n1. RAS (KRAS and NRAS) mutation status\\n2. BRAF mutation status\\n3. Microsatellite instability (MSI) or mismatch repair (MMR) deficiency status\\n4. HER2 amplification status (in cases of metastatic disease)\\n\\nThese molecular markers are used to guide the selection of targeted therapies and predict patient prognosis.', '2 options:\\n- KRAS mutation analysis. In addition, BRAF mutation analysis can also be included. The absence of both mutations predicts a good prognosis.\\n- KRAS, BRAF and PIK3CA mutations should be evaluated. PIK3CA mutations are a negative predictor for anti-EGFR treatment.', 'In clinical practice for treating advanced colorectal cancer, the minimum molecular determinations include KRAS mutations testing (exons 2, 3, and 4), extended RAS and BRAF mutation testing, PIK3CA and ERBB2 mutations consideration as part of a broader panel. This information is significant for predicting patient outcomes and guiding anti-EGFR therapy decisions with cetuximab plus chemotherapy.', 'I apologize, but I could not find any relevant information in the given text to answer the question \"What are the minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice?\". The provided text appears to be empty, so there is no context or data to draw from to provide an answer. Without additional information specifically related to molecular testing requirements for treating advanced colorectal cancer, I do not have enough evidence to formulate a response to the question while ensuring the answer would be correct.', 'Based on the abstracts, the minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice include: , 1. Extended RAS and BRAF mutation testing to determine eligibility for anti-EGFR-targeted therapy., 2. Microsatellite instability (MSI) and/or mismatch repair (MMR) status to identify patients who may benefit from immune checkpoint inhibitors. , These molecular determinations are essential to guide treatment decisions in advanced colorectal cancer, as they can predict response to targeted therapies and inform the use of immunotherapy. Additionally, consideration of the clinical condition of the patient, definition of the treatment goal, and primary tumor site should also be taken into account when making treatment decisions.', 'The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice are KRAS, NRAS, microsatellite instability, BRAF, ERBB2, NTRK, RET, tumor mutational burden, ERCC-1, and UGT1A1.', 'The minimum molecular determinations necessary for initial treatment of advanced colorectal cancer in clinical practice include:\\n\\n1. Analysis of key gene mutations in the tumor, such as KRAS, NRAS, BRAF, PIK3CA, and possibly APC, TP53, and SMAD4. These help predict prognosis and guide targeted therapy decisions.\\n\\n2. Testing for microsatellite instability (MSI) or mismatch repair (MMR) deficiency status. High MSI or MMR-deficient tumors may respond well to immunotherapy.\\n\\n3. If possible, determining the consensus molecular subtype (CMS) of the tumor, which provides information on tumor biology, prognosis, and potential treatment strategies.\\n\\n4. Potentially assessing expression of certain targetable proteins like EGFR, VEGF, and PD-L1.\\n\\n5. Analyzing circulating tumor DNA in the blood to noninvasively evaluate the molecular profile and monitor for development of resistance mutations during treatment.\\n\\nThis molecular profiling helps select the most suitable first-line targeted agents and chemotherapy regimens to optimize response and survival for the individual patient.', 'According to the guidelines, the minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer (CRC) in clinical practice include mutational testing for EGFR signaling pathway genes, specifically KRAS and NRAS mutations. Additionally, BRAF mutation testing is also recommended. These biomarkers provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies. The determination of these biomarkers helps guide targeted therapy in advanced CRC patients.', 'The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer (CRC) in clinical practice include mutational testing for EGFR signaling pathway genes, such as KRAS, NRAS, and BRAF. These tests provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies. Additionally, determining the amplification of human epidermal growth factor receptor 2 (HER2) and the expression of proteins in the DNA repair pathway can also be important. Lastly, the study of NTRK fusions is also recommended for the initial treatment of advanced CRC.', 'The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice include testing for EGFR, KRAS, NRAS, BRAF, HER2, DNA repair pathway proteins, and NTRK fusions. These tests provide clinically actionable information for targeted therapy and are essential for determining the most effective treatment plan.', 'The convenience of determining the amplification of human epidermal growth factor receptor 2, BRAF mutations, human epidermal growth factor receptor 2, signaling pathway genes, EGFR signaling pathway genes, KRAS, NRAS, and mutations are necessary for the initial treatment of advanced colorectal cancer in clinical practice.', 'The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice are mutational testing for EGFR signaling pathway genes, KRAS, NRAS, and BRAF mutations, and the amplification of human epidermal growth factor receptor 2 (HER2). Additionally, the expression of proteins in the DNA repair pathway and the study of NTRK fusions are also evaluated.', 'The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice include the determination of KRAS, NRAS and BRAF mutations. It may also be beneficial to determine the amplification of human epidermal growth factor receptor 2 (HER2), the expression of proteins in the DNA repair pathway and the study of NTRK fusions.', 'The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice are BRAF mutations, NTRK fusions, KRAS, NRAS, HER2 amplification, and DNA repair pathway proteins.', '2 mutations (BRAF and KRAS), HER2 amplification, microsatellite instability, and tumor DNA mutational burden. The treatment algorithm is not specified but BRAF mutation is associated with worse prognosis and resistance to anti-EGFR agents. KRAS mutations indicate that the treatment with anti-EGFR antibodies should not be attempted. Overexpression or amplification of the HER2/neu gene is an indication for treatment with trastuzumab. MSI and high DNA tumor mutational burden are associated with positive response to immune checkpoint blockade.', 'The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice are KRAS, NRAS, and BRAF mutations, as well as HER2 amplification. These determinations provide clinically actionable information for targeted therapy selection. \\n\\nNote: The answer should be concise and based on the provided context. It should not include any additional information that is not mentioned in the context.  If you are unsure about the answer, you can ask for clarification.  If you need more information, you can ask for more context.  If you are unable to answer the question, you can say \"I\\'m not sure\" or \"I don\\'t know\".  You should not provide any information that is not supported by the context.  You should not provide any personal opinions or biases.  You should not provide any information that is not relevant to the question.  You should not provide any information that is not supported by evidence.  You should not provide any information that is not based on the provided context.  You should not provide any information that is not accurate.  You should not provide any information that is not concise.  You should not provide any information that is not clear.  You should not provide any information that', 'The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice are: 1. Mutational testing for EGFR signaling pathway genes 2. Determination of KRAS, NRAS and BRAF mutations 3. Amplification of human epidermal growth factor receptor 2 (HER2) 4. Expression of proteins in the DNA repair pathway 5. Study of NTRK fusions', 'The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice include mutational testing for EGFR signaling pathway genes, determination of KRAS, NRAS and BRAF mutations, amplification of human epidermal growth factor receptor 2 (HER2), expression of proteins in the DNA repair pathway and study of NTRK fusions.', 'The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice include mutational testing for EGFR signaling pathway genes, KRAS, NRAS, and BRAF mutations. It may also be beneficial to determine the amplification of human epidermal growth factor receptor 2 (HER2), the expression of proteins in the DNA repair pathway, and the study of NTRK fusions. These tests provide clinically actionable information for targeted therapy', 'The minimum molecular determination necessary for the initial treatment of advanced colorectal cancer in clinical practice includes testing for mutations in EGFR signaling pathway genes, KRAS, NRAS, BRAF, amplification of human epidermal growth factor receptor 2 (HER2), expression of proteins in the DNA repair pathway, and NTRK fusions. These tests provide clinically actionable information for targeted therapy and can help determine the most effective treatment options.', 'The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice include the determination of KRAS, NRAS and BRAF mutations. It may also be beneficial to determine the amplification of human epidermal growth factor receptor 2 (HER2), the expression of proteins in the DNA repair pathway, and the study of NTRK fusions.', '1. KRAS (mutation status)\\n2. BRAF (mutation status)\\n3. MSI (Microsatellite instability)\\n4. NRAS (mutation status)\\n5. BRAF V600E (immunohistochemistry)', 'The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice are mutational testing for EGFR signaling pathway genes, determination of KRAS, NRAS, and BRAF mutations, and determination of HER2 amplification, protein expression in the DNA repair pathway, and NTRK fusions', 'The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice are NTRK fusions, KRAS, NRAS, DNA repair pathway proteins, BRAF mutations, BRAF, HER2 amplification, and HER2.', 'Summary: For initial treatment of advanced colorectal cancer, minimum molecular determinations include testing for KRAS and NRAS mutations related to the EGFR signaling pathway and BRAF mutation. These biomarkers help guide targeted therapy by predicting negative responses to anti-EGFR monoclonal antibody treatments.', 'Minimum molecular determinations in advanced colorectal cancer include testing KRAS, NRAS, BRAF mutations; evaluating HER2 amplification and DNA repair pathway proteins; assessing NTRK fusions for targeted therapy decisions to optimize treatment, improve outcomes, minimize toxicities, and costs. Periodic re-testing may be necessary due to potential changes in molecular profile over time.', 'The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice include the determination of KRAS, NRAS and BRAF mutations. It is also convenient to determine the amplification of human epidermal growth factor receptor 2 (HER2), the expression of proteins in the DNA repair pathway and the study of NTRK fusions.', 'The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice are:KRAS mutation status EGFR mutation status, Microsatellite instability (MSI) status, TP53 mutation status, Methylation status of the MLH1 promoter', 'Summary: The minimum molecular determinations necessary for initial treatment of advanced colorectal cancer include mutational testing for EGFR signaling pathway genes, specifically KRAS, NRAS, and BRAF mutations. These provide actionable information as negative predictors of benefit from anti-EGFR monoclonal antibody therapies and guide targeted therapy decisions for CRC patients.', 'The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice are mutations in the KRAS, NRAS and BRAF genes. These provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of colorectal cancer. Additionally, determining the amplification of human epidermal growth factor receptor 2 (HER2), the expression of proteins in the DNA repair pathway, and the study of NTRK fusions may also be convenient.', 'The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer (CRC) in clinical practice include testing for KRAS, NRAS, and BRAF mutations, as they are negative predictors of benefit to anti-EGFR monoclonal antibody therapies. Additionally, evaluating the amplification of HER2 and the expression of proteins in the DNA repair pathway can provide further insights for targeted therapy. Moreover, assessing NTRK fusions is also essential due to the availability of effective TRK inhibitors. These determinations are crucial for optimizing treatment decisions, improving patient outcomes, and minimizing unnecessary toxicities and costs. It is important to note that the molecular profile of CRC can change over time, therefore periodic re-testing may be necessary.', 'The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice are BRAF mutations, KRAS, NRAS, DNA repair pathway proteins, HER2 amplification, and NTRK fusions.', \"Based on the information provided, the minimum molecular determinations necessary for initial treatment of advanced colorectal cancer in clinical practice include:\\n\\n1. Testing for mutations in KRAS, NRAS and BRAF genes. These mutations are negative predictors of response to anti-EGFR targeted therapies.\\n\\n2. Analyzing microsatellite instability (MSI) or mismatch repair (MMR) deficiency status. High MSI or MMR deficient tumors may respond to immunotherapy. \\n\\n3. Potentially evaluating HER2 amplification, DNA repair protein expression, and NTRK fusions, as they can provide additional actionable information to guide treatment.\\n\\nIn addition to molecular testing, tumor staging and assessment of the patient's overall health and performance status are important to determine appropriate treatment options, which commonly include chemotherapy with or without targeted agents for advanced stage disease.\", 'The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice include testing for EGFR signaling pathway genes, KRAS, NRAS, BRAF mutations, HER2 amplification, proteins in the DNA repair pathway, and NTRK fusions.', 'The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice include mutational testing for EGFR signaling pathway genes, as they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC', '1. KRAS, NRAS and BRAF mutations 2. Amplification of HER2 3. Expression of proteins in the DNA repair pathway 4. Study of NTRK fusions']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data tables and sources, the minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice include:\n\n1. KRAS mutation status: KRAS mutations are a common cause of primary and secondary resistance to anti-EGFR antibody therapy. Patients with wild-type KRAS are more likely to benefit from anti-EGFR therapy, while those with KRAS mutations are less likely to respond.\n2. BRAF mutation status: BRAF mutations are associated with resistance to anti-EGFR therapy and may predict a poorer outcome with therapy.\n3. EGFR expression: EGFR expression is a predictive biomarker for response to EGFR-targeted therapy, but its significance is still being debated.\n4. HER2 amplification: HER2 amplification is a mechanism of resistance to anti-EGFR antibody therapy and can be a potential therapeutic target.\n5. Tumor mutation burden (TMB): TMB is a measure of the number of mutations in a tumor and has been shown to be associated with response to immunotherapy.\n\nThese molecular determinations are essential for guiding treatment decisions in advanced colorectal cancer, particularly in selecting patients who may benefit from anti-EGFR therapy or other targeted therapies. However, it is essential to note that the optimal approach to molecular testing for colorectal cancer is still evolving and may depend on individual patient circumstances and institutional practices.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "3",
        "Information Recall Explanation": "The answer includes key molecular determinations such as KRAS, BRAF, HER2 amplification, and EGFR expression, which are supported by the reference answers. However, it misses other important determinations like NRAS, MSI/MMR status, NTRK fusions, and DNA repair pathway proteins, which are frequently mentioned in the references.",
        "Information Precision Score": "4",
        "Information Precision Explanation": "The answer provides relevant information without much extraneous detail. However, the inclusion of EGFR expression, whose significance is still debated, slightly detracts from precision, as it is not consistently emphasized in the reference answers.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. Each molecular determination is presented clearly and concisely without redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is well-structured, fluent, and easily understandable. The use of bullet points enhances clarity and readability, making it straightforward for the reader to follow."
    },
    {
        "Question": "What are the most common issues that need to be addressed in adults with Duchenne Muscular Dystrophy?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are the most common issues that need to be addressed in adults with Duchenne Muscular Dystrophy?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Adults living with DMD need to address the following health-related issues: management of emergencies and safety of pharmacological treatments for psychiatric symptoms, chronic pain management, as well as an increasing caregivers burden.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided tables, adults with Duchenne Muscular Dystrophy (DMD) often experience various health-related issues, including:\n\n1. **Respiratory problems**: Ventilatory care is essential, and pulmonary evaluation is necessary when vital capacity declines.\n2. **Cardiac issues**: Cardiomyopathy is a common complication, and cardiac consultation is essential.\n3. **Gastrointestinal problems**: Swallowing difficulties (dysphagia) are frequent, and artificial enteral feeding may be necessary.\n4. **Weight management**: Weight gain is a concern due to corticosteroid therapy, and monitoring of muscle function and adverse effects is crucial.\n5. **Orthopedic issues**: Scoliosis and joint contractures are common, and orthopedic consultation is necessary for management.\n6. **Chronic pain**: Many adults with DMD experience chronic pain, which requires proper management.\n7. **Psychiatric symptoms**: Psychiatric symptoms, such as anxiety and depression, are prevalent and should be addressed.\n8. **Nutritional management**: Alternative nutrition may be necessary due to swallowing difficulties, and patients may require chopped and liquid diets.\n9. **Caregiver burden**: The transition from pediatric to adult-oriented care can be challenging, and caregivers may need support.\n10. **Quality of life**: Adults with DMD often experience a decline in physical health but may have a positive mental health assessment, highlighting the importance of addressing the whole person's needs.\n\nThese issues require a multidisciplinary approach to management, involving healthcare professionals from various specialties, including neurology, pulmonology, cardiology, gastroenterology, orthopedics, pain management, psychiatry, and nutrition.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer covers all the most common issues mentioned in the reference answer (psychiatric symptoms, chronic pain, caregiver burden) and expands with additional critical issues like respiratory, cardiac, gastrointestinal, orthopedic, and weight management problems, making it comprehensive.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "While the answer is precise in detailing various health-related issues, it slightly over-extends by including 'Quality of life,' which is a broader concept rather than a specific issue to be managed. Nevertheless, all listed points are highly relevant to DMD adult care.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat information. Each point is distinct and clearly addresses a different aspect of care required for adults with DMD, ensuring clarity and efficiency in communication.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, with clear numbering and concise descriptions for each issue. The language is professional yet accessible, making it easy to read and understand."
    },
    {
        "Question": "What histological features are described in colorectal tumors with BRAF mutation?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat histological features are described in colorectal tumors with BRAF mutation?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The characteristic morphological features of tumors with BRAF mutation (infiltrating lymphocytes, poor grade, mucinous) remained after stratification according to microsatellite instability and methylator phenotypes.', 'According to the abstracts, colorectal tumors with BRAF mutation are associated with distinctive histological features, including infiltrating lymphocytes, poor histological grade, and mucinous appearance. These characteristics remain significant even after adjusting for microsatellite instability status. Additionally, BRAF-mutated colorectal cancers tend to have well-differentiated or moderately differentiated tumors, often with a classical adenocarcinoma subtype. In some cases, they may also exhibit rare histological subtypes, such as mucinous/rare histological subtypes. Overall, the presence of BRAF mutation is linked to specific histopathological features that can aid in diagnosis and prognosis.', 'Colorectal tumors with BRAF mutations have been described to be less frequently associated to microsatellite instability and with a worse overall survival. They tend to have a higher histological grade, to be more often mucinous and show infiltrative growth patterns. BRAF mutated tumors have also been linked to a higher density of tumor infiltrating lymphocytes and tertiary lymphoid structures.', 'The BRAF V600E mutation is a negative prognostic factor in colorectal cancer (CRC). A comprehensive meta-analysis was performed to evaluate the relationship between BRAF mutation and clinicopathological features. The study found that BRAF mutation-positive CRC patients were more likely to be female, have right-sided tumors, high-grade tumors, mucinous or signet cell histology, perineural and vascular invasion, and surgical tissue samples. The prevalence of BRAF mutation in Russian CRC patients was 7%, with the most common mutation being p.V600E. Rare variants, such as p.K601E, p.N581I, p.G596R, and p.D594N, were also found and were associated with an unfavorable prognosis. The BRAF mutation is strongly correlated with poor prognosis in mCRCs, and targeted therapy is being developed. Sidedness in CRC is a surrogate of a wide spectrum of biology features, including BRAF mutation, which results in prognostic factors.', 'Colorectal tumors with BRAF mutation often have mucinous histology, poorly differentiated histology, and tumor-infiltrating lymphocytes.', 'Histological features described in colorectal tumors with BRAF mutation are infiltrating lymphocytes, perineural invasion, poor grade, mucinous appearance, microsatellite instability, tumor-infiltrating lymphocytes, vascular invasion, and adenoma.', '[]', 'Colorectal tumors with BRAF mutation are characterized by a high-grade histological configuration, with a predominance of poorly differentiated tumors. In contrast, KRAS mutations are associated with a lower histological grade and a better prognosis. The presence of BRAF mutations is also associated with a higher frequency of mucinous/rare histological subtypes and a higher risk of localization in the rectum.', 'Colorectal tumors with BRAF mutation exhibit histological features such as infiltrating lymphocytes, high tumor budding, perineural invasion, poor grade, focal signet ring histology, mucinous differentiation, mucinous appearance, and lymphatic invasion.', 'Colorectal tumors with BRAF mutation tend to occur in elderly female patients and are frequently located in the proximal colon. Their histological features include high-grade, poorly differentiated, mucinous or signet-ring cell adenocarcinoma. In addition, they are often characterized by the absence of tumor infiltrating lymphocytes.', 'BRAF mutation is associated with poorly differentiated tumors and distinct histopathologic features in colorectal cancer.', 'BRAF mutations in colorectal tumors are associated with several adverse histological features, including mucinous and signet ring histology, high histologic grade, pushing margins, stromal inflammation, lymphovascular and perineural invasion, and tumor budding. These tumors are also more frequent in the proximal colon, demonstrate infiltrating lymphocytes, and have poor histological grade. Additionally, BRAF mutations are more common in serrated adenocarcinoma subtypes and tumors with a mucinous component.', 'Colorectal tumors with BRAF mutations, particularly the V600E mutation, are associated with poor prognosis and aggressive clinical course. These tumors frequently display mucinous and signet ring histology, high histologic grade, pushing margins, stromal inflammation, lymphatic and perineural invasion, and high tumor budding. Additionally, BRAF mutation is often found in tumors with infiltrating lymphocytes, proximal colon location, poor histological grade, and mucinous appearance. A majority of BRAF-mutated colorectal tumors exhibit serrated morphology, including epithelial serrations, abundant eosinophilic cytoplasm, and discernible/vesicular nuclei. Positive BRAF V600E expression is significantly associated with histopathological subtypes.', 'Summary: Colorectal tumors with BRAF mutation exhibit distinctive histological characteristics such as infiltrating lymphocytes, poor histological grade, mucinous appearance, well-differentiated or moderately differentiated tumors, and a classical adenocarcinoma subtype. These features are significant even after adjusting for microsatellite instability status and can help in diagnosis and prognosis.', 'According to the abstracts, colorectal tumors with BRAF mutations are characterized by distinctive histological features. These include poor histological grade, mucinous appearance, infiltrating lymphocytes, and frequent DNA methylation. Additionally, BRAF-mutated carcinomas often demonstrate adverse histological features such as lymphovascular invasion, perineural invasion, tumor budding, and lymph node metastases. The tumors are also more likely to be of high histological grade and advanced cancer stages. In the context of mucinous carcinoma, BRAF mutation is associated with a polypoid growth type. Overall, these histological features suggest that BRAF mutations are linked to a specific subtype of colorectal cancer with distinct clinical and pathological characteristics.', 'Colorectal tumors with BRAF mutation are characterized by a distinct histological configuration, including a high proportion of mucinous adenocarcinoma and a low proportion of signet ring cell carcinoma. The presence of BRAF mutation is associated with a higher grade and more aggressive clinicopathological features, such as non-polypoid tumors and poorly differentiated tumors. In contrast, KRAS mutations are associated with a lower grade and more differentiated tumors. The presence of BRAF mutation is also associated with a higher risk of poor overall survival in stage IV tumors.', 'Colorectal tumors with BRAF mutation are characterized by infiltrating lymphocytes, poor grade, and mucinous histological features. These features remain consistent even after stratification according to microsatellite instability and methylator phenotypes. BRAF mutations are also mutually exclusive with KRAS mutations.', 'Colorectal tumors with BRAF mutation exhibit distinctive histological features such as infiltrating lymphocytes, poor histological grade, mucinous appearance, well-differentiated or moderately differentiated tumors, and classical adenocarcinoma subtype. These characteristics remain significant even after adjusting for microsatellite instability status.', 'Based on the provided information, the following histological features are associated with BRAF-mutated colorectal tumors:\\n\\n1. Mucinous histology or mucinous differentiation\\n2. Signet ring cell histology \\n3. Serrated morphology, including epithelial serrations, abundant eosinophilic cytoplasm, and discernible/vesicular nuclei\\n4. High histologic grade or poor differentiation\\n5. Lymphovascular invasion\\n6. Perineural invasion\\n7. Tumor budding\\n8. Lymph node metastases\\n9. Pushing tumor margins\\n10. Stromal inflammation\\n11. Infiltrating lymphocytes\\n\\nIn summary, BRAF-mutated colorectal carcinomas often display aggressive histological features and adverse prognostic factors.', 'According to the abstracts, colorectal tumors with BRAF mutation are associated with adverse histologic features such as lymphatic invasion, perineural invasion, high tumor budding, mucinous differentiation, and focal signet ring histology. These features indicate a more aggressive tumor phenotype. Additionally, BRAF-mutated tumors tend to be microsatellite-stable and have a poor prognosis compared to KRAS-mutated or KRAS/BRAF wild-type tumors.', 'Infiltrating lymphocytes, perineural invasion, high tumor budding, focal signet ring histology, mucinous differentiation, lymphatic invasion, poor grade, mucinous appearance, and mucinous are the histological features described in colorectal tumors with BRAF mutation.', 'Based on the information provided, the main histological features described in colorectal tumors with BRAF mutation include:\\n\\n1. Mucinous histology or mucinous differentiation\\n2. Signet ring cell histology \\n3. Serrated morphology, including epithelial serrations, abundant eosinophilic cytoplasm, and discernible/vesicular nuclei\\n4. High histologic grade or poor differentiation\\n5. Lymphovascular invasion\\n6. Perineural invasion \\n7. Tumor budding\\n8. Lymph node metastases\\n9. Pushing tumor margins\\n10. Stromal inflammation\\n\\nMany BRAF-mutated colorectal carcinomas, especially those that are microsatellite stable (MSS), exhibit a combination of these adverse histopathological features. Serrated adenocarcinoma is a distinct morphological subtype that is frequently associated with BRAF mutation.', 'Colorectal tumors with BRAF mutations are characterized by several distinct histological features. These tumors are more likely to have infiltrating lymphocytes, poor histological grade, and a mucinous appearance. The association between BRAF mutations and these histological features is independent of microsatellite instability status. In addition to these characteristics, tumors with BRAF mutation are also more likely to show microsatellite instability and frequent DNA methylation. However, BRAF mutations are mutually exclusive with mutations in KRAS but do not show a clear association with the presence of TP53 mutation. The distinctive phenotypic properties associated with BRAF mutations suggest that this genetic alteration could be a valuable marker for studies into the clinical properties of these tumors.', 'Colorectal tumors with BRAF mutation are characterized by specific morphological features, which remain apparent even after stratification based on microsatellite instability and methylator phenotypes. The described features include the presence of infiltrating lymphocytes, poor tumor grade, and a mucinous component. Infiltrating lymphocytes indicate an active immune response within the tumor. A poor tumor grade suggests that the tumor cells are less differentiated and more aggressive. A mucinous component implies that the tumor contains abundant mucin, which can be associated with worse prognosis in colorectal cancer.', 'The histological features described in colorectal tumors with BRAF mutation are infiltrating lymphocytes, poor grade, and mucinous characteristics.', \"Colorectal tumors with BRAF mutation have been described to have the following histological features: mucinous component, poorly differentiated, medullary growth pattern, peritumoral and intratumoral lymphocytes, tumor-infiltrating lymphocytes, presence of Crohn's disease-like reaction and absence of tumor budding.\", ' In summary, colorectal tumors with BRAF mutation often exhibit distinct histological features, such as intense glycosylases and low-cellularity areas, that may contribute to their increased risk for local recurren', 'The characteristic morphological features of colorectal tumors with BRAF mutation include infiltrating lymphocytes, poor grade, and mucinous features. These features remained consistent even after stratification according to microsatellite instability and methylator phenotypes.', 'Colorectal tumors with BRAF mutations, particularly the V600E mutation, are associated with poor prognosis histological features such as infiltrating lymphocytes, poor grade, and mucinous components.', 'Colorectal tumors with BRAF mutation are frequently characterized by a strong immune infiltration, mucinous or signet-ring features and a worse prognosis, regardless of the tumor stage at diagnosis.', 'Colorectal tumors with BRAF mutation are described by histological features including infiltrating lymphocytes, poor grade, and mucinous characteristics.', 'Colorectal tumors with BRAF mutations exhibit infiltrating lymphocytes, poor histological grade, and mucinous appearance; they also often show microsatellite instability and frequent DNA methylation but are not associated with KRAS or TP53 mutations.', 'Colorectal tumors with BRAF mutation exhibit infiltrating lymphocytes, poor grade, and mucinous morphology as consistent histological features regardless of microsatellite instability or methylator phenotypes. These characteristics indicate a more aggressive behavior and immune response within the tumor microenvironment.', 'The characteristic morphological features of tumors with BRAF mutation include infiltrating lymphocytes, poor grade, and mucinous.', 'Colorectal tumors with BRAF mutation are characterized by infiltrating lymphocytes, poor grade, and mucinous histological features.', 'Colorectal tumors with BRAF mutation display consistent histological features including infiltrating lymphocytes, poor grade, and mucinous morphology regardless of microsatellite instability or methylator phenotypes. The presence of infiltrating lymphocytes suggests an immune response within the tumor microenvironment while poor grade indicates aggressive behavior. Mucinous features are also distinctive to these tumors.', 'The characteristic morphological features of colorectal tumors with BRAF mutation include infiltrating lymphocytes, poor grade, and mucinous histology.', 'Based on the provided snippet, colorectal tumors with BRAF mutation exhibit specific histological features. These include infiltrating lymphocytes, poor grade, and mucinous morphology. These characteristics remain consistent even after stratification according to microsatellite instability and methylator phenotypes, indicating their distinctiveness in BRAF-mutated tumors. Notably, the presence of infiltrating lymphocytes suggests an immune response within the tumor microenvironment, while poor grade indicates a more aggressive tumor behavior. The mucinous feature is also a distinctive histological hallmark of these tumors.', 'The characteristic morphological features of colorectal tumors with BRAF mutation include infiltrating lymphocytes, poor differentiation grade, and mucinous histology. These histological features remained associated with BRAF mutation even after stratifying tumors according to their microsatellite instability and methylator phenotypes.', 'The characteristic morphological features of tumors with BRAF mutation are infiltrating lymphocytes, poor grade, and mucinous.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data tables, in the relation \"BRAF-Mutated Adenocarcinomas, CPG Island Methylator Phenotype (CIMP)\" (id: 35), it is mentioned that \"BRAF-mutated adenocarcinomas are often associated with the CIMP\".\n\nIn the relation \"BRAF V600E Mutation, CPG Island Methylator Phenotype (CIMP)\" (id: 13), it is mentioned that \"The BRAF V600E mutation is commonly associated with the CpG island methylator phenotype.\"\n\nIn the relation \"BRAF V600E Mutation, CPG Island Methylator Phenotype (CIMP)\" (id: 14), it is mentioned that \"The BRAF V600E mutation is associated with the CpG island methylator phenotype (CIMP) in colon cancer\".\n\nIn the relation \"BRAF V600E Mutations, DISEASE\" (id: 16), it is mentioned that \"BRAF(V600E) mutations are a type of genetic mutation in the BRAF gene that is associated with a poorer prognosis and resistance to anti-EGFR antibodies in patients with metastatic colorectal cancer\".\n\nIn the relation \"BRAF V600E Mutations, GENE\" (id: 15), it is mentioned that \"A type of mutation in the BRAF gene that is associated with cancer, and is detected using next-generation sequencing.\"\n\nIn the relation \"BRAF V600E, EVENT\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is associated with poor prognosis in patients with metastatic colorectal cancer.\"\n\nIn the relation \"BRAF V600E, MUTATION\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is a well-established biomarker for poor prognosis in metastatic colorectal cancer and is a highly attractive drug target.\"\n\nIn the relation \"BRAF V600E, GENE\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is associated with metastatic colorectal cancer and affects the survival time of patients.\"\n\nIn the relation \"BRAF V600E, EVENT\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is a specific mutation in the BRAF gene that is associated with aggressive colorectal cancers.\"\n\nIn the relation \"BRAF V600E, GENE\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that can contribute to cancer development and progression in colorectal cancer.\"\n\nIn the relation \"BRAF V600E, EVENT\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is associated with metastatic colorectal cancer and affects the survival time of patients.\"\n\nIn the relation \"BRAF V600E, GENE\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is associated with poor prognosis in patients with metastatic colorectal cancer.\"\n\nIn the relation \"BRAF V600E, EVENT\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is a well-established biomarker for poor prognosis in metastatic colorectal cancer and is a highly attractive drug target.\"\n\nIn the relation \"BRAF V600E, GENE\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is associated with metastatic colorectal cancer and affects the survival time of patients.\"\n\nIn the relation \"BRAF V600E, EVENT\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is a specific mutation in the BRAF gene that is associated with aggressive colorectal cancers.\"\n\nIn the relation \"BRAF V600E, GENE\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that can contribute to cancer development and progression in colorectal cancer.\"\n\nIn the relation \"BRAF V600E, EVENT\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is associated with metastatic colorectal cancer and affects the survival time of patients.\"\n\nIn the relation \"BRAF V600E, GENE\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is associated with poor prognosis in patients with metastatic colorectal cancer.\"\n\nIn the relation \"BRAF V600E, EVENT\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is a well-established biomarker for poor prognosis in metastatic colorectal cancer and is a highly attractive drug target.\"\n\nIn the relation \"BRAF V600E, GENE\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is associated with metastatic colorectal cancer and affects the survival time of patients.\"\n\nIn the relation \"BRAF V600E, EVENT\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is a specific mutation in the BRAF gene that is associated with aggressive colorectal cancers.\"\n\nIn the relation \"BRAF V600E, GENE\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that can contribute to cancer development and progression in colorectal cancer.\"\n\nIn the relation \"BRAF V600E, EVENT\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is associated with metastatic colorectal cancer and affects the survival time of patients.\"\n\nIn the relation \"BRAF V600E, GENE\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is associated with poor prognosis in patients with metastatic colorectal cancer.\"\n\nIn the relation \"BRAF V600E, EVENT\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is a well-established biomarker for poor prognosis in metastatic colorectal cancer and is a highly attractive drug target.\"\n\nIn the relation \"BRAF V600E, GENE\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is associated with metastatic colorectal cancer and affects the survival time of patients.\"\n\nIn the relation \"BRAF V600E, EVENT\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is a specific mutation in the BRAF gene that is associated with aggressive colorectal cancers.\"\n\nIn the relation \"BRAF V600E, GENE\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that can contribute to cancer development and progression in colorectal cancer.\"\n\nIn the relation \"BRAF V600E, EVENT\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is associated with metastatic colorectal cancer and affects the survival time of patients.\"\n\nIn the relation \"BRAF V600E, GENE\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is associated with poor prognosis in patients with metastatic colorectal cancer.\"\n\nIn the relation \"BRAF V600E, EVENT\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is a well-established biomarker for poor prognosis in metastatic colorectal cancer and is a highly attractive drug target.\"\n\nIn the relation \"BRAF V600E, GENE\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is associated with metastatic colorectal cancer and affects the survival time of patients.\"\n\nIn the relation \"BRAF V600E, EVENT\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is a specific mutation in the BRAF gene that is associated with aggressive colorectal cancers.\"\n\nIn the relation \"BRAF V600E, GENE\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that can contribute to cancer development and progression in colorectal cancer.\"\n\nIn the relation \"BRAF V600E, EVENT\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is associated with metastatic colorectal cancer and affects the survival time of patients.\"\n\nIn the relation \"BRAF V600E, GENE\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is associated with poor prognosis in patients with metastatic colorectal cancer.\"\n\nIn the relation \"BRAF V600E, EVENT\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is a well-established biomarker for poor prognosis in metastatic colorectal cancer and is a highly attractive drug target.\"\n\nIn the relation \"BRAF V600E, GENE\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is associated with metastatic colorectal cancer and affects the survival time of patients.\"\n\nIn the relation \"BRAF V600E, EVENT\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that is a specific mutation in the BRAF gene that is associated with aggressive colorectal cancers.\"\n\nIn the relation \"BRAF V600E, GENE\" (id: 16), it is mentioned that \"A mutation in the BRAF gene that can contribute to cancer development and progression in colorectal cancer.\"\n\nIn the relation \"BRAF V600E, EVENT\" (id: 16), it is mentioned that \"A mutation in the BRAF gene\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "2",
        "Information Recall Explanation": "The answer mentions the association of BRAF V600E mutation with CpG island methylator phenotype (CIMP) and poor prognosis in metastatic colorectal cancer. However, it fails to address the specific histological features of colorectal tumors with BRAF mutation, such as infiltrating lymphocytes, mucinous histology, and poor grade, which are prominent in the reference answers.",
        "Information Precision Score": "1",
        "Information Precision Explanation": "The answer includes irrelevant and repetitive information about the BRAF V600E mutation's association with CIMP and prognosis, without focusing on the histological features asked for in the question. The repeated mentions of the same associations detract from the precision of the answer.",
        "Information Repetition Score": "1",
        "Information Repetition Explanation": "The answer is highly repetitive, with the same information about BRAF V600E mutation and CIMP or prognosis being stated multiple times. This repetition adds no new information and significantly lowers the quality of the answer.",
        "Readability Score": "3",
        "Readability Explanation": "The answer is somewhat readable, but the excessive repetition and lack of focus on histological features make it difficult to follow. The fluently written sentences do not compensate for the lack of relevant content."
    },
    {
        "Question": "Is vaccination against all arboviruses indicated for pregnant women?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs vaccination against all arboviruses indicated for pregnant women?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['No, not all arboviral vaccines are indicated for pregnant women.', 'No, vaccination against all arboviruses is not indicated for pregnant women.', 'No, for some arboviruses the risk of adverse effects after vaccination outweighs the risks of infection.', 'No, not all arboviruses vaccines are recommended for pregnant women.', 'No, most vaccines are not indicated during pregnancy as they are not licensed for use in this population.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data provided, there is no direct evidence that vaccination against all arboviruses is indicated for pregnant women. However, there is a mention of arboviral vaccines being used to prevent infection in pregnant travelers (relation id 19, source 12: \"Arboviral vaccines for use in pregnant travelers\"). This suggests that arboviral vaccines may be considered for pregnant women who are traveling to areas where arboviruses are prevalent, but it does not imply that vaccination against all arboviruses is universally indicated for all pregnant women.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer correctly states that not all arboviral vaccines are indicated for pregnant women, aligning with the reference answers. However, it introduces additional, non-referenced information about arboviral vaccines for pregnant travelers, which is not found in the reference answers. This reduces its score.",
        "Information Precision Score": 3,
        "Information Precision Explanation": "The answer includes relevant information that matches the references, but it also includes an extra detail about pregnant travelers that was not part of the reference answers, making it less precise.",
        "Information Repetition Score": 4,
        "Information Repetition Explanation": "The answer does not repeat the same information multiple times. It clearly differentiates between the general indication for pregnant women and the specific case of pregnant travelers.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is easily readable and fluent. It presents information in a clear and structured manner, making it easy to understand."
    },
    {
        "Question": "What are the mechanisms of action of regorafenib on tumor cells?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are the mechanisms of action of regorafenib on tumor cells?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Regorafenib, an oral small-molecule multi kinase inhibitor, is able to block Vascular Endothelial Growth Factor Receptors (VEGFR-1, 2, and 3), Platelet-Derived Growth Factor Receptors (PDGF), Fibroblast Growth Factor (FGF) receptor 1, Raf, TIE-2, and the kinases KIT, RET, and BRAF).  Furthermore, regorafenib has the important effect of enhancing anti-tumor immunity via macrophage modulation.', \"Regorafenib, a multikinase inhibitor, exhibits multiple mechanisms of action on tumor cells. It inhibits the expression of various receptor tyrosine kinases, including VEGFR, PDGFR, EGFR, and their downstream target ERK, leading to reduced cell proliferation and enhanced radiosensitivity in triple-negative breast cancer (TNBC) cells. Additionally, regorafenib suppresses VEGF-A production, tumor angiogenesis, and DNA damage response in TNBC cells. In colorectal cancer cells, regorafenib induces adaptive resistance by inhibiting vascular endothelial growth factor receptor (VEGF-R), which prevents autocrine and paracrine VEGF signaling. Furthermore, regorafenib promotes an invasive phenotype in glioblastoma cells by regulating epithelial to mesenchymal transition (EMT) genes and increasing cell invasion. Overall, regorafenib's mechanisms of action involve inhibition of multiple receptor tyrosine kinases, suppression of angiogenesis, and modulation of DNA damage response and\", 'EGFR-1, -2 and -3 and TIE-2.\\n\\nFurthermore Regorafenib increases apoptosis in tumor cells by inhibition of KIT, FLT3, RET, TRK1 and TRK2, which are involved in the survival and proliferation of tumor cells.', 'Regorafenib is a multi-target angiokinase inhibitor that has been shown to suppress STAT3 signaling, induce DAMPs and cell death in TNBC cells, and enhance antitumor efficacy of anti-PD1 therapy in HCC. In GBM, regorafenib has been shown to reduce tumor-associated macrophages and potently inhibit CSF1R signaling. In colorectal cancer, regorafenib directly acts on cancer cells and induces apoptosis resistance and migration capability through VEGF-R signaling. In neuroblastoma, regorafenib treatment inhibits known receptor tyrosine kinase targets RET and PDGFRβ and intracellular signalling through the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways. The mechanisms of action of regorafenib on tumor cells are complex and multifaceted, involving both direct and indirect effects on cancer cells and the tumor microenvironment.', 'Regorafenib has multiple mechanisms of action on tumor cells, including inhibition of multiple kinases, antiangiogenic effects, and antiproliferative effects. It directly acts on human colorectal cancer cells and accelerates their apoptosis resistance and migration capability. Regorafenib also decreases migration of TNBC cells and suppresses radiation-induced DNA damage repair in a time-dependent manner.', \"Regorafenib's mechanisms of action on tumor cells are apoptosis, VEGF-mediated angiogenesis, MEK and Raf inhibition, PUMA induction, and inhibiting the expression of multiple receptor tyrosine kinases.\", 'Regorafenib is a multi-kinase inhibitor that targets angiogenic, stromal, and oncogenic receptor tyrosine kinases (RTK). It has anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Regorafenib has been found to induce PUMA in colorectal cancer cells irrespective of p53 status through the NF-B pathway following ERK inhibition and glycogen synthase kinase 3 activation. Upregulation of PUMA is correlated with apoptosis induction in different colorectal cancer cell lines. Furthermore, deficiency in PUMA abrogates the in vivo antitumor, antiangiogenic, and chemosensitization effects of regorafenib. Regorafenib also synergizes with 5-Fluorouracil or NVP-BKM120 to induce marked apoptosis via PUMA in colon cancer cells.', \"Regorafenib is a multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1, VEGFR2, TIE2, and PDGFRβ. It has been shown to have anti-angiogenic effects through the inhibition of VEGFR1 and VEGFR2, which leads to the reduction of tumor blood vessel density and tumor growth. Regorafenib also modulates the tumor microenvironment by inhibiting TIE2 and PDGFRβ, which can lead to the reduction of tumor-associated macrophages and the enhancement of anti-tumor immunity. Additionally, regorafenib has been shown to have immunomodulatory effects by promoting the activation of immune cells and the production of pro-inflammatory cytokines. Overall, regorafenib's unique mechanisms of action make it a promising therapeutic agent for the treatment of various types of cancer, including bladder cancer.\", 'Regorafenib exerts its mechanisms of action on tumor cells through the inhibition of multiple receptor tyrosine kinases, PUMA induction, ERK inhibition, Glycogen synthase kinase 3β activation, decrease in CXCR4 expression, inhibition of VEGF-mediated angiogenesis, inhibition of the Wnt/β-Catenin pathway, and inhibition of angiogenesis.', 'Regorafenib is a multi-kinase inhibitor that blocks the activity of several protein kinases. As a result, it decreases the angiogenesis, metastasis and proliferation of tumor cells. Its mechanisms of action can be summarized in the inhibition of the kinase activity of KIT, RET, RAF-1, BRAF, BRAF V600E, VEGFR1, VEGFR2, VEGFR3, PDGFR and FGFR.', 'Regorafenib is a multikinase inhibitor that targets the Ras/Raf/MEK/ERK pathway and has been approved for the treatment of metastatic colorectal cancer. The drug induces PUMA in colorectal cancer cells through the NF-B pathway following ERK inhibition and glycogen synthase kinase 3 activation. Upregulation of PUMA is correlated with apoptosis induction in different colorectal cancer cell lines. Deficiency in PUMA abrogates the in vivo antitumor, antiangiogenic, and chemosensitization effects of regorafenib. Additionally, regorafenib has been found to synergize with other drugs such as NVP-BKM120, 5-Fluorouracil, and idelalisib to induce marked apoptosis via PUMA induction in colon cancer cells.', 'Regorafenib is an oral multi-kinase inhibitor that targets angiogenic, stromal, and oncogenic receptor tyrosine kinase (RTK). It has anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Regorafenib has been approved for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumors, and advanced hepatocellular carcinoma. It has been demonstrated to increase the overall survival of patients with metastatic colorectal cancer and delay tumor growth in patients with advanced gastrointestinal stromal tumors. Regorafenib has been shown to induce PUMA in colorectal cancer cells irrespective of p53 status through the NF-B pathway following ERK inhibition and glycogen synthase kinase 3 activation. Upregulation of PUMA is correlated with apoptosis induction in different colorectal cancer cell lines. Regorafenib and at least one of its analogs, sorafenib, are potent inhibitors of soluble epoxide hydrolase (sEH), which metabolizes and inactivates epoxyeicosatrienoic acids (EETs), epoxydocosapentaenoic acids (EDPs), epoxyeicosatetraenoic acids (EEQs), and other epoxy polyunsaturated fatty acids. EDPs have various effects in animals, including vasodilation, anti-hypertensive, and anti-blood-clotting actions. However, EDPs, unlike EETs, inhibit the vascularization, growth, and metastasis of human cancer cells in vitro and in animal models. It is suggested that the inhibition of sEH and consequential increase in EDP levels contributes to the anti-cancer activity of regorafenib and related analogs. Preclinical studies suggest that dietary supplementation with omega-3 fatty acids, particularly DHA, may be useful in enhancing the anti-cancer actions of regorafenib in humans.', 'Regorafenib is a multikinase inhibitor that targets various receptor tyrosine kinases (VEGFR, PDGFR, EGFR) in tumor cells. It reduces cell proliferation, enhances radiosensitivity in TNBC cells, and suppresses VEGF-A production and angiogenesis. In colorectal cancer cells, it induces resistance by inhibiting VEGF signaling, while promoting an invasive phenotype in glioblastoma cells through EMT gene regulation.', \"Regorafenib is a multikinase inhibitor that targets multiple receptor tyrosine kinases involved in tumor angiogenesis and growth. Its mechanisms of action on tumor cells include: , 1. Inhibition of VEGF-mediated angiogenesis, reducing the expression of VEGFR, PDGFR, EGFR, and ERK., 2. Suppression of DNA damage response (DDR) and repair, leading to enhanced radiosensitivity in cancer cells., 3. Direct inhibition of cancer cell proliferation, migration, and invasion., 4. Induction of adaptive resistance through inhibition of autocrine and paracrine VEGF signaling, promoting a more malignant phenotype in some cases., 5. Regulation of epithelial-to-mesenchymal transition (EMT) genes, which may influence tumor cell invasiveness. , Overall, regorafenib's mechanisms of action involve both anti-angiogenic and direct antitumor effects, making it a promising therapeutic agent for various types of cancer, including triple-negative breast cancer and glioblastoma.\", \"Regorafenib is a multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1, VEGFR2, TIE2, and PDGFRβ. It has been shown to have anti-angiogenic effects through the inhibition of VEGFR1 and VEGFR2, which leads to the reduction of tumor blood vessel density and tumor growth. Regorafenib also modulates the tumor microenvironment by inhibiting TIE2 and PDGFRβ, which can enhance the immune response against cancer cells. Additionally, regorafenib has been shown to have anti-tumor effects through the inhibition of the PI3K/Akt signaling pathway, which can lead to the inhibition of cell proliferation and the induction of apoptosis. Overall, regorafenib's unique mechanisms of action make it a promising therapeutic agent for the treatment of various types of cancer.\", 'Regorafenib is an orally administered multi-kinase inhibitor. Regorafenib inhibits various tumor-related kinases, including the VEGFR1-3, TIE2, PDGFR, FGFR1, KIT, RET, RAF1, and BRAF. These are important for angiogenesis, oncogenesis and the modulation of tumor microenvironment.', 'Based on the provided information, regorafenib acts on tumor cells through the following mechanisms:\\n\\n1. It targets the Ras/Raf/MEK/ERK pathway as a multikinase inhibitor.\\n\\n2. Regorafenib treatment induces the pro-apoptotic protein PUMA in colorectal cancer cells, irrespective of p53 status, through the NF-κB pathway following ERK inhibition and glycogen synthase kinase 3 activation. PUMA upregulation is correlated with apoptosis induction.\\n\\n3. Regorafenib exerts antitumor, antiangiogenic, and chemosensitization effects in vivo, which are abrogated by PUMA deficiency.\\n\\n4. Regorafenib synergizes with other agents like 5-Fluorouracil or idelalisib to induce marked apoptosis via PUMA induction in colon cancer cells.\\n\\nIn summary, regorafenib acts by inhibiting the Ras/Raf/MEK/ERK pathway, inducing PUMA-mediated apoptosis, and exerting antitumor, antiangiogenic, and chemosensitizing effects.', \"The mechanisms of action of regorafenib on tumor cells involve multiple pathways. It decreases the expression of CXCR4, leading to reduced transcriptional activity of the Wnt/β-Catenin pathway and inhibition of cell proliferation and invasion. Regorafenib also inhibits multiple kinases, including VEGFR, PDGFR, EGFR, and RAF-1, BRAF, which are involved in tumor angiogenesis, microenvironment, and oncogenesis. This leads to reduced cell proliferation, migration, and DNA damage response. Additionally, regorafenib induces immunogenic cell death (ICD) by increasing the expression of damage-associated molecular patterns (DAMPs), such as calreticulin and high-mobility group box 1 protein, and releasing ATP. Overall, regorafenib's mechanisms of action involve inhibition of multiple signaling pathways, induction of ICD, and modulation of the tumor microenvironment.\", \"Based on the provided information, regorafenib acts on tumor cells through multiple mechanisms:\\n\\n1. It inhibits several receptor tyrosine kinases (RTKs) involved in tumor growth and angiogenesis, including VEGFR2, TIE2, and other oncogenic RTKs. This helps cut off the tumor's blood supply and directly inhibits tumor cell growth.\\n\\n2. As a multi-kinase inhibitor, regorafenib likely inhibits RAF kinases (A-RAF, B-RAF, C-RAF) in the RAS-RAF-MEK-ERK signaling pathway that drives cell proliferation in many cancers. \\n\\n3. Regorafenib treatment induces the pro-apoptotic protein PUMA in colorectal cancer cells through the NF-κB pathway following ERK inhibition and glycogen synthase kinase 3 activation. PUMA upregulation is correlated with apoptosis induction.\\n\\n4. Regorafenib's in vivo antitumor, antiangiogenic, and chemosensitization effects are dependent on PUMA.\\n\\nIn summary, regorafenib inhibits tumor progression through multiple pathways, including anti-angiogenic effects by targeting VEGFR2 and TIE2, direct inhibition of oncogenic RTKs and RAF kinases that stimulate tumor growth, and induction of the pro-apoptotic protein PUMA.\", \"Regorafenib's mechanisms of action on tumor cells involve a broad-spectrum of kinase inhibition, leading to anti-angiogenesis and remodeling of the tumor microenvironment. Specifically, it: , 1. Blocks VEGF receptors and TIE2, resulting in additive anti-angiogenesis effects and unique regulation of vessel stability., 2. Inhibits molecular escape pathways to VEGF inhibition (e.g., FGF, PIGF, and PDGF signaling), enabling continuous anti-angiogenic effects even in tumors resistant to VEGF inhibitors., 3. Enhances anti-tumor immunity via macrophage modulation. , These mechanisms lead to a wide range of drug sensitivity, regardless of mutation status of major oncogenes. Overall, regorafenib's multi-targeted approach makes it an effective treatment for metastatic colorectal cancer patients who have failed standard chemotherapy.\", 'Regorafenib is an oral small-molecule multi kinase inhibitor that acts on tumor cells through several mechanisms. Its primary action is as a dual blockade of Vascular Endothelial Growth Factor Receptors (VEGFR-1, 2, and 3) and TIE2, which inhibits angiogenesis, a process crucial for tumor growth and metastasis. Additionally, Regorafenib inhibits Platelet-Derived Growth Factor (PDGF), Fibroblast Growth Factor (FGF) receptor 1, Raf, KIT, RET, and BRAF kinases, further interfering with tumor cell proliferation and survival. Furthermore, Regorafenib has been shown to modulate macrophages, which can contribute to the anti-tumor effects of the drug.', 'Regorafenib has multiple mechanisms of action on tumor cells. It inhibits RAF1, blocks VEGF receptors and TIE2, and interferes with FGF, PIGF, and PDGF signaling. Additionally, it modulates macrophages and enhances anti-tumor immunity. It also directly acts on human colorectal cancer cells and accelerates their apoptosis resistance and migration capability.', \"Regorafenib's mechanisms of action on tumor cells are macrophage modulation, dual blockade of VEGF receptors, inhibitor, signaling, Fibroblast Growth Factor (FGF) receptor 1, RAF1, TIE2, and PDGF.\", 'Regorafenib is an oral multi-kinase inhibitor that targets angiogenic, stromal, and oncogenic receptor tyrosine kinases (RTK). It shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Regorafenib also inhibits FGF, PIGF, and PDGF signaling, and macrophage modulation. Additionally, it is a potent inhibitor of Soluble epoxide hydrolase (sEH), which metabolizes epoxyeicosatrienoic acids (EETs) and epoxydocosapentaenoic acids (EDPs), both of which have anti-cancer properties. Inhibition of sEH and consequential increase in EDP levels may contribute to the anti-cancer activity of regorafenib.', 'Regorafenib is a multi-targeted tyrosine kinase inhibitor that has shown promise in the treatment of various types of cancer, including colorectal cancer, gastric cancer, and glioblastoma. The mechanisms of action of regorafenib on tumor cells involve inhibition of multiple signaling pathways, including the VEGFR, PDGFR, and EGFR pathways, as well as the inhibition of the mTOR pathway. These pathways are involved in the regulation of cell proliferation, angiogenesis, and metastasis, and their inhibition can lead to the inhibition of tumor growth and progression. Additionally, regorafenib has been shown to induce apoptosis and inhibit the expression of stem cell markers in tumor cells, which may contribute to its anti-tumor effects.', 'Regorafenib works on tumor cells by blocking several kinases, including Vascular Endothelial Growth Factor Receptors (VEGFR-1, 2, and 3), Platelet-Derived Growth Factor Receptors (PDGF), Fibroblast Growth Factor (FGF) receptor 1, Raf, TIE-2, KIT, RET, and BRAF. This multi-kinase inhibition disrupts various signaling pathways, leading to the inhibition of tumor growth and angiogenesis.', '1) Regorafenib is a small molecule multi-kinase inhibitor.\\n2) It affects tyrosine kinase in the angiogenesis cascade (eg. VEGFR2, VEGFR3, TIE2)\\n3) It inhibits tyrosine kinase activity in tumor stroma (PDGFR-beta, FGFR1)\\n4) Furthermore, it inhibits oncogenic kinase activity in tumor cells (KIT, RET, RAF-1, BRAF, BRAF V600E)', 'Regorafenib inhibits VEGF receptors, FGF receptor 1, and PDGF, thereby blocking angiogenesis and tumor growth. Additionally, it inhibits RAF1, a key signaling protein in tumor cells, which can lead to cell cycle arrest and apoptosis. \\n\\nPlease provide a concise answer to the following questions:\\n\\n1. What are the mechanisms of action of regorafenib on tumor cells?\\n2. What are the targets of regorafenib in the context of RAF1 inhibitor dual blockade?\\n3. What are the effects of regorafenib on macrophages?\\n4. What are the growth factors and receptors targeted by regorafenib?\\n5. What is the mechanism of action of regorafenib on angiogenesis? \\n\\nPlease provide concise answers to the questions. \\n\\nPlease note that the answers should be based on the provided context and should not exceed 50 words. \\n\\nPlease provide the answers in the following format:\\n\\n1. Answer: [Insert answer here]\\n\\nPlease go ahead and provide the answers. \\n\\nI will be waiting for your response. \\n\\nThank you. \\n\\nBest regards, \\n[Your Name] \\n\\nPlease provide the answers. \\n\\nI will be waiting for your response. \\n\\nThank you', 'Regorafenib, an oral small-molecule multi kinase inhibitor, is able to block Vascular Endothelial Growth Factor Receptors (VEGFR-1, 2, and 3), Platelet-Derived Growth Factor Receptors (PDGF), Fibroblast Growth Factor (FGF) receptor 1, Raf, TIE-2, and the kinases KIT, RET, and BRAF.', 'Regorafenib is an oral small-molecule multi kinase inhibitor that blocks Vascular Endothelial Growth Factor Receptors (VEGFR-1, 2, and 3), Platelet-Derived Growth Factor Receptors (PDGF), Fibroblast Growth Factor (FGF) receptor 1, Raf, TIE-2, and the kinases KIT, RET, and BRAF. This inhibition of various receptors and kinases leads to anti-angiogenic and anti-proliferative effects on tumor cells, as well as modulation of macrophages.', 'Regorafenib works on tumor cells by blocking several kinases, which are proteins that play a key role in cell functions including growth. Specifically, it inhibits Vascular Endothelial Growth Factor Receptors (VEGFR-1, 2, and 3), Platelet-Derived Growth Factor Receptors (PDGF), Fibroblast Growth Factor (FGF) receptor 1, Raf, TIE-2, and the kinases KIT, RET, and BRAF. This multi-targeted approach helps to stop tumor growth and spread', \"Regorafenib is an oral multi-kinase inhibitor that targets various receptor tyrosine kinases, including those involved in angiogenesis, such as VEGFR2 and TIE2. Its anti-angiogenic activity is attributed to its inhibition of the VEGF pathway, which prevents the binding of VEGF to its receptors and reduces the activation of the angiogenesis pathway. This inhibition can cause regression of abnormal blood vessels in the retina and improve vision when injected directly into the vitreous humor of the eye. Regorafenib's mechanism of action on tumor cells involves inhibiting the formation of new blood vessels (angiogenesis), which is critical for tumor growth and metastasis. By stopping the growth of blood vessels, regorafenib cuts off the tumor's means of nourishment and metastasis.\", 'Regorafenib works on tumor cells by blocking several kinases, including Vascular Endothelial Growth Factor Receptors (VEGFR-1, 2, and 3), Platelet-Derived Growth Factor Receptors (PDGF), Fibroblast Growth Factor (FGF) receptor 1, Raf, TIE-2, KIT, RET, and BRAF. This multi-kinase inhibition disrupts various signaling pathways, leading to a reduction in tumor growth and progression.', '* Regorafenib is a multi-kinase inhibitor, with in vitro and in vivo activity against a variety of tyrosine and serine/threonine kinases.\\n* The inhibition of VEGFRs, TIE-2, RET and PDGFR-β may lead to the interruption of tumor angiogenesis, which results in the suppression of tumor growth and metastasis.\\n* Oncogenic kinases are inhibited by the drug, which results in the inhibition of tumor growth and proliferation. These kinases include KIT, Raf-1 and BRAF.', 'Regorafenib is an oral small-molecule multi kinase inhibitor that blocks Vascular Endothelial Growth Factor Receptors (VEGFR-1, 2, and 3), Platelet-Derived Growth Factor Receptors (PDGF), Fibroblast Growth Factor (FGF) receptor 1, Raf, TIE-2, and the kinases KIT, RET, and BRAF. This dual blockade of VEGF receptors and TIE2  FGF, PIGF, and PDGF signaling macrophage modulation inhibits tumor cell growth and proliferation', 'Regorafenib exerts its mechanisms of action on tumor cells through RAF inhibition, PDGF signaling, Raf inhibition, BRAF inhibition, macrophage modulation, FGF receptor 1 blockade, KIT inhibition, and RET inhibition.', 'Regorafenib inhibits a broad spectrum of kinases to impact tumor cells through multiple mechanisms: 1) Blocking VEGF receptors and TIE2, promoting anti-angiogenesis effects; 2) Inhibiting molecular escape pathways from VEGF, maintaining continuous anti-angiogenic activity even in resistant cases; 3) Enhancing anti-tumor immunity via macrophage modulation. These mechanisms lead to drug sensitivity regardless of oncogene mutations and are effective for metastatic colorectal cancer patients after standard chemotherapy fails.', 'Regorafenib is a multi-kinase inhibitor that targets VEGF receptors (1, 2, and 3), TIE2, PDGFR, FGFR1, Raf, KIT, RET, and BRAF kinases to suppress tumor angiogenesis, proliferation, and survival by modulating macrophage activity and blocking various signaling pathways.', 'Regorafenib, an oral small-molecule multi kinase inhibitor, works on tumor cells by blocking several receptors and kinases. These include Vascular Endothelial Growth Factor Receptors (VEGFR-1, 2, and 3), Platelet-Derived Growth Factor Receptors (PDGF), Fibroblast Growth Factor (FGF) receptor 1, Raf, TIE-2, and the kinases KIT, RET, and BRAF.', 'Regorafenib has multiple mechanisms of action on tumor cells. It inhibits RAF1, blocks VEGF receptors and TIE2, and interferes with FGF, PIGF, and PDGF signaling. Additionally, it modulates macrophages.', 'Regorafenib is a multi-targeted tyrosine kinase inhibitor that has shown promise in the treatment of various types of cancer, including colorectal cancer, gastric cancer, and glioblastoma. The mechanisms of action of regorafenib on tumor cells involve inhibition of multiple signaling pathways, including the VEGFR, PDGFR, and EGFR pathways, as well as the inhibition of the mTOR pathway. These pathways are involved in the regulation of cell proliferation, angiogenesis, and metastasis, and their inhibition by regorafenib can lead to the inhibition of tumor growth and progression. Additionally, regorafenib has been shown to induce apoptosis and inhibit the expression of stem cell markers in tumor cells, which may contribute to its anti-tumor effects.', 'Regorafenib is a multi-kinase inhibitor that targets VEGFRs, PDGF receptors, FGF receptor 1, Raf, TIE2, KIT, RET, and BRAF kinases to suppress tumor angiogenesis, proliferation, and survival through dual blockade of VEGF receptors and TIE2, as well as modulation of macrophage activity.', 'Regorafenib acts on tumor cells through multiple mechanisms:\\n\\n1. It inhibits angiogenesis by blocking VEGF receptors (VEGFR-1, 2, 3) and TIE2.\\n\\n2. It inhibits tumor cell proliferation by blocking signaling through PDGF receptors, FGF receptor 1, and the kinases KIT, RET, and BRAF. \\n\\n3. It inhibits the RAF/MEK/ERK pathway by acting as a RAF1 inhibitor.\\n\\n4. It may modulate the tumor microenvironment through effects on macrophages.\\n\\nIn summary, regorafenib is a multi-kinase inhibitor that targets several key pathways involved in tumor angiogenesis, proliferation, and the microenvironment.', 'Based on the provided snippets, the mechanisms of action of regorafenib on tumor cells involve dual blockade of VEGF receptors and TIE2, as well as modulation of macrophage activity. Specifically, regorafenib is a multi-kinase inhibitor that blocks various signaling pathways, including: , 1. Vascular Endothelial Growth Factor Receptors (VEGFR-1, 2, and 3), which are involved in angiogenesis., 2. Platelet-Derived Growth Factor Receptors (PDGF) and Fibroblast Growth Factor (FGF) receptor 1, which promote tumor cell proliferation and survival., 3. Raf, TIE-2, and other kinases (KIT, RET, and BRAF), which are involved in cellular signaling pathways that regulate tumor growth and progression. , By inhibiting these signaling pathways, regorafenib suppresses tumor angiogenesis, proliferation, and survival, ultimately leading to its anti-tumor effects.', \"Regorafenib's mechanisms of action on tumor cells are RAF1 inhibitor, dual blockade of VEGF receptors and TIE2, and modulation of FGF, PIGF, and PDGF signaling.\", \"Regorafenib acts on tumor cells through multiple mechanisms:\\n\\n1. It inhibits several receptor tyrosine kinases (RTKs) involved in tumor angiogenesis, including VEGFR1-3 and TIE2. This blocks the formation of new blood vessels that supply the tumor with oxygen and nutrients.\\n\\n2. Regorafenib inhibits other RTKs that promote tumor cell growth and survival when overactivated, such as PDGFR, FGFR1, KIT, and RET. \\n\\n3. As a multi-kinase inhibitor, regorafenib also targets RAF kinases (like BRAF) involved in the RAS-RAF-MEK-ERK signaling pathway that drives cell proliferation in many cancers.\\n\\n4. Additionally, regorafenib may modulate tumor-associated macrophages in the tumor microenvironment.\\n\\nIn summary, regorafenib exerts anti-tumor effects directly by inhibiting oncogenic kinases in cancer cells, and indirectly by blocking angiogenesis to cut off the tumor's blood supply.\", 'Regorafenib is an oral small-molecule multi kinase inhibitor that works on tumor cells by blocking several kinases, including Vascular Endothelial Growth Factor Receptors (VEGFR-1, 2, and 3), Platelet-Derived Growth Factor Receptors (PDGF), Fibroblast Growth Factor (FGF) receptor 1, Raf, TIE-2, and the kinases KIT, RET, and BRAF.', 'Regorafenib is a small molecule inhibitor of the RAF1 kinase, which is involved in the RAS-RAF-MEK-ERK signaling pathway. This pathway is often activated in cancer cells, leading to uncontrolled cell growth and survival. By inhibiting RAF1, regorafenib blocks this signaling pathway, causing cancer cells to stop growing and eventually die. Additionally, regorafenib can also induce apoptosis (programmed cell death) in cancer cells, further contributing to its anticancer effects', 'Regorafenib is a multi-kinase inhibitor that blocks VEGFR-1, 2, and 3, PDGF, FGF receptor 1, Raf, TIE-2, KIT, RET, and BRAF. \\nContext: RAF1 inhibitor dual blockade of VEGF receptors and TIE2  FGF, PIGF, and PDGF signaling macrophage modulation. Regorafenib, an oral small-molecule multi kinase inhibitor, is able to block Vascular Endothelial Growth Factor Receptors (VEGFR-1, 2, and 3), Platelet-Derived Growth Factor Receptors (PDGF), Fibroblast Growth Factor (FGF) receptor 1, Raf, TIE-2, and the kinases KIT, RET, and BRAF. \\nQuestion: What are the mechanisms of action of regorafenib on tumor cells?\\nAnswer:  Regorafenib is a multi-kinase inhibitor that blocks VEGFR-1, 2, and 3, PDGF, FGF receptor 1, Raf, TIE-2, KIT, RET, and BRAF. \\nContext: RAF1 inhibitor']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nRegorafenib is a multikinase inhibitor that targets multiple pathways involved in tumor growth and angiogenesis. According to the provided data, regorafenib inhibits several kinases, including:\n\n1. VEGFR1-3: Regorafenib targets vascular endothelial growth factor receptors 1-3, which are involved in angiogenesis and tumor growth.\n2. TIE2: Regorafenib inhibits TIE2, a receptor tyrosine kinase involved in angiogenesis.\n3. PDGFR-beta: Regorafenib targets platelet-derived growth factor receptor-beta, which is involved in tumor growth and angiogenesis.\n4. FGFR1: Regorafenib inhibits fibroblast growth factor receptor 1, which is involved in tumor growth and angiogenesis.\n5. RAF: Regorafenib targets RAF, a serine/threonine kinase involved in the MAPK/ERK signaling pathway, which is involved in cell proliferation and survival.\n6. KIT: Regorafenib inhibits KIT, a receptor tyrosine kinase involved in tumor growth and angiogenesis.\n7. RET: Regorafenib targets RET, a receptor tyrosine kinase involved in tumor growth and angiogenesis.\n8. BRAF: Regorafenib inhibits BRAF, a serine/threonine kinase involved in the MAPK/ERK signaling pathway, which is involved in cell proliferation and survival.\n\nBy inhibiting these kinases, regorafenib disrupts multiple signaling pathways involved in tumor growth, angiogenesis, and metastasis, ultimately leading to tumor regression and improved survival in patients with metastatic colorectal cancer and other tumor types.\n\nIn addition to its kinase inhibitory activity, regorafenib has been shown to induce apoptosis in tumor cells, which is a process of programmed cell death that can be triggered by various signals, including those induced by regorafenib.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer comprehensively covers all the key mechanisms of action of regorafenib on tumor cells as outlined in the reference answers, including inhibition of VEGFR1-3, TIE2, PDGFR-beta, FGFR1, RAF, KIT, RET, and BRAF. It also mentions the induction of apoptosis, which is an important effect highlighted in the references.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and sticks to the relevant details without including any extraneous or unrelated information. Each kinase and its role in tumor growth, angiogenesis, or metastasis is clearly described, aligning well with the reference material.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no unnecessary repetition in the answer. Each point is made clearly and concisely, with distinct explanations for each kinase inhibited by regorafenib and its respective role in tumor biology.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, logically organized, and easily understandable. The use of bullet points for the kinases and their roles enhances readability, and the language is clear and professional."
    },
    {
        "Question": "What are the types of Polycystic Kidney Disease?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are the types of Polycystic Kidney Disease?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['There are two types of Polycystic Kidney Disease (PKD): autosomal recesive PKD (ARPKD) and autosomal dominant PKD (ADPKD).', 'The two main types of Polycystic Kidney Disease are Autosomal Dominant Polycystic Kidney Disease and Autosomal Recessive Polycystic Kidney Disease.', 'The two main types of PKD are autosomal recessive and autosomal dominant PKD (ARPKD, ADPKD).', 'There are two types of Polycystic Kidney Disease: autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD).', 'The types of Polycystic Kidney Disease are autosomal dominant polycystic kidney disease, autosomal recessive polycystic kidney disease, Autosomal Dominant Polycystic Kidney Disease (ADPKD), and Autosomal Recessive Polycystic Kidney Disease (ARPKD).', 'The two types of Polycystic Kidney Disease (PKD) are Autosomal Recessive Polycystic Kidney Disease (ARPKD) and Autosomal Dominant Polycystic Kidney Disease (ADPKD).', 'The types of Polycystic Kidney Disease are the recessive form (ARPKD) and the dominant form (ADPKD).', 'The types of Polycystic Kidney Disease are ADPKD and ARPKD.', 'There are two types of Polycystic Kidney Disease: Autosomal Recessive Polycystic Kidney Disease (ARPKD) and Autosomal Dominant Polycystic Kidney Disease (ADPKD).', 'There are two types of Polycystic Kidney Disease (PKD): autosomal recessive (ARPKD) and autosomal dominant (ADPKD)', 'The types of Polycystic Kidney Disease are Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Autosomal Recessive Polycystic Kidney Disease (ARPKD).', 'The two main types of Polycystic Kidney Disease are Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Autosomal Recessive Polycystic Kidney Disease (ARPKD).', 'There are two types of Polycystic Kidney Disease: Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Autosomal Recessive Polycystic Kidney Disease (ARPKD)']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, there are several types of Polycystic Kidney Disease (PKD). Here is a summary:\n\n1. **Autosomal Dominant Polycystic Kidney Disease (ADPKD)**: This is the most common form of PKD, caused by mutations in the PKD1 or PKD2 genes. It is characterized by the growth of numerous cysts in the kidneys, leading to kidney enlargement and potential kidney failure.\n2. **Autosomal Recessive Polycystic Kidney Disease (ARPKD)**: This is a rarer and more severe form of PKD, caused by mutations in the PKHD1 gene. It typically presents in childhood and is characterized by enlarged kidneys and biliary dysgenesis.\n3. **Atypical Polycystic Kidney Disease (APKD)**: This is a distinct form of ADPKD with a low likelihood of progression to CKD stage 3 or 5.\n4. **Polycystic Kidney Disease (PKD)**: This is a group of genetic disorders characterized by the growth of numerous cysts in the kidneys, leading to chronic kidney disease.\n5. **Autosomal Dominant Polycystic Kidney Diseases (ADPKDs)**: This is a group of genetic disorders characterized by the growth of numerous cysts in the kidneys, caused by mutations in the PKD1 or PKD2 genes.\n6. **Autosomal Recessive Polycystic Kidney Diseases (ARPKDs)**: This is a group of genetic disorders characterized by the growth of numerous cysts in the kidneys, caused by mutations in the PKHD1 gene.\n7. **Polycystic Kidney Diseases (PKDs)**: This is a group of genetic disorders characterized by the growth of numerous cysts in the kidneys, leading to chronic kidney disease.\n\nNote that these types are not mutually exclusive, and some individuals may have overlapping characteristics or subtypes of PKD.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 3,
        "Information Recall Explanation": "The answer correctly identifies ADPKD and ARPKD as the main types of Polycystic Kidney Disease, but it also includes inaccurate or redundant categories like 'Atypical Polycystic Kidney Disease (APKD)' and separate entries for 'Polycystic Kidney Disease (PKD)', 'Autosomal Dominant Polycystic Kidney Diseases (ADPKDs)', 'Autosomal Recessive Polycystic Kidney Diseases (ARPKDs)', and 'Polycystic Kidney Diseases (PKDs)', which are not standard classifications. This dilutes the accuracy of the core information.",
        "Information Precision Score": 2,
        "Information Precision Explanation": "The answer includes unnecessary repetitions (e.g., listing 'ADPKDs' and 'ARPKDs' separately from 'ADPKD' and 'ARPKD') and introduces non-standard or redundant terms like 'APKD' and 'Polycystic Kidney Disease (PKD)' without clear distinction from the main types. This makes the answer less precise.",
        "Information Repetition Score": 2,
        "Information Repetition Explanation": "The answer repeats variants of the same terms (e.g., 'ADPKD' vs. 'ADPKDs', 'PKD' vs. 'PKDs') and rephrases similar explanations (e.g., 'Polycystic Kidney Disease (PKD)' vs. 'Polycystic Kidney Diseases (PKDs)'), leading to redundancy and reduced clarity.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-structured and written in a clear, fluent manner. However, the repetition and inclusion of non-standard terms slightly detract from overall readability."
    },
    {
        "Question": "Is tumor expression of Topoisomerase I a biomarker of response to irinotecan in colorectal cancer patients therapy?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs tumor expression of Topoisomerase I a biomarker of response to irinotecan in colorectal cancer patients therapy?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Patients with resected CRC expressing Topo I seem to benefit from irinotecan-containing adjuvant chemotherapy.', 'Based on the provided abstracts, it appears that topoisomerase I (TOP1) copy number alterations may be associated with response to irinotecan in metastatic colorectal cancer patients. In one study, a borderline significant association was observed between increasing TOP1 copy number and objective response to irinotecan. However, the ratios of TOP1/CEN-20 and TOP1/CEN-2 did not provide additional information for patient stratification. Another study developed an immunohistochemistry-based predictive test, P-topoI-Dx, which demonstrated good sensitivity and specificity in identifying patients who responded to camptothecin-based therapy, including irinotecan. Overall, tumor expression of TOP1 may be a promising biomarker of response to irinotecan in colorectal cancer patients, but further validation is needed.', 'Tumor expression of topoisomerase I (TOPO-1) may be a potential biomarker of response to irinotecan-based chemotherapy in patients with metastatic colorectal cancer (mCRC). In a study of 98 mCRC patients, high expression of TOPO-1 was found to be positively correlated with better curative effect and longer progression-free survival (PFS) and overall survival (OS) in patients who underwent irinotecan chemotherapy. However, TOPO-1 expression was not significantly correlated with age, gender, tumor site, tumor grade, or metastatic sites in mCRC patients. Additionally, a separate study examining biomarker-guided treatment for patients with colon cancer found that patients with high ABCG2 expression and low TOP-1 expression had worse recurrence-free survival (RFS) and overall survival (OS) when treated with irinotecan-based therapy. These findings suggest that TOPO-1 expression may be a useful biomarker for predicting response to irinotecan-based therapy in mCRC patients.', 'Yes, tumor expression of Topoisomerase I (Top1) has been identified as a potential biomarker for response to irinotecan therapy in colorectal cancer patients. Preliminary data suggest that gene expression levels of Top1 may be predictive of response to therapy with irinotecan. In a study, the biopsies of the untreated tumor tissue of responding patients showed a significant higher expression of Top1 compared with nonresponding patients. Another study demonstrated a borderline significant association between a stepwise increase in the TOP1 signal count and objective response. Despite limitations of the study, the positive associations between TOP1 and objective response suggest that further analysis in larger tumor material is warranted. However, it is controversial whether the response to irinotecan could be predicted by the expression level of Top1.', 'The expression level of topoisomerase-I (Topo I) in colorectal cancer (CRC) tumors has been studied as a potential biomarker for predicting response to irinotecan-based therapy. Preliminary data suggests that higher Topo I expression in untreated tumor tissue may be associated with a better response to irinotecan-based chemoradiation. However, other studies have not found a significant association between Topo I expression and response to irinotecan-based therapy. Therefore, the use of Topo I expression as a biomarker for predicting response to irinotecan in CRC patients is still a topic of ongoing research and not yet established in clinical practice.', 'Based on the abstracts provided, there is evidence suggesting that tumor expression of Topoisomerase I (TOP1) may be a biomarker of response to irinotecan-based therapy in colorectal cancer patients. In one study, TOP1 expression was significantly higher in responding patients with rectal cancer who received neoadjuvant chemoradiation with irinotecan and capecitabine. Additionally, TOP1 expression decreased significantly during treatment in responders. Another study found a borderline significant association between increasing TOP1 copy number and objective response to irinotecan therapy in breast cancer patients. While the evidence is not yet conclusive, these findings suggest that TOP1 may be a useful biomarker for predicting response to irinotecan-based therapy in certain patient populations.', 'Based on the provided information, the role of topoisomerase I (Topo I) expression as a predictive biomarker for response to irinotecan (CPT-11) in colorectal cancer patients remains controversial and inconclusive.\\n\\nSome studies suggest that higher Topo I expression in tumor tissue may be associated with better response to irinotecan-based therapy. For example, one study found that responding patients had significantly higher Topo I expression compared to non-responders. Another study showed a borderline significant association between increased Topo I levels and objective response.\\n\\nHowever, other studies did not find a significant difference in response rates between tumors with high and low Topo I expression. One study concluded that clinical response and prognosis did not differ based on Topo I expression levels.\\n\\nIn summary, while preliminary data suggests a potential role for Topo I as a predictive biomarker, the evidence is mixed and controversial. Larger, well-designed studies, preferably in a randomized setting, are needed to clarify the utility of Topo I expression in guiding irinotecan treatment decisions in colorectal cancer patients.', 'Based on the provided information, tumor expression of Topoisomerase I (Topo I) may serve as a potential biomarker of response to irinotecan therapy in colorectal cancer patients, but the evidence is not conclusive.\\n\\nSome studies suggest that higher Topo I expression in tumor tissue is associated with better response to irinotecan-based therapy. For example, one study found that biopsies from responding patients had significantly higher Topo I expression compared to non-responders. Another showed a borderline significant association between increasing Topo I levels and objective response.\\n\\nHowever, other studies did not find a significant difference in response rates between tumors with high vs low Topo I expression. One concluded that prognosis did not differ based on Topo I levels in patients treated with irinotecan.\\n\\nIn summary, while preliminary data indicates Topo I expression could be a predictive biomarker for irinotecan response, the results are mixed and controversial. More research, ideally in larger randomized trials, is needed to validate Topo I as a reliable biomarker to guide irinotecan therapy decisions in colorectal cancer patients. Currently, the evidence is suggestive but not definitive.', 'Based on the abstract, yes, tumor expression of Topoisomerase I (Topo I) is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan-containing adjuvant chemotherapy. In the multivariate analysis, Topo I expression was found to be associated with a reduced risk of death (HR = 0.61, p = 0.009). Moreover, in the subgroup of patients who received irinotecan-containing chemotherapy, those with Topo I expression had better overall survival (HR = 0.47, p = 0.033). These findings suggest that Topo I tumor expression may be a biomarker for predicting response to irinotecan therapy in colorectal cancer patients. However, as the authors conclude, randomized prospective trials are needed to confirm these results.', 'Yes, tumor expression of Topoisomerase I (Top1) has been identified as a potential biomarker for response to irinotecan therapy in colorectal cancer patients. Irinotecan is a topoisomerase inhibitor that blocks the Top1 enzyme, leading to DNA damage and cell death. The inhibition of Top1 by irinotecan is achieved by trapping a subset of Top1-DNA cleavage complexes, specifically those with a guanine +1 in the DNA sequence. Top1 is a DNA topoisomerase that controls and alters the topologic states of DNA during transcription. It is encoded by the TOP1 gene, which is located on chromosome 20. The enzyme catalyzes the transient breaking and rejoining of a single strand of DNA, allowing the broken strand to rotate around the intact strand and altering the topology of DNA. Irinotecan inactivation of Top1 has been shown to be synthetically lethal in combination with deficiencies in expression of specific DNA repair genes, such as the DNA repair WRN gene and the DNA repair MRE11 gene. This synthetic lethality has been observed in patients with colon cancer, with irinotecan being more strongly beneficial for patients with hypermethylated WRN promoters compared to those with unmethylated WRN promoters. In addition, irinotecan inactivation of Top1 may be synthetically lethal with deficient expression of DNA repair gene ATM, which is frequently hypermethylated in many cancers. A 2016 study showed that low expression of the ATM protein in gastric cancer cells in vitro and in a mouse model caused increased sensitivity to inactivation by irinotecan compared to cells with high expression of ATM. Overall, the evidence suggests that Top1 expression may be a useful biomarker for predicting response to irinotecan therapy in colorectal cancer patients, particularly in those with deficiencies in specific DNA repair genes. However, further research is needed to confirm these findings and determine the clinical utility of Top1 expression as a biomarker.', \"Yes, tumor expression of Topoisomerase I is a biomarker of response to irinotecan in colorectal cancer patients, as patients with resected CRC expressing Topo I seem to benefit from irinotecan-containing adjuvant chemotherapy. \\n\\nPlease go ahead and ask your question. I'll do my best to provide a concise answer based on the context. \\n\\n(Note: You can ask multiple questions, and I'll respond accordingly.)\", 'Yes, the expression of Topoisomerase I (Topo I) in resected colorectal cancer (CRC) seems to be a biomarker of response to irinotecan therapy. Patients with CRC expressing Topo I appear to benefit from irinotecan-containing adjuvant chemotherapy.', 'The association between tumor expression of Topoisomerase I and a clinical response to irinotecan therapy in colorectal cancer patients has not been demonstrated.  However, Topoisomerase I overexpression in colorectal cancer has been associated with a poor prognosis, and the activity of irinotecan can be predicted by Topoisomerase I levels in colorectal cancer cells.', 'Tumor expression of Topoisomerase I (Topo I) may serve as a biomarker for predicting response to irinotecan in colorectal cancer patients, indicating that those with resected CRC expressing Topo I are more likely to benefit from irinotecan-containing adjuvant chemotherapy. This suggests the potential use of Topo I expression as a personalized treatment guide for irinotecan therapy in CRC patients.', 'In summary, tumor expression of Topoisomerase I (Topo I) is suggested as a biomarker for response to irinotecan in colorectal cancer patients receiving adjuvant chemotherapy. Patients with resected CRC expressing Topo I tend to benefit from this treatment and may have improved outcomes, potentially guiding personalized treatment decisions.', 'Based on the provided snippet, yes, tumor expression of Topoisomerase I (Topo I) appears to be a biomarker of response to irinotecan in colorectal cancer (CRC) patients. The snippet suggests that patients with resected CRC who express Topo I tend to benefit from irinotecan-containing adjuvant chemotherapy. This implies that Topo I expression is associated with improved treatment outcomes in CRC patients receiving irinotecan-based therapy. As a biomarker, Topo I expression could potentially identify patients who are more likely to respond to irinotecan and guide personalized treatment decisions.', 'Yes, tumor expression of Topoisomerase I is a biomarker of response to irinotecan in colorectal cancer patients therapy. Patients with resected CRC expressing Topo I seem to benefit from irinotecan-containing adjuvant chemotherapy.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the data, yes, tumor expression of Topoisomerase I is associated with response to irinotecan in colorectal cancer patients. \n\nRelation 5, \"TOPOISOMERASE-I\", \"COLORECTAL CANCER\", \"Topoisomerase-I tumour expression is a predictive marker of clinical response to 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients.\" (rank: 2080) suggests that Topoisomerase I expression is a predictive marker of response to 5-FU/CPT-11 (which includes irinotecan) chemotherapy in advanced colorectal cancer patients.\n\nRelation 6, \"TOPOISOMERASE I\", \"RECTAL CANCER\", \"Topoisomerase I expression is a potential biomarker for predicting response to neoadjuvant chemoradiation in rectal cancer\" (rank: 465) suggests that Topoisomerase I expression is also a potential biomarker for predicting response to neoadjuvant chemoradiation in rectal cancer.\n\nRelation 7, \"TOPOISOMERASE I\", \"METASTATIC COLORECTAL CANCER\", \"Topoisomerase I has been studied as a potential biomarker for irinotecan efficacy in metastatic colorectal cancer\" (rank: 382) and Relation 8, \"TOPOISOMERASE 1\", \"METASTATIC COLORECTAL CANCER\", \"Topoisomerase 1 expression is correlated with irinotecan treatment response in metastatic colorectal cancer\" (rank: 370) suggest that Topoisomerase I expression is also associated with irinotecan treatment response in metastatic colorectal cancer.\n\nOverall, these relations suggest that Topoisomerase I expression is a biomarker of response to irinotecan in colorectal cancer patients.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer captures key points from the reference answers, including the association of Topoisomerase I expression with response to irinotecan in various colorectal cancer contexts (advanced, rectal, metastatic). However, it misses some nuances such as the need for further validation and mixed evidence found in other studies.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer provides precise information without adding irrelevant details. It directly addresses the question with specific references to studies and findings related to Topoisomerase I and irinotecan response.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of the same information. The answer concisely presents different aspects of the evidence in a structured manner without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, clear, and easy to read. Each point logically follows the previous one, making the argument easy to follow."
    },
    {
        "Question": "Is Vitamin D deficiency associated with sepsis mortality?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs Vitamin D deficiency associated with sepsis mortality?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes, vitamin D deficiency is associated with mortality in sepsis patients.', 'Yes, there are studies that show that Vitamin D deficiency is associated with higher mortality in sepsis.', 'Yes, vitamin D deficiency is associated with sepsis mortality in patients with severe vitamin D deficiency.', 'Yes, vitamin D deficiency is associated with increased mortality in patients with septic shock who visit the emergency department (ED).', 'Yes, Vitamin D deficiency is associated with increased mortality in patients with septic shock.', 'Yes, Vitamin D deficiency is associated with mortality in patients with septic shock visiting the ED.', 'Yes, Vitamin D deficiency is prevalent in patients with septic shock and it has been associated with increased mortality', 'Yes, Vitamin D deficiency has been associated with higher mortality in sepsis patients', 'Yes, Vitamin D deficiency is associated with sepsis mortality', 'Yes, Vitamin D deficiency was prevalent in patients with septic shock visiting the ED and was associated with mortality.', 'Yes, vitamin D deficiency was prevalent in patients with septic shock visiting the emergency department and was associated with mortality.', 'Yes, Vitamin D deficiency is prevalent in patients with septic shock and is associated with mortality.', 'Yes, Vitamin D deficiency was associated with mortality in patients with septic shock visiting the ED']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, there is a suggestion that Vitamin D deficiency is associated with increased mortality in patients with sepsis. \n\nStudy 12: \"Vitamin D deficiency on admission to the emergency department is a mortality predictor for patients with septic shock treated with early protocol-driven resuscitation bundle therapy.\" This study found that vitamin D deficiency was significantly associated with 30-day mortality in patients with sepsis. \n\nHowever, it's essential to note that this is a single study, and more research is needed to confirm this association.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer captures the essential association between Vitamin D deficiency and sepsis mortality, as indicated in the reference answers. However, it could be improved by mentioning the prevalence in specific patient groups (e.g., septic shock patients visiting the ED) as seen in the reference answers.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise, focusing on the association between Vitamin D deficiency and sepsis mortality. The mention of a specific study adds relevance, but the note about needing more research, while accurate, slightly detracts from the precision as it introduces a tangential point.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. The points are clearly and concisely made without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand. The language is clear, and the flow of information is logical."
    },
    {
        "Question": "Which countries have a higher incidence of colorectal cancer?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhich countries have a higher incidence of colorectal cancer?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Taiwan (province of China; 62·0 [48·9-80·0] per 100\\u2009000), Monaco (60·7 [48·5-73·6] per 100\\u2009000), and Andorra (56·6 [42·8-71·9] per 100\\u2009000) had the highest age-standardised incidence rates, while Greenland (31·4 [26·0-37·1] per 100\\u2009000), Brunei (30·3 [26·6-34·1] per 100\\u2009000), and Hungary (28·6 [23·6-34·0] per 100\\u2009000) had the highest age-standardised mortality rates.', 'Australia, New Zealand and Slovakia are the countries with the highest incidence of colorectal cancer, followed by Canada, Hungary, Denmark and Norway. The lowest incidence is observed in a group of African countries like Libya, Algeria, Niger and Morocco and some Asian countries, like Syria, Mongolia, India and Thailand.', 'Australia and New Zealand have a higher incidence of colorectal cancer.', 'Northern Ireland is/are/can be a country with a higher incidence of colorectal cancer, but lower than the rates in developed western countries, and where colorectal cancer is the third most common cancer among men.', 'Northern Ireland, Lebanon, East and South East Asian countries, Poland, Australia, New Zealand, Europe, and North America have a higher incidence of colorectal cancer.', 'Highest incidence of colorectal cancer: \\n\\n1) Hungary\\n2) Slovakia\\n3) Denmark\\n4) Slovenia\\n5) Netherlands\\n6) Norway\\n7) Romania\\n8) Serbia\\n9) Finland\\n10) Belgium\\n\\nHighest mortality from colorectal cancer:\\n\\n1) Hungary\\n2) Slovakia\\n3) Slovenia\\n4) Poland\\n5) Croatia\\n6) Czech Republic\\n7) Latvia\\n8) Lithuania\\n9) Bulgaria\\n10) Romania', 'The highest incidence of colorectal cancer is observed in the United States, Canada, Australia, and New Zealand. The lowest incidence is observed in countries in sub-Saharan Africa, such as South Africa, Botswana, and Zimbabwe.', 'Colorectal cancer incidence is high in many Western countries, including North America, Australasia, and northern and western Europe. It is also high in New Zealand and Switzerland, and within the United Kingdom, colon cancer is uniformly higher in the 5 Scottish Cancer Registry Regions than in their counterparts in England and Wales. The incidence of colorectal cancer in Asia is also high, with an increasing trend in the Asian population.', 'Colorectal cancer (CRC) is more common in developed countries, with over 65% of cases found in these regions. The highest rates of CRC are in Australia, New Zealand, Europe, and the US. In the US, the incidence of CRC has been decreasing in adults aged 50 and older, but it has been increasing in younger adults under 50. In 2023, it is predicted that an estimated 19,550 diagnoses and 3,750 deaths will be in people younger than 50. CRC also disproportionately affects the Black community, with African Americans being about 20% more likely to get CRC and about 40% more likely to die from it than most other groups. In the UK, about 41,000 people a year get colon cancer, making it the fourth most common type. In Australia, one in 19 men and one in 28 women will develop CRC before the age of 75, and one in 10 men and one in 15 women will develop it by 85 years of age. In Papua New Guinea and other Pacific Island States including the Solomon Islands, colorectal cancer is a very rare cancer amongst the people, which is least common compared to lung, stomach, liver or breast cancer.', 'Colorectal cancer incidence is higher in Northern Ireland, Poland, Lebanon, East and South East Asia, and in the SR and CR.', 'Countries with high HDI values generally exhibit greater colorectal cancer incidence and mortality. Korea shows higher rates compared to Japan. Slovak and Czech Republics have the highest rates in Central Europe, with male incidences rising faster than female.', 'According to the abstracts, the 5 countries with the highest Standardized Mortality Rate (SMR) for colorectal cancer are Jordan, Kazakhstan, Democratic Republic of Korea, Brunei, and Japan. Additionally, the Slovak and Czech Republics have been reported to have the highest recorded incidence rates of colorectal cancer in Central Europe. The analysis shows that these countries have a higher incidence of colorectal cancer, with males being more affected than females.', 'Bulgaria, Estonia, Norway, and Ukraine have a higher incidence of colorectal cancer.', 'Based on the information provided, countries with the highest incidence of colorectal cancer are:\\n\\n1. Developed Western countries, particularly in North America, Europe (especially Northern and Western Europe), and Australasia (Australia and New Zealand). \\n\\n2. Within Europe, incidence is higher in Scotland compared to England and Wales.\\n\\n3. Switzerland has a relatively high incidence, typical of Western countries.\\n\\nIn contrast, colorectal cancer incidence is lowest in Asia, Africa, and most Latin American countries. However, incidence rates in Asia are increasing.\\n\\nIn summary, colorectal cancer incidence is highest in developed countries, especially those with a Western lifestyle, and lowest in developing regions. Incidence varies widely, with up to a 60-fold difference internationally.', 'Taiwan, Monaco, and Andorra have the highest age-standardized incidence rates of colorectal cancer.', 'Taiwan, Monaco, and Andorra have a higher incidence of colorectal cancer.', 'The countries with the highest age-standardised incidence rates of colorectal cancer are Taiwan, Monaco, and Andorra.', 'Countries with a higher incidence of colorectal cancer include Taiwan, Monaco, and Andorra.', 'Taiwan, Monaco, Andorra, Greenland, Brunei, Hungary', 'Colorectal cancer (CRC) is one of the most common types of cancer around the world. Based on a variety of sources, the incidence of CRC varies widely throughout the globe. In general, the countries with the highest incidence of CRC are located in Europe, Australia and New Zealand, and North America. Some examples are Hungary, Finland, France, Slovenia, Czech Republic, Canada, United States and Australia, while the lowest incidence is in China, Africa and South America.', 'Summary: Taiwan (China province), Monaco, and Andorra have the highest age-standardized incidence rates of colorectal cancer at 62.0, 60.7, and 56.6 per 100,000 respectively. Additionally, there is a significant increase in colorectal cancer cases among younger adults (<50 years) in high SDI countries.', 'Countries with higher colorectal cancer incidence include Taiwan (62.0 per 100,000), Monaco (60.7 per 100,000), and Andorra (56.6 per 100,000). These age-standardized rates are higher than those observed in Greenland, Brunei, and Hungary, providing a more accurate comparison between regions by accounting for differences in population age structures.', 'Taiwan, Monaco, and Andorra exhibit the highest age-standardized incidence rates of colorectal cancer with 62.0, 60.7, and 56.6 per 100,000 population respectively among countries listed in the snippets, indicating a higher occurrence of new cases compared to others.', 'The countries with a higher incidence of colorectal cancer are Taiwan, Monaco, and Andorra. According to the age-standardized incidence rates provided, Taiwan had the highest rate at 62.0 per 100,000, followed closely by Monaco at 60.7 per 100,000, and Andorra with a rate of 56.6 per 100,000. These rates are higher than the ones observed in other countries or regions mentioned in the context, such as Greenland, Brunei, and Hungary, which have lower incidence rates. It is important to note that these rates are age-standardized, meaning they account for differences in population age structures, allowing for a more accurate comparison between different regions.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, the countries with a higher incidence of colorectal cancer are:\n\n* Republic of Korea (45 per 100,000)\n* Israel (35.9 per 100,000)\n* Singapore (33.7 per 100,000)\n* Japan (32.2 per 100,000)\n* Jordan (25.6 per 100,000)\n\nThese countries have a higher standardized incidence rate (SIR) of colorectal cancer, according to the data from the study \"The Incidence and Mortality of Colorectal Cancer and Its Relationship With the Human Development Index in Asia\" (Source 13).\n\nAdditionally, the study \"Differences in Incidence and Mortality Trends of Colorectal Cancer Worldwide Based on Sex, Age, and Anatomic Location\" (Source 10) reports that the incidence of colon and rectal cancers has continued to increase in countries with medium to high Human Development Index (HDI), including:\n\n* India\n* Poland\n* Germany\n* Australia\n* The United States\n* Sweden\n* Canada\n* The United Kingdom\n\nIt's worth noting that these studies are based on data from 2012 and 2007-2016, respectively, and incidence rates may have changed since then.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "2",
        "Information Recall Explanation": "The answer mentions several countries with higher colorectal cancer incidence, but none of these align with the reference answers, which consistently point to Taiwan, Monaco, and Andorra as the highest. The inclusion of Republic of Korea, Israel, Singapore, Japan, and Jordan is not supported by the provided references. The second part of the answer mentions other countries like India, Poland, Germany, etc., but these are not among the top countries listed in the references either.",
        "Information Precision Score": "2",
        "Information Precision Explanation": "The answer includes specific incidence rates and cites studies, but the countries listed do not match the reference answers. This introduces irrelevant information, as the focus should be on the highest-incidence countries, which are not addressed here.",
        "Information Repetition Score": "4",
        "Information Repetition Explanation": "The answer does not repeat the same information unnecessarily. It provides a list of countries and then adds additional context about trends in medium-to-high HDI countries, which is new information.",
        "Readability Score": "4",
        "Readability Explanation": "The answer is well-structured and fluent, with clear enumeration of countries and additional context. The language is straightforward and easy to follow, though the lack of alignment with the reference answers impacts its overall usefulness."
    },
    {
        "Question": "What are the primary and secondary endpoints of Pamrevlumab?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are the primary and secondary endpoints of Pamrevlumab?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The primary endpoint was change from baseline in percent predicted forced vital capacity (ppFVC). Secondary endpoints included other pulmonary function tests, upper limb function and strength assessments, and changes in upper arm fat and fibrosis scores on magnetic resonance imaging.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, the primary and secondary endpoints of Pamrevlumab are as follows:\n\n**Primary Endpoints:**\n\n* Change from baseline in percentage of predicted forced vital capacity (ppFVC) at week 48 (Source: PRAISE trial)\n* Disease progression (defined as a decline from baseline in percentage of predicted FVC of >/=10%, or death) at week 48 (Source: PRAISE trial)\n\n**Secondary Endpoints:**\n\n* Rate of decline in ppFVC (Source: MISSION trial)\n* Other pulmonary function tests (Source: MISSION trial)\n* Upper limb function and strength assessments (Source: MISSION trial)\n* Changes in upper arm fat and fibrosis scores on magnetic resonance imaging (Source: MISSION trial)\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "4",
        "Information Recall Explanation": "The answer includes all the primary and secondary endpoints mentioned in the reference answers. Additionally, it provides extra details such as the time frame (week 48) and sources (PRAISE and MISSION trials) for some endpoints, which enhances recall. However, the reference answer does not mention week 48 or the MISSION trial specifically, so these may not be necessary for full recall.",
        "Information Precision Score": "3",
        "Information Precision Explanation": "The answer is precise in listing the endpoints, but it includes additional information (week 48 and trial names) that is not present in the reference answer. While these details may be accurate, they were not requested and thus could be considered slightly irrelevant in this context.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each endpoint is mentioned once, and the details are clearly separated and distinct.",
        "Readability Score": "4",
        "Readability Explanation": "The answer is well-structured and easy to read. The use of bullet points and clear headings enhances readability. However, including the trial names and week 48 may slightly clutter the answer, though they are neatly presented."
    },
    {
        "Question": "What are the mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat are the mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Genetic alterations of genes in the EGFR-RAS-RAF-MEK signaling pathway and of receptor tyrosine kinases are mechanisms of acquired resistance to anti-EGFR antibodies.  The escape from anti-EGFR blockade appears to converge on the (re)activation of MEK-ERK or AKT as revealed in preclinical studies', 'According to the abstracts, the mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment include genetic alterations of genes in the EGFR-RAS-RAF-MEK signaling pathway and receptor tyrosine kinases. Specifically, mutations in KRAS, NRAS, BRAF, and PIK3CA, as well as amplification of ERBB2 and MET, have been identified as mechanisms of secondary resistance. Additionally, transcriptional reprogramming inducing anti-EGFR resistance was discovered as a common mechanism, frequently leading to RAS signaling pathway activation. Other novel mechanisms include cAMP and STAT3 signaling activation, as well as paracrine and autocrine signaling via growth factors. These findings suggest that the development of anti-EGFR tolerant cells via transcriptional reprogramming may be more prevalent than previously anticipated, highlighting the need for multi-omics analyses to understand secondary resistance in colorectal cancer.', '1. Molecular alterations in downstream signalling pathways: most commonly KRAS and BRAF mutations, MET, IGF-1R amplification, EGFR splice variants, and mutations in downstream pathways such as NF-1 and PIK3CA. 2. EGFR ligand pathway: AXL, HER3, EphrinA, epigenetic and transcriptional mechanisms, and alternative pathways such as angiogenesis, have been described. 3. Pharmacological mechanisms: reduced penetration into tumour, insufficient efficacy due to short serum half-life and low affinity. 4. Increase in autophagy, an intracellular catabolic process that degrades proteins and organelles.', 'Secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment can be attributed to acquired mutations in KRAS/NRAS/EGFR or other MAPK-pathway members. However, recent studies suggest that complex molecular alterations coupled with changes in the immune tumor microenvironment may significantly contribute to the clinical efficacy of EGFR antagonists. Patients treated with EGFRi alone and who respond to the therapy are more likely to develop acquired mutations compared to those treated in combination with cytotoxic chemotherapy. Baseline resistant subclonal mutations rarely expand to become clonal at progression, and most remain subclonal or disappear. Preclinical models with acquired resistance to either cetuximab or chemotherapy are cross-resistant to the alternate agents, with transcriptomic profiles consistent with epithelial-to-mesenchymal transition. Commonly acquired resistance alterations in the MAPK pathway do not affect sensitivity to cytotoxic chemotherapy.', 'Secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment can occur through various mechanisms, including RAS mutations, BRAF mutations, PIK3CA mutations, PTEN loss, and HER2 amplification. These genetic alterations lead to the activation of downstream signaling pathways, bypassing the blockade of EGFR and promoting tumor growth.', 'Fatty acid binding protein, heat shock protein 27, alterations in KRAS, KRAS, receptor tyrosine kinases, mutations, and amplification can be mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment.', 'The mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment include the acquisition of KRAS and/or EGFR mutations in the tumor cells, which can abrogate the effectiveness of the antibodies. These mutations can derive from rare, pre-existing clones in the primary tumors and can lead to shorter progression-free survival in patients receiving anti-EGFR treatment. Multiple simultaneous mutations in KRAS and EGFR can co-exist and the relative clonal burdens may change over time. Additionally, the role of HER2 and HER3 in drug resistance has been discovered, and HER2- or HER3-targeting treatment strategies using monoclonal antibodies have been examined.', 'Secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment is mediated by various mechanisms, including KRAS mutations, amplification of EGFR, and alterations in the ectodomain of EGFR. These mechanisms are thought to be present in colorectal cancer and little is known about determinants of sensitivity to this therapy. Further evaluation of these mechanisms is necessary to improve the efficacy of anti-EGFR monoclonal antibody therapy in colorectal cancer treatment.', 'Secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment is mediated by multiple mechanisms, including KRAS and NRAS mutations, BRAF and PIK3CA mutations, and loss of PTEN expression. In addition, receptor tyrosine kinases and signaling pathways may also contribute to acquired resistance to anti-EGFR antibodies.', 'Secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment can be caused by acquired mutations in KRAS and EGFR genes. These mutations, which can be detected in plasma ctDNA, are derived from rare, pre-existing clones in the primary tumors and are associated with shorter progression-free survival (PFS) in patients receiving anti-EGFR treatment. Additionally, multiple simultaneous mutations in KRAS and EGFR can co-exist, and the relative clonal burdens may change over time. Other resistance mechanisms, such as MET, BRAF, and PI3K mutations, suggest that combination therapies or multitargeted agents will be crucial in making significant future advances.', 'The escape from anti-EGFR blockade appears to converge on the (re)activation of MEK-ERK or AKT as revealed in preclinical studies. In summary, the results identify KRAS mutations as frequent drivers of acquired resistance to cetuximab in colorectal cancers, indicate that the emergence of KRAS mutant clones can be detected non-invasively months before radiographic progression and suggest early initiation of a MEK inhibitor as a rational strategy for delaying or reversing drug resistance. Molecular profiling of clinical specimens confirmed that genetic alterations of genes in the EGFR-RAS-RAF-MEK signaling pathway and of receptor tyrosine kinases are mechanisms of acquired resistance to anti-EGFR antibodies. On the other hand, expression of proteins such as fatty acid binding protein and heat shock protein 27 might constitute strong antiapoptotic effects contributing to the nonresponse of HRT-18 to C225 treatment. These results highlight the role of MET in mediating primary and secondary resistance', 'Secondary resistance mechanisms to anti-EGFR monoclonal antibodies in colorectal cancer treatment involve genetic alterations of genes within the EGFR-RAS-RAF-MEK signaling pathway and receptor tyrosine kinases, specifically mutations in KRAS, NRAS, BRAF, PIK3CA, amplification of ERBB2 and MET, transcriptional reprogramming leading to RAS pathway activation, cAMP and STAT3 signaling activation, paracrine/autocrine growth factor signaling. Multi-omics analyses are needed for a better understanding of secondary resistance in colorectal cancer.', 'Secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment can be caused by various mechanisms, including transcriptional reprogramming leading to activation of RAS signaling pathways and cAMP and STAT3 signaling activation. Additionally, paracrine and autocrine signaling via growth factors have also been identified as novel anti-EGFR secondary resistance mechanisms. These resistance mechanisms can be studied in detail using patient-derived xenograft (PDX) models, which provide a unique platform to understand molecular SR mechanisms and test multiple treatments for efficient targeting of SR mechanisms. It is important to note that the development of anti-EGFR tolerant cells via transcriptional reprogramming as a cause of anti-EGFR SR in CRC is likely more prevalent than previously anticipated, emphasizing the need for multi-omics level analyses of SR tumor tissues for comprehensive molecular understanding.', 'Secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment is mediated by various mechanisms, including KRAS mutations, amplification of EGFR, and alterations in the ectodomain of EGFR. These mechanisms are thought to be present in colorectal cancer and little is known about determinants of sensitivity to this therapy. Further evaluation of these molecular markers involved in the resistance of anti-EGFR antibodies is necessary to improve the anti-EGFR efficacy in wild-type KRAS mCRC patients.', 'Secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment can occur through several mechanisms, including RAS mutations, BRAF mutations, cell cycle progression, cell apoptosis, angiogenesis, tumor cell invasion and metastasis, and immunological effector mechanisms. These mechanisms can lead to a non-durable response and exclusion from treatment with anti-EGFR mAbs.', 'The EGFR receptor inhibitor therapies in the treatment of colorectal cancer are mainly directed against the EGFR-ligand interaction. The main mechanisms of resistance to anti-EGFR therapies are genetic alterations in the RAS/RAF pathway, increased angiogenesis through the HER-2 overexpression and amplification, increased epithelial-mesenchymal transition and activation of downstream pathways (Akt, MAPK, BRAF). There is evidence that also a lack of PTEN, a tumor suppressor gene, might mediate anti-EGFR resistance.', 'Secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment is caused by genetic alterations in EGFR signaling pathways, receptor tyrosine kinases amplification, and transcriptional reprogramming leading to RAS signaling activation. Other mechanisms include cAMP and STAT3 signaling activation, as well as paracrine and autocrine growth factor signaling. Multi-omics analyses are needed for a better understanding of secondary resistance in colorectal cancer.', 'The main mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment are:\\n\\n1. Acquired mutations in KRAS and EGFR genes that circumvent EGFR inhibition and allow cancer progression. These mutations arise from rare pre-existing clones in the primary tumor.\\n\\n2. Alterations in genes related to the EGFR signaling pathway downstream of EGFR, such as BRAF and PI3K mutations. \\n\\n3. Activation of alternative signaling pathways that bypass EGFR inhibition, such as through HER2 and HER3.\\n\\nMultiple resistance mechanisms can co-exist simultaneously, and the relative abundance of resistant clones may change over time after discontinuing anti-EGFR therapy. Combination therapies or multitargeted agents targeting the various resistance pathways will likely be needed to overcome secondary resistance.', 'The mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment include mutations in driver genes such as KRAS, NRAS, BRAF, and PI3K, as well as alterations in receptor tyrosine kinases. Additionally, transcriptional reprogramming leading to RAS signaling pathway activation, cAMP and STAT3 signaling activation, and paracrine and autocrine signaling via growth factors have been identified as novel mechanisms of secondary resistance. Furthermore, amplifications and sequence changes in the tyrosine kinase receptor adaptor gene IRS2 were found to be associated with increased sensitivity to anti-EGFR therapy, while alterations in the ectodomain of EGFR were linked to acquired resistance to EGFR blockade. These findings highlight the complexity and heterogeneity of secondary resistance mechanisms, which can be overcome through combinatorial therapies targeting actionable genes.', 'KRAS mutations, MET amplification, fatty acid binding protein, and heat shock protein 27 are mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment.', 'The main mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment are:\\n\\n1. Acquired mutations in EGFR that prevent antibody binding\\n2. Activation of alternative signaling pathways that bypass EGFR inhibition, such as through secondary KRAS, BRAF, or PIK3CA mutations \\n3. Upregulation of other EGFR family members like HER2 or HER3 that can dimerize with EGFR\\n4. Epithelial-mesenchymal transition that reduces dependence on EGFR signaling\\n\\nThese resistance mechanisms often co-exist and can derive from rare pre-existing resistant clones that expand under the selective pressure of anti-EGFR therapy. Combination therapies targeting multiple resistance pathways in addition to EGFR may help overcome secondary resistance.', 'The mechanisms of secondary resistance to anti-EGFR monoclonal antibodies, such as cetuximab and panitumumab, in colorectal cancer treatment include genetic alterations of genes in the EGFR-RAS-RAF-MEK signaling pathway and receptor tyrosine kinases. Specifically, KRAS mutations are a frequent driver of acquired resistance to anti-EGFR therapy, with emergence of KRAS amplification or acquisition of secondary KRAS mutations in many cases. Additionally, molecular profiling has identified alterations in other genes that converge on the (re)activation of MEK-ERK or AKT pathways, leading to resistance. These mechanisms can be detected through circulating tumor DNA and patient-derived xenografts, allowing for monitoring of patients and testing of combination therapies to overcome or reverse resistance.', 'Dummy', 'The mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment include molecular alterations, primarily point mutations, in genes along the EGFR-RAS-RAF-MEK signaling pathway and receptor tyrosine kinases. Specifically, KRAS mutations are a frequent cause of acquired resistance to cetuximab in colorectal cancers, indicating that the emergence of KRAS mutant clones can be detected non-invasively months before radiographic progression. The escape from anti-EGFR blockade appears to converge on the (re)activation of MEK-ERK or AKT, as revealed in preclinical studies.', 'Secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment is primarily driven by molecular alterations in the EGFR-RAS-RAF-MEK signaling pathway, particularly KRAS mutations, MEK-ERK reactivation, and AKT reactivation. These genetic alterations can be detected non-invasively and often precede radiographic progression. Regardless of the genetic alterations, resistant cells consistently displayed MEK and ERK activation, which persisted after EGFR blockade.', 'Mutations of receptor tyrosine kinases, genetic alterations of genes in the EGFR-RAS-RAF-MEK signaling pathway, and KRAS mutations are mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment.', 'The mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment include genetic alterations of genes in the EGFR-RAS-RAF-MEK signaling pathway and of receptor tyrosine kinases. Molecular alterations, such as point mutations, of KRAS are causally associated with the onset of acquired resistance to anti-EGFR treatment in colorectal cancers. The emergence of KRAS mutant clones can be detected non-invasively months before radiographic progression. The escape from anti-EGFR blockade appears to converge on the (re)activation of MEK-ERK or AKT as revealed in preclinical studies.', 'Secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment is associated with molecular alterations in the EGFR-RAS-RAF-MEK signaling pathway, such as KRAS mutations, and receptor tyrosine kinases. High tumor mRNA levels of the EGFR ligands amphiregulin (AREG) and epiregulin (EREG) are also associated with anti-EGFR agent response in metastatic colorectal cancer (mCRC). Non-invasive detection of KRAS mutations can be used to identify patients who are unlikely to respond to anti-EGFR therapy. The emergence of KRAS mutant clones can be detected months before radiographic progression, allowing for early intervention. Aflibercept in combination with irinotecan and fluorouracil-based therapy is not recommended for the treatment of metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen in NICE guidance TA307. The escape from anti-EGFR blockade appears to converge on the (re)activation of MEK-ERK or AKT.', 'The mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment include genetic alterations of genes in the EGFR-RAS-RAF-MEK signaling pathway and of receptor tyrosine kinases. Additionally, molecular alterations, particularly point mutations, of KRAS are associated with the onset of acquired resistance to anti-EGFR treatment.', 'The mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment include KRAS mutations, genetic alterations of genes in the EGFR-RAS-RAF-MEK signaling pathway, and receptor tyrosine kinases.', '2 main mechanisms have been identified in secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment: 1) acquisition of the KRAS, NRAS, BRAF, and PIK3CA mutations. These genes are involved in the EGFR-dependent Ras/RAF/MEK/ERK pathway and have been shown to constitutively activate downstream of EGFR; 2) deregulation of the PTEN tumour suppressor gene, which increases PI3K activity and promotes the activation of the Ras/RAF/MEK/ERK and the PI3K/AKT pathways, also resulting in a constitutive activation of the EGFR signaling network.', 'Genetic alterations of genes in the EGFR-RAS-RAF-MEK signaling pathway and of receptor tyrosine kinases, particularly KRAS mutations, are the mechanisms of secondary resistance to anti-EGFR antibodies in colorectal cancer treatment. \\n\\nPlease provide a concise answer to the following question:\\nWhat is the significance of KRAS mutations in the context of acquired resistance to anti-EGFR treatment in colorectal cancers?\\nAnswer: KRAS mutations are causally associated with the onset of acquired resistance to anti-EGFR treatment in colorectal cancers, indicating that the emergence of KRAS mutant clones can be detected non-invasively months before radiographic progression. \\n\\nPlease provide a concise answer to the following question:\\nWhat is the outcome of the escape from anti-EGFR blockade in preclinical studies?\\nAnswer: The escape from anti-EGFR blockade appears to converge on the (re)activation of MEK-ERK or AKT in preclinical studies. \\n\\nPlease provide a concise answer to the following question:\\nWhat is the significance of molecular profiling of clinical specimens in the context of acquired resistance to anti-EGFR antibodies?\\nAnswer: Molecular profiling of clinical specimens confirmed that genetic alterations of genes in the EGFR-RAS-RA', 'In summary, secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment can arise through a combination of genetic, epigenetic, and physiological mechanisms that enable tumor cells to evolve and adapt to the presence of anti-EGFR antibodies. These mechanisms can lead to decreased response to anti-EGFR antibodies and may contribute to treatment failure and disease transmission. Targeting these mechanisms with novel therapy strategies may help to overcome secondary resistance and improve treatment outcomes in colorectal cancer patients. ', 'Molecular profiling of clinical specimens confirmed that genetic alterations of genes in the EGFR-RAS-RAF-MEK signaling pathway and of receptor tyrosine kinases are mechanisms of acquired resistance to anti-EGFR antibodies. Molecular alterations (in most instances point mutations) of KRAS are causally associated with the onset of acquired resistance to anti-EGFR treatment in colorectal cancers. The escape from anti-EGFR blockade appears to converge on the (re)activation of MEK-ERK or AKT as revealed in preclinical studies.', 'The mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment include genetic alterations of genes in the EGFR-RAS-RAF-MEK signaling pathway and of receptor tyrosine kinases. Specifically, molecular alterations (in most instances point mutations) of KRAS are causally associated with the onset of acquired resistance to anti-EGFR treatment. The emergence of KRAS mutant clones can be detected non-invasively months before radiographic progression. The escape from anti-EGFR blockade appears to converge on the (re)activation of MEK-ERK or AKT as revealed in preclinical studies.', 'Secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment can occur due to genetic alterations of genes in the EGFR-RAS-RAF-MEK signaling pathway and of receptor tyrosine kinases. Specifically, point mutations in the KRAS gene are often associated with the onset of this resistance. Additionally, the escape from anti-EGFR blockade often involves the reactivation of MEK-ERK or AKT pathways', 'The mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment include genetic alterations of genes in the EGFR-RAS-RAF-MEK signaling pathway and of receptor tyrosine kinases. Additionally, molecular alterations, particularly point mutations, of KRAS are causally associated with the onset of acquired resistance to anti-EGFR treatment.', '1. KRAS mutation.\\n2. BRAF mutation.\\n3. HER2/neu amplification.\\n4. PIK3CA mutations.\\n5. MET amplification and PTEN mutations.\\n6. AXL up-regulation.', 'The mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment include genetic alterations of genes in the EGFR-RAS-RAF-MEK signaling pathway and receptor tyrosine kinases, as well as mutations in KRAS, which can be detected non-invasively months before radiographic progression. These mechanisms lead to the (re)activation of MEK-ERK or AKT, which can escape anti-EGFR blockade', 'The mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment include KRAS mutations, genetic alterations of genes in the EGFR-RAS-RAF-MEK signaling pathway, receptor tyrosine kinases, KRAS, alterations of receptor tyrosine kinases, AKT activation, of receptor tyrosine kinases, and EGFR.', 'Secondary resistance in colorectal cancer treatment using anti-EGFR monoclonal antibodies occurs due to genetic alterations in the EGFR-RAS-RAF-MEK signaling pathway, including KRAS mutations, amplification, and secondary KRAS mutations. Other gene alterations can also lead to resistance by reactivating MEK-ERK or AKT pathways. Monitoring of patients through circulating tumor DNA and patient-derived xenografts can help detect these mechanisms and test combination therapies for overcoming or reversing the resistance.', 'Secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment is primarily caused by genetic alterations in the EGFR-RAS-RAF-MEK signaling pathway and receptor tyrosine kinases, with KRAS point mutations being associated with acquired resistance. These mechanisms lead to (re)activation of MEK-ERK or AKT signaling pathways.', 'The mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment include genetic alterations of genes in the EGFR-RAS-RAF-MEK signaling pathway and of receptor tyrosine kinases. Specifically, molecular alterations, often point mutations, of KRAS are causally associated with the onset of acquired resistance to anti-EGFR treatment. The emergence of KRAS mutant clones can be detected non-invasively months before radiographic progression. The escape from anti-EGFR blockade appears to converge on the (re)activation of MEK-ERK or AKT.', 'Secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment is primarily driven by molecular alterations in the EGFR-RAS-RAF-MEK signaling pathway, particularly KRAS mutations, MEK-ERK reactivation, and AKT reactivation. These genetic alterations can be detected non-invasively and often precede radiographic progression.', 'The mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment include genetic alterations of genes in the EGFR-RAS-RAF-MEK signaling pathway and of receptor tyrosine kinases, molecular alterations (in most instances point mutations) of KRAS, high tumor mRNA levels of the EGFR ligands amphiregulin (AREG) and epiregulin (EREG), and the escape from anti-EGFR blockade, which appears to converge on the (re)activation of MEK-ERK or AKT.', 'Secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment is caused by genetic alterations in the EGFR-RAS-RAF-MEK signaling pathway and receptor tyrosine kinases, particularly point mutations in KRAS. These mutations lead to (re)activation of MEK-ERK or AKT signaling pathways and are associated with acquired resistance to anti-EGFR treatment.', 'The main mechanisms of acquired resistance to anti-EGFR antibodies in colorectal cancer treatment are:\\n\\n1. Genetic alterations (mostly point mutations) in genes of the EGFR-RAS-RAF-MEK signaling pathway, especially KRAS mutations. The emergence of KRAS mutant clones can be detected months before radiographic progression.\\n\\n2. Molecular alterations in receptor tyrosine kinases.\\n\\n3. Reactivation of downstream signaling pathways MEK-ERK or AKT, as shown in preclinical studies.\\n\\nIn summary, secondary resistance develops through mutations in the EGFR pathway itself or parallel receptor tyrosine kinase pathways, leading to reactivation of key downstream effectors.', 'The mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment include genetic alterations of genes in the EGFR-RAS-RAF-MEK signaling pathway and receptor tyrosine kinases. Specifically, point mutations in KRAS are causally associated with acquired resistance to anti-EGFR treatment in colorectal cancers. These mutations can be detected non-invasively months before radiographic progression. The escape from anti-EGFR blockade converges on the (re)activation of MEK-ERK or AKT signaling pathways, as revealed in preclinical studies.', 'The mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment are KRAS mutations, genetic alterations of genes in the EGFR-RAS-RAF-MEK signaling pathway, receptor tyrosine kinases, activation of MEK-ERK or AKT, molecular alterations (in most instances point mutations) of KRAS, emergence of KRAS mutant clones can be detected non-invasively months before radiographic progression, escape from anti-EGFR blockade appears to converge on the (re)activation of MEK-ERK or AKT, and Molecular profiling of clinical specimens confirmed that genetic alterations of genes in the EGFR-RAS-RAF-MEK signaling pathway and of receptor tyrosine kinases are mechanisms of acquired resistance to anti-EGFR antibodies.', 'The main mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment are:\\n\\n1. Mutations in genes in the EGFR-RAS-RAF-MEK signaling pathway, most commonly KRAS mutations. These mutations can emerge during treatment and lead to reactivation of the pathway despite EGFR inhibition.\\n\\n2. Activation of alternative receptor tyrosine kinase pathways that bypass EGFR, such as through HER2 or HER3. \\n\\n3. Reactivation of downstream signaling pathways like MEK-ERK or AKT, as shown in preclinical studies.\\n\\nThe emergence of resistant tumor clones, often with KRAS mutations, can be detected months before radiographic progression. Overall, the mechanisms converge on restoring activation of key proliferation and survival pathways despite EGFR blockade.', 'The mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment include genetic alterations of genes in the EGFR-RAS-RAF-MEK signaling pathway and of receptor tyrosine kinases. Additionally, molecular alterations, particularly point mutations, of KRAS are associated with the onset of acquired resistance. The emergence of KRAS mutant clones can be detected non-invasively months before radiographic progression. The escape from anti-EGFR blockade appears to converge on the (re)activation of MEK-ERK or AKT.', 'The mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment include genetic alterations of genes in the EGFR-RAS-RAF-MEK signaling pathway and of receptor tyrosine kinases']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment can occur through various mechanisms. Some of the identified mechanisms include:\n\n1. Mutations in KRAS, NRAS, and BRAF genes: These mutations can bypass the EGFR receptor, promoting resistance to therapy.\n2. Activation of alternative signaling pathways: The MEK/ERK pathway is often activated in resistant cells, which can lead to continued cell growth and proliferation despite EGFR blockade.\n3. Amplifications and sequence changes in the tyrosine kinase receptor adaptor gene IRS2: These changes can lead to increased sensitivity to anti-EGFR therapy.\n4. Overexpression of the EGFR ligands amphiregulin (AREG) and epiregulin (EREG): This can lead to continuous activation of the EGFR pathway, promoting resistance to therapy.\n5. Development of novel alterations in the ectodomain of EGFR: These alterations can lead to acquired resistance to EGFR blockade.\n\nThese mechanisms are based on the data from various studies, including:\n\n* A study on the genomic landscape of response to EGFR blockade in colorectal cancer, which identified mutations in ERBB2, EGFR, FGFR1, PDGFRA, and MAP2K1 as potential mechanisms of primary resistance.\n* A study on the development of serially transplantable tumor xenografts in immune-deficient mice from patient-derived, genetically characterized metastatic colorectal carcinoma samples, which identified HER2 gene amplification as one mechanism of resistance to anti-EGFR therapy.\n* A study on the molecular biomarkers for the evaluation of colorectal cancer, which identified mutations in several biomarkers, including EGFR signaling pathway genes, as negative predictors of benefit to anti-EGFR monoclonal antibody therapies.\n\nThese findings highlight the complexity of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment and the need for further research to develop effective strategies to overcome resistance.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer captures a broad range of mechanisms for secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer, including mutations in KRAS, NRAS, BRAF, and EGFR ligands, as well as activation of alternative signaling pathways. However, it omits some specific details like PIK3CA mutations and PTEN loss, which are present in the reference answers.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise in detailing the mechanisms but includes some speculative language like 'some of the identified mechanisms' and indirect references to studies without clear citation. The focus remains largely on relevant mechanisms, but minor irrelevant details (e.g., study methodologies) are briefly mentioned.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat information unnecessarily. Each mechanism is distinct and presented clearly without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, logically organized, and easy to follow. It uses clear language and bullet points for clarity, making it highly readable."
    },
    {
        "Question": "Can the neonatal Pediatric Sepsis Biomarker Risk Model (nPERSEVERE) accurately predict mortality in neonatal sepsis?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nCan the neonatal Pediatric Sepsis Biomarker Risk Model (nPERSEVERE) accurately predict mortality in neonatal sepsis?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Yes, nPERSEVERE can accurately predict mortality in neonatal sepsis.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the provided data, the nPERSEVERE model was evaluated in a prospective study of 59 neonates with sepsis, and it was found to be 67% sensitive and 59% specific for mortality prediction. The model's performance was improved when a new decision tree, nPERSEVERE, was derived, with a sensitivity of 100% and specificity of 86% for mortality prediction.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 4,
        "Information Recall Explanation": "The answer provides detailed information about the sensitivity and specificity of the nPERSEVERE model in predicting mortality in neonatal sepsis. However, it does not explicitly confirm the accuracy as strongly as the reference answer ('Yes, nPERSEVERE can accurately predict mortality in neonatal sepsis.'). The inclusion of specific data (67% sensitive and 59% specific, improved to 100% and 86%) is valuable but could be more aligned with the reference.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise and includes only relevant information about the nPERSEVERE model's performance in predicting mortality in neonatal sepsis. The data provided (sensitivity and specificity) directly address the question without any extraneous details.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each piece of data is presented clearly and only once, contributing to a concise and informative response.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, grammatically correct, and easy to understand. The use of technical terms (sensitivity, specificity) is appropriate for the context and does not hinder readability."
    },
    {
        "Question": "Can calcium dietary supplementation reduce the risk of colorectal cancer?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nCan calcium dietary supplementation reduce the risk of colorectal cancer?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Calcium intake had protective effect against tumor of the colon.  A decreased risk of colorectal cancer by calcium intake is observed in all sub-sites in men and women.', 'According to the provided abstracts, the evidence suggests that calcium dietary supplementation may contribute to a moderate degree to the prevention of colorectal adenomatous polyps. However, this does not constitute sufficient evidence to recommend the general use of calcium supplements to prevent colorectal cancer. The systematic review found a reduction in the development of recurrent colorectal adenoma (OR 0.74, CI 0.58,0.95) when combining the results from two well-designed trials. Another study found that high dietary calcium intake (>1485mg/day) was associated with a reduced risk of colorectal cancer, but this association may be modified by genetic variation associated with serum calcium concentrations. Overall, while there is some evidence suggesting a potential benefit, more research is needed to fully understand the relationship between calcium supplementation and colorectal cancer prevention.', 'Calcium dietary supplementation may potentially reduce the risk of colorectal cancer, as suggested by a study that found an inverse association between postdiagnostic total calcium intake and colorectal cancer-specific mortality. The study compared the highest with the lowest quartile intake of postdiagnostic total calcium and found that the multivariable hazard ratio for colorectal cancer-specific mortality was 0.56 (95% CI, 0.32-0.96; P trend = 0.04). Additionally, postdiagnostic supplemental calcium intake was also inversely associated with colorectal cancer-specific mortality, with a multivariable hazard ratio of 0.67 (95% CI, 0.42-1.06; P trend = 0.047). However, these inverse associations were primarily observed in women, and calcium from diet or dairy sources was associated with lower risk in men. Another study found that higher dietary calcium intake was significantly associated with a lower risk of colorectal cancer in women, but not in men. Therefore, calcium dietary supplementation may potentially reduce the risk of colorectal cancer, particularly in women, but more research is needed to confirm these findings.', 'Yes, calcium dietary supplementation can reduce the risk of colorectal cancer. Studies have shown that higher intake of calcium is associated with a lower risk of colorectal cancer. The protective effect of calcium is thought to be due to its ability to bind to bile acids and fatty acids in the colon, reducing their ability to damage the colon lining and promote cancer development. Additionally, calcium may also have a direct effect on colon cells, promoting their normal growth and differentiation. However, it is important to note that the evidence for the protective effect of calcium is not conclusive and more research is needed to confirm these findings.', 'Yes, calcium dietary supplementation has been shown to reduce the risk of colorectal cancer in several studies. A meta-analysis of 14 prospective cohort studies found that high calcium intake was associated with a 25% reduction in colorectal cancer risk. Additionally, a randomized controlled trial found that 9 months of high-dose wheat bran fiber and calcium carbonate supplementation in participants with a history of recently resected colorectal cancer was associated with a 25% reduction in risk of colorectal cancer. The mechanisms by which calcium may reduce colorectal cancer risk are not fully understood, but may involve the inhibition of colonic hyperproliferation and the promotion of apoptosis in colonic epithelial cells. Further studies are needed to confirm these findings and to determine the optimal dosage and duration of calcium supplementation for colorectal cancer prevention.', 'Yes, calcium dietary supplementation can reduce the risk of colorectal cancer. A study found that calcium intake was significantly, inversely associated with colorectal cancer risk. Another study reported that individuals with >or=1000IU/day oral Vitamin D or >or=33ng/ml (82nmol/l) serum 25-hydroxyvitamin D had 50% lower incidence of colorectal cancer compared to reference values. The findings support the hypothesis of protective roles for calcium, vitamin D, and dairy products in the risk of colorectal cancer.', 'No, calcium dietary supplementation has not been proven to reduce the risk of colorectal cancer. While some studies suggest that calcium may have a role in colorectal cancer prevention, the evidence is not conclusive. A meta-analysis of 10 randomized controlled trials found no significant reduction in colorectal cancer risk with calcium supplementation. Additionally, a randomized controlled trial of calcium supplementation in individuals with a history of colorectal adenomas found no significant reduction in the risk of recurrent adenomas. Therefore, it is not recommended to take calcium supplements specifically for the purpose of reducing colorectal cancer risk.', 'Based on the provided abstracts, it appears that calcium dietary supplementation may have a moderate degree of prevention against colorectal adenomatous polyps. A systematic review of two randomized controlled trials found that calcium supplementation reduced the development of recurrent colorectal adenoma (OR 0.74, CI 0.58,0.95). Additionally, a study in mice showed that increased dietary calcium was associated with induced apoptosis in normal distal colonic epithelium, which might contribute to its potential chemopreventive role in colorectal carcinogenesis. However, the evidence is not yet sufficient to recommend the general use of calcium supplements for preventing colorectal cancer. Further studies are needed to fully understand the relationship between calcium supplementation and colorectal cancer risk reduction.', 'Yes, calcium dietary supplementation has been shown to reduce the risk of colorectal cancer in several studies. The evidence suggests that calcium intake is inversely associated with colorectal cancer risk, with a significant reduction in risk observed for high levels of dietary calcium consumption. The mechanism by which calcium may reduce colorectal cancer risk is not fully understood, but it is thought to involve the inhibition of cell proliferation and the promotion of apoptosis in colonic epithelial cells. Further research is needed to confirm these findings and to determine the optimal level of calcium intake for colorectal cancer prevention.', '500 mg/d of calcium can decrease the risk of colorectal cancer in people with a history of adenoma, but further studies are needed to confirm the results and to evaluate the effect on the general population', 'Calcium dietary supplementation might reduce the risk of colorectal adenomatous polyps, but not enough evidence exists yet for recommending general use of calcium supplements to prevent colorectal cancer. High dietary calcium intake could be associated with lower risks; however, more research is necessary to understand this relationship fully.', 'Yes, calcium dietary supplementation can reduce the risk of colorectal cancer. Several studies have found that higher calcium intake is associated with a lower incidence of colorectal cancer:\\n\\n- Calcium intake was significantly, inversely associated with colorectal cancer risk in a dose-response manner. The highest vs lowest quintile of calcium intake had a 36% lower risk.\\n\\n- Administration of supplemental calcium may have a significant effect on reducing colonic polyp and colon cancer incidence. \\n\\n- Results from a large study support the hypothesis that calcium modestly reduces risk of colorectal cancer.\\n\\n- Calcium intake, along with vitamin D, appears to play a protective role in reducing the risk of colorectal cancer.\\n\\nThe evidence suggests calcium supplementation, especially in combination with vitamin D, can help prevent colorectal cancer. A dose-response relationship has been observed, with higher calcium intake providing greater risk reduction.', 'The evidence suggests that calcium dietary supplementation might contribute to a moderate degree to the prevention of colorectal adenomatous polyps, but it is not sufficient to recommend the general use of calcium supplements to prevent colorectal cancer. Two well-designed trials with 13,446 subjects found a reduction in recurrent colorectal adenoma with calcium supplementation (OR 0.74, CI 0.58-0.95). However, other studies have inconsistent results, and it is unclear whether the decrease in labeling index correlates with a decrease in occurrence or recurrence of colonic tumors. Additionally, a recent study found that only high dietary calcium intake (>1485 mg/day) was associated with a reduced risk of colorectal cancer, but supplementation had no significant effect. Further replication in other studies is needed to confirm these findings.', 'Based on the evidence from multiple studies, calcium dietary supplementation may reduce the risk of colorectal cancer, but the effect appears to be modest. Several studies found an inverse association between higher calcium intake and colorectal cancer incidence. Calcium, along with vitamin D, may play a protective role through a joint action in colorectal carcinogenesis.\\n\\nHowever, while the evidence suggests calcium supplementation could be beneficial, the magnitude of risk reduction is not definitive. More research is needed to establish clear recommendations on dosage and to determine the extent of protection provided by calcium supplements alone versus in combination with vitamin D.\\n\\nIn summary, calcium supplementation shows promise as part of a preventive strategy against colorectal cancer, but should be considered alongside other important lifestyle factors like a balanced diet, regular exercise, and avoiding smoking and excessive alcohol consumption. The benefits of supplementation must be weighed against potential risks on an individual basis. Current evidence supports a modest protective effect, but is not conclusive enough to universally recommend calcium supplements solely for colorectal cancer prevention.', 'Based on the information provided, it is not possible to conclude that calcium dietary supplementation can reduce the risk of colorectal cancer. The first abstract describes a case-control study showing an inverse relationship between dietary calcium intake and colorectal cancer risk in a Korean population with relatively low calcium intake. However, a randomized controlled trial described in the second abstract found no significant difference in colorectal cancer incidence between women who received calcium plus vitamin D supplementation and those who received placebo. A meta-analysis of observational studies in the third abstract suggests that higher consumption of milk/dairy products reduces the risk of colon cancer, and high calcium intake reduces the risk of colorectal cancer (CRC), but it does not specifically evaluate calcium supplementation. Therefore, more research is needed to determine whether calcium dietary supplementation can reduce the risk of colorectal cancer.', 'Daily supplementation of calcium with vitamin D for seven years did not affect the overall incidence of colorectal cancer among postmenopausal women. However, high calcium intake was found to have a greater protective effect against tumors of the distal colon and rectal cancer compared to proximal colon cancer. The risk reduction associated with calcium was similar for both dietary and supplemental sources. Additionally, calcium consumption was inversely related to colorectal cancer risk in a Korean population, where the national average calcium intake level is lower than in Western countries. Therefore, while calcium dietary supplementation may not reduce the overall risk of colorectal cancer, it could potentially have a protective effect against certain sub-sites of the colon and rectal cancer, and its risk reduction effects may be more pronounced in populations with lower calcium intake levels.', 'No, daily supplementation of calcium with vitamin D for seven years had no effect on the incidence of colorectal cancer among postmenopausal women. The long latency associated with the development of colorectal cancer, along with the seven-year duration of the trial, may have contributed to this null finding. Ongoing follow-up will assess the longer-term effect of this intervention.', 'The evidence on the effect of calcium dietary supplementation on colorectal cancer risk is mixed. Some studies suggest that high calcium intake, from both dietary and supplemental sources, may have a protective effect against colorectal cancer, particularly in the distal colon and rectum. However, other studies have found no effect of calcium supplementation on colorectal cancer risk. The inconsistency in findings may be due to differences in study design, population characteristics, and the duration and dose of calcium supplementation. More research is needed to determine the role of calcium supplementation in colorectal cancer prevention.', 'Calcium dietary supplementation has been shown to reduce the risk of colorectal cancer, particularly in the distal colon and rectal cancer. However, the null finding in a recent trial among postmenopausal women may be due to the long latency associated with colorectal cancer development and the duration of the trial. Further follow-up is needed to assess the longer-term effect of calcium supplementation on colorectal cancer risk. Additionally, the inverse association between calcium consumption and colorectal cancer risk has been observed in various populations, including Korean men and women. While procalcitonin can guide the identification of children at higher risk of morbidity and mortality, the optimal monitoring and treatment strategies for these individuals are not yet clear. Finally, while CT colonography may be more costly and result in more deaths than colonoscopy, the latter remains the dominant strategy for colorectal cancer screening in Canada.', \"Yes, several studies suggest that calcium intake, either through diet or supplements, can potentially reduce the risk of colorectal cancer. However, the protective effect seems to be more significant for tumors of the distal colon and rectal cancer compared to the proximal colon. It's also worth noting that a seven-year trial found no effect of daily supplementation of calcium with vitamin D on the incidence of colorectal cancer among postmenopausal women, suggesting that the impact of calcium may vary depending on other factors such as age, gender, and the specific location of the cancer within the colon\", 'The evidence on the association between calcium dietary supplementation and the risk of colorectal cancer is not conclusive. Some studies suggest that calcium may help reduce the risk by binding to bile and fatty acids in the gut, but other studies have not found a significant association. High calcium intake may have a greater protective effect against tumors of the distal colon and rectal cancer compared to proximal colon. However, excessive calcium intake can lead to hypercalcemia, which may cause symptoms such as anorexia, nausea, vomiting, memory loss, confusion, muscle weakness, increased urination, dehydration, and metabolic bone disease. Therefore, it is recommended to maintain appropriate calcium levels through a balanced diet and, if necessary, supplementation under the guidance of a healthcare professional.', 'While randomized clinical trials have not found a significant reduction in the risk of colorectal cancer, a meta-analysis of prospective studies suggested a modest reduction of 15% in colorectal cancer risk in people with the highest intakes of calcium.', \"Yes, calcium dietary supplementation may reduce the risk of colorectal cancer, especially in postmenopausal women. However, the effectiveness of calcium supplementation may depend on the individual's calcium intake level and the duration of supplementation\", \"Based on available studies and a meta-analysis, there isn't sufficient evidence that calcium dietary supplementation reduces the risk of colorectal cancer. Some observational studies suggest an inverse relationship between calcium intake from dairy products and CRC risk, but this association is not definitive in randomized controlled trials or when specifically assessing calcium supplementation. More research is needed to confirm a direct protective effect of calcium dietary supplements against colorectal cancer.\", 'The mixed data on the impact of calcium supplementation for reducing colorectal cancer risk shows no significant effect from a study involving postmenopausal women over seven years, though this could be due to trial length and latency. However, high calcium intake is linked with greater protective effects against distal colon and rectal cancers, and the inverse relationship between calcium consumption and colorectal cancer risk has been observed in a Korean population with lower national average calcium intake levels. A decreased colorectal cancer risk associated with calcium was also seen across all subgroups studied.', 'Calcium dietary supplementation has been shown to reduce the risk of colorectal cancer, particularly in the distal colon and rectal cancer. However, the effect of calcium supplementation on colorectal cancer risk is not consistent across all studies and may depend on the source of calcium (dietary vs. supplemental) and the duration of supplementation. While some studies have found no effect of calcium supplementation on colorectal cancer risk, others have reported a reduced risk associated with higher calcium intake. The long latency associated with the development of colorectal cancer and the duration of supplementation may contribute to the inconsistent findings. Further research is needed to determine the optimal dosage and duration of calcium supplementation for colorectal cancer prevention.', 'Yes, calcium dietary supplementation can reduce the risk of colorectal cancer by providing a protective effect against tumors in the distal colon and rectal cancer. This inverse relationship between calcium consumption and colorectal cancer risk has been observed across various populations regardless of gender or source (dietary or supplemental). While initial trials showed no effect on incidence, ongoing follow-ups may provide further evidence for long-term benefits.', 'Yes, calcium intake from dietary or supplemental sources appears to reduce the risk of colorectal cancer, especially for tumors in the distal colon and rectum. However, one study found that daily supplementation of calcium with vitamin D for seven years did not affect colorectal cancer incidence in postmenopausal women, possibly due to the long latency period for colorectal cancer development. The protective effect of calcium was observed in a Korean population with relatively low average calcium intake compared to Western countries.', 'Based on the provided snippets, the data regarding calcium dietary supplementation reducing the risk of colorectal cancer is mixed. One study found that daily supplementation of calcium with vitamin D for seven years had no effect on the incidence of colorectal cancer among postmenopausal women. However, this null finding may be due to the long latency associated with colorectal cancer development and the relatively short duration of the trial. , On a positive note, high calcium intake was found to have a greater protective effect against tumors of the distal colon and rectal cancer versus proximal colon. The risk reduction associated with calcium was similar for dietary and supplemental sources. Furthermore, calcium consumption was inversely related to colorectal cancer risk in a Korean population where national average calcium intake level is relatively lower than Western countries. A decreased risk of colorectal cancer by calcium intake was also observed in all sub', \"The evidence on whether calcium supplementation can reduce the risk of colorectal cancer is mixed and inconclusive. Some observational studies suggest that higher calcium intake may be associated with a reduced colorectal cancer risk, especially for distal colon and rectal tumors. However, a large clinical trial found that daily supplementation of calcium with vitamin D for seven years had no effect on colorectal cancer incidence among postmenopausal women. The long latency period for colorectal cancer development and the trial's duration may have contributed to this null finding. While calcium consumption was inversely related to colorectal cancer risk in a Korean population study, more research is needed to clarify calcium supplementation's role in colorectal cancer prevention.\"]\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data tables and sources, the evidence suggests that calcium dietary supplementation may have a potential role in reducing the risk of colorectal cancer. Several studies have investigated the association between calcium intake and colorectal cancer risk, and the results are summarized as follows:\n\n* A case-control study of 2380 patients with colorectal cancer and 2389 controls in China found that higher dietary vitamin D and calcium intakes were associated with a 43% and 52% reduction in colorectal cancer risk, respectively (Source 19).\n* A meta-analysis of 26,335 cases from 60 observational studies found that high milk and dairy product intake was associated with a 22% reduced risk of colon cancer, and high calcium intake was associated with a 14% reduced risk of colorectal cancer (Source 11).\n* A prospective cohort study of 61,463 women found that high calcium intake was associated with a reduced risk of colorectal cancer, with a rate ratio of 0.72 (95% CI: 0.56-0.93) for the highest quintile of calcium intake compared to the lowest quintile (Source 12).\n* A systematic review of two randomized controlled trials found that calcium supplementation may contribute to a moderate degree to the prevention of colorectal adenomatous polyps, with a reduction in risk of 0.74 (95% CI: 0.58-0.95) (Source 13).\n* However, another randomized, double-blinded, placebo-controlled trial found that oral calcium supplementation had no significant effect on epithelial cell proliferation in the rectum, sigmoid, and descending colon in first-degree relatives of hereditary nonpolyposis colorectal cancer patients (Source 15).\n\nOverall, while the evidence suggests that calcium dietary supplementation may have a potential role in reducing the risk of colorectal cancer, the results are not conclusive, and further research is needed to confirm these findings.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer effectively recalls all the necessary information from the reference answers, including specific studies, statistics, and varying conclusions about the role of calcium supplementation in reducing colorectal cancer risk. It covers protective effects, non-effects, and the need for further research.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise, focusing on the relationship between calcium supplementation and colorectal cancer without straying into irrelevant details. However, it could slightly improve by succinctly summarizing the inconsistent findings more sharply.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no unnecessary repetition of information. Each point is distinct and contributes to a comprehensive understanding of the topic, from beneficial associations to null findings.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured and clearly written, with logical flow and fluent language. It uses bullet points effectively to break down complex information, enhancing readability."
    },
    {
        "Question": "What is the prevalence of intellectual developmental disorders in Duchenne Muscular Dystrophy?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat is the prevalence of intellectual developmental disorders in Duchenne Muscular Dystrophy?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The prevalence of intellectual developmental disorders in Duchenne Muscular Dystrophy is 22%.', 'The prevalence of intellectual developmental disorders (IDD) in Duchenne Muscular Dystrophy (DMD) is 22%.', 'The prevalence of intellectual developmental disorders in Duchenne muscular dystrophy is 22%', 'The prevalence of intellectual developmental disorder (IDD) in Duchenne muscular dystrophy (DMD) is 22%.', 'The prevalence of intellectual developmental disorders in Duchenne Muscular Dystrophy (DMD) is approximately 22%.', 'The global prevalence of intellectual developmental disorder (IDD) is 22% in Duchenne muscular dystrophy (DMD).']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nUnfortunately, the provided data tables do not contain information on the prevalence of intellectual developmental disorders in Duchenne Muscular Dystrophy.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "1",
        "Information Recall Explanation": "The answer fails to provide the necessary information on the prevalence of intellectual developmental disorders in Duchenne Muscular Dystrophy (DMD) as indicated by the reference answers. Instead, it states that the data tables do not contain this information, which is incongruent with the reference answers.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise in stating that the data tables do not contain the required information. It does not include any irrelevant details or deviate from this point.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "The answer does not repeat any information. It succinctly communicates its message without redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is clear, concise, and easily understandable. The sentence structure and flow are fluent and effective."
    },
    {
        "Question": "Is treatment with acetyl salicylic acid indicated to prevent colorectal adenomas?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nIs treatment with acetyl salicylic acid indicated to prevent colorectal adenomas?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['Daily use of aspirin is associated with a significant reduction in the incidence of colorectal adenomas in patients with previous colorectal cancer.', 'Yes, treatment with acetylsalicylic acid (ASA), also known as aspirin, is indicated to prevent colorectal adenomas. Multiple studies have shown that regular use of aspirin reduces the risk of colorectal cancer by approximately 50%. Additionally, randomized controlled trials report a decrease in the relative risk of adenoma recurrence of approximately 17%. The optimal dose and duration of aspirin required to obtain this effect remain to be defined, but longer treatment durations (even for more than 10 years) and possibly higher doses may have greater protective effects. However, it is essential to consider these benefits in the context of all health effects of prolonged aspirin use, both positive and negative.', 'Acetyl salicylic acid has been shown to reduce the risk of recurrent colorectal adenomas.', 'No, treatment with acetyl salicylic acid is not indicated to prevent colorectal adenomas.', 'Yes, treatment with acetyl salicylic acid is indicated to prevent colorectal adenomas. The results of a recent study suggest that treatment with aspirin, a nonsteroidal anti-inflammatory drug (NSAID), may reduce the risk of colorectal adenomas. The study found that aspirin use was associated with a lower risk of colorectal adenoma in patients with a history of colorectal adenoma. The study also found that the protective effect of aspirin was most pronounced in patients with a history of multiple colorectal adenomas. The mechanism by which aspirin reduces the risk of colorectal adenoma is not fully understood, but it is thought to involve the inhibition of inflammation and the regulation of cellular proliferation.', 'Yes, treatment with acetyl salicylic acid is indicated to prevent colorectal adenomas.', 'Yes, treatment with acetyl salicylic acid (aspirin) may prevent colorectal adenomas.', 'Yes, treatment with acetyl salicylic acid (aspirin) is indicated to prevent colorectal adenomas in individuals with a history of these lesions. Multiple randomized, double-blind, placebo-controlled trials have established that regular aspirin use reduces the risk for recurrent colorectal adenoma. The relative risks of any adenoma were found to be significantly lower in the high dose of aspirin groups, low dose of aspirin groups, and both aspirin combined groups, compared with the placebo group. The reduction in the occurrence of advanced adenomas and any adenoma was 28% and 17%, respectively. Aspirin can produce regression of existing colorectal adenomas and prevent the formation of new polyps.', 'Yes, treatment with acetyl salicylic acid (aspirin) is indicated to prevent colorectal adenomas. Multiple studies and meta-analyses have shown that aspirin reduces the risk of recurrent colorectal adenomas in patients with a history of these lesions. The relative risks of any adenoma were found to be significantly lower in high and low dose aspirin groups compared to the placebo group. However, it is essential to consider the potential risks of gastrointestinal side effects and consult primary sources for a more definitive answer.', 'According to the abstracts, treatment with acetylsalicylic acid (ASA) is indicated to prevent colorectal adenomas. The studies consistently show that ASA reduces the recurrence of colorectal adenomas. A meta-analysis of randomized controlled trials found that ASA significantly reduced the recurrence of any new adenoma and advanced adenoma. Another study demonstrated that daily soluble aspirin prevented colorectal adenoma recurrence at 1-year follow-up, although this effect was not sustained at 4-year follow-up. Additionally, a study on patients with a history of colorectal adenomas found that ASA decreased adenoma recurrence significantly. Overall, the evidence suggests that ASA is an effective chemopreventive agent for colorectal adenomas.', 'Yes, treatment with acetyl salicylic acid is indicated to prevent colorectal adenomas. The results of several studies have shown that aspirin, a nonsteroidal anti-inflammatory drug (NSAID), can prevent colorectal adenomas from developing and progressing to colorectal cancer. The exact mechanism by which aspirin exerts its protective effects is not fully understood, but it is thought to involve the inhibition of inflammation and the regulation of cellular signaling pathways. The use of aspirin as a chemopreventive agent in patients with colorectal adenomas is a promising area of research and may lead to the development of new strategies for the prevention and treatment of colorectal cancer.', 'Yes, low-dose aspirin reduces the risk of colorectal adenomas.', 'Summary: Aspirin (acetylsalicylic acid), when used regularly, reduces colorectal cancer risk by approximately 50% due to its preventive effect against adenomas. This is supported by numerous studies showing a decrease in recurrence risks by about 17%. The optimal dose and treatment duration are still under investigation but longer treatments or higher doses may have greater protective effects, although potential negative health impacts from long-term use should also be considered.', 'Yes, aspirin (acetylsalicylic acid) is indicated to prevent recurrent colorectal adenomas in patients with a history of these lesions. Several randomized, placebo-controlled trials have shown that regular aspirin use significantly reduces the risk of recurrent sporadic colorectal adenomas. A meta-analysis found that low-dose aspirin (80-160 mg/day) taken for 2 to 4 years reduces the relative risk of recurrent colorectal adenomas by 20% in patients with a previous history of colorectal cancer or adenomas. Aspirin is the best studied chemopreventive agent for colorectal cancer, with evidence demonstrating its efficacy in reducing adenoma recurrence in higher risk patients.', 'Yes, treatment with acetyl salicylic acid (aspirin) is indicated to prevent colorectal adenomas. Studies have consistently shown that aspirin reduces the risk of colorectal adenomas and cancer. The optimal duration of treatment and dosage required to achieve this effect are still being defined, but longer treatment durations and higher doses may lead to greater protective effects. Additionally, combining aspirin with omega-3 polyunsaturated fatty acids may enhance its preventative effects. Factors such as lipid metabolism and liver function can influence the suppressive effect of aspirin on colorectal adenoma recurrence. Overall, aspirin is a promising and inexpensive agent for preventing colorectal adenomas and cancer, particularly when used in combination with other beneficial nutrients.', 'Yes, acetylsalicylic acid is indicated to prevent colorectal adenomas.', 'Yes, treatment with acetylsalicylic acid (aspirin) is indicated to help prevent colorectal adenomas in certain patients. Several randomized controlled trials have shown that regular aspirin use reduces the risk of recurrent colorectal adenomas in patients with a previous history of these lesions. Meta-analyses suggest aspirin decreases recurrence of any adenoma by approximately 17-20% and advanced adenomas by 28% compared to placebo. The effect is seen with low-dose aspirin (80-160 mg/day) taken for at least 1-4 years. However, the benefits must be balanced against the risks of long-term aspirin use, particularly gastrointestinal bleeding. Aspirin is recommended for adenoma prevention in select higher-risk patients, such as those with a personal history of colorectal neoplasia, but is not currently advised for average-risk individuals. Screening colonoscopy with polyp removal remains the primary approach for preventing progression of adenomas to colorectal cancer.', 'Yes, based on the findings of this randomized trial, treatment with acetyl salicylic acid (aspirin) is indicated for the prevention of colorectal adenomas in patients with previous colorectal cancer. The study found that daily use of aspirin was associated with a significant reduction in the incidence of colorectal adenomas, the precursors to most colorectal cancers, compared to placebo (17% vs 27%, P=0.004). The mean number of adenomas was also lower in the aspirin group, and the time to detection of a first adenoma was longer. These results suggest that aspirin use may decrease the risk of colorectal adenomas and potentially colorectal cancer in this high-risk population. However, it is important to consider the potential risks and benefits of long-term aspirin use on an individual basis, including gastrointestinal bleeding and other adverse', \"The use of aspirin, also known as acetyl salicylic acid, has been associated with a significant reduction in the incidence of colorectal adenomas in patients with a history of colorectal cancer. This suggests that treatment with aspirin could be a potential preventative measure for colorectal adenomas. However, it is important to consider the potential risks and side effects of aspirin use, as well as the individual patient's medical history and overall health, before making a treatment recommendation. Further research is needed to fully understand the benefits and risks of aspirin use for the prevention of colorectal adenomas.\", 'Yes, treatment with acetyl salicylic acid (aspirin) is indicated to prevent colorectal adenomas in patients with previous colorectal cancer.', 'No, daily use of aspirin is associated with a significant reduction in the incidence of colorectal adenomas in patients with previous colorectal cancer.', 'Yes, treatment with acetyl salicylic acid (aspirin) is indicated to prevent colorectal adenomas. Daily use of aspirin is associated with a significant reduction in the incidence of colorectal adenomas in patients with previous colorectal cancer. Additionally, aspirin has been shown to have anti-tumoral effects, via inhibition of the PTTG1 gene, which is often overexpressed in tumors. Aspirin may also reduce the overall risk of both getting cancer and dying from cancer, with substantial evidence for lowering the risk of colorectal cancer (CRC) when taken for at least 10–20 years. However, the benefits are greater than the risks due to bleeding in those at average risk, and some clinical perspectives of aspirin and anti-inflammatory agents in the treatment of colorectal adenomas remain uncertain.', 'Yes, daily use of aspirin, which contains acetyl salicylic acid, is associated with a significant reduction in the incidence of colorectal adenomas, especially in patients with previous colorectal cancer.', 'Yes, daily use of aspirin is associated with a significant reduction in the incidence of colorectal adenomas in patients with previous colorectal cancer.', \"Yes, daily use of aspirin (acetyl salicylic acid) has been shown to reduce the incidence of colorectal adenomas in patients with previous colorectal cancer. \\n\\nPlease go ahead and ask your question. I'll respond accordingly. \\n\\n(Note: Please keep your questions concise and relevant to the context.)\", 'In summary, while acetyl salicylic acid has been suggested to have potential benefits for colorectal adenomas, the overall role of acetyl salicylic acid in cancer prevention and treatment remains an active area of research and discussion among medical professionals. ', 'Yes, treatment with acetyl salicylic acid (aspirin) is associated with a significant reduction in the incidence of colorectal adenomas in patients with previous colorectal cancer.', 'Yes, daily use of aspirin (acetyl salicylic acid) is associated with a significant reduction in the incidence of colorectal adenomas in patients with previous colorectal cancer. However, it is important to note that this should be discussed with a healthcare provider to weigh the potential benefits and risks.', 'Yes, daily use of aspirin, also known as acetyl salicylic acid, has been associated with a significant reduction in the incidence of colorectal adenomas, especially in patients with a history of colorectal cancer', 'Yes, daily use of aspirin (acetyl salicylic acid) has been associated with a significant reduction in the incidence of colorectal adenomas in patients with previous colorectal cancer.', 'Yes, daily use of acetyl salicylic acid, also known as aspirin, is associated with a significant reduction in the incidence of colorectal adenomas, especially in patients with previous colorectal cancer.', 'The results from various clinical trials suggest that aspirin reduces the incidence of adenomas in a dose-dependent manner.  However, there is a lack of evidence that low dose aspirin taken for a long period of time has a significant effect on prevention of colorectal cancer.', 'Yes, treatment with acetyl salicylic acid, commonly known as aspirin, is indicated to prevent colorectal adenomas. Daily use of aspirin has been shown to significantly reduce the incidence of colorectal adenomas in patients with previous colorectal cancer', 'effects. In summary, yes, based on a randomized trial, daily aspirin treatment can help prevent colorectal adenomas in patients with previous colorectal cancer; however, potential risks should be evaluated before long-term use.', 'Treatment with acetyl salicylic acid (aspirin) is recommended for preventing colorectal adenomas, especially in those with previous colorectal cancer history. Studies show that daily aspirin use reduces the incidence of these precursors to colorectal cancer, suggesting a chemoprevention role. However, optimal dose and duration are still uncertain.', 'Yes, daily use of aspirin, also known as acetyl salicylic acid, is associated with a significant reduction in the incidence of colorectal adenomas in patients with previous colorectal cancer.', 'Answer: Yes, acetyl salicylic acid (aspirin) can prevent colorectal adenomas, especially in those with previous colorectal cancer history. It is recommended for patients with such history or adenomas due to its proven ability to reduce the incidence of adenomas and potentially help chemoprevent colorectal cancer. Optimal dose and duration are still unclear.', 'Yes, daily use of aspirin (acetylsalicylic acid) is associated with a significant reduction in the incidence of colorectal adenomas in patients with previous colorectal cancer.', 'Yes, treatment with acetyl salicylic acid (aspirin) is indicated to prevent colorectal adenomas, particularly in patients with a history of previous colorectal cancer. Studies have consistently shown that daily aspirin use reduces the incidence of colorectal adenomas, which are precursors to colorectal cancer. This suggests that aspirin may play a role in chemoprevention of colorectal cancer. The evidence is strong enough to recommend aspirin therapy as an adjunct to standard care for patients with a history of colorectal cancer or adenomas, although the optimal dose and duration of treatment remain unclear.', 'Yes, daily use of aspirin is associated with a significant reduction in the incidence of colorectal adenomas.', \"Based on the available evidence, daily aspirin (acetylsalicylic acid) use may help prevent colorectal adenomas and colorectal cancer, but the benefits must be carefully weighed against the risks for each individual patient.\\n\\nThe provided study found that daily aspirin significantly reduced the incidence of colorectal adenomas in patients with previous colorectal cancer. However, the Wikipedia summary notes that aspirin likely needs to be taken for at least 10-20 years to reduce colorectal cancer risk, and more recent trial data has questioned the benefit of aspirin for primary cancer prevention.\\n\\nAdditionally, long-term aspirin use carries a risk of gastrointestinal bleeding. Current guidelines only recommend low-dose aspirin for colorectal cancer prevention in select patients aged 50-59 with elevated cardiovascular risk but low bleeding risk.\\n\\nTherefore, while aspirin may help prevent adenomas, it is not routinely indicated for all patients. The decision to use aspirin for this purpose should be made on a case-by-case basis considering the patient's baseline risk, expected benefit, potential complications, and personal preferences. Screening colonoscopy with polyp removal remains the primary approach for preventing progression of adenomas to colorectal cancer.\", 'Yes, daily use of acetyl salicylic acid, also known as aspirin, is associated with a significant reduction in the incidence of colorectal adenomas in patients with previous colorectal cancer.', 'Yes, treatment with acetyl salicylic acid, commonly known as aspirin, is indicated to prevent colorectal adenomas', 'Yes, treatment with acetyl salicylic acid is indicated to prevent colorectal adenomas']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, treatment with acetyl salicylic acid (ASA), also known as aspirin, is indicated to prevent colorectal adenomas. \n\nSeveral studies have shown that regular use of low-dose aspirin reduces the risk of developing colorectal adenomas. For example, a systematic review and meta-analysis of randomized controlled trials found that low-dose aspirin (80-160 mg/day) significantly reduced the risk of recurrent colorectal adenomas in patients with a previous history of colorectal cancer or adenomas (RR = 0.80, 95% CI = 0.70-0.92).\n\nAdditionally, a randomized controlled trial found that long-term use of aspirin (100 or 300 mg/day) reduced the occurrence or recurrence of colorectal adenomas in patients with Lynch syndrome (a condition that increases the risk of colorectal cancer).\n\nHowever, it's essential to note that the optimal dose and duration of aspirin treatment for preventing colorectal adenomas are still being studied, and the potential risks and benefits of long-term aspirin use should be carefully considered.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer effectively recalls key information from the reference answers, including the reduction in risk of colorectal adenomas with low-dose aspirin, specific dosages (80-160 mg/day, 100 or 300 mg/day), and the context of Lynch syndrome. It also mentions the need for further study on optimal dose and duration.",
        "Information Precision Score": 5,
        "Information Precision Explanation": "The answer is precise, focusing only on relevant details such as the efficacy of aspirin, specific dosages, and patient populations (those with a history of colorectal cancer or adenomas, and Lynch syndrome). It avoids irrelevant information.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "The answer does not repeat any information unnecessarily. Each point is clearly articulated without redundancy.",
        "Readability Score": 5,
        "Readability Explanation": "The answer is well-structured, fluent, and easy to understand. It uses clear language and logical flow, making it highly readable."
    },
    {
        "Question": "What medications were tested in the COSMIC-313 trial?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhat medications were tested in the COSMIC-313 trial?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The COSMIC-313 phase 3 randomized controlled trial tested the triplet combination of cabozantinib with nivolumab and ipilimumab in comparison with nivolumab plus ipilimumab control as fist-line systemic therapy in metastatic clear cell renal cell carcinoma.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nAccording to the data, the COSMIC-313 trial tested the combination of cabozantinib, nivolumab, and ipilimumab in patients with previously untreated advanced renal-cell carcinoma.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": "5",
        "Information Recall Explanation": "The answer correctly recalls all the necessary information from the reference answers, including the triplet combination of cabozantinib, nivolumab, and ipilimumab, and the context of the trial in previously untreated advanced renal-cell carcinoma.",
        "Information Precision Score": "5",
        "Information Precision Explanation": "The answer is precise and does not include any irrelevant information. It accurately reports the medications tested and the patient population without adding extraneous details.",
        "Information Repetition Score": "5",
        "Information Repetition Explanation": "There is no repetition of information in the answer. Each piece of information is presented clearly and concisely without redundancy.",
        "Readability Score": "5",
        "Readability Explanation": "The answer is highly readable, with clear and fluent language that effectively communicates the necessary information."
    },
    {
        "Question": "Where would Odocoileus virginianus be found?",
        "Sys_prompt": "---Role---\nYou are a biomedical expert tasked with evaluating the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n",
        "Prompt": "You will evaluate the answer to the questions based on some reference answers and four criteria: **Information Recall**, **Information Precision**, **Information Repetition**, and **Readability**.\n\n- **Information Recall**: All the necessary information is reported.\n- **Information Precision**: No irrelevant information is reported.\n- **Information Repetition**: The answer does not repeat the same information multiple times.\n- **Readability**: The answer is easily readable and fluent.\n\nAn 1–5 scale will be used in all four criteria (1 for \"very poor\" and 5 for \"excellent\") and provide reasons.\n\nHere is the question:\nWhere would Odocoileus virginianus be found?\n\nHere are some reference answers:\n\n**Reference Answers:**\n['The White tailed deer, Odocoileus virginianus is found in North America', 'White-tailed deer (Odocoileus virginianus) are the most widely distributed large mammals in the Americas and can be found in the United States, Canada, Mexico, and South America.', 'White-tailed deer (Odocoileus virginianus) are native to North America.', 'White-tailed deer (Odocoileus virginianus) would be found in the eastern USA.', 'Odocoileus virginianus is found in North America.', 'Odocoileus virginianus, also known as the white-tailed deer, is commonly found in the eastern USA.', 'Odocoileus virginianus, commonly known as the White-tailed Deer, is a species of deer native to North America, Central America, and South America, and is the most widely distributed wild ungulate in the Western Hemisphere.', 'Odocoileus virginianus is a species of deer found in North America.', 'White-tailed deer (Odocoileus virginianus) would be found in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Virginia, and Texas.', 'Odocoileus virginianus, or the white-tailed deer, is commonly found in the eastern United States, including states like Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, and Virginia.', 'Odocoileus virginianus (white-tailed deer) can be found primarily in North America including the United States, with a distribution extending into Central and some parts of Northern South America. They are ecologically and economically significant species studied across multiple US states such as Florida and Texas.', 'Odocoileus virginianus, also known as the white-tailed deer, is native to North America.', 'Odocoileus virginianus is found in the United States.', 'White-tailed deer (Odocoileus virginianus) are found in northeastern Mexico.', 'Odocoileus virginianus, also known as the white-tailed deer, can be found in Alabama.', 'Free-ranging white-tailed deer (Odocoileus virginianus) are found in North America.', 'Free-ranging white-tailed deer (Odocoileus virginianus) would be found in North America.', 'Odocoileus virginianus, the white-tailed deer, is found in North America.', 'Odocoileus virginianus, commonly known as the white-tailed deer, can be found across North America, including Washington, D.C. and 26 states in the United States. They are widely distributed and are a common sight in both rural and suburban areas.', 'Odocoileus virginianus, also known as white-tailed deer, can be found in North America and the United States.', 'Odocoileus virginianus, commonly known as white-tailed deer, are found in United States.', ' Oducocoides viridianus is a bacterium commonly found in the lower respiratory tract of humans and other mammals.</s>', 'Odocoileus virginianus can be found in North America, including Washington, D.C. and 26 states in the United States.', 'Odocoileus virginianus, also known as white-tailed deer, are found in North America. Specifically, they have been studied in Washington, D.C. and 26 states in the United States.', 'Odocoileus virginianus, commonly known as the white-tailed deer, can be found across a wide range of North America. They are prevalent in the United States, including areas like Washington, D.C., and 26 states as mentioned in the study on their interaction with SARS-CoV-2. Additionally, they inhabit parts of Canada and extend into regions of Central and South America', 'Odocoileus virginianus, also known as white-tailed deer, are found in North America. They are widely distributed across the United States and Washington, D.C.', 'Odocoileus virginianus, commonly known as the white-tailed deer, is a species of deer native to the United States, Canada, Mexico, and Central and South America. It is most commonly found in a wide variety of forest, woodland, and transitional areas in North America, Central America, and South America', 'Odocoileus virginianus, also known as the white-tailed deer, can be found in the United States, specifically in Washington, D.C. and 26 states across the country.', 'Odocoileus virginianus, or white-tailed deer, can be found across Washington, D.C., 26 states in the U.S., and broadly within North America.', 'Odocoileus virginianus (white-tailed deer) is native to North America, particularly the United States and Canada. Historically decimated by deforestation but rebounded with reforestation and climate warming. Now found widely in eastern US up to the Canadian border, parts of Central & South America due to human introduction.', 'Odocoileus virginianus, commonly known as the white-tailed deer, can be found in North America, including across Washington, D.C. and 26 states in the United States.', 'Odocoileus virginianus, also known as white-tailed deer, can be found in North America, specifically in the United States. They are widely distributed across the country, including in Washington, D.C. and 26 states.', 'Odocoileus virginianus, also known as the white-tailed deer, is primarily found in North America and throughout the United States.', 'Odocoileus virginianus, commonly known as the white-tailed deer, can be found in the United States, particularly across Washington, D.C. and 26 states.', 'Odocoileus virginianus, commonly known as the white-tailed deer, can be found in various habitats across the United States.']\n\nHere are the answer that need to be evaluated:\n\n**Answer:**\nBased on the provided data, Odocoileus virginianus, also known as the white-tailed deer, can be found in the following locations:\n\n1. North America (relation id: 7, description: \"White-tailed deer are found in North America.\")\n2. United States (relation id: 6, description: \"White-tailed deer are found in the United States.\")\n3. Southeastern United States (relation id: 11, description: \"White-tailed deer are native to and have been restored in the southeastern USA\")\n4. Virginia (relation id: 7, description: \"A state in the southeastern United States where the meningeal worm is widely distributed.\")\n5. Maine (relation id: 14, description: \"A state in the northeastern United States where white-tailed deer are found.\")\n6. Illinois (relation id: 12, description: \"White-tailed deer are found in forest preserves, including those around Chicago, Illinois.\")\n7. Saskatchewan (relation id: 20, description: \"Polioencephalomalacia in white-tailed deer (Odocoileus virginianus) in Saskatchewan.\")\n8. Texas (relation id: 22, description: \"Identification of White-tailed Deer (Odocoileus virginianus) as a Novel Reservoir Species for Trypanosoma cruzi in Texas, USA.\")\n9. North Dakota (relation id: 23, description: \"CLIMATE AND HABITAT INFLUENCE PREVALENCE OF MENINGEAL WORM INFECTION IN NORTH DAKOTA, USA.\")\n10. Missouri (relation id: 24, description: \"An epizootic of hemorrhagic disease in white-tailed deer (Odocoileus virginianus) in Missouri: necropsy findings and population impact.\")\n11. Iowa (relation id: 25, description: \"Parelaphostrongylus tenuis (Nematoda) in white-tailed deer (Odocoileus virginianus) in central Iowa.\")\n12. Atlantic Forest region (relation id: 21, description: \"Amblyomma aureolatum is found in the Atlantic Forest region\")\n13. Pampulha Lake region (relation id: 31, description: \"The Municipal Ecological Park is located in the Pampulha Lake region.\")\n\nPlease note that this is not an exhaustive list, as the provided data may not contain all the locations where Odocoileus virginianus can be found.\n\nEvaluate answer using the four criteria listed above and provide detailed explanations for each criterion.\n\nOutput your evaluation in the following JSON format:\n{\n    \"Information Recall\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Precision\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Information Repetition\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    },\n    \"Readability\": {\n        \"Score\": \"1–5\",\n        \"Explanation\": \"[Provide explanation here]\"\n    }\n}\n",
        "Information Recall Score": 5,
        "Information Recall Explanation": "The answer provides a comprehensive list of locations where Odocoileus virginianus can be found, including regions in North America, the United States, and specific states and ecological regions. The answer also acknowledges that this may not be an exhaustive list, which aligns well with the reference answers.",
        "Information Precision Score": 4,
        "Information Precision Explanation": "The answer is precise, listing specific states and regions where the species is found. However, it includes some details (e.g., relation ids and descriptions like \"meningeal worm is widely distributed\") that while relevant to the context, may not be fully pertinent to the simple question of where the species is found.",
        "Information Repetition Score": 5,
        "Information Repetition Explanation": "There is no repetition of the same information multiple times. Each location is listed distinctly, making the answer concise and clear.",
        "Readability Score": 4,
        "Readability Explanation": "The answer is well-structured and easily readable, with each location clearly listed. The inclusion of relation ids and descriptions is slightly distracting from the main point but does not significantly hinder readability. The note at the end adds to the clarity by acknowledging the non-exhaustiveness of the list."
    }
]